<SEC-DOCUMENT>0001104659-22-009095.txt : 20220622
<SEC-HEADER>0001104659-22-009095.hdr.sgml : 20220622
<ACCEPTANCE-DATETIME>20220128172406
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-22-009095
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		89
FILED AS OF DATE:		20220128
<PUBLIC-REL-DATE>20220622
DATE AS OF CHANGE:		20220131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-05970
		FILM NUMBER:		22570197

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>As confidentially submitted to the Securities
and Exchange Commission on January&nbsp;28, 2022. This draft<BR>
 registration statement has not been filed publicly with the Securities and
Exchange Commission, and all <BR>
information herein remains strictly confidential.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; width: 100%"><DIV STYLE="text-align: center; font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;10</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>GENERAL FORM&nbsp;FOR REGISTRATION OF SECURITIES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION&nbsp;12(b)&nbsp;OR 12(g)&nbsp;OF</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROMIS NEUROSCIENCES INC.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>98-0647155</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>incorporation&nbsp;or&nbsp;organization)</B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(I.R.S.&nbsp;employer</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>identification&nbsp;no.)</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Suite&nbsp;200, 1920 Yonge Street</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Toronto, Ontario</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>M4S 3E2</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices and
zip code)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>415-341-5783</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Registrant&#8217;s telephone number, including
area code)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities to be registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Shares</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Title of class)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities to be registered pursuant to Section&nbsp;12(g)&nbsp;of
the Act:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; width: 19%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="text-align: right; width: 4%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&nbsp;growth&nbsp;company </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financing accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_005"></A><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><A HREF="#fulla_001">Implications of Being an
    Emerging Growth Company</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><A HREF="#fulla_001">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#v_001">Smaller Reporting Company Status</A></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><A HREF="#fulla_001">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fulla_002">Use of Names</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_002">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fulla_003">Currency</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_003">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_004">Trademarks, Trade Names and Service
    Marks</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_004">ii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_006">Disclosure Regarding Forward-Looking
    Statements</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_006">&nbsp;iii</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_007">Risk Factors Summary</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_007">iv</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#b_2">Glossary of Key Terms and Definitions</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_004">vi</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#b_3">ITEM 1. BUSINESS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#b_3">1</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#d_001">ITEM 1A. RISK FACTORS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#d_001">33</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#g_001">ITEM 2. FINANCIAL INFORMATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#g_001">86</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#g_003">ITEM 3. PROPERTIES</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#g_003">93</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#g_004">ITEM 4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
    OWNERS AND MANAGEMENT</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#g_004">93</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%"><A HREF="#g_005">ITEM 5. DIRECTORS AND EXECUTIVE OFFICERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><A HREF="#g_005">94</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>


<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%"><A HREF="#h2">ITEM 6. EXECUTIVE COMPENSATION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%"><A HREF="#h2">101</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#h3">ITEM 7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#h3">108</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_015">ITEM 8. <FONT STYLE="text-transform: uppercase">Legal
    Proceedings</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_015">110</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_017">ITEM 9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT&#8217;S COMMON EQUITY AND RELATED SHAREHOLDER MATTERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_017">110</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_022">ITEM 10. RECENT SALES OF UNREGISTERED SECURITIES</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_022">111</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_024">ITEM 11. DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES TO BE REGISTERED</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_024">114</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_025">ITEM 12. INDEMNIFICATION OF DIRECTORS AND OFFICERS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_025">115</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_026">ITEM 13. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_026">117</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_027">ITEM 14. CHANGES IN AND DISAGREEMENTS WITH AUDITORS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_027">117</A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#fulla_028">ITEM 15. FINANCIAL STATEMENTS AND EXHIBITS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#fulla_028">F-1</A></TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_001"></A>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.07&nbsp;billion
in revenue during our most recently completed fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in Section&nbsp;2(a)&nbsp;of
the Securities Act of 1933, as amended, which we refer to as the &#8220;<B>Securities Act</B>,&#8221; as modified by the Jumpstart Our
Business Startups Act of 2012, or the &#8220;<B>JOBS Act</B>.&#8221; As an emerging growth company, we may take advantage of specified
reduced disclosure and other exemptions from requirements that are otherwise applicable to public companies that are not emerging growth
companies. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Reduced disclosure about our executive compensation arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Exemptions from non-binding shareholder advisory votes on executive compensation or golden parachute arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our election under Section&nbsp;107(b)&nbsp;of the JOBS Act to delay adoption of new or revised accounting
standards with different effective dates for public and private companies until those standards would otherwise apply to private companies;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may take advantage of these exemptions for
up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company
if we have more than $1.07&nbsp;billion in annual revenues as of the end of a fiscal year, if we are deemed to be a large-accelerated
filer under the rules&nbsp;of the Securities and Exchange Commission (the &#8220;<B>SEC</B>&#8221;) or if we issue more than $1.0&nbsp;billion
of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this document or to which we have referred you. We have not authorized anyone to provide you with information that is different. You
should assume that the information contained in this document is accurate as of the date of this Registration Statement only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once this Registration Statement becomes effective
(the &#8220;<B>Effective Date</B>&#8221;), we will become subject to the reporting requirements of Section&nbsp;13(a)&nbsp;under Securities
Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;) and will be required to file annual reports on Form&nbsp;10-K,
quarterly reports on Form&nbsp;10-Q and current reports on Form&nbsp;8-K, and we will be required to comply with all other obligations
of the Exchange Act applicable to issuers filing registration statements pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B><A NAME="v_001"></A>Smaller
Reporting Company Status</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a &ldquo;smaller reporting company&rdquo;
as defined in Exchange Act Rule&nbsp;12b-2. As a result, the Company is eligible to take advantage of certain reduced disclosure and other
requirements that are otherwise applicable to public companies including, but not limited to, not being subject to the auditor attestation
requirements of Section&nbsp;404(b)&nbsp;of the Sarbanes-Oxley Act of 2002. The Company will remain a smaller reporting company until
the last day of the fiscal year in which (1)&nbsp;the aggregate worldwide market value of its common stock held by non-affiliates equaled
or exceeded $250 million as of the prior June&nbsp;30th, or (2)&nbsp;its annual revenues equaled or exceeded $100 million during such
completed fiscal year and the aggregate worldwide market value of its common shares held by non-affiliates equaled or exceeded $700 million
as of the prior June&nbsp;30<SUP>th</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_002"></A>Use
of Names</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Registration Statement, unless the context
otherwise requires, the terms &#8220;<B>we</B>,&#8221; &#8220;<B>us</B>,&#8221; &#8220;<B>our</B>,&#8221; &#8220;<B>Company</B>&#8221;
or &#8220;<B>ProMIS</B>&#8221; refer to ProMIS Neurosciences Inc., together with its wholly-owned subsidiary, ProMIS Neurosciences (US)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_003"></A>Currency</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all references to
 &#8220;$&#8221; or &#8220;US$&#8221; in this Registration Statement refer to United States dollars, and all references to &#8220;C$&#8221;
refer to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-transform: uppercase; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_004"></A>Trademarks,
Trade Names and Service Marks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement contains certain trademarks
which are protected under applicable intellectual property laws and are the Company&#8217;s property. Solely for convenience, the Company&#8217;s
trademarks and trade names referred to in this Registration Statement may appear without the &reg; or &#8482; symbol, but such references
are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, its rights to
these trademarks and trade names.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_006"></A>Disclosure
Regarding Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement contains statements
that we believe are, or may be considered to be, &#8220;forward-looking statements.&#8221; Forward-looking statements are neither historical
facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future
of the business, future plans and strategies, operational results and other future conditions of the Company. All statements other than
statements of historical fact included in this Registration Statement regarding the prospects of our industry or our prospects, plans,
financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can
be identified by the use of forward-looking words such as &#8220;plans,&#8221; &#8220;expects&#8221; or &#8220;does not expect,&#8221;
 &#8220;is expected,&#8221; &#8220;look forward to,&#8221; &#8220;budget,&#8221; &#8220;scheduled,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221;
 &#8220;will continue,&#8221; &#8220;intends,&#8221; &#8220;the intent of,&#8221; &#8220;have the potential,&#8221; &#8220;anticipates,&#8221;
 &#8220;does not anticipate,&#8221; &#8220;believes,&#8221; &#8220;should,&#8221; &#8220;should not,&#8221; or variations of such words
and phrases that indicate that certain actions, events or results &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;might,&#8221;
or &#8220;will,&#8221; &#8220;be taken,&#8221; &#8220;occur,&#8221; or &#8220;be achieved,&#8221; or the negative of these terms or variations
of them or similar terms. Furthermore, forward-looking statements may be included in various filings that we make with the SEC or press
releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations
reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These
forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual
results to differ materially from those reflected in these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other forward-looking statements will not be achieved. We caution readers not to place undue reliance
on these statements as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives,
expectations, anticipations, estimates and intentions expressed in such forward-looking statements. Risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future
results, performance or achievements expressed or implied by such forward-looking information and statements include, but are not limited
to, the risks described under the heading &#8220;<I>Risk Factors Summary</I>&#8221; and in Item 1A&#8212;&#8220;<I>Risk Factors</I>&#8221;
in this </FONT>Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Readers
are cautioned not to place undue reliance on any forward-looking statements contained in this </FONT>Registration Statement, which
reflect management&#8217;s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or
publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional
disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or
persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fulla_007"></A><FONT STYLE="text-transform: uppercase"><B>Risk
Factors Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves risks. You
should carefully consider the risks described in Item 1A&#8212;&#8220;<I>Risk Factors</I>&#8221; beginning on page&nbsp;33 before
deciding to invest in our securities. If any of these risks actually occurs, our business, financial condition and results of operations
would likely be materially adversely affected. In such case, the trading price of our securities would likely decline, and you may lose
all or part of your investment. Set forth below is a summary of some of the principal risks we face:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the COVID-19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our business and operations may be adversely affected by the evolving and ongoing COVID-19 global pandemic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The ongoing COVID-19 pandemic may negatively impact the availability of scientific staff, physicians and
other healthcare professionals, which may negatively impact our business, financial condition and results of operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Development of Our Product
Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our product candidates are still in the early stages of development and there is significant uncertainty
that any such products will actually be developed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We have concentrated a portion of our research and development efforts on the treatment of AD, a field
that has to date seen very limited success in drug development.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our business is heavily dependent on the successful development, regulatory approval and commercialization
of PMN310 and any future product candidates that we may develop or acquire, including PMN442 and PMN267.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our approach to the potential treatment of AD is based on a novel therapeutic approach, which exposes
us to unforeseen risks.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may not successfully expand our pipeline of product candidates, including by pursuing additional indications
for PMN310 or by in-licensing or acquiring additional product candidates for other diseases.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Nonclinical and clinical drug development involves a lengthy, expensive and uncertain process. The results
of nonclinical studies and early clinical trials are not always predictive of future results. PMN310 or any other product candidate that
we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Clinical failure can occur at any stage of clinical development and we have never completed a clinical
trial or submitted NDA, BLA, or marketing authorization application, or MAA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may incur additional costs or experience delays in completing, or ultimately be unable to complete,
the development and commercialization of our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Adverse side effects, properties or other safety risks associated with PMN310, PMN442, PMN267 or any future
product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon further development,
limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may experience delays or difficulties in the enrollment and retention of patients in clinical trials,
which could delay or prevent our receipt of necessary regulatory approvals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Interim, &#8220;top-line&#8221; and preliminary results from our clinical trials that we announce or publish
from time to time may change as more data become available and is subject to audit and verification procedures that could result in material
changes in the final data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We cannot be certain that PMN310, PMN442, PMN267 or any of our future product candidates will receive
regulatory approval, and without regulatory approval we will not be able to market our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our lead product candidate, PMN310, is being developed for the treatment of AD, a disease that has seen
limited success in drug development.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may in the future conduct clinical trials for our product candidates outside the United States, and
the FDA, EMA and other foreign regulatory authorities may not accept data from such trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may not be successful in our efforts to build a pipeline of additional product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization
of our products may be delayed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may develop PMN310, PMN442, PMN267 and future product candidates for use in combination with other
therapies, which could expose us to additional regulatory risks.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Changes in methods of product candidate manufacturing or formulation may result in additional costs or
delay.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Commercialization of Our
Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Successful commercialization of our products, if approved, will depend on a number of factors and we cannot
guarantee that we will be able to successfully commercialize our products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The market opportunities for PMN310, PMN442, PMN267, and future product candidates, if approved, may be
smaller than we anticipate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Even if our current or future product candidates obtain regulatory approval, they may fail to achieve
the broad degree of adoption and use by physicians, patients, hospitals, healthcare payors and others in the medical community necessary
for commercial success.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our product candidates have never been manufactured on a commercial scale, and there are risks associated
with scaling up manufacturing to commercial scale. In particular, we will need to develop a larger scale manufacturing process that is
more efficient and cost-effective to commercialize our potential products, which may not be successful.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The successful commercialization of our product candidates will depend in part on the extent to which
governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain
or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those drugs
and decrease our ability to generate revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may
not be able to market and sell our product candidates effectively in the United States and foreign jurisdictions, if approved, or generate
product revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Position and
Capital Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We will require additional financing to achieve our goals, and a failure to obtain this necessary capital
when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization
efforts or other operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We have no product candidates approved for commercial sale, we have never generated any revenue from sales
and we may never be profitable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Dependence on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We will rely on third parties to supply components, research, develop, test, and manufacture our product
candidates and market, if approved. The loss of any of these third party relationships or the failure of any of them to meet their obligations
to us could affect our ability to develop and obtain approval of our product candidates in a timely manner.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We intend to rely on contract research organizations, or CROs, and other third parties to conduct, supervise
and monitor a significant portion of our research and nonclinical testing and clinical trials for our product candidates, and if those
third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily,
we may not be able to obtain regulatory approval or commercialize product candidates, or such approval or commercialization may be delayed,
and our business may be substantially harmed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If any of our third-party manufacturers encounter difficulties in production of PMN310, PMN442, PMN267
or any future product candidate we develop, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of
our product candidates for clinical trials or, if approved, for commercial sale could be delayed or stopped, or we may be unable to maintain
a commercially viable cost structure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We will likely seek collaborations with third parties for the development or commercialization of our
product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of those product
candidates, including PMN310, PMN442, and PMN267.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates,
and other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad,
our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our
product candidates, and other proprietary technologies if approved, may be adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we do not obtain patent term extension for our product candidates our business may be materially harmed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we fail to comply with our obligations in the agreements under which we license intellectual property
rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license
rights that are important to our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or
eliminated for non-compliance with these requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability
to protect our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may not be able to protect our intellectual property rights throughout the world.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual
property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may not be successful in obtaining or maintaining necessary rights to product components and processes
for our development pipeline through in-licenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery
and development efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or
our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which
could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged
in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual
property rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual
property rights against third parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position
would be harmed. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor
will discover them or that our trade secrets will be misappropriated or disclosed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Any collaboration arrangements that we may enter into in the future may not be successful, which could
adversely affect our ability to develop and commercialize our future products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Intellectual property discovered through government funded programs may be subject to federal regulations
such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such
regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Legal and Regulatory Compliance
Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD>
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
<TD STYLE="text-align: justify">Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Even if we obtain regulatory approval for PMN310, PMN442, PMN267 or any future product candidates, they
will remain subject to ongoing regulatory oversight, which may result in significant additional expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Failure to comply with health and data protection laws and regulations could lead to government enforcement
actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and
business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Even if we obtain FDA or EMA approval any of our product candidates in the United States or European Union,
we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their
full market potential.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Healthcare legislative or regulatory reform measures may have a negative impact on our business and results
of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly
harm our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our insurance policies are expensive and only protect us from some business risks, which will leave us
exposed to significant uninsured liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_1"></A>Risks Related to Our
Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We face significant competition in an environment of rapid technological and scientific change, and there
is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective
than ours.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Ownership of Our Common Shares
and Our Status as a U.S. Public Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Investment in the Company&#8217;s Common Shares is speculative, involves risk, and there is no guarantee
of a return.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If equity research analysts do not publish research or reports, or publish unfavorable research or reports,
about us, our business or our market, our share price and trading volume could decline.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Concentration of ownership of our Common Shares among our existing executive officers, directors and principal
shareholders may prevent new investors from influencing significant corporate decisions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Anti-takeover provisions in our governing documents and under Canadian Law could prevent or delay transactions
that shareholders may favor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S.
corporation and these differences may make our Common Shares less attractive to investors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we fail to attract and retain senior management and key scientific personnel, our business may be materially
and adversely affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be
required to limit commercialization of our current or future product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We may explore strategic collaborations that may never materialize or may fail.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and, as
a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies,
our Common Shares may be less attractive to investors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We have never paid dividends on our capital shares and we do not intend to pay dividends for the foreseeable
future. Consequently, any gains from an investment in our Common Shares will likely depend on whether the price of our Common Shares increases.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We are subject to the continued listing criteria of the TSX and our failure to satisfy these criteria
may result in a delisting of our Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We cannot assure you that our Common Shares will become listed on Nasdaq and, if listed, our failure to meet Nasdaq&rsquo;s continued
listing requirements could result in a delisting of our Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our internal controls over financial reporting may not be effective, which could have a material and adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The elimination of monetary liability against our directors, officers, and employees under British Columbia
law and the existence of indemnification rights for our obligations to our directors, officers, and employees may result in substantial
expenditures by us and may discourage lawsuits against our directors, officers, and employees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">There may be difficulty in enforcing judgments and effecting service of process on directors and officers
that are not citizens of the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If we are characterized as a passive foreign investment company, U.S. Holders may be subject to adverse
U.S. federal income tax consequences.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">We will incur increased costs and demands upon management as a result of being a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Comprehensive tax reform legislation could adversely affect our business and financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency
in our cybersecurity or a natural disaster.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Disruptions at the FDA, the Commission and other government agencies caused by funding shortages or global
health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from
being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on
which the operation of our business may rely, which could negatively impact our business.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.15in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Unfavorable global economic conditions could adversely affect our business, financial condition or results
of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_2"></A>Glossary
of Key Terms and Definitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Registration Statement, unless otherwise
indicated or the context otherwise requires, the following terms shall have the indicated meanings. Words importing the singular include
the plural and vice versa and words importing any gender include all genders. A reference to an agreement means the agreement as it may
be amended, supplemented or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>A&#946;</B>&#8221; means Amyloid beta,
an extracellular brain protein whose toxic misfolded form is implicated as a root cause of AD;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>A&#946;O</B>&#8221; means Amyloid beta
oligomers; misfolded A&#946;O are widely considered a root cause of AD;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>AChE</B>&#8221; means Acetylcholinesterase;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>AD</B>&#8221; means Alzheimer&#8217;s
disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>aducanumab</B>&#8221; means Biogen&#8217;s
monoclonal antibody targeting amyloid beta;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>ALS</B>&#8221; means amyotrophic lateral
sclerosis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>a-syn</B>&#8221; means alpha-synuclein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Biogen</B>&#8221; means Biogen Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Board</B>&#8221; means the board of
directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CBCA</B>&#8221; means the <I>Canada
Business Corporations Act</I>, R.S.C. 1985, c. C-44, and the regulations made under that enactment, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CBD</B>&#8221; means corticobasal degeneration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CEO</B>&#8221; means Chief Executive
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CFO</B>&#8221; means Chief Financial
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CMS</B>&#8221; means Centers for Medicare
and Medicaid Services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Collective Coordinates</B>&#8221; means
an algorithmic method which employs protein molecular dynamics to predict novel therapeutic targets in AD and other neurodegenerative
diseases; and is complementary to ProMIS&#8217; predictive algorithm technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Common Shares</B>&#8221; means the common
shares in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Company</B>&#8221; or &#8220;<B>ProMIS</B>&#8221;
means ProMIS Neurosciences Inc., incorporated pursuant to the CBCA on January&nbsp;23, 2004 under number 4203801;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CPT</B>&#8221; means the Current Procedural
Terminology code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>CSO</B>&#8221; means Chief Scientific
Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DLB</B>&#8221; means Dementia with Lewy
bodies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DSEs</B>&#8221; means disease specific
epitopes on the molecular surface of misfolded proteins;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DSU</B>&#8221; refers to a deferred
share unit awarded under the DSU Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>DSU Plan</B>&#8221; means the deferred
share unit plan for non-employee directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>FDA</B>&#8221; means the U.S. Food and
Drug Administration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>FTLD</B>&#8221; means frontotemporal
lobar degeneration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>GMP</B>&#8221; means Good Manufacturing
Practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>HD</B>&#8221; means Huntington&#8217;s
disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>LATE</B>&#8221; means limbic-predominant
age-related TDP-43 encephalopathy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>LBD</B>&#8221; means Lewy body dementia,
a severe form of Parkinson&#8217;s disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>mAb</B>&#8221; means monoclonal antibody;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>management</B>&#8221; means all members
of the Board as well as the senior executive officers of ProMIS;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>MCI</B>&#8221; means mild cognitive
impairment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>MSA</B>&#8221; means Multiple System
Atrophy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>Nasdaq</B>&#8221;
means the </FONT>Nasdaq Stock Market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Options</B>&#8221; means options granted
under the terms of the Company&#8217;s Stock Option Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PD</B>&#8221; means Parkinson&#8217;s
disease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PMN310</B>&#8221; means a mAb targeting
toxic prion-like forms of A&#946;O, and designated as the Company&#8217;s first lead product candidate for development in AD;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PMN442</B>&#8221; means a mAb targeting
toxic prion-like forms of a-syn and designated as the Company&#8217;s second lead product candidate for development in MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PMN267</B>&#8221; means a mAb targeting
toxic prion-like forms of TDP-43 and designated as the Company&#8217;s third lead product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Preferred Shares</B>&#8221; means preferred
shares in the authorized capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>ProMIS USA</B>&#8221; means ProMIS Neurosciences
(US),&nbsp;Inc., a subsidiary corporation of ProMIS, which subsidiary was incorporated on January&nbsp;14, 2016 pursuant to the General
Corporation Law of the State of Delaware;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>PSP</B>&#8221; means progressive supranuclear
palsy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Stock Option Plan</B>&#8221; means the
Company&#8217;s incentive stock option plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>SOD1</B>&#8221; means superoxide dismustase
1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>TDP-43</B>&#8221; means TAR-DNA binding
protein 43;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>TSX</B>&#8221; means the Toronto Stock
Exchange and any successor thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>UBC</B>&#8221; means the University
of British Columbia, Vancouver, British Columbia, Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>USPTO</B>&#8221; means the U.S. Patent
Trademark Office; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>U.S.</B>&#8221; and &#8220;<B>USA</B>&#8221;
means the United States of America, its territories, any State of the United States and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_3"></A>ITEM
1. BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_4"></A>Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Name, Address and Incorporation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS Neurosciences Inc. was incorporated on
January&nbsp;23, 2004 under the name 4203801 Canada Inc. pursuant to the <I>Canada Business Corporations Act</I>. The Company changed
its name to Amorfix Life Sciences Ltd. on August&nbsp;24, 2004 and to ProMIS Neurosciences Inc. effective July&nbsp;8, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &#8220;<I>Description of the Registrant&#8217;s
Securities to be Registered</I>&#8221; for more information about our Common Shares. The Company&#8217;s Common Shares are listed on the
TSX under the symbol, &#8220;PMN.&#8221; The Company&#8217;s Common Shares also trade on the OTCQB Venture Market in the United States
under the symbol, &#8220;ARFXF.&#8221; The Company has also submitted an application for listing of its Common Shares on the Nasdaq under the symbol &ldquo;PMN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office is located at 1920 Yonge Street,
Suite&nbsp;200, Toronto, Ontario, Canada M4S 3E2 and our registered and records office is located at 1055 West Georgia Street, Vancouver,
British Columbia, Canada V6E 4N7. Our telephone number is (416) 847-6898 and our website address is www.promisneurosciences.com. The information
provided on our website is not part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intercorporate Relationships</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS has one wholly-owned U.S. subsidiary, ProMIS
Neurosciences (US) Inc. (&#8220;<B>ProMIS USA</B>&#8221;), which was incorporated in Delaware on January&nbsp;14, 2016. ProMIS USA has
had no activities to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="b_5"></A>Business of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS is applying its patented technology platform
to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases and
other mis-folded protein diseases, which may include AD, MSA, ALS, PD, LBD, FTLD, PSP, CBD, and schizophrenia. These diseases share a
common biologic cause &#8211; misfolded versions of proteins, that otherwise perform a normal function. The misfolded versions kill neurons
and produce disease. ProMIS&#8217; technology platform is an example of the advances in drug discovery enabled by computational power,
<I>in silico</I> discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting
the toxic misfolded proteins with therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ProMIS&#8217; Platform Technology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS&#8217; scientific foundation is centered
on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Genetic and experimental
research in the neuroscience community has demonstrated that propagating, neurotoxic, misfolded proteins (also referred to as prion-like
particles or toxic soluble oligomers) are fundamental drivers of multiple neurodegenerative diseases, including AD, MSA, and ALS. ProMIS&#8217;
platform technology allows for the identification of conformational epitopes that become exposed on toxic, misfolded forms of a given
protein but are not present on the properly folded form of the same protein. Such DSEs can then be used to
generate therapeutic antibody candidates that selectively target toxic forms of the protein without interfering with essential functions
of the healthy protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company first licensed the exclusive
rights to the ProMIS<SUP>TM</SUP> target identification technology from UBC to predict novel DSEs on the molecular surface of
misfolded proteins. ProMIS<SUP>TM</SUP> is an &#8220;in silico&#8221; rational selection approach that can be applied to any protein
where the normal folding structure is at least partially known. The Company also acquired a worldwide license from UBC to
 &#8220;Collective Coordinates&#8221;, a method to predict novel therapeutic targets in AD and other neurodegenerative diseases.
Developed principally by the Company&#8217;s former Chief Physics Officer, Steven Plotkin, PhD, the Collective Coordinates method is
a computational algorithm employing protein molecular dynamics simulations, and is complementary to the ProMIS<SUP>TM</SUP>
predictive algorithm technology. The addition of Collective Coordinates to its computational discovery platform gave ProMIS a
unique, proprietary and robust engine to predict DSEs on the molecular surface of misfolded proteins. The amino acid sequence of the
toxic, misfolded form and the healthy, properly folded form of a target protein are exactly the same but the two differ in their
shape, or conformation. The ProMIS platform offers the ability to identify targets unique to the toxic, misfolded form. These
conformational epitopes are used to immunize mice or rabbits to generate selective mAbs that can attack the
disease-causing form of the protein without interfering with the healthy form of the same protein. The mAbs raised
in animals are humanized (the critical binding regions are inserted into a human antibody framework) for potential use in
patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Pipeline</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are developing a pipeline of antibodies aimed
at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential
functions of the same properly folded proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg11.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ADDITIONAL DEVELOPMENT PROGRAMS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg12.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ProMIS&rsquo; Objectives for 2022</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s priorities for 2022 fall into the following four
key areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Continue to progress PMN310 antibody lead program for AD</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Continue to progress PMN442 antibody for MSA</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: left">Continue to progress PMN267 antibody for ALS</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Use of the ProMIS proprietary platform to support portfolio expansion</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRODUCT CANDIDATES</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development of a Therapy for the Treatment
of Alzheimer&#8217;s Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AD Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AD, a progressive neurodegenerative disease, is
the most common type of dementia, accounting for approximately 60-80% of all dementia cases. Early symptoms of AD include recent memory
loss, as well as apathy and depression. As the disease progresses inexorably, language deterioration, impaired ability to mentally manipulate
visual information, poor judgment, confusion, restlessness, and profound mood swings develop. Eventually AD destroys cognition, personality,
and the ability to function. The early symptoms of AD, especially at the inaugural stage of MCI, are often missed because they are frequently
and mistakenly taken for &#8216;natural signs of ageing&#8217;. In 2020 current reports conclude that 50% of primary care physicians believe
the medical profession is not prepared to meet the expected increase in demands the projected rise in AD and dementia cases will create.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2020, it was estimated there were 5.8 million
Americans living with AD and that number is projected to rise to 14 million by 2050.<SUP> </SUP> In the United States, one in three
seniors dies of AD or another dementia, which kills more people than breast cancer and prostate cancer combined. AD is the 6th leading
cause of death in the United States, according to the Alzheimer&#8217;s Association. In 2020, AD and other dementias cost the United States
$305 billion and those costs are projected to rise to $1.1 trillion by 2050. It is reported that 16 million Americans are unpaid caregivers,
who in 2020 provided 18.6 billion hours of support, valued at $244 billion, to people with AD and other dementias.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Alzheimer&#8217;s Association,
AD is the sixth leading cause of death in the United States. Among people aged 70 with AD, 61% die before age 80, or twice the death rate
(30%) of those without AD. Deaths from AD, as recorded on death certificates, have increased 146% over the last two decades. In the United
States and Canada combined, an estimated 6.3 million people have AD currently, 9.5 million have MCI, and 42.3 million have evidence of
potential pathology with no symptoms. In the United States, AD costs the health system $305 billion, and that number is projected to grow
to $1.1 trillion by 2050 if there are no advances in treatment and prevention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a growing body of consistent
scientific evidence that the root cause starts with misfolded, toxic oligomers of A&#946;, an otherwise normal protein in the brain.
These misfolded toxic oligomers cause another normal brain protein (tau) to misfold as well and produce toxic oligomers. Toxic
misfolded A&#946; and tau, directly cause the death of neurons and, consequently, the loss of synaptic connections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, a major challenge in AD has been
diagnosis. Twenty years ago, diagnosis of AD could only be confirmed by autopsy. Two years ago, consensus guidelines were developed that
established new diagnostic criteria &#8211; A/T/N. The methods used were based on sophisticated approaches to brain imaging: amyloid
positron emission tomography (&#8220;<B>PET</B>&#8221;) scans measuring amyloid plaque as a proxy for pathology, tau PET scans measuring
tau tangles as a proxy for pathology, and cortical magnetic resonance imaging (&#8220;<B>MR</B>I&#8221;) measuring the thickness of the
frontal cortex of the brain as a measure of neurodegeneration. Each of these tests costs thousands of dollars, affordable perhaps to
diagnose patients for a clinical trial, but not practical for screening millions of people who might be at risk or have pre-symptomatic
AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are now blood-based biomarkers (diagnostic
assays) that can provide information that correlates with expensive A/T/N imaging so that it is possible to detect and monitor AD neuropathology
in blood. Two measures have been scientifically validated: NfL, which measures the rate of neuronal loss, and phosphorylated tau which
measures the level of toxic, misfolded tau. Blood levels of these have been shown to correlate with brain imaging measures, as well as
disease status or progression. These advances have implications for ProMIS&#8217; strategy. Better diagnostics can facilitate more efficient
clinical trials, both in terms of identifying potential subjects for the trial and also detecting a potential treatment effect in early,
small trials. Secondly, the ability to diagnose disease prior to symptoms raises the possibility of preventive treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the World Alzheimer Report 2015,
the current dementia market comprises two product categories, namely, AChE inhibitors and N-methyl-D-aspartate receptor antagonists. AChE
inhibitors dominate the market. The overall market is dominated by four leading brands &#8211; Aricept, Namenda, Exelon and Ebixa. Aricept,
whose active ingredient is an AChE inhibitor, accounted for over 40% of the total market in 2019. The U.S. was the largest market for
AD drugs in 2019, accounting for approximately 35% of total worldwide AD pharmaceutical sales in that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PMN310</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS&#8217; lead therapeutic program is PMN310,
a mAb designed to treat AD by selectively targeting the toxic misfolded form of A&#946;. PMN310 was designed to be more
selective for the toxic oligomer of amyloid than aducanumab, Biogen Inc.&#8217;s anti-A&#946; antibody, and BAN 2401, currently being
co-developed by Eisai Co. and Biogen. There are three forms of amyloid protein in the brain &#8211; monomers, oligomers, and plaque. Only
certain misfolded oligomers are toxic, leading to the neuronal death and synaptic loss that causes AD-related cognitive decline. Monomers
are simple strings of amino acids that play a role in normal brain health. Plaque is insoluble &#8211; solid deposits of amyloid (similar
to plaque in arteries) that can build up over time. Both aducanumab and BAN2401 bind oligomers, but also plaque. This off-target binding
of plaque frequently leads to a side effect, ARIA-E, potentially limits the benefit of aducanumab and BAN2401 by both limiting the highest
dose that can be safely administered and by &#8220;wasting&#8221; a substantial portion of the administered antibody which binds plaque,
reducing what is available to neutralize the toxic oligomers that cause disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In contrast to aducanumab (which has accelerated
approval from the FDA), BAN2401 and donanemab, which have shown positive clinical trial outcomes, all other A&#946;-targeted therapies
to date have failed in clinical trials. The results of numerous clinical trials with A&#946;-related therapies are in line with the latest
scientific understanding that the toxic oligomer is the pathogen and needs to be the target for therapy. PMN310 is selective for the toxic
oligomer form of amyloid and, as a result, we believe it may possess the features necessary to potentially be &#8220;best in class&#8221;
if approved, with a possibly more favorable clinical safety and efficacy profile than aducanumab, donanemab, or BAN2401.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
from genetic and experimental studies supports a causative role for A</FONT><FONT STYLE="font-family: Symbol">b</FONT> in the pathogenesis
of AD. Views on the nature of the A<FONT STYLE="font-family: Symbol">b</FONT> species responsible for progressive neurodegeneration have
evolved considerably along with a greater understanding of AD disease biology. While the presence of A<FONT STYLE="font-family: Symbol">b
</FONT>plaque is a hallmark of AD, it is now recognized that the synaptic loss and neurodegenerative spread of AD is primarily mediated
by soluble oligomers of misfolded A<FONT STYLE="font-family: Symbol">b</FONT> rather than plaque. It is believed that a subset of misfolded
A&#946;O can propagate in a prion-like manner and form a seed or template capable of converting surrounding A<FONT STYLE="font-family: Symbol">b
</FONT>into the toxic oligomer form. There is also evidence that such misfolded &#8220;A<FONT STYLE="font-family: Symbol">b</FONT> prions&#8221;
can catalyze the misfolding of tau, another protein involved in the pathogenesis of AD. Targeting of A&#946;O with selective antibodies,
therefore, represents a strategy to inhibit progression of the neurodegenerative A<FONT STYLE="font-family: Symbol">b</FONT>-tau cascade.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
premise is supported by recent results of clinical trials, conducted by third parties, with therapeutic mAbs targeting
</FONT>A<FONT STYLE="font-family: Symbol">b</FONT>. Antibodies that bind A&#946; monomers (e.g., bapineuzumab, solanezumab, crenezumab)
showed a lack of efficacy suggesting that high selectivity for low abundance toxic A&#946;O is desirable to prevent mAbs from being consumed
by unproductive binding to non-pathogenic, abundant monomers (target distraction). Other antibodies with reduced binding to monomers produced
more promising results, but their binding to insoluble deposits of A&#946; in the vasculature and plaque (e.g., aducanumab, BAN2401, donanemab),
was associated with the dose-limiting adverse events of ARIA-E (brain edema) and ARIA-H (microhemorrhages). We believe that a selective,
oligomer-specific antibody that does not bind monomers or plaque would circumvent these issues and potentially provide an improved product
profile. We believe ProMIS&#8217; clinical candidate, PMN310, displays these desired characteristics (see below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using
the ProMIS platform, six different conformational epitopes were identified as potential targets exposed on toxic </FONT>A&#946;O but not
A&#946; monomers or plaque. MAbs raised against these epitopes displayed selectivity for A&#946; oligomers vs monomers
and inhibited A&#946;O toxicity and propagation <I>in vitro</I>. <FONT STYLE="font-size: 10pt">I</FONT>n January&nbsp;2017, the Company
designated the PMN310 antibody (binds conformational epitope 301) as its first lead candidate for development in AD. In preclinical studies,
PMN310 displayed the desired A&#946;O-selective binding profile with little or no binding to A&#946; monomers, plaque or vascular deposits.
<I>In vitro</I>, PMN310 inhibited A&#946;O propagation and toxicity (Fig. 1). PMN310 prevented A&#946;O-induced loss of memory formation
in mice (Fig. 2) and reduced biomarkers of synaptic loss and inflammation in their brain. In a study using cadaveric brain tissue from
individuals with AD, PMN310 also showed binding to brain fractions indicating that PMN310 can potentially recognize toxic A&#946;O species
present in the brain. Systemic administration of PMN310 in mice resulted in brain exposure and kinetics comparable to those of other therapeutic
mAbs suggesting that PMN310 is similarly able to cross the blood-brain barrier to reach its target. The Company believes that the greater
selectivity of PMN310 for A&#946;O may result in greater neutralization of this disease-causing species (no target distraction) and may
potentially be better tolerated (allowing for higher doses) due to a reduced risk of the ARIA adverse events that have been reported associated
with plaque-binding antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 43%">Figure 1A</TD>
  <TD STYLE="text-align: justify; width: 57%">1B</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="tm2135630d1_drsimg13.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 1. Inhibition of aggregation propagation
<I>in vitro</I> (thioflavin-based assay) (A)&nbsp;and inhibition of A&#946;O toxicity for primary mouse neurons <I>in vitro</I> (B).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg14.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 2. Administration of PMN310 to mice prevented
the loss of short-term memory formation caused by toxic A&#946;O.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company successfully humanized PMN310 in
a human IgG1 framework. Producer cell line development is progressing using Selexis' proprietary and high performance SURE<I>technology
</I>Platform. Cell banks and drug product candidate will be generated in partnership with KBI. An Investigational New Drug Application
(&#8220;<B>IND</B>&#8221;) for Phase 1 testing of PMN310 is planned for 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development of a Therapy for the Treatment
of MSA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Multiple System Atrophy Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MSA is a rare neurodegenerative disease with an
estimated prevalence of 3.4-4.9 cases per 100,000 population. MSA is characterized by rapidly progressive autonomic failure and motor
symptoms with predominant parkinsonian features (MSA-P) or dominant cerebellar features (MSA-C). There is no effective treatment and the
mean survival from the onset of symptoms is 6-10 years. Histologically, the disease is characterized by a-syn aggregates in the cytoplasm
of oligodendrocytes and, to a lesser extent, in neurons and other glial cells. The causative role of a-syn aggregates in MSA pathogenesis
is supported by experimental evidence showing that a-syn aggregates from MSA brain homogenates propagate in a prion-like manner <I>in
vitro</I> and <I>in vivo</I>, and cause MSA-like neurodegeneration in mice. The characteristics of MSA, although devastating for the patients,
present several advantages for clinical testing: disease progression is rapid, potentially allowing for earlier detection of an efficacy
signal; high levels of NfL in serum represent a potential biomarker for inhibition of neuronal damage; and no placebo effects have been
observed in clinical trials to date. Even though MSA is a rare disease, recruitment is facilitated by the unmet need and existence of
a global MSA Registry (GLOMAR), along with supporting organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PMN442</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research discussed in the literature indicates
that misfolded toxic a-syn is a primary driver of disease. Multiple studies indicate that pathogenic aggregates of a-syn can propagate
from cell to cell in a prion-like manner causing progressive neuronal damage and disease symptoms. In order to target pathogenic a-syn
without interfering with normal a-syn, the ProMIS platform was used to generate several mAbs against predicted conformational
epitopes of misfolded, toxic a-syn. These mAbs showed the ability to selectively bind the pathogenic forms of a-syn (toxic oligomers and
small soluble fibrils) but not the normal forms of a-syn (monomers, physiologic tetramers) that play important functional roles in the
brain (Fig. 3). <I>In vitro</I> studies showed that the mAbs were able to protect rat dopaminergic neurons (neurons that are destroyed
in PD) against toxic a-syn oligomers (Fig. 4). In separate assays, the mAbs also neutralized the seeding activity of a-syn soluble fibrils
(Fig. 5) which is involved in the cell to cell propagation of disease. Importantly, the mAbs recognize toxic species of a-syn present
in brain homogenates from patients with synucleinopathies (Fig. 6). Taken together, the results support the potential for using these
antibodies to selectively target and protect against a-syn pathogenic species in patients with synucleinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg15.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
3. Selectivity of mAbs for pathogenic species of a-syn. The binding response of a representative mAb to various concentrations of a</FONT>-syn
monomers, toxic oligomers and soluble fibrils (sonicated PFFs) measured in a Millipore immunoassay. Mean <U>+</U> SD of triplicates shown
with the calculated lower limit of quantitation (LLOQ) for each species.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg16.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 4. Protection against neurotoxicity. mAb
inhibition of oligomer toxicity for dopaminergic neurons. Cultures of primary rat dopaminergic neurons were exposed to toxic a-syn oligomers
with or without mAbs. Survival is expressed as the percentage of viable neurons compared to a control culture with vehicle only (CTL).
Results shown are the mean <U>+</U> SEM of 6 replicate cultures. BDNF was used as a positive control. # p = 0.0004 vs. CTL, *p <U>&lt;</U>
0.002 vs. a-synO, **p <U>&lt;</U> 0.003 vs. a-synO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_drsimg1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 5. Inhibition of seeding activity. mAb inhibition
of the recruitment of endogenous rat a-syn into phosphorylated aggregates. Cultures of primary rat hippocampal neurons were exposed to
soluble human a-syn preformed fibrils (PFF) with or without mAbs. CTL = neurons incubated with vehicle alone. Results are expressed as
a percentage of the phosphorylated rat a-syn staining area with PFF alone and show the mean <U>+</U> SEM of 6 replicate cultures. *p&lt;0.02
vs PFF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drsimg2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
6. Binding to native pathogenic a-syn species in patient brain extract. The binding response of immobilized mAbs to a</FONT>-syn in brain
extract from DLB (A)&nbsp;and MSA (B)&nbsp;patients was measured by SPR. A pan a-syn reactive antibody and mouse IgG1 (mIgG1) were used
as controls. Results shown are the mean <U>+</U> SEM of two (A)&nbsp;or four (B)&nbsp;independent studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Using the ProMIS platform, several
conformational epitopes were identified as likely to become exposed on misfolded, pathogenic forms of a-syn (toxic oligomers and
soluble seeding fibrils). MAbs were raised against these epitopes and were tested for the desired binding profile
and ability to protect neurons against toxic a-syn species <I>in vitro</I>. Multiple mAbs were screened and PMN442 emerged as the
lead candidate for this program with the desired characteristics. PMN442 showed robust binding to a-syn oligomers and seeding
fibrils, with negligible binding to a-syn monomers and physiologic tetramers which are required for normal neuronal function. PMN442
also reacted with native toxic a-syn present in brain homogenates from individuals with MSA and DLB. In addition, PMN442 did not
stain dense deposits of a-syn in Lewy bodies and Lewy dendrites in brain sections from diseased individuals. Although characteristic
of disease, Lewy bodies/Lewy dendrites are not believed to be a major driver of toxicity and can actually act as a sink, diverting
antibodies away from the pathogenic species (oligomers and seeding fibrils).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In activity assays, PMN442 protected rat dopaminergic
neurons against killing by a-syn toxic oligomers. PMN442 also inhibited the processes involved in the cell-to-cell propagation of a-syn
aggregates: it reduced the uptake of human a-syn seeding fibrils by neurons and the subsequent formation of intracellular aggregates,
as well as the recruitment of endogenous normal a-syn into those aggregates. These results support the potential of PMN442 to selectively
target and protect against a-syn pathogenic species in patients with MSA and other synucleinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development of a Therapy for the Treatment
of ALS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ALS Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ALS, commonly known as Lou Gehrig&#8217;s Disease,
is a progressive neurodegenerative disease that causes muscle weakness, paralysis and, ultimately, respiratory failure. ALS attacks randomly,
occurs throughout the world with no racial, ethnic or socioeconomic boundaries. Most people with ALS only live two to five years after
their first signs of disease. It is estimated there are currently 30,000 people in North America and 450,000 people worldwide, suffering
from ALS, with approximately 5,000 new cases arising in North America annually. Patients with ALS present symptoms such as progressive
weakness, muscle atrophy and spasticity. These neurodegenerative and neuromuscular symptoms arise due to the ultimate degeneration of
motor neurons in the spinal cord, the brain stem and in the brain cortex. Incurable and usually fatal within five years, ALS gradually
robs a patient of the ability to walk, talk and breathe. Currently, there is no confirmatory test for ALS and many people go undiagnosed
at early phases of the disease. Approximately two-thirds of those afflicted by ALS are currently undergoing some form of symptomatic treatment.
There are no therapies approved that halt or significantly slow progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The biological mechanisms that cause ALS are only
partially understood. There are scientific research results indicating that toxic, misfolded forms of TDP-43 are believed to play an important
role in the development of ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PMN267</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Misfolded, aggregated TDP-43 forming inside neurons
has been implicated in the pathogenesis of ALS, FTLD and LATE through direct toxicity, loss of function of normal TDP-43, induction of
misfolding of other neuronal proteins, and prion-like, cell-to-cell propagation of disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Experimentally, misfolded aggregates of TDP-43
are toxic to neural cells, and the prion-like propagation of TDP-43 aggregates has been demonstrated in cell culture and animal models.
Importantly, misfolded TDP-43 has been found to induce the misfolding of other proteins into pathogenic aggregates (e.g., SOD1, nuclear
pore proteins and transport proteins, DISC1), such that targeting misfolded TDP-43 potentially represents an opportunity to not only neutralize
TDP-43 pathology but also interrupt this pathogenic interactome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Identification of epitopes present on misfolded
TDP-43 through the ProMIS discovery platform allowed for the generation of high affinity antibodies (Fig. 7) showing selective recognition
of misfolded cytoplasmic aggregates of TDP-43 with no detectable interaction with normal TDP-43 which is located in the nucleus and is
important for normal cell function (Fig. 8). The antibodies also recognized and stained pathogenic TDP-43 aggregates in spinal cord sections
from ALS patients and brain sections from FTLD patients (immunohistochemistry) indicating that they have the potential to target disease-causing
TDP-43 in these patients. <I>In vitro</I> data showed that such antibodies can inhibit the cell to cell transmission of misfolded TDP-43
in the extracellular space thereby offering the potential to inhibit spreading of pathology (Fig. 9).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drsimg3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 7. High affinity mAbs. In SPR studies, serial
dilutions of test mAbs were flowed over the target epitope immobilized on sensorchips to assess the binding kinetics and affinity. Binding
curves were fitted to a Langmuir 1:1 interaction model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_drsimg4.jpg" ALT="" STYLE="height: 183px; width: 581px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 8. Selective binding of mAb to misfolded,
cytoplasmic aggregates of TDP-43. Staining of HEK293 cells transfected with mutant TDP-43 shows cytoplasmic aggregates of misfolded TDP-43
(red). Staining of the same cells with a PMN mAb (green) shows co-localization with TDP-43 aggregates with no staining of endogenous,
normal TDP-43 in the nucleus (nuclei stained blue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drsimg5.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 9. Inhibition of cell-to-cell transmission
of misfolded TDP-43 by mAbs. Supernatant from HEK293 cells transfected with misfolding mutant TDP-43 was incubated with test antibodies
and added to na&iuml;ve recipient cells to assess transmission of misfolding TDP-43 (HA-tagged). Compared to a mouse IgG1 negative control
(mIgG1), several mAbs inhibited transmission to recipient cells as determined by a reduction in the density of the HA band on a Western
blot of recipient cell lysate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intrabody versions of the TDP-43 antibodies were
also generated. Intrabodies (from intracellular and antibody) are expressed from within the cell and were designed to target intracellular
aggregates of TDP-43. Testing indicated that intrabodies expressed inside HEK293 cells associated selectively with pathogenic aggregates
of TDP-43 in the cytoplasm (Fig. 10) and promoted degradation of the aggregates without affecting normal TDP-43 function or harming the
cells (Fig. 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drsimg6.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 10. Co-localization of intrabody with misfolded,
cytoplasmic aggregates of TDP-43. Staining of HEK293 cells co-transfected with mutant TDP-43 (green) and plasmid encoding a PMN intrabody
(red) shows co-localization of the two. There was no interaction of the intrabody with endogenous, normal TDP-43 in the nucleus (nuclei
stained blue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 11</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_drsimg8.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 11. Clearance of TDP-43 aggregates by intrabody.
Transfection of HEK293 cells with a ProMIS intrabody results in degradation of HA-tagged mutant TDP-43 (dNLS) aggregates as measured by
reduction in the density of the HA band on a Western blot of cell lysate compared to an empty vector (EV) control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These results support the potential for using
these mAbs to selectively target and protect against pathogenic TDP-43. We believe the antibodies could be used to interfere with the
cell to cell spread of misfolded aggregates of TDP-43 in the extracellular space while intrabody constructs delivered inside the cells
via gene therapy vectors could be used to degrade intracellular aggregates and prevent further propagation (concept illustrated in Fig.
12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drs3-12.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Using the ProMIS platform several epitopes were
identified as likely to become exposed on misfolded, pathogenic forms of TDP-43, but not on the properly folded, functional protein. MAbs were raised against these epitopes and tested for selective reactivity with misfolded TDP-43 aggregates and protective activity.
Screening of multiple mAbs yielded PMN267 as the lead candidate exhibiting the desired properties. PMN267 bound its target epitope with
high affinity in the 10E-11M range. In a cell system, PMN267 showed selective recognition of misfolded, cytoplasmic TDP-43 aggregates
and no detectable interaction with endogenous normal TDP-43 in the nucleus. Similarly, PMN267 did not react with TDP-43 in stress granules
which are important in protection against oxidative stress. PMN267 also showed binding to exosomes derived from the brains of deceased
FTLD individuals. <I>In vivo</I> studies are ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An intrabody version of PMN267 (single chain
antibody sequence encoded into a plasmid) expressed from within cells showed co-localization with cytoplasmic aggregates of TDP-43
and no detectable binding to normal, nuclear TDP-43. Expression of the intrabody promoted degradation of the misfolded TDP-43
aggregates. The Company believes that the observed selectivity of PMN267 for misfolded TDP-43 and avoidance of normal TDP-43 has the
potential to allow for inhibition of disease without compromising essential TDP-43 function. Intrabody development would involve
collaboration with a partner with gene therapy expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DEVELOPMENT PROGRAMS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expansion to Include Other Neurodegenerative
and Mis-folded Protein Diseases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ProMIS discovery platform is also being applied
to other toxic proteins that drive neurodegenerative and other mis-folded protein diseases including a-syn in PD and LBD, tau in AD, FTLD,
PSP, and CBD, RACK1 in ALS and HD, SOD1 in ALS and DISC1 in schizophrenia. Under disease conditions, misfolding
of these proteins leads to the formation of toxic aggregates inside brain cells that are capable of spreading damage by propagating from
cell-to-cell. Disease-associated conformational epitopes identified through ProMIS&#8217; computational platform can be used to potentially
generate therapeutic antibodies or potentially form the basis for the development of vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alpha-synuclein</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evidence from genomic analysis, cell culture,
and <I>in vivo</I> studies points to a-syn as a major driver of PD and other synucleinopathies. A large body of data suggests that soluble
aggregates (oligomers, soluble fibrils) are the most toxic form of a-syn and can spread pathology from neuron to neuron. In contrast,
a-syn monomers and physiological tetramers are non-toxic and are required for normal neuronal function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to develop a potential therapy with maximal
safety and efficacy, the ProMIS computational platform was used to identify epitopes that are selectively exposed on toxic misfolded species
of a-syn, in a conformation that distinguishes it from that of monomers, physiological tetramers and insoluble fibrils (Lewy body/Lewy
neurites). The analyses suggest that immunization with these conformational epitopes led to the generation of mAbs that
selectively bind the toxic forms of a-syn as determined by several methods (surface plasmon resonance, immunohistochemistry and dot blot
analysis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PD is a progressive neurodegenerative disorder
characterized by loss of dopaminergic neurons located in the midbrain and the presence of intraneuronal inclusions (Lewy bodies/Lewy neurites)
consisting mainly of aggregates of a-syn. Accumulation of insoluble a-syn fibrils in the brain is also observed in LBD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PD is the second most common neurodegenerative
disorder after AD. It is estimated there are over 10 million patients diagnosed worldwide and up to 10 million total subjects with PD,
including undiagnosed individuals. The prevalence of PD increases with age, affecting approximately 1.1% of the population over the age
of 60. Currently, the Parkinson&#8217;s Foundation Prevalence Project estimates 930,000 people in the United States live with PD, and
this number is expected to rise to 1.2 million by 2030. As global life expectancy increases, so will the burden of PD. It is estimated
that the global number of people with PD will grow by 88% between 2020 and 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Global Data estimates that drug sales for PD will,
according to the U.S. National Institute of Environmental Health Sciences, grow from 2020 to 2027 by approximately 11.3% to reach $4.76
billion across the seven largest markets by 2027. Over the seven year forecast period, the market is expected to grow driven by the launch
of late-stage pipeline products and growth of the PD population. North America dominates the PD market. Nearly 1 million people in the
United States are living with PD with the average age of onset being 60 and the prevalence of PD in the population increases from 1% at
age 60 (5 &#8211; 10% of whom had early onset from age 50) to 4% at age 80. It is predicted by the U.S. National Institute of Health that
by 2030, due to the aging population in the United States, approximately 1.2 million people will be suffering from PD. The Asia Pacific
market is also expected to record significant growth in this market, centered on China, Japan and India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Scientific studies indicate that toxic oligomers
and small soluble fibrils, derived from naturally occurring a-syn, are the root cause of disease development and progression in PD. Recent
findings suggest that physiological a-syn tetramers inhibit aggregation and must be preserved for normal a-syn homeostasis. Maximal therapeutic
efficacy is expected to require antibodies selective for the toxic forms of a-syn oligomers and/or small soluble fibrils, while avoiding
physiologic forms of a-syn. Selectivity for only the toxic forms of a-syn represents the essential feature of a successful antibody therapy,
for it is critical that treatment not hinder normal forms of a-syn that play an important functional role in the brain. Traditional methods
are unable to generate antibodies with adequate precision to selectively target these neurotoxic forms of a-syn. ProMIS is using its
proprietary technology platform for discovering and developing antibodies that can uniquely and precisely target these specific toxic
forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current treatments center on the management of
dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the PD market for the past 50 years. These
therapies provide initial relief of symptoms at a low annual cost of therapy, with Sinemet (carbidopa/levodopa, Merck Sharp&nbsp;&amp;
Dohme) and Madopar (benserazide/levodopa, Roche) being the two most popular branded drugs. However, dopamine replacement or dopamine agonist
(bromocriptine) therapies only provide temporary symptomatic relief, are associated with debilitating long-term side effects and do not
affect the underlying neurodegeneration and progression of disease related to toxic forms of a-syn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Tau</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propagation
of misfolded, pathogenic aggregates of tau has also been implicated in AD and other tauopathies such as PSP, CBD, and FTLD-tau. The ProMIS
platform was therefore used to identify epitopes and raise mAbs against pathogenic forms of tau (toxic oligomers and
small soluble fibrils). A set of mAbs has been generated that preferentially bind pathogenic tau aggregates as opposed to physiologic
tau monomers. </FONT>The Company believes that selectivity of antibodies for tau pathogenic species, as opposed to pan-tau reactivity
(binding to all forms of tau), is needed both in order to preserve normal tau function and to minimize the diversion of active antibody
from the target through unproductive binding to more abundant non-toxic forms of tau. In binding assays, the ProMIS mAbs recognized toxic
species of tau in brain homogenates from individuals with AD (Fig. 13) indicating that the mAbs can recognize toxic tau species present
in the brain. In activity assays, the mAbs were able to inhibit the seeding activity of AD brain homogenate resulting in decreased induction
of tau aggregation in a cell system. (Fig. 14). These results suggest that these mAbs may be useful in targeting pathogenic tau in AD
and potentially other tauopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, mAbs against additional epitopes are
being generated and screened. The next steps will entail selecting the best candidates for <I>in vivo</I> testing and eventual selection
of additional product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 13</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_drs3-13.jpg" ALT="" STYLE="height: 260px; width: 381px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
13. Binding to native pathogenic tau species in the brain extracts of individuals with AD.</FONT> The binding response of a representative
immobilized mAb to tau in brain extract from 3 different individuals with AD was measured by SPR. Mouse IgG1 (muIgG1) was used as a negative
control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drs3-16.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
14. Inhibition of seeding activity of AD brain homogenate.</FONT> Brain homogenate +/- mAbs was transduced into Biosensor cells with
Lipofectamine 200. FRET signal was measured 48 hours later by flow cytometry. Results are expressed as Normalized Integrated FRET density
defined as the percent of FRET positive cells multiplied by the Median Fluorescence Intensity of those FRET positive cells and normalized
to cells treated with IgG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The immediate goal for the ProMIS extended therapeutic
portfolio is to achieve further scientific characterization and validation of one or more of these programs. Based on results of this
evaluation the most promising program or programs will be advanced in development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>SOD1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Misfolded SOD1 is abundant in both familial
(FALS) and sporadic (SALS) forms of ALS but is not found in samples from normal controls or patients with other neurodegenerative
disorders<I>. </I>Misfolding of SOD1 can be induced by mutations (FALS) or other factors such as oxidative stress and interaction
with misfolded TDP-43, as mentioned above. Like TDP-43, misfolded SOD1 aggregates are toxic and have the ability to propagate from
cell to cell causing spreading of disease. In order to target pathogenic SOD1 in ALS, the ProMIS platform was used to successfully
generate mAbs against different regions of SOD1 predicted to be exposed in misfolded SOD1 but inaccessible in the normal, properly
folded protein. These antibodies were shown to bind misfolded SOD1 in spinal cord homogenates from both FALS and SALS patients, with
no recognition of normal SOD1 in control normal spinal cord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In <I>in vitro</I> assays, ProMIS mAbs inhibited
the cell to cell propagation of misfolded SOD1 while administration of mAb in a mouse model of ALS significantly prolonged survival of
the animals. These results support the potential use of such mAbs to selectively target and protect against pathogenic SOD1 in ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, mAbs against additional epitopes are
being generated for screening. The next steps will entail additional <I>in vitro</I> and <I>in vivo</I> studies for eventual selection
of a lead(s)&nbsp;for development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>RACK1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receptor of activated protein C kinase 1 (&ldquo;<B>RACK1</B>&rdquo;)
is a core ribosomal protein of the eukaryotic small (40S) ribosomal subunit. It is a scaffold protein that interacts with several other
proteins thereby regulating a variety of signaling pathways critical for cell proliferation, transcription and protein synthesis. It
is essential for proper neuronal function. In ALS, our own findings and those of others indicate that misfolded RACK1 co-localizes in
cytoplasmic aggregates in motor neurons of the spinal cord suggesting an involvement in disease. Indeed, in a cell system, mutant TDP-43
has been reported to suppress global protein synthesis by co-aggregating with RACK1 on polyribosomes, a finding that we have reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To investigate RACK1 as a potential target for
ALS and HD, ProMIS explored the impact of RACK1 knock-down (KD) <I>in vitro </I>and <I>in vivo</I> (i.e., what happens in the absence of
RACK1). In a cell system, as expected, RACK1 was observed to co-aggregate with misfolded mutant TDP-43 in the cytoplasm. Knock-down of
RACK1 expression resulted in disaggregation of cytoplasmic TDP-43 and even relocation to the nucleus (normal location) in some of the
cells (Fig. 15). The disaggregation was accompanied by a reversal of the suppression of protein synthesis by mutant TDP-43 (Fig. 16).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tm2135630d1_drs3-17.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
15. Disaggregation of mutant TDP-43. RACK1 (red) normally co-localizes with mutant TDP-43 aggregates in the cytoplasm (green) in the
top panels. With RACK1 KD (bottom panels), TDP-43 disaggregates and localizes in the nucleus in some of the cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_drsimg19.jpg" ALT=""></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
16. Reversal of protein synthesis suppression. Protein synthesis (red) is suppressed in cells expressing aggregated mutant TDP-43 (green)
in the top panels. RACK1 KD (bottom panels) disaggregates TDP-43 and restores protein synthesis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In fruit fly studies, genetic KD of RACK1 in retinal
neurons protected against neurodegeneration caused by overexpression of TDP-43 (Fig. 17)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_drsimg0001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
17. Protection against neuronal degeneration. </FONT>Fruit flies overexpressing human TDP-43 in retinal neurons show degeneration (loss
of ommatidia pointed by arrow). TDP-43 pathology is prevented by RACK1 KD in these flies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results from the literature and ProMIS&#8217;
proof of concept data using RACK1 KD support intracellular targeting of RACK1 as a potential therapeutic approach for ALS and HD. Knock-down
of RACK1 is non-selective (all forms knocked-down) and may not be well-tolerated in humans. We are therefore using the ProMIS platform
to identify epitopes present on misfolded RACK1 and generate antibodies selective for pathogenic, aggregated RACK1. Such antibodies can
then be converted into intrabodies with the goal of targeting intracellular, misfolded RACK1 while preserving normal cell function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS has so far generated 5 mAbs with the desired
selectivity (representative example in Fig. 18). Next steps involve generation and screening of additional antibodies, followed by <I>in
vitro</I> and <I>in vivo</I> studies for the eventual selection of a candidate(s)&nbsp;for development. Development of intrabodies will
be best executed in collaboration with a partner offering gene therapy expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 18</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg22.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
18. Selectivity for misfolded RACK1 in aggregates. </FONT>Representative mAb showing co-localization of staining (green) with RACK1 in
TDP-43 aggregates (yellow) but not normal diffuse RACK1 elsewhere in the cytoplasm (purple).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Schizophrenia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DISC1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protein misfolding and proteostasis have
been found to play a role in neurodevelopment disease. DISC1, a candidate for misfolding protein in schizophrenia was first
identified in a Scottish family with an autosomal dominant neurodevelopmental syndrome including schizophrenia, which was found to
be due to a balanced translocation of part of the C-terminus of a gene subsequently named &#8220;disrupted in schizophrenia&#8221;. DISC1 is an important hub protein participating in neurogenesis, mitochondrial transport and dynamics in dendrites,
cytoskeletal function, and protein translation in adults, especially at the synapse and under conditions of oxidative stress. DISC1
has also been deemed a scaffold protein, and it is possible that proteins of this class are inherently more susceptible to
misfolding and aggregation, which is generally associated with both loss-of-function and toxic gain-of-function. However, a true
scaffold protein can change its conformation and that of its interactors, and no current evidence exists that the extensive
interactome/regulome of DISC1 undergoes conformational change. However, we believe that DISC1 can change conformation in disease, as
exemplified by decreased detergent solubility in brains of individuals dying with schizophrenia or psychotic mood disorders and the
induced co-aggregation of DISC1 by TDP-43<SUP>+</SUP> inclusions in human frontotemporal dementia. Missense and frameshift mutations
in DISC1 have been identified that are linked to familial schizophrenia (R37W, L607F, 4bd deletion extreme 3' end of exon 12), but
the role of these mutations has been disputed, and there is no GWAS signal for DISC1 that is statistically significant. However,
many variants in interactors of DISC1 show significant association with schizophrenia and cognitive decline. DISC1 itself can
oligomerize, which may be associated with toxic gain-of-function as well as loss-of function.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Application of the ProMIS platform to DISC1 and
its interactome offers the potential to generate selective antibodies to probe the pathobiology of DISC1, gain insight into the biology
of schizophrenia and potentially intervene therapeutically. Epitopes predicted to be presented on misfolded DISC1 have been identified
and will be used to generate mAbs for further studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alzheimer&#8217;s Vaccine Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recent development of blood-based biomarkers
for neurodegeneration allows for increased screening to potentially diagnose and identify individuals at risk of developing AD. A vaccine
capable of inducing an effective antibody response against A&#946;O could therefore be administered prophylactically to at-risk individuals
to potentially prevent development of symptomatic disease; and the vaccine could be given therapeutically to individuals living with a
diagnosis of AD to potentially inhibit disease progression. ProMIS initiated a program to construct and test a multivalent peptide vaccine
candidate for AD containing conformational epitopes identified by the ProMIS platform. The demonstrated ability of these conformational
epitopes to induce mAbs with selectivity and protective activity against A&#946;O (see above) supports their potential as vaccine candidates.
In addition, the Company believes that a multivalent vaccine containing several B cell epitopes has the potential to maximize &#8220;coverage&#8221;
by immunizing simultaneously against multiple epitopes that can be expressed at variable levels on A&#946;O.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the same peptide antigens that
generate a monoclonal antibody infusion therapy can be used to create a therapeutic vaccine. The goal of a therapeutic vaccine is to spur
the human immune system to generate antibodies that neutralize toxic oligomers, just as the infusion antibodies will hopefully do. The
advantage is that a single course of therapy, usually an initial vaccination followed by a booster, can potentially provide years of therapeutic
benefit, eliminating the need for frequent costly infusions. The disadvantage of a vaccine approach is that there is no opportunity to
improve or refine the antibodies created by the patient&#8217;s immune system. With infusion antibodies, the final drug candidate may
have gone through a significant amount of refinement and optimization. With therapeutic vaccines, the treatment is only as good as the
peptide antigens on which it is based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In studies conducted by third parties, a first
generation vaccine consisting of aggregated human A&#946; protein with QS1 adjuvant induced antibody production in AD patients but elicited
meningoencephalitis (brain inflammation) and had to be discontinued for safety reasons. Subsequent studies indicated that T helper (&ldquo;<B>Th</B>&rdquo;)
cell epitopes in the A&#946; vaccine gave rise to a pro-inflammatory Th1-type response against the same A&#946; epitopes in the brain<I>)</I>.
The Company believes it can avoid this issue with a vaccine candidate consisting of its A&#946;O B cell epitopes (no A&#946; Th epitopes)
conjugated to keyhole limpet hemocyanin (KLH) as a carrier protein. KLH has been used in humans and provides Th cell epitopes that are
needed to help the development of an antibody response by B cells. Since KLH is a foreign protein not present in human brain, immunization
is expected to result in an antibody response against A&#946;O without a potentially detrimental Th cell inflammatory response (Fig.
19). This premise is supported by initial preclinical studies conducted in collaboration with the University of Saskatchewan&#8217;s
Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), a global leader in vaccine research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
these studies, immunization of mice with a vaccine candidate construct containing ProMIS&#8217; A&#946;O 301 peptide epitope linked
to KLH and formulated with different adjuvants showed induction of a robust antibody response against the A&#946;O epitope as
measured by ELISA (Fig. 20). ELISPOT analysis of spleen cells (immune cells) from immunized mice showed a lack of Th cell cytokine
production in response to stimulation with the A&#946;O epitope thereby indicating that the peptide only contains a B cell epitope.
As expected, T cell help was provided by the carrier protein and stimulation with KLH gave rise to the production of Th
cytokines. These results support the premise that a vaccine consisting of A&#946;O-restricted conformational B cell epitopes
conjugated to KLH for T cell help may successfully induce a protective antibody response against A&#946;O without eliciting a
potentially inflammatory A</FONT><FONT STYLE="font-family: Symbol">b</FONT>- directed Th response. Optimization of adjuvant
formulation and dosing regimen and evaluation of a multivalent construct are ongoing, to be followed by <I>in vivo</I> studies of
protective activity in AD mouse models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 19</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg23.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fig. 19. Illustration of vaccine concept</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm2135630d1_drsimg24.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fig.
20. Induction of robust antibody response against A&#946;O epitope</FONT>. Titers of IgG antibodies against the 301 peptide epitope were
measured by ELISA. Values for individual mice at baseline and on days 28 and 48 post-immunization are shown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Using the ProMIS discovery platform, our aim is
to devise a safe and effective vaccine to induce a specific immune response against toxic A&#946;Os. We have identified a set of six different
peptide epitopes selectively exposed on toxic A&#946;Os. Immunization of mice with each of these individual epitopes produced mAbs that
selectively bind A&#946;Os, not monomers or fibrils. The immediate goals for this program are to create and evaluate a multivalent AD
vaccine comprised of several ProMIS peptide antigens associated with toxic misfolded A&#946;<B><I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ProMIS&#8217; Technology Platform and Intellectual
Property Portfolio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The basis of ProMIS&#8217; proprietary technology
platform is the ability to identify small regions of toxic proteins, including their specific shape or &#8220;conformation&#8221; that
are displayed only on the toxic forms of that protein. We have developed patented methods and know-how combining biology and physics,
to identify these small regions of proteins which can be the targets for antibodies. When displayed on the toxic protein, these small
regions are known as &#8220;epitopes&#8221;. ProMIS makes copies of these epitopes, in a precisely defined shape. These drug development
tools are called peptide antigens and are the key to our efficient methods of creating potentially &#8220;best in class&#8221; antibody
therapies, vaccines, and diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ProMIS computational platform consists of two proprietary patented algorithms, the ProMIS</FONT><SUP>TM</SUP> and Collective Coordinates
algorithms. Both are molecular dynamics algorithms which combine physics and biology to simulate the folding, or misfolding of proteins.
The ProMIS<SUP>TM</SUP> algorithm was our first to be developed. Collective Coordinates was developed after the ProMIS<SUP>TM</SUP> algorithm
and is the more powerful algorithm for prediction/determination of conformational epitopes. ProMIS has successfully applied these computational
algorithms to several misfolded protein categories, looking for epitopes exposed only on a misfolded toxic form which can be used as an
antigen to generate an antibody.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peptide
antigens are the key to creating selective antibodies that target toxic misfolded proteins, like our lead therapeutic antibody candidate
(PMN310 for AD). PMN310 was created using a peptide antigen that we correctly predicted to be exposed only on toxic A</FONT>&#946;Os,
not the monomeric or plaque forms of A&#946;. ProMIS has generated a portfolio of over 20 peptide antigens that have led to selective
antibodies against toxic misfolded forms of A&#946; for AD, a-syn for MSA and PD, tau for AD, FTLD, PSP, and CBD, TDP-43 and SOD1 for
ALS, RACK1 for ALS and HD, and DISC1 for schizophrenia. Those peptide antigens, and the corresponding selective antibodies, represent
proprietary reagents that potentially can be used to create proprietary diagnostic tests in neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finally, peptide antigens are also a potential
key to making vaccines. Therapeutic vaccines are designed to treat a disease by causing the patient&#8217;s immune system to make antibodies
(or T-Cells, in some areas like cancer) that neutralize the toxic disease driver. The potential advantage of a therapeutic vaccine, if
effective, is that a single course of therapy might provide benefit for many years, not requiring frequent, expensive and inconvenient
infusions. In preventive therapy, we believe such an approach may be particularly valuable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Overview of ProMIS&#8217; Intellectual Property
(IP) Portfolio</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ProMIS IP program consists of a three layered
strategy. The first layer of protection comprises two computational algorithms, ProMIS<SUP>TM </SUP>and Collective Coordinates, obtained
under worldwide exclusive license from the UBC. These algorithms are used to predict the specific site and shape (conformation) of epitopes
on misfolded proteins implicated in the development of neurodegenerative diseases and on other complex proteins. PCT applications for
these disease specific epitopes have been submitted and comprise the second layer of IP protection. Finally, the third layer of protection
consists of the composition of matter for the antibodies targeting these disease related epitopes, including use(s)&nbsp;thereof. A brief
summary of the ProMIS patent portfolio is shown in the table below.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-top: 3pt; border: Black 1pt solid; width: 50%; text-align: justify; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent estate </B></FONT></TD>
    <TD STYLE="padding-top: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; width: 50%; text-align: justify; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-top: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-right: 3pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Platform Technologies for epitope prediction</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collective Coordinates ProMIS<SUP>TM</SUP></P></TD>
    <TD STYLE="padding-top: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Collective
    Coordinates International PCTs filed Nov.&nbsp;2016</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ProMIS<SUP>TM</SUP>
    patents Issued Japan, Aus., pending USA, CDN, EU</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD></TR>
  <TR>
    <TD STYLE="padding-top: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-right: 3pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Antibody portfolio&nbsp;&amp; disease specific
    epitopes</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A&#946;</FONT>&amp;
    tau (AD)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a-syn (PD)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TDP-43 (ALS)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RACK1 (various neurodegenerative diseases)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD STYLE="padding-top: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;PCT
    applications with priority dates from Nov.&nbsp;2016 (A&#946;) to May&nbsp;2020 (RACK1)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Applications
    for conformational antibodies&nbsp;&amp; their use</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Antibodies
    described by specific epitope, CDR and other sequences</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Search
    reports indicated antibodies and immunogens are novel and non-obvious.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-top: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-right: 3pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOD1</B></FONT>
    Family of SOD1 related assets covering immunogens, antibodies, pharmaceutical compositions, treatment and diagnostics</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD STYLE="padding-top: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 3pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Methods&nbsp;&amp;
    and compositions to treat&nbsp;&amp; detect misfolded SOD1-mediated diseases.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Issued
    in USA, CDN, Europe, Hong Kong, Japan</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to those developments discussed elsewhere
in this Registration Statement, the following is a summary of the significant developments of the Company which have occurred since March&nbsp;2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;24, 2020, ProMIS announced that
it had received approval from the TSX to amend the exercise price of an aggregate of 44,182,530 outstanding common share purchase warrants
(excluding common share purchase warrants held by Insiders) (the &#8220;<B>Repriced Warrants</B>&#8221;). The exercise price of the Repriced
Warrants was amended to $0.13 per share, effective April&nbsp;8, 2020 until May&nbsp;22, 2020. At the end of such period, the Repriced
Warrants reverted to their original exercise price. All other terms of the Repriced Warrants remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&nbsp;22, 2020, the Company announced </FONT>the resignation of Anthony Giovinazzo from the Board. It also announced the initiation
of a program to construct and test a multivalent peptide vaccine for AD. The critical first steps in vaccine development will be carried
out by VIDO-InterVac, a global leader in vaccine research and development based on the campus of the University of Saskatchewan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;David Wishart, Distinguished University
Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, was appointed to the Scientific
Advisory Board on October&nbsp;29, 2020. Dr.&nbsp;Wishart has studied protein folding and misfolding for more than 30 years using a combination
of computational and experimental approaches. The experimental approaches include NMR spectroscopy, circular dichroism, fluorescence spectroscopy,
electron microscopy, protein engineering and molecular biology. The computational methods include molecular dynamics, agent-based modeling,
bioinformatics and machine learning. Over the course of his career, Dr.&nbsp;Wishart has published more than 430 scientific papers, cited
more than 78,000 times, covering many areas of protein science including structural biology, protein metabolism and computational biochemistry.
Dr.&nbsp;Wishart has been with the University of Alberta since 1995. He also holds adjunct appointments with the Faculty of Pharmaceutical
Sciences and the Department of Pathology and Laboratory Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January&nbsp;1, 2021, James Kupiec resigned as Chief Medical Officer
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February&nbsp;1, 2021, Johannes Roth resigned from the </FONT>Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March&nbsp;22, 2021, ProMIS completed a US$7M (C$8.75) private placement of convertible unsecured debentures (the &#8220;<B>Debentures</B>&#8221;).
The Debentures are convertible into Common Shares at the option of the holder at a conversion price of US$0.10 per share and accrue </FONT>interest
at 1% per annum, which is payable annually. At the Company&#8217;s election, accrued interest may be paid in cash or Common Shares (such
number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price, or &#8220;VWAP,&#8221; of
the Common Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debentures will mature on March&nbsp;22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion
price upon raising US$50</FONT> million in equity and/or debt cumulatively. On the maturity date, the Company may redeem the outstanding
principal amount of the Debentures in either cash or Common Shares (at the then 5-day VWAP less a 10% discount) or a combination thereof
at its election. Amounts redeemed in Common Shares on the maturity date are subject to prior TSX acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors were granted a right to participate, on a pro rata basis, in subsequent </FONT>Company offerings of equity securities for cash
consideration pursuant to a public offering or a private placement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May&nbsp;12, 2021, ProMIS appointed Dr.&nbsp;Rudolph Tanzi, as Chair
of its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&nbsp;13, 2021, ProMIS appointed Neil Warma to the </FONT>Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May&nbsp;21, 2021, the Company announced the initiation of producer cell line development for PMN310, which is the first step in the manufacturing
of antibody therapeutics. This program will be carried out by Selexis, SA, using Selexis</FONT>&#8217; proprietary SUREtechnology Platform&#8482;.
PMN310, is a humanized monoclonal antibody that binds with high affinity and selectivity to toxic oligomers of A&#946; (a recognized root
cause of AD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May&nbsp;27, 2021, ProMIS appointed Dr.&nbsp;David Wishart as Chief
Physics Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August&nbsp;25, 2021, ProMIS completed a public offering of 125,781,250
units at a price of $0.16 per unit for gross proceeds of $20,125,000. Each unit consisted of one common share and one-quarter purchase
warrant. Each warrant entitles the holder thereof to purchase one common share at an exercise price of $0.21 per shar eat any time for
five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&nbsp;1, 2021, ProMIS appointed Josh Mandel-Brehm to the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September&nbsp;22, 2021, ProMIS appointed Maggie Shafmaster to the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October&nbsp;22, 2021, ProMIS appointed Gavin Malenfant as Chief
Operating Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October&nbsp;22, 2021, Dr.&nbsp;Elliot Goldstein stepped down from
his role as Chief Executive Officer and President of ProMIS and Eugene Williams accepted the role of Chairman and Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December&nbsp;1, 2021, we held our special meeting of shareholders
where our shareholders voted and approved the share consolidation resolution, which authorizes the Board, at any time before July&nbsp;1,
2023, to consolidate our Common Shares <FONT STYLE="background-color: white">within a range from a ratio of thirty pre-consolidation common
shares to one post consolidation common share up to a ratio of sixty pre-consolidation common shares for one post-consolidated common
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;18, 2022, ProMIS appointed Dr.&nbsp;Carsten
Korth to its Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Markets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS is applying its patented technology platform
to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody based therapies in neurodegenerative diseases and
other mis-folded protein diseases, which may include AD, MSA, ALS, PD, LBD, FTLD, PSP, CBD, and schizophrenia. These diseases share a
common biologic cause &#8211; misfolded versions of proteins, that otherwise perform a normal function, kill neurons and produce disease.
ProMIS&#8217; technology platform is an example of the advances in drug discovery enabled by computational power, <I>in silico</I> discovery,
and artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins
with therapeutics or detecting them with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Marketing Plans and Milestones</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because ProMIS&#8217; technology potentially has
many human and animal applications for both diagnostic and therapeutic uses, its development, marketing and commercial launch schedule
must be planned in relation to its available resources. ProMIS intends to out-license the marketing and sales of its product applications
to major international healthcare firms for commercial exploitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory Approval and Certification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All commercial applications of ProMIS&#8217;
technology will be subject to substantial regulation and certification in the jurisdictions in which ProMIS or its strategic
partners intend to sell its therapeutic products. The initial markets for ProMIS&#8217; product candidates are the U.S. and because
the Canadian healthcare (diagnostic and therapeutic) market-place is regulated in a similar manner as in the U.S., ProMIS intends to
conform its regulatory and certification scheme to the more rigorous standards imposed by the FDA. Some countries throughout
the world provide reciprocal approval based upon the receipt by an innovator of an FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Human Therapeutic Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS&#8217; human therapeutic product applications
will also be subject to rigorous preclinical and clinical testing and other approval procedures by the FDA and similar regulatory agencies
in other countries. First, preclinical testing of human therapeutics is conducted on animals in the laboratory to evaluate the potential
efficacy, safety and toxicity of a pharmaceutical product candidate. The results of these studies, along with a GMP compliant manufacturing
dossier are submitted to the FDA as part of an IND. An IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless
the FDA, within the 30-day time period, notifies the applicant of safety concerns or questions related to one or more proposed clinical
trials and places the trial on a clinical hold. Typically, the clinical evaluation process involves three phases. In Phase 1, clinical
trials are conducted with a small number of healthy human subjects, or in some diseases in patients to determine the early safety profile,
the pattern of therapeutic drug distribution and metabolism. The total number of subjects included in Phase 1 clinical trials varies but
is generally in the range of 20 to 80. In Phase 2, clinical trials are conducted with groups of patients afflicted with a specific disease
to determine preliminary evidence of efficacy, the optimal dosages, and more extensive evidence of safety. Phase 2 clinical trials are
typically controlled and conducted in a limited population, usually involving no more than several hundred subjects. In Phase 3, large
scale, statistically-driven multi-center, well-controlled clinical trials are conducted with patients afflicted with a target disease
in order to provide enough data to demonstrate the efficacy and safety required by the FDA. Phase 3 clinical trials usually involve several
hundred to several thousand subjects. In most, though not all, cases, the FDA requires two adequate and well-controlled Phase 3 clinical
trials to support approval of a drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Data from clinical trials conducted outside the
United States may be accepted by the FDA subject to certain conditions. For example, the clinical trial must be conducted in accordance
with Good Clinical Practices (&#8220;<B>GCP</B>&#8221;) requirements and/or the FDA must be able to validate the data from the clinical
trial through an onsite inspection if it deems such inspection necessary. Where data from foreign clinical trials are intended to serve
as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data
alone unless those data are considered applicable to the U.S. patient population and U.S. medical practice, the clinical trials were
performed by clinical investigators of recognized competence, and the data is considered valid without the need for an on&#45;site inspection
by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on&#45;site inspection
or other appropriate means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Marketing Approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming successful completion of the required
clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s
chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of a New Drug Application
(&#8220;<B>NDA</B>&#8221;) or Biologics License Application (&#8220;<B>BLA</B>&#8221;) requesting approval to market the product for
one or more indications. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription
Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of&#8201;&#8220;filing&#8221;
of a standard NDA or BLA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from
the date the NDA or BLA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA conducts a preliminary review of all NDAs
or BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete
to permit substantive review. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the
application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA
accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA
or BLA to determine, among other things, whether the drug or biologic is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality, and purity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may refer an application for a novel drug
or biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving an NDA or BLA, the FDA typically
will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to ensure consistent production
of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical
trial sites to assure compliance with  current good clinical practice, or cGCP, requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After evaluating the NDA or BLA and all related
information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and
clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter
generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA or BLA and may require
additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information,
the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions
have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial
marketing of the drug with specific prescribing information for specific indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if the FDA approves a product, it may limit
the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s or biologic&#8217;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, or REMS,
which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a
product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved
product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements
and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expedited Development and Review Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA maintains several programs intended
to facilitate and expedite development and review of new drugs or biologics to address unmet medical needs in the treatment of
serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation,
Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of
important new drugs to get them to patients more quickly than standard FDA review timelines typically permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A drug is eligible for Fast Track designation
if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical
needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during
preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review
means that the agency may review portions of the marketing application before the sponsor submits the complete application. In addition,
a drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation
provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program, and FDA
organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary
review, where appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any product submitted to the FDA for approval,
including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to
expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority
Review designation, once an NDA or BLA is submitted, if the drug that is the subject of the marketing application has the potential to
provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition.
Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for
a standard review. Products are eligible for Accelerated Approval if they can be shown  for a serious or life-threatening condition
and to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on an intermediate clinical
endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an
effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accelerated Approval is usually contingent on
a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The
FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails
to verify the predicted clinical benefit of the product, other evidence demonstrates that the product is not shown to be safe and effective
under conditions of use, or required post-approval studies are not conducted with due diligence. In addition, the FDA generally requires,
as a condition for Accelerated Approval, that all advertising and promotional materials intended for dissemination or publication within
120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has
passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination
or publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if a product qualifies for one or more of
these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA
review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated
Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though
they may expedite the development or review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drugs or biologics manufactured or
distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,
requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and
reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee
requirements for any marketed products and the establishments where such products are manufactured, as well as new application fees
for supplemental applications with clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may impose a number of post-approval requirements
as a condition of approval of an NDA or BLA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials,
and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, drug and biologic manufacturers and
other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments
with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being
implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers
must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once an approval of a drug or biologic is granted,
the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks;
or imposition of distribution or other restrictions under a REMS program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA strictly regulates marketing, labeling,
advertising and promotion of products that are placed on the market. Drugs or biologics may be promoted only for the approved indications
and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In many foreign countries, drugs and biologics
are subject to regulatory requirements in addition to and sometimes different than the U.S. requirements described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Companion Diagnostics</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA defines <I>in vitro</I>, or IVD, companion
diagnostic device as an <I>in vitro</I> diagnostic device that provides essential information for the safe and effective use of a corresponding
therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product is stipulated in the instructions for use
in the labeling of both the diagnostic device and the corresponding therapeutic product, including the label. Applications for an IVD
companion diagnostic device and its corresponding therapeutic product will be reviewed and approved according to applicable regulatory
requirements. The IVD companion diagnostic device application will be reviewed and approved or cleared under the device authorities of
the Federal Food, Drug, and Cosmetic Act (&#8220;<B>FD&amp;C Act</B>&#8221;) and relevant medical device regulations; the therapeutic
product application will be reviewed and approved under section 505 of the FD&amp;C Act (i.e., drug products) or section 351 of the Public
Health Service Act (i.e., biological products) and relevant drug and biological product regulations. The FDA intends to review each IVD
companion diagnostic device submission within the context of, or in conjunction with, its corresponding therapeutic product, and FDA review
of the IVD companion diagnostic device and the therapeutic product will be carried out collaboratively among relevant FDA offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ideally, a therapeutic product and its
corresponding IVD companion diagnostic device should be developed contemporaneously, with the clinical performance and clinical
significance of the IVD companion diagnostic device established using data from the clinical development program of the
corresponding therapeutic product. Some of our current and future product development candidates may depend upon co-development of
accurate genetic and potentially other IVDs. Thus, we will likely need to comply with both FDA drug and medical device regulations.
This adds additional cost and complexity to our development programs. The availability of IVD companion diagnostics can allow more
efficient development programs and more appropriate use of products in the marketplace with more predictable outcomes for patients
and higher value medicines. Ultimately FDA approval of the IVD will be required to allow approval of some of our products. However,
technical difficulties or other issues could delay or disrupt the development of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Healthcare Fraud and Abuse Laws and
Compliance Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various federal and state laws
targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs
for drugs and biologics. In addition, we may be subject to patient privacy regulation by both the federal government and the states in
which we conduct our business. The laws that may affect such operations include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">the federal Anti-Kickback Statute is a criminal statute which prohibits, among other things, persons from
soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return
for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal
healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include
anything of value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">federal false claims and civil monetary penalties laws, including the federal civil False Claims Act,
which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including
Medicare and Medicaid) claims for items or services that are false or fraudulent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">provisions of federal Health Insurance Portability and Accountability Act of 1996 (&#8220;<B>HIPAA</B>&#8221;),
which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare
benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. In
addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;<B>HITECH</B>&#8221;)
and its implementing regulations, impose certain requirements relating to the privacy, security and transmission of individually identifiable
health information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">the federal Physician Payments Sunshine Act requirements, under the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, which
require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S.
physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">the Foreign Corrupt Practices Act of 1977 (&#8220;<B>FCPA</B>&#8221;) which prohibits U.S. businesses
and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a
foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other
improper advantage in order to obtain or retain business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Environmental Regulation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also be subject to foreign
and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard
control and disposal of hazardous or potentially hazardous substances. There can be no assurance that the Company will not incur
significant costs to comply with laws and regulations in the future or that such laws or regulations will not have a material
adverse effect upon the Company&#8217;s business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pricing and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Precision therapeutic products and their accompanying
companion diagnostic are largely paid for based on third party payor reimbursement. In the U.S., concurrent with approval for commercialization
of such therapeutic products by the FDA, each therapeutic product is assigned a product code, and its associated companion diagnostic
assigned a similar code, or Current Procedural Terminology code (&#8220;<B>CPT</B>&#8221;). Each product code and CPT is then assigned
a reimbursement level by the Centers for Medicare and Medicaid Services (&#8220;<B>CMMS</B>&#8221;). Third party insurance payors typically
establish a specific fee to be paid for each code submitted. Third party payor reimbursement policies are generally determined with reference
to the reimbursement for CPT codes for Medicare patients which themselves are determined on a national basis by CMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, Congress has considered reductions
in Medicare reimbursement levels for drugs administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs,
also has authority to revise reimbursement rates and to implement coverage restrictions for some drugs. Cost reduction initiatives and
changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products.
While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal
legislation or regulation may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parallel to this regulatory reimbursement scheme
in the U.S., other countries also regulate reimbursement similar to the U.S. Therefore, it is important that ProMIS establish for its
human diagnostic and therapeutic products reimbursement schemes, which provide ultimate financial payment for ProMIS&#8217; products consistent
with its business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare Reform Measures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. and many foreign jurisdictions have enacted
or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments
also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Affordable Care Act substantially changed the way healthcare
is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care
Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies
against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new
taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things,
the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the
minimum Medicaid rebate for both branded and generic drugs, expanded the 340B program, and revised the definition of average
manufacturer price (&#8220;<B>AMP</B>&#8221;), which could increase the amount of Medicaid drug rebates manufacturers are required
to pay to states. The legislation also extended Medicaid drug rebates, previously due only on fee-for-service Medicaid utilization,
to include the utilization of Medicaid managed care organizations as well and created an alternative rebate formula for certain new
formulations of certain existing products that is intended to increase the number of rebates due on those drugs. On February&nbsp;1,
2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Affordable Care Act. These
regulations became effective on April&nbsp;1, 2016. Since that time, there have been significant ongoing efforts to modify or
eliminate the Affordable Care Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Affordable Care Act has been subject to challenges
in the courts. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in
its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December&nbsp;18, 2019, the Fifth Circuit U.S.
Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider
its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&nbsp;17, 2021, the
U.S. Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to
the allegedly unlawful conduct.&nbsp; As a result, the U.S. Supreme Court did not rule&nbsp;on the constitutionality of the Affordable
Care Act or any of its provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other legislative changes have been proposed and
adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee
on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted
deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic
reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers
of up to 2.0% per fiscal year. The Bipartisan Budget Act of 2018 retained the federal budget &#8220;sequestration&#8221; Medicare payment
reductions of 2%, and extended it through 2027 unless congressional action is taken, and also increased labeler responsibility for prescription
costs in the Medicare Part&nbsp;D coverage gap. On January&nbsp;2, 2013, the American Taxpayer Relief Act was signed into law, which,
among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further legislative and regulatory changes under
the Affordable Care Act remain possible, although the Biden Administration has signaled that it plans to build on the Affordable Care
Act and expand the number of people who are eligible for subsidies under it. President Biden indicated that he intends to use executive
orders to undo changes to the Affordable Care Act made by the Trump administration and would advocate for legislation to build on the
Affordable Care Act. It is unknown what form any such changes or any law would take, and how or whether it may affect our business in
the future. We expect that changes or additions to the Affordable Care Act, the Medicare and Medicaid programs, allowing the federal government
to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access,
financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that additional federal, state and foreign
healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will
pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products,
if approved, or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B></B></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation Outside of the United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulations in the U.S., we
may be subject to a variety of regulations in foreign jurisdictions that govern, among other things, clinical trials and any
commercial sales and distribution of our products, if approved, either directly or through our distribution partners. Whether or not
we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign
jurisdictions prior to the commencement of clinical trials or marketing and sale of the product in those countries. The foreign
regulatory approval process and the time required to obtain approval in other countries and jurisdictions might differ from and be
longer than that required to obtain FDA approval. Some foreign jurisdictions have a drug product approval process similar to that in
the U.S., which requires the submission of a clinical trial application much like the IND prior to the commencement of clinical
studies. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay
in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Moreover,
some nations may not accept clinical studies performed for U.S. approval to support approval in their countries or require that
additional studies be performed on natives of their countries. In addition, in certain foreign markets, the pricing of drug products
is subject to government control and reimbursement may in some cases be unavailable or insufficient. We face the risk that the
resulting prices would be insufficient to generate an acceptable return to us or any future partner of ours. If we fail to comply
with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of
regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commercial Marketing Plans and Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS does not intend to market its therapeutic
products and companion diagnostics it develops that require extensive distribution channels. Instead, ProMIS intends to license to, or
enter into strategic alliances with, larger pharmaceutical entities that are equipped to manufacture and/or market ProMIS&#8217; products
through their distribution networks. ProMIS may license some or all of its patent rights to more than one company to achieve the fullest
development, marketing and distribution of its products. To this end ProMIS intends to continue to develop and improve its proprietary
technologies and to expand the applications of its technologies in the healthcare markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Generate Product Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues, if any, from its precision therapeutics
pipeline and companion diagnostics are expected to be generated from research funding, license fees, milestone payments, co-development
funding, and royalties from partnerships to be completed by ProMIS with selected third-party, multi-national health care firms. As of
the date of this form, ProMIS has not generated any significant product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Develop Collaborative Customer-Funded Commercialization
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to increase market exposure of its products
and to capitalize on a partner&#8217;s clinical development competencies, market position, and distribution capabilities, ProMIS intends
to develop its projects with collaborative commercial partners who will fund further product development projects incorporating ProMIS&#8217;
technology. These collaborative arrangements typically will provide for a jointly funded development project and contemplate a licensing
arrangement (which may be entered into at the same time as the development project or at a later date) under which, if a project is commercialized
by the collaborative partner, ProMIS would potentially receive license fees, royalty payments from product sales and manufacturing revenue.
ProMIS believes that such arrangements with major commercial partners will serve to validate its proprietary technologies in human healthcare
areas and thereby assist ProMIS in attracting additional licensing arrangements on favorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enhance Out-licensing of ProMIS Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where practical, ProMIS will outsource its product manufacturing
and has explored and will continue to evaluate the possibility of entering into strategic manufacturing alliances with appropriate third
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Human Healthcare Products Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS will compete with many large and
small pharmaceutical companies that are developing and/or marketing therapeutic compounds for AD, ALS and/or PD. Many large
pharmaceutical companies and smaller biotechnology companies maintain well-funded research departments concentrating on therapeutic
approaches to neurodegenerative diseases. ProMIS expects substantial competition from these companies as they develop different
and/or novel approaches to the treatment of these diseases. Some of these approaches may directly compete with the technology that
ProMIS is currently developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the intense competitive environment that is
the human pharmaceutical industry, those companies that complete clinical trials, obtain regulatory approval and commercialize their therapeutic
products first may enjoy competitive advantages. ProMIS believes that it will develop compounds with characteristics that may enable them,
if fully developed, to have a market impact. A number of major human pharmaceutical companies have significant programs to develop drugs
for the treatment of neurodegenerative disease. These companies include Eisai/Pfizer, Novartis, Merck, Genentech, Lilly, Biogen, Amgen
and Johnson&nbsp;&amp; Johnson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Proprietary Protection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS has acquired the rights to certain proprietary
discovery platforms for the identification of proteins involved in misfolding diseases embodied in various national and international
patent applications. ProMIS has also filed international patent applications related to immunotherapy targeting toxic forms of SOD1 and
TDP-43 for ALS, toxic oligomers of A&#946; for AD and toxic aggregates for a-syn for PD to further protect its intellectual property rights
related to its therapeutic programs. In addition, the Company has obtained proprietary rights to two computational algorithms (ProMIS<SUP>TM</SUP>
and Collective Coordinates) for identification of DSEs in protein misfolding diseases as well as predicted DSEs against multiple disease
targets. ProMIS intends to aggressively protect the commercial applications for diagnostic, therapeutic and prophylactic applications
of these discoveries. In addition, ProMIS has developed know-how, which it may elect to keep as trade secrets and not publicly disclose
in patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMIS seeks to hire qualified scientists and
key employees as needed. As of January&nbsp;10, 2022, the Company had three total employees, consisting of three full-time employees.
The remainder of the scientists and key personnel had consulting agreements with ProMIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="d_001"></A>ITEM
1A. RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following specific factors could materially adversely affect the Company and should be considered when deciding whether to make an investment
in the Company. The risks and uncertainties described in this </FONT>Registration Statement and the information incorporated by reference
herein are those we currently believe to be material, but they are not the only ones we face. Additionally, investors should not interpret
the disclosure of a risk to imply that the risk has not already materialized. If any of the following risks, or any other risks and uncertainties
that we have not identified or that we currently consider not to be material, actually occur or become material risks, our business, prospects,
financial condition, results of operations and cash flows, and consequently the price of the Common Shares could be materially and adversely
affected. In all these cases, the trading price of our securities could decline, and prospective investors could lose all or part of their
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors should carefully consider the risk factors
set out below and consider all other information contained herein and in the Company&#8217;s other public filings before making an investment
decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the COVID-19 Pandemic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business and operations may be adversely
affected by the evolving and ongoing COVID-19 global pandemic.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business and operations may be adversely
affected by the effects of the recent and evolving COVID-19 virus, and the efforts to mitigate it, which was declared a global
pandemic by the World Health Organization in March&nbsp;2020. The COVID-19 pandemic has resulted in travel and other restrictions in
order to reduce the spread of the disease, including public health directives and orders in the United States and the European Union
that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed
businesses and governmental agencies to cease non-essential operations at physical locations, prohibited certain non-essential
gatherings and events and ordered cessation of non-essential travel. Future remote work policies and similar government orders or
other restrictions on the conduct of business operations related to the COVID-19 pandemic may negatively impact productivity and may
disrupt our ongoing research and development activities and our clinical programs and timelines, the magnitude of which will depend,
in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary
course. Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and
manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The spread of COVID-19, which has caused a broad
impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19
may be difficult to assess or predict, the continued widespread pandemic could result in significant disruption of global financial markets,
reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market
correction resulting from the spread of COVID-19 could materially affect our business and the value of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global COVID-19 pandemic continues to rapidly
evolve. The extent to which the COVID-19 pandemic impacts our business and operations, including our clinical development and regulatory
efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence as of the filing of this
Registration Statement, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of
business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing
requirements and business closures in the United States and other countries to contain and treat the disease. Accordingly, we do not yet
know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the
global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and
growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent the ongoing COVID-19
pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks
and uncertainties described in this &#8220;<I>Risk Factors</I>&#8221; section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The ongoing COVID-19 pandemic may negatively
impact the availability of scientific staff, physicians and other healthcare professionals, which may negatively impact our business,
financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on the availability of scientific staff,
physicians and other healthcare professionals to provide testing services. If scientific staff, physicians and other healthcare professionals
were unable or unwilling to provide these services in the future due to any reason including infection due to COVID-19, this would cause
interruptions in our business until mitigated accordingly. As such, vacancies and disabilities relating to our current staff may cause
interruptions in our business and result in lower revenues.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we expand our operations, we may encounter
difficulty in securing the necessary professional scientific, medical and skilled support staff to support our expanding operations which
may adversely affect our business, financial condition and results of operations. Additionally, we follow posted health guidelines, as
and when posted, to protect the health of our employees and decrease the potential impact of serious illness, including COVID- 19, on
our operations. However, should an employee of, or visitor to, our offices or research and development facilities become infected with
COVID-19, it could place our workforce at risk, which could result in the disruption or suspension of operations at our facilities. Such
a suspension in operations could also be mandated by governmental authorities in response to the COVID-19 pandemic. This would negatively
impact our operations which could adversely impact our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_029"></A><B>Risks Related to the Development of Our Product
Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates are still in the
early stages of development and there is significant uncertainty that any such products will actually be developed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates are at an early stage of
development. Significant additional investment in research and development, product validation, technology transfer to manufacturing,
production scale-up, manufacturing, clinical testing, and regulatory submissions of such product candidates is required prior to commercialization.
There can be no assurance that any such product candidates will actually be developed and, if developed, will be approved. The development
and regulatory processes may require access to rare biofluid and tissue samples from people and animals which may not be available to
us in sufficient amounts or in a timely fashion to allow us to complete the development or receive regulatory approval of any product
candidate or process. A commitment of substantial time and resources is required to conduct research and clinical trials if we are to
complete the development of any product candidate. It is not known whether any of these product or process candidates will meet applicable
health regulatory standards and obtain required regulatory approvals, or whether such products, if approved, can be produced in commercial
quantities at reasonable costs and be successfully marketed, or if our investment in any such products will be recovered through sales
or royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to incur substantial capital expenditures
in connection with the development of our product candidates. If we fail to successfully develop and sell all or any of our product candidates,
then we will not earn any return on our investment in these future products, which will adversely affect our results of operations and
could adversely affect the market price of the Common Shares. Our success in developing and selling new products will depend upon multiple
factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">our ability to develop safe and effective products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">our serology assays and vaccines achieving the desired sensitivity for antibody-based immunity and immune
response, as applicable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">acceptance of the product by the medical community and by patients and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">inherent development risks, such as the product proving to be unsafe or unreliable, or not having the
anticipated effectiveness; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 95%">our ability to develop repeatable processes to manufacture new products in sufficient quantities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of these factors cannot be overcome, we
may not be able to develop and introduce our products in a timely or cost-effective manner, which could adversely affect our future growth
and results of operations. Our failure to develop and obtain approval of our product candidates could adversely affect the market price
of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have concentrated a portion of our research
and development efforts on the treatment of AD, a field that has to date seen very limited success in drug development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have focused our research and development
efforts on developing effective treatments for AD. Collectively, efforts by pharmaceutical companies in the field of AD have seen
very limited successes in drug development. There are few approved products available for patients with AD. Only one
disease-modifying therapeutic option has been approved by the FDA. Biogen&#8217;s Aduhelm (aducanumab), a monoclonal antibody
administered via infusion, received accelerated approval from the FDA on June&nbsp;7, 2021. We cannot be certain that our approach
will lead to the development of approvable or marketable products. With the exception of Aduhelm, the only drugs approved by the FDA
to treat patients with AD address the symptoms of the disease. Since 2003, over 500 clinical studies have been completed and only
Aduhelm has been approved by the FDA, compared to a success rate of 50% to 80% for all other drug candidates. As a result, the FDA
has a limited set of products to rely on in evaluating PMN310. This could result in a longer than expected regulatory review
process, increased expected development costs or the delay or prevention of commercialization of PMN310 for the treatment of AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is heavily dependent on the
successful development, regulatory approval and commercialization of PMN310 and any future product candidates that we may develop or acquire,
including PMN442 and PMN267.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no products approved for sale,
and our lead product candidate is in early stages of development. The success of our business, including our ability to finance our company
and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of
our product candidates and, in particular, the advancement of PMN310. However, given our stage of development, it may be many&nbsp;years,
if we succeed at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization.
We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive
regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The clinical and commercial success of PMN310
and any future product candidates that we may develop or acquire will depend on a number of factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to raise any additional required capital on acceptable terms, or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to complete an IND enabling studies and successfully submit INDs or comparable applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">timely completion of our preclinical studies and clinical trials, which may be significantly slower or
cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">delays or difficulties in enrolling and retaining patients in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical
trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product
candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications
of our product candidates by the FDA and similar foreign regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the
safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the prevalence, duration and severity of potential side effects or other safety issues experienced with
our product candidates or future approved products, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and
maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any
future product candidates or approved products, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial
supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate
and maintain commercially viable manufacturing processes that are compliant with cGMPs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the convenience of our treatment or dosing regimen;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates
or any future product candidates, if approved, including relative to alternative and competing treatments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product
candidates or any future product candidates, if approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party
payors and adequate market share and revenue for any approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment, patients
discontinuing their treatment or follow up visits or changes to trial protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates
or any future product candidates in the United States and internationally, if approved for</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in
collaboration with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patient demand for our product candidates, if approved, including patients&#8217; willingness to pay out-of-pocket
for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to establish and enforce intellectual property rights in and to our product candidates or
any future product candidates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to avoid third-party patent interference, intellectual property challenges or intellectual
property infringement claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the FDA or other regulatory agencies
may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions.
We have not yet conducted an end of Phase&nbsp;2 meeting with the FDA to discuss the registration pathway for PMN310, and our current
clinical development plans for PMN310 in AD may change as a result of future interactions with the FDA. For example, the FDA may not accept
the results of the ongoing PMN310 clinical trials and may require that we conduct additional trials, including more than one pivotal trial,
in order to gain approval in AD. Furthermore, any approval of PMN310 for AD may be limited to PMN310 in combination with the existing
standard of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These factors, many of which are beyond our control,
could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates.
Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly,
we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future
product candidates to continue our business or achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our approach to the potential treatment
of AD is based on a novel therapeutic approach, which exposes us to unforeseen risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no current scientific or general
consensus on the causation of AD or method of action to treat AD. We have discovered and are developing PMN310, a humanized antibody
that selectively targets A&#946;O, or A&#946;Os, to treat AD. Our approach is based on research on A&#946;Os, globular assemblies of
the A&#946; peptide that are distinct from other forms of amyloid. A&#946;Os have gained scientific acceptance as primary toxins
involved in the initiation and propagation of AD pathology. Based on the results of our nonclinical studies to date, we believe
PMN310 is different from current and prior clinical-stage anti-amyloid drugs and product candidates based on its selectivity for
A&#946;Os. We believe that this is a novel mechanism which has the potential to provide more clinically meaningful benefits, with a
possible improved safety profile, as compared to approved therapies and product candidates in development and may potentially slow
disease progression. However, we may ultimately discover that PMN310 does not possess properties required for therapeutic
effectiveness. We have no evidence regarding the efficacy, safety or tolerability of PMN310 in humans. We may spend substantial
funds attempting to develop PMN310 or other product candidates and never succeed in doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market for any products that we successfully
develop, if any, will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it would
cost to commercially manufacture PMN310, if approved, and the actual cost to manufacture PMN310 or any drug we develop in the future could
materially and adversely affect the commercial viability of the drug. We may also find that the manufacture of our product candidates
is more difficult than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical
trials or, if approved, commercial supply. If we do not successfully develop PMN310 or any other drug we develop with drug product cannot
be reliably and economically manufactured at scale, we will not become profitable, which would materially and adversely affect the value
of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not successfully expand our pipeline
of product candidates, including by pursuing additional indications for PMN310 or by in-licensing or acquiring additional product candidates
for other diseases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A key element of our strategy is to build and
expand our pipeline of product candidates, including by developing PMN310 for the treatment AD, and by identifying other product candidates.
In addition, we may in-license or acquire additional product candidates for other diseases. We may not be able to identify or develop
additional product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the
potential product candidates that we identify, in-license or acquire may not be suitable for clinical development. For example, our research
methodology may be unsuccessful in identifying potential drug candidates or those we identify may be shown to have harmful side effects
or other characteristics that make them unmarketable or unlikely to receive regulatory approval. We cannot guarantee that we will be successful
in identifying additional potential drug candidates, or that we will be able to successfully identify and in-license new and valuable
product candidates from other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Nonclinical and clinical drug development
involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive
of future results. PMN310 or any other product candidate that we advance into clinical trials may not achieve favorable results in later
clinical trials, if any, or receive marketing approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The research and development of product candidates
is extremely risky. Only a small percentage of product candidates that enter the development process ever receive marketing approval.
Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete nonclinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing
is expensive and can take many years to complete, and its outcome is inherently uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of nonclinical studies and early
clinical trials are not necessarily predictive of future results and PMN310, or any other product candidate that we may develop, may
not be further developed or have favorable results in later studies or trials. Clinical trial failure may result from a multitude of
factors including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria and
failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A
number of companies in the pharmaceutical industry have suffered setbacks in the advancement of their product candidates into
later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding results in earlier nonclinical
studies or clinical trials. In addition, the results of clinical trials in one set of patients or disease indications may not be
predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results
between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set
forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and
other clinical trial protocols and the rate of dropout among clinical trial participants. A number of companies in the
pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable
safety issues, notwithstanding promising results in earlier trials. This is particularly true in AD, where failure rates
historically are higher than in most other disease areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of negative or inconclusive results,
we may decide, or regulatory authorities may require us, to conduct additional clinical trials or nonclinical studies. In addition, data
obtained from clinical trials and nonclinical studies is susceptible to varying interpretations, and regulatory authorities may not interpret
our data as favorably as we do, which may further delay, limit or prevent development efforts, clinical trials or marketing approval.
Furthermore, as more competing product candidates within a particular class of drugs proceed through clinical development to regulatory
review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to complete nonclinical studies
or clinical trials of PMN310 or future product candidates, due to safety concerns or otherwise, or if the results of these trials are
not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization
on a timely basis or at all. Even if we are able to obtain marketing approval for PMN310 or any future product candidates, those approvals
may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely affect
our ability to generate revenue from sales of those product candidates. Moreover, if we are not able to differentiate our product candidate
against other approved product candidates within the same class of drugs, or if any of the other circumstances described above occur,
our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical failure can occur at any stage
of clinical development and we have never completed a clinical trial or submitted NDA, BLA, or marketing authorization application, or
MAA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are early in our development efforts for PMN310,
and will need to successfully complete our ongoing and planned clinical trials, including pivotal clinical trials, in order to obtain
FDA approval to market PMN310 or any other product candidate we seek to develop. Carrying out clinical trials and the submission of a
successful BLA is a complicated process. Although members of our team have significant experience in clinical development of drugs through
regulatory approval, as an organization, we have just begun conducting our first clinical trial, we have no experience in conducting any
clinical trials, we have limited experience in preparing regulatory submissions and we have not previously submitted a BLA for any product
candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have had limited interactions
with the FDA and cannot be certain how many clinical trials of PMN310 will be required or how such trials should be designed. Consequently,
we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to BLA submission
and approval of PMN310 or any other product candidate. We may require more time and incur greater costs than our competitors and may not
succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned
clinical trials, could prevent us from or delay us in commercializing PMN310 or any future product candidates we may develop, and failure
to successfully complete any of these activities in a timely manner could have a material adverse impact on our business and financial
performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may incur additional costs or experience
delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience numerous unforeseen events during,
or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product
candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities,&nbsp;Institutional Review Boards, or IRBs, or Ethics Committees, or ECs, may not authorize us or our investigators
to commence a clinical trial or conduct a clinical trial at a prospective trial site or we may fail to reach a consensus with regulatory
authorities on trial design;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities in jurisdictions in which we seek to conduct clinical trials may differ from each other on our trial design,
and it may be difficult or impossible to satisfy all such authorities with one approach;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with
prospective trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different contract
research organizations, or CROs, and trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we may be unable to add or be delayed in adding a sufficient number of clinical trial sites and obtaining IRB or independent EC approval
at each clinical trial site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce negative or inconclusive results,
and we may decide, or regulatory authorities may require us, to conduct additional clinical trials or abandon drug development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">enrollment in our clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher
rate than we anticipate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>difficulties in having subjects complete a clinical trial or returning for post-treatment follow-up;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>changes to clinical trial protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our third-party contractors, including clinical investigators, contract manufacturers and vendors may fail to comply with applicable
regulatory requirements, lose their licenses or permits, or otherwise fail, or lose the ability to, meet their contractual obligations
to us in a timely manner, or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the
participants are being exposed to unacceptable health risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons,
including noncompliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected
characteristics, or that the participants are being exposed to unacceptable health risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may lack adequate funding to continue
one or more clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates
may be insufficient or inadequate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>clinical trial sites may deviate from clinical trial protocol or drop out of a clinical trial; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">occurrence of serious adverse events in trials of the same class of agents conducted by other companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adverse side effects, properties or other
safety risks associated with PMN310, PMN442, PMN267 or any future product candidates could delay or preclude approval, cause us to suspend
or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label or result in significant
negative consequences following marketing approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is the case with pharmaceuticals generally,
it is possible that there may be side effects and adverse events associated with the use of PMN310, PMN442, PMN267 or any future product
candidates we may develop. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects
or unexpected characteristics as the clinical trials progress to greater exposures and a larger number of patients. Undesirable side effects
caused by, or unexpected or unacceptable characteristics associated with, PMN310, PMN442, PMN267 or any future product candidates we may
develop, could result in the delay, suspension or termination of clinical trials by us, the FDA or other regulatory authorities, or IRBs
for a number of reasons. We may also elect to limit their development to more narrow uses or subpopulations in which the undesirable side
effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the
commercial expectations for such product candidate if approved. If we elect or are required to further delay, suspend or terminate any
clinical trial of any product candidates we may develop, the commercial prospects of such product candidates will be harmed and our ability
to generate drug revenues from any such product candidates will be delayed or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is possible that, as we test our product candidates
in clinical trials, or as the use of a product candidate becomes more widespread if it receives regulatory approval, we may identify additional
adverse events that were not identified or not considered significant in our earlier trials. If such side effects become later known in
development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly.
If we or others later identify undesirable side effects, a number of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>regulatory authorities may withdraw, suspend or limit approval of a product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we may be required to recall a drug or change the way such drug is administered to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities may require additional warnings or statements in the labeling, such as a boxed warning or a contraindication
or issue safety alerts, press releases or other communications containing warnings or other safety information about the product candidate,
for example, field alerts to physicians and pharmacies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory authorities may require us to implement a REMS to ensure that the benefits of the drug outweigh its risks, which could
include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">we may be required to change the way a drug is distributed or administered, conduct additional clinical trials or be required to conduct
additional post-marketing studies or surveillance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we may be subject to regulatory investigations and government enforcement actions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we may decide to remove such product candidates from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>we could be sued and held liable for harm caused to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>sales of the drug may decrease significantly or become less competitive; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these events could prevent us from achieving
or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, financial condition,
results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may experience delays or difficulties
in the enrollment and retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful and timely completion of clinical trials
will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical trials,
is affected by many factors, including the size and nature of the patient population and competition for patients eligible for our clinical
trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat the same indications
as one or more of our product candidates or approved products for the conditions for which we are developing our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trials may be subject to delays as a result of
patient enrollment taking longer than anticipated or patient withdrawal. We may not be able to initiate or continue clinical trials for
our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as
required by the FDA, EMA or foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future
clinical trials. Subject enrollment is affected by other factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the severity and difficulty of diagnosing the disease under investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the eligibility and exclusion criteria for the trial in question;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the size of the patient population and process for identifying patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>our ability to recruit clinical trial investigators with the appropriate competencies and experience;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the design of the trial protocol;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the perceived risks and benefits of the product candidate in the trial, including relating to cell therapy approaches;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the availability of competing commercially available therapies and other competing therapeutic candidates&#8217; clinical trials for
the disease or condition under investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the willingness of patients to be enrolled in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the efforts to facilitate timely enrollment in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">potential disruptions caused by the COVID-19 pandemic, including difficulties in initiating clinical sites, enrolling and retaining
participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and
other factors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the patient referral practices of physicians;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the ability to monitor patients adequately during and after treatment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>the proximity and availability of clinical trial sites for prospective patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our inability to enroll a sufficient number of
patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether.
Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the
value of our company to decline and limit our ability to obtain additional financing. Furthermore, we expect to rely on CROs and clinical
trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, even if we are able to enroll a sufficient
number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interim, &#8220;top-line&#8221; and preliminary
results from our clinical trials that we announce or publish from time to time may change as more data become available and is subject
to audit and verification procedures that could result in material changes in the final data.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may publish interim, top-line
or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that
one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary
or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final
data are reported. Differences between preliminary, top-line or interim data and final data could significantly harm our business prospects
and may cause the trading price of our Common Shares to fluctuate significantly. We also make assumptions, estimations, calculations and
conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.
As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations
may qualify such results, once additional data have been received and fully evaluated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, others, including regulatory agencies
may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance
of data differently, which could impact the value of the particular development program, the approvability or commercialization of the
particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding
a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we
determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose
may ultimately be deemed meaningful by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding
a particular product candidate or our business. If the interim, top-line or preliminary data that we report differ from actual results,
or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
product candidates may be harmed, which could significantly harm our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be certain that PMN310, PMN442,
PMN267 or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to
market our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have no product candidates approved
for sale and we cannot guarantee that we will ever have marketable product candidates. Our ability to generate revenue related to sales
of PMN310, PMN442, and PMN267, if ever, will depend on the successful development and regulatory approval of such product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development of a product candidate and
its approval and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling,
storage, approval, advertising, promotion, sale, distribution, import and export are subject to extensive regulation by the FDA, the
EMA and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to
market our product candidates in the United States, Europe or other countries until we receive approval of a BLA from the FDA or MAA
from the EMA, respectively. We have not submitted any marketing applications for any product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BLAs and MAAs, and other foreign equivalents must
include extensive nonclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness
for each desired indication. BLAs and MAAs must also include significant information regarding the chemistry, manufacturing and controls
for the drug. Obtaining approval of a BLA or a MAA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining
approval. The FDA and the EMA review processes can take years to complete and approval is never guaranteed. If we submit a BLA to the
FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted
for filing and review by the FDA. Regulators of other jurisdictions, such as the EMA, have their own procedures for approval of product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if a drug is approved, the FDA or the EMA,
or other foreign equivalent, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings
on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities
in countries outside of the United States and Europe also have requirements for approval of product candidates with which we must comply
prior with marketing in those countries. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure
that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications
in the United States, Europe or other countries may be based upon many factors, including regulatory requests for additional analyses,
reports, data, nonclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results,
changes in regulatory policy during the period of drug development and the emergence of new information regarding PMN310, PMN442, PMN267
or other product candidates we may develop in the future. Also, regulatory approval for any of our product candidates may be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before we submit a BLA to the FDA or a MAA to
the EMA for a product candidate, we will be required to successfully complete our clinical trials. The FDA generally requires two pivotal
clinical trials to support approval. In addition, we must scale up manufacturing and complete other standard nonclinical and clinical
studies. We cannot predict whether clinical trials will be successful or whether regulators will agree with our conclusions regarding
the nonclinical studies and the clinical trials we conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our lead product candidate, PMN310, is being
developed for the treatment of AD, a disease that has seen limited success in drug development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Efforts by biopharmaceutical and pharmaceutical
companies in treating AD have seen limited success in drug development. Only one disease-modifying therapeutic option has been approved
by the FDA. Biogen&rsquo;s Aduhelm, a monoclonal antibody administered via infusion, received accelerated approval from the FDA on June
7, 2021. We cannot be certain that our oral, small-molecule approach will lead to the development of approvable or marketable products.
With the exception of Aduhelm, the only drugs approved by the FDA to treat patients with AD address the symptoms of the disease. Since
2003, over 500 clinical studies have been completed and only Aduhelm has been approved by the FDA. As a result, the FDA has a limited
set of products to rely on in evaluating PMN310. This could result in a longer than expected regulatory review process, increased expected
development costs or the delay or prevention of commercialization of PMN310 for the treatment of AD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the significant uncertainty related
to insurance coverage and reimbursement of all newly-approved products, there is greater uncertainty for products approved for the treatment
of AD.&nbsp; For example, the yearly wholesale acquisition cost of the maintenance dose of Aduhelm is $28,200. The Centers for Medicare
and Medicaid Services recently issued a draft determination that proposes to cover the cost of anti-amyloid monoclonal antibodies, including
Aduhelm,&nbsp;only in the context of clinical trials approved by CMS or by the National Institutes of Health. They include only randomized
controlled trials conducted in hospital-based outpatient settings, and require patient diversity reflecting that of the U.S. population
diagnosed with AD. &nbsp;CMS does not presently intend to cover the cost of these drugs outside the context of clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may in the future conduct clinical trials
for our product candidates outside the United States, and the FDA, EMA and other foreign regulatory authorities may not accept data from
such trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may in the future choose to conduct one or
more of our clinical trials outside the United States, including in Europe. The acceptance of study data from clinical trials conducted
outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authorities may be subject to certain
conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing
approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the
data are applicable to the United States population and United States medical practice; and (ii)&nbsp;the trials were performed by clinical
investigators of recognized competence and pursuant to cGCP, regulations. Additionally, the FDA&#8217;s
clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory
bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign
jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any other foreign regulatory authority will
accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA or any applicable foreign
regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming
and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization
in the applicable jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be successful in our efforts
to build a pipeline of additional product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to identify and successfully
develop new product candidates. Even if we are successful in building our product pipeline, the potential product candidates that we identify
may not be suitable for clinical development or, if deemed suitable for clinical development, successful in any clinical trials. For example,
product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be successfully
developed, much less receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product
candidates, we will not be able to obtain product revenue in future periods, which would result in significant harm to our financial position
and adversely affect our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not achieve our projected development
goals in the time frames we announce and expect, the commercialization of our products may be delayed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may estimate the timing
of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes
refer to as milestones. These milestones may include the commencement or completion of nonclinical studies and clinical trials and the
submission of regulatory filings, including BLA submissions. From time to time, we may publicly announce the expected timing of some of
these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can
vary significantly compared to our estimates, in some cases for reasons beyond our control. We may experience numerous unforeseen events
during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval
or commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may develop PMN310, PMN442, PMN267, and
future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may develop PMN310, PMN442, PMN267 and future
product candidates for use in combination with one or more other approved therapies for the disease state being studied. Even if any product
candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we
would continue to be subject to the risk that the FDA, EMA or comparable foreign regulatory authorities could revoke approval of the therapy
used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing
therapies. This could result in our own products being removed from the market or being less successful commercially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, we will not be able to market and sell
any product candidate we develop in combination with an unapproved therapy for a combination indication if that unapproved therapy does
not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved therapies face the same
risks described with respect to our product candidates currently in development, including the potential for serious adverse effects,
delay in their clinical trials and lack of FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in methods of product candidate
manufacturing or formulation may result in additional costs or delay.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As product candidates proceed through nonclinical
studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development
program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and product characteristics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such changes carry the risk that they will not
achieve our intended objectives. Any such changes could cause our product candidates to perform differently and affect the results of
planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes
may also require additional testing, FDA notification approval. This could delay completion of clinical trials, require the conduct of
bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product
candidates and jeopardize our ability to commence sales and generate revenue. In addition, we may be required to make significant changes
to our upstream and downstream processes across our pipeline, which could delay the development of our future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Commercialization of Our
Product Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Successful commercialization of our products,
if approved, will depend on a number of factors and we cannot guarantee that we will be able to successfully commercialize our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful commercialization of our products,
if at all, will depend on a number of factors, including our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">raise sufficient capital to fund future commercialization efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">build a commercial team and supporting organizational infrastructure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain necessary licenses, on commercially reasonable terms, for certain offerings the Company may contemplate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">establish partnerships and alliances with third parties to secure commercial capabilities that we may
not wish to build;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">market and distribute our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">distinguish our products from others available on the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">obtain any necessary regulatory approvals for our facilities, products and processes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">gain reimbursement by third-party payors, such as private health insurers, managed-health organizations,
and state-sponsored health insurance plans for each jurisdiction in which our products are offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">educate physicians and change physician behavior to secure clinical adoption of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">promote awareness of our products to increase market penetration; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">publish in peer-reviewed journals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that we will be successful
in these areas. Any failure or delay in such areas could have a material adverse impact on our business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The market opportunities for PMN310, PMN442,
PMN267, and future product candidates, if approved, may be smaller than we anticipate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to seek approval for product candidates
for various neurodegenerative diseases and other mis-folded protein diseases. Our estimates of market potential have been derived from
a variety of sources, including scientific literature, patient foundations and market research and may prove to be incorrect. Even if
we obtain significant market share for our product candidates after FDA approval, the potential target populations may be too small to
consistently generate revenue, and we may never achieve profitability without obtaining marketing approval for additional indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if our current or future product candidates
obtain regulatory approval, they may fail to achieve the broad degree of adoption and use by physicians, patients, hospitals, healthcare
payors and others in the medical community necessary for commercial success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if one or more of our product candidates
receive FDA or other regulatory approvals, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare
payors and others in the medical community. Most of our product candidates target mechanisms for which there are limited or no currently
approved products, which may result in slower adoption by physicians, patients and payors. If our product candidates do not achieve an
adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance
of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the clinical indications for which the product is approved and patient demand for approved products that
treat those indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the safety and efficacy of our product as compared to other available therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the availability of coverage and adequate reimbursement from governmental healthcare plans or third party
payors for any of our product candidates that may be approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">physician and patient willingness to adopt a new therapy over other available therapies to treat approved
indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">overcoming any biases physicians or patients may have toward particular therapies for the treatment of
approved indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">proper training and administration of our product candidates by physicians and medical staff;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">public misperception regarding the use of our therapies, if approved for commercial sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">patient satisfaction with the results and administration of our product candidates and overall treatment
experience, including, for example, the convenience of any dosing regimen;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement
levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors,
physicians and patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the revenue and profitability that our products may offer a physician as compared to alternative therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">limitations or warnings contained in the FDA-approved labeling for our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">any FDA requirement to undertake a REMS;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the effectiveness of our sales, marketing and distribution efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">adverse publicity about our products or favorable publicity about competitive products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">potential product liability claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that our current or future
product candidates, if approved, will achieve broad market acceptance among physicians, patients, healthcare payors and others in the
medical community. Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such
product candidate will be more effective than other commercially available alternatives or successfully commercialized. Any approval we
may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes
significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical
trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory
authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a REMS. Any failure
by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our
reputation, ability to raise additional capital, financial condition, results of operations and business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates have never been manufactured
on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale. In particular, we will need to
develop a larger scale manufacturing process that is more efficient and cost-effective to commercialize our potential products, which
may not be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates have never been manufactured
on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost
overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability
of raw materials. There is no assurance that our third-party manufacturers will be successful in establishing a larger-scale commercial
manufacturing process for our product candidates which achieves our objectives for manufacturing capacity and cost of goods. In addition,
there is no assurance that any third-party manufacturers will be able to manufacture our product candidates to specifications acceptable
to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of
such products or to meet potential future demand. Our failure to properly or adequately scale up manufacturing for commercial scale would
adversely affect our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The successful commercialization of our
product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage,
reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates,
if approved, could limit our ability to market those drugs and decrease our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The availability and adequacy of coverage
and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party
payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved.
Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health
insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Even if we
obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or
may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United
States, the European Union or elsewhere will be available for our product candidates or any product that we may develop, and any
reimbursement that may become available may be decreased or eliminated in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors increasingly are challenging
prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement
for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible
that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the
less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing
of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny
or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too
low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is
available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain
a satisfactory financial return on our investment in the development of product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant uncertainty related to the
insurance coverage and reimbursement of newly-approved products. In the United States, third-party payors, and governmental healthcare
plans, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will
be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental
payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of
coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot
predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No uniform policy for coverage and reimbursement
for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly
from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us
to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage
and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&nbsp;and regulations regarding
reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules&nbsp;and regulations are likely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, international operations
are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on
cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage
of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of
national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company
profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge
for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced
compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, increasing efforts by governmental
and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both
coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate
payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates
due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative
changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures
and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We currently have no sales organization. If we are unable to
establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively
in the United States and foreign jurisdictions, if approved, or generate product revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not have a marketing or sales
organization. &nbsp;In order to commercialize our product candidates in the United States and foreign jurisdictions, if approved, we intend
to make arrangements with third parties to perform these services, and we may not be successful in doing so. If we are unable to enter
into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates, if approved.
 &nbsp;If we are not successful in commercializing our product candidates or any future product candidates, if approved, either on our
own or through arrangements with third parties, we may not be able to generate any product revenue and we would incur significant additional
losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Position and
Capital Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will require additional financing to
achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay,
limit, reduce or terminate our development programs, commercialization efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of biopharmaceutical therapeutic candidates is capital-intensive. We expect our expenses to increase in connection with our
ongoing activities, particularly as we conduct our ongoing and planned preclinical studies of our development programs, initiate clinical
trials for our therapeutic candidates and seek regulatory approval for our current therapeutic candidates and any future therapeutic candidates
we may develop. If we obtain regulatory approval for any of our therapeutic candidates, we also expect to incur significant commercialization
expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical
trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization
of our therapeutic candidates. Furthermore, following the effectiveness of this Registration Statement, we expect to incur additional
costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection
with our continuing operations. </FONT>We had negative working capital of $909,759 as of December&nbsp;31, 2020. Our ability to raise
additional financing and maintain operations in the future could be at substantial risk. We will require substantial additional funds
for further research and development, planned clinical testing, regulatory approvals, establishment of manufacturing capabilities and,
if necessary, the marketing and sale of its products. There can be no assurance that additional funding or partnerships will be available
on acceptable terms and that would foster successful commercialization of our products. Failing to raise capital when needed or on attractive
terms could force us to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may attempt to raise additional funds for these
purposes through public or private equity or debt financing, collaborations with other biopharmaceutical companies and/or from other sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have no product candidates approved for
commercial sale, we have never generated any revenue from sales and we may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no product candidates approved for sale, have never generated any revenue from sales, have never been profitable and do not expect
to be profitable in the foreseeable future. </FONT>To date, we have not recorded any revenues from the sale of biopharmaceutical products.
As at December&nbsp;31, 2020, we had a deficit of $52,401,095. Since we changed our name and focus in July&nbsp;2015, the cumulative deficit
incurred since that date through December&nbsp;31, 2020 was $23,281,770. We expect to incur additional losses during the periods of research
and development, clinical testing, and application for regulatory approval of its product candidates. We also expect to incur losses unless
and until such time as payments from corporate collaborations, product sales and/or royalty payments generate sufficient revenues to fund
its continuing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have devoted most of our financial
resources to research and development of PMN310, including our nonclinical development activities of PMN310, and corporate overhead. We
expect that it will be several years, if ever, before we have a product candidate approved and ready for commercialization. We expect
to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and
seek regulatory approvals for, PMN310 and any other product candidate we may develop in the future, prepare for and begin the commercialization
of any approved product candidates and add infrastructure and personnel to support our drug development efforts and operations as a public
company. We anticipate that any such losses could be significant for the next several years. These net losses and negative cash flows
have had, and will continue to have, an adverse effect on our shareholders&#8217; equity and working capital. Further, these net losses
may fluctuate significantly from quarter-to-quarter or year-to-year. To become and remain profitable, we must develop and eventually commercialize
PMN310 or another drug with significant revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may never succeed in developing a commercial
drug and, even if we succeed in commercializing one or more product candidates, we may never generate revenues that are large enough to
achieve profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown
challenges. Because of these numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased expenses
or when, or if, we will be able to generate revenues or achieve profitability. If we do achieve profitability, we may not be able to sustain
or increase profitability on a quarterly or annual basis, and we will continue to incur substantial research and development costs and
other expenditures to develop and market additional product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Dependence on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will rely on third parties to supply
components, research, develop, test, and manufacture our product candidates and market, if approved. The loss of any of these third party
relationships or the failure of any of them to meet their obligations to us could affect our ability to develop and obtain approval of
our product candidates PMN310 in a timely manner.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our</FONT>
activities will require us to enter into various arrangements with corporate and academic collaborators, licensors, licensees and others
for the research, development, clinical testing, manufacturing, marketing and commercialization of our products. We intend to attract
corporate partners and enter into additional research collaborations. There can be no assurance, however, that we will be able to establish
such additional collaborations on favorable terms, if at all, or that our current or future collaborations will be successful. Failure
to attract commercial partners for our products may result in substantial clinical testing, manufacturing and commercialization costs
prior to realizing any revenue from product sales or result in delays or program discontinuance if funds are not available in sufficient
quantities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should any collaborative partner fail to
develop, manufacture, or successfully commercialize any product to which we have rights, or any partner&#8217;s product to which we
will have rights, our business may be adversely affected. Failure of a collaborative partner to continue to participate in any
particular program could delay or halt the development or commercialization of products generated from such program. In addition,
there can be no assurance that the collaborative partners will not pursue other technologies or develop alternative products either
alone or in collaboration with others, including our competitors, as a means for developing treatments for the diseases targeted by
our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, we will hold licenses for certain
technologies and there can be no assurance that these licenses will not be terminated, or that they will be renewed on acceptable conditions.
We intend to negotiate additional licenses in respect of technologies developed by other companies and academic institutions. Terms of
license agreements to be negotiated may include, <I>inter alia</I>, a requirement to make milestone payments, which may be substantial.
We will also be obligated to make royalty payments on the sales, if any, of products resulting from licensed technology and, in some instances,
may be responsible for the costs of filing and prosecuting patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We intend to rely on contract research organizations,
or CROs, and other third parties to conduct, supervise and monitor a significant portion of our research and nonclinical testing and clinical
trials for our product candidates, and if those third parties do not successfully carry out their contractual duties, comply with regulatory
requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize product candidates,
or such approval or commercialization may be delayed, and our business may be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to engage CROs and other third parties
to conduct our planned nonclinical studies or clinical trials, and to monitor and manage data. We expect to continue to rely on third
parties, including clinical data management organizations, medical institutions and clinical investigators, in the future. Any of these
third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time for convenience.
If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative
third parties or to do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires
management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur,
which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships
with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges
will not have a material adverse impact on our business, financial condition and prospects. Further, the performance of our CROs and other
third parties conducting our trials may also be interrupted by the ongoing COVID-19 pandemic, including due to travel or quarantine policies,
heightened exposure of a CRO or clinical site or other vendor staff who are healthcare providers to COVID-19 or prioritization of resources
toward the pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any third parties conducting our
clinical trials will not be our employees, and, except for remedies available to us under our agreements with such third parties, we cannot
control whether or not they devote sufficient time and resources to our clinical programs. If these third parties do not successfully
carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy
of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for
other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or
successfully commercialize our product candidates. Consequently, our results of operations and the commercial prospects for our product
candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on these parties for execution of
our nonclinical studies and clinical trials and generally do not control their activities. Our reliance on these third parties for
research and development activities will reduce our control over these activities but will not relieve us of our responsibilities.
For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general
investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with Good Clinical Practices, or GCPs,
which are standards for conducting, recording and reporting the results of clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. If we or any of
our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our
clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given
regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In
addition, our clinical trials must be conducted with product produced under cGMPs conditions. Our failure to comply with these
regulations may require us to repeat clinical trials, which would delay the regulatory approval process, or may result in fines,
adverse publicity and civil and criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also are required to register certain ongoing
clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within
specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, principal investigators for our clinical
trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.
Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial
relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial.
The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical
trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and
may ultimately lead to the denial of marketing approval for PMN310 or any other product candidate we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also expect to rely on other third parties
to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay
clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses
and depriving us of potential revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If any of our third-party manufacturers
encounter difficulties in production of PMN310, PMN442, PMN267 or any future product candidate we develop, or fail to meet rigorously
enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or, if approved, for commercial
sale could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The processes involved in manufacturing PMN310,
PMN442, PMN267 and any other product candidate we may develop are highly-regulated and subject to multiple risks. As product candidates
are developed through nonclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various
aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results.
Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates
to perform differently and affect the results of planned clinical trials or other future clinical trials. When changes are made to the
manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality,
purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities
of our third-party manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination,
which could delay clinical trials and adversely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to conduct clinical trials of our
product candidates, or supply commercial product candidates, if approved, we will need to manufacture them in both small and large
quantities. We currently rely on third parties to manufacture our product candidates, and our manufacturing partners will have to
modify and scale-up the manufacturing process when we transition to commercialization of our product candidates, if approved. Our
manufacturing partners may be unable to successfully modify or scale-up the manufacturing capacity for any of our product candidates
in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our
manufacturing partners are unable to successfully scale-up the manufacture of our product candidates in sufficient quality and
quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory
approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.
In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design and
execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the manufacturing process for any
product candidates that we may develop will be subject to FDA, EMA and foreign regulatory requirements, and continuous oversight, and
we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including
complying with cGMPs on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce product candidates in
accordance with the requirements of the FDA, EMA or other regulatory authorities, we may not obtain or maintain the approvals we need
to commercialize such product candidates. Even if we obtain regulatory approval for any of our product candidates, there is no assurance
that either we or our third party contract manufacturers will be able to manufacture the approved product in accordance with the requirements
of the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch
of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging
clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates,
impair commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results
of operations and growth prospects. Significant non-compliance could also result in the imposition of sanctions, including warning or
untitled letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product
candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions
and criminal prosecutions, any of which could damage our reputation and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will likely seek collaborations with
third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not
be able to capitalize on the market potential of those product candidates, including PMN310, PMN442, and PMN267.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will likely seek third-party collaborators
for the commercialization of PMN310, PMN442, and PMN267 and any of our future product candidates, in the United States and may enter into
collaboration agreements for the development and commercialization of any of our product candidates outside the United States. In the
United States, commercialization partners are likely to include large biotechnology or pharmaceutical companies. Our likely collaborators
outside the United States would most likely include regional and national pharmaceutical companies and biotechnology companies. If we
enter into such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that
our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these
arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaborations involving our product candidates
would pose the following risks to us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>collaborators may not perform their obligations as expected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect
not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217;
strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon
a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
under terms that are more economically attractive than ours;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates
or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may
not commit sufficient resources to the marketing and distribution of such products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course
of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead
to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would
be time-consuming and expensive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information
in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose
us to potential litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional
capital to pursue further development or commercialization of the applicable product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaboration agreements may not lead to development
or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours were to be involved
in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed,
diminished or terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face significant competition in seeking
appropriate collaborators. Whether we reach a definitive agreement for any collaboration will depend, among other things, upon our
assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the
proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials,
the likelihood of approval by the FDA, EMA or similar regulatory authorities outside the United States, the potential market for the
subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the
potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there
is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The
collaborator may also consider alternative product candidates or technologies for similar indications that may be available to
collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.
Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent
business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future
collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to negotiate additional collaborations
on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate,
reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce
the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities
at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need
to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may
not be able to further develop our product candidates or bring them to market and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain</I></B></FONT><B><I> sufficient intellectual property protection for our product candidates, and
other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad,
our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our
product candidates, and other proprietary technologies if approved, may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success will depend in part on
our ability to obtain and maintain a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual
property related to our product candidates, and other proprietary technologies we develop. If we are unable to obtain or maintain patent
protection with respect to our product candidates, and other proprietary technologies we may develop, our business, financial condition,
results of operations, and prospects could be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent position of biotechnology and pharmaceutical
companies is highly uncertain and involves complex legal, scientific, and factual questions and has been the subject of frequent litigation
in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.
Our patent applications may not result in patents being issued that protect our product candidates and other proprietary technologies
we may develop or that effectively prevent others from commercializing competitive technologies and products. Further, no consistent policy
regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many jurisdictions outside
of the United States. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may
diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the patents
that may be issued from the applications we may own or license from third parties. Further, if any patents we obtain or license are deemed
invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent application process is subject to numerous
risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators will be successful
in protecting our product candidates and other proprietary technologies and their uses by obtaining, defending and enforcing patents.
These risks and uncertainties include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the United States Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with
a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result
in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patent applications may not result in any patents being issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issued patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or may otherwise not provide
any competitive advantage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make,
use and sell our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">other parties may have designed around our claims or developed technologies that may be related or competitive to ours, may have filed
or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications and/or
patents, either by claiming the same composition of matter, methods or formulations or by claiming subject matter that could dominate
our patent position;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies
or the successful commercialization of any product candidate that we may develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot
be certain that we or our licensors were the first to file any patent application related to our product candidates and other proprietary
technologies and their uses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any
of the subject matter covered by the patent claims of any application with an effective filing date before March&nbsp;16, 2013;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection
both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide
health concerns; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing
foreign competitors a better opportunity to create, develop, and market competing product candidates in those countries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent prosecution process is expensive, time-consuming,
and complex, and we may not be able to file, prosecute, or maintain all necessary or desirable patent applications at a reasonable cost
or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before
it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have
access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific
collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements
and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection for such output.
In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions
and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific
literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically
not published until 18 months after filing, or in some cases not at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The degree of future protection for our proprietary
rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain
or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may
be able to use our product candidates and other proprietary technologies and erode or negate any competitive advantage we may have, which
could have a material adverse effect on our financial condition and results of operations. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we might not have been the first to file patent applications for these inventions;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others may independently develop similar or alternative technologies or duplicate any of our technologies;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any patents that we obtain may not provide us with any competitive advantages;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we may not develop additional proprietary technologies that are patentable;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our competitors might conduct research and development activities in countries where we do not have patent rights or where patent
protection is weak and then use the information learned from such activities to develop competitive products for sale in our major commercial
markets;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before
the relevant patents that we own or license expire; or</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the patents of others may have an adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Others have filed, and in the future are likely
to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our
business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed
or in-licensed by us, or that we or our licensors will not be involved in interference, opposition or invalidity proceedings before U.S.
or non-U.S. patent offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that claims in an issued
patent covering our product candidates will be considered patentable by the USPTO, courts in the United States, or by patent offices and
courts in foreign countries. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in
the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual
property internationally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The strength of patents in the biotechnology and
pharmaceutical fields involves complex legal and scientific questions and can be uncertain. Patent applications that we file or in-license
may fail to result in issued patents with claims that cover our product candidates in the United States or in foreign countries. Even
if such patents do successfully issue, third parties may challenge the ownership, validity, enforceability, or scope thereof, which may
result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to our patents could deprive us of
exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged,
our patents may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from
designing around our claims. If the breadth or strength of protection provided by our patents with respect to our product candidates is
threatened, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For U.S. patent applications in which claims are
entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party or instituted by the
USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our patents or patent applications.
An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party.
Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in
an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For U.S. patent applications containing a claim
not entitled to priority before March&nbsp;16, 2013, there is greater level of uncertainty in the patent law. In September&nbsp;2011,
the Leahy-Smith America Invents Act, or America Invents Act, was signed into law. The America Invents Act includes a number of significant
changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent
litigation. The USPTO is developing regulations and procedures to govern the administration of the America Invents Act, and many of the
substantive changes to patent law associated with the America Invents Act, and in particular, the &#8220;first to file&#8221; provisions,
were enacted on March&nbsp;16, 2013. This will require us to be cognizant going forward of the time from invention to filing of a patent
application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications
on our inventions. It remains unclear what impact the America Invents Act will have on the operation of our business. As such, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the
enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to protect
our competitive position on our product candidates for an adequate amount of time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of any individual patent depends on applicable
law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally
has a term of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under
certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. When the terms of all patents
covering our product candidates expire, our business may become subject to competition from competitive products, including biosimilar
version of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates are protected by certain
patents, which expire at varying times. We cannot be certain that we will file and, if filed, obtain patent protection for our product
candidates beyond our rights in our current patent portfolio. If we are unable to obtain additional patent protection on our product candidates,
our primary protection from biosimilar market entries will be limited to regulatory biologic exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not obtain patent term extension
for our product candidates our business may be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depending upon the timing, duration, and specifics
of any FDA marketing approval of our product candidates, one or more of patents issuing from U.S. patent applications that we file or
license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984,
or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term, or PTE, of up to five years as compensation for
patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond
a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug,
a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization
delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection
Certificate, or SPC. If we encounter delays in our development efforts, including our future clinical trials, the period of time during
which we could market our product candidates under patent protection would be reduced. Additionally, we may not receive an extension if
we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable
requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are
unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which
we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products
following our patent expiration, and our revenue could be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
in the agreements under which we license intellectual property rights from third parties, or otherwise experience disruptions to our business
relationships with our licensors, we could lose license rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensing of intellectual property rights is of
critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our
licensors regarding intellectual property rights subject to a license agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the scope of rights granted under the license agreement and other interpretation-related issues;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not
subject to the license agreement;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our right to sublicense intellectual property rights to third parties under collaborative development relationships;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization
of our product candidates, and what activities satisfy those diligence obligations; and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us
and our partners.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If disputes over intellectual property rights
that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms and/or to secure
our rights to the licensed intellectual property, our business, results of operations, financial condition, and prospects may be adversely
affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could
suffer adverse consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The USPTO and various foreign governmental patent
agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent process.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are
due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. We have
systems in place to remind us to pay these fees, and we employ outside counsel to pay these fees due to foreign patent agencies. While
an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there
are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market with
similar or identical products or technology earlier than should otherwise have been the case, which would have a material adverse effect
on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in U.S. patent law could diminish
the value of patents in general, thereby impairing our ability to protect our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is the case with other biotechnology and
pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing
patents. Our patent rights may be affected by developments or uncertainty in U.S. or foreign patent statutes, patent case law, USPTO
rules&nbsp;and regulations or the rules&nbsp;and regulations of foreign patent offices. Obtaining and enforcing patents in the
biotechnology and pharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming
and inherently uncertain. In addition, the United States may, at any time, enact changes to U.S. patent law and regulations,
including by legislation, by regulatory rule-making, or by judicial precedent, that adversely affect the scope of patent protection
available and weaken the rights of patent owners to obtain patents, enforce patent infringement and obtain injunctions and/or
damages. For example, the scope of patentable subject matter under 35 U.S.C. 101 has evolved significantly over the past several
years as the Court of Appeals for the Federal Circuit and the Supreme Court issued various opinions, and the USPTO modified its
guidance for practitioners on multiple occasions. Other countries may likewise enact changes to their patent laws in ways that
adversely diminish the scope of patent protection and weaken the rights of patent owners to obtain patents, enforce patent
infringement, and obtain injunctions and/or damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the United States and other governments
may, at any time, enact changes to law and regulation that create new avenues for challenging the validity of issued patents. For example,
the America Invents Act created new administrative post-grant proceedings, including post-grant review, <I>inter partes</I> review, and
derivation proceedings that allow third parties to challenge the validity of issued patents. This applies to all of our U.S. patents,
even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding
sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first
presented in a district court action. In addition to increasing uncertainty with regard to our ability to obtain patents in the future,
this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the
U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could
weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect our intellectual
property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents are of national or regional effect. Filing,
prosecuting, and defending patents on our product candidates, and other proprietary technologies we develop in all countries throughout
the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights
in the same manner and to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from
practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have
not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where
we have patent protection, but enforcement of such patent protection is not as strong as that in the United States. These products may
compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The requirements for patentability may differ
in certain countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires
a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval
for a drug and its patent status. In addition to India, certain countries in Europe and developing countries, including China, have compulsory
licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability
of patents against government agencies or government contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In those countries, we may have limited remedies
if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those
patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around
the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property
protection, particularly those relating to biotechnology or pharmaceutical products, which could make it difficult for us to stop
the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any,
may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become subject to claims challenging
the inventorship or ownership of our patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to claims that former employees
(including former employees of our licensors), collaborators or other third parties have an interest in our patents rights, trade secrets,
or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result
in the patents issuing thereon being unenforceable. For example, we may have inventorship disputes arise from conflicting views regarding
the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the
development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates
or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other
claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of
our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome
could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be successful in obtaining or
maintaining necessary rights to product components and processes for our development pipeline through in-licenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presently we have intellectual property rights
to our product candidates through a license from the UBC. We also have an intellectual property license through a license with the University
Hospital Network (&#8220;<B>UHN</B>&#8221;), Toronto, and, if this agreement remains in place, we could be required to pay low single
digit royalties to UBC and UHN in the future. Because our program may require the use of additional proprietary rights held by third parties,
the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition,
our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We
may be unable to acquire or in-license, on reasonable terms, proprietary rights related to any compositions, formulations, methods of
use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates.
Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to
the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license
replacement technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where we obtain licenses from or collaborate
with third parties, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to
maintain or enforce the patents, covering technology that we license from third parties, or such activities, if controlled by us,
may require the input of such third parties. If any of our licensors or collaboration partners fail to prosecute, maintain and
enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of
all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our
exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely
affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we
have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be
adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to the date upon
which we assumed control over patent prosecution. We may also require the cooperation of our licensors and collaborators to enforce
any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be
prosecuted and enforced in a manner consistent with the best interests of our business, or in compliance with applicable laws and
regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such
application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we will likely have obligations under
our current or future licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give
our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications,
could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail
to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed
patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.
Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third
parties may gain the freedom to seek regulatory approval of, and to market, products identical or similar to ours. Moreover, our licensors
may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of
their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine
the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant.
The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully
develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve
or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The licensing and acquisition of third-party proprietary
rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing
strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize
our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater
clinical development and commercialization capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, we have collaborated and may in the
future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements
with these institutions. Typically, these institutions provide us with an option to negotiate an exclusive license to any of the institution&#8217;s
proprietary rights in technology resulting from the collaboration. Regardless of such option to negotiate a license, we may be unable
to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution
may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. In
addition, disputes may arise under our existing or future license agreements with these institutions or with other counterparties which
may, among other things, lead to the termination or renegotiation of these agreements, or otherwise require us to incur significant financial
obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, companies that perceive us to be
a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license
or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at
all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms,
our ability to commercialize our products, and our business, financial condition, and prospects for growth, could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third-party claims alleging intellectual
property infringement may prevent or delay our drug discovery and development efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on our avoiding
infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and
outside the United States, involving patents and other intellectual property rights in the biotechnology and pharmaceutical
industries, as well as administrative proceedings for challenging patents, including <I>inter partes</I> review, interference and
reexamination proceedings before the USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. The America
Invents Act introduced new procedures including <I>inter partes</I> review and post grant review. The implementation of these
procedures brings uncertainty to the possibility of challenges to our patents in the future and the outcome of such challenges.
Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in
which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are
issued, the risk increases that our activities related to our product candidates may give rise to claims of infringement of the
patent rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries
have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various
types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not
always uniform. We cannot assure you that any of our current or future product candidates will not infringe existing or future patents.
We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties may assert that we are employing
their proprietary technology without authorization. There may be third-party patents of which we are currently unaware with claims to
materials, compositions, formulations, methods of manufacture or methods for treatment related to our product candidates, or the use or
manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months
or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our
product candidates, and other proprietary technologies may infringe, or which such third parties claim are infringed by the use of our
technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product
candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion
of management and other employee resources from our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we collaborate with third parties in the development
of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information
or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties,
which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against
certain intellectual property infringement claims brought by third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any claims of patent infringement asserted by
third parties would be time-consuming and could:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">result in costly litigation;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">divert the time and attention of our technical personnel and management;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">cause development delays;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">prevent us from commercializing our product candidates until the asserted patent expires or is finally held invalid, unenforceable,
or not infringed in a court of law;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble
damages if we are found to have been willfully infringing such intellectual property;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found
to be willfully infringing; and/or</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require us to enter into royalty or license agreements, which may not be available on commercially reasonable terms, or at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are sued for patent infringement, we would
need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims
are invalid or unenforceable, and we may not be able to do either. Proving invalidity or unenforceability is difficult. For example, in
the United States, proving invalidity before federal courts requires a showing of clear and convincing evidence to overcome the presumption
of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s
time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing
the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge
the validity or enforceability of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources
to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology,
fail to defend an infringement action successfully or have infringed patents declared invalid or unenforceable, we may incur substantial
monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from developing, manufacturing
or selling our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not always conduct independent reviews of
pending patent applications of and patents issued to third parties. We cannot be certain that any of our or our licensors&#8217; patent
searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims
or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and
every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization
of our product candidates in any jurisdiction, because:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">some patent applications in the United States may be maintained in secrecy until the patents are issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned
patents or applications can be revived;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could
cover our technologies, our product candidates or their uses;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect
due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patent applications in the United States are typically not published until 18 months after the priority date; and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">publications in the scientific literature often lag behind actual discoveries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the scope of a patent claim is
determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can
involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending
application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine
that our technologies or product candidates are not covered by a third party patent or may incorrectly predict whether a third
party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any
patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability
to develop and market our products or product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitors may have filed, and may in the
future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that
could limit our ability to make, use, sell, offer for sale or import our product candidates or future products or impair our competitive
position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing
product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture
or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over
one of our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another
party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared
by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible
that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention
prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar
laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our competitors may be able to sustain
the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any
uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to
raise the funds necessary to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a third party prevails in a patent infringement
lawsuit against us, we may have to stop making and selling the infringing product, pay substantial damages, including treble damages and
attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third
parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict whether any such license would
be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation,
we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may
fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further
develop and commercialize our product candidates, which could harm our business significantly. Even if we were able to obtain a license,
the rights may be nonexclusive, which may give our competitors access to the same intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims that we have
wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information
or trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As is common in the biotechnology and pharmaceutical
industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates,
and other proprietary technologies. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors.
We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other
information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights
or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could
result in substantial costs and be a distraction to our management team and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be involved in lawsuits to protect
or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued
patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or
other proceedings relating to patent and other intellectual property rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties including competitors may infringe,
misappropriate or otherwise violate our patents, patents that may issue to us in the future, or the patents of our licensors that are
licensed to us. To counter infringement or unauthorized use, we may need to or choose to file infringement claims, which can be expensive
and time-consuming. We may not be able to prevent, alone or with our licensors, infringement, misappropriation, or other violation of
our intellectual property, particularly in countries where the laws may not protect those rights as fully as in the United States, or
if we require, but do not receive, the consent or cooperation of our licensors to enforce such intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we choose to go to court to stop another party
from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule&nbsp;that such patents
are invalid, unenforceable, or should not be enforced against that third party for any number of reasons. In patent litigation in the
United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include
an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, lack of written
description, indefiniteness, or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected
with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution, i.e., committed
inequitable conduct. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms
for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation,
cancellation, or amendment of any foreign patents we or our licensors hold now or in the future. The outcome following legal assertions
of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant
were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interference or derivation proceedings provoked
by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our
patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology
or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us
a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the
same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs
and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse
effect on our ability to raise the funds necessary to conduct our future clinical trials, continue our research programs, license necessary
technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates
to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not have sufficient financial or
other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of
such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting
from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the
marketplace. Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may
cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities.
In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments
and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the
price of our Common Shares. Such litigation or proceedings could substantially increase our operating losses and reduce the
resources available for development activities or any future sales, marketing, or distribution activities. Furthermore, because of
the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during this type of litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to enforce our patent rights depends
on our ability to establish standing in a court of competent jurisdiction. Whether a patent holder or licensee of a patent has standing
can be uncertain and the considerations complex. However, if a licensor is required to be joined, and they are unwilling to do so, we
may be unable to proceed with an infringement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to enforce our patent rights depends
on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are
used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in
a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages
or other remedies awarded if we were to prevail may not be commercially meaningful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because of the expense and uncertainty of
litigation, we may not be in a position to enforce our intellectual property rights against third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the expense and uncertainty of litigation,
we may conclude that even if a third party is infringing our issued patent or patents that may issue from patent applications or other
intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best
interest of our company or our shareholders. In such cases, we may decide that the more prudent course of action is to simply monitor
the situation or initiate or seek some other non-litigious action or solution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade
secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on trade secrets to protect our proprietary
technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult
to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored
researchers, and/or other advisors, and inventions agreements with employees, consultants, and advisors, to protect our trade secrets
and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information
using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all
such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may
not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently
discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering
whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets
or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future,
if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure
to obtain or maintain trade secret protection could adversely affect our competitive business position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, such security measures may not
provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an
employee, consultant, customer, or third party with authorized access. Our security measures may not prevent an employee, consultant
or customer from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct
may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we
do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also
attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Even though we use commonly
accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts
inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain
this information or may come upon this or similar information independently, and we would have no right to prevent them from using that
technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent development,
the publication of journal articles, and the movement of personnel skilled in the art from company to company or academic to industry
scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators,
licensors, suppliers, third-party contractors, and/or consultants to publish data potentially relating to our trade secrets, our agreements
may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by
a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could
harm our competitive position. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution
of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and
other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by
our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.
If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced
and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise
maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection
or to protect our trade secret information may be jeopardized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our trademarks or trade names, once registered,
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect
our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets
of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity
and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by
owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over
the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete
effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors.
Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements
or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our
trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets,
domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
and could adversely affect our financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, any names we may propose to use
with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or
applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of
potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction)
objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort
to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third
parties, and be acceptable to the FDA. Similar requirements exist in Europe. Furthermore, in many countries, owning and maintaining
a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a
senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding
our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or
trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our
registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the
marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has
superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any collaboration arrangements that we may
enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our future products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any future collaborations that we enter into may
not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators.
Collaborations are subject to numerous risks, which may include that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or
commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products,
availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product
candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit sufficient resources
to or otherwise not perform satisfactorily in carrying out these activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary
information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property
or proprietary information or expose us to potential liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disputes may arise between us and a collaborator that causes the delay or termination of the research, development, or commercialization
of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or
commercialization of the applicable current or future products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in
such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting
in civil or criminal proceedings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property discovered through
government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements
and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract
with non-U.S. manufacturers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our patents may have been generated through
the use of U.S. government funding, and we may acquire or license in the future intellectual property rights that have been generated
through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in
inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide
license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances,
to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines
that: (1)&nbsp;adequate steps have not been taken to commercialize the invention; (2)&nbsp;government action is necessary to meet public
health or safety needs; or (3)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also
referred to as &#8220;march-in rights&#8221;). If the U.S.&nbsp;government exercised its march-in rights in our existing or future intellectual
property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual
property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation
from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if
the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property
within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements,
compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying
any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This
preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual
property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that
would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially
feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered
by such intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Legal and Regulatory Compliance
Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our relationships with customers, healthcare
providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and
abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with
such laws, we could face substantial penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare providers, including physicians, and
third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates
for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants,
customers and third- party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without
limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the
Physician Payments Sunshine Act and regulations promulgated under such laws. These laws will impact, among other things, our clinical
research, proposed sales, marketing and educational programs, and other interactions with healthcare professionals. In addition, we may
be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The
laws that will affect our operations include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly and willfully
                                                                     soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly,
                                                                     overtly or covertly, in cash or in kind in return for, or to induce, either the referral of an individual, or the purchase, lease,
                                                                     order or arrangement for or recommendation of the purchase, lease, order or arrangement for any good, facility, item or service for
                                                                     which payment may be made, in whole or in part, under a federal healthcare program,
such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value.
Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the
exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing,
purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person does not need
to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal civil and criminal false claims laws, including, without limitation, the federal False Claims Act, which can be enforced
by private citizens through civil whistleblower or qui tam actions, and civil monetary penalty laws which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from the federal government,
including Medicare, Medicaid and other government payors, that are false or fraudulent or knowingly making, using or causing to be made
or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money
to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. federal government.
Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers
with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing
false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. In
addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">HIPAA which created additional federal criminal statutes which prohibit, among other things, a person from knowingly and willfully
executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly
and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement
in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute,
a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a
violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the federal transparency laws, including the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs,
medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s
Health Insurance Program, with specific exceptions, to report annually to the CMS, information related to: (i)&nbsp;payments or other
 &#8220;transfers of value&#8217;&#8217; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors)
and teaching hospitals, and (ii)&nbsp;ownership and investment interests held by physicians and their immediate family members. Effective
January&nbsp;1, 2022, these reporting obligations  extended to include transfers of value made during the previous year to physician
assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and
certified nurse midwives; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">analogous state and foreign laws and regulations; state laws that require manufacturers to report information related to payments
and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing; state laws that require
pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government, or that otherwise restrict payments that may be made to healthcare providers; and state
and local laws that require the registration of pharmaceutical sales representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the breadth of these laws and the
narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our
business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or
other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in federal and state funded
healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a
corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages,
diminished profits and future earnings, reputational harm and the curtailment or restructuring of our operations, any of which could
harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk of our being found in violation of these
laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their
provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with
applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if
we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from
the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to
comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a healthcare company
may run afoul of one or more of the requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain regulatory approval for
PMN310, PMN442, PMN267 or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in
significant additional expense.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we obtain any regulatory approval for
PMN310, PMN442 and PMN267 or any future product candidates, such product candidates will be subject to ongoing regulatory requirements
applicable to research, development, testing, manufacturing, labeling, packaging, storage, advertising, promoting, sampling, record-keeping
and submission of safety and other post-market information, among other things. Any regulatory approvals that we receive for PMN310, PMN442,
PMN267 or any future product candidates may also be subject to Risk Evaluation and Mitigation Strategy, or REMS, limitations on the approved
indicated uses for which the drug may be marketed or to the conditions of approval or requirements that we conduct potentially costly
post-marketing testing and surveillance studies, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy
of the drug. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.
We will further be required to immediately report any serious and unexpected adverse events and certain quality or production problems
with our products to regulatory authorities along with other periodic reports. Any new legislation addressing drug safety issues could
result in delays in product development or commercialization, or increased costs to assure compliance. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States
or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if
we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, drug manufacturers are subject to
payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP
requirements and adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover
previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility
where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory
authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring
withdrawal of the drug from the market or suspension of manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to comply with applicable regulatory
requirements following approval of a product candidate, a regulatory authority may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue a Form&nbsp;483, an untitled letter or warning letter asserting that we are in violation of the law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issue a safety alert, Dear Healthcare Provider letter, press release or other communication containing warnings or safety information
about the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">mandate corrections to promotional materials and labeling or issuance of corrective information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspend or withdraw regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspend any ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse to approve a pending marketing application or supplement to an approved application or comparable foreign marketing application
(or any supplements thereto) submitted by us or our strategic partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">restrict the marketing or manufacturing of the drug;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">seize or detain the drug or otherwise require the withdrawal of the drug from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse to permit the import or export of products or product candidates; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refuse to allow us to enter into supply contracts, including government contracts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any government investigation of alleged violations
of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of
any event or penalty described above may inhibit our ability to commercialize a product candidate, if approved, and harm our business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with health and data protection
laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity
and could negatively affect our operating results and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to or affected by federal, state
and foreign data protection laws and regulations which address privacy and data security. In the United States, numerous federal and state
laws and regulations, including HIPAA, as amended by HITECH, state data breach notification laws, state health information privacy laws
and federal and state consumer protection laws, including Section&nbsp;5 of the Federal Trade Commission Act, which govern the collection,
use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of any
future collaborators. In addition, we may obtain health information from third parties, including research institutions from which we
obtain clinical trial data that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and other privacy
and data security laws. Depending on the facts and circumstances, we could be subject to significant administrative, civil and criminal
penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner
that is not authorized or permitted by HIPAA. Further, various states have implemented similar privacy laws and regulations. For example,
California also recently enacted the California Consumer Privacy Act of 2018, or CCPA. The CCPA gives California residents expanded rights
to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about
how their personal information is used. The CCPA also provides for civil penalties for violations, as well as a private right of action
for data breaches that is expected to increase data breach litigation. The CCPA went into effect on January&nbsp;1, 2020 and grants the
California Attorney General the power to bring enforcement actions for violations beginning July&nbsp;1, 2020. The CCPA has been amended
from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted.
As currently written, the CCPA may impact our business activities and as a result may increase our compliance costs and potential liability.
Many similar privacy laws have been proposed at the federal level and in other states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign data protection laws, including Regulation&nbsp;2016/679,
known as the General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information data subjects
in the EU or the United Kingdom, or UK. The GDPR went into effect on May&nbsp;25, 2018. Companies that must comply with the GDPR face
increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential
fines for noncompliance of up to &#8364;20&nbsp;million or 4% of annual global revenue of the noncompliance company, whichever is greater.
The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal information of EU or UK data subjects,
including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border
transfers of personal information, and honoring and providing for the rights of EU or UK individuals in relation to their personal information,
including the right to access, correct and delete their data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with U.S. and foreign data protection
laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance
exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217;
ability to operate in certain jurisdictions. Failure to comply with U.S. and foreign data protection laws and regulations could result
in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and
could negatively affect our operating results and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, clinical trial subjects about whom we
or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually
limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply
with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming
to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain FDA or EMA approval any
of our product candidates in the United States or European Union, we may never obtain approval for or commercialize any of them in any
other jurisdiction, which would limit our ability to realize their full market potential.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market any products in any particular
jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a&nbsp;country-by-country&nbsp;basis regarding
safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approval by the FDA in the United States or the
EMA in the European Union does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure
to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted
in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee
regulatory approval in any other country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approval processes vary among countries and can
involve additional product testing and validation and additional administrative review periods. In many jurisdictions outside the United
States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases,
the price that we intend to charge for our products is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Seeking foreign regulatory approval could
result in difficulties and increased costs for us and require additional nonclinical studies or clinical trials which could be
costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the
introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction,
including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we
fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory
approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market
potential of any product we develop will be unrealized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare legislative or regulatory reform
measures may have a negative impact on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. and many foreign jurisdictions have enacted
or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments
also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Affordable Care Act substantially changed
the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable
Care Act is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against
healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees
on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care
Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for
both branded and generic drugs, expanded the 340B program, and revised the definition of AMP, which could increase the amount of Medicaid
drug rebates manufacturers are required to pay to states. The legislation also extended Medicaid drug rebates, previously due only on
fee-for-service Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an alternative
rebate formula for certain new formulations of certain existing products that is intended to increase the number of rebates due on those
drugs. On February&nbsp;1, 2016, CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Affordable
Care Act. These regulations became effective on April&nbsp;1, 2016. Since that time, there have been significant ongoing efforts to modify
or eliminate the Affordable Care Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Affordable Care Act has been subject to challenges
in the courts. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in
its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On December&nbsp;18, 2019, the Fifth Circuit U.S.
Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider
its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&nbsp;17, 2021, the
U.S. Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to
the allegedly unlawful conduct.&nbsp; As a result, the U.S. Supreme Court did not rule&nbsp;on the constitutionality of the Affordable
Care Act or any of its provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other legislative changes have been proposed and
adopted since passage of the Affordable Care Act and we expect that additional federal, state and foreign healthcare reform measures will
be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and
services, which could result in limited coverage and reimbursement and reduced demand for our product candidates, if approved, or additional
pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business activities may be subject to
the FCPA and similar anti-bribery and anti-corruption laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business activities may be subject to
the FCPA, U.S. domestic bribery statutes, and similar anti-bribery or anti-corruption laws, regulations or rules&nbsp;of other
countries in which we may operate, including the U.K. Bribery Act of 2010. The FCPA generally prohibits offering, promising, giving,
or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to
influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books
and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of
internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public
officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by
the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. There is no certainty
that all of our employees, agents, contractors or those of our affiliates, will comply with all applicable laws and regulations,
particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines,
criminal sanctions against us, our officers, or our employees, the closing down of our facilities, implementation of compliance
programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our
product candidates in one or more countries and could materially damage our reputation, our brand, our international expansion
efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees, independent contractors,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements and insider trading, which could significantly harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to the risk of fraud or other misconduct
by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional
failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators,
comply with health care fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately
or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject
to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws
and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course
of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify
and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure
to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact
on our business, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our insurance policies are expensive and
only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not carry insurance for all categories of
risk that our business may encounter. Some of the policies we currently maintain include general liability, products liability and directors&#8217;
and officers&#8217; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Our
inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims
could prevent or inhibit the commercialization of PMN310 or any other product candidate. Any significant uninsured liability may require
us to pay substantial amounts, which would adversely affect our financial position and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_008"></A>Risks Related to Our Business
and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face significant competition in an environment
of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us
or develop therapies that are safer or more effective than ours.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of new drugs
is highly competitive. Moreover, the AD field is characterized by strong competition and a strong emphasis on intellectual property. We
may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical
companies, specialty pharmaceutical companies and biotechnology companies worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Potential competitors also include academic institutions,
government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, PMN310 will compete with therapies currently approved for the treatment of patients with AD, which have primarily been developed
to treat the symptoms of AD rather than the underlying cause of the disease, such as memantine and cholinesterase inhibitors. PMN310 may
also compete with one or more potentially disease-modifying therapeutics that target A</FONT>&#946; or amyloid plaques. Biogen Inc.&#8217;s
aducanumab was approved by the FDA in June&nbsp;2021 under the accelerated approval pathway, which allows for earlier approval of drugs
that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. Regulatory approval of aducanumab is
pending in Europe and Japan. Other companies known to be developing therapies with A&#946;/amyloid plaque-related targets include Alzheon,&nbsp;Inc.,
Alzinova AB, Chugai Pharmaceutical Co. Ltd., Cognition Therapeutics,&nbsp;Inc., Eisai Co.,&nbsp;Ltd., Eli Lilly and Company, Grifols,
S.A., KalGene Pharmaceuticals,&nbsp;Inc., Neurimmune AG, Novartis AG, Acumen Pharmaceuticals Inc., Prothena Biosciences,&nbsp;Inc., Roche
Holding AG (including Genentech, its wholly owned subsidiary) and Wren Therapeutics,&nbsp;Inc. Additionally, PMN310, if approved, may
also compete with other potential therapies intended to address underlying causes of AD that are being developed by several companies,
including AbbVie Inc., AC Immune SA, Alector,&nbsp;Inc., Anavex Life Sciences Corp., Annovis Bio,&nbsp;Inc., Athira Pharma,&nbsp;Inc.,
Biohaven Pharmaceuticals,&nbsp;Inc., Cassava Sciences,&nbsp;Inc., Cortexyme,&nbsp;Inc., Denali Therapeutics,&nbsp;Inc., Johnson&nbsp;&amp;
Johnson (including Janssen, its wholly-owned subsidiary) and Takeda Pharmaceutical Co. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our current or potential competitors,
either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development,
manufacturing, nonclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved product candidates
than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated
if our competitors develop and commercialize product candidates that are safer, more effective, have fewer or less severe side effects,
are more convenient, or are less expensive than any product candidates that we may develop. Furthermore, currently approved product candidates
could be discovered to have application for treatment of AD, which could give such product candidates significant regulatory and market
timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA or other regulatory approval for their
product candidates more rapidly than we may obtain approval for ours from the FDA, which could result in our competitors establishing
a strong market position before we are able to enter the market. Additionally, product candidates or technologies developed by our competitors
may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates
we may develop against competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our competitors market product candidates that
are more effective, safer or less expensive than our product candidates, if approved, or that reach the market sooner than our product
candidates, we may not achieve commercial success. In addition, the pharmaceutical industry is characterized by rapid technological change.
If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or product
candidates developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Ownership of Our Common Shares
and Our Status as a U.S. Public Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investment in the Company&rsquo;s Common
Shares is speculative, involves risk, and there is no guarantee of a return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no guarantee that the Common Shares will
earn any positive return in the short term or long term. A holding of Common Shares is speculative and involves a high degree of risk
and should be undertaken only by holders whose financial resources are sufficient to enable them to assume such risks and who have no
need for immediate liquidity in their investment. A holding of Common Shares is appropriate only for holders who have the capacity to
absorb a loss of some or all of their holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our
market, our </I></B></FONT><B><I>share price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our Common Shares will
be influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company,
we anticipate having only limited research coverage by equity research analysts. Equity research analysts may elect not to provide research
coverage of our Common Shares, and such lack of research coverage may adversely affect the market price of our Common Shares. In the event
we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their
reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable
commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly,
demand for our shares could decrease, which in turn could cause our shares price or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Concentration of ownership of our Common
Shares among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant
corporate decisions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on their shareholdings as of January 10,
2022, our directors, executive officers and beneficial owners of greater than 5% of our outstanding shares and their respective affiliates
will beneficially own, in the aggregate, approximately 25% of our outstanding Common Shares.
As a result, these persons, acting together, would be able to significantly influence all matters requiring shareholder approval, including
the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets or other significant
corporate transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of these persons or entities may have interests
different than yours. For example, because many of these shareholders purchased their shares at prices substantially below the estimated
public offering price and have held their shares for a longer period, they may be more interested in selling our Company to an acquirer
rather than other investors, or they may want us to pursue strategies that deviate from the interests of other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Anti-takeover provisions in our governing
documents and under Canadian Law could prevent or delay transactions that shareholders may favor.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions of our governing documents and the
CBCA may discourage, delay or prevent a merger or acquisition that shareholders may consider favorable, including transactions in which
shareholders might otherwise receive a premium for their Common Shares, and may also frustrate or prevent any attempt by shareholders
to change the direction or management. For example, these provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require a 66 <SUP>2</SUP>/3% majority of shareholder votes cast in favor of a resolution to effect various amendments to the Articles
of Incorporation of the Company, as amended (the &#8220;<B>articles</B>&#8221;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">require that in the event of shareholders of the Company vote via written resolution, that such resolution must be signed by all shareholders
of the Company entitled to vote on that resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">establish advance notice requirements for nominations for election to the Board at any annual or special meeting of shareholders of
the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
transaction in which a third party seeks to acquire our voting securities or equity securities that would result in the acquiror holding
greater than 20% of the securities of that class may be governed by Multilateral Instrument 62-104&#8212;<I>Take-Over Bids and Issuer
Bids </I>(the &quot;<B>Takeover Bid Rules</B>&quot;) promulgated by the Canadian Securities Administrators. The &quot;General Principles&quot;
of the Takeover Bid Rules&nbsp;and certain important aspects of the Takeover Bid Rules&nbsp;are described more fully in the section entitled
 &quot;<I>Description of the Registrant&#8217;s Securities to be Registered</I>&quot; on page&nbsp;114</FONT>; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company is party to a shareholder
                                            rights plan agreement (the &#8220;<B>Shareholder Rights Plan</B>&#8221;) dated as of January&nbsp;22,
                                            2016 and amended and extended as of May&nbsp;15, 2019 between the Company and Computershare
                                            Trust Company of Canada as rights agent to ensure, to the extent possible, that all shareholders
                                            of the Company are treated fairly in connection with any takeover bid for the Company. The
                                            Board authorized the issuance of one right in respect of each Common Share outstanding at
                                            5:00 p.m.&nbsp;(ET) on January&nbsp;22, 2016 and each Common Share issued thereafter. The
                                            rights will become exercisable if a person, together with their affiliates, associates and
                                            joint actors, acquires or announces an intention to acquire beneficial ownership of Common
                                            Shares which, when aggregated with its holdings, total 20% or more of our outstanding Common
                                            Shares (determined in the manner set out in the Shareholder Rights Plan). Following the acquisition
                                            of 20% or more of the outstanding Common Shares, each right held by a person other than the
                                            acquiring person and its affiliates, associates and joint actors would, upon exercise, entitle
                                            the holder to purchase that number of Common Shares at a substantial discount to the market
                                            price of the Common Shares at that time. Shareholder rights plans generally deter potential
                                            acquirors from making a take-over bid for securities of a company as it increases the cost
                                            of the securities of the company the acquiror is attempting to acquire.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The rights of our shareholders may differ
from the rights typically offered to shareholders of a U.S. corporation and these differences may make our Common Shares less attractive
to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the federal laws of Canada, and, therefore, certain of the rights of holders
of our shares are governed by Canadian law, including the provisions of the CBCA, and by our articles. These rights differ in
certain respects from the rights of shareholders in typical U.S. corporations and these differences may make our Common Shares less
attractive to investors. The principal differences are described in the section entitled &quot;<I>Description of the
Registrant&#8217;s Securities to be Registered</I>&quot; on page&nbsp;114</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to attract and retain senior
management and key scientific personnel, our business may be materially and adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends in part on our continued
ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon
members of our senior management, particularly our Chief Executive Officer, Eugene Williams, as well as our senior scientists and other
members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of
our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any
future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition for qualified personnel in the biopharmaceutical
field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need
to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract
and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be
subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information,
or that their former employers own their research output.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face an inherent risk of product liability
as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For
example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design,
a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant
financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">decreased demand for our current
                                            or future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">injury to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">withdrawal of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">costs to defend the related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">diversion of management&#8217;s
                                            time and our resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">substantial monetary awards to trial
                                            participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory investigations, product
                                            recalls, withdrawals or labeling, marketing or promotional restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">loss of revenue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the inability to commercialize our
                                            current or any future product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to obtain and maintain sufficient
product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization
of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance
covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment
or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for
which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage
limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts.
Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us
against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage
to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable
terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may explore strategic collaborations
that may never materialize or may fail.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may attempt to broaden the global reach
of our platform by selectively collaborating with leading therapeutic companies and other organizations. As a result, we may
periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product
candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. In the event we
do form such collaborations, we intend to retain significant economic and commercial rights to our programs in key geographic areas
that are core to our long-term strategy. We are likely to face significant competition in seeking appropriate strategic
collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to
negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any
additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &#8220;emerging growth company&#8221;
and a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging
growth companies and smaller reporting companies, our Common Shares may be less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &#8220;emerging growth company&#8221;
as defined in the JOBS Act and we intend to take advantage of some of the exemptions from reporting requirements that are applicable
to other public companies that are not emerging growth companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>not being required to comply with the auditor attestation requirements
                                            in the assessment of our internal control over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">not being required to comply with any requirement that may be
                                            adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation
                                            or a supplement to the auditor&#8217;s report providing additional information about the
                                            audit and the financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">reduced disclosure obligations regarding executive compensation
                                            in our periodic reports, proxy statements and registration statements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">not being required to hold a nonbinding advisory vote on executive
                                            compensation and shareholder approval of any golden parachute payments not previously approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict if investors will find our
Common Shares less attractive because we will rely on these exemptions. If some investors find our Common Shares less attractive as a
result, there may be a less active trading market for our Common Shares and our share price may be more volatile. We may take advantage
of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the
earlier of the last day of the fiscal year (i)&nbsp;following the fifth anniversary of the closing of our initial public offering, (ii)&nbsp;in
which we have total annual gross revenue of at least $1.07&nbsp;billion, or (iii)&nbsp;in which we are deemed to be a large accelerated
filer, which means the market value of our Common Shares that are held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th,
and the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the JOBS Act, emerging growth companies
can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected
to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced
disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject
to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies,
which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information
that we provide in this Registration Statement may be different than the information you may receive from other public companies in which
you hold equity interests. In addition, it is possible that some investors will find our Common Shares less attractive as a result of
these elections, which may result in a less active trading market for our Common Shares and higher volatility in our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &#8220;smaller reporting
company&#8221; as defined in the  Exchange Act. We may continue to be a smaller
reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures
available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting Common
Shares held by non-affiliates is more than $250&nbsp;million measured on the last business day of our second fiscal quarter, or our
annual revenues are more than $100&nbsp;million during the most recently completed fiscal year and our voting and non-voting Common
Shares held by non-affiliates is more than $700&nbsp;million measured on the last business day of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have never paid dividends on our capital
shares and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our Common Shares
will likely depend on whether the price of our Common Shares increases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any dividends
on our Common Shares and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future
earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future
will be at the discretion of our Board. Accordingly, investors must rely on sales of their Common Shares after price appreciation, which
may never occur, as the only way to realize any future gains on their investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to the continued listing
criteria of the TSX and our failure to satisfy these criteria may result in a delisting of our Common Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Shares are currently listed on the
TSX. In order to maintain our listing on TSX, we must maintain certain financial and share distribution targets, including maintaining
a minimum number of public shareholders. In addition to objective standards, the TSX may delist the securities of any issuer if, in its
opinion, an issuer&rsquo;s financial condition and/or operating results appear unsatisfactory, if it appears that the extent of public
distribution or the aggregate market value of a security has become so reduced as to make continued listing on the TSX inadvisable, if
the issuer sells or disposes of principal operating assets or ceases to be an operating company, if an issuer fails to comply with the
listing requirements of TSX, or if any other event occurs or any condition exists which makes continued listing on the TSX, in the opinion
of the TSX, inadvisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the TSX delists our Common Shares, investors
may face material adverse consequences, including, but not limited to, a lack of trading market for the Common Shares, reduced liquidity,
decreased analyst coverage of the Company, and an inability for us to obtain additional financing to fund our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot assure you that our Common Shares
will become listed on Nasdaq and, if listed, our failure to meet Nasdaq&rsquo;s continued listing requirements could result in a delisting
of our Common Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
we have submitted an application to list our Common Shares on Nasdaq, we cannot assure you that we will be able to meet the initial listing
standards, including the minimum per share price and minimum capitalization requirements, or that we will be able to maintain a listing
of our Common Shares on any such trading venue.</FONT> If, after listing, we fail to satisfy Nasdaq&rsquo;s continued listing requirements,
such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our Common
Shares. Such a delisting would likely have a negative effect on the price of our Common Shares and would impair your ability to sell or
purchase our Common Shares when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us
to restore compliance with listing requirements would allow our Common Shares to become listed again, stabilize the market price or improve
the liquidity of our Common Shares, prevent our Common Shares from dropping below the required minimum bid price or prevent future non-compliance
with Nasdaq listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our internal controls over financial reporting
may not be effective, which could have a material
and adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to reporting and other
obligations under applicable Canadian securities laws and rules&nbsp;of any stock exchange on which the Common Shares are listed, including
NI 52-109, and upon effectiveness of this Registration Statement, will be subject to U.S. securities reporting and regulatory requirements.
These reporting and other obligations place significant demands on our management, administrative, operational and accounting resources.
If we are unable to accomplish any such necessary objectives in a timely and effective manner, our ability to comply with our financial
reporting obligations and other rules&nbsp;applicable to reporting issuers could be impaired. Moreover, any failure to maintain effective
internal controls could cause us to fail to satisfy our reporting obligations or result in material misstatements in our financial statements.
If we cannot provide reliable financial reports or prevent fraud, our reputation and operating results could be materially adversely
affected, which could also cause investors to lose confidence in our reported financial information, which could result in a reduction
in the trading price of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not expect that its disclosure
controls and procedures and internal controls over financial reporting will prevent all error or fraud. A control system, no matter how
well-designed and implemented, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be
met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls
must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide
absolute assurance that all control issues within an organization are detected. The inherent limitations include the realities that judgments
in decision making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented
by individual acts of certain persons, by collusion of two or more people or by management override of the controls. Due to the inherent
limitations in a control system, misstatements due to error or fraud may occur and may not be detected in a timely manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The elimination of monetary liability against
our directors, officers, and employees under Canadian law and the existence of indemnification rights for our obligations to
our directors, officers, and employees may result in substantial expenditures by us and may discourage lawsuits against our directors,
officers, and employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
by-laws </FONT>provide that, subject to the CBCA, we may indemnify a director or officer or a former director or officer or a corporation
of which the we are or were a shareholder or creditor and their heirs and legal representatives of such person against all costs, charges,
and expenses including and amount to be paid to settle an action or satisfy a judgment, reasonably incurred in respect of any civil,
criminal or administrative action or proceeding to which they are made a party by reason of being or having been a director or officer
of us or a director or officer of any such corporation. Each director and officer upon being elected and appointed shall be deemed to
have contracted with us on the terms of this indemnity. The failure of a director or officer to comply with the provisions of the CBCA
or the articles or the by-laws shall not invalidate any indemnity to which they are entitled under the by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also have contractual indemnification
obligations under any future employment agreements with our officers or agreements entered into with our directors. The foregoing indemnification
obligations could result in us incurring substantial expenditures to cover the cost of settlement or damage awards against directors
and officers, which we may be unable to recoup. These provisions and the resulting costs may also discourage us from bringing a lawsuit
against directors and officers for breaches of their fiduciary duties, and may similarly discourage the filing of derivative litigation
by our shareholders against our directors and officers even though such actions, if successful, might otherwise benefit us and our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be difficulty in enforcing judgments
and effecting service of process on directors and officers that are not citizens of the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporated under the CBCA and some of
our directors and officers reside outside of the United States, in Canada. Consequently, it may not be possible for an investor to effect
service of process within the United States on us or those persons. Furthermore, it may not be possible for an investor to enforce judgments
obtained in United States courts based upon the civil liability provisions of United States federal securities laws or other laws of
the United States against us or those persons. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities
based upon United States federal securities laws and as to the enforceability in Canadian courts of judgments of United States courts
obtained in actions based upon the civil liability provisions of the United States federal securities laws. Therefore, it may not be
possible to enforce those actions against us and certain of our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are characterized as a passive foreign
investment company (&#8220;PFIC&#8221;), U.S. Holders may be subject to adverse U.S. federal income tax consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our current operations, income, assets
and certain estimates and projections, including as to the relative values of our assets, including goodwill, which is based on the expected
price of our Common Shares, we were not a PFIC for the 2020 taxable year and do not expect to be a PFIC for the 2021 taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, we must make an annual
determination as to whether we are a PFIC based on the types of income we earn and the types and value of our assets from time to
time, all of which are subject to change. Therefore, we cannot assure you that we will not be a PFIC for our current taxable year or
any future taxable year. A non-U.S. corporation generally will be considered a PFIC for any taxable year if either (1)&nbsp;at least
75% of its gross income is passive income or (2)&nbsp;at least 50% of the value of its assets (based on an average of the quarterly
values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income.
The market value of our assets may be determined in large part by the market price of the Common Shares, which is likely to
fluctuate. In addition, the composition of our income and assets will be affected by how, and how quickly, we use any cash that we
raise. If we were to be treated as a PFIC for any taxable year during which you hold Common Shares, certain adverse U.S. federal
income tax consequences could apply to U.S. Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this discussion, a &#8220;U.S.
Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of Common Shares, and who is: (i)&nbsp;an
individual who is a citizen or individual resident of United States; (ii)&nbsp;a corporation, or other entity taxable as a corporation,
created or organized in or under the laws of the United States, any state therein or the District of Columbia; (iii)&nbsp;an estate the
income of which is subject to U.S. federal income taxation regardless of its source; or (iv)&nbsp;a trust if (1)&nbsp;a U.S. court is
able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all
substantial decisions of the trust or (2)&nbsp;the trust has a valid election in effect to be treated as a U.S. person under applicable
U.S. Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur increased costs and demands
upon management as a result of being a public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company listed in the United States,
we will incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial
results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations
implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time-consuming. These
laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over
time as new guidance is provided by regulatory and governing bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to invest resources to comply with
evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion
of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts
to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against
us and our business may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to comply with these rules&nbsp;might
also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might
be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The
impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our Board, on committees
of our Board or as members of senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Comprehensive tax reform legislation could
adversely affect our business and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New income, sales, use or other tax laws, statutes,
rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance.
Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to
us. For example, the Tax Cuts and Jobs Act of 2017 (the &ldquo;<B>Tax Act</B>&rdquo;) enacted many significant changes to
the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect
us, and certain aspects of the Tax Act could be repealed or modified in future legislation. Furthermore, the "Coronavirus Aid, Relief,
and Economic Security Act" modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states
will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred
tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future
reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges,
and could increase our future U.S. tax expense. Among the changes made by the Tax Act was a reduction of the business tax credit for
certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#8220;orphan
drugs.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, the recent presidential and congressional
elections in the United States could also result in significant changes in, and uncertainty with respect to, tax legislation, regulation
and government policy directly affecting us and our business. For example, the United States government may enact significant changes
to the taxation of business entities including, among others, a permanent increase in the corporate income tax rate, elimination of certain
exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted
or implemented is unclear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge investors to consult with their legal
and tax advisers regarding the implications potential changes in U.S. tax laws on an investment in our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business and operations would suffer
in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or a natural disaster.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the implementation of security measures,
our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware,
natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach
or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development
programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption
or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur material legal claims and liability and damage to our reputation, and the further development of our product
candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disruptions at the FDA, the SEC and
other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key
leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or
otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which
could negatively impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the FDA to review and approve
new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key
personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have
fluctuated in recent years as a result. In addition, government funding of the SEC  and other government agencies on which our
operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently
fluid and unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Disruptions at the FDA and other agencies may
also slow the time necessary for new drugs or biologics to be reviewed and approved by necessary government agencies, which would adversely
affect our business. For example, over the last several years, including most recently from December&nbsp;22, 2018 to January&nbsp;25,
2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to
furlough critical FDA, SEC  and other government employees and stop critical activities. If a prolonged government shutdown occurs,
it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA and regulatory authorities outside the United
States may adopt policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. In response
to the COVID-19 pandemic, on March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing
facilities and products while local, national and international conditions warrant. On March&nbsp;18, 2020, the FDA announced its intention
to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct
of clinical trials, which the FDA continues to update. As of June&nbsp;23, 2020, the FDA noted it was continuing to ensure timely reviews
of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals and conducting mission
critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. As of July&nbsp;2020,
utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based on data about the virus&#8217;
trajectory in a given state and locality and the rules&nbsp;and guidelines that are put in place by state and local governments, FDA
is either continuing to, on a case-by-case basis, conduct only mission critical inspections, or, where possible to do so safely, resuming
prioritized domestic inspections, which generally include pre-approval inspections. Foreign pre-approval inspections that are not deemed
mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on a case-by-case basis. FDA
will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and advisable to do so. The FDA may
not be able to maintain this pace and delays or setbacks are possible in the future. Should FDA determine that an inspection is necessary
for approval, and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally
intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability
of a facility, FDA may defer action on the application until an inspection can be completed. Additionally, regulatory authorities outside
the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their
regulatory activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a prolonged government shutdown occurs, or
if global health concerns prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections,
reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory
submissions, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unfavorable global economic conditions
could adversely affect our business, financial condition or results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our results of operations could be adversely
affected by general conditions in the global economy and in the global financial markets. Portions of our future clinical trials may
be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make
those clinical trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression
resulting from the current COVID-19 pandemic or political disruption could result in a variety of risks to our business, including weakened
demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed
on acceptable terms, if at all. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which
the political or economic climate and financial market conditions could seriously harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="g_001"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
2. FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="g_002"></A>MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>All references in this management&rsquo;s
discussion and analysis, or MD&amp;A, to the &ldquo;Company&rdquo;, &ldquo;ProMIS&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, or
 &ldquo;our&rdquo; refer to ProMIS Neurosciences Inc., unless otherwise indicated or the context requires otherwise. The following
MD&amp;A is prepared as of January 28, 2022 for the year ended December 31, 2020 and 2019 and should be read in conjunction with the
audited consolidated financial statements for the year ended December 31, 2020 and 2019 (the &ldquo;<B>Financial
Statements</B>&rdquo;), which have been prepared by management in accordance with United States generally accepted accounting
principles (&ldquo;<B>U.S. GAAP</B>&rdquo;) as issued by the Financial Accounting Standards Board (&ldquo;<B>FASB</B>&rdquo;). All
dollar amounts refer to United States dollars, except as stated otherwise.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We are applying our patented
technology platform to build a portfolio of antibody therapies, therapeutic vaccines, and other antibody based therapies in neurodegenerative
diseases and other mis-folded protein diseases, including AD, MSA, ALS, PD, LBD, FTLD, PSP, CBD and schizophrenia. These diseases share
a common biologic cause &#8211; misfolded versions of proteins, that otherwise perform a normal function, kill neurons and produce disease.
Our technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial
intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics
or detecting them with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We are developing a pipeline of antibodies aimed
at selectively targeting misfolded toxic forms of proteins that drive neurodegenerative diseases without interfering with the essential
functions of the same properly folded proteins. Our product candidates are PMN310, PMN442 and PMN267. Our lead therapeutic program is
PMN310, a monoclonal antibody designed to treat AD by selectively targeting the toxic misfolded form of A&#946;. In light of research
suggesting that misfolded toxic a-syn is a primary driver of disease, our second lead product, PMN442, shows robust binding to a-syn oligomers
and seeding fibrils, with negligible binding to a-syn monomers and physiologic tetramers which are required for normal neuronal function.
PMN267 is our third lead product candidate, which has been shown to selectively recognize misfolded, cytoplasmic TDP-43 aggregates without
interacting with endogenous normal TDP-43. TDP-43 is believed to play an important role in the development of ALS. We also have a number
of development programs as discussed in the Business section of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We are incorporated under
the CBCA and located at 1920 Yonge Street, Toronto, Ontario. We are traded on the TSX under the symbol PMN and on the OTCQB Venture Market
under the symbol ARFXF. We have a wholly-owned U.S. subsidiary, ProMIS USA, which was incorporated in January 2016 in the State of Delaware.
ProMIS USA has had no activity and has no financial impact on our consolidated financial statements. Since our inception, we have devoted
substantially all of our resources to developing our platform technologies, building our intellectual property portfolio, business planning,
raising capital and providing general and administrative support for these operations. We have principally financed our operations through
private placements of common shares and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We have incurred significant
operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the
successful development and eventual commercialization of our product candidates and any future product candidates. Our net losses were
$4.3&nbsp;million and $5.5&nbsp;million for the years ended December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively. As of December&nbsp;31,
2020, we had an accumulated deficit of $52.4 million. We expect to continue to incur net losses for the foreseeable future and expect
our research and development expenses, general and administrative expenses and capital expenditures to increase. In particular, we expect
our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire
additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being
a public company. In addition, if we obtain marketing approval for any product candidates, we expect to incur significant commercialization
expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the in-licensing
or acquisition of additional product candidates. Furthermore, upon the effectiveness of this Registration Statement, we expect to incur
additional costs associated with operating as a public company in the United States, including significant legal, accounting, investor
relations, compliance and other expenses that we did not incur as a public Canadian company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">As a result, we will
need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can
generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt
financings, or other capital sources, which may include collaborations with other companies or other strategic transactions. We may
be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.
If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or
eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential
in-licenses or acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Because of the numerous risks
and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or
if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable.
If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations
at planned levels and be forced to reduce or terminate our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We expect that our cash
of $0.8&nbsp;million as of December 31, 2020, together with the gross proceeds of $7.0 million from a convertible debt offering in March
2021 and $20.1 million of proceeds from a public offering in August 2021 will fund our operating expenses and capital expenditure requirements
through first quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available
capital resources sooner than we expect. See &#8220;<I>Liquidity and Capital Resources</I>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Components of Operating Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We have not generated any
revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all. If our
product candidates are successful and result in marketing approval or if we enter into collaboration or license agreements with third
parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Research
and Development</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Research and development
expenses consist primarily of costs incurred in connection with the development and research of our platform technologies, as well as
unrelated discovery program expenses. We expense research and development costs as incurred. These expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">employee-related expenses, including salaries, related benefits and share-based compensation expense,
for employees engaged in research and development functions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">external research and development expenses incurred under arrangements with third parties, such as contract
research organizations or CROs, and consultants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of acquiring, developing, and manufacturing clinical study materials; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Costs associated with preclinical and clinical activities and regulatory operations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 44.75pt 0pt 0.75in; text-align: justify; text-indent: -19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We enter into consulting,
research, and other agreements with commercial entities, researchers, universities, and others for the provision of goods and services.
Such arrangements are generally cancelable upon reasonable notice and payment of costs incurred. Costs are considered incurred based
on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective
vendors, including our clinical sites. These costs consist of direct and indirect costs associated with our platform technologies, as
well as fees paid to various entities that perform certain research on our behalf. Depending upon the timing of payments to the service
providers, we recognize prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s
estimates of the work performed under service agreements, milestones achieved, and experience with similar contracts. We monitor each
of these factors and adjust estimates accordingly. See &#8220;<I>Item 1A. Risk Factors</I>&#8221; in this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Research and development
activities account for a significant portion of our operating expenses. We expect our research and development expenses to increase for
the foreseeable future as we continue to implement our business strategy, which includes advancing our platform technologies through clinical
development as well as other product candidates into clinical development, expanding our research and development efforts, including hiring
additional personnel to support our research efforts, our clinical and product development efforts, and seeking regulatory approvals for
our product candidates that successfully complete clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We use our personnel and
infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates.
Our direct research and development expenses consist primarily of external costs, including fees paid to consultants, contractors and
CROs in connection with our development activities and the cost of acquiring, developing, and manufacturing clinical study materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">General
and Administrative</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">General and
administrative expenses consist primarily of personnel costs including salary, bonus, employee-benefits and share-based
compensation, costs incurred in development and protection of intellectual property, professional service fees, and other general
overhead and facility costs, (including rent) depreciation and amortization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Result of Operations</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Comparison of the Years Ended December 31, 2020 and 2019</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-style: normal; font-weight: normal">The
following table summarizes our results of operations for the years ended December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; width: 61%">Operating expenses</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 61%; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,224,650 </FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,211,282 </FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(986,632</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,026,957</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,336,990</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(310,033</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in; font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 61%">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">4,251,607</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">5,548,272</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">(1,296,665</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,251,607</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,548,272</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,296,665</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,327</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">905</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">422</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,250,280</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(5,547,367</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,297,087</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and Development</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-style: normal; font-weight: normal">Research
and development expenses consisted of the following:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Years Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt; text-align: left">Direct research and development expenses by program:</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">725,381</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,052,791</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(327,410</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Indirect research and development expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Personnel related, including share-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,358,575</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,891,351</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(532,776</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Consulting expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">129,013</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">260,693</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(131,680</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Other operating costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,681</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,447</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,234</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,224,650</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,211,282</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(986,632</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Research
and development expenses decreased by $1.0 million or 31% for the year ended December 31, 2020, compared to the year ended December 31,
2019. The decrease represents a conservation of cash resources and decreased personnel related costs of $0.5 million, decreased spending
on external contract research organizations for direct research and development programs $0.3 million and decreased external consulting expense of $0.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and Administrative</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-style: normal; font-weight: normal">General
and administrative expenses consisted of the following:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-size: 10pt; text-align: left">Personnel related, including share-based compensation</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">736,529</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">829,077</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(92,548</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Professional and consulting fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">973,979</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,071,974</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(97,995</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256,126</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">308,561</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(52,435</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; width: 61%">Facility-related and other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">60,323</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">127,378</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">(67,055</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,026,957</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,336,990</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(310,033</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">General and administrative
expenses decreased by $0.3 million or 13% for the year ended December 31, 2020, compared to the year ended December 31, 2019. The decrease
is primarily attributable to  decreased personnel related costs of $0.1 million, decreased consulting fees of $0.1 million due to scale
down of investor relations activities, and decreased legal professional fees and foreign exchange gains of $0.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Income</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Other
income increased $422 or 47% for the year ended December 31, 2020, compared to the same period ended December 31, 2019, primarily due
to an increase in legacy royalty income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity and Capital Resources</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sources of Liquidity</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We are a development stage
company as we have had minimal recurring revenues to date and do not expect to have significant revenues until we are able to sell a product
candidate after obtaining applicable regulatory approvals or we establish collaborations that provide funding, such as licensing fees,
milestone payments, royalties, research funding or otherwise. Operations have been financed since inception, through the sale of equity
securities and the conversion of common share purchase warrants and share options. Our objectives, when managing capital, are to ensure
there are sufficient funds available to carry out our research, development and eventual commercialization programs. When we have excess
funds, we manage our liquidity risk by investing in highly liquid corporate and government bonds with staggered maturities to provide
regular cash flow for current operations. We do not hold any asset-backed commercial paper and our cash is not subject to any external
restrictions. We also manage liquidity risk by frequently monitoring actual and projected cash flows. The Board reviews and
approves the Company&#8217;s operating and capital budgets, as well as any material transactions not in the ordinary course of business.
The majority of our accounts payable and accrued liabilities have maturities of less than three months. We are dependent on our ability
to generate revenues from our products or secure additional financing in order to continue our research and development activities and
meet our ongoing obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In January 2019, we completed
a private placement of 9,560,000 common share units at a price of C$0.23 per unit resulting in gross proceeds of $1.7 million ($1.6 million,
net of issuance costs). Each unit consisted of one common share and one common share warrant. Each warrant is exercisable into one common
share at a price of C$0.48 per share at any time for five years. The expiry date of the warrants is subject to acceleration if, after
four months from issuance, the 20-day VWAP of the common shares exceeds C$1.00 or the Company
enters into a collaborative deal within 18 months of closing a qualifying transaction and the 20-day VWAP is greater than C$0.48 at any
time following the announcement of such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In June 2019, we completed
a private placement of 4,680,000 common share units at a price of C$0.25 per unit resulting in gross proceeds of $0.9 million ($0.8 million,
net of issuance costs). Each unit consisted of one common share and one common share warrant. Each warrant is exercisable into one common
share at a price of C$0.35 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In November and December
2019, we completed a private placement of 14,001,664 common share units at a price of C$0.20 per unit resulting in gross proceeds of $2.1
million ($2.0 million, net of issuance costs). Each unit consisted of one common share and one common share warrant. The common shares
are subject to a four-month hold period from the date of issuance. Each warrant is exercisable into one common share at a price of C$0.35
per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">During 2019, the Company
received proceeds from the exercise of warrants of approximately $0.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In March 2020, we announced
we had received approval from the TSX to amend the exercise price of an aggregate of 44,182,530 outstanding warrants. The exercise price
of the warrants repriced was C$0.13 per share, effective April 8, 2020 until May 22, 2020. At the end of the warrant repricing period,
all unexercised warrants will revert to the original exercise price. All other terms of the warrants shall remain unchanged. There was
a total of 44,182,530 warrants repriced and of the repriced warrants, 9,532,276 were exercised during the repricing period ending on May
22, 2020, for total proceeds of $0.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
November 2020, we closed on a special warrant financing (&quot;<B>Special Warrants</B>&quot;). We issued 16,219,581 Special Warrants for
gross proceeds of $1.5 million ($1.3 million, net of issuance costs). Each Special Warrant is exercisable, without payment of any additional
consideration by the holder, into one common share and one common share warrant (&ldquo;<B>Warrant</B></FONT>&rdquo;). Each Warrant
entitles the holder to acquire one common share at an exercise price at C$0.20 per warrant share for a period of 60 months until November
4, 2025. Each Special Warrant will automatically convert at the earlier of the date that is (i) the third business day after a receipt
for a final prospectus qualifying the distribution of the shares and warrants issuable upon the conversion of the Special Warrants and
(ii) four months and one day after the issue date of the Special Warrants. In March 2021, the Special Warrants automatically converted
into 16,219,581 common shares and 16,219,581 common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In March 2021, we completed
a $7.0 million private placement of unsecured convertible debentures (&quot;<B>Debentures</B>&quot;). The Debentures are convertible into
common shares at the option of the holder at a conversion price of $0.10 and accrue interest at 1% per annum, which is payable annually.
At the Company&rsquo;s election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the
interest due by the five-day VWAP of the common shares. The Debentures mature on March 22, 2026. Prior to the maturity date, the Company
may force conversion of the Debentures at the conversion price upon raising an aggregate of $50 million in equity and/or debt. On the
maturity date, the Company may redeem the outstanding principal amount of the Debentures in either cash or common shares (at the then
five-day VWAP less a 10% discount) or a combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In August 2021, we announced
the closing of a public offering of 125,781,250 units at a price of $0.16 per common share unit for gross proceeds of $20.1 million. Each
unit consisted of one common share and one-quarter common share warrant. Each warrant entitles the holder thereof to purchase one common
share at an exercise price of $0.21 per share at any time for five years.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We incurred a net loss of
$4.3 million for the year ended December 31, 2020 and reported an accumulated deficit of $52.4 million. In March 2021, we completed a
private placement of convertible unsecured debentures for proceeds of $7.0 million. In August 2021, we completed a public offering with
gross proceeds of $20,125,000. We expect available funds, including the proceeds from the March 2021 financing and August 2021 financing, will be
sufficient to fund our operating expenses through Q1 2024. However, additional funding will be necessary to fund future research, pre-clinical
and clinical activities. We will seek additional funding through public financings, debt financings, collaboration agreements, strategic
alliances and licensing agreements. Although we have been successful in raising capital in the past, there is no assurance of success
in obtaining such additional financing on terms acceptable to us, if at all, and there is no assurance that we will be able to enter into
collaborations or other arrangements. If we are unable to obtain funding, it could force to delay, reduce or eliminate research and development
programs, product portfolio expansion or commercialization efforts, which could adversely affect future business prospects, and the ability
to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">The following table summarizes
our sources and uses of cash for each of the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Years ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2019</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Net cash used in operating activities</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(3,232,532</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(4,484,017</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,251,485</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net cash used in investing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(83,089</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(156</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(82,933</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net cash provided by financing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,864,918</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,939,629</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,074,711</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Foreign exchange impact on cash</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(24,235</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">74,637</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(98,872</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 13.7pt"><FONT STYLE="font-size: 10pt">Net decrease in cash</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(474,938</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(469,907</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(5,031</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Cash
Flows from Operating Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Cash
used in operating activities was $3.2 million for the year ended December 31, 2020, <FONT STYLE="background-color: white">which consisted
of a net loss of $4.3 million, partially offset by $0.4&nbsp;million in non-cash charges and a net change of $0.7&nbsp;million in our
net operating assets and liabilities. The non-cash charges primarily consisted of share-based compensation of $0.4 million</FONT>. Changes
in cash flows related to operating assets and liabilities primarily consisted of a $0.6 million increase in deferred compensation for
management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Cash
used in operating activities was $4.5 million for the year ended December 31, 2019, <FONT STYLE="background-color: white">which consisted
of a net loss of $5.5 million, partially offset by $0.5&nbsp;million in non-cash charges and a net change of $0.5&nbsp;million in our
net operating assets and liabilities. The non-cash charges primarily consisted of share-based compensation of $0.5 million. </FONT>Changes
in cash flows related to operating assets and liabilities primarily consisted of a $0.7 million increase in deferred compensation for
management, partially offset by a $0.2 million decrease in accrued liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Cash
Flows from Investing Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Cash
used in investing activities was $0.1 million for the year ended December 31, 2020, <FONT STYLE="background-color: white">which related
primarily to purchases of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">There
was nominal cash used in investing activities for the year ended December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Cash
Flows from Financing Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Cash
provided by financing activities was $2.9 million for the year ended December 31, 2020, <FONT STYLE="background-color: white">which consisted
of $1.6 million of proceeds from the issuance of common shares related to the exercise of warrants and $1.3 million of proceeds from the
issuance of special warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Cash
provided by financing activities was $3.9 million for the year ended December 31, 2019, <FONT STYLE="background-color: white">which primarily
consisted of $3.9 million of net proceeds from the issuance of common share units. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify">Critical Accounting Policies
and Estimates</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Our
management&#8217;s discussion and analysis of our financial condition and consolidated results of operations is based on our consolidated
financial statements, which have been prepared in conformity with U.S GAAP. The preparation of these consolidated financial statements
in conformity with U.S. GAAP requires us to make certain estimates, judgements and assumptions that affect the reported amounts of assets
and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well
as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">While
our significant accounting policies are described in the notes to our consolidated financial statements, we believe that the following
critical accounting policies are most important to understanding and evaluating our reported financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white"><B><I>Share-based
Compensation </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Share-based compensation
expense related to share awards granted to employees, directors and non-employees is recognized based on the grant-date estimated fair
values of the awards using the Black&nbsp;Scholes option pricing model (&quot;<B>Black Scholes</B>&quot;). The value is recognized as
expense ratably over the requisite service period, which is generally the vesting term of the award. We adjust the expense for actual
forfeitures as they occur. Share based compensation expense is classified in the accompanying consolidated statements of operations and
comprehensive loss based on the function to which the related services are provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Black-Scholes requires a
number of assumptions, of which the most significant are expected volatility, expected option term (the time from the grant date until
the options are exercised or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company.
The risk-free interest rate is based on the yield of Canadian government bonds with a remaining term equal to the expected life of the
option. Expected dividend yield is zero because we have never paid cash dividends on common shares, and we do not expect to pay any cash
dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-style: normal">Contractual
Arrangements and Commitments</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In February 2009, we entered
into an agreement with the  UBC to further the development of, and to commercialize certain technology
developed in part the Company&#8217;s Chief Scientific Officer. Under the agreement, we are committed to make milestone payments up to
C$1.4 million per product developed using this technology based on the successful outcomes of predefined clinical and regulatory outcomes,
and royalty payments based on revenue earned from the licensed technology. A minimum annual license fee of C$25,000 per calendar year
is payable for the term of the agreement. The agreement remains effective unless terminated under terms of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In April 2006, and additional
amendments through November 2013, we entered into an agreement with the UHN, Toronto, to license certain technology
and related intellectual property. Under the agreement, we are committed to make milestone payments of up to C$0.6 million based on the
successful outcomes of predefined clinical and regulatory outcomes, and royalty payments based on revenue earned from licensed technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We indemnify our directors
and officers against any and all claims and losses reasonably incurred in the performance of their service to the Company. We have and
maintain liability insurance for our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance&nbsp;Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Since
our inception, we have not engaged in any&nbsp;off-balance&nbsp;sheet arrangements, as defined in the rules and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Recent Accounting
Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">See
Note 2 to our audited consolidated financial statements included elsewhere in this annual report for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Quantitative and Qualitative
Disclosures About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">In
the normal course of business, we are exposed to a number of financial risks that can affect our operating performance. These risks are
credit risk, liquidity risk and market risk. Our overall risk management program and prudent business practices seek to minimize any potential
adverse effects on the Company&#8217;s financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Financial instruments
that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and short-term investments.
We manage our exposure to credit loss by placing our cash with accredited financial institutions, which at times, may exceed federally
insured limits, and when we have excess funds, such funds are invested in high-quality government and corporate issuers with low credit
risk. Cash held is not subject to any external restrictions. As of December 31, 2020, a hypothetical 10% relative change in interest rates
would not have a material impact on our condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><B><I>Liquidity Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Our exposure to
liquidity risk is dependent on purchasing obligations and raising funds to meet commitments and sustain operations. We are a pre-revenue
development stage company, and we rely on external fundraising to support our operations. We also manage liquidity risk by continuously
monitoring actual and projected cash flows. Our Board review and approve the Company&#8217;s operating budget, as well as
any material transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><B><I>Foreign Currency Exchange Risk </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">We are exposed
to foreign exchange risk on our US dollar denominated cash and US dollar denominated liabilities. As of December 31, 2020, we held USD
$0.1 million of cash, short-term investments and prepaid expenses and USD $1.3 million of accounts payable, deferred compensation and
accrued liabilities. A 10% change in the USD exchange rate on the December 31, 2020 balances would impact net loss by $0.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.15pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Inflation Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Inflation generally affects us by increasing our
cost of labor, outside consultants and CRO&#8217;s. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the years ended December&nbsp;31, 2020 or 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 7 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="g_003"></A>ITEM
3. PROPERTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not own or lease any material
properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="g_004"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the expected beneficial ownership of the Company&#8217;s Common Shares as of January&nbsp;10, 2022 for (i)&nbsp;each
member of the </FONT>Board, (ii)&nbsp;each named executive officer (as defined below), (iii)&nbsp;each person known to the Company to
be the beneficial owner of more than 5% of the Company&#8217;s securities and (iv)&nbsp;the members of the Board and the executive officers
of the Company as a group. Beneficial ownership is determined according to the rules&nbsp;of the SEC. Generally, a person has beneficial
ownership of a security if the person possesses sole or shared voting or investment power of that security, including any securities
of which a person has the right to acquire beneficial ownership within 60 days. Information with respect to beneficial owners of more
than 5% of the Company&#8217;s securities is based on completed questionnaires and related information provided by such beneficial owners
as of January&nbsp;10, 2022. Except as indicated, all shares of the Company&#8217;s securities will be owned directly, and the person
or entity listed as the beneficial owner has sole voting and investment power. Unless otherwise indicated, the address of all listed
shareholders is 1920 Yonge Street, Suite&nbsp;200, Toronto, Ontario, M4S 3E2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify; padding-bottom: 1pt"><B>Name
    and Position of Beneficial Owner</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
                                            and Nature of Beneficial<BR>
                                            Ownership<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: left"><B><SUP>&nbsp;</SUP></B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent
                                            of<BR>
                                            Class</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><B>Directors and Executive Officers</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; text-align: right"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><B><SUP>&nbsp;</SUP></B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; text-align: right"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: left; padding-bottom: 1pt">Eugene Williams, Chairman&nbsp;&amp; Chief Executive Officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">16,598,838</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">3.77</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Daniel Geffken, Chief Financial Officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,068,374</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Elliot Goldstein, Former CEO &amp; President</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,002,921</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(4)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.63</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Neil Cashman, Chief Scientific Officer&nbsp;&amp; Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,195,712</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Madge &ldquo;Maggie&rdquo; K. Shafmaster, Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(6)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">William Wyman, Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,415,831</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(7)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Patrick Kirwin, Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,455,850</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(8)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.03</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Richard Gregory, Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(9)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Josh Mandel-Brehm, Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">718,750</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(10)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Neil K. Warma, Director</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">375,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(11)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
directors and executive officers as a group (10 people)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,172,105</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(12)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><SUP>&nbsp;</SUP></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><B>&gt;5% Shareholders</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; text-align: right"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><B><SUP>&nbsp;</SUP></B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; text-align: right"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Title 19 Investments LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,468,750</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(13)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Crocker Mountain LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34,562,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><SUP>(14)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.75</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">* Represents less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of this table,
    beneficial ownership has been determined in accordance with the provisions of Rule&nbsp;13d-3 of the Exchange Act, under which, in
    general, a person is deemed to be the beneficial owner of a security if he or she has or shares the power to vote or direct the voting
    of the security or the power to dispose of or direct the disposition of the security, or if he or she has the right to acquire beneficial
    ownership of the security within 60 days (&#8220;presently exercisable&#8221;).&nbsp;&nbsp;Except as otherwise indicated, each director
    or executive officer has sole voting and investment power with respect to the shares shown, and none of such shares are pledged.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 7,948,583 Common
    Shares underlying options and 646,439 Common Shares underlying warrants. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 541,667 Common
    Shares underlying options and 175,569 Common Shares underlying warrants, which are held by Danforth Advisors LLC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify">Includes 7,948,583 Common Shares underlying options and 646,439 Common Shares underlying warrants.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 6,948,583 Common
    Shares underlying options, 1,152,777 Common Shares underlying warrants and 63,708 Common Shares underlying deferred share units.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents Common Shares
    underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 1,200,000 Common
    Shares underlying options and 439,582 Common Shares underlying warrants.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 939,900 Common
    Shares held by Patrick D. Kirwin Professional Corporation and 143,000 Common Shares held by Patrick Kirwin in a Tax Free Savings
    Account. Mr.&nbsp;Kirwin exercises the power to vote or direct the voting or the power to dispose or direct disposition of such securities.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents Common Shares
    underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents 218,750 Common
    Shares underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents Common Shares
    underlying options.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify">Includes 1,093,750 Common Shares underlying options</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 30,000,000 Common
Shares underlying Debentures and 15,468,750 Common Shares underlying units, which units include 12,375,000 Common Shares and 3,093,750
Common Shares underlying warrants.&nbsp;&nbsp;The address of Title 19 Investments LLC is c/o JDJFOS, P.O. Box 962049, Boston, MA 02196.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 9,000,000 Common
Shares underlying Debentures and 25,562,500 Common Shares underlying units, which units include 20,450,000 Common Shares and 5,112,500
Common Shares underlying warrants. The address of Crocker Mountain LLC is 33 Boylston Street, Ste. 3000, Chestnut Hill, MA 02467.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="g_005"></A>ITEM
5. DIRECTORS AND EXECUTIVE OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the individuals
who we anticipate will be the directors and executive officers of the Company as of the filing of this Registration Statement and their
respective positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 33%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
    Williams</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 53%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&nbsp;&amp;
    Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    E. Geffken</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gavin
    Malenfant</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Cashman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer&nbsp;&amp; Director</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maggie
    Shafmaster</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Wyman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    Kirwin</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Gregory</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh
    Mandel-Brehm</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Warma</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_009"></A>Director and Executive
Officer Biographies</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Eugene Williams, Chairman&nbsp;&amp; CEO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Williams has served as Chairman and
Chief Executive Officer of the Company since October&nbsp;2021. Prior thereto, Mr.&nbsp;Williams served as Executive Chairman of the
Company since July&nbsp;2015. Prior thereto, Mr.&nbsp;Williams served as Chairman and Chief Executive Officer of Akashi (f/k/a DART Therapeutics,&nbsp;Inc.)
from June&nbsp;2010 to January&nbsp;2014. Previously Mr.&nbsp;Williams was a senior executive at Genzyme, where he had broad management
responsibilities in drug development, commercialization, and licensing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Williams graduated from Harvard College
with an Artium Baccalaureus degree in Economics and earned a Master of Business Administration from Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Daniel E. Geffken, CFO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Geffken has served as Chief Financial
Officer of the Company since March&nbsp;2017. He is a co-founder of Danforth Advisors LLC since June&nbsp;2011, and has served as Managing
Director. Mr.&nbsp;Geffken has served on the board of directors of a number of public companies, including Windtree Therapeutics,&nbsp;Inc.
since 2019, Arcturus Therapeutics,&nbsp;Inc. from November&nbsp;2017 to May&nbsp;2018, and Alcobra Pharmaceuticals Inc. from May&nbsp;2013
to November&nbsp;2017. Mr.&nbsp;Geffken has served on the board of directors of Elicio Therapeutics, a private company, since 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Geffken earned a Bachelor of Science
degree from the University of Pennsylvania and a Master of Business Administration from Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Gavin T. Malenfant, COO</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Malenfant has served as Chief Operating
Officer of the Company since October&nbsp;2021.&nbsp; Prior to ProMIS Neurosciences, Gavin operated his own consulting business for series
A companies. &nbsp;Gavin&#8217;s experience is backed by nearly twenty-years with Genzyme, leading the rare disease program management
organization and head of operations for research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.&nbsp;Malenfant
earned a Bachelor of Science degree in Biology from the University of Massachusetts at Boston</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Neil Cashman, CSO&nbsp;&amp; Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Cashman has served as Chief Scientific
Officer and as a director of the Company since May&nbsp;2004 and June&nbsp;2010, respectively<SUP></SUP>. Dr.&nbsp;Cashman has served
as a Professor at the University of British Columbia (UBC) since July&nbsp;2005 and will become Professor Emeritus as of February&nbsp;1,
2022. He has also served as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC from 2005 to 2019.
He is also director of the ALS Clinic at Vancouver General Hospital since July&nbsp;2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Cashman earned a Bachelor of Arts degree
in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr.&nbsp;Cashman served his
residency in neurology with the University of Chicago Hospitals&nbsp;&amp; Clinics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Madge &#8220;Maggie&#8221; K. Shafmaster,
Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Shafmaster has served as a director
of the Company since September&nbsp;2021. Dr.&nbsp;Shafmaster has over 25 years of experience providing intellectual property advice
to the biotechnology and pharmaceutical industries. Since 2014, Dr.&nbsp;Shafmaster has served as an independent intellectual
property consultant to the biotech and pharma industries. Prior to this, she served from 2011 to 2014 as Vice President, Chief
Patent Counsel for Sanofi Pasteur and from 2007 to 2011 as Senior Vice President, Chief Patent Counsel for Genzyme Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Shafmaster earned her Ph.D. in Molecular
Biology and Virology from Cornell University Graduate School of Medical Sciences, a Juris Doctor from New York Law School and a Bachelor
of Arts in Biology from the University of California Santa Cruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>William Wyman, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wyman has served as a director of the
Company since March&nbsp;2014. In 1984, Mr.&nbsp;Wyman co-founded Oliver Wyman&nbsp;&amp; Co., a general management consulting firm.
Since his retirement from the firm in 1995, Mr.&nbsp;Wyman has served as a director and advisor to nearly two dozen public and private
companies in the finance and technology industries. Mr.&nbsp;Wyman has also served as a consultant and owner of Wyman Consulting Associates
since 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wyman has been a member of the board
of trustees<SUP></SUP> of Dartmouth Hitchcock Medical Center, Mary Hitchcock Hospital and the Dartmouth Hitchcock Clinic, and currently
serves on the Board Joint Development Committee. He is currently a member of the Board of Trustees of New England College. He served
as a director of Allston Trading, LLC, a trading firm, since 2008, and as a member of the board of advisors of several private equity firms since 1995. He has also served on the National Academy of Sciences'
committee on health equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Wyman earned his Bachelor of Arts degree
in Economics from Colgate University and his Master of Business Administration from the Harvard Business School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patrick Kirwin, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Kirwin has served as a director of the
Company since June&nbsp;2015. Mr.&nbsp;Kirwin is senior partner at the law firm Kirwin LLP. Mr.&nbsp;Kirwin earned a Bachelor of Arts
degree in Economics from the University of Alberta and a Juris Doctor from the University of Toronto Law School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Richard Gregory, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Gregory has served as a director of
the Company since October&nbsp;2016. He has served as Executive Vice President and Chief Scientific Officer of ImmunoGen,&nbsp;Inc. from
2015 to 2019. Dr.&nbsp;Gregory has been a Fellow of the American Institute for Medical and Biological Engineering since 2015. He has
served on the board of directors of Homology Medicines,&nbsp;Inc. and Cambridge Therapeutic Technologies since 2015 and March&nbsp;2021,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Gregory earned a Bachelor of Science
degree in Biochemistry from Virginia Polytechnic Institute and State University (Virginia Tech) and a Ph.D. in Biochemistry from the
University of Massachusetts Amherst.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Josh Mandel-Brehm, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Mandel-Brehm has served as a director
of the Company since September&nbsp;2021. Mr.&nbsp;Mandel-Brehm has served as President and Chief Executive Officer of CAMP4 Therapeutics
Corporation since May&nbsp;2017 and as entrepreneur partner<SUP></SUP> with Polaris Partners. Prior to May&nbsp;2017,
Mr.&nbsp;Mandel-Brehm served in business development for Biogen Corporation from May&nbsp;2013 to May&nbsp;2017. He has also been a founder
and board member for Vico Therapeutics B.V. since October&nbsp;2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Mandel-Brehm earned a Bachelor of Arts
degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Neil K. Warma, Director</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Warma has served as a director of the
Company since May&nbsp;2021.&nbsp;Mr.&nbsp;Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous
biotechnology and pharmaceutical companies across the globe. Mr.&nbsp;Warma has served as the General Manager of I-Mab Biopharma U.S.,
a publicly-traded global biopharmaceutical company since September&nbsp;2019.&nbsp; Mr.&nbsp;Warma was founder and from 2018 to 2019
served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr.&nbsp;Warma was President
and CEO and a member of the board of directors of Opexa Therapeutics,&nbsp;Inc., a publicly-traded biopharmaceutical company from 2008
to 2017.&nbsp;He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions
at Novartis AG in Basel, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Warma has served as a director for Genexine
Ltd.,&nbsp;a public company, and Biotechnology Innovation Organization since March&nbsp;2021 and November&nbsp;2020, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;Warma earned a Bachelor of Science degree
in Neuroscience from the University of Toronto and a Master of Business Administration from York University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Significant Employee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Johanne Kaplan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr.&nbsp;Kaplan has served as the Company&#8217;s
Chief Development Officer (&#8220;<B>CDO</B>&#8221;) since 2016, assuming the role in a full-time capacity on January&nbsp;1, 2022. Prior
to taking on the CDO role full-time, Dr.&nbsp;Kaplan also served as Chief Scientific Officer at Shepherd Therapeutics from 2016 to 2021
and as Chief Scientific Officer at Epiva Biosciences from 2015 to 2016. Before joining the Company, Dr.&nbsp;Kaplan held increasing positions
of responsibility at Sanofi Genzyme, from 1992 through 2015, most recently serving as Vice President of Research at Sanofi Genzyme from
2005 until her retirement in 2015. As Vice President of Neuroimmunology Research, she led the contribution of the Genzyme science team
supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis.
She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr.&nbsp;Kaplan
was an Associate Immunopathologist at SmithKline Beecham where she established an immunotoxicology program. Her work has resulted in
over 70 scientific publications and multiple patents. Dr.&nbsp;Kaplan holds a PhD in Microbiology&nbsp;&amp; Immunology from McGill University
in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While Dr.&nbsp;Kaplan does not serve in a policy-making
function for the Company and is therefore not an executive officer, her scientific background and experience play an important role in
the Company&#8217;s operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_010"></A><B>Board Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: White">
    <TD STYLE="border: Black 1pt solid; vertical-align: bottom; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Member</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; width: 12%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; width: 31%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
    Governance and <BR>
Nominating</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
    Williams</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Cashman</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maggie
    Shafmaster</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Wyman</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick
    Kirwin</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Gregory</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh
    Mandel-Brehm</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; width: 14%; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 12%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 31%; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil
    Warma</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uuml;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The audit committee of the Board (the &#8220;<B>Audit
Committee</B>&#8221;) assists the Company&#8217;s Board in fulfilling its oversight responsibilities relating to financial accounting
and reporting process and internal controls for the Company and ensuring the adequacy and effectiveness of the Company&#8217;s risk management
programs. The Audit Committee reviews the financial reports and other financial information provided by the Company to regulatory authorities
and its shareholders, as well as reviews the Company&#8217;s system of internal controls regarding finance and accounting, including auditing,
accounting and financial reporting processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of the Audit Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of filing of this Registration
Statement, the following are the members of the Audit Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left; width: 33%">Name&nbsp;of&nbsp;Member</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 31%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financially&nbsp;Literate<SUP>(2)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">William Wyman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Patrick Kirwin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Neil Warma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A member of the Audit Committee is independent if he or she has no direct or indirect &#8216;material relationship&#8217; with the Company. A material relationship is a relationship which could, in the view of the Company&#8217;s Board, reasonably interfere with the exercise of a member&#8217;s independent judgment. Any executive officer of the Company is deemed to have a material relationship with the Company. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A member of the Audit Committee is financially literate if he or she has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company&#8217;s financial statements. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Relevant Education and Experience</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each member of the Audit Committee has experience
relevant to his or her responsibilities as an Audit Committee member. See Item 5&#8212;&#8220;<I>Directors and Executive Officers</I>&#8221;
for a description of the education and experience of each Audit Committee member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee Oversight</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At no time since the commencement of the Company&#8217;s
most recently completed financial year were any audit committee recommendations to nominate or compensate an external auditor not adopted
by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for
the Audit Committee, which sets out the Audit Committee&#8217;s responsibilities. The Audit Committee performs a number of roles
including (i)&nbsp;assisting directors to meet their oversight responsibilities, (ii)&nbsp;enhancing communication between directors
and the external auditors; (iii)&nbsp;ensuring the independence of the external auditors; (iv)&nbsp;increasing the credibility and
objectivity of financial reports; and (v)&nbsp;strengthening the role of the directors by facilitating in-depth discussions among
directors, management and the external auditor. The Audit Committee has been delegated responsibility for: (i)&nbsp;the
Company&#8217;s internal audit function; (ii)&nbsp;the integrity of our consolidated financial statements and accounting and
financial processes and the audits of our consolidated financial statements; (iii)&nbsp;compliance with legal and regulatory
requirements; (iv)&nbsp;the&nbsp;external auditors&#8217; qualifications and independence; (v)&nbsp;the work and performance of
financial management and external auditors; and (vi)&nbsp;the&nbsp;system of disclosure controls and procedures and system of
internal controls regarding finance, accounting, legal compliance and risk management established by management and the Board. The
Audit Committee has unrestricted access to all books and records of the Company and may request any information as it may deem
appropriate. It also has the authority to retain and compensate special legal, accounting, financial and other consultants or
experts in the performance of its duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Corporate Governance and Nominating Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporate Governance and Nominating Committee
of the Board assists the Board in fulfilling its oversight responsibilities relating to the corporate governance of the Company and the
size, structure, and membership of the Board and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of the Corporate Governance and
Nominating Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Registration Statement,
the following are the members of the Corporate Governance and Nominating Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 84%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name&nbsp;of&nbsp;Member</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Josh Mandel-Brehm</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maggie Shafmaster</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil Warma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;</FONT>A
member of the Corporate Governance and Nominating Committee is independent if he or she has no direct or indirect &#8216;material relationship&#8217;
with the Company. A material relationship is a relationship which could, in the view of the Company&#8217;s Board, reasonably interfere
with the exercise of a member&#8217;s independent judgment. Any executive officer of the Company is deemed to have a material relationship
with the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Governance and Nominating Committee
Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for the
Corporate Governance and Nominating Committee, which sets out the Corporate Governance and Nominating Committee&#8217;s responsibilities.
The Corporate Governance and Nominating Committee has been delegated responsibility for: i) reviewing the appropriate skills and characteristics
required of Board members in the context of the current make-up of the Board; and ii) assess the Board&#8217;s compliance with laws and
policies relating to the independence of certain Board members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee of the Board assists
the Board in fulfilling its oversight responsibilities relating to the recruitment, compensation, evaluation and retention of senior management
and other key employees, and in particular the Chief Executive Officer, with the skills and expertise needed to enable the Company to
achieve its goals and strategies at competitive compensation and with appropriate performance incentives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of the Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Registration Statement,
the following are the members of the Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 84%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name&nbsp;of&nbsp;Member</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 13%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Independent<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Gregory</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil Warma</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Wyman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;</FONT>A
member of the Compensation Committee is independent if he or she has no direct or indirect &#8216;material relationship&#8217; with the
Company. A material relationship is a relationship which could, in the view of the Company&#8217;s Board, reasonably interfere with the
exercise of a member&#8217;s independent judgment. Any executive officer of the Company is deemed to have a material relationship with
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation Committee Charter</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has adopted a written charter for
the Compensation Committee, which sets out the Compensation Committee&#8217;s responsibilities. The Compensation Committee has been
delegated responsibility for reviewing: i) compensation policies and guidelines for supervisory and management personnel of the
Company; ii) corporate benefits, bonuses and other incentives, including share options and restricted share awards; iii) corporate
goals and objectives relevant to chief executive officer compensation; iv) non-chief executive officer and director compensation,
incentive compensation plans and equity-based plans; v) the competitiveness and appropriateness of the Company&#8217;s policies
relating to the compensation of executive officers; and vi) any material changes or trends in human resources policy, procedure,
compensation and benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_011"></A>Board Qualifications <SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that each of the members of our Board
has the experience, qualifications, attributes and skills that make him or her suitable to serve as our director, in light of our highly
regulated cryptocurrency business, our complex operations and large number of employees. See Item 5&#8212;&#8221;<I>Directors and Executive
Officers</I>&#8221; for a description of the education and experience of each director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eugene Williams&#8217;s specific qualifications,
experience, skills and expertise include<SUP></SUP>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience as Chairman and Chief Executive Officer of the Company and in other executive leadership capacities in the pharmaceutical and biotechnology industries. </FONT></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A deep understanding of entrepreneurship, of drug development and of the pharmaceutical and biotechnology industries. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate strategy. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neil Cashman&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical and biotechnology industry and academic expertise in protein misfolding, neurodegeneration, and neurological clinical care. </FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience as Chief Scientific Officer. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous history on the Company&#8217;s Board.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Maggie Shafmaster&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience providing intellectual property advice to the biotechnology and pharmaceutical industries.&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive business experience in various executive level roles.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate strategy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">William Wyman&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous history on the Company&#8217;s Board.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive business experience in various executive and board level roles.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and management experience.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patrick Kirwin&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previous history on the Company&#8217;s Board.</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Knowledge of past and current business strategies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Richard Gregory&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive business experience in various executive and board level roles.</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical and biotechnology industry knowledge. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate governance. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Josh Mandel-Brehm&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extensive business experience in various executive level roles in the biotechnology industry. </FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A deep understanding of entrepreneurship and of the biotechnology industry. </FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Strategy. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neil K. Warma&#8217;s specific qualifications,
experience, skills and expertise include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experience in executive level roles in the pharmaceutical and biotechnology industries. </FONT></TD></TR>
  <TR>
    <TD STYLE="width: 4%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; padding-bottom: 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 12pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating and management experience.</FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A deep understanding of entrepreneurship and of the pharmaceutical and biotechnology industries. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board believes these qualifications bring
a broad set of complementary experience to the Board&#8217;s discharge of its responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="h1"></A><B>Conflicts of Interest&#8212;Board Leadership
Structure and Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conflicts of interest may arise as a result of
the directors and officers of the Company also holding positions as directors or officers of other companies. Some of the individuals
that are directors and officers of the Company have been and will continue to be engaged in the identification and evaluation of assets,
businesses and companies on their own behalf and on behalf of other companies, and situations may arise where the directors and officers
of the Company will be in direct competition with the Company. Conflicts, if any, will be subject to the procedures and remedies provided
under the Company&#8217;s Code of Business Conduct and Ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="h2"></A><B>ITEM
6. EXECUTIVE COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion describes
the significant elements of the compensation of each person who served as the Company&#8217;s Chief Executive Officer (&#8220;<B>CEO</B>&#8221;)
during 2021 and two most highly compensated executive officers (collectively, the &#8220;<B>named executive officers</B>&#8221; or &#8220;<B>NEOs</B>&#8221;).
As at December&nbsp;31, 2021, the NEOs of the Company were Eugene Williams (Executive Chairman&nbsp;&amp; CEO), Elliot Goldstein (former
CEO and President), Daniel Geffken (Chief Financial Officer) and Neil Cashman (Chief Scientific Officer).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s policy with respect to compensation
of the named executive officers and other officers of the Company is based upon the principles that total compensation must: (1)&nbsp;be
competitive in order to help attract and retain the talent needed to lead and grow the Company&#8217;s business; (2)&nbsp;provide a strong
incentive for executives and key employees to work towards the achievement of the Company&#8217;s goals; and (3)&nbsp;ensure that the
interests of management and the Company&#8217;s shareholders are aligned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When determining the compensation of its
executive officers, the Compensation Committee considers: (i)&nbsp;recruiting and retaining executives critical to the success of
the Company and the enhancement of shareholder value; (ii)&nbsp;providing fair and competitive compensation compared to the
remuneration paid by other reporting issuers similarly placed within the same business as the Company; (iii)&nbsp;balancing the
interests of management and the Company&#8217;s shareholders; and (iv)&nbsp;rewarding performance, both on an individual basis and
with respect to operations in general. In order to achieve these objectives, the compensation paid to the Company&#8217;s executive
officers consists of two components: (i)&nbsp;base salary; and (ii)&nbsp;long-term equity incentives in the form of share options.
In making compensation determinations, external sources are consulted when deemed necessary by the Compensation Committee. The
members of the Compensation Committee are disclosed under Item 5 of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total compensation paid to each of the
named executive officers of the Company consists of a base salary or consulting fee and share options to reward and retain NEOs.
Total compensation paid to each NEO reflects the executive&#8217;s overall experience, responsibility and time committed to the
organization. The goal of the Company is to pay base salary compensation to retain the NEOs in the range of industry peers, while
maintaining the overall goal that total compensation should include variable and long-term components as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the CEO&#8217;s compensation in
particular, the CEO&#8217;s base salary is determined after considering the salary levels of other executives with similar responsibilities
and experience. The CEO&#8217;s base salary is compared to salary levels of comparable executives at a variety of companies, with particular
emphasis on biotechnology companies with similar market capitalizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options are granted by the Board to employees,
executive officers, including the named executive officers, and directors pursuant to the Company&#8217;s Stock Option Plan. The purpose
of the Stock Option Plan is to attract, retain and motivate these individuals and create incentives for them to contribute toward the
long-term goals of the Company. Moreover, the Stock Option plan aims to align the interests of participants with the Company&#8217;s Shareholders
through opportunities of increased equity-based ownership in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may also grant deferred share units
(&#8220;<B>DSUs</B>&#8221;) to senior officers, including any named executive officers, under the Company&#8217;s Deferred Share Unit
Plan, which provides an alternative form of compensation to satisfy annual and special bonuses payable to senior officers. The number
of DSUs granted is determined by dividing the applicable bonus amount by the fair market value of the Common Shares as at the last trading
day before calculation in accordance with TSX policies. Recipients of DSUs cannot exercise their DSUs until such time as they cease to
be a senior officer at which time they may elect to receive one Common Share for each whole DSU they hold at the time they cease to be
eligible to participate in the DSU Share Unit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Approach to Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board understands that
compensation practices can have unintended risk consequences. The Compensation Committee continually reviews the Company&#8217;s compensation
policies to identify any practice that might encourage an employee to expose the Company to unacceptable risk. At the present time, the
Compensation Committee is satisfied that the current executive compensation program does not encourage the Company&#8217;s executive officers,
including the NEOs, to expose the Company to inappropriate risk. The Board takes a conservative approach to executive compensation, rewarding
individuals for the success of the Company once that success has been demonstrated and encouraging them to continue that success through
the grant of long-term incentive awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Hedging Policy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no specific requirements
to prevent an NEO or director from purchasing financial instruments including, for greater certainty, prepaid variable forward contracts,
equity swaps, collars, or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities
granted as compensation or held, directly or indirectly, by the NEO or director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table for 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
paid to or earned by the named executive officers of the Company in the last fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Name
    and<BR> Principal Position</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Year</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary<BR>
    ($)<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
    Awards<BR> ($)<SUP>(2)</SUP></B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
    Other<BR> Compensation<BR> ($)<SUP>(3)</SUP></B></FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Total
    <BR> ($)</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify; width: 38%"><FONT STYLE="font-size: 10pt">Eugene
    Williams <BR><I>Executive Chairman&nbsp;&amp; CEO</I></FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 7%; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">360,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right">&mdash;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;21,057</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">381,057</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 7pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Elliot
                                            Goldstein</FONT></P> <P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Former
                                            CEO&nbsp;&amp; President<SUP>(4)</SUP></I></FONT></P></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">12,677</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">62,677</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Daniel Geffken <BR><I>Chief
    Financial Officer</I></FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">71,670</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">97,200</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">168,870</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Neil Cashman <BR><I>Chief
    Scientific Officer</I></FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">79,017</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">79,017</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;The
amounts reported in the Salary column reflect payments made pursuant to various consulting agreements. </FONT>In addition, during 2021
the named executive officers were paid salary that had been accrued for service in prior years but not paid in those prior years, as follows:
Eugene Williams, $257,677; Elliot Goldstein, $257,677.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;The amounts reported in the Option Awards
column reflects aggregate grant date fair value computed in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation. These
amounts reflect our calculation of the value of these awards at the grant date and do not necessarily correspond to the actual value that
may ultimately be realized by the named executive officer. The assumptions used in the calculation of these amounts are as follows: risk-free
interest rate 0.95%, dividend yield 0%, expected volatility 92%, expected life of 4.5 years. Option Awards granted in 2021 with respect
to Mr.&nbsp;Geffken&#8217;s service were granted to Danforth Advisors, LLC. Mr.&nbsp;Geffken serves as Managing Director of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)&nbsp;Amounts reported in the All Other Compensation
column reflect payments made to Mr.&nbsp;Williams and Dr.&nbsp;Goldstein for health insurance costs. The amount reported for Mr.&nbsp;Geffken
reflects payments made to Danforth Advisors, LLC as a retainer for Mr.&nbsp;Geffken&#8217;s services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4)&nbsp;Dr.&nbsp;Goldstein ceased serving as
CEO of the Company on October&nbsp;1, 2021 and ceased serving as President and a director on December&nbsp;31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 8 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consulting and Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eugene
Williams</I></B></FONT>. The Chairman and CEO services provided by Mr.&nbsp;Williams to the Company were historically provided pursuant
to a consulting agreement entered into between the Company and Virtua, LLC dated June&nbsp;29, 2015 (the &#8220;<B>Virtua Consulting Agreement</B>&#8221;).
Pursuant to the terms of the Virtua Consulting Agreement, Mr.&nbsp;Williams was appointed Executive Chair of the Company beginning on
the date of the agreement and continuing until either party provides notice of its intent to terminate the agreement for any reason, at
any time, upon 30 days&#8217; written notice, which was able to be waived by either party, upon 15 days written notice in the event of
a breach by either party, or on the written agreement of both parties. Subject to adjustment by the Board, the Company agreed to pay Virtua,
LLC a $30,000 fixed fee per month, with $10,000 of that monthly fee to be allocated for services provided by Mr.&nbsp;Williams, plus reimbursement
for reasonable expenses. The Virtua Consulting Agreement also provided for the grant of options to Mr.&nbsp;Williams under the Company&#8217;s
Stock Option Plan equal to five percent of the shares issued and outstanding immediately following the completion or termination of the
private placement offering announced by the Company on May&nbsp;22, 2015. Such options expire 10 years following their grant date and
entitle Mr.&nbsp;Williams to acquire shares at the market price on the grant date, with one quarter of such options immediately vesting
and the balance vesting in equal installments on the last day of each month for 36 months, except, in the event of a change of control
or in the case where there is a termination without good reason, on the occurrence of which the entire balance shall vest immediately.
In the event the Virtua Consulting Agreement is terminated other than for a change of control or where there is a termination without
good reason, unvested options were to cease vesting as of such termination date. The foregoing description is qualified in its entirety
by reference to the Virtua Consulting Agreement, which is included as Exhibit&nbsp;10.11 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">On December&nbsp;21, 2021,
the Company extended to Mr.&nbsp;Williams an offer of employment (the &#8220;<B>Williams Offer Letter</B>&#8221;) to serve as the Company&#8217;s
Chief Executive Officer beginning January&nbsp;1, 2022. Pursuant to the terms of the of the Williams Offer, Mr.&nbsp;Williams&#8217;
compensation for service as the Company&#8217;s CEO is set at $480,000 and Mr. Williams is eligible to participate in any and all bonus
and benefit programs that the Company makes available to its employees. In addition, subject to Board approval, Mr.&nbsp;Williams will
be awarded up to 3,000,000 share options, which will be priced at a trailing 5-day volume weighted average trading price, which will
vest at 1/48<SUP>th</SUP> monthly over a four-year period, with the options expiring on January&nbsp;1, 2031. Upon termination, all vested
options will be exercisable at any time during the twelve months following termination. In the event of termination of Mr.&nbsp;Williams&#8217;
employment by the Company without cause, by Mr.&nbsp;Williams with good reason, or termination by way of a change in control, then upon
Mr.&nbsp;Williams&#8217; execution of a release of claims, Mr.&nbsp;Williams is entitled to an aggregate amount equivalent to eighteen
months of his then-current base salary The Williams Offer Letter supersedes all prior agreements regarding Mr.&nbsp;Williams&#8217; services
to and compensation from the Company, including the Williams Consulting Agreement. The foregoing description is qualified in its entirety
by reference to the Williams Offer Letter, which is included as Exhibit&nbsp;10.36<SUP></SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Elliot
Goldstein</I></B></FONT>. Dr.&nbsp;Goldstein was party to a consulting agreement with the Company dated April&nbsp;1, 2021 for CEO consulting
services (the &#8220;<B>Goldstein Consulting Agreement&#8221;</B>). Under the Goldstein Consulting Agreement, Dr.&nbsp;Goldstein agreed
to provide the Company CEO consulting services for a six month period in exchange for a monthly payment of $5,000, subject to increases
as approved by the Board. Dr.&nbsp;Goldstein is no longer engaged to perform services for the Company under the Goldstein Consulting
Agreement or any other agreement or arrangement. Prior to entry into the Goldstein Consulting Agreement, Mr.&nbsp;Goldstein provided
services to the Company under the Virtua Consulting Agreement. Pursuant to the terms of the Virtua Consulting Agreement, Mr.&nbsp;Goldstein
was appointed Chief Executive Officer of the Company beginning on the date of the agreement and continuing until either party provides
notice of its intent to terminate the agreement for any reason, at any time, upon 30 days&#8217; written notice, which was able to be
waived by either party, upon 15 days written notice in the event of a breach by either party, or on the written agreement of both parties.
The Company agreed to pay Virtua, LLC a $30,000 fixed fee per month, with $20,000 of that monthly fee to be allocated for services provided
by Mr.&nbsp;Goldstein, plus reimbursement for reasonable expenses. The foregoing descriptions are qualified in their entirety by reference
to the Goldstein Consulting Agreement and Virtua Consulting Agreement, which are included as Exhibits 10.8<SUP></SUP> and 10.11<SUP></SUP>
hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Daniel
Geffken</I></B></FONT>. The CFO services provided by Mr.&nbsp;Geffken are provided pursuant to a consulting agreement entered into between
the Company and Danforth Advisors, LLC dated October&nbsp;17, 2016, and as amended from time-to-time (the &#8220;<B>Danforth Consulting
Agreement</B>&#8221;). Under the Danforth Consulting Agreement, Mr.&nbsp;Geffken agreed to provide the Company the customary services
of a CFO at an hourly rate of $325 for a one year term. On March&nbsp;27, 2017, the Danforth Consulting Agreement was amended to provide
for services based on a $5,000 monthly retainer, subject to a 4% annual increase, plus expenses. The Danforth Consulting Agreement was
subsequently amended on December&nbsp;12, 2017 to extend the term for an additional year and on August&nbsp;31, 2018 to extend the term
for an additional year. The Danforth Consulting Agreement was further amended on November&nbsp;10, 2021 to extend the term of the consulting
agreement through October&nbsp;29, 2024 and to set Mr.&nbsp;Geffken&#8217;s compensation at a fixed monthly fee of $15,000. The Danforth
Consulting Agreement provides for an extension of terms by the mutual agreement of the parties and that either party may terminate the
agreement upon sixty days prior written notice to the other, or 30 days in the case of termination for cause. The foregoing description
is qualified in its entirety by reference to the Danforth Consulting Agreement and the amendments thereto, which are included as Exhibits
10.12 and 10.12.1, 10.12.2, 10.12.3 and 10.12.4 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Neil
Cashman</I></B></FONT>. Dr.&nbsp;Cashman is party to a consulting and advisory agreement with the Company dated March&nbsp;1, 2005 (the
 &#8220;<B>Cashman Consulting Agreement</B>&#8221;) for CSO consulting services. The Cashman Consulting Agreement provides that it shall
remain in effect until terminated by either party, with the Company agreeing to provide Dr.&nbsp;Cashman six month&#8217;s written notice
and Dr.&nbsp;Cashman agreeing to provide the Company thirty day&#8217;s written notice. In return for the CSO services, the Company agreed
to pay Dr.&nbsp;Cashman a monthly consulting fee of $5,000, plus expenses, subject to adjustment as approved by the Board. The foregoing
description is qualified in its entirety by reference to the Cashman Consulting Agreement, which is included as Exhibit&nbsp;10.10<SUP>
</SUP>hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outstanding Equity Awards Table for 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth outstanding equity
awards for the named executive officers of the Company at fiscal 2021 year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option Awards</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock Awards</B></FONT><B><SUP>(1)</SUP></B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number&nbsp;of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options&nbsp;(#)<BR>
Exercisable</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number&nbsp;of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options&nbsp;(#)<BR>
Unexercisable</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity <BR>
Incentive <BR>
Plan Awards: <BR>
Number of <BR>
Securities <BR>
Underlying <BR>
Unexercised <BR>
Unearned <BR>
Options <BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
Exercise<BR>
Price<BR>
($)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
Expiration<BR>
Date</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of<BR>
shares or <BR>
units of<BR>
stock<BR>
 that<BR>
have not<BR>
vested<BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market<BR>
value of<BR>
shares or<BR>
units of <BR>
stock<BR>
 that<BR>
have not<BR>
vested <BR>
(US$)</B></FONT><B><SUP>(2)</SUP></B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity<BR>
incentive<BR>
plan<BR>
awards:<BR>
number of<BR>
unearned<BR>
shares,<BR>
 units <BR>
or other<BR>
rights that <BR>
have not<BR>
vested <BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity<BR>
incentive plan<BR>
awards:<BR>
market or<BR>
payout value<BR>
of unearned<BR>
shares,<BR>
 units <BR>
or other<BR>
rights that <BR>
have not<BR>
vested <BR>
($)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 11%; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Williams</FONT></TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 18%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,729,300 Common Shares</FONT></TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 9%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.032</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(3)</FONT></TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/6/2025</FONT></TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 0%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,219,283
Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(4)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2025</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000 Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.364</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(5)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/29/2028</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot Goldstein</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,729,300
Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.032</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(3)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/6/2025</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,219,283
Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(4)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2025</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000 Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.364</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(5)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/29/2028</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Geffken<SUP>(6)</SUP></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000 Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.135</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(7)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/1/2027</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500,000 Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">458,333 Common Shares</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.143</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(8)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/12/2031</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neil Cashman</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,729,300 Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.032</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(3)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/6/2025</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,484</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,548</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,219,283 Common Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">(4)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2025</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,938</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,994</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,286</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,829</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;The Company&#8217;s only share-based
awards are DSUs (other than options) that have been granted under the DSU Plan. DSUs only vest in full upon separation from service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;The value of the unvested share-based
awards was calculated based on the closing price of the Company&#8217;s Common Shares on the TSX on December&nbsp;30, 2021, which was
C$0.13 (US$0.10). The Bank of Canada exchange rate as of December&nbsp;30, 2021 was US$1.00 to C$1.2678.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)&nbsp;</FONT>The
option was granted on July&nbsp;6, 2015 with an exercise price of $0.032. The option vested &frac14; immediately with balance having vested
ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&nbsp;</FONT>The
option was granted on July&nbsp;31, 2015 with an exercise price of $0.03. The option vested &frac14; immediately with balance having vested
ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)&nbsp;</FONT>The
option was granted on March&nbsp;29, 2018 with an exercise price of $0.364. The option vested &frac14; immediately with balance having
vested ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)&nbsp;</FONT>Options
are held by Danforth Advisors, LLC. Mr.&nbsp;Geffken serves as Managing Director of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)&nbsp;</FONT>The
option was granted on March&nbsp;1, 2017 with an exercise price of $0.135. The option vested 1/5 immediately with balance having vested
ratably over 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)&nbsp;</FONT>The
option was granted on November&nbsp;12, 2021 with an exercise price of $0.143. The option vests ratably over 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Retirement Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have any retirement benefit
plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Termination and Change in Control Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not offer a formal plan providing
for any termination or change in control benefits. For information about change in control benefits for Messrs.&nbsp;Williams and Malenfant,
see &#8220;<I>Consulting and Employment Agreements</I>&#8221; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DIRECTOR
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2021, the Company had
eight directors, two of whom were also employees: Eugene Williams (Chairman and CEO) and Neil Cashman (Chief Scientific Officer). The
remaining six directors were considered independent directors at such time, namely Richard Gregory, Patrick Kirwin, Josh Mandel-Brehm,
Maggie Shafmaster, Neil K. Warma and William Wyman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors who hold positions as executive officers
with the Company do not receive additional compensation for their service as directors. Mr.&nbsp;Williams and Dr.&nbsp;Cashman did not
receive any additional compensation for their services as directors during the year ended December&nbsp;31, 2021. For a description of
the compensation paid to Mr.&nbsp;Williams and Dr.&nbsp;Cashman, see&nbsp;<I>&#8220;Summary Compensation Table for 2021</I>,<I>&#8221;</I>&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each member of the Company&#8217;s Board is entitled
to reimbursement for reasonable travel and other expenses incurred in connection with attending Board meetings and meetings for any committee
on which he or she serves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The form and amount of director compensation is
reviewed annually and as deemed advisable by the Compensation Committee, which shall make recommendations to the Board based on such review.
The Compensation Committee reviews director compensation on an annual basis to ensure that the Company offers director compensation that
is: (i)&nbsp;commensurate with the efforts the Company expects from existing Board members; (ii)&nbsp;competitive in the Company&#8217;s
industry in order that the Company might attract the best possible candidates to assist the Company and its shareholders in a fiduciary
capacity; and (iii)&nbsp;aligned with shareholder interests as the Company grows. The Board retains the ultimate authority to determine
the form and amount of director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation for 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
paid to or earned by each director of the Company during fiscal year 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT><SUP>(1)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fees&nbsp;Earned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>or<BR>
                                            Paid&nbsp;in&nbsp;Cash<BR> ($)</B></FONT><B><SUP>(2)</SUP></B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option<BR> Awards</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)<SUP>(3)</SUP></B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total&nbsp;($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: justify">Richard Gregory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">67,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">107,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Patrick Kirwin</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Josh Mandel-Brehm</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83,297</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">96,630</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Maggie Shafmaster</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">61,182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Neil Warma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">74,302</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99,302</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">William Wyman</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107,269</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johannes Roth<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">--</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT>&nbsp;Mr.&nbsp;Williams,
Dr.&nbsp;Cashman and Dr.&nbsp;Goldstein, who served as executive officers during 2021, did not receive any compensation for their Board
service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT>&nbsp;Cash
fees paid to non-employee directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT>&nbsp;The
amounts reported in the Option Awards column reflects aggregate grant date fair value computed in accordance with ASC Topic 718, Compensation&#8212;Stock
Compensation. These amounts reflect our calculation of the value of these awards at the grant date and do not necessarily correspond to
the actual value that may ultimately be realized by the director. The assumptions used in the calculation of these amounts are as follows:
risk-free interest rate 0.95%, dividend yield 0%, expected volatility 92%, expected life of 4.5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT>&nbsp;Mr.&nbsp;Roth
resigned from the Board on February&nbsp;1, 2021 and did not receive any compensation for his service in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee Interlocks and Insider
Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 7 &#8212; &#8220;<I>Certain Relationships
and Related Transactions and Director Independence</I>&#8221; for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the Company&#8217;s executive officers
served as a member of the compensation committee (or other Board committee performing equivalent functions or, in the absence of any such
committee, the entire Board) of another entity, one of whose executive officers served as a director of the Company or on the Compensation
Committee, during the fiscal year ended December&nbsp;31, 2021. None of the Company&#8217;s executive officers served as a director of
another entity, one of whose executive officers served on the Compensation Committee, during the fiscal year ended December&nbsp;31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="h3"></A><B>ITEM
7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND<BR>
DIRECTOR INDEPENDENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_012"></A>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company, a related party transaction includes
any transaction or proposed transaction in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the Company is or will be a participant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the aggregate amount involved exceeds $17,000 (approximately 1% of the Company&#8217;s average assets
for the last two fiscal years) in any fiscal year; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">any related party has or will have a direct or indirect material interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related parties include any person who is or was
(since the beginning of the last fiscal year, even if such person does not presently serve in that role) an executive officer or director
of the Company, any shareholder beneficially owning more than 5% of any class of the Company&#8217;s voting securities or an immediate
family member of any such persons. Immediate family member means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, sister-in-law, and any person (other than a tenant or employee) sharing the
household of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee is charged with oversight
over related party transactions entered into by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_013"></A>Company Transactions with Related Parties <SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into related party transactions
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Neil
Cashman</I></B></FONT>. Dr.&nbsp;Cashman is a Professor of Neurology with UBC. Please see Item 1 &#8212; &#8220;<I>Business</I>&#8221;
for more information regarding the Company&#8217;s relationship with UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Eugene
Williams</I></B></FONT><I>. </I>Payments for Mr. William&rsquo;s services were pursuant to a consulting agreement with Virtua, LLC. Virtua, LLC&#8217;s sole line
of business was providing management services to the Company. Details regarding the consulting agreement are set forth in Item 6 &#8211;
 &#8220;<I>Executive Compensation</I>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Daniel
Geffken</I></B></FONT>. Mr.&nbsp;Geffken serves as Managing Director of Danforth Advisors, LLC. Payments for CFO services provided to the
Company by Mr.&nbsp;Geffken are made to Danforth Advisors, LLC. For the years ended 2021, 2020 and
2019, the Company paid $326,619.75, $232,083.40 and $227,755.74, respectively, to Danforth Advisors, LLC for services provided
pursuant to a consulting agreement. Additionally, on March 1, 2017 and November 12, 2021, the Company granted 500,000 and 500,000
share options, respectively, to Danforth Advisors, LLC pursuant to the same agreement. For additional information regarding this agreement and the amounts
paid for Mr.&nbsp;Geffken&#8217;s services, see Item 6 &#8211; &#8220;<I>Executive Compensation</I>.&#8221;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Elliot
Goldstein</I></B></FONT>. Dr.&nbsp;Goldstein previously served as CEO and President of the Company. Payments for
Dr.&nbsp;Goldstein&#8217;s services were pursuant to a consulting agreement with Virtua, LLC. Virtua, LLC&rsquo;s sole line of business
was providing management services to the Company. Details regarding the consulting agreement are set forth in Item 6 &#8211; <I>&#8220;Executive
Compensation.&#8221;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Gavin
Malenfant</I></B></FONT>. Mr.&nbsp;Malenfant was paid $41,300 as a consultant in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see Item 6 &#8212;
 &#8220;<I>Executive Compensation</I>&#8221; for details regarding executive and director compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_014"></A><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Registration Statement, the
independence of our directors is determined under the corporate governance rules&nbsp;of the Nasdaq. The independence rules&nbsp;of Nasdaq
include a series of objective tests, including that an &#8220;independent&#8221; person will not be employed by us and will not be engaged
in various types of business dealings with us. In addition, the Board is required to make a subjective determination as to each person
that no material relationship exists with the Company either directly or as a partner, shareholder or officer of an organization that
has a relationship with the Company. It has been determined by the Board that six of our directors that we expect to be on the Board as
of the Effective Date are independent persons under the independence rules&nbsp;of the Nasdaq: Richard Gregory, Patrick Kirwin, Josh Mandel-Brehm,
Maggie Shafmaster, Neil K. Warma and William Wyman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_015"></A><B>ITEM
8. Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_016"></A><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, to the Company&#8217;s
knowledge, there are no material pending legal proceedings or regulatory actions to which the Company is or was a party to or of
which any of its property is or was the subject of, and no such proceedings or actions are known by the Company to be
contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_017"></A>ITEM
9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT&#8217;S COMMON EQUITY<BR>
AND RELATED SHAREHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_018"></A><B>Trading Price and Volume</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares of the Company are traded on
the TSX under the symbol &#8220;PMN.&#8221; The following table sets forth trading information for the Common Shares for the periods indicated,
as quoted on the TSX:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Period<SUP></SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Low&nbsp;Trading&nbsp;Price<BR> (C$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">High Trading Price<BR> (C$)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Year Ending December&nbsp;31, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify">Fourth Quarter (December&nbsp;30, 2021)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.20</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Third Quarter (September&nbsp;30, 2021)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.18</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.27</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Second Quarter (June&nbsp;30, 2021)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.17</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">First Quarter (March&nbsp;31, 2021)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.08</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Year Ending December&nbsp;31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fourth Quarter (December&nbsp;31, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.08</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.17</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Third Quarter (September&nbsp;30, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.13</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.24</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Second Quarter (June&nbsp;30, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.12</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.31</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">First Quarter (March&nbsp;31, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares of the Company are also traded
on the OTCQB Venture Market under the symbol &#8220;ARFXF.&#8221; The following table sets forth trading information for the Common Shares
for the periods indicated, as quoted on the OTCQB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Period<SUP></SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Low&nbsp;Trading&nbsp;Price<BR> ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">High Trading Price<BR> ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Year Ending December&nbsp;31, 2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify">Fourth Quarter (December&nbsp;31, 2021)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.11</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Third Quarter (September&nbsp;30, 2021)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.14</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.15</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Second Quarter (June&nbsp;30, 2021)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.17</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.19</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">First Quarter (March&nbsp;31, 2021)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.18</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Year Ending December&nbsp;31, 2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fourth Quarter (December&nbsp;31, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.06</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.09</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Third Quarter (September&nbsp;30, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Second Quarter (June&nbsp;30, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">First Quarter (March&nbsp;31, 2020)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.09</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.09</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_019"></A><B>Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January&nbsp;10, 2022, there were 123 holders
of record of our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="fulla_020"></A>Dividends</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in the Company&#8217;s
articles, by-laws or elsewhere, which would prevent the Company from paying dividends. No dividends have been declared or paid on the
Common Shares in the last five fiscal years, and it is not expected that dividends will be declared or paid in the immediate or foreseeable
future. Consequently, to date there have been no distributions made by the Company. The policy of the Board is to reinvest all available
funds in operations. The Board will reassess this policy from time to time. Any decision to pay dividends on the Common Shares will be
made by the Board based on the assessment of, among other factors, earnings, capital requirements and the operating and financial condition
of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="fulla_021"></A><B>Equity Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth securities authorized
for issuance under the Stock Option Plan and the DSU Plan as of December&nbsp;31, 2021. Figures below are presented on an as-converted
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="12" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="fulla_023"></A><B>Equity Compensation Plan Information</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of<BR>
securities<BR>
to be issued upon<BR>
exercise of<BR>
outstanding options,<BR>
warrants and rights</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted-average<BR>
exercise price of<BR>
outstanding options,<BR>
warrants and rights</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of securities<BR>
remaining available<BR>
for future issuance<BR>
under equity<BR>
compensation plans</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 39%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity compensation plans approved by security holders</B></FONT><B><FONT STYLE="font-size: 10pt"><SUP>(</SUP></FONT></B><FONT STYLE="font-size: 10pt"><SUP>1)</SUP></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,345,956</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.14</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,844,112</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity compensation plans not approved by security holders</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&#8212;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,345,956</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.14</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,844,112</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;The total number of Common Shares that
may be reserved and available for issuance under the Stock Option Plan shall not exceed the number of Common Shares equal to twenty percent
(20%) of the total issued and outstanding Common Shares from time to time less any Common Shares reserved for issuance under the DSU Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fulla_022"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
10. RECENT SALES OF UNREGISTERED SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following information represents securities sold by</FONT> the Company within the past three years through January&nbsp;21, 2022 &#8206;which
were not registered under the Securities Act. Included are new issues, securities issued in exchange for &#8206;property, services or
other securities and new &#8206;securities resulting from the modification of outstanding securities. The Company sold all of the securities
listed below pursuant &#8206;to the exemption from registration provided by Section&nbsp;4(a)(2)&nbsp;of the Securities Act, or Regulation
D or Regulation S &#8206;promulgated thereunder.&#8206;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;2, 2019, the Company granted 1,000,000
Stock Options with an exercise price per Stock Option of C$0.25 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;22, 2019, the Company completed
a private placement of 9,560,000 Units at C$0.23 per Unit, for gross proceeds of C$2,198,800. Each Unit consisted of one Common Share and
one Common Share purchase warrant. Each warrant entitles the holder to purchase one Common Share at an exercise price of C$0.48 each at
any time for five years following closing of the private placement, subject to earlier expiry upon 30 days&#8217; notice if, at any time
after four months from closing (until January&nbsp;23, 2024), the 20-day VWAP of Common Shares is greater than C$1.00, and ProMIS may
accelerate the expiry of the Warrants by issuing a press release announcing the reduced term and expiry not less than 30 days after the
publication date of such press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 9 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;15, 2019, the Company issued 250,000
Common Shares at a price per share of C$0.30 for total aggregate consideration of C$75,000 upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;26, 2019, the Company issued 87,500
Common Shares at a price per share of C$0.20 for total aggregate consideration of C$17,500 upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June&nbsp;2019, the Company closed a private
placement, consisting of 4,680,000 Units at C$0.25 for gross proceeds of C$1,170,000. Each Unit consisted of one Common Share and one
warrant, with each warrant entitling the holder thereof to purchase one Common Share at an exercise price of C$0.35 per Common Share at
any time for five years (until June&nbsp;26, 2024) following the closing of the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;19, 2019, the Company granted
250,000 Stock Options with a price per Stock Option of C$0.23 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;31, 2019, the Company completed
a private placement, on December&nbsp;31, 2019, of 14,001,664 Units at C$0.20 per Common Share for total gross proceeds of C$2,800,333,
with each Unit consisting of one Common Share and one warrant, with each warrant entitling the holder thereof to purchase one Common Share
at an exercise price of C$0.35 per Common Share at any time up to five years following closing of the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2020</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;25, 2020, the Company reported
a total of 4,790,251 of the Common Share purchase warrants issued on February&nbsp;10 and February&nbsp;21, 2017 in a non-brokered private
placement were exercised at a price of C$0.20 per Common Share for gross proceeds of C$958,051, which warrants expired on February&nbsp;21,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;28, 2020, the Company granted
400,000 Stock Options with an exercise price per Stock Option of C$0.20 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;24, 2020, the Company announced
that it had received Toronto Stock Exchange approval to reprice to C$0.13 each, in aggregate, 44,182,530 outstanding warrants issued between
August&nbsp;9, 2017 and December&nbsp;30, 2019, all expiring 5 years from the original date of issuance. The warrant repricing period
was effective from April&nbsp;8, 2020 to May&nbsp;22, 2020. In April&nbsp;and May&nbsp;2020, the Company received gross proceed of C$1,239,195
from the exercise of 9,532,276 warrants from the warrant repricing program. At the end of the warrant repricing period, the warrants reverted
to the original exercise price. All other terms of the warrants remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;15, 2020, the Company granted 150,000
Stock Options with an exercise price per Stock Option of C$0.15 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&nbsp;23, 2020, the Company proceeded
with a private placement offering (the &#8220;<B>Offering</B>&#8221;) of special warrants (&#8220;<B>Special Warrant</B>&#8221;) on October&nbsp;23,
2020, at a price of C$0.12 per Special Warrant, for gross proceeds of up to C$3,000,000. The Company received subscriptions in excess
of the minimum threshold of $1.5 million. Each Special Warrant is exercisable without payment of any additional consideration by the
holder, into one Common Share and one transferable Common Share purchase warrant (&#8220;<B>Warrant</B>&#8221;). Each Warrant entitles
the holder thereof to acquire one Common Share (&#8220;<B>Warrant Share</B>&#8221;) at an exercise price of C$0.20 per Warrant Share
for a period of 60 months after Closing, subject to acceleration of the expiry date described as follows. If at any time after the expiry
of the four-month hold period applicable to the Warrants, the twenty-day VWAP of the Common Shares on the TSX, or such other exchange
on which the Common Shares may be listed, is greater than C$0.60, the Company may deliver a notice to the holders of Warrants accelerating
the expiry date to a date that is not less than 30 days following the date of such notice. The first tranche of the Offering sold 13,819,581
Warrants, and closed on November&nbsp;5, 2020 raising gross proceeds of C$1,658,349.72, with a second tranche that closed on November&nbsp;16,
2020, which sold 2,400,000 Warrants and raised gross proceeds of C$288,000 for an aggregate total of C$1,946,349.72 in gross proceeds
raised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March, 22, 2021, the Company completed a private
placement for gross proceeds of $7 million by debentures convertible into Common Shares, at the option of the debenture holder, at $0.10
per Common Share and accrue interest at 1% per annum, which is payable annually. Interest may be paid in cash or in Common Shares, at
the option of ProMIS (such number of Common Shares area to be determined by dividing the interest due by the 5-day VWAP of the Common
Shares). The Debentures mature on March&nbsp;22, 2026, and ProMIS has the option, prior to the maturity date, to force conversion of the
Debentures at the conversion price upon raising $50 million in equity and/or debt cumulatively. At maturity ProMIS may redeem the outstanding
principal amount of the Debentures in either cash or Common Shares at the then current 5-day VWAP less a 10% discount, or at its election,
a combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;30, 2021, the Company granted 1,500,000
Stock Options with an exercise price per Stock Option of C$0.17 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May&nbsp;14, 2021, the Company granted 750,000
Stock Options with an exercise price per Stock Option of C$0.18 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;30, 2021, the Company granted 50,000
Stock Options with an exercise price per Stock Option of C$0.21 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;30, 2021, the Company granted 2,437,500
Stock Options with an exercise price per Stock Option of C$0.30 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&nbsp;12, 2021, the Company granted 100,000
Stock Options with an exercise price per Stock Option of C$0.24 to certain directors, executives and employees. No consideration was received
by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&nbsp;25, 2021, the Company completed a public offering of 125,781,250 units at a price of $0.16 for gross proceeds of $20,125,000.
</FONT> Each unit consisted of one Common Share and one-quarter purchase warrant. Each warrant entitles the holder thereof to purchase
one common share at an exercise price of $0.21 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;1, 2021, the Company granted
500,000 Stock Options with an exercise price per Stock Option of C$0.21 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&nbsp;22, 2021, the Company granted
3,500,000 Stock Options with an exercise price per Stock Option of C$0.19 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November&nbsp;12, 2021, the Company granted
500,000 Stock Options with an exercise price per Stock Option of C$0.18 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;9, 2021, the Company granted
2,500,000 Stock Options with an exercise price per Stock Option of C$0.14 to certain directors, executives and employees. No consideration
was received by the Company for the issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fulla_024"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
11. DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES TO BE REGISTERED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Description of the Company&#8217;s Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement relates to the Company&#8217;s
Common Shares. The Company is authorized to issue an unlimited number of Common Shares, of which there are 431,731,592 Common Shares
issued and outstanding as of January&nbsp;10, 2022, and an unlimited number of preferred shares, of which there no preferred shares issued
and outstanding as of January&nbsp;10, 2022. The following description may not be complete and is subject to, and qualified in its entirety
by reference to, the terms and provisions of our articles and by-laws, as amended (the &#8220;<B>Constating Documents</B>&#8221;), which
are included as exhibits to this Registration Statement<FONT STYLE="text-transform: uppercase">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January&nbsp;10, 2022, the Common Shares
collectively represent 100% of our total issued and outstanding shares and 100% of the voting power attached to all of our issued and
outstanding shares. The Company refers to its Common Shares as &#8220;shares.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Common Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Voting Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of Common Shares shall be entitled
to receive notice of all meetings of shareholders, and to attend, vote and speak at such meetings, except those meetings at which only
holders of another specified class or series of shares of the Company are entitled to vote separately as a class or series. A quorum for
a meeting of Shareholders shall be two shareholders, or two proxyholders representing shareholders, or any combination thereof, holding
not less than one-twentieth of the issued shares entitled to be voted at the meeting. On all matters upon which holders of shares are
entitled to vote, each Common Share is entitled to one vote per Common Share. Unless a different majority is required by law or the Constating
Documents, resolutions to be approved by holders of shares require approval by a simple majority of the total number of votes of all shares
cast at a meeting of Shareholders at which a quorum is present.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Dividend Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no restrictions in the Company&#8217;s
articles or elsewhere, which would prevent the Company from paying dividends. No dividends have been declared or paid on the Common Shares
of the Company in the last five fiscal years, and it is not expected that dividends will be declared or paid in the immediate or foreseeable
future. Consequently, to date there have been no distributions made by the Company. The policy of the Board is to reinvest all available
funds in operations. The Board will reassess this policy from time to time. Any decision to pay dividends on the Common Shares of the
Company will be made by the Board based on the assessment of, among other factors, earnings, capital requirements and the operating and
financial condition of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Liquidation Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the liquidation, dissolution or
winding-up of the Company or any other distribution of the Company&#8217;s assets for the purpose of winding up the Company&#8217;s affairs,
after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <I>pari passu</I> to receive any remaining
property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Pre-emptive and Redemption Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of Common Shares do not have any pre-emptive
or redemption rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Shareholder Rights Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;18, 2016 the Board adopted
the Shareholder Rights Plan effective January&nbsp;22, 2016. The Shareholder Rights Plan had an initial three-year term to the end of
ProMIS&#8217; 2019 annual shareholders meeting. At the Corporation&#8217;s annual shareholders meeting held June&nbsp;27, 2019, the
shareholders ratified and approved the Shareholder Rights Plan, as amended and extended, for continuation for a further
three-year period &#8211; specifically until the end of the annual shareholders meeting to be held in June&nbsp;2022. A copy of the
Shareholder Rights Plan, as amended and extended, is filed under the Corporation&#8217;s profile at www.sedar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shareholder Rights Plan is intended to ensure, to the
extent possible, that the ProMIS&#8217; Board and shareholders have adequate time to consider and evaluate any unsolicited takeover bid
and to identify, solicit, develop and negotiate any value enhancing alternatives that would be considered appropriate. This will encourage
fair treatment of ProMIS&#8217; shareholders in connection with any unsolicited takeover bid. The Shareholder Rights Plan was not adopted in response
to, or in anticipation of, any acquisition or take-over offer and is not intended to prevent a take-over of ProMIS, to secure continuity
of current management or the directors in office or to deter fair offers for the Common Shares of ProMIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board authorized the issuance of one right
in respect of each Common Share of ProMIS outstanding at 5:00 p.m.&nbsp;(ET) on January&nbsp;22, 2016 and each Common Share issued thereafter.
The rights will become exercisable if a person, together with their affiliates, associates and joint actors, acquires or announces an
intention to acquire beneficial ownership of Common Shares which, when aggregated with its holdings, total 20% or more of the outstanding
Common Shares of ProMIS (determined in the manner set out in the Shareholder Rights Plan). Following the acquisition of 20% or more of the outstanding
Common Shares, each right held by a person other than the acquiring person and its affiliates, associates and joint actors would, upon
exercise, entitle the holder to purchase that number of Common Shares at a substantial discount to the market price of the Common Shares
at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Shareholder Rights Plan permits the acquisition of control
of ProMIS through a &#8220;permitted bid&#8221;, a &#8220;competing permitted bid&#8221; or a negotiated transaction. A &#8220;permitted
bid&#8221; is one that, among other things, is made to all holders of Common Shares, is open for a minimum of 120 days and is subject
to an irrevocable minimum tender condition of at least 50% of the Common Shares held by independent shareholders. The Board has the discretion
to defer the time at which the rights become exercisable and to waive the application of the Shareholder Rights Plan.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preferred Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preferred shares of ProMIS may be issued in
one or more series and the directors are authorized to fix the number of preferred shares in each series and to determine the designation,
rights, privileges, restrictions and conditions attached to the preferred shares of each series. ProMIS preferred shares rank on parity
with the Common Shares with respect to the payment of dividends unless one or more series of ProMIS preferred shares are entitled to cumulative
dividends. ProMIS preferred shares also rank on parity with the preferred shares of every other series and are entitled to a priority
over any other class of shares ranking junior to the ProMIS preferred shares, and all series of preferred shares participate rateably
with respect to the distribution of assets upon the liquidation, dissolution or winding-up of ProMIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_025"></A><B>ITEM
12. INDEMNIFICATION OF DIRECTORS AND OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indemnification of our officers and our directors
is subject to the provisions of the CBCA, principally section 124 of the CBCA, which provides as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Indemnification</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;A corporation may indemnify a director
or officer of the corporation, a former director or officer of the corporation or another individual who acts or acted at the corporation&#8217;s
request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses,
including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal,
administrative, investigative or other proceeding in which the individual is involved because of that association with the corporation
or other entity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Advance of Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;A corporation may advance moneys to a
director, officer or other individual for the costs, charges and expenses of a proceeding referred to above in subsection (1). The individual
shall repay the moneys if the individual does not fulfil the conditions of subsection (3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Limitation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3)&nbsp;A corporation may not indemnify an individual
under subsection (1)&nbsp;unless the individual:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acted
honestly and in good faith with a view to the best interests of the corporation, or, as the case may be, to the best interests of the
other entity for which the individual acted as director or officer or in a similar capacity at the corporation&#8217;s request; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds
for believing that the individual&#8217;s conduct was lawful.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Indemnification in Derivative Actions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)&nbsp;</FONT>A
corporation may with the approval of a court, indemnify an individual referred to in subsection (1), or advance moneys under subsection
(2), in respect of an action by or on behalf of the corporation or other entity to procure a judgment in its favor, to which the individual
is made a party because of the individual&#8217;s association with the corporation or other entity as described in subsection (1)&nbsp;against
all costs, charges and expenses reasonably incurred by the individual in connection with such action, if the individual fulfils the conditions
set out in subsection (3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Right to Indemnity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)&nbsp;</FONT>Despite
subsection (1), an individual referred to in that subsection is entitled to indemnity from the corporation in respect of all costs, charges
and expenses reasonably incurred by the individual in connection with the defense of any civil, criminal, administrative, investigative
or other proceeding to which the individual is subject because of the individual&#8217;s association with the corporation or other entity
as described in subsection (1), if the individual seeking indemnity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;was
not judged by the court or other competent authority to have committed any fault or omitted to do anything that the individual ought to
have done; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fulfils
the conditions set out in subsection (3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Insurance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)&nbsp;</FONT>A
corporation may purchase and maintain insurance for the benefit of an individual referred to in subsection (1)&nbsp;against any liability
incurred by the individual:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the individual&#8217;s capacity as a director or officer of the corporation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the individual&#8217;s capacity as a director or officer, or similar capacity, of another entity, if the individual acts or acted in that
capacity at the corporation&#8217;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Application to Court</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)&nbsp;</FONT>A
corporation, an individual or an entity referred to in subsection (1)&nbsp;may apply to a court for an order approving an indemnity under
this section and the court may so order and make any further order that it sees fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Notice to Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(8)&nbsp;An applicant under subsection (7)&nbsp;shall
give the Director notice of the application and the Director is entitled to appear and be heard in person or by counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Notice</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(9)&nbsp;On an application under subsection (7)&nbsp;the
court may order notice to be given to any interested person and the person is entitled to appear and be heard in person or by counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our by-laws provide subject to the CBCA, we
may indemnify a director or officer or a former director or officer or a corporation of which we are or were or shareholder or
creditor and their heirs and legal representatives of such person against all costs, charges, and expenses including and amount to
be paid to settle an action or satisfy a judgment, reasonably incurred in respect of any civil, criminal or administrative action or
proceeding to which they are made a party by reason of being or having been a director or officer of us or a director or officer of
any such corporation. Each director and officer of on being elected and appointed shall be deemed to have contracted with us on the
terms of this indemnity. The failure of a director or officer to comply with the provisions of the CBCA, the articles or the by-laws
shall not invalidate any indemnity to which they are entitled under  our by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into indemnification agreements
or employment agreements containing indemnification provisions with certain of our executive officers and our directors. See &ldquo;<I>Consulting
and Employment Agreements</I>&rdquo; above for more information about our employment agreements. Under these indemnification provisions,
an indemnified person is entitled, subject to the terms and conditions thereof, to the right of indemnification by the Company for certain
expenses to the fullest extent permitted by applicable law. We believe that these indemnification agreements are necessary to attract
and retain qualified individuals to serve as directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may cause us to purchase and maintain
insurance for the benefit of any person who is or was serving as a director, officer, employee or agent of us or as a director, officer,
employee or agent of any corporation of which we are or were a shareholder and their heirs or personal representatives against any liability
incurred as a director, officer, employee or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an insurance policy covering our directors
and officers, within the limits and subject to the limitations of the policy, with respect to certain liabilities arising out of claims
based on acts or omissions in their capacities as directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="fulla_026"></A><B>ITEM
13. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statements required to be included in this Registration Statement are included in Item 15 and begin on page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="fulla_027"></A>ITEM
14. CHANGES IN AND DISAGREEMENTS WITH AUDITORS ON ACCOUNTING AND FINANCIAL DISCLOSURE<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December&nbsp;10, 2021, the Company engaged
Baker Tilly US, LLP (&ldquo;<B>Baker Tilly</B>&rdquo;) to perform an audit (the &ldquo;<B>U.S. Audit</B>&rdquo;) in accordance with the
standards of the Public Company Accounting Oversight Board of the Company&rsquo;s financial statements prepared in conformity with accounting
principles generally accepted in the U.S. for its fiscal years ended December&nbsp;31, 2019 and 2020, which financial statements are included
in this Registration Statement. Baker Tilly&rsquo;s engagement was recommended to the Company&rsquo;s Board by the Audit Committee and
approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to engaging Baker Tilly to conduct the U.S.
Audit, the Company had not consulted Baker Tilly regarding the application of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s financial statements, nor did the Company
consult with Baker Tilly regarding any matter that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv)&nbsp;of
Item 304 of Regulation S-K) or a reportable event (as described in paragraph (a)(1)(v)&nbsp;of Item 304 of Regulation S-K).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of filing of this Registration
Statement, PricewaterhouseCoopers LLP remains engaged as the Company&#8217;s independent auditor in Canada. PricewaterhouseCoopers LLP
has served as the Company&#8217;s auditors since 2004 and has conducted its most recent audits under Canadian Auditing Standards of the
Company&#8217;s financial statements prepared in accordance with International Financial Reporting Standards. In connection with the
effectiveness of this Registration Statement, if and when such effectiveness may occur, the Company anticipates that it will request
PricewaterhouseCoopers LLP to resign as its auditor.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 10 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fulla_028"></A><FONT STYLE="text-transform: uppercase"><B>ITEM
15. FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Years Ended December 31, 2020 and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Index to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; margin-bottom: 5.75pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 88%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 12%"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited Consolidated Financial Statements</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#ss1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Registered
Public Accounting Firm</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#ss2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#ss3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive
Loss</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#ss4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo;
Equity (Deficit)</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#ss5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#ss6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="#ss6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></A></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors of ProMIS Neurosciences,
Inc. and Subsidiary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of ProMIS Neurosciences, Inc. and Subsidiary (the &ldquo;Company&rdquo;) as of December 31, 2020 and 2019, and the related
consolidated statements of operations and comprehensive loss, changes in shareholders&rsquo; equity (deficit), and cash flows for each
of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &ldquo;consolidated financial
statements&rdquo;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years the period
ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Baker Tilly US, LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2021.</P></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tewksbury, Massachusetts</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 28, 2022</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss2"></A>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2019</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Assets</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Current assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 74%; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">806,887</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,281,825</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Short-term investments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32,963</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32,264</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Prepaid and other current assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">133,022</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">248,238</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Total current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">972,872</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,562,327</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Property and equipment, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">78,111</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Intangible assets, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32,637</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37,252</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,353</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,085,973</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,599,579</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Liabilities and Shareholders' Equity (Deficit)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Current liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Accounts payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">437,441</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">358,712</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Accrued liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">46,201</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">165,908</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Deferred compensation</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,398,989</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">767,854</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt">Total current liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,882,631</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,292,474</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Commitments and contingencies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Shareholders' (deficit) equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Common shares, no par value, unlimited shares authorized, 289,730,760 and 275,408,233 shares issued and outstanding as of December&nbsp;31, 2020 and 2019, respectively</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">51,655,168</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48,435,848</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Accumulated other comprehensive (loss) income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(50,731</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22,072</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(52,401,095</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(48,150,815</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total shareholders' (deficit) equity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(796,658</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">307,105</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total liabilities and shareholders' (deficit) equity</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,085,973</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,599,579</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss3"></A>Consolidated Statements of Operations and Comprehensive
Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Years Ended December&nbsp;31,</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 74%; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,224,650</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,211,282</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,026,957</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,336,990</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,251,607</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,548,272</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,251,607</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,548,272</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,327</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">905</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,250,280</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,547,367</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive (loss) income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign currency translation adjustment </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(72,803</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,072</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,323,083</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,525,295</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share, basic and diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.01</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.02</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average shares outstanding of common shares, basic and diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">285,599,827</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259,795,156</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss4"></A>Consolidated Statements of Changes in Shareholders&#8217;
Equity (Deficit)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Common Shares</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Additional <BR>
Paid-in <BR>
Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Accumulated <BR>
Other <BR>
Comprehensive <BR>
Income (Loss)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Accumulated <BR>
Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; font: 10pt Times New Roman, Times, Serif">Balance, January&nbsp;1, 2019</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">246,829,069</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">43,455,768</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">(42,603,448</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">852,320</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Exercise of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">337,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,566</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,566</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Issuance of common share units - net of issuance costs of
                                                                                                  $203,879</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,241,664</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,445,930</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,445,930</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">464,584</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">464,584</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign currency translation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,072</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,072</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,547,367</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,547,367</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance, December&nbsp;31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">275,408,233</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,435,848</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,072</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(48,150,815</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">307,105</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Exercise of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,322,527</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,608,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,608,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Issuance of Special Warrants - net of issuance costs of $226,703</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,256,828</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,256,828</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">354,402</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">354,402</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign currency translation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(72,803</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(72,803</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,250,280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,250,280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance, December&nbsp;31, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">289,730,760</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">51,655,168</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(50,731</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(52,401,095</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(796,658</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss5"></A>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in US dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Years Ended December&nbsp;31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash flows from operating activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,250,280</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,547,367</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">354,402</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">464,584</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation of property and equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,726</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,422</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of intangible assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,955</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in operating assets and liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid and other current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117,549</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,933</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83,976</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(115,978</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(190,955</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred compensation</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">585,693</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">749,701</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in operating activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,232,532</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,484,017</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash flows from investing activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase of short-term investments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31,220</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31,501</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of short-term investment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,064</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,345</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase of property and equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(80,705</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other investing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,228</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash used in investing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83,089</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(156</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash flows from financing activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from issuance of common shares from exercise of warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,608,090</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,566</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from issuance of Special Warrants &ndash; net of issuance costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,256,828</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from issuance of common share units - net of issuance costs</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,870,063</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash provided by financing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,864,918</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,939,629</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of exchange rates on cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,235</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,637</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net decrease in cash</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(474,938</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(469,907</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash at beginning of year</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,281,825</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,751,732</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash at end of year</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">806,887</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,281,825</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Noncash financing activities</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common share units related to settlement
    of escrow liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">473,579</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of compensation warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,618</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,631</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value adjustment for modification of warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,005</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common share units for services</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,288</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="ss6"></A>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><B>DESCRIPTION
OF BUSINESS</B></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Business Description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ProMIS Neurosciences,&nbsp;Inc.
(the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>ProMIS</B>&rdquo;) is applying its patented technology platform to build a portfolio
of antibody therapies, therapeutic vaccines, and other antibody-based therapies in neurodegenerative diseases and other mis-folded
protein diseases, including Alzheimer&rsquo;s disease (&ldquo;<B>AD</B>&rdquo;), multiple system atrophy, amyotrophic lateral
sclerosis, Parkinson&rsquo;s disease, Lewis body dementia, frontotemporal lobar degeneration, progressive supranuclear palsy,
corticobasal degeneration and schizophrenia. These diseases share a common biologic cause &ndash; misfolded versions of proteins
that otherwise perform a normal function, kill neurons and produce disease. ProMIS&rsquo; technology platform is an example of the
advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. ProMIS believes this
platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics or detecting them
with diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company was incorporated on
January 23, 2004 under the Canada Business Corporations Act and is located at 1920 Yonge Street, Toronto, Ontario. The Company is
traded on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the symbol PMN and on the OTCQB Venture Market under the
symbol ARFXF. The Company has a wholly-owned U.S. subsidiary, ProMIS Neurosciences (US) Inc. (&ldquo;<B>ProMIS USA</B>&rdquo;),
which was incorporated in January&nbsp;2016 in the State of Delaware. As of December 31, 2021, ProMIS USA has had no activity and
has no financial impact on the Company&#8217;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The success of the Company is dependent on obtaining
the necessary regulatory approvals of its product candidates, to market the products and achieving profitable operations. The continuation
of the research and development activities and the commercialization of its products, if approved, are dependent on the Company&#8217;s
ability to successfully complete these activities and to obtain additional financing through a combination of financing activities and
operations. It is not possible to predict either the outcome of future research and development or commercialization programs, or the
Company&#8217;s ability to fund these programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Impacts resulting from the COVID-19 pandemic have
resulted in a widespread health crisis that has already adversely affected the economies and financial markets of many countries around
the world. The international response to the spread of COVID-19 has led to significant restrictions on travel; temporary business closures;
quarantines; global stock market and financial market volatility; a general reduction in consumer activity; operating, supply chain and
project development delays and disruptions; and declining trade and market sentiment; all of which have and could further affect the world
economy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The extent to which the novel coronavirus
may impact the Company&#8217;s business, preclinical research and development activities will depend on future developments which
are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social
distancing in Canada, the United States and other countries, business closures or business disruptions and the effectiveness of
actions taken by governments around the globe to contain and treat the disease. International scientific conferences at which the
Company has been invited to present have been postponed, cancelled or will be held online instead, which diminishes exposure and the
opportunity to meet with collaborators and potential partners. These scientific conferences have started to be held in person with
an option to attend online. Vendors performing work for the Company have remained open, although they have indicated that their
timelines are now somewhat longer. The current global uncertainty and its effect on the local and global economies may also have an
adverse effect on the Company&#8217;s ability to secure additional financing to continue its research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 11 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B> dollars, except
share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Liquidity Consideration</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying consolidated financial
statements were prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future
and will be able to realize its assets and discharge its liabilities in the normal course of business. To date, the Company has not generated
revenues from its activities. The Company had a net loss of $4,250,280, for the year ended December&nbsp;31, 2020 and an accumulated deficit
of $52,401,095 as of December&nbsp;31, 2020. In March&nbsp;2021, the Company completed a $7.0 million private placement of convertible
unsecured debentures (Note 16). In August&nbsp;2021, the Company completed a public offering on the TSX, with gross proceeds of $20,125,000.
Available funds, including the proceeds from the March&nbsp;2021 financing and August&nbsp;2021 financing, are expected to be sufficient
to fund the Company&rsquo;s operating expenses for at least 12 months from the date the financial statements are issued. However, additional
funding will be necessary to fund future research, pre-clinical and clinical activities. The Company will seek additional funding through
public financings, debt financings, collaboration agreements, strategic alliances and licensing agreements. Although the Company has been
successful in raising capital in the past, there is no assurance of success in obtaining such additional financing on terms acceptable
to us, if at all, and there is no assurance that the Company will be able to enter into collaborations or other arrangements. If the Company
is unable to obtain funding, it could force delays, reduce or eliminate research and development programs, product portfolio expansion
or commercialization efforts, which could adversely affect future business prospects, and the ability to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may continue to incur net
losses for at least the next several years as the Company advances its product candidates. The Company is actively pursuing additional
financing to further develop certain of the Company&#8217;s scientific initiatives, but there is no assurance these initiatives will be
successful, timely or sufficient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>BASIS
OF PRESENTATION AND Summary of Significant Accounting Policies</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Basis of <B>Presentation</B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying consolidated financial
statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&ldquo;<B>GAAP</B>&rdquo;).
Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards
Codification (&ldquo;<B>ASC</B>&rdquo;) and as amended by Accounting Standards Updates (&ldquo;<B>ASU</B>&rdquo;) of the Financial Accounting
Standards Board (&ldquo;<B>FASB</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Principles of Consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in
consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of consolidated financial
statements in conformity with GAAP requires management to make certain estimates, judgements and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying
consolidated financial statements include, but are not limited to, the valuation of intangible assets, accrual for research and development
expenses, the valuation of share-based compensation and the valuation of warrants. Actual results could differ from those estimates, and
such differences could be material to the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Segment Information</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Operating segments are identified as
components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision
maker (&ldquo;<B>CODM</B>&rdquo;), or decision-making group, in making decisions on how to allocate resources and assess performance.
The Company has one operating segment and its Chief Executive Officer and Executive Chairman of the Board of Directors collectively serve
as the CODM. Substantially all of the Company&#8217;s assets are located in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Foreign Currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Comprehensive loss is defined as a
change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The reporting
currency of the Company is the United States dollar (&ldquo;<B>USD</B>&rdquo;) and the functional currency of the Company is the
Canadian dollar. The assets and liabilities of the Company are translated to USD at exchange rates in effect at the balance sheet
date. All income statement accounts are translated at average exchange rates. Resulting foreign currency translation adjustments are
recorded directly in accumulated other comprehensive income (loss) as a separate component of shareholders&rsquo; equity (deficit).
Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the
functional currency are included in general and administrative expenses in the accompanying consolidated statements of operations
and comprehensive loss when realized and are not material for the years ended December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: #231f20"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company considers all highly liquid
investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December&nbsp;31,
2020 and 2019 the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Short-term Investments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Short-term investments consist of guaranteed
certificates of deposit with a maturity greater than 90 days and up to one year at the time of purchase. Accordingly, all short-term investments
are classified as current assets in the accompanying consolidated balance sheets. The short-term investment is being held as collateral
for the Company&rsquo;s credit cards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Concentration of Credit Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial instruments that potentially
subject the Company to a significant concentration of credit risk consist of cash and short-term investments. Cash is deposited in checking
and money market accounts at accredited financial institutions, which at times, may exceed federally insured limits. The short-term investment
is deposited in a guaranteed certificate of deposit with an accredited financial institution that guarantees 100% of the original amount
invested. Management believes that these financial institutions are financially sound, and, accordingly, minimal credit risk exists with
respect to these high-quality financial institutions. As of December&nbsp;31, 2020, the Company has not experienced any losses on its
cash or short-term investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Fair Value Measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">FASB ASC 820, <I>Fair Value Measurements
and Disclosures, </I>(ASC 820) defines fair value as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to
be classified and disclosed in one of the following three levels of the fair value hierarchy, as established by ASC 820, of which the
first two are considered observable and the last is considered unobservable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1 &#8211; Observable inputs, such as unadjusted, quoted prices in active markets for identical assets
or liabilities at the measurement date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2 &#8211; Inputs (other than Level 1 quoted prices) are either directly or indirectly observable
inputs for similar assets or liabilities. These include quoted prices in active markets for similar assets or liabilities, quoted prices
in markets that are not active for identical or similar assets or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant
to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the extent that the valuation is
based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment.
Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level
3. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The carrying amounts of prepaid and
other current assets, short-term investments, accounts payable, and accrued expenses are generally considered to be representative of
their fair value based on the short-term nature of these financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Impairment of Long-Lived Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company evaluates its
long-lived assets, which consist of property and equipment and definite-lived intangible assets, for impairment whenever events or
changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated future undiscounted net cash flows
expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by
the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairments have been identified as of
December&nbsp;31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Property and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Property and equipment, net are stated
at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life
of each asset. Laboratory and equipment are depreciated over two to five year lives. Computer equipment is depreciated over two to three
years. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accompanying
consolidated balance sheets and any resulting gain or loss is included in loss from operations in the accompanying consolidated statement
of operations and comprehensive loss. Expenditures for repairs and maintenance are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Intangible Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Definite-lived intangible assets are
stated at cost less accumulated amortization and any accumulated impairment losses. An intangible asset&rsquo;s carrying amount is assessed
for impairment whenever there is an indication that the asset may be impaired. The Company&rsquo;s definite-lived intangible assets consist
of acquired rights and patents. Intangible assets are amortized on a straight-line basis over the lesser of the life of the patent or
its estimated useful life, which is 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Collaboration Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may enter into
collaboration arrangements with pharmaceutical and biotechnology partners. The Company analyzes its collaboration arrangements to
assess whether they are within the scope of FASB ASC 808, <I>Collaborative Arrangements, </I>(ASC 808), to determine whether such
arrangements involve joint operating activities performed by the parties that are both active participants in the activities and
exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed
throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. ASC 808 does not
provide guidance on the recognition of consideration exchanged or accounting for the obligations that may arise between parties. The
Company concluded that ASC Topic 730, <I>Research and Development, </I>should be applied by analogy to payments between parties
during the development activities of its collaboration arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>General and Administrative</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">General and administrative expenses
consist primarily of personnel costs including salary, bonus, employee-benefits and share-based compensation, professional service fees,
and other general overhead and facility costs, including rent, depreciation and amortization, which relate to the Company&rsquo;s general
and administrative functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Research and development expenses consist
primarily of costs incurred in connection with the development and research of the Company&rsquo;s platform technology, as well as discovery
program expenses. The Company expenses research and development costs as incurred. These expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">employee-related expenses, including salaries, related benefits and share-based compensation expense,
for employees engaged in research and development functions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">external
                                            research and development expenses incurred under arrangements with third parties, such as
                                            contract research organizations (&ldquo;<B>CROs</B>&rdquo;), and consultants;</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the cost of acquiring, developing, and manufacturing clinical study materials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Costs associated with preclinical and clinical activities and regulatory operations; and costs incurred
in development and protection of intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Prepaid and Accrued Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Substantial portions of the Company&rsquo;s
pre-clinical trials are performed by third-party laboratories, medical centers, CROs and other vendors. These vendors generally bill monthly
for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated
percentage of work completed and the remaining contract milestones. At times, the Company is obligated to make upfront payments upon execution
of research and development agreements. Upfront payments, including nonrefundable amounts, for goods or services that will be used or
rendered for future research and development activities are capitalized as prepaid expenses until such goods are delivered or the related
services are performed. The Company estimates the period over which such services will be performed based on the terms of the agreements
as well as the level of effort to be expended in each period. Sometimes the actual timing of performance or the level of effort varies
from the estimate, and if that does occur, the Company will adjust the amounts recorded accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Patent Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All patent-related costs incurred in
connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company issues warrants on its common
shares in connection with financings as well as for compensation of intermediaries and advisors. The Company accounts for warrants as
either equity instruments or as liabilities depending on the specific terms of the warrant agreements in accordance with FASB ASC Topic
815, <I>Derivatives and Hedging</I>. Generally, warrants are classified as equity, within additional paid-in-capital as opposed to liabilities,
as the agreements do not include the potential for a cash settlement or an adjustment to the exercise price and therefore deemed to be
indexed to the Company&rsquo;s own shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Share-based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Share-based compensation expense related
to share awards granted to employees, directors and non-employees is recognized based on the grant-date estimated fair values of the awards
using the Black- Scholes option pricing model (&ldquo;<B>Black-Scholes</B>&rdquo;). The value is recognized as expense ratably over the
requisite service period, which is generally the vesting term of the award. The Company adjusts the expense for actual forfeitures as
they occur. Share based compensation expense is classified in the accompanying consolidated statements of operations and comprehensive
loss based on the function to which the related services are provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Black Scholes requires a number of assumptions,
of which the most significant are expected volatility, expected option term (the time from the grant date until the options are exercised
or expire) and risk-free rate. Expected volatility is determined using the historical volatility for the Company. The risk-free interest
rate is based on the yield of Canadian government bonds with a remaining term equal to the expected life of the option. Expected dividend
yield is zero because the Company has never paid cash dividends on common shares and the Company does not expect to pay cash dividends
in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is a taxable entity under
the Income Tax Act (Canada). Deferred income tax assets and liabilities are determined based on differences between the financial statement
carrying amounts and the respective income tax bases of assets and liabilities, measured using substantively enacted income tax rates
and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are recognized to the extent
it is more likely than not that taxable income will be available against which the deferred tax asset can be utilized. Deferred tax assets
are reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company follows the provisions of
ASC 740-10, <I>Uncertainty in Income Taxes</I>. The Company has not recognized a liability as a result of the implementation of ASC 740-10.
A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized
benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of
ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits
in interest expense and penalties in operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Basic and Diluted Net Loss Per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Basic net loss per common share is computed
by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common
shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and
warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average
number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are
not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the
same, as any additional share equivalents would be anti-dilutive. As the Company has reported a net loss for all periods presented, diluted
net loss per common share is the same as basic net loss per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Emerging Growth Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is an Emerging Growth Company,
as defined in Section&nbsp;2(a)&nbsp;of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (&ldquo;<B>JOBS&nbsp;Act</B>&rdquo;).
Under the JOBS&nbsp;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment
of the JOBS&nbsp;Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies until
the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opts out of
the extended transition period provided in the JOBS&nbsp;Act. As a result, these consolidated financial statements may not be comparable
to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February&nbsp;2016, the FASB issued
ASU No.&nbsp;2016-02, Leases (&ldquo;<B>Topic 842</B>&rdquo;), which requires lessees to recognize the following for all leases (with
the exception of short-term leases) at the commencement date: a lease liability, which is a lessee&rsquo;s obligation to make lease payments
arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&rsquo;s right
to use, or control the use of, a specified asset for the lease term. In July&nbsp;2018, the FASB issued ASU 2018-11 to amend certain aspects
of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition
method, an entity initially applies the transition requirements in Topic 842 at that Topic&rsquo;s effective date with the effects of
initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components
of equity or net assets, as appropriate) in the period of adoption. On April&nbsp;8, 2020, the FASB changed the effective date of this
standard applicable to the Company as an emerging growth company to January&nbsp;1, 2022. The Company is currently evaluating the potential
impact of this standard on its consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December 2019, the FASB issued ASU
No 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>, as part of its simplification initiative to
reduce the cost and complexity in accounting for income taxes. The amendments in ASU 2019-12 removes certain exceptions related to the
approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred
tax liabilities for outside basis differences. ASU 2019-12 also amends other aspects of the guidance to help simplify and promote consistent
application of GAAP. The guidance is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted.
For emerging growth companies, the standard is effective for fiscal years beginning after December 15, 2021. The Company is currently
evaluating the potential impact adopting ASU 2019-12 will have on the Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2020, the FASB issued
ASU No.&nbsp;2020-06, <I>Debt&mdash;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in
Entity s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s Own Equity</I>. ASU 2020-06
will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments
and convertible preferred shares. Limiting the accounting models results in fewer embedded conversion features being separately recognized
from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (i)&nbsp;those
with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative,
and that do not qualify for a scope exception from derivative accounting and (ii)&nbsp;convertible debt instruments issued with substantial
premiums for which the premiums are recorded as additional paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope
exception for contracts in an entity&rsquo;s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be
effective for the Company for fiscal years beginning after December&nbsp;15, 2023. Early adoption is permitted, but no earlier than fiscal
years beginning after December&nbsp;15, 2020, including interim periods within those fiscal years. The Company is currently evaluating
the potential impact adopting ASU 2020-06 will have on the Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Recently Adopted Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In June&nbsp;2018, the FASB issued ASU
2018-07, <I>Compensation&mdash;Stock Compensation (Topic 718): Improvements to Employee Share-based Payment Accounting</I>. ASU 2018-07
aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance under ASC 718 for share-based
payments to employees. Under ASU 2018-07, the measurement of equity-classified nonemployee awards is fixed at the grant date at the fair
value of the award. ASU 2018-07 permits an entity to make an entity-wide policy election for all nonemployee awards to either (1)&nbsp;estimate
forfeitures or (2)&nbsp;recognize forfeitures when they occur. Nonemployee awards that contain a performance condition that affects the
quantity or other terms of the award are measured based on the outcome that is probable. The Company adopted ASU 2018-07 in January&nbsp;2019
and it did not have a material impact on the Company&rsquo;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2018, the FASB issued ASU 2018-13,
<I>Fair Value Measurement (ASC 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</I>. ASU 2018-13
removes certain disclosures, modifies certain disclosures, and adds additional disclosures. The Company early adopted ASU 2018-13 in January&nbsp;2019
and it did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD><B>FAIR VALUE MEASUREMENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following are the major categories of assets measured at fair value
on a recurring basis as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31, 2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Short-term investments</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total assets measured at fair value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,963</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 13.7pt">Short-term investments</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,264</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,264</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 27.35pt">Total assets measured at fair value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,264</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,264</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No transfers between levels have occurred in either
reporting period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD><B>PREPAID EXPENSES AND OTHER CURRENT ASSETS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Prepaid expenses and other current assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Upfront research payments</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">30,714</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">20,295</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Goods and services tax receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">54,724</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Insurance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27,335</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,401</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dues and subscriptions</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,133</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Consultants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,929</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">107,131</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deposits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,818</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,671</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,077</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,883</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">133,022</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">248,238</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD><B>PROPERTY AND EQUIPMENT</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Property and equipment, net, consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory equipment</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">151,114</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">66,221</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Computer equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,498</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,554</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total property and equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">162,612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">77,775</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(84,501</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(77,775</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">78,111</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expense was $6,726 and $1,422 for
the years ended December&nbsp;31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Intangible assets</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has intangible assets consisting
of licenses and patents with finite lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2012, the Company acquired rights
to a certain patented technology that it had licensed from its Chief Scientific Officer for C$100,000. The Company is amortizing this
asset over its expected useful life of 15 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Intangible assets</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">78,417</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">77,139</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: accumulated amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(45,780</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(39,887</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,637</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">37,252</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Amortization expense was $4,955 and $5,025 for
the years ended December&nbsp;31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2020, the estimated
expected amortization expense related to the Company&rsquo;s intangible assets for each year through the years ended 2025 is $5,232 and,
thereafter totals $6,477.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DEFERRED COMPENSATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has deferred cash payment
of management compensation for the Executive Chairman. Chief Executive Officer, Chief Scientific Officer, Chief Medical Officer and Chief
Development Officer, to future periods when future funding is received. Deferred compensation was $1,398,989 and $767,854 for the years
ended December&nbsp;31, 2020 and 2019, respectively. As of December&nbsp;31, 2021, all deferred compensation to management was paid in
full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 12 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Collaboration agreements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In July&nbsp;2020, the Company entered into two collaborative
agreements (&ldquo;<B>BCNI Collaborations</B>&rdquo;) with BC Neuroimmunology Lab Inc. (<B>&ldquo;BCNI&rdquo;</B>) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><I>Neurodegenerative Diseases </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company and BCNI
(&ldquo;<B>Neurodegen Collaboration</B>&rdquo;) will develop and offer highly accurate and objective tests for detection, diagnosis
and monitoring of AD. The operation will first offer existing blood-based assays for NfL and P-tau181. Further assays will be added,
potentially incorporating the Company&rsquo;s proprietary peptide antigens and tests for additional neurodegenerative diseases. The
agreement was accounted for as a collaboration arrangement. Beginning in October&nbsp;2020, each party contributed up to Canadian
C$12,500 each month to cover operating costs up to the time that the operation becomes cashflow positive. The Company and BCNI
acquired laboratory equipment that they jointly control. The Company contributed $115,900 during 2020, of which $9,655 were recorded
in research and development expenses in the accompanying consolidated statement of operations and comprehensive loss and the
$106,245 is reflected in property and equipment, net, in the accompanying  consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Covid-19</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company and BCNI (&ldquo;<B>Covid-19
Collaboration</B>&rdquo;) will provide the service of highly sensitive and specific serological assays for the detection and characterization
of antibodies to the SARS-CoV-2 virus that is responsible for COVID-19. The Company and BCNI agreed to create an independent entity for
the Covid-19 Collaboration to be established in 2021. The Company acquired 50% ownership interest in the future entity for $2,353. The
Company recorded its investment in the future entity using the equity method of accounting and is reflected in other assets in the accompanying
consolidated balance sheets. The Company is responsible for the funding of all operating expenses, with &nbsp;prior notification of the
planned expenditures, to bring the assay through approval. As of December 31, 2020, operations were conducted through the Company and
BCNI. The agreement was accounted for as a collaboration arrangement. The Company contributed $10,306 during 2020, which was recorded
as research and development expense on the accompanying consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>C<FONT STYLE="text-transform: uppercase"><B>OMMON SHARES</B></FONT></B></FONT></TD>
</TR></TABLE>
<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has authorized an unlimited
number of both common and preferred shares. As of December 31, 2020 and 2019, the Company has 289,730,760 and 275,408,233 issued and outstanding
common shares and no preferred shares as of December&nbsp;31, 2020 and 2019, respectively. The common shares have no par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Common shares reserved for future issuance
consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif">Warrants</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">37,165,711</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">54,381,981</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Special Warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,439,162</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options issued and outstanding under <FONT STYLE="text-transform: capitalize">stock
    option plan</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38,771,749</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38,323,749</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Deferred share units</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63,708</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63,708</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Common shares available for grant under
    <FONT STYLE="text-transform: capitalize">stock option plan</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,387,190</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,835,190</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total common shares reserved for future issuance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">118,827,520</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,604,628</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The rights of the common shares are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">Subject to any special voting rights
or restrictions, holders of common shares entitled to vote shall have one vote per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s board of directors
may from time to time declare and authorize payment of dividends, if any, as they may deem advisable and need not give notice of such
declaration to any shareholder. Subject to the rights of common shareholders, if any, holding shares with specific rights as to dividends,
all dividends on common shares shall be declared and paid according to the number of such shares held and paid in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Liquidation Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of the liquidation, dissolution
or winding-up of the Company or any other distribution of the Company&rsquo;s assets for the purpose of winding up the Company&rsquo;s
affairs, after the payment of dividends declared but unpaid, the holders of Common Shares shall be entitled <I>pari passu</I> to receive
any remaining property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Equity Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In November&nbsp;2019, the Company announced
a private placement offering of up to 32.5 million common share units at a price of C$0.20 per unit for gross proceeds of up to C$6,500,000.
Each common share unit consisted of one common share and one common share purchase warrant. The common shares are subject to a four-month
holding period from the date of issuance. Each warrant entitles the holder thereof to purchase one common share at an exercise price of
C$0.35 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company completed closings in November&nbsp;and
December&nbsp;2019, issuing 14,001,664 common share units, resulting in gross proceeds of $2,121,776 ($2,054,060, net of issuance costs).
In connection with the offering, the Company issued 675,000 common share units with a fair value of $102,288 to an advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related to the financing, the Company
paid to certain intermediaries $24,610 and issued 162,400 compensation warrants, which have the same terms as the common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The allocation of the C$0.20 per common
share unit issue price to the common shares and the common share warrants was determined based on the relative fair values of the common
shares and warrants. The fair value of the warrants was determined using Black-Scholes. The common shares issued were allocated a price
of C$0.11 per share and the common share warrants were allocated a price of C$0.09.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In June&nbsp;2019, the Company completed
a private placement of 4,680,000 common share units at a price of C$0.25 per unit, resulting in gross proceeds of $874,397 ($817,219,
net of issuance costs). Each unit consisted of one common share and one common share warrant. Each warrant is exercisable into one common
share at a price of C$0.35 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The allocation of the C$0.25 per common
share unit issue price to the common shares and the common share warrants was determined based on the relative fair values of the common
shares and warrants. The fair value of the warrants was determined using Black Scholes. The common shares issued were allocated a price
of C$0.135 per share and the common share warrants were allocated a price of C$0.115.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December&nbsp;2018, the Company received
escrow payments totaling C$628,795 ($473,579) in advance of the closing of a private placement that occurred in January&nbsp;2019. In
January&nbsp;2019, the Company completed a private placement of 9,560,000 common share units at a price of C$0.23 per unit resulting in
gross proceeds of $1,653,636 ($1,574,651, net of share issuance costs). Each unit consisted of one common share and one common share warrant.
Each warrant is exercisable into one common share at a price of C$0.48 per share at any time for five years. The expiry date of the warrants
is subject to acceleration if, after four months from issuance, the 20-day volume weighted average trading price (<B>&ldquo;VWAP&rdquo;</B>)
of the common shares exceeds C$1.00 or the Company enters into a collaborative deal within 18 months of closing a qualifying transaction
and the 20-day VWAP is greater than C$0.48 at any time following the announcement of such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The allocation of the C$0.23 per unit
issue price to the common shares and the common share warrants was determined based on the relative fair values of the common shares and
warrants. The fair value of the warrants was determined using a Monte Carlo simulation. The common shares issued were allocated a price
of C$0.18 per share and the common share warrants were allocated a price of C$0.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related to the financing, the Company
compensated certain intermediaries cash fees equal to 7% of the gross proceeds totaling to $29,665 and issued 164,500 warrants, which
have the same terms as the common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Warrants</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In November&nbsp;2020, the Company closed
on a special warrant financing (<B>&ldquo;Special Warrants&rdquo;</B>). The Company issued 16,219,581 Special Warrants, resulting in proceeds
of $1,483,531 ($1,256,828, net of issuance costs). Each Special Warrant is exercisable, without payment of any additional consideration
by the holder, into one common share and one transferrable common share warrant (<B>&ldquo;Warrants&rdquo;</B>). Each Warrant entitles
the holder to acquire one common share at an exercise price at C$0.20 per warrant share for 60 months until November&nbsp;2025. Each Special
Warrant will automatically convert at the earlier of the date that is (i)&nbsp;the third business day after a receipt for a final prospectus
qualifying the distribution of the shares and warrants issuable upon the conversion of the Special Warrants and (ii)&nbsp;four months
and one day after the issue date of the Special Warrants (Note 16).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related to the special warrant financing,
the Company compensated certain intermediaries cash fees equal to 7% of the gross proceeds totaling $53,929 and issued 557,200 warrants,
which have the same terms as the common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During March&nbsp;2020, the Company
announced a repricing of various warrants to an exercise price of C$0.13, effective April&nbsp;8, 2020 and expiring on May&nbsp;22, 2020.
The warrants repriced ranged in exercise prices of C$0.285 to C$0.48. At the end of the warrant repricing period, the warrants revert
to the original exercise price. All other terms of the warrants shall remain unchanged. A total of 44,182,530 warrants were repriced,
and, of the repriced warrants, 9,532,276 were exercised during the repricing period ending on May&nbsp;22, 2020, for total proceeds of
$894,272. In connection with the repricing, the Company recorded a fair value adjustment on the date of the modification of $85,005, which
was treated as transaction costs and recorded to additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During February&nbsp;2020, 4,790,251
warrants were exercised for total proceeds of $713,818 and 3,450,943 warrants expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the year ended December&nbsp;31,
2019, 337,500 warrants were exercised for total proceeds of $69,566.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As at December&nbsp;31, 2020, outstanding
common share warrants and exercise prices denominated in C$, related to unit offerings are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Exercise<BR>
 Price $</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid"><B>Number of</B> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><BR>
W</B></FONT><B>arrants</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiry date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 31%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.300</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 31%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,860,543</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: right">August&nbsp;2022</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.285</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,265,010</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">August&nbsp;2022</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,004,394</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">April&nbsp;2023</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.480</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,379,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">January&nbsp;2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,100,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">June&nbsp;2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,049,066</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">November&nbsp;2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,949,998</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">December&nbsp;2024</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">557,200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt">November&nbsp;2025</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">37,165,711</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD><B>SHARE-BASED COMPENSATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>2007 Stock Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the 2007 Stock Option Plan (<B>&ldquo;2007 Option Plan&rdquo;</B>). In June&nbsp;2015, the 2007 Option Plan was amended
from a fixed option plan to a rolling share option plan pursuant to which the Company </FONT>is authorized to grant options of up to
20% of its issued and outstanding common shares. Share options granted vest at various rates and have a term not exceeding ten years.
As of December&nbsp;31, 2020 and 2019, the Company had 10,387,190 and 10,835,190 options, respectively, available for grant under the
2007 Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes the activity
of the share options under the 2007 Option Plan for the years ended December&nbsp;31, 2020 and 2019. All amounts are denominated in C$,
except year and share amounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR>
 Share Options</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Exercise<BR> Price Per Share</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<BR> Remaining<BR> Contractual<BR> Term (years)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR> Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif">Outstanding as of January&nbsp;1, 2019</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">37,213,749</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.13</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6.6</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,884,372</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">Granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(140,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.78</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Outstanding as of December&nbsp;31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38,323,749</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,855,797</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 9pt">Granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">550,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(102,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.28</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding as of December&nbsp;31, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">38,771,749</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">4.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,155,145</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested and exercisable as of December&nbsp;31, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">37,490,499</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">0.13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">4.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,155,145</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aggregate intrinsic value of options outstanding,
exercisable, and vested and exercisable is calculated as the difference between the exercise price of the underlying options, and the
fair value of the Company&#8217;s common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31, 2020
and 2019, the Company granted share options with a grant date fair value of C$78,347 and C$226,115, respectively. During the years ended
December&nbsp;31, 2020 and 2019, there were no options exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The fair value of the share options granted was
estimated using Black Scholes with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>Year Ended December&nbsp;31,</B></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -9.35pt; padding-left: 9.35pt">Weighted average fair value of common shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">C$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">C$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Expected volatility</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">105.0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">109.0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Risk-free interest rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Expected dividend yield</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Expected term (years)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Expected volatility is based on historical
volatility of our shares over the expected life of the option, as our options are not readily tradable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>DSU Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has a deferred share unit
plan (&ldquo;<B>DSU Plan</B>&rdquo;) for senior officers. Under the DSU Plan, rights to the Company&rsquo;s common shares may be awarded
on a deferred payment basis up to a maximum of 1,000,000 common share units. Each common share unit will fully vest upon cessation of
employment with the Company and then can be redeemed for one common share of the Company by the unitholder. The Company has 63,708 units
outstanding as of December&nbsp;31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">S<B>hare-based Payment Expense</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following table summarizes total share-based
compensation included in the Company&#8217;s accompanying consolidated statements of operations and comprehensive loss:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 94%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">267,525</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">360,060</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,877</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">104,524</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">354,402</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">464,584</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2020, there
was $192,940 of unrecognized share-based compensation related to options outstanding, which were expected to be recognized over weighted-average
remaining service period of 0.83 year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Income taxes</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2020 and 2019, the
net deferred tax assets have not been recognized in the accompanying financial statements. A valuation allowance is recognized to reduce
the deferred tax asset as it is more likely than not that a tax benefit will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following are the significant components of the Company&rsquo;s
deferred taxes as of December&nbsp;31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Non-capital losses carried forward</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">8,981,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">7,924,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development expenditures</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,230,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,276,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Investment tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,078,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,108,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax value of technology rights and property and equipment in excess of accounting basis</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">293,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">361,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Share issue costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">138,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">151,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred income tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,720,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,820,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,720,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,820,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net deferred income tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2020, the Company has
available research and development expenditure credits for income tax purposes of approximately $12,190,000, which may be carried forward
without expiration to reduce future taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2020, the Company has
non-capital income tax loss carry-forwards of approximately $33,889,000 available to reduce future income for income tax purposes. The
income tax loss carry-forwards have expiry dates between the years 2026 and 2036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2020, the Company has
approximately $2,728,000 of non-refundable investment tax credits available to offset future income taxes. The non-refundable investment
tax credits have expiry dates between 2026 and 2035.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A reconciliation of the combined federal and provincial
statutory income tax rate applied to the net loss for the year to the income tax recovery as of December&nbsp;31 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -7.9pt; padding-left: 7.9pt">Basic combined Canadian statutory income tax rate</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26.5</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26.5</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Income tax recovery based on statutory rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,126,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,392,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Permanent differences</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Share issue costs recorded, net of equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(61,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(54,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.9pt; padding-left: 7.9pt">Expiration of investment tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">131,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -7.9pt; padding-left: 7.9pt">Unrecognized benefit of current year tax losses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,093,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,270,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -8pt; padding-left: 8pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company does not expect a significant change in the amount of unrecognized
tax benefits over the next 12 months. However, any adjustments arising from certain ongoing examinations by tax authorities could alter
the timing or amount of taxable income or deductions and these adjustments could differ from the amount accrued. The Company&rsquo;s federal
and provincial income tax returns files for all years remain subject to examination by the taxation authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Related party transactions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31,
2020 and 2019, the Company paid $231,354 and $228,042, respectively, for consulting services to a firm specializing in finance and strategic
support for life science companies. The Chief Financial Officer of the Company is a managing director of the consulting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
April&nbsp;2016, the Company entered into a three-year, collaborative research agreement (&ldquo;<B>CRA</B>&rdquo;) with the University
of British Columbia (&ldquo;<B>UBC</B></FONT>&rdquo;) and the Vancouver Coastal Health Authority in the amount of C$787,500, with
the Company&rsquo;s Chief Scientific Officer, as principal investigator at the UBC. In March&nbsp;2018, the CRA was amended and funding
was increased to C$892,500 over three years. In July&nbsp;2018, the total funding commitment to UBC increased to C$1,130,000 over the
period of the agreement. In February&nbsp;2019, the CRA was amended, and funding was increased to C$2,130,000 for an additional two-year
period. In September&nbsp;2019, the CRA was amended, and funding was increased to C$2,630,000 for an additional one- year period. During
the years ended December&nbsp;31, 2020 and 2019, the Company incurred costs of $353,253 and $391,483, respectively, related to this research
agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the years ended December&nbsp;31,
2020 and 2019, the Company paid $666,096 and $841,132, respectively, for management services to a company owned by the Company&rsquo;s
Chief Executive Officer and Executive Chairman for services rendered. The Company also reimbursed at cost the rental of an office, which
is used by the Company. During the years ended December&nbsp;31, 2020 and 2019, the Company incurred rental expense of $27,093 and $33,058,
respectively, and are included in general and administrative expenses in the accompanying consolidated statements of operations and comprehensive
loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Commitments and contingencies</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Research, Development and License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company enters into research, development
and license agreements with various parties in the ordinary course of business where the Company receives research services and rights
to proprietary technologies. The agreements require compensation to be paid by the Company, typically, by a combination of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">fees comprising amounts due initially on entering into the agreements and additional amounts due either on specified timelines or
defined services to be provided;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">milestone payments that are dependent on products developed under the agreements proceeding toward specified plans of clinical trials
and commercial development; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">royalty payments calculated as a percentage of net sales, commencing on commercial sale of any product candidates developed from the
technologies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Milestone and royalty related amounts that
may come due under various agreements are dependent on, among other factors, preclinical safety and efficacy, clinical trials,
regulatory approvals and, ultimately, the successful development and commercial launch of a new drug, the outcomes and timings of
which are uncertain. Amounts due per the various agreements for milestone payments will accrue once the occurrence of a milestone is
likely. Amounts due as royalty payments will accrue as commercial revenues from the product are earned. Through December&nbsp;31,
2020, no events have occurred that require accrual of any milestone or royalty related amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>UBC and the Vancouver Coastal
Health Authority Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In April 2016, the Company entered into a three-year, CRA
with the UBC and the Vancouver Coastal Health Authority. The agreement was amended various times through September 2019. Refer to Note
13 Related Party Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>UBC Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In February&nbsp;2009, the Company entered
into an agreement with UBC to further the development and commercialization of certain technology developed, in part, by the Company&rsquo;s
Chief Scientific Officer. Under the agreement, the Company is committed to make milestone payments of up to C$1,400,000 per product, based
on the successful outcomes of predefined clinical and regulatory outcomes, and royalty payments based on revenue earned from the licensed
technology. An annual license fee of C$25,000 is payable over the term of the agreement. The agreement remains effective unless terminated
under the provisions of the agreement. Through December&nbsp;31, 2020, no accruals for any milestones or royalty payments have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>University Health Network Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In April&nbsp;2006, an additional amendments
through November&nbsp;2013, the Company entered into an agreement with the University Health Network, Toronto, to license certain technology
and related intellectual property. Under the agreement, the Company is committed to make milestone payments of up to C$635,000 based on
the successful outcomes of clinical and regulatory outcomes, and royalty payments based on revenue earned from the licensed technology.
As of December&nbsp;31, 2020 and 2019, no accruals for any milestones or royalty payments have been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the ordinary course of business, the Company
enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless
and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to
those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum
potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has
never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered
into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against
liabilities that may arise by reason of their status or service as directors or officers. The Company currently has directors&#8217; and
officers&#8217; insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the years ended December&nbsp;31, 2020 and 2019, the
Company made short-term lease payments in the amount of $19,071 and $18,601, respectively, and are included in general and administrative
expenses in the accompanying consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>15.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>NET LOSS PER SHARE</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth the computation of basic and diluted
net loss per share attributable to common shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Years Ended December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">Numerator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 0.5in">Net loss attributable to common shareholders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,250,280</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 13%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,547,367</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">Denominator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 0.5in"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Weighted-average shares outstanding used in computing net loss per
share attributable to common shareholders, basic and diluted</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">285,599,827</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">259,795,156</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Net loss per share attributable to common shareholders, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following outstanding potentially
dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because
including them would have been antidilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Common share options</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">38,771,749</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">38,323,749</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -9.35pt; padding-left: 9.35pt">Warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,165,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">54,381,981</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Special warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,439,162</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Deferred share units</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,708</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,708</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">108,440,330</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">92,769,438</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 13 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ProMIS
Neurosciences,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(expressed in <B>US </B>dollars, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: uppercase"><B>16.</B></FONT></TD><TD><FONT STYLE="text-transform: uppercase"><B>Subsequent events</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In January&nbsp;2021,&nbsp;Covid-19
Collaboration became an independent entity. In February&nbsp;2021, the Company funded C$25,000 of expenses, which will be paid back out
of the profits, if any. The Company and BCNI each own 50% of the independent entity as of January&nbsp;2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2021, the Company completed
a $7.0 million private placement of Debentures. The Debentures are convertible into common shares at the option of the holder at a conversion
price of $0.10 and accrue interest at 1% per annum, which is payable annually. At the Company&rsquo;s election, accrued interest may be
paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day VWAP of the common shares).
The Debentures mature on March&nbsp;22, 2026. Prior to the maturity date, the Company may force conversion of the Debentures at the conversion
price upon raising an aggregate of $50 million in equity and/or debt. On the maturity date, the Company may redeem the outstanding principal
amount of the Debentures in either cash or common shares (at the then 5-day VWAP less a 10% discount) or a combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March&nbsp;2021, the Special Warrants
issued by the Company in connection with the November&nbsp;2020 financing, automatically converted into 16,219,581 common shares and 16,219,581
common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In August&nbsp;2021, the Company announced
the closing of a public offering of 125,781,250 common share units at a price of $0.16 per unit for gross proceeds of $20,125,000. Each
unit consisted of one common share and one-quarter common share warrant. Each warrant entitles the holder thereof to purchase one common
share at an exercise price of $0.21 per share at any time for five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Related to the financing, the Company
paid certain intermediaries $1,408,750 and issued 8,804,687 compensation warrants, which have the same terms as the common share warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In December&nbsp;2021, The BCNI Collaborations
were terminated. The Covid-19 Collaboration redeemed the shares purchased by the Company for an aggregated redemption price of $2,353.
A payment to the Company of C$128,000, which included the share redemption payment, and for the portion of the equipment purchased and
related expenses incurred by the Company in relation to the Neurodegen Collaboration, was received by the Company on December&nbsp;21,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December&nbsp;31, 2021, all deferred
compensation to management was paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section&nbsp;12 of the Securities Exchange Act of 1934, the registrant has duly caused this </FONT>Registration
Statement to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS NEUROSCIENCES INC.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chairman and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: January&nbsp;28, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 152; Options: NewSection; Value: 118 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; vertical-align: top; width: 10%; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 88%; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Exhibit</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-1d1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-1d1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Articles</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By-laws</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex3-2d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By-law No.&nbsp;2</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder Rights Plan Agreement dated January&nbsp;22, 2016, Amended and Extended as of May&nbsp;15, 2019, by and between ProMIS Neurosciences Inc. and Computershare Trust Company of Canada as Rights Agent.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2*</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex4-2.htm" STYLE="-sec-extract: exhibit">Unsecured Convertible Debenture dated March 22, 2021.</A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Venture Agreement dated July&nbsp;7, 2020 by and between ProMIS Neurosciences Inc. and BC Neuroimmunology Lab Inc.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Venture Agreement dated July&nbsp;8, 2020 by and between ProMIS Neurosciences Inc. and BC Neuroimmunology Lab Inc.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.1*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;1 dated February&nbsp;13, 2017 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.2*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;2 dated July&nbsp;5, 2018 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.3*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;3 dated February&nbsp;13, 2019 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.4*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-3d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;4 dated September&nbsp;9, 2019 to the Collaborative Research Agreement by and between The University of British Columbia and Provincial Health Services Authority (on behalf of Children&#8217;s&nbsp;&amp; Women&#8217;s Health Centre of British Columbia Branch, a public hospital) and ProMIS Neurosciences Inc. effective April&nbsp;1, 2016.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated License Agreement dated October&nbsp;6, 2015 by and between The University of British Columbia and ProMIS Neurosciences Inc. </FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
Agreement dated August&nbsp;3, 2006 by and between Amorfix Life Sciences Ltd. and an Affiliate of Biogen Idec Inc.<SUP></SUP></FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
License Agreement dated July&nbsp;14, 2010 by and between Amorfix Life Sciences Ltd. and Biogen Idec MA Inc.<SUP></SUP></FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement dated April&nbsp;4, 2006 by and between University Health Network and Amorfix Life Sciences Inc.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment dated July&nbsp;13, 2006 to the License Agreement dated April&nbsp;4, 2006 by and between University Health Network and Amorfix Life Sciences Inc.</FONT></A></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 153; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 10%; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.2*+</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;2 dated July&nbsp;11, 2007 to the License Agreement dated April&nbsp;4, 2006 by and between University Health Network and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7.3*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-7d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;3 dated November&nbsp;4, 2013 to the to the License Agreement dated April&nbsp;4, 2006 by and between University Health Network and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated April&nbsp;1, 2021 by and between Elliot Paul Goldstein, MD and ProMIS Neurosciences,&nbsp;Inc.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory Consulting Agreement dated May&nbsp;26, 2021 by and between ProMIS Neurosciences Inc. and David Wishart.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting and Advisory Agreement dated March&nbsp;1, 2005 by and between Amorfix Life Sciences Ltd. And Neil Cashman.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated June&nbsp;29, 2015 by and between Amorfix Life Sciences Ltd. and Virtua, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences,&nbsp;Inc. and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.1*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;1 dated March&nbsp;27, 2017 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences,&nbsp;Inc. and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.2*&#8224;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;2 dated December&nbsp;12, 2017 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences,&nbsp;Inc. and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.3*&#8224;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;3 dated August&nbsp;28, 2018 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences,&nbsp;Inc. and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12.4*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-12d4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.&nbsp;4 dated March&nbsp;27, 2017 to Consulting Agreement dated October&nbsp;17, 2016 by and between ProMIS Neurosciences,&nbsp;Inc. and Danforth Advisors, LLC.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Finder&#8217;s Warrant Certificate dated April&nbsp;30, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Non-US Warrant Certificate dated April&nbsp;30, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Employee Stock Option Commitment.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for Non-U.S. Subscribers dated February&nbsp;25, 2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for Non-U.S. Subscribers dated June&nbsp;17, 2019. </FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for U.S. Subscribers dated November&nbsp;27, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for U.S. Subscribers dated October&nbsp;21, 2019. </FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for U.S. Subscribers dated April&nbsp;13, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for Non-U.S. Subscribers dated April&nbsp;13, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for Non-U.S. Subscribers dated November&nbsp;27, 2018.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Unit Subscription Agreement for Non-U.S. Subscribers dated October&nbsp;21, 2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-24.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-24.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Finder&#8217;s Warrant Certificate dated November&nbsp;2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-25.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-25.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Non-U.S. Finder&#8217;s Warrant Certificate dated January&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-26.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-26.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Non-U.S. Warrant Certificate dated January&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-27.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-27.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Non-U.S. Warrant Certificate dated June&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-28.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-28.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of U.S. Warrant Certificate dated January&nbsp;2019.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-29.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-29.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of U.S. Warrant Certificate dated November&nbsp;2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-30.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-30.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Special Warrant Certificate dated November&nbsp;4, 2020.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 154; Value: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: justify"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify; width: 10%"><A HREF="tm2135630d1_ex10-31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31*</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify; width: 88%"><A HREF="tm2135630d1_ex10-31.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of U.S. Special Warrant Certificate dated November&nbsp;4, 2020.</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-32.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Warrant Certificate dated November&nbsp;2020.</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology License Agreement dated February&nbsp;1, 2006 by and between Dr.&nbsp;Neil Roy Cashman and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-34.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-34.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service Agreement dated September&nbsp;1, 2020 by and between The University of Saskatchewan and ProMIS Neurosciences,&nbsp;Inc.</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-35.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35*+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-35.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
    Agreement dated February&nbsp;18, 2005 by and between Neil R. Cashman and Marty Lehto and the Governing Council of the University of
    Toronto and Amorfix Life Sciences Ltd.</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-35d1.htm" STYLE="-sec-extract: exhibit">10.35.1*</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-35d1.htm" STYLE="-sec-extract: exhibit">Amendment Agreement dated April 1, 2005 to the Assignment Agreement dated February 18, 2005 by and between Neil R. Cashman and Marty Lehto
and the Governing Council of the University of Toronto and Amorfix Life Sciences Ltd.</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-36.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-36.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement of Eugene Williams dated December&nbsp;31, 2021.</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-37.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37*&#8224;+</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-37.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement of Gavin Malenfant dated December&nbsp;31, 2021.</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify; width: 10%"><A HREF="tm2135630d1_ex10-38.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38*&#8224;</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify; width: 88%"><A HREF="tm2135630d1_ex10-38.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS Neruosciences Inc. 2015 Stock Option Plan.</FONT></A></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-39.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39*&#8224;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; text-align: justify"><A HREF="tm2135630d1_ex10-39.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amorfix Life Sciences Ltd. Deferred Share Unit Plan for Canadian Senior Officers.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates a management contract or compensatory plan or arrangement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 97%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;and/or Item 601(b)(10)(iv)&nbsp;of Regulation S-K.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 155; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: 0; width: 15%; vertical-align: middle"><IMG SRC="tm2135630d1_ex3-1img01.jpg" ALT=""><B>&nbsp;&nbsp;&nbsp;</B></TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 15%; vertical-align: middle"><B>Industry Canada</B></TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 70%; vertical-align: middle"><B>Industrie Canada</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>of Amalgamation</B></P></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificat</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>de fusion</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Canada Business</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporations Act</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Loi canadienne sur</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>les soci&egrave;t&egrave;s par actions</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMORFIX LIFE SCIENCES LTD</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 206.25pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of corporation-D&egrave;nomination de law soci&egrave;t&egrave;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I hereby certify that the above-named corporation resulted from an
    amalgamation, under section 185 of the <I>Canada Business Corporations Act</I>, of the corporations set out in the attached articles of
    amalgamation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Richard G. Shaw</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 206.25pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Richard G. Shaw</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Director &#8211; Directeur</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 4%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 48%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>432461-7</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 208.55pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporation number-Num&egrave;ro de la soci&egrave;t&egrave;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Je certifie que la soci&egrave;t&egrave; susmentionn&egrave;e est issue
    d'une fusion, en vertu de l'article 185 de la <I>Loi Canadienne sur les soci&egrave;t&egrave;s par actions, </I>des soci&egrave;t&egrave;s
    don&#8217;t les denominations apparaissent dans les stats de fusion ci-joints</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 21, 2005 / le 21 septembre 2005</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Amalgamation &#8211; Date de fusion</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_ex3-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 0.25in; text-indent: 0; width: 15%">&nbsp;<IMG SRC="tm2135630d1_ex3-1img03.jpg" ALT=""></TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 15%; vertical-align: middle"><B>Industry Canada</B></TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 70%; vertical-align: middle"><B>Industrie Canada</B></TD></TR>
</TABLE>


<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada Business</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporations Act</P></TD>
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loi Canadienne Sur les</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Soci&egrave;t&egrave;s par actions</P></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 9</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF AMALGAMATION</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(SECTION 185)</B></P></TD>
    <TD STYLE="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORMULE 9</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTS DE FUSION</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(ARTICLE 185)</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1 - Name of the Amalgamated Corporation</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMORFIX LIFE SCIENCES LTD.</B></P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Denomination sociale de Ia societe issue de la fusion</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">2 - The province or territory in Canada
    where the registered office is to be situated</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">British Columbia</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">La province ou le territoire au Canada o&ugrave; se situera le siege social </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 12pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">3 - The classes and any maximum number of shares that the corporation is authorized to issue</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Categories et le nombre maximal d'actions que la soci&egrave;t&egrave; est autoris&egrave;e &agrave; &egrave;mettre</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Unlimited number of Common shares without par value; Unlimited Preferred shares, each having the rights, privileges, restrictions and conditions stated on the attached Schedule &quot;A&quot; which is incorporated into this form.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">4 - Restrictions, if any, on share transfers</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">None</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Restrictions sur le transfert des actions, s'il y a lieu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">5 - Number (or minimum and maximum number)
    of directors</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Minimum of three and a maximum of ten.</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Nombre (ou nombre minimal et maximal) d'administrateurs</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">6 - Restrictions, if any, on business
    the corporation may carry on</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">None</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Limites imposees &agrave; l'activite commerciale de la societe, s'il y a lieu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">7 - Other provisions, if any</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Autres dispositions, s'il y a lieu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">The directors may appoint one or more additional directors, who shall hold office for a term expiring not later than the close of the next annual meeting of shareholders, but the total number of directors so appointed may not exceed one third of the number of directors elected at the previous annual meeting of shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 6pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">8 - The amalgamation has been approved pursuant to that section or subsection of the Act which is indicated as follows:</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">La fusion a &egrave;t&egrave; approuv&egrave;e en accord avec radicle
    ou le paragraphe de la Loi indiquec l-apr&egrave;s</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#120;</FONT> 183</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> 184(1)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>184(2)</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-bottom: 6pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">9 - Name of the amalgamating corporations D&egrave;nomination sociale de Ia societe fusionnantes</FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Corporation No.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: center; text-indent: -12pt">No del a societe</P>
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-align: center; text-indent: -12pt">&nbsp;</P></TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 13%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Title </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 6pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Amorfix Life Sciences Ltd.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">420380-1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">/s/</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Sept. <U>20</U> <BR>
2005</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Vice-President, Corporate Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 6pt; padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Luxor Developments Inc.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">432450-9</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">/s/</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Sept. <U>20<BR>
</U>2005</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Departmental Use Only</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A rusage du ministere seulement</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Corporation No.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">N' de Ia soci&egrave;t&egrave;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed - Depos&egrave;e</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2135630d1_ex3-1img04.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE &quot;A&quot;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TO THE ARTICLES<BR>
OF<BR>
AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">The rights, privileges, restrictions and conditions of the Common
shares are as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B><U>Voting</U></B>. The holders of the Common shares shall be entitled to receive notice of and to attend
all meetings of the shareholders of the Corporation and shall have one vote for each Common share held at all meetings of the shareholders
of the Corporation, except meetings at which only holders of another specified class or series of shares of the Corporation are entitled
to vote separately as a class or series;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B><U>Dividends</U></B>. The holders of Common shares shall be entitled to receive out of all profits
or surplus available for dividends, any dividend declared by the Corporation on the Common shares; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B><U>Participation or Liquidation</U></B>. In the event of the liquidation, dissolution or winding up
of the Corporation or any distribution of its assets for the purpose of winding up its affairs, after the payment of dividends declared
but unpaid, the holders of Common shares shall be entitled pari passu to receive any remaining property of the Corporation, subject to
any rights of the holders of Preferred shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The rights, privileges, restrictions and conditions of the Preferred
shares are as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B><U>One or More Series</U></B>. The directors may issue Preferred shares in one or more series;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B><U>Creation or Deletion of Series</U></B>. The directors may alter by resolution the Articles of the
Corporation or, if applicable, the By-Laws of the Corporation to fix or change the number of shares in, and to determine the designation,
rights, privileges, restrictions and conditions attaching to the shares of, each series of Preferred shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B><U>Voting</U></B>. The directors may confer on the holders of any series of Preferred shares the right
to notice of or to be present or to vote, either in person or by proxy, at any general meeting of the shareholders of the Corporation
other than a separate meeting of the holders of the Preferred shares, or of the holders of shares of a series of the Preferred shares,
as the case may be;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B><U>Dividends</U></B>. The special rights or restrictions which the directors may create, define or
attach to any series of Preferred shares may allow the directors to declare dividends with respect to the Common shares only or with respect
to any series of Preferred shares only or with respect to any combination of two or more such classes or series of classes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><B><U>If Series Entitled to Cumulative Dividend</U></B>. Where the Preferred shares or one or more series
of Preferred shares are entitled to cumulative dividends, and where cumulative dividends in respect of the
Preferred shares or a series of Preferred shares are not paid in full, the shares of all series of Preferred shares entitled to cumulative
dividends shall participate rateably in respect of accumulated dividends in accordance with the amounts that would be payable on those
shares if all the accumulated dividends were paid in full;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><B><U>All Series of Preferred Shares Participate Rateably on Winding-Up</U></B>. Where amounts payable
on a winding-up are not paid in full or on the occurrence of any other event where the holders of the shares of all series of Preferred
shares are entitled to a return of capital but are not paid in full, the shares of all series of Preferred shares shall participate rateably
in a return of capital in respect of Preferred shares in accordance with the amounts that would be payable on the return of capital if
all amounts so payable were paid in full;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><B><U>No Priority</U></B>. No special rights or restrictions attached to a series of Preferred shares
shall confer on the series priority over another series of Preferred shares then outstanding respecting:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">dividends, or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">a return of capital:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">on winding-up; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">on the occurrence of another event that would result in the holders of all series of Preferred shares
being entitled to a return of capital;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><B><U>Special Rights and Restrictions of Issued Series</U></B>. A directors' resolution pursuant to paragraph
2(b) above must be passed before the issue of shares of the series to which the resolution relates, and after the issue of shares of that
series the number of shares in, the designation of, and the special rights and restrictions attached to that series may be added to, altered,
varied or abrogated only in accordance with the Canada Business Corporations Act, and the directors shall send to the Director articles
of amendment in the prescribed form; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><B><U>Priority on Liquidation</U></B>. Except as provided herein, in the event of the liquidation, dissolution
or winding-up of the Corporation or any distribution of its assets for the purpose of winding-up its affairs, after the payment of dividends
declared but unpaid, the holders of the Preferred shares shall be entitled pari passu to be paid such amount as the special rights and
restrictions attaching to such shares shall provide, or in the absence of any express provision with respect thereto, the amount of capital
paid up in respect thereof per share for each Preferred share held by them, out of the assets of the Corporation in preference to and
with priority over any payment or distribution of any capital asset or monies among the holders of any Common shares of the Corporation.
The foregoing provisions of these Articles shall apply to all Preferred shares except as expressly provided in the special rights and
restrictions which the directors may create, define or attach to any series of Preferred shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1(1)
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-weight: bold; text-align: right; margin: 0">Exhibit 3.1.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
  <TD><IMG SRC="tm2135630d1_ex3-1d1img01.jpg" ALT="">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: center; width: 40%"><B>Certificate of Amendment</B></TD><TD STYLE="width: 20%; text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center; width: 40%"><B>Certificat de modification</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="font-style: italic; text-align: center"> Canada Business Corporations Act</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-style: italic; text-align: center">Loi Canadienne sur les soci&egrave;t&egrave;s par actions</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 36%">ProMIS Neurosciences Inc.</TD>
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">Corporate name / D&egrave;nomination sociale</TD>
<TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 36%">432461-7</TD>
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">Corporation number / Num&egrave;ro de soci&egrave;t&egrave;</TD>
<TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%">
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-right: 10; width: 45%; padding-left: 10">I HEREBY CERTIFY that the articles of the above-named corporation are amended
under section 178 of the <I>Canada Business Corporations Act</I> as set out in the attached articles of amendment.</TD><TD STYLE="padding-right: 10; text-align: left; width: 10%; padding-left: 10">&nbsp;</TD><TD STYLE="padding-right: 10; text-align: justify; width: 45%; padding-left: 10">JE
                                            CERTIFIE que les statuts de la soci&eacute;t&eacute; susmentionn&eacute;e sont modifi&eacute;s
                                            aux termes de l'article 178 de la <I>Loi canadienne sur les soci&eacute;t&eacute;s par actions</I>,
                                            tel qu'il est indiqu&eacute; dans les clauses modificatrices ci-jointes.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 36%">/s/ Virginie Ethier </TD>
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">Virginie Ethier </TD>
<TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">Director / Directeur </TD>
<TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 36%">2015-07-08</TD>
<TD STYLE="text-align: center; width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">Date of Amendment (YYYY-MM-DD)</TD>
<TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"> Date de modification (AAAA-MM-JJ)</TD>
<TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2135630d1_ex3-1d1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
  <TD><IMG SRC="tm2135630d1_ex3-1d1img01.jpg" ALT="">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 4</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Articles of Amendment</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Canada Business Corporations Act</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(CBCA (s. 27 or 177)</I></P></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Formulaire 4</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Clauses modificatrices</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Loi canadienne sur les societes par <BR>
actions
    (LCSA) (art. 27 ou 177)</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 7in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">1</TD>
<TD STYLE="border-top: Black 1pt solid; width: 95%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Corporate name</P>
                                                                      <P STYLE="margin-top: 0; margin-bottom: 0">Denomination sociale</P></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">AMORFIX LIFE SCIENCES LTD.</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>2</TD>
<TD STYLE="border-top: Black 1pt solid; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Corporation number</P>
                                                          <P STYLE="margin-top: 0; margin-bottom: 0">Numero de la societe</P></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">432461-7</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>3</TD>
<TD STYLE="border-top: Black 1pt solid; text-align: left">The articles are amended as follows<BR>
Les statuts sont modifies de la faoon suivante</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">The corporation changes its name to:<BR>
La denomination sociale est modifiee pour :</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">ProMIS
Neurosciences Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>4</TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Declaration: I certify that I
am a director or an officer of the corporation.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">Declaration : J'atteste que je suis un administrateur ou un dirigeant de la societe.</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #767171">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Original signed by / Original signe par</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot Paul Goldstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elliot Paul Goldstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">415-341-5783</FONT></TD></TR>
  </TABLE>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #767171">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Misrepresentation constitutes an offence and, on summary conviction,
a person is liable to a fine not exceeding $5000 or to imprisonment for a term not exceeding six months or both (subsection 250 (1) of
the CBCA).</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Faire une fausse d&egrave;claration constitue une infraction et son
auteur, sur declaration de culpabilite par procedure sommaire, est passible d'une amende maximale de 5 000 $ et d'un emprisonnement maximal
de six mois, ou l'une de ces peines (paragraphe 250(1) de la LCSA).</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">You are providing information required by the CBCA. Note that both
the CBCA and the <I>Privacy Act</I> allow this information to be disclosed to the public. It will be stored in personal information bank
number IC/PPU-049.</P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Vous fournissez des renseignements exiges par la LCSA. Il est a noter
que la LCSA et la <I>Loi sur les renseignements personnels</I> permettent que de tels renseignements soient divulgues au public. Ils seront
stockes dans la banque de renseignements personnels numero IC/PPU-049.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm2135630d1_ex3-1d1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following is an extract of the minutes
of the Annual Meeting of Shareholders of ProMIS Neurosciences Inc. dated June 28, 2017 held at 9:00 AM.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approval of Amendments to the By-laws </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;Be it RESOLVED that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify">The following amendments to By-Laws of the Corporation are hereby confirmed:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify; padding-right: 0.9in">Section 10.4 is deleted and replaced with the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 1in; text-align: justify">&#8220;<U>Certificates</U>. Every
shareholder is entitled, without charge and at his option, to a share certificate representing the share or shares of each class or series
held by him or to a nontransferable written certificate of acknowledgment of his right to obtain a share certificate, stating the number
and class or series of shares held by him as shown in the securities register; provided that, in respect of a share or shares held jointly
by several persons, the Corporation shall not be bound to issue more than one share certificate or written certificate of acknowledgment,
as the case may be, and delivery of a share certificate or written certificate of acknowledgment to one of several joint registered holders
or to his duly authorized agent shall be sufficient delivery to all; and provided further that the Corporation shall not be bound to issue
certificates representing redeemable shares, if such shares are to be redeemed within one month of the date on which they were allotted.
Any certificate may be sent through the mail by prepaid mail to the shareholder entitled thereto, and neither the Corporation nor any
transfer agent shall be liable for any loss occasioned to the shareholder owing to any such certificate so sent being lost in the mail
or stolen.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify">The making on or prior to the date hereof of any other amendments to the By-laws as the Corporation may
consider necessary or advisable to satisfy the requirements of the TSX or the Corporation&#8217;s transfer agent in order to conform the
language in the By-laws relating to uncertificated shares to language currently prevalent for reporting issuers in Canada, is hereby approved.&#8221;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">INTERPRETATION</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">1</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">DIRECTORS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">2</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">MEETING OF DIRECTORS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">4</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">REMUNERATION OF DIRECTORS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">6</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">SUBMISSION OF CONTRACTS OR TRANSACTIONS TO SHAREHOLDERS FOR APPROVAL</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">6</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">FOR THE PROTECTION OF DIRECTORS AND OFFICERS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in"> 6</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">INDEMNITIES TO DIRECTORS AND OFFICERS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">7</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">OFFICERS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">7</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">SHAREHOLDERS&#8217; MEETINGS</TD>
                                                          <TD STYLE="text-align: right; width: 0.5in">9</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">SHARES</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">15</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                                           <TD STYLE="text-align: right">&nbsp;</TD></TR>
                                                                                                                   <TR STYLE="vertical-align: top">
<TD>11.</TD><TD STYLE="text-align: justify">TRANSFER OF SECURITIES</TD>
                                                           <TD STYLE="text-align: right">18</TD></TR>
                                                                                                                   </TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">DIVIDENDS</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">20</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">VOTING SHARES AND SECURITIES IN OTHER COMPANIES</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">22</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">INFORMATION AVAILABLE TO SHAREHOLDERS</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">22</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">NOTICES</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">22</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">CHEQUES, DRAFTS AND NOTES</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">24</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">CUSTODY OF SECURITIES</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">24</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify">EXECUTION OF INSTRUMENTS</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">24</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify">FINANCIAL YEAR</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">26</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify">BORROWING</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">26</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify">DISCLOSURE OF INTEREST OF DIRECTORS</TD>
                                                           <TD STYLE="text-align: right; width: 0.5in">27</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BY-LAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">By-laws relating generally to the conduct of the
affairs of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BE IT ENACTED AND IT IS HEREBY ENACTED as the
by-laws of <B>Amorfix Life Sciences Ltd. </B>(the &#8220;Corporation&#8221;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">INTERPRETATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in">1.1</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><U>Definitions</U>. <FONT STYLE="font-style: normal; font-weight: normal">In
    these by-laws of the Corporation, unless the context otherwise specifies or requires:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Act&#8221; means the Canada Business Corporations Act, R.S.C. 1985, c. C-44 as from time to time amended
and every statute that may be substituted therefor and, in the case of such substitution, any references in the by-laws of the Corporation
to provisions of the Act shall be read as references to the substituted provisions therefor in the new statute or statutes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&#8220;Regulations&#8221; means the Regulations under the Act as published or from time to time amended
and every regulation that may be substituted therefor and, in the case of such substitution, any references in the by-laws of the Corporation
to provisions of the Regulations shall be read as references to the substituted provisions therefor in the new regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&#8220;by-laws&#8221; means any by-laws of the Corporation from time to time in force and effect;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&#8220;registered owner&#8221; or &#8220;registered holder&#8221; when used with respect to a share in
the authorized capital of the Corporation means the person registered in the register of shareholders or a branch register of shareholders
in respect of such share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&#8220;shareholder&#8221; means those persons defined as such in the Act and includes any person who owns
shares in the capital of the Corporation and whose name is entered in the register of shareholders or a branch register of shareholders;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&#8220;writing&#8221;, &#8220;in writing&#8221; and like expressions include all modes of representing,
or reproducing and recording words in visible form, including: printing; lithographing; typewriting; and photostatic, electrostatic and
mechanical copying;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">all terms which are contained in the by-laws of the Corporation and which are defined in the Act or the
Regulations shall have the meanings given to such terms in the Act or the Regulations; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">the singular shall include the plural and the plural shall include the singular; the masculine shall include
the feminine; and the word &#8220;person&#8221; shall include bodies corporate, corporations, companies, partnerships,
syndicates, trusts and any number or aggregate of persons.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">DIRECTORS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><U>Number.
</U>The number of directors shall, subject to the articles of the Corporation and any unanimous shareholder agreement, be fixed by the
directors or if not so fixed, shall be the number of directors elected or continued as directors at the immediately preceding annual
meeting of the Corporation. The business and affairs of the Corporation shall be managed by a board of directors of whom at least twenty-five
percent shall be resident Canadians and of whom, if any of the issued securities of the Corporation are or were a part of a distribution
to the public, at least two shall not be officers or employees of the Corporation or any affiliate of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Election and Removal</U>.</B> At each annual meeting of the Corporation, all the directors shall retire and the shareholders
entitled to vote thereat shall elect a board of directors consisting of the number of directors for the time being fixed pursuant to the
by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Retiring</U>.</B> A retiring director shall be eligible for re-election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Meeting</U>.</B> Where the Corporation fails to hold an annual meeting in accordance with the Act, the directors then in
office shall be deemed to have been elected or appointed as directors on the last day on which the annual meeting could have been held
pursuant to the Act and the by-laws and they may hold office until other directors are appointed or elected or until the day on which
the next annual meeting is held, whichever shall first occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Continued</U>.
</B>If at any meeting at which there should be an election of directors the places of any of the retiring directors are not filled by
such election, such of the retiring directors who are not reelected as may be requested by the newly elected directors shall, if willing
to do so, continue in office to complete the number of directors for the time being fixed pursuant to the by-laws until further new directors
are elected at a general meeting convened for the purpose. If any such election or continuance of directors does not result in the election
or continuance of the number of directors for the time being fixed pursuant to the by-laws, such number shall be fixed at the number
of directors actually elected or continued in office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Casual
Vacancy</U>.</B> The remaining directors or director shall have the power from time to time to appoint any person as a director to fill
any casual vacancy occurring in the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Additional
Directors</U>.</B> Between successive annual meetings the directors shall have power to appoint one or more additional directors but
the number of additional directors shall not be more than one-third of the number of directors elected or appointed at the last annual
meeting. Any director so appointed shall hold office only until the next following annual meeting of the Corporation but shall be eligible
for election at such meeting and, so long as he is an additional director, the number of directors shall be increased accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.6in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0; text-align: justify; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Alternate
Directors</U>.</B> Any director may by instrument in writing delivered to the Corporation appoint any person to be his alternate to act
in his place at meetings of the directors at which he is not present unless the directors shall have reasonably disapproved the appointment
of such person as an alternate director and shall have given notice to that effect to the director appointing the alternate director
within a reasonable time after delivery of such instrument to the Corporation. Every such alternate shall be entitled to notice of meetings
of the directors and to attend and vote as a director at a meeting at which the person appointing him is not personally present, and,
if he is a director, to have a separate vote on behalf of the director he is representing in addition to his own vote. A person may be
appointed as an alternate for more than one director and shall have a separate vote for each director so represented. A director may
at any time in writing by instrument, telegram, telex, facsimile or any method of transmitting legibly recorded messages delivered to
the Corporation revoke the appointment of an alternate appointed by him. The remuneration payable to such an alternate shall be payable
out of the remuneration of the director appointing him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacation
of Office</U>.</B> The office of a director shall ipso facto be vacated: (a) if he becomes bankrupt or suspends payments of his debts
generally or compromises with his creditors or makes an authorized assignment or is declared insolvent; (b) if he is found to be a mentally
incompetent person; or (c) if by notice in writing to the Corporation he resigns his office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Ceasing</U>.
</B>A director ceases to hold office when he:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">dies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">resigns his office by notice in writing delivered to the Corporation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">is convicted of an indictable offence and the other directors shall have resolved to remove him;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">ceases to be qualified to act as a director pursuant to the Act; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">is removed in accordance with the Act and this by-law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Resignation</U>.
</B>Every resignation of a director becomes effective at the time a written resignation is delivered to the Corporation or at the time
specified in the resignation, whichever is later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Removal</U>.
</B>Subject to the Act, the Corporation may by ordinary resolution remove any director before the expiration of his period of office
and may by an ordinary resolution appoint another person in his stead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Powers</U>.
</B>The directors shall manage or supervise the management of the affairs and business of the Corporation and shall have the authority
to exercise all such powers of the Corporation as are not, by the Act or by the articles or by-laws, required to be exercised by the
Corporation in general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Attorney</U>. </B>The
directors may from time to time by power of attorney or other instrument under seal appoint any person to be the attorney of the
Corporation for such purposes, and with such powers, authorities and discretions (not exceeding those vested in or exercisable by
the directors under these by-laws and excepting the powers of the directors relating to the constitution of the Board and of any of
its committees and the appointment or removal of officers and the power to declare dividends) and for such period, with such
remuneration and subject to such conditions as the directors may think fit, and any such appointment may be made in favour of any of
the directors or any of the shareholders of the Corporation or in favour of any corporation, or of any of the shareholders,
directors, nominees or managers of any corporation, firm or joint venture and any such power of attorney may contain such provisions
for the protection or convenience of persons dealing with such attorney as the directors think fit. Any such attorney may be
authorized by the directors to sub-delegate all or any of the powers. authorities and discretions for the time being vested in
him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Committee
of Directors</U>.</B> The directors may appoint from among their number a committee of directors and subject to the Act may delegate
to such committee any of the powers of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Shareholder
Qualification</U>.</B> A director shall not be required to hold a share in the capital of the Corporation as qualification for his office
but shall be qualified as required by the Act to become or act as a director. Any director who is not a shareholder shall be deemed to
have agreed to be bound by the provisions of the articles and by-laws of the Corporation to the same extent as if he were a shareholder
of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">MEETING OF DIRECTORS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Place of Meeting</U>.</B> Meetings of the board of directors and of a committee of directors (if any) may be held within or
outside of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Call</U>.
</B>A director may, and the Secretary or an Assistant Secretary upon request of a director shall, call a meeting of the board at any
time. Reasonable notice shall be given for any meeting specifying the place, day and hour of such meeting and shall be given by mail,
postage prepaid, addressed to each of the directors and alternate directors at his address as it appears on the books of the Corporation
or by leaving it at his usual business or residential address or by telephone, telex, facsimile, email or any method of transmitting
legibly recorded messages. Accidental omission to give notice of a meeting of directors to, or by the non-receipt of notice by, any director
shall not invalidate the proceedings at that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waive Notice</U>.</B> Any director of the Corporation may file with the Secretary a document executed by him waiving notice
of any past, present or future meeting or meetings of the directors being, or required to have been, sent to him and may at any time withdraw
such waiver with respect to meetings held thereafter. After the filing of such waiver with respect to future meetings, and until such
waiver is withdrawn, no notice of any meeting of the directors need be given to such director or, unless the director otherwise requires
in writing to the Secretary, to his alternate director, and all meetings of the directors so held shall be deemed not to be improperly
called or constituted by reason of notice not having been given to such director or alternate director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Notice</U>.</B> It shall not be necessary to give notice of a meeting of directors to any director or alternate director if such meeting
is to be held immediately following a general meeting at which such director shall have been elected or is the meeting of directors at
which such director is appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Chair</U>.
</B>The Chairman of the Board, if any, or in his absence any Vice-Chairman or the President, shall preside as chairman at every meeting
of the directors, or if neither the Chairman of the Board, Vice-Chairman nor the President is present within fifteen minutes of the time
appointed for holding the meeting or is willing to act as chairman, or, if the Chairman of the Board, if any, any Vice-Chairman and the
President have advised the Secretary that they will not be present at the meeting, the directors present shall choose one of their number
to be chairman of the meeting. With the consent of the meeting, the solicitor of the Corporation may act as chairman of a meeting of
the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in"><B>3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacancy</U>.
</B>The directors may act notwithstanding any vacancy in their body, but, if and so long as their number is reduced below the number
fixed pursuant to the by-laws of the Corporation as the necessary quorum of directors, the directors may act for the purpose of increasing
the number of directors to that number, or to summon a special meeting of the Corporation, but for no other purpose. If the directors
fail to call a meeting or if there are no directors then in office, the meeting may be called by any shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Defect</U>.</B> Subject to the provisions of the Act, all acts done at any meeting of the directors or of a committee of directors,
or by any person acting as a director, shall, notwithstanding that it be afterwards discovered that there was some defect in the qualification,
election or appointment of any such directors or of the members of such committee or person acting as aforesaid, or that they or any of
them were disqualified, be as valid as if every such person had been duly elected or appointed and was qualified to be a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Quorum</U>.
</B>The board of directors may from time to time fix the quorum required for the transaction of business at a meeting of the board of
directors and until so fixed the quorum will be a majority of the then current number of directors, or if the number of directors is
fixed at one, shall be one director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Meetings by Telephone or Electronic Conference</U></B>. A director may participate in a meeting of the board or of any committee
of the directors by means of conference telephones or other communications facilities by means of which all directors participating in
the meeting can hear each other. A director participating in a meeting in accordance with this by-law shall be deemed to be present at
the meeting and to have so agreed and shall be counted in the quorum therefor and be entitled to speak and vote thereat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voting</U>.
</B>The directors may meet together for the dispatch of business, adjourn and otherwise regulate their meetings, as they think fit. Questions
arising at any meeting shall be decided by a majority of votes. In case of an equality of votes the chairman shall not have a second
or casting vote. Meetings of the board held at regular intervals may be held at such place, at such time and upon such notice (if any)
as the board may by resolution from time to time determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Resolution
in Lieu of Meeting</U>.</B> Notwithstanding any of the foregoing provisions of this by-law, a resolution consented to in writing, whether
by document, telegram, telex, facsimile or any method of transmitting legibly recorded messages, by all of the directors or their alternates
shall be as valid and effectual as if it had been passed at a meeting of the directors duly called and held. Such resolution may be in
two or more counterparts which together shall be deemed to constitute one resolution in writing. Such resolution shall be filed with
the minutes of the proceedings of the directors and shall be effective on the date stated thereon or on the latest day stated on any
counterpart. A resolution may be consented to by a director or alternate director who has an interest in the subject matter of the resolution
provided that he has otherwise complied with the provisions of the articles, by-laws and the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Seconds</U>.
</B>No resolution proposed at a meeting of directors need be seconded, and the chairman of any meeting may move or propose a resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">REMUNERATION OF DIRECTORS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remuneration</U>.
</B>The remuneration of the directors may from time to time be determined by the directors or, if the directors so decide, by ordinary
resolution of the shareholders. Such remuneration may be in addition to any salary or other remuneration paid to any director in his
capacity as officer or employee of the Corporation. The directors shall be reimbursed for reasonable travelling, hotel and other expenses
they incur in and about the business of the Corporation and if any director shall perform any professional or other services for the
Corporation that in the opinion of the directors are outside the ordinary duties of a director or shall otherwise be specially occupied
in or about the Corporation&#8217;s business, he may be paid a remuneration to be fixed by the board, or, at the option of such director,
by the Corporation in general meeting, and such remuneration may be either in addition to, or in substitution for any other remuneration
that he may be entitled to receive. The directors on behalf of the Corporation, unless otherwise determined by ordinary resolution, may
pay a gratuity or pension or allowance on retirement to any director who has held any office or position with the Corporation or to his
spouse or dependents and may make contributions to any fund and pay premiums for the purchase or provision of any such gratuity, pension
or allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">SUBMISSION OF CONTRACTS OR TRANSACTIONS TO SHAREHOLDERS FOR APPROVAL</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Ratification.</U></B> The board of directors in its discretion may submit any contract, act or transaction for approval or ratification
at any annual meeting of the shareholders or at any special meeting of the shareholders called for the purpose of considering the same
and, subject to the Act, any such contract, act or transaction that shall be approved or ratified or confirmed by a resolution passed
by a majority of the votes cast at any such meeting (unless any different or additional requirement is imposed by the Act or by the Corporation&#8217;s
articles or any other by-law) shall be as valid and as binding upon the Corporation and upon all the shareholders as though it had been
approved, ratified or confirmed by every shareholder of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">FOR THE PROTECTION OF DIRECTORS AND OFFICERS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conflicts. </U></B>
In supplement of and not by way of limitation upon any rights conferred upon directors by the Act, it is declared that no director
shall be disqualified from his office or vacate his office by reason of holding any office or place of profit under the Corporation
or under any body corporate in which the Corporation shall be a shareholder or by reason of being otherwise in any way directly or
indirectly interested or contracting with the Corporation either as vendor, purchaser or otherwise or being concerned in a contract
or arrangement made or proposed to be entered into with the Corporation in which he is in any way directly or indirectly interested
either as vendor, purchaser or otherwise, nor shall any director be liable to account to the Corporation or any of its shareholders
or creditors for any profit arising from any such office or place of profit; and, subject to the Act, no contract or arrangement
entered into by or on behalf of the Corporation in which any director shall be in any way directly or indirectly interested shall be
avoided or voidable and no director shall be liable to account to the Corporation or any of its shareholders or creditors for any
profit realized by or from any such contract or arrangement by reason of any fiduciary relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">INDEMNITIES TO DIRECTORS AND OFFICERS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Indemnity.</U></B> Subject to the Act, the Corporation may indemnify a director or officer or former director or officer of
the Corporation or of a corporation of which the Corporation is or was a shareholder or creditor and the heirs and legal representatives
of any such person against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably
incurred by him or them in respect of any civil, criminal or administrative action or proceeding to which he is or they are made a party
by reason of his being or having been a director or officer of the Corporation or a director or officer of such corporation, including
any action brought by the Corporation or any such corporation. Each director or officer of the Corporation on being elected or appointed
shall be deemed to have contracted with the Corporation on the terms of the foregoing indemnity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Failure.
</B>The failure of a director or officer of the Corporation to comply with the provisions of the Act or of the articles or the by-laws
shall not invalidate any indemnity to which he is entitled under the by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Insurance.
</U></B>The directors may cause the Corporation to purchase and maintain insurance for the benefit of any person who is or was serving
as a director, officer, employee or agent of the Corporation or as a director, officer, employee or agent of any corporation of which
the Corporation is or was a shareholder and his heirs or personal representatives, against any liability incurred by him as such director,
officer, employee or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">OFFICERS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Appointment.
</U></B>The board of directors shall annually or as often as may be required appoint such officers of the Corporation as are deemed advisable,
which may include a Chairman of the Board, a Vice-Chairman of the Board, a Managing Director, a President, a Chief Executive Officer,
one or more Vice-Presidents, a Secretary, a Treasurer, one or more Assistant Secretaries and/or one or more Assistant Treasurers. A director
may be appointed to any office of the Corporation but none of the officers except the Chairman of the Board, the Vice-Chairman of the
Board and the Managing Director need be a member of the board of directors. Two or more of the aforesaid offices may be held by the same
person. In case and whenever the same person holds the offices of Secretary and Treasurer he may, but need not be, known as the Secretary-Treasurer.
The board of directors may from time to time appoint any other officers and agents as it shall deem necessary who shall have such authority
and shall perform such duties as may from time to time be prescribed by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacancies.</U></B> If the office of any officer of the Corporation shall be or become vacant by reason of death, resignation,
disqualification or otherwise, the directors by resolution shall, in the case of the President, and may, in the case of any other office,
appoint a person to fill such vacancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remuneration
and Removal.</U></B> The fact that any officer or employee is a director or shareholder of the Corporation shall not disqualify him from
receiving remuneration in his role as an officer or employee as may be determined by the board of directors. All officers, in the absence
of agreement to the contrary, shall be subject to removal by resolution of the board of directors at any time, with or without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Powers
and Duties.</U></B> All officers shall sign such contracts, documents or instruments in writing as require their respective signatures
and shall respectively have and perform all powers and duties incident to their respective offices and such other powers and duties respectively
as may from time to time be assigned to them by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Duties may be Delegated.</U></B> In case of the absence or inability to act of any officer of the Corporation, or for any other
reason that the board of directors may deem sufficient, the board of directors may delegate all or any of the powers of such officer to
any other officer or to any director for the time being.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Chairman
of the Board.</U></B> The Chairman of the Board (if any) shall, when present, preside at all meetings of the board of directors, the
executive committee of directors (if any) and the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vice-Chairman
of the Board.</U></B> If the Chairman of the Board is absent or is unable or refuses to act, the Vice-Chairman of the Board (if any)
shall, when present, preside at all meetings of the board of directors, the executive committee of directors (if any) and the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Managing
Director.</U></B> The Managing Director shall be a resident Canadian and shall exercise such powers and have such authority as may be
delegated to him by the board of directors in accordance with the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>President.</U></B> Unless the Board determines otherwise, the President shall be the Chief Executive Officer of the Corporation.
He shall be vested with and may exercise all the powers and shall perform all the duties of the Chairman of the Board and/or Vice-Chairman
of the Board if none be appointed or if the Chairman of the Board and the Vice-Chairman of the Board are absent or are unable or refuse
to act; provided, however, that unless he is a director he shall not preside as chairman at any meeting of directors or of the executive
committee of directors (if any) or, subject to paragraph 9.9 of this by-law, at any meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vice-President.</U></B> The Vice-President or, if more than one, the Vice-Presidents, in order of seniority, shall be vested
with all the powers and shall perform all the duties of the President in the absence or inability or refusal to act of the President;
provided, however, that a Vice-President who is not a director shall not preside as chairman at any meeting of directors or of the executive
committee of directors (if any) or, subject to paragraph 9.9 of this by-law, at any meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Secretary.</U></B> &nbsp;The Secretary shall give or cause to be given notices for all meetings of the board of directors, the executive
committee of directors (if any) and the shareholders when directed to do so and shall have charge of the minute books of the Corporation
and, subject to the provisions of this by-law, of the records (other than accounting records) referred to in the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Treasurer.
</U>&nbsp;</B>Subject to the provisions of any resolution of the board of directors, the Treasurer shall have the care and custody of all the
funds and securities of the Corporation and shall deposit the same in the name of the Corporation in such bank or banks or with such
other depositary or depositaries as the board of directors may direct. He or she shall keep or cause to be kept the accounting records
referred to in the Act. He or she may be required to give such bond for the faithful performance of his duties as the board of directors
in its uncontrolled discretion may require but no director shall be liable for failure to require any such bond or for the insufficiency
of any such bond or for any loss by reason of the failure of the Corporation to receive any indemnity thereby provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>Assistant
Secretary and Assistant Treasurer. The Assistant Secretary or, if more than one, the Assistant Secretaries in order of seniority, and
the Assistant Treasurer or, if more than one, the Assistant Treasurers in order of seniority, shall respectively perform all the duties
of the Secretary and the Treasurer, respectively, in the absence or inability or refusal to act of the Secretary or the Treasurer, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>General Manager or Manager.</U></B> The board of directors may from time to time appoint one or more General Managers or Managers
and may delegate to him or them full powers to manage such matters and duties as by law must be transacted or performed by the board of
directors and/or by the shareholders and to employ and discharge agents and employees of the Corporation or may delegate to him or them
any lesser authority. A General Manager or Manager shall conform to all lawful orders given to him by the board of directors of the Corporation
and shall at all reasonable times give to the directors or any of them all information they may require regarding the affairs of the Corporation.
Any agent or employee appointed by a General Manager or Manager shall be subject to discharge by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conflicts.</U></B> &nbsp;Every officer of the Corporation who holds any office or possesses any property whereby, whether directly
or indirectly, duties or interests might be created in conflict with his duties or interests as an officer of the Corporation shall, in
writing, disclose to the President the fact and the nature, character and extent of the conflict in accordance with the provisions of
the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">SHAREHOLDERS&#8217; MEETINGS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Annual Meeting.</U></B> Subject to the Act and the Articles, the annual meeting of the shareholders shall be held on such day
in each year and at such time as the directors may by resolution determine at any place within Canada or, if all the shareholders entitled
to vote at such meeting so agree, outside Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Special
Meetings.</U></B> Subject to the Act and the Articles, special meetings of the shareholders may be convened by order of the board of
directors at any date and time and at any place within Canada or, if all the shareholders entitled to vote at such meeting so agree,
outside Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>Meetings
by Telephone or Electronic Conference. A shareholder may participate in a meeting of the shareholders by means of conference telephones
or other communications facilities by means of which all shareholders participating in the meeting can hear each other. A person participating
in a meeting by such means in accordance with this bylaw shall be deemed to be present at the meeting and to have so agreed shall be
entitled to vote by means of telephonic, electronic or other communication facility that the Corporation has made available for that
purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notice. </B>A notice stating the day, hour and place of meeting shall be given by serving such notice on such persons as are entitled
by law or under this by-law to receive such notice from the Corporation in the manner specified in paragraph 15.1 of this by-law or in
such manner as may be prescribed by the directors, not less than twenty-one days or more than fifty days (in each case exclusive of the
day on which the notice is delivered or sent and of the day for which notice is given) before the day of the meeting. Notice of a meeting
at which special business is to be transacted shall state: (a) the nature of that business in sufficient detail to permit the shareholder
to form a reasoned judgment thereon; and (b) the text of any special resolution to be submitted to the meeting. Except as otherwise provided
by the Act, where any special business at a general meeting includes considering, approving, ratifying, adopting or authorizing any document
or the execution thereof or the giving of effect thereto, the notice convening the meeting shall, with respect to such document, be sufficient
if it states that a copy of the document or proposed document is or will be available for inspection by shareholders at the registered
office or records office of the Corporation or at some other place designated in the notice during usual business hours up to the date
of such general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waiver
of Notice.</U></B> &nbsp;A shareholder and any other person entitled to attend a meeting of shareholders may in any manner waive notice or
reduce the period of notice of a meeting of shareholders and attendance of any such person at a meeting of shareholders shall constitute
a waiver of notice of the meeting except where such person attends a meeting for the express purpose of objecting to the transaction
of any business on the grounds that the meeting is not lawfully called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Omission
of Notice.</U></B> &nbsp;The accidental omission to give notice of any meeting or any irregularity in the notice of any meeting or the non-receipt
of any notice by any shareholder or shareholders, director or directors or the auditor of the Corporation shall not invalidate any resolution
passed or any proceedings taken at any meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Votes.
</B>Subject to the Act, every question submitted to any meeting of shareholders shall be decided in the first instance by a show of hands
unless (before or on the declaration of the result of the show of hands) a poll is directed by the Chairman or a shareholder or proxyholder
entitled to vote at the meeting has demanded a ballot and in the case of an equality of votes the chairman of the meeting shall on a
show of hands or on a ballot not have a second or casting vote in addition to the vote or votes to which he may be otherwise entitled
as a member or proxyholder and this provision shall apply notwithstanding the Chairman is interested in the subject matter of the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Declaration.</U></B> &nbsp;At any meeting, unless a ballot is demanded, a declaration by the chairman of the meeting that a resolution
has been carried or carried unanimously or by a particular majority or lost or not carried by a particular majority shall be conclusive
evidence of the fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><U>Chair.
</U>The Chairman of the Board, if any, or in his absence the President of the Corporation or in his absence a Vice-President of the Corporation,
if any, shall be entitled to preside as chairman at every meeting of shareholders of the Corporation. Notwithstanding the foregoing,
with the consent of the meeting, which consent may be expressed by the failure to object of any person present and entitled to vote,
the solicitor of the Corporation may act as chairman of the meeting of shareholders. If at any meeting of shareholders neither the Chairman
of the Board nor President nor a Vice-President is present within fifteen minutes after the time appointed for holding the meeting or
is willing to act as chairman, the Directors present, shall choose someone of their number, or the solicitor of the Corporation, to be
chairman. If all the Directors present, and the solicitor of the Corporation, decline to take the chair or fail to so choose or if no
Director be present, the persons present and entitled to vote shall choose some person in attendance, who need not be a shareholder,
to be chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>Ballot. A ballot may be demanded either before or after any vote by a show of hands by any person entitled to vote at the meeting.
No poll may be demanded on the election of the chairman. If at any meeting a ballot is demanded on the question of adjournment it shall
be taken forthwith without adjournment. If at any meeting a ballot is demanded on any other question or as to the election of directors,
the vote shall be taken by ballot in such manner and either at once, later in the meeting or after adjournment as the chairman of the
meeting directs but in no event later than seven days after the meeting. The result of a ballot shall be deemed to be the resolution of
the meeting at which the ballot was demanded. Any business other than that upon which the poll has been demanded may be proceeded with
pending the taking of the poll. A demand for a ballot may be withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><U>Determination.</U>&nbsp;In
the case of any dispute as to the admission or rejection of a vote. whether by show of hands or on a poll, the chairman shall determine
the same, and his determination made in good faith is final and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>Action.
Unless the Act, the articles or the by-laws otherwise provide, any action to be taken by a resolution of the shareholders may be taken
by an ordinary resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B>Votes. Subject to any special voting rights or restrictions attached to any class of shares and the restrictions on joint registered
holders of shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">on a show of hands:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">every shareholder who is present in person and entitled to vote shall have one vote; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a proxyholder duly appointed by a holder of a share who would have been entitled to vote shall have one
vote; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">on a poll, every shareholder shall have one vote for each share of which he is the registered holder and
may exercise such vote either in person or by proxy.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><U>Not Registered.</U> &nbsp;Any person who is not registered as a shareholder but is entitled to vote at any meeting in respect
of a share, may vote the share in the same manner as if he were a shareholder: but, unless the directors have previously admitted his
right to vote at that meeting in respect of the share. he shall satisfy the directors of his right to vote the share before the time
for holding the meeting, or adjourned meeting, as the case may be, at which he proposes to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><U>Corporate
Representative.</U> Any corporation not being a subsidiary which is a shareholder of the Corporation may by resolution of its directors
or other governing body authorize such person as it thinks fit to act as its representative at any general meeting or class meeting.
The person so authorized shall be entitled to exercise in respect of and at such meeting the same powers on behalf of the corporation
which he represents as that corporation could exercise if it were an individual shareholder of the Corporation personally present, including,
without limitation, the right, unless restricted by such resolution, to appoint a proxyholder to represent such corporation, and shall
be counted for the purpose of forming a quorum if present at the meeting. Evidence of the appointment of any such representative may
be sent to the Corporation in writing by written instrument, telegram, telex, facsimile or any method of transmitting legibly recorded
messages. Notwithstanding the foregoing, a corporation being a shareholder may appoint a proxyholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Unsound
Mind.</U></B> &nbsp;A shareholder of unsound mind entitled to attend and vote, in respect of whom an order has been made by any court having
jurisdiction, may vote, whether on a show of hands or on a poll, by his committee or curator bonis or other person in the nature of a
committee or curator bonis appointed by that court, and any such committee or curator bonis, or other person may appoint a proxyholder.
The chairman may require such proof of such appointment as he sees fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Joint Registered Holders.</U></B> &nbsp;In the case of joint registered holders of a share, the vote of the senior who exercises a
vote, whether in person or by proxyholder, shall be accepted to the exclusion of the votes of the other joint registered holders; and
for this purpose, seniority shall be determined by the order in which the names stand in the register of shareholders. Several legal personal
representatives of a deceased shareholder whose shares are registered in his sole name shall, for the purpose of this by-law, be deemed
joint registered holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Proxyholders.
</U>&nbsp;</B>A shareholder holding more than one share in respect of which he is entitled to vote shall be entitled to appoint one or more
(but not more than five) proxyholders to attend. act and vote for him on the same occasion. If such a shareholder should appoint more
than one proxyholder for the same occasion he shall specify the number of shares each proxyholder shall be entitled to vote. A shareholder
may also appoint one or more alternate proxyholders to act in the place and stead of an absent proxyholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Proxyholders.</U></B> &nbsp;Any person, having attained the age of majority, may act as proxyholder whether or not he is entitled
on his own behalf to be present and to vote at the meeting at which he acts as proxyholder. The proxy may authorize the person so appointed
to act as proxyholder for the appointor for the period, at any meeting or meetings, and to the extent permitted by the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Proxyholder.</U>&nbsp;</B>A
person appointed by proxy need not be a shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Proxies.
</U></B>A proxy shall be in writing under the hand of the appointor or of his attorney duly authorized in writing, or, if the appointor
is a corporation, either under the seal of the corporation or under the hand of a duly authorized officer or attorney of that corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.22<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Deposit of Proxies.</U></B> Unless the directors fix some other time by which proxies must be deposited, a proxy and the power
of attorney or other authority, if any, under which it is signed, or a notarially certified copy thereof, shall be deposited at the registered
office of the Corporation or at such other place as is specified for that purpose in the notice convening the meeting or form of proxy,
not less than 48 hours (excluding Saturdays and holidays) before the time for holding the meeting in respect of which the person named
in the instrument is appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Deposit
of Proxies.</U></B> In addition to any other method of depositing proxies provided for in the by-laws, the directors may by resolution
make regulations relating to the depositing of proxies at any place or places and fixing the time for depositing the proxies. If the
Corporation is or becomes a reporting company, the time so fixed shall not exceed 48 hours (excluding Saturdays and holidays) preceding
the meeting or adjourned meeting specified in the notice calling a meeting of shareholders and providing for particulars of such proxies
to be sent to the Corporation or any agent of the Corporation in writing or by letter, telegram, telex, facsimile or any method of transmitting
legibly recorded messages so as to arrive before the commencement of the meeting or adjourned meeting at the office of the Corporation
or of any agent of the Corporation appointed for the purpose of receiving such particulars and providing that proxies so deposited may
be acted upon as though the proxies themselves were deposited as required by this Part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Death
or Incapacity.</U></B> &nbsp;A vote given in accordance with the terms of a proxy is valid notwithstanding the previous death or incapacity
of the shareholder giving the proxy or the revocation of the proxy or of the authority under which the form of proxy was executed or
the transfer of the share in respect of which the proxy is given, provided that no notification in writing of such death, incapacity,
revocation or transfer shall have been received at the registered office of the Corporation or by the chairman of the meeting or adjourned
meeting for which the proxy was given before the vote was taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.25<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Retain
Ballots.</U></B> &nbsp;Every ballot cast upon a poll and every proxy appointing a proxyholder who casts a ballot upon a poll shall be retained
by the Secretary for such period and be subject to such inspection as the Act may provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.26<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Votes on Poll.</U></B> On a poll a person entitled to cast more than one vote need not, if he votes, use all his votes or cast
all the votes he uses in the same way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.27<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Determinations.</U></B> The chairman of the meeting may determine whether or not a proxy, deposited for use at such meeting,
which may not strictly comply with the requirements of this Part as to form, execution, accompanying documentation, time of filing, or
otherwise, shall be valid for use at such meeting and any such determination made in good faith shall be final, conclusive and binding
upon such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.28<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Form of Proxy.</U></B> Subject to the provisions of Part IV of the Regulations, a proxy may be in the following form or in any
other form that the directors or the chairman of the meeting shall approve or accept:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&#8220;The undersigned shareholder
of _____________ hereby appoints, __________________, of ________________________ or failing him, of ___________________ as the nominee
of the undersigned to attend, act and vote for the undersigned and on behalf of the undersigned at the _______________ meeting of the
shareholders of the said corporation to be held on the ____ day of ___________ and at any adjournment or adjournments thereof in the same
manner, to the same extent and with the same powers as if the undersigned were present at the said meeting or such adjournment or adjournments
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.1in; text-align: justify">DATED this _________ day of ___________________,
____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.1in; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 1.1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 4in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature of Shareholder</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.29<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Revocation.</U></B> &nbsp;Every proxy may be revoked by an instrument in writing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">executed by the shareholder giving the same or by his attorney authorized in writing or where the shareholder
is a corporation, by a duly authorized officer or attorney of the corporation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">delivered either at the registered office of the Corporation at any time up to and including the last
business day preceding the day of the meeting, or any adjournment thereof at which the proxy is to be used, or to the chairman of the
meeting on the day of the meeting or any adjournment thereof before any vote in respect of which the proxy is to be used shall have been
taken,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or in any other manner provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.30<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Adjournment.
</U></B>&nbsp;The chairman of any meeting may and shall, if so directed by the meeting, adjourn the same from time to time to a fixed time
and place and no notice of such adjournment need to be given to the shareholders unless the meeting is adjourned by one or more adjournments
for an aggregate of thirty days or more in which case notice of the adjourned meeting shall be given as for an original meeting. Any
business may be brought before or dealt with at any adjourned meeting for which no notice is required which might have been brought before
or dealt with at the original meeting in accordance with the notice calling the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.31<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Seconds.
</U></B>&nbsp;No motion proposed at a general meeting need be seconded and the chairman may propose a motion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.32<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Quorum.
</U></B>Save as herein otherwise provided, a quorum for a meeting of shareholders shall be two shareholders, or two proxyholders representing
shareholders, or any combination thereof, holding not less than one-twentieth of the issued shares entitled to be voted at the meeting.
If there is only one shareholder the quorum is one person present and being, or representing by proxy, such shareholder. The directors,
the Secretary or, in his absence, an Assistant Secretary, and the solicitor of the Corporation shall be entitled to attend at any meeting
of shareholders but no such person shall be counted in the quorum or be entitled to vote at any meeting of shareholders unless he shall
be a shareholder or proxyholder entitled to vote thereat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.33<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Quorum.</U></B> &nbsp;If within half an hour from the time appointed for a meeting of shareholders a quorum is not present, the meeting,
if convened upon requisition by the shareholders shall be dissolved. In any other case, it shall stand adjourned to the same day in the
next week, at the same time and place but may not transact any other business. If at the adjourned meeting a quorum is not present within
half an hour from the time appointed for the meeting, the person or persons present and being, or representing by proxy, a shareholder
or shareholders entitled to attend and vote at the meeting shall be a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.34<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Opening
Quorum.</U></B> &nbsp;No business other than the election of the chairman or the adjournment of the meeting shall be transacted at any general
meeting unless a quorum of shareholders entitled to attend and vote is present at the commencement of the meeting, but the quorum need
not be present throughout the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.35<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Resolution in lieu of Meeting.</U></B> Notwithstanding any of the foregoing provisions of this by-law, a resolution in writing
signed by all the shareholders entitled to vote on that resolution at a meeting of the shareholders is, subject to the Act, as valid as
if it had been passed at a meeting of the shareholders. Such resolution may be in two or more counterparts which together shall be deemed
to constitute one resolution in writing. Such resolution shall be filed with the minutes of the proceedings of the shareholders and shall
be effective on the date stated thereon or on the latest day stated on any counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.36<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><U>Class Meetings.</U> Unless the Act, the articles or by-laws otherwise provide, the provisions of this by-law relating to
meetings shall apply with the necessary changes, and so far as they are applicable, to a class meeting of shareholders holding a particular
class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">SHARES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Allotment
and Issuance</U></B>. Subject to the provisions of the Act, the shares shall be under the control of the directors who may, subject to
the rights of the holders of the shares of the Corporation for the time being outstanding, issue, allot, sell or otherwise dispose of,
and/or grant options on or otherwise deal in, shares authorized but not outstanding, and outstanding shares held by the Corporation,
at such times, to such persons (including directors), in such manner, upon such terms and conditions and at such price or for such consideration,
as the directors, in their absolute discretion, may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Fully
Paid</U></B>. No share may be issued until it is fully paid and the Corporation shall have received the full consideration therefor in
cash, property or past services actually performed for the Corporation. The value of property or services for the purposes of this by-law
shall be the value determined by the directors by resolution to be, in all circumstances of the transaction, the fair market value thereof,
and the full consideration received for a share issued by way of dividend shall be the amount declared by the directors to be the amount
of the dividend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Discounts</U></B>.
Subject to the Act, the Corporation or the directors on behalf of the Corporation, may pay a commission or allow a discount to any
person in consideration of his subscribing or agreeing to subscribe, whether absolutely or conditionally, for any shares,
debentures, share rights, warrants or debenture stock in the Corporation, or procuring or agreeing to procure subscriptions, whether
absolutely or conditionally, for any such shares, debentures, share rights, warrants or debenture stock, provided that the rate of
the commission and discount shall not in the aggregate exceed 25 per cent of the amount of the subscription price of such shares.
The Corporation may also pay such brokerage fees as may be lawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certificates</U></B>. Every shareholder is entitled, without charge, to one certificate representing the share or shares of
each class or series held by him; provided that, in respect of a share or shares held jointly by several persons, the Corporation shall
not be bound to issue more than one certificate, and delivery of a certificate for a share to one of several joint registered holders
or to his duly authorized agent shall be sufficient delivery to all; and provided further that the Corporation shall not be bound to issue
certificates representing redeemable shares, if such shares are to be redeemed within one month of the date on which they were allotted.
Any share certificate may be sent through the mail by prepaid mail to the shareholder entitled thereto, and neither the Corporation nor
any transfer agent shall be liable loss occasioned to the shareholder owing to any such share certificate so sent being lost in the mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certificates</U></B>.
Every share certificate issued by the Corporation shall be in such form as the directors approve and shall comply with the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Replacement
Certificates</U></B>. If a share certificate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">is worn or defaced, the directors shall, upon production to them of the said certificate and upon such
other terms, if any, as they may think fit, order the said certificate to be cancelled and shall issue a new certificate in lieu thereof;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">is lost, stolen or destroyed, then, upon proof thereof to the satisfaction of the directors and upon such
indemnity, if any, as the directors deem adequate being given, a new share certificate in lieu thereof shall be issued to the person entitled
to such lost, stolen or destroyed certificate; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85in 0pt 0.15in; text-align: justify"><I>The following section of the
By-laws was approved at the Annual Meeting of Shareholders of ProMis Neurosciences Inc. dated June 28, 2017 held at 9:00 AM.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85in 0pt 0.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify">Section 10.4 is deleted and replaced
with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.5in; text-align: justify"><U>&#8220;Certificates.</U>
Every shareholder is entitled, without charge and at his option, to a share certificate representing the share or shares of each
class or series held by him or to a non-transferable written certificate of acknowledgment of his right to obtain a share
certificate, stating the number and class or series of shares held by him as shown in the securities register; provided that, in
respect of a share or shares held jointly by several persons, the Corporation shall not be bound to issue more than one share
certificate or written certificate of acknowledgment, as the case may be, and delivery of a share certificate or written certificate
of acknowledgment to one of several joint registered holders or to his duly authorized agent shall be sufficient delivery to all;
and provided further that the Corporation shall not be bound to issue certificates representing redeemable shares, if such shares
are to be redeemed within one month of the date on which they were allotted. Any certificate may be sent through the mail by prepaid
mail to the shareholder entitled thereto, and neither the Corporation nor any transfer agent shall be liable for any loss occasioned
to the shareholder owing to any such certificate so sent being lost in the mail or stolen.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">represents more than one share and the registered owner thereof surrenders it to the Corporation with
a written request that the Corporation issue in his name two or more certificates each representing a specified number of shares and in
the aggregate representing the same number of shares as the certificate so surrendered, the Corporation shall cancel the certificate so
surrendered and issue in lieu thereof certificates in accordance with such request.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There shall be paid to the Corporation such sum
as the directors may from time to time fix, for each certificate to be issued under this by-law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Trust</U>. </B>Except as required by law, statute or the by-laws, no person shall be recognized by the Corporation as holding
any share upon any trust, and the Corporation shall not be bound by or compelled in any way to recognize (even when having notice thereof)
any equitable, contingent, future or partial interest in any share or in any fractional part of a share or (except only as by law, statute
or the bylaws provided or as ordered by a court of competent jurisdiction) any other rights in respect of any share except an absolute
right to the entirety thereof in its registered holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Two Names</U>.</B> The certificate representing shares registered in the name of two or more persons shall be delivered to the
person first named on the register of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Redemption
of Shares</U>.</B> Subject to the Act, the articles and the special rights and restrictions attached to any class of shares of the Corporation,
the Corporation may, by a resolution of the directors and in compliance with the Act, purchase any of its shares in accordance with the
special rights and restrictions attaching thereto. No such purchase or redemption shall be made if the Corporation is insolvent at the
time of the proposed purchase or redemption or if the proposed purchase or redemption would render the Corporation insolvent. Subject
to the Act, any shares purchased or redeemed by the Corporation may be sold or, if cancelled, reissued by it, but while such shares are
held by the Corporation. it shall not exercise any vote in respect of such shares and no dividend or other distribution shall be paid
or made thereon. If the Corporation proposes at its option to redeem some but not all of the shares of any class or series, the directors
may, subject to the special rights and restrictions attached to such shares, decide the manner in which the shares to be redeemed shall
be selected and such redemption may or may not be made pro rata among every shareholder holding any such shares as the directors may
determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Signatures</U>.
</B>Subject to the Act, the signature of the Chairman of the Board, the Vice-Chairman of the Board, the Managing Director, the President,
a Vice-President or any other director or officer of the Corporation may be printed, engraved, lithographed or otherwise mechanically
reproduced upon certificates for shares of the Corporation. Certificates so signed shall be deemed to have been manually signed by the
Chairman of the Board, the Vice-Chairman of the Board, the Managing Director. the President, the Vice-President, the director or the
officer whose signature is so printed, engraved, lithographed or otherwise mechanically reproduced thereon and shall be as valid to all
intents and purposes as if they have been signed manually. Where the Corporation has appointed a registrar, transfer agent, branch registrar
or branch transfer agent for the shares (or for the shares of any class or classes) of the Corporation, the signature of the Secretary
or Assistant Secretary may also be printed, engraved. lithographed or otherwise mechanically reproduced on certificates representing
the shares (or the shares of the class or classes in respect of which any such appointment has been made) of the Corporation and when
countersigned by or on behalf of a registrar, transfer agent, branch registrar or branch transfer agent. such certificates so signed
shall be as valid to all intents and purposes as if they had been signed manually. A share certificate containing the signature of a
person which is printed, engraved. lithographed or otherwise mechanically reproduced thereon may be issued notwithstanding that the person
has ceased to be an officer of the Corporation and shall be as valid as if he were an officer at the date of its issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">TRANSFER OF SECURITIES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transfer
of Shares</U>.</B> Subject to the restrictions, if any, set forth in the articles and the by-laws, any shareholder may transfer any of
his shares by instrument in writing executed by or on behalf of such shareholder and delivered to the Corporation or its transfer agent.
The instrument of transfer of any share of the Corporation shall be in the form, if any, on the back of the Corporation&#8217;s share
certificates or in such other form as the directors may from time to time approve or accept. If the directors so determine, each instrument
of transfer shall be in respect of only one class of share. Except to the extent that the Act may otherwise provide, the transferor shall
be deemed to remain the holder of the shares until the name of the transferee is entered in the register of shareholders or a branch
register of shareholders in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Signature.
</U></B>The signature of the registered owner of any shares, or of his duly authorized attorney, upon an authorized instrument of transfer
shall constitute a complete and sufficient authority to the Corporation, its directors, officers and agents to register, in the name
of the transferee as named in the instrument of transfer, the number of shares specified therein or, if no number is specified, all the
shares of the registered owner represented by share certificates deposited with the instrument of transfer. If no transferee is named
in the instrument of transfer, the instrument of transfer shall constitute a complete and sufficient authority to the Corporation, its
directors, officers and agents to register, in the name of the person on whose behalf any certificate for the shares to be transferred
is deposited with the Corporation for the purpose of having the transfer registered, the number of shares if specified in the instrument
of transfer or, if no number is specified, all the shares represented by all share certificates deposited with the instrument of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferee</U>.</B> Neither the Corporation nor any director, officer or agent thereof shall be <B>bound </B>to enquire into
the title of the person named in the form of transfer as transferee, or, if no person is named therein as transferee, of the person on
whose behalf the certificate is deposited with the Corporation for the purpose of having the transfer registered or be liable to any claim
by such registered owner or by any intermediate owner or holder of the certificate or of any of the shares represented thereby or any
interest therein for registering the transfer, and the transfer, when registered, shall confer upon the person in whose name the shares
have been registered a valid title to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Instrument of Transfer</U>.</B> Every instrument of transfer shall be executed by the transferor and left at the registered
office of the Corporation or at the office of its transfer agent or registrar for registration together with the share certificate for
the shares to be transferred and such other evidence, if any, as the directors or the transfer agent or registrar may require to prove
the title of the transferor or his right to transfer the shares and the right of the transferee to have the transfer registered. All instruments
of transfer, where the transfer is registered, shall be retained by the Corporation or its transfer agent or registrar and any instrument
of transfer, where the transfer is not registered, shall be returned to the person depositing the same together with the share certificate
which accompanied the same when tendered for registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fees</U>. </B>There shall be paid to the Corporation in respect of the registration of any transfer such sum, if any, as the
directors may from time to time determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restriction on Transfers</U>.</B> Notwithstanding any other provision of the by-laws, while the Corporation is, or becomes a
corporation which is not a reporting issuer as defined in the Securities Act (British Columbia), then no shares shall be transferred and
entered on the register of shareholders without the previous consent of the directors expressed by a resolution of the board and the directors
shall not be required to give any reason for refusing to consent to any such proposed transfer. The consent of the board required by this
by-law may be in respect of a specific proposed trade or trades or trading generally, whether or not over a specified period of time,
or by specific persons or with such other restrictions or requirements as the directors may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transmission
of Shares</U>.</B> In the case of the death of a shareholder, the survivor or survivors, where the deceased was a joint registered holder,
and the legal personal representative of the deceased, where he was the sole holder, shall be the only persons recognized by the Corporation
as having any title to his interest in the shares. Before recognizing any legal personal representative the directors may require him
to deliver to the Corporation the original or a court-certified copy of a grant of probate or letters of administration in British Columbia
or such other evidence and documents as the directors consider appropriate to establish the right of the personal representative to such
title to the interest in the shares of the deceased shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Death or Bankruptcy</U>.</B> Upon the death or bankruptcy of a shareholder, his personal representative or trustee in bankruptcy,
although not a shareholder, shall have the same rights, privileges and obligations that attach to the shares formerly held by the deceased
or bankrupt shareholder if the documents required by the Act shall have been deposited with the Corporation. This by-law does not apply
on the death of a shareholder with respect to shares registered in his name and the name of another person in joint tenancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Death
or Bankruptcy</U>.</B> Any person becoming entitled to a share in consequence of the death or bankruptcy of a shareholder shall,
upon such documents and evidence being produced to the Corporation as the Act requires, or who becomes entitled to a share as a
result of an order of a Court of competent jurisdiction or a statute, has the right either to be registered as a shareholder in his
representative capacity in respect of such share, or, if he is a personal representative, instead of being registered himself, to
make such transfer of the shares as the deceased or bankrupt person could have made; but the directors shall, as regards a transfer
by a personal representative or trustee in bankruptcy, have the same right, if any, to decline or suspend registration of a
transferee as they would have in the case of a transfer of a share by the deceased or bankrupt person before the death or
bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Agent and Registrar.</U></B> The directors may from time to time by resolution appoint or remove one or more transfer
agents and/or branch transfer agents and/or registrars and/or branch registrars (which may or may not be the same individual or body corporate)
for the securities issued by the Corporation in registered form (or for such securities of any class or classes) and may provide for the
registration of transfers of such securities (or such securities of any class or classes) in one or more places and such transfer agents
and/or branch transfer agents and/or registrars and/or branch registrars shall keep all necessary books and registers of the Corporation
for the registering of such securities (or such securities of the class or classes in respect of which any such appointment has been made).
In the event of any such appointment in respect of the shares (or the shares of any class or classes) of the Corporation, all share certificates
issued by the Corporation in respect of the shares (or the shares of the class or classes in respect of which such appointment has been
made) of the Corporation shall be countersigned by or on behalf of one of the said transfer agents and/or branch transfer agents or by
or on behalf of one of the said registrars and/or branch registrars, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Securities Registrars</U>.</B> A central securities register of the Corporation shall be kept at the registered office of the
Corporation or at such other office or place in Canada as may from time to time be designated by resolution of the board of directors
and a branch securities register or registers may be kept at such office or offices of the Corporation or other place or places, either
in or outside Canada, as may from time to time be designated by resolution of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Shareholder Indebted to the Corporation</U>.</B> If so provided in the articles or by-laws of the Corporation, the Corporation
has a lien on a share registered in the name of a shareholder or his legal representative for a debt of that shareholder to the Corporation.
By way of enforcement of such lien the directors may refuse to permit the registration of a transfer of such share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">DIVIDENDS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dividends</U></B>. The directors may from time to time declare and authorize payment of such dividends, if any, as they may
deem advisable and need not give notice of such declaration to any shareholder. No dividend shall be paid otherwise than out of funds
and/or assets properly available for the payment of dividends and a declaration by the directors as to the amount of such funds or assets
available for dividends shall be conclusive. The Corporation may pay any such dividend wholly or in part by the distribution of specific
assets, and in particular by paid up shares, bonds, debentures or other securities of the Corporation or any other corporation, or in
any one or more such ways as may be authorized by the Corporation or the directors, and where any difficulty arises with regard to such
a distribution the directors may settle the same as they think expedient, and in particular may fix the value for distribution of such
specific assets or any part thereof, and may determine that cash payments in substitution for all or any part of the specific assets to
which any shareholders are entitled shall be made to any shareholders on the basis of the value so fixed to adjust the rights of all parties,
and may vest any such specific assets in trustees for the persons entitled to the dividend as may seem expedient to the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Payment Date</U>.</B> Any dividend declared on shares of any class by the directors may be made payable on such date as is
fixed by the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Declaration</U>.</B> Subject to the rights of shareholders (if any) holding shares with specific rights as to dividends, all
dividends on shares of any class shall be declared and paid according to the number of such shares held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Funds</U>. </B>The directors may, before declaring any dividend, set aside out of the funds properly available for the payment
of dividends such sums as they think proper as a reserve or reserves. which shall, at the discretion of the directors, be applicable for
meeting contingencies, or for equalizing dividends, or for any other purpose to which such funds of the Corporation may be properly applied,
and pending such application may, at the like discretion, either be employed in the business of the Corporation or be invested in such
investments as the directors may from time to time think fit. The directors may also, without placing the same in reserve, carry forward
such funds which they think prudent not to divide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Joint Holders</U>.</B> If several persons are registered as joint holders of any share, any one of them may give an effective
receipt for any dividend, bonus or other moneys payable in respect of the share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Interest.</U></B> No dividend shall bear interest against the Corporation. Where the dividend to which a shareholder is entitled
includes a fraction of a cent, such fraction shall be disregarded in making payment thereof and such payment shall be deemed to be payment
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery</U>.</B> Any dividend, bonus or other moneys payable in cash in respect of shares may be paid by cheque or warrant
sent through the post directed to the registered address of the holder, or in the case of joint holders, to the registered address of
that one of the joint holders who is first named on the register, or to such person and to such address as the holder or joint holders
may direct in writing. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent. The mailing of
such cheque or warrant shall, to the extent of the sum represented thereby (plus the amount of any tax required by law to be deducted)
discharge all liability for the dividend, unless such cheque or warrant shall not be paid on presentation or the amount of tax so deducted
shall not be paid to the appropriate taxing authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Surplus.</U></B> Notwithstanding anything contained in the by-laws, the directors may from time to time capitalize any undistributed
surplus on hand of the Corporation and may from time to time issue as fully paid and non-assessable any unissued shares, or any bonds,
debentures or debt obligations of the Corporation as a dividend representing such undistributed surplus on hand or any part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Fractions</U>.</B>
Notwithstanding any other provisions of the by-laws, should any dividend result in any shareholders being entitled to a fractional
part of a share of the Corporation, the directors shall have the right to pay such shareholders in place of that fractional share,
the cash equivalent thereof calculated on the price or consideration for which such shares were or were deemed to be issued, and
shall have the further right and complete discretion to carry out such distribution and to adjust the rights of the shareholders
with respect thereon on as practical and equitable a basis as possible including the right to arrange through a fiscal agent or
otherwise for the sale, consolidation or other disposition of those fractional shares on behalf of those shareholders of the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">VOTING SHARES AND SECURITIES IN OTHER COMPANIES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting Other Securities</U>.</B> All of the shares or other securities carrying voting rights of any other body corporate held
from time to time by the Corporation may be voted at any and all meetings of shareholders, bondholders, debenture holders or holders of
other securities (as the case may be) of such other body corporate and in such manner and by such person or persons as the board of directors
of the Corporation shall from time to time determine. The proper signing officers of the Corporation may also from time to time execute
and deliver for and on behalf of the Corporation proxies and/or arrange for the issuance of voting certificates and/or other evidence
of the right to vote in such names as they may determine without the necessity of a resolution or other action by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify">INFORMATION AVAILABLE TO SHAREHOLDERS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Information</U>.</B> Except as provided by the Act, no shareholder shall be entitled to discovery of any information respecting
any details or conduct of the Corporation&#8217;s business which in the opinion of the directors it would be inexpedient in the interests
of the Corporation to communicate to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Inspection</U>.</B> The directors may from time to time, subject to rights conferred by the Act, determine whether and to what
extent and at what time and place and under what conditions or regulations the documents, books and registers and accounting records of
the Corporation or any of them shall be open to the inspection of shareholders and no shareholder shall have any right to inspect any
document or book or register or accounting record of the Corporation except as conferred by statute or authorized by the board of directors
or by a resolution of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify">NOTICES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Service</U>. </B>Any notice or other document required by the Act, the Regulations, the articles or the by-laws to be sent to
any shareholder or director or to the auditor shall be delivered personally or sent by prepaid mail, fax, email, cable, telegram or telex
to any such shareholder at his latest address as shown in the records of the Corporation or its transfer agent and to any such director
at his latest address as shown in the records of the Corporation or in the last notice filed under section 106 or 113 of the Act. and
to the auditor at his business address; provided always that notice may be waived or the time for the notice may be waived or abridged
at any time with the consent in writing of the person entitled thereto. If a notice or document is sent to a shareholder by prepaid mail
in accordance with this paragraph and the notice or document is returned on three consecutive occasions because the shareholder cannot
be found, it shall not be necessary to send any further notices or documents to the shareholder until he informs the Corporation in writing
of his new address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Shares Registered in More than One Name</U></B>. All notices or other documents with respect to any shares registered in more
than one name shall be given to whichever of such persons is named first in the records of the Corporation and any notice or other document
so given shall be sufficient notice or delivery to all the holders of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Persons Becoming Entitled by Operation of Law</U></B>. Subject to the Act, every person who by operation of law, transfer or
by any other means whatsoever shall become entitled to any share or shares shall be bound by every notice or other document in respect
of such share or shares which, previous to his name and address being entered in the records of the Corporation, shall be duly given to
the person or person from who he derives his title to such share or shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deceased Shareholders</U>.</B> Subject to the Act, any notice or other document delivered or sent by post, fax, email, cable,
telegram or telex or left at the address of any shareholder as the same appears in the records of the Corporation shall, notwithstanding
that such shareholder be then deceased, and whether or not the Corporation has notice of his decease, be deemed to have been duly served
in respect of the shares held by such shareholder (whether held solely or with any other person or persons) until some other person be
entered in his stead in the records of the Corporation as the holder or one of the holders thereof and such service shall for all purposes
be deemed a sufficient service of such notice or document on his heirs, executors or administrators and on all persons, if any, interested
with him in such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Signature to Notices</U>.</B> The signature of any director or officer of the Corporation to any notice or document to be given
by the Corporation may be written, stamped, typewritten or printed or partly written, stamped, typewritten or printed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Computation of Time</U>.</B> Where a given number of days&#8217; notice or notice extending over a period is required to be
given under any provisions of the articles or by-laws of the Corporation the day of service or posting of the notice or document shall,
unless it is otherwise provided, be counted in such number of days or other period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proof of Service</U>.</B> With respect to every notice or other document sent by post it shall be sufficient to prove that the
envelope or wrapper containing the notice or other document was properly addressed as provided in paragraph 15.1 of this by-law and put
into a post office or into a letter box. A certificate of an officer of the Corporation in office at the time of the making of the certificate
or of a transfer officer of any transfer agent or branch transfer agent of shares of any class of the Corporation as to facts in relation
to the sending or delivery of any notice or other document to any shareholder, director, officer or auditor or publication of any notice
or other document shall be conclusive evidence thereof and shall be binding on every shareholder, director, officer or auditor of the
Corporation as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Record Dates</U>.</B> The directors may fix in advance a date, which shall not be more than the maximum number of days permitted
by the Act, preceding the date of any meeting of shareholders. including class and series meetings, or of the payment of any dividend
or to participate in a liquidation distribution or of the proposed taking of any other proper action requiring the determination of shareholders,
as the record date for the determination of the shareholders entitled to notice of, or to attend and vote at, any such meeting and any
adjournment thereof, or entitled to receive payment of any such dividend or for any other proper purpose and, in such case, notwithstanding
anything elsewhere contained in the by-laws, only shareholders of record on the date so fixed shall be deemed to be shareholders for the
purposes aforesaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Record Date</U>.</B> Where no record date is so fixed for the determination of shareholders as provided in the preceding by-law,
the record date of the determination of shareholders entitled to receive notice of a meeting of shareholders shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">at the close of business on the day immediately preceding the day on which the notice is given; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">if no notice is given, the day on which the meeting is held; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the record date for the determination of shareholders
for any purpose other than to establish a shareholders&#8217; right to receive notice of a meeting or to vote shall be at the close of
business on the day on which the directors pass the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify">CHEQUES, DRAFTS AND NOTES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cheques</U>.</B> All cheques, drafts or orders for the payment of money and all notes and acceptances and bills of exchange
shall be signed by such officer or officers or person or person, whether or not officers of the Corporation, and in such manner as the
board of directors may from time to time designate by resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify">CUSTODY OF SECURITIES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Custody.</U></B> All shares and securities owned by the Corporation may be lodged (in the name of the Corporation) with a chartered
bank or trust company or in a safety deposit box or, if so authorized by resolution of the board of directors, with such other depositaries
or in such other manner as may be determined from time to time by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nominees.</U></B> All share certificates, bonds, debentures, notes or other obligations belonging to the Corporation may be
issued or held in the name of a nominee or nominees of the Corporation (and if issued or held in the name of more than one nominee shall
be held in the names of the nominees jointly with the right of survivorship) and shall be endorsed in blank with endorsement guaranteed
in order to enable transfer to be completed and registration to be effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify">EXECUTION OF INSTRUMENTS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in"><B>18.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Execution</U>.</B> Contracts, documents or instruments in writing requiring the signature of the Corporation may be signed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any two officers who have been appointed by the board of directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any two directors; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any one officer who has been appointed by the board of directors and any one director,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and all contracts, documents and instruments
in writing so signed shall be binding upon the Corporation without any further authorization or formality. The board of directors
shall have power from time to time by resolution to appoint any director or directors, officer or officers, or any person or
persons, on behalf of the Corporation either to sign contracts, documents and instruments in writing generally or to sign specific
contracts, documents or instruments in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Seal</U></B>. The corporate seal (if any) of the Corporation may be affixed to contracts. documents and instruments in writing
signed as aforesaid or by any officer or officers, person or persons. appointed as aforesaid by resolution of the board of directors,
but any such contract, document or instrument is not invalid merely because the corporate seal is not affixed thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definition</U></B>. The term &#8220;contracts, documents or instruments in writing&#8221; as used in this by-law shall include
deeds, mortgages, hypothecs, charges, conveyances, transfers and assignments of property real or personal, immovable or movable, agreements,
releases, receipts and discharges for the payment of money or other obligations, conveyances, transfers and assignments of shares, share
warrants, stocks, bonds, debentures or other securities and all paper writings<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Securities</U></B>. In particular without limiting the generality of the foregoing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Chairman of the Board, the Vice-Chairman of the Board, the Managing Director, the President or a Vice-President
together with the Secretary or the Treasurer, or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any two directors; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any director or directors, officer or officers, or any person or person, on behalf of the Corporation
appointed from time to time by resolution of the board of directors;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">shall have authority to sell, assign, transfer,
exchange, convert or convey any and all shares, stocks, bonds, debentures, rights, warrants or other securities owned by or registered
in the name of the Corporation and to sign and execute (under the seal of the Corporation or otherwise) all assignments, transfers, conveyances,
powers of attorney and other instruments that may be necessary for the purpose of selling, assigning. transferring, exchanging, converting
or conveying any such shares, stocks, bonds, debentures, rights, warrants or other securities<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Signatures</U></B>.
The signature or signatures of the Chairman of the Board, the Vice-Chairman of the Board, the Managing Director, the President, the
Chief Executive Officer, a Vice-President, the Secretary, the Treasurer, an Assistant Secretary or an Assistant Treasurer or any
director of the Corporation and/or of any other officer or officers, person or persons, appointed as aforesaid by resolution of the
board of directors may, if specifically authorized by resolution of the directors. be printed, engraved, lithographed or otherwise
mechanically reproduced upon any contracts, documents or instruments in writing or bonds, debentures or other securities of the
Corporation executed or issued by or on behalf of the Corporation and all contracts, documents or instruments in writing or bonds,
debentures or other securities of the Corporation on which the signature or signatures of any of the foregoing officers or persons
authorized as aforesaid shall be so reproduced pursuant to special authorization by resolution of the directors shall be deemed to
have been manually signed by such officers or persons whose signature or signatures is or are so reproduced and shall be as valid to
all intents and purposes as if they had been signed manually and notwithstanding that the officers or persons whose signature or
signatures is or are so reproduced may have ceased to hold office at the date of the delivery or issue of such contracts, documents
or instruments in writing or bonds, debentures or other securities of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify">FINANCIAL YEAR</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in"><B>19.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Year End</U></B>. The financial year of the Corporation shall terminate on such date in each year as the directors may from
time to time by resolutions determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify">BORROWING</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in"><B>20.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Borrowing</U></B>. Subject to the provisions of the Act, the directors may from time to time authorize the Corporation to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46px"></TD><TD STYLE="width: 57px">(a)</TD><TD STYLE="text-align: justify">borrow money on the credit of the Corporation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46px"></TD><TD STYLE="width: 57px">(b)</TD><TD STYLE="text-align: justify">issue, resell, sell or pledge debt obligations of the Corporation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46px"></TD><TD STYLE="width: 57px">(c)</TD><TD STYLE="text-align: justify">give a guarantee on behalf of the Corporation to secure performance of an obligation of<SUP>-</SUP>any
person;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46px"></TD><TD STYLE="width: 57px">(d)</TD><TD STYLE="text-align: justify">mortgage, charge, hypothecate, pledge or otherwise create a security interest on all or any property of
the Corporation, owned or subsequently acquired to secure any obligation of the Corporation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 46px"></TD><TD STYLE="width: 57px">(e)</TD><TD STYLE="text-align: justify">give financial assistance to any person, directly or indirectly, by way of loan, guarantee, the provision
of security or otherwise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>The directors may make any bonds, debentures or other debt obligations issued by the Corporation by their terms assignable
free from any equities between the Corporation and the person to whom they may be issued or any other person who lawfully acquires them
by assignment, purchase or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>The directors may authorize the issue of any bonds, debentures or other debt obligations of the Corporation at a discount,
premium or otherwise and with special or other rights or privileges as to redemption, surrender, drawings, allotment of or conversion
into or exchange for shares, attending and voting at general meetings of the Corporation and otherwise as the directors may determine
at or before the time of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>The Corporation shall keep or cause to be kept at its registered office in accordance with the Act a register of its debentures
and a register of debentureholders, which registers may be combined. and, subject to the provisions of the Act, may keep or cause to be
kept one or more branch registers of its debentureholders at such place or places as the directors may from time to time determine and
the directors may by resolution, regulation or otherwise make such provisions as they think fit respecting the keeping of such branch
registers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B>Every
bond, debenture or other debt obligation of the Corporation shall be signed manually by at least one director or officer of the
Corporation or by or on behalf of a trustee, registrar. branch registrar, transfer agent or branch transfer agent for the bond,
debenture or other debt obligations appointed by the Corporation or under any instrument under which the bond, debenture or other
debt obligation is issued and any additional signatures may be printed or otherwise mechanically reproduced thereon and, in such
event, a bond, debenture or other debt obligation so signed is as valid as if signed manually notwithstanding that any person whose
signature is so printed or mechanically reproduced shall have ceased to hold the office that he is stated on such bond, debenture or
other debt obligation to hold at the date of the issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>The Corporation shall keep or cause to be kept a register of its indebtedness to ever director or officer of the Corporation
or an associate of any of them in accordance with the provisions of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify">DISCLOSURE OF INTEREST OF DIRECTORS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conflicts.</U> A </B>director who is in any way, directly or indirectly, interested in an existing or proposed contract or transaction
with the Corporation or who holds any office or possesses any property whereby, directly or indirectly, a duty or interest might be created
to conflict with his duty or interest as a director shall declare the nature and extent of his interest in such contract or transaction
or of the conflict or potential conflict with his duty and interest as a director, as the case may be, in accordance with the provisions
of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>A director shall not vote in respect of any such contract or transaction with the Corporation in which he is interested and
if he shall do so his vote shall not be counted, but he shall be counted in the quorum present at the meeting at which such vote is taken.
Subject to the provisions of the Act, the prohibitions contained in this by-law shall not apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any contract or transaction relating to a loan to the Corporation, the repayment of all or part of which
a director or a specified corporation or a specified firm in which he has an interest has guaranteed or joined in guaranteeing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any contract or transaction made, or to be made, with or for the benefit of an affiliated corporation
of which a director is a director or officer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any contract by a director to subscribe for or underwrite shares or debentures to be issued by the Corporation
or a subsidiary of the Corporation, or any contract, arrangement or transaction in which a director is, directly or indirectly interested
if all the other directors are also, directly or indirectly interested in the contract, arrangement or transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">determining the remuneration of the directors in that capacity;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">purchasing and maintaining insurance to cover directors against liability incurred by them as directors;
or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">the indemnification of any director by the Corporation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These exceptions may from time to time be suspended
or amended to any extent approved by the Corporation in general meeting and permitted by the Act, either generally or in respect of any
particular contract or transaction or for any particular period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B> The interest of a director in any matter described in this by-law or otherwise shall not affect such director&#8217;s alternate
director and such alternate director may be counted in a quorum and may vote upon such matter notwithstanding disqualification of the
director, nor shall a disqualification of an alternate director affect the ability of a director to be counted in a quorum or to vote
on a matter in which such director&#8217;s alternate director shall be disqualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>A director may hold any office or position with the Corporation, other than the office of auditor of the Corporation, in conjunction
with his office of director for such period and on such terms, as to remuneration or otherwise, as the directors may determine and no
director or intended director shall be disqualified by his office from contracting with the Corporation either with regard to his tenure
of any such other office or position or as vendor, purchaser or otherwise, and, subject to compliance with the provisions of the Act,
no contract or transaction entered into by or on behalf of the Corporation in which a director is in any way interested shall be liable
to be voided by reason thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>Subject to compliance with the provisions of the Act, a director or his firm may act in a professional capacity for the Corporation
and he or his firm shall be entitled to remuneration for professional services as if he were not a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>A director may be or become a director or other officer or employee of, or otherwise interested in, any corporation or firm
in which the Corporation may be interested as a shareholder or otherwise, and, subject to compliance with the provisions of the Act, such
director shall not be accountable to the Corporation for any remuneration or other benefits received by him as director, officer or employee
of, or from his interest in, such other corporation or firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MADE by resolution of the Board of Directors on
the 21<SUP>st</SUP> day of September, 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ George Adams</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="text-align: justify; width: 50%">Director</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONFIRMED by the Shareholders in accordance with
the Canada Business Corporations Act on the 21st day of September, 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ George Adams</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="text-align: justify; width: 50%">Director</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2(1)
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.2.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY-LAW NO. 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>A BY-LAW RELATING TO THE NOMINATION OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMORFIX LIFE SCIENCES LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(THE &#8220;CORPORATION&#8221;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONTENTS:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Interpretation</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">2.</TD><TD STYLE="text-align: justify">Nomination of Directors</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">3.</TD><TD STYLE="text-align: justify">Nominations of Directors by Nominating Shareholders</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">4.</TD><TD STYLE="text-align: justify">Eligibility Requirements for Nominated Candidates</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">5.</TD><TD STYLE="text-align: justify">Board Discretion</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BY-LAW NO. 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border-top: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is committed to: (i) facilitating
an orderly and efficient annual or, where the need arises, special meeting, process; (ii) ensuring that all shareholders receive adequate
notice of director nominations and sufficient information with respect to all nominees; (iii) allowing the Corporation and shareholders
to evaluate all nominees&#8217; qualifications and suitability as a director of the Corporation; and (iv) allowing shareholders to cast
an informed vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of this By-Law No. 2 is to provide
shareholders, directors and management of the Corporation with guidance on the nomination of directors. This By-Law No. 2 is the framework
by which the Corporation seeks to fix a deadline by which holders of record of common shares of the Corporation must submit director nominations
to the Corporation prior to any annual or special meeting of shareholders and sets forth the information that a shareholder must include
in the notice to the Corporation for the notice to be in proper written form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is the position of the Corporation that this
By-Law No. 2 is beneficial to shareholders and other stakeholders. This By-Law No. 2 will be subject to an annual review, and will reflect
changes as required by securities regulatory agencies or stock exchanges, or so as to meet industry standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Interpretation </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conflicts between By-Laws</U> &#8211; This By-Law No. 2 amends the Corporation&#8217;s existing By-Laws to the extent necessary
to give effect to this By-Law No. 2. In the case of an inconsistency between By-Law No. 2 and the Corporation&#8217;s existing By-Laws,
the provisions of By-Law No. 2 shall prevail over the inconsistent provisions in the Corporation&#8217;s existing By-Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions </U>&#8211; In By-Law No. 2, unless the context otherwise requires:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Act</B>&#8221; shall mean the Canada
Business Corporations Act, and any statute that may be substituted therefore, as from time to time amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Affiliate</B>&#8221;, when used to indicate
a relationship with a person, shall mean a person that directly, or indirectly through one or more intermediaries, controls, or is controlled
by, or is under common control with, such specified person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Applicable Securities Laws</B>&#8221;
shall mean the Securities Act (British Columbia) and the equivalent legislation in the other provinces and in the territories of Canada,
as amended from time to time, the rules, regulations and forms made or promulgated under any such statute and the published national instruments,
multilateral instruments, policies, bulletins and notices of the securities commissions and similar regulatory authorities of each of
the applicable provinces and territories of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><I>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</I></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BY-LAW NO. 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Associate</B>&#8221;, when used to indicate
a relationship with a specified person, shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any corporation or trust of which such person owns beneficially, directly or indirectly, voting securities carrying more than 10%
of the voting rights attached to all voting securities of such corporation or trust for the time being outstanding,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> any partner of that person,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any trust or estate in which such person has a substantial beneficial interest or as to which such person serves as trustee or
in a similar capacity,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a spouse of such specified person,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any person of either sex with whom such specified person is living in conjugal relationship outside marriage, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any relative of such specified person or of a person mentioned in clauses (iv) or (v) of this definition if that relative has the
same residence as the specified person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Derivatives Contract</B>&#8221; shall
mean a contract between two parties (the &#8220;<B>Receiving Party</B>&#8221; and the &#8220;<B>Counterparty</B>&#8221;) that is designed
to expose the Receiving Party to economic benefits and risks that correspond substantially to the ownership by the Receiving Party of
a number of shares in the capital of the Corporation or securities convertible into such shares specified or referenced in such contract
(the number corresponding to such economic benefits and risks, the &#8220;<B>Notional Securities</B>&#8221;), regardless of whether obligations
under such contract are required or permitted to be settled through the delivery of cash, shares in the capital of the Corporation or
securities convertible into such shares or other property, without regard to any short position under the same or any other Derivatives
Contract. For the avoidance of doubt, interests in broad-based index options, broad-based index futures and broad-based publicly traded
market baskets of stocks approved for trading by the appropriate governmental authority shall not be deemed to be Derivatives Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Meeting of Shareholders</B>&#8221; shall
mean such annual shareholders meeting or special meeting at which one or more persons are nominated for election to the board by a Nominating
Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>Nominating Shareholder</B>&#8221; shall
mean any person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>who, at the close of business on the date of the giving of the notice provided for below in this By-Law No. 2 and on the record
date for notice of such meeting, is entered in the securities register as a holder of one or more shares carrying the right to vote at
such meeting or who beneficially owns shares that are entitled to be voted at such meeting, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>who complies with the notice procedures set forth below in this By-Law No. 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>owned beneficially</B>&#8221;, &#8220;<B>owns
beneficially</B>&#8221;, and &#8220;<B>beneficially owns</B>&#8221; means, in connection with the ownership of shares in the capital of
the Corporation by a person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>any
such shares as to which such person or any of such person&#8217;s Affiliates or Associates owns at law or in equity, or has the
right to acquire or become the owner at law or in equity, where such right is exercisable immediately or after the passage of time
and whether or not on condition or the happening of any contingency or the making of any payment, upon the exercise of any
conversion right, exchange right or purchase right attaching to any securities, or pursuant to any agreement, arrangement, pledge or
understanding whether or not in writing,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><I>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</I></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BY-LAW NO. 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border-top: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any such shares as to which such person or any of such person&#8217;s Affiliates or Associates has the right to vote, or the right
to direct the voting, where such right is exercisable immediately or after the passage of time and whether or not on condition or the
happening of any contingency or the making of any payment, pursuant to any agreement, arrangement, pledge or understanding whether or
not in writing,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any such shares which are beneficially owned, directly or indirectly, by a Counterparty (or any of such Counterparty&#8217;s Affiliates
or Associates) under any Derivatives Contract (without regard to any short or similar position under the same or any other Derivatives
Contract) to which such person or any of such person&#8217;s Affiliates or Associates is a Receiving Party; provided, however that the
number of shares that a person owns beneficially pursuant to this clause (iii) in connection with a particular Derivatives Contract shall
not exceed the number of Notional Securities with respect to such Derivatives Contract; provided, further, that the number of securities
owned beneficially by each Counterparty (including their respective Affiliates and Associates) under a Derivatives Contract shall for
purposes of this clause be deemed to include all securities that are owned beneficially, directly or indirectly, by any other Counterparty
(or any of such other Counterparty&#8217;s Affiliates or Associates) under any Derivatives Contract to which such first Counterparty (or
any of such first Counterparty&#8217;s Affiliates or Associates) is a Receiving Party and this proviso shall be applied to successive
Counterparties as appropriate, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any such shares which are owned beneficially within the meaning of this definition by any other person with whom such person is
acting jointly or in concert with respect to the Corporation or any of its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>public announcement</B>&#8221; shall
mean disclosure in a press release reported by a national news service in Canada, or in a document publicly filed by the Corporation or
its agents under its profile on the System of Electronic Document Analysis and Retrieval at www.sedar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Nomination of Directors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Eligibility</U> - Subject only to the Act, only persons who are nominated in accordance with the following procedures shall
be eligible for election as directors of the Corporation. Nominations of persons for election to the board may be made at any annual meeting
of shareholders, or at any special meeting of shareholders (but only if the election of directors is a matter specified in the notice
of meeting given by or at the direction of the person calling such special meeting):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><I>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</I></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BY-LAW NO. 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border-top: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by or at the direction of the board or an authorized officer of the Corporation, including pursuant to a notice of meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> by or at the direction or request of one or more shareholders pursuant to a proposal made in accordance with the provisions of
the Act or a requisition of the shareholders made in accordance with the provisions of the Act; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by any Nominating Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Nominations of Directors by Nominating Shareholders </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Formal Requirements</U> &#8211; In addition to any other applicable requirements, for a nomination to be made by a Nominating
Shareholder, such person must have given:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>timely notice thereof in proper written form to the chief executive officer of the Corporation at the principal executive offices
of the Corporation in accordance with this By-Law No. 2; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the representation and agreement with respect to each candidate for nomination as required by, and within the time period specified
in, section 4.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Timely Notice</U> &#8211; To be timely under section 3.01(a), a Nominating Shareholder&#8217;s notice to the chief executive
officer of the Corporation must be made:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the case of an annual meeting of shareholders, not less than 30 nor more than 65 days prior to the date of the annual meeting
of shareholders; provided, however, that in the event that the annual meeting of shareholders is called for a date that is less than 40
days after the date (the &#8220;Notice Date&#8221;) on which the first public announcement of the date of the annual meeting was made,
notice by the Nominating Shareholder may be made not later than the tenth (10th) day following the Notice Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the case of a special meeting (which is not also an annual meeting) of shareholders called for the purpose of electing directors
(whether or not called for other purposes), not later than the fifteenth (15th) day following the day on which the first public announcement
of the date of the special meeting of shareholders was made. Notwithstanding the foregoing, the board may, in its sole discretion, waive
any requirement in this section 3.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proper Written Form for Notice</U> &#8211; To be in proper written form, a Nominating Shareholder&#8217;s notice to the chief
executive officer of the Corporation, under section 2.01(a), must set forth</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as to each person whom the Nominating Shareholder proposes to nominate for election as a director:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the name, age, business address and residence address of the person,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the principal occupation or employment of the person,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><I>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</I></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BY-LAW NO. 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border-top: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> the class or series and number of shares in the capital of the Corporation which are controlled or which are owned beneficially
or of record by the person as of the record date for the Meeting of Shareholders (if such date shall then have been made publicly available
and shall have occurred) and as of the date of such notice,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a statement as to whether such person would be &#8220;independent&#8221; of the Corporation (within the meaning of sections 1.4
and 1.5 of National Instrument 52-110 - Audit Committees of the Canadian Securities Administrators, as such provisions may be amended
from time to time) if elected as a director at such meeting and the reasons and basis for such determination, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any other information relating to the person that would be required to be disclosed in a dissident&#8217;s proxy circular in connection
with solicitations of proxies for election of directors pursuant to the Act and Applicable Securities Laws; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as to the Nominating Shareholder giving the notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any information relating to such Nominating Shareholder that would be required to be made in a dissident&#8217;s proxy circular
in connection with solicitations of proxies for election of directors pursuant to the Act and Applicable Securities Laws, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the class or series and number of shares in the capital of the Corporation which are controlled or which are owned beneficially
or of record by the Nominating Shareholder as of the record date for the Meeting of Shareholders (if such date shall then have been made
publicly available and shall have occurred) and as of the date of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Eligibility Requirements for Nominated Candidates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Written Consent, Representation of Qualifications and Agreement to Comply</U> &#8211; To be eligible to be a candidate for election
as a director of the Corporation and to be duly nominated, a candidate must be nominated in the manner prescribed in this By-Law No. 2
and the candidate for nomination, whether nominated by the board or otherwise, must have previously delivered to the chief executive officer
of the Corporation at the principal executive offices of the Corporation, not less than 5 days prior to the date of the Meeting of Shareholders,
a written consent to act as a director of the Corporation, a representation in form acceptable to the Corporation that the candidate for
nomination is not disqualified from acting as a director as provided in the Act, and agreement (in form provided by the Corporation) that
such candidate for nomination, if elected as a director of the Corporation will comply with all applicable corporate governance, conflict
of interest, confidentiality, share ownership, and insider trading policies and other policies and guidelines of the Corporation applicable
to directors and in effect during such person&#8217;s term in office as a director (and, if requested by any candidate for nomination,
the chief executive officer of the Company shall provide to such candidate for nomination all such policies and guidelines then in effect).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><I>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</I></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BY-LAW NO. 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">AMORFIX LIFE SCIENCES LTD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="border-top: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Effect of Non-Compliance</U> &#8211; No person shall be eligible for election as a director of the Corporation unless nominated
in accordance with the provisions of this By-Law No. 2; provided, however, that nothing in this By-Law No. 2 shall be deemed to preclude
discussion by a shareholder (as distinct from nominating directors) at a meeting of shareholders of any matter in respect of which it
would have been entitled to submit a proposal pursuant to the provisions of the Act. The chairman of the meeting shall have the power
and duty to determine whether a nomination was made in accordance with the procedures set forth in the foregoing provisions and, if any
proposed nomination is not in compliance with such foregoing provisions, to declare that such defective nomination shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Notice</U> - Notwithstanding any other provision of this By-Law No. 2, notice or any delivery given to the chief
executive officer of the Corporation pursuant to this By-Law No. 2 may only be given by personal delivery, facsimile transmission or by
email (provided that the chief executive officer of the Corporation has stipulated an email address for purposes of this notice, at such
email address as stipulated from time to time), and shall be deemed to have been given and made only at the time it is served by personal
delivery, email (at the address as aforesaid) or sent by facsimile transmission (provided that receipt of confirmation of such transmission
has been received) to the chief executive officer at the address of the principal executive offices of the Corporation; provided that
if such delivery or electronic communication is made on a day which is a not a business day or later than 5:00 p.m. (Vancouver time) on
a day which is a business day, then such delivery or electronic communication shall be deemed to have been made on the subsequent day
that is a business day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Extension of Notice Period</U> &#8211; In no event shall any adjournment or postponement of a meeting of shareholders or
the announcement thereof commence a new time period for the giving of a Nominating Shareholder&#8217;s notice as described in section
3.03(a) or the delivery of a consent, representation and agreement as described in section 4.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><U>Board Discretion</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U> &#8211; Notwithstanding the foregoing, the board may in its sole discretion, waive any requirement of this By-Law
No. 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"><I>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</I></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>FINAL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DATED AS OF JANUARY 22, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND EXTENDED AS OF MAY&nbsp;15, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BETWEEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMPUTERSHARE TRUST COMPANY OF CANADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS RIGHTS AGENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Article&nbsp;1 - INTERPRETATION</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in; width: 10%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 85%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 5%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">1.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Certain Definitions</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">1.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Currency</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">1.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Headings and Interpretation</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">1.4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Calculation of Number and Percentage of Beneficial Ownership of Outstanding Voting Shares</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">1.5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Acting Jointly or in Concert</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">1.6.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Generally Accepted Accounting Principles</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Article&nbsp;2 - THE RIGHTS</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issue of Rights: Legend on Common Share Certificates</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Initial Exercise Price; Exercise of Rights; Detachment of Rights</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Adjustments to Exercise Price; Number of Rights</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Date on Which Exercise Is Effective</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Execution, Authentication, Delivery and Dating of Rights Certificates</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.6.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Registration, Transfer and Exchange</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.7.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Mutilated, Destroyed, Lost and Stolen Rights Certificates</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.8.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Persons Deemed Owners of Rights</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.9.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Delivery and Cancellation of Certificates</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.10.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Agreement of Rights Holders</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">2.11.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Holder of Rights Not Deemed a Shareholder</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Article&nbsp;3 - ADJUSTMENTS TO THE RIGHTS IN THE EVENT OF A FLIP-IN EVENT</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">3.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Flip-in Event</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Article&nbsp;4 - THE RIGHTS AGENT</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">4.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">General</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">4.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Merger, Amalgamation or Consolidation or Change of Name of Rights Agent</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">4.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Duties of Rights Agent</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">34</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">4.4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change of Rights Agent</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">4.5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Compliance with Money Laundering Legislation</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">4.6.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Privacy Provision</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Article&nbsp;5 - MISCELLANEOUS</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.1.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Redemption and Waiver</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.2.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Expiration</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.3.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of New Rights Certificates</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.4.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Supplements and Amendments</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.5.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Fractional Rights and Fractional Shares</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.6.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Rights of Action</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.7.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Regulatory Approvals</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.8.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-Canadian Holders</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in; width: 10%">5.9.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%">Notices</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 5%">43</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.10.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Costs of Enforcement</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.4in; text-align: left">5.11. </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Successors</TD>
    <TD STYLE="font-size: 10pt; text-align: right">44</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.12.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Benefits of this Agreement</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.13.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Governing Law</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.14.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Severabilitv</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.15.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Effective Date and Confirmation</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.16.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Determinations and Actions by the Board of Directors</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.17.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Force Majeure</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.18.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Time of the Essence</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.4in">5.19.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Execution in Counterparts</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATTACHMENT
1</B></FONT><B><FONT STYLE="font-size: 13pt">- </FONT><FONT STYLE="font-size: 10pt">FORM&nbsp;OF RIGHTS CERTIFICATE<BR>
ATTACHMENT 2 </FONT><FONT STYLE="font-size: 13pt">- </FONT><FONT STYLE="font-size: 10pt">FORM&nbsp;OF ASSIGNMENT<BR>
ATTACHMENT 3 </FONT><FONT STYLE="font-size: 13pt">- </FONT><FONT STYLE="font-size: 10pt">FORM&nbsp;OF ELECTION TO EXERCISE ATTACHMENT
4 </FONT><FONT STYLE="font-size: 13pt">- </FONT><FONT STYLE="font-size: 10pt">CERTIFICATE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SHAREHOLDER RIGHTS PLAN AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THIS
AGREEMENT </B></FONT>originally dated as of <B>January&nbsp;22, 2016</B>, and amended and extended as of <B>May&nbsp;15, 2019</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BETWEEN:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROMIS
NEUROSCIENCES INC.</B></FONT>, a company incorporated under the laws of Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(the &ldquo;<B>Company</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AND:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPUTERSHARE
TRUST COMPANY OF CANADA</B></FONT>, a trust company incorporated under the laws of Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(the &ldquo;<B>Rights Agent</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">The Board of Directors of the Company has determined that it is in the best interests of the Company to
adopt a shareholder rights plan to ensure, to the extent possible, that all shareholders of the Company are treated fairly in connection
with any take-over bid for the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">In order to implement the adoption of the shareholder rights plan, the Board of Directors has authorized
and declared a distribution of one Right effective the close of business (Toronto Time) on <B>January&nbsp;22, 2016</B>, and amended and
extended as of <B>May&nbsp;15, 2019</B>, in respect of each Common Share outstanding at the Record Time and has further authorized the
issuance of one Right in respect of each Common Share issued after the Record Time and prior to the earlier of the Separation Time and
the Expiration Time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">Each Right entitles the holder thereof, after the Separation Time, to purchase securities of the Company
pursuant to the terms and subject to the conditions set forth herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">The Company desires to appoint the Rights Agent to act on behalf of the Company and the holders of Rights,
and the Rights Agent is willing to so act, in connection with the issuance, transfer, exchange and replacement of Rights Certificates
(as hereinafter defined), the exercise of Rights and other matters referred to herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW
THEREFORE, </B></FONT>in consideration of the premises and the respective covenants and agreements set forth herein, and subject to such
covenants and agreements, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;1
</B></FONT><B>- INTERPRETATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.1.</B></TD><TD STYLE="text-align: justify"><B><U>Certain Definitions</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
the following terms have the meanings indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Acquiring Person</B>&rdquo; means any Person who is the Beneficial Owner of 20% or more of the
outstanding Voting Shares; provided, however, that the term &ldquo;<B>Acquiring Person</B>&rdquo; shall not include:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Company or any Subsidiary of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any Person who becomes the Beneficial Owner of 20% or more of the outstanding Voting Shares as a result
of one or any combination of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a Voting Share Reduction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a Permitted Bid Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">an Exempt Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">a Pro Rata Acquisition; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">a Convertible Security Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">provided, however, that if a Person becomes
the Beneficial Owner of 20% or more of the outstanding Voting Shares by reason of one or any combination of a Voting Share Reduction,
a Permitted Bid Acquisition, an Exempt Acquisition, a Pro Rata Acquisition or a Convertible Security Acquisition and such Person's Beneficial
Ownership of Voting Shares thereafter increases by more than 1% of the number of Voting Shares outstanding (other than pursuant to one
or any combination of a Voting Share Reduction, a Permitted Bid Acquisition, an Exempt Acquisition, a Pro Rata Acquisition or a Convertible
Security Acquisition), then as of the date such Person becomes the Beneficial Owner of such additional Voting Shares, such Person shall
become an &ldquo;<B>Acquiring Person</B>&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">for a period of 10 days after the Disqualification Date (as defined below), any Person who becomes the
Beneficial Owner of 20% or more of the outstanding Voting Shares as a result of such Person becoming disqualified from relying on Subsection
1.1(f)(v)&nbsp;solely because such Person or the Beneficial Owner of such Voting Shares is making or has announced an intention to make
a Take-over Bid, either alone or by acting jointly or in concert with any other Person; (For the purposes of this definition, &ldquo;<B>Disqualification
Date</B>&rdquo; means the first date of public announcement that such Person is making or has announced an intention to make a Take-over
Bid alone of jointly or in concert with any other Person);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">an underwriter or member of a banking or selling group that becomes the Beneficial Owner of 20% or more
of the Voting Shares in connection with a distribution of securities of the Company pursuant to a prospectus or by way of a private placement;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">a Person (a &ldquo;<B>Grandfathered Person</B>&rdquo;) who is the Beneficial Owner of 20% or more of the
outstanding Voting Shares of the Company determined as at the Record Time, provided, however, that this exception shall not be, and shall
cease to be, applicable to a Grandfathered Person in the event that such Grandfathered Person shall, after the Record Time, become the
Beneficial Owner of additional Voting Shares of the Company that increases its Beneficial Ownership of Voting Shares by more than 1 %
of the number of Voting Shares outstanding as at the Record Time (other than pursuant to one or any combination of a Voting Share Reduction,
a Permitted Bid Acquisition, an Exempt Acquisition, Convertible Security Acquisition or a Pro Rata Acquisition);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo;, when used to indicate a relationship with a Person means a Person that
directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, such specified
Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Agreement</B>&rdquo; means this shareholder rights plan agreement between the Company and the
Rights Agent, as the same may be amended or supplemented or restated from time to time; &ldquo;hereof, &ldquo;herein&rdquo;, &ldquo;hereto&rdquo;
and similar expressions mean and refer to this Agreement as a whole and not to any particular part of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>annual cash dividend</B>&rdquo; means cash dividends paid in any fiscal year of the Company
to the extent that such cash dividends do not exceed, in the aggregate, the greatest of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">200% of the aggregate amount of cash dividends declared payable by the Company on its Common Shares in
its immediately preceding fiscal year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">300% of the arithmetic mean of the aggregate amounts of the annual cash dividends declared payable by
the Company on its Common Shares in its three immediately preceding fiscal years; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">100% of the aggregate consolidated net income of the Company, before extraordinary items, for its immediately
preceding fiscal year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Associate</B>&rdquo;, when used to indicate a relationship with a specified Person, means:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">a spouse of such specified Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any Person of either the same or the opposite gender with whom that specified Person is living in a conjugal
relationship outside marriage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">a child of that Person; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">a relative of such specified Person or of a Person mentioned in clauses (i)&nbsp;or (ii)&nbsp;of this
definition if that relative has the same residence as the specified Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">A Person shall be deemed the &ldquo;<B>Beneficial Owner</B>&rdquo; of, and to have &ldquo;<B>Beneficial
Ownership</B>&rdquo; of, and to &ldquo;<B>Beneficially Own</B>&rdquo;,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">any securities as to which such Person or any of such Person's Affiliates or Associates is the owner at
law or in equity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any securities as to which such Person or any of such Person's Affiliates or Associates has the right
to become the owner at law or in equity (where such right is exercisable immediately or within a period of 60 days thereafter and whether
or not on condition or the happening of any contingency or the making of any payment or payment of instalments), upon the conversion,
exchange or exercise of any right attaching to Convertible Securities or pursuant to any agreement, arrangement, pledge or understanding,
whether or not in writing, other than:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">customary agreements with and between underwriters and banking group members and/or selling group members
(or any of the foregoing) with respect to a public offering or private placement of securities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(B)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">pledges of securities in the ordinary course
of business), </FONT>or upon the exercise of any conversion right, exchange right, share purchase right (other than the Rights), warrant
or option; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any securities which are Beneficially Owned within the meaning of Subsections (i)&nbsp;or (ii)&nbsp;of
this definition by any other Person with whom such Person or such Person's Affiliates is acting jointly or in concert;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">provided, however, that a Person shall
not be deemed to be the &ldquo;<B>Beneficial Owner</B>&rdquo; of, or to have &ldquo;<B>Beneficial Ownership</B>&rdquo; of, or to &ldquo;<B>Beneficially
Own</B>&rdquo;, any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">where such security has been or has been agreed to be deposited or tendered pursuant to a Permitted Lock-up
Agreement or is otherwise deposited or tendered to any Take-over Bid made by such Person, made by any of such Person's Affiliates or Associates
or made by any other Person acting jointly or in concert with such Person until such deposited or tendered security has been taken up
or paid for, whichever shall first occur;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">where such Person, any of such Person's Affiliates or Associates or any other Person acting jointly or
in concert with such Person holds such security provided that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the ordinary business of any such Person (the &ldquo;<B>Investment Manager</B>&rdquo;) includes the management
of investment funds for others (which others, for greater certainty, may include or be limited to one or more employee benefit plans or
pension plans) or mutual funds and such security is held by the Investment Manager in the ordinary course of such business in the performance
of such Investment Manager's duties for the account of any other Person (a &ldquo;<B>Client</B>&rdquo;) including a non-discretionary
account held on behalf of a Client by a broker or dealer appropriately registered under applicable law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(B)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">such Person (the &ldquo;<B>Trust Company</B>&rdquo;)
is licensed to carry on the business of a trust company under applicable laws and, as such, acts as trustee or administrator or in a similar
capacity in relation to the estates of deceased </FONT>or incompetent Persons (each an &ldquo;<B>Estate Account</B>&rdquo;) or in relation
to other accounts (each an &ldquo;<B>Other Account</B>&rdquo;) and holds such security in the ordinary course of such duties for such
Estate Account or for such Other Accounts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">such Person is established by statute for purposes that include, and the ordinary business or activity
of such Person (the &ldquo;<B>Statutory Body</B>&rdquo;) includes, the management of investment funds for employee benefit plans, pension
plans, insurance plans or various public bodies and the Statutory Body holds such securities for the purpose of its activities as such;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">such Person (the &ldquo;<B>Administrator</B>&rdquo;) is the administrator or trustee of one or more pension
funds or plans (a &ldquo;<B>Plan</B>&rdquo;), or is a Plan, registered under the laws of Canada or any Province thereof or the laws of
the United States of America or any State thereof; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">such Person (the &ldquo;<B>Crown Agent</B>&rdquo;) is a Crown agent or agency;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">provided, in any of the above cases,
that the Investment Manager, the Trust Company, the Statutory Body, the Administrator, the Plan or the Crown Agent, as the case may be,
is not then making a Take-over Bid or has not then announced an intention to make a Take-over Bid alone or acting jointly or in concert
with any other Person, other than an Offer to Acquire Voting Shares or other securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(F)</TD><TD STYLE="text-align: justify">pursuant to a distribution by the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(G)</TD><TD STYLE="text-align: justify">by means of a Permitted Bid; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(H)</TD><TD STYLE="text-align: justify">by means of ordinary market transactions (including prearranged trades entered into in the ordinary course
of business of such Person) executed through the facilities of a stock exchange or organized over-the-counter market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">where such Person is: (A)&nbsp;a Client of the same Investment Manager as another Person on whose account
the Investment Manager holds such security, (B)&nbsp;an Estate Account or an Other Account of the same Trust Company as another Person
on whose account the Trust Company holds such security, or (C)&nbsp;a Plan with the same Administrator as another Plan on whose account
the Administrator holds such security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">where such Person is: (A)&nbsp;a Client of an Investment Manager and such security is owned at law or
in equity by the Investment Manager, (B)&nbsp;an Estate Account or an Other Account of a Trust Company and such security is owned at law
or in equity by the Trust Company, or (C)&nbsp;a Plan and such security is owned at law or in equity by the Administrator of the Plan;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">where such Person is a registered holder of such security solely as a result of carrying on the business
of, or acting as a nominee of, a securities depositary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Board of Directors</B>&rdquo; means the board of directors of the Company or any duly constituted
and empowered committee thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business Day</B>&rdquo; means any day other than a Saturday, Sunday or a day on which banking
institutions in Toronto, Ontario are authorized or obligated by law to close;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Canada Business Corporations Act</I></B>&rdquo; means the <I>Canada Business Corporations
Act</I>, R.S.C., 1985, c. C-44, as amended, and the regulations made thereunder and any comparable or successor laws or regulations thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B>Canadian-U.S. Exchange Rate</B>&rdquo; means, on any date, the inverse of the U.S.-Canadian
Exchange Rate in effect on such date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">&ldquo;<B>Canadian Dollar Equivalent</B>&rdquo; of any amount which is expressed in United States dollars
means, on any date, the Canadian dollar equivalent of the amount determined by multiplying the amount by the U.S.-Canadian Exchange Rate
in effect on such date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B>close of business</B>&rdquo; on any given date means the time on such date (or, if such date
is not a Business Day, the time on the next succeeding Business Day) at which the principal transfer office in Toronto, Ontario of the
transfer agent for the Common Shares (or, after the Separation Time, the principal transfer office in Toronto, Ontario of the Rights Agent)
is closed to the public;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&ldquo;<B>Common Shares</B>&rdquo; means the common shares in the capital of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">&ldquo;<B>Competing Permitted Bid</B>&rdquo; means a Take-over Bid that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">is made after a Permitted Bid or another Competing Permitted Bid has been made and prior to the expiry
of such Permitted Bid or Competing Permitted Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">satisfies all provisions of the definition of a Permitted Bid other than the requirement set out in Subsection
1.1(jj)(ii)(A)&nbsp;of the definition of Permitted Bid; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">contains, and the take-up and payment for securities tendered or deposited is subject to, an irrevocable
and unqualified condition that no Voting Shares will be taken up or paid for pursuant to the Take-over Bid prior to the close of business
on a date that is no earlier than the later of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the earliest date on which Voting Shares may be taken up and paid for under any Permitted Bid or other
Competing Permitted Bid outstanding on the date of commencement of such Competing Permitted Bid; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">35 days after the date of the Take-over Bid constituting such Competing Permitted Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">provided always, for greater certainty,
that a Competing Permitted Bid will cease to be a Competing Permitted Bid at any time when such bid ceases to meet any of the provisions
of this definition and provided that, at such time, any acquisition of Voting Shares made pursuant to such Competing Permitted Bid, including
any acquisitions of Voting Shares theretofore made, will cease to be a Permitted Bid Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">&ldquo;<B>controlled</B>&rdquo;: a Person is &ldquo;<B>controlled</B>&rdquo; by another Person or two
or more other Persons acting jointly or in concert if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in the case of a body corporate, securities entitled to vote in the election of directors of such body
corporate carrying more than 50% of the votes for the election of directors are held, directly or indirectly, by or for the benefit of
the other Person or Persons and the votes carried by such securities are entitled, if exercised, to elect a majority of the board of directors
of such body corporate; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in the case of a Person which is not a body corporate, more than 50% of the voting or equity interests
of such entity are held, directly or indirectly, by or for the benefit of the other Person or Persons,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and &ldquo;<B>controls</B>&rdquo;, &ldquo;<B>controlling</B>&rdquo;
and &ldquo;<B>under common control with</B>&rdquo; shall be interpreted accordingly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">&ldquo;<B>Convertible Securities</B>&rdquo; shall mean, at any time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">any right (contractual or otherwise, regardless of whether it would be considered a security); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any securities issued by the Company (including rights, warrants and options but not including the Rights)
carrying any purchase, exercise, conversion or exchange right,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">pursuant to which the holder thereof
may acquire Voting Shares or other securities convertible into or exercisable or exchangeable for Voting Shares (in each case, whether
such right is exercisable immediately or after a specified period and whether or not on condition or the happening of any contingency);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">&ldquo;<B>Convertible Security Acquisition</B>&rdquo; means the acquisition of Voting Shares from the
Company upon the exercise or pursuant to the terms and conditions of any Convertible Securities acquired by a Person pursuant to a Permitted
Bid Acquisition, an Exempt Acquisition or a Pro Rata Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">&ldquo;<B>Co-Rights Agents</B>&rdquo; has the meaning ascribed thereto in Subsection 4.1(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">&ldquo;<B>Disposition Date</B>&rdquo; has the meaning ascribed thereto in Subsection 5.1(h);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">&ldquo;<B>Dividend Reinvestment Acquisition</B>&rdquo; means an acquisition of Voting Shares pursuant
to a Dividend Reinvestment Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">&ldquo;<B>Dividend Reinvestment Plan</B>&rdquo; means a regular dividend reinvestment or other plan of
the Company made available by the Company to holders of its securities or to holders of securities of a Subsidiary where such plan permits
the holder to direct that some or all of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">dividends paid in respect of shares of any class of the Company or a Subsidiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">proceeds of redemption of shares of the Company or a Subsidiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">interest paid on evidences of indebtedness of the Company or a Subsidiary; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">optional cash payments,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">be applied to the purchase from the Company
of Voting Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means the date of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">&ldquo;<B>Election to Exercise</B>&rdquo; has the meaning ascribed thereto in Subsection 2.2(d)(ii);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exempt Acquisition</B>&rdquo; means an acquisition of Voting Shares or Convertible Securities:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">in respect of which the Board of Directors has waived the application of Section&nbsp;3.1 pursuant to
the provisions of Subsection 5.1(a), (h)&nbsp;or (j); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">pursuant to a distribution of Voting Shares or Convertible Securities made by the Company pursuant to
a prospectus or a securities exchange take-over bid, by way of a private placement, provided that such private placement has received
the approval of the Board of Directors and all applicable securities regulatory authorities, or pursuant to an amalgamation, merger, plan
of arrangement or other statutory procedure requiring shareholder approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exercise Price</B>&rdquo; means, as of any date, the price at which a holder may purchase the
securities issuable upon exercise of one whole Right which, until adjustment thereof in accordance with the terms hereof, shall be an
amount equal to three times the Market Price per Common Share determined as at the Separation Time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD STYLE="text-align: justify">&ldquo;<B>Expansion Factor</B>&rdquo; has the meaning ascribed thereto in Subsection 2.3(a)(A)(1);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD STYLE="text-align: justify">&ldquo;<B>Expiration Time</B>&rdquo; shall have the meaning ascribed thereto in subsection 5.15(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Flip-in Event</B>&rdquo; means a transaction in or pursuant to which any Person becomes an Acquiring
Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(cc)</TD><TD STYLE="text-align: justify">&ldquo;<B>holder</B>&rdquo; has the meaning ascribed thereto in Section&nbsp;2.8;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(dd)</TD><TD STYLE="text-align: justify">&ldquo;<B>Independent Shareholders</B>&rdquo; means holders of Voting Shares, other than:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">any Acquiring Person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">any Offeror (other than any Person who, by virtue of Subsection 1.1(f)(v), is not deemed to Beneficially
Own the Voting Shares held by such Person);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any Affiliate or Associate of any Acquiring Person or Offeror;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">any Person acting jointly or in concert with any Acquiring Person or Offeror; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">any employee benefit plan, deferred profit sharing plan, stock participation plan and any other similar
plan or trust for the benefit of employees of the Company or a Subsidiary unless the beneficiaries of the plan or trust direct the manner
in which the Voting Shares are to be voted or withheld from voting or direct whether the Voting Shares are to be tendered to a Take-over
Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ee)</TD><TD STYLE="text-align: justify">&ldquo;<B>Market Price</B>&rdquo; per share of any securities on any date of determination means the average
of the daily closing prices per share of such securities (determined as described below) on each of the 20 consecutive Trading Days through
and including the Trading Day immediately preceding such date; provided, however, that if an event of a type analogous to any of the events
described in Section&nbsp;2.3 hereof shall have caused the closing prices used to determine the Market Price on any Trading Days not to
be fully comparable with the closing price on such date of determination (or, if the date of determination is not a Trading Day, on the
immediately preceding Trading Day), each closing price so used shall be appropriately adjusted in a manner analogous to the applicable
adjustment provided for in Section&nbsp;2.3 hereof in order to make it fully comparable with the closing price on such date of determination
or if the date of determination is not a Trading Day, on the immediately preceding Trading Day. The closing price per share of any securities
on any date shall be:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the closing board lot sale price or, in case no such sale takes place on such date, the average of the
closing bid and asked prices for each of such securities as reported by the principal Canadian stock exchange on which such securities
listed and admitted to trading;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if for any reason none of such prices is available on such day or the securities are not listed or posted
for trading on a Canadian stock exchange, the last sale price or, in case no such sale takes place on such date, the average of the closing
bid and asked prices for each of such securities as reported by the principal national United States securities exchange on which such
securities are listed or admitted to trading;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if for any reason none of such prices is available on such day or the securities are not listed or admitted
to trading on a Canadian stock exchange, national United States stock exchange or any other stock exchange, the last sale price or, in
case no sale takes place on such date, the average of the high bid and low asked prices for each of the securities in the over-the-counter
market, as quoted by any recognized reporting system then in use (as determined by the Board of Directors); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">if for any reason none of such prices is available on such day or the securities are not listed or admitted
to trading on a Canadian stock exchange, a national United States securities exchange or any other stock exchange or quoted by any reporting
system, the average of the closing bid and asked prices as furnished by a professional market maker making a market in the securities
selected in good faith by the Board of Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">provided,
however, that if for any reason none of such prices is available on such day, the closing price per share of the securities on such date
means the fair value per share of the securities on such date as determined by a nationally recognized investment dealer or investment
banker selected by the Board of Directors. The Market Price shall be expressed in Canadian dollars. Provided further that if an event
of a type analogous to any of the events described in Section&nbsp;2.3 hereof shall have caused any price used to determine the Market
Price on any Trading Day not to be fully comparable with the price as so determined on the Trading Day immediately preceding such date
of determination, each such price so used shall be appropriately adjusted in a manner analogous to the applicable adjustment provided
for in Section&nbsp;2.3 hereof in order to make it fully </FONT>comparable with the price on the Trading Day immediately preceding such
date of determination. If any relevant amount used in calculating the Market Price happens to be in United States dollars, such amount
shall be translated into Canadian dollars on that date at the Canadian Dollar Equivalent thereof,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ff)</TD><TD STYLE="text-align: justify">&ldquo;<B>Nominee</B>&rdquo; has the meaning ascribed thereto in Subsection 2.2(c);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(gg)</TD><TD STYLE="text-align: justify">&ldquo;Offer to Acquire&rdquo; includes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an offer to purchase or a solicitation of an offer to sell Voting Shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">an acceptance of an offer to sell Voting Shares, whether or not such offer to sell has been solicited;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">or any combination thereof, and the Person
accepting an offer to sell shall be deemed to be making an Offer to Acquire to the Person that made the offer to sell;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(hh)</TD><TD STYLE="text-align: justify">&ldquo;<B>Offeror</B>&rdquo; means a Person who has announced, and has not withdrawn, an intention to
make or who has made, and has not withdrawn, a Take-over Bid, other than a Person who has completed a Permitted Bid, a Competing Permitted
Bid or an Exempt Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Offeror's Securities</B>&rdquo; means Voting Shares Beneficially Owned by an Offeror on the
date of the Offer to Acquire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(jj)</TD><TD STYLE="text-align: justify">&ldquo;<B>Permitted Bid</B>&rdquo; means a Take-over Bid made by a Person by way of take-over bid circular
which also complies with the following additional provisions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Take-over Bid is made to all holders of Voting Shares as registered on the books of the Company, other
than the Person making the Take-over Bid (the &ldquo;<B>Permitted Bid Offeror</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Take-over Bid contains, and the take-up and payment for securities tendered or deposited is subject
to, an irrevocable and unqualified provision that no Voting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Shares will be taken up or paid for pursuant
to the Take-over Bid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">prior to the close of business on the date which is not less than 120 days following the date the take-over
bid circular is sent to holders of Voting Shares; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">unless at such date more than 50% of the then outstanding Voting Shares held by Independent Shareholders
shall have been deposited or tendered pursuant to the Take-over Bid and not withdrawn;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">unless the Take-over Bid is withdrawn, the Take-over Bid contains an irrevocable and unqualified provision
that Voting Shares may be deposited pursuant to such Take-over Bid at any time during the period of time described in Subsection 1.1(jj)(ii)(A)&nbsp;and
that any Voting Shares deposited pursuant to the Take-over Bid may be withdrawn until taken up and paid for; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">unless the Take-over Bid is withdrawn, the Take-over
Bid contains an irrevocable and unqualified provision that in the event that the deposit condition set forth in Subsection 1.1(jj)(ii)(B)&nbsp;is
satisfied the Permitted Bid Offeror will make a public announcement of that fact and the Take-over Bid will remain open for deposits and
tenders of Voting Shares for not less than ten Business Days from the date of such public announcement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided always that a Permitted Bid will cease
to be a Permitted Bid at any time when such bid ceases to meet any of the provisions of this definition and provided that, at such time,
any acquisition of Voting Shares made pursuant to such Permitted Bid, including any acquisitions of Voting Shares theretofore made, will
cease to be a Permitted Bid Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(kk)</TD><TD STYLE="text-align: justify">&ldquo;<B>Permitted Bid Acquisition</B>&rdquo; means an acquisition of Voting Shares made pursuant to
a Permitted Bid or a Competing Permitted Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ll)</TD><TD STYLE="text-align: justify">&ldquo;<B>Permitted Lock-up Agreement</B>&rdquo; means an agreement between an Offeror, any of its Affiliates
or Associates or any other Person acting jointly or in concert with the Offeror and a Person (the &ldquo;<B>Locked-up Person</B>&rdquo;)
who is not an Affiliate or Associate of the Offeror or a Person acting jointly or in concert with the Offeror (the terms of which agreement
are publicly disclosed and a copy of which is made available to the public (including the Company) not later than the date the Lock-up
Bid (as defined below) is publicly announced or if the Lock-up Bid has been made prior to the date on which such agreement is entered
into, forthwith, and in any event not later than the date following the date of such agreement) whereby the Locked-up Person agrees to
deposit or tender the Voting Shares held by the Locked-up Person to the Offeror's Take-over Bid or to any Take-over Bid made by any of
the Offerer's Affiliates or Associates or made by any other Person acting jointly or in concert with the Offeror (the &ldquo;<B>Lock-up
Bid</B>&rdquo;) provided such agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">permits the Locked-up Person to withdraw the Voting Shares from the agreement in order to tender or deposit
the Voting Shares to another Take-over Bid or to support another transaction (whether by way of merger, amalgamation, arrangement, reorganization
or other transaction) (the &ldquo;<B>Superior Offer Consideration</B>&rdquo;) that in either case will provide a greater cash equivalent
value per Voting Share to the holders of Voting Shares than the Locked-up Person otherwise would have received to pay under the Lock-up
Bid (the &ldquo;<B>Lock-up Bid Consideration</B>&rdquo;). Notwithstanding the above, the Lock-Up Agreement may require that the Superior
Offer Consideration must exceed the Lock-up Bid Consideration by a specified percentage before such withdrawal right takes effect, provided
such specified percentage is not greater than seven percent (7%);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(and, for greater clarity, such agreement
may contain a right of first refusal or require a period of delay to give an Offeror an opportunity to match a higher price in another
Takeover Bid or transaction and may provide for any other similar limitation on a Locked-up Person's right to withdraw Voting Shares from
the agreement, as long as the limitation does not preclude the exercise by the Locked-up Person of the right to withdraw Voting Shares
during the period of the other Take-over Bid or other transaction); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">does not provide for any &ldquo;break-up&rdquo; fees, &ldquo;top-up&rdquo; fees, penalties, expenses,
or other amounts that exceed in the aggregate the greater of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the cash equivalent of 2.5% of the price or value payable under the Lockup Bid to a Locked-Up Person;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">50% of the amount by which the price or value payable under another Take-over Bid or transaction exceeds
the price or value of the consideration that such Locked-up Person would have received under the Lock-up Bid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">being payable or forfeited by a Locked-up
Person pursuant to the agreement in the event a Locked-up Person fails to deposit or tender Voting Shares to the Lock-up Bid, withdraws
Voting Shares previously tendered thereto to another Take-over Bid or supports another transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(mm)</TD><TD STYLE="text-align: justify">&ldquo;<B>Person</B>&rdquo; includes any individual, firm, partnership, association, trust, trustee, executor,
administrator, legal personal representative, body corporate, joint venture, corporation, unincorporated organization, syndicate, governmental
entity or other entity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(nn)</TD><TD STYLE="text-align: justify">&ldquo;<B>Pro Rata Acquisition</B>&rdquo; means an acquisition by a Person of Voting Shares or Convertible
Securities pursuant to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">a Dividend Reinvestment Acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a stock dividend, stock split or other event in respect of securities of the Company of one or more particular
classes or series pursuant to which such Person becomes the Beneficial Owner of Voting Shares on the same pro rata basis as all other
holders of securities of the particular class, classes or series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the acquisition or the exercise by the Person of only those rights to purchase Voting Shares distributed
by the Company to that Person in the course of a distribution to all holders of securities of the Company of one or more particular classes
or series pursuant to a rights offering or pursuant to a prospectus, provided that the Person does not thereby acquire a greater percentage
of such Voting Shares, or securities convertible into or exchangeable for Voting Shares, so offered than the Person's percentage of Voting
Shares Beneficially Owned immediately prior to such acquisition and that such rights are acquired directly from the Company and not from
any other Person; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">a distribution of Voting Shares, or securities convertible into or exchangeable for Voting Shares (and
the conversion or exchange of such convertible or exchangeable securities), by the Company, provided that the Person does not thereby
acquire a greater percentage of such Voting Shares, or securities convertible into or exchangeable for Voting Shares, so offered in the
distribution than the Person's percentage of Voting Shares Beneficially Owned immediately prior to such acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(oo)</TD><TD STYLE="text-align: justify">&ldquo;<B>Record Time</B>&rdquo; means close of business (Toronto Time) on the date of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(pp)</TD><TD STYLE="text-align: justify">&ldquo;<B>Redemption Price</B>&rdquo; has the meaning ascribed thereto under Subsection 5.1(b)&nbsp;of
this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(qq)</TD><TD STYLE="text-align: justify">&ldquo;<B>Right</B>&rdquo; means a right to purchase a Common Share upon the terms and subject to the
conditions set forth in this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(rr)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Certificate</B>&rdquo; means the certificates representing the Rights after the Separation
Time, which shall be substantially in the form attached hereto as Attachment 1 or such other form as the Company and the Rights Agent
may agree;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ss)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Holders' Special Meeting</B>&rdquo; means a meeting of the holder of Rights called by
the Board of Directors for the purpose of approving a supplement or amendment to this Agreement pursuant to Subsection 5.4(c);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(tt)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Register</B>&rdquo; has the meaning ascribed thereto in Subsection 2.6(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(uu)</TD><TD STYLE="text-align: justify">&ldquo;<B>Rights Registrar</B>&rdquo; has the meaning ascribed thereto in Subsection 2.6(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Securities Act </I>(British Columbia)</B>&rdquo; means the <I>Securities Act</I>, R.S.B.C.
1996 c.418, as amended, and the regulations and rules&nbsp;thereunder, and any comparable or successor laws or regulations and rules&nbsp;thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(vv)</TD><TD STYLE="text-align: justify">&ldquo;<B>Separation Time</B>&rdquo; means the close of business on the 10<SUP>th</SUP> Trading Day after
the earlier of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Stock Acquisition Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the date of the commencement of or first public announcement of the intent of any Person (other than the
Company or any Subsidiary of the Company) to commence a Take-over Bid (other than a Permitted Bid or a Competing Permitted Bid); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the date on which a Permitted Bid or Competing Permitted Bid ceases to be such;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">or such later time as may be determined
by the Board of Directors, and provided that, if any Take-over Bid referred to in Subsection (ii)&nbsp;or Permitted Bid or Competing Permitted
Bid referred to in Subsection (iii)&nbsp;is not made, expires, is cancelled, terminated or otherwise withdrawn prior to the Separation
Time, such Take-over Bid, Permitted Bid or Competing Permitted Bid, as applicable, shall be deemed, for the purposes of this definition,
never to have been made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ww)</TD><TD STYLE="text-align: justify">&ldquo;<B>Special Meeting</B>&rdquo; means a special meeting of the holder of Voting Shares, called by
the Board of Directors for the purpose of approving a supplement or amendment to this Agreement pursuant to Subsection 5.4(b);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(xx)</TD><TD STYLE="text-align: justify">&ldquo;<B>Stock Acquisition Date</B>&rdquo; means the first date of public announcement (which, for purposes
of this definition, shall include, without limitation, a report filed pursuant to section 5.2 of Multilateral Instrument 62-104 or section
102.1 of the <I>Securities Act </I>(Ontario), as any of the aforementioned legislation may be amended or substituted from time to time)
by the Company or an Acquiring Person indicating that an Acquiring Person has become such;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(yy)</TD><TD STYLE="text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo;: a corporation is a Subsidiary of another corporation if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">it is controlled by:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">that other;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">that other and one or more corporations, each of which is controlled by that other; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">two or more corporations, each of which is controlled by that other; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">it is a Subsidiary of a corporation that is that other's Subsidiary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(zz)</TD><TD STYLE="text-align: justify">&ldquo;<B>Take-over Bid</B>&rdquo; means an Offer to Acquire Voting Shares, or Convertible Securities
if, assuming that the Voting Shares or Convertible Securities subject to the Offer to Acquire are acquired and are Beneficially Owned
at the date of such Offer to Acquire by the Person making such Offer to Acquire, such Voting Shares (including Voting Shares that may
be acquired upon the conversion, exchange or exercise of the rights under such Convertible Securities into Voting Shares) together with
the Offerer's Securities, constitute in the aggregate 20% or more of the outstanding Voting Shares at the date of the Offer to Acquire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aaa)</TD><TD STYLE="text-align: justify">&ldquo;<B>Termination Time</B>&rdquo; means the time at which the right to exercise Rights shall terminate
pursuant to Subsection 5.1(e);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bbb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Trading Day</B>&rdquo;, when used with respect to any securities, means a day on which the principal
stock exchange in Canada on which such securities are listed or admitted to trading is open for the transaction of business or, if the
securities are not listed or admitted to trading on any Canadian stock exchange, a Business Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ccc)</TD><TD STYLE="text-align: justify">&ldquo;U.S.-Canadian Exchange Rate&rdquo; means, on any date:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if on such date the Bank of Canada sets an average noon spot rate of exchange for the conversion of one
United States dollar into Canadian dollars, such rate; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in any other case, the rate for such date for the conversion of one United States dollar into Canadian
dollars calculated in such manner as may be determined by the Board of Directors from time to time acting in good faith;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ddd)</TD><TD STYLE="text-align: justify">&ldquo;<B>Voting Share Reduction</B>&rdquo; means an acquisition or redemption by the Company of Voting
Shares which, by reducing the number of Voting Shares outstanding, increases the proportionate number of Voting Shares Beneficially Owned
by any Person to 20% or more of the Voting Shares then outstanding; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(eee)</TD><TD STYLE="text-align: justify">&ldquo;<B>Voting Shares</B>&rdquo; means the Common Shares and any other shares in the capital of the
Company entitled to vote generally in the election of all directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.2.</B></TD><TD STYLE="text-align: justify"><B><U>Currency</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All sums of money which are
referred to in this Agreement are expressed in lawful money of Canada, unless otherwise specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.3.</B></TD><TD STYLE="text-align: justify"><B><U>Headings and Interpretation</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The division of this Agreement
into Articles, Sections, Subsections, Clauses, Paragraphs, Subparagraphs or other portions hereof and the insertion of headings, subheadings
and a table of contents are for convenience of reference only and shall not affect the construction or interpretation of this Agreement.
In this Agreement, where the context so admits, words importing the singular include the plural and vice versa and words importing gender
includes the masculine, feminine and neuter genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.4.</B></TD><TD STYLE="text-align: justify"><B><U>Calculation of Number and Percentage of Beneficial Ownership of Outstanding Voting Shares</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Agreement,
the percentage of Voting Shares Beneficially Owned by any Person, shall be and be deemed to be the product (expressed as a percentage)
determined by the formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">x</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A</TD><TD STYLE="text-align: justify">=&#8239;&#8239;&#8239;&#8239;&#8239;the number of votes for the election of all directors generally attaching to the Voting Shares Beneficially
Owned by such Person; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B</TD><TD STYLE="text-align: justify">=&#8239;&#8239;&#8239;&#8239;&#8239;the number of votes for the election of all directors generally attaching to all outstanding Voting
Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where any Person is deemed to Beneficially Own
unissued Voting Shares, such Voting Shares shall be deemed to be outstanding for the purpose of calculating the percentage of Voting Shares
Beneficially Owned by such Person, but no other unissued Voting Shares shall, for the purposes of such calculation, be deemed to be outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.5.</B></TD><TD STYLE="text-align: justify"><B><U>Acting Jointly or in Concert</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purposes of this Agreement,
a Person is acting jointly or in concert with every Person who is a party to any agreement, commitment or understanding (whether formal
or informal and whether or not in writing) with the first Person (the &ldquo;<B>First Person</B>&rdquo;) or any Associate or Affiliate
thereof or any other Person acting jointly or in concert with the First Person, to acquire or offer to acquire Voting Shares (other than
customary agreements: (i)&nbsp;with and between underwriters or banking group members or selling group members with respect to a public
offering or private placement of securities or pledges of securities in the ordinary course of business, and (ii)&nbsp;among shareholders
of the Company for legitimate corporate governance activities).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.6.</B></TD><TD STYLE="text-align: justify"><B><U>Generally Accepted Accounting Principles</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Wherever
in this Agreement reference is made to generally accepted accounting principles, such reference shall be deemed to be the recommendations
at the relevant time of the Canadian Institute of Chartered Accountants, or any successor institute, applicable on a consolidated basis
(unless otherwise specifically provided herein to be applicable on an unconsolidated basis) as at the date on which a calculation is made
or required to be made in accordance with Canadian generally accepted accounting principles. Where the character or amount of any asset
or liability or item of revenue or expense is required to be determined, or any consolidation or other accounting computation is required
to be made </FONT>for the purpose of this Agreement or any document, such determination or calculation shall, to the extent applicable
and except as otherwise specified herein or as otherwise agreed in writing by the parties, be made in accordance with generally accepted
accounting principles applied on a consistent basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;2
</B></FONT><B>- THE RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.1.</B></TD><TD STYLE="text-align: justify"><B><U>Issue of Rights: Legend on Common Share Certificates</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">One Right shall be issued on the Effective Date in respect of each Common Share outstanding at the Record
Time and one Right shall be issued in respect of each Common Share issued after the Record Time and prior to the earlier of the Separation
Time and the Expiration Time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Certificates representing Common Shares which are issued prior to the earlier of the Separation Time and
the Expiration Time shall evidence one Right for each Common Share represented thereby. Certificates representing Common Shares that are
issued after the Record Time but prior to the earlier of the Separation Time and the Expiration Time shall have impressed on, printed
on, written on or otherwise affixed to them a legend substantially in the following form:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;Until the Separation Time (defined
in the Agreement below), this certificate also evidences the holder's rights described in a Shareholder Rights Plan Agreement dated as
of January&nbsp;22, 2016, and amended and extended as of May&nbsp;15, 2019 (the &ldquo;Agreement&rdquo;) between ProMIS Neurosciences
Inc. (the &ldquo;Company&rdquo;) and Computershare Trust Company of Canada, as the same may from time to time be amended, the terms of
which are incorporated herein by reference and a copy of which is on file at the principal office of the Company. Under certain circumstances
set out in the Agreement, the Rights may be amended or redeemed, may expire, may become void (if, in certain circumstances, they are &ldquo;Beneficially
Owned&rdquo; by an &ldquo;Acquiring Person&rdquo;, as such terms are defined in the Agreement, or a transferee thereof) or may be evidenced
by separate certificates and no longer evidenced by this certificate. The Company will mail or arrange for the mailing of a copy of the
Agreement to the holder of this certificate without charge as soon as practicable after the receipt of a written request therefor.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Certificates representing Common Shares
that are issued and outstanding at the Record Time shall evidence one Right for each Common Share evidenced thereby, notwithstanding the
absence of a legend in accordance with this Subsection 2.1(b), until the earlier of the Separation Time and the Expiration Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Registered holders of Common Shares who
have not received a share certificate and are entitled to do so on the earlier of the Separation Time and Expiration Time shall be entitled
to Rights as if such certificates had been issued and such Rights shall for all purposes hereof be evidenced by the corresponding entries
on the Company's securities register for Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.2.</B></TD><TD STYLE="text-align: justify"><B><U>Initial Exercise Price; Exercise of Rights; Detachment of Rights</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to Subsection 3.1(a)&nbsp;and adjustment
as herein set forth, each Right will entitle the holder thereof, from and after the Separation Time and prior to the Expiration Time,
to </FONT>purchase one Common Share for the Exercise Price (and the Exercise Price and number of Common Shares are subject to adjustment
as set forth below). Notwithstanding any other provision of this Agreement, any Rights held by the Company or any of its Subsidiaries
shall be void.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Until the Separation Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Rights shall not be exercisable and no Right may be exercised; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">for administration purposes, each Right will be evidenced by the certificate for the associated Common
Share registered in the name of the holder thereof (which certificate shall also be deemed to represent a Rights Certificate) and Will
be transferable only together with, and will be transferred by a transfer of, such associated Common Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">From and after the Separation Time and prior to the Expiration Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Rights shall be exercisable; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the registration and transfer of Rights shall be separate from and independent of Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Promptly following the Separation Time,
the Company will prepare and the Rights Agent will mail to each holder of record of Common Shares as of the Separation Time (other than
an Acquiring Person and, in respect of any Rights Beneficially Owned by such Acquiring Person which are not held of record by such Acquiring
Person, the holder of record of such Rights (a &ldquo;<B>Nominee</B>&rdquo;)), at such holder's address as shown by the records of the
Company (the Company hereby agreeing to furnish copies of such records to the Rights Agent for this purpose):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">a Rights Certificate appropriately completed, representing the number of Rights held by such holder at
the Separation Time and having such marks of identification or designation and such legends, summaries or endorsements printed thereon
as the Company may deem appropriate and as are not inconsistent with the provisions of this Agreement, or as may be required to comply
with any law, rule&nbsp;or regulation or with any rule&nbsp;or regulation of any self-regulatory organization, stock exchange or quotation
system on which the Rights may from time to time be listed or traded, or to conform to standard usage; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">a disclosure statement prepared by the Company describing the Rights, provided that a Nominee shall be
sent the materials provided for in clauses (A)&nbsp;and (B)&nbsp;in respect of all Common Shares held of record by it which are not Beneficially
Owned by an Acquiring Person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Rights may be exercised, in whole or in part, on any Business Day after the Separation Time and prior
to the Expiration Time by submitting to the Rights Agent:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Rights Certificate evidencing such Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">an election to exercise such Rights (an &ldquo;<B>Election to Exercise</B>&rdquo;) substantially in the
form attached to the Rights Certificate appropriately completed and duly executed by the holder or his executors or administrators or
other personal representatives or his or their legal attorney duly appointed by an instrument in writing in form and executed in a manner
satisfactory to the Rights Agent; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">payment by certified cheque, banker's draft or money order payable to the order of the Company, of a sum
equal to the Exercise Price multiplied by the number of Rights being exercised and a sum sufficient to cover any transfer tax or charge
which may be payable in respect of any transfer involved in the transfer or delivery of Rights Certificates or the issuance or delivery
of certificates for Common Shares in a name other than that of the holder of the Rights being exercised.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Upon receipt of a Rights Certificate, together with a completed Election to Exercise executed in accordance
with Subsection 2.2(d)(ii), which does not indicate that such Right is null and void as provided by Subsection 3.1(b), and payment as
set forth in Subsection 2.2(d)(iii), the Rights Agent (unless otherwise instructed by the Company in the event that the Company is of
the opinion that the Rights cannot be exercised in accordance with this Agreement) will thereupon promptly:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">requisition from the Company's transfer agent certificates representing the number of such Common Shares
to be purchased (the Company hereby irrevocably authorizing its transfer agent to comply with all such requisitions);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">when appropriate, requisition from the Company the amount of cash to be paid in lieu of issuing fractional
Common Shares in accordance with Subsection 5.5(b);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">after receipt of the certificates referred to in Clause 2.2(e)(i), deliver the same to or upon the order
of the registered holder of such Rights Certificates, registered in such name or names as may be designated by such holder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">when appropriate, after receipt, deliver the cash referred to in Subsection 2.2(e)(ii)&nbsp;to or to the
order of the registered holder of such Rights Certificate; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">tender to the Company all payments received on exercise of Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">In case the holder of any Rights shall exercise less than all the Rights evidenced by such holder's Rights
Certificate, a new Rights Certificate evidencing the Rights remaining unexercised (subject to the provisions of Subsection 5.5(a)) will
be issued by the Rights Agent to such holder or to such holder's duly authorized assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">The Company covenants and agrees that it will:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">take all such action as may be necessary and within its power to ensure that all Common Shares delivered
upon exercise of Rights shall, at the time of delivery of the certificates for such Common Shares (subject to payment of the Exercise
Price), be duly and validly authorized, executed, issued and delivered as fully paid and non-assessable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">use reasonable efforts to cause all Common Shares issued upon exercise of Rights to be listed on the principal
stock exchanges on which such Common Shares were traded immediately prior to the Stock Acquisition Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">cause to be reserved and kept available out of the authorized and unissued Common Shares, the number of
Common Shares that, as provided in this Agreement, will from time to time be sufficient to permit the exercise in full of all outstanding
Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">pay when due and payable, if applicable, any and all federal, provincial and municipal transfer taxes
and charges (not including any income or capital taxes of the holder or exercising holder or any liability of the Company to withhold
tax) which may be payable in respect of the original issuance or delivery of the Rights Certificates, or certificates for Common Shares
to be issued upon exercise of any Rights, provided that the Company shall not be required to pay any transfer tax or charge which may
be payable in respect of any transfer involved in the transfer or delivery of Rights Certificates or the issuance or delivery of certificates
for Common Shares in a name other than that of the holder of the Rights being transferred or exercised; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">after the Separation Time, except as permitted by Section&nbsp;5.1, not take (or permit any Subsidiary
to take) any action if at the time such action is taken it is reasonably foreseeable that such action will diminish substantially or otherwise
eliminate the benefits intended to be afforded by the Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.3.</B></TD><TD STYLE="text-align: justify"><B><U>Adjustments to Exercise Price; Number of Rights</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Exercise Price, the number
and kind of securities subject to purchase upon exercise of each Right and the number of Rights outstanding are subject to adjustment
from time to time as provided in this Section&nbsp;2.3 or Article&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">In the event the Company shall at any time after the date of this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">declare or pay a dividend on Common Shares payable in Common Shares (or other securities exchangeable
for or convertible into or giving a right to acquire Common Shares or other securities of the Company) other than pursuant to any optional
stock dividend program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">subdivide or change the then outstanding Common Shares into a greater number of Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">consolidate or change the then outstanding Common Shares into a smaller number of Common Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">issue any Common Shares (or other securities
exchangeable for or convertible into or giving a right to acquire Common Shares or other securities of the Company) in respect of, in
lieu of or in exchange for existing Common Shares except as otherwise provided in this Section&nbsp;2.3, </FONT>the Exercise Price and
the number of Rights outstanding, or, if the payment or effective date therefor shall occur after the Separation Time, the securities
purchasable upon exercise of Rights shall be adjusted as of the payment or effective date in the manner set forth below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">If the Exercise Price and number of Rights outstanding are to be adjusted:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">the Exercise Price in effect after such adjustment will be equal to the Exercise Price in effect immediately
prior to such adjustment divided by the number of Common Shares (or other capital stock) that a holder of one Common Share immediately
prior to such dividend, subdivision, change, consolidation or issuance would hold immediately thereafter as a result thereof (for the
purpose of this Agreement, &ldquo;<B>Expansion Factor</B>&rdquo; shall mean the number of Common Shares (or other capital stock) that
a holder of one Common Share immediately prior to such dividend, subdivision, change, consolidation or issuance would hold immediately
thereafter as a result thereof divided by one Common Share); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">each Right held prior to such adjustment will become that number of Rights equal to the Expansion Factor,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and the adjusted number of Rights will be deemed
to be distributed among the Common Shares with respect to which the original Rights were associated (if they remain outstanding) and the
shares issued in respect of such dividend, subdivision, change, consolidation or issuance, so that each such Common Share (or other capital
stock) will have exactly one Right associated with it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For greater certainty, if the securities purchasable
upon exercise of Rights are to be adjusted, the securities purchasable upon exercise of each Right immediately after such adjustment will
be the securities that a holder of the securities purchasable upon exercise of one Right immediately prior to such dividend, subdivision,
change, consolidation or issuance would hold immediately thereafter, including as a result of such dividend, subdivision, change, consolidation
or issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, after the Record Time and prior to the Expiration
Time, the Company shall issue any shares of capital stock other than Common Shares in a transaction of a type described in Subsections
2.3(a)(i)&nbsp;or (iv), shares of such capital stock shall be treated herein as nearly equivalent to Common Shares as may be practicable
and appropriate under the circumstances and the Company and the Rights Agent agree to amend this Agreement in order to effect such treatment.
If an event occurs which would require an adjustment under both this Section&nbsp;2.3 and Subsection 3.1(a)&nbsp;hereof, the adjustment
provided for in this Section&nbsp;2.3 shall be in addition to and shall be made prior to any adjustment required pursuant to Subsection
3.1(a)&nbsp;hereof. Adjustments pursuant to this Subsection 2.3(a)&nbsp;shall be made successively, whenever an event referred to in this
Subsection 2.3(a)&nbsp;occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the Company shall at any time after
the Record Time and prior to the Separation Time issue any Common Shares otherwise than in a transaction referred to in this Subsection
2.3(a), each such Common Share so issued shall automatically have one new Right associated with it, which Right shall be evidenced by
the certificate representing such associated Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In the event the Company shall at any time after the Record Time and prior to the Separation Time fix
a record date for the issuance of rights, options or warrants to all holders of Common Shares entitling them (for a period expiring within
45 calendar days after such record date) to subscribe for or purchase Common Shares (or securities convertible into or exchangeable for
or carrying a right to purchase Common Shares) at a price per Common Share (or, if a security convertible into or exchangeable for or
carrying a right to purchase or subscribe for Common Shares, having a conversion, exchange or exercise price, including the price required
to be paid to purchase such convertible or exchangeable security or right per share) less than 90% of the Market Price per Common Share
on such record date, the Exercise Price to be in effect after such record date shall be determined by multiplying the Exercise Price in
effect immediately prior to such record date by a fraction:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the numerator of which shall be the number of Common Shares outstanding on such record date, plus the
number of Common Shares that the aggregate offering price of the total number of Common Shares so to be offered (and/or the aggregate
initial conversion, exchange or exercise price of the convertible or exchangeable securities or rights so to be offered, including the
price required to be paid to purchase such convertible or exchangeable securities or rights) would purchase at such Market Price per Common
Share; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the denominator of which shall be the number of Common Shares outstanding on such record date, plus the
number of additional Common Shares to be offered for subscription or purchase (or into which the convertible or exchangeable securities
or rights so to be offered are initially convertible, exchangeable or exercisable).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In case such subscription price may
be paid by delivery of consideration, part or all of which may be in a form other than cash, the value of such consideration shall be
as determined in good faith by the Board of Directors, whose determination shall be described in a statement filed with the Rights Agent
and shall be binding on the Rights Agent and the holders of Rights. Such adjustment shall be made successively whenever such a record
date is fixed, and in the event that such rights, options or warrants are not so issued, or if issued, are not exercised prior to the
expiration thereof, the Exercise Price shall be readjusted to the Exercise Price which would then be in effect if such record date had
not been fixed, or to the Exercise Price which would be in effect based upon the number of Common Shares (or securities convertible into,
or exchangeable or exercisable for Common Shares) actually issued upon the exercise of such rights, options or warrants, as the case may
be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">For purposes of this Agreement, the
granting of the right to purchase Common Shares (whether from treasury or otherwise) pursuant to any Dividend Reinvestment Plan or any
employee benefit, stock option or similar plans shall be deemed not to constitute an issue of rights, options or warrants by the Company;
provided, however, that, in all such cases, the right to purchase Common Shares is at a price per share of not less than 90% of the current
Market Price per share (determined as provided in such plans) of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">In the event the Company shall at any time after the Record Time and prior to the Separation Time fix
a record date for the making of a distribution to all holders of Common Shares (including any such distribution made in connection with
a merger or amalgamation or statutory arrangement) of evidences of indebtedness, cash (other than an annual, quarterly monthly or routine
cash dividend or a dividend referred to in Subsection 2.3(a)(i),but including any dividend payable in other securities of the Company
other than Common Shares), assets or rights, options or warrants (excluding those referred to in Subsection 2.3(b)), the Exercise Price
to be in effect after such record date shall be determined by multiplying the Exercise Price in effect immediately prior to such record
date by a fraction:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the numerator of which shall be the Market Price per Common Share on such record date, less the fair market
value (as determined in good faith by the Board of Directors, whose determination shall be described in a statement filed with the Rights
Agent and shall be binding on the Rights Agent and the holders of Rights), on a per share basis, of the portion of the cash, assets, evidences
of indebtedness, rights, options or warrants so to be distributed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the denominator of which shall be such Market Price per Common Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Such adjustments shall be made successively
whenever such a record date is fixed, and in the event that such a distribution is not so made, the Exercise Price shall be adjusted to
be the Exercise Price which would have been in effect if such record date had not been fixed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Notwithstanding anything herein to the contrary, no adjustment in the Exercise Price shall be required
unless such adjustment would require an increase or decrease of at least one per cent in the Exercise Price; provided, however, that any
adjustments which by reason of this Subsection 2.3(d)&nbsp;are not required to be made shall be carried forward and taken into account
in any subsequent adjustment. All calculations under Section&nbsp;2.3 shall be made to the nearest cent or to the nearest ten-thousandth
of a share. Notwithstanding the first sentence of this Subsection 2.3(d), any adjustment required by Section&nbsp;2.3 shall be made no
later than the earlier of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">three years from the date of the transaction which gives rise to such adjustment; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Expiration Time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">In the event the Company shall at any time after the Record Time and prior to the Separation Time issue
any shares of capital stock (other than Common Shares), of rights, options or warrants to subscribe for or purchase any such capital stock,
in a transaction referred to in Subsections 2.3(a)(i)&nbsp;or (iv)&nbsp;above, if the Board of Directors acting in good faith determines
that the adjustments contemplated by Subsections 2.3(a), (b)&nbsp;and (c)&nbsp;above in connection with such transaction will not appropriately
protect the interests of the holders of Rights, the Board of Directors may determine what other adjustments to the Exercise Price, number
of Rights and/or securities purchasable upon exercise of Rights would be appropriate and, notwithstanding Subsections 2.3(a), (b)&nbsp;and
(c)&nbsp;above, such adjustments rather than the adjustments contemplated by Subsections 2.3(a), (b)&nbsp;and (c)&nbsp;above, shall be
made. Subject to the prior consent of the holders of the Voting Shares or Rights obtained as set forth in Subsections 5.4(b)&nbsp;or (c),
the Company and the Rights Agent shall have authority to amend this Agreement as appropriate to provide for such adjustments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Each Right originally issued by the Company subsequent to any adjustment made to the Exercise Price hereunder
shall evidence the right to purchase, at the adjusted Exercise Price, the number of Common Shares purchasable from time to time hereunder
upon exercise of a Right immediately prior to such issue, all subject to further adjustment as provided herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Irrespective of any adjustment or change in the Exercise Price or the number of Common Shares issuable
upon the exercise of the Rights, the Rights Certificates theretofore and thereafter issued may continue to express the Exercise Price
per Common Share and the number of Common Shares which were expressed in the initial Rights Certificates issued hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In any case in which this Section&nbsp;2.3
shall require that an adjustment in the Exercise Price be made effective as of a record date for a specified event, the Company may elect
to defer until the occurrence of such event the issuance to the holder of any Right exercised after such record date the number of Common
Shares and other securities of the Company, if any, issuable upon such exercise over and above the number of Common Shares and other securities
of the Company, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such adjustment; provided, however,
that the Company shall deliver to such holder an appropriate instrument evidencing such holder's right to receive such additional shares
(fractional or otherwise) or other securities upon the occurrence of the event requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Notwithstanding anything contained in this Section&nbsp;2.3 to the contrary, the Company shall be entitled
to make such reductions in the Exercise Price, in addition to those adjustments expressly required by this Section&nbsp;2.3, as and to
the extent that in their good faith judgment the Board of Directors shall determine to be advisable, in order that any:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">consolidation or subdivision of Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">issuance (wholly or in part for cash) of Common Shares or securities that by their terms are convertible
into or exchangeable for Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">stock dividends; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">issuance of rights, options or warrants referred to in this Section&nbsp;2.3, hereafter made by the Company
to holders of its Common Shares, shall not be taxable to such shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Whenever an adjustment to the Exercise Price or a change in the securities purchasable upon exercise of
the Rights is made pursuant to this Section&nbsp;2.3, the Company shall promptly and in any event, where such change or adjustment occurs
prior to the Separation Time, not later than the Separation Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">file with the Rights Agent and with each transfer agent for the Common Shares a certificate specifying
the particulars of such adjustment or change; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">cause notice of the particulars of such adjustment or change to be given to the holders of the Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Failure to file such certificate or to
cause such notice to be given as aforesaid, or any defect therein, shall not affect the validity of such adjustment or change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.4.</B></TD><TD STYLE="text-align: justify"><B><U>Date on Which Exercise Is Effective</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Person in whose name
any certificate for Common Shares or other securities, if applicable, is issued upon the exercise of Rights shall for all purposes be
deemed to have become the holder of record of the Common Shares or other securities, if applicable, represented thereby, and such certificate
shall be dated the date upon which the Rights Certificate evidencing such Rights was duly surrendered in accordance with Subsection 2.2(d)&nbsp;(together
with a duly completed Election to Exercise) and payment of the Exercise Price for such Rights (and any applicable transfer taxes and other
governmental charges payable by the exercising holder hereunder) was made; provided, however, that if the date of such surrender and payment
is a date upon which the Common Share transfer books of the Company are closed, such Person shall be deemed to have become the record
holder of such shares on, and such certificate shall be dated, the next succeeding Business Day on which the Common Share transfer books
of the Company are open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.5.</B></TD><TD STYLE="text-align: justify"><B><U>Execution, Authentication, Delivery and Dating of Rights Certificates</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Rights Certificates shall be executed on behalf of the Company by its Chairman of the Board, Chief
Executive Officer, President, Chief Financial Officer, any Vice-President or its Corporate Secretary. The signature of any of these officers
on the Rights Certificates may be manual or facsimile. Rights Certificates bearing the manual or facsimile signatures of individuals who
were at any time the proper officers of the Company shall bind the Company, notwithstanding that such individuals or any of them have
ceased to hold such offices either before or after the countersignature and delivery of such Rights Certificates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Promptly after the Company learns of the Separation Time, the Company will notify the Rights Agent of
such Separation Time and will deliver Rights Certificates executed by the Company to the Rights Agent for countersignature, and the Rights
Agent shall manually countersign (in a manner satisfactory to the Company) and send such Rights Certificates to the holders of the Rights
pursuant to Subsection 2.2(c)&nbsp;hereof. No Rights Certificate shall be valid for any purpose until countersigned by the Rights Agent
as aforesaid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Each Rights Certificate shall be dated the date of countersignature thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.6.</B></TD><TD STYLE="text-align: justify"><B><U>Registration, Transfer and Exchange</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company will cause to be kept a register (the &ldquo;<B>Rights Register</B>&rdquo;) in which, subject
to such reasonable regulations as it may prescribe, the Company will provide for the registration and transfer of Rights. The Rights Agent
is hereby appointed registrar for the Rights (the &ldquo;<B>Rights Registrar</B>&rdquo;) for the purpose of maintaining the Rights Register
for the Company and registering Rights and transfers of Rights as herein provided and the Rights Agent hereby accepts such appointment.
In the event that the Rights Agent shall cease to be the Rights Registrar, the Rights Agent will have the right to examine the Rights
Register at all reasonable times.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
the Separation Time and prior to the Expiration Time, upon surrender for registration of transfer or exchange of any Rights Certificate,
and subject to the </FONT>provisions of Subsection 2.6(c), the Company will execute, and the Rights Agent will manually countersign and
deliver, in the name of the holder or the designated transferee or transferees, as required pursuant to the holder's instructions, one
or more new Rights Certificates evidencing the same aggregate number of Rights as did the Rights Certificates so surrendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">All Rights issued upon any registration of transfer or exchange of Rights Certificates shall be the valid
obligations of the Company, and such Rights shall be entitled to the same benefits under this Agreement as the Rights surrendered upon
such registration of transfer or exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Every Rights Certificate surrendered for registration of transfer or exchange shall be duly endorsed,
or be accompanied by a written instrument of transfer satisfactory in form to the Company or the Rights Agent, as the case may be, duly
executed by the holder thereof or such holder's attorney duly authorized in writing. As a condition to the issuance of any new Rights
Certificate under this Section&nbsp;2.6, the Company may require the payment of a sum sufficient to cover any tax or other governmental
charge that may be imposed in relation thereto and any other expenses (including the reasonable fees and expenses of the Rights Agent)
connected therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.7.</B></TD><TD STYLE="text-align: justify"><B><U>Mutilated, Destroyed, Lost and Stolen Rights Certificates</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If any mutilated Rights Certificate is surrendered to the Rights Agent prior to the Expiration Time, the
Company shall execute and the Rights Agent shall countersign and deliver in exchange therefor a new Rights Certificate evidencing the
same number of Rights as did the Rights Certificate so surrendered.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If there shall be delivered to the Company and the Rights Agent prior to the Expiration Time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">evidence to their reasonable satisfaction of the destruction, loss or theft of any Rights Certificate;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">such security and indemnity as may be reasonably required by them to save each of them and any of their
agents harmless;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">then, in the absence of notice to the
Company or the Rights Agent that such Rights Certificate has been acquired by a bona fide purchaser, the Company shall execute and upon
the Company's request the Rights Agent shall countersign and deliver, in lieu of any such destroyed, lost or stolen Rights Certificate,
a new Rights Certificate evidencing the same number of Rights as did the destroyed, lost or stolen Rights Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">As a condition to the issuance of any new Rights Certificate under this Section&nbsp;2.7, the Company
may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and
any other expenses (including the reasonable fees and expenses of the Rights Agent) connected therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Every new Rights Certificate issued pursuant
to this Section&nbsp;2.7 in lieu of any destroyed, lost or stolen Rights Certificate shall evidence the contractual obligation of the
Company, whether or not the destroyed, lost or stolen Rights Certificate shall be at any time </FONT>enforceable by anyone, and shall
be entitled to all the benefits of this Agreement equally and proportionately with any and all other Rights duly issued hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.8.</B></TD><TD STYLE="text-align: justify"><B><U>Persons Deemed Owners of Rights</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, the Rights Agent
and any agent of the Company or the Rights Agent may deem and treat the Person in whose name a Rights Certificate (or, prior to the Separation
Time, the associated Common Share certificate) is registered as the absolute owner thereof and of the Rights evidenced thereby for all
purposes whatsoever and the Company and the Rights Agent shall not be affected by any notice or knowledge to the contrary except as required
by statute or by order of a court of competent jurisdiction. As used in this Agreement, unless the context otherwise requires, the term
 &ldquo;<B>holder</B>&rdquo; of any Rights shall mean the registered holder of such Rights (or, prior to the Separation Time, of the associated
Common Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Options: NewSection; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.9.</B></TD><TD STYLE="text-align: justify"><B><U>Delivery and Cancellation of Certificates</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Rights Certificates surrendered
upon exercise or for redemption, registration of transfer or exchange shall, if surrendered to any Person other than the Rights Agent,
be delivered to the Rights Agent and, in any case, shall be promptly cancelled by the Rights Agent. The Company may at any time deliver
to the Rights Agent for cancellation any Rights Certificates previously countersigned and delivered hereunder which the Company may have
acquired in any manner whatsoever, and all Rights Certificates so delivered shall be promptly cancelled by the Rights Agent. No Rights
Certificate shall be countersigned in lieu of or in exchange for any Rights Certificates cancelled as provided in this Section&nbsp;2.9,
except as expressly permitted by this Agreement. The Rights Agent shall, subject to applicable laws, and its ordinary business practices,
destroy all cancelled Rights Certificates and deliver a certificate of destruction to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.10.</B></TD><TD STYLE="text-align: justify"><B><U>Agreement of Rights Holders</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every holder of Rights, by
accepting the same, consents and agrees with the Company and the Rights Agent and with every other holder of Rights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to be bound by and subject to the provisions of this Agreement, as amended from time to time in accordance
with the terms hereof, in respect of all Rights held;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">that prior to the Separation Time, each Right will be transferable only together with, and will be transferred
by a transfer of, the associated Common Share certificate representing such Right;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">that after the Separation Time, the Rights Certificates will be transferable only on the Rights Register
as provided herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">that prior to due presentment of a Rights Certificate (or, prior to the Separation Time, the associated
Common Share certificate) for registration of transfer, the Company, the Rights Agent and any agent of the Company or the Rights Agent
may deem and treat the Person in whose name the Rights Certificate (or, prior to the Separation Time, the associated Common Share certificate)
is registered as the absolute owner thereof and of the Rights evidenced thereby (notwithstanding any notations of ownership or writing
on such Rights Certificate or the associated Common Share certificate made by anyone other than the Company or the Rights Agent) for all
purposes whatsoever, and neither the Company nor the Rights Agent shall be affected by any notice to the contrary;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">that such holder of Rights has waived his right to receive any fractional Rights or any fractional shares
or other securities upon exercise of a Right (except as provided herein);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">notwithstanding anything in this Agreement to the contrary, neither the Company nor the Rights Agent shall
have any liability to any holder of a Right or any other Person as a result of its inability to perform any of its obligations under this
Agreement by reason of any preliminary or permanent injunction or other order, decree or ruling issued by a court of competent jurisdiction
or by a governmental, regulatory or administrative agency or commission, or any statute, rule, regulation or executive order promulgated
or enacted by any governmental authority, prohibiting or otherwise restraining performance of such obligation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">that, subject to the provisions of Section&nbsp;5.4, without the approval of any holder of Rights or Voting
Shares and upon the sole authority of the Board of Directors, this Agreement may be supplemented or amended from time to time to cure
any ambiguity or to correct or supplement any provision contained herein which may be inconsistent with the intent of this Agreement or
is otherwise defective, as provided herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.11.</B></TD><TD STYLE="text-align: justify"><B><U>Holder of Rights Not Deemed a Shareholder</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No holder, as such, of any
Rights or Rights Certificate shall be entitled to vote, receive dividends or be deemed for any purpose whatsoever the holder of any Common
Share or any other share or security of the Company which may at any time be issuable on the exercise of such Rights, nor shall anything
contained herein or in any Rights Certificate be construed or deemed or confer upon the holder of any Right or Rights Certificate, as
such, any right, title, benefit or privilege of a holder of Common Shares or any other shares or securities of the Company or any right
to vote at any meeting of shareholders of the Company whether for the election of directors or otherwise or upon any matter submitted
to holders of Common Shares or any other shares of the Company at any meeting thereof, or to give or withhold consent to any action of
the Company, or to receive notice of any meeting or other action affecting any holder of Common Shares or any other shares of the Company
except as expressly provided herein, or to receive dividends, distributions or subscription rights, or otherwise, until the Right or Rights
evidenced by Rights Certificates shall have been duly exercised in accordance with the terms and provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;3
</B></FONT><B>- ADJUSTMENTS TO THE RIGHTS IN THE EVENT OF A FLIP-IN EVENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.1.</B></TD><TD STYLE="text-align: justify"><B><U>Flip-in Event</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Subject to Subsection 3.1(b)&nbsp;and Section&nbsp;5.1, if prior to the Expiration Time a Flip-in Event
occurs, each Right shall constitute, effective at the close of business on the 10<SUP>th</SUP> Trading Day after the Stock Acquisition
Date, the right to purchase from the Company, upon exercise thereof in accordance with the terms hereof, that number of Common Shares
having an aggregate Market Price on the date of consummation or occurrence of such Flip-in Event equal to twice the Exercise Price for
an amount in cash equal to the Exercise Price (such right to be appropriately adjusted in a manner analogous to the applicable adjustment
provided for in Section&nbsp;2.3 in the event that after such consummation or occurrence, an event of a type analogous to any of the events
described in Section&nbsp;2.3 shall have occurred).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Agreement to the contrary, upon the occurrence of any Flip-in Event,
any Rights that are or were Beneficially Owned on or after the earlier of the Separation Time or the Stock Acquisition Date by:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">an Acquiring Person (or any Affiliate or Associate of an Acquiring Person or any Person acting jointly
or in concert with an Acquiring Person or any Affiliate or Associate of an Acquiring Person); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a transferee of or other successor in title or ownership to Rights (a &ldquo;<B>transferee</B>&rdquo;),
directly or indirectly, from an Acquiring Person (or any Affiliate or Associate of an Acquiring Person or any Person acting jointly or
in concert with an Acquiring Person or any Affiliate or Associate of an Acquiring Person), where such transferee becomes a transferee
concurrently with or subsequent to the Acquiring Person becoming an Acquiring Person in a transfer that the Board of Directors has determined
is part of a plan, arrangement or scheme of an Acquiring Person (or any Affiliate or Associate of an Acquiring Person or any Person acting
jointly or in concert with an Acquiring Person or any Affiliate or Associate of an Acquiring Person), that has the purpose or effect of
avoiding Subsection 3.1(b)(i),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">shall become null and void without any
further action, and any holder of such Rights (including transferees) shall thereafter have no right to exercise or transfer such Rights
under any provision of this Agreement and further shall thereafter not have any other rights whatsoever with respect to such Rights, whether
under any provision of this Agreement or otherwise. The holder of any Rights represented by a Rights Certificate which is submitted to
the Rights Agent upon exercise or for registration of transfer or exchange on which the holder fails to certify upon the transfer or exchange
in the place set forth in the Rights Certificate establishing that such holder is not a Person described in either Subsections 3.1(b)(i)&nbsp;or
(ii)&nbsp;above shall be deemed to be Beneficially Owned by an Acquiring Person for the purposes of this Subsection 3.1(b)&nbsp;and such
rights shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">From and after the Separation Time, the Company shall do all such acts and things as shall be necessary
and within its power to ensure compliance with the provisions of this Section&nbsp;3.1, including without limitation, all such acts and
things as may be required to satisfy the requirements of the <I>Canada Business Corporations Act</I>, the <I>Securities Act </I>(British
Columbia) and the securities laws or comparable legislation of each of the Provinces of Canada and of the United States of America and
each of the States thereof and any other applicable law, rule&nbsp;or regulation in respect of the issue of Common Shares upon the exercise
of Rights in accordance with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any Rights Certificate that represents Rights Beneficially Owned by a Person described in either Subsections
3.1(b)(i)&nbsp;or (ii)&nbsp;or transferred to any nominee of any such Person, and any Rights Certificate issued upon transfer, exchange,
replacement or adjustment of any other Rights Certificate referred to in this sentence, shall contain the following legend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;The Rights represented by this
Rights Certificate were issued to a Person who was an Acquiring Person or an Affiliate or an Associate of an Acquiring Person (as such
terms are defined in the Rights Agreement) or a Person who was acting jointly or in concert with an Acquiring Person or an Affiliate or
Associate of an Acquiring Person. This Rights Certificate and the Rights represented hereby are void or shall become void in the circumstances
specified in Subsection 3.1(b)&nbsp;of the Rights Agreement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">provided, however, that the Rights Agent
shall not be under any responsibility to ascertain the existence of facts that would require the imposition of such legend but shall impose
such legend only if instructed to do so by the Company in writing or if a holder fails to certify upon transfer or exchange in the space
provided on the Rights Certificate that such holder is not a Person described in such legend. Notwithstanding the foregoing, the issuance
of a Rights Certificate which does not bear the legend referred to in this Subsection 3.1(d)&nbsp;shall not invalidate or have any effect
on the provisions of Subsection 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;4
</B></FONT><B>- THE RIGHTS AGENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.1.</B></TD><TD STYLE="text-align: justify"><B><U>General</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company hereby appoints the Rights Agent to act as agent for the Company and the holders of the Rights
in accordance with the terms and conditions hereof, and the Rights Agent hereby accepts such appointment. The Company may from time to
time appoint such co-Rights Agents (&ldquo;<B>Co-Rights Agents</B>&rdquo;) as it may deem necessary or desirable, subject to the approval
of the Rights Agent. In the event the Company appoints one or more Co-Rights Agents, the respective duties of the Rights Agent and Co-Rights
Agents shall be as the Company may determine, with the approval of the Rights Agent and the Co-Rights Agents. The Company agrees to pay
all reasonable fees and expenses of the Rights Agent in respect of the performance of its duties under this Agreement. The Company also
agrees to indemnify the Rights Agent, its officers, directors, and employees for, and to hold them harmless against, any loss, liability,
or expense, incurred without gross negligence, bad faith or wilful misconduct on the part of the Rights Agent, for anything done or omitted
by the Rights Agent in connection with the acceptance and administration of this Agreement, including the costs and expenses of defending
against any claim of liability, which right to indemnification will survive the termination of this Agreement or the resignation or removal
of the Rights Agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Rights Agent shall be protected and shall incur no liability for or in respect of any action taken,
suffered or omitted by it in connection with its administration of this Agreement in reliance upon any certificate for Common Shares,
Rights Certificate, certificate for other securities of the Company, instrument of assignment or transfer, power of attorney, endorsement,
affidavit, letter, notice, direction, consent, certificate, opinion, statement, or other paper or document believed by it in good faith
to be genuine and to be signed, executed and, where necessary, verified or acknowledged, by the proper Person or Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Company shall inform the Rights Agent in a reasonably timely manner of events which may materially
affect the administration of this Agreement by the Rights Agent and, at any time upon request, shall provide to the Rights Agent an incumbency
certificate certifying the then current officers of the Company; provided that failure to inform the Rights Agent of any such events,
or any defect therein shall not affect the validity of any action taken hereunder in relation to such events.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Notwithstanding any other provision of this Agreement, and whether such losses or damages are foreseeable
or unforeseeable, the Rights Agent shall not be liable under any circumstances whatsoever for any: (i)&nbsp;breach by any other party
of securities law or other rule&nbsp;of any securities regulatory authority, (ii)&nbsp;lost profits, or (iii)&nbsp;special, indirect,
incidental, consequential, exemplary, aggravated or punitive losses or damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Notwithstanding any other provision of this Agreement, any liability of the Rights Agent shall be limited,
in the aggregate, to the amount of fees paid by the Company to the Rights Agent under this Agreement in the 12 months immediately prior
to the Rights Agent receiving the first notice of the claim.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.2.</B></TD><TD STYLE="text-align: justify"><B><U>Merger, Amalgamation or Consolidation or Change of Name of Rights Agent</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Any corporation into which the Rights Agent may be merged or amalgamated or with which it may be consolidated,
or any corporation resulting from any merger, amalgamation, statutory arrangement or consolidation to which the Rights Agent is a party,
or any corporation succeeding to the shareholder or stockholder services business of the Rights Agent, will be the successor to the Rights
Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided
that such corporation would be eligible for appointment as a successor Rights Agent under the provisions of Section&nbsp;4.4 hereof. If,
at the time such successor Rights Agent succeeds to the agency created by this Agreement, any of the Rights Certificates have been countersigned
but not delivered, the successor Rights Agent may adopt the countersignature of the predecessor Rights Agent and deliver such Rights Certificates
so countersigned; and if, at that time, any of the Rights have not been countersigned, any successor Rights Agent may countersign such
Rights Certificates in the name of the predecessor Rights Agent or in the name of the successor Rights Agent; and in all such cases such
Rights Certificates will have the full force provided in the Rights Certificates and in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If, at any time, the name of the Rights Agent is changed and at such time any of the Rights Certificates
have been countersigned but not delivered, the Rights Agent may adopt the countersignature under its prior name and deliver Rights Certificates
so countersigned; and if, at that time, any of the Rights Certificates have not been countersigned, the Rights Agent may countersign such
Rights Certificates either in its prior name or in its changed name; and in all such cases such Rights Certificates shall have the full
force provided in the Rights Certificates and in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.3.</B></TD><TD STYLE="text-align: justify"><B><U>Duties of Rights Agent</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights Agent undertakes
the duties and obligations imposed by this Agreement upon the following terms and conditions, all of which the Company and the holders
of Rights and Rights Certificates, by their acceptance thereof, shall be bound:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Rights Agent, at the expense of the Company, may consult with and retain legal counsel (who may be
legal counsel for the Company) and such other experts as it reasonably considers necessary to perform its duties hereunder, and the opinion
of such counsel or other expert will be full and complete authorization and protection to the Rights Agent as to any action taken or omitted
by it in good faith and in accordance with such opinion;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">whenever in the performance of its duties under this Agreement, the Rights Agent deems it necessary or
desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact
or matter (unless other evidence in respect thereof is specifically prescribed herein) is deemed to be conclusively proved and established
by a certificate signed by a Person believed by the Rights Agent to be the Chairman of the Board, President, Chief Executive Officer,
Chief Financial</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Officer, any Vice-President or Corporate
Secretary of the Company and delivered to the Rights Agent; and such certificate will be full authorization to the Rights Agent for any
action taken or suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">notwithstanding anything to the contrary, the Rights Agent will be liable hereunder for its own gross
negligence, bad faith or wilful misconduct;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Rights Agent will not be liable for or by reason of any of the statements of fact or recitals contained
in this Agreement or in the certificates for Common Shares or the Rights Certificates (except its countersignature thereof) or be required
to verify the same, but all such statements and recitals are and will be deemed to have been made by the Company only;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the Rights Agent will not have any responsibility in respect of the validity of this Agreement or the
execution and delivery hereof (except the due authorization, execution and delivery hereof by the Rights Agent) or in respect of the validity
or execution of any certificate for a Common Share or Rights Certificate (except its countersignature thereof); nor will it be responsible
for any breach by the Company of any covenant or condition contained in this Agreement or in any Rights Certificate; nor will it be responsible
for any change in the exercisability of the Rights (including the Rights becoming void pursuant to Subsection 3.1(b)&nbsp;hereof) or any
adjustment required under the provisions of Section&nbsp;2.3 hereof or responsible for the manner, method or amount of any such adjustment
or the ascertaining of the existence of facts that would require any such adjustment (except with respect to the exercise of Rights after
receipt of the certificate contemplated by Section&nbsp;2.3 describing any such adjustment); nor is it deemed by any act hereunder to
make any representation or warranty as to the authorization of any Common Shares to be issued pursuant to this Agreement or any Rights
or as to whether any Common Shares will, when issued, be duly and validly authorized, executed, issued and delivered and fully paid and
non-assessable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">the Company agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed,
acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent
for the carrying out or performing by the Rights Agent of the provisions of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">the Rights Agent is hereby authorized and directed to accept instructions in writing with respect to the
performance of its duties hereunder from any individual believed by the Rights Agent to be the Chairman of the Board, President, Chief
Executive Officer, Chief Financial Officer, any Vice-President or Corporate Secretary of the Company, and to apply to such individuals
for advice or instructions in connection with its duties, and it shall not be liable for any action taken or suffered by it in good faith
in accordance with instructions of any such individual;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">the Rights Agent and any shareholder or stockholder, director, officer or employee of the Rights Agent
may buy, sell or deal in Common Shares, Rights or other securities of the Company or become pecuniarily interested in any transaction
in which the Company may be interested, or contract with or lend money to the Company or otherwise act as fully and freely as though it
were not Rights Agent under this Agreement and nothing herein shall preclude the Rights Agent from acting in any other capacity for the
Company or for any other legal entity; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any
duty hereunder either itself or by or through its attorneys or agents, and the Rights Agent will not be answerable or accountable for
any act, default, neglect or misconduct of any such attorneys or agents or for any loss to the Company resulting from any such act, default,
neglect or misconduct, provided reasonable care was exercised in the selection and continued employment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.4.</B></TD><TD STYLE="text-align: justify"><B><U>Change of Rights Agent</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights Agent may resign
and be discharged from its duties under this Agreement upon 60 days' notice (or such lesser notice as is acceptable to the Company) in
writing mailed to the Company and to each transfer agent of Common Shares by registered or certified mail. The Company may remove the
Rights Agent upon 30 days' notice in writing, mailed to the Rights Agent and to each transfer agent of the Common Shares by registered
or certified mail. If the Rights Agent should resign or be removed or otherwise become incapable of acting, the Company will appoint a
successor to the Rights Agent. If the Company fails to make such appointment within a period of 30 days after removal or 60 days after
it has been notified in writing of the resignation or incapacity by the resigning or incapacitated Rights Agent, then by prior written
notice to the Company the resigning Rights Agent or the holder of any Rights (which holder shall, with such notice, submit such holder's
Rights Certificate, if any, for inspection by the Company), may apply to a court of competent jurisdiction for the appointment of a new
Rights Agent, at the Company's expense. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be a corporation
incorporated under the laws of Canada or a province thereof. After appointment, the successor Rights Agent will be vested with the same
powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor
Rights Agent, upon receipt of all outstanding fees and expenses owing to it, shall deliver and transfer to the successor Rights Agent
any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the
purpose. Not later than the effective date of any such appointment, the Company will file notice thereof in writing with the predecessor
Rights Agent and each transfer agent of the Common Shares and mail a notice thereof in writing to the holders of the Rights in accordance
with Section&nbsp;5.9. Failure to give any notice provided for in this Section&nbsp;4.4, however, or any defect therein, shall not affect
the legality or validity of the resignation or removal of the Rights Agent or the appointment of any successor Rights Agent, as the case
may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.5.</B></TD><TD STYLE="text-align: justify"><B><U>Compliance with Money Laundering Legislation</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights Agent shall retain
the right not to act and shall not be liable for refusing to act if, due to a lack of information or for any other reason whatsoever,
the Rights Agent reasonably determines that such an act might cause it to be in non-compliance with any applicable anti-money laundering
or antiterrorist legislation, regulation or guideline. Further, should the Rights Agent reasonably determine at any time that its acting
under this Agreement has resulted in it being in non-compliance with any applicable anti-money laundering or anti-terrorist legislation,
regulation or guideline, then it shall have the right to resign on 10 days' written notice to the Company, provided: (i)&nbsp;that the
Rights Agent's written notice shall describe the circumstances of such non-compliance; and (ii)&nbsp;that if such circumstances are rectified
to the Rights Agent's satisfaction within such 10-day period, then such resignation shall not be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.6.</B></TD><TD STYLE="text-align: justify"><B><U>Privacy Provision</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
parties acknowledge that federal and/or provincial legislation that addresses the protection of individual's personal information (collectively,
 &ldquo;<B>Privacy Laws</B>&rdquo;) applies to obligations and activities under this Agreement. Despite any other provision of this Agreement,
neither party will take or direcy </FONT>any action that would contravene, or cause the other to contravene, applicable Privacy Laws.
The Company will, prior to transferring or causing to be transferred personal information to the Rights Agent, obtain and retain required
consents of the relevant individuals to the collection, use and disclosure of their personal information, or will have determined that
such consents either have previously been given upon which the parties can rely or are not required under the Privacy Laws. The Rights
Agent will use commercially reasonable efforts to ensure that its services hereunder comply with Privacy Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;5
</B></FONT><B>- MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.1.</B></TD><TD STYLE="text-align: justify"><B><U>Redemption and Waiver</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Board of Directors acting in good faith may, until the occurrence of a Flip-in Event, upon prior written
notice delivered to the Rights Agent, waive the application of Section&nbsp;3.1 to that particular Flip-in Event provided that the particular
Flip-in Event would result from a Take-over Bid made by way of take-over bid circular sent to all holders of record of Voting Shares (which
for greater certainty shall not include the circumstances described in Subsection 5.1(h)); provided that if the Board of Directors waives
the application of Section&nbsp;3.1 to a particular Flip-in Event pursuant to this Subsection 5.1(a), the Board of Directors shall be
deemed to have waived the application of Section&nbsp;3.1 to any other Flip-in Event occurring by reason of any Take-over Bid which is
made by means of a take-over bid circular to all holders of record of Voting Shares prior to the expiry of any Take-over Bid (as the same
may be extended from time to time) in respect of which a waiver is, or is deemed to have been, granted under this Subsection 5.1(a).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to the prior consent of the holders of the Voting Shares or the Rights as set forth in Subsections
5.4(b)&nbsp;or (c), as the case may be, the Board of Directors of the Company acting in good faith may, at its option, at any time prior
to the provisions of Section&nbsp;3.1 becoming applicable as a result of the occurrence of a Flip-in Event, elect to redeem all but not
less than all of the outstanding Rights at a redemption price of $0.00001 per Right appropriately adjusted in a manner analogous to the
applicable adjustment provided for in Section&nbsp;2.3 if an event of the type analogous to any of the events described in Section&nbsp;2.3
shall have occurred (such redemption price being herein referred to as the &ldquo;<B>Redemption Price</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Where, pursuant to a Permitted Bid, a Competing Permitted Bid, an Exempt Acquisition or an acquisition
for which a waiver has been granted under Subsection 5.1(a), a Person acquires more than 50% of the outstanding Voting Shares, other than
Voting Shares Beneficially Owned by such Person at the date of the Permitted Bid, the Competing Permitted Bid, the Exempt Acquisition
or an acquisition for which a waiver has been granted under Subsection 5.1(a), then the Board of Directors of the Company shall, notwithstanding
Subsection 5.1(b), immediately upon the consummation of such acquisition without further formality and without any approval under Subsections
5.4(b)&nbsp;or (c)&nbsp;be deemed to have elected to redeem the Rights at the Redemption Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Where a Take-over Bid that is not a Permitted Bid or a Competing Permitted Bid expires, is withdrawn or
otherwise terminates after the Separation Time has occurred and prior to the occurrence of a Flip-in Event, the Board of Directors may
elect to redeem all the outstanding Rights at the Redemption Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">If the Board of Directors is deemed under Subsection 5.1(c)&nbsp;to have elected, or elects under either
of Subsections 5.1(b)&nbsp;or (d), to redeem the Rights, the right to exercise the Rights will thereupon, without further action and without
notice, terminate and the only right thereafter of the holders of Rights so redeemed shall be to receive the Redemption Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Within 10 days after the Board of Directors is deemed under Subsection 5.1(c)&nbsp;to have elected, or
elects under Subsections 5.1(b)&nbsp;or (d), to redeem the Rights, the Company shall give notice of redemption to the holders of the then
outstanding Rights by publication of a notice in any newspaper distributed nationally in Canada or by mailing such notice to each such
holder at his last address as it appears upon the registry books of the Rights Agent or, prior to the Separation Time, on the registry
books of the transfer agent for the Voting Shares. Any notice which is mailed in the manner provided herein shall be deemed given, whether
or not the holder receives the notice. Each notice of redemption will state the method by which the payment of the Redemption Price will
be made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Upon the Rights being redeemed pursuant to Subsection 5.1(d), the directors shall be deemed to have distributed
new Rights to the holders of Voting Shares as of such date and in respect of each additional Voting Share issued thereafter, on the same
basis as Rights were first distributed hereunder and thereafter all the provisions of this Agreement shall continue to apply to such redistributed
Rights as if the Separation Time referred to in Subsection 5.1(d)&nbsp;had not occurred and which for all purposes of this Agreement shall
be deemed not to have occurred and the new Rights shall be outstanding and attached to the outstanding Common Shares as of and after such
date, subject to and in accordance with the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">The Board of Directors may waive the application of Section&nbsp;3.1 in respect of the occurrence of any
Flip-in Event if the Board of Directors has determined within 10 Trading Days following a Stock Acquisition Date that a Person became
an Acquiring Person by inadvertence and without any intention to become, or knowledge that it would become, an Acquiring Person under
this Agreement and, in the event that such a waiver is granted by the Board of Directors, such Stock Acquisition Date shall be deemed
not to have occurred. Any such waiver pursuant to this Subsection 5.1(h)&nbsp;must be on the condition that such Person, within 14 days
after the foregoing determination by the Board of Directors or such earlier or later date as the Board of Directors may determine (the
 &ldquo;<B>Disposition Date</B>&rdquo;), has reduced its Beneficial Ownership of Voting Shares so that the Person is no longer an Acquiring
Person. If the Person remains an Acquiring Person at the close of business on the Disposition Date, the Disposition Date shall be deemed
to be the date of occurrence of a further Stock Acquisition Date and Section&nbsp;3.1 shall apply thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company shall give prompt written notice to the Rights Agent of any waiver of the application of Section&nbsp;3.1
made by the Board of Directors under this Section&nbsp;5.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until the occurrence of a Flip-in Event as to
which the application of Section&nbsp;3.1 has not been waived pursuant to this section, upon written notice to the Rights Agent, the Board
of Directors, with the prior consent of the holders of Voting Shares given in accordance with Subsection 5.4(b), may determine, if such
Flip-in Event would occur by reason of an acquisition of Voting Shares otherwise than pursuant to a Take-over Bid made by means of a take-over
bid circular to all holders of Voting Shares and otherwise than in the </FONT>circumstances set forth in Subsection 5.1(h), to waive the
application of Section&nbsp;3.1 to such Flip-in Event. If the Board of Directors proposes such a waiver, the Board of Directors will extend
the Separation Time to a date subsequent to and not more than 10 Business Days following the meeting of shareholders called to approve
such waiver.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.2.</B></TD><TD STYLE="text-align: justify"><B><U>Expiration</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Person shall have any rights
whatsoever pursuant to this Agreement or in respect of any Right after the Expiration Time, except the Rights Agent as specified in Section&nbsp;4.1
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.3.</B></TD><TD STYLE="text-align: justify"><B><U>Issuance of New Rights Certificates</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any of the
provisions of this Agreement or the Rights to the contrary, the Company may, at its option, issue new Rights Certificates evidencing Rights
in such form as may be approved by the Board of Directors to reflect any adjustment or change in the number or kind or class of securities
purchasable upon exercise of Rights made in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.4.</B></TD><TD STYLE="text-align: justify"><B><U>Supplements and Amendments</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company may at any time, by resolution of the Board of Directors, supplement or make amendments to
this Agreement to correct any clerical or typographical error or, subject to Subsection 5.4(e), which supplements or amendments are required
to maintain the validity of this Agreement as a result of any change in any applicable legislation, rules&nbsp;or regulations thereunder
or policies of securities regulatory authorities or stock exchanges. The Company may, by resolution of the Board of Directors, prior to
the date of its shareholders' meeting referred to in Subsection 5.15(b), supplement or amend this Agreement without the approval of any
holders of Rights or Voting Shares (whether or not such action would adversely affect the interest of the holders of Rights or Voting
Shares generally) in order to make any changes which the Board of Directors acting in good faith may deem necessary or desirable. Notwithstanding
anything in this Section&nbsp;5.4 to the contrary, no such supplement or amendment shall be made to the provisions of Article&nbsp;4 except
with the written concurrence of the Rights Agent to such supplement or amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to Subsection 5.4(a), the Company may, with the prior consent of the holders of Voting Shares
obtained as set forth below, at any time before the Separation Time, amend, vary or rescind any of the provisions of this Agreement and
the Rights (whether or not such action would materially adversely affect the interests of the holders of Rights generally). Such consent
shall be deemed to have been given if provided by the holders of Voting Shares at a Special Meeting, which Special Meeting shall be called
and held in compliance with applicable laws and regulatory requirements and the requirements in the articles of the Company. Subject to
compliance with any requirements imposed by the foregoing, consent shall be given if the proposed amendment, variation or rescission is
approved by the affirmative vote of a majority of the votes cast by Independent Shareholders present or represented in person or by proxy
at and entitled to be voted at the Special Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company may, with the prior consent of the
holders of Rights obtained as set forth below, at any time after the Separation Time and before the Expiration Time, amend, vary or rescind
any of the provisions of this Agreement and the Rights (whether or not such action would materially adversely affect the interests of
the holders of Rights </FONT>generally), provided that no such amendment, variation or deletion shall be made to the provisions of Article&nbsp;4
except with the written concurrence of the Rights Agent thereto. Such consent shall be deemed to have been given if provided by the holders
of Rights at a Rights Holders' Special Meeting, which Rights Holders' Special Meeting shall be called and held in compliance with applicable
laws and regulatory requirements and, to the extent possible, with the requirements in the articles of the Company applicable to meetings
of holders of Voting Shares, applied mutatis mutandis. Subject to compliance with any requirements imposed by the foregoing, consent shall
be given if the proposed amendment, variation or rescission is approved by the affirmative vote of a majority of the votes cast by holders
of Rights (other than holders of Rights whose Rights have become null and void pursuant to Subsection 3.1(b)), represented in person or
by proxy at and entitled to be voted at the Rights Holders' Special Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any approval of the holders of Rights shall be deemed to have been given if the action requiring such
approval is authorized by the affirmative votes of the holders of Rights present or represented at and entitled to be voted at a meeting
of the holders of Rights and representing a majority of the votes cast in respect thereof. For the purposes hereof, each outstanding Right
(other than Rights which are void pursuant to the provisions hereof) shall be entitled to one vote, and the procedures for the calling,
holding and conduct of the meeting shall be those, as nearly as may be, which are provided in the Company's articles and the <I>Canada
Business Corporations Act </I>with respect to meetings of shareholders of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Any supplements or amendments made by the Company to this Agreement pursuant to Subsection 5.4(a)&nbsp;which
are required to maintain the validity of this Agreement as a result of any change in any applicable legislation, rule&nbsp;or regulation
thereunder or policies of any securities regulatory authority or stock exchange shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if made before the Separation Time, be submitted to the shareholders of the Company at the next meeting
of shareholders and the shareholders may, by the majority referred to in Subsection 5.4(b), confirm or reject such amendment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if made after the Separation Time, be submitted to the holders of Rights at a meeting to be called for
on a date not later than immediately following the next meeting of shareholders of the Company called after the Separation Time and the
holders of Rights may, by resolution passed by the majority referred to in Subsection 5.4(d), confirm or reject such amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any such amendment shall be effective
from the date of the resolution of the Board of Directors adopting such amendment, until it is confirmed or rejected or until it ceases
to be effective (as described in the next sentence) and, where such amendment is confirmed, it continues in effect in the form so confirmed.
If such amendment is rejected by the shareholders or the holders of Rights or is not submitted to the shareholders or holders of Rights
as required, then such amendment shall cease to be effective from and after the termination of the meeting at which it was rejected or
to which it should have been but was not submitted or from and after the date of the meeting of holders of Rights that should have been
but was not held, and no subsequent resolution of the Board of Directors to amend this Agreement to substantially the same effect shall
be effective until confirmed by the shareholders or holders of Rights referred to in Subsection 5.4(b)&nbsp;or 5.4(c), as the case may
be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Company shall provide the Rights Agent with notice in writing of any amendment, variation or deletion
to this Agreement as referred to in this Section&nbsp;5.4 within five Business Days of effecting such amendment, variation or deletion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.5.</B></TD><TD STYLE="text-align: justify"><B><U>Fractional Rights and Fractional Shares</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company shall not be required to issue fractions of Rights or to distribute Rights Certificates which
evidence fractional Rights. After the Separation Time, in lieu of issuing fractional Rights, the Company shall pay to the holders of record
of the Rights Certificates (provided the Rights represented by such Rights Certificates are not void pursuant to the provisions of Subsection
3.1(b), at the time such fractional Rights would otherwise be issuable), an amount in cash equal to the fraction of the Market Price of
one whole Right that the fraction of a Right that would otherwise be issuable is of one whole Right, provided that the Company shall not
be required or obligated to make any payment provided for above unless the amount payable by the Company to a certain holder exceeds $1O.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Company shall not be required to issue fractions of Common Shares upon exercise of Rights or to distribute
certificates which evidence fractional Common Shares. In lieu of issuing fractional Common Shares, the Company shall pay to the registered
holders of Rights Certificates, at the time such Rights are exercised as herein provided, an amount in cash equal to the fraction of the
Market Price of one Common Share that the fraction of a Common Share that would otherwise be issuable upon the exercise of such Right
is of one whole Common Share at the date of such exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Rights Agent shall have no obligation to make any payments in lieu of issuing fractions of Rights
or Common Shares pursuant to Subsections 5.5(a)&nbsp;or (b), respectively, unless and until the Company shall have provided to the Rights
Agent the amount of cash to be paid in lieu of issuing such fractional Rights or Common Shares, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.6.</B></TD><TD STYLE="text-align: justify"><B><U>Rights of Action</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of this
Agreement, all rights of action in respect of this Agreement, other than rights of action vested solely in the Rights Agent, are vested
in the respective holders of the Rights. Any holder of Rights, without the consent of the Rights Agent or of the holder of any other Rights,
may, on such holder's own behalf and for such holder's own benefit and the benefit of other holders of Rights, enforce, and may institute
and maintain any suit, action or proceeding against the Company to enforce such holder's right to exercise such holder's Rights, or Rights
to which such holder is entitled, in the manner provided in such holder's Rights Certificate and in this Agreement. Without limiting the
foregoing or any remedies available to the holders of Rights, it is specifically acknowledged that the holders of Rights would not have
an adequate remedy at law for any breach of this Agreement and will be entitled to specific performance of the obligations under, and
injunctive relief against actual or threatened violations of the obligations of any Person subject to, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.7.</B></TD><TD STYLE="text-align: justify"><B><U>Regulatory Approvals</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
obligation of the Company or action or event contemplated by this Agreement shall be subject to the receipt of requisite approval or consent
from any governmental or regulatory authority having jurisdiction, and without limiting the generality of the foregoing, while any securities
of the Company are listed and admitted for trading thereon, necessary approvals of the TSX and other </FONT>exchanges shall be obtained,
in relation to the issuance of the Common Shares upon the exercise of Rights under Subsection 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.8.</B></TD><TD STYLE="text-align: justify"><B><U>Non-Canadian Holders</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If in the opinion of the Board of Directors (who
may rely upon the advice of counsel) any action or event contemplated by this Agreement would require compliance by the Company with the
securities laws or comparable legislation of a jurisdiction outside Canada, the Board of Directors acting in good faith shall take such
actions as it may consider appropriate to ensure such compliance or avoid the application thereof. In no event shall the Company or the
Rights Agent be required to issue or deliver Rights or securities issuable on exercise of Rights to persons who are citizens, residents
or nationals of any jurisdiction other than Canada, in which such issue or delivery would be unlawful without registration of the relevant
Persons or securities for such purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.9.</B></TD><TD STYLE="text-align: justify"><B><U>Notices</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notices or demands authorized or required by this Agreement to be given or made by the Rights Agent or
by the holder of any Rights to or on the Company shall be sufficiently given or made if delivered, sent by registered or certified mail,
postage prepaid (until another address is filed in writing with the Rights Agent), or sent by facsimile or other form of recorded electronic
communication, charges prepaid and confirmed in writing, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">ProMIS Neurosciences Inc.<BR>
Suite&nbsp;200, 1920 Yonge Street<BR>
Toronto, Ontario M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Chief
Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notices or demands authorized or required by this Agreement to be given or made by the Company or by the
holder of any Rights to or on the Rights Agent shall be sufficiently given or made if delivered, sent by registered or certified mail,
postage prepaid (until another address is filed in writing with the Company), or sent by facsimile or other form of recorded electronic
communication, charges prepaid and confirmed in writing, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Computershare
Trust Company of Canada<BR>
510 Burrard Street, 3<SUP>rd</SUP> Floor<BR>
</FONT>Vancouver, British Columbia V6C 3B9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Manager,
Client Services<BR>
Fax No.:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(604) 661-9401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Except as otherwise provided hereunder, notices or demands authorized or required by this Agreement to
be given or made by the Company or the Rights Agent to or on the holder of any Rights shall be sufficiently given or made if delivered
or sent by registered or certified mail, postage prepaid, addressed to such holder at the address of such holder as it appears upon the
register of the Rights Agent or, prior to the Separation Time, on the register of the Company for its Common Shares. Any notice which
is mailed or sent in the manner herein provided shall be deemed given, whether or not the holder receives the notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any notice given or made in accordance with this Section&nbsp;5.9 shall be deemed to have been given and
to have been received on the day of delivery, if so delivered, on the third Business Day (excluding each day during which there exists
any general interruption of postal service due to strike, lockout or other cause) following the mailing thereof, if so mailed, and on
the day of telecopying or sending of the same by other means of recorded electronic communication (provided such sending is during the
normal business hours of the addressee on a Business Day and if not, on the first Business Day thereafter). Each of the Company and the
Rights Agent may from time to time change its address for notice by notice to the other given in the manner aforesaid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.10.</B></TD><TD STYLE="text-align: justify"><B><U>Costs of Enforcement</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agrees that if
the Company fails to fulfil any of its obligations pursuant to this Agreement, then the Company will reimburse the holder of any Rights
for the costs and expenses (including legal fees) reasonably incurred by such holder to enforce his rights pursuant to any Rights or this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%"></TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.11.</B></TD><TD STYLE="text-align: justify"><B><U>Successors</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All the covenants and provisions
of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and enure to the benefit of their respective successors
and assigns hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.12.</B></TD><TD STYLE="text-align: justify"><B><U>Benefits of this Agreement</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Agreement
shall be construed to give to any Person other than the Company, the Rights Agent and the holders of the Rights any legal or equitable
right, remedy or claim under this Agreement; further, this Agreement shall be for the sole and exclusive benefit of the Company, the Rights
Agent and the holders of the Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.13.</B></TD><TD STYLE="text-align: justify"><B><U>Governing Law</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and each Right
issued hereunder shall be deemed to be a contract made under the laws of the Province of Ontario and for all purposes shall be governed
by and construed in accordance with the laws of such Province applicable to contracts to be made and performed entirely within such Province.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.14.</B></TD><TD STYLE="text-align: justify"><B><U>Severabilitv</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any term or provision hereof
or the application thereof to any circumstance shall, in any jurisdiction and to any extent, be invalid or unenforceable, such term or
provision shall be ineffective only as to such jurisdiction and to the extent of such invalidity or unenforceability in such jurisdiction
without invalidating or rendering unenforceable or ineffective the remaining terms and provisions hereof in such jurisdiction or the application
of such term or provision in any other jurisdiction or to circumstances other than those as to which it is specifically held invalid or
unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.15.</B></TD><TD STYLE="text-align: justify"><B><U>Effective Date and Confirmation</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">This Agreement is effective and in full force and effect in accordance with its terms from and after the
date hereof and shall expire and be of no further force and effect from and after the earlier of (i)&nbsp;the Termination Time, and (ii)&nbsp;the
time at which the annual meeting of holders of Voting Shares held in 2022 terminates (the &ldquo;<B>Expiration Time</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding Subsection 5.15(a), at the first annual or special meeting of holders of Voting Shares
following the date hereof, the Company shall request confirmation of this Agreement by the holders of its Voting Shares. If this Agreement
is not confirmed by resolution passed by a majority of the votes cast by holders of Voting Shares of the Company who vote in respect of
confirmation of this Agreement at a meeting of the Company's shareholders to be held on or prior to July&nbsp;29, 2022, then this Agreement
and all outstanding Rights shall terminate and be void and of no further force and effect on and from that date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%"></TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.16.</B></TD><TD STYLE="text-align: justify"><B><U>Determinations and Actions by the Board of Directors</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All actions, calculations
and determinations (including all omissions with respect to the foregoing) which are done or made by the Board of Directors, in good faith,
for the purposes hereof shall not subject the Board of Directors or any director of the Company to any liability to the holders of the
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.17.</B></TD><TD STYLE="text-align: justify"><B><U>Force Majeure</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No party shall be liable to the other, or held
in breach of this Agreement, if prevented, hindered, or delayed in the performance or observance of any provision contained herein by
reason of act of God, riots, terrorism, acts of war, epidemics, governmental action or judicial order, earthquakes, or any other similar
causes (including, but not limited to, mechanical, electronic or communication interruptions, disruptions or failures). Performance times
under this Agreement shall be extended for a period of time equivalent to the time lost because of any delay that is excusable under this
Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.18.</B></TD><TD STYLE="text-align: justify"><B><U>Time of the Essence.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Time shall be of the essence
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>[REMAINDER OF PAGE LEFT
BLANK]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%"></TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.19.</B></TD><TD STYLE="text-align: justify"><B><U>Execution in Counterparts</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be executed
in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts
shall together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">/s/</TD><TD STYLE="text-align: justify">&ldquo;<I>Elliot Goldstein</I>&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%">Per:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Elliot Goldstein, Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
                                                                                                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>COMPUTERSHARE TRUST COMPANY OF CANADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">/s/</TD><TD STYLE="text-align: justify"><I>&ldquo;Billy Chau&rdquo;</I></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%">Per:</TD><TD STYLE="text-align: justify; width: 45%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; text-align: justify">Authorized Signatory</TD>
    <TD>&nbsp;</TD></TR>
                                                                                                                                                             </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">/s/</TD><TD STYLE="text-align: justify"><I>&ldquo;Evelyn Hsu&rdquo;</I></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 5%">Per:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">Authorized Signatory</TD>
    <TD>&nbsp;</TD></TR>
                                           </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 33%"></TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATTACHMENT 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF RIGHTS CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: left">Certificate No.&nbsp;_______ &nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 49%; font: 10pt Times New Roman, Times, Serif">_______Rights</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE RIGHTS ARE SUBJECT TO TERMINATION ON THE
TERMS SET FORTH IN THE SHAREHOLDER RIGHTS PLAN AGREEMENT. UNDER CERTAIN CIRCUMSTANCES (SPECIFIED IN SUBSECTION&nbsp;3.1(b)&nbsp;OF THE
SHAREHOLDER RIGHTS PLAN AGREEMENT), RIGHTS BENEFICIALLY OWNED BY AN ACQUIRING PERSON OR CERTAIN RELATED PARTIES, OR TRANSFEREES OF AN
ACQUIRING PERSON OR CERTAIN RELATED PARTIES AND THEIR TRANSFEREES, MAY&nbsp;BECOME VOID WITHOUT FURTHER ACTION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rights Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This certifies that _______________________________<U>,</U>
or registered assigns, is the registered holder of the number of Rights set forth above, each of which entitles the registered holder
thereof, subject to the terms, provisions and conditions of the Shareholder Rights Plan Agreement, originally dated as of January&nbsp;22,
2016, and amended and extended as of May&nbsp;15, 2019 (the &ldquo;<B>Shareholder Rights Agreement</B>&rdquo;), between <B>ProMIS Neurosciences
Inc. </B>(the &ldquo;<B>Company</B>&rdquo;), a company duly incorporated under the <I>Canada Business Corporations Act</I>, and Computershare
Trust Company of Canada, a trust company incorporated under the laws of Canada (the &ldquo;<B>Rights Agent</B>&rdquo;) (which term shall
include any successor Rights Agent under the Shareholder Rights Agreement), to purchase from the Company at any time after the Separation
Time (as such term is defined in the Shareholder Rights Agreement) and prior to the Expiration Time (as such term is defined in the Shareholder
Rights Agreement), one fully paid common share of the Company (a &ldquo;<B>Common Share</B>&rdquo;) at the Exercise Price referred to
below, upon presentation and surrender of this Rights Certificate with the Form&nbsp;of Election to Exercise (in the form provided hereinafter)
duly executed and submitted to the Rights Agent at its principal office in the City of Toronto, Ontario, Canada. Until adjustment thereof
in certain events as provided in the Shareholder Rights Agreement, the Exercise Price shall be an amount equal to three times the Market
Price (as such term is defined in the Rights Plan Agreement) per Common Share determined as at the Separation Time and shall be subject
to adjustment in certain events as provided in the Shareholder Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain circumstances described
in the Rights Agreement, the number of Common Shares which each Right entitles the registered holder thereof to purchase shall be adjusted
as provided in the Shareholder Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Rights Certificate is
subject to all of the terms and provisions of the Shareholder Rights Agreement, which terms and provisions are incorporated herein by
reference and made a part hereof and to which Shareholder Rights Agreement reference is hereby made for a full description of the rights,
limitations of rights, obligations, duties and immunities thereunder of the Rights Agent, the Company and the holders of the Rights. Copies
of the Shareholder Rights Agreement are on file at the registered office of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Rights Certificate, with or without other Rights Certificates, upon surrender at any of the offices of the Rights Agent designated for
such purpose, may be exchanged for another Rights Certificate or Rights Certificates of like tenor and date evidencing an aggregate number
of Rights equal to the aggregate number of Rights evidenced by the Rights Certificate or Rights Certificates surrendered. If this Rights
Certificate shall be exercised in part, the registered holder shall be entitled to receive, upon </FONT>surrender hereof, another Rights
Certificate or Rights Certificates for the number of whole Rights not exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Shareholder Rights Agreement, the Rights evidenced by this Certificate may be redeemed by the Company at a redemption price of
$0.00001 per Right, subject to adjustment in certain events, under certain circumstances at its option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional Common Shares
will be issued upon the exercise of any Rights evidenced hereby, but in lieu thereof a cash payment will be made, as provided in the Shareholder
Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No holder of this Rights Certificate,
as such, shall be entitled to vote or receive dividends or be deemed for any purpose the holder of Common Shares or of any other securities
which may at any time be issuable upon the exercise hereof, nor shall anything contained in the Shareholder Rights Agreement or herein
be construed to confer upon the holder hereof, as such, any of the rights of a shareholder of the Company or any right to vote for the
election of directors or upon any matter submitted to shareholders at any meeting thereof, or to give or withhold consent to any corporate
action, or to receive notice of meetings or other actions affecting shareholders (except as provided in the Shareholder Rights Agreement),
or to receive dividends or subscription rights, or otherwise, until the Rights evidenced by this Rights Certificate shall have been exercised
as provided in the Shareholder Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Rights Certificate shall
not be valid or obligatory for any purpose until it shall have been countersigned by the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WITNESS the facsimile signature of the proper
officers of the Company and its corporate seal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT><FONT STYLE="font-size: 10pt">___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per:</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 45%"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>Elliot Goldstein</TD>
    <TD>&nbsp;</TD></TR>
                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>COMPUTERSHARE TRUST COMPANY OF CANADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 47%"></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>Authorized Signatory</TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 47%"></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>Authorized Signatory</TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATTACHMENT 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(To be executed by the registered holder if such
holder desires to transfer the Rights evidenced by this Rights Certificate.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FOR&#8239;VALUE&#8239;RECEIVED&#8239;_______________________________&#8239;hereby&#8239;sells,&#8239;assign&#8239;and&#8239;transfers&#8239;unto&#8239;_________________________________________ ___________________________________________________</FONT>__________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Please print name and address of transferee.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Rights represented by this Rights Certificate,
together with all right, title and interest therein, and does hereby irrevocably constitute and appoint ______________________________________________________________,
as attorney, to transfer the within Rights on the books of the Company, with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: __________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Signature Guaranteed:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Signature</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">(Signature must correspond to name as written upon the face of this Rights Certificate in every particular, without alteration or enlargement
or any change whatsoever.)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature must be guaranteed by a Canadian chartered
bank or an eligible guarantor institution with membership in an approved signature medallion guarantee program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be completed if true.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned party transferring Rights hereunder,
hereby represents, for the benefit of all holders of Rights and Common Shares, that the Rights evidenced by this Rights Certificate are
not, and, to the knowledge of the undersigned, have never been, Beneficially Owned by an Acquiring Person or an Affiliate or Associate
thereof or a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate thereof. Capitalized terms shall
have the meaning ascribed thereto in the Shareholder Rights Plan Agreement originally dated as of January&nbsp;22, 2016, and amended and
extended as of May&nbsp;15, 2019 between ProMIS Neurosciences Inc. and Computershare Trust Company of Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%">Signature</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="border-top: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif">(To be attached to each Rights Certificate)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATTACHMENT 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF ELECTION TO EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(To
be executed by the registered holder if such holder desires to exercise the Rights</FONT> Certificate.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">TO:</TD><TD STYLE="text-align: justify">PROMIS NEUROSCIENCES INC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left">AND TO:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left">COMPUTERSHARE TRUST COMPANY OF CANADA</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">The
undersigned hereby irrevocably elects to exercise <U><SUB>BBBBBBBBBBBBBB</SUB></U> whole Rights represented by the attached Rights Certificate
to purchase the Common Shares or other securities, if applicable, issuable upon the exercise of such Rights and requests that certificates
for such securities be issued in the name of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">(Name)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">( (Address)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">( (City, Province and Postal Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">(Social Insurance Number or other taxpayer identification number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such number of Rights shall not be all the
Rights evidenced by this Rights Certificate, a new Rights Certificate for the balance of such Rights shall be registered in the name of
and delivered to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">(Name)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">( Address)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">( City, Province and Postal Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">(Social Insurance Number or other taxpayer identification number)</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: _________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature Guaranteed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%">Signature</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Signature must correspond to name as written upon the face
of this Rights Certificate in every particular, without alteration or enlargement or any change whatsoever.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature must be guaranteed by a Canadian chartered
bank or an eligible guarantor institution with membership in an approved signature medallion guarantee program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATTACHMENT 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(To be completed if true.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned party exercising Rights hereunder,
hereby represents, for the benefit of all holders of Rights and Common Shares, that the Rights evidenced by this Rights Certificate are
not, and, to the knowledge of the undersigned, have never been, Beneficially Owned by an Acquiring Person or an Affiliate or Associate
thereof or a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate thereof. Capitalized terms shall
have the meaning ascribed thereto in the Shareholder Rights Plan Agreement, originally dated as of January&nbsp;22, 2016, and amended
and extended as of May&nbsp;15, 2019 between ProMIS Neurosciences Inc. and Computershare Trust Company of Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%">Signature</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">(To be attached to each Rights Certificate)</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the certification set forth above
in the Form&nbsp;of Assignment and Form&nbsp;of Election to Exercise, as applicable, is not completed, the Company will deem the Beneficial
Owner of the Rights evidenced by this Rights Certificate to be an Acquiring Person or an Affiliate or Associate thereof. No Rights Certificates
shall be issued in exchange for a Rights Certificate owned or deemed to have been owned by an Acquiring Person or an Affiliate or Associate
thereof, or by a Person acting jointly or in concert with an Acquiring Person or an Affiliate or Associate thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security (or the common shares issuable on conversion
thereof) before JULY 23, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES
ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE
 &ldquo;1933 ACT&rdquo;), OR THE LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE
BENEFIT OF THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B)
OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS
AND REGULATIONS, (C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE,
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE 1933
ACT OR ANY APPLICABLE STATE SECURITIES LAWS AND, IN THE CASE OF (C) AND (D) ABOVE, AFTER THE SELLER FURNISHES TO THE CORPORATION AN OPINION
OF COUNSEL OF RECOGNIZED STANDING OR OTHER EVIDENCE IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION TO SUCH EFFECT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE PRESENCE OF THIS LEGEND MAY IMPAIR THE
ABILITY OF THE HOLDER HEREOF TO EFFECT &ldquo;GOOD DELIVERY&rdquo; OF THE SECURITIES REPRESENTED HEREBY ON A CANADIAN STOCK EXCHANGE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">UNSECURED
CONVERTIBLE DEBENTURE CERTIFICATE</FONT></P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">PROMIS
NEUROSCIENCES INC.<BR>
<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(Incorporated under
the federal laws of Canada)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT><BR></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>DEBENTURE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>CERTIFICATE NO. 2021-CD-2</B></P></TD>
    <TD STYLE="width: 51%; text-align: right; font-size: 10pt"><B>PRINCIPAL AMOUNT US$900,000</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B> (the &ldquo;<B>Company</B>&rdquo;),
for value received, hereby acknowledges itself indebted and promises to pay or to the order of Crocker Mountain LLC (hereinafter referred
to as the &ldquo;<B>Holder</B>&rdquo;), at any time following <B>March 22, 2021</B> (the &ldquo;<B>Issue Date</B>&rdquo;) but on or prior
to <B>March 22, 2026 </B>(the &ldquo;<B>Maturity Date</B>&rdquo;), the Principal Amount (set forth above) in the manner hereinafter provided,
and to pay interest on the Principal Amount outstanding from time to time owing hereunder to the date of payment as hereinafter provided,
both before and after maturity or demand, default and judgement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms set forth herein including,
without limitation, the right of the Company to convert the Debenture into common shares of the Company (&ldquo;<B>Common Shares</B>&rdquo;)
in certain circumstances as more particularly described herein, the Holder has the right, from time to time and at any time on or prior
to 5:00 p.m. (Vancouver time) on the Business Day immediately preceding the Maturity Date, to convert all or any portion of the outstanding
Principal Amount into Common Shares, at a price, with respect to the Principal Amount, equal to US$0.10 per Common Share, provided no
partial conversion shall be for less than the Minimum Threshold Amount. On conversion, the Holder will receive any accrued and unpaid
interest in cash, or at the election of the Company, may be satisfied, in lieu of cash, by the issuance of Common Shares at the Market
Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except upon the occurrence of an Event of
Default (as defined below) after which the following transfer restriction will no longer apply, this Debenture shall be
non-transferrable, in whole or in part, to anyone without the express prior written consent of the Company. For the purposes of this
Debenture, a &ldquo;transfer&rdquo; includes any sale, exchange, transfer, assignment, gift, pledge, encumbrance, hypothecation,
alienation or other transaction, whether voluntary, involuntary or by operation of law, whether in whole or in part, by which the
legal or beneficial ownership of, or any security interest or other interest in the Debenture, passes from one person to another,
indirectly or directly, or to the same person in a different capacity, whether or not for value. Notwithstanding the foregoing, the
Holder may transfer the Debenture without the prior express written consent of the Company to: (i) the spouse of the Holder; or (ii)
a corporation of which the Holder or the spouse of the Holder is/are the sole registered and beneficial shareholder(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conversion of all or any part of the Debenture
may only be completed at the head office of the Company at Suite 200, 1920 Yonge Street, Toronto, Ontario M4S 3E2, Attention: CFO, or
such other office as the Company may advise the Holder in writing. This Debenture is issued subject to the terms and conditions appended
hereto as <B>Schedule&nbsp;&ldquo;A&rdquo;</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Company has caused this
Debenture to be executed by a duly authorized officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this 22<SUP>nd</SUP> day of March, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PROMIS NEUROSCIENCES INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Per:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Eugene Williams</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>





<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SCHEDULE &ldquo;A&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TERMS AND CONDITIONS
FOR DEBENTURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;1<BR>
INTERPRETATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">1.1</FONT></TD><TD STYLE="text-align: justify">Defined Terms</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In this Debenture, unless there
is something in the subject matter or context inconsistent therewith, the following words and terms shall have the meanings set out below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Applicable Securities Laws</B>&rdquo; any and all securities laws including, statutes, rules,
regulations, by-laws, policies, guidelines, orders, decisions, rulings and awards, applicable in the jurisdiction in which the Debenture
will be offered, sold and issued or where the Company carries on business;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business Day</B>&rdquo; means a day, other than a Saturday, Sunday or statutory or civic holiday
in the City of Toronto, Ontario;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Capital Reorganization</B>&rdquo; has the meaning set forth in Section&nbsp;4.3(a);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Common Shares</B>&rdquo; means fully-paid and non-assessable common shares in the capital of
the Company as constituted on the date hereof which the Holder is entitled to receive upon the conversion of the Debenture pursuant to
Article&nbsp;4, and after the date hereof, such common shares in the capital of the Company or any other shares, securities, money or
property, which the Holder is entitled to receive in respect or substitution of such common shares, upon conversion of the Debenture pursuant
to Article&nbsp;4;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Company</B>&rdquo; means ProMIS Neurosciences Inc. and its successors and assigns;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Conversion Date</B>&rdquo; means the date on which a notice of conversion is received by the
Company pursuant to Section&nbsp;4.2(a);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Conversion Price</B>&rdquo; means, subject to Section&nbsp;4.3, US$0.10 per Common Share;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B>Conversion Rights</B>&rdquo; means the rights of the Holder to convert the Debenture into Common
Shares pursuant to Article&nbsp;4;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Convertible Securities</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(a);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B>Cure Period</B>&rdquo; shall have the meaning set forth in Section&nbsp;6.1;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">&ldquo;<B>Current Market Price</B>&rdquo; shall have the meaning set forth in Section&nbsp;4.3(c);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B>Debenture</B>&rdquo; means this Debenture as supplemented, amended or otherwise modified, renewed
or replaced from time to time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&ldquo;<B>Holder</B>&rdquo; shall have the meaning set forth on the cover page of this Debenture;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">&ldquo;<B>Distributed Securities</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(a);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">&ldquo;<B>Distribution</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(a);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">&ldquo;<B>Events of Default</B>&rdquo; shall have the meaning set forth in Section&nbsp;5.1;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">&ldquo;<B>Exempt Issuances</B>&rdquo; means (i) securities issued upon the conversion or exercise of any
debenture, warrant, option or other convertible security existing as of the Issue Date, (ii) Common Shares issuable upon a share split,
share dividend or similar transaction, (iii) Common Shares (or options to purchase Common Shares) issued or issuable to employees, officers,
directors or consultants of the Company pursuant to any stock option plan or other long term incentive plan approved by the board of directors
of the Company, and (iv) the issuance of securities in connection with acquisition transactions, as approved by the board of directors
of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">&ldquo;<B>Forced Conversion Notice</B>&rdquo; shall have the meaning set forth in Section 4.7;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">&ldquo;<B>Forced Conversion Shares</B>&rdquo; shall have the meaning set forth in Section 4.7;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">&ldquo;<B>Forced Conversion Trigger</B>&rdquo; shall have the meaning set forth in Section 4.7;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">&ldquo;<B>Interest Due Date</B>&rdquo; shall have the meaning set forth in Section 2.2;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Issue Price</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(b);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">&ldquo;<B>Market Price</B>&rdquo; means the five (5) day volume weighted average trading price of the
Common Shares determined by dividing the total value by total volume of the Common Shares traded on the TSX for the five (5) trading days
immediately prior to the relevant date;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&ldquo;<B>Maturity Date</B>&rdquo; mean March 22, 2026;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">&ldquo;<B>Minimum Threshold Amount</B>&rdquo; means the minimum Principal Amount of this Debenture that
may be partially converted or redeemed, as applicable, such amount being US$100,000;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD STYLE="text-align: justify">&ldquo;<B>Official Body</B>&rdquo; means any government or political subdivision or any agency, authority,
bureau, central bank, monetary authority, commission, department or instrumentality thereof, or any court, tribunal or arbitrator, whether
foreign or domestic;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD STYLE="text-align: justify">&ldquo;<B>person</B>&rdquo; means an individual, partnership, corporation, trust, unincorporated association,
joint venture or government or any agent, instrument or political subdivision thereof;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Pre-emptive Notice</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(c);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(cc)</TD><TD STYLE="text-align: justify">&ldquo;<B>Pre-emptive Right</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(a);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(dd)</TD><TD STYLE="text-align: justify">&ldquo;<B>Principal Amount</B>&rdquo; means the principal amount outstanding under this Debenture from
time to time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ee)</TD><TD STYLE="text-align: justify">&ldquo;<B>Receiver</B>&rdquo; means any receiver or receiver-manager of the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ff)</TD><TD STYLE="text-align: justify">&ldquo;<B>Reclassification of Common Shares</B>&rdquo; shall have the meaning set forth in Section 4.3(d);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(gg)</TD><TD STYLE="text-align: justify">&ldquo;<B>Redemption Date</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.5;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(hh)</TD><TD STYLE="text-align: justify">&ldquo;<B>Redemption Notice</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.5;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&ldquo;<B>Special Distribution</B>&rdquo; shall have the meaning set forth in Section&nbsp;4.3(c);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(jj)</TD><TD STYLE="text-align: justify">&ldquo;<B>Subscription Securities</B>&rdquo; shall have the meaning set forth in Section&nbsp;2.7(b);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(kk)</TD><TD STYLE="text-align: justify">&ldquo;<B>TSX</B>&rdquo; means the Toronto Stock Exchange or, if the Common Shares are listed or posted
for trading on any other stock exchange or over-the-counter market, then such other exchange or market if the Common Shares are not at
the applicable time listed on the TSX;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ll)</TD><TD STYLE="text-align: justify">&ldquo;<B>United States</B>&rdquo; or &ldquo;<B>U.S.</B>&rdquo; means, as the context requires, the United
States of America, its territories and possessions, any state of the United States and/or the District of Columbia; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(mm)</TD><TD STYLE="text-align: justify">&ldquo;<B>U.S. person</B>&rdquo; has the meaning ascribed to that term in Rule 902(k) of Regulation S
under the 1933 Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">1.2</FONT></TD><TD STYLE="text-align: justify">Currency</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All references to dollar amounts
herein are references to currency of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;2<BR>
DEBENTURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.1</FONT></TD><TD STYLE="text-align: justify">Principal Amount</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company agrees to repay
to the Holder the Principal Amount of the Debenture, together with interest thereon, by 5:00 p.m. (Vancouver time) on the Maturity Date,
subject to the right to convert the Debenture pursuant to Section&nbsp;4.1 or Section 4.7 and the Company&rsquo;s right to redeem the
Principal Amount and interest thereon in Common Shares pursuant to Section 2.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.2</FONT></TD><TD STYLE="text-align: justify">Interest on Debenture</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Interest shall accrue on the
Principal Amount of the Debenture, from day to day, before as well as after maturity, before as well as after default and before as well
as after judgement, at a rate of 1.0% per annum, calculated and payable annually in arrears, commencing on March 22, 2022 and every anniversary
thereafter (each, an &ldquo;<B>Interest Due Date</B>&rdquo;) until the Maturity Date. At the election of the Company and subject to receipt
of approval of the TSX, accrued interest payable on an Interest Due Date or the Maturity Date may be satisfied, in lieu of cash, by the
issuance of Common Shares at the Market Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If the Company fails to make
the payment of Principal Amount or interest required to be made hereunder, on the day on which the same is due and payable, the Company
will pay interest on the amount or amounts so required to have been paid at the rate of interest as aforesaid calculated and payable from
the date of such failure until the date of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.3</FONT></TD><TD STYLE="text-align: justify">Interest on Redemption or Conversion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Upon redemption or conversion
of all or part of the Principal Amount of the Debenture, any accrued and unpaid interest in respect of such redeemed or converted Principal
Amount will be paid in cash, or at the election of the Company and subject to receipt of approval of the TSX, may be satisfied, in lieu
of cash, by the issuance of Common Shares at the Market Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.4</FONT></TD><TD STYLE="text-align: justify">Redemption of Debenture in Common Shares</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to receipt of approval
of the TSX (and, if applicable, shareholders of the Company), the Company may redeem all or a portion of the Principal Amount plus any
accrued and unpaid interest, if applicable, on the Maturity date, by issuing Common Shares in lieu of cash, provided that the Company
provides notice to the Holder pursuant to Section 2.5. The number of Common Shares to be issued pursuant to any such redemption shall
be calculated by dividing the redemption amount by the greater of: (i) the Market Price as of the date of the Redemption Notice less a
10% discount, and (ii) the minimum price permitted by the rules of the TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.5</FONT></TD><TD STYLE="text-align: justify">Notice of Redemption</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company will give
notice of redemption (the &ldquo;<B>Redemption Notice</B>&rdquo;), in accordance with Section&nbsp;7.2 hereof, to the Holder not
less than fourteen (14) Business Days but not more than thirty (30) Business Days prior to the date of redemption (the
 &ldquo;<B>Redemption Date</B>&rdquo;). The Redemption Notice shall specify the aggregate Principal Amount of the Debenture to be
redeemed, the accrued and unpaid interest in respect of such redeemed Principal Amount and whether the Company will redeem all or a
part of the Principal Amount and accrued and unpaid interest in cash or Common Shares. Upon receiving a Redemption Notice whereby
the Company is electing to redeem all or part of the Principal Amount, the Holder will be entitled (on written notice being given by
the Holder to the Company at least one (1) Business Day before the Redemption Date) to convert the Principal Amount called for
redemption at the Conversion Price pursuant to Article&nbsp;4 at any time prior to the Redemption Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.6</FONT></TD><TD STYLE="text-align: justify">Payment of Amount Redeemed</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Upon a Redemption Notice being
given, that portion of the Debenture that is being redeemed will become due and payable on the Redemption Date specified in the Redemption
Notice and the Company may not withdraw the Redemption Notice without the prior consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">2.7</FONT></TD><TD STYLE="text-align: justify">Pre-emptive Right</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Subject to any required approval by, or notice to, the TSX under the rules and regulations of the TSX
(and where applicable, any required shareholder approval), in the event of any private placement (i.e., a capital raising, prospectus-exempt
offering) or public offering (i.e., a capital raising, prospectus offering) from and after the Issue Date (in each case, a &ldquo;<B>Distribution</B>&rdquo;),
other than, for greater certainty, Exempt Issuances, of Common Shares or of securities convertible or exchangeable into Common Shares
or otherwise presenting a right to acquire Common Shares (&ldquo;<B>Convertible Securities</B>&rdquo; and, together with the Common Shares,
the &ldquo;<B>Distributed Securities</B>&rdquo;), the Holder shall have the right (the &ldquo;<B>Pre-emptive Right</B>&rdquo;) to subscribe
for that number of Common Shares or Convertible Securities, as the case may be, on the same terms and conditions, including subscription
or exercise price, as applicable, sufficient for the Holder to maintain the same percentage ownership in the Common Shares (on an as-converted
basis, as the case may be) as the Holder had immediately prior to the Distribution, on a fully diluted basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">To the extent that any Pre-emptive Right is exercised, in whole or in part, the securities underlying
such Pre-emptive Right (the &ldquo;<B>Subscription Securities</B>&rdquo;) shall be issued and must be paid for concurrently with the completion
of the Distribution and payment to the Company of the issue price for the Distributed Securities, at the price (the &ldquo;<B>Issue Price</B>&rdquo;)
at which the Distributed Securities are then being issued or distributed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">At least seven (7) Business Days prior to the closing of any proposed Distribution, the Company shall
deliver to the Holder a notice (the &ldquo;<B>Pre-emptive Notice</B>&rdquo;) in writing offering the Holder the opportunity to subscribe
for the applicable number of Subscription Securities. The Pre-emptive Notice will contain a description of the terms and conditions relating
to the Distributed Securities and will, to the extent known, state the Issue Price at which the Distributed Securities will be distributed
and the date on which the issuance of Distributed Securities is to be completed. If the Holder wishes to subscribe for Subscription Securities,
the Holder may do so only by giving written notice of the exercise of the Pre-emptive Right within five (5) Business Days after the date
of the Pre-emptive Notice.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;3<BR>
COVENANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">3.1</FONT></TD><TD STYLE="text-align: justify">Covenants of the Company</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company covenants and agrees
with the Holder that, unless otherwise consented to in writing by the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Observe Obligations.</B> The Company will duly pay or cause to be paid to the Holder the Principal
Amount and interest of this Debenture and any other amounts owed to the Holder at the dates and places, and in the manner set forth herein;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Reservation of Common Shares.</B> The Company shall at all times have reserved for issuance out of
its authorized capital a sufficient number of Common Shares to satisfy its obligations to issue and deliver Common Shares upon the due
conversion of the Debenture;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>Approvals and Filings.</B> The Company shall, in connection with the execution and delivery of
                                                           this Debenture, the conversion of the Debenture into Common Shares or the election to satisfy the payment of interest by the issunce of Common Shares, obtain any
and all requisite approvals of the shareholders of the Company and statutory and regulatory approvals required to effect and complete
the same and shall file all notices, reports and other documents required to be filed by or on behalf of the Company pursuant to Applicable
Securities Laws in respect thereof, including the rules and regulations of the TSX;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B>Resale Restrictions.</B> All Common Shares issued to the Holder upon conversion of the Debenture or
any part thereof from time to time will be subject to resale restrictions imposed under Applicable Securities Laws and applicable federal
and &ldquo;blue sky&rdquo; securities laws of the United States of America and the rules of regulatory bodies having jurisdiction over
the Company including, without limiting the generality of the foregoing, that the Common Shares so issued shall not be traded for a period
of four months from the date of the execution of this Debenture except as permitted by Applicable Securities Laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><B>Restrictions in the U.S.</B> This Debenture and the securities deliverable upon conversion hereof have
not been and will not be registered under the 1933 Act, or the securities laws of any state of the United States. This Debenture may not
be converted in the United States, or by or for the account or benefit of a U.S. person or a person in the United States, unless (i) the
underlying Common Shares are registered under the 1933 Act and the applicable laws of any U.S. state, or (ii) an exemption from such registration
requirements is available, and (iii) the Holder has complied with the requirements set forth in the Conversion Form attached hereto as
Schedule &ldquo;B&rdquo;;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><B>Certificate Legend.</B> A legend will be placed on the certificates representing the Common Shares
issued on Conversion of the Debenture denoting the restrictions on transfer imposed by Applicable Securities Laws, if applicable, including
but not limited to the following legend:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><B>&ldquo;UNLESS PERMITTED UNDER
SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE JULY 23, 2021.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><B>Listing.</B> The Company shall at all times while this Debenture is outstanding, use its best efforts
to maintain its status as a &ldquo;reporting issuer&rdquo; not in default in the provinces of British Columbia, Alberta and Ontario and
the listing of the Common Shares on the TSX. In addition, the Company shall use commercially reasonable efforts to list the Common Shares
on the Nasdaq, if the board of directors of the Company determines that it would be in the best interest of the Company to seek such listing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify"><B>Canadian Securities Laws.</B> All Common Shares issued to the Holder upon conversion of the Debenture
or any part thereof shall be made pursuant to an exemption from prospectus and registration requirements available to the Holder or the
Company in respect of the transactions contemplated herein under Applicable Securities Laws; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><B>Holder Approval.</B> The Company shall not issue any convertible debt ranking senior to the Debentures
without the written consent of holders of at least 60% of the then outstanding Debentures unless: (i) more than 50% of the Debentures
have been converted or redeemed, (ii) the Market Price of the Common Shares at the time of issuance of such convertible debt is greater
than two times the Conversion Price, or (iii) such convertible debt is issued on or after March 22, 2025.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;4<BR>
CONVERSION Of principal amount</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.1</FONT></TD><TD STYLE="text-align: justify">Conversion Privilege and Conversion Price</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Holder shall have the right, from time to time and at any time following the Issue Date and at any
time on or prior to 5:00 p.m. (Vancouver time) on the Business Day immediately preceding the Maturity Date, to convert to Common Shares,
all or any part of the outstanding Principal Amount of the Debenture on the Conversion Date, at the Conversion Price, provided no partial
conversion shall be for less than the Minimum Threshold Amount.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In the event the Holder receives a Redemption Notice from the Company in accordance with Section&nbsp;2.5
hereof, the Holder shall have the right to convert to Common Shares all or any part of the outstanding Principal Amount of the Debenture
on the Conversion Date at the Conversion Price, subject to the Holder having provided the Company, at least one (1) Business Day prior
to the Redemption Date, with notice of such election in accordance with Section&nbsp;4.2 below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.2</FONT></TD><TD STYLE="text-align: justify">Manner of Exercise of Right to Convert or Purchase</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Holder may, at any time commencing following the Issue Date and at any time on or prior to 5:00 p.m.
(Vancouver time) on the Business Day immediately preceding the Maturity Date, convert the outstanding Principal Amount of the Debenture
on the Conversion Date, in whole or in part, provided that no conversion shall be for less than the Minimum Threshold Amount, into Common
Shares at the Conversion Price, by delivering to the Company, the conversion form attached hereto as Schedule B executed by the Holder
or the Holder&rsquo;s attorney duly appointed by an instrument in writing, exercising the Holder&rsquo;s right to convert the Debenture
in accordance with the provisions of this Article&nbsp;4. Thereupon, the Holder or, subject to payment of all applicable stamp or security
transfer taxes or other governmental charges, the Holder&rsquo;s nominee(s) or assignee(s) shall be entitled to be entered in the books
of the Company as at the Conversion Date (or such later date as is specified in Section 4.2(b) as the holder of the number of Common Shares
into which the Debenture is convertible in accordance with the conversion form then received by the Company and the provisions of this
Article&nbsp;4 and, as soon as practicable thereafter, the Company shall deliver to the Holder and/or, subject as aforesaid, the Holder&rsquo;s
nominee(s) or assignee(s), a certificate or certificates for such Common Shares affixed with all required legends;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">For the purposes of this Article&nbsp;4, the Debenture shall be deemed to be converted on the Conversion
Date on which the conversion form under Section 4.2(a) is actually received by the Company, provided that if such conversion form or notice
is received on a day on which the register of Common Shares is closed, the person or persons entitled to receive Common Shares shall become
the holder or holders of record of such Common Shares as at the date on which such register is next reopened;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Any part of the Principal Amount of the Debenture may be converted as provided in Section 4.2(a) and if
this Debenture is tendered for partial conversion, the Debenture shall be cancelled as to the Principal Amount thereunder that is being
converted and the Debenture shall be deemed to be in the amount of the remaining Principal Amount; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Holder shall be entitled in respect of Common Shares issued upon conversion of the Debenture to dividends
declared in favour of shareholders of record of the Company on and after the Conversion Date or such later date as the Holder shall become
the holder of record of such Common Shares pursuant to Section 4.2(b), from which applicable date any Common Shares so issued to the Holder
shall for all purposes be and be deemed to be outstanding as fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.3</FONT></TD><TD STYLE="text-align: justify">Adjustment of Conversion Price</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Conversion Price in effect
at any date shall be subject to adjustment from time to time as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If and whenever at any time prior to the close of business of the Company up to and including the Maturity
Date, (referred to in this Section&nbsp;4.3 as the &ldquo;<B>Time of Expiry</B>&rdquo;), the Company shall:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">subdivide, redivide or change its Common Shares into a greater number of shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">consolidate, reduce or combine its Common Shares into a lesser number of shares; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">issue Common Shares to all or substantially all of the holders of its Common Shares by way of a stock
dividend or other distribution on such Common Shares payable in Common Shares (other than dividends paid in the ordinary course),</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(any such event being hereinafter referred
to as a &ldquo;<B>Capital Reorganization</B>&rdquo;), the Conversion Price shall be adjusted by multiplying the Conversion Price in effect
on the effective date of such event referred to in Section 4.3(a)(i) or Section 4.3(a)(ii) or on the record date of such stock dividend
referred to in Section 4.3(a)(iii), as the case may be, by a fraction, the numerator of which shall be the number of Common Shares outstanding
before giving effect to such Capital Reorganization and the denominator of which shall be the number of Common Shares outstanding after
giving effect to such Capital Reorganization. Such adjustment shall be made successively whenever any Capital Reorganization shall occur
and any such issue of Common Shares by way of a stock dividend or other such distribution shall be deemed to have been made on the record
date thereof for the purpose of calculating the number of outstanding Common Shares under Sections&nbsp;4.3(a)(i) and 4.3(a)(ii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If and whenever at any time prior to the Time of Expiry, the Company shall fix a record date for the distribution
to all or substantially all the holders of its Common Shares of:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">shares of any class whether of the Company or any other corporation (excluding dividends paid in the ordinary
course);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">rights or options;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">evidences of indebtedness; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">other assets or property (excluding dividends paid in the ordinary course),</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and if such distribution does not constitute
a Capital Reorganization or does not consist of rights or options entitling the holders, for a period expiring not more than forty-five
(45) days after such record date, to subscribe for or purchase Common Shares at a price per share or having a conversion or exchange price
per share of at least 95% of the Current Market Price per Common Share on such record date (any such non-excluded event being hereinafter
referred to as a &ldquo;<B>Special Distribution</B>&rdquo;), the Conversion Price shall be adjusted immediately after such record date
so that it shall equal the price determined by multiplying the Conversion Price in effect on such record date by a fraction, of which
the numerator shall be the total number of Common Shares outstanding on such record date multiplied by the Current Market Price per Common
Share determined on such record date, less the excess of the fair market value (as determined by the board of directors of the Company,
which determination shall be conclusive and subject to TSX acceptance) of such Special Distribution over the fair market value (as determined
by the board of directors of the Company, which determination shall be conclusive and subject to TSX acceptance) of the consideration
therefor, if any, received by the Company and of which the denominator shall be the total number of Common Shares outstanding on such
record date multiplied by such Current Market Price per Common Share. Any Common Shares owned by or held for the account of the Company
shall be deemed not to be outstanding for the purposes of any such computation. Such adjustment shall be made successively whenever such
a record date is fixed. The extent that such Special Distribution is not so made or to the extent any such rights, options are not exercised
prior to the expiration thereof, the Conversion Price shall then be readjusted to the Conversion Price which would then be in effect if
such record date had not been fixed or if such expired rights or options had not been issued;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">For the purpose of any computation under Section 4.3(b), the &ldquo;<B>Current Market Price</B>&rdquo;
per Common Share at any date shall be the Market Price per share of such Common Shares on the TSX ending three Business Days immediately
preceding such date, or, if the Common Shares are not listed on the TSX, any other exchange on which the Common Shares are listed or,
if the Common Shares are not listed on any exchange, on any over-the-counter market on which the Common Shares are quoted;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If and whenever at any time prior to the Time of Expiry, there is a reclassification or change of
                                                           Common Shares into other shares or there is a consolidation, merger, reorganization or amalgamation of the Company with or into
                                                           another corporation or entity that results in any reclassification of Common Shares or a change of Common Shares into other shares
                                                           or there is a transfer of the undertaking or assets of the Company as an entirety or substantially as an entirety to another person
                                                           (any such event being hereinafter referred to as a &ldquo;<B>Reclassification of Common Shares</B>&rdquo;), the Holder shall be
                                                           entitled to receive and shall accept, upon the exercise of the Holder&rsquo;s right of conversion at any time after the effective
                                                           date thereof, in lieu of the number of Common Shares of the Company to which
the Holder was theretofore entitled on conversion, the kind and amount of shares or other securities or money or other property that the
Holder would have been entitled to receive as a result of such Reclassification of Common Shares, if, on the effective date thereof, the
Holder had been the registered holder of the number of such Common Shares to which the Holder was theretofore entitled upon conversion,
subject to adjustment thereafter in accordance with provisions the same, as nearly as may be possible, as those contained in this Section&nbsp;4.3;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">In any case in which this Section&nbsp;4.3 shall require that an adjustment become effective immediately
after a record date or agreement date for an event referred to herein, the Company may defer, until the occurrence of such event, issuing
or transferring to the Holder who converts on a Conversion Date after such record date or agreement date and before the occurrence of
such event the additional Common Shares issuable upon conversion by reason of the adjustment of the Conversion Price required by such
event before giving effect to such adjustment; provided, however, that the Company shall deliver to the Holder an appropriate instrument
evidencing the Holder's right to receive such additional Common Shares upon the occurrence of the event requiring such adjustment and
the right to receive any distributions made on such additional Common Shares on and after the Conversion Date or such later date as the
Holder would, but for the provisions of this Section 4.3(e), have become the holder of record of such additional Common Shares pursuant
to Section 4.3(b);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">In case the Company after the date hereof shall take any action affecting its Common Shares, other than
any action described in this Section&nbsp;4.3, which in the opinion of the Holder, acting reasonably, would materially affect the conversion
rights of the Holder, the Conversion Price shall be adjusted in such manner, at such time and by such action by the directors of the Company,
as they may determine, acting reasonably, to be equitable to the Holder and the Company in the circumstances, but subject in all cases
to any necessary regulatory approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">The adjustments provided for in this Section&nbsp;4.3 are cumulative and shall apply to successive subdivisions,
redivisions, reductions, combinations, consolidations, distributions, issues or other events resulting in any adjustment under the provisions
of this Section, provided that, notwithstanding any other provision of this Section, no adjustment shall be made which would result in
any increase in the Conversion Price (except upon a consolidation, reduction or combination of outstanding Common Shares) and no adjustment
of the Conversion Price shall be required unless such adjustment would require a decrease of at least 1% in the Conversion Price then
in effect; provided, however, that any adjustments which by reason of this subsection (h) are not required to be made shall be carried
forward and taken into account in any subsequent adjustment;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">In the event of any dispute arising with respect to the adjustments provided in this Section&nbsp;4.3,
such question shall be conclusively determined by a firm of chartered professional accountants appointed by the Company (who may be auditors
of the Company) and acceptable to the Holder. Such accountants shall have access to all necessary records of the Company and such determination
shall be binding upon the Company and the Holder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Notwithstanding any other provision herein contained, no adjustment to the Conversion Price shall be made
in respect of any event described in this Section&nbsp;4.3, if the Holder is entitled, without converting the Debenture, to participate
in such event, subject to TSX acceptance, on the same terms mutatis mutandis as if the Holder had converted the Debenture into Common
Shares prior to or on the effective date or record date of such event; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">If any Common Shares to be issued upon the conversion of the Debenture hereunder require any filing or
registration with or approval of any Official Body in Canada or the United States or compliance with any other requirement under any law
of Canada or the United States or province or state thereof before such shares may be validly issued upon such conversion or traded by
the person to whom they are issued pursuant to such conversion, the Company will take all reasonable action as may be necessary to secure
such filing, registration, approval or compliance as the case may be.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.4</FONT></TD><TD STYLE="text-align: justify">No Requirement to Issue Fractional Shares</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company shall not be required
to issue fractional Common Shares upon the conversion of the Debenture pursuant to this Article&nbsp;4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.5</FONT></TD><TD STYLE="text-align: justify">Certificate as to Adjustment</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company shall from time
to time forthwith after the occurrence of any event which requires adjustment or readjustment as provided in Section&nbsp;4.3, deliver
to the Holder at the Holder&rsquo;s address set forth on the final page hereof, an officer's certificate specifying the nature of the
event requiring the same and the amount of the adjustment necessitated thereby and setting forth in reasonable detail the method of calculation
and the facts upon which such calculation are based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.6</FONT></TD><TD STYLE="text-align: justify">Limits on Conversion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Subject to Section 4.6(b), at any given time during the term of this Debenture until the Maturity Date,
the Holder may only convert such amount of the Principal Amount that, upon issuance of the Common Shares issuable upon conversion thereof,
together with any other Common Shares and securities convertible or exercisable into Common Shares, calculated on an &ldquo;as if converted&rdquo;
and &ldquo;as if exercised basis&rdquo;, that are beneficially owned or controlled or directed by the Holder, will result in the Holder
owning, or having control or direction over, less than 10% of the issued and outstanding Common Shares. For greater clarity, the Holder
may not convert any portion of the Principal Amount if the Common Shares issued upon the conversion thereof together with any other securities
beneficially owned or controlled or directed by the Holder will result in the Holder owning or having control or direction over or being
deemed to own or have control or direction over 10% or more of the Company&rsquo;s issued and outstanding securities such that the Holder
will become a reporting insider under Applicable Securities Laws by virtue of such conversion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Section 4.6(a) shall not apply to the Holder provided that the Holder gives no less than sixty-one (61)
days notice to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">4.7</FONT></TD><TD STYLE="text-align: justify">Forced Conversion</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Provided there is no Event of
Default as contemplated herein, if at any time after the Issue Date until the Maturity Date, the Company raises gross proceeds of US$50,000,000
or more in the aggregate, in one or more equity or debt financings (the &ldquo;<B>Forced Conversion Trigger</B>&rdquo;), the Company may
upon not less than five (5) Business Days&rsquo; and not more than twenty (20) Business Days&rsquo; prior written notice to the Holder
(the &ldquo;<B>Forced Conversion Notice</B>&rdquo;), require the conversion of all or part of the Principal Amount into Common Shares
at the Conversion Price (the &ldquo;<B>Forced Conversion Shares</B>&rdquo;). Any accrued and unpaid interest in respect of such converted
Principal Amount will be paid in cash, or at the election of the Company and subject to receipt of approval of the TSX, may be satisfied,
in lieu of cash, by the issuance of Common Shares at the Market Price. The Company shall issue and deliver to the Holder a share certificate
representing the Forced Conversion Shares and any Common Shares issued in lieu of cash for the payment of any accrued and unpaid interest
within five (5) Business Days of the date of conversion specified in any Forced Conversion Notice, which conversion date shall be no later
than five (5) Business Days after the closing date of the applicable financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;5<BR>
EVENTS OF DEFAULT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">5.1</FONT></TD><TD STYLE="text-align: justify">General</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The occurrence of any one or
more of the following events (&ldquo;<B>Events of Default</B>&rdquo;) will constitute a default hereunder (whether any such event is voluntary
or involuntary or is effected by operation of law or pursuant to or in compliance with any judgment, decree or order of any court of any
order, rule or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Non-Compliance.</B> The Company fails to observe or perform one or more covenants, agreements, conditions
or obligations in favour of the Holder, including a failure to pay any or all of the Principal Amount, interest and other monies due under the Debenture
when due, and such failure continues unremedied for a period of fifteen (15) days after the Holder gives notice thereof to the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Ceasing to Carry on Business. </B>The Company ceases or threatens to cease to carry on business;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>Bankruptcy or Insolvency.</B> The Company becomes insolvent or makes a voluntary assignment or proposal
in bankruptcy or otherwise acknowledges its insolvency, or a bankruptcy petition is filed or presented against the Company, or the Company
commits or threatens to commit an act of bankruptcy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B>Receivership.</B> A receiver or receiver manager of the Company or its subsidiary is appointed under
any statute or pursuant to any document issued by the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><B>Compromise or Arrangement.</B> Any proceedings with respect the Company are commenced under the compromise
or arrangement provisions of the corporation statute pursuant to which the Company is governed, or the Company enter into an arrangement
or compromise with any or all of their respective creditors pursuant to such provisions or otherwise;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><B>Companies&rsquo; Creditors Arrangement Act.</B> Any proceedings with respect to the Company are commenced
in any jurisdiction under the <I>Companies' Creditors Arrangement Act</I> (Canada) or any similar legislation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><B>Liquidation.</B> An order is made, a resolution is passed, or a petition is filed, for the liquidation,
dissolution or winding-up of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;6<BR>
RIGHTS, REMEDIES AND POWERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">6.1</FONT></TD><TD STYLE="text-align: justify">Upon Default</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">If any Event of Default shall
occur, the Holder may provide the Company with notice of such Event of Default (the &ldquo;<B>Default Notice</B>&rdquo;). Upon receipt
of such notice, the Company shall have the option to cure such Event of Default within thirty (30) days (the &ldquo;<B>Cure Period</B>&rdquo;).
If the Event of Default has not been cured by the Company to the reasonable satisfaction of the Holder during the Cure Period, the Holder
shall be entitled to exercise any and all of its rights pursuant to this Debenture, including declaring the Principal Amount of the Debenture
and interest then outstanding on such date and all other amounts outstanding to be due and payable forthwith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">6.2</FONT></TD><TD STYLE="text-align: justify">Waiver</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Holder in its absolute discretion
may at any time and from time to time by written notice waive any breach by the Company of any of its covenants or agreements herein.
No failure or delay on the part of the Holder to exercise any right, remedy or power given herein or by any other existing or future agreement
or now or hereafter existing by statute, at law or in equity will operate as a waiver thereof, nor will any single or partial exercise
of any such right, remedy or power preclude any other exercise thereof or the exercise of any other such right, remedy or power, nor will
any waiver by the Holder be deemed to be a waiver of any subsequent, similar or other event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;7<BR>
OTHER AGREEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.1</FONT></TD><TD STYLE="text-align: justify">Withholding Taxes</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If the Company is obliged to
withhold any payment hereunder on account of present or future taxes, duties, assessments or other governmental charges required by law,
the Company shall make such withholding or deduction and pay the balance owing to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.2</FONT></TD><TD STYLE="text-align: justify">Amendment and Waiver</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Neither this Debenture nor any
provision hereof may be amended, waived, discharged or terminated except by a document in writing executed by the party against whom enforcement
of the amendment, waiver, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.3</FONT></TD><TD STYLE="text-align: justify">Notices and Other Instruments</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any notice, demand or other
communication required or permitted to be given to any party hereunder shall be in writing and shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">personally delivered to such party; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">except during a period of strike, lock-out or other postal disruption, sent by double registered mail,
postage prepaid to the address of such party set forth on page one; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">sent by facsimile transmission or other means of electronic communication to the address of such party
set forth on page one;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">and shall be deemed to have
been received by such party on the earliest of the date of delivery under Section 7.2(a), the actual date of receipt when mailed under
Section&nbsp;7.2(b) and the Business Day following the date of communication under Section 7.2(c). Any party may give written notice to
the other parties of a change of address to some other address, in which event any communication shall thereafter be given to such party
as hereinbefore provided, at the last such changed address of which the party communication has received written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.4</FONT></TD><TD STYLE="text-align: justify">Maximum Rate</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding any other provisions
of this Debenture or any other agreement, the maximum amount (including interest, fees, bonus and any other consideration) payable to
the Holder in connection with the Debenture and each part thereof shall not exceed the maximum allowable return permitted under the laws
of Ontario and the laws of Canada applicable therein, and the provisions of this Debenture and all other existing and future agreements
are hereby modified to the extent necessary to effect the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.5</FONT></TD><TD STYLE="text-align: justify">Successors and Assigns</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Debenture shall be binding
upon the Company, its successors and permitted assigns, and shall enure to the benefit of the Holder and its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.6</FONT></TD><TD STYLE="text-align: justify">Headings, etc.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The division of this Debenture
into sections and subsections and the insertion of headings are for convenience of reference only and shall not affect the construction
or interpretation hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.7</FONT></TD><TD STYLE="text-align: justify">Severability</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The provisions of this Debenture
are intended to be severable. If any provision of this Debenture shall be deemed by any court of competent jurisdiction or held to be
invalid or void or unenforceable in whole or in part in any jurisdiction, such provision shall, as to such jurisdiction, be ineffective
to the extent of such invalidity or unenforceability without in any manner affecting the validity or enforceability thereof in any other
jurisdiction or the remaining provisions hereof in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.8</FONT></TD><TD STYLE="text-align: justify">Holder&rsquo;s Rights and Remedies</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition to the
foregoing without limitation: (i) the Holder&rsquo;s rights and remedies hereunder, shall be cumulative and not exclusive of any
rights or remedies which it would otherwise have; no delay or omission by the Holder in exercising or enforcing any of the
Holder&rsquo;s rights and remedies hereunder shall operate as, or constitute, a waiver thereof; no waiver by the Holder of any Event
of Default shall operate as a waiver of any other default hereunder; no single or partial exercise of any of the Holder&rsquo;s
rights or remedies hereunder, and no express or implied agreement or transaction of whatever nature entered into between the Holder
and any person, at any time, shall preclude the other or further exercise of the Holder&rsquo;s rights and remedies hereunder; no
waiver by the Holder of any of the Holder&rsquo;s rights and remedies hereunder on any one occasion shall be deemed a waiver on any
subsequent occasion, nor shall it be deemed a continuing waiver; and (ii) the Holder&rsquo;s rights and remedies hereunder may be
exercised at such time or times and in such order of preference as the Holder may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.9</FONT></TD><TD STYLE="text-align: justify">Governing Law</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Debenture shall be governed
by and construed in accordance with the laws of the Province of Ontario and of Canada applicable therein and shall be treated in all respects
as a Ontario contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.10</FONT></TD><TD STYLE="text-align: justify">Counterparts</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Agreement may be executed
in counterparts and, when each party has executed a counterpart, each of such counterparts shall be deemed to be an original and all of
such counterparts when taken together shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><FONT STYLE="font-weight: normal">7.11</FONT></TD><TD STYLE="text-align: justify">Electronic Copies</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Agreement may be executed
by the parties and transmitted by e-mail and if so executed and transmitted, this Agreement will be for all purposes as effective as if
the parties had delivered and executed an original Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SCHEDULE b<BR>
<BR>
</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">CONVERSION FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TO:&#9;PROMIS NEUROSCIENCES INC. (the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The undersigned, being the Holder
pursuant to a Debenture dated <B>March 22, 2021</B> granted by the Company to the undersigned (the &ldquo;<B>Debenture</B>&rdquo;), hereby
irrevocably elects to convert the Principal Amount of US$_________ under the Debenture into _________ Common Shares of <B>PROMIS NEUROSCIENCES
INC.</B> in accordance with the terms of the Debenture and directs that the Common Shares issuable and deliverable upon the conversion
be issued and delivered to the person indicated below. (If Common Shares are to be issued in the name of a person other than the Holder,
all requisite transfer taxes or fees must be tendered by the undersigned).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The undersigned Holder represents, warrants and certifies as follows (only one) of the following must
be checked):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>A.
<I>Regulation S </I>&ndash; The undersigned Holder (i) is not in the United States; (ii) is not a &ldquo;U.S. person&rdquo; as defined
in Regulation S under the United States Securities Act of 1933, as amended (the &ldquo;<B>1933 Act</B>&rdquo;), and is not converting
the Principal Amount (or portion thereof) on behalf of a U.S. person or a person in the United States; and (iii) did not execute or deliver
this notice form in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. <I>Section 3(a)(9) of
the 1933 Act - </I>The undersigned Holder has not been solicited to convert the Principal Amount (or portion thereof) by any person, or
if the undersigned has been solicited to convert the Principal Amount (or portion thereof) the undersigned has confirmed that no commission
or remuneration has been or will be paid or given, directly or indirectly, for soliciting such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. <I>Rule 506(b) of Regulation
D under the 1933 Act - </I>The undersigned Holder has been solicited to convert the Principal Amount (or portion thereof) but the undersigned
has been unable to confirm that no commission or remuneration has been or will be paid or given, directly or indirectly, for soliciting
such conversion. The undersigned (i) is the original purchaser of the Debenture, having participated in the unregistered private placement
offering of Debentures by the Company, (ii) is converting the Principal Amount (or portion thereof) solely for the undersigned&rsquo;s
own account for investment purposes only, and (iii) the undersigned continues to qualify as an &ldquo;accredited investor&rdquo; (as defined
in Rule 501(a) of Regulation D under the 1933 Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. <I>Other - </I>The undersigned
Holder has delivered to the Company an opinion of counsel reasonably satisfactory to the Company to the effect that an exemption from
the registration requirements of the 1933 Act and applicable state securities laws is available. (Note: If this box is to be checked,
the Holder is encouraged to consult with the Company in advance to determine that the legal opinion tendered in connection with conversion
will be reasonably satisfactory in form and substance to the Company.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">&ldquo;<B>United States</B>&rdquo; and &ldquo;<B>U.S. person</B>&rdquo; are as defined in Regulation S
under the 1933 Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Certificates or other instruments representing Common Shares will not be registered or delivered to an
address in the United States unless Box (B) or (C) above is checked.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">If the undersigned has marked Box (B) and the Debenture bears a U.S. restrictive legend (or is otherwise
identified as a &ldquo;restricted security&rdquo; in the Company&rsquo;s records), or if the undersigned has marked Box (C) above, the
undersigned acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Common Shares will be issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144(a)(3)
under the 1933 Act) and that the 1933 Act and the rules of the United States Securities and Exchange Commission provide in substance that
the undersigned may dispose of the Common Shares only pursuant to an effective registration statement under the 1933 Act or an exemption
or exclusion therefrom;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">if the undersigned decides to offer, sell or otherwise transfer any of the Common Shares, the undersigned
must not, and will not, offer, sell or otherwise transfer any of such Common Shares directly or indirectly, unless:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the sale is to the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the sale is made outside the United States in a transaction meeting the requirements of Rule 904 of Regulation
S under the 1933 Act and in compliance with applicable local laws and regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the sale is made pursuant to the exemption from the registration requirements under the 1933 Act provided
by Rule 144 thereunder and in accordance with any applicable state securities or &ldquo;blue sky&rdquo; laws; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the Common Shares are sold in a transaction that does not require registration under the 1933 Act or any
applicable state laws and regulations governing the offer and sale of securities, and it has prior to such sale furnished to the Company
an opinion of counsel reasonably satisfactory to the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the certificates or other instruments representing the Common Shares as well as all certificates issued
in exchange for or in substitution of therefor, until such time as is no longer required under the applicable requirements of the 1933
Act and applicable state securities laws, will bear, on the face of such certificate or other instrument, the following legend:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 1.5in; text-align: justify; text-indent: 0in"><B>THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;1933
ACT&rdquo;), OR THE LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF
THE CORPORATION THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE
UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE 1933 ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS,
(C) IN COMPLIANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE 1933 ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS OR (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE 1933 ACT OR ANY APPLICABLE
STATE SECURITIES LAWS AND, IN THE CASE OF (C) AND (D) ABOVE, AFTER THE SELLER FURNISHES TO THE CORPORATION AN OPINION OF COUNSEL OF RECOGNIZED
STANDING OR OTHER EVIDENCE IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION TO SUCH EFFECT. DELIVERY OF THIS CERTIFICATE MAY NOT
CONSTITUTE &ldquo;GOOD DELIVERY&rdquo; IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.</B>&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 1.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">provided that if the
Common Shares are being sold outside the United States in compliance with the requirements of Rule 904 of Regulation S and the Company
was a &ldquo;foreign issuer&rdquo; as defined in Regulation S at the time of issuance of the Common Shares, the legend set forth above
may be removed by providing a declaration to the registrar and transfer agent of the Company, as set forth in Appendix 1 hereto (or in
such other form as the Company may prescribe from time to time) and, if requested by the Company or transfer agent, an opinion of counsel
of recognized standing in form and substance satisfactory to the Company to the effect that the transfer is in compliance with Rule 904;
and provided, further, that, if any Securities are being sold otherwise than in accordance with Regulation S and other than to the Company,
the legend may be removed by delivery to the registrar and transfer agent and the Company of an opinion of counsel, of recognized standing
reasonably satisfactory to the Company, that such legend is no longer required under applicable requirements of the 1933 Act or state
securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Company is not obligated to remain a &ldquo;foreign issuer&rdquo;; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the Company has no obligation to register any of the Common Shares or to take any other action so as to
permit sales pursuant to the 1933 Act (including Rule 144 thereunder).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">If the undersigned has marked Box (B) or Box (C) above, the undersigned represents and warrants that the
funds representing the purchase price for the Common Shares which will be advanced by the undersigned to the Company will not represent
proceeds of crime for the purposes of the United States <I>Uniting and Strengthening America by Providing Appropriate Tools Required to
Intercept and Obstruct Terrorism Act</I> (the &ldquo;<B>PATRIOT Act</B>&rdquo;), and the undersigned acknowledges that the Company may
in the future be required by law to disclose the undersigned&rsquo;s name and other information relating to this Warrant Exercise Form
and the undersigned&rsquo;s subscription hereunder, on a confidential basis, pursuant to the PATRIOT Act. No portion of the purchase price
to be provided by the undersigned (i) has been or will be derived from or related to any activity that is deemed criminal under the laws
of the United States, or any other jurisdiction, or (ii) is being tendered on behalf of a person or entity who has not been identified
to or by the undersigned, and the undersigned shall promptly notify the Company if the undersigned discovers that any of such representations
ceases to be true and provide the Company with appropriate information in connection therewith.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated the _______________ day of _______________,
________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%">(Please print full name)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Signature)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%">(Print full address, including postal code)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares are to be issued as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; vertical-align: top; width: 50%; padding-right: 0.55in; text-align: left"><B>Registration Instructions: Register the<BR>
 Common Shares as set forth below:</B></TD>
    <TD STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; vertical-align: bottom; width: 50%; padding-right: 0.5in; text-align: left"><B>Delivery Instructions: Deliver the Common <BR>
Shares as set forth below:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 16.5pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 13.6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 16.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Address, including postal code</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 13.6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Address, including postal code</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 16.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Telephone Number</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Instructions:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The registered holder may exercise its right to receive Common Shares by completing this form and surrendering
this form and the Debenture Certificate representing the Debenture being converted to the head office of the Company at Suite 200, 1920
Yonge Street, Toronto, Ontario M4S 3E2, Attention: CFO, or such other office as the Company may advise the holder in writing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">If the Conversion Form indicates that Common Shares are to be issued to a person or persons other than
the registered holder of the Debenture Certificate, the signature of such holder of the Conversion Form <U>must</U> be guaranteed by an
authorized officer of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">If the Conversion Form is signed by a trustee, exercise, administrator, curator, guardian, attorney, officer
of a corporation or any person acting in a judiciary or representative capacity, the certificate must be accompanied by evidence of authority
to sign satisfactory to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">APPENDIX &ldquo;1&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF DECLARATION FOR REMOVAL OF LEGEND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>TO:</B></FONT></TD><TD STYLE="text-align: justify; width: 85%"><FONT STYLE="font-size: 10pt">The registrar and transfer agent
                                         for the Corporation</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
                                                                                                                                       <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt"><B>AND TO:</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ProMIS Neurosciences, Inc. (the &ldquo;<B>Corporation</B>&rdquo;)</FONT></TD></TR>
                                                                                                                                                                   </TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (A) acknowledges that the sale
of _______________________ of the Corporation represented by certificate number _____________ or held in Direct Registration System (DRS)
account number _____________, to which this declaration relates, is being made in reliance on Rule 904 of Regulation S (&ldquo;<B>Regulation
S</B>&rdquo;) under the United States Securities Act of 1933, as amended (the &ldquo;<B>1933 Act</B>&rdquo;), and (B) certifies that (1)
the undersigned is not (i) an &ldquo;affiliate&rdquo; (as that term is defined in Rule 405 under the 1933 Act) of the Corporation, except
solely by virtue of being an officer or director of the Corporation , (ii) a &ldquo;distributor&rdquo; as defined in Regulation S, or
(iii) an affiliate of a distributor; (2) the offer of such securities was not made to a person in the United States and either (a) at
the time the buy order was originated, the buyer was outside the United States, or the seller and any person acting on its behalf reasonably
believed that the buyer was outside the United States, or (b) the transaction was executed on or through the facilities of a &ldquo;designated
offshore securities market&rdquo; (such as the TSX Venture Exchange, the Toronto Stock Exchange or the Canadian Securities Exchange )
and neither the seller nor any person acting on its behalf knows that the transaction has been prearranged with a buyer in the United
States; (3) neither the seller nor any affiliate of the seller nor any person acting on their behalf has engaged or will engage in any
directed selling efforts in the United States in connection with the offer and sale of such securities; (4) the sale is bona fide and
not for the purpose of &ldquo;washing off&rdquo; the resale restrictions imposed because the securities are &ldquo;restricted securities&rdquo;
(as that term is defined in Rule 144(a)(3) under the 1933 Act); (5) the seller does not intend to replace securities sold in reliance
on Rule 904 of Regulation S with fungible unrestricted securities; and (6) the contemplated sale is not a transaction, or part of a series
of transactions, which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions
of the 1933 Act. Terms used herein have the meanings given to them by Regulation S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 41%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized signatory</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Seller (<B>please print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of authorized signatory (<B>please print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of authorized signatory (<B>please print</B>)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Affirmation By Seller&rsquo;s Broker-Dealer<BR>
(required for sales in accordance with Section (B)(2)(b) above)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have read the foregoing representations
of our customer, _________________________ (the &ldquo;<B>Seller</B>&rdquo;) dated _______________________, with regard to our sale,
for such Seller&rsquo;s account, of the securities of the Corporation described therein (the &ldquo;<B>Securities</B>&rdquo;). We
have executed sales of the Securities pursuant to Rule 904 of Regulation S under the United States Securities Act of 1933, as
amended (the &ldquo;<B>1933 Act</B>&rdquo;), on behalf of the Seller. In that connection, we hereby represent to you as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">no offer to sell Securities was made to a person in the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the sale of the Securities was executed in, on or through the facilities of the Toronto Stock Exchange,
the TSX Venture Exchange, the Canadian Securities Exchange or another designated offshore securities market (as defined in Rule 902(b)
of Regulation S under the 1933 Act), and, to the best of our knowledge, the sale was not pre-arranged with a buyer in the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">no &ldquo;directed selling efforts&rdquo; were made in the United States by the undersigned, any affiliate
of the undersigned, or any person acting on behalf of the undersigned; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">we have done no more than execute the order or orders to sell the Securities as agent for the Seller and
will receive no more than the usual and customary broker&rsquo;s commission that would be received by a person executing such transaction
as agent.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of these representations: &ldquo;<B>affiliate</B>&rdquo;
means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control
with, the undersigned; &ldquo;<B>directed selling efforts</B>&rdquo; means any activity undertaken for the purpose of, or that could reasonably
be expected to have the effect of, conditioning the market in the United States for the Securities (including, but not be limited to,
the solicitation of offers to purchase the Securities from persons in the United States); and &ldquo;<B>United States</B>&rdquo; means
the United States of America, its territories or possessions, any State of the United States, and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal counsel to the Corporation shall be entitled
to rely upon the representations, warranties and covenants contained herein to the same extent as if this affirmation had been addressed
to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name of Firm</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by:
[***]</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">JOINT VENTURE AGREEMENT<BR>
PROMIS - BCNI<BR>
STAGE ONE: SERVICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Joint Venture Agreement ( &ldquo;AGREEMENT&rdquo;) is entered
into effective July 7, 2020 (the &ldquo;Effective Date&rdquo;), by and between ProMIS Neurosciences, Inc., a Canadian corporation with
an address at 1920 Yonge Street, Toronto, ON, M4S 3E2 Canada (&ldquo;<B>PROMIS</B>&rdquo;), and BC Neuroimmunology Lab Inc <B>(BCNI</B>)
an accredited, CAP certified diagnostic lab in British Columbia, with an address at UBC Hospital, S157-2211 Wesbrook Mall, Vancouver BC
V6T 2B5 (&ldquo;<B>BCNI</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whereas ProMIS is a publicly traded (TSX) development stage biotechnology
company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as
Disease Specific Epitopes on the molecular surface of proteins. In the infectious disease setting, these disease-specific epitopes represent
peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence
of antibodies that arise in response to a specific infection, such as COVID-19. These peptide antigens can also be used to create potential
therapeutic antibodies to treat active infection, as well as serve as the basis for development of vaccines. ProMIS&rsquo; proprietary
technology platform has created a portfolio of patented or patent pending antibodies and peptide antigens, which can be used as both therapeutics
(antibodies, vaccines, gene therapy) and as reagents in proprietary diagnostic assays.; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whereas BC Neuroimmunology Lab Inc. (BCNI) is a private full service
clinical neuroimmunology lab located in the University of British Columbia (Vancouver) hospital. BCNI is accredited by both the College
of American Pathologists (CAP) and Diagnostic accreditation program (DAP) at the College of Physicians and Surgeons of BC (CPSBC) following
the ISO15189 guidelines. BCNI is the North American reference center for six high complexity serological immunoassays. BCNI has extensive
experience and expertise in Surface Plasmon Resonance (SPR), live and fixed cell-based assays, radio immunoprecipitation assays, ELISA,
immunoblot, and immunohistochemistry assays in a clinical assay setting, servicing the neurology community in North America and Worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whereas PROMIS and BCNI wish to enter into a joint venture business
arrangement to provide the service of highly sensitive and specific serological assays for the detection and characterization (neutralizing
activity for example) of antibodies to the SARS-CoV-2 corona virus that is responsible for COVID-19 , (the &ldquo;JV SERVICE&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE, in consideration of the mutual covenants and premises
set forth herein, the Parties agree as follows;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
I</B></FONT>. <B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In this Agreement, unless the context indicates otherwise, the words
and expressions set out below shall have the meanings assigned to them and cognate expressions shall have a corresponding meaning, namely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Agreement&rdquo; </B>means this Service Joint Venture Agreement,
together with any validly executed amendments, schedules and appendices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Applicable Law</B>&rdquo; means, as to any person, any statute,
law, rule, regulation, administrative guidance, directive, treaty, judgment, order, decree or injunction of any governmental authority
that is applicable to or binding upon such person or any of its properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Background Intellectual Property</B>&rdquo; means any Intellectual
Property excluding Foreground Intellectual Property owned or controlled by either Party prior to commencement of or independently from
the JV SERVICES, and which the owning Party contributes or uses in the course of performing the JV SERVICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Commercialize&rdquo; or &ldquo;Commercialization&rdquo; </B>includes
the development, distribution, sale, license, transfer or any other venture through which the JV SERVICE or a Party seeks to promote,
market, sell, distribute, manufacture or develop the JV SERVICES, or having any of the foregoing done on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Confidential Information</B>&rdquo; means any information
disclosed by one Party to the other that is not publicly available information, and which is either identified as confidential at the
time of disclosure or which would reasonably be considered to be confidential by its nature or the context of disclosure, including without
limitation Background Intellectual Property disclosed by one Party to the other for use in the JV SERVICES/LICENSED SERVICES and identified
as confidential before or at the time of disclosure, any business information pertaining to a Party or its products or services, and any
products, processes, samples, biological or proprietary materials provided or disclosed pursuant to this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Definitive Agreements</B>&rdquo; means such agreements as
may be necessary to set up the JV SERVICE and/or Immusafe Labs Inc. and complete its organization as contemplated herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Field&rdquo; </B>means (i) the development, production and
use of serological assays for the detection and characterization of antibodies to the SARS-CoV-2 corona virus for the screening and monitoring
of subjects with prior exposure to the virus responsible for COVID-19 and for evaluation and monitoring of antibody response following
exposure to vaccine during vaccine development and post marketing follow up.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Foreground Intellectual Property</B>&rdquo; means any Intellectual
Property which is generated or first reduced to practice by either Party directly as a result of the work undertaken in accordance with
this Agreement, and which is relevant to the JV SERVICE and the Licensed Services/Licensed Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Improvement(s)&rdquo; </B>means any modification, development,
alteration, derivative or technical advance in or relating to the Licensed Technology/Licensed Services which cannot be used or practiced
without infringing the Background Intellectual Property Rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&lsquo;Intellectual Property Rights&rsquo; </B>means any and all
existing and future legal protection recognized by law (whether by statute, in equity, at common law or otherwise) anywhere in the world
in respect of the Licensed Technology and Licensed Services, including without limitation trade secret and confidential information protection,
Know-How, patents, Patents, copyright and copyright registration, industrial design registration and trade-marks and trade-mark registrations
and other registrations or grants of rights analogous thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Joint Venture&rdquo; </B>means the business arrangement between
the Parties as described in this Agreement, including the JV SERVICE and Immusafe Labs Inc..</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;JV SERVICE&rdquo; </B>means the service of providing highly
sensitive and specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 corona virus that is
responsible for COVID-19 to pharmaceutical companies/vaccine developers and governmental agencies, using Licensed Services and/or Licensed
Technology, as well as other technology that may be available to the Joint Venture;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Know-how&rdquo; </B>means all the research results, data,
reports, dossiers, technical information, expertise, practice, experience, skill and technical knowledge of industrial significance and
all unpatented trade secrets, manufacturing methods and technologies, SOP&rsquo;s, QA and QC procedures, designs, processes, techniques,
information, drawings and specifications, and technical data acquired by and in the possession of PROMIS, BCNI, or JV SERVICE, and not
in the public domain, and relating to the Licensed Technology or Licensed Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&lsquo;Licensed Service(s)&rsquo; </B>means any assay that is/are
derived in whole or in part by the use of any of the Intellectual Property Rights and/or the Licensed Technology, of either Party, including
without limitation PROMIS proprietary antigen peptides for development of highly sensitive and specific serological assays for the detection
and characterization of antibodies to the SARS-CoV-2 corona virus that is responsible for COVID-19, as listed in this Agreement or added
to it by validly executed amendment.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Licensed Technology&rdquo; </B>means the platforms owned
by PROMIS and/or BCNI that will be used by the JV SERVICE and Immusafe Labs Inc. to develop and provide the serological antibody assays,
and any Intellectual Property Rights therein or thereto, necessary or useful to develop, manufacture or Commercialize the Licensed Service(s)
within the Field in the Territory. The Licensed Technology includes, without limitation, the Technology and Patents listed on Appendix
A.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Net Revenue&rdquo; </B>shall mean Revenue, less such of the
following items but only insofar as they are separately itemized on the invoice and actually paid or allowed: (i) discounts or rebates
(ii) credits or allowances upon claims or returns, (iii) taxes or other government charges, and (iv) shipping and insurance costs, brokerage
and customs duties.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Immusafe Labs Inc.</B>&rdquo; means the corporate entity
which is established by BCNI and related companies for the purpose to conduct the business and operations of the JV SERVICE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Patents&rdquo; </B>means those patents and patent applications
listed in, or which may be added to, Appendix A from time to time hereunder, any divisional applications, continuation applications, continuation-in-part
applications, reissues, or re-examinations claiming priority to either of these, and all patent applications and patents corresponding
to or derived from any of the above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Party</B>&rdquo; means PROMIS or BCNI, if individually referred
to, and &ldquo;<B>Parties</B>&rdquo; shall mean PROMIS and BCNI together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Revenue&rdquo; </B>means the gross amount of consideration
received by JV SERVICE or Immusafe Labs Inc., as the case may be, in respect of the provision of the JV SERVICE, including money, goods
and services, royalties, milestone payments and any other consideration that may be received from a Sale of any of the services provided
by the JV SERVICE or Immusafe Labs Inc..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Sale&rdquo; </B>means any sale, lease, use and services associated
with provision of a JV SERVICE, Licensed Service or service relating to a Licensed Service and <B>&ldquo;Sales&rdquo; </B>and <B>&ldquo;Sell&rdquo;
</B>have corresponding meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;SARS-CoV-2&rdquo;</B> means the novel coronavirus responsible
for the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Technology&rdquo; </B>includes inventions, discoveries, designs,
ideas, works, creations, developments, algorithms, drawings, compilations of information, analyses experiments, data, reports, Know-How,
formulae, methods, processes, techniques, moulds, prototypes, products, samples, equipment, tools, machines, software and documentation
therefore, flow-charts, specifications and source code listings; and includes any modifications or improvements thereto, whether patentable
or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Term</B>&rdquo; is defined in Section 27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Territory</B>&rdquo; is defined in Section 14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
II</B></FONT>. <B>PURPOSE OF THE JOINT VENTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
2.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The purpose of this Joint Venture is to establish, and operate the JV SERVICE to provide highly sensitive and specific serological
assays for the detection and characterization of antibodies against the SARS- CoV-2 corona virus that is responsible for COVID-19 to the
medical community, government agencies and pharmaceutical companies/vaccine developers, using Licensed Services and/or Licensed Technology,
as well as other technology that may be available to the Joint Venture;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Joint Venture will focus on building the foundation for a revenue base providing (&ldquo;JV SERVICE&rdquo;) highly sensitive and
specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 corona virus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The companies shall continue to interact with and seek partnerships with platform diagnostic companies, public healthcare payors,
research institutions, private healthcare payors, national defence organizations and vaccine
developers for revenue expansion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Conducting clinical validation, developing algorithms to increase prediction accuracy in multiplex assay formats based in Bayesian
Statistics and pursuing regulatory approvals required to develop revenue, if those activities are adequately funded by third parties,
or by mutual consent funded by either or both ProMIS or BCNI; and,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>Pursuing potential collaborations with diagnostic labs outside of BCNI lab, or potentially licensing/partnering deals with platform
companies or global diagnostics players, to develop revenue beyond what the Joint Venture can realize at BCNI.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
III</B></FONT>. <B>BACKGROUND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
3.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Experience of the Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Both Parties bring significant experience with respect to development
and provision of diagnostic assay services to this Joint Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Specifically, ProMIS is a development stage biotechnology company whose unique core technology is the ability to rationally predict
the site and shape (conformation) of novel targets known as Disease Specific Epitopes on the molecular surface of proteins. In the infectious
disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate
and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19.
These peptide antigens can also be used to create potential therapeutic antibodies to treat active infection, as well as serve as the
basis for development of vaccines. ProMIS&rsquo; proprietary technology platform has created a portfolio of patented or patent pending
antibodies and peptide antigens, which can be used as both therapeutics (antibodies, vaccines, gene therapy) and as reagents in proprietary
diagnostic assays. ProMIS is also well-connected in the scientific, medical and pharmaceutical communities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">BCNI is an accredited, ISO and CAP certified diagnostic lab in British Columbia, with expertise and experience in validating and accrediting
assays with ISO and College of American Pathologists. BCNI also has experience in marketing and sales of such assays to the neurologist
community, larger labs with vast distribution, and pharmaceutical companies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
IV</B></FONT>. <B>CONTRIBUTIONS OF THE PARTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Parties will faithfully dedicate reasonable commercial and technological
resources to help the business of the JV SERVICE succeed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 4.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Joint Contributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The parties expect operating expenses to conduct the evaluation of peptide antigens and improved serologic assays, regular operating
costs, legal costs at the JV/Immusafe and costs to bring the assay through Health Canada and FDA approvals. ProMIS will fund those costs,
with prior notification of planned expenditures, and those accrued costs will be repaid from initial profits, if any, to the JV. BCNI
has spent significant resources, including approximately USD [***] cash, 5-800 hundreds&rsquo; of highly qualified worker manhours and
world class expertise (e.g. Dr. Hans Frykman has contributed crucial scientific height) to develop this assay to current excellence and
best in class state. In recognition of this, no further expenses should be expected to be carried by BCNI for the lifetime of this JV
or in Immusafe Labs Inc.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Major expense projects (such as a vaccine validation clinical trial) are not expected, unless funded by third parties such as global
platform partners, vaccine manufacturers, government agencies, or others.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Immusafe Labs Inc. was established by BCNI and related companies to provide the JV SERVICE. ProMIS will acquire 50% of the shares
for CAD [***]. Additional non-voting shares in Immusafe Labs Inc. can be sold to familiar and supportive 3rd parties such as ProMIS shareholders
and friends and family of the founders up to value of USD $[***] and at a pre-money value agreeable to BCNI and ProMIS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
4.02.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Individual Contributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>In addition, PROMIS&rsquo;s contribution to the JV SERVICE will include:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Provide at cost proprietary antigens and peptides which can be used as reagents in proprietary serological antibody assays for the
JV SERVICE;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">License to the JV SERVICE its proprietary technology platforms (&ldquo;Licensed Technology&rdquo;) to predict better specificity for
diagnostic purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Apply its existing proprietary reagents to assay development and will continue develop and contribute new proprietary reagents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD>Regulatory and development support;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">Take the lead on market related activities, including outreach to KOLs, pharma companies/vaccine developers, government agencies and
other revenue development opportunities and will together with BCNI assign or hire staff in Immusafe Labs Inc. to lead that effort.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD>Continuous scientific, technological, marketing, strategic, updating process development, and support.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>In addition, BCNI&rsquo;s contribution to the JV SERVICE will include:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">General management of the JV SERVICE: Dr. Hans Frykman of BCNI will serve as lab director and initial CEO of Immusafe Labs Inc. at
the Vancouver site with deferred payment until the JV is cashflow positive and can carry his salary, and BCNI will initially hire and
manage capable staff with full pay from Immusafe Labs Inc., and will manage the operations of the accredited laboratories.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>Perform all serological assays at cost, calculated by an internal standard method normally used;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Provide guidance in marketing and sales of the assays/or JV service to government organizations, public healthcare payors, private
healthcare payors, pharmaceutical companies/vaccine developers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">Contribute (at deferred cost as described above) its expertise and experience in validating and accrediting the assays with CPSBC
(DAP) and College of American Pathologists (CAP);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">Assume primary responsibility for dealing with health and regulatory authorities in the Territory, including, without limitation,
presentation, submission and approval of any necessary marketing/regulatory authorizations for the JV SERVICE and Licensed Services.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
V</B></FONT>. <B>ALLOCATION AND DISTRIBUTION OF REVENUES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Ownership</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS and BCNI shall each own 50% of the JV SERVICE and Immusafe Labs
Inc. which has been established by BCNI and related companies to provide the JV SERVICE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.02.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Revenue from the JV SERVICE will be distributed to each Party equally,
except as otherwise specified in this Agreement. JV SERVICE revenue will be recognized by JV SERVICE/Immusafe Labs Inc.. Direct expenses
associated with that revenue will be covered by that revenue to the extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.03.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Working Capital, Operating Losses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Working capital needs, or operating losses will be covered equally
by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.04.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Investment Decisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment decisions will require mutual consent and will be funded
by ProMIS, or come from current revenue and operating profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 5.05.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Surplus, Operating Cash Flow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Cash surpluses resulting from assay tests carried out at BCNI lab on behalf of Immusafe Labs Inc., defined as operating cash flow
after paying current expenses and not allocated to capital investment or other costs by mutual consent, will be distributed equally (50/50
split) to both parties on a time schedule to be agreed - not more frequent than monthly, not less frequent than quarterly.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The first USD [***] cash surplus generated from labs or partnerships other than BCNI will be distributed equally (50/50 split).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Subsequent to generation of the first USD [***] cash surplus as per item (ii) above, net revenue from assays conducted by labs or
partnerships other than BCNI will be distributed equally (50/50 split) if such assays do not incorporate any ProMIS proprietary reagents;
the net revenue from assays conducted by labs or partnerships other than BCNI will be distributed according to an 80/20 split in favor
of ProMIS, if such assays incorporate any ProMIS proprietary reagents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
VI</B></FONT>. <B>NAME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The name of Immusafe Labs Inc. is mutually agreed by PROMIS and BCNI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
VII</B></FONT>. <B>PRINCIPAL PLACE OF BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The principal place of business of JV SERVICE/Immusafe Labs Inc. shall
be initially at the BCNI premises in Vancouver, BC, unless PROMIS and BCNI later decide otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
VIII</B></FONT>. <B>INTELLECTUAL PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
8.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Ownership of Intellectual Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Background Intellectual Property </B>All Background Intellectual Property including any proprietary materials provided and used
in connection with the JV SERVICE and/or the Licensed Services shall remain the property of the Party introducing the same. Neither Party
will make any representation or do any act which may be taken to indicate that it has any right, title or interest in or to the ownership
or use of any of the Background Intellectual Property of the other party except under the terms of this Agreement. Each Party acknowledges
and confirms that nothing contained in this Agreement shall give it any right, title or interest in or to the Background Intellectual
Property of the other Party save as granted by this Agreement. The Parties agree that any Improvements to a Party&rsquo;s Background Intellectual
Property arising from the Joint Venture will be deemed to form part of that Party&rsquo;s Background Intellectual Property.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD><B>Foreground Intellectual Property.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Each Party shall own any Foreground Intellectual Property developed solely by it and shall grant to the JV SERVICE a royalty-free,
perpetual non-exclusive license to such Foreground Intellectual Property that is necessary or useful to the JV SERVICE. Such license shall
be transferable to Immusafe Labs Inc. established by BCNI and related companies to operate the JV SERVICE. The Party owning such Foreground
Intellectual Property shall have the responsibility of registering, maintaining and enforcing any protection for such Foreground Intellectual
Property.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Any Foreground Intellectual Property jointly developed in the JV SERVICE prior to ProMIS acquiring 50% ownership in Immusafe Labs
Inc. shall be owned jointly by the Parties, with the intention that such ownership shall be transferred to Immusafe Labs Inc. which is
established by the BCNI and related companies to operate the business of the JV SERVICES. Any IP developed in Immusafe Labs Inc. will
be owned by Immusafe Labs Inc. In the interim, the Parties shall be jointly responsible for registering, maintaining and enforcing any
protection for such Foreground Intellectual Property, and ProMIS bear the costs with the preference to recovering those costs from profits
if any at a future date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
IX</B></FONT>. <B>LICENSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The JV SERVICE will have the non-exclusive license to use the Licensed
Technology to make, market and sell in the Territory the Licensed Services contemplated by this Agreement. Each Party hereby grants to
the JV SERVICE a royalty-based, non-exclusive license for the duration of the Agreement to use its Background Intellectual Property for
the sole purpose of providing the Licensed Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
X</B></FONT>. <B>REPORTS &amp; RECORDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
10.01.</B></FONT><B> Reports and Other Deliveries.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Within thirty (30) days of the receipt of Revenue in respect of any
services provided by the JV SERVICE, the JV SERVICE shall provide to PROMIS and BCNI a written report detailing any Revenue received in
respect of the JV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SERVICE from any source and the amount thereof, and calculating the
payment due to each Party in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
10.02.</B></FONT><B> Books and Records.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The JV SERVICE shall keep complete, true and accurate books of
account containing all particulars that may be necessary for the purpose of showing the amounts payable to PROMIS and BCNI. Such
books of account shall normally be kept at the JV SERVICE&rsquo;S principal place of business. Upon reasonable notice to the JV
SERVICE during regular working hours, all applicable books and the supporting data shall be available for inspection by PROMIS or
BCNI or their agents, on a confidential basis, at all reasonable times for up to five years following the end of the calendar year
to which they pertain, for the purpose of verifying such JV SERVICE accounting of payments and compliance in other respects with
this Agreement. If such inspection determines that any amount that should have been paid has not been paid, the JV SERVICE shall
promptly pay such amount. If an additional payment is 5% or greater than the amount previously reported and paid for in the relevant
period, then the JV SERVICE shall pay PROMIS/BCNI any such deficiency as well as the expenses of the examination. The cost of
accounting services (initially at BCNI) shall be carried by the JV at cost. Costs for the bookkeeping, records and accounting shall
be carried by the JV or Immusafe Labs Inc. and initially provided at cost to the JV or Immusafe by BCNI staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XI</B></FONT><B>. NO VIOLATION OF AGREEMENT DUE TO OTHER ACTIVITIES </B>Subject to any exclusivity provisions set forth in this Agreement,
BCNI acknowledges that PROMIS is involved in research and development projects and agreements which involve the development, manufacturing
and commercialization of biologic products and that this does not infringe this Agreement between BCNI and PROMIS. PROMIS, acknowledge
that BCNI is involved in the research and development, manufacturing and commercialization of diagnostic products primarily but not exclusively
in the field of Neuroimmunology and that this does not infringe this agreement between BCNI and PROMIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XII</B></FONT>. <B>GOVERNANCE AND MANAGEMENT OF JV SERVICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
12.01.</B></FONT><B> Lab Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">In Stage One, Hans Frykman of BCNI will serve as lab director at the Vancouver site, or BCNI will initially hire and manage capable
staff and will manage the operations of the accredited laboratories in Canada. Dr. Hans Frykman will defer his fees for service until
the JV is cash flow positive and when it can carry such cost without forsaking future opportunities. Such professional fees, will at that
time, have preference to paying shareholders or the JV partners. Other staff at BCNI involved in the working for this JV and Immusafe
Labs Inc. will be reimbursed on a monthly basis at cost starting July 10.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
12.02.</B></FONT><B> Key Decisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Parties will discuss all material decisions affecting the operations, expenditures and commitments of the JV SERVICE, and BCNI
or its designates shall not make any key decisions concerning such operations, expenditures and commitments without the prior written
consent of PROMIS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XIII</B></FONT>. <B>TERRITORY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Territory in which the JV SERVICE will operate, and for which the
licenses hereunder are granted is Worldwide</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
XIV</B></FONT>. <B>TRANSPARENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to applicable confidentiality provisions and Applicable Laws,
all financial and commercial documentation is to be transparent, available at all times and to be open for review by both Parties whenever
requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XV</B></FONT>. <B>CONFIDENTIALITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All Confidential Information disclosed by one Party to the other pursuant
to this Agreement will be treated as strictly confidential, and will not be disclosed to anyone except the agents, employees and representatives
of the Parties, and then only on a &ldquo;need-to-know&rdquo; basis for the purposes of fulfilling a Party&rsquo;s role and responsibilities
hereunder. Anyone to whom such a disclosure is made shall be subject to confidentiality restrictions to the Party receiving such Confidential
Information that is no less stringent than that between the Parties hereto. Neither Party will use the Confidential Information of the
other for any purpose other than as set out in this Agreement, and only in compliance with its obligations in the Joint Venture. A Party&rsquo;s
obligation of confidentiality hereunder is for a period of five (5) years after the expiry or termination of this Agreement or any subsequent
agreement that supersedes or replaces it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XVI</B></FONT>. <B>GOVERNING LAW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The interpretation and construction of this Agreement shall be governed
by the laws of the Province of Ontario, excluding any conflicts or choice of law rule or principle that might otherwise refer interpretation
or construction of this Agreement to the substantive law of another jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XVII</B></FONT>. <B>PRESS RELEASES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any press release pertaining to the JV SERVICE or this Agreement is
subject to mutual approval of the Parties, which shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XVIII</B></FONT>. <B>SEVERABILITY; ENFORCEABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If, for any reason, any part of this Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, then such adjudication shall not, to the extent feasible, affect or impair,
in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall
remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XIX</B></FONT>. <B>INSURANCE &amp; LIABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
19.01.</B></FONT><B> INSURANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JV SERVICE/BCNI/Immusafe Labs Inc., as the case may be, will procure
such insurance e.g., commercial general liability insurance .Once the JV/Immusafe Labs Inc. is profitable and is operating in a clinical
setting, then product liability, eventual clinical trials, public liability insurance will be evaluated by both partners for suitability
and cost vs. utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any insurance will be placed with a reputable and financially secure
insurance carrier and will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>include PROMIS and BCNI, its officers, directors and employees as additional insured;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>provide coverage regarding all relevant activities contemplated under this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>include a waiver of subrogation against PROMIS and BCNI, and a severability of interest and cross-liability clauses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>provide that the insurer will endeavour to notify PROMIS and BCNI at least 30 days prior to the cancellation of the policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">JV SERVICE/BCNI/Immusafe Labs Inc., on request, will provide to PROMIS certificates of insurance evidencing the insurance coverages
(and any renewals) of the JV SERVICE/BCNI/Immusafe Labs Inc., and its subcontractors in respect of the activities of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
19.02.</B></FONT><B> DISCLAIMERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>&lsquo;As Is&rsquo; Basis: </B>The Licensed Technology is provided by PROMIS and BCNI on an &lsquo;as is&rsquo; basis, and neither
BCNI or PROMIS makes no warranties, representations or conditions, express or implied, of any nature, and disclaims all warranties, representations
or conditions, for the Licensed Technology or Confidential Information including, without limitation, merchantability, quality, fitness
for any or a particular purpose, commercial utility or practical purpose, latent or other defects, infringement or non-infringement of
Patents or other third party rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Disclaimer of Statutorily Implied Warranties: </B>No legal or equitable warranties or conditions implied by law or convention under
any domestic, foreign or international legal regime, or from a course of dealing or usage of trade, shall apply to this Agreement. The
JV SERVICE/Immusafe Labs Inc. and BCNI, as the case may be, acknowledges this disclaimer and is estopped from relying on any such representations,
warranties or conditions against PROMIS. The JV SERVICE/Immusafe Labs Inc. and ProMIS, as the case may be, acknowledges this disclaimer
and is estopped from relying on any such representations, warranties or conditions against BCNI.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>Licensee Shall Obtain Regulatory Permissions: </B>JV SERVICE/Immusafe Labs Inc., or BCNI, as the case may be, shall obtain any
authorizations, permits, certificates or other regulatory permissions which may be required in order for JV SERVICE/Immusafe Labs Inc.
or BCNI as the case may be, to legally carry out all of its activities under this Agreement, including but not limited to Commercialization<B>.
</B>Any costs associated with the regulatory permissions should be carried by the JV service/Immusafe Labs Inc.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
XX</B></FONT>. <B>ENTIRE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement together with any Appendices or attachments, reflects
the entire agreement between the Parties with respect to the subject matter hereof and supersedes all other agreements between the Parties
concerning such subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXI</B></FONT>. <B>MODIFICATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No amendment, modification or supplement of any provision of the Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer or director of each party. No provision of
the Agreement shall be waived by any act, omission or knowledge of any party or its agents or employees except by an instrument in writing
expressly waiving such provision and signed by a duly authorized officer or director of the waiving party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXII</B></FONT>. <B>COUNTERPARTS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Agreement may be executed in any number of counterparts. A signed
Agreement received by a Party hereto via email will be deemed an original, and binding upon the Party who signed it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXIII</B></FONT>. <B>INDEPENDENT CONTRACTORS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relationship between PROMIS and BCNI created herein is one of independent
contractors and neither party shall have the power or authority to bind or obligate the other. Nothing in this Agreement shall be interpreted
to create a partnership between the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXIV</B></FONT>. <B>TIME.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Time is of the essence in the performance of obligations of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXV</B></FONT>. <B>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any notice to be given under this Agreement must be in writing and
delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its address given below, or at any address such Party has previously
designated by prior written notice to the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to BCNI, notices must be addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">BC Neuroimmunology Lab Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn. Dr. Hans B Frykman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">UBC Hospital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">S157 - 2211 Wesbrook Mall</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Vancouver BC V6T 2B5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to PROMIS, notices must be addressed to: ProMIS Neurosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn. Dr. Elliot Goldstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1920 Yonge St., suite 200,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Toronto, Ont. M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event of a change of notice address, recipient or both, a Party
shall provide the other Party written notice setting forth the new address and/or recipient, as appropriate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXVI</B></FONT>. <B>TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
26.01.</B></FONT><B> Term</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement shall come into effect on the Effective Date first written
above and shall endure until it is terminated on one of the following possible grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
26.02.</B></FONT><B> Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement may be terminated: (i) by mutual agreement of the Parties;
(ii) for material breach by one of the Parties hereto of its respective obligations under this Agreement; (iii) if the Parties enter into
Definitive Agreements superseding or replacing this Agreement or (iv) if JV SERVICE is wound up, acquired by or merged with another entity,
or otherwise ceases to exist or to do business as contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
26.03.</B></FONT><B> Notice of Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Party seeking to terminate this Agreement shall provide written
notice to the other Party, such written notice to specify in reasonable detail the reasons for termination. Any termination based on clause
(ii) above, namely material breach, shall provide at least 90 Business Days for the breaching party to cure the material breach before
such termination is deemed effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
26.04.</B></FONT><B> Effects of Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by ProMIS in this Agreement shall be terminated automatically and all rights
shall revert to PROMIS, unless PROMIS agrees, in writing, in its exclusive judgement and discretion to extend the time period for (ii)
above, or to modify this Agreement to allow for its continuance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by BCNI in this Agreement shall be terminated automatically and all rights shall
revert to BCNI, unless BCNI agrees, in writing, in its exclusive judgement and discretion to extend the time period for (ii) above, or
to modify this Agreement to allow for its continuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXVII</B></FONT>. <B>ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement may not be assigned by a Party without the prior
written consent of the other Party except in connection with the sale or transfer of all or substantially all of the assets of such
Party relevant to the subject matter hereof, or in connection with a corporate reorganization, provided that the other Party is
notified of the assignment and the assignee expressly undertakes in writing to be bound by all of the provisions of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Agreement
by their respective, duly authorized representatives as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">ProMIS Neurosciences Inc.</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">BC Neuroimmunology Inc</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">/s/ Elliot Goldstein</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">/s/ Hans Frykman</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; width: 11%">NAME:</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; width: 39%">Elliot Goldstein, MD</TD>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; width: 11%">NAME:<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; width: 39%">Dr. Hans Frykman</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">TITLE:</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">President &amp; CEO</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">TITLE</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">CEO</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LICENSED TECHNOLOGY: PATENTS AND APPLICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProMIS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[LIST OF RELEVANT ProMIS PATENTS AND APPLICATIONS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BCNI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[LIST OF RELEVANT BCNI PATENTS AND APPLICATIONS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.2</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by:
[***]</I></B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">JOINT VENTURE AGREEMENT<BR>
PROMIS - BCNI<BR>
STAGE ONE: SERVICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Joint Venture Agreement ( &ldquo;AGREEMENT&rdquo;) is entered
into effective July 8, 2020 (the &ldquo;Effective Date&rdquo;), by and between ProMIS Neurosciences, Inc., a Canadian corporation with
an address at 1920 Yonge Street, Toronto, ON, M4S 3E2 Canada (&ldquo;<B>PROMIS</B>&rdquo;), and BC Neuroimmunology Lab Inc (<B>BCNI</B>)
an accredited, CAP certified diagnostic lab in British Columbia, with an address at UBC Hospital, S157-2211 Wesbrook Mall, Vancouver BC
V6T 2B5 (&ldquo;<B>BCNI</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whereas ProMIS is a publicly traded (TSX) biotech company focused primarily
on the field of neurodegenerative diseases including Alzheimer&rsquo;s Disease and dementia, with a proprietary technology platform that
has created a portfolio of patented or patent pending antibodies and peptide antigens, which can be used as both therapeutics (antibodies,
vaccines, gene therapy) and as reagents in proprietary diagnostic assays.; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whereas BC Neuroimmunology Lab Inc. (BCNI) is a private full service
clinical neuroimmunology lab located in the University of British Columbia (Vancouver) hospital. BCNI is accredited by both the College
of American Pathologists (CAP) and Diagnostic accreditation program (DAP) at the College of Physicians and Surgeons of BC (CPSBC) following
the ISO15189 guidelines. BCNI is the North American reference center for six high complexity serological immunoassays. BCNI has extensive
experience and expertise in Surface Plasmon Resonance (SPR), live and fixed cell-based assays, radio immunoprecipitation assays, ELISA,
immunoblot, and immunohistochemistry assays in a clinical assay setting, servicing the neurology community in North America and Worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Whereas PROMIS and BCNI wish to enter into a joint venture business
arrangement to provide the services of neurodegenerative disease screening, diagnostics and monitoring, using proprietary blood-based
biomarkers (the &ldquo;JV SERVICE&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE, in consideration of the mutual covenants and premises
set forth herein, the Parties agree as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
I. </B></FONT><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In this Agreement, unless the context indicates otherwise, the words
and expressions set out below shall have the meanings assigned to them and cognate expressions shall have a corresponding meaning, namely:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Neurodegenerative diseases&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These diseases include but are not limited to Alzheimer&rsquo;s disease,
Parkinson disease, ALS, FTD, traumatic or insidious brain injury; They do not include traditional neuroimmunology diseases such as Myasthenia
Gravis, NMOSD, Guillain Barre syndrome and other nodal and paranodal diseases, autoimmune encephalitis and paraneoplastic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Agreement&rdquo; </B>means this Service Joint Venture Agreement,
together with any validly executed amendments, schedules and appendices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Applicable Law</B>&rdquo; means, as to any person, any statute,
law, rule, regulation, administrative guidance, directive, treaty, judgment, order, decree or injunction of any governmental authority
that is applicable to or binding upon such person or any of its properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Background Intellectual Property</B>&rdquo; means any Intellectual
Property excluding Foreground Intellectual Property owned or controlled by either Party prior to commencement of or independently from
the JV SERVICES, and which the owning Party contributes or uses in the course of performing the JV SERVICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Commercialize&rdquo; or &ldquo;Commercialization&rdquo; </B>includes
the development, distribution, sale, license, transfer or any other venture through which the JV SERVICE or a Party seeks to promote,
market, sell, distribute, manufacture or develop the JV SERVICES, or having any of the foregoing done on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Confidential Information</B>&rdquo; means any information
disclosed by one Party to the other that is not publicly available information, and which is either identified as confidential at the
time of disclosure or which would reasonably be considered to be confidential by its nature or the context of disclosure, including without
limitation Background Intellectual Property disclosed by one Party to the other for use in the JV SERVICES/LICENSED SERVICES and identified
as confidential before or at the time of disclosure, any business information pertaining to a Party or its products or services, and any
products, processes, samples, biological or proprietary materials provided or disclosed pursuant to this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Definitive Agreements</B>&rdquo; means such agreements as
may be necessary to set up the JV SERVICE and/or the Newco and complete its organization as contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Field&rdquo; </B>means (i) the production and use of biomarker
assays for the screening, diagnosis and monitoring of neurodegenerative disease, and/or (ii) the commercialization of such biomarker assays
for the diagnosis and monitoring of Alzheimer&rsquo;s Disease as a service to third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Foreground Intellectual Property</B>&rdquo; means any Intellectual
Property which is generated or first reduced to practice by either Party directly as a result of the work undertaken in accordance with
this Agreement, and which is relevant to the JV SERVICE and the Licensed Services/Licensed Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Improvement(s)&rdquo; </B>means any modification, development,
alteration, derivative or technical advance in or relating to the Licensed Technology/Licensed Services which cannot be used or practiced
without infringing the Background Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&lsquo;Intellectual Property Rights&rsquo; </B>means any and all
existing and future legal protection recognized by law (whether by statute, in equity, at common law or otherwise) anywhere in the world
in respect of the Licensed Technology and Licensed Services, including without limitation trade secret and confidential information protection,
Know-How, patents, Patents, copyright and copyright registration, industrial design registration and trade-marks and trade-mark registrations
and other registrations or grants of rights analogous thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Joint Venture&rdquo; </B>means the business arrangement between
the Parties as described in this Agreement, including the JV SERVICE and a planned Newco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;JV SERVICE&rdquo; </B>means the service of providing lab
services and blood-based assays for Alzheimer&rsquo;s Disease diagnosis and monitoring to the scientific, medical and pharmaceutical communities,
using Licensed Services and/or Licensed Technology, as well as other technology that may be available to the Joint Venture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Know-how&rdquo; </B>means all the research results, data,
reports, dossiers, technical information, expertise, practice, experience, skill and technical knowledge of industrial significance and
all unpatented trade secrets, manufacturing methods and technologies, SOP&rsquo;s, QA and QC procedures, designs, processes, techniques,
information, drawings and specifications, and technical data acquired by and in the possession of PROMIS, BCNI, or JV SERVICE, and not
in the public domain, and relating to the Licensed Technology or Licensed Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&lsquo;Licensed Service(s)&rsquo; </B>means any assay that is/are
derived in whole or in part by the use of any of the Intellectual Property Rights and/or the Licensed Technology, of either Party, including
without limitation PROMIS proprietary antibodies and antigen peptides for blood-based biomarker assays for the screening, diagnosis and
monitoring of neurodegenerative diseases, as listed in this Agreement or added to it by validly executed amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Licensed Technology&rdquo; </B>means the platforms owned
by PROMIS and/or BCNI that will be used by the JV SERVICE and NEWCO to develop and provide the neurodegenerative screening, diagnostics
and monitoring services, and any Intellectual Property Rights therein or thereto, necessary or useful to develop, manufacture or Commercialize
the Licensed Service(s) within the Field in the Territory. The Licensed Technology includes, without limitation, the Technology and Patents
listed on Appendix A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Net Revenue&rdquo; </B>shall mean Revenue, less such of the
following items but only insofar as they are separately itemized on the invoice and actually paid or allowed: (i) discounts or rebates
(ii) credits or allowances upon claims or returns, (iii) taxes or other government charges, and (iv) shipping and insurance costs, brokerage
and customs duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Newco</B>&rdquo; means a corporate entity which is planned
in the near future to be established by the Parties to conduct the business and operations of the JV SERVICE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Patents&rdquo; </B>means those patents and patent applications
listed in, or which may be added to, Appendix A from time to time hereunder, any divisional applications, continuation applications, continuation-in-part
applications, reissues, or re-examinations claiming priority to either of these, and all patent applications and patents corresponding
to or derived from any of the above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Party</B>&rdquo; means PROMIS or BCNI, if individually referred
to, and &ldquo;<B>Parties</B>&rdquo; shall mean PROMIS and BCNI together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Revenue&rdquo; </B>means the gross amount of consideration
received by BCNI, JV SERVICE or NEWCO, as the case may be, in respect of the provision of the JV SERVICE, including money, goods and services,
royalties, milestone payments and any other consideration that may be received from a Sale of any of the services provided by the JV SERVICE
or Newco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Sale&rdquo; </B>means any sale, lease, use and services associated
with provision of a JV SERVICE, Licensed Service or service relating to a Licensed Service and <B>&ldquo;Sales&rdquo; </B>and <B>&ldquo;Sell&rdquo;
</B>have corresponding meanings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&ldquo;Technology&rdquo; </B>includes inventions, discoveries, designs,
ideas, works, creations, developments, algorithms, drawings, compilations of information, analyses experiments, data, reports, Know-How,
formulae, methods, processes, techniques, moulds, prototypes, products, samples, equipment, tools, machines, software and documentation
therefore, flow-charts, specifications and source code listings; and includes any modifications or improvements thereto, whether patentable
or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Term</B>&rdquo; is defined in Section 27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>Territory</B>&rdquo; is defined in Section 14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
II. </B></FONT><B>PURPOSE OF THE JOINT VENTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
2.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>STAGE ONE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The purpose of this Joint Venture is to establish, fund and operate the JV SERVICE to provide CSF and blood-based Alzheimer&rsquo;s
Disease and other neurodegenerative disease screening, diagnostics and monitoring to the scientific, medical and pharmaceutical communities,
through a combination of both Parties&rsquo; expertise, intellectual property and relevant assets, including without limitation the Licensed
Technology and Licensed Service(s).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Stage One of the Joint Venture will focus on building the foundation for a revenue base providing diagnostic services, (&ldquo;JV
SERVICE&rdquo;) initially for NfL and pTau181 blood-based assays.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">During Stage One, opportunities for an expanded assay portfolio will be explored by the Parties, including the development of proprietary
assays using ProMIS&rsquo; proprietary reagents, in addition to identification and evaluation of potential third-party assays to offer
as part of the JV SERVICE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The parties will jointly evaluate the feasibility of developing equally accurate or superior assays for NfL and pTau181 on SPR and
other high throughput platforms.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Section 2.02.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stage
Two</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The parties plan to expand the scope of the Joint Venture in the near future (by October/November 2020) and enter into a Stage Two
of the arrangement, and, will enter into such further agreements as may be required at the time, including but not limited to: governance
and decision making, revenue recognition, reporting requirements, creating a jointly owned corporation to employ and compensate key staff.
The parties agree that the general principles contained in this Agreement, including roles, economic shares, and the Field will be maintained
in future additional or updated agreements.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Stage Two will focus on expanding the revenue base of diagnostic services in the Field. The specific activities will be contingent
on results and market developments during Stage One, but will likely include:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Expanding diagnostic capacity at BCNI for the JV SERVICE, with equipment, space, and personnel (this expansion can precede the revenue
stage, as outlined above, by mutual consent);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Building or acquiring a USA-based lab facility in 2021. The new USA lab is anticipated to be owned and operated by the Newco, likely
via a USA C corporation fully owned by the Newco. BCNI will provide an exclusive license of best in class proprietary and unique neuroimmunology
assays to this lab for sole use on the USA market, assuring strong financial stability to the USA lab. Once the USA lab is operating,
the service at BCNI will focus on the Canada market together with research and development, while the USA lab will service the USA market
only;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>Continuing to build the portfolio of assays offered, both proprietary assays and third-party assays;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD>Pursuing sales and marketing approaches to expand the customer base and revenue base in North America;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD>Conducting R&amp;D, clinical validation, and pursuing regulatory approvals required to develop revenue; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">Pursuing collaborations with diagnostic labs outside of North America, or potentially licensing/partnering deals with platform companies
or global diagnostics players, to develop revenue beyond what the Joint Venture can realize in laboratories it operates in North America.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
III. </B></FONT><B>BACKGROUND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
3.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Experience of the Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Both Parties bring significant experience with respect to development
and provision of diagnostic assay services to this Joint Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Specifically, PROMIS possesses expertise in neurodegenerative diseases including Alzheimer&rsquo;s Disease and dementia, together
with proprietary technology platforms to predict better specificity for diagnostic purposes. ProMIS owns a portfolio of patented or patent
pending antibodies and peptide antigens which are useful for the purpose of diagnostics. ProMIS is also well-connected in the scientific,
medical and pharmaceutical communities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">BCNI is an accredited, DAP and CAP certified diagnostic lab in British Columbia, with expertise and experience in validating and accrediting
assays with DAP and College of American Pathologists. BCNI also has experience in marketing and sales of such assays to the neurologist
community, larger labs with vast distribution, and pharmaceutical companies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
IV. </B></FONT><B>CONTRIBUTIONS OF THE PARTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Parties will faithfully dedicate reasonable commercial and technological
resources to help the business of the JV SERVICE succeed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
4.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Joint Contributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The parties will fund (by loan) equally operating costs associated with Stage One activities, expected not to exceed CAD $[***] per
month. Therefore, each Party will contribute CAD $[***] each month following until the JV SERVICE is cashflow positive</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Each Party will lend the JV SERVICE CAD $[***] by no later than September 15,2020 for the purchase of a Quanterix SIMOA HD-X.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Any additional capital expenditures, or major expense projects (such as a validation clinical trial) will require the consent of both
parties and will be funded 50/50 unless otherwise agreed by both parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Newco, a new BC registered corporation is planned to be established in the near future to provide the JV SERVICE, and additional
non-voting shares in the Newco can be sold to familiar and supportive 3rd parties such as ProMIS shareholders and friends and family of
the founders up to value of USD $[***] and at a pre-money value agreeable to BCNI and ProMIS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
4.02.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Individual Contributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>In addition, PROMIS&rsquo;s contribution to the JV SERVICE will include:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Provide at cost proprietary antigens and peptides which can be used as reagents in proprietary diagnostic assays for the JV SERVICE;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Share expertise in neurodegenerative diseases including Alzheimer&rsquo;s Disease and dementia;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">License to the JV SERVICE its proprietary technology platforms (&ldquo;Licensed Technology&rdquo;) to predict better specificity for
diagnostic purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">Apply its existing proprietary reagents to assay development and will continue develop and contribute new proprietary reagents.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">Regulatory and clinical development support;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">Take the lead on market related activities, including outreach to KOLs, physician customers, CROs, global distribution partners, other
revenue development etc. and will together with BCNI, assign or hire staff in the Newco to lead that effort</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">Continuous scientific, technological, marketing, strategic, updating process development, and support.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In addition, BCNI&rsquo;s contribution to the JV SERVICE will include:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">General management of the JV SERVICE: Dr. Hans Frykman of BCNI will serve as lab director at the Vancouver site, with deferred payment
until the JV/ Newco is cashflow positive and can carry his salary. These payments to Dr. Hans B Frykman Medical Corp will supersede paying
shareholders at that time. BCNI will initially hire and manage capable staff, and will manage the operations of the accredited laboratories.
This staff will be paid at cost by JV/Newco, a CEO of the Newco will be jointly appointed by BCNI and ProMIS;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Perform all Neurodegenerative assays at cost, calculated by an internal standard method normally used;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Provide guidance in marketing and sales of the assays to the hospital labs, neurologist community in North America, test distributors,
larger labs with vast distribution, and pharmaceutical companies; Will together with ProMIS assign and hire staff in Newco to lead this
effort</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">Contribute (Dr. Hans Frykman at deferred cost as described above and other staff at normal salary cost) its expertise and experience
in validating and accrediting the assays with DAP and College of American Pathologists; with aim to also acquire Health Canada and FDA
approvals. Particulary for proprietary assays.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">Assume primary responsibility for dealing with health and regulatory authorities in the Territory, including, without limitation,
presentation, submission and approval of any necessary marketing/regulatory authorizations for the JV SERVICE and Licensed Services; Will
together with ProMIS hire staff for this purpose</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">In the case of any clinical trial sponsored by ProMIS, BCNI/JV SERVICE/Newco will supply the NfL and pTau181 assays at cost, based
on the jointly acquired Quanterix machine and/or the mutually developed SPR assays. This discount will survive the termination of the
Joint Venture, as long as the Quanterix or SPR assays are operational and available at BCNI/JV SERVICE/Newco in exchange for any funds
owed to ProMIS for purchase of Quanterix or SPR equipment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
V. </B></FONT><B>ALLOCATION AND DISTRIBUTION OF REVENUES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Ownership</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROMIS and BCNI (and related companies) shall each own 50% of the JV
SERVICE and the Newco is planned to be established to provide the JV SERVICE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.02.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Net Revenue from the JV SERVICE will be distributed to each Party equally,
except as otherwise specified in this Agreement. JV SERVICE revenue will be recognized by BCNI/JV SERVICE/Newco. Direct expenses, rental
expenses, staff expenses, and capital expenses associated with that revenue will be covered by that revenue to the extent possible before
any revenue is distributed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.03.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Working Capital, Operating Losses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Working capital needs, or operating losses will be covered equally
by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.04.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;</B></FONT><B>Investment Decisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment decisions will require mutual consent and will be funded
equally, which funding may come from current revenue and operating profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.05.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Surplus, Operating Cash Flow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash surpluses, operating cash flow after paying current expenses and
not allocated to capital investment by mutual consent, will be distributed equally (50/50 split) to both parties on a time schedule to
be agreed - not more frequent than monthly, not less frequent than quarterly. (With the exception of cash surpluses generated from partnerships
or labs outside of North America, see below)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
5.06.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Additional Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Notwithstanding the foregoing, however, Net Revenue to the JV
SERVICE/Newco which comes from sources other than labs operated by the JV SERVICE in North America will be disbursed equally (50/50
split) for revenue derived from assays not incorporating ProMIS proprietary reagents. For revenue derived from collaborations with
labs in regions of the world other than North America, who choose to sell proprietary assays developed by the JV SERVICE/Newco, only
if promis proprietary knowledge, reagents/ chemicals were used as a deciding factor to improve accuracy of assay, the disbursement
will be 80% to ProMIS and 20% to BCNI (80/20 split). Prior to finalizing any such deal both parties will confirm that this economic
split applies and is dependent on the relative contribution of each party into the Intellectual Property Rights developed for such
JV SERVICES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
VI. </B></FONT><B>JV Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">JV meetings will be held weekly. Minutes of the meetings will be maintained on file.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Either ProMIS or BCNI can call a special meeting to resolve urgent issues that require a vote and that cannot wait for the next regularly
scheduled meeting. When calling a special meeting, the other party must be provided with reasonable notice. Where a special meeting has
been called, the meeting will be restricted to the specific purpose for which the meeting was called.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">All meetings will be held at a time and in a location that is reasonable, convenient and practical considering the situation of BCNI
and ProMIS.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
VII. </B></FONT><B>NAME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The name of JV SERVICE and BC &ldquo;Newco&rdquo; shall be as mutually
agreed by PROMIS and BCNI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
VIII. </B></FONT><B>PRINCIPAL PLACE OF BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The principal place of business of JV SERVICE/Newco shall be initially
at the BCNI premises in Vancouver, BC, unless PROMIS and BCNI later decide otherwise. The Newco will be a BC corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
IX. </B></FONT><B>INTELLECTUAL PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
9.01.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Ownership Of Intellectual Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Background Intellectual Property </B>All Background Intellectual Property including any proprietary materials provided and used
in connection with the JV SERVICE and/or the Licensed Services shall remain the property of the Party introducing the same. Neither Party
will make any representation or do any act which may be taken to indicate that it has any right, title or interest in or to the ownership
or use of any of the Background Intellectual Property of the other party except under the terms of this Agreement. Each Party acknowledges
and confirms that nothing contained in this Agreement shall give it any right, title or interest in or to the Background Intellectual
Property of the other Party save as granted by this Agreement. The Parties agree that any Improvements to a Party&rsquo;s Background Intellectual
Property arising from the Joint Venture will be deemed to form part of that Party&rsquo;s Background Intellectual Property.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD><B>Foreground Intellectual Property.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Each Party shall own any Foreground Intellectual Property developed solely by it, and shall grant to the JV SERVICE a royalty-free,
perpetual non-exclusive license to such Foreground Intellectual Property that is necessary or useful to the JV SERVICE. Such license shall
be transferable to any Newco established by the Parties to operate the JV SERVICE. The Party owning such Foreground Intellectual Property
shall have the responsibility of registering, maintaining and enforcing any protection for such Foreground Intellectual Property.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Any Foreground Intellectual Property jointly developed in the JV SERVICE prior to the establishment of any Newco shall be owned jointly
by the Parties, with the intention that such ownership shall be transferred to any Newco which is established by the Parties to operate
the business of the JV SERVICES. Any IP developed in the Newco will the owned by the Newco. In the interim, the Parties shall be jointly
responsible for registering, maintaining and enforcing any protection for such Foreground Intellectual Property, and shall bear the costs
equally.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
X. </B></FONT><B>LICENSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The JV SERVICE will have the non-exclusive license to use the Licensed
Technology to make, market and sell in the Territory the Licensed Services contemplated by this Agreement. Each Party hereby grants to
the JV SERVICE a royalty-based, non-exclusive licence for the duration of the Agreement to use its Background Intellectual Property for
the sole purpose of providing the Licensed Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XI. </B></FONT><B>REPORTS &amp; RECORDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
11.01.</B></FONT><B> Reports and Other Deliveries.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Within thirty (30) days of the receipt of Revenue in respect of any
services provided by the JV SERVICE, the JV SERVICE shall provide to PROMIS and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">BCNI a written report detailing any Revenue received in respect of
the JV SERVICE from any source and the amount thereof, and calculating the payment due to each Party in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
11.02.</B></FONT><B> Books and Records.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JV SERVICE shall keep complete, true and
accurate books of account containing all particulars that may be necessary for the purpose of showing the amounts payable to PROMIS
and BCNI. Such books of account shall normally be kept at the JV SERVICE&rsquo;S principal place of business. Upon reasonable notice
to the JV SERVICE during regular working hours, all applicable books and the supporting data shall be available for inspection by
PROMIS or BCNI or their agents, on a confidential basis, at all reasonable times for up to five years following the end of the
calendar year to which they pertain, for the purpose of verifying such JV SERVICE accounting of payments and compliance in other
respects with this Agreement. If such inspection determines that any amount that should have been paid has not been paid, the JV
SERVICE shall promptly pay such amount. If an additional payment is 5% or greater than the amount previously reported and paid for
in the relevant period, then the JV SERVICE shall pay PROMIS/BCNI any such deficiency as well as the expenses of the examination.
The cost of accounting services (initially at BCNI) shall be carried by the JV at cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XII. </B></FONT><B>NO VIOLATION OF AGREEMENT DUE TO OTHER ACTIVITIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Subject to any exclusivity provisions set forth in this Agreement,
BCNI acknowledges that PROMIS is involved in research and development projects and agreements which involve the development, manufacturing
and commercialization of biologic products and that this does not infringe this Agreement between BCNI and PROMIS. PROMIS acknowledge
that BCNI is involved in the research and development, manufacturing and commercialization of diagnostic products primarily but not exclusively
in the field of Neuroimmunology and that this does not infringe this agreement between BCNI and PROMIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XIII. </B></FONT><B>STAGE ONE GOVERNANCE AND MANAGEMENT OF JV SERVICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
13.01.</B></FONT><B> Lab Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">In Stage One, Hans Frykman of BCNI will serve as lab director at the Vancouver site, or BCNI will initially hire and manage capable
staff, and will manage the operations of the accredited laboratories in Canada. Dr. Hans Frykman, will defer his fees for service until
the JV is cash flow positive and when it can carry such cost without forsaking future opportunities. His professional fees, paid to Dr.
Hans B Frykman Medical Corp., will at that time, have preference to paying shareholders or the JV partners.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
13.02.</B></FONT><B> Key Decisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">In Stage One, the Parties will discuss all material decisions affecting the operations, expenditures and commitments of the JV SERVICE
/ newco, and PROMIS, BCNI or its designates shall not make any key decisions concerning such operations, expenditures and commitments
without the prior written consent of PROMIS and BCNI.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XIV. </B></FONT><B>TERRITORY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Territory in which the JV SERVICE will operate, and for which the
licenses hereunder are granted is Worldwide</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XV. </B></FONT><B>TRANSPARENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Subject to applicable confidentiality provisions and Applicable Laws,
all financial and commercial documentation is to be transparent, available at all times and to be open for review by both Parties whenever
requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
XVI. CONFIDENTIALITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">All Confidential Information disclosed by one Party to the other pursuant
to this Agreement will be treated as strictly confidential, and will not be disclosed to anyone except the agents, employees and representatives
of the Parties, and then only on a &ldquo;need-to-know&rdquo; basis for the purposes of fulfilling a Party&rsquo;s role and responsibilities
hereunder. Anyone to whom such a disclosure is made shall be subject to confidentiality restrictions to the Party receiving such Confidential
Information that is no less stringent than that between the Parties hereto. Neither Party will use the Confidential Information of the
other for any purpose other than as set out in this Agreement, and only in compliance with its obligations in the Joint Venture. A Party&rsquo;s
obligation of confidentiality hereunder is for a period of five (5) years after the expiry or termination of this Agreement or any subsequent
agreement that supersedes or replaces it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XVII. </B></FONT><B>DUTY OF LOYALTY AND NON-COMPETE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Neither BCNI or ProMIS will engage in any business, venture or transaction,
whether directly or indirectly, that might be competitive with the business of the Venture or that would be in direct conflict of interest
to the Venture. Any potential conflicts of interest will be deemed an Involuntary Withdrawal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A dissociated or withdrawing Member will not carry on a similar business
to the business of the Venture within any established or contemplated market regions of the Venture for a period of at least one year
from the date of dissociation or withdrawal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XVIII. </B></FONT><B>GOVERNING LAW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The interpretation and construction of this Agreement shall be governed
by the laws of the Province of British Columbia, excluding any conflicts or choice of law rule or principle that might otherwise refer
interpretation or construction of this Agreement to the substantive law of another jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XIX. </B></FONT><B>PRESS RELEASES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any press release pertaining to the JV SERVICE or this Agreement is
subject to mutual approval of the Parties. Once Newco is funded and operational, a certain amount of secrecy to operations is warranted
to better manage competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XX. </B></FONT><B>SEVERABILITY; ENFORCEABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, for any reason, any part of this Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, then such adjudication shall not, to the extent feasible, affect or impair,
in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall
remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
XXI. INSURANCE &amp; LIABILITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
21.01.</B></FONT><B> INSURANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">JV SERVICE/BCNI/ProMIS/Newco, as the case may be, will procure such
insurance e.g., commercial general liability insurance, paid by the JV/Newco. Once the JV/Newco is profitable and is operating in a clinical
setting, then product liability, clinical trials, public liability insurance will be evaluated by both partners for suitability and cost
vs. utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any insurance will be placed with a reputable and financially secure
insurance carrier and will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>include PROMIS and BCNI, its officers, directors and employees as additional insured;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>provide coverage regarding all relevant activities contemplated under this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>include a waiver of subrogation against PROMIS and BCNI, and a severability of interest and cross-liability clauses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>provide that the insurer will endeavour to notify PROMIS and BCNI at least 30 days prior to the cancellation of the policy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">JV SERVICE/Newco, on request, will provide to PROMIS and BCNI certificates of insurance evidencing the insurance coverages (and any
renewals) of the JV SERVICE/Newco, and its subcontractors in respect of the activities of this Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
21.02.</B></FONT><B> DISCLAIMERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>&lsquo;As Is&rsquo; Basis: </B>The Licensed Technology is provided by PROMIS and BCNI on an &lsquo;as is&rsquo; basis, and neither
BCNI or PROMIS makes any warranties, representations or conditions, express or implied, of any nature, and disclaims all warranties, representations
or conditions, for the Licensed Technology or Confidential Information including, without limitation, merchantability, quality, fitness
for any or a particular purpose, commercial utility or practical purpose, latent or other defects, infringement or non-infringement of
Patents or other third party rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Disclaimer of Statutorily Implied Warranties: </B>No legal or equitable warranties or conditions implied by law or convention under
any domestic, foreign or international legal regime, or from a course of dealing or usage of trade, shall apply to this Agreement. The
JV SERVICE/Newco and BCNI, as the case may be, acknowledges this disclaimer and is stopped from relying on any such representations, warranties
or conditions against PROMIS. The JV/Newco and ProMIS acknowledge this disclaimer and is stopped from relying on any such representations,
warranties or conditions against BCNI.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>Licensee Shall Obtain Regulatory Permissions: </B>JV SERVICE/Newco, or BCNI and ProMIS, as the case may be, shall obtain any authorizations,
permits, certificates or other regulatory permissions which may be required in order for JV SERVICE/Newco or BCNI and ProMIS as the case
may be, to legally carry out all of its activities under this Agreement, including but not limited to Commercialization<B>.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXII. </B></FONT><B>ENTIRE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement together with any Appendices or attachments, reflects
the entire agreement between the Parties with respect to the subject matter hereof and supersedes all other agreements between the Parties
concerning such subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXIII. </B></FONT><B>MODIFICATIONS</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">No amendment, modification or supplement of any provision of the Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer or director of each party. No provision of
the Agreement shall be waived by any act, omission or knowledge of any party or its agents or employees except by an instrument in writing
expressly waiving such provision and signed by a duly authorized officer or director of the waiving party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXIV. </B></FONT><B>COUNTERPARTS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Agreement may be executed in any number of counterparts. A signed
Agreement received by a Party hereto via email will be deemed an original, and binding upon the Party who signed it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXV. </B></FONT><B>TIME.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Time is of the essence in the performance of obligations of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXVI. </B></FONT><B>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Any notice to be given under this Agreement must be in writing and
delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its address given below, or at any address such Party has previously
designated by prior written notice to the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to BCNI, notices must be addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">BC Neuroimmunology Lab Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn. Dr. Hans B Frykman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">C/O MORTON LAW LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Corporate &amp; Securities Lawyers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1200-750 W. Pender Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Vancouver, British Columbia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Canada, V6C 2T8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to PROMIS, notices must be addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn. Dr. Elliot Goldstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1920 Yonge St, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Toronto Ont. M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In the event of a change of notice address, recipient or both, a Party
shall provide the other Party written notice setting forth the new address and/or recipient, as appropriate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article
XXVII. </B></FONT><B>TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
27.01.</B></FONT><B> Term</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This Agreement shall come into effect on the Effective Date first written
above and shall endure until it is terminated on one of the following possible grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
27.02.</B></FONT><B> Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This Agreement may be terminated: (i) by mutual agreement of the Parties;
(ii) for material breach by one of the Parties hereto of its respective obligations under this Agreement; (iii) if the Parties enter into
Definitive Agreements superseding or replacing this Agreement (for instance, upon entering Stage Two of the Joint Venture); or (iv) if
JV SERVICE is wound up, acquired by or merged with another entity, or otherwise ceases to exist or to do business as contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
27.03.</B></FONT><B> Notice of Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Party seeking to terminate this Agreement shall provide written
notice to the other Party, such written notice to specify in reasonable detail the reasons for termination. Any termination based on clause
(ii) above, namely material breach, shall provide at least 90 Business Days for the breaching party to cure the material breach before
such termination is deemed effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section
27.04.</B></FONT> Effects of Termination</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by ProMIS or BCNI in this Agreement shall be terminated automatically and all
rights shall revert to PROMIS or BCNI respectively, unless either party agrees, in writing, in its exclusive judgement and discretion
to extend the time period for (ii) above, or to modify this Agreement to allow for its continuance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by BCNI in this Agreement shall be terminated automatically and all rights shall
revert to BCNI, unless BCNI agrees, in writing, in its exclusive judgement and discretion to extend the time period for (ii) above, or
to modify this Agreement to allow for its continuance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
XXVIII. ASSIGNMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement may not be assigned by a Party without the prior written
consent of the other Party except in connection with the sale or transfer of all or substantially all of the assets of such Party relevant
to the subject matter hereof, or in connection with a corporate reorganization, provided that the other Party is notified of the assignment
and the assignee expressly undertakes in writing to be bound by all of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Agreement
by their respective, duly authorized representatives as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">ProMIS Neurosciences Inc.</TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">BC Neuroimmunology Inc</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">/s/ Elliot Goldstein</TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">/s/ Hans Frykman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">NAME: Elliot Goldstein, MD</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">NAME: Dr. Hans Frykman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">TITLE:&nbsp;&nbsp;CEO</TD>
    <TD STYLE="border: Black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">TITLE:&nbsp;&nbsp;CEO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">APPENDIX A<BR>
LICENSED TECHNOLOGY: PATENTS AND APPLICATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProMIS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[LIST OF RELEVANT ProMIS PATENTS AND APPLICATIONS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BCNI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[LIST OF RELEVANT BCNI PATENTS AND APPLICATIONS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Certain identified information
has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both
not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated
by: <I>[***]</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">UBC
File: F20-03911</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COLLABORATIVE RESEARCH AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BETWEEN:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>THE UNIVERSITY OF BRITISH COLUMBIA</B>,
a corporation continued under the <I>University Act </I>of British Columbia with offices at 103 &#8211; 6190 Agronomy Road, Vancouver,
British Columbia, V6T 1Z3 (&#8220;<B>UBC</B>&#8221;) <B>AND PROVINCIAL HEALTH SERVICES AUTHORITY</B> (on behalf of Children&#8217;s &amp;
Women&#8217;s Health Centre of British Columbia Branch, a public hospital) having its research administrative offices at 4500 Oak Street,
Vancouver, British Columbia, Canada V6H 3N1 (&#8220;<B>PHSA</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(UBC <FONT STYLE="font-weight: normal">and
</FONT>PHSA <FONT STYLE="font-weight: normal">collectively, the &#8220;</FONT>Institution<FONT STYLE="font-weight: normal">&#8221;)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AND:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B>, a corporation
incorporated under the laws of Canada, with a registered office at 1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">(the &#8220;<B>Sponsor</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(<B>Institution</B> and the <B>Sponsor</B> are
referred to in this <B>Agreement</B> individually as a &#8220;<B>Party</B>&#8221;, and collectively as the &#8220;<B>Parties</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 40.5pt">A.</TD><TD STYLE="text-align: justify">UBC and Sponsor entered into an Amended
                                            and Restated License Agreement effective October 6, 2015 (the &#8220;<B>License Agreement</B>&#8221;)
                                            attached as Schedule &#8220;<B>A</B>&#8221;, which grants to the Sponsor certain rights to
                                            Technology and Improvements (as defined in the License Agreement and any amendments thereto);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 40.5pt">B.</TD><TD STYLE="text-align: justify">It is UBC&#8217;s objective to generate
                                            research in a manner consistent with UBC&#8217;s status as a non-profit, tax exempt educational
                                            institution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 40.5pt">C.</TD><TD STYLE="text-align: justify">The research program contemplated by this
                                            Agreement is of mutual interest and benefit to UBC and to the Sponsor, will further the instructional
                                            and research objectives of UBC in a manner consistent with its status as a non-profit, tax-exempt,
                                            educational institution, and may derive benefits for both the Sponsor and UBC through inventions,
                                            improvements and discoveries; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 40.5pt">D.</TD><TD STYLE="text-align: justify">Under UBC research policy and in agreement
                                            with its affiliated hospitals, UBC owns inventions and/or results and data arising from research
                                            performed by the Institution and which are conceived and/or made by the Institution&#8217;s
                                            researchers who have an appointment with UBC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">UBC
File: F20-03911</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE PARTIES AGREE AS FOLLOWS:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>1.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>DEFINITIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">In this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&#8220;<B>Confidential Information</B>&#8221;
                                            means all information, regardless of its form:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">disclosed by the Institution to the Sponsor
                                            and which is clearly identified in writing as &#8220;Confidential&#8221; either at the time
                                            of disclosure or within 30 calendar days thereafter,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">disclosed by the Sponsor to the Institution
                                            and which is clearly identified in writing as &#8220;Confidential&#8221; either at the time
                                            of disclosure or within 30 calendar days thereafter, except that &#8220;Confidential Information&#8221;
                                            does not include information:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">possessed by the recipient (the &#8220;<B>Recipient</B>&#8221;)
                                            prior to receipt from the disclosing Party (the &#8220;Discloser&#8221;), other than through
                                            prior confidential disclosure by the Discloser, as evidenced by the Recipient&#8217;s business
                                            records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">published or available to the general public
                                            otherwise than through a breach of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">obtained by the Recipient from a third party
                                            with a valid right to disclose it, provided that the third party is not under a confidentiality
                                            obligation to the Discloser in respect of the same; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">independently developed by employees, agents
                                            or consultants of the Recipient who had no knowledge of or access to the Discloser&#8217;s
                                            information as evidenced by the Recipient&#8217;s business records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&#8220;<B>Contract Period</B>&#8221; means
                                            the period commencing on the Effective Date and ending 6 months after the Start Date as set
                                            out in Article 2.1 of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&#8220;<B>Effective Date</B>&#8221; means
                                            the date on which the last of the Parties executes this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&#8220;<B>Inventions</B>&#8221; means
                                            any new and useful art, process, machine, manufacture or composition of matter, or any new
                                            and useful improvement in any art, process, machine, manufacture or composition of matter,
                                            but excludes the Technology and Improvements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&#8220;<B>Investigator</B>&#8221; means
                                            Dr. Blair Leavitt of the Department of Medical Genetics at UBC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&#8220;<B>Joint Intellectual Property</B>&#8221;
                                            means any and all Inventions made jointly by the Institution and the Sponsor during the Contract
                                            Period in the performance of the Project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&#8220;<B>Project</B>&#8221; means the
                                            research project as described in Schedule &#8220;<B>B</B>&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&#8220;<B>Sponsor Intellectual Property</B>&#8221;
                                            means, any and all Inventions made solely by the Sponsor during the Contract Period in the
                                            performance of the Project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&#8220;<B>UBC Intellectual Property </B>&#8220;
                                            means, any and all Inventions made solely by the Institution during the Contract Period in
                                            the performance of the Project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>2.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>RESEARCH
                                            WORK</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">The Institution will commence the performance
                                            of the Project after UBC&#8217;s receipt of the first payment set out in Article 4.1 (the
                                            &#8220;<B>Start Date</B>&#8221;) and will use reasonable efforts to perform the Project substantially
                                            in accordance with the terms and conditions of this Agreement. The Sponsor and the Institution
                                            may at any time amend the Project by mutual written agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">If the Investigator becomes unable or unwilling
                                            to continue the Project, and a mutually acceptable substitute is not available, the Institution
                                            and the Sponsor will each have the option to terminate the Project and this Agreement by
                                            providing the other Party with written notice of same.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>3.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>REPORTS
                                            &amp; CONFERENCES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">During the Contract Period, the Institution
                                            will keep the Sponsor informed, orally or in writing, as to the progress of the Project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">The Institution will submit a final report
                                            to the Sponsor within 60 calendar days after the conclusion of the Contract Period or early
                                            termination of this Agreement, whichever is sooner.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>4.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>COSTS,
                                            INVOICES &amp; OTHER SUPPORT</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">The Parties understand and agree that, subject
                                            to Article 4.4, and excluding any intellectual property related costs under Section 7, the
                                            total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge
                                            that any budget categories that may be described in the Project are estimates only and that
                                            changes from category to category may be made at the Institution&#8217;s discretion. The
                                            Sponsor will pay to UBC the amounts on the following due dates:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1)</TD><TD STYLE="text-align: justify; padding-right: 0.55in">On the Effective
                                            Date of this Agreement...........................$[***]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Sponsor may make payments by wire
transfer or direct deposit to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: right">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Beneficiary Bank:</TD>
    <TD STYLE="width: 69%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">[***]</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Beneficiary:</TD>
    <TD STYLE="width: 69%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The University of British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4<SUP>th</SUP> Floor, Suite 409</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vancouver, BC, Canada, V6T 1Z3</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Remittance detail:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Please email [***] &#8211; Ref FAS #[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">UBC reserves the right to suspend work
on the Project or to terminate the Project and this Agreement by delivering written notice of same to the Sponsor if the Sponsor fails
to pay any invoiced amount within 30 calendar days from the due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Sponsor will pay interest on all
amounts owing to UBC not paid on the due date, at the rate of [***]% per annum. The interest accrues on the outstanding balance from
the due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">UBC will retain title to any equipment purchased
                                            with funds provided by the Sponsor under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify">UBC will be entitled to retain any funds paid
                                            by the Sponsor to UBC under this Agreement, subject to Article 4.4.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">Notwithstanding anything contained in this
                                            Article 4, in the event of early termination of this Agreement, the Sponsor will pay all
                                            costs and liabilities relating to the Project which have been incurred by the Institution
                                            as of the date of receipt of notice of such termination. Such costs and liabilities will
                                            include all non-cancellable obligations including payments in lieu of reasonable notice for
                                            technicians, graduate students and other staff assigned to the Project, but will not, in
                                            the aggregate, exceed the total amount payable by the Sponsor set out in Article 4.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>5.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>CONFIDENTIALITY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">Each Party will keep and use the other Party&#8217;s
                                            Confidential Information in confidence and will not, without the other Party&#8217;s prior
                                            written consent, disclose the other Party&#8217;s Confidential Information to any person
                                            or entity, except to the Party&#8217;s directors, officers, employees, faculty, students
                                            and professional advisors who require the Confidential Information to assist such Party in
                                            performing its obligations and exercising its rights under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">Any Party required by judicial or administrative
                                            process to disclose the other Party&#8217;s Confidential Information will promptly notify
                                            the other Party and allow it reasonable time to oppose the process before disclosing the
                                            Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">Notwithstanding any termination or expiration
                                            of this Agreement, the obligations set out in this Article 5 survive and continue to bind
                                            the Parties, their successors and assigns until 3 years after such termination or expiration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>6.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>PUBLICATION</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">UBC is not restricted from presenting at symposia,
                                            national or regional professional meetings, or from publishing in journals or other publications,
                                            results from the Project, provided that the Sponsor is provided with copies of the proposed
                                            disclosure at least 30 calendar days before the presentation or publication date and does
                                            not, within 15 calendar days after delivery of the proposed disclosure, give notice to UBC
                                            indicating that it objects to the proposed disclosure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify">The Sponsor may object to the proposed disclosure
                                            on the grounds that (i) it contains Confidential Information that was disclosed to the Institution
                                            by the Sponsor; or (ii) that it discloses patentable subject matter which needs protection.
                                            If the Sponsor makes objection on the grounds of the inclusion of the Sponsor&#8217;s Confidential
                                            Information, UBC will remove such Confidential Information immediately from the proposed
                                            disclosure, after which UBC is free to present and/or publish the proposed disclosure. If
                                            the Sponsor makes an objection on the grounds of protection of patentable subject matter:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">it will be deemed to be a direction to UBC
                                            to file a patent application as set out in Article 7.6; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">UBC will delay the proposed disclosure
                                            until UBC has filed one or more patent applications with one or more patent offices directed
                                            to such patentable subject matter (the &#8220;<B>Delay</B>&#8221;). A provisional patent
                                            application will be considered to be a patent application in the United States of America
                                            for the purposes of this Agreement. The Delay will be no longer than 3 months from the date
                                            UBC delivered the proposed disclosure to the Sponsor, after which UBC is free to present
                                            and/or publish the proposed disclosure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.3</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Agreement,
                                            the Parties acknowledge and agree that no delay is permitted for the defense of a student&#8217;s
                                            thesis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>7.0</B></FONT></TD><TD STYLE="text-align: justify"><B>INTELLECTUAL
                                            PROPERTY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Parties acknowledge and agree that Technology
                                            and Improvements are subject to the License Agreement and any amendments thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">The Sponsor acknowledges and agrees that UBC
                                            owns all right, title and interest in and to UBC Intellectual Property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.3</TD><TD STYLE="text-align: justify">UBC acknowledges and agrees that the Sponsor
                                            owns all right, title and interest in and to Sponsor Intellectual Property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.4</TD><TD STYLE="text-align: justify">The Parties acknowledge and agree that UBC
                                            and the Sponsor have joint right, title and interest in and to Joint Intellectual Property.
                                            Notwithstanding the applicable patent or other intellectual property laws in any jurisdiction,
                                            neither of the Parties may commercially exploit any Joint Intellectual Property, except as
                                            specifically provided for in Article 7.9 and 8.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.5</TD><TD STYLE="text-align: justify">UBC will promptly notify the Sponsor of any
                                            UBC Intellectual Property. The Parties will promptly notify one another of any Joint Intellectual
                                            Property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.6</TD><TD STYLE="text-align: justify">The Sponsor may direct that UBC file one or
                                            more patent applications for UBC Intellectual Property and/or Joint Intellectual Property.
                                            UBC will then promptly prepare, file and prosecute patent applications in the name of UBC
                                            for UBC Intellectual Property and/or in joint names of UBC and the Sponsor for Joint Intellectual
                                            Property. UBC will be responsible for making final decisions regarding the scope and content
                                            of the patent applications and their prosecution. UBC will notify the Sponsor of any significant
                                            developments on all patent applications and will promptly supply the Sponsor with copies
                                            of papers received and filed in connection thereto in sufficient time for the Sponsor&#8217;s
                                            review and input.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.7</TD><TD STYLE="text-align: justify">The Sponsor will bear all costs incurred in
                                            connection with the preparation, filing, prosecution and maintenance of the patent applications.
                                            Within 30 calendar days of UBC&#8217;s written request, the Sponsor will pay to UBC a reasonable
                                            payment as an advance against expected patent expenses. The Sponsor will assist UBC in a
                                            timely manner to ensure that the patent applications cover, to the best of the Sponsor&#8217;s
                                            knowledge, all items of commercial interest and importance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.8</TD><TD STYLE="text-align: justify">If UBC wishes to obtain patent protection
                                            for UBC Intellectual Property and/or Joint Intellectual Property over and above that for
                                            which the Sponsor wishes to provide its financial support pursuant to Article 7.7, UBC will
                                            be free to file any patent applications, including new applications, at its own expense.
                                            If Sponsor discontinues its financial support for prosecution or maintenance of any patents
                                            or patent applications for UBC Intellectual Property and/or Joint Intellectual Property,
                                            UBC will be free to continue the prosecution or maintain such patents or patent applications
                                            at its own expense. In any event, UBC will not have any obligation to the Sponsor under Article
                                            8 (Grant of Rights) relating to such patent protection.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.9</TD><TD STYLE="text-align: justify">In the event that the Sponsor wishes to discontinue
                                            the financial support for prosecution or maintenance of any patents or patent applications
                                            for Joint Intellectual Property (the &#8220;<B>Event</B>&#8221;), the Sponsor will notify
                                            UBC in writing at least 30 calendar days prior to the Event (the &#8220;<B>Notice to Discontinue</B>&#8221;)
                                            and UBC will be free to continue the prosecution or maintenance of any such patents or patent
                                            applications for Joint Intellectual Property. The Sponsor will then promptly execute and
                                            deliver to UBC any assignment or documents UBC may deem necessary or desirable to vest in
                                            UBC all right, title and interest in the patents and patent applications. Sponsor will pay
                                            for all expenses incurred in connection with the patents and patent applications prior to
                                            the Event and for 30 calendar days from UBC&#8217;s receipt of the Notice to Discontinue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>8.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>GRANT
                                            OF RIGHTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.1</TD><TD STYLE="text-align: justify">UBC grants the Sponsor the
                                            option to negotiate a royalty-bearing license to use and exploit UBC Intellectual Property
                                            and UBC&#8217;s rights in Joint Intellectual Property subject to terms and conditions determined
                                            in accordance with Article 8.2 (the &#8220;<B>Option</B>&#8221;). The Option will subsist
                                            with respect to each item of UBC Intellectual Property and Joint Intellectual Property for
                                            a period of 6 months after UBC has disclosed said item in writing to the Sponsor (the &#8220;<B>Option
                                            Period</B>&#8221;). The Sponsor may exercise the Option within the Option Period by delivering
                                            written notice of same to UBC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.2</TD><TD STYLE="text-align: justify">If the Sponsor exercises the Option pursuant
                                            to Article 8.1, the Parties will negotiate in good faith to determine the specific terms
                                            and conditions on which a license will be granted by UBC to the Sponsor. Such license will
                                            contain commercially reasonable financial terms and will be generally consistent with the
                                            terms and conditions of the license agreements then being entered into by UBC with its other
                                            licensees. If UBC and the Sponsor, acting reasonably, are unable to agree upon such specific
                                            terms and conditions within a period of 6 months after the date when the Sponsor exercised
                                            the Option, the Parties acknowledge and agree that the Option will expire.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.3</TD><TD STYLE="text-align: justify">If the Sponsor does not exercise the Option
                                            pursuant to Article 8.1, UBC will be entitled to license from the Sponsor the Sponsor&#8217;s
                                            interest in Joint Intellectual Property and the Parties will negotiate in good faith to determine
                                            the specific terms and conditions, including royalty rates, on which the license will be
                                            granted by the Sponsor to UBC. The Sponsor will have no right to use Joint Intellectual Property
                                            for any purpose and will not license, sell, assign or otherwise transfer the Sponsor&#8217;s
                                            interest in the Joint Intellectual Property to any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.4</TD><TD STYLE="text-align: justify">The Sponsor acknowledges and agrees that UBC
                                            may use Joint Intellectual Property without charge in any manner at all for research, scholarly
                                            publication, educational and all other non-commercial uses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>9.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>TERM</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">This Agreement will be effective from the
                                            Effective Date for the full duration of the Contract Period unless terminated earlier under
                                            Article 10.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>10.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>TERMINATION</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">Either Party may terminate this Agreement
                                            upon 30 calendar days prior written notice to the other.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.2</TD><TD STYLE="text-align: justify">If either Party commits any breach or default
                                            of any terms or conditions of this Agreement and also fails to remedy such breach or default
                                            within 30 calendar days after receipt of a written notice from the other Party, the Party
                                            giving notice may terminate this Agreement by sending a notice of termination in writing
                                            to the Party in breach. This termination will be effective as of the date of the receipt
                                            of such notice. The termination may be in addition to any other remedies available at law
                                            or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.3</TD><TD STYLE="text-align: justify">This Agreement may be terminated by the Institution
                                            if the Sponsor is in breach of any other agreement between the Sponsor and the Institution,
                                            which breach has not been cured within the time provided for the curing of such breach under
                                            the terms of such other agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.4</TD><TD STYLE="text-align: justify">No termination of this Agreement, however
                                            effectuated, will release the Parties from their rights and obligations under Articles 4
                                            (non-cancelable costs), 5.0 (Confidentiality), 7.0 (Intellectual Property), 8.0 (Grant of
                                            Rights), 10.7 (cessation of use of Confidential Information) and 12.1 (Indemnity).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.5</TD><TD STYLE="text-align: justify">Neither of the Parties shall be deemed to
                                            be in default of, or to have breached, any provision of this Agreement as a result of any
                                            delay, failure in performance or interruption of service, resulting directly or indirectly
                                            from natural disasters, pandemics, epidemics, disease, acts of civil or military authorities,
                                            civil disturbances, wars, strikes or other labour disputes, fires, transportation contingencies,
                                            laws, regulations, acts or orders of any government or agency or official thereof, other
                                            catastrophes or any other similar occurrences beyond such Party&#8217;s reasonable control.
                                            In every case, the delay or failure in performance or interruption of service must be without
                                            the fault or negligence of the Party claiming excusable delay, and the Party claiming excusable
                                            delay must promptly notify the other Party of such delay.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.6</TD><TD STYLE="text-align: justify">The Parties acknowledge that as a result
                                            of the ongoing global pandemic, the Institution may determine it is necessary to suspend
                                            or cease the performance of the Project. If the Institution, in its sole discretion, determines
                                            it is necessary to suspend or cease the performance of the Project, the Institution will
                                            notify the Sponsor, and the Parties will determine whether to amend or terminate this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.7</TD><TD STYLE="text-align: justify">Upon the termination of this Agreement, the
                                            Recipient will cease to use the Discloser&#8217;s Confidential Information in any manner
                                            whatsoever and upon the written request of the Discloser, will deliver to the Discloser all
                                            of the Discloser&#8217;s Confidential Information in the Recipient&#8217;s possession or
                                            control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.8</TD><TD STYLE="text-align: justify">The Parties may extend this Agreement in
                                            writing for additional periods under mutually agreeable terms and conditions. Said extension
                                            will be effective upon signature by both Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>11.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>DISCLAIMER
                                            OF WARRANTY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">The Institution makes no representations
                                            or warranties, either express or implied, regarding data or other results arising from the
                                            Project or regarding Confidential Information the Institution may disclose to the Sponsor.
                                            The Institution specifically disclaims any implied warranty of non-infringement or merchantability
                                            or fitness for a particular purpose and the Institution will, in no event, be liable for
                                            any loss, whether direct, consequential, incidental, or special or other similar damages
                                            arising from any defect, error or failure to perform, even if the Institution has been advised
                                            of the possibility of such damages. The Sponsor acknowledges that the Project is of an experimental
                                            and exploratory nature, that no particular results can be guaranteed, and that the Sponsor
                                            has been advised by the Institution to undertake its own due diligence with respect to all
                                            matters arising from this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>12.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>INDEMNITY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.1</TD><TD STYLE="text-align: justify">The Sponsor indemnifies,
                                            holds harmless and defends the Institution, their Board of Governors, directors, officers,
                                            employees, faculty, students, invitees and agents against any and all claims (including all
                                            reasonable legal fees and disbursements) arising out of the receipt or use by the Sponsor
                                            of any Institution&#8217;s Confidential Information, UBC Intellectual Property, Joint Intellectual
                                            Property, or any data or other results arising from the Project including, without limitation,
                                            any damages or losses, consequential or otherwise, arising from or out of the Project, however
                                            they may arise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>13.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>INSURANCE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">The Institution has liability insurance applicable
                                            to their directors, officers, employees, faculty, students and agents while acting within
                                            the scope of their employment by the Institution. The Institution has no liability insurance
                                            policy that can extend protection to any other person. Therefore, subject to Article 12.1
                                            (Indemnity), each Party hereby assumes any risks of personal injury and property damage attributable
                                            to the negligent acts or omissions of that Party and its directors, officers, employees and
                                            agents, and where applicable faculty and students.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>14.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>GOVERNING
                                            LAW</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.1</TD><TD STYLE="text-align: justify">This Agreement is governed by, and will be
                                            construed in accordance with, the laws of British Columbia and the laws of Canada in force
                                            in that province, without regard to its conflict of law rules. The Parties agree that by
                                            executing this Agreement, they have attorned to the exclusive jurisdiction of the Supreme
                                            Court of British Columbia.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>15.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>ASSIGNMENT</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.1</TD><TD STYLE="text-align: justify">Neither Party may assign this Agreement without
                                            the prior written consent of the other Party, which consent will not be unreasonably withheld.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>16.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>NOTICES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.1</TD><TD STYLE="text-align: justify">All payments, reports and notices or other
                                            documents that a Party is required or may want to deliver to any other Party will be delivered:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in writing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">either by email, personal delivery or
                                            by registered or certified mail (with all postage and other charges prepaid) at the address
                                            for the receiving Party as set out in Article 16.2 or as varied by any notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Any notice personally delivered is deemed
to have been received at the time of delivery. Any notice mailed in accordance with this Article 16.1 is deemed to have been received
at the end of the fifth business day after it is posted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.2</TD><TD STYLE="text-align: justify">Addresses for delivery of notices:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sponsor</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProMIS Neurosciences, Inc.<BR>
    1920 Yonge St, Suite 200<BR>
    Toronto, Ontario, M4S 3E2<BR>
    Att: Dr. Elliot Goldstein (CEO)<BR>
    Telephone: [***]<BR>
    Fax: [***]<BR>
    Email: [***]<BR>
    With cc to: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UBC</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry Contracts &amp; Agreements Manager</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">University-Industry Liaison Office</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">#103 &#8211; 6190 Agronomy Road</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The University of British Columbia Vancouver,
    British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Canada V6T 1Z3</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Telephone: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PHSA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Wyeth Wasserman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: left; text-indent: -17.1pt">Vice-President
    Research, BC Children&#8217;s Hospital,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PHSA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A2-146</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">950 West 28<SUP>th</SUP> Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vancouver, British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Canada V5Z 4H4</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fax: [***]</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.3</TD><TD STYLE="text-align: justify">The Sponsor may direct questions of a scientific
                                            nature or regarding financial matters to the Institution through the following contacts:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; font-size: 10pt"><B>Scientific Matters</B></TD>
    <TD STYLE="width: 52%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><B>Financial Matters</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Blair Leavitt</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Department of Medical Genetics</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The University of British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">980 West 28th Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver, British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada V5Z 4H4</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Telephone: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [***]</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Manager, Research Finance Office</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The University of British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4<SUP>th</SUP> Floor &#8211; TEF 3</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">409-6190 Agronomy Road</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver, British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada V6T 1Z3</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Telephone: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: [***]</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>17.0</B></FONT></TD><TD STYLE="text-align: justify"><B><U>GENERAL</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.1</TD><TD STYLE="text-align: justify">Nothing contained in this Agreement is to
                                            be deemed or construed to create between the Parties a partnership or joint venture. No Party
                                            has the authority to act on behalf of any other Party, or to commit any other Party in any
                                            manner at all or cause any other Party&#8217;s name to be used in any way not specifically
                                            authorized by this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">UBC File: F20-03911</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.2</TD><TD STYLE="text-align: justify">No Party may use the other Party&#8217;s
                                            name, trademarks or insignia for any advertising or any promotional purposes, including but
                                            not limited to media releases, without the other Party&#8217;s prior written consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.3</TD><TD STYLE="text-align: justify">Either Party may identify the title of the
                                            Project, the Parties to this Agreement, the name of the Investigator, the Contract Period
                                            and the amount of funding provided by the Sponsor for the Project for administrative or regulatory
                                            purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.4</TD><TD STYLE="text-align: justify">Subject to the limitations in this Agreement,
                                            this Agreement operates for the benefit of and is binding on the Parties and their respective
                                            successors and permitted assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.5</TD><TD STYLE="text-align: justify">No condoning, excusing or overlooking by
                                            any Party of any default, breach or nonobservance by any other Party at any time or times
                                            regarding any terms of this Agreement operates as a waiver of that Party&#8217;s rights under
                                            this Agreement. A waiver of any term, or right under this Agreement will be in writing signed
                                            by the Party entitled to the benefit of that term or right, and is effective only to the
                                            extent set out in the written waiver<B>.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.6</TD><TD STYLE="text-align: justify">No exercise of a specific right or remedy
                                            by any Party precludes it from or prejudices it in exercising another right or pursuing another
                                            remedy or maintaining an action to which it may otherwise be entitled either at law or in
                                            equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.7</TD><TD STYLE="text-align: justify">Headings in this Agreement are for reference
                                            only and do not form a part of this Agreement and are not be used in the interpretation of
                                            this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.8</TD><TD STYLE="text-align: justify">All terms in this Agreement which require
                                            performance by the Parties after the expiry or termination of this Agreement, will remain
                                            in force despite this Agreement&#8217;s expiry or termination for any reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.9</TD><TD STYLE="text-align: justify">Part or all of any Article that is indefinite,
                                            invalid, illegal or otherwise voidable or unenforceable, may be severed from this Agreement
                                            and the balance of this Agreement will continue in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.10</TD><TD STYLE="text-align: justify">At the request of the Institution or the
                                            Sponsor, the non-requesting Party will obtain the execution of any agreement or instrument
                                            (including from its employees, agents, contractors, consultants or representatives) that
                                            may be required to consummate the transactions contemplated in this Agreement, including
                                            assigning any rights, waiving any rights or perfecting any rights in such Party&#8217;s name.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.11</TD><TD STYLE="text-align: justify">This Agreement and the Schedules set out
                                            the entire understanding between the Parties and no changes to this Agreement are binding
                                            unless in writing and signed by the Parties to this Agreement. The Parties will be bound
                                            by the Schedules, except to the extent that they may conflict with the terms and conditions
                                            contained in this Agreement, in which case the terms and conditions of this Agreement will
                                            govern.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.12</TD><TD STYLE="text-align: justify">In this Agreement, unless the contrary intention
                                            appears, the singular includes the plural and vice versa and words importing a gender include
                                            other genders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.13</TD><TD STYLE="text-align: justify">This Agreement may be executed in counterpart
                                            by the Parties, either through original copies or by facsimile or electronically each of
                                            which will be deemed an original and all of which will constitute the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%; background-color: White">SIGNED BY THE PARTIES AS AN AGREEMENT
    <FONT STYLE="font-style: normal; font-weight: normal">effective as of the date on which the last of the Parties executes this Agreement.</FONT></TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-style: normal; font-weight: normal">SIGNED
    FOR AND ON BEHALF of</FONT> <B>THE UNIVERSITY OF BRITISH COLUMBIA</B> by its duly authorized signatory:</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White">/s/ Mario Kasapi</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name:</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title: Associate Director, UILO</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Date: October 5, 2020</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">SIGNED FOR AND ON BEHALF of PROVINCIAL HEALTH SERVICES
    AUTHORITY by its duly authorized signatory:</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White">/s/ Wyeth W. Wasserman</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name: Wyeth W. Wasserman, Ph. D.</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title: Vice-President Research, BC Children's Hospital</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Date: October 8, 2020</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">SIGNED FOR AND ON BEHALF of PROMIS NEUROSCIENCES INC.
    by its duly authorized signatory:</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White">/s/ Elliot Goldstein</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name: Elliot Goldstein, MD</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title: President &amp; CEO</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Date: Oct. 5, 2020</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Read and acknowledged by:</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White">/s/ Dr. Blair Leavitt</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name: Dr. Blair Leavitt</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title: Professor</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Date: October 5, 2020</TD>
    <TD STYLE="background-color: White">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE &#8220;A&#8221;<BR>
<BR>
LICENSE AGREEMENT<BR>
<BR>
(.PDF &#8211; 34 PAGES)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED LICENSE AGREEMENT<BR>
<BR>
BETWEEN<BR>
<BR>
THE UNIVERSITY OF BRITISH COLUMBIA<BR>
<BR>
and<BR>
<BR>
PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">UBC File: F20-03911</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED LICENSE AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amended and Restated License Agreement (&#8220;Agreement&#8221;)
made effective the 6th day of October, 2015,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BETWEEN:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">THE UNIVERSITY OF BRITISH COLUMBIA, a
corporation continued under the <I>University Act </I>of British Columbia with its administrative offices at 2075 Wesbrook Mall, Vancouver,
British Columbia, V6T 1W5 (&#8220;UBC&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AND:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>PROMIS NEUROSCIENCES INC., </B>a corporation
continued under the laws of Canada, with a registered office at, 1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2 (the <B>&#8220;Licensee&#8221;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">UBC has been engaged in research during
                                            the course of which it has invented, developed and/or acquired certain technology relating
                                            to misfolded proteins (UBC file 09-093 the &#8220;ProMIS Technology&#8221;) which research
                                            was undertaken by Dr. Neil Cashman and William Guest in the UBC Department of Medicine and
                                            Dr. Steve Plotkin in the UBC Department of Physics and Astronomy (collectively, the <B>&#8220;Investigators&#8221;);</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">It is UBC&#8217;s objective to exploit
                                            its technology for the public benefit, and to generate further research in a manner consistent
                                            with its status as a non-profit, tax exempt educational institution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Licensee, under its previous name
                                            (Amorfix Life Sciences Ltd.), and UBC entered into an exclusive license agreement effective
                                            February 4, 2009 (the &#8220;2009 License Agreement&#8221;) in which the Licensee gained
                                            exclusive worldwide rights to develop and commercialize intellectual property rights belonging
                                            to UBC, based on the ProMIS Technology. The ProMIS Technology is useful in predicting the
                                            locations of disease-specific epitopes (DSEs) exposed by the misfolding of protein structures
                                            in neurodegenerative diseases. These DSEs can then be targeted for diagnostic and therapeutic
                                            purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The 2009 License Agreement has been amended
                                            three times, each time to add new IP to Schedule A. The first amendment (April 2009) added
                                            a prion disease marker (UBC file 09-146), the second (April 2013) added misfolded proteins
                                            as a marker for senescent cells (UBC file 13-093), and the third (March 2014) added certain
                                            misfolding-specific epitopes in FasR (UBC file 15-172) predicted by the algorithm;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Schedule A to License Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Steve Plotkin, has invented a complimentary
                                            technology to the ProMIS Technology, also relating to protein misfolding (UBC file 16-073),
                                            the &#8220;Collective Coordinates Technology&#8221; or &#8220;CCT&#8221;) and the Parties
                                            wish to include that technology in the exclusive license granted to the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">In addition, the Parties wish to amend
                                            and supplement the provisions of the 2009 License Agreement, as amended, as set out herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, therefore, in consideration of the premises
set forth herein, as well as other good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged,
the parties agree as follows:.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1in">Article 1.</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">DEFINITIONS AND INTERPRETATION</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in">Section 1.01</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">In this Agreement:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&#8220;Affiliated Company&#8221; or &#8220;Affiliated
                                            Companies&#8221; means two or more corporations where the relationship between them is one
                                            in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation,
                                            or 50% or more of the voting shares of each of them is owned or controlled by the same person,
                                            corporation or other legal entity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&#8220;Agreement&#8221; means this license
                                            agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&#8220;Annual Report&#8221; means a report
                                            in the form referred to in Article 12;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&#8220;Bug&#8221; means a code syntax
                                            error originating solely from the Software developed by UBC that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">prevents the Software from running on a
                                            computer system which meets the specified minimum hardware/software requirements; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">causes the Software to malfunction when
                                            used within the bounds of applicability specified in any UBC supplied help file or users&#8217;
                                            manual.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Specifically excluded from the definition
                                            of a &#8220;Bug&#8221; are any errors due, or related, to any hardware, software, update
                                            or improvement developed by any party other than UBC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&#8220;Confidential Information&#8221;
                                            means all information, regardless of its form disclosed by either Party to the other and
                                            designated by the discloser as confidential, whether orally or in writing, including without
                                            limitation all information and documents related to the Technology, Improvements or IP Rights
                                            (including all derived analyses and conclusions) and this Agreement, except that &#8220;Confidential
                                            Information&#8221; does not include information:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">possessed by the recipient (the &#8220;Recipient&#8221;)
                                            prior to receipt from the disclosing party (the &#8220;Discloser&#8221;), other than through
                                            prior disclosure by the Discloser, as evidenced by the Recipient&#8217;s business records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">published or available to the general public
                                            otherwise than through a breach of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">obtained by the Recipient from a Third
                                            Party with a valid right to disclose it, provided that the Third Party is not under a confidentiality
                                            obligation to the Discloser; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">independently developed by employees, agents
                                            or consultants of the Recipient who had no knowledge of or access to the Discloser&#8217;s
                                            information as evidenced by the Recipient&#8217;s business records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&#8220;Data&#8221; is defined in Section
                                            2.07;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&#8220;Dispute&#8221; is defined in Section
                                            11.05;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&#8220;Effective Termination Date&#8221;
                                            means the date on which this Agreement is terminated under Article 18;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&#8220;FDA&#8221; means the United States
                                            Food and Drug Administration or its successor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&#8221;First Commercial Sale&#8221; means
                                            the first commercial sale of a Product on a Product by Product basis and on a country by
                                            country basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">&#8220;Field&#8221; means diseases in
                                            mammals, including, without limitation, the diagnosis of the presence of disease, the prediction
                                            of the risk of disease or disease outcome, the prediction of the response to therapy, and
                                            the guiding, developing and conducting a course of therapy; as well as the cure, mitigation,
                                            treatment and prevention of diseases in mammals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&#8220;Human Clinical Trials&#8221; means
                                            any clinical Product testing involving human subjects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&#8220;Improvements&#8221; means collectively
                                            the UBC Improvements, PROMIS Improvements and Joint Improvements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">&#8220;IP Rights&#8221; means:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Patent Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">all copyrights relating to the Technology
                                            or any Improvements granted or existing, whether registered under any Copyright Act or not;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">all trade secret and
                                            other know-how rights in and to all data, information, compositions, chemical compounds or
                                            biological materials and other technology (including, but not limited to, formulae, procedures,
                                            protocols, techniques and results of experimentation and testing) which are necessary or
                                            useful to make, have made, use, develop, sell, import or seek regulatory approval to market,
                                            a Product, or to practice any method or process, at any time claimed or disclosed in any
                                            issued patent or pending patent application relating to the Technology or any Improvements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">&#8220;Investigators&#8221; is defined
                                            in Recital &#8220;A&#8221;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">&#8220;Joint Improvements&#8221; means
                                            improvements, variations, updates, modifications, and enhancements relating to the Technology,
                                            including without limitation any compositions, chemical compounds or biological materials
                                            discovered, identified or developed using the Software, which:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">are made, developed and/or acquired at any
                                            time after the Start Date jointly by:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Investigators while employed by UBC,
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the Licensee, the Licensee&#8217;s Affiliated
                                            Companies, any Sublicensees or any Affiliated Companies of such Sublicensees or any combination
                                            of the forgoing, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">cannot be legally used or practiced without
                                            infringing the Technology or IP Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">&#8220; Annual License Fee&#8221; is defined
                                            in Section 6.01;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">&#8220;New Drug Application&#8221; means
                                            an application that would satisfy the requirements for an application for FDA approval to
                                            market a new drug as defined in U.S. FDA 21 C.F.R. 314 (or any U.S. successor legislation)
                                            or similar regulations in a country outside the US.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">&#8220;Objectionable Material&#8221; is
                                            defined in Section 10.03;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">&#8220;Object Code&#8221; means the machine-readable
                                            and executable version of the Software;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">&#8220;Patents&#8221; means the patents
                                            and patent applications identified in Schedule &#8220;A&#8221;, (as amended from time to
                                            time), and all:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">counterparts, continuations, divisional,
                                            continuing prosecution applications, continuations-in-part, and requests for continued examinations,
                                            extensions, term restorations, renewals, reissues, re- examinations, or substitutions thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">corresponding international patent applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">corresponding foreign patent applications,
                                            including supplementary protection certificates and other administrative protections; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">foreign counterpart patents resulting therefrom;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all of which will be deemed to be added
                                            to Schedule &#8220;A&#8221; from time to time. For greater clarity the Patents shall also
                                            include any patents and patent applications that cover or claim Improvements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&#8220;Patent Rights&#8221; means collectively
                                            the rights in and to any and all inventions that are disclosed in the Patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">&#8220;Payment Report&#8221; means a report
                                            in the form referred to in Article 12 setting out in reasonable detail how the amount of
                                            Revenue was determined;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">&#8220;Phase II Clinical Trial&#8221;
                                            means a Human Clinical Trial that would satisfy the requirements for a Phase 2 study as defined
                                            in U.S. FDA 21 C.F.R. 312.21(b) (or any U.S. successor legislation) or similar regulations
                                            in a country outside the U.S.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">&#8220;Phase III Clinical Trial&#8221;
                                            means a Human Clinical Trial that would satisfy the requirements for a Phase 3 study as defined
                                            in U.S. FDA 21 C.F.R. 312.21(c) (or any U.S. successor legislation) or similar regulations
                                            in a country outside the U.S.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD STYLE="text-align: justify">&#8220;Product&#8221; means any product
                                            or service manufactured or provided that if made, used, sold, offered for sale or imported
                                            absent the license granted hereunder would infringe any of the IP Rights to the Technology
                                            or any Improvements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD STYLE="text-align: justify">&#8220;PROMIS Improvements&#8221; means
                                            improvements, variations, updates, modifications, and enhancements relating to the Technology,
                                            including without limitation any compositions, chemical compounds or biological materials
                                            discovered, identified or developed using the Software, which are:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">made, developed and/or acquired at any time
                                            after the Start Date by the Licensee, the Licensee&#8217;s Affiliated Companies, any Sublicensees
                                            or any Affiliated Companies of such Sublicensees, or jointly by any combination of the forgoing,
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">which cannot be legally used or practiced
                                            without infringing the Technology or IP Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bb)</TD><TD STYLE="text-align: justify">&#8220;Revenue&#8221; means all revenues,
                                            receipts, money, and the fair market value of any shares or other securities, or other consideration
                                            directly or indirectly collected or received whether by way of cash, credit or other value
                                            received <B>by the Licensee or the Licensee&#8217;s Affiliated Companies, but not including
                                            monies collected from any sublicensee of the Licensee or the Licensee&#8217;s Affiliated
                                            Companies, from the development, </B>marketing, manufacturing, sale, use or distribution
                                            of the Technology and any Improvements, and/or any Products, less:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">amounts actually credited, rebated or allowed
                                            for rejections, returns or recalls of Products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">sales, use, value-added and other direct
                                            taxes incurred on the sale of Products, including applicable customs duties, surcharges and
                                            other governmental charges incurred in exporting or importing Products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">any bona fide discounts, rebates, credits,
                                            allowances or refunds claimed by an arms length purchaser of Products and actually allowed
                                            by the Licensee or the Licensee&#8217;s Affiliated Companies to such purchaser; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">freight and insurance costs incurred by
                                            the Licensee or the Licensee&#8217;s Affiliated Companies, in transporting such Product to
                                            an purchaser, provided that such charges are not directly or indirectly paid or refunded
                                            to the Licensee or the Licensee&#8217;s Affiliated Companies by such purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(cc)</TD><TD STYLE="text-align: justify">&#8220;Royalty Calculation Dates&#8221;
                                            means the last day of March, June, September and December of each year during the Term;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(dd)</TD><TD STYLE="text-align: justify">&#8220;Royalty Term&#8221; means the
                                            longer of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the life of the Patents, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">10 years following the First Commercial
                                            Sale of a Product in any country;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ee)</TD><TD STYLE="text-align: justify">&#8220;Sublicensee&#8221; means any entity
                                            who has obtained directly or indirectly through the Licensee or any Affiliated Companies
                                            of the Licensee any rights to Technology, Improvements, IP Rights or Products, and shall
                                            include all sub- sublicensees, or any entities that have entered into agreements with the
                                            Licensee or any Affiliated Companies of the Licensee for the use, development, co-development,
                                            partnered development, manufacture, distribution, marketing or sale of Products or granting
                                            rights to such entities in the Technology, Improvements or IP Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ff)</TD><TD STYLE="text-align: justify">&#8220;Sublicensing Revenue&#8221; means
                                            all revenues, receipts, monies, and the fair market value of any shares or other securities
                                            and all other consideration directly or indirectly collected or received whether by way of
                                            cash, credit or other value received by the Licensee or the Licensee&#8217;s Affiliated Companies
                                            under each agreement relating to sublicense, grant or transfer of the Licensee&#8217;s rights
                                            in the Technology and any Improvements, and/or any Products whether by way of sublicense,
                                            assignment development agreement or otherwise. Without limiting the generality of the forgoing
                                            Sublicensing Revenue will include all:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">milestone payments, royalties, license fees,
                                            option fees, and the fair market value of all consideration received in connection with any
                                            assignment or transfer of the Licensee&#8217;s rights in the Technology and any Improvements,
                                            and/or any Products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">research or development fees in excess
                                            of the direct reimbursement for the actual costs of such research and development incurred
                                            by the Licensee under a written research plan and agreement, received by the Licensee or
                                            the Licensee&#8217;s Affiliated Companies from any sublicensee relating to the Licensee&#8217;s
                                            rights in the Technology, Improvements or any Products;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(gg)</TD><TD STYLE="text-align: justify">&#8220;Software&#8221; means all Source
                                            Code and Object Code relating to the algorithms for identification of stable and unstable
                                            protein structural elements and materials described in Schedule &#8220;A&#8221;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(hh)</TD><TD STYLE="text-align: justify">&#8220;Source Code&#8221; means the human
                                            readable version of the Software which is capable, upon compilation, of being translated
                                            into machine executable Object Code;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">&#8220;Start Date&#8221; means February
                                            4, 2009;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(jj)</TD><TD STYLE="text-align: justify">&#8220;Technology&#8221; means the Patents,
                                            the Software, the ProMIS Technology, the Collective Coordinates Technology and all knowledge,
                                            know-how and/or technique or techniques invented, developed and/or acquired by the Investigators
                                            while employed at UBC relating to and including, the algorithm for identification of stable
                                            and unstable protein structural elements and materials described in Schedule &#8220;A&#8221;,
                                            as amended from time to time, including, without limitation, all related research, data,
                                            specifications, instructions, manuals, papers or other related materials of any nature at
                                            all, whether written or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(kk)</TD><TD STYLE="text-align: justify">&#8220;Term&#8221; is defined in Section
                                            17.01;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ll)</TD><TD STYLE="text-align: justify">&#8220;Third Party&#8221; means any person
                                            other than UBC or the Licensee or any of their respective Affiliated Companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(mm)</TD><TD STYLE="text-align: justify">&#8220;UBC Improvements&#8221; means
                                            improvements, variations, updates, modifications, and enhancements relating to the Technology,
                                            including without limitation any compositions, chemical compounds or biological materials
                                            discovered, identified or developed using the Software, which are:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">made, developed and/or acquired at any time
                                            after the Start Date by the Investigators while employed by UBC, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">which cannot be legally used or practiced
                                            without infringing the Technology or IP Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(nn)</TD><TD STYLE="text-align: justify">&#8220;UBC Trade-marks&#8221; means any
                                            mark, trade-mark, service mark, logo, insignia, seal, design, symbol or device used by UBC
                                            in any manner at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 1.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For greater clarity, for the purposes of this Agreement the parties confirm that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&#8220;First Commercial Sale&#8221; shall
                                            be deemed to occur on the following dates:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                             </TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">if a Product does not require regulatory
                                            approval for sale by the FDA or a regulatory equivalent of the FDA in another country, then
                                            the &#8220;First Commercial Sale&#8221; of a Product shall be deemed to occur on the first
                                            sale of commercial quantities of a Product to arms length purchasers in the applicable country;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if a Product requires regulatory approval
                                            for sale by the FDA or a by a regulatory equivalent of the FDA in another country, then the
                                            &#8220;First Commercial Sale&#8221; of a Product shall be deemed to occur in the United States
                                            on the regulatory approval for the sale of the Product by the FDA and, in any country other
                                            than the United States, the first regulatory approval for sale by the regulatory authority
                                            equivalent to the FDA in such country;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">all Improvements or other intellectual
                                            property contributions made by Dr. Neil Cashman and Dr. Steve Plotkin shall be in their capacity
                                            as faculty members at UBC and shall be assigned to UBC according to UBC Policy #88 (www.universitycounsel.ubc.ca/files/2015/03/policy88.pdf).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 1.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For the purposes of this Agreement, all calculations will be made using, and all defined and undefined terms will be construed
in accordance with, Canadian generally accepted accounting principles, consistently applied, and consistent with generally accepted costing
methods for similar products in the pharmaceutical industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 1.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any reference in this Agreement to Canadian generally accepted accounting principles refers to generally accepted accounting principles
in Canada (or International Financial Reporting Standards once adopted in Canada) as approved from time to time by the Canadian Institute
of Chartered Accountants or any successor institute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>PROPERTY
RIGHTS IN &amp; TO THE TECHNOLOGY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC represents and warrants to the Licensee that to the best of the knowledge of the University Industry Liaison Office manager
responsible for the management of the commercialization of the Technology, that as of the Start Date, and at the date of each amendment
to add additional IP Rights to this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">all necessary consents, approvals and
                                            authorizations of all governmental authorities and other persons or entities required to
                                            be obtained by UBC in connection with this Agreement have been obtained;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the execution, delivery and performance
                                            of this Agreement have been duly authorized by all necessary corporate action on the part
                                            of UBC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">UBC is the assignee of the Technology
                                            by way of assignment from the Investigators; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there are no threatened or pending actions,
                                            lawsuits, claims or arbitration proceedings in any way relating to the Technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 22; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Subject to the terms of this Agreement, the parties acknowledge and agree that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">UBC owns all right, title and interest
                                            in and to the Technology, all UBC Improvements and all related IP Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">UBC and the Licensee jointly own all right,
                                            title and interest in and to the Joint Improvements and all related IP Rights; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Licensee owns all right, title and
                                            interest in and to the PROMIS Improvements and all related IP Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will, at the request of UBC, sign all documents as may be required to ensure that ownership of the Technology, any
UBC Improvements and related IP Rights remain with UBC and that all Joint Improvements and related IP Rights are owned jointly by UBC
and the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within 30 days after the last day of June and December of each year during the Term:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Licensee will give notice to UBC of
                                            the details of all PROMIS Improvements and Joint Improvements which the Licensee and, to
                                            its knowledge, any sublicensees have developed and/or acquired during the previous 6 month
                                            period; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">UBC will give notice to the Licensee of
                                            the details of all UBC Improvements developed and/or acquired during the previous 6 month
                                            period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC shall provide the Licensee with a copy of the Source Code within ten days of the Effective Date of this Agreement. Upon the
request, each party shall promptly and fully disclose to the other the Improvements for which notice has been given under Section 2.04.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.06<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will at all times securely store the Technology, the Improvements and in particular the Source Code. In the event
of an unauthorized or accidental disclosure of the Source Code the Licensee will immediately:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">notify UBC and will provide to UBC full
                                            particulars of all information in the Licensee&#8217;s possession or control regarding the
                                            circumstances of such unauthorized use or disclosure; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">take (in full consultation with UBC) and
                                            at the Licensee&#8217;s sole cost and expense all reasonable steps deemed necessary by UBC
                                            to remedy any such unauthorized use or disclosure, and take all reasonable steps necessary
                                            (including the commencement of any legal action or proceedings) to recover the Source Code
                                            and to prevent its unauthorized use by any Third Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 2.07<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC and the Licensee acknowledge and agree that subject to Section 2.02, they will jointly own the results of any testing, evaluation,
analysis or use of the Technology and any Improvements conducted by, or for, the Licensee or any sublicensee during the Term, including
any data, test results, specifications, papers or other materials prepared in connection with such testing, evaluation, analysis or use
(the &#8220;Data&#8221;). The Licensee shall return the Data to UBC on any expiry or termination of this Agreement but may retain a copy
of the Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>GRANT
OF LICENSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 3.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to and in accordance with the terms and conditions set out in this Agreement, UBC grants to the Licensee a worldwide exclusive
license (including, without limitation, the exclusive right to grant sublicenses through multiple tiers in accordance with Article 4)
under its IP Rights to the Technology and any Improvements to research, discover, develop, use, make, manufacture, have made, distribute,
offer to sell, import and sell Products in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 3.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee acknowledges and agrees that UBC reserves a non-assignable, non-sublicensable, non-transferable right to use, without
charge in any manner, the Technology, Improvements and IP Rights for research, scholarly publication and educational purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>SUBLICENSING
AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 4.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee shall have the right to grant sublicenses to Third Parties and Affiliated Companies and allow such sublicensees to
grant further sub-sublicenses of the Technology, Improvements and IP Rights provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Licensee will cause each Affiliated
                                            Company so sublicensed to perform the terms of this Agreement as if such Affiliated Company
                                            were the Licensee hereunder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">each Affiliated Company so sublicensed
                                            shall unconditionally and irrevocably covenant and agree with UBC as primary obligor, to
                                            adopt as its own obligations every obligation of the Licensee contained or set forth in this
                                            Agreement to the extent pertinent to the scope of such sublicense;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Licensee unconditionally guarantees
                                            the performance of each Affiliated Company hereunder as if they were signatories to this
                                            Agreement to the extent the performance or lack of performance is a breach of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the obligations and liabilities of each
                                            Affiliated Company and the Licensee under this Agreement shall be joint and several and UBC
                                            shall not be obliged to seek recourse against an Affiliated Company before enforcing its
                                            rights against the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the Licensee will monitor the performance
                                            of each sublicensee that is not an Affiliated Company and will make reasonable commercial
                                            efforts to cause each such sublicensee to fully comply with the terms and conditions of such
                                            sublicensee&#8217;s sublicense agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">all sublicense agreements shall contain
                                            an obligation on each sublicensee to account for, and report, its sales of Product on the
                                            same basis as if such sales were sales of the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">each sublicense agreement (including all
                                            sub-sublicense agreements) shall contain covenants by the sublicensee for the benefit of
                                            UBC to observe and perform similar terms and conditions to those in this Agreement including
                                            without limitation the mandatory sublicense terms contained in Schedule &#8220;B&#8221;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">any sublicensee who wishes to grant a
                                            further sublicense shall comply with the terms of this Article as if the further sublicense
                                            were a sublicense hereunder, including providing to UBC and the Licensee the information
                                            described in this Article 4; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">within 10 business days of the signing
                                            any sublicense agreement, the Licensee will provide to UBC a fully executed copy of such
                                            sublicense agreement (which copy may be redacted provided that in no event shall the mandatory
                                            sublicensing provisions contained in Schedule &#8220;B&#8221; be redacted in such copy) and
                                            a certificate signed by a senior officer of the Licensee to clarify that such sublicense
                                            agreement is consistent with the terms and conditions of this Agreement and includes the
                                            mandatory sublicensing provisions contained in Schedule &#8220;B&#8221;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 4.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As part of the Annual Report, the Licensee shall provide UBC with the names of the parties of all service agreements entered into
by the Licensee related to the Technology, Improvements and IP Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 4.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event of the termination of this Agreement, the Licensee shall provide notice to each sublicensee of such termination.
Upon written request being given to UBC by such sublicensee within 60 days of receiving notice from UBC of the termination of this Agreement
and provided that such sublicensee is not in breach of its obligations under its sublicense at the time of such request, UBC shall offer
to grant to such sublicensee a direct license to UBC&#8217;s IP Rights to the Technology and any UBC Improvements to the extent sublicensed
under such sublicensing agreement and otherwise having terms and conditions no more onerous to UBC, and no less favourable to UBC, than
the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>FINANCIAL
CONSIDERATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 5.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In consideration of the licenses granted under this Agreement, the Licensee will pay to UBC during the Royalty Term, the following
royalties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">on Revenue received by the Licensee or
                                            the Licensee&#8217;s Affiliated Companies a royalty rate equal to <FONT STYLE="font-size: 10pt">[***]
                                            percent</FONT> (<FONT STYLE="font-size: 10pt">[***]</FONT>%) of the Revenue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">on Sublicensing Revenue received by the
                                            Licensee or the Licensee&#8217;s Affiliated Companies from any sublicensees a royalty rate
                                            equal to <FONT STYLE="font-size: 10pt">[***]</FONT> percent (<FONT STYLE="font-size: 10pt">[***]</FONT>%)
                                            of the Sublicensing Revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 5.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The royalties set out in Section 5.01 are due and payable within 60 days of each respective Royalty Calculation Date and are to
be calculated based on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in the case of sales by the Licensee or
                                            the Licensee&#8217;s Affiliated Companies, on the Revenue received by the Licensee and the
                                            Licensee&#8217;s Affiliated Companies, during the 3 month period immediately before the applicable
                                            Royalty Calculation Date, provided that the Licensee shall make all commercially reasonable
                                            efforts to collect in a timely manner such Revenue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in the case of sales by any Sublicensees
                                            or any Affiliated Companies of such Sublicensees, the Sublicensing Revenue received by the
                                            Licensee from the Sublicensee during the 3 month period immediately before the applicable
                                            Royalty Calculation Date,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 5.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All payments made by the Licensee to UBC under this Agreement will be in Canadian dollars without any reduction or deduction of
any nature or kind at all other than withholding or other taxes which may be required to be withheld under the laws of the jurisdiction
giving rise to the Revenue. Revenue which may be derived in a currency other than Canadian dollars shall be converted to Canadian dollars
in accordance with the accounting policies of the Licensee in accordance with Canadian generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>ANNUAL
PAYMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 6.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will pay to UBC an annual license fee of $<FONT STYLE="font-size: 10pt">[***]</FONT> (Canadian funds) (the &#8220;Annual
License Fee&#8221;) for each calendar year during the Term beginning after 2011. The Annual License Fee will be paid within 30 days of
the beginning of each calendar year, starting on January 30, 2012. The Annual License Fee will not be refunded to the Licensee under
any circumstances, provided that the royalties actually paid by the Licensee under Article 5 will be credited against the Annual License
Fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>PATENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 7.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee may identify any process, use or products arising out of the Technology, any UBC Improvements or Joint Improvements
that may be patentable, and may decide to file a patent application on same, subject to Section 7.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 7.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the filing of a patent application under Section 7.01, the Licensee will become the licensee of the patent application on the
terms and conditions set out in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 7.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee shall have the right to control, at its sole cost, the preparation, filing, prosecution and maintenance of all patents
and patent applications within the Patent Rights to the Technology or any Improvements, and shall consider in good faith the interests
of UBC in connection therewith. UBC shall cooperate with the Licensee, execute all lawful papers and instruments and make all rightful
oaths and declarations as may be necessary in connection therewith. The Licensee shall keep UBC timely and fully informed of the progress
of the preparation, filing, prosecution and maintenance of the Patent Rights to the Technology or any Improvements, and will give UBC
and UBC&#8217;s counsel reasonable opportunity to review and comment on the text of each patent application and other submissions relating
thereto before filing. The Licensee shall provide UBC with a copy of such patent application as filed, together with notice of its filing
date and serial number, and each such submission. The Licensee shall provide UBC with copies of all patent applications, amendments,
related correspondence, and other relevant documentation relating to such prosecution. UBC shall have the right to consult regarding
the preparation, filing, prosecution and maintenance of the Patent Rights to the Technology or any Improvements. The Licensee shall implement
reasonable and timely requests made by UBC regarding the Patent Rights to the Technology or any Improvements. The Licensee shall not
abandon or allow to lapse any Patent Rights to the Technology, any UBC Improvements or Joint Improvements without the prior written consent
of UBC if such abandonment or lapse of the Patent Right or Rights would have an adverse impact on the net benefits receivable by UBC
under Article 5 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 7.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will not contest the validity or scope of any patents assigned to, or owned by UBC, relating to the Technology, any
UBC Improvements or any Joint Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 7.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will ensure proper patent marking for all uses of the Technology and any Improvements licensed under this Agreement
and will clearly mark the appropriate patent numbers on any Products made using the Technology and any Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>DISCLAIMER
OF WARRANTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 8.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Other than expressly set out in Section 2.01, UBC makes no representations, conditions or warranties, either express or implied,
regarding the Technology, Improvements, IP Rights or the Products. Without limitation, UBC specifically disclaims any implied warranty,
condition or representation that the Technology, Improvements, IP Rights or the Products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">correspond with a particular description;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">are of merchantable quality;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">are fit for a particular purpose; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">are durable for a reasonable period of
                                            time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UBC is not liable for any loss, whether direct,
consequential, incidental or special, which the Licensee, the Licensee&#8217;s Affiliated Companies, any Sublicensees or any Affiliated
Companies of such Sublicensees or other Third Parties suffer arising from any defect, error or fault of the Technology, Improvements,
IP Rights or Products, or their failure to perform, even if UBC is aware of the possibility of the defect, error, fault or failure. The
Licensee acknowledges that it has been advised by UBC to undertake its own due diligence regarding the Technology, Improvements, IP Rights
or Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 8.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nothing in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">constitutes a warranty or representation
                                            by UBC as to title to the Technology, Improvements or IP Rights, or that anything made, used,
                                            sold or otherwise disposed of under the license granted in this Agreement will not infringe
                                            the patents, copyrights, trademarks, industrial designs or other intellectual property rights
                                            of any Third Parties, or any patents, copyrights, trade-marks, industrial design or other
                                            intellectual property rights owned, in whole or in part, by UBC, or licensed by UBC to any
                                            Third Parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">constitutes an express or implied warranty
                                            or representation by UBC that the Licensee has, or will have the freedom to operate or practice
                                            the Technology, Improvements or IP Rights, or the freedom to make, have made, use, sell or
                                            otherwise dispose of Products; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">imposes an obligation on UBC to bring,
                                            prosecute or defend actions or suits against Third Parties for infringement of patents, copyrights,
                                            trade-marks, industrial designs or other intellectual property or contractual rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 8.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding Section 8.02, if there is an alleged infringement of the Technology, UBC Improvements, Joint Improvements, IP
Rights or Products, the Licensee may prosecute litigation designed to enjoin such infringers, on receiving the prior written consent
of UBC, which consent will not be unreasonably withheld. Provided that it has first granted its prior written consent, UBC agrees to
reasonably co-operate to the extent of signing all necessary documents and to vest in the Licensee the right to start the litigation,
provided that all the direct and indirect costs and expenses of bringing and conducting the litigation or settlement are paid by the
Licensee. All amounts recovered by the Licensee as the result of such litigation will accrue to the benefit of the Licensee, provided
that such amounts will be included in the Licensee&#8217;s Revenue and subject to payment of a royalty to UBC in accordance with Article
5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 8.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any complaint alleging infringement of any patent or other proprietary rights is made against the Licensee, the Licensee&#8217;s
Affiliated Companies, any Sublicensees or any Affiliated Companies of such Sublicensees regarding the use of the Technology, Improvements
or IP Rights, or the manufacture, use, sale or importation of the Products, the following procedure will be adopted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Licensee will promptly notify UBC
                                            on receipt of the complaint and will keep UBC fully informed of the actions and positions
                                            taken by the complainant and taken or proposed to be taken by the Licensee on behalf of itself
                                            or a Sublicensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">except as provided in Section 8.04(d),
                                            all costs and expenses incurred by the Licensee or any Sublicensee in investigating, resisting,
                                            litigating and settling the complaint, including the payment of any award of damages and/or
                                            costs to any Third Party, will be paid by the Licensee or any Sublicensee, as the case may
                                            be;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">no decision or action concerning or governing
                                            any final disposition of the complaint will be taken without consultation with UBC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">UBC may cooperate to participate as a
                                            party in any litigation involving the complaint to the extent that the court may permit,
                                            but any additional expenses generated by such participation will be paid by UBC (subject
                                            to the possibility of recovery of some or all of the additional expenses from the complainant);
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the Licensee will pay all royalties payable
                                            under Section 5.01 of this Agreement to UBC in trust from the date UBC receives notice of
                                            the complaint and until a resolution of the complaint has been finalized. If the complainant
                                            is successful, then the royalties paid to UBC in trust under this Section 8.04(e) will be
                                            returned to the Licensee, provided that the amount being returned to the Licensee is no more
                                            than the amount paid by the Licensee to the complainant in the settlement or other disposition
                                            of the complaint. If the complainant does not succeed, then UBC retains all royalties paid
                                            to it under this Section 8.04(e).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>INDEMNITIES
AND LIMITATION OF LIABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 9.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee indemnifies, holds harmless and defends UBC, its Board of Governors, officers, employees, faculty, students, invitees
and agents against any and all claims (including all associated legal fees and disbursements reasonably and actually incurred) arising
out of the exercise of any rights under this Agreement, including without limitation against any damages or losses, consequential or
otherwise, arising in any manner at all from or out of the use of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">UBC&#8217;s Technology, Improvements,
                                            IP Rights; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Products by the Licensee and, subject
                                            to Section 9.02, by the Licensee&#8217;s Affiliated Companies, any Sublicensees or any Affiliated
                                            Companies of such Sublicensees, and their respective collaborators, customers or end-users.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 9.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to UBC entering into a direct agreement with a Sublicensee under which such Sublicensee agrees to provide an indemnity
directly to UBC consistent with the indemnity provided in this Agreement by the Licensee, then the indemnity provided by the Licensee
in Section 9.01 shall exclude such Sublicensee, and its respective collaborators, customers or end-users.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 9.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to Section 9.04, UBC&#8217;s total liability, whether under the express or implied terms of this Agreement, in tort (including
negligence) or at common law, for any loss or damage suffered by the Licensee or the Licensee&#8217;s Affiliated Companies, whether direct,
indirect or special, or any other similar damage that may arise or does arise from any breaches of this Agreement by UBC, is limited
to the amount of CDN $50,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 9.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee acknowledges and agrees that UBC will not be liable for consequential or incidental damages arising from any breach
or breaches of this Agreement, except for those arising from the gross negligence by UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 9.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the termination or expiration of this Agreement, the rights and obligations in Article 9 will survive and continue
to bind each party and its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>PUBLICATION
 &amp; CONFIDENTIALITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 10.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Each party will keep and use the other party&#8217;s Confidential Information in confidence and will not, without the other party&#8217;s
prior written consent, disclose the other party&#8217;s Confidential Information to any person or entity, except to the party&#8217;s
directors, officers, employees, faculty, students and professional advisors who require the Confidential Information to assist such party
in performing its obligations under this Agreement. Each party will maintain an appropriate internal program limiting the distribution
of the other&#8217;s Confidential Information to only those officers, employees, faculty, students and professional advisors who require
such Confidential Information in performing the such party&#8217;s obligations under this Agreement and who have signed appropriate non-disclosure
agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 10.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Any party required by judicial or administrative process to disclose the other party&#8217;s Confidential Information will promptly
notify the other party and allow it reasonable time to oppose the process before disclosing the Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 10.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>UBC is not restricted from presenting at symposia, national or regional professional meetings, or from publishing in journals
or other publications, accounts of its research relating to the Technology, Improvements or IP Rights, provided that with respect to
the Confidential Information only, the Licensee is provided with copies of the proposed disclosure at least 60 days before the presentation
or publication date and does not, within 30 days after delivery of the proposed disclosure, give notice to UBC indicating that it objects
to the proposed disclosure. Any objection to a proposed disclosure will specify the portions of the proposed disclosure considered objectionable
(the &#8220;Objectionable Material&#8221;). On receiving notice from the Licensee that any proposed disclosure contains Objectionable
Material, UBC and the Licensee agree to work together to revise the proposed disclosure to remove or alter the Objectionable Material
in a manner acceptable to both the Licensee and UBC, in which case the Licensee will withdraw its objection. UBC is not restricted from
publishing or presenting the proposed disclosure as long as the Licensee&#8217;s Confidential Information has been removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 10.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee requires of UBC, and to the extent permitted by law UBC agrees, that this Agreement, and each part of it, is confidential
and will not be disclosed to Third Parties, as the Licensee claims that the disclosure would or could reveal commercial, scientific or
technical information and would significantly harm the Licensee&#8217;s competitive position and/or interfere with the Licensee&#8217;s
negotiations with prospective Sublicensees. Notwithstanding anything contained in Article 10, the Licensee acknowledges and agrees that
UBC may identify the title of this Agreement, the parties to this Agreement and the names of the inventors of the Technology, Improvements,
or IP Rights, and that UBC may also disclose to the inventors the amount of all payments made to UBC by the Licensee under this Agreement,
the manner or method by which such payments were calculated and all Payment Reports delivered to UBC by the Licensee in connection with
such payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 10.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the termination or expiry of this Agreement, the rights and obligations in Article 10 survive and continue to
bind the parties, their successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>PRODUCTION
 &amp; MARKETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 11.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will not use the UBC Trade-marks or make reference to UBC or its name in any advertising or publicity, without the
prior written consent of UBC. Except as required by law, a stock exchange or regulatory authority, the Licensee will not issue a press
release regarding this Agreement or the Technology, UBC Improvements or IP Rights without first obtaining UBC&#8217;s written approval,
such approval not to be unreasonably withheld or delayed. If the Licensee is required by law to act in breach of this Article, the Licensee
will provide UBC with prior notice to permit UBC to bring an application or other proceeding to contest the requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 30; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 11.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee represents to UBC that it has the infrastructure, expertise and resources to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">develop and commercialize the Technology,
                                            Improvements and IP Rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">track and monitor on an ongoing basis
                                            performance under the terms of each sublicense entered into by the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">monitor patent infringement regarding
                                            any patent relating to the Technology, Improvements and IP Rights licensed under this Agreement;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">handle the Technology, Improvements, IP
                                            Rights and any Products with care and without danger to the Licensee, its employees, agents,
                                            or the public.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 11.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Section 11.03 The Licensee represents and warrants to UBC that it will, throughout the Term use commercially reasonable efforts
to research, develop and commercialize at least one Product. As used herein this Article 11, &#8220;commercially reasonable efforts&#8221;
means those efforts and resources consistent with the exercise of prudent scientific and business judgment as applied by Licensee to
its internal programs of similar market potential and market size, risk, and at a similar stage of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>ACCOUNTING
RECORDS &amp; REPORTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 12.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will maintain separate accounts and records of all Revenue received by the Licensee and the Licensee&#8217;s Affiliated
Companies and of all business done in connection with the Technology, Improvements. IP Rights and Products. The accounts and records
will be in sufficient detail to enable proper returns to be made under this Agreement and the Licensee will cause its Sublicensees and
the Affiliated Companies of such Sublicensees, to keep similar accounts and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 12.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will complete and deliver to UBC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">within 60 days of each and every Royalty
                                            Calculation Date, completed Payment Reports substantially in the form attached as Schedule
                                            &#8220;C&#8221;, together with the amounts payable under this Agreement. A separate Payment
                                            Report will be prepared and delivered for the Revenue received by each Affiliated Company
                                            of the Licensee. The first Payment Report will be submitted within 60 days of the first Royalty
                                            Calculation Date after the receipt of the first Revenue, and thereafter Payment Reports will
                                            be delivered every 3 months regardless of whether any Revenue was received in the preceding
                                            period; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">on or before April 1 of each year during
                                            the Term, starting on April 1, 2010, an Annual Report substantially in the form attached
                                            as Schedule &#8220;D&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 12.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Licensee agrees to keep, for at least 3 years, complete and accurate books of account in which the particulars of all Revenue
are recorded in sufficient detail to enable royalties payable hereunder to be determined. Once a year, at the request and expense of
UBC, upon at least 30 days&#8217; prior written notice, Licensee shall permit a nationally recognized, independent, public accounting
firm appointed by UBC to examine records solely to the extent necessary to verify such calculations. Results of any such examination
shall be made available to both parties. If such examination reveals an underpayment of royalties by 10% or more, Licensee shall pay
all costs of such examination. In the event such accountant concludes that additional royalties were owed, Licensee shall have a 30 day
period to have such conclusions reviewed by its own accountants, and if they concur, the additional royalties shall be paid within 30
days of the date of such concurrence. In the event that Licensee&#8217;s accountants do not concur with the conclusions of the accountants
retained by UBC, the parties agree to negotiate in good faith to resolve such disagreement as soon as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 12.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>All information provided to UBC or its representatives under this Article 12 shall be treated as confidential by UBC.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>INSURANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 13.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>During the Term and for a period which is the longer of either 3 years after the end of the Term, or 3 years after the last Product
is sold, the Licensee will procure and maintain insurance (including public liability and commercial general liability insurance), as
would be acquired by a reasonable and prudent businessperson carrying on a similar line of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 13.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding Section 13.01, prior to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the start of any Human Clinical Trials;
                                            or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the first use of the Technology or any
                                            Improvement, in exchange for valuable consideration,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Licensee will procure the insurance
(e.g., product liability, clinical trials, public liability, and commercial general liability insurance and such other appropriate types
of insurance) as would be acquired by a reasonable and prudent businessperson carrying on a similar line of business. This insurance
will be placed with a reputable and financially secure insurance carrier and will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">include UBC, its Board of Governors, faculty,
                                            and officers as additional insureds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">provide coverage regarding all activities
                                            under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">include a waiver of subrogation against
                                            UBC, and a severability of interest and cross-liability clauses; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">provide that the insurer will endeavour
                                            to notify UBC at least 30 days&#8217; prior to cancellation of the policy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 13.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will provide to UBC certificates of insurance on each annual renewal evidencing the insurance coverages of the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 13.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will also require each Sublicensee to procure and maintain:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">public liability and commercial general
                                            liability insurance and such other types of insurance as would be acquired by a reasonable
                                            and prudent businessperson carrying on a similar line of business; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in any event before any Human Clinical
                                            Trials or the first use of the Technology or any Improvements in exchange for valuable consideration
                                            by the Sublicensee, the applicable product liability, clinical trials, public liability and
                                            commercial general liability insurance in reasonable amounts, with a reputable and financially
                                            secure insurance carrier.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Licensee will undertake commercially
                                            reasonably efforts to ensure that all Sublicensees&#8217; policies of insurance include UBC
                                            as an additional insured.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>ASSIGNMENT
 &amp; CHANGE OF CONTROL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 14.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will not assign, transfer, mortgage, pledge, financially encumber, grant a security interest, permit a lien to be
created, charge or otherwise dispose of any or all of the rights granted to it under this Agreement without the prior written consent
of UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 14.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Neither party shall assign its rights or obligations under this Agreement without the prior written consent of the other party;
provided, however, that either party may, without such consent, assign this Agreement and its rights and obligations hereunder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to any Affiliated Company, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in connection with the transfer or sale
                                            of all or substantially all of its business, or in the event of its merger, consolidation,
                                            change in control, corporate reorganization or similar transaction,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">provided that the permitted assignee shall
                                            assume all obligations of its assignor under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>GOVERNING
LAW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 15.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>This Agreement is governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in
force in that province, without regard to its Conflict of law rules. All parties agree that by executing this Agreement they have attorned
to the jurisdiction of the Supreme Court of British Columbia. Subject to the alternative dispute procedure set out in Article 22, the
parties agree that the British Columbia Supreme Court has exclusive jurisdiction over this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 16.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>All reports and notices or other documents that a party is required or may want to deliver to any other party will be delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in writing; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">either by personal delivery or by registered
                                            or certified mail or by confirmed electronic transmission (fax or email) at the address for
                                            the receiving party set out in Section 16.2 or as varied by any notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice personally delivered is deemed to
have been received at the time of delivery. Any notice mailed in accordance with this Article 16.1 is deemed to have been received at
the end of the fifth day after it is posted. Any notice sent by confirmed electronic transmission is deemed to have been received on
the date of confirmed transmission if a Business Day in the jurisdiction in which it is delivered, or if not, the next Business Day occurring
thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 16.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The address for delivery of notices and instructions for making payments to USC are set out in the attached Schedule &#8220;E&#8221;.
The address for delivery of notices to the Licensee shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ProMIS Neurosciences Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1920 Yonge Street, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attention: Mr. Elliot Goldstein, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Telephone: <FONT STYLE="font-size: 10pt">[***]
</FONT>Fax:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Email: <FONT STYLE="font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>TERM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 17.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The term (the &#8220;Term&#8221;) of this Agreement starts on the Start Date and expires (unless terminated earlier under Article
18), on a. Product by Product and country by <B>country basis </B>on the expiry of the Licensee&#8217;s obligation to pay royalties to
UBC under Section 5.01. Upon expiry of this Agreement with respect to any Product in a particular country, the Licensee shall have with
respect to such Product and country a fully paid-up, non-exclusive license in respect of any know-how rights to make, have made, use,
sell, offer for sale and import into such country the Product for use in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>TERMINATION
OF AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>This Agreement automatically and immediately terminates without notice to the Licensee if any proceeding under the Bankruptcy
and Insolvency Act of Canada, or any other statute of similar purpose, is started by the Licensee or against the Licensee and which is
not dismissed within 120 days after the date on which the proceeding is started.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>UBC may, at its option, immediately terminate this Agreement by giving notice to the Licensee if one or more of the following
occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Licensee becomes insolvent, as evidenced,
                                            for example (without limitation) by the appointment of a receiver, a receiver manager, the
                                            vacation of the Licensee&#8217;s chief place of business or the Licensee ceasing or threatening
                                            to cease carrying on business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any execution or other process of any
                                            court becomes enforceable against the Licensee under this Agreement or on any money due to
                                            UBC hereunder and is not released or satisfied by the Licensee within 30 days from the process
                                            becoming enforceable; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any resolution is passed by or order made
                                            against or other steps taken by the Licensee for the winding up, liquidation or other termination
                                            of the existence of the Licensee.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Provided that the Licensee or any Affiliated Company of the Licensee is not in default of any term of this Agreement, the Licensee
shall have the right to terminate this Agreement in its entirety, in its sole discretion, upon 60 days written notice to UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Other than as set out in Sections 18.01 to 18.03, if a party is in material breach of this Agreement, the other party may elect
to give the party in breach written notice describing the alleged breach. If the breaching party has not cured such breach within 60
days after receipt of such notice, the notifying party shall be entitled, in addition to any other rights it may have under this Agreement,
to terminate this Agreement effective immediately. However, if such party alleged to be in breach disputes in good faith such breach
by written notice to the other party within such 60 day period, the matter will be submitted to mediation as provided herein. In such
event, such notifying party shall not have the right to terminate this Agreement until the parties have concluded the mediation proceeding,
and such party in breach further fails to cure such breach within 30 days after the conclusion of such mediation proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>If this Agreement is terminated under Sections 18.01 to 18.03, the Licensee will make all outstanding royalty payments due to
UBC under Articles 5 and 6, and UBC may proceed to enforce payment of all outstanding royalties or other monies owed to UBC and to exercise
any or all of the rights and remedies available under this Agreement or otherwise available by law or in equity, successively or concurrently,
at the option of UBC. Within 30 days of the Effective Termination Date, the Licensee will deliver and transfer to UBC all Technology,
UBC Improvements and IP Rights in its possession or control and has no further right of any nature at all in the Technology UBC Improvements
and IP Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.06<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee and, subject to Section 4.03, the Licensee&#8217;s Affiliated Companies, any Sublicensees or any Affiliated Companies
of such Sublicensees will cease to use the Technology, UBC Improvements and IP Rights in any manner at all or to manufacture or sell
the Products within 5 days from the Effective Termination Date. The Licensee will then deliver to UBC an accounting within 30 days from
the Effective Termination Date. The accounting will specify, in or on such terms as UBC may in its sole discretion require, the inventory
or stock of Products manufactured and remaining unsold on the Effective Termination Date. UBC will instruct that the unsold Products
be stored, destroyed or sold under its direction, provided this Agreement was terminated under Section 18.02, 18.03 or 18.04. Without
limitation, if this Agreement is terminated under Section 18.01, no Products will be sold without the prior written consent of UBC. The
Licensee will continue to make royalty payments to UBC in the same manner specified in Articles 5 and 6 on all Products that are sold
in accordance with this Section 18.06, notwithstanding anything contained in, or any exercise of rights by UBC, under Section 18.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 18.07<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the termination for any reason or expiration of this Agreement:</P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">neither party shall be released by the
                                            other party from any liability which, at the time of such termination, has already accrued
                                            to the other party or which is attributable to a period prior to such termination, nor preclude
                                            either party from pursuing any rights and remedies it may have hereunder or at law or in
                                            equity which accrued or are based upon any event occurring prior to such termination or expiration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Article 12 remains in full force and effect
                                            until 3 years after all payments of royalty required to be made by the Licensee to UBC under
                                            this Agreement have been made by the Licensee to UBC and any other claim or claims of any
                                            nature or kind at all of UBC against the Licensee has been settled; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Article 4.03 and 10.0 shall survive such
                                            termination or expiration of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>MISCELLANEOUS
COVENANTS OF LICENSEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 19.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee represents and warrants to UBC that the Licensee is a corporation duly organized, existing and in good standing under
the laws of Canada and has the power, authority and capacity to enter into this Agreement and to carry out the transactions contemplated
by this Agreement, all of which have been duly and validly authorized by all requisite corporate proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 19.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will comply with all laws, regulations and ordinances, whether Federal, State, Provincial, County, Municipal or otherwise,
with respect to the Technology, Improvements, IP Rights, Products and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 19.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee and UBC will be responsible to pay all taxes and any related interest or penalty designated in any manner at all
and imposed upon each party as a result of the existence or operation of this Agreement. If requested, each party will provide to the
other party evidence as may be required by Canadian authorities to establish that the tax has been paid. The payments specified in this
Agreement are exclusive of taxes and if either UBC or the Licensee is required to collect or remit a tax to be paid by the other Party,
then the Party required to pay such tax will pay the tax to the other Party on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 19.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The obligation of the Licensee to make all payments under this Agreement is absolute and unconditional and is not, except as expressly
set out in this Agreement, affected by any circumstance, including without limitation any set-off, compensation, counterclaim, recoupment,
defence or other right which the Licensee may have against UBC, or anyone else for any reason at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 19.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will pay interest on all amounts due and owing to UBC under this Agreement but not paid by the Licensee on the due
date at the prime business interest rate of the Bank of Montreal, as published, plus 5% per annum calculated annually not in advance.
The interest accrues on the balance of unpaid amounts from time to time outstanding, from the date on which portions of the amount become
due and owing until payment in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 36; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>MANAGEMENT
OF CONFLICTS OF INTEREST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 20.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee acknowledges that it is aware of UBC&#8217;s Conflict of Interest Policy #97, Patent and Licensing Policy #88 and
Research Policy #87 (which are available at www.universitycounsel.ubc.ca/policies/policies.html), and that UBC may amend these policies
or introduce new policies from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 20.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Subject to Section 20.03 the Licensee and UBC agree that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the facilities and research programs of
                                            the Licensee will be conducted independently of all UBC facilities, faculty, students or
                                            staff, and in particular, independently of and from the Investigators and the laboratory
                                            facilities made available to the Investigators by reason of the Investigators&#8217; employment
                                            at UBC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">no students, post-doctoral fellows or
                                            other UBC staff will participate or be involved in the Licensee&#8217;s research, projects
                                            or utilize its facilities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any disclosures of inventions made by
                                            the Investigators to the Licensee will be immediately forwarded by the Licensee to UBC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 20.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The Licensee and UBC may, from time to time, enter into written agreements to permit activities which would otherwise be prohibited
by Article 20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>MAINTENANCE
 &amp; TECHNICAL SUPPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 21.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>UBC will have no obligation to provide ongoing support services to the Licensee other than to make reasonable efforts to support
the Licensee in fixing Bugs in any UBC developed Software. The Licensee acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">such support in fixing Bugs will be provided
                                            by UBC without any specific warranty as to the functionality of the Software, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">that UBC is not in the business of providing
                                            support services, and that the level of any support which can be offered by UBC will at all
                                            times be subject to UBC having the necessary resources to reasonably provide such services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Licensee will promptly reimburse UBC for all disbursements
and travel expenses incurred by UBC in providing any of the above services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 21.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>UBC shall make reasonable efforts to provide such technical assistance to the Licensee as the Licensee reasonably requests regarding
the Technology. Without limiting the generality of the foregoing, during such the Term, UBC shall make Dr. Neil R. Cashman, Dr. Steve
Plotkin and any other UBC employees and consultants who are inventors of the IP Rights and the Technology or Improvements available to
the Licensee for consultation, provided that Dr. Cashman, Dr. Plotkin and such other inventors are at such time employed by or under
contract with UBC and are willing to consult with the Licensee. The Licensee shall pay UBC for any such technical assistance at a commercially
reasonable consulting rate that is mutually acceptable to both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 37; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>MEDIATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 22.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>If there is a dispute between UBC and the Licensee concerning this Agreement, then the following dispute resolution procedure
will apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">if such dispute relates to a party&#8217;s
                                            default or failure to comply with the terms of this Agreement then the non-defaulting party
                                            will, if applicable, give notice of such default in accordance with Section 18.04;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">if such dispute relates to any other matter,
                                            or if the party alleged to be in default under Section 18.04 disputes such default, then
                                            one party (the &#8220;Applicant&#8221;) will deliver to the other party (the &#8220;Respondent&#8221;)
                                            written notice setting out the particulars of any dispute;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the parties will then have a 15 day period
                                            in which to settle the dispute;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">if still unresolved at the end of the
                                            15 day period, the matter will then be referred to mediation. The Respondent will choose
                                            a qualified mediator acceptable to both the Respondent and Applicant. The mediator will then
                                            meet with the parties to assist the parties in reaching a resolution of the dispute. If the
                                            parties are unable to resolve their dispute following such meeting or meetings with the mediator,
                                            the mediator will prepare a non-binding confidential report setting out the mediator&#8217;s
                                            proposed resolution of the dispute, and will deliver this report to the parties within 15
                                            days from the date of the mediator&#8217;s last meeting with the parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">if the mediator is unable to facilitate
                                            a binding agreement between the parties to resolve the dispute, the parties will then have
                                            a further 15 days to resolve the dispute from receipt of the mediator&#8217;s report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">all information or documents disclosed
                                            by either party under this Article 22 must be kept confidential and must not be used except
                                            to attempt to resolve the dispute as contemplated under this Article 22; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">each party must bear its own costs of
                                            complying with Article 22 and the parties must bear equally the costs of any mediator engaged.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 22.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>If the dispute is not resolved in accordance with the procedures set out in Section 21.01 above, then the dispute may be submitted
for resolution to the jurisdiction of the Supreme Court of British Columbia in accordance with Section 15.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 22.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Nothing in this Article 22 is intended to prevent a party hereto from applying to a court of competent jurisdiction for interim
protection such as, by way of example, an interim injunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Article 23.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>GENERAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Nothing contained in this Agreement is to be deemed or construed to create between the parties a partnership or joint venture.
No party has the authority to act on behalf of any other party, or to commit any other party in any manner at all or cause any other
party&#8217;s name to be used in any way not specifically authorized by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Subject to the limitations in this Agreement, this Agreement operates for the benefit of and is binding on the parties and their
respective successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>No condoning, excusing or overlooking by any party of any default, breach or nonobservance by any other party at any time or times
regarding any terms of this Agreement operates as a waiver of that party&#8217;s rights under this Agreement. A waiver of any term, or
right under, this Agreement will be in writing signed by the party entitled to the benefit of that term or right, and is effective only
to the extent set out in the written waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right or pursuing
another remedy or maintaining an action to which it may otherwise be entitled either at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>No party shall be responsible or liable to the other for failure or delay in the performance of this Agreement due to war, fire,
accident or other casualty, labour disturbance, act of the public enemy, act of God, or any other contingency beyond that party&#8217;s
reasonable control. In the event of applicability of this Article, the party affected by such force majeure shall use its best efforts
to eliminate, cure and overcome any such causes and resume performance of its obligations as soon as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.06<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>The parties agree to execute, acknowledge and deliver all such further instruments, and to do all such other acts, as may be necessary
or appropriate to carry out the intent and purpose of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.07<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>All terms which require performance by the parties after the expiry or termination of this Agreement, will remain in force despite
this Agreement&#8217;s expiry or termination for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.08<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Part or all of any Article that is indefinite, invalid, illegal or otherwise voidable or unenforceable may be severed and the
balance of this Agreement will continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.09<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>This Agreement sets out the entire understanding between the parties and no changes are binding unless signed in writing by the
parties to this Agreement Section 23.10 Time is of the essence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>Unless the contrary intention appears, the singular includes the plural and vice versa and words importing a gender include other
genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 23.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>This Agreement may be executed in two counterparts, each of which shalt be deemed an original and which together shall constitute
one instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 0.5in">UBC File: F20-03911</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESSETH WHEREOF, the Parties have executed
this Agreement effective the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.5pt; border: Black 1pt solid; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SIGNED FOR AND ON BEHALF OF THE UNIVERSITY OF BRITISH
    COLUMBIA</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ J.P. Heale</P></TD>
    <TD STYLE="padding: 0.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AN ON BEHALF OF<BR>
    <B>PROMIS NEUROSCIENCES INC</B>.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Elliot Goldstein</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt">J.P. Heale, PhD, MBA</TD>
    <TD STYLE="padding: 0.5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">Elliot Goldstein, MD</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Managing Director</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">University-Industry Liaison Office</P></TD>
    <TD STYLE="padding: 0.5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">President &amp; CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt">Authorized signatory</TD>
    <TD STYLE="padding: 0.5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">Authorized signatory</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Schedule A to License Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Signature Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A<BR>
PATENTS &amp; TECHNOLOGY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Schedule A to License Agreement <BR>
Schedule A-1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE B<BR>
MANDATORY SUBLICENSING PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Sublicensee shall acknowledge all ownership
                                            of the sublicensed Technology, Improvements, IP Rights and Patents as set out in Section
                                            2.02 of the License Agreement between UBC and PROMIS NEUROSCIENCES INC. (in this Schedule
                                            &#8220;B&#8221;, the &#8220;License Agreement&#8217;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Sublicensee shall acknowledge that UBC
                                            reserves a right to use the Technology, Improvements and IP Rights without charge in any
                                            manner for research, scholarly publication, and educational purposes in accordance with the
                                            terms of the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Publication and Confidentiality:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify; padding-right: 0.55in">The Sublicensee
                                            shall keep and use all of UBC&#8217;s Confidential Information in confidence and will not,
                                            without UBC&#8217;s prior written consent, disclose any of UBC&#8217;s Confidential Information
                                            to any person or entity, except those of the Sublicensee&#8217;s directors, officers, employees,
                                            technical consultants and professional advisors who require said Confidential Information
                                            in connection with the Sublicensee performing its obligations or exercising its rights under
                                            the sublicense agreement. The Sublicensee shall also covenant and agree that it will initiate
                                            and maintain an appropriate internal program limiting the internal distribution of UBC&#8217;s
                                            Confidential Information to only those directors, officers, employees, technical consultants
                                            and professional advisors who require said Confidential Information in connection with the
                                            Sublicensee performing its obligations or exercising its rights under the sublicense agreement
                                            and who are under obligations of confidentiality consistent to those of the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify; padding-right: 0.55in">The Sublicensee
                                            shall acknowledge that UBC shall not be restricted from presenting at symposia, national
                                            or regional professional meetings, or from publishing in journals or other publications,
                                            accounts of its research relating to the Technology, Improvements and IP Rights in accordance
                                            with the terms of the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The Sublicensee shall agree not to use UBC&#8217;s
                                            names, trade-marks, service marks, logos, insignia, seal, or designs without the prior written
                                            consent of UBC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">The Sublicensee shall procure and maintain
                                            insurance in accordance with Section 13.04 of the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">The Sublicensee shall acknowledge and agree
                                            that UBC make no representations, conditions or warranties, either express or implied, with
                                            respect to the Technology, Improvements, IP Rights or Products. Without limiting the generality
                                            of the foregoing, the Sublicensee shall acknowledge that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify; padding-right: 0.55in">UBC specifically
                                            disclaim any express or implied warranty, condition or representation as to title to the
                                            Technology, Improvements or IP Rights or that anything made, used, sold or otherwise disposed
                                            of under the license granted in the sublicense agreement will not infringe the patents, copyrights,
                                            trade-marks, industrial designs or other intellectual property rights of any third parties,
                                            including any patents, copyrights, trade-marks, industrial design or other intellectual property
                                            rights owned, in whole or in part, by UBC or licensed by UBC to any third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify; padding-right: 0.55in">UBC makes no express
                                            or implied warranty, condition or representation that the Licensee or Sublicensee has, or
                                            will have the freedom to operate or practice the Technology, Improvement or IP Rights, or
                                            the freedom to make, have made, use, sell or otherwise dispose of Products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify; padding-right: 0.55in">UBC is under
                                            no obligation to bring, prosecute or defend actions or suits against third parties for infringement
                                            of patents, copyrights, trade-marks, industrial designs or other intellectual property or
                                            contractual rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">The Sublicensee shall acknowledge and agree
                                            that UBC will not be liable for any loss, whether direct, consequential, incidental or special,
                                            which the Sublicensee or any other third parties suffer, arising from any defect, error or
                                            fault of the Technology, Improvements, IP Rights or Products, or their failure to perform,
                                            even if UBC is aware of the possibility of a defect, error, fault or failure. The Sublicensee
                                            will also acknowledge that it has been advised to undertake its own due diligence regarding
                                            the Technology, Improvements, IP Rights and Products, and that UBC are under no obligation
                                            to bring, prosecute or defend actions or suits against third parties for infringement of
                                            patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual
                                            rights in relation to the Technology, Improvements, IP Rights or Products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">The Sublicensee shall indemnify holds harmless
                                            and defend UBC and its Board of Governors, officers, employees, faculty, students, invitees
                                            and agents against any and all third party claims against such indemnities (including all
                                            associated legal fees and disbursements actually incurred) arising out of the exercise by
                                            Sublicensee of any rights under the Sublicense Agreement, including without limitation against
                                            any damages or losses, consequential or otherwise, resulting from such third party claims
                                            based in any manner at all from or out of the use of the Technology, Improvements, IP Rights
                                            or Products by the Sublicensee or its Affiliated Companies, and their respective collaborators,
                                            customers or end users.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">The Sublicensee shall agree to limit its claims
                                            against UBC, whether under the express or implied terms of the sublicense agreement or the
                                            License Agreement, in tort (including negligence) or at common law, for any loss or damage
                                            suffered by the Sublicensee or any Affiliated Companies of the Sublicensee, whether direct,
                                            indirect or special, or any other similar damage that may arise or do arise from any actions
                                            or inactions, defaults or breaches by UBC, or its Board of Governors, officers, employees,
                                            faculty, students or agents, to is limited to the amount that is the lesser of CDN $<FONT STYLE="font-size: 10pt">[***]
                                            </FONT>and the amount paid to UBC pursuant to License.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">The Sublicensee shall also acknowledge and
                                            agree that UBC will not be liable for consequential or incidental damages, including any
                                            consequential or incidental damages arising from any breach or breaches of the sublicense
                                            agreement or the License Agreement except for those arising from the gross negligence by
                                            UBC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">The Sublicense shall include termination provisions
                                            such that the sublicense agreement shall terminate on equivalent termination provisions as
                                            those in the license.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">The Sublicensee shall cease to use the Technology,
                                            Improvements and IP Rights in any manner whatsoever and shall cease to manufacture Products
                                            within five days from the effective date of termination of the Sublicense Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">The Sublicensee shall maintain separate accounts
                                            and records of all business done in connection with the Technology, Improvements, IP Rights,
                                            including without limitation accounts and records of all Revenue received from Products.
                                            These accounts and records will be in sufficient detail to enable proper returns to be made
                                            by the Licensee to UBC under the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &#8220;C&#8221;<BR>
</U>Payment Report For The Period: dd/mm/yy to dd/mm/yy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &#8220;D&#8221;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UBC License Agreement Annual Report</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &#8220;E&#8221;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ADDRESS FOR NOTICES &amp; PAYMENT INSTRUCTIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The address for delivery of notices to UBC
                                            is:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Director University &#8212; Industry Liaison Office</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The University of British Columbia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">#103 &#8212; 6190 Agronomy Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Vancouver, British Columbia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">V6T 1Z3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax:&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Payment of all amounts due to UBC under the
                                            terms of this license may be made as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a)</TD><TD STYLE="text-align: justify">by cheque made payable to &#8220;The University
                                            of British Columbia&#8221; delivered to UBC at the above address; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b)</TD><TD STYLE="text-align: justify">by wire transfer in accordance with the
                                            instructions set out below: Note: Please ensure ALL of the information is provided for efficient
                                            receipt of wire payments:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border: Black 1pt solid; padding-left: 0.125in; padding-top: 5pt; width: 52%; text-align: justify; font-size: 10pt; padding-bottom: 5pt"><B>For
    Canadian $ Deposits via wire (General)</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 0.125in; padding-top: 5pt; width: 48%; text-align: justify; font-size: 10pt; padding-bottom: 5pt"><B><U>For
    US $ Deposits via wire:</U></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt"><B>Pay
    Via: </B><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt"><B>Pay
    Via: </B><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt"><B>Pay
    to:</B> <FONT STYLE="font-size: 10pt">[***]</FONT>- SWIFT Address <FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt"><B>Pay
    to: </B><FONT STYLE="font-size: 10pt">[***]</FONT>&#8211; SWIFT Address <FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-bottom: 2pt"><B>Bank
    Address:</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><B>Bank
    Address:</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt"><B>For
    Account: </B><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt"><B>For
    Account: </B><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-bottom: 2pt"><B>Beneficiary:
    </B>The University of British Columbia<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reference: </B>Finance Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Phone: </B><FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Re: </B>Dept ID 352000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For <B>Royalties </B>use JHJQ</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For <B>Patent Fees </B>use EFGE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dept Name: </B>UILO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><B>Beneficiary:
    T</B>he University of British Columbia<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reference: </B>Finance Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Phone: </B><FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Re: </B>Dept ID 352000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For <B>Royalties </B>use JHJQ</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For <B>Patent Fees </B>use EFGE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dept Name: </B>UILO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.125in; padding-top: 2pt; border-bottom: Black 1pt solid; padding-bottom: 2pt"><B>Cover/Reimbursement:
    </B>SWIFT <FONT STYLE="font-size: 10pt">[***]</FONT>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Receiving Bank: </B><FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 89.1pt; text-align: justify">(<FONT STYLE="font-size: 10pt">[***]</FONT>)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Beneficiary Bank: </B>/<FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 98.1pt; text-align: justify">[***]</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE &#8220;B&#8221;<BR>
RESEARCH PROPOSAL<BR>
AND BUDGET<BR>
(3 pages)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 48; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(1)
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2135630d1_ex10-3d1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">February 13, 2017 &nbsp;</TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt">UBC File: F16-05805</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EMAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Elliot Goldstein<BR>
President and CEO<BR>
ProMis Neurosciences, Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, ON<BR>
M4S 3E2<BR>
[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Dr. Goldstein,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1pt solid; width: 0.5in; font-size: 10pt"><B>Re:</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify; font-size: 10pt"><B>Collaborative Research Agreement between The University of British Columbia (&ldquo;UBC&rdquo;) and Vancouver Coastal Health Authority (&ldquo;Hospital&rdquo;) (UBC and Hospital collectively, the &ldquo;Institution&rdquo;) and ProMis Neurosciences, Inc. (the &ldquo;Sponsor&rdquo;) effective April 1, 2016 (the &ldquo;Agreement&rdquo;)<BR>
<BR>
Amendment No. 1</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Article 4.1 shall be revised and read as follows: </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT>&ldquo;</FONT>4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution&rsquo;s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">1)</TD>
    <TD STYLE="white-space: nowrap; width: 3%; font-size: 10pt">Amount already received by UBC</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right; font-size: 10pt">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">2)</TD>
    <TD STYLE="white-space: nowrap; width: 3%; font-size: 10pt">Amount paid in November and December 2017</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right; font-size: 10pt">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">3)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">January 1, 2018</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">4)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">April 1, 2018 - March 31,2019 equal quarterly payments totaling</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">All other terms and conditions
of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment
No. 1 will be read together and constitute one agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2135630d1_ex10-3d1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Jacqueline Lee</U><BR>
Jacqueline Lee<BR>
Industry Grants Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>THE UNIVERSITY OF BRITISH COLUMBIA<BR>
</B>by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Mario Kasapi</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Mario Kasapi</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>Associate Director, UILO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>March 16, 2018</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>THE UNIVERSITY OF BRITISH COLUMBIA<BR>
</B>by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ J. P. Heale</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Dr. J. P. Heale</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>Managing Director, UILO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>March 29, 2018</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>VANCOUVER COASTAL HEALTH AUTHORITY</B><BR>
by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ W. Robert McMaster</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Dr. W. Robert McMaster, D. Phil.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>Vice President Research</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>March 21, 2018</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>PROMIS NEUROSCIENCES, INC. </B><BR>
by its authorized signatory:<BR>
<BR>
<U>/s/ Elliot Goldstein</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Elliot Goldstein, MD</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>President &amp; CEO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>March 11, 2018</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[signature page]</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledged by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ Neil Cashman</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Neil Cashman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Investigator<BR>
Department of Neurology<BR>
Date: March 11, 2018</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[acknowledgement page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(2)
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3.2</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2135630d1_ex10-3d1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><P STYLE="margin: 0pt 0">July 5, 2018</P></TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt">UBC File: F16-05805</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EMAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Elliot Goldstein<BR>
President and CEO<BR>
ProMis Neurosciences, Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, ON<BR>
M4S 3E2<BR>
[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Dr. Goldstein,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: left; font-size: 10pt; width: 0.5in"><B>Re:</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify; font-size: 10pt"><B>Collaborative Research Agreement between The University of British Columbia (&ldquo;UBC&rdquo;) and Vancouver Coastal Health Authority (&ldquo;Hospital&rdquo;) (UBC and Hospital collectively, the &ldquo;Institution&rdquo;) and ProMis Neurosciences, Inc. (the &ldquo;Sponsor&rdquo;) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017 (the &ldquo;Agreement&rdquo;)<BR>
<BR>
Amendment No. 2</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Article 4.1 shall be revised and read as follows: </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT>&ldquo;</FONT>4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution&rsquo;s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">1)</TD>
    <TD STYLE="white-space: nowrap; width: 3%; font-size: 10pt">Amount already received by UBC</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: right; font-size: 10pt">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">2)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">Amount due upon signature of this Amendment No. 2</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">3)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">August 1, 2018</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">4)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">October 1, 2018</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">5)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">January 1, 2019</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All other terms and conditions of the Agreement will remain in full
force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No. 2 will be read together and
constitute one agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2135630d1_ex10-3d1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Jacqueline Lee</U><BR>
Jacqueline Lee<BR>
Industry Grants Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>THE UNIVERSITY OF BRITISH COLUMBIA<BR>
</B>by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>THE UNIVERSITY OF BRITISH COLUMBIA<BR>
</B>by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>VANCOUVER COASTAL HEALTH AUTHORITY</B><BR>
by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>PROMIS NEUROSCIENCES, INC. </B><BR>
by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ Elliot Goldstein</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Dr. Elliot Goldstein, MD</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>President &amp; CEO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>July 20, 2018</TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[signature page]</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledged by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Neil Cashman</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Neil Cashman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Investigator<BR>
Department of Neurology<BR>
Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[acknowledgement page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(3)
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.3.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2135630d1_ex10-3d1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">February 13, 2019</TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt">UBC File: F16-05805</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EMAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Elliot Goldstein<BR>
President and CEO<BR>
ProMis Neurosciences, Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, ON<BR>
M4S 3E2<BR>
[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Dr. Goldstein,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 3pt; font-size: 10pt; width: 0.5in"><B>Re:</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 3pt; text-align: justify; font-size: 10pt"><B>Collaborative Research Agreement between The University of British Columbia (&ldquo;UBC&rdquo;) and Vancouver Coastal Health Authority (&ldquo;Hospital&rdquo;) (UBC and Hospital collectively, the &ldquo;Institution&rdquo;) and ProMis Neurosciences, Inc, (the &ldquo;Sponsor&rdquo;) effective April 1, 2016 and amended by Amendment No.&nbsp;1 dated December 13, 2017 and Amendment No.2 dated July 5, 2018 (the &ldquo;Agreement&rdquo;)<BR>
<BR>
Amendment No. 3</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Institution and Sponsor have executed the Agreement and hereby
agree to amend the Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Article 4.1 shall be revised and read as follows: </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT>&ldquo;</FONT>4.1
The Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7,
the total costs to the Sponsor hereunder will be $[***] (Canadian funds). The Parties acknowledge that any budget categories that may
be described in the Project are estimates only and that changes from category to category may be made at the Institution&rsquo;s discretion.
The Sponsor will pay to UBC the amounts of the following due dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">1)</TD>
    <TD STYLE="white-space: nowrap; width: 3%; font-size: 10pt">Amount already received by UBC</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: right; font-size: 10pt">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">2)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">Amount due upon signature of this Amendment No. 3</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">3)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">June 1, 2019</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">4)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">September 1, 2019</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">5)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">December 1, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">6)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">March, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">7)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">June 1, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$125,000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">8)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">September 1, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$125,000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">9)</TD>
    <TD STYLE="white-space: nowrap; width: 3%">December 1, 2020</TD>
    <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right; width: 1%">$125,000</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">All other terms and conditions
of the Agreement will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment
No. 3 will be read together and constitute one agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2135630d1_ex10-3d1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment to the Agreement may be signed in counterparts either
through original copies or by facsimile or electronically each of which will be deemed an original and all of which will constitute the
same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Jacqueline Lee</U><BR>
Jacqueline Lee<BR>
Industry Grants Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>THE UNIVERSITY OF BRITISH COLUMBIA<BR>
</B>by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ Mario Kasapi</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Mario Kasapi</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>Associate Director, UILO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">March 6, 2019</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>THE UNIVERSITY OF BRITISH COLUMBIA<BR>
</B>by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ J. P. Heale</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Dr. J. P. Heale</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>Managing Director, UILO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">March 6, 2019</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>VANCOUVER COASTAL HEALTH AUTHORITY</B><BR>
by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ W. Robert McMaster</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Dr. W. Robert McMaster, D. Phil.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>Vice President Research</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">March 7, 2019</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of<BR>
<B>PROMIS NEUROSCIENCES, INC. </B><BR>
by its authorized signatory:<BR>
<BR>
<U>/s/ Elliot Goldstein</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Name:</TD>
  <TD>Elliot Goldstein, MD</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Title:</TD>
  <TD>President &amp; CEO</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.4in">Date:</TD>
  <TD>April 15, 2019</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[signature page]</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledged by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
<U>/s/ Neil Cashman</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Neil Cashman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Investigator<BR>
Department of Neurology<BR>
Date: March 8, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[acknowledgement page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3(4)
<SEQUENCE>14
<FILENAME>filename14.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv) because it is both not material
and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2135630d1_ex10-3d4img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">UBC File: F16-05805</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September 9, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>VIA EMAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Elliot Goldstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ProMis Neurosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Suite 200, 1920 Yonge Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Toronto, ON</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Dr. Goldstein,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="text-align: justify">Collaborative Research Agreement between The University of British Columbia (&#8220;UBC&#8221;)
and Vancouver Coastal Health Authority (&#8220;Hospital&#8221;) (UBC and Hospital collectively, the &#8220;Institution&#8221;) and ProMis
Neurosciences, Inc. (the &#8220;Sponsor&#8221;) effective April 1, 2016 and amended by Amendment No. 1 dated December 13, 2017, Amendment
No.2 dated July 5, 2018 and Amendment No.3 dated February 13, 2019 (the &#8220;Agreement&#8221;)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Amendment No. 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Institution and Sponsor have <FONT STYLE="color: windowtext">executed</FONT>
the Agreement and hereby agree to amend the Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Article 4.1 shall be revised and read as follows:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;4,1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;</FONT>The
Parties understand and agree that, subject to Article 4.3, and excluding any intellectual property related costs under Section 7, the
total costs to the Sponsor hereunder will be $<FONT STYLE="color: windowtext">[***] </FONT>(Canadian funds). The Parties acknowledge that
any budget categories that may be described in the Project are estimates only and that changes from category to category may be made at
the Institution&#8217;s discretion, The Sponsor will pay to UBC the amounts of the following due dates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">1.</TD><TD STYLE="white-space: nowrap; text-align: left; width: 3%">Amount already received by UBC&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; text-align: right; width: 90%"></TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">2.</TD><TD STYLE="white-space: nowrap; text-align: left; width: 3%">Amount due upon signature of this Amendment No. 4&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">3.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">December 1, 2019&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%"></TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">4.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">March 1, 2020&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">5.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">June 1, 2020&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">6.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">September 1, 2020&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">7.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">December 1, 2020&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">8.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">March 1, 2021&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">9.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">June 1, 2021&#9;</TD>
                                                              <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                              <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">10.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">September 1, 2021&#9;</TD>
                                                               <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                               <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 3%">11.</TD><TD STYLE="white-space: nowrap; text-align: justify; width: 3%">December 1, 2021&#9;</TD>
                                                               <TD STYLE="border-bottom: Black 1pt dotted; white-space: nowrap; text-align: justify; width: 90%">&nbsp;</TD>
                                                               <TD STYLE="text-align: right; width: 1%">$[***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor may make payments by wire transfer
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pay Via: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pay to: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Account number for Canadian dollars: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficiary: The University of British Columbia</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment Details: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UBC reserves the right to suspend work on all
Projects or to terminate all Projects and this Agreement by delivering written notice of same to the Sponsor if the Sponsor fails to pay
any invoiced amount within 30 calendar days from the due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor will pay interest on all amounts owing
to UBC but not paid on the due date, at the rate of [***]% per annum, calculated annually not in advance. The interest accrues on the
balance of unpaid amounts from time to time outstanding, from the date on which portions of the amounts become due and owing until payment
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All other terms and conditions of the Agreement
will remain in full force and effect and will continue for the duration of the Agreement. The Agreement and this Amendment No. 4 will
be read together and constitute one agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amendment to the Agreement may be signed
in counterparts either through original copies or by facsimile or electronically each of which will be deemed an original and all of which
will constitute the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(signature page follows)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>THE UNIVERSITY OF BRITISH COLUMBIA</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">by its authorized signatory:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 6%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 44%">/s/</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Date:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>THE UNIVERSITY OF BRITISH COLUMBIA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">by its authorized signatory:</P>

 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Date:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>VANCOUVER COASTAL HEALTH AUTHORITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">by its authorized signatory:</P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Date:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED FOR AND ON BEHALF of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROMIS NEUROSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">by its authorized signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Elliot Goldstein</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="font-size: 10pt">Elliot Goldstein, MD</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">President &amp; CEO</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Date:</TD>
    <TD STYLE="font-size: 10pt">Oct. 7 2019</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Signature Page - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Acknowledged
by</FONT></P></TD>
    <TD STYLE="padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Dr. Neil Cashman</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Principal Investigator</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Department of
    Neurology</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Date:</FONT></P></TD>
    <TD STYLE="padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Signature Page - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>15
<FILENAME>filename15.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K or pursuant to Item 601(b)(10)(iv)
because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information
is indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE UNIVERSITY OF BRITISH COLUMBIA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AMENDED AND RESTATED
LICENSE AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amended and Restated License Agreement (&ldquo;Agreement&rdquo;)
made effective the 6th day of October, 2015,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BETWEEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>THE UNIVERSITY OF BRITISH COLUMBIA, </B>a corporation
continued under the <I>University Act</I> of British Columbia with its administrative offices at 2075 Wesbrook Mall, Vancouver, British
Columbia, V6T 1W5 <B>(&ldquo;UBC&rsquo;&rsquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AND:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>PROMIS NEUROSCIENCES INC., </B>a corporation continued
under the laws of Canada, with a registered office at, 1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2 (the <B>&ldquo;Licensee&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UBC has been engaged in
research during the course of which it has invented, developed and/or acquired certain technology relating to misfolded proteins (UBC
file 09-093 the &ldquo;ProMIS Technology&rdquo;) which research was undertaken by Dr. Neil Cashman and William Guest in the UBC Department
of Medicine and Dr. Steve Plotkin in the UBC Department of Physics and Astronomy (collectively, the &ldquo;Investigators&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is UBC&rsquo;s objective
to exploit its technology for the public benefit, and to generate further research in a manner consistent with its status as a non-profit,
tax exempt educational institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Licensee, under its
previous name (Amorfix Life Sciences Ltd.), and UBC entered into an exclusive license agreement effective February 4, 2009 (the &ldquo;2009
License Agreement&rdquo;) in which the Licensee gained exclusive worldwide rights to develop and commercialize intellectual property rights
belonging to UBC, based on the ProMIS Technology. The ProMIS Technology is useful in predicting the locations of disease-specific epitopes
(DSEs) exposed by the misfolding of protein structures in neurodegenerative diseases. These DSEs can then be targeted for diagnostic and
therapeutic purposes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2009 License Agreement
has been amended three times, each time to add new IP to Schedule A. The first amendment (April 2009) added a prion disease marker (UBC
file 09-146), the second (April 2013) added misfolded proteins as a marker for senescent cells (UBC file 13-093), and the third (March
2014) added certain misfolding-specific epitopes in FasR (UBC file 15-172) predicted by the algorithm;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Steve Plotkin, has invented
a complimentary technology to the ProMIS Technology, also relating to protein misfolding (UBC file 16-073), the &ldquo;Collective Coordinates
Technology&rdquo; or &ldquo;CCT&rdquo;) and the Parties wish to include that technology in the exclusive license granted to the Licensee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the Parties
wish to amend and supplement the provisions of the 2009 License Agreement, as amended, as set out herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Now, therefore, in consideration of the premises set forth herein,
as well as other good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, the parties agree
as follows:.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; </FONT></FONT>DEFINITIONSAND INTERPRETATION</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 1.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In this Agreement:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Affiliated Company&rdquo; or &ldquo;Affiliated Companies&rdquo; means two or more corporations where the relationship between
them is one in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation, or 50% or more of the
voting shares of each of them is owned or controlled by the same person, corporation or other legal entity;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Agreement&rdquo; means this license agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Annual Report&rdquo; means a report in the form referred to in Article 12;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Bug&rdquo; means a code syntax error originating solely from the Software developed by UBC that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>prevents the Software from running on a computer system which meets the specified minimum hardware/software requirements; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>causes the Software to malfunction when used within the bounds of applicability specified in any UBC supplied help file or users&rsquo;
manual.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Specifically excluded from the definition of a &ldquo;Bug&rdquo; are any errors due, or related, to any hardware, software, update
or improvement developed by any party other than UBC;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Confidential Information&rdquo; means all information, regardless of its form disclosed by either Party to the other and
designated by the discloser as confidential, whether orally or in writing, including without limitation all information and documents
related to the Technology, Improvements or IP Rights (including all derived analyses and conclusions) and this Agreement, except that
 &ldquo;Confidential Information&rdquo; does not include information:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>possessed by the recipient (the &ldquo;Recipient&rdquo;) prior to receipt from the disclosing party (the &ldquo;Discloser&rdquo;),
other than through prior disclosure by the Discloser, as evidenced by the Recipient&rsquo;s business records;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>published or available to the general public otherwise than through a breach of this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> obtained by the Recipient from a Third Party with a valid right to disclose it, provided that the Third Party is not under a confidentiality
obligation to the Discloser; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>independently developed by employees, agents or consultants of the Recipient who had no knowledge of or access to the Discloser&rsquo;s
information as evidenced by the Recipient&rsquo;s business records;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Data&rdquo; is defined in Section 2.07;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Dispute&rdquo; is defined in Section 11.05;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Effective Termination Date&rdquo; means the date on which this Agreement is terminated under Article 18;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;FDA&rdquo; means the United States Food and Drug Administration or its successor;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;First Commercial Sale&rdquo; means the first commercial sale of a Product on a Product by Product basis and on a country
by country basis;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo; Field&rdquo; means diseases in mammals, including, without limitation, the diagnosis of the presence of disease, the prediction
of the risk of disease or disease outcome, the prediction of the response to therapy, and the guiding, developing and conducting a course
of therapy; as well as the cure, mitigation, treatment and prevention of diseases in mammals;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Human Clinical Trials&rdquo; means any clinical Product testing involving human subjects;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Improvements&rdquo; means collectively the UBC Improvements, PROMIS Improvements and Joint Improvements;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;IP Rights&rdquo; means:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Patent Rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all copyrights relating to the Technology or any Improvements granted or existing, whether registered under any Copyright Act or
not; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all trade secret and other know-how rights in and to all data, information, compositions, chemical compounds or biological materials
and other technology (including, but not limited to, formulae, procedures, protocols, techniques and results of experimentation and testing)
which are necessary or useful to make, have made, use, develop, sell, import or seek regulatory approval to market, a Product, or to practice
any method or process, at any time claimed or disclosed in any issued patent or pending patent application relating to the Technology
or any Improvements;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Investigators&rdquo; is defined in Recital &ldquo;A&rdquo;;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;Joint Improvements&rdquo; means improvements, variations, updates, modifications, and enhancements relating to the Technology,
including without limitation any compositions, chemical compounds or biological materials discovered, identified or developed using the
Software, which:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>are
made, developed and/or acquired at any time after the Start Date jointly by:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Investigators while employed by UBC, and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee, the Licensee&rsquo;s Affiliated Companies, any Sublicensees or any Affiliated Companies of such Sublicensees or any
combination of the forgoing, and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>cannot be legally used or practiced without infringing the Technology or IP Rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo; Annual License Fee&rdquo; is defined in Section 6.01;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;New Drug Application&rdquo; means an application that would satisfy the requirements for an application for FDA approval
to market a new drug as defined in U.S. FDA 21 C.F.R. 314 (or any U.S. successor legislation) or similar regulations in a country outside
the US.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Objectionable Material&rdquo; is defined in Section 10.03;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Object Code&rdquo; means the machine-readable and executable version of the Software;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Patents&rdquo; means the patents and patent applications identified in Schedule &ldquo;A&rdquo;, (as amended from time to
time), and all:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>counterparts, continuations, divisionals, continuing prosecution applications, continuations-in-part, and requests for continued
examinations, extensions, term restorations, renewals, reissues, re- examinations, or substitutions thereof;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>corresponding international patent applications;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>corresponding foreign patent applications, including supplementary protection certificates and other administrative protections;
and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>foreign counterpart patents resulting therefrom;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all of which will be deemed to be added to Schedule &ldquo;A&rdquo; from time to time. For greater clarity the Patents shall also
include any patents and patent applications that cover or claim Improvements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;Patent Rights&rdquo; means collectively the rights in and to any and all inventions that are disclosed in the Patents;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Payment Report&rdquo; means a report in the form referred to in Article 12 setting out in reasonable detail how the amount
of Revenue was determined;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Phase II Clinical Trial&rdquo; means a Human Clinical Trial that would satisfy the requirements for a Phase 2 study as defined
in U.S. FDA 21 C.F.R. 312.21 (b) (or any U.S. successor legislation) or similar regulations in a country outside the U.S.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Phase III Clinical Trial&rdquo; means a Human Clinical Trial that would satisfy the requirements for a Phase 3 study as
defined in U.S. FDA 21 C.F.R. 312.21 (c) (or any U.S. successor legislation) or similar regulations in a country outside the U.S.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Product&rdquo; means any product or service manufactured or provided that if made, used, sold, offered for sale or imported
absent the license granted hereunder would infringe any of the IP Rights to the Technology or any Improvements;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;PROMIS Improvements&rdquo; means improvements, variations, updates, modifications, and enhancements relating to the Technology,
including without limitation any compositions, chemical compounds or biological materials discovered, identified or developed using the
Software, which are:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>made, developed and/or acquired at any time after the Start Date by the Licensee, the Licensee&rsquo;s Affiliated Companies, any
Sublicensees or any Affiliated Companies of such Sublicensees, or jointly by any combination of the forgoing, and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>which cannot be legally used or practiced without infringing the Technology or IP Rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Revenue&rdquo; means all revenues, receipts, money, and the fair market value of any shares or other securities, or other
consideration directly or indirectly collected or received whether by way of cash, credit or other value received by the Licensee or the
Licensee&rsquo;s Affiliated Companies, but not including monies collected from any sublicensee of the Licensee or the Licensee&rsquo;s
Affiliated Companies, from the development, marketing, manufacturing, sale, use or distribution of the Technology and any Improvements,
and/or any Products, less:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amounts actually credited, rebated or allowed for rejections, returns or recalls of Products;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sales, use, value-added and other direct taxes incurred on the sale of Products, including applicable customs duties, surcharges
and other governmental charges incurred in exporting or importing Products;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any bona fide discounts, rebates, credits, allowances or refunds claimed by an arms length purchaser of Products and actually allowed
by the Licensee or the Licensee&rsquo;s Affiliated Companies to such purchaser; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> freight and insurance costs incurred by the Licensee or the Licensee&rsquo;s Affiliated Companies, in transporting such Product
to an purchaser, provided that such charges are not directly or indirectly paid or refunded to the Licensee or the Licensee&rsquo;s Affiliated
Companies by such purchaser;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Royalty Calculation Dates&rdquo; means the last day of March, June, September and December of each year during the Term;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Royalty Term&rdquo; means the longer of:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the life of the Patents, and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>10 years following the First Commercial Sale of a Product in any country;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Sublicensee&rdquo; means any entity who has obtained directly or indirectly through the Licensee or any Affiliated Companies
of the Licensee any rights to Technology, Improvements, IP Rights or Products, and shall include all sub- sublicensees, or any entities
that have entered into agreements with the Licensee or any Affiliated Companies of the Licensee for the use, development, co-development,
partnered development, manufacture, distribution, marketing or sale of Products or granting rights to such entities in the Technology,
Improvements or IP Rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Sublicensing Revenue&rdquo; means all revenues, receipts, monies, and the fair market value of any shares or other securities
and all other consideration directly or indirectly collected or received whether by way of cash, credit or other value received by the
Licensee or the Licensee&rsquo;s Affiliated Companies under each agreement relating to sublicense, grant or transfer of the Licensee&rsquo;s
rights in the Technology and any Improvements, and/or any Products whether by way of sublicense, assignment development agreement or otherwise.
Without limiting the generality of the forgoing Sublicensing Revenue will include all:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>milestone payments, royalties, license fees, option fees, and the fair market value of all consideration received in connection
with any assignment or transfer of the Licensee&rsquo;s rights in the Technology and any Improvements, and/or any Products; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>research or development fees in excess of the direct reimbursement for the actual costs of such research and development incurred
by the Licensee under a written research plan and agreement, received by the Licensee or the Licensee&rsquo;s Affiliated Companies from
any sublicensee relating to the Licensee&rsquo;s rights in the Technology, Improvements or any Products;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Software&rdquo; means all Source Code and Object Code relating to the algorithms for identification of stable and unstable
protein structural elements and materials described in Schedule &ldquo;A&rdquo;;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Source Code&rdquo; means the human readable version of the Software which is capable, upon compilation, of being translated
into machine executable Object Code;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;Start Date&rdquo; means February 4, 2009;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Technology&rdquo; means the Patents, the Software, the ProMIS Technology, the Collective Coordinates Technology and all
knowledge, know-how and/or technique or techniques invented, developed and/or acquired by the Investigators while employed at UBC relating
to and including, the algorithm for identification of stable and unstable protein structural elements and materials described in Schedule
 &ldquo;A&rdquo;, as amended from time to time, including, without limitation, all related research, data, specifications, instructions,
manuals, papers or other related materials of any nature at all, whether written or otherwise;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Term&rdquo; is defined in Section 17.01;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;Third Party&rdquo; means any person other than UBC or the Licensee or any of their respective Affiliated Companies;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;UBC Improvements&rdquo; means improvements, variations, updates, modifications, and enhancements relating to the Technology,
including without limitation any compositions, chemical compounds or biological materials discovered, identified or developed using the
Software, which are:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>made, developed and/or acquired at any time after the Start Date by the Investigators while employed by UBC, and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>which cannot be legally used or practiced without infringing the Technology or IP Rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;UBC Trade-marks&rdquo; means any mark, trade-mark, service mark, logo, insignia, seal, design, symbol or device used by
UBC in any manner at all.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 1.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For greater clarity, for the purposes of this Agreement the parties confirm that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;First Commercial Sale&rdquo; shall be deemed to occur on the following dates:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if a Product does not require regulatory approval for sale by the FDA or a regulatory equivalent of the FDA in another country,
then the &ldquo;First Commercial Sale&rdquo; of a Product shall be deemed to occur on the first sale of commercial quantities of a Product
to arms length purchasers in the applicable country; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 155px">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if a Product requires regulatory approval for sale by the FDA or a by a regulatory equivalent of the FDA in another country, then
the &ldquo;First Commercial Sale&rdquo; of a Product shall be deemed to occur in the United States on the regulatory approval for the
sale of the Product by the FDA and, in any country other than the United States, the first regulatory approval for sale by the regulatory
authority equivalent to the FDA in such country;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Improvements or other intellectual property contributions made by Dr. Neil Cashman and Dr. Steve Plotkin shall be in their
capacity as faculty members at UBC and shall be assigned to UBC according to UBC Policy #88 (www.universitycounsel.ubc.ca/files/2015/03/policy88.pdf).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 1.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For
the purposes of this Agreement, all calculations will be made using, and all defined and undefined terms will be construed in accordance
with, Canadian generally accepted accounting principles, consistently applied, and consistent with generally accepted costing methods
for similar products in the pharmaceutical industry.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 1.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
reference in this Agreement to Canadian generally accepted accounting principles refers to generally accepted accounting principles in
Canada (or International Financial Reporting Standards once adopted in Canada) as approved from time to time by the Canadian Institute
of Chartered Accountants or any successor institute.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; </FONT></FONT>&nbsp;&nbsp;PROPERTY RIGHTS IN &amp;
TO THE TECHNOLOGY</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC represents and warrants to the Licensee that to the best of the knowledge of the University Industry Liaison Office manager
responsible for the management of the commercialization of the Technology, that as of the Start Date, and at the date of each amendment
to add additional IP Rights to this Agreement:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to
be obtained by UBC in connection with this Agreement have been obtained;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part
of UBC;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC is the assignee of the Technology by way of assignment from the Investigators; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>there are no threatened or pending actions, lawsuits, claims or arbitration proceedings in any way relating to the Technology;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms of this Agreement, the parties acknowledge and agree that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC owns all right, title and interest in and to the Technology, all UBC Improvements and all related IP Rights;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC and the Licensee jointly own all right, title and interest in and to the Joint Improvements and all related IP Rights; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee owns all right, title and interest in and to the PROMIS Improvements and all related IP Rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The
Licensee will, at the request of UBC, sign all documents as may be required to ensure that ownership of the Technology, any UBC
Improvements and related IP Rights remain with UBC and that all Joint Improvements and related IP Rights are owned jointly by UBC
and the Licensee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within 30 days after the last day of June and December of each year during the Term:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee will give notice to UBC of the details of all PROMIS Improvements and Joint Improvements which the Licensee and, to
its knowledge, any sublicensees have developed and/or acquired during the previous 6 month period; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC will give notice to the Licensee of the details of all UBC Improvements developed and/or acquired during the previous 6 month
period.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC shall provide the Licensee with a copy of the Source Code within ten days of the Effective Date of this Agreement. Upon the
request, each party shall promptly and fully disclose to the other the Improvements for which notice has been given under Section 2.04.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will at all times securely store the Technology, the Improvements and in particular the Source Code. In the event
of an unauthorized or accidental disclosure of the Source Code the Licensee will immediately:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>notify UBC and will provide to UBC full particulars of all information in the Licensee&rsquo;s possession or control regarding
the circumstances of such unauthorized use or disclosure; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>take (in full consultation with UBC) and at the Licensee&rsquo;s sole cost and expense all reasonable steps deemed necessary by
UBC to remedy any such unauthorized use or disclosure, and take all reasonable steps necessary (including the commencement of any legal
action or proceedings) to recover the Source Code and to prevent its unauthorized use by any Third Party.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 2.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC and the Licensee acknowledge and agree that subject to Section 2.02, they will jointly own the results of any testing, evaluation,
analysis or use of the Technology and any Improvements conducted by, or for, the Licensee or any sublicensee during the Term, including
any data, test results, specifications, papers or other materials prepared in connection with such testing, evaluation, analysis or use
(the &ldquo;Data&rdquo;). The Licensee shall return the Data to UBC on any expiry or termination of this Agreement but may retain a copy
of the Data.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</FONT></FONT>GRANT OF LICENSE</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 3.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subject
to and in accordance with the terms and conditions set out in this Agreement, UBC grants to the Licensee a worldwide exclusive license
(including, without limitation, the exclusive right to grant sublicenses through multiple tiers in accordance with Article 4) under its
IP Rights to the Technology and any Improvements to research, discover, develop, use, make, manufacture, have made, distribute, offer
to sell, import and sell Products in the Field.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 3.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee acknowledges and agrees that UBC reserves a non-assignable, non- sublicensable, non-transferable right to use, without
charge in any manner, the Technology, Improvements and IP Rights for research, scholarly publication and educational purposes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>SUBLICENSING AGREEMENTS</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 4.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Licensee shall have the right to grant sublicenses to Third Parties and Affiliated Companies and allow such sublicensees to grant further
sub-sublicenses of the Technology, Improvements and IP Rights provided that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee will cause each Affiliated Company so sublicensed to perform the terms of this Agreement as if such Affiliated Company
were the Licensee hereunder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>each Affiliated Company so sublicensed shall unconditionally and irrevocably covenant and agree with UBC as primary obligor, to
adopt as its own obligations every obligation of the Licensee contained or set forth in this Agreement to the extent pertinent to the
scope of such sublicense;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee unconditionally guarantees the performance of each Affiliated Company hereunder as if they were signatories to this
Agreement to the extent the performance or lack of performance is a breach of this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the obligations and liabilities of each Affiliated Company and the Licensee under this Agreement shall be joint and several and
UBC shall not be obliged to seek recourse against an Affiliated Company before enforcing its rights against the Licensee;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee will monitor the performance of each sublicensee that is not an Affiliated Company and will make reasonable commercial
efforts to cause each such sublicensee to fully comply with the terms and conditions of such sublicensee&rsquo;s sublicense agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all sublicense agreements shall contain an obligation on each sublicensee to account for, and report, its sales of Product on the
same basis as if such sales were sales of the Licensee;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>each sublicense agreement (including all sub-sublicense agreements) shall contain covenants by the sublicensee for the benefit
of UBC to observe and perform similar terms and conditions to those in this Agreement including without limitation the mandatory sublicense
terms contained in Schedule &ldquo;B&rdquo;;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any sublicensee who wishes to grant a further sublicense shall comply with the terms of this Article as if the further sublicense
were a sublicense hereunder, including providing to UBC and the Licensee the information described in this Article 4; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> within 10 business days of the signing any sublicense agreement, the Licensee will provide to UBC a fully executed copy of such
sublicense agreement (which copy may be redacted provided that in no event shall the mandatory sublicensing provisions contained in Schedule
 &ldquo;B&rdquo; be redacted in such copy) and a certificate signed by a senior officer of the Licensee to clarify that such sublicense
agreement is consistent with the terms and conditions of this Agreement and includes the mandatory sublicensing provisions contained in
Schedule &ldquo;B&rdquo;;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 4.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As part of the Annual Report, the Licensee shall provide UBC with the names of the parties of all service agreements entered into
by the Licensee related to the Technology, Improvements and IP Rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 4.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event of the termination of this Agreement, the Licensee shall provide notice to each sublicensee of such termination. Upon
written request being given to UBC by such sublicensee within 60 days of receiving notice from UBC of the termination of this Agreement
and provided that such sublicensee is not in breach of its obligations under its sublicense at the time of such request, UBC shall offer
to grant to such sublicensee a direct license to UBC&rsquo;s IP Rights to the Technology and any UBC Improvements to the extent sublicensed
under such sublicensing agreement and otherwise having terms and conditions no more onerous to UBC, and no less favourable to UBC, than
the terms and conditions of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; </FONT></FONT>FINANCIAL CONSIDERATION</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 5.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In consideration of the licenses granted under this Agreement, the Licensee will pay to UBC during the Royalty Term, the following
royalties:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>on Revenue received by the Licensee or the Licensee&rsquo;s Affiliated Companies a royalty rate equal to [***] percent ([***]%)
of the Revenue; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>on Sublicensing Revenue received by the Licensee or the Licensee&rsquo;s Affiliated Companies from any sublicensees a royalty rate
equal to [***] percent ([***]%) of the Sublicensing Revenue.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 5.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The royalties set out in Section 5.01 are due and payable within 60 days of each respective Royalty Calculation Date and are to
be calculated based on:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the case of sales by the Licensee or the Licensee&rsquo;s Affiliated Companies, on the Revenue received by the Licensee and
the Licensee&rsquo;s Affiliated Companies, during the 3 month period immediately before the applicable Royalty Calculation Date, provided
that the Licensee shall make all commercially reasonable efforts to collect in a timely manner such Revenue; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the case of sales by any Sublicensees or any Affiliated Companies of such Sublicensees, the Sublicensing Revenue received by
the Licensee from the Sublicensee during the 3 month period immediately before the applicable Royalty Calculation Date,</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 5.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>All
payments made by the Licensee to UBC under this Agreement will be in Canadian dollars without any reduction or deduction of any
nature or kind at all other than withholding or other taxes which may be required to be withheld under the laws of the jurisdiction
giving rise to the Revenue. Revenue which may be derived in a currency other than Canadian dollars shall be converted to Canadian
dollars in accordance with the accounting policies of the Licensee in accordance with Canadian generally accepted accounting
principles.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</FONT></FONT>ANNUAL PAYMENTS</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 6.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Licensee will pay to UBC an annual license fee of $[***] (Canadian funds) (the &ldquo;Annual License Fee&rdquo;) for each calendar year
during the Term beginning after 2011. The Annual License Fee will be paid within 30 days of the beginning of each calendar year, starting
on January 30, 2012. The Annual License Fee will not be refunded to the Licensee under any circumstances, provided that the royalties
actually paid by the Licensee under Article 5 will be credited against the Annual License Fee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>PATENTS</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 7.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee may identify any process, use or products arising out of the Technology, any UBC Improvements or Joint Improvements
that may be patentable, and may decide to file a patent application on same, subject to Section 7.03</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 7.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the filing of a patent application under Section 7.01, the Licensee will become the licensee of the patent application on the
terms and conditions set out in this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 7.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Licensee shall have the right to control, at its sole cost, the preparation, filing, prosecution and maintenance of all patents and patent
applications within the Patent Rights to the Technology or any Improvements, and shall consider in good faith the interests of UBC in
connection therewith. UBC shall cooperate with the Licensee, execute all lawful papers and instruments and make all rightful oaths and
declarations as may be necessary in connection therewith. The Licensee shall keep UBC timely and fully informed of the progress of the
preparation, filing, prosecution and maintenance of the Patent Rights to the Technology or any Improvements, and will give UBC and UBC&rsquo;s
counsel reasonable opportunity to review and comment on the text of each patent application and other submissions relating thereto before
filing. The Licensee shall provide UBC with a copy of such patent application as filed, together with notice of its filing date and serial
number, and each such submission. The Licensee shall provide UBC with copies of all patent applications, amendments, related correspondence,
and other relevant documentation relating to such prosecution. UBC shall have the right to consult regarding the preparation, filing,
prosecution and maintenance of the Patent Rights to the Technology or any Improvements. The Licensee shall implement reasonable and timely
requests made by UBC regarding the Patent Rights to the Technology or any Improvements. The Licensee shall not abandon or allow to lapse
any Patent Rights to the Technology, any UBC Improvements or Joint Improvements without the prior written consent of UBC if such abandonment
or lapse of the Patent Right or Rights would have an adverse impact on the net benefits receivable by UBC under Article 5 of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 7.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will not contest the validity or scope of any patents assigned to, or owned by UBC, relating to the Technology, any
UBC Improvements or any Joint Improvements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 7.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee will ensure proper patent marking for all uses of the Technology and any Improvements licensed under this Agreement
and will clearly mark the appropriate patent numbers on any Products made using the Technology and any Improvements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</FONT></FONT>DISCLAIMER OF WARRANTY</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 8.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Other
than expressly set out in Section 2.01, UBC makes no representations, conditions or warranties, either express or implied, regarding
the Technology, Improvements, IP Rights or the Products. Without limitation, UBC specifically disclaims any implied warranty, condition
or representation that the Technology, Improvements, IP Rights or the Products:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>correspond with a particular description;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>are of merchantable quality;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>are fit for a particular purpose; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>are durable for a reasonable period of time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">UBC is not liable for any loss, whether direct, consequential, incidental
or special, which the Licensee, the Licensee&rsquo;s Affiliated Companies, any Sublicensees or any Affiliated Companies of such Sublicensees
or other Third Parties suffer arising from any defect, error or fault of the Technology, Improvements, IP Rights or Products, or their
failure to perform, even if UBC is aware of the possibility of the defect, error, fault or failure. The Licensee acknowledges that it
has been advised by UBC to undertake its own due diligence regarding the Technology, Improvements, IP Rights or Products.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 8.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nothing in this Agreement:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>constitutes a warranty or representation by UBC as to title to the Technology, Improvements or IP Flights, or that anything made,
used, sold or otherwise disposed of under the license granted in this Agreement will not infringe the patents, copyrights, trademarks,
industrial designs or other intellectual property rights of any Third Parties, or any patents, copyrights, trade-marks, industrial design
or other intellectual property rights owned, in whole or in part, by UBC, or licensed by UBC to any Third Parties;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>constitutes an express or implied warranty or representation by UBC that the Licensee has, or will have the freedom to operate
or practice the Technology, Improvements or IP Rights, or the freedom to make, have made, use, sell or otherwise dispose of Products;
or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> imposes an obligation on UBC to bring, prosecute or defend actions or suits against Third Parties for infringement of patents,
copyrights, trade-marks, industrial designs or other intellectual property or contractual rights.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 8.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
Section 8.02, if there is an alleged infringement of the Technology, UBC Improvements, Joint Improvements, IP Rights or Products, the
Licensee may prosecute litigation designed to enjoin such infringers, on receiving the prior written consent of UBC, which consent will
not be unreasonably withheld. Provided that it has first granted its prior written consent, UBC agrees to reasonably co-operate to the
extent of signing all necessary documents and to vest in the Licensee the right to start the litigation, provided that all the direct
and indirect costs and expenses of bringing and conducting the litigation or settlement are paid by the Licensee. All amounts recovered
by the Licensee as the result of such litigation will accrue to the benefit of the Licensee, provided that such amounts will be included
in the Licensee&rsquo;s Revenue and subject to payment of a royalty to UBC in accordance with Article 5.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 8.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any complaint alleging infringement of any patent or other proprietary rights is made against the Licensee, the Licensee&rsquo;s
Affiliated Companies, any Sublicensees or any Affiliated Companies of such Sublicensees regarding the use of the Technology, Improvements
or IP Rights, or the manufacture, use, sale or importation of the Products, the following procedure will be adopted:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee will promptly notify UBC on receipt of the complaint and will keep UBC fully informed of the actions and positions
taken by the complainant and taken or proposed to be taken by the Licensee on behalf of itself or a Sublicensee;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as provided in Section 8.04(d), all costs and expenses incurred by the Licensee or any Sublicensee in investigating, resisting,
litigating and settling the complaint, including the payment of any award of damages and/or costs to any Third Party, will be paid by
the Licensee or any Sublicensee, as the case may be;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>no decision or action concerning or governing any final disposition of the complaint will be taken without consultation with UBC;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC may cooperate to participate as a party in any litigation involving the complaint to the extent that the court may permit,
but any additional expenses generated by such participation will be paid by UBC (subject to the possibility of recovery of some or all
of the additional expenses from the complainant); and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Licensee will pay all royalties payable under Section 5.01 of this Agreement to UBC in trust from the date UBC receives notice
of the complaint and until a resolution of the complaint has been finalized. If the complainant is successful, then the royalties paid
to UBC in trust under this Section 8.04(e) will be returned to the Licensee, provided that the amount being returned to the Licensee is
no more than the amount paid by the Licensee to the complainant in the settlement or other disposition of the complaint. If the complainant
does not succeed, then UBC retains all royalties paid to it under this Section 8.04(e).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>INDEMNITIES AND LIMITATION
OF LIABILITY</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 9.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee indemnifies, holds harmless and defends UBC, its Board of Governors, officers, employees, faculty, students, invitees
and agents against any and all claims (including all associated legal fees and disbursements reasonably and actually incurred) arising
out of the exercise of any rights under this Agreement, including without limitation against any damages or losses, consequential or otherwise,
arising in any manner at all from or out of the use of:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 85px">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC&rsquo;s Technology, Improvements, IP Rights; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 85px">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Products</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">by the Licensee and, subject to Section 9.02, by the Licensee&rsquo;s
Affiliated Companies, any Sublicensees or any Affiliated Companies of such Sublicensees, and their respective collaborators, customers
or end-users.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 9.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to UBC entering into a direct agreement with a Sublicensee under which such Sublicensee agrees to provide an indemnity
directly to UBC consistent with the indemnity provided in this Agreement by the Licensee, then the indemnity provided by the Licensee
in Section 9.01 shall exclude such Sublicensee, and its respective collaborators, customers or endusers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 9.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to Section 9.04, UBC&rsquo;s total liability, whether under the express or implied terms of this Agreement, in tort (including
negligence) or at common law, for any loss or damage suffered by the Licensee or the Licensee&rsquo;s Affiliated Companies, whether direct,
indirect or special, or any other similar damage that may arise or does arise from any breaches of this Agreement by UBC, is limited to
the amount of CDN $50,000.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 9.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Licensee acknowledges and agrees that UBC will not be liable for consequential or incidental damages arising from any breach
or breaches of this Agreement, except for those arising from the gross negligence by UBC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 9.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
the termination or expiration of this Agreement, the rights and obligations in Article 9 will survive and continue to bind each party
and its successors and assigns.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>PUBLICATION
 &amp; CONFIDENTIALITY</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 10.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; &nbsp;&nbsp;</FONT>Each
party will keep and use the other party&rsquo;s Confidential Information in confidence and will not, without the other party&rsquo;s
prior written consent, disclose the other party&rsquo;s Confidential Information to any person or entity, except to the
party&rsquo;s directors, officers, employees, faculty, students and professional advisors who require the Confidential Information
to assist such party in performing its obligations under this Agreement. Each party will maintain an appropriate internal program
limiting the distribution of the other&rsquo;s Confidential Information to only those officers, employees, faculty, students and
professional advisors who require such Confidential Information in performing the such party&rsquo;s obligations
under this Agreement and who have signed appropriate non-disclosure agreements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 10.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Any party required by judicial or administrative process to disclose the other party&rsquo;s Confidential Information will promptly
notify the other party and allow it reasonable time to oppose the process before disclosing the Confidential Information.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 10.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>UBC is not restricted from presenting at symposia, national or regional professional meetings, or from publishing in journals or
other publications, accounts of its research relating to the Technology, Improvements or IP Rights, provided that with respect to the
Confidential Information only, the Licensee is provided with copies of the proposed disclosure at least 60 days before the presentation
or publication date and does not, within 30 days after delivery of the proposed disclosure, give notice to UBC indicating that it objects
to the proposed disclosure. Any objection to a proposed disclosure will specify the portions of the proposed disclosure considered objectionable
(the &ldquo;Objectionable Material&rdquo;). On receiving notice from the Licensee that any proposed disclosure contains Objectionable
Material, UBC and the Licensee agree to work together to revise the proposed disclosure to remove or alter the Objectionable Material
in a manner acceptable to both the Licensee and UBC, in which case the Licensee will withdraw its objection. UBC is not restricted from
publishing or presenting the proposed disclosure as long as the Licensee&rsquo;s Confidential Information has been removed.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 10.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee requires of UBC, and to the extent permitted by law UBC agrees, that this Agreement, and each part of it, is confidential
and will not be disclosed to Third Parties, as the Licensee claims that the disclosure would or could reveal commercial, scientific or
technical information and would significantly harm the Licensee&rsquo;s competitive position and/or interfere with the Licensee&rsquo;s
negotiations with prospective Sublicensees. Notwithstanding anything contained in Article 10, the Licensee acknowledges and agrees that
UBC may identify the title of this Agreement, the parties to this Agreement and the names of the inventors of the Technology, Improvements,
or IP Rights, and that UBC may also disclose to the inventors the amount of all payments made to UBC by the Licensee under this Agreement,
the manner or method by which such payments were calculated and all Payment Reports delivered to UBC by the Licensee in connection with
such payments.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 10.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Notwithstanding the termination or expiry of this Agreement, the rights and obligations in Article 10 survive and continue to bind
the parties, their successors and assigns.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>PRODUCTION &amp; MARKETING</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 11.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will not use the UBC Trade-marks or make reference to UBC or its name in any advertising or publicity, without the
prior written consent of UBC. Except as required by law, a stock exchange or regulatory authority, the Licensee will not issue a press
release regarding this Agreement or the Technology, UBC Improvements or IP Rights without first obtaining UBC&rsquo;s written approval,
such approval not to be unreasonably withheld or delayed. If the Licensee is required by law to act in breach of this Article, the Licensee
will provide UBC with prior notice to permit UBC to bring an application or other proceeding to contest the requirement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 11.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee represents to UBC that it has the infrastructure, expertise and resources to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>develop and commercialize the Technology, Improvements and IP Rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>track and monitor on an ongoing basis performance under the terms of each sublicense entered into by the Licensee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>monitor patent infringement regarding any patent relating to the Technology, Improvements and IP Rights licensed under this Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>handle
the Technology, Improvements, IP Rights and any Products with care and without danger to the Licensee, its employees, agents, or the
public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 11.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee represents and warrants to UBC that it will, throughout the Term use commercially reasonable efforts to research,
develop and commercialize at least one Product. As used herein this Article 11, &ldquo;commercially reasonable efforts&rdquo; means those
efforts and resources consistent with the exercise of prudent scientific and business judgment as applied by Licensee to its internal
programs of similar market potential and market size, risk, and at a similar stage of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>ACCOUNTING
RECORDS &amp; REPORTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 12.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will maintain separate accounts and records of all Revenue received by the Licensee and the Licensee&rsquo;s Affiliated
Companies and of all business done in connection with the Technology, Improvements. IP Rights and Products. The accounts and records will
be in sufficient detail to enable proper returns to be made under this Agreement and the Licensee will cause its Sublicensees and the
Affiliated Companies of such Sublicensees, to keep similar accounts and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 12.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will complete and deliver to UBC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>within
60 days of each and every Royalty Calculation Date, completed Payment Reports substantially in the form attached as Schedule &ldquo;C&rdquo;,
together with the amounts payable under this Agreement. A separate Payment Report will be prepared and delivered for the Revenue received
by each Affiliated Company of the Licensee. The first Payment Report will be submitted within 60 days of the first Royalty Calculation
Date after the receipt of the first Revenue, and thereafter Payment Reports will be delivered every 3 months regardless of whether any
Revenue was received in the preceding period; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>on
or before April 1 of each year during the Term, starting on April 1, 2010, an Annual Report substantially in the form attached as Schedule
 &ldquo;D&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 12.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>Licensee
agrees to keep, for at least 3 years, complete and accurate books of account in which the particulars of all Revenue are recorded in
sufficient detail to enable royalties payable hereunder to be determined. Once a year, at the request and expense of UBC, upon at
least 30 days&rsquo; prior written notice, Licensee shall permit a nationally recognized, independent, public accounting firm
appointed by UBC to examine records solely to the extent necessary to verify such calculations. Results of any such examination
shall be made available to both parties. If such examination reveals an underpayment of royalties by 10% or more, Licensee shall pay
all costs of such examination. In the event such accountant concludes that additional royalties were owed, Licensee shall have a 30
day period to have such conclusions reviewed by its own accountants, and if they concur, the additional royalties shall be paid
within 30 days of the date of such concurrence. In the event that Licensee&rsquo;s accountants do not concur with the conclusions of
the accountants retained by UBC, the parties agree to negotiate in good faith to resolve such disagreement as soon as
practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 12.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>All information provided to UBC or its representatives under this Article 12 shall be treated as confidential by UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>INSURANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 13.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>During the Term and for a period which is the longer of either 3 years after the end of the Term, or 3 years after the last Product
is sold, the Licensee will procure and maintain insurance (including public liability and commercial general liability insurance), as
would be acquired by a reasonable and prudent businessperson carrying on a similar line of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 13.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Notwithstanding Section 13.01, prior to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
start of any Human Clinical Trials; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
first use of the Technology or any Improvement, in exchange for valuable consideration,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Licensee will procure the insurance (e.g., product liability, clinical
trials, public liability, and commercial general liability insurance and such other appropriate types of insurance) as would be acquired
by a reasonable and prudent businessperson carrying on a similar line of business. This insurance will be placed with a reputable and
financially secure insurance carrier and will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>include UBC, its Board of Governors, faculty, and officers as additional insureds;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>provide coverage regarding all activities under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>include a waiver of subrogation against UBC, and a severability of interest and cross-liability clauses; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>provide that the insurer will endeavour to notify UBC at least 30 days&rsquo; prior to cancellation of the policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 13.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will provide to UBC certificates of insurance on each annual renewal evidencing the insurance coverages of the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 13.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will also require each Sublicensee to procure and maintain:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>public
liability and commercial general liability insurance and such other types of insurance as would be acquired by a reasonable and prudent
businessperson carrying on a similar line of business; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in any event before any Human Clinical Trials or the first use of the Technology or any Improvements in exchange for valuable consideration
by the Sublicensee, the applicable product liability, clinical trials, public liability and commercial general liability insurance in
reasonable amounts, with a reputable and financially secure insurance carrier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Licensee will undertake commercially reasonably efforts to ensure that all Sublicensees&rsquo; policies of insurance include UBC as an
additional insured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>ASSIGNMENT &amp; CHANGE OF CONTROL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 14.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will not assign, transfer, mortgage, pledge, financially encumber, grant a security interest, permit a lien to be
created, charge or otherwise dispose of any or all of the rights granted to it under this Agreement without the prior written consent
of UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 14.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Neither party shall assign its rights or obligations under this Agreement without the prior written consent of the other party;
provided, however, that either party may, without such consent, assign this Agreement and its rights and obligations hereunder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>to
any Affiliated Company, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in connection with the transfer or sale of all or substantially all of its business, or in the event of its merger, consolidation,
change in control, corporate reorganization or similar transaction,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>provided that the permitted assignee shall assume all obligations of its assignor under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>GOVERNING LAW</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 15.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>This
Agreement is governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in force in
that province, without regard to its Conflict of law rules. All parties agree that by executing this Agreement they have attorned to
the jurisdiction of the Supreme Court of British Columbia. Subject to the alternative dispute procedure set out in Article 22, the
parties agree that the British Columbia Supreme Court has exclusive jurisdiction over this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>NOTICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 16.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>All reports and notices or other documents that a party is required or may want to deliver to any other party will be delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in writing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>either
by personal delivery or by registered or certified mail or by confirmed electronic transmission (fax or email) at the address for the
receiving party set out in Section 16.2 or as varied by any notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any notice personally delivered is deemed to have been received at
the time of delivery. Any notice mailed in accordance with this Article 16.1 is deemed to have been received at the end of the fifth day
after it is posted. Any notice sent by confirmed electronic transmission is deemed to have been received on the date of confirmed transmission
if a Business Day in the jurisdiction in which it is delivered, or if not, the next Business Day occurring thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 16.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The address for delivery of notices and instructions for making payments to USC are set out in the attached Schedule &ldquo;E&rdquo;.
The address for delivery of notices to the Licensee shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1920 Yonge Street, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Mr. Elliot Goldstein, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Telephone: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>TERM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 17.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The term (the &ldquo;Term&rdquo;) of this Agreement starts on the Start Date and expires (unless terminated earlier under Article
18), on a Product by Product and country by country basis on the expiry of the Licensee&rsquo;s obligation to pay royalties to UBC under
Section 5.01. Upon expiry of this Agreement with respect to any Product in a particular country, the Licensee shall have with respect
to such Product and country a fully paid-up, non-exclusive license in respect of any knowhow rights to make, have made, use, sell, offer
for sale and import into such country the Product for use in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>TERMINATION
OF AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 18.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>This
Agreement automatically and immediately terminates without notice to the Licensee if any proceeding under the Bankruptcy and
Insolvency Act of Canada, or any other statute of similar purpose, is started by the Licensee or against the Licensee and which is
not dismissed within 120 days after the date on which the proceeding is started.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 18.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>UBC may, at its option, immediately terminate this Agreement by giving notice to the Licensee if one or more of the following occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Licensee becomes insolvent, as evidenced, for example (without limitation) by the appointment of a receiver, a receiver manager,
the vacation of the Licensee&rsquo;s chief place of business or the Licensee ceasing or threatening to cease carrying on business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
execution or other process of any court becomes enforceable against the Licensee under this Agreement or on any money due to UBC hereunder
and is not released or satisfied by the Licensee within 30 days from the process becoming enforceable; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
resolution is passed by or order made against or other steps taken by the Licensee for the winding up, liquidation or other termination
of the existence of the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 18.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Provided that the Licensee or any Affiliated Company of the Licensee is not in default of any term of this Agreement, the Licensee
shall have the right to terminate this Agreement in its entirety, in its sole discretion, upon 60 days written notice to UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">Section 18.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Other than as set out in Sections 18.01 to 18.03, if a party is in material breach of this Agreement, the other party may elect
to give the party in breach written notice describing the alleged breach. If the breaching party has not cured such breach within 60 days
after receipt of such notice, the notifying party shall be entitled, in addition to any other rights it may have under this Agreement,
to terminate this Agreement effective immediately. However, if such party alleged to be in breach disputes in good faith such breach by
written notice to the other party within such 60 day period, the matter will be submitted to mediation as provided herein. In such event,
such notifying party shall not have the right to terminate this Agreement until the parties have concluded the mediation proceeding, and
such party in breach further fails to cure such breach within 30 days after the conclusion of such mediation proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 18.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>If this Agreement is terminated under Sections 18.01 to 18.03, the Licensee will make all outstanding royalty payments due to UBC
under Articles 5 and 6, and UBC may proceed to enforce payment of all outstanding royalties or other monies owed to UBC and to exercise
any or all of the rights and remedies available under this Agreement or otherwise available by law or in equity, successively or concurrently,
at the option of UBC. Within 30 days of the Effective Termination Date, the Licensee will deliver and transfer to UBC all Technology,
UBC Improvements and IP Rights in its possession or control and has no further right of any nature at all in the Technology UBC Improvements
and IP Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 18.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>The
Licensee and, subject to Section 4.03, the Licensee&rsquo;s Affiliated Companies, any Sublicensees or any Affiliated Companies of
such Sublicensees will cease to use the Technology, UBC Improvements and IP Rights in any manner at all or to manufacture or sell
the Products within 5 days from the Effective Termination Date. The Licensee will then deliver to UBC an accounting within 30 days
from the Effective Termination Date. The accounting will specify, in or on such terms as UBC may in its sole discretion require, the
inventory or stock of Products manufactured and remaining unsold on the Effective Termination Date. UBC will instruct that the
unsold Products be stored, destroyed or sold under its direction, provided this Agreement was terminated under Section 18.02, 18.03
or 18.04. Without limitation, if this Agreement is terminated under Section 18.01, no Products will be sold without the prior
written consent of UBC. The Licensee will continue to make royalty payments to UBC in the same manner specified in Articles 5 and 6
on all Products that are sold in accordance with this Section 18.06, notwithstanding anything contained in, or any exercise of
rights by UBC, under Section 18.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 18.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Notwithstanding the termination for any reason or expiration of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>neither party shall be released by the other party from any liability which, at the time of such termination, has already accrued
to the other party or which is attributable to a period prior to such termination, nor preclude either party from pursuing any rights
and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination
or expiration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Article 12 remains in full force and effect until 3 years after all payments of royalty required to be made by the Licensee to
UBC under this Agreement have been made by the Licensee to UBC and any other claim or claims of any nature or kind at all of UBC against
the Licensee has been settled; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Article 4.03 and 10.0 shall survive such termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>MISCELLANEOUS COVENANTS OF LICENSEE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 19.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee represents and warrants to UBC that the Licensee is a corporation duly organized, existing and in good standing under
the laws of Canada and has the power, authority and capacity to enter into this Agreement and to carry out the transactions contemplated
by this Agreement, all of which have been duly and validly authorized by all requisite corporate proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 19.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will comply with all laws, regulations and ordinances, whether Federal, State, Provincial, County, Municipal or otherwise,
with respect to the Technology, Improvements, IP Rights, Products and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 19.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee and UBC will be responsible to pay all taxes and any related interest or penalty designated in any manner at all and
imposed upon each party as a result of the existence or operation of this Agreement. If requested, each party will provide to the other
party evidence as may be required by Canadian authorities to establish that the tax has been paid. The payments specified in this Agreement
are exclusive of taxes and if either UBC or the Licensee is required to collect or remit a tax to be paid by the other Party, then the
Party required to pay such tax will pay the tax to the other Party on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 19.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>The
obligation of the Licensee to make all payments under this Agreement is absolute and unconditional and is not, except as expressly
set out in this Agreement, affected by any circumstance, including without limitation any set-off, compensation, counterclaim,
recoupment, defence or other right which the Licensee may have against UBC, or anyone else for any reason at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 19.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee will pay interest on all amounts due and owing to UBC under this Agreement but not paid by the Licensee on the due
date at the prime business interest rate of the <FONT STYLE="font-size: 10pt">B</FONT>ank of Montreal, as published, plus 5% per annum
calculated annually not in advance. The interest accrues on the balance of unpaid amounts from time to time outstanding, from the date
on which portions of the amount become due and owing until payment in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>MANAGEMENT
OF CONFLICTS OF INTEREST</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 20.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee acknowledges that it is aware of UBC&rsquo;s Conflict of Interest Policy #97, Patent and Licensing Policy #88 and
Research Policy #87 (which are available at www.universitycounsel.ubc.ca/policies/pol icies.html), and that UBC may amend these policies
or introduce new policies from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 20.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Subject to Section 20.03 the Licensee and UBC agree that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the facilities and research programs of the Licensee will be conducted independently of all UBC facilities, faculty, students or
staff, and in particular, independently of and from the Investigators and the laboratory facilities made available to the Investigators
by reason of the Investigators&rsquo; employment at UBC;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>no students, post-doctoral fellows or other UBC staff will participate or be involved in the Licensee&rsquo;s research, projects
or utilize its facilities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
disclosures of inventions made by the Investigators to the Licensee will be immediately forwarded by the Licensee to UBC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 20.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The Licensee and UBC may, from time to time, enter into written agreements to permit activities which would otherwise be prohibited
by Article 20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
21.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>MAINTENANCE
 &amp; TECHNICAL SUPPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 21.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>UBC will have no obligation to provide ongoing support services to the Licensee other than to make reasonable efforts to support
the Licensee in fixing Bugs in any UBC developed Software. The Licensee acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>such support in fixing Bugs will be provided by UBC without any specific warranty as to the functionality of the Software, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>that UBC is not in the business of providing support services, and that the level of any support which can be offered by UBC will
at all times be subject to UBC having the necessary resources to reasonably provide such services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Licensee will promptly reimburse UBC for all disbursements and
travel expenses incurred by UBC in providing any of the above services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Section 21.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>UBC shall make reasonable efforts to provide such technical assistance to the Licensee as the Licensee reasonably requests regarding
the Technology. Without limiting the generality of the foregoing, during such the Term, UBC shall make Dr. Neil R. Cashman, Dr. Steve
Plotkin and any other UBC employees and consultants who are inventors of the IP Rights and the Technology or Improvements available to
the Licensee for consultation, provided that Dr. Cashman, Dr. Plotkin and such other inventors are at such time employed by or under
contract with UBC and are willing to consult with the Licensee. The Licensee shall pay UBC for any such technical assistance at a commercially
reasonable consulting rate that is mutually acceptable to both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
22.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>MEDIATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 22.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>If there is a dispute between UBC and the Licensee concerning this Agreement, then the following dispute resolution procedure will
apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
such dispute relates to a party&rsquo;s default or failure to comply with the terms of this Agreement then the non-defaulting party will,
if applicable, give notice of such default in accordance with Section 18.04;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if such dispute relates to any other matter, or if the party alleged to be in default under Section 18.04 disputes such default,
then one party (the &ldquo;Applicant&rdquo;) will deliver to the other party (the &ldquo;Respondent&rdquo;) written notice setting out
the particulars of any dispute;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
parties will then have a 15 day period in which to settle the dispute;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if still unresolved at the end of the 15 day period, the matter will then be referred to mediation. The Respondent will choose
a qualified mediator acceptable to both the Respondent and Applicant. The mediator will then meet with the parties to assist the parties
in reaching a resolution of the dispute. If the parties are unable to resolve their dispute following such meeting or meetings with the
mediator, the mediator will prepare a non-binding confidential report setting out the mediator&rsquo;s proposed resolution of the dispute,
and will deliver this report to the parties within 15 days from the date of the mediator&rsquo;s last meeting with the parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
the mediator is unable to facilitate a binding agreement between the parties to resolve the dispute, the parties will then have a further
15 days to resolve the dispute from receipt of the mediator&rsquo;s report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>all
information or documents disclosed by either party under this Article 22 must be kept confidential and must not be used except to attempt
to resolve the dispute as contemplated under this Article 22; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>each
party must bear its own costs of complying with Article 22 and the parties must bear equally the costs of any mediator engaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 22.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>If the dispute is not resolved in accordance with the procedures set out in Section 21.01 above, then the dispute may be submitted
for resolution to the jurisdiction of the Supreme Court of British Columbia in accordance with Section 15.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 22.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Nothing in this Article 22 is intended to prevent a party hereto from applying to a court of competent jurisdiction for interim
protection such as, by way of example, an interim injunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-transform: uppercase">Article
23.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>GENERAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.01.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Nothing contained in this Agreement is to be deemed or construed to create between the parties a partnership or joint venture.
No party has the authority to act on behalf of any other party, or to commit any other party in any manner at all or cause any other party&rsquo;s
name to be used in any way not specifically authorized by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.02.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Subject to the limitations in this Agreement, this Agreement operates for the benefit of and is binding on the parties and their
respective successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.03.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>No condoning, excusing or overlooking by any party of any default, breach or non- observance by any other party at any time or
times regarding any terms of this Agreement operates as a waiver of that party&rsquo;s rights under this Agreement. A waiver of any term,
or right under, this Agreement will be in writing signed by the party entitled to the benefit of that term or right, and is effective
only to the extent set out in the written waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.04.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right or pursuing
another remedy or maintaining an action to which it may otherwise be entitled either at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.05.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>No
party shall be responsible or liable to the other for failure or delay in the performance of this Agreement due to war, fire,
accident or other casualty, labour disturbance, act of the public enemy, act of God, or any other contingency beyond that
party&rsquo;s reasonable control. In the event of applicability of this Article, the party affected by such force majeure shall use
its best efforts to eliminate, cure and overcome any such causes and resume performance of its obligations as soon as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">Section 23.06.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>The parties agree to execute, acknowledge and deliver all such further instruments, and to do all such other acts, as may be necessary
or appropriate to carry out the intent and purpose of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.07.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>All terms which require performance by the parties after the expiry or termination of this Agreement, will remain in force despite
this Agreement&rsquo;s expiry or termination for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.08.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Part or all of any Article that is indefinite, invalid, illegal or otherwise voidable or unenforceable may be severed and the balance
of this Agreement will continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.09.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>This Agreement sets out the entire understanding between the parties and no changes are binding unless signed in writing by the
parties to this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Time is of the essence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Unless the contrary intention appears, the singular includes the plural and vice versa and words importing a gender include other
genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Section 23.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>This Agreement may be executed in two counterparts, each of which shalt be deemed an original and which together shall constitute
one instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESSETH WHEREOF, the Parties have executed this Agreement effective
the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; width: 49%; border-left: Black 1pt solid">SIGNED FOR AND ON BEHALF OF</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 51%; border-right: Black 1pt solid; border-left: Black 1pt solid">SIGNED FOR AND ON BEHALF OF</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid"><B>THE UNIVERSITY OF BRITISH COLUMBIA</B></TD>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid"><B>PROMIS NEUROSCIENCES INC.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid">/s/ J.P. Heale</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">/s/ Elliot Goldstein</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid">J.P. Heale, PhD, MBA</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">Elliot Goldstein, MD</TD></TR>
  <TR>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-left: Black 1pt solid">Managing Director, University-Industry Liaison Office</TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: top; border-right: Black 1pt solid; border-left: Black 1pt solid">President &amp; CEO</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Authorized signatory</TD>
    <TD STYLE="border: Black 1pt solid">Authorized signatory</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PATENTS &amp; TECHNOLOGY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"><B>MANDATORY SUBLICENSING PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall acknowledge all ownership of the sublicensed Technology,
Improvements, IP Rights and Patents as set out in Section 2.02 of the License Agreement between UBC and PROMIS NEUROSCIENCES INC. (in
this Schedule <B>&quot;B&quot;, </B>the &quot;License <B>Agreement').</B></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                                                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall acknowledge that UBC reserves a right to use the Technology,
Improvements and IP Rights without charge in any manner for research, scholarly publication, and educational purposes in accordance with
the terms of the License Agreement.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                             </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Publication
and Confidentiality:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall keep and use all of UBC's Confidential Information in confidence
and will not, without UBC's prior written consent, disclose any of UBC's Confidential Information to any person or entity, except those
of the Sublicensee's directors, officers, employees, technical consultants and professional advisors who require said Confidential Information
in connection with the Sublicensee performing its obligations or exercising its rights under the sublicense agreement. The Sublicensee
shall also covenant and agree that it will initiate and maintain an appropriate internal program limiting the internal distribution of
UBC's Confidential Information to only those directors, officers, employees, technical consultants and professional advisors who require
said Confidential Information in connection with the Sublicensee performing its obligations or exercising its rights under the sublicense
agreement and who are under obligations of confidentiality consistent to those of the License Agreement.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                                                                                                  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall acknowledge that UBC shall not be restricted from presenting
at symposia, national or regional professional meetings, or from publishing in journals or other publications, accounts of its research
relating to the Technology, Improvements and IP Rights in accordance with the terms of the License Agreement.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                                                                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall agree not to use UBC's names, trade-marks, service marks,
logos, insignia, seal, or designs without the prior written consent of UBC.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall procure and maintain insurance in accordance with Section
13.04 of the License Agreement.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                         </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify; padding-right: 0.05in">The Sublicensee shall acknowledge and agree that UBC make no representations, conditions
or warranties, either express or implied, with respect to the Technology, Improvements, IP Rights or Products. Without limiting the generality
of the foregoing, the Sublicensee shall acknowledge that:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.95in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify; padding-right: 0.05in">UBC specifically disclaim any express or implied warranty, condition or representation
as to title to the Technology, Improvements or IP Rights or that anything made, used, sold or otherwise disposed of under the license
granted in the sublicense agreement will not infringe the patents, copyrights, trade-marks, industrial designs or other intellectual property
rights of any third parties, including any patents, copyrights, trade-marks, industrial design or other intellectual property rights owned,
in whole or in part, by UBC or licensed by UBC to any third parties;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify; padding-right: 0.05in">&nbsp;</TD></TR>
                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC makes no express or implied warranty, condition or representation that the Licensee or Sublicensee has, or will have the freedom
to operate or practice the Technology, Improvement or IP Rights, or the freedom to make, have made, use, sell or otherwise dispose of
Products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>UBC is under no obligation to bring, prosecute or defend actions or suits against third parties for infringement of patents, copyrights,
trade-marks, industrial designs or other intellectual property or contractual rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">7.</TD><TD STYLE="text-align: justify">The Sublicensee shall acknowledge and agree that UBC will not be liable for any loss, whether direct,
consequential, incidental or special, which the Sublicensee or any other third parties suffer, arising from any defect, error or fault
of the Technology, Improvements, IP Rights or Products, or their failure to perform, even if UBC is aware of the possibility of a defect,
error, fault or failure. The Sublicensee will also acknowledge that it has been advised to undertake its own due diligence regarding the
Technology, Improvements, IP Rights and Products, and that UBC are under no obligation to bring, prosecute or defend actions or suits
against third parties for infringement of patents, copyrights, trade-marks, industrial designs or other intellectual property or contractual
rights in relation to the Technology, Improvements, IP Rights or Products.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">8.</TD><TD STYLE="text-align: justify">The Sublicensee shall indemnify holds harmless and defend UBC and its Board of Governors, officers, employees,
faculty, students, invitees and agents against any and all third party claims against such indemnitiees (including all associated legal
fees and disbursements actually incurred) arising out of the exercise by Sublicensee of any rights under the Sublicense Agreement, including
without limitation against any damages or losses, consequential or otherwise, resulting from such third party claims based in any manner
at all from or out of the use of the Technology, Improvements, IP Rights or Products by the Sublicensee or its Affiliated Companies, and
their respective collaborators, customers or end users.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">9.</TD><TD STYLE="text-align: justify">The Sublicensee shall agree to limit its claims against UBC, whether under the express or implied terms
of the sublicense agreement or the License Agreement, in tort (including negligence) or at common law, for any loss or damage suffered
by the Sublicensee or any Affiliated Companies of the Sublicensee, whether direct, indirect or special, or any other similar damage that
may arise or do arise from any actions or inactions, defaults or breaches by UBC, or its Board of Governors, officers, employees, faculty,
students or agents, to is limited to the amount that is the lesser of CDN $25,000 and the amount paid to UBC pursuant to License.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">10.</TD><TD STYLE="text-align: justify">The Sublicensee shall also acknowledge and agree that UBC will not be liable for consequential or incidental
damages, including any consequential or incidental damages arising from any breach or breaches of the sublicense agreement or the License
Agreement except for those arising from the gross negligence by UBC.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">11.</TD><TD STYLE="text-align: justify">The Sublicense shall include termination provisions such that the sublicense agreement shall terminate
on equivalent termination provisions as those in the license.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">12.</TD><TD STYLE="text-align: justify">The Sublicensee shall cease to use the Technology, Improvements and IP Rights in any manner whatsoever
and shall cease to manufacture Products within five days from the effective date of termination of the Sublicense Agreement.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.45in">13.</TD><TD STYLE="text-align: justify">The Sublicensee shall maintain separate accounts and records of all business done in connection with the
Technology, Improvements, IP Rights, including without limitation accounts and records of all Revenue received from Products. These accounts
and records will be in sufficient detail to enable proper returns to be made by the Licensee to UBC under the License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE &quot;C&quot; </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"><B><U>SCHEDULE &quot;D&quot; </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Value: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE &quot;E&quot;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ADDRESS FOR NOTICES &amp; PAYMENT INSTRUCTIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The address for delivery of notices to UBC is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in">The Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in">University &mdash; Industry Liaison Office<BR>
The University of British Columbia<BR>
#103 &mdash; 6190 Agronomy Road<BR>
Vancouver, British Columbia<BR>
V6T 1Z3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in">Telephone:&#9;[***]<BR>
Fax: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Payment of all amounts due to UBC under the terms of this license may be made as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by cheque made payable to &quot;The University of British Columbia&quot; delivered to UBC at the above address; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85in 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by wire transfer in accordance with the instructions set out below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85in 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85in 0pt 4.5pt">Note: Please ensure ALL of the information is provided
for efficient receipt of wire payments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>For Canadian $ Deposits via wire (General)</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 45%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B><U>For US S Deposits via wire:</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Pay Via:</B> SWIFT [***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Pay Via: </B>SWIFT [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pay to:</B> [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Pay to: </B>[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bank Address:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bank Address:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Account:</B> [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>For Account: </B>[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Beneficiary</B>: The University of British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reference</B>: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phone</B>: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Re</B>: [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For <B>Royalties</B> use [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For <B>Patent Fees</B> use [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dept Name:</B> [***]</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Beneficiary: </B>The University of British Columbia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reference: </B>[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phone: </B>[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Re: </B>[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For <B>Royalties </B>use [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For <B>Patent Fees </B>use [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dept Name: </B>[***]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.8pt 0pt 0"><B>Cover/Reimbursement:
    </B>SWIFT [***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.8pt 0pt 0"><B>Receiving Bank: </B>[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">([***])</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Beneficiary Bank: </B>/[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT>-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>16
<FILENAME>filename16.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6)
of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type
of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LICENSE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">THIS LICENSE AGREEMENT (this
 &#8220;Agreement&#8221;) dated as of August 3rd, 2006 (the &#8220;Effective Date&#8221;) is entered into between AMORFIX LIFE SCIENCES
LTD., a corporation amalgamated under the laws of Canada (&#8220;Amorfix&#8221;), having a place of business at 3080 Yonge St., Suite
6020, Toronto, Ontario M4N 3N1, Canada, and BIOGEN DEC MA INC., a Massachusetts corporation (&#8220;Biogen Idec&#8221;) and an Affiliate
of Biogen Idec Inc., having a place of business at 14 Cambridge Center, Cambridge, Massachusetts 02142, U.S.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Amorfix owns or
has rights in the Technology (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Biogen Idec desires
to obtain an exclusive license under Arnorfix&#8217;s rights in the Technology on the terms and conditions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DEFINITIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">For purposes of this Agreement,
the terms defined in this Section 1 shall have the respective meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Affiliate</U>&#8221; shall mean, with respect to any Person, any other Person which directly or indirectly controls,
is controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns,
or directly or indirectly controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other Person,
or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person
by any means whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Amorfix Agreements</U>&#8221; shall mean all agreements (as modified, amended or restated as of the Effective Date),
pursuant to which Amorfix and its Affiliates derive any right, title or interest in or to the IP Rights. The Amorfix Agreements shall
include without limitation those agreements listed on Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Antibody Equivalent</U>&#8221; shall mean a whole antibody (including a murine, chimeric, human, humanized, human sequence,
recombinant, transgenic, grafted, phage display derived and single chain antibody or the like) or fragment thereof, soluble receptor,
fusion protein or similar molecule (such as an aptamer), but excluding any small molecule having a molecular weight less than 1,100 daltons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>BLA</U>&#8221; shall mean a Biologics License Application, Product License Application, New Drug Application, or similar
application for marketing approval of an Product submitted by Biogen Idec to the FDA (or the equivalent application submitted to the
governing authority of any other jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Commercially Reasonable Efforts</U>&#8221; shall mean, with respect to a Product, those efforts and resources that Biogen
Idec would use were it developing, promoting and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> detailing its own pharmaceutical products which are of similar market potential as such Product, taking into account such factors
(without limitation) as product labeling, market potential, past performance, economic return, the regulatory environment and competitive
market conditions in the therapeutic area, all as measured by the facts and circumstances at the time such efforts are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;FDA&#8221; shall mean the United States Food and Drug Administration, or its successor agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Field</U>&#8221; shall mean the prevention or treatment of all forms or expressions of amyotrophic lateral sclerosis
(&#8220;ALS&#8221;) in humans, including without limitation Familial ALS (&#8220;fALS&#8221;) and Sporadic ALS (&#8220;sALS&#8221;).
For greater certainty, the Field excludes all diagnostic applications related to ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>First Commercial Sale</U>&#8221; shall mean, with respect to each Product, the first sale of such Product in a country
after all applicable marketing and pricing approvals (if any) have been granted by the applicable governing health authority of such
country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>IP Rights</U>&#8221; shall mean, collectively, the Patent Rights and the Know-How Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Know-How Rights</U>&#8221; shall mean all trade secret and other know-how rights of Amorfix and its Affiliates in and
to all data, information, compositions and other technology (including, but not limited to, formulae, procedures, protocols, techniques
and results of experimentation and testing) which are necessary or useful for Biogen Idec to make, have made, use, develop, sell, import
or seek regulatory approval to market a composition, or to practice any method or process, at any time claimed or disclosed in any issued
patent or pending patent application within the Patent Rights or which otherwise relates to the Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Net Sales</U>&#8221; shall mean, with respect to any Product, the gross sales price of such Product invoiced by Biogen
Idec, its Affiliates or sublicensees to customers who are not Affiliates or sublicensees (or are Affiliates or sublicensees but are the
end users of such Product) less, to the extent actually paid or accrued (in accordance with United States generally accepted accounting
principles) and reasonable practices with respect to sales of Product, consistently applied, by Biogen Idec, its Affiliate or sublicensees
(as applicable), (a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers for spoiled,
damaged, out-dated and returned Product; (b) freight and insurance costs incurred by Biogen Idec, its Affiliate or sublicensees (as applicable)
in transporting such Product to such customers; (c) cash, quantity and trade discounts, rebates and other price reductions for such Product
given to such customers under price reduction programs; (d) sales, use, value-added and other direct taxes incurred on the sale of such
Product to such customers (but only to the extent such taxes are actually incurred, and are not reimbursable, refundable or creditable);
and (e) customs duties, surcharges and other governmental charges incurred in exporting or importing such Product to such customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Patent Rights</U>&#8221; shall mean (a) the patents and patent applications listed on Exhibit B, (b) all U.S. and foreign
patents and patent applications that claim or cover the Technology, or its use in the Field, in which Amorfix or any of its Affiliates
heretofore or hereafter has an ownership or (sub)licensable interest, (c) all divisions, continuations, continuations-in-part, that claim
priority to, or common priority with, the patent applications listed in clauses (a) - (b) above or the patent applications that resulted
in the patents described in clauses (a) - (b) above, and (d) all patents that have issued or in the future issue from any of the foregoing
patent applications, including utility, model and design patents and certificates of invention, together with any reissues, renewals,
extensions or additions thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Person</U>&#8221; shall mean an individual, corporation, partnership, limited liability company, trust, business trust,
association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority
or any other form of entity not specifically listed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Phase I Clinical Trial</U>&#8221; shall mean a human clinical trial that is intended to initially evaluate the safety
and/or pharmacological effect of a Product conducted by Biogen Idec in accordance with 21 CFR 312.21(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Phase II Clinical Trial</U>&#8221; shall mean a human clinical trial that is intended to initially evaluate the effectiveness
of a Product for a particular indication or indications in patients with the disease or indication under study conducted by Biogen Idec
in accordance with 21 CFR 312.21(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Phase III Clinical Trial</U>&#8221; shall mean a pivotal human clinical trial the results of which could be used to
establish safety and efficacy of a Product as a basis for a BLA conducted by Biogen Idec in accordance with 21 CFR 312.21(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Product(s)</U>&#8221; shall mean any product that (a) comprises an Antibody Equivalent, and (b) either (i) if made,
used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim, or (ii) otherwise uses or
incorporates the Know-How Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Royalty Term</U>&#8221; shall mean, with respect to each Product in each country, the longer of (a) the term for which
a Valid Claim remains in effect and would be infringed but for the license granted by this Agreement, by making, having made, using,
offering for sale, selling, importing or having imported such Product in such country, and (b) ten (10) years following the date of the
First Commercial Sale of any Product in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Target</U>&#8221; shall mean any misfolded, toxic, mutated or other deviant form of Human Superoxidase Dismutase-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Technology</U>&#8221; shall mean (a) any Target, (b) any Antibody Equivalent that binds to, modulates or otherwise affects
any Target, (c) any nucleotide sequence that encodes such Antibody Equivalent, (d) any cells that contain, express or secrete any Target
or any such Antibody Equivalent, or genetic materials that encode any Target or any such Antibody Equivalent, (e) all methods, uses and
strategies involving any of the foregoing (including the removal of such Human Superoxidase Dismutase-1 and vaccination strategies),
and (f) all information regarding the foregoing (and all tangible and intangible embodiments thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.22<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &#8220;<U>Territory</U>&#8221; shall mean all the countries of the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Third Party</U>&#8221; shall mean any Person other than Amorfix, Biogen Idec and their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">1.24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<U>Valid Claim</U>&#8221; shall mean either (a) a claim of an issued and unexpired patent included within the Patent Rights,
which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable
through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application included within the Patent Rights, which claim
was filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or refiling of such application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>REPRESENTATIONS AND WARRANTIES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mutual Representations and Warranties</U>. Each party hereby represents and warrants to the other party as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">2.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Corporate Existence</U>. Such party is a corporation duly organized, validly existing and in good standing under the laws of
the state or federal jurisdiction in which it is incorporated or amalgamated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">2.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization and Enforcement of Obligations</U>. Such party (a) has the corporate power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate action on its part to
authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly
executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in
accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Consents</U>. All necessary consents, approvals and authorizations of all governmental authorities and other Persons required
to be obtained by such party in connection with this Agreement have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Conflict</U>. The execution and delivery of this Agreement and the performance of such party&#8217;s obligations hereunder
(a) do not conflict with or violate any requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a
default under, any contractual obligation of it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amorfix Representations and Warranties</U>. Amorfix hereby represents and warrants to Biogen Idec as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">2.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>IP Rights</U>. Amorfix is the sole owner or exclusive licensee of the IP Rights and has not granted to any Third Party any
license or other interest in the IP Rights to make, use, offer for sale, sell or import Antibody Equivalents for use in the Field or
to conduct research and development for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">2.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>No Infringement</U>. Amorfix is not aware of (a) any Third Party patent, patent application or other intellectual property
rights that would be infringed (i) by practicing any process or method or by making, using or selling any composition which is claimed
or disclosed in the Patent Rights or which constitutes Know-How Rights, or (ii) by making, using or selling Products, or (b) except as
disclosed in writing to Biogen Idec prior to the Effective Date, any infringement or misappropriation by a Third Party of the IP Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">2.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amorfix Agreements</U>. All Amorfix Agreements (including all modifications, amendments and restatements) are listed in Exhibit
A. Amorfix has provided Biogen Idec with copies of all Amorfix Agreements, and there have been no modifications, amendments or restatements
other than as provided to Biogen Idec prior to July 1, 2006. The Amorfix Agreements are in full force and effect in accordance with their
terms, and there are no defaults or events of default thereunder. Amorfix has not transferred or granted, and Amorfix shall not transfer
or grant, to any Third Party any license or other interest in the Amorfix Agreements to make, use, offer for sale, sell or import Antibody
Equivalents for use in the Field or to conduct research and development for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>LICENSE GRANT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>IP Rights</U>. Subject to the terms of this Agreement, Amorfix hereby grants to Biogen Idec, and Biogen Idec hereby accepts,
an exclusive license (including the exclusive right to grant sublicenses through multiple tiers in accordance with Section 3.2) under
the IP Rights (a) to conduct research and development for the purpose of making, having made, using, offering for sale, selling, importing
or having imported Products in the Territory for use in the Field, and (b) to make, have made, use, offer for sale, sell and import Products
in the Territory for use in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sublicenses</U>. Biogen Idec shall have the right to grant sublicenses pursuant to Section 3.1 without the prior written consent
of Amorfix subject to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">3.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Promptly
after execution of a sublicensing agreement, Biogen Idec shall provide Amorfix with written notice thereof including the name of the
sublicensee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">3.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event of the termination of this Agreement, provided that a sublicensee is not in breach of its obligations under this
Agreement, upon written request of such sublicensee, Amorfix shall grant to such sublicensee a direct license under the IP Rights to
the extent sublicensed to it under such sublicensing agreement and otherwise having terms and conditions no more onerous than the terms
and conditions of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">3.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>all
sublicenses shall include an obligation for each sublicensee to account for and report its sales of Product on the same basis as if such
sales were sales of Biogen Idec, and Amorfix shall receive compensation in the same amounts as if the sales of Product by the sublicensee
were sales of Biogen Idec; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">3.2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Biogen
Idec shall remain responsible to Amorfix for the compliance of each sublicensee with the financial and other obligations due under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Availability of the IP Rights</U>. Amorfix shall provide Biogen Idec with a copy of all information available to Amorfix relating
to the IP Rights or the Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reservation of Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">3.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Amorfix reserves all IP Rights that are not expressly granted to Biogen Idec under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">3.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
license grant is subject to the non-assignable, non-sublicensable, non-transferable, perpetual, royalty-free, nonexclusive reservation
of rights set forth in the Amorfix Agreements listed on Exhibit A in favor of Neil R. Cashman, Marty Lehto, the University Health Network
and The Governing Council of the University of Toronto set forth in the Amorfix Agreements listed on Exhibit A for research, teaching
and administrative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Technical Assistance</U>. For a period of seven (7) years following the Effective Date, Amorfix shall provide such technical
assistance to Biogen Idec as Biogen Idec reasonably requests regarding the IP Rights or the Technology as applied to the Field. Without
limiting the generality of the foregoing, during such period, Amorfix (a) shall make Neil R. Cashman, and any other Amorfix employees
and consultants who are inventors of the IP Rights and the Technology and at the time of such request are employed by or under contract
with Amorfix or its Affiliates, available to Biogen Idec for consultation, and (b) shall use commercially reasonable efforts to make
all other inventors of the IP Rights and the Technology available to Biogen Idec for consultation. Such technical assistance shall be
at no cost to Biogen Idec up to an aggregate of one-half (1/2) day per month. Biogen Idec shall pay to Amorfix for any such technical
assistance in excess of such amount per month at a commercially reasonable consulting rate that is mutually acceptable to both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Compete</U>. During the term of this Agreement, Amorfix shall not, and shall cause its Affiliates not to, engage directly
or indirectly (or having any interest in, or performing any services for, any Person directly or indirectly) in any activity relating
to the research, development, manufacture or commercialization of any Antibody Equivalent that binds to, modulates or otherwise affects
any Target for use in the Field, other than for the benefit of Biogen Idec. If (a) as a result of Amorfix&#8217;s research regarding
the Technology or the IP Rights results in subject matter which may be of commercial use to Biogen Idec but is not covered by the IP
Rights, or (b) if Amorfix acquires rights in subject matter which results from the research of Neil R. Cashman, Marty Lehto, the University
Health Network and The Governing Council of the University of Toronto regarding the Technology or the IP Rights and which may be of commercial
use to Biogen Idec but is not covered by the IP Rights (such subject matter, collectively, the &#8220;<U>Subject Matter</U>&#8221;<U>),
</U>then Amorfix shall provide Biogen Idec with written notice of such Subject Matter and copies of such data and information relating
thereto that Biogen Idec reasonably requests. Subject to the exceptions set forth in Section 8.2, such notice, data and information shall
be considered the Confidential Information of Amorfix for the purposes of this Agreement. Upon receipt of such written notice, data and
information regarding such Subject Matter, Biogen Idec shall have ninety (90) days to notify Amorfix of its intent to enter into negotiations
with Amorfix regarding a license of rights in and to such Subject Matter The terms of such license may be substantially different than
the terms of this Agreement. If Biogen Idec fails to provide written notice of its intent within ninety (90) days, or if such negotiations
between Biogen Idec and Amorfix do not result in a final executed license agreement within one hundred and twenty (120) days of receipt
of written notice by Amorfix, Amorfix shall be free to commercialize the Subject Matter itself, or license others (including Third Parties
and Affiliates) to do so; provided, however, that Amorfix shall not offer to any Third Party rights in or to such Subject Matter on terms
and conditions taken as a whole more favorable to such Third Party than those last offered to Biogen Idec, unless Amorfix first offers
in writing to Biogen Idec such more favorable terms and conditions and Biogen Idec fails to accept such more favorable terms within sixty
(60) days after receipt of such written offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amorfix Agreements</U>. Amorfix shall keep the Amorfix Agreements in full force and effect, and shall not breach any of its
obligations thereunder. In the event of any breach of the Amorfix Agreements, Amorfix shall give to Biogen Idec prompt written notice
thereof describing in reasonably specific detail the breach. Amorfix shall not amend, modify, alter or waive in any respect the Amorfix
Ageements in any respect that could have an adverse effect on the rights or interests of Biogen Idec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINANCIAL CONSIDERATIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Royalties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Royalty Rate during Royalty Term</U>. In consideration for the licenses granted to Biogen Idec herein, during the Royalty Term
for a Product, Biogen Idec shall pay to Amorfix royalties, with respect to Net Sales of such Product by Biogen Idec, its Affiliates or
sublicensees, equal to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***] percent ([***]%) of Net Sales of such Product that was sold in a country where there exists a Valid Claim claiming such
Product, up to the first [***] dollars ($[***] USD) of Net Sales of such Product in a calendar year; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***] percent ([***]%) of Net Sales of such Product that was sold in a country where there exists a Valid Claim claiming such
Product, in excess of the first [***]dollars ($[***] USD), but equal to or less than [***] dollars ($[***] USD) of Net Sales of such
Product, in a calendar year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***] percent ([***]%) of Net Sales of such Product that was sold in a country where there exists a Valid Claim claiming such
Product, in excess of [***] dollars ($[***] USD) of Net Sales of such Product, in a calendar year; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 2in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***] percent ([***]%) of Net Sales of such Product that was sold in a country where there does not exist any Valid Claim claiming
such Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Only one royalty shall be
owing for a Product regardless of how many Valid Claims claim such Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">4.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third Party Royalties</U>. If Biogen Idec, its Affiliates or sublicensees is required to pay royalties to any Third Party in
order to exercise its rights hereunder to make, have made, use, sell, offer to sale, import or export any Product, then Biogen Idec shall
have the right to credit fifty percent (50%) of such Third Party royalty payments against the royalties owing to Amorfix under Section
4.1.1(a) &#8212; (c) above with respect to sales of such Product in such country; <U>provided, however,</U> that Biogen Idec shall not
reduce the amount of the royalties paid to Amorfix under Sections 4.1.1(a) &#8212; (c) above by reason of this Section 4.1.2, with respect
to sales of such Product in such country, to less than [***] percent ([***]%) of Net Sales of such Product in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Combination Products</U>. If a Product consists of components that are claimed by a Valid Claim and at least one other active
ingredient that is not claimed by a Valid Claim, then for purposes of the royalty payments under Section 4.1 for Net Sales of such Products,
such Net Sales, prior to the royalty calculation set forth in Section 4.1, first shall be multiplied by the fraction A/(A+B), where A
is the value of the component claimed by the Valid Claim as reasonably determined by Biogen Idec, and B is the value of the other active
ingredients that are not claimed by the Valid Claim as reasonably determined by Biogen Idec, and such resulting amount shall be the &#8220;Net
Sales&#8221; for purposes of the royalty calculation in Section 4.1 for such Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Milestones</U>. Biogen Idec shall pay to Amorfix the following milestone payments within thirty (30) days following the first
achievement of the applicable milestone:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt; width: 18%"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify; width: 82%"><FONT STYLE="font-size: 10pt">administration to the first patient in the first Phase I
  Clinical Trial of the first Product that is specifically intended and labeled for fALS;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">administration to the first patient in the first Phase II Clinical Trial of the first Product that
  is specifically intended and labeled for fALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">administration to the first patient in the first Phase III Clinical Trial of the first Product that
  is specifically intended and labeled for fALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">upon receipt of the first required marketing approval (and pricing approval, if any is required for
  commercial sale) from the FDA for the first Product that is specifically intended and labeled for fALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">upon receipt of the first required marketing approval (and pricing approval, if any is required for
  commercial sale) from the applicable regulatory authority in the European Union for the first Product that is specifically intended
  and labeled for fALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">upon receipt of the first required marketing approval (and pricing approval, if any is required for
  commercial sale) from the applicable regulatory authority in Japan for the first Product that is specifically intended and labeled
  for fALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">administration to the first patient in the first Phase I Clinical Trial of the first Product that is
  specifically intended and labeled for sALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">administration to the first patient in the first Phase II Clinical Trial of the first Product that
  is specifically intended and labeled for sALS;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt; width: 18%"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify; width: 82%">administration to the first patient in the first Phase III Clinical Trial of the first
  Product that is specifically intended and labeled for sALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">upon receipt of the first required marketing approval (and pricing approval, if any is required for
  commercial sale) from the FDA for the first Product that is specifically intended and labeled for sALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">upon receipt of the first required marketing approval (and pricing approval, if any is required for
  commercial sale) from the applicable regulatory authority in the European Union for the first Product that is specifically intended
  and labeled for sALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">upon receipt of the first required marketing approval (and pricing approval, if any is required for
  commercial sale) from the applicable regulatory authority in Japan for the first Product that is specifically intended and labeled
  for sALS;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">following the first calendar year in which annual Net Sales of a Product exceeded [***] <FONT STYLE="font-size: 10pt">dollars
  ($</FONT>[***] <FONT STYLE="font-size: 10pt">USD); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD>
  <TD STYLE="text-align: justify">following the first calendar year in which annual Net Sales of a Product exceeded [***] <FONT STYLE="font-size: 10pt">dollars
  ($</FONT>[***] <FONT STYLE="font-size: 10pt">USD).</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any clinical trials are
initiated and/or approvals are sought for a Product that is specifically intended and labeled for both fALS and sALS, then the applicable
milestones shall both be due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maintenance Fee</U>. If any of Biogen Idec, its Affiliates or sublicensees have not initiated a Phase I Clinical Trial by the
four (4) year anniversary of the Effective Date, Biogen Idec shall pay to Amorfix, within thirty (30) days following the fourth, fifth,
sixth and seventh anniversary dates a fully creditable (against royalties owing under Section 4.1) annual maintenance fee until (but
not after) a Phase I Clinical Trial is commenced, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; width: 49%; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Anniversary</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 49%; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Maintenance Payment</FONT></TD></TR>
  <TR>
    <TD STYLE="text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Fourth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD></TR>
  <TR>
    <TD STYLE="text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Fifth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD></TR>
  <TR>
    <TD STYLE="text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Sixth</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0.5in"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 12pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Seventh</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 12pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">$</FONT>[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ROYALTY REPORTS AND ACCOUNTING</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Royalty Reports</U>. Within forty five (45) days after the end of each calendar quarter during the term of this Agreement following
the First Commercial Sale of a Product, Biogen Idec shall furnish to Amorfix a quarterly written report showing in reasonably specific
detail (a) the calculation of Net Sales during such calendar quarter; (b) the calculation of the royalties, if any, that shall have accrued
based upon such Net Sales; (c) the withholding taxes, if any, required by law to be deducted with respect to such sales; and (d) the
exchange rates, if any, used in determining the amount of United States dollars. With respect to sales of Products invoiced in United
States dollars, the gross sales, Net Sales and royalties payable shall be expressed in United States dollars. With respect to Net Sales
invoiced in a currency other than United States dollars, all such amounts shall be expressed both in the currency in which the distribution
is invoiced and in the United States dollar equivalent. The United States dollar equivalent shall be calculated using the average of
the exchange rate (local currency per US$1) published in <U>The Wall Street Journal,</U> Western Edition, under the heading &#8220;Currency
Trading&#8221; on the last business day of each month during the applicable calendar quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Audits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">5.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Timing</U>. Upon the written request of Amorfix and not more than once in each calendar year, Biogen Idec shall permit an independent
certified public accounting firm of nationally recognized standing selected by Amorfix and reasonably acceptable to Biogen Idec, at Amorfix&#8217;s
expense, to have access during normal business hours to such of the financial records of Biogen Idec as may be reasonably necessary to
verify the accuracy of the payment reports hereunder for the eight (8) calendar quarters immediately prior to the date of such request
(other than records for which Amorfix has already conducted an audit under this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">5.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cost</U>. If such accounting firm concludes that additional amounts were owed during the audited period, Biogen Idec shall
pay such additional amounts within thirty (30) days after the date Amorfix delivers to Biogen Ides such accounting firm&#8217;s written
report so concluding. The fees charged by such accounting firm shall be paid by Amorfix; provided, however, if the audit discloses that
the royalties payable by Biogen Idec for such period are more than one hundred ten percent (110%) of the royalties actually paid for
such period, then Biogen Idec shall pay to Amorfix (a) the reasonable fees and expenses charged by such accounting firm, plus (b) such
disclosed royalties which should have been paid plus interest thereon at a rate equal to the prime lending rate then charged by RBC Royal
Bank at its main branch in Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">5.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financial Information</U>. Amorfix shall cause its accounting firm to retain all financial information subject to review under
this Section 5.2 in strict confidence; provided, however, that Biogen Idec shall have the right to require that such accounting firm,
prior to conducting such audit, enter into an appropriate non-disclosure agreement with Biogen Idec regarding such financial information.
The accounting firm shall disclose to Amorfix only whether the reports are correct or not and the amount of any discrepancy. No other
information shall be shared. Amorfix shall treat all such financial information as Biogen Idec&#8217;s Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PAYMENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment Terms</U>. All amounts set forth in this Agreement are in United States Dollars (USD). Royalties shown to have accrued
by each royalty report provided for under Section 5 above shall be due on the date such royalty report is due. Payment of royalties in
whole or in part may be made in advance of such due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exchange Control</U>. If at any time legal restrictions prevent the prompt remittance of part or all royalties with respect
to any country in the Territory where the Product is sold, Biogen Idec shall have the right, in its sole discretion, to make such payments
by depositing the amount thereof in local currency to Amorfix&#8217;s account in a bank or other depository institution in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #1A1A1A">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Withholding Taxes</U>. Biogen Idec shall be entitled to deduct the amount of any withholding taxes, value-added taxes
or other taxes, levies or charges with respect to such amounts, other than United States taxes, payable by Biogen Idec, its Affiliates
or sublicensees, or any taxes required to be withheld by Biogen Idec, its Affiliates or sublicensees, to the extent Biogen Idec, its
Affiliates or sublicensees pay to the appropriate governmental authority on behalf of Amorfix such taxes, levies or charges. Biogen Idec
shall use reasonable efforts to minimize any such taxes, levies or charges required to be withheld on behalf of Amorfix by Biogen Idec,
its Affiliates or sublicensees. Biogen Idec promptly shall deliver to Amorfix proof of payment of all such taxes, levies and other charges,
together with copies of all <FONT STYLE="color: #1A1A1A">communications from or with such governmental authority with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DEVELOPMENT AND COMMERCIALIZATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Diligence</U>. Biogen Idec shall use Commercially Reasonable Efforts to develop and commercialize at least one Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation of Amorfix</U>. Biogen Idec shall endeavor to include Neil R. Cashman in its internal clinical trial design process
for Products; provided, however, that the failure to so include Neil R. Cashman shall neither constitute a breach of this Agreement nor
give rise to any remedy in favor of Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reports</U>. Within forty-five (45) days following the end of each calendar year prior to the First Commercial Sale of a Product,
Biogen Idec shall prepare, and provide to Amorfix, a confidential, written summary report which shall describe the work performed by
Biogen Idec to during such calendar year regarding its efforts to develop and seek regulatory approval for Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>CONFIDENTIALITY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidential Information</U>. During the term of this Agreement, and for a period of five (5) years following the expiration
or earlier termination hereof, each party shall maintain in confidence all information of the other party that is disclosed by the other
party and identified as, or acknowledged to be, confidential at the time of disclosure (the &#8220;Confidential Information&#8221;),
and shall not use, disclose or grant the use of the Confidential Information except on a need-to-know basis to those directors, officers,
affiliates, employees, permitted licensees, permitted assignees and agents, consultants, clinical investigators or contractors, to the
extent such disclosure is reasonably necessary in connection with performing its obligations or exercising its rights under this Agreement.
To the extent that disclosure is authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any such
Person to hold in confidence and not make use of the Confidential Information for any purpose other than those permitted by this Agreement.
Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party&#8217;s Confidential
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Permitted Disclosures</U>. The confidentiality obligations contained in Section 8.1 above shall not apply to the extent that
(a) any receiving party (the &#8220;Recipient&#8221;) is required (i) to disclose information by law, regulation or order of a governmental
agency or a court of competent jurisdiction, or (ii) to disclose information to any governmental agency for purposes of obtaining approval
to test or market a product, provided in either case that the Recipient shall provide written notice thereof to the other party and sufficient
opportunity to object to any such disclosure or to request confidential treatment thereof; or (b) the Recipient can demonstrate that
(i) the disclosed information was public knowledge at the time of such disclosure to the Recipient, or thereafter became public knowledge,
other than as a result of actions of the Recipient in violation hereof; (ii) the disclosed information was rightfully known by the Recipient
(as shown by its written records) prior to the date of disclosure to the Recipient by the other party hereunder; (iii) the disclosed
information was disclosed to the Recipient on an unrestricted basis from a source unrelated to any party to this Agreement and not under
a duty of confidentiality to the other party; or (iv) the disclosed information was independently developed by the Recipient without
use of the Confidential Information disclosed by the other party. Notwithstanding any other provision of this Agreement, Biogen Idec
may disclose Confidential Information of the Amorfix relating to information developed pursuant to this Agreement to any Person with
whom Biogen Idec has, or is proposing to enter into, a business relationship, as long as such Person has entered into a confidentiality
agreement with Biogen Idec on terms at least as stringent as those contained in the agreements which Biogen Idec uses to protect its
own Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Permitted Disclosure Related to Research and Teaching</U>. Biogen Idec acknowledges that Neil R. Cashman, Marty Lehto, the
University Health Network and The Governing Council of the University of Toronto has retained certain rights to conduct research regarding
the Technology and the IP Rights both in the Field and outside of the Field, and that Amorfix itself has retained rights to conduct research
regarding the Technology and the IP Rights in the Field under the Research Program and outside of the Field. If Amorfix or any of Neil
R. Cashman, Marty Lehto, Avi Chakrabarrty and Rishi Rakhit (the &#8220;Collaborators&#8221;) desires to make a publication (including
without limitation any oral disclosure made without obligation of confidentiality) of any results of the Research Program or any other
results of the research regarding the Technology and the IP Rights, Amorfix or such Collaborator shall provide Biogen Idec with a copy
of the proposed written publication at least forty-five (45) days prior to submission for publication, or an outline of such oral disclosure
at least fifteen (15) days prior to presentation. Biogen Idec shall have the right (a) to propose modifications to the publication for
patent reasons, and (b) to request a reasonable delay in publication in order to protect patentable information. If Biogen Idec requests
such a delay, Amorfix or such Collaborator shall delay submission or presentation of the publication for a period of sixty (60) days
to permit the preparation and filing of patent applications acceptable to Biogen Idec. Upon the expiration of such forty-five (45) day
period (in the case of proposed written disclosures) or fifteen (15) day period (in the case of proposed written disclosures) from receipt
by Biogen Idec, Amorfix or such Collaborator, as the case may be, shall be free to proceed with the written publication or the presentation,
respectively, unless Biogen Idec has requested the delay described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agreement to be Bound</U>. Amorfix shall use commercially reasonable efforts to obtain the agreement of each of the Collaborators
to be bound by the provisions of Section 8.3 of this Agreement within three (3) months following the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Terms of this Agreement</U>. Except as otherwise provided in Sections 8.2 and 8.3 above, Amorfix and Biogen Idec shall not
disclose any terms or conditions of this Agreement to any Third Party without the prior consent of the other party. Notwithstanding the
foregoing, prior to execution of this Agreement, Biogen Idec and Amorfix have agreed upon the substance of information that can be used
to describe the terms of this transaction, and Biogen Idec and Amorfix may disclose such information, as modified by mutual agreement
from time to time, without the other party&#8217;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>PATENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Division of Patents</U>. Promptly following the Effective Date, the parties shall meet and establish a mutually acceptable
strategy for filing divisional patent applications, to the extent permitted by applicable law and regulation and consistent with prudent
patent prosecution practices, to separate from the Patent Rights those claims that do not have any application to the Field. Notwithstanding
anything to the contrary in this Agreement, such divisional patent applications shall be excluded from the definition of Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Patent Prosecution and Maintenance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">9.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms and conditions of the Amorfix Agreements, Biogen Idec shall have the right to control, at its sole cost,
the preparation, filing, prosecution and maintenance of all patents and patent applications within the Patent Rights, and shall consider
in good faith the interests of Amorfix in connection therewith. Amorfix shall cooperate with Biogen Idec, execute all lawful papers and
instruments and make all rightful oaths and declarations as may be necessary in connection therewith. Biogen Idec shall keep Amorfix
timely and fully informed of the progress of the preparation, filing, prosecution and maintenance of the Patent Rights, and give Amorfix
and Amorfix&#8217;s counsel reasonable opportunity to review and comment on the text of each patent application within Patent Rights
and other submissions relating thereto before filing. Biogen Idec shall provide Amorfix with a copy of such patent application as filed,
together with notice of its filing date and serial number, and each such submission. Biogen Idec shall provide Amorfix with copies of
all patent applications, amendments, related correspondence, and other relevant documentation relating to such prosecution. Amorfix shall
have the right to consult regarding the preparation, filing, prosecution and maintenance of the Patent Rights. Biogen Idec shall implement
reasonable and timely requests made by Amorfix regarding the Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">9.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Biogen Idec, in its sole discretion, decides to abandon the preparation, filing, prosecution or maintenance of any patent or
patent application in the Patent Rights, then Biogen Idec shall notify Amorfix in writing thereof and following the date of such notice
Amorfix shall have the right to control, at its sole cost, the preparation, filing, prosecution and maintenance of such patents and patent
applications (which thereafter shall no longer be Patent Rights), in which case such patents or patent applications shall be excluded
from the definition of Patent Rights, and Biogen Idec shall cooperate with Amorfix, execute all lawful papers and instruments and make
all rightful oaths and declarations as may be necessary in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Notification of Infringement</U>. Each party shall notify the other party of any substantial infringement in the Territory
known to such party of any Patent Rights and shall provide the other party with the available evidence, if any, of such infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforcement of Patent Rights</U>. Biogen Idec, at its sole expense, shall have the right to determine the appropriate course
of action to enforce Patent Rights or otherwise abate the infringement thereof, to take (or refrain from taking) appropriate action to
enforce Patent Rights, to defend any declaratory judgments seeking to invalidate or hold the Patent Rights unenforceable, to control
any litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation, declaratory judgments
or other enforcement action with respect to Patent Rights, in each case in Biogen Idec&#8217;s own name and, if required by law, in the
name of Amorfix and shall consider, in good faith, the interests of Amorfix in so doing. In so doing, Biogen Idec shall reasonably consider
the rights and interests of Amorfix in the Patent Rights (if any) outside the Field. If Biogen Idec does not, within one hundred twenty
(120) days of receipt of notice from Amorfix, abate the infringement or file suit to enforce the Patent Rights against at least one infringing
party in the Territory, Amorfix shall have the right to take whatever action it deems appropriate to enforce the Patent Rights; provided,
however, that, (a) in so doing, Amorfix shall reasonably consider the rights and interests of Biogen Idec in the Patent Rights in the
Field, and (b) within thirty (30) days after receipt of notice of Amorfix&#8217;s intent to file such suit, Biogen Idec shall have the
right to jointly prosecute such suit and to fund up to one-half (<SUP>1</SUP>/<SUB>2</SUB>) the costs of such suit. The party controlling
any such enforcement action shall not settle the action or otherwise consent to an adverse judgment in such action that diminishes the
rights or interests of the non-controlling party without the prior written consent of the other party. All monies recovered upon the
final judgment or settlement of any such suit to enforce the Patent Rights shall be shared, after reimbursement of expenses, in relation
to the damages suffered by each party. If Biogen Idec does not receive sufficient monies from a final judgment or settlement to cover
its expenses for such suit, Biogen Idec shall have the right to credit up to fifty percent (50%) of such expenses against any royalties
or other fees owing by Biogen Idec pursuant to Section 4 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforcement or Defense Cooperation</U>. In any suit to enforce and/or defend the License Patent Rights pursuant to this Section
9, the party not in control of such suit shall, at the request and expense of the controlling party, cooperate in all respects and, to
the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens,
and the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>INDEMNIFICATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>. Each party shall indemnify and hold harmless the other party, and its directors, officers, employees and
agents, from and against all losses, liabilities, damages and expenses, including reasonable legal fees and costs resulting from any
claims, demands, actions or other proceedings by any Third Party to the extent resulting from the material breach of any representation,
warranty or covenant by such party under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedure</U>. If a party (the &#8220;Indemnitee&#8221;) intends to claim indemnification under this Section 10, it shall promptly
notify the other party (the &#8220;Indemnitor&#8221;) in writing of any claim, demand, action or other proceeding for which the Indemnitee
intends to claim such indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so
desires, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an Indemnitee shall
have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee
by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee
and any other party represented by such counsel in such proceeding. The obligations of this Section 10 shall not apply to amounts paid
in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor,
which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable
time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor of
any obligation to the Indemnitee under this Section 10, but the omission so to deliver written notice to the Indemnitor shall not relieve
it of any obligation that it may have to any party claiming indemnification otherwise than under this Section 10. The Indemnitee, its
employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any claim,
demand, action or other proceeding covered by this Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>TERMINATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expiration</U>. Subject to Sections 11.2, 11.3 and 11.4 below, this Agreement shall expire on the expiration of Biogen Idec&#8217;s
obligation to pay royalties to Amorfix under Section 4.1 above. Upon expiration of this Agreement, Biogen Idec shall have a fully paid-up,
non-exclusive license under the Know-How Rights to make, have made, use, sell, offer for sale and import Products in the Territory for
use in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by Biogen Idec</U>. Biogen Idec may terminate this Agreement, in its sole discretion, upon thirty (30) days prior
written notice to Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination for Invalidity Challenge</U>. If Biogen Idec or one of its Affiliates asserts in any court or other governmental
agency of competent jurisdiction that a Patent Right is invalid, unenforceable, then unless Biogen Idec or such Affiliate, within thirty
(30) days after written notice thereof by Amorfix, withdraws its filing, submission or other process commenced in any court or other
governmental agency of competent jurisdiction to challenge the validity or enforceability or any Patent Right, this Agreement shall terminate
upon the expiration of such thirty (30) day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">11.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination for Cause</U>. Except as otherwise provided in Section 12, Amorfix may terminate this Agreement upon or after the
breach of any material provision of this Agreement by Biogen Idec if Biogen Idec has not cured such breach within sixty (60) days after
notice thereof by Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">11.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Expiration or Termination</U>. Expiration or termination of this Agreement shall not relieve the parties of any obligation
accruing prior to such expiration or termination, and the provisions of Sections 6 (but only to the extent of payment obligations accrued
prior to the date of expiration or termination), 8, 10 and 13 shall survive the expiration or termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">11.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon termination of this Agreement, Biogen Idec shall (a) return to Amorfix upon request any and all material containing the Confidential
Information of Amorfix (provided that Biogen Idec shall have the right to retain one (1) copy for its legal records to determine its
obligations under this Agreement); and (b) execute upon request such documents and carry out such acts as Amorfix may reasonably direct
in order to ensure that the rights to control the preparation, filing, prosecution and maintenance of all patents and patent applications
within the Patent Rights are returned to Amorfix (provided, however that Amorfix shall pay all of Biogen Idec&#8217;s reasonable out-of-pocket
expenses associated therewith, including without limitation, any registry filing fees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">11.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon termination of this Agreement, Amorfix promptly shall return to Biogen Idec upon request any and all material containing
the Confidential Information of Biogen Idec (provided that Amorfix shall have the right to retain one (1) copy for its legal records
to determine its obligations under this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">11.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon termination of this Agreement, upon request by Amorfix at its option in its sole discretion, the parties shall enter into
a mutually acceptable written agreement pursuant to which (a) Biogen Idec shall provide Amorfix with copies of any and all data, information
and technology specifically regarding the Technology developed by Biogen Idec in the exercise of Biogen Idec&#8217;s rights under this
Agreement; (b) Biogen Idec shall allow Amorfix to cross reference any 1NDs, BLAs, clinical data or other submissions filed with the FDA
(or the equivalent application submitted to the governing authority of any other jurisdiction) regarding Products; (c) Amorfix shall
reimburse Biogen Idec upon demand for all amounts paid by Biogen Idec under this Agreement (or as a condition to entering into this Agreement);
and (d) Amorfix shall pay and account to Biogen Idec royalties, milestone fees and maintenance fees in the same amount and in accordance
with the same provisions as such royalties, milestone fees and maintenance fees would have been payable by Biogen Idec to Amorfix under
Sections 4 and 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FORCE MAJEURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Neither party shall be held
liable or responsible to the other party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling
or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes
beyond the reasonable control of the affected party including but not limited to fire, floods, embargoes, war, acts of war (whether war
be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of
God or acts, omissions or delays in acting by any governmental authority or the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>MISCELLANEOUS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties
hereto to the other party shall be in writing, delivered by any lawful means to such other party at its address indicated below, or to
such other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this Agreement)
shall be effective upon receipt by the addressee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; width: 20%">If to Amorfix:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%">Amorfix Life Sciences Ltd.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">3080 Yonge St., Suite 6020</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Toronto, Ontario M4N 3N1, Canada</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Attention: Dr. George Adams, Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">with a copy to:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Lang Michener
LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">1500 &mdash; 1055 West Georgia Street</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Vancouver, British Columbia V6E 4N7, Canada</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Attention: Gary Floyd</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">If to Biogen Idec:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Biogen Idec MA Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">14 Cambridge Center</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cambridge, Massachusetts 02142, U.S.A.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Attention: General Counsel</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">with a copy to:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Biogen
Idec Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">5200 Research Place</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">San Diego, California 92122, U.S.A.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Attention: John M. Dunn</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Publicity</U>. Except as required by law, stock exchange or regulatory authority: (a) neither party, nor any of its Affiliates,
shall originate any publicity, news release or other public announcement, written or oral, relating to this Agreement without the prior
written approval of the other party and agreement upon the nature and text of such announcement or disclosure, which approval shall not
be unreasonably withheld or delayed; and (b) the party desiring to make any such public announcement or other disclosure shall inform
the other party of the proposed announcement or disclosure in reasonably sufficient time prior to public release, and shall provide the
other party with a written copy thereof, in order to allow such other party to comment upon such announcement or disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts,
without regard to the conflicts of law principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment</U>. Neither party shall assign its rights or obligations under this Agreement without the prior written consent
of the other party; <U>provided, however,</U> that either party may, without such consent, assign this Agreement and its rights and obligations
hereunder (a) to any Affiliate, or (b) in connection with the transfer or sale of all or substantially all of its business, or in the
event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of
its assignor under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers and Amendments</U>. No change, modification, extension, termination or waiver of this Agreement, or any of the provisions
herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement embodies the entire agreement between the parties and supersedes any prior representations,
understandings and agreements between the parties regarding the subject matter hereof. There are no representations, understandings or
agreements, oral or written, between the parties regarding the subject matter hereof that are not fully expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Any of the provisions of this Agreement which are determined to be invalid or unenforceable in any jurisdiction
shall be ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable
the remaining provisions hereof and without affecting the validity or enforceability of any of the terms of this Agreement in any other
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. The waiver by either party hereto of any right hereunder or the failure to perform or of a breach by the other
party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar
nature or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">13.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have executed this Agreement effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">AMORFIX LIFE<SUP>-</SUP>SCIENCES LTD.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ George Adams</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">George Adams</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">President &amp; CEO</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">BIOGEN IDEC MA INC.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Michael F. Phelps</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">Michael F. Phelps</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">Vice President &amp; Treasurer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A<BR>
<BR>
<U>Amorfix Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Assignment Agreement dated February 18, 2005
(as amended April 1, 2005) between Neil R. Cashman, Marty Lehto and The Governing Council of the University of Toronto, on the one hand,
and Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">License Agreement between Dr. Neil Roy Cashman
and Amorfix Life Sciences Ltd. dated February 1, 2006, and related letter of Consent from University of Toronto dated February 13, 2006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">License Agreement between University Health Network
and Amorfix Life Sciences Ltd. dated April 4, 2006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B<BR>
<BR>
<U>Patent Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[TO BE COMPLETED ON EXECUTION]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">I, Neil R. Cashman, hereby
agree that, in the event of the termination of the Amorfix Agreement to which I am a party, provided that Biogen Idec is not in breach
of its obligations under this Agreement, upon written request of Biogen Idec, I shall grant to Biogen Idec a direct license under the
IP Rights which are the subject of such Amorfix Agreement to the extent licensed to Biogen Idec under this Agreement and otherwise having
terms and conditions no more onerous than the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 6.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Neil R. Cashman</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>17
<FILENAME>filename17.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="color: #141414; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #141414; margin: 0pt 0; text-align: right">Exhibit 10.6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141414; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141414; text-align: justify"><I>Certain identified information
has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item
601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential.
Redacted information is indicated by: [***]</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; color: #141414; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #141414; text-align: right">Execution Copy</P>

<P STYLE="color: #141414; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="color: #141414; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXCLUSIVE LICENSE AGREEMENT</P>

<P STYLE="color: #141414; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Exclusive License Agreement
(this &quot;<U>Agreement</U>&quot;) is made effective as of July <FONT STYLE="color: windowtext">14,</FONT> 2010 (the &quot;<U>Effective
Date</U>&quot;) by and between Amorfix Life Sciences Ltd., a Canadian corporation with a principal place of business at 3403 American
Drive, Mississauga, Ontario, L4V 1T4, Canada (&quot;<U>Amorfix</U>&quot;). and Biogen Idec MA Inc., a Massachusetts corporation with a
place of business at 14 Cambridge Centre, Cambridge, MA 02142 (&quot;<U>Biogen Idec</U>&quot;). Amorfix and Biogen Idec are each hereafter
referred to individually as a &quot;<U>Party</U>&quot; and together as the &quot;<U>Parties</U>.&quot;</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Amorfix is the owner of
or otherwise controls certain proprietary Licensed Patent Rights and Licensed Technology (as defined below);</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Biogen Idec desires to
obtain an exclusive license from Amorfix under such Licensed Patent Rights and Licensed Technology to develop and commercialize Licensed
Products; and</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Amorfix desires to grant
such license to Biogen Idec on the terms and subject to the conditions of this Agreement.</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the Parties hereby agree as follows:</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">Capitalized terms used in this Agreement
shall have the meanings specified below or elsewhere herein.</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Additional Agreements</U>&quot; means all agreements with Third Parties, other than Upstream Agreements, pursuant to which
Amorfix has provided or is obligated to provide any materials within the Licensed Technology or granted any rights-under the Licensed
Technology in any field, including the right to perform research or publish the results of any research relating to the Licensed Technology,
which agreements includes the agreements listed on <U>Exhibit F</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Affiliate</U>&quot; means any corporation, firm, limited liability company, partnership or other entity that controls
or is controlled by or is under common control with a Party to this Agreement. For purposes of this Section 1.2, &quot;control&quot; means
ownership, directly or indirectly through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote
for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any
other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a party controls or has the
right to control the Board of Directors or equivalent governing body of a corporation or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &quot;<U>Combination Product Reduction</U>&quot; has the meaning set forth in Section 1.17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Confidential Information</U>&quot; means with respect to a Party (the &quot;<U>Receiving Party</U>&quot;), all information
in any form (including written, visual, electronic, oral and otherwise) that is (i) disclosed by the other Party (the &quot;<U>Disclosing
Party</U>&quot;) to the Receiving Party and (ii) marked &quot;Confidential&quot; or &quot;Proprietary,&quot; or if disclosed not in writing,
identified as confidential or proprietary when disclosed and confirmed in writing as such within 30 days of disclosure; provided, however,
that Confidential Information shall not include information that the Receiving Party can demonstrate by written record or other suitable
documentary evidence, (a) as of the date of disclosure is demonstrably known to the Receiving Party or its Affiliates other than by virtue
of a prior confidential disclosure to such Party or its Affiliates; (b) as of the date of disclosure is in, or subsequently enters, the
public domain, through no fault or omission of the Receiving Party; (c) is obtained from a Third Party having a lawful right to make such
disclosure free from any obligation of confidentiality; or (d) is independently developed by or for the Receiving Party without reference
to or reliance upon any Confidential Information of the Disclosing Party. For greater certainty, Amorfix's Confidential Information includes
the terms of all Upstream Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Control</U>&quot; or &quot;<U>Controlled</U>&quot; means with respect to any Patent Rights or Technology, the possession
by a Party of the ability to grant a license or sublicense of such Patent Rights, or Technology, as provided for herein without violating
the terms of any arrangement or agreements between such Party and any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;Data&quot; means any data, information and reports relating to the Existing Products that are part of the Licensed Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>First Commercial Sale</U>&quot; means, on a country-by-country basis, the date of the first arm's length transaction,
transfer or disposition for value by or on behalf of Biogen Idec or any Affiliate or Sublicensee of Biogen Idec to a Third Party of a
Licensed Product for end use or consumption of such Product . First Commercial Sale excludes any sale or other distribution for use in
a clinical trial or other development activity, or for compassionate use or on a named patient basis, where same has been disclosed to
Amorfix in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>FDA</U>&quot; means the United States Food and Drug Administration and any successor agency or authority thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>IND</U>&quot; means an investigational new drug application (as defined in Title 21 of the United States Code of Federal
Regulations or any successor law or regulations thereto, as amended from time to time) filed or to be filed with the FDA with regard to
any Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Indication</U>&quot; means a distinct illness, sickness, interruption, cessation or disorder of a particular bodily function,
system, tissue type or organ, or sign or symptom of any such items or conditions, regardless of the severity, frequency or route of any
treatment, dosage strength or patient class, for which Regulatory Approval is being sought and which will be referenced on any Licensed
Product labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &quot;<U>Indemnitee</U>&quot; mean an Amorfix Indemnitee or a Biogen Idec Indemnitee, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Licensed Field</U>&quot; means treatment, including Theranostics, and prevention of the Indication amyotrophic lateral
sclerosis (&quot;ALS&quot;) in humans, and such Indications as may be expanded by mutual agreement of the Parties or in accordance with
Section 2.2 (Option to Expand Licensed Field). &quot;Licensed Field&quot; (including any Option Indications) specifically excludes vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Licensed Patent Rights</U>&quot; means all Patent Rights which are Controlled by Amorfix or an Amorfix Affiliate as of
the Effective Date or become Controlled by Amorfix or an Amorfix Affiliate during the Term, that cover the research, development, manufacture,
use or sale of the Licensed Products, whether or not for commercial purposes, or that would otherwise be necessary or useful for the manufacture,
use or sale of Licensed Products. The Licensed Patent Rights as of the Effective Date include the Patent Rights listed in <U>Exhibit A</U>.
Exhibit A shall be updated by Amorfix by written notice to Biogen Idec on a semi-annual basis during the Term to include any additional
patents and patent applications not previously listed; however, the exclusion of a patent or patent application from <U>Exhibit A</U>
is not to be deemed a conclusive indication of whether that patent or application is or should be considered a &quot;Licensed Patent Right&quot;
for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Licensed Product</U>&quot; means any one or more of the (i) the Existing Product and (ii) Other Products, defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">1.14.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Existing Product</U>&quot; means any composition that contains a monoclonal antibody (including affinity-matured derivatives
thereof), or fragment thereof, that binds to misfolded Human Superoxide Dismutase-1 (SOD-1) and is listed on <U>Exhibit B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">1.14.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Other Product</U>&quot; means any composition (other than an Existing Product) that contains a monoclonal antibody, or
fragment thereof, that binds to misfolded Human Superoxide Dismutase-1 (SOD-1) and either (i) is derived from any one or more antibodies
(or genetic materials encoding them) provided to Biogen Idec as part of the Licensed Technology, or (ii) the manufacture or sale of which
would, absent the license granted herein, infringe a Valid Claim of the Licensed Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Licensed Technology</U>&quot; means and includes all Technology, whether or not patentable, Controlled by Amorfix or its
Affiliates as of the Effective Date or which becomes Controlled by Amorfix or an Amorfix Affiliate during the Term that is necessary or
useful for the research, development, manufacture, use or sale of the Licensed Products, including antibodies identified during the Term.
The Licensed Technology includes, without limitation, the Technology listed on Exhibit C but excludes any Technology expressly excluded
on Exhibit C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Major Market Countries</U>&quot; means Canada, France, Germany, Italy, Japan, Spain, the United Kingdom and the United
States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&quot;<U>Net
Sales</U>&quot; means the gross invoiced sales price for all Licensed Products sold by Biogen Idec, its Affiliates or Sublicensees
to Third Parties throughout the Territory during each calendar quarter, less the following amounts incurred or paid by Biogen Idec
or its Affiliates or Sublicensees during such calendar quarter with respect to sales of Licensed Products regardless of the calendar
quarter in which such sales were made:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>trade,
cash and quantity discounts or rebates actually allowed or taken, including discounts or rebates to governmental or managed care organizations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>credits
or allowances actually given or made for rejection of, and for uncollectible amounts on, or return of previously sold Licensed Products
(including Medicare and similar types of rebates);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
charges for insurance, freight, and other transportation costs directly related to the delivery of Licensed Product to the extent included
in the gross invoiced sales price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of a Licensed Product (including any
tax such as a value added or similar tax or government charge) borne by the seller thereof which is not refundable to the seller, other
than franchise or income tax of any kind whatsoever; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
import or export duties or their equivalent borne by the seller.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&quot;Net Sales&quot; shall not include sales or transfers
between Biogen Idec and its Affiliates or Sublicensees, unless the Licensed Product is consumed by the Affiliate or Sublicensee. For ease
of administration, Net Sales by Sublicensees may be calculated using the deductions set forth in the applicable sublicense agreement instead
of the deductions set forth above, so long as such deductions are commercially reasonable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">In the event that a Licensed Product is covered by a Valid
Claim in the country sold and is sold in combination with another active ingredient or component having independent therapeutic effect
or diagnostic utility, then &quot;Net Sales,&quot; for purposes of determining royalty payments on the combination, shall be calculated
using one of the following methods (the &quot;Combination Product Reduction&quot;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>By multiplying the Net Sales of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty paying
period in question, of the Licensed Product sold separately, and B is the gross selling price, during the royalty period in question,
of the other active ingredients or components sold separately; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that no such separate sales are made of the Licensed Product or any of the active ingredients or components in such
combination package during the royalty paying period in question, Net Sales, for the purposes of determining royalty payments shall be
calculated using the above formula where A is the commercial value, as reasonably estimated by Biogen Idec consistent with standard industry
practices, of the Licensed Product sold separately and B is the commercial value, as reasonably estimated by Biogen Idec consistent with
standard industry practices, of the other active ingredients sold separately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &quot;<U>Option Indication</U>&quot; means each Indication designated in writing by Biogen Idec in connection with its exercise
of an Option Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Patent Rights</U>&quot; means the rights and interests in and to issued patents and pending patent applications (including
inventor's certificates and utility models) in any country or jurisdiction within the Territory, including all provisionals, substitutions,
continuations, continuations-in-part, divisionals, supplementary protection certificates, renewals, all letters patent granted thereon,
and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, patents of addition thereof, PCTs and foreign
counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Phase I Clinical Trial</U>&quot; means a human clinical trial, the principal purpose of which is a determination of metabolism,
pharmacokinetics and/or preliminary safety in healthy individuals or patients with the disease being studied, as further described in
21 C.F.R. &sect;312.21(a) (including any such equivalent clinical study in any country other than the United States).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Phase II Clinical Trial</U>&quot; means a human clinical trial conducted on patients with the disease being studied for
the principal purpose of achieving a preliminary determination of efficacy and selection of the dose regimen(s) to be studied in a Phase
III Clinical Trial of a Licensed Product, as further described in 21 C.F.R. &sect;312.21(b), and, if the defined end-points are met, is
sufficient to allow the conduct of such a Phase III Clinical Trial (including any such equivalent clinical study in any country other
than the United States), all in accordance with the trial protocol. For clarity: (a) to be a Phase II Clinical Trial, the protocol must
include at least one primary end-point pertaining to efficacy; and (b) if a trial is planned as a two-stage trial, in which the first
stage is a Phase I Clinical Trial, and if the defined safety endpoints are met as described in the protocol for such trial, the trial
proceeds to a second stage that meets the criteria above for a Phase II Clinical Trial, then only such second, Phase II stage of such
trial shall be deemed a Phase II Clinical Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.22<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Phase III Clinical Trial</U>&quot; means a human clinical trial, the principal purpose of which is to establish safety
and efficacy in patients with the disease being studied, as further described in 21 C.F.R. &sect;312.21(c) (including any such equivalent
clinical study in any country other than the United States), which is designed and intended to be of a size and statistical power sufficient
to serve as a pivotal study to support the filing of a Regulatory Approval for the Indication being studied, all in accordance with the
trial protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt">1.23<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>&quot;<U>Protected Antibodies</U>&quot; means the monoclonal antibodies known as 3H1 and 10E1 1C11, including affinity-matured
derivatives and fragments thereof, that bind to SOD-1; provided that 3H1 and/or 10E11C11 (and affinity-matured derivatives and fragments
thereof) may be deemed to no longer be Protected Antibodies in accordance with <FONT STYLE="font-size: 10pt">Section 2.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Qualified Study</U>&quot; means a well-controlled, blinded efficacy study in a standard animal model with well-accepted
endpoints showing a dose response that is relevant to one or more Option Indications identified in the protocol for such study. For purposes
of illustration, an example is set forth on Exhibit D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.25<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &quot;<U>Regulatory Approval</U>&quot; means all approvals, licenses, registrations or authorizations of all government agencies
in a country, necessary for the manufacture, use, storage, import, marketing and sale of a Licensed Product in such country, including
any pricing and reimbursement approvals legally or practically required to market or sell a Licensed Product in such country. With respect
to the EU, a Licensed Product shall be deemed to have received Regulatory Approval upon receipt of all regulatory approvals, marketing
authorizations and pricing and/or reimbursement approvals required in the jurisdiction in question. Further, a Licensed Product will not
be deemed to have received Regulatory Approval in the EU unless it has been approved in a Major Market Country within the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.26<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Royalty Term</U>&quot; means, with respect to each Licensed Product, the period commencing on the Effective Date and continuing
on a country-by-country, and product-by-product basis until the later of (i) the last to expire of the Licensed Patent Rights covering
the sale of the Licensed Product in such country or (ii) ten (10) years from the First Commercial Sale in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.27<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Sublicensee</U>&quot; means any Third Party to whom Biogen Idec grants a sublicense in writing of some or all of the rights
granted to Biogen Idec under this Agreement on terms and conditions consistent with those set out in this Agreement, provided that a copy
of the sublicense is provided to Amorfix within 30 days of its execution and delivery and that Biogen Idec may reasonably redact such
copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.28<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Technology</U>&quot; means and include any and all unpatented, proprietary ideas, inventions, discoveries, Confidential
Information, biological materials, data, results, formulae, designs, specifications, methods, processes, formulations, techniques, ideas,
know-how, technical information (including, without limitation, structural and functional information), process information, pre-clinical
information, clinical information, and any and all proprietary biological, chemical, pharmacological, toxicological, pre-clinical, clinical,
assay, control and manufacturing data and materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.29<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Term</U>&quot; means the period commencing on the Effective Date and continuing until the expiration or termination of
this Agreement in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.30<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Territory</U>&quot; means worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #1C1C1C">1.31<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>&quot;<U>Theranostics</U>&quot; means the testing of a human subject who has been diagnosed with or is at risk of developing
a given Indication with the goal of predicting the likelihood of success or the risk of side effects of anti-SOD 1 therapy for such Indication,
<FONT STYLE="color: #1C1C1C">including tests for neutralizing antibodies against a therapeutic and predictive tests used in the course
of researching or developing a Licensed Product, but for greater certainty Theranostics does not include diagnostics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.32<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Third Party</U>&quot; means any person or entity other than Biogen Idec, Amorfix and their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.33<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>&quot;<U>Upstream
Agreement</U>&quot; means each agreement between Amorfix and a Third Party pursuant to which Amorfix has in-licensed or been
assigned any of the Licensed Patent Rights or any item of Licensed Technology, including the agreements listed on <U>Exhibit E</U>,
as amended from time to time pursuant to Section 7.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.34<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Upstream Entities</U>&quot; means each party to an Upstream Agreement who (or which) grants a license or assigns rights
thereunder to Amorfix, or who (or which) acknowledges or gives any consent to such a license or assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.35<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Valid Claim</U>&quot; means a claim in an issued, unexpired patent or in a pending patent application within the Licensed
Patent Rights that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of
competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or
other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered
unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding. Notwithstanding the foregoing,
if a claim of a pending patent application within the Licensed Patent Rights has not issued as a claim of a patent within the five (5)
years after the PCT filing date (or the first national filing date if no PCT was filed), such claim shall not be a Valid Claim for the
purposes of this Agreement, unless and until such claim issues as a claim of an issued patent (from and after which time the same shall
be deemed a Valid Claim subject to paragraphs (a) and (b) above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">1.36<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Definitions</U>. Each of the following terms shall have the meaning described in the corresponding section of this
Agreement indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 26%; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C"><B>Term</B></FONT></TD>
    <TD STYLE="text-align: center; width: 17%; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C"><B>Section</B></FONT></TD>
    <TD STYLE="width: 32%; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C"><B>Term</B></FONT></TD>
    <TD STYLE="width: 25%; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C"><B>Section</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Agreement</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Recitals</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">New Data</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">9.5</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">ALS</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #1C1C1C">1.12</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Notice to Partner</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">2.2.1(i)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Amorfix</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Recitals</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Option Exercise</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">2.2.1(ii)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Notice</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Amorfix Indemnitee</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #1C1C1C">8.1,1</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Option Right</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">2.2.1</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Ancillary Confidential Information</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #1C1C1C">5.2</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Party and Parties</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Recitals</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Biogen Idec</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Biogen Idec</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">8.1.2</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">Prosecution Costs</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt; color: #1C1C1C">6.2</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Indemnitee</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Effective Date</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Recitals</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Released Antibody</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">2.4</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Collaborators</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">5.3.2</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Required Disclosure</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">5.3.2</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Developments</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">7.1(k)</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Required Filings</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">6.1.2</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Indemnifying Party</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">8.2</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Term</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">9.1</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Initiation</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">4.3.1(iii)</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">Negotiation Period</FONT></TD>
    <TD STYLE="text-align: center; padding-bottom: 10pt"><FONT STYLE="font-size: 10pt">2.2.1(ii)</FONT></TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>GRANT
OF RIGHTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>License to Biogen Idec.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">2.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Grant of License</U>. Subject to the terms and conditions of this Agreement, Amorfix hereby grants to Biogen Idec an exclusive
license, including the right to grant sublicenses to Sublicensees, under the Licensed Patent Rights and Licensed Technology, to research,
have researched, develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export
and have exported, Licensed Products and to practice the Licensed Technology, in the Territory, for any and all uses within the Licensed
Field. For greater certainty, this license does not grant to Biogen Idec any right to exploit the algorithm disclosed in PCT/CA2009/001413
to identify target epitopes in any protein other than SOD1, or the epitope protection assay disclosed in W005/019828 for purposes of detecting
a target other than SOD1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">2.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Retained Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Biogen
Idec agrees that Amorfix may permit academic and other not-for-profit research institutions to utilize the Licensed Patent Rights and
Licensed Technology solely for <I>in vitro </I>and animal studies for non-commercial research purposes (i.e., research purposes that
do not involve any use in humans and which do not use the Licensed Patent Rights or Licensed Technology in the production or manufacture
of products for sale or the performance of services for a fee), except that any use for research purposes commencing after the date of
this Agreement within the Licensed Field shall require Biogen Idec's prior approval on a case-by-case basis. Amorfix shall disclose to
Biogen Idec the identity of any entity to which it proposes to provide access (whether inside or outside the Licensed Field) to the Licensed
Patent Rights or Licensed Technology (including the provision of antibodies) after the date of this Agreement and provide a copy of the
research plan and all data and reports generated by such entity in connection with such research plan and all proposed and actual publications
relating thereto. Amorfix agrees to include the foregoing restrictions and disclosure obligations in a written agreement with the recipient
of such rights and any related materials. Notwithstanding the foregoing, Biogen Idec agrees that pursuant to the Upstream Agreements,
upstream licensors may have research rights that are retained by Amorfix on behalf of such upstream licensors on the terms and conditions
set out in the Upstream Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Amorfix
shall use reasonable efforts to ensure that any intellectual </FONT> property arising from such research activities, including under
all Upstream Agreements, that is necessary or useful for the research, development, manufacture, use or sale of the Licensed Products
shall be automatically included in the rights licensed to Biogen Idec, and if, despite reasonable efforts, Amorfix is unable to do so,
Amorfix shall ensure (1) that such intellectual property is subject to at least an option in a form reasonably acceptable to Biogen Idec
and directly exercisable by Biogen Idec for an exclusive worldwide license at a reasonable rate to be negotiated in good faith and (2)
that copies of notices of new inventions be sent directly to Biogen Idec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding the foregoing, Amorfix shall not provide any of the Protected Antibodies, or their fragments or derivatives, or
any materials related to the production thereof, to any Third Party without the prior approval of Biogen Idec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Option
to Expand Licensed Field.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">2.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Option Right</U>. Amorfix hereby grants to Biogen Idec the right (&quot;<U>Option Right</U>&quot;) to expand the Indications
covered by the Licensed Field on the following terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Partner</U>. In the event that a Qualified Study is completed for any composition that would qualify as a Licensed
Product, Amorfix shall provide notice in writing to Biogen Idec (&quot;<U>Notice to Partner</U>&quot;) of the occurrence of such event.
The Notice to Partner must include a confidential data package of form, content and manner reasonably similar to that which would be provided
to a Third Party interested in acquiring rights in the applicable composition. Amorfix will provide any additional information requested
by Biogen Idec that is available concerning the Qualified Study, including its objectives, methods, key findings and outcomes. Within
ninety (90) days of the receipt of a properly submitted Notice to Partner, Biogen Idec will, if it wishes to exercise its Option Right,
designate one or more Option Indications, which shall be reasonably related to the Qualified Study, and notify Amorfix as to whether it
has elected to exercise the Option Right with respect to the applicable Option Indication(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Option Right</U>. If Biogen Idec sends notice to Amorfix of its election to exercise the Option Right with respect
to the Option Indication(s) (the &quot;<U>Option Exercise Notice</U>&quot;), the Parties shall negotiate in good faith the financial terms
for the expansion of the Licensed Field to include the Option Indication(s), including royalty rates, license fees and milestone payments
applicable thereto. The Parties agree to engage in such good-faith negotiations for a period of ninety (90) days from the date of the
Option Exercise Notice or such longer period of time as the Parties may agree to in writing (the &quot;<U>Negotiation Period</U>&quot;).
During the Negotiation Period Amorfix shall not offer any rights for the Option Indication(s) to any Third Party or engage in any discussions,
negotiations or other communications with any Third Party concerning such rights. The Parties agree that the financial terms for the expansion
of the Licensed Field to include the Option Indication(s) shall reflect commercially reasonable terms reflecting the value of the market
for a Licensed Product for such Option Indication(s) and the degree of risk involved in developing a Licensed Product for the Option Indication(s).
For clarity, neither Party shall be required during the course of such negotiations to re-negotiate any non-financial provisions of this
Agreement with respect to such Option Indication(s) or any provisions with respect to any Licensed Product or Indication that is already
licensed to Biogen Idec hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon reaching written agreement (which shall be subject to appropriate management approvals) upon such financial terms, the Parties
shall amend this Agreement in compliance with Section 11.5 (Entire Agreement; Amendment) such that the Licensed Field shall include the
Option Indication(s) and the financial terms applicable thereto shall be incorporated into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> In the event that the Parties do not reach a definitive agreement upon the financial terms for the Option Indication(s) prior
to the expiration of the Negotiation Period, Amorfix shall be free to offer Third Parties a license under the Licensed Patent Rights and
the Licensed Technology for the Option Indication(s), excluding any rights in the Protected Antibodies, on financial terms that are no
less favorable in the aggregate to Amorfix than the financial terms last offered in writing by Biogen Idec to Amorfix unless such less
favorable financial terms in the aggregate are also offered to Biogen Idec, which shall have a period of thirty (30) days in which to
accept such terms. Further, Amorfix will, concurrent with the offer of such terms to Biogen Idec, provide Biogen Idec with the confidential
data package that it provided to such Third Party. If Biogen Idec has not accepted such terms within thirty (30) days, Amorfix will be
free to consummate a transaction for such rights with a Third Party on such terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Determination Not to Proceed</U>. If Biogen Idec elects not to exercise the Option Right, Amorfix may grant to a Third Party
a license to such Option Indication(s) under the Licensed Patent Rights and Licensed Technology, excluding any rights in the Protected
Antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Carve-Out for Alzheimer's Disease</U>. Amorfix represents and warrants that the Indication of Alzheimer's Disease is subject
to a contract with a Third Party whereby Amorfix is not permitted to extend the Licensed Field to Alzheimer's Disease. Therefore, the
Option Right shall exclude Alzheimer's Disease; provided, however, that if such contractual restriction actually terminates or expires
for any reason, Amorfix will promptly notify Biogen Idec and, whether or not such notice is provided, the Option Right shall automatically
be deemed to apply to Alzheimer's Disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Representation and Warranties</U>. With respect to each Notice to Partner, Amorfix covenants and warrants that the
Qualified Study will be conducted in compliance with all applicable laws and regulations and in a professional manner consistent with
industry standards, and that, to the best of its knowledge, all of the information, including any data package, in connection with the
Qualified Study will be accurate and complete in all material respects and Amorfix will not have failed to disclose any material information
or data of which it has actual knowledge that would be necessary to make such information not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">2.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless expressly approved in writing by Biogen Idec on a case-by-case basis and subject to the remainder of this Section 2.2.2,
Amorfix may not (i) grant to any Third Party or Affiliate any rights or license under the Licensed Patent Rights or Licensed Technology
to any Indication outside of the Licensed Field, or (ii) directly or indirectly, conduct or have conducted any human clinical trial with
respect to any composition that would qualify as a Licensed Product, unless such Indication or composition, as the case may be, had been
subject to Biogen Idec's Option Right and Biogen Idec had elected not to exercise its Option Right with respect thereto or, following
Biogen Idec's exercise of its Option Right, the Parties failed to enter into a definitive agreement with respect to such composition or
Indication despite Amorfix's strict compliance with Section 2.2.1. For greater certainty, nothing in this Section 2.2 shall restrict Amorfix
from pursuing the development of vaccines in any field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Unless expressly approved in writing by Biogen Idec on a case-by-case basis, Amorfix and its Affiliates shall not, under any circumstances,
(x) perform any research or development work relating to a Protected Antibody, or their fragments or derivatives, for its own account
or on behalf of any Third Party, or (y) grant any right or license to any Protected Antibody, or their fragments or derivatives, to any
Third Party in any field or for any use except in connection with vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Upstream Agreements; Notifications Pertaining to Licensed Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">2.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Licensed Patent Rights</U>. Amorfix shall provide written notice of all Licensed Patent Rights Controlled by Amorfix or its
Affiliates that come under the Control of Amorfix or its Affiliates after the Effective Date during the Term. Such notice shall be provided
within ten (10) business days following the event pursuant to which such Control arises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">2.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Upstream Agreements and Additional Agreements</U>. Amorfix shall promptly provide to Biogen Idec copies of any notices it receives
from any Third Party in connection with any Upstream Agreement or Additional Agreement, including without limitation, notices related
to proposed publications or other disclosures, notices of Developments or other new inventions or breaches, any assertion of an assignment
back of rights, revocation of any assignment, or the termination or threatened termination of the Upstream Agreement. Amorfix agrees to
use commercially reasonable efforts to exercise, on behalf of and in consultation with Biogen Idec, all rights available to Amorfix under
the Upstream Agreements and Additional Agreements with respect to Licensed Technology in the Licensed Field, including options to negotiate
commercial licenses under Developments or other new inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Cessation as Protected Antibody. </B>On or before the date that is twenty-four (24) months after the Effective Date, Biogen
Idec will notify Amorfix as to whether it has determined that a Protected Antibody(ies) is not sufficiently promising to warrant further
development as a lead candidate for the Licensed Field (a &quot;Released Antibody&quot;). Any such Released Antibody shall, as of the
date of such notice, no longer be deemed to be a Protected Antibody under this Agreement. For the avoidance of doubt, any designation
of a Released Antibody shall not limit or reduce any of the licenses granted to Biogen Idec under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>DEVELOPMENT
AND COMMERCIALIZATION OF LICENSED PRODUCTS.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Technology Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">3.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Technology
Transfer and Assistance</U>. Amorfix shall provide its reasonable assistance to effect the orderly transfer to Biogen Idec of the
Licensed Technology as specified in this Section 3.1.1. For this purpose, Amorfix will deliver to Biogen Idec within thirty (30)
business days after the Effective Date all items of Licensed Technology that exist in tangible form or in writing (including
electronic media) except to the extent where same is necessary or useful to Amorfix in connection with its retained rights described
in this Agreement or necessary or useful to Amorfix outside of the licenses granted hereunder, in which case Amorfix's obligation
shall be limited to provide a reasonable supply of same or copies thereof in a manner agreed upon between the parties. Amorfix will
make Dr. Neil Cashman and its other consultants and personnel available to provide answers to Biogen Idec's questions during normal
business hours, for a period of one hundred eighty (180) calendar days after the Effective Date, to assist Biogen Idec in
understanding and implementing the Licensed Technology to carry out research and development of Licensed Products as contemplated in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">3.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Updated List</U>. If, during the Term, Biogen Idec or Amorfix identifies any Technology Controlled by Amorfix or its Affiliates
as of the Effective Date or which becomes Controlled by Amorfix or an Amorfix Affiliate during the Term that is necessary or useful for
Biogen Idec to practice the license granted to it under this Agreement, Amorfix shall provide its reasonable assistance to promptly effect
the orderly transfer to Biogen Idec of such Licensed Technology consistent with this Section 3.1 and <U>Exhibit C</U> shall be updated
to include such additional Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">3.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Responsibility</U>. From and after the Effective Date, Biogen Idec shall have full control and authority over the research,
development and commercialization of Licensed Products in the Licensed Field in the Territory. All activities relating to research, development
and commercialization under this Agreement shall be undertaken at Biogen Idec's sole cost and expense, except as otherwise expressly provided
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">3.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Diligence</U>. Biogen Idec will, itself or through its Affiliates or Sublicensees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>exercise
commercially reasonable efforts to develop and commercialize Licensed Products, such reasonable efforts and diligence to be in accordance
with the efforts and resources Biogen Idec would use for a product candidate owned by it or to which it has rights, which is at a similar
stage of development and is of similar market potential as the applicable Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>During
the six-year period following the Effective Date, invest in the aggregate at least [***] US dollars (US$[***]) on research and development
of one or more Licensed Products in the Licensed Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Initiate the filing of an IND within six (6) years of the Effective Date; provided, however, that if an IND has not been filed
by the date that is six (6) years after the Effective Date, Biogen Idec may make the following payments to Amorfix to extend the deadline
for filing the IND by one (1) additional year beyond the then-current deadline:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within thirty (30) days of the sixth anniversary of the Effective Date: [***] US Dollars (US$[***]);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within thirty (30) days of the seventh anniversary of the Effective Date: [***] US Dollars ($[***]);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within thirty (30) days of the eighth anniversary of the Effective Date: [***] US Dollars ($[***]);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Within thirty (30) days of the ninth anniversary of the Effective Date: [***] US Dollars (US$[***]).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Status Reports</U>. During the Term, Biogen Idec shall provide Amorfix on or before January 31st of each year with an annual
written report summarizing in reasonable detail its progress in developing and commercializing Licensed Products during the prior calendar
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>PAYMENTS
AND ROYALTIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>License
Fee</U>. On the Effective Date, Biogen Idec shall pay Amorfix a non-creditable, non-refundable license fee in the amount of [***] US
Dollars ($[***]) payable by wire transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Payment
of Royalties; Royalty Rates; Minimum Royalties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Royalty Payments</U>. Subject to the other terms of this Agreement (including the remainder of this Section 4.2), commencing
on the date of the First Commercial Sale of each Licensed Product in each country in the Territory and continuing for the duration of
the Royalty Term in such country, Biogen Idec shall pay to Amorfix a royalty on Net Sales in such country as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For
Existing Products,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if there is a Valid Claim that covers the Existing Product in the country where such Existing Product is sold,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #1A1A1A">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;$300M
Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #1A1A1A">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$300M
- $700M Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #1A1A1A">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&gt;$700M
Net Sales in calendar year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.15in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: #1A1A1A">if there are no Valid Claims then in force that cover the </FONT> Existing Product in the country
where such Existing Product is sold, but a Valid Claim covering the Existing Product has been issued and remains in force in all of the
Major Market Countries,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;$300M
Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$300M
- $700M Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&gt;$700M
Net Sales in calendar year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if (x) there are no Valid Claims then in force that cover the Existing Product in the country where such Existing Product is sold,
and (y) in at least one (1) of the Major Market Countries there are no Valid Claims that have been issued and remain in force covering
the Existing Product, [***] percent ([***]%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For Other Products,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> if there is a Valid Claim that covers the Other Product in the country where such Other Product is sold,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;$300M
Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$300M
- $700M Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&gt;$700M
Net Sales in calendar year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if there are no Valid Claims then in force that cover the Other Product in the country where such Other Product is sold, but a
Valid Claim covering the Other Product has been issued and remains in force in all of the Major Market Countries,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;$300M
Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$300M
- $700M Net Sales in calendar year</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">[***]<FONT STYLE="font-size: 10pt; color: #151515">%&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&gt;$700M
Net Sales in calendar year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if (x) there are no Valid Claims then in force that cover the Other Product in the country where such Other Product is sold, and
(y) in at least one of the Major Market Countries, there are no Valid Claims that have been issued and remain in force covering the Other
Product, [***] percent ([***]%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Annual
Net Sales, and the royalty steps indicated above, will be determined on a calendar year and product-by-product basis, and the rates above
shall be applicable to the incremental portion of Net Sales as set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Royalty Offset</U>. Solely with respect to Licensed Products that are covered by Valid Claims in the country where sold, the
royalty paid to Amorfix hereunder shall be reduced by fifty percent (50%) of the amount of any royalty that Biogen Idec or any Affiliate
or Sublicensee pays to a Third Party for intellectual property that is necessary or useful to the research, development, manufacture,
use or sale of the Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reduction Cap</U>. In no event may the aggregate reduction on the royalty rate under Section 4.2.2 and the Combination Product
Reduction reduce the applicable royalty rate to less than fifty percent (50%) of the royalty rate that would otherwise have applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0.05in; text-indent: 1.5in">4.2.4 <U>One Royalty</U>. Only
one royalty shall be payable to Amorfix hereunder for each sale of a Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.55in 0pt 0.05in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Milestone
Payments</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment</U>. Subject to the other terms and conditions of this Agreement, Biogen Idec shall make the following payments to Amorfix
within thirty (30) days of the initial occurrence of each of the following events by Biogen Idec or its Affiliates or Sublicenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Development
    and Regulatory Milestones applicable solely to<BR>
    Familial ALS (where the clinical trial patient entry criteria <BR>
    includes only familial forms of ALS)</U></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Payment</U></B></FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of Phase 1 Clinical Trial</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of Phase 2 Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of Phase 3 Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Regulatory Approval</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU Regulatory Approval</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Development and Regulatory
    Milestones applicable to</U></B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Payment</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>sporadic forms of ALS</U></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of Phase 1 Clinical Trial</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of Phase 2 Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiation of Phase 3 Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Regulatory Approval</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU Regulatory Approval</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Commercial Milestones</U></B></FONT></TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Payment</U></B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first time that global annual Net Sales of Licensed Products</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US$[***]</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">exceed US$100,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">The first time that global annual Net Sales of Licensed Products</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">US$</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">exceed US$500,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except with respect to the Commercial Milestones, if the Licensed Product achieving a milestone is an Other Product, then the payment
amount for such milestone shall be reduced by fifty percent (50%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It is hereby acknowledged and agreed that any milestone payment shall be made only once, with respect to the first achievement
of the relevant milestone for the first Licensed Product, regardless of how many times such milestones are achieved by Licensed Products
and regardless of how many times a particular Licensed Product achieves such milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&quot;<U>Initiation</U>&quot; of a clinical trial means the date the first patient is dosed with the relevant Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
greater certainty, (A) if Biogen Idec or its Affiliates or Sublicensees achieve more than one milestone in the same occurrence (for
example, if both familial and sporadic forms of ALS are covered by the achievement of a milestone, or if both Commercial Milestones
are achieved in the same year), Biogen Idec shall make the payment for each such achieved milestone, and (B) with respect to Option
Indications, the parties will negotiate milestones in accordance with Section 2.2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Determination that Payments are Due</U>. Biogen Idec shall promptly (and in any event within thirty (30) business days) provide
Amorfix with written notice upon its achievement of each of the milestones set forth in Section 4.3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Payment
Terms</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Royalties and Milestones</U>. Unless otherwise expressly provided, Biogen Idec shall make any milestone, license
or royalty payments owed to Amorfix hereunder in arrears on a calendar quarterly basis, within sixty (60) days from the end of each quarter
in which such payment accrues. Each payment shall be accompanied by a report for each country in the Territory in which sales of Licensed
Products occurred in the calendar quarter covered by such statement, specifying: the gross sales (if available) and Net Sales in each
country's currency; the applicable royalty rate under this Agreement; the royalties payable in each country's currency, including an accounting
of deductions taken in the calculation of Net Sales in accordance with Biogen Idec's accounting practices; and any details with respect
to the achievement of milestones; in each case in sufficient detail to allow the accuracy of the calculation hereunder to be confirmed;
the applicable exchange rate to convert from each country's currency to United States Dollars under this Section 4.4; and the royalties
payable in United States Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounting</U>. All payments hereunder shall be made in the United States in United States dollars. Conversion of foreign currency
to United States dollars shall be made at the average monthly conversion rate existing in the United States (as reported on the OandA
website, <FONT STYLE="font-size: 10pt; color: Black"><U>www.oanda.com</U></FONT>, or any successor website address thereto) during the
applicable calendar quarter, If the OandA website ceases to be made available to the public, then the rate of exchange to be used shall
be that reported on in The Wall Street Journal, or such other recognized exchange rate website as the Parties may agree or in such other
business publication of national circulation in the United States as the Parties agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Withholding; Restrictions on Payment</U>. All payments hereunder shall be made free and clear of any taxes, duties, levies,
fees or charges, except for withholding taxes (to the extent applicable). Biogen Idec shall make any applicable withholding payments due
on behalf of Amorfix and shall provide Amorfix upon request with such written documentation regarding any such payment as available to
Biogen Idec relating to an application by Amorfix for a foreign tax credit for such payment with the Canadian tax authority, or if Amorfix
is not then domiciled in Canada, the tax authority of the primary country in which Amorfix is domiciled for purposes of income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Records
Retention; Review</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Royalties</U>.
Commencing as of the date of First Commercial Sale of the first Licensed Product hereunder, Biogen Idec and its Affiliates and
Sublicensees shall keep for at least three (3) years from the end of the calendar year to which they pertain complete and accurate
records of sales by Biogen Idec or its Affiliates and Sublicensees, as the case may be, of each Licensed Product, in sufficient
detail to allow the accuracy of the payments hereunder to be confirmed. Commencing on the date of this Agreement, Biogen Idec and
its Affiliates shall keep for at least three (3) years from the end of the calendar year to which they pertain accurate records of
the commercialization and development of each Licensed Product in sufficient detail to allow the accuracy of milestone payments
hereunder, as well as compliance with obligations under Section 3.2.2(ii) and (iii), to be confirmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">4.5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Review</U>. Subject to the other terms of this Section 4.5.2, at the request of Amorfix, which shall not be made more frequently
than once per calendar year during the Term, upon at least thirty (30) days' prior written notice from Amorfix, and at the expense of
Amorfix (except as otherwise provided herein), Biogen Idec shall permit an independent certified public accountant reasonably selected
by Amorfix and reasonably acceptable to Biogen Idec to inspect (during regular business hours) the relevant records required to be maintained
by Biogen Idec under this Section 4.5. In every case the accountant must have previously entered into a confidentiality agreement with
both Parties substantially similar to the provisions of Article 5 and limiting the disclosure and use of such information by such accountant
to authorized representatives of the Parties and the purposes germane to this Section 4.5. Results of any such review shall be binding
on both Parties absent manifest error. Each Party agrees to treat the results of any such accountant's review of the other Party's records
under this Section 4.5 as Confidential Information of the other Party subject to the terms of Article 5. If any review reveals a deficiency
in the calculation and/or payment of royalties by Biogen Idec, then (a) Biogen Idec shall promptly pay Amorfix the amount remaining to
be paid, and (b) if such underpayment is by five percent (5%) or more, Biogen Idec shall pay the reasonable out-of-pocket costs and expenses
incurred by Amorfix in connection with the review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certain
Financial Adjustments</U>. The Parties acknowledge that if Amorfix's rights to any Licensed Technology terminates for any reason, including
a termination by an Upstream Entity of an Upstream Agreement, Biogen Idec should not have to pay in the aggregate milestone payments
or royalties exceeding the milestone payments or royalties set forth in this Agreement for all such Licensed Technology (and Technology
that was formerly Licensed Technology). Therefore the Parties agree that, notwithstanding anything else and without limiting any remedies
of Biogen Idec, the milestone payments and royalty paid to Amorfix hereunder for the research, development, manufacture, use or sale
of a Licensed Product shall be reduced by the amount of any milestone payment or royalty that Biogen Idec or any Affiliate or Sublicensee
pays to an Upstream Entity for any intellectual property that would have been licensed to Biogen Idec under this Agreement were it not
for such changed circumstance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>TREATMENT OF CONFIDENTIAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Confidential
Obligations. </B>Amorfix and Biogen Idec each recognize that the other Party's Confidential Information constitutes highly valuable and
proprietary confidential information. Amorfix and Biogen Idec each agree that during the Term and for five (5) years thereafter, it will
keep confidential, and will cause its employees, consultants (including without limitation, academic collaborators, CROs and manufacturers),
professional advisors, Affiliates and, in the case of Biogen Idec, Sublicensees to keep confidential, all Confidential Information of
the other Party. Neither Amorfix nor Biogen Idec nor any of their respective employees, consultants, Affiliates or, in the case of Biogen
Idec, Sublicensees, shall use Confidential Information of the other Party for any purpose whatsoever other than exercising any rights
granted to it or reserved by it hereunder. Without limiting the foregoing, each Party may disclose information to the extent such disclosure
is reasonably necessary to (a) file and prosecute patent applications and/or maintain patents which are filed or prosecuted in accordance
with the provisions of this Agreement, or (b) file, prosecute or defend litigation in accordance with the provisions of this Agreement
or (c) comply with applicable laws, regulations or court orders; provided, however, that if a Party is required to make any such disclosure
of the other Party's Confidential Information in connection with any of the foregoing, it will give reasonable advance notice to the
other Party of such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure confidential
treatment of such information required to be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #0C0C0C">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><B>Limited
Disclosure and Use. </B>Each Party may disclose the other Party's Confidential Information to any of its officers, employees,
consultants, agents or Affiliates, or in the case of Biogen Idec, Sublicensees, if and only to the extent necessary to carry out its
rights and responsibilities under this Agreement. Such disclosures shall be limited to the maximum extent possible consistent with
such rights and responsibilities and shall only be made to the extent any such persons receiving the other Party's Confidential
Information are bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such
Confidential Information except as expressly permitted by this Agreement. Amorfix and Biogen Idec each agree not to disclose or
transfer the other Party's Confidential Information to any Third Parties under any circumstance without the prior written approval
from the other Party (such approval not to be unreasonably withheld), <FONT STYLE="color: #0C0C0C">except as otherwise required by
law, and except as otherwise expressly permitted under this Section 5.2 or elsewhere in this Agreement. Each Party shall take such
action, and shall cause its Affiliates, and in the case of Biogen Idec, Sublicensees, to take such action, to preserve the
confidentiality of each other's Confidential Information as it would customarily take to preserve the confidentiality of its own
Confidential Information, using, in all such circumstances, not less than reasonable care. Each Party, upon the request of the other
Party, will return all the Confidential Information disclosed or transferred to it by the other Party pursuant to this Agreement,
including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of such request or,
if earlier, the termination or expiration of this Agreement; provided however, that a Party may retain (a) any Confidential
Information of the other Party relating to any license which expressly survives such termination and (b) one (1) copy of all other
Confidential Information in inactive archives solely for the purpose of establishing the contents thereof. With respect to
Confidential Information in electronic form on non-removable media, a party's obligation to return it consists of an obligation to
notify the disclosing party of it, provide a copy thereof to the disclosing party in a reasonable form, and thereafter delete it,
and for this purpose a party will be deemed to have deleted it when it executes a commercially reasonable application- or operating
system-level &quot;delete&quot; function thereupon, notwithstanding that same may be forensically or through backup systems
recoverable, provided that the party thereafter does not commit or permit any such recovery. Notwithstanding the foregoing, Amorfix
acknowledges that Biogen Idec, as of the Effective Date hereof, possesses confidential information of its own and of third parties
relating to potential therapies and treatments for ALS, including but not limited to monoclonal antibodies and fragments thereof,
including such antibodies and fragments specific for the SOD-1 protein </FONT>(&quot;<U>Ancillary Confidential
Information</U>&quot;), and that Biogen Idec may continue to acquire Ancillary Confidential Information during the term of this
Agreement. Nothing in this Article 5 shall prevent Biogen from using such Ancillary Confidential Information for any purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Publicity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">5.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>By Biogen Idec</U>. Biogen Idec shall not disclose to any Third Party the existence or terms or any other matter of fact regarding
this Agreement without the prior written consent of Amorfix; <U>provided</U>, <U>however</U>, that Biogen Idec may make such a disclosure
(a) to the extent required by law or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter
market on which Biogen Idec has its securities listed or traded, or (b) to any acquirers, potential acquirers, investors, prospective
investors, lenders and other potential financing sources who are obligated to keep such information confidential. In the event that Biogen
Idec is required or wishes to make a disclosure that is subject to Section 5.3.1, Biogen Idec shall make reasonable efforts to provide
Amorfix with notice beforehand and to coordinate with Amorfix with respect to the wording and timing of any such disclosure. Once any
press release or any other written statement is approved for disclosure by Amorfix, Biogen Idec may make subsequent public disclosure
of the contents of such statement without the further approval of Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">5.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>By Amorfix</U>. Amorfix shall not disclose to any Third Party, whether orally, in writing or in any other manner, the existence
or terms or any other matter of fact regarding this Agreement without the prior written consent of Biogen Idec; provided, <U>however</U>,
that Amorfix may make such a disclosure to the extent required by law or by the requirements of any nationally recognized securities exchange,
quotation system or over-the-counter market on which Amorfix has its securities listed or traded (each of the foregoing, a &quot;<U>Required
Disclosure</U>&quot;). In the event that a Required Disclosure must be made, Amorfix shall use its best efforts to provide Biogen Idec
with notice beforehand and to coordinate with Biogen Idec with respect to the wording and timing of the Required Disclosure. With respect
to proposed disclosures that are not Required Disclosures, Biogen Idec shall not unreasonably withhold its consent to any such proposed
disclosure, provided that the disclosure is made only to Amorfix's acquirers, potential acquirers, investors, prospective investors, lenders
and other potential financing sources who are obligated to keep such information confidential. For clarity, other than Required Disclosures
and disclosures that meet the requirements of the preceding sentence, Biogen Idec shall have sole discretion to grant or withhold consent
to all other disclosures proposed by Amorfix. Amorfix acknowledges and agrees that, notwithstanding Biogen Idec's rights of review pursuant
to this Section 5.3.2, Biogen Idec shall have no liability in connection with the content of any Required Disclosure or any other disclosure
by Amorfix, and Amorfix shall be solely responsible for ensuring that its disclosures comply with all applicable laws and the requirements
of each securities exchange, quotation system or over-the-counter market on which Amorfix has its securities listed or traded. Once any
press release or any other written statement is approved for disclosure by Biogen Idec, Amorfix may make subsequent disclosures of the
contents of such statement without the further approval of Biogen Idec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">5.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Without
restricting the generality of the foregoing, Biogen Idec acknowledges that Neil R. Cashman, University Health Network and The
Governing Council of the University of Toronto has retained certain rights to conduct research regarding the Licensed Technology and
the Licensed Patent Rights both in the Licensed Field and outside of the Licensed Field, and that Amorfix itself has retained rights
to conduct research regarding the Licensed Technology and the Licensed Patent Rights in the Licensed Field under the Research
Program and outside of the Licensed Field. If Amorfix or any of Neil R. Cashman, Steve Plotkin, Will Guest, Avi Chakrabarrty and
Rishi Rakhit (the &quot;<U>Collaborators</U>&quot;) desires to make a publication (including without limitation any oral disclosure
made without obligation of confidentiality) of any results of the Research Program or any other results of the research regarding
the Licensed Technology and the Licensed Patent Rights, Amorfix or such Collaborator shall provide Biogen Idec with a copy of the
proposed written publication at least sixty (60) days prior to submission for publication, or an outline of such oral disclosure at
least thirty (30) days prior to presentation. Biogen Idec shall have the right (a) to propose modifications to the publication for
patent reasons, and (b) to request a reasonable delay in publication in order to protect patentable information. If Biogen Idec
requests such a delay, Amorfix or such Collaborator shall delay submission or presentation of the publication for a period of ninety
(90) days to permit the preparation and filing of patent applications acceptable to Biogen Idec. Upon the expiration of such sixty
(60) day period (in the case of proposed written disclosures) or thirty (30) day period (in the case of proposed written
disclosures) from receipt by Biogen Idec, Amorfix or such Collaborator, as the case may be, shall be free to proceed with the
written publication or the presentation, respectively, unless Biogen Idec has requested the delay described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #1A1A1A">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><B>Use of Name. </B>Neither Party shall employ or use the name of the other Party in any promotional materials or advertising
without the prior express written <FONT STYLE="color: #1A1A1A">permission of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>PROVISIONS
CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #1A1A1A">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><B>Patent Filing, Prosecution and Maintenance of Licensed Patent <FONT STYLE="color: #1A1A1A">Rights. </FONT></B><FONT STYLE="color: #1A1A1A">Subject
to the other terms of this Section 6.1, Amorfix shall have the right to control preparing, filing, prosecuting, obtaining and maintaining,
using patent counsel reasonably acceptable to Biogen Idec, all Licensed Patent Rights throughout the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">6.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Amorfix
shall consult with Biogen Idec in good faith regarding the preparation, filing, prosecution and maintenance of all Licensed Patent
Rights. Amorfix: (x) will provide Biogen Idec with a copy of any proposed patent application within the Licensed Patent Rights and
any response or submission to any patent office for review and comment at least twenty (20) calendar days prior to the initial
filing or response deadline, and (y) will keep Biogen Idec reasonably informed of the status of such filing, prosecution and
maintenance, including, without limitation: (A) by providing Biogen Idec with copies of all material communications received from or
filed in patent office(s) with respect to such filing, and (B) to the extent not covered in subclause (x), by providing Biogen Idec,
a reasonable time prior to taking or failing to take any action that would materially affect the scope or validity of any such
filing, with prior written notice of such proposed action or inaction so that Biogen Idec has a reasonable opportunity to review and
comment. If Amorfix determines not to prosecute any claim or Patent Right within the Licensed Patent Rights, then Amorfix shall
provide Biogen Idec with written notice of such decision at least ninety (90) calendar days prior to the deadline for filing any
such prosecution action for any claim or Patent Right or the date on which the abandonment of any such claim or Patent Right would
become effective. In such event, Biogen Idec shall have the right, but not the obligation, at its expense, to control the
preparation, filing, prosecution and maintenance of such claim or Patent Right. Biogen Idec's right to assume such control shall not
relieve Amorfix of its obligations pursuant to Section 6.1.2. In furtherance of the foregoing requirements, Amorfix shall instruct
and ensure that its outside patent counsel forward to Biogen Idec at the same time that it forwards to Amorfix a copy of all
correspondence received from or sent to any patent office relating to the Licensed Patent Rights, and Biogen Idec and Amorfix each
agree to enter into a reasonable commonality of interest agreement if deemed advisable by Amorfix's or Biogen Idec's outside patent
counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">6.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to Section 6.1.1, Amorfix shall (i) file patent applications for and diligently prosecute certain core claims identified
in writing by Biogen Idec in all Major Market Countries designated by Biogen Idec in writing from time to time and shall consider in good
faith such filing and prosecution for all non-Major Market Countries designated by Biogen Idec in writing from time to time, and (ii)
apply for, or as applicable, cooperate with Biogen Idec or its Affiliates or Sublicensees' applications for, patent term extensions, supplementary
protection certificates and their respective equivalents in all Major Market Countries as directed in writing by Biogen Idec and shall
consider in good faith such applications for all non-Major Market Countries as directed in writing by Biogen Idec (collectively, all of
(i) and (ii) are the &quot;<U>Required Filings</U>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Reimbursement
of Patent Costs</B>. Biogen Idec shall reimburse Amorfix for fifty percent (50%) of its reasonable, documented out-of-pocket costs for
the prosecution and maintenance of the Licensed Patent Rights (&quot;<U>Prosecution Costs</U>&quot;)<U>;</U> provided that Biogen Idec
shall have no obligation to reimburse for the preparation, filing, prosecution or maintenance of patents or patent applications for countries
other than the Major Market Countries or with respect to any Required Filings unless otherwise expressly agreed by Biogen Idec; provided
further that, if Amorfix grants any licenses under the Licensed Patent Rights to any Third Party outside of the Licensed Field, Biogen
Idec shall pay only a pro rata share of fifty percent (50%) of such Prosecution Costs. For purposes of illustration, if Amorfix grants
two (2) licenses under the Licensed Patent Rights in addition to the license granted under this Agreement, Biogen Idec shall reimburse
Amorfix for sixteen and two-thirds percent (16.67%) of the Prosecution Costs. Notwithstanding the foregoing, if Biogen Idec wishes to
pursue a Required Filing that is not desired by any other licensees of Amorfix, Biogen Idec shall pay fifty percent (50%) of such Prosecution
Costs provided that Amorfix's written agreement with each such non-contributing licensee stipulates that such licensee shall have no
license under any patents that issue from such Required Filings in the absence of a pro rata contribution to the applicable Prosecution
Costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Notice
of Infringement. </B>If, during the Term, Amorfix learns of any actual, alleged or threatened infringement by a Third Party of any Licensed
Patent Rights under this Agreement, Amorfix shall promptly notify Biogen Idec and Amorfix and shall provide Biogen Idec with available
evidence of such infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B>Infringement
of Patent Rights. </B>Biogen Idec shall have the first right (but not the obligation), at its own expense and with legal counsel of
its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of the
Licensed Patent Rights in the Licensed Field. Amorfix shall have the right, at its own expense, to be represented in any such action
by counsel of Amorfix's own choice; provided, however, that under no circumstances shall the foregoing affect the right of Biogen
Idec to control the suit as described in the first sentence of this Section 6.4. If Biogen Idec does not file any action or
proceeding against any such material infringement within six (6) months after the later of (i) either Party's notice to the other
under Section 6.3 above, or (ii) a written request from Amorfix to take action with respect to such infringement, then Amorfix shall
have the right (but not the obligation), at its own expense, to bring suit (or take other appropriate legal action) against such
actual, alleged or threatened infringement, with legal counsel of its own choice, but shall not be permitted to settle any such suit
without the prior consent of Biogen Idec, which consent shall not be unreasonably withheld. Any damages, monetary awards or other
amounts recovered, whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken under this
Section 6.4, shall applied as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.05in; text-indent: 1.5in; color: #1A1A1A">6.4.1 First, to
reimburse the Parties for their respective costs and expenses (including reasonable attorneys' fees and costs) incurred in prosecuting
such enforcement action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.6in 0pt 0.05in; text-indent: 1.5in; color: #1A1A1A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.05in; text-indent: 1.5in; color: #1A1A1A"><FONT STYLE="color: #1A1A1A">6.4.2 Second, to Biogen Idec
in reimbursement for lost profits (net of royalties) associated with Licensed Products and to Amorfix in reimbursement for lost royalties
</FONT>owing hereunder based on such lost sales;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.05in; text-indent: 1.5in; color: #1A1A1A">6.4.3 Third, if the proceeding is
filed by Biogen Idec (regardless of whether Amorfix is joined as a necessary party), any amounts remaining shall be allocated eighty percent
(80%) to Biogen Idec and twenty percent (20%) to Amorfix, or if the proceeding is filed by Amorfix (regardless of whether Biogen Idec
is joined as a necessary party), any amounts remaining shall be allocated eighty percent (80%) to Amorfix and twenty percent (20%) to
Biogen Idec.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.05in; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Parties agree that if a Party brings any such action or proceeding hereunder, the other Party agrees to be joined as party
plaintiff(s) if necessary to prosecute such action or proceeding, and to give the Party bringing such action or proceeding reasonable
assistance and authority to file and prosecute the suit; provided, however, that neither Party shall be required to transfer any right,
title or interest in or to any property to the other Party or any Third Party to confer standing on a Party hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Amorfix Representations. </B>Amorfix represents, warrants and covenants to Biogen Idec that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized
by all appropriate Amorfix corporate action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>this
Agreement is a legal and valid obligation binding upon Amorfix and enforceable in accordance with its terms, and the execution, delivery
and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Amorfix is
a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Amorfix has the full right and legal capacity to grant the rights granted to Biogen Idec hereunder without violating the rights
of any Third Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the best of Amorfix's knowledge, the Licensed Patent Rights have been properly filed and prosecuted and Amorfix is the sole
owner or exclusive licensee of the Licensed Patent Rights and Licensed Technology;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Amorfix is not aware of any Third Party patent, patent application or other intellectual property rights that would be infringed
(i) by practicing any process or method or by making, using or selling any composition which is claimed or disclosed in, or which constitutes,
Licensed Technology, or (ii) by making, using, offering for sale, selling or importing Licensed Products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except for Patent Rights and Technology licensed to Amorfix under the Upstream Agreements, Amorfix is not aware of any intellectual
property of any Third Party that was utilized or incorporated into the Licensed Technology transferred to Biogen Idec pursuant to Section
3.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Amorfix is not aware of any infringement or misappropriation by a Third Party of the Licensed Technology;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exhibit E</U> contains a complete list of all Upstream Agreements as of the Effective Date, and Amorfix has supplied to Biogen
Idec a complete and correct copy of each Upstream Agreement and all amendments thereto, and, during the Term, Amorfix shall not agree
to any amendment of any Upstream Agreement without the prior written consent of Biogen Idec, which consent (a) will not be unreasonably
withheld, conditioned or delayed if such amendments do not materially affect Biogen Idec, the Licensed Technology or the Licensed Patent
Rights in an adverse manner, and (b) in any event will be given or withheld within forty-five (45) days of Amorfix's notice to Biogen
Idec thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Amorfix
is not in default of any obligation under any Upstream Agreement, and Amorfix shall perform its obligations under each Upstream Agreement,
and keep each Upstream Agreement in full force and effect, throughout the Term;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Exhibit
F</U> contains a complete list as of the Effective Date of all Additional Agreements, and Amorfix has supplied to Biogen Idec a complete
and correct copy of each such agreement and all amendments thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of the Effective Date, no Developments (as defined in the material transfer agreements within the Additional Agreements) or
other inventions relating to the Licensed Technology have arisen under any of the Additional Agreements that are not subject to the license
granted to Biogen Idec pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(I)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amorfix
has clearly identified and disclosed in writing to Biogen Idec, on or before the Effective Date, all Improvements by UHN (as defined
in the UHN Agreement) that have arisen on or before the Effective Date, and has duly exercised its option under the UHN Agreement to
include such Improvements by UHN under the licenses granted therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the best of Amorfix's knowledge, the Data is accurate and complete in all material respects and Amorfix has not failed to disclose
any material information or data that would be necessary to make such Data not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in"></P>

<!-- Field: Page; Sequence: 23; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Biogen Idec Representations. Biogen Idec covenants, represents and warrants to Amorfix that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized
by all appropriate Biogen Idec corporate action; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>this Agreement is a legal and valid obligation binding upon Biogen Idec and enforceable in accordance with its terms, and the execution,
delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Biogen
Idec is a party of or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>No Warranties</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">7.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nothing in this Agreement is or shall be construed as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 2in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a warranty or representation by either Party as to the validity or scope of any patent application or patent licensed hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a warranty or representation by either Party that anything made, used, sold or otherwise disposed of under any license granted
pursuant to this Agreement is or will be free from infringement of patents, copyrights, and other rights of Third Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">7.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT
OF ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR AS TO THE SUCCESS OR LIKELIHOOD OF SUCCESS OF THE RESEARCH,
DEVELOPMENT OR COMMERCIALIZATION OF LICENSED PRODUCTS UNDER THIS AGREEMENT, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>INDEMNIFICATION; INSURANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Indemnification</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">8.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Biogen
Idec Indemnity</U>. Biogen Idec shall indemnify, defend and hold harmless Amorfix, its Affiliates and its and their respective
directors, officers, employees, stockholders and agents and all of their respective successors, heirs and assigns (the
 &quot;<U>Amorfix </U>Indemnitees&quot;) from and against any liability, damage, loss or expense (including reasonable attorneys'
fees and expenses of litigation) incurred by or imposed upon such Amorfix Indemnitees, or any of them, in connection with any Third
Party claims, suits, actions, demands or judgments, including, without limitation, personal injury and product liability matters, to
the extent arising out of (a) the development, testing, production, manufacture, supply, promotion, import, sale or use by any
person of any Licensed Product (or any component thereof) manufactured or sold by or on behalf of Biogen Idec or any Affiliate or
Sublicensee under this Agreement, (b) any material breach of this Agreement by Biogen Idec, its Affiliates or its Sublicensees, or
(c) the gross negligence or willful misconduct on the part of Biogen Idec or any Affiliate or Sublicensee, in any such case under
this Section 8.1.1, except to the extent of Amorfix's responsibility therefor under Section 8.1.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">8.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amorfix Indemnity</U>. Subject to Section 8.1.1 above, Amorfix shall indemnify, defend and hold harmless Biogen Idec, Sublicensees,
its and their Affiliates and its and their respective directors, officers, employees, and agents, and all of their respective successors,
heirs and assigns (the &quot;<U>Biogen Idec Indemnitees</U>&quot;) from and against any liability, damage, loss or expense (including
reasonable attorneys' fees and expenses of litigation) incurred by or imposed upon such Biogen Idec Indemnitees, or any of them, in connection
with any Third Party claims, suits, actions, demands or judgments, including, without limitation, personal injury and product liability
matters (but excluding any patent infringement matters, which are governed by Article 6 above), to the extent arising out of (a) any material
breach of this Agreement by Amorfix, or (b) the gross negligence or willful misconduct on the part of Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Indemnification Procedures. </B>In the event that any Indemnitee is seeking indemnification under Section 8.1 above from a Party
(the &quot;<U>Indemnifying Party</U>&quot;), the other Party shall notify the Indemnifying Party of such claim with respect to such Indemnitee
as soon as reasonably practicable after the Indemnitee receives notice of the claim, and the Party (on behalf of itself and such Indemnitee)
shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim
solely for monetary consideration) and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim.
The indemnification obligations under Article 8 shall not apply to (a) any harm suffered to the extent directly resulting from any delay
in notice to the Indemnifying Party hereunder or (b) amounts paid in settlement of any claim, demand, action or other proceeding if such
settlement is effected without the consent of the Indemnifying Party. The Indemnifying Party shall not unreasonably withhold or delay
its consent to a settlement solely for monetary consideration that is proposed by the Indemnitee. The Indemnitee, its employees and agents,
shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigation of any claim, demand, action
or other proceeding covered by Section 8.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Insurance</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">8.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Biogen
Idec Insurance</U>. Biogen Idec shall, either itself or, if Biogen Idec does not directly commercialize Licensed Products, through
its Sublicensees, maintain insurance during the Term and for a period of at least three (3) years after the last commercial sale of
a Licensed Product in the Licensed Field in the Territory under this Agreement, or, if development of Licensed Products ceases prior
to Regulatory Approval, three (3) years after termination of such development, with a reputable, solvent insurer in an amount
appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under this
Agreement. Specifically, Biogen Idec, and, as applicable, its Sublicensees, shall maintain product and clinical trial liability
insurance of at least Five Million ($5,000,000) per occurrence on a worldwide basis. Notwithstanding the foregoing, Biogen Idec, or,
as applicable, its Sublicensees, may satisfy the obligations of this Section 8.3 through a program of self-insurance, provided it
has assets and earnings sufficient to cover the potential indemnified losses contemplated in Section 8.1. Biogen Idec will further
ensure compliance with all foreign local clinical trial liability insurance requirements that may apply with respect to Licensed
Product(s). Upon request, Biogen Idec shall provide Amorfix with evidence of the existence and maintenance of such insurance
coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">8.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amorfix Insurance</U>. Amorfix shall maintain insurance during the Term and for a period of at least three (3) years after the
expiration or termination of this Agreement with a reputable, solvent insurer in an amount appropriate to meet its potential liabilities
under Section 8.2 or otherwise under this Agreement, and in no event less than at least Five Million ($5,000,000) per occurrence on a
worldwide basis. Upon request, Amorfix shall provide Biogen Idec with evidence of the existence and maintenance of such insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>TERM AND TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Term;
Expiration. </B>The term of this Agreement (&quot;Term&quot;) shall expire upon the expiration of the final payment obligation under
Article 4 above. Upon the expiration of the Royalty Term in a given country on a product-by-product basis (but for clarity, not upon
the early termination of this Agreement), the licenses and rights granted by Amorfix under this Agreement will continue on an irrevocable,
fully paid-up, royalty-free basis in such country, and upon the expiration (but for clarity, not upon the early termination of this Agreement)
of the Term, the licenses and rights granted by Amorfix under this Agreement will continue on an irrevocable, fully paid-up, royalty-free
basis throughout the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Termination
for Breach. </B>Subject to the other terms of this Agreement, this Agreement and the rights and options granted herein may be terminated
by either Party upon any material breach by the other Party of any material obligation or condition, effective forty-five (45) days after
giving written notice to the breaching Party of such termination in the case of a payment breach and one hundred twenty (120) days after
giving written notice to the breaching Party of such termination in the case of any other breach, which notice shall describe such breach
in reasonable detail. The foregoing notwithstanding, if such default or breach is cured or remedied or shown to be non-existent within
the aforesaid forty-five (45) or one hundred twenty (120) day period, the notice shall be automatically withdrawn and of no effect. Furthermore,
if either Party gives notice of the initiation of proceedings pursuant to Section 10 during the applicable termination notice period,
no termination shall take effect during the pendency of such proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Voluntary
Termination. </B>Biogen Idec shall have the right to terminate this Agreement at any time upon ninety (90) days' written notice to Amorfix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B>Termination
for Bankruptcy. </B>In the event that either Party files for protection under bankruptcy laws, makes an assignment for the benefit
of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or
insolvency act or has any such petition filed against it which is not discharged within sixty (60) days of the filing thereof, then
the other Party may terminate this Agreement effective immediately upon written notice to such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #1A1A1A">9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><B>Effects of Termination. </B>Upon any termination of this Agreement by Amorfix pursuant to Sections 9.2 (Termination for
Breach) or 9.4 (Termination for Bankruptcy) or by Biogen Idec pursuant to Section 9.3 (Voluntary Termination), as of the effective date
of such termination all relevant licenses and sublicenses granted by Amorfix to Biogen Idec hereunder shall terminate automatically, Biogen
Idec shall return all Confidential Information of Amorfix as required by Section 5, Biogen Idec shall return all Licensed Technology and
Data that were originally provided by Amorfix to Biogen Idec in a manner consistent with the manner in which Amorfix is required to deliver
under Section 3.1, and Biogen Idec shall deliver to Amorfix copies of Data, or at Biogen Idec's discretion a report summarizing the Data,
generated during the term of this Agreement by Biogen Idec or its Sublicensees based specifically on the Existing Products (&quot;<U>New
Data</U>&quot;). Biogen Idec and its Sublicensees provide such New Data on an &quot;AS IS&quot; basis without any warranties of <FONT STYLE="color: #1A1A1A">any
kind, including any warranty of non-infringement. Amorfix understands and agrees that such New Data may have been produced with the use
of Third Party intellectual property and that Biogen Idec and its Sublicensees are not granting any rights under any Third Party intellectual
property, unless otherwise expressly agreed by Biogen Idec. Notwithstanding the foregoing, except in the case of termination by Biogen
Idec pursuant to Section 9.3 (Voluntary Termination), (a) no such termination of this Agreement shall be construed as a termination of
any valid sublicense of any Sublicensee hereunder, and thereafter each such Sublicensee shall be considered a direct licensee of Amorfix,
provided that (i) such Sublicensee is then in full compliance with all terms and conditions of its sublicense, (ii) all accrued payments
obligations to Amorfix have been paid, and (iii) such Sublicensee agrees in writing to assume all applicable obligations of Biogen Idec
under this Agreement. Upon any termination of this Agreement by Biogen Idec pursuant to Section 9.2 (Termination for Breach), all licenses
and option rights granted by Amorfix to Biogen Idec hereunder shall continue in full force and effect as if this Agreement had not been
terminated, provided that Biogen Idec continues to make all payments due hereunder that would have been due hereunder if this Agreement
had not been terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">9.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Remedies. </B>Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 9 are in
addition to any other relief and remedies available to either Party at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">9.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Surviving Provisions. </B>Notwithstanding any provision herein to the contrary, the rights and obligations of the Parties set
forth in Articles and Sections 1 (Definitions), 5 (Treatment of Confidential Information), 8 (Indemnification), 9.4 (Effects of Termination),
9.5 (Remedies), 9.6 (Surviving Provisions), 10 (Disputes) and 11 (Miscellaneous) as well as any rights or obligations otherwise accrued
hereunder (including any accrued payment obligations), shall survive the expiration or termination of the Term. Without limiting the generality
of the foregoing, Biogen Idec shall have no obligation to make any milestone or royalty payment to Amorfix that has not accrued prior
to the effective date of any termination of this Agreement, but shall remain liable for all such payment obligations accruing prior to
the effective date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>DISPUTES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; color: #141414">Any dispute, controversy or claim initiated
by either Party arising out of. resulting from or relating to this Agreement, or the performance by either Party of its obligations under
this Agreement, whether before or after termination of this Agreement, shall be subject to the sole jurisdiction of, and venue in, the
U.S. federal courts of competent jurisdiction located within Boston, Massachusetts, USA., if available, and otherwise the state courts
of competent jurisdiction located within Boston, Massachusetts, USA. Biogen Idec and Amorfix each irrevocably consent to the jurisdiction
of such courts, irrevocably waive any objection based on inconvenience of forum, and agree that process may be served in the manner provided
herein for giving notices or otherwise as allowed by Massachusetts or applicable federal law. Notwithstanding the foregoing, either Party
shall have the right, without waiving any right or remedy available to such Party under this Agreement or otherwise, to seek and obtain
from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property
of such Party.</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Notification. </B>All notices, requests and other communications hereunder shall be in writing, shall be addressed to the receiving
party's address set forth below or to such other address as a party may designate by notice hereunder, and shall be either (i) delivered
by hand, (ii) made by facsimile transmission (to be followed with written fax confirmation), (iii) sent by private courier service providing
evidence of receipt, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. The addresses and other
contact information for the parties are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">If to Amorfix:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amorfix</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">3403 American Drive<BR>
Mississauga, Ontario<BR>
L4V 1T4 Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Robert Gundel, PhD, MBA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; color: #191916">President
 &amp; CEO Facsimile: </FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #191916">Phone: </FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #191916">Lang Michener LLP<BR>
1500-1055 West Georgia Street<BR>
PO Box 11117<BR>
Vancouver, BC V6E 4N7<BR>
Attention: Gary C. Floyd<BR>
Facsimile: </FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">If to Biogen Idec:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #191916">Biogen Idec MA Inc.<BR>
14 Cambridge Center<BR>
Cambridge MA 02142<BR>
Attention:<BR>
Susan Alexander, Esq.<BR>
General Counsel<BR>
Facsimile: </FONT>[***]<FONT STYLE="font-size: 10pt; color: #191916"><BR>
Phone: </FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">With a copy to (which shall not constitute notice hereunder):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #191916">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #191916">Biogen Idec MA Inc.<BR>
14 Cambridge Center<BR>
Cambridge MA 02142<BR>
Attention: Head of Business Development<BR>
</FONT><FONT STYLE="font-size: 10pt">Facsimile: </FONT>[***]<FONT STYLE="font-size: 10pt"><BR>
Phone: </FONT>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.05in">All notices, requests and other communications hereunder
shall be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of
such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged
by the recipient, (iii) if sent by private courier, on the day such notice is delivered to the recipient, or (iv) if sent by registered
or certified mail, on the fifth (5th) business day following the day such mailing is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0.05in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Language. </B>The parties hereto have requested that this Agreement and any related documents be drafted in English. <I>Les
parties aux presentes ont exige que le present contrat et tous les documents qui s 'y rattachent soit rediges en anglais. </I>Any translation
of this Agreement or any part hereof into a language other than English is for convenience only, and only the original English language
version of this Agreement, as it may be amended from time to time as permitted herein, shall have legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Governing Law. </B>This Agreement will be construed, interpreted and applied in accordance with the laws of the Commonwealth
of Massachusetts (excluding its body of law controlling conflicts of law). The UN Convention for the International Sale of Goods shall
not apply to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Limitations. </B>Except as expressly set forth in this Agreement, neither Party grants to the other Party any right or license
to any of its intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Entire Agreement; Amendment. </B>This is the entire Agreement between the Parties with respect to the subject matter hereof
and supersedes all prior representations, understandings and agreements between the Parties with respect to the subject matter hereof,
unless otherwise expressly agreed by the Parties. No modification shall be effective unless in writing with specific reference to this
Agreement and signed by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B>Waiver. </B>The terms or conditions of this Agreement may be waived only by a written instrument executed by the Party waiving
compliance. The failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect
its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing waiver
of such condition or term or of another condition or term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Headings. </B>Article, section and subsection headings are inserted for convenience of reference only and do not form part of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #1A1A1A">11.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><B>Assignment. </B>Neither this Agreement nor any right or obligation hereunder may be assigned, delegated or otherwise
transferred, in whole or part, by either Party without the prior express written consent of the other; provided, however, that either
Party may, without the written consent of the other but upon written notice to the other, assign this Agreement in its entirety to its
Affiliates, or in connection with the transfer or <FONT STYLE="color: #1A1A1A">sale of all or substantially all of such Party's assets
or business related to this Agreement, or in the event of its merger, consolidation, change in control or similar transaction. Amorfix
shall not assign or otherwise transfer to any Affiliate or any Third Party ownership of any of the Licensed Patent Rights or Licensed
Technology unless such Affiliate or Third Party agrees in writing to be bound by this Agreement and an executed copy of such agreement
is provided to Biogen Idec. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment
in violation of this Section 11.8 shall be void. The terms and conditions of this Agreement shall be binding upon and inure to the benefit
of the permitted successors and assigns of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Force Majeure. </B>Neither Party shall be liable for failure of or delay in performing obligations set forth in this Agreement,
and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the
reasonable control of such Party (excluding a lack of credit, cash or financing), provided that the Party so affected (a) notifies the
other Party as soon as practicable in the circumstances of the occurrence of, and expected duration of, such event or circumstance, and
(b) uses its reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder as soon as commercially
practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Construction. </B>The Parties hereto acknowledge and agree that: (i) each Party and its counsel reviewed and negotiated the
terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities
are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions
of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party
was generally responsible for the preparation of this Agreement. In this Agreement: (a) the word &quot;including&quot; shall be deemed
to be followed by the phrase &quot;without limitation&quot; or like expression; (b) the singular shall include the plural and <I>vice
versa; </I>(c) masculine, feminine and neuter pronouns and expressions shall be interchangeable, and (d) all references to dollars or
$ are to United States dollars, whether or not so expressly stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B>Severability. </B>If
any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of the
Parties that such provision(s) be deemed to be severed from this Agreement and the remainder of this Agreement shall not be affected
thereby. The Parties hereto agree to renegotiate any such severed provision in good faith in order to provide a reasonably
acceptable, valid alternative to the severed provision, it being the intent of the Parties that the basic purposes of this Agreement
are to be effectuated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Status. </B>Nothing in this Agreement is intended or shall be deemed to constitute a partner, agency, employer-employee, or
joint venture relationship between the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt; color: #0C0C0C">11.13<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><B>No Set-Off. </B>Except as expressly set out in this Agreement, any payment obligation under this Agreement is absolute
and unconditional and is not affected by any circumstance, including without limitation any set-off, compensation, counterclaim, <FONT STYLE="font-size: 10pt; color: #0C0C0C">recoupment,
defense or other right that a Party may have against the other Party or anyone else for any reason at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section 365(n). </B>All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy
Code, licenses of right to &quot;intellectual property&quot; as defined in Section 101 of such Code and any equivalent foreign legislation.
The Parties agree that Biogen Idec may fully exercise all of its rights and elections under the U.S. Bankruptcy Code and any foreign equivalent
thereto in any country having jurisdiction over a Party or its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Further Assurances. </B>Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">11.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Counterparts. </B>This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0C0C0C"><B>[Remainder of page
intentionally left blank; Signature Page Follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0C0C0C">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0C0C0C"></P>

<!-- Field: Page; Sequence: 31; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0C0C0C">&nbsp;</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have executed this Agreement as of the date first set forth above.</P>

<P STYLE="color: #141414; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">BIOGEN IDEC MA INC.</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">AMORFIX LIFE SCIENCES LTD. </TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">By:</TD>
                                                    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%">Title:&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 44%">VP, Discovery Neuroloy</TD><TD STYLE="text-align: left; width: 6%">&nbsp;</TD><TD STYLE="text-align: justify; width: 3%">Title:&nbsp;</TD>
                                                                                      <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 44%">Authorized
                                            Director</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616"><U>Licensed Patent Rights</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616"></P>

<!-- Field: Page; Sequence: 33; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #161616">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"><U>Existing Product</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #161616"><B><U>Exhibit C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #161616">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #161616"><U>Licensed Technology</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #161616">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Qualified Study Example</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1in 0pt 0.1in"><B><U>THE FOLLOWING QUALIFIED STUDY EXAMPLE IS CONFIDENTIAL
INFORMATION OF BIOGEN IDEC</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.1in 0pt 0.1in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"><B><U>Exhibit E</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center"><B><U>Upstream Agreements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0E0E0E"><B><U>Exhibit F</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0E0E0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0E0E0E"><B><U>Additional Agreements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: center; color: #0E0E0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>18
<FILENAME>filename18.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.7</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv)&nbsp;because
it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is
indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNIVERSITY HEALTH NETWORK LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement made as of the 4th day of April&nbsp;2006
(the &#8220;Effective Date&#8221;) between the following Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNIVERSITY
HEALTH NETWORK</B></FONT> an Ontario corporation incorporated by special statute under the <I>Toronto Hospital Act, 1997</I>, having a
principal office at 610 University Ave 7-504 Toronto, Ontario M5G 2M9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(hereinafter referred to as &#8220;UHN&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-AND-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AMORFIX
LIFE SCIENCES INC.</B></FONT> a Canada corporation with offices located at 3080 Yonge St., Suite&nbsp;6020 Toronto, Ontario, M4N 3M1,
Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(hereinafter referred to as the &#8220;Licensee&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BACKGROUND:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
Neil Cashman (&#8220;Cashman&#8221;) while employed at the University of Toronto (&#8220;UT&#8221;) together with Avi Chakrabarrty and
Rishi Rakhit, coinventors from UHN (&#8220;UHN-Coinventors&#8221;), have invented an SOD1 exposed dimer interface antibody (&#8220;Technology&#8221;),
and have filed a US Provisional Patent application through UHN entitled &#8220;Methods and Compositions for Detecting Amyotrophic Lateral
Sclerosis&#8221; on December&nbsp;2nd, 2005 (the &#8220;Patent&#8221;) attached as Schedule A; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
Cashman disclosed the Technology to UT by way of an invention disclosure form, attached as Schedule B, (&#8220;UT Invention Disclosure&#8221;)
on February&nbsp;14, 2006; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
Cashman in the UT Invention Disclosure defined his inventive contributions and participation in the creation of the Technology (&#8220;Cashman-IP);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
subject to reserved rights by UT to use the Cashman-IP for teaching and administrative purposes and under UT Invention Policy, UT on March&nbsp;29,
2006 approved for Cashman to sell the rights to Cashman-IP to the Licensee; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
UHN owns a portion of the Technology (&#8220;UHN-IP&#8221;), as defined in UHN Invention Disclosure dated November&nbsp;16, 2005; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
Licensee, subject to approval by Toronto Stock Venture Exchange, wishes to commercialize, develop, manufacture, market, distribute and
sell products which may be derived in whole or in part from the practice of the Technology and therefore desires to obtain a license to
UHN&#8217;s ownership rights in the Technology; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>
UHN is willing to grant a license under the terms and conditions set forth hereinafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW
THEREFORE THIS AGREEMENT WITNESSES</B></FONT> that in consideration for the mutual promises, representations, covenants and agreements
of the Parties contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Parties agree as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;1.0
- INTERPRETATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Defined Terms</B>. For the purposes of this Agreement, unless the context otherwise requires, the following
terms shall have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&#8220;<B>Agreement</B>&#8221; means this agreement and all Schedules attached hereto, and the terms &#8220;herein&#8221;,
 &#8220;hereunder&#8221;, &#8220;hereto&#8221; and such similar expressions shall refer to this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&#8220;<B>Confidential Information</B>&#8221; of a party means any and all information of a Party and/or
any of its affiliates (in this definition called the &#8220;Disclosing Party&#8221;) which has or will come into the possession or knowledge
of the other Party and/or any of its affiliates (in this definition called the &#8220;Recipient Party&#8221;) in connection with or as
a result of entering into this Agreement including information concerning the Disclosing Party&#8217;s past, present and future customers,
suppliers, technology, markets, research and business. For the purposes of this definition, &#8220;Confidential Information&#8221; includes
any and all Intellectual Property, Technology, Product, commercial, research, scientific, customer, or market information, analyses or
conclusions drawn or derived therefrom, this Agreement and information developed or disclosed hereunder, or any Party&#8217;s raw materials,
processes, formulations, analytical procedures, methodologies, products, samples, specimens, functions, Know-how, data, patents, copyrights,
trade secrets, processes, techniques, programs, designs, formulae, marketing, advertising, financial, commercial, sales or programming
materials, written materials, compositions, drawings, diagrams, computer programs, studies, work in progress, visual demonstrations, ideas,
concepts, and other data, in oral, written, graphic, electronic, or any other form or medium whatsoever;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&#8220;<B>Contract Year</B>&#8221; means each successive twelve calendar month period during the term
of this Agreement. The first Contract Year shall begin on the Effective Date of this Agreement. The last Contract Year shall end on the
day this Agreement expires, or is earlier terminated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&#8220;<B>First Commercial Sale</B>&#8221; means the first sale of a Licensed Product and Services using
the Technology in the Territory (as hereinafter defined), by Licensee or its affiliates (or their sub-licensee(s)) to any third party
as evidenced by an invoice or other relevant document to such third party;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&#8220;<B>Funded Research</B>&#8221; means a pending Sponsored Research Agreement (&#8220;SRA&#8221;)
between UHN and Licensee to develop Improvements by UHN at a gross estimated budget of $200,000, excluding the 30% institutional overhead
costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&#8220;<B>Gross Revenue</B>&#8221; means gross amount invoiced by Licensee or others on its behalf for
all Products and Services using the Technology. Any Products and Services used by the Licensee or by a non-arms-length third Party shall
be deemed to be invoiced for the fair market value of the Product or Service. Gross Revenue does not include any Products or Services
used by Licensee or non-arms-length third party prior to the First Commercial sale in a given territory;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&#8220;<B>Including</B>&#8221; means including without limitation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&#8220;<B>Improvements by UHN</B>&#8221; means any and all improvements related to Amyotrophic Lateral
Sclerosis (ALS), whether patentable or not, arising from a Funded Research agreement by Amorfix (&#8220;Funded Research&#8221;) to the
Technology developed at UHN by or under the direction of <B>Avi Chakrabarrty</B> after the date of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&#8220;<B>Intellectual Property</B>&#8221; mean inventions, discoveries, written material, compounds,
patentable and unpatentable information, Know-how, trade secrets, copyright, designs, plant breeders&#8217; rights, integrated circuit
topographies, ideas (including but not limited to any computer software), formulae, algorithms, concepts, proprietary data, techniques,
instructions, processes, expert opinions, information, Materials, program listings, flow charts, logic diagrams, manuals, specifications,
instructions, or any copies of the foregoing in any medium, or the expression thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&#8220;<B>Intellectual Property Rights</B>&#8221; means any rights in Intellectual Property, including
ALS-related rights arising from the Funded Research, any regular or provisional patent applications filed in the U.S., Canada or any other
jurisdiction, divisions, continuations, patents issuing thereon or renewals, or reissues, and any and all patents and patent applications
in other countries corresponding thereto for the Technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">&#8220;<B>Know-how</B>&#8221; means any information pertaining to the Technology which is not disclosed
in a patent or published patent application. Know-how, as used herein, includes trade-secrets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&#8220;<B>License</B>&#8221; shall have the meaning provided in Section&nbsp;2.1;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&#8220;<B>Materials</B>&#8221; means any materials pertaining to the Technology which is disclosed and/or
provided to the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">&#8220;<B>Net Sales</B>&#8221; means the Gross Revenue received by the Licensee net of standard industry
discounts, refunds, returns, written-off bad debts and taxes, all as determined from the books and records of the Licensee, or its parent
and subsidiaries, maintained in accordance with Canadian generally accepted accounting principles consistently applied;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">&#8220;<B>Notice</B>&#8221; shall have the meaning provided in Section&nbsp;13.0;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">&#8220;<B>Parties</B>&#8221; means UI-IN and the Licensee collectively and &#8220;Party&#8221; means each
individually;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">&#8220;<B>Product</B>&#8221; means any product that includes, in whole or in part, the Technology and/or
is manufactured using the Technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">&#8220;<B>Publication</B>&#8221; means any means of making available to the public information by way
of speech, talk, paper, drawing, photograph, printed work, tape, video recording or other electronic means, or any other disclosure given
or distributed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">&#8220;<B>Quarter Yearly Period</B>&#8221; means each successive three calendar month period during the
term of this Agreement ending January&nbsp;31, April&nbsp;30, July&nbsp;31 and October&nbsp;31 of each Contract Year. The first and last
Quarter Yearly Periods may be less than three calendar months and will commence on the Effective Date of this Agreement and terminate
on the date this Agreement expires or is earlier terminated respectively;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">&#8220;<B>Service</B>&#8221; means any service provided using, in whole or in part, the Technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">&#8220;<B>Technology</B>&#8221; means all allowed claims in Intellectual Property in and to the invention
described in and/or listed in Schedule &#8220;A&#8221; and all Intellectual Property Rights related to or arising therefrom, excluding
Improvements by UHN and Improvements by Licensee; and,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">&#8220;<B>Territory</B>&#8221; means the World.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Sections and Headings</B>. The division of this Agreement into articles, sections and subsections and
the insertion of headings are for reference purposes only and shall not affect the interpretation of this Agreement. Unless otherwise
indicated, any reference herein to a particular article, section, subsection or Schedule refers to the specified article, section or subsection
of or Schedule to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Number, Gender and Persons</B>. In this Agreement, words importing the singular number shall include
the plural and vice versa, words importing gender shall include all genders and words importing persons shall include individuals, corporations,
partnerships, associations, trusts, unincorporated organizations, governmental bodies and other legal or business entities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Currency</B>. All monetary amounts in this Agreement are in Canadian funds.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.5</B></FONT></TD><TD STYLE="text-align: justify"><B>Schedules</B>. The following Schedules are annexed to and form part of this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Schedule A &#8211; Patent<BR>
Schedule B - UT Invention Disclosure<BR>
Schedule C Considerations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.6</B></FONT></TD><TD STYLE="text-align: justify"><B>Accounting Principles</B>. Any reference in this Agreement to generally accepted accounting principles
refers to generally accepted accounting principles as approved from time to time by the Canadian Institute of Chartered Accountants or
any successor institute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.7</B></FONT></TD><TD STYLE="text-align: justify"><B>Best of Knowledge</B>. &#8220;To the best of the knowledge&#8221; or &#8220;to the knowledge&#8221;,
unless otherwise qualified hereunder means a statement of the declarent&#8217;s knowledge of the actual facts or circumstances to which
such phrase relates without having made any inquiries or investigations in connection with such facts and circumstances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;2.0
- GRANT OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Licensee</B>. Subject to the terms and conditions of this Agreement, UHN grants to Licensee an exclusive,
license in any and all its rights to the Technology, including to manufacture, have manufactured, sell or have sold, and use the Technology,
and to produce and reproduce work in the Technology or any substantial part thereof in the Territory, unless otherwise restricted by law
(the &#8220;License&#8221;). The License will only be transferable by the Licensee with the whole business of the Licensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Buyout Option</B>. Licensee is granted a buyout option where UHN shall assign its commercial rights
to the Technology to Licensee in exchange for a lump sum payment. The monetary amount is defined in Schedule C. Briefly, the buyout amount
is $180,000 less any previous milestone payment(s)&nbsp;for diagnostic righs and $800,000 less any previous milestone payment(s)&nbsp;for
ALS-related therapeutic rights. Licensee shall pay UHN at the time of the execution of the assignment documents. This buyout option for
the diagnostic shall terminate upon the first diagnostic Product approval in Canada, USA, Europe or Japan and the option for the therapeutic
applications shall terminate upon initiation of the first Phase III clinical trial in any jurisdiction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Restriction</B>. The License granted to the Licensee under Section&nbsp;2.1and the assignment under
Section&nbsp;2.2 herein is subject to UHN&#8217;s retention of its rights to use the Technology and Improvements by UHN without charge
solely for research, scholarly publication, educational or other non-commercial use, subject to the Confidential Information provisions
of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Improvements by UHN</B>. UHN will notify the Licensee, in writing, of all ALS- related
                                                                                                                                  Improvements related to the Technology or arising from the Funded Research within fourteen (14) days from the date of a UHN
                                                                                                                                  Invention Disclosure (&#8220;Notice of Disclosure&#8221;). Licensee will have sixty (60) days after receiving the written Notice of
                                                                                                                                  Disclosure to notify UHN its intent, in writing, to license
said improvement (.&#8221;Notice of Intent&#8221;) If UHN does not receive a Notice of Intent within sixty (60) days, UHN will be free
to dispose of the Improvement by UHN as it sees fit. After a Notice of Intent has been received, an Amendment shall be made such that
these Improvements will be included under the definition of Technology and terms hereunder. In the event that the technologies that are
not ALS-related arose from Funded Research, Licensee shall have the first right of refusal to negotiate a new license within sixty (60)
days from a written notice of UHN Invention Disclosure. Any such license shall be on terms and conditions that are consistent with other
such licenses within the industry and satisfactory to UHN.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.5</B></FONT></TD><TD STYLE="text-align: justify"><B>Sublicenses</B>. The Licensee shall have the right to grant sublicenses or cross-licenses that are
consistent with and no less favorable than the terms of this Agreement and that the sublicensee consents to be bound by the terms and
obligations of this Agreement as if it were a Party hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.6</B></FONT></TD><TD STYLE="text-align: justify"><B>Technology Milestones and Best Efforts</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Licensee shall use best efforts to meet the following technical milestones for development of the Technology:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Year
2:</B></FONT><BR>
Develop assay to determine presence of DSE (&#8220;DSE&#8221; defined in the Patent as SED epitope) in human Cerebro-Spinal Fluid (&#8220;CSF&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Year
3:</B></FONT><BR>
Develop assay to determine presence of DSE in human blood</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Year
4:<BR>
</B></FONT>Submit CSF or blood DSE assay for FDA regulatory evaluation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.7</B></FONT></TD><TD STYLE="text-align: justify">Failure to meet the milestones as set out in Section&nbsp;2.6(a)&nbsp;or pay milestone payments due under
Schedule C may result in termination of this Agreement, at UHN&#8217;s option and upon sixty (60) days notice to the Licensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.8</B></FONT></TD><TD STYLE="text-align: justify">The Licensee shall use best efforts to develop, commercialize and/or market the Technology licensed herein
and to maximize Net Sales.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;3.0
- CONSIDERATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Consideration</B>. In consideration of the License granted herein, Licensee agrees to make payments
to UHN according to Schedule C.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Date of Sale</B>. Products and Services will be deemed sold 60 days after product is shipped by Licensee
and invoiced</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Interest</B>. All monies payable to UHN by Licensee hereunder and not paid when due bear interest at
the prime rate of interest quoted by the Bank of Canada, plus [***]% ([***] percent) per annum until the date paid
to UHN. UHN will be entitled to that interest in addition to any other rights or remedies available to it in respect to default in payment
by Licensee.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Withholdings</B>. In the event that the Licensee is required by any law to withhold and/or make payments
to tax authorities in respect of any payments payable by Licensee to UHN under this Agreement, the liability of Licensee under this Agreement
shall be to that extent satisfied, and such amounts shall be deemed to have been paid to UT-IN on their due dates, provided that Licensee
shall furnish to URN acceptable evidence of such payments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.5</B></FONT></TD><TD STYLE="text-align: justify"><B>Royalty Report</B>. The Licensee shall prepare a report (the &#8220;Royalty Report&#8221;), setting
out the Gross Revenue, the number of Products manufactured, and Services rendered, an itemized statement of all costs and disbursements
and the Net Sales, if any, for the relevant period. For so long as the Gross Revenue of the Licensee is less than $10,000 in any consecutive
12-month period, the Licensee shall prepare one Royalty Report for every 12-month period. If no payments are due for any reporting period,
then the Royalty Report shall so state. Once the Gross Revenue of the Licensee is at least $10,000 in any consecutive 12-month period,
the Licensee shall prepare a Royalty Report for each Quarter Yearly Period. Royalty Reports are due within thirty (30) days of the end
of the reporting period being reported.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.6</B></FONT></TD><TD STYLE="text-align: justify"><B>Complete Records</B>. The Licensee shall keep true and accurate records and hooks of account containing
all data reasonably required for the computing of an verification of all payments owed by Licensee to UHN hereunder, including records
for Gross Revenue, the number of Products manufactured and Services rendered, costs/disbursements, Net Sales in accordance with generally
accepted accounting principles. Such records shall be maintained by the Licensee for at least six (6)&nbsp;years from the date of the
payment to which such records are relevant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.7</B></FONT></TD><TD STYLE="text-align: justify"><B>Inspection of Records</B>. The records specified in this Agreement shall be available for inspection
to UHN or its duly appointed auditor for the sole purpose of verifying payments owed under this Agreement, during normal business hours
at the principal place of business of the Licensee, upon reasonable notice to the Licensee. The costs of any such inspection shall be
borne by UHN unless the report of an auditor shows that the Royalty Report was understated by more than five percent (5%), in which case
the costs of the examination shall be paid by the Licensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.8</B></FONT></TD><TD STYLE="text-align: justify"><B>Discrepancy in Records</B>. In the event the said inspection conducted under Section&nbsp;3.7 herein
reveals any underpayment of royalties due to UHN, Licensee will promptly pay UHN the full amount of that underpayment together with interest
thereon at the rate of interest referred to in Section&nbsp;3.3 herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.9</B></FONT></TD><TD STYLE="text-align: justify"><B>Patent Expiry</B>. Subject to earlier termination as set forth in the Agreement, payment of royalties
shall cease in any one country on the date when the last of the patents issued on the Technology expires in such country.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;4.0
- WARRANTIES AND COVENANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.1</B></FONT></TD><TD STYLE="text-align: justify"><B>UHN Warranties</B>. UHN represents and warrants to the Licensee that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">UHN is duly incorporated and organized and validly existing under the laws of Ontario and has all requisite
corporate power and authority to enter into and perform its obligations under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">UHN has taken all necessary corporate action, steps and proceedings to approve or authorize, validly and
effectively, the execution and delivery of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Licensee Warranties</B>. The Licensee represents and warrants to UHN that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Licensee is duly incorporated and organized and validly existing under the laws of Canada and has
all the requisite corporate power and authority to enter into and perform its obligations under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Licensee has taken all necessary corporate action, steps and proceedings to approve or authorize,
validly and effectively, the execution and delivery of this Agreement and the performance of its obligations hereunder and to cause all
necessary meetings of directors and shareholders of the Licensee to be held for such purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the execution and delivery of this Agreement by the Licensee and the performance of its obligations hereunder
shall not result in either a breach or violation of any of the provisions of, or constitute a default under, or conflict with or cause
the acceleration of any obligation of the Licensee under:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">any agreement to which the Licensee is a party or bound by;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">any of the terms and provisions of the constating documents or by-laws, or resolutions of the board of
directors (or any committee thereof), of the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">any judgment, decree, order or award of any court, governmental body or arbitrator having jurisdiction
over the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">any license, permit, approval, consent or authorization held by the Licensee; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">any applicable law, statute, ordinance, regulation or rule;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Limited Warranties</B>. EXCEPT AS OTHERWISE EXPRESSLY SET OUT IN THIS AGREEMENT:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">URN EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED OR EXPRESS WARRANTIES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES
OF MERCHANTABILITY, SAFETY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE TECHNOLOGY;</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">UHN DOES NOT WARRANT OR REPRESENT THAT ISSUED PATENTS, OR PENDING PATENT APPLICATIONS WILL ISSUE, OR WHEN
ISSUED WILL BE VALID, OR THAT THE PRACTICE OF ANY TECHNICAL INFORMATION OR KNOW-HOW DISCLOSED TO LICENSEE PURSUANT TO THIS AGREEMENT DOES
NOT CONSTITUTE INFRINGEMENT OF RIGHTS OF PERSONS NOT PARTIES HERETO. NOTWITHSTANDING THE FOREGOING, UHN WARRANTS THAT IT HAS NOT KNOWINGLY
GRANTED RIGHTS ESSENTIALLY SIMILAR TO THIS LICENSE TO PERSONS NOT PARTIES HERETO-;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">UHN SHALL NOT BE LIABLE TO THE LICENSEE FOR ANY DAMAGE,&nbsp;INCLUDING ANY DIRECT,&nbsp;INDIRECT, SPECIAL
OR CONSEQUENTIAL DAMAGE SUFFERED BY THE LICENSEE RESULTING FROM THE USE OF THE TECHNOLOGY LICENSED HEREIN. FURTHER, UHN MAKES NO REPRESENTATION
THAT THE TECHNOLOGY LICENSED HEREIN IS FREE FROM DEFECT OR LIABILITY OF INTELLECTUAL PROPERTY INFRINGEMENT; AND</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">UHN&#8217;S ENTIRE LIABILITY TO THE LICENSEE FOR DAMAGES OR ALLEGED DAMAGES HEREUNDER, WHETHER IN CONTRACT,
TORT OR ANY OTHER LEGAL THEORY,&nbsp;IS LIMITED TO, AND WILL NOT EXCEED AN AMOUNT EQUAL TO THE SUM OF TOTAL ROYALTIES PAID BY THE LICENSEE
TO UHN IN THE MOST RECENT 4 CONSECUTIVE QUARTER YEARLY PERIODS UNDER SECTION&nbsp;3.1(I)&nbsp;HEREOF.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Licensee Covenants</B>. The Licensee covenants and agrees for the benefit of UHN that it shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">exercise the License granted herein in accordance with all applicable laws, statutes, ordinances, regulations,
guidelines and rules, including, all applicable statutes and regulations and applicable guidelines set forth by the Canadian Institutes
of Health Research (CIHR), National Institutes of Health (NIH) or other governmental agencies where applicable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">ensure that all employees, consultants, sublicensees, and any other persons having access to the subject
matter of this Agreement are aware of any and all obligations under this Agreement, including any and all confidentiality obligations,
and have agreed to be legally bound by them;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">cause to be applied to pertinent papers denoting any Products or Services that same are produced or rendered
under license from UHN;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">cause to be applied to Products and Services where appropriate any markings required by applicable government
statutes and laws to maintain continued validity and enforcement of Intellectual Property
Rights and will confirm to UHN that such markings are required and if so, will confirm that same are being adhered to;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">include terms and conditions in any agreement with its customers in connection with the Products and/or
Services relating to the Technology limitations of representations, warranties and conditions, limits of liability and indemnities from
its customers and users which extend the benefit of such provisions to UHN; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;5.0
- MANAGEMENT OF INTELLECTUAL PROPERTY RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Registration by UHN</B>. UHN shall partially own all applications and registrations for Intellectual
Property Rights for the Technology, as defined in UHN Invention Disclosure and own all rights to Improvements made solely by UHN. Licensee
shall be responsible for the preparation, filing, prosecution and maintenance of patent applications.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Patent Cooperation</B>. The Licensee shall have the right to identify any process, use or products
relating to the Technology arising out of the Licensee&#8217;s Development Program, and/or any jurisdiction in which, in the opinion of
the Licensee, a patent is necessary, and UHN shall, upon receipt of such request from the Licensee, take all reasonable steps to cooperate
with the Licensee in the applications and filing of patents, provided that the Licensee pays all costs of applying for, registering, and
maintaining any such patents in any jurisdiction in which the Licensee determines that a patent is required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Information to UHN</B>. Licensee will keep the UHN promptly informed of all patent applications and
registrations by Licensee filed in accordance with Section&nbsp;5.1 and 5.2 hereof, and the UHN shall have the right to comment on such
applications within the timeframes of the patent filing process and deadlines. Licensee will endeavor to use all such comments of the
UHN where practical and reasonable to modify such applications.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Cooperation and Notice</B>. Each Party shall cooperate with the other Party fully in the preparation,
filing, prosecution and maintenance of any applications and registrations for Intellectual Property Rights under Article&nbsp;5 hereof,
including executing all papers and instruments required in order to enable either Party to apply for, to prosecute and to maintain applications
and registrations in any country. Each Party shall provide to the other prompt notice as to all matters which come to its attention and
which may affect the preparation, filing, prosecution or maintenance of any such applications or registrations, and shall at all times
keep the other fully and promptly informed of all developments in the preparation, filing, prosecution and maintenance of any such applications
or registrations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.5</B></FONT></TD><TD STYLE="text-align: justify"><B>Costs</B>. The Licensee as of the Effective Date, shall assume all prior and future costs associated
with the filing, maintenance, and prosecution of Intellectual Property Rights licensed to it under this Agreement, including for all patent
and patent applications. Licensee will reimburse UHN for any and all such actual and reasonable documented costs incurred by UHN prior
to the date of this Agreement (the &#8220;Prior Patent Costs&#8221;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.6</B></FONT></TD><TD STYLE="text-align: justify"><B>Infringement</B>. If any infringement or threatened infringement of the Intellectual Property Rights
under this Agreement is perceived by UHN or Licensee, the said Party will immediately notify the other Party giving particulars thereof.
The Parties shall co-operate fully in the enforcement of any Intellectual Property Rights. Licensee shall have carriage and authority
over the commencement, conduct and settlement of any infringement action against a third party, however; Licensee shall consult with UHN
prior to such decisions. The Parties shall agree on any course of action taken.The Licensee shall be responsible for all reasonable costs,
including legal fees, disbursements and awards by the Court against UHN or the Licensee pertaining to the enforcement of any Intellectual
Property Rights. Any monies awarded to Licensee as result of any action or settlement shall first go to reimburse the Licensee for the
costs. Any remainder monies shall then be treated as Net Sale income and UHN shall receive a royalty according to rates defined in Schedule
C.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.7</B></FONT></TD><TD STYLE="text-align: justify"><B>No Actions</B>. Licensee agrees not to knowingly take any action which would jeopardize the obtaining
or maintaining of UHN&#8217;s Intellectual Property Rights relating to the Technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.8</B></FONT></TD><TD STYLE="text-align: justify"><B>No Challenges</B>. The Licensee shall not challenge the validity of any of UHN&#8217;s Intellectual
Property Rights under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;6.0
- CONFIDENTIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Confidentiality</B>. The Licensee shall take all proper measures, and at least the same measures as
it takes in respect of its own Confidential Information, to keep confidential the Confidential Information of UHN. The Licensee will ensure
that everyone having access to the Confidential Information is under a legal obligation to maintain such Confidential Information in confidence
and is duly informed of this obligation. The Licensee will neither use nor disclose to any other party any of the Confidential Information
except as expressly permitted hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Exceptions</B>. The above obligations of confidentiality set forth in this section, shall not apply
to information and materials which:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">are part of the public domain, or becomes part of the public domain without breach of Section&nbsp;6.1
herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">are obtained from a third party who is not under a duty of confidentiality respecting the Confidential
Information and the third party has a legal right to disclose it;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">are required to be disclosed by law or an order of a court, tribunal, or government agency, but the receiving
Party shall promptly notify the disclosing Party and give the disclosing Party a reasonable opportunity to seek a confidentiality order
or the like;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">identified in writing as no longer constituting Confidential Information, by the Party whose Confidential
Information it is to the Party to which it was disclosed; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">already known at the time of disclosure thereof to the Party to which it is disclosed, such that Party
can show by written records was so already known.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Disclosure to Advisors</B>. Notwithstanding the confidentiality obligations herein, each Party shall
be permitted to disclose the terms of this Agreement without the prior written consent of the other Party to advisors, shareholders, investors,
potential investors, underwriters and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof,
or to the extent required by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;7.0
- PUBLICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Publications</B>. At the request of UHN or Licensee respectively, the Licensee or UHN shall acknowledge
the contribution and ownership of UHN and/or Licensee to the Technology,&nbsp;Improvements by UHN or Improvements by Licensee, as the
case may be. No Publication by a Party shall disclose the Confidential Information of the other Party without prior written consent of
that Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;8.0
- TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Term</B>. Except as otherwise specifically provided for herein or mutually agreed to by the Parties,
this Agreement and all the rights and obligations hereunder shall remain in full force and effect until the expiry of the last patent
issued on any of the Technology under License in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Events of Termination</B>. This Agreement shall terminate:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">at least one day prior to the occurrence of any of the following events:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Licensee files a voluntary petition in bankruptcy or insolvency or shall petition for reorganization
under any bankruptcy law, or makes a general assignment for the benefit of creditors, or otherwise acknowledges insolvency or is adjudged
bankrupt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Licensee shall consent to an involuntary petition in bankruptcy or if a receiving order is given against
it under the <I>Bankruptcy and Insolvency Act</I> (or such other equivalent Act in the respective jurisdiction); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the appointment of a receiver or other similar representative for the Licensee by a court of competent
jurisdiction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">at the discretion of UHN, UHN can immediately effect termination of this Agreement upon notice to
                                                               the Licensee, if the Licensee materially breaches any of its obligations under this Agreement including payment of royalties and
                                                               other considerations as required under Section&nbsp;3.1,
and fails to, refuses to, or cannot remedy the breach within hundred and twenty (120) days after being given written notice thereof by
UHN in accordance with Section&nbsp;13 hereof; or</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">at the end of the Term as defined in Section&nbsp;8.1 or earlier if by mutual consent under Section&nbsp;8.3</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Termination by Mutual Consent</B>. UHN and the Licensee may terminate this Agreement at any time by
mutual consent, which consent shall be evidenced by a written agreement duly executed by both Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Obligations on Insolvency</B>. In the event that this Agreement is terminated for insolvency as described
in Section&nbsp;8.2, the License and any sublicenses or cross-licenses granted in accordance with this Agreement will be automatically
terminated, and all rights of use of the Technology and Intellectual Property granted by UHN to the Licensee, or granted by the Licensee
by way of sublicenses to sublicensees or cross-licenses to cross-licensees, shall revert to UHN. Notwithstanding exercise of the Buyout
Option under section 2.2, UHN-IP and Improvements by UHN shall not in any manner form part of the assets of the Licensee or the assets
of any cross-licensee or sublicensee of the Licensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;9.0
- EVENTS UPON TERMINATION/POST-TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Post-Termination. In the event
of termination of this Agreement:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding provisions of section 2.2, the Licensee shall cease and desist any use of the subject
matter licensed under this Agreement and within thirty (30) days upon the request of UHN and in its sole discretion, destroy or return
to UHN all of UHN&#8217;s property, including all UHN-IP and Confidential Information belonging to UHN, and cease to make, use, sell,
or reproduce any or otherwise benefit from the UHN-IP or Improvements made solely by UHN. The Licensee; however, is entitled to keep one
copy for archival purpose;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Licensee shall within thirty (30) days of the termination, pay UHN all payments pursuant to Article&nbsp;3
hereunder due by the day of termination;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">all sublicenses or cross-licenses granted by the Licensee in relation to the UHN-IP and/or Improvements
by UHN shall terminate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">each Party shall take all necessary steps in a prudent business manner to effect the orderly termination
of this Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the Licensee, and any sublicensees or cross-licensees, may continue to sell any existing stock of any
Products manufactured or Services offered under License at fair market value and pay UHN royalties according to Article&nbsp;3 herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.2</B></FONT></TD><TD STYLE="text-align: justify"><B>Survival</B>. The Parties agree the provisions of Articles 1, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14 in
their entirety and Sections 3.2-3.8 shall remain in force and effect after the termination of this Agreement, until such time as the Parties
mutually agree to the release of the obligations contained therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;10.0
- INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Indemnification</B>. The Licensee for and in consideration of and as a condition to the granting of
this License, agrees to indemnify, save harmless, and defend UHN, its directors, officers, researchers, inventors, employees, students,
and agents, against any and all claims, suits, losses, damages, costs, fees, and expenses (including reasonable legal expenses), resulting
from and arising out of this Agreement including but not limited to any product liability and Intellectual Property infringement or alleged
infringement claims and any damages, losses, or liabilities, whatsoever with respect to death or injury to any person and damage to any
property arising from this Agreement and the License granted herein, including the manufacture, design, distribution, offer for sale,
of Products, materials, processes, information, or Technology produced in the course of or used in the results of any subject matter arising
under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;11.0
- INSURANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.1</B></FONT></TD>
<TD STYLE="width: 0.5in">(a)&nbsp;</TD><TD STYLE="text-align: justify"><B>Licensee Insurance</B>. No later than thirty (30) days prior
to the first use of Technology in humans, the Licensee, at Licensee&#8217;s expense, shall obtain and maintain appropriate general liability
and product liability insurance (the &#8220;Licensee Insurance&#8221;) at an overall level, incident level, and deductible amount as
are standard in the industry at such time (but in no case will the incident level be less than two (2)&nbsp;million and the overall level
be less than two (2)&nbsp;million) naming both the Licensee and UHN as co-insured. The Licensee shall provide to UHN a Certificate of
Insurance evidencing compliance with this provision within thirty (30) days prior to such first use and, in no event, shall the Licensee
use the Technology in humans prior to the delivery to UHN of the Certificate of Insurance. The Licensee shall, at its own expense, obtain
and maintain from the date required by this 11.1 (a)&nbsp;until the end of the Term of this Agreement (as described in Article&nbsp;8
hereof) and for a period of six (6)&nbsp;years thereafter, the Licensee Insurance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B>Sublicensees&#8217; Insurance</B>. The Licensee shall ensure that all approved sublicensees or cross-licensees,
at the sublicensees&#8217;, cross-licensees&#8217; or Licensee&#8217;s expense, obtain and maintain appropriate liability insurance at
a level commensurate with the Licensee Insurance, naming both the Licensee and UHN as co-insured. The Licensee shall provide to UHN a
Certificate of Insurance evidencing compliance with this provision, within thirty (30) days prior to the first use of the Technology in
humans under any sublicense or cross-license agreement. The Licensee shall ensure that in no event, shall the sublicensee or cross-licensee
use the Technology in humans under this or any sublicense or cross-license agreement prior to the delivery to UHN of the Certificate of
Insurance. The Licensee shall ensure that sublicensees or cross-licensees, as the
case may be and at no expense to UHN, obtain and maintain from the date required in by this Section&nbsp;11.1 (b)&nbsp;until the end of
the Term of this Agreement and for a period of six (6)&nbsp;years thereafter, a policy of appropriate liability insurance at a level commensurate
with the Licensee Insurance.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B>Qualified Insurance</B>. All insurance policies required in accordance with this Section&nbsp;11.1
shall be obtained from a qualified insurance company licensed to do business in the jurisdictions governed by this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B>Notice</B>. All insurance policies required in accordance with this Section&nbsp;11.1 shall provide
for fifteen (15) business days written notice by the insurer to the Licensee and UHN by registered or certified mail in the event of any
modification, cancellation or termination of such insurance policy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><B>Copy of Policy</B>. The Licensee shall, on written request, provide UHN with a copy of the insurance
policy in force at the time of the request and this provision shall survive the termination or expiration of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><B>Incomplete Insurance</B>. In the event the Licensee is unable to obtain the insurance coverage required
by this Article, or if any portion of the Licensee Insurance or other required coverage is cancelled and not immediately replaced, the
Licensee shall promptly inform UHN and UHN may at its sole option maintain such insurance as it reasonably considers necessary, at the
expense of the Licensee. If UHN is unable or unwilling to secure such insurance as it reasonably considers necessary and the Licensee
continues to use the Technology in humans, then UHN shall be free to terminate this Agreement in accordance with Section&nbsp;8.2(b)&nbsp;hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;12.0
- DISPUTE RESOLUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of any dispute, controversy or claim
among the Parties arising out of or in connection with this Agreement, or the breach thereof, or in respect of any defined legal relationship
associated therewith or derived therefrom, the Parties agree to resolve the dispute in accordance with the following procedures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.1</B></FONT></TD>
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Good Faith Negotiations</B>. A Party may notify the other Party in writing that a dispute has
arisen. The Parties will, in the first instance, attempt to resolve the dispute, controversy, claim or allegation of breach by entering
into good faith negotiations. The Parties shall meet to attempt, in good faith, to resolve the dispute by negotiation, either directly
or through the assistance of such advisors as they may engage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If, within seven (7)&nbsp;days, the Parties do not reach agreement on the resolution of the dispute, the
Parties agree to proceed to mediation as set out in Section&nbsp;12.2 below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.2</B></FONT></TD>
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Mediation</B>. Subject to Section&nbsp;12.1, the Parties shall mediate their dispute before
a mediator who is a member of Ontario&#8217;s Mandatory Mediation Program Roster of mediators. If the Parties fail to agree on a mediator
within fourteen (14) days after the decision to proceed to mediation, either Party may apply to a court of competent jurisdiction to appoint
an appropriately qualified mediator.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Mediation shall be carried out by the mediator within twenty-one (21) days of the mediator&#8217;s appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.3</B></FONT></TD>
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>Arbitration</B>. Subject to Sections 12.1 and 12.2, if the Parties fail to resolve their dispute
within seven (7)&nbsp;days of the start of the mediation, the Parties will appoint an arbitrator who will conduct an arbitration of the
dispute. If the Parties cannot agree on a mutually acceptable arbitrator within seven (7)&nbsp;days of the decision to proceed to arbitration,
either Party may apply to a court of competent jurisdiction to appoint an appropriately qualified arbitrator.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The arbitration shall be conducted in accordance with the Arbitration Act, 1991 (Ontario) and the arbitrator
shall also be empowered to hear injunctive proceedings in accordance therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Notwithstanding Section&nbsp;12.4 below, the arbitrator may include in its award an order as to the payment
of the costs of the proceedings and reasonable counsel fees. Any Party ordered to pay costs may avail itself of any procedure for the
taxing of costs, provided, however, that the Parties specifically agreed that the officer taxing such costs need not be bound by any statutory
scale of costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The arbitrator will make its decision in writing within fifteen (15) days of the hearing and, unless the
Parties otherwise agree, the arbitrator&#8217;s reasons will be set out in the award. The award shall be final and binding on the Parties
and shall not be subject to any appeal although either Party may request clarification of the award and the arbitrator&#8217;s reasons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Parties consent to the award of the arbitrator being entered in any court having jurisdiction for
the purposes of enforcement. In addition, if it appears to any Party that the arbitrator lacks the power to give effective interim relief,
such Party may apply to any appropriate court for such relief.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">All matters in dispute, all claims, submissions, evidence and findings, and the award itself shall be
kept confidential by the arbitrator, and no information regarding any of the foregoing will be released to any third party or otherwise
made public without the written consent of the Parties, except as otherwise contemplated herein and except for such information which
is not Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">The Parties may with mutual consent, expand or abridge the time periods provided for in this Section&nbsp;12.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.4</B></FONT></TD>
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B>General</B>. Subject to the immediately following sentence, the expenses of the mediation or
arbitration shall be borne equally by the Parties{ unless otherwise determined by}. Notwithstanding the foregoing, the mediator or arbitrator
may include in his or her award an order as to the payment of the costs of the proceedings and reasonable counsel or other advisor fees.
Any party ordered to pay costs may avail itself of any procedure for the taxing of costs, provided, however, that the parties specifically
agree that the officer taxing such costs need not be bound by any statutory scale of costs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">All meetings and hearings will be in private unless the Parties otherwise agree.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Any Party may be represented at any meetings or hearings by legal counsel or any other advisor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.5</B></FONT></TD><TD STYLE="text-align: justify">Termination under Article&nbsp;8.2 and/or for inadequate insurance under Article&nbsp;11 shall not be
subject to Article&nbsp;12.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;13.0
- NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>13.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Notice</B>. All Notices which are required or permitted to be given hereunder including judicial payment
notices must be in writing. All such Notices must be sent as follows:</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">to UHN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in">Attention :</TD><TD>Bob McArthur<BR>
Director, Research Business Development Office<BR>
University Health Network<BR>
101 College Street -- Suite&nbsp;150<BR>
Heritage Building &#8212; MaRS Centre<BR>
Toronto, Ontario M5G 1L7</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Telephone No.: [***]<BR>
Facsimile No.: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">and to Licensee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in">Attention:</TD><TD>Dr.&nbsp;George Adams<BR>
President and CEO<BR>
Amorfix Life Sciences Ltd.<BR>
3080 Yonge Street, Suite&nbsp;6020<BR>
Toronto, M4N 3N1</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Telephone No.: [***]<BR>
Facsimile No.: [***]<BR>
email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or to such other address as the recipient may
have designated by Notice given in accordance with this Section. Any such Notice may be delivered by hand, by registered mail, or sent
by facsimile and will be deemed to have been delivered on the date of delivery if delivered by hand, five (5)&nbsp;days after mailing
if sent by registered mail, or on the first business day following the date of sending, if sent by telecopy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ARTICLE&nbsp;14.0
- GENERAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.1</B></FONT></TD><TD STYLE="text-align: justify"><B>Entire Agreement</B>. The Parties hereto acknowledge that this Agreement and its Schedules, together
with Ancillary Agreements, set forth the entire agreement and understanding of the Parties hereto as to the subject matter hereof, and
supersedes all prior discussions, agreements and writings in respect hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.2</B></FONT></TD><TD STYLE="text-align: justify"><B>General Assurances</B>. The Parties hereto agree to do all such things and to execute such instruments
and documents as may be necessary or desirable in order to carry out the provisions and intent of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.3</B></FONT></TD><TD STYLE="text-align: justify"><B>Enure to Benefit</B>. This Agreement shall enure to the benefit of and be binding upon the respective
Parties hereto and, where the context admits or requires, their respective permitted successors or assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.4</B></FONT></TD><TD STYLE="text-align: justify"><B>Assignment</B>. This Agreement cannot be assigned, sold, transferred or encumbered in any manner by
the Licensee (1)&nbsp;without the expressed written consent of UHN, which consent will not be unreasonably withheld, or (2)&nbsp;with
the whole business of the Licensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.5</B></FONT></TD><TD STYLE="text-align: justify"><B>No Use of Names</B>. The Licensee shall not use the name trade-mark or trade-name of UHN in connection
with any products, publicity, promotion news release, advertising or similar public statements or otherwise without the prior written
consent of UHN.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.6</B></FONT></TD><TD STYLE="text-align: justify"><B>No Joint Venture</B>. Each Party is and will remain at all times independent of each other. The Parties
are not and shall not be considered to be joint venturers, partners or agents of each other and neither of them shall have the power to
bind or obligate the other except as set forth in this Agreement. The Parties mutually covenant and agree that neither shall they, in
any way, incur any contractual or other obligation in the name of the other, nor shall they have liability for any debts incurred by the
other. No representation will be made or acts taken by any of the Parties which could establish any apparent relationship of agency, joint
venture, partnership or employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.7</B></FONT></TD><TD STYLE="text-align: justify"><B>Waiver</B>. No amendment, supplement or waiver of any provision of this Agreement shall be binding
on any Party unless consented to in writing by such Party. No waiver of any provision of this Agreement shall constitute a waiver of any
other provision, nor shall any waiver constitute a continuing waiver unless otherwise expressly provided. Further, no failure or delay
by any Party in exercising any right or remedy shall operate as a waiver thereof, nor shall any single or partial exercise or waiver of
any right or remedy preclude its further exercise or the exercise of any other right or remedy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.8</B></FONT></TD><TD STYLE="text-align: justify"><B>Time of the Essence</B>. Time is of the essence in this Agreement and of each and every term and condition
hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.9</B></FONT></TD><TD STYLE="text-align: justify"><B>Joint Preparation</B>. This Agreement shall be deemed to be jointly prepared by the Parties, and any
ambiguity herein shall not be construed for or against any party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.10</B></FONT></TD><TD STYLE="text-align: justify"><B>Governing Law</B>. This Agreement shall be governed by the laws of the Province of Ontario and the
laws of Canada and shall be treated as an Ontario contract. Each Party subject to Article&nbsp;12.0 irrevocably and unconditionally submits
to the non-exclusive jurisdiction the courts of such Province and all courts competent to hear appeals therefrom in connection with any
matters arising under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.11</B></FONT></TD><TD STYLE="text-align: justify"><B>Severability of Provisions</B>. In the event that any provisions of this Agreement are determined to
be invalid or unenforceable by a court of competent jurisdiction in any jurisdiction, the remainder of the Agreement shall remain in full
force and effect without said provision in said jurisdiction and such determination shall not affect the validity or enforceability of
such provision or the Agreement in any other jurisdiction. The Parties shall in good faith negotiate a substitute clause for any provision
declared invalid or unenforceable, which shall most nearly approximate the intent of the Parties in entering this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.12</B></FONT></TD><TD STYLE="text-align: justify"><B>Force Majeure</B>. In the event that any one of the Parties is prevented from fulfilling any of its
obligations herein by acts of God, war, strikes, riots, storms, fires, governmental orders or restrictions or any other cause beyond its
control, the payment of royalties, or the applicable pro rata portion thereof, shall be suspended during the full period of any such prevention,
but payment of royalties which has accrued for payment prior to, or after such cause shall not be excused.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.13</B></FONT></TD><TD STYLE="text-align: justify"><B>Counterparts</B>. This Agreement may be executed in counterparts each of which shall be deemed an original
but all of which together shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Parties hereto have executed
this Agreement on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>UNIVERSITY HEALTH NETWORK (UHN)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
    Christopher Paige&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Dr.&nbsp;Christopher Paige&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Vice President Research</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMORFIX
    LIFT SCIENC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
    George Adams&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Dr.&nbsp;George Adams&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;
    President and CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SCHEDULE
A<BR>
</B></FONT>(Technology)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UT Invention Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Milestone Payments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 98%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront fee upon signing of UHN-IP rights and inclusion of any Improvement developed by UHN under Funded Research for diagnostic use</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Detection of Disease Specific Epitope in CSF (&#8220;DSE&#8221; defined in the Patent as SED epitope in CSF samples in humans)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Detection of DSE epitope in blood samples</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. First product approval in Canada, USA, Europe or Japan</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront fee upon inclusion of any Improvement developed by UHN under Funded Research for therapeutic use</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Completion of Phase I studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Completion of Phase II studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c. Completion of Phase III studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d. First product approval in Canada, USA, Europe or Japan</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  </TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Buyout Payments under section 2.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 98%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing of this Agreement</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Detection of Disease Specific Epitope in CSF (&#8220;DSE&#8221; defined in the Patent as SED epitope in CSF samples in humans)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Detection of DSE epitope in blood samples</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing of this Agreement</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Completion of Phase I studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Completion of Phase II studies</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  </TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Royalty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 98%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application of <BR>
Technology or <BR>
Improvements from <BR>
Funded Research</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 75%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent Royalty rate from Net Sales received by the Licensee or <BR>
sublicensees in each Quarter Yearly Period for all Products and <BR>
Services sold. Each payment shall be made within thirty (30) <BR>
days of the end of each Quarter Yearly Period; and, </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
  </TABLE><BR STYLE="clear: both">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>SCHEDULE &#8220;A&#8221;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Patent Description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: Methods and Compositions for Detecting Amyotrophic Lateral Sclerosis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent application: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>SCHEDULE &#8220;B&#8221;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Invention Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>SCHEDULE &#8220;C&#8221;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cashman Assignment to University</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>SCHEDULE &#8220;D&#8221;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">University Assignment to Cashman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7(1)
<SEQUENCE>19
<FILENAME>filename19.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.7.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: justify">This Amendment to the UNIVERSITY HEALTH NETWORK LICENSE AGREEMENT is made as of the <U>13</U>
day of July&nbsp;2006 (the &#8220;Effective Date&#8221;) between the following Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNIVERSITY
HEALTH NETWORK</B></FONT> an Ontario corporation incorporated by special statute under the Toronto Hospital Act, 1997, having a principal
office at 610 University Ave 7-504 Toronto, Ontario M5G 2M9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(hereinafter referred to as &#8220;UI-IN&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">-AND-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AMORFIX
LIFE SCIENCES INC.</B></FONT> a Canada corporation with offices located at 3080 Yonge St., Suite&nbsp;6020 Toronto, Ontario, M4N 3M1,
Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(hereinafter referred to as the &#8220;Licensee&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties entered into a License Agreement dated as of April&nbsp;4, 2006, (the &#8220;License Agreement&#8221;) pursuant to which the
Licensee obtained an exclusive license to the UHN&#8217;s ownership rights in the Technology as defined in the License Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Pursuant
to Section&nbsp;2.5 of the License Agreement, the Licensee has the right to grant sublicenses or cross-licenses that are consistent with
and no less favorable than the terms of the License Agreement and that require the sublicensee to be bound by the terms and obligations
of the License Agreement as if it were a Party thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties wish to amend the License Agreement to permit a sublicensee to obtain a license directly with UHN in certain circumstances as
described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW
THEREFORE THIS AMENDMENT WITNESSES</B></FONT> that in consideration of the premises and mutual agreements and covenants herein contained
(the receipt and adequacy of such consideration being mutually acknowledged by each Party), the Parties covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subsection
9.1(c)&nbsp;of the License Agreement shall be amended by deleting the phrase &#8220;shall terminate&#8221; and replacing it with the
phrase &#8220;subject to Subsection 9.1(f), shall terminate within sixty (60) days of the date notice of termination is sent to the applicable
sublicensee&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subsection
9.1(d)&nbsp;of the License Agreement shall be amended by deleting the word &#8220;and&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subsection
9.1(e)&nbsp;of the License Agreement shall be amended by deleting the period and replacing it with a semi-colon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Article&nbsp;9
of the License Agreement shall be amended by adding, immediately after the existing Subsection 9.1(e), the following new Subsection 9.1(f):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8220;(f)&nbsp;provided that a sublicensee
is not in breach of its obligations under a sublicensing agreement made with the Licensee, upon written request of such sublicensee (a
 &#8220;Requesting Sublicensee&#8221;), UHN shall grant to the Requesting Sublicensee a direct license to the extent that UHN&#8217;s
interest in and to the Technology is sublicensed to the Requesting Sublicensee under such sublicensing agreement, which direct license
shall have terms and conditions no more onerous on the Requesting Licensee than the terms and conditions of this Agreement.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Article&nbsp;7
of the License Agreement shall be amended by adding, immediately after the existing Section&nbsp;7.1, the following new Section&nbsp;7.2:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8220;7.2 During the term of this Agreement,
subject to Sections 2.2 and 7.1 of this Agreement, if UHN and UHN-Coinventors desire to make a publication (including without limitation
any oral disclosure made without obligation of confidentiality) related to or arising from the UHN-IP or any research results arising
from the Funded Research, UHN and UHN-Coinventors shall disclose to the Licensee the draft at least forty five (45) days prior to submission
for written publication and an outline of the presentation at least fifteen (15) days prior to oral publication. The Licensee shall have
the right (a)&nbsp;to propose modifications to the publication for patent reasons, and (b)&nbsp;to request a reasonable delay in publication
in order to protect patentable information. If the Licensee requests such a delay, UHN and UHN-Coinventors shall delay submission or
presentation of the publication for a period of sixty (60) days to permit the preparation and filing of patent applications acceptable
to the Licensee. Upon the expiration of such forty-five (45) day period (in the case of proposed written disclosures) or fifteen (15)
day period (in the case of proposed written disclosures) from receipt by the Licensee, UHN or such UHN-Coinventors, as the case may be,
shall be free to proceed with the written publication or the presentation, respectively, unless the Licensee has requested the delay
described above.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties hereto agree to do all such things and to execute such instruments and documents as may be necessary or desirable in order to
carry out the provisions and intent of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Amendment shall be governed by the laws of the Province of Ontario and the laws of Canada and shall be treated as an Ontario contract.
Each Party irrevocably and unconditionally submits to the non-exclusive jurisdiction the courts of such Province and all courts competent
to hear appeals therefrom in connection with any matters arising under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Amendment may be executed in as many counterparts as may be necessary or by facsimile and each such counterpart agreement or facsimile
so executed shall be deemed to be an original and such counterparts and facsimile copies together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the Parties hereto have executed
this Amendment on the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">UNIVERSITY HEALTH NETWORK (UHN)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-size: 10pt">/s/
    Christopher Paige</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Dr.&nbsp;Christopher Paige</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Vice President Research</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><B>AMORFIX LICE SCIENCES</B></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-size: 10pt">/s/
    George Adams</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name: Dr.&nbsp;George Adams</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: President and CEO</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7(2)
<SEQUENCE>20
<FILENAME>filename20.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.7.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Certain
identified information has been excluded from the exhibit pursuant to Item 601(b)(10)(iv) because it is both not material and is the
type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This second
Amendment to the UNIVERSITY HEALTH NETWORK LICENSE AGREEMENT is made as of the 11<SUP>th</SUP> day of July, 2007 (the &ldquo;Effective
Date&rdquo;) between the following Parties:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNIVERSITY
HEALTH NETWORK </B>an Ontario corporation incorporated by special statute under the <I>Toronto Hospital Act, </I>1997, having a principal
office at 190 Elizabeth Street, R. Fraser Elliott Building &mdash; Room 1S-417, Toronto, Ontario M5G 2C4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(hereinafter
referred to as &ldquo;UHN&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">-AND-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AMORFIX
LIFE SCIENCES INC. </B>a Canada corporation with offices located at 3080 Yonge St., Suite 6020, Toronto, Ontario, M4N 3M1, Canada</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(hereinafter
referred to as the &ldquo;Licensee&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(A)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Parties entered into a License Agreement dated as of April 4, 2006, (the &ldquo;License Agreement&rdquo;), which was amended
on July 13, 2006, pursuant to which the Licensee obtained an exclusive license to the UHN's ownership rights in the Technology as defined
in the License Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(B)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subsequent thereto, the parties have recognized that UHN possessed further ownership rights in the Technology that should have
been identified in the original License Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(C)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Certain Improvements have been identified as originating with UHN and which the parties agree should now be included in the License
Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(D)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties wish to amend the License Agreement in recognition of these events and to incorporate these features.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(E)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Amorfix agrees upon validation of the URN Epitopes, similar to DSE1, to make Milestone Payments in Accordance with Schedule C;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW
THEREFORE THIS AMENDMENT WITNESSES </B>that in consideration of the premises and mutual agreements and covenants herein contained (the
receipt and adequacy of such consideration being mutually acknowledged by each Party), the Parties covenant and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Replace Schedule
                                            A with Amended Schedule A attached hereto, thereby to add reference to the PCT patent application
                                            filed March 5, 2006, for &ldquo;Methods and Compositions to Treat and Detect Misfolded SOD1
                                            Mediated Disorders&rdquo;, to the US counterpart thereof, and to priority applications referenced
                                            therein, and to update the schedule with respect to the originally identified US provisional
                                            application.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Replace Schedule
                                            C with Amended Schedule C attached hereto, thereby to set out the consideration for Improvements
                                            identified in new Schedule D;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Add Schedule
                                            D to identify, as Improvements, the disease specific epitopes designated DSE4 and DSE7.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">In Article
                                            2.4, insert -- on Schedule D and -- after &ldquo;...these Improvements will be included&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
Article 2.4 now reads:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Improvements
by UHN. </B>UHN will notify the Licensee, in writing, of all ALS-related Improvements related to the Technology or arising from the Funded
Research within fourteen (14) days from the date of a UHN Invention Disclosure (&ldquo;Notice of Disclosure&rdquo;). Licensee will have
sixty (60) days after receiving the written Notice of Disclosure to notify UHN its intent, in writing, to license said improvement (&ldquo;Notice
of Intent&rdquo;). If UHN does not receive a Notice of Intent within sixty (60) days, UHN will be free to dispose of the Improvement
by UHN as it sees fit. After a Notice of Intent has been received, an Amendment shall be made such that these Improvements will be included
on Schedule D and under the definition of Technology and terms hereunder. In the event that the technologies that are not ALS-related
arose from Funded Research, Licensee shall have the first right of refusal to negotiate a new license within sixty (60) days from a written
notice of UHN Invention Disclosure. Any such license shall be on terms <B>and </B>conditions that are consistent with other such licenses
within the industry and satisfactory to UHN.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This Amendment
may be executed in as many counterparts as may be necessary or by facsimile and each such counterpart agreement or facsimile so executed
shall be deemed to be an original and such counterparts and facsimile copies together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN WITNESS
WHEREOF, the Parties hereto have executed this Amendment on the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIVERSITY
    HEALTH NETWORK (UHN)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Christopher Paige</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Christopher Paige</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President Research</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMORFIX
    LIFE SCIENCES</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    George Adams</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    George Adams</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and CEO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;AMENDED
SCHEDULE A&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Intentionally
Omitted]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">AMENDED
SCHEDULE C</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Milestone
Payments</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="text-indent: 2pt; padding-top: 3pt; border: black 1pt solid; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-top: 3pt; border-left: black 1pt solid; padding-bottom: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upfront
    fee upon signing of UHN-IP rights under the Technology and inclusion of any Improvement developed by UHN under Funded Research for
    diagnostic use, where Improvement includes the:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disease Specific Epitope (DSE/SED)
    DSE 1<SUP>*</SUP>;</FONT></TD>
    <TD STYLE="border-right: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">b.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">DSE 4 or DSE 7, upon confirmation
    that antibody thereto binds selectively to misfolded SOD <I>1</I></FONT></TD>
    <TD STYLE="border-right: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&ldquo;DSE1&rdquo;
    is synonymous with SEDI</I></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-left: 0.125in; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Detection
    of any DSE in CSF samples in humans where the DSE is DSE 1, DSE 4, DSE 7</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: center; width: 5%; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; width: 73%; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Detection
    of any DSE epitope in blood samples where the DSE is DSE 1, DSE 4, DSE 7</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 22%; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Product approval in Canada, USA, Europe or Japan where the Product incorporates any of DSE1, DSE 4, DSE 7 antibody / antibodies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-indent: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
    fee upon inclusion of any UHN-IP rights under the Technology or Improvement developed by UHN under Funded Research for therapeutic
    use</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of Phase I studies where the DSE is DSE 1, DSE 4 or DSE 7 antibody / antibodies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of Phase II studies where the DSE is DSE 1, DSE 4 or DSE 7 antibody / antibodies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of Phase III studies where the DSE is DSE 1, DSE 4 or DSE 7 antibody / antibodies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Product approval in Canada, USA, Europe or Japan where the Product incorporates DSE1, DSE4 or DSE7 antibody / antibodies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  </TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Buyout
Payments under section 2.2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="text-indent: 2pt; border: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Payment</B></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-indent: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    signing of this Agreement</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">[***]</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">a.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Detection
    of Disease Specific Epitope DSE 1, DSE 4 or DSE 7 in CSF human samples</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">[***]</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">b.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Detection
    of Disease Specific Epitope DSE 1, DSE 4 or DSE 7 in blood samples</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">[***]</FONT></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-indent: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Therapeutic</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-indent: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    signing of this Agreement</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">[***]</FONT></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">a.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.25in; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completion
    of Phase I studies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">[***]</FONT></FONT></TD></TR>
  <TR>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">b.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 0.25in; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completion
    of Phase II studies</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">[***]</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Royalty</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 5pt; padding-left: 2pt; border: black 1pt solid; width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Application
    of Technology or Improvements from Funded Research</B></FONT></TD>
    <TD STYLE="padding-bottom: 5pt; padding-left: 2pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 61%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Percent
    Royalty rate from Net Sales received by the Licensee or sublicensees in each Quarter Yearly Period for all Products and Services
    sold.&nbsp;&nbsp;Each payment shall be made within thirty (30) days of the end of each Quarter Yearly Period; and,</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-left: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DSE
    1, DSE 4 or DSE 7 Diagnostic</B></FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-left: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-left: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DSE
    1 , DSE 4 or DSE 7 Therapeutic</B></FONT></TD>
    <TD STYLE="padding-bottom: 10pt; padding-left: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">SCHEDULE
D &ndash; Improvements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Intentionally
Omitted]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7(3)
<SEQUENCE>21
<FILENAME>filename21.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.7.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns or pursuant
to Item 601(b)(10)(iv)&nbsp;because it is both not material and is the type of information that the registrant treats as private or confidential.
Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">This third amendment to the UNIVERSITY HEALTH NETWORK
- AMORFIX LIFE SCIENCES LICENSE AGREEMENT (the &#8220;<B>Third Amendment</B>&#8221;) is made effective this <U>4th</U> day of November,
2013, (the &#8220;<B>Effective Date</B>&#8221;) by and between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNIVERSITY HEALTH NETWORK, an Ontario corporation
incorporated by special statute under the <I>Toronto Hospital Act, 1997</I>, having a business office at 101 College Street, Suite&nbsp;150,
Heritage Building, MaRS Centre, Toronto, Ontario M5G 1L7 Canada (&#8220;<B>UHN</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMORFIX LIFE SCIENCES LTD., a Canada corporation
with offices located at 3403 American Drive, Mississauga, ON L4V 1T4, (&#8220;<B>AMF</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Parties entered into an exclusive license agreement effective the 4th day of April, 2006 (the &#8220;<B>Agreement</B>&#8221;),
which was amended on the 13th day of July, 2006 (the &#8220;<B>First Amendment</B>&#8221;), was further amended on the 11th day of July&nbsp;2007
(the &#8220;<B>Second Amendment</B>&#8221;) and was further amended pursuant to a letter agreement as between UHN, AMF and Biogen in order
to accommodate a sublicense as between AMF and Biogen (the &#8220;<B>Letter Agreement</B>&#8221;) all collectively the &#8220;<B>License
Agreements</B>&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The Agreement dictates that UHN grants to AMF an exclusive license in any and all of its rights to the Technology, and Technology
is defined in the Agreement both as (i)&nbsp;&#8220;a SOD1 [human superoxide dismutase 1] exposed dimer interface antibody&#8221; and
later as (ii)&nbsp;&#8220;all allowed claims in Intellectual Property in and to the invention described in and/or listed in Schedule &#8220;A&#8221;
and all Intellectual Property Rights related to or arising therefrom, excluding Improvements by UHN and Improvements by Licensee&#8221;.
Pursuant to the Agreement, &#8220;Improvements by UHN&#8221; is a defined term, but &#8220;Improvements by Licensee&#8221; is not. None
of the License Agreements provide a definition of Improvements by Licensee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">The Second Amendment recognized that UHN possessed further ownership rights in the &#8220;Technology&#8221; that should have been
identified in the original Agreement, and replaced Schedule &#8220;A&#8221; with Amended Schedule &#8220;A&#8217; which lists various
intellectual property including the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.2in">a.</TD><TD STYLE="text-align: justify">priority patent applications [***]; [***], and [***] and [***] [sic [***]] and the PCT counterpart,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.2in">b.</TD><TD STYLE="text-align: justify">all applications that may be filed based on the foregoing, including, without limitation, all regular, divisional or continuation,
applications based in whole or in part on the foregoing, and all applications corresponding to the foregoing filed in any country</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.2in">c.</TD><TD STYLE="text-align: justify">all issued and unexpired patents resulting from any of the applications described above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.2in">d.</TD><TD STYLE="text-align: justify">all issued and unexpired reissues, reexaminations, renewals or extensions that may be based on any of the patents described above
(the &#8220;<B>Amended Schedule &#8220;A&#8221; Intellectual Property</B>&#8221;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD STYLE="text-align: justify">Pursuant to the License Agreements, &#8220;UHN shall partially own all applications and registrations for Intellectual Property Rights
for the Technology&#8221;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">E.</TD><TD STYLE="text-align: justify">AMF has had the primary responsibility for prosecuting all intellectual property relating to human superoxide dismutase 1 (&#8220;<B>SOD
1</B>&#8221;). AMF has dropped UHN ownership in US application no. [***] (now issued as [***]) and US application no. [***] (now issued
as [***]) which is a continuation in part application of [***]. Both [***] and [***] are considered Amended Schedule &#8220;A&#8221; Intellectual
Property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">F.</TD><TD STYLE="text-align: justify">AMF is now requesting that UHN assign ownership in <B>US Application No.&nbsp;</B>[***] filed on June&nbsp;8, 2011 entitled Methods
and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases, which is a continuation application of [***] and <B>US Application
No.&nbsp;</B>[***], filed on December&nbsp;24, 2010 entitled Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases,
(the &#8220;<B>Applications</B>&#8221;) in order to overcome and obviousness double patenting rejections with Amended Schedule A Intellectual
Property now solely owned by AMF;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">G.</TD><TD STYLE="text-align: justify">The Parties agree that ownership of the Amended Schedule &#8220;A&#8221; Intellectual Property by UHN is not of primary concern. Instead,
the Parties wish to ensure that UHN&#8217;s contribution the patented technology relating to disease specific epitopes of human superoxide
dismutase I, via its inventors Avi Chakrabartty and Rishi Rakhit, is appropriately rewarded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW THEREFORE this Amendment witnesses that in consideration of the
premises and mutual agreements and covenants herein contained, the receipt and sufficiency of which is hereby mutually acknowledged, the
Parties covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Amended
and Restated License Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties shall amend and restate the License Agreements (the &#8220;<B>Amended and Restated License Agreement</B>&#8221;) to ensure that
the Amended and Restated License Agreement is consistent with the License Agreements as further clarified by this Third Amendment. To
the extent that there is a question of the intention of the Parties when drafting the Amended and Restated License Agreement, the intention
of the Parties as determined with reference to this Third Amendment shall govern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Amended and Restated License Agreement shall amend Section&nbsp;3.1 (dealing with the consideration of the License granted), such that
the Licensee agrees to make payments to UHN according to new Schedule &#8220;C&#8221; attached hereto as Appendix &#8220;A&#8221; (&#8220;<B>New
Schedule &#8220;C&#8221;</B>&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Amended and Restated License Agreement shall define the Technology to be &#8220;the invention(s)&nbsp;described in and/or listed in Amended
Schedule &#8220;A&#8221; and all Intellectual Property Rights therein&#8221;, regardless of ownership, on the basis that the Parties recognize
that of primary relevance to the intention of the Parties is the consideration as outlined in New Schedule &#8220;C&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Amended and Restated License Agreement shall clarify that the Buyout Option applies when UHN assigns all interests pursuant to New Schedule
 &#8220;C&#8221; and any residual ownership interests in the Technology (as newly defined in Section&nbsp;1.3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Amended and Restated License Agreement shall clarify that the Licensee will not challenge the validity of any Intellectual Property Rights
in the Technology (as newly defined in Section&nbsp;1.3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Amended
and Restated License Agreement</B>. UHN shall assign to AMF its ownership rights in the Applications in the assignment document attached
hereto as Appendix &#8220;B&#8221; (the &#8220;<B>Assignment</B>&#8221;) and shall further assign all other ownership rights in and to
any Intellectual Property Rights in the Technology (as newly defined in Section&nbsp;1.3) required to give effect to the intention of
the Parties as outlined in this Third Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Counterparts</B>.
This Third Amendment may be executed in as many counterparts as may be necessary or by facsimile and each such counterpart or facsimile
so executed shall be deemed to be an original and such counterparts and facsimile copies together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In witness whereof the Parties hereto have executed this Amendment
effective the date first written above,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; border: Black 1pt solid; width: 50%; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSITY HEALTH NETWORK</B></FONT></TD>
    <TD STYLE="padding-right: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMORFIX LIFE SCIENCES LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 3pt; border-left: Black 1pt solid; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Christopher J. Paige</P></TD>
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Warren Whitehead</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per: Christopher J. Paige, PhD</FONT></TD>
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per: Warren Whitehead</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Vice President Research</FONT></TD>
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have the authority to bind the entity.</FONT></TD>
    <TD STYLE="padding-right: 3pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have the authority to bind the entity.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">APPENDIX &#8220;A&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New Schedule &#8220;C&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Milestone Payments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; width: 74%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront fee upon the signing of the Agreement.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first detection of any Disease Specific Epitope (DSE) in a human CSF sample where such detection would infringe a Valid Claim of the Technology (where a <B>Valid Claim</B> as defined in this Appendix A is an allowed claim or a claim that later becomes allowed, irrespective of whether such claim is subsequently abandoned, disclaimed or dedicated to the public) where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are <B>Inventors</B> of some or all of the subject matter encompassed within the Valid Claim (as inventorship is defined pursuant to U.S. Patent Law)</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first detection of any DSE epitope in a human blood sample, where such detection would infringe a Valid Claim of the Technology where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are inventors of the subject matter encompassed in the Valid Claim, are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Product approval in Canada, USA, Europe or Japan where the Product would infringe a Valid Claim of the Technology where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront fee upon the signing of the Second Amendment.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of Phase I studies where the activities pursuant to the Phase I studies, or the use of the product for which Phase I studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-bottom: 2pt; text-align: justify; width: 74%; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of Phase II studies where the activities pursuant to the Phase II studies, or the use of the product for which Phase II studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-bottom: 2pt; width: 26%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of Phase III studies where the activities pursuant to the Phase III studies, or the use of the product for which Phase III studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 12.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Product approval in Canada, USA, Europe or Japan where the Product and/or the use thereof would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Buyout Payments under section 2.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; width: 74%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing of this Agreement</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Detection of any DSE Epitope, in CSF human samples where such detection would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Detection of any DSE Epitope in blood samples where such detection would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon signing of this Agreement</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. Completion of Phase I studies where the activities pursuant to the Phase I studies, or the use of the product for which Phase I studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; text-align: justify; width: 74%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b. Completion of Phase II studies where the activities pursuant to the Phase II studies, or the use of the product for which Phase II studies are being done, would infringe a Valid Claim of the Technology, where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are Inventors of some or all of the subject matter encompassed within the Valid Claim.</FONT></TD>
    <TD STYLE="padding-bottom: 2pt; width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Royalty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; width: 36%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; width: 64%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Percent Royalty rate from Net Sales received by the Licensee or sublicensees
    in each Quarter Yearly Period for all Products and Services sold, where such Product or Service infringes a Valid Claim of the Technology,
    where Avi Chakrabartty and/or Rishi Rakhit (whether alone or in conjunction with non-UHN inventors) are inventors are Inventors of some
    or all of the subject matter encompassed within the Valid Claim.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each payment shall be made within thirty (30) days of the end of each
    Quarter Yearly Period; and,</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Diagnostic Use</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Therapeutic Use</B></FONT></TD>
    <TD STYLE="padding-bottom: 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX B:<BR>
ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ASSIGNMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, <B>Amorfix Life Sciences Ltd.</B> whose
full post office address is <B>3403 American Drive, Mississauga, Ontario L4V 1T4, Canada</B>, and University Health Network whose full
post office address is <B>R. Fraser Elliott Building, 1st Floor 190 Elizabeth St., Toronto, ON M5G 2C4, Canada</B> are the owners of the
inventions disclosed in U.S. Patent Application No.&nbsp;<B>12/978,478</B>, filed on <B>December&nbsp;24, 2010</B> entitled <B>Methods
and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases</B>, and in U.S. Patent Application No.&nbsp;<B>13/155,939</B>,
filed on <B>June&nbsp;8, 2011</B> entitled <B>Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases</B> (hereinafter
 &#8220;the <B>Applications</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, <B>Amorfix Life Sciences Ltd.</B> desires
to acquire all the rights in and to the <B>Applications</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW THEREFORE, in consideration of the execution
of the <B>Third Amendment</B> to which this Assignment is attached as Appendix &#8220;B&#8221;, and other good and valuable consideration,
the receipt and sufficiency of all of which is hereby acknowledged, <B>University Health Network</B> agrees to and does hereby sell, transfer
and set over to <B>Amorfix Life Sciences Ltd.</B>, all their right, title and interest in and to the <B>Applications</B> in the United
States of America, and all Patents and continuing applications deriving therefrom, including any divisionals, continuations, re-examinations,
reissues and extensions thereof in the United States of America, to be held and enjoyed by <B>Amorfix Life Sciences Ltd.</B> its assigns
and successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Amorfix
Life Sciences Ltd.</B></FONT> and <B>University Health Network</B> authorize and empower Bereskin&nbsp;&amp; Parr LLP/S.E.N.C.R.L., s.r.l.,
whose complete address is Scotia Plaza, 40 King Street West, 40th Floor, Toronto, Ontario M5H 3Y2, to insert on this Assignment any further
identification which may be necessary or desirable in order to comply with the rules&nbsp;for recordation of this document in the United
States and to correct any clerical error in this assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Commissioner of Patents&nbsp;&amp; Trademarks
is hereby authorized and requested to issue any Letters Patent for the <B>Applications</B>, and all related applications thereon, to the
Assignee, to the full end of the term for which Letters Patent may be granted, as fully and entirely as the same would have been held
by the Assignors had this Assignment not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Parties confirm their express wish that this
Assignment be drawn up in the English language. <I>Les parties conferment leur volonte expresse que cette cession soft recligee en langue
anglaise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SIGNED AT <U>Toronto</U>, <U>ON</U>, this <U>6<SUP>th</SUP></U>
day of <U>November</U>, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">/s/ Jacquel S</TD>
    <TD STYLE="font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">/s/ Christopher Paige</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">Witness</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">University Health Network</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">SIGNED AT <U>Toronto</U>, <U>ON</U>, this <U>4<SUP>th</SUP></U>
day of <U>November</U>, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Lynda Covello&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Warren Whitehead</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Witness</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Amorflix Life Sciences Ltd.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>22
<FILENAME>filename22.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.8</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation
S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONSULTING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THIS AGREEMENT made as of and effective from</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;1, 2021, BETWEEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ELLIOT PAUL GOLDSTEIN, MD<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(hereinafter called the &#8220;Consultant&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AND:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProMIS Neurosciences,&nbsp;Inc., a corporation existing under the laws
of the Province of Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1920 Yonge St., Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toronto, Ontario, M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(hereinafter called &#8220;ProMIS&#8221; or the &#8220;Sponsor&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS Dr.&nbsp;Goldstein is to be retained for CEO consulting services,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AND WHEREAS ProMIS wishes to retain the services of Dr.&nbsp;Gioldstein
to provide certain services as consulting CEO;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THIS AGREEMENT WITNESSETH that in consideration of the mutual covenants
herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>1.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Consulting
Services</FONT></B><FONT STYLE="font-size: 10pt">: ProMIS hereby retains the Consultant and the Consultant agrees to be available to perform
services as described in Appendix A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>2.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Term</FONT></B><FONT STYLE="font-size: 10pt">:
Subject to termination in accordance with Section&nbsp;13.0, ProMIS hereby retains the Consultant for a term of 6 months commencing April&nbsp;1,
2021. This Agreement may be renewed upon mutual agreement on substantially the same terms herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>3.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Compensation</FONT></B><FONT STYLE="font-size: 10pt">:
In exchange for the advice and services to be provided by the Consultant as set out in Section&nbsp;1.0 and Appendix A, ProMIS agrees
to pay and the Consultant hereby acknowledges that the following compensation represents payment in full for such services and advice:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">ProMIS shall pay Consultant for his services at the rate of US $5000.00 per month (five thousand US dollars).
During the contract term, it is understood that the Consultant shall be available for the requirements of ProMIS to achieve the objectives
set out in Appendix A. During the contract term, it is also understood that the Consultant
will devote, on average 2 days per week up to a maximum of 8 days per month of his time to achieve the Objectives set forth in Appendix
A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Expenses</FONT></B><FONT STYLE="font-size: 10pt">.
If the Consultant incurs out-of-pocket expenses in the course of providing the services hereunder, ProMIS shall reimburse the Consultant
for such expenses, provided that the Consultant has obtained approval in writing from ProMIS prior to incurring any such expense of $500
or greater. The Consultant shall provide receipts for expenses to ProMIS with any request for reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>5.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Terms
of Payment</FONT></B><FONT STYLE="font-size: 10pt">. Payment is due and payable not more than 15 calendar days after receipt of an invoice
by ProMIS from the Consultant. ProMIS shall send payment to the Consultant at the address set out on the first page&nbsp;hereof or such
other address as the Consultant may advise ProMIS in writing from time to time, or<B>; preferably send such payment via wire transfer
to the Consultant&#8217;s personal bank account.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>6.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Hours</FONT></B><FONT STYLE="font-size: 10pt">.
Notwithstanding anything contained in this Agreement, the parties acknowledge and agree that the Consultant shall spend no more than eight
days per month on the performance of the services hereunder; provided, however, that the Consultant may, in his sole discretion, consent
in writing to a greater number of hours per month in unique or special circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>7.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Non-Competition</FONT></B><FONT STYLE="font-size: 10pt">.
Consultant may, at any time during the term of this Agreement and thereafter, provide services to other corporations or business entities
provided that such services do not directly compete with those business activities of ProMIS .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>8.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><FONT STYLE="font-size: 10pt">Non-Disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Consultant agrees that any information provided by ProMIS to the Consultant or which the Consultant learns about the business of ProMIS
as a result of providing services hereunder (&#8220;Confidential Information&#8221;) shall be considered confidential and the Consultant
agrees that he will not divulge or use for his own purposes or benefit such information without the prior written consent of ProMIS or
as may be required to properly provide the services of the Consultant herein. It is hereby expressly acknowledged that the Consultant
may be bound by confidentiality agreements other than with ProMIS and the Consultant hereby covenants and agrees to abide by the provisions
of such other agreements and to indemnify and hold ProMIS harmless with respect to the breach of any other confidentiality or non-disclosure
agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
restrictions set out in subsection 8.1 shall not apply to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any information which is, at the commencement of the term of this Agreement or at some later date, publicly
known under circumstances involving no breach of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">disclosure of Confidential Information where such disclosure is required by law, court order, court proceedings
or the rules&nbsp;of policies of any stock exchange or government or regulatory
authority having jurisdiction in the matter;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">disclosure of Confidential Information where such disclosure is consented to in writing by the Sponsor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">any knowledge of Confidential Information that the Consultant independently obtained, other than through
a breach of this Agreement, either before or after the date of this Agreement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">disclosure of Confidential Information in accordance with the provisions of Section&nbsp;9.0 hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>9.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Intellectual
Property. </FONT></B><FONT STYLE="font-size: 10pt">Both parties agree that intellectual property including all inventions and discoveries
arising from the consulting services and activities of the Consultant shall be the property of ProMIS Neurosciences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>10.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Independent
Contractor. </FONT></B><FONT STYLE="font-size: 10pt">In the performance of the services hereunder, the Consultant shall be an independent
contractor and shall not be an employee of the Sponsor. As such, the Consultant shall have full and complete discretion in determining
the manner, times and places for the performance of the services hereunder. Without limitation, the Sponsor acknowledges and agrees that
the Consultant shall also have or may have other outside consulting and business interests and that the Consultant is not obligated to
provide services to the Sponsor on an exclusive basis. Nothing contained herein shall be construed as creating a joint venture or partnership
between the Consultant and the Sponsor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>11.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Governing
Laws. </FONT></B><FONT STYLE="font-size: 10pt">The provisions hereof shall be construed in accordance with the laws of the Province of
Ontario and the laws of Canada applicable therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>12.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><FONT STYLE="font-size: 10pt">Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>13.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><FONT STYLE="font-size: 10pt">Either
party may terminate this Agreement upon 30 calendar days prior written notice to the other.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
either party commits any breach or default of any terms or conditions of this Agreement and also fails to remedy such breach or default
within 15 calendar days after receipt of a written notice from the other party, the party giving notice may terminate this Agreement by
sending a notice of termination in writing to the party in breach. This termination will be effective as of the date of the receipt of
such notice. Such termination will be in addition to all other remedies available at law or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event of any termination of this Agreement, the Sponsor shall pay the Consultant within 15 calendar days of receipt of an invoice
therefor, all consulting fees, reimbursable expenses and other amounts owing to the Consultant pursuant to the terms of this Agreement
to the date of termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>14.0</B></FONT><B><FONT STYLE="text-transform: uppercase">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Communications.
</FONT></B><FONT STYLE="font-size: 10pt">Any notice or other communication to be given in connection with this Agreement shall be given
in writing and may be given by personal delivery, electronic transmission or by registered or certified mail addressed to the recipient
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To : Eugene Williams</FONT></TD>
    <TD STYLE="width: 56%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProMIS Executive Chairman</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProMIS Neurosciences Inc,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1920 Yonge St., Suite&nbsp;200</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toronto, Ontario, M4S 3E2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [***]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Consultant:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eliot Goldstein, MD</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [***]</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or such other address or individual as may <FONT STYLE="color: #1f1f1f">be</FONT>
designated <FONT STYLE="color: #1f1f1f">by notice by</FONT> any <FONT STYLE="color: #1f1f1f">party</FONT> to the other. Any such <FONT STYLE="color: #1f1f1f">notice
or other</FONT> communication shall <FONT STYLE="color: #1f1f1f">be</FONT> deemed to <FONT STYLE="color: #1f1f1f">have</FONT> been given
on the day <FONT STYLE="color: #1f1f1f">delivered if delivered by</FONT> personal delivery, on the day of transmittal thereof if given
by electronic <FONT STYLE="color: #2e2e2e">transmission, and</FONT> <FONT STYLE="color: #1f1f1f">on</FONT> <FONT STYLE="color: #2e2e2e">the
fifth</FONT> <FONT STYLE="color: #1f1f1f">business day</FONT> <FONT STYLE="color: #2e2e2e">following the date of</FONT> <FONT STYLE="color: #1f1f1f">posting</FONT>
<FONT STYLE="color: #2e2e2e">if mailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #1f1f1f"><B>15.0</B></FONT><B><FONT STYLE="text-transform: uppercase; color: #1f1f1f">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><B><FONT STYLE="font-size: 10pt; color: #1f1f1f">Assignment.</FONT></B>
<FONT STYLE="font-size: 10pt">This Agreement is <FONT STYLE="color: #1f1f1f">not</FONT> assignable <FONT STYLE="color: #1f1f1f">by</FONT>
either party without <FONT STYLE="color: #1f1f1f">the prior</FONT> written consent of the other <FONT STYLE="color: #1f1f1f">party,</FONT>
which shall not <FONT STYLE="color: #1f1f1f">be unduly</FONT> withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #1f1f1f"><B>16.0</B></FONT><B><FONT STYLE="text-transform: uppercase; color: #1f1f1f">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">Enurement.
</FONT></B><FONT STYLE="font-size: 10pt">This Agreement shall enure to the benefit of and be <FONT STYLE="color: #1f1f1f">binding</FONT>
upon the parties <FONT STYLE="color: #1f1f1f">to</FONT> this Agreement and their respective <FONT STYLE="color: #1f1f1f">heirs,</FONT>
executors, administrators, successors and <FONT STYLE="color: #1f1f1f">permitted </FONT>assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #1f1f1f"><B>17.0</B></FONT><B><FONT STYLE="text-transform: uppercase; color: #1f1f1f">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B><B><FONT STYLE="font-size: 10pt; color: #1f1f1f">Counterparts.</FONT></B>
<FONT STYLE="font-size: 10pt">This Agreement <FONT STYLE="color: #1f1f1f">may be</FONT> executed <FONT STYLE="color: #1f1f1f">in</FONT>
one or more <FONT STYLE="color: #1f1f1f">counterparts,</FONT> each of which when executed shall <FONT STYLE="color: #1f1f1f">be deemed</FONT>
to <FONT STYLE="color: #1f1f1f">be</FONT> an <FONT STYLE="color: #1f1f1f">original, but</FONT> all of which taken together shall constitute
<FONT STYLE="color: #1f1f1f">one</FONT> and <FONT STYLE="color: #1f1f1f">the</FONT> same agreement. Counterparts <FONT STYLE="color: #1f1f1f">may</FONT>
be executed either <FONT STYLE="color: #1f1f1f">in</FONT> original or faxed form, or other form <FONT STYLE="color: #1f1f1f">of</FONT>
electronic transmission and the <FONT STYLE="color: #1f1f1f">parties</FONT> adopt any signatures <FONT STYLE="color: #1f1f1f">received
by</FONT> a <FONT STYLE="color: #1f1f1f">receiving</FONT> fax <FONT STYLE="color: #1f1f1f">machine or by</FONT> e-mail as original signatures
of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN <FONT STYLE="color: #1f1f1f">WI </FONT>TNESS WHEREOF <FONT STYLE="color: #1f1f1f">the
parties</FONT> hereto have executed <FONT STYLE="color: #1f1f1f">this</FONT> Agreement as of <FONT STYLE="color: #1f1f1f">the day</FONT>
and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #1f1f1f">On
behalf</FONT> <FONT STYLE="color: #2e2e2e">of ProMIS Neurosciences</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">Per</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ Eugene Williams</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Name/title: Eugene Williams, Executive Chairman</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">On behalf of the Consultant</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Per</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> /s/ Elliot Goldstein</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Name/title: Elliot Goldstein, MD</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Appendix A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title&nbsp;&amp; objectives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Consultant CEO will report directly to the Executive Chairman. Objectives
will be set in agreement with the Executive Chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>23
<FILENAME>filename23.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.9</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns or pursuant
to Item 601(b)(10)(iv)&nbsp;because it is both not material and is the type of information that the registrant treats as private or confidential.
Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVISORY CONSULTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THIS
AGREEMENT</B></FONT> is dated as of May&nbsp;26, 2021 (the &#8220;Effective Date&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BETWEEN:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ProMIS
Neurosciences Inc.</B></FONT>, a corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite&nbsp;200,
Toronto, Ontario, M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &#8220;<B>Company</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AND:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>David Wishart, PhD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with an address at [***],</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(the &#8220;<B>Advisor</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">The Company wishes to engage the Advisor as the Company&#8217;s Chief Physics Officer and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
CONSIDERATION OF </B></FONT>the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt
and sufficiency of which is hereby mutually acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROVISION OF SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Services</B>.
Commencing on May&nbsp;26, 2021 (the &#8220;<B>Start Date</B>&#8221;), the Advisor will perform for the Company (as an independent contractor
and not as employee, agent, partner or joint venturer) the services described in Schedule A (collectively, the &#8220;<B>Services</B>&#8221;).
Schedule A forms an integral part of this Agreement and is hereby incorporated by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Quality
of Service</B>. The Advisor represents, warrants, and covenants that it will (and will cause the Advisor Representatives to) a) perform
the Services in a timely, competent and professional manner in accordance with the standards and practices commonly expected of qualified
and experienced providers of similar services, (b)&nbsp;perform the Services in compliance with all applicable laws, rules, ordinances
and regulations that are now applicable to the Advisor, the Advisor Representatives or the Services, whether federal, state, provincial,
municipal or otherwise, and (c)&nbsp;at all times act in the best interests of the Company and perform the Services in a faithful manner
to the best ability of the Advisor and each of the Advisor Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Subcontracting
and Assignment</B>. The Advisor will not, without the prior written consent of the Company (which consent the Company may in its sole
discretion withhold), subcontract, delegate or otherwise assign any or all of the Advisor&#8217;s obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 8pt; margin: 0pt; text-align: right"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Term</B>.
The term of this Agreement will be twelve months from the effective date. This contract may be renewed for a subsequent period or periods
of 12 months, upon mutual consent of both parties. This agreement may be terminated by either Party, as described in Schedule A. <B>Effect
of Termination</B>. If this Agreement is terminated as provided herein, the Company&#8217;s sole liability shall be to pay the Advisor
for all properly performed Services to the effective date of termination and neither the Advisor nor the Advisor Representatives will
have any other claim for compensation, losses, costs or damages of any nature or kind based on such termination. All obligations and rights
that, by their nature, are intended to survive the termination or expiration of this Agreement will so survive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FEES AND EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Fees
and Expenses</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration for performing the Services,
exchange for the advice and services to be provided by the Consultant as set out in Section&nbsp;1.0 and Appendix A, ProMIS agrees to
pay and the Consultant hereby acknowledges that the following compensation represents payment in full for such services and advice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">ProMIS shall, on the basis of monthly invoices from Consultant, pay Consultant for his services at the
rate of CDN $[***] ([***] Canadian dollars) per month (plus GST if applicable). During the contract term, it is understood that the Consultant
shall be available for the requirements of ProMIS to achieve the goals and objectives set out in Appendix A. During the contract term,
it is also understood that the Consultant will devote, on average over any calendar month, up to one day per week of his time to achieve
the Objectives set forth in Appendix A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">ProMIS will grant the Advisor [***] share options in the Corporation, at a strike price equal to the volume
weighted average share price of the preceding 5 days. One third of the share options will vest immediately, and the remainder will vest
in equal monthly portions over 24 months. In case of change of control, all options, whether vested or not will immediately vest. The
Company will reimburse the Advisor in accordance with its normal policies and practices for the Advisor&#8217;s reasonable, out-of-pocket
expenses or disbursements actually and necessarily incurred or made by the Advisor in connection with the performance of the Services
(collectively, &#8220;<B>Expenses</B>&#8221;). All reasonable business-related expenses will be reimbursed upon submission of receipts and expense
reimbursement request. Any individual expense exceeding US $500.00 (five hundred US dollars) requires advance written approval from ProMIS
Neurosciences.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Taxes
and Benefits</B>. The Advisor represents, warrants and covenants that the Advisor is acting and will act only as independent contractor
(and, in any event, never as an employee of the Company). The Advisor acknowledges and agrees that, in its performance under this Agreement,
neither the Advisor nor either Advisor Representative, will be entitled to any employee-like benefits or any direct or indirect compensation
other than that expressly set out in this Agreement. The Advisor will, as an independent contractor, collect and/or remit as required,
all amounts, and will register with any workers&#8217; compensation entities or other governmental bodies, and deal with all tax and other
requirements, and satisfy all applicable compliance requirements, as required or permitted under law by all municipal, provincial, state
or federal governments. The Advisor agrees that the Company will not be responsible for registering under any workers&#8217; compensation
legislation or for withholding or remitting any amounts for income taxes, social security taxes, (un)employment insurance, or other deductions
that would be required in an employment relationship in any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONFIDENTIALITY AND RESTRICTIVE COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Definitions</B>.
In this Agreement,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&#8220;<B>Company Entities</B>&#8221; means the Company and its subsidiary, parent and affiliate corporations,
to the extent that such reference does not require any subsidiary party to be added as a party to this Agreement other than as a third
party beneficiary, each of whom will be expressly deemed an intended third party beneficiary of this Agreement and will have the right
to enforce the terms and conditions of this Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&#8220;<B>Confidential Information</B>&#8221; means all information in any form (including all electronic,
magnetic, physical, intangible, visual and oral forms) and whether or not such information has been marked or indicated as confidential,
that is known, held, used or disclosed by or on behalf of the Company Entities in connection with its business, and that, at the time
of its disclosure: (i)&nbsp;is not available or known to the general public; (ii)&nbsp;by its nature or the nature of its disclosure,
would reasonably be determined to be confidential; or (iii)&nbsp;is marked or indicated as proprietary or confidential; and includes patent
applications, trade secrets, technology, know-how, technical information, supplier and customer information (whether past, present, future
and prospective), strategic plans, financial information, marketing information, information as to business opportunities, strategies
and research and development, consultation records and plans, communications, meetings, conversations, surveys, third party data and studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Confidentiality</B>.
In connection with the Advisor&#8217;s performance under this Agreement, the Company has furnished or may furnish to the Advisor, or the
Advisor may acquire, develop or conceive of, Confidential Information, all of which the Advisor will treat strictly in accordance with
this Agreement. For greater clarity, the parties hereby acknowledge and agree that Confidential Information can encompass information
regardless of whether it was disclosed prior to the date of this Agreement or after. In connection with this,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><B><I>Obligations</I></B>-at all times during and after this Agreement (subject to &sect;8(b)), the Advisor
will protect the Confidential Information using a reasonable degree of care, and will take all reasonable steps to safeguard the Confidential
Information from unauthorized disclosure, and without limiting the foregoing will not, directly or indirectly, (i)&nbsp;copy or reproduce
any of the Confidential Information, (ii)&nbsp;use any Confidential Information for any purpose other than the proper performance of the
Advisor&#8217;s duties, or (iii)&nbsp;subject to &sect;8(c), disclose any of the Confidential Information except strictly to those of
the Company&#8217;s directors, officers, Advisors, attorneys, accountants, advisors and personnel to whom disclosure is necessary to carry
out the Advisor&#8217;s duties,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><B><I>Exceptions</I></B>-this &sect;8 imposes no obligation upon any person with respect to any information
or part thereof that the Advisor can establish that, other than as a result of a breach of this Agreement, (i)&nbsp;was in the Advisor&#8217;s
possession prior to entering into this Agreement without any restriction of confidentiality owed to any Company Entity, (ii)&nbsp;is or
becomes generally available to the public rightfully without restrictions of confidentiality, or (iii)&nbsp;becomes available to the Advisor
after the term of this Agreement from a third party (other than any Company Entity) who has no obligation of confidentiality with respect
thereto,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><B><I>Required Disclosures</I></B>-if the Advisor is requested or required (including, without restriction,
by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or other similar process)
by any law to disclose any Confidential Information, he may disclose strictly that Confidential Information for which disclosure is required
to comply with any such applicable law, provided that the Advisor (i)&nbsp;unless prohibited by such applicable law, provides the Company
with written notice as soon as practicable in the circumstances so that the Company may contest the disclosure or seek an appropriate
protective order, and (ii)&nbsp;cooperates reasonably and in good faith with the Company in its efforts to prevent, restrict or contest
such required or requested disclosure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><B><I>Acknowledgement</I></B>-the Advisor acknowledges and agrees that the right to maintain the confidentiality
of Confidential Information, and the right to preserve the Company&#8217;s goodwill therein, constitute proprietary rights which the Company
is entitled to protect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>No
Liability</B>. In no event will the Company or its Company Entities be liable for any claims made by the Advisor, the Advisor Representatives
or any third party for any special, indirect, incidental, or consequential damages in connection with this Agreement, whether for negligence
or breach of contract, including without limitation loss of business opportunities, profits or revenues, and whether or not the possibility
of such damages or loss of opportunities, profits or revenues has been disclosed by the Advisor in advance or could have been reasonably
foreseen by the Company. The Company&#8217;s liability for any and all direct damages in connection with this Agreement will not, in any
event, in aggregate exceed the total fees actually paid or payable to the Advisor for the Services performed under the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Severability</B>.
If any provision of this Agreement is held invalid, illegal or unenforceable, the remaining provisions will not be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Governing
Law</B>. This Agreement will be governed by and interpreted in accordance with the laws of the Province of British Columbia and the laws
of Canada applicable therein without reference to its conflict of laws principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Notice</B>.
Every notice, request, demand or direction (each, for the purposes of this section, a &#8220;<B>notice</B>&#8221;) to be given pursuant
to this Agreement by either party to another will be in writing and will be delivered or sent by registered or certified mail postage
prepaid and mailed in any government post office or by email, or other similar form of written communication, in each case, addressed
as above or to another address as notified hereunder from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Interpretation</B>.
In this Agreement, (a)&nbsp;&#8220;<B>&sect;</B>&#8221; means a section, subsection, paragraph or sub-paragraph of this Agreement and
 &#8220;Part&#8221; means a captioned part of this Agreement, (b)&nbsp;any word in this Agreement is deemed to include the masculine, feminine,
neuter, singular or plural form thereof as the context so required, (c)&nbsp;the captions and headings used in this Agreement are for
convenience only and do not constitute substantive matter and are not to be construed as interpreting the contents of this Agreement,
and (d)&nbsp;the word &#8220;<B>including</B>&#8221; is not limiting (whether or not non-limiting language such as &#8220;without limitation&#8221;
or &#8220;but not limited to&#8221; or other words of similar import are used with reference thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Entire
Agreement</B>. This Agreement, including all Schedules hereto, forms the entire agreement among the parties and supersedes all prior
agreements, proposals or communications relative to the subject matter of this Agreement. Amendments to or waivers of this Agreement
will be effective only if in writing and signed by authorized representatives of all </FONT>parties. Unless otherwise expressly
stated, if there is any necessary conflict between any of the terms of this Agreement and Schedules to this Agreement, this
Agreement will take precedence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Acceptance.
</B>This Agreement is executed effective as of the day and year first above written and may be executed in counterparts, each of which
will constitute an original and all of which taken together will constitute one and the same instrument, and delivery of the counterparts
may be effected by means of electronic transmission. The reproduction of signatures by electronic transmission will be treated as binding
as if originals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ProMIS Neurosciences Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Elliot Goldstein</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dr.&nbsp;Elliot P Goldstein, President and CEO</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advisor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><U STYLE="text-decoration: none">/s/ David Wishart</U>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">David Wishart, PhD</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>24
<FILENAME>filename24.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="color: Black"><B>Exhibit 10.10</B>&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0"><FONT STYLE="color: Black"><B><I>Certain identified information has been excluded from the
exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black"><B><U>CONSULTING
AND ADVISORY AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">THIS AGREEMENT MADE
AS OF THE 1st DAY OF MARCH, 2005 (the &#8220;Effective Date&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">BETWEEN:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B><U>AMORFIX
LIFE SCIENCES LTD</U></B></FONT><FONT STYLE="color: Black">., a company incorporated under the laws of Canada having a business office
care of TANZ Neurosciences Building, 6 Queen&#8217;s Park Crescent West, Toronto, Ontario, M5S 3H2;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="color: Black">(the &#8220;Company&#8221;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">AND:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B><U>NEIL
CASHMAN</U></B></FONT><FONT STYLE="color: Black">, having a business address care of [***];</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="color: Black">(the &#8220;Consultant&#8221;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">WHEREAS the Consultant
is the scientist behind the Prion technology used by the Company (the &#8220;Expertise&#8221;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">AND WHEREAS the Company
would like to engage the Consultant to provide services to the Company as the Chairman of the Board and Chief Scientific Officer of the
Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">NOW THEREFORE THIS
AGREEMENT WITNESSES that in consideration of the mutual covenants and agreements herein contained, the parties hereto agree (the &#8220;Agreement&#8221;)
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>1.</B></FONT><B><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Engagement</U></FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">During
                                            the Term of this Agreement, the Consultant will provide the Services described on Schedule
                                            &#8220;A&#8221; hereto to the Company (the &#8220;Services&#8221;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">This
                                            Agreement shall be in effect (the &#8220;Term&#8221;) until terminated by either party. The
                                            Consultant may terminate on 30 days written notice to the Company, and the Company on 6 months
                                            written notice to the Consultant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                            Consultant is cognizant of the sensitive and confidential nature of the interactions contemplated
                                            under this Agreement and, in this regard, agrees to adhere to high ethical standards when
                                            carrying out its engagement. In providing his Services to the Company hereunder, the Consultant
                                            will:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">act
                                            honestly, in good faith and in the best interests of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">exercise
                                            the care and diligence of a prudent advisor and consultant; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">use
                                            his best efforts to well and faithfully serve the interests of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                            parties may elect, at any time, by mutual agreement, to turn this relationship from a consulting
                                            relationship to an employment relationship, and amend the terms of this Agreement accordingly.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>2.</B></FONT><B><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remuneration</U></FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">For
                                            providing his Services, the Company will:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">pay
                                            to the Consultant a consultancy and advisory fee (the &#8220;Fee&#8221;) of $5,000 per month,
                                            plus GST, commencing for the month of March, 2005; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">reimburse
                                            the Consultant for all reasonable expenses (the &#8220;Expenses&#8221;) incurred by the Consultant
                                            in meeting its obligations hereunder, provided any Expenses exceeding $200 per month are
                                            pre-approved, such approval not to be unreasonably withheld.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                            Consultant will invoice the Company, no less frequently than monthly, for all Fees and Expenses
                                            incurred. Invoices will be due for payment immediately upon delivery to the Company and should
                                            the Company not pay the full amount outstanding on the invoice to the Consultant within 10
                                            days of receipt of the invoice, interest will accrue on the outstanding balance at a rate
                                            of 18% per annum. If this Agreement is terminated during a calendar month, the Fees will
                                            be prorated for that month to the termination date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                            Company will grant to the Consultant, from time to time, stock options to acquire shares
                                            of the Company. The terms and conditions of the stock options will be in accordance with
                                            the stock option plan then in effect and will be subject to the approval of the Board of
                                            the Company. The number of stock options will be an amount that properly reflects the position
                                            of the Consultant with the Company when put in context of the overall organization of the
                                            Company, and the exercise price will be at least as favourable as for other stock options
                                            being granted.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>3.</B></FONT><B><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Confidentiality
and Protection of Interests</U></FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Each
                                            party will keep this Agreement and all aspects of it confidential during the Term of this
                                            Agreement and for a period of two years thereafter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                            Consultant shall not, during the Term of this Agreement or at any time thereafter, use for
                                            his own purposes or for any purposes other than those of the Company any intellectual property
                                            or knowledge or confidential information of any kind whatsoever he may acquire in relation
                                            to the Company&#8217;s business or the business of its subsidiaries, and such shall be and
                                            remain the property of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>4.</B></FONT><B><FONT STYLE="color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>General</U></FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                            headings and section references in this Agreement are for convenience of reference only and
                                            do not form a part of this Agreement and are not intended to interpret, define or limit the
                                            scope, extent or intent of this Agreement or any provision thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Time
                                            is hereby expressly made of the essence of this Agreement with respect to the performance
                                            by the parties of their respective obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">This
                                            Agreement shall enure to the benefit of and be binding upon the parties hereto and their
                                            respective heirs, executors, administrators, personal representatives, successors and permitted
                                            assigns. This Agreement may not be assigned by either party hereto without the prior express
                                            written consent of the other party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">This
                                            Agreement constitutes the entire agreement between the parties hereto relating to the subject
                                            matter hereof and may not be amended, waived or discharged except by an instrument in writing
                                            executed by the party against whom enforcement of such amendment, waiver or discharge is
                                            sought and this Agreement supersedes all prior agreements between the parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Each
                                            of the parties hereto hereby covenants and agrees to execute such further and other documents
                                            and instruments and do such further acts and other things as may be necessary to implement
                                            and carry out the intent of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: Black">4.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">All
                                            notices, requests, demands and other communications hereunder shall be in writing and shall
                                            be deemed to have been duly given if sent or delivered as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="color: Black">To
                    the Company:</FONT></P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: Black">Amorfix Life Sciences Ltd.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: Black">c/o [***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;&nbsp;&nbsp;Attention:</TD>
    <TD STYLE="width: 82%">Dr.&nbsp;Vigen Nazarian, President&nbsp;&amp; acting CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;&nbsp;&nbsp;Email:</TD>
    <TD><FONT STYLE="color: Black">[***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;<FONT STYLE="color: Black">To
                    the Consultant:</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%"><FONT STYLE="color: Black">Neil Cashman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="color: Black">c/o [***]</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;&nbsp;&nbsp;Email:</TD>
    <TD STYLE="width: 82%">[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">or to such other address
as may be given in writing by the Company or the Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">IN WITNESS WHEREOF
this Agreement has been duly executed by the parties hereto effective as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Signed, sealed
                           and delivered by <B>AMORFIX LIFE SCIENCES LTD</B>. per:</FONT></P></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Vigen Nazarian</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dr.&nbsp;Vigen Nazarian</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">SIGNED,
                                            SEALED and DELIVERED by <B>NEIL CASHMAN</B> in the presence of:</FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">/s/ Neil Cashman</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; font-size: 10pt">Signature of Witness</TD><TD STYLE="width: 2%; font-size: 10pt; color: Black">)</TD>
    <TD STYLE="width: 49%; font-size: 10pt; color: Black; font-weight: bold; text-align: left">NEIL CASHMAN</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Name of Witness</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Address of Witness</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; color: Black">Scientist</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: Black">Occupation of Witness</TD><TD STYLE="font-size: 10pt">)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #3a393a"><FONT STYLE="color: Black"><B>SCHEDULE
 &#8220;A&#8221;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #3a393a"><FONT STYLE="color: Black"><B><U>DESCRIPTION
OF SERVICES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #3a393a"><FONT STYLE="color: Black">[Intentionally
omitted]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>25
<FILENAME>filename25.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.11</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv)&nbsp;because
it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is
indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSULTING
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
AGREEMENT </B></FONT>is dated as of June&nbsp;29, 2015 (the &#8220;<B>Effective Date</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BETWEEN:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3in 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMORFIX
LIFE SCIENCES LTD. (to be renamed ProMIS Neurosciences Inc.)</B></FONT>, a corporation existing under the federal laws of Canada with
a registered address at 1500-1055 West Georgia, Vancouver V6E 4N7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(the &#8220;<B>Company</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AND:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIRTUA,
LLC</B></FONT>, a limited liability company formed pursuant to the laws of Delaware</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(the &#8220;<B>Consultant</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Company wishes to engage the Consultant to provide executive management services to the Company; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The Company and the Consultant wish to specify the terms of the engagement herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>In
consideration of</B></FONT> the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt
and sufficiency of which is hereby mutually acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROVISION OF SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Services</B>.
Commencing on June&nbsp;29, 2015 (the &#8220;<B>Start Date</B>&#8221;), the Consultant will perform for the Company (as an independent
contractor and not as employee, agent, partner or joint venturer) the services described in Schedule A (collectively, the &#8220;<B>Services</B>&#8221;).
Schedule A forms an integral part of this Agreement and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Consultant
Representatives</B>. The Consultant agrees that it will make available each of Elliot Goldstein (&#8220;<B>Goldstein</B>&#8221;) and Eugene
Williams (&#8220;<B>Williams</B>&#8221; and together with Goldstein, the &#8220;<B>Consultant Representatives</B>&#8221; and each a &#8220;<B>Consultant
Representative</B>&#8221;) to perform the Services and that each of the Consultant Representatives will devote their best efforts, skills
and attention to the performance of their respective duties and responsibilities in respect of the offices of the Company or any of its
subsidiaries to which the Consultant Representatives may be appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Quality
of Service</B>. The Consultant represents, warrants, and covenants that it will (and will cause the Consultant Representatives to) a)
perform the Services in a timely, competent and professional manner in accordance with the standards and practices commonly expected of
qualified and experienced providers of similar services, (b)&nbsp;perform the Services in compliance with all applicable laws, rules,
ordinances and regulations that are now applicable to the Consultant, the Consultant Representatives or the Services, whether federal,
state, provincial, municipal or otherwise, and (c)&nbsp;at all times act in the best interests of the Company and perform the Services
in a faithful manner to the best ability of the Consultant and each of the Consultant Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Licenses
and Approvals</B>. The Consultant will, at the Consultant&#8217;s own expense, obtain and maintain ordinary course business licenses (such
as municipal licenses or registration as a Delaware LLC) required by the Consultant and the Consultant Representatives to perform the
Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Subcontracting
and Assignment</B>. The Consultant will not, without the prior written consent of the Company (which consent the Company may in its sole
discretion withhold), subcontract, delegate or otherwise assign any or all of the Consultant&#8217;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Term.
</B>The term of this Agreement will be as set out on Schedule A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect
of Termination</B>. If this Agreement is terminated as provided herein, except as expressly set out in Schedule A, the Company&#8217;s
sole liability shall be to pay the Consultant for all properly performed Services to the effective date of termination and neither the
Consultant nor the Consultant Representatives will have any other claim for compensation, losses, costs or damages of any nature or kind
based on such termination. All obligations and rights that, by their nature, are intended to survive the termination or expiration of
this Agreement will so survive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FEES AND EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Fees</B>.
In consideration for performing the Services, the Company will pay the Consultant those fees (the &#8220;<B>Fees</B>&#8221;), and reimburse
those expenses (the &#8220;<B>Expenses</B>&#8221;), set out in Schedule A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Taxes
and Benefits.</B> The Consultant represents, warrants and covenants that the Consultant is acting and will act only as independent contractor
(and, in any event, never as an employee of the Company). The Consultant acknowledges and agrees that, in its performance under this
Agreement, neither the Consultant nor either Consultant Representative, will be entitled to any employee-like benefits or any direct
or indirect compensation other than that expressly set out in this Agreement. The Consultant will, as an independent contractor, collect
and/or remit as required, all amounts, and will register with any workers&#8217; compensation entities or other governmental bodies,
and deal with all tax and other requirements, and satisfy all applicable compliance requirements, as required or permitted under law
by all municipal, provincial, state or federal governments. The Consultant agrees that the Company will not be responsible for registering
under any workers&#8217; compensation legislation or for withholding or remitting any amounts for income taxes, social security taxes,
(un)employment insurance, or other deductions that would be required in an employment relationship in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONFIDENTIALITY AND RESTRICTIVE COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Definitions</B>.
In this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&#8220;<B>Company
Entities</B>&#8221; means the Company and its subsidiary, parent and affiliate corporations, to the extent that such reference does not
require any subsidiary party to be added as a party to this Agreement other than as a third party beneficiary, each of whom will be expressly
deemed an intended third party beneficiary of this Agreement and will have the right to enforce the terms and conditions of this Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&#8220;<B>Confidential
Information</B>&#8221; means all information in any form (including all electronic, magnetic, physical, intangible, visual and oral forms)
and whether or not such information has been marked or indicated as confidential, that is known, held, used or disclosed by or on behalf
of the Company Entities in connection with its business, and that, at the time of its disclosure: (i)&nbsp;is not available or known to
the general public; (ii)&nbsp;by its nature or the nature of its disclosure, would reasonably be determined to be confidential; or (iii)&nbsp;is
marked or indicated as proprietary or confidential; and includes patent applications, trade secrets, technology, know-how, technical information,
supplier and customer information (whether past, present, future and prospective), strategic plans, financial information, marketing information,
information as to business opportunities, strategies and research and development, consultation records and plans, communications, meetings,
conversations, surveys, third party data and studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidentiality</B>.
In connection with the Consultant&#8217;s performance under this Agreement, the Company has furnished or may furnish to the Consultant,
or the Consultant may acquire, develop or conceive of, Confidential Information, all of which the Consultant will treat strictly in accordance
with this Agreement. For greater clarity, the parties hereby acknowledge and agree that Confidential Information can encompass information
regardless of whether it was disclosed prior to the date of this Agreement or after. In connection with this,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Obligations</I></B>&#8212;at
all times during and after this Agreement (subject to &sect;11(b)), the Consultant will protect the Confidential Information using a reasonable
degree of care, and will take all reasonable steps to safeguard the Confidential Information from unauthorized disclosure, and without
limiting the foregoing will not, directly or indirectly, (i)&nbsp;copy or reproduce any of the Confidential Information, (ii)&nbsp;use
any Confidential Information for any purpose other than the proper performance of the Consultant&#8217;s duties, or (iii)&nbsp;subject
to &sect;11(c), disclose any of the Confidential Information except strictly to those of the Company&#8217;s directors, officers, consultants,
attorneys, accountants, advisors and personnel to whom disclosure is necessary to carry out the Consultant&#8217;s duties,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Exceptions</I></B>&#8212;this
 &sect;11 imposes no obligation upon any person with respect to any information or part thereof that the Consultant can establish that,
other than as a result of a breach of this Agreement, (i)&nbsp;was in the Consultant&#8217;s possession prior to entering into this Agreement
without any restriction of confidentiality owed to any Company Entity, (ii)&nbsp;is or becomes generally available to the public rightfully
without restrictions of confidentiality, or (iii)&nbsp;becomes available to the Consultant after the term of this Agreement from a third
party (other than any Company Entity) who has no obligation of confidentiality with respect thereto,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Required
Disclosures</I></B>&#8212;if the Consultant is requested or required (including, without restriction, by oral questions, interrogatories,
requests for information or documents, subpoena, civil investigative demand or other similar process) by any law to disclose any Confidential
Information, he may disclose strictly that Confidential Information for which disclosure is required to comply with any such applicable
law, provided that the Consultant (i)&nbsp;unless prohibited by such applicable law, provides the Company with written notice as soon
as practicable in the circumstances so that the Company may contest the disclosure or seek an appropriate protective order, and (ii)&nbsp;cooperates
reasonably and in good faith with the Company in its efforts to prevent, restrict or contest such required or requested disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Acknowledgement</I></B>&#8212;the
Consultant acknowledges and agrees that the right to maintain the confidentiality of Confidential Information, and the right to preserve
the Company&#8217;s goodwill therein, constitute proprietary rights which the Company is entitled to protect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>No
Liability</B>. In no event will the Company or its Company Entities be liable for any claims made by the Consultant, the Consultant Representatives
or any third party for any special, indirect, incidental, or consequential damages in connection with this Agreement, whether for negligence
or breach of contract, including without limitation loss of business opportunities, profits or revenues, and whether or not the possibility
of such damages or loss of opportunities, profits or revenues has been disclosed by the Consultant in advance or could have been reasonably
foreseen by the Company. The Company&#8217;s liability for any and all direct damages in connection with this Agreement will not, in any
event, in aggregate exceed the total fees actually paid or payable to the Consultant for the Services performed under the terms of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability</B>.
If any provision of this Agreement is held invalid, illegal or unenforceable, the remaining provisions will not be affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing
Law</B>. This Agreement will be governed by and interpreted in accordance with the laws of the Province of British Columbia and the laws
of Canada applicable therein without reference to its conflict of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;Notice</B>.
Every notice, request, demand or direction (each, for the purposes of this section, a &#8220;<B>notice</B>&#8221;) to be given pursuant
to this Agreement by either party to another will be in writing and will be delivered or sent by registered or certified mail postage
prepaid and mailed in any government post office or by email, or other similar form of written communication, in each case, addressed
as above or to another address as notified hereunder from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretation</B>.
In this Agreement, (a)&nbsp;&#8220;<B>&sect;</B>&#8221; means a section, subsection, paragraph or sub-paragraph of this Agreement and
 &#8220;Part&#8221; means a captioned part of this Agreement, (b)&nbsp;any word in this Agreement is deemed to include the masculine, feminine,
neuter, singular or plural form thereof as the context so required, (c)&nbsp;the captions and headings used in this Agreement are for
convenience only and do not constitute substantive matter and are not to be construed as interpreting the contents of this Agreement,
and (d)&nbsp;the word &#8220;<B>including</B>&#8221; is not limiting (whether or not non-limiting language such as &#8220;without limitation&#8221;
or &#8220;but not limited to&#8221; or other words of similar import are used with reference thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire
Agreement</B>. This Agreement, including all Schedules hereto, forms the entire agreement among the parties and supersedes all prior agreements,
proposals or communications relative to the subject matter of this Agreement. Amendments to or waivers of this Agreement will be effective
only if in writing and signed by authorized representatives of all parties. Unless otherwise expressly stated, if there is any necessary
conflict between any of the terms of this Agreement and Schedules to this Agreement, this Agreement will take precedence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Acceptance</B>.
This Agreement is executed effective as of the day and year first above written and may be executed in counterparts, each of which will
constitute an original and all of which taken together will constitute one and the same instrument, and delivery of the counterparts may
be effected by means of electronic transmission. The reproduction of signatures by electronic transmission will be treated as binding
as if originals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AMORFIX LIFE SCIENCES LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Per:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">VIRTUA LLC &nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Eugene Williams</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Eugene Williams</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Elliot Goldstein</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Elliot Goldstein</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SCHEDULE
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SERVICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Services
(Scope of Work)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Goldstein</I></B>.
Goldstein shall be appointed by the Company as the Chief Executive Officer (&#8220;<B>CEO</B>&#8221;) and a director of the Company (subject
to any applicable shareholder approval) and to hold such offices as the Board of Directors of the Company and the Consultant agree from
time to time. Goldstein&#8217;s duties will generally be to provide the Company and its subsidiaries with executive managerial services
(the &#8220;<B>CEO Services</B>&#8221;) customary for a CEO of a public company working for the Company on a full time basis and to perform
any and all duties and responsibilities reasonably assigned to it from time to time by the Board of Directors of the Company in connection
therewith. The Consultant will (and will cause the Consultant Representatives to) dedicate appropriate attention, time and effort to Company
in connection with the Services. The parties expect that the Services will generally consume Goldstein&#8217;s full working time and attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Williams</I></B>.
Williams shall be appointed the Executive Chair (the &#8220;<B>Chair</B>&#8221;) of the Company and a director of the Company (subject
to any applicable shareholder approval) and to hold such offices as the Board of Directors of the Company and the Consultant agree from
time to time. Williams&#8217; duties will generally be to provide the Company and its subsidiaries with the executive services (the &#8220;<B>Chair
Services</B>&#8221;, and collectively with the CEO Services, the &#8220;<B>Services</B>&#8221;) customary for a Chair of a public company
and to perform any and all duties and responsibilities reasonably assigned to him from time to time by the Board of Directors of the Company
in connection therewith. The parties expect that Williams will devote the working time and attention commensurate with the duties of an
Executive Chair.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Location</B>.
The parties expect that Goldstein will generally perform the Services from San Francisco, California, and that Williams will generally
perform the Services from his own office in Boston, Massachusetts, though the Company may require that the Consultant Representatives
to travel from time to time (such travel to be reimbursed in accordance with the provisions of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TERM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B>.
The term of this Agreement will commence on the Effective Date and will continue until terminated earlier in accordance with &sect;A4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination</B>.
This Agreement may be terminated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the Consultant for any reason at any time upon thirty (30) days&#8217; written notice to the Company, which the Company may abridge or
waive in its sole discretion;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the Consultant immediately upon notice if the Company has materially breached this Agreement and such breach remains uncured after fifteen
(15) days&#8217; written notice from the Consultant to the Company describing the reasonable particulars of such breach;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the Company immediately upon written notice if the Consultant has materially breached this Agreement and such breach remains uncured after
fifteen (15) days&#8217; written notice from the Company to the Consultant describing the reasonable particulars of such breach;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the Company in circumstances where &sect;A4(c)&nbsp;does not apply, for any reason at any time upon thirty (30) days&#8217; written notice
to the Consultant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;automatically
upon the death or permanent disability of one of the Consultant&#8217;s Representatives; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;upon
the written, mutual agreement of both parties.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FEES AND PAYMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Fees</B>.
The fixed Fees for performing the Services are [***] US DOLLARS (US$[***]) on a fixed fee basis per month (to be allocated for the Company&#8217;s
purposes as to US$[***] for Goldstein&#8217;s services and US$[***] for Williams&#8217; services) plus Applicable Taxes. The Company will
pay the Consultant in equal, monthly installments as a monthly retainer on the first business day of each such period commencing upon
the Start Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Expenses</B>.
The Company will reimburse the Consultant in accordance with its normal policies and practices for the Consultant&#8217;s reasonable,
out-of-pocket expenses or disbursements actually and necessarily incurred or made by the Consultant in connection with the performance
of the Services (collectively, &#8220;<B>Expenses</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Option
Grant</B>. The Company plans to complete the private placement (the &#8220;<B>Private Placement</B>&#8221;) that was announced by the
Company on May&nbsp;22, 2015 in more than one closing (with a first closing on July&nbsp;6, 2015) and, in connection therewith, will grant
to each of the Consultant&#8217;s Representatives on each closing date of the Private Placement the maximum number of options (the &#8220;<B>Options</B>&#8221;)
permitted under the Company&#8217;s Stock Option Plan (being a grant to each optionee of 5% of the Company&#8217;s then issued and outstanding
shares) until each of the Consultant&#8217;s Representatives has been granted Options equal to five percent of the shares issued and outstanding
immediately following the completion or termination of the Private Placement. All such Options will be subject to the Company&#8217;s
Stock Option Plan, as amended from time to time, will expire on the date that is 10 years after the grant date and will entitle the optionee
to acquire shares at the Market Price (as defined in the TSX Company Manual) on the grant date (the &#8220;<B>Strike Price</B>&#8221;
for such Options), subject to vesting as follows: one quarter will vest immediately on the grant of the Options and the balance will vest
in equal installments on the last day of each month for 36 months following the Effective Date, except, in the event of a Change of Control
or in the case where there is a termination Without Good Reason, on the occurrence of which the entire balance shall vest immediately.
In the event this Agreement is terminated other than for a Change of Control or where there is a termination Without Good Reason, unvested
Options will cease vesting as of such termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Taxes</B>.
From time to time, the Consultant will advise the Company of the Consultant&#8217;s applicable sales or service tax registration numbers
and will be responsible for collecting from the Company and remitting all applicable excise, sales, goods and services, and use taxes
imposed by any federal, state, provincial, municipal or other governmental authority (each an &#8220;<B>Applicable Tax</B>&#8221;) on
the Services. The Company will pay all such Applicable Taxes to the Consultant. The Consultant will be responsible for any error or omission
of Applicable Taxes and will promptly indemnify the Company for any liability the Company incurs as a result of such error or omission
by the Consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SCHEDULE
B<BR>
CHANGE OF CONTROL<BR>
DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8220;<B>Acquiror</B>&#8221; means
a person, or a group of persons (including their Affiliates) acting jointly and in concert, who are different from (i)&nbsp;a person or
group of persons holding the securities or the assets of the Company, as the case may be immediately prior to a transaction, or (ii)&nbsp;the
affiliates of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8220;<B>Change of Control</B>&#8221;
means</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
merger, consolidation, amalgamation, arrangement or reorganization of the Company (or series of such transactions) that results in the
transfer of more than fifty percent 50% of the total voting power of the Company&#8217;s (or resulting entity&#8217;s) outstanding securities
to an Acquiror when compared against the total voting power of the Company prior to such transaction or series of transactions,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
direct or indirect sale or other transfer of beneficial ownership of all or substantially all of the issued and outstanding securities
of the Company to an Acquiror,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
direct or indirect sale or other transfer of beneficial ownership of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;securities
of the Company possessing more than twenty-fifty percent (25%) of the total combined voting power of the Company&#8217;s outstanding securities,
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
right to appoint a majority of the board of directors of the Company or otherwise directly or indirectly control the management, affairs
and business of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">to an Acquiror, the result of which is
that a majority of the Company&#8217;s board of directors elected at a proximate annual or special meeting of shareholders of the Company
are non-incumbent individuals who are nominees of such Acquiror, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
direct or indirect sale or other disposition of all or substantially all of the assets of the Company to an Acquiror.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#8220;Without
Good Reason&#8221;</B></FONT> means the occurrence of one of the following events without the applicable Consultant Representative&#8217;s
written consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">upon
termination under section A4(b);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">change
in the location from which a Consultant Representative is required to perform his Services; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
material reduction in the responsibilities, title or reporting of the applicable Consultant Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>26
<FILENAME>filename26.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.12</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv)&nbsp;because it
is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated
by: [***]</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSULTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Consulting Agreement (the &ldquo;Agreement&rdquo;)
is made effective as of October&nbsp;17, 2016 (the of &ldquo;Effective Date&rdquo;), by and between ProMIS Neurosciences,&nbsp;Inc. a
Canadian corporation, with its principal place of business being 1920 Yonge Street, Suite&nbsp;200, Toronto, Ontario M4S 3E2 (the &ldquo;Company&rdquo;)
and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being [***] (&ldquo;Danforth&rdquo;).
The Company and Danforth are herein sometimes referred to individually as a &ldquo;Party&rdquo; and collectively as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company possesses
know-how and proprietary technology related to the development of precision medicine therapeutics for the effective treatment of neurodegenerative
diseases, including Alzheimer&rsquo;s and ALS; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Danforth has expertise
in financial and corporate operations and strategy; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Danforth desires
to serve as an independent consultant for the purpose of providing the Company with certain strategic and financial advice and support
services, as more fully described in <U>Exhibit&nbsp;A</U> attached hereto, (the &ldquo;Service&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company wishes
to engage Danforth on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW THEREFORE, in consideration
of the foregoing and for other good and valuable consideration, the receipt of which are hereby acknowledged, the Parties agree and covenant
as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>Services of Consultant</U>. Danforth will assist the Company with matters relating to the Services.
The Services are more fully described in <U>Exhibit&nbsp;A</U> attached hereto. Danforth and the Company will review the Services on a
monthly basis to prioritize and implement the tasks listed on <U>Exhibit&nbsp;A</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Compensation for Services</U>. In full consideration of Danforth&rsquo;s full, prompt and faithful
performance of the Services, the Company shall compensate Danforth a consulting fee more fully described in <U>Exhibit&nbsp;A</U> (the
 &ldquo;Consulting Fee&rdquo;). Danforth shall, from time to time, but not more frequently than twice per calendar month, invoice the Company
for Services rendered, and such invoice will be paid upon (15) days of receipt. Each month the Parties shall evaluate jointly the current
fee structure and scope of Services. Danforth reserves the right to an annual increase in consultant rates of up to 4%, effective January&nbsp;1
of each year. Upon termination of this Agreement pursuant to Section&nbsp;3, no compensation or benefits of any kind as described in this
Section&nbsp;2 shall be payable or issuable to Danforth after the effective date of such termination. In addition, the Company will reimburse
Danforth for reasonable out-of-pocket business expenses, including but not limited to travel and parking, incurred by Danforth in performing
the Services hereunder, upon submission by Danforth of supporting documentation reasonably acceptable to the Company. Any such accrued expenses in
any given three (3)&nbsp;month period that exceed one thousand dollars ($1,000) shall be submitted to the Company for its prior written
Approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Danforth invoices and
billing matters should be addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; width: 49%; text-align: left"><FONT STYLE="font-size: 10pt">Company Accounts
    Payable Contact:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-size: 10pt">Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">With copy to:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Janet Clennet</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">All Company payments and billing inquiries should be addressed to:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">Danforth Accounting:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Betsy Sherr</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Term and Termination</U>. The term of this Agreement will commence on the Effective Date and Will continue
through the anniversary of such date in the next calendar year (the y r &ldquo;Term&rdquo;). This Agreement may be extended for an additional
period by mutual written agreement. This Agreement may be terminated by either Party hereto: (a)&nbsp;with Cause (as defined below), upon
thirty (30) days prior written notice to the other Party; or (b)&nbsp;without cause upon sixty (60) days prior written notice to the other
Party. For purposes of this Section&nbsp;3, &ldquo;Cause&rdquo; shall include: (i)&nbsp;a breach of the terms of this Agreement which
is not cured within thirty (30) days of written notice of such default or (ii)&nbsp;the commission of any act of fraud, embezzlement or
deliberate disregard of a rule&nbsp;or policy of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>Time Commitment</U>. Danforth will devote such time to perform the Services under this Agreement as
may reasonably be required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Place of Performance</U>. Danforth will perform the Services at such locations upon which the Company
and Danforth may mutually agree. Danforth will not, without the prior written consent of the Company, perform any of the Services at any
facility or in any manner that might give anyone other than the Company any rights to or allow for disclosure of any Confidential Information
(as defined below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>Compliance with Policies and Guidelines</U>. Danforth will perform the Services in accordance with
all rules&nbsp;or policies adopted by the Company that the Company discloses in writing to Danforth.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>Confidential Information</U>. Danforth acknowledges and agrees that during the course of performing
the Services, the Company may furnish, disclose or make available to Danforth information, including, but not limited
to, material, compilations, data, formulae, models, patent disclosures, procedures, processes, business plans, projections, protocols,
results of experimentation and testing, specifications, strategies and techniques, and all tangible and intangible embodiments thereof
of any kind whatsoever (including, but not limited to, any apparatus, biological or chemical materials, animals, cells, compositions,
documents, drawings, machinery, patent applications, records and reports), which is owned or controlled by the Company and is marked or
designated as confidential at the time of disclosure or is of a type that is customarily considered to be confidential information (collectively
the &ldquo;Confidential Information&rdquo;). Danforth acknowledges that the Confidential Information or any part thereof is the exclusive
property of the Company and shall not be disclosed to any third party without first obtaining the written consent of the Company. Danforth
further agrees to take all practical steps to ensure that the Confidential Information, and any part thereof, shall not be disclosed or
issued to its affiliates, agents or employees, except on like terms of confidentiality. The above provisions of confidentiality shall
apply for a period of five (5)&nbsp;years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>Intellectual Property</U>. Danforth agrees that all ideas, inventions, discoveries, creations, manuscripts,
properties, innovations, improvement&rsquo;s, know-how, inventions, designs, developments, apparatus, techniques, methods, and formulae
that Danforth conceives, makes, develops or improves as a result of performing the Services, whether or not reduced to practice and whether
or not patentable, alone or in conjunction with any other party and whether or not at the request or upon the suggestion of the Company
(all of the foregoing being hereinafter collectively referred to as the &ldquo;Inventions&rdquo;), shall be the sole and exclusive property
of the Company. Danforth hereby agrees in consideration of the Company&rsquo;s agreement to engage Danforth and pay compensation for the
Services rendered to the Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged
that Danforth shall not, without the prior written consent of the Company, directly or indirectly, consult for, or become an employee
of, any company which conducts business in the Field of Interest anywhere in the world. As used herein, the term &ldquo;Field of Interest&rdquo;
shall mean the research, development, manufacture and/or sale of the products resulting from the Company&rsquo;s technology. The limitations
on competition contained in this Section&nbsp;8 shall continue during the time that Danforth performs any Services for the Company, and
for a period of three (3)&nbsp;months following the termination of any such Services that Danforth performs for the Company. If any part
of this section should be determined by a court of competent jurisdiction to be unreasonable in duration, geographic area, or scope, then
this Section&nbsp;8 is intended to and shall extend only for such period of time, in such area and with respect to such activity as is
determined to be reasonable. Except as expressly provided herein, nothing in this Agreement shall preclude Danforth from consulting for
or being employed by any other person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>Non Solicitation</U>. All personnel representing Danforth are employees or contracted agents of Danforth.
As such, they are obligated to provide the Services to the Company and are obligated to Danforth under confidentiality, non-compete, and
non-solicitation agreements. Accordingly, they are not retainable
as employees or contractors by the Company and the Company hereby agrees not to solicit, hire or retain their services for so long as
they are contracted agents of Danforth and for two (2)&nbsp;years thereafter. Should the Company violate this restriction, it agrees to
pay Danforth liquidated damages equal to equal to thirty percent (30%) of the employee&rsquo;s starting annual base salary and target
annual bonus for each Danforth contracted agent hired by the Company in violation of this Agreement, plus Danforth&rsquo;s reasonable
attorneys&rsquo; fees and costs incurred in enforcing this agreement should the Company fail or refuse to pay the liquidated damages amount
in full within thirty (30) days following its violation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><U>Placement Services</U>. In the event that Danforth refers a potential employee to the Company and that
individual is hired, Danforth shall receive a fee equal to twenty percent (20%) of the employee&rsquo;s starting annual base salary and
target annual bonus. This fee is due and owing whether an individual is hired, directly or indirectly on a permanent basis or on a contract
or consulting basis by the Company, as a result of Danforth&rsquo;s efforts within one (1)&nbsp;year of the date applicant(s)&nbsp;are
submitted to the Company. Such payment is due within thirty (30) days of the employee&rsquo;s start date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>No Implied Warranty</U>. Except for any express warranties stated herein, the Services are provided
on an &ldquo;as is&rdquo; basis, and the Company disclaims any and all other warranties, conditions, or representations (express, implied,
oral or written), relating to the Services or any part thereof. Further, in performing the Services Danforth is not engaged to disclose
illegal acts, including fraud or defalcations, which may have taken place. The foregoing notwithstanding, Danforth will promptly notify
the Company if Danforth becomes aware of any such illegal acts during the performance of the Services. Because the Services do not constitute
an examination in accordance with standards established by the American Institute of Certified Public Accountants (the &ldquo;AICPA&rdquo;),
Danforth is precluded from expressing an opinion as to whether financial statements provided by the Company are in conformity with generally
accepted accounting principles or any other standards or guidelines promulgated by the AICPA, or whether the underlying financial and
other data provide a reasonable basis for the statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><U>Indemnification</U>. Each Party hereto agrees to indemnify and hold the other Party hereto, its directors,
officers, agents and employees harmless against any claim based upon circumstances alleged to be inconsistent with such representations
and/or warranties contained in this Agreement. Further, the Company shall indemnify and hold harmless Danforth and any of its subcontractors
against any claims, losses, damages or liabilities (or actions in respect thereof) that arise out of or are based on the Services performed
hereunder, except for any such claims, losses, damages or liabilities arising out of the gross negligence or willful misconduct of Danforth
or any of its subcontractors. The Company will endeavor to add Consultant and any applicable subcontractor to its insurance policies as
additional insureds.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><U>Independent Contractor</U>. Danforth is not, nor shall Danforth be deemed to be at any time during
the term of this Agreement, an employee of the Company, and therefore Danforth shall not be entitled to any benefits provided by the Company
to its employees, if applicable. Danforth&rsquo;s status and relationship with the Company shall be that of an independent contractor
and consultant. Danforth shall not state or imply, directly or indirectly, that Danforth is empowered to bind the Company without the
Company&rsquo;s prior written consent. Nothing herein shall create, expressly or by implication, a partnership, joint venture or other
association between the parties. Danforth will be solely responsible for payment of all charges and taxes arising from his or her relationship
to the Company as a consultant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><U>Records</U>. Upon termination of Danforth&rsquo;s relationship with the Company, Danforth shall deliver
to the Company any property or Confidential Information of the Company relating to the Services which may be in its possession including
products, project plans, materials, memoranda, notes, records, reports, laboratory notebooks, or other documents or photocopies and any
such information stored using electronic medium.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any notice under this Agreement shall be in writing (except in the case of verbal communications,
emails and teleconferences updating either Party as to the status of work hereunder) and shall be deemed delivered upon personal delivery,
one day after being sent via a reputable nationwide overnight courier service or two days after deposit in the mail or on the next business
day following transmittal via facsimile. Notices under this Agreement shall be sent to the following representatives of the Parties:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; width: 20%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Name:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Title:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Address:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Phone:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">E-mail:</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 78%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Eugene Williams</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Executive Chairman</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><BR>
    [***]<BR>
    [***]</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to
    Danforth:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Name:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Title:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Address:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Phone:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">E-mail:</FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Gregg Beloff</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Managing Director</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[***]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[***]</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify"><U>Assignment and Successors</U>. This Agreement may not be assigned by a Party without the consent
                                                           of the other which consent shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights,
                                                           obligations and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all or substantially all
                                                           of its assets or to any successor corporation
resulting from any merger or consolidation of such Party with or into such corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify"><U>Force Majeure</U>. Neither Party shall be liable for failure of or delay in performing obligations
set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters
or any causes beyond the reasonable control of either Party. In the event of such force majeure, the Party affected thereby shall use
reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify"><U>Headings</U>. The Section&nbsp;headings are intended for convenience of reference only and are not
intended to be a part of or to affect the meaning or interpretation of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify"><U>Integration; Severability</U>. This Agreement is the sole agreement with respect to the subject matter
hereof and shall supersede all other agreements and understandings between the Parties with respect to the same. If any provision of this
Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention
of the Parties that the remainder of the Agreement shall not be affected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of
the Commonwealth of Massachusetts, excluding choice of law principles. The Parties agree that any action or proceeding arising out of
or related in any way to this Agreement shall be brought solely in a Federal or State court of competent jurisdiction sitting in the Commonwealth
of Massachusetts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in counterparts, each of which will be deemed an original,
but all of which together will constitute one agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are in agreement with the foregoing, please
sign where indicated below, whereupon this Agreement shall become effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">DANFORTH ADVISORS, LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">PROMIS NEUROSCIENCES,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Daniel Geffken&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Eugene Williams&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 8%"><FONT STYLE="font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 41%"><FONT STYLE="font-size: 10pt">Daniel Geffken</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 41%"><FONT STYLE="font-size: 10pt">Eugene Williams</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">Managing Director</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">Executive Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">October&nbsp;17, 2016</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">October&nbsp;17, 2016</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12(1)
<SEQUENCE>27
<FILENAME>filename27.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Exhibit 10.12.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Amendment #1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Consulting Agreement dated October 17, 2016 between<BR>
<U>ProMIS Neurosciences, Inc. and Danforth Advisors, LLC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No. 1 to Consulting
Agreement (&#8220;Amendment&#8221;) is made as of March 27, 2017 (&#8220;Effective Date&#8221;), by and between ProMIS Neurosciences,
Inc. (&#8220;Company&#8221;) and Danforth Advisors, LLC (&#8220;Consultant&#8221; or &#8220;Danforth&#8221;). Capitalized terms used but
not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors and the Company
dated as of October 17, 2016 (&#8220;Agreement&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>Danforth is
engaged by the Company under the terms and conditions of the Consulting Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the Company
and Consultant mutually desire to amend the scope of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in
consideration of the premises and the mutual covenants and agreements herein contained and for the other good and valuable consideration,
receipt of which is hereby acknowledge, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Exhibit A, Description of Services and Schedule of Fees, shall be hereby modified to:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#111;</FONT></FONT></TD><TD STYLE="text-align: justify">Add Kristi Lanier as a VP of Finance Consultant at an hourly rate of $215/hour. The Services to be provided
are more fully described in Exhibit A-1.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#111;</FONT></FONT></TD><TD STYLE="text-align: justify">Replace the Fee Section entirely, as illustrated in Exhibit A-1. Notably, the CFO Services provided by
Daniel Geffken will now be provided under a retainer agreement.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified
and shall remain in full force and effect.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amendment may be executed in one or more
counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same Amendment,
and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Amendment
has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DANFORTH ADVISORS, LLC</B>&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROMIS NEUROSCIENCES, INC.</B>&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.75pt; width: 3%">By:</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left; padding-right: 5.75pt; width: 42%">/s/ Gregg Beloff&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-right: 5.75pt; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; padding-right: 5.75pt; width: 47%">/s/ Eugene Williams &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<TR STYLE="vertical-align: top">

<TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">Print Name: Gregg Beloff</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">Print Name: Eugene Williams</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">Title: Managing Director</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">Title: Executive Chairman</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">Date: 3/30/17</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.75pt">Date: 3/28/17</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><U>EXHIBIT A-1</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Description of Additional Services</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Intentionally Omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="text-align: justify; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12(2)
<SEQUENCE>28
<FILENAME>filename28.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT NO. 2 TO CONSULTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No.&nbsp;2
to Consulting Agreement (&ldquo;Amendment No.&nbsp;2&rdquo;) is made as of last date of signature below (&ldquo;Amendment No.&nbsp;2 Effective
Date&rdquo;), by and between ProMIS Neurosciences,&nbsp;Inc. with a principal place of business being 1920 Yonge Street, Suite&nbsp;200,
Toronto, ON M4S 3E2 (&ldquo;Company&rdquo;) and Danforth Advisors, LLC, with a principal place of business being 91 Middle Road, Southborough,
MA 01772 (&ldquo;Danforth&rdquo;). Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting
Agreement by and between Danforth Advisors and the Company dated as of October&nbsp;17, 2016 (&ldquo;Agreement&rdquo;). Collectively,
Danforth and Company may be referred to as &ldquo;Parties&rdquo; and either individually as &ldquo;Party&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
Danforth is engaged by the Company under the terms and conditions of the Agreement to provide certain Services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
the Term of the Agreement was set to expire on October&nbsp;17, 2017; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
Parties now agree to extend the Term of the Agreement such that it will expire on October&nbsp;17, 2018 and modify the agreement as further
detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B></FONT>, the Agreement is revised to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Section&nbsp;3. <U>Term and Termination</U> The term of this Agreement will commence on the Effective
Date and will continue through October&nbsp;17, 2018 (the &ldquo;Term&rdquo;). This Agreement may be extended for an additional period
by mutual written agreement. This Agreement may be terminated by either Party hereto: (a)&nbsp;with Cause (as defined below), upon thirty
(30) days prior written notice to the other Party; or (b)&nbsp;without cause upon sixty (60) days prior written notice to the other Party.
For purposes of this Section&nbsp;3, &ldquo;Cause&rdquo; shall include: (i)&nbsp;a breach of the terms of this Agreement which is not
cured within thirty (30) days of written notice of such default or (ii)&nbsp;the commission of any act of fraud, embezzlement or deliberate
disregard of a rule&nbsp;or policy of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as specifically provided for in this Amendment
No.&nbsp;2, the terms of the Agreement shall be unmodified and shall remain in full force and effect. For avoidance of doubt this Agreement
remained in effect the entire time between October&nbsp;17, 2017 and the Effective Date of this Amendment No.&nbsp;2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amendment No.&nbsp;2 may be executed in one
or more counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same
Amendment No.&nbsp;2, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to
the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Amendment
No.&nbsp;2 has been executed by the Company and Danforth to be effective as of Amendment No.&nbsp;2 Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DANFORTH ADVISORS, LLC</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS NEUROSCIENCES,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregg Beloff</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregg Beloff</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/7/17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/12/17 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12(3)
<SEQUENCE>29
<FILENAME>filename29.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.12.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amendment #3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement dated October&nbsp;17, 2016
between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ProMIS Neurosciences,&nbsp;Inc. and Danforth
Advisors, LLC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No.&nbsp;3
to Consulting Agreement (&ldquo;Amendment&rdquo;) is made as of August&nbsp;28, 2018 (&ldquo;Effective Date&rdquo;), by and between ProMIS
Neurosciences,&nbsp;Inc. (&ldquo;Company&rdquo;) and Danforth Advisors, LLC (&ldquo;Consultant&rdquo; or &ldquo;Danforth&rdquo;). Capitalized
terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors
and the Company dated as of October&nbsp;17, 2016 (&ldquo;Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Danforth is
engaged by the Company under the terms and conditions of the Consulting Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Company
and Consultant mutually desire to amend the term and scope of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises and the mutual covenants and agreements herein contained and for the other good and valuable consideration,
receipt of which is hereby acknowledge, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Section&nbsp;3. <U>Term and Termination</U> is hereby modified to extend the term of the Agreement until
October&nbsp;17, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Exhibit&nbsp;A, Description of Services and Schedule of Fees, shall be hereby modified to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Add Lucy Sennett as a Controller Consultant at an hourly rate of $155/hour. The Services to be provided
are more fully described in Exhibit&nbsp;A-3.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified
and shall remain in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Amendment may be executed in one
or more counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same
Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Amendment
has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>DANFORTH ADVISORS, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PROMIS NEUROSCIENCES,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">/s/ Gregg Beloff</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">/s/ Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Print Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gregg Beloff</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Print Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Title: &nbsp;&nbsp;Managing Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Title: &nbsp;&nbsp;Executive Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date:&nbsp;&nbsp;&nbsp; <U>8/31/18</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;A-3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Description of Additional Services</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally Omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12(4)
<SEQUENCE>30
<FILENAME>filename30.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 10.12.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(b)(10)(iv)&nbsp;because it is both not material and is the type of
information that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amendment #4</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consulting Agreement dated October&nbsp;17, 2016
between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ProMIS Neurosciences,&nbsp;Inc. and Danforth
Advisors, LLC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No.&nbsp;4
to Consulting Agreement (&ldquo;Amendment&rdquo;) is made as of October&nbsp;1, 2021 (&ldquo;Effective Date&rdquo;), by and between ProMIS
Neurosciences,&nbsp;Inc. (&ldquo;Company&rdquo;) and Danforth Advisors, LLC (&ldquo;Consultant&rdquo; or &ldquo;Danforth&rdquo;). Capitalized
terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors
and the Company dated as of October&nbsp;17, 2016 (&ldquo;Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
Danforth is engaged by the Company under the terms and conditions of the Consulting Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
the Company and Consultant mutually desire to amend the term and scope of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B></FONT>, in consideration of the premises and the mutual covenants and agreements herein contained and for the other good
and valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Section&nbsp;3. <U>Term and Termination</U> is hereby modified to extend the term of the Agreement until
October&nbsp;29, 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Exhibit&nbsp;A to the Agreement is hereby modified to allow Danforth to add the services of various Danforth
employees to perform the Services required and approved, such approval to be provided verbally or by email, by the Company at each such
Danforth employee&rsquo;s billable rate in effect at the time they are added to the Agreement. The billable rates in effect as of the
date of this Amendment No.1 are as described in Exhibit&nbsp;A-4.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified
and shall remain in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Amendment may be executed in one
or more counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same
Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this Amendment
has been executed by the Company and Danforth to be effective as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DANFORTH ADVISORS, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS NEUROSCIENCES,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Chris Connors</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chris Connors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    &nbsp;&nbsp;Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    &nbsp;&nbsp;Executive Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>11/10/2021</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eugene Williams</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A-4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Description of Services and Schedule of Fees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Danforth will perform mutually agreed to finance
and accounting functions which are necessary to support the management and operations of the Company including, but not limited to, the
functions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Role</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 15%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hourly
    Rate</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Function</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Advisor</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Advisory </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Officer </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. HR Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Resources </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Resources</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VP Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr HR Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Resources </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr Controller/FP&amp;A</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HR Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human Resources </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sr. Consultant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asst. Controller </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]/hour</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff Accountant</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mr.</FONT>&nbsp;Daniel
Geffken will work for a monthly fixed fee of $15,000 (estimated at a 35 hour commitment /month), commencing October&nbsp;1, 2021. As additional
consideration for the fixed fee arrangement, the Board of Directors of the Company will vote at its next Board Meeting on November&nbsp;11,
2021 to provide Danforth an option (the &ldquo;Danforth Option&rdquo;) to purchase 500,000 shares of common stock. The Danforth Option
shall have a 10-year term an exercise price equal to the fair value of the common stock as determined by the Board of Directors of the
Company on the date such option is issued and shall vest ratably over 12 months commencing on the Effective Date, subject to the continued
provision of services to the Company by Danforth as of each vesting date. If this agreement is terminated by the Company within 6 months
of the Effective Date, for other than cause, then shares as to 50% of the Danforth Option shall vest. The Company and Danforth will enter
into a separate stock option agreement within 30 days of the Effective Date, to be negotiated in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>31
<FILENAME>filename31.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.13</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE AUGUST 31, 2018.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M.&nbsp;(EST) ON APRIL 30, 2023 (WHICH EXPIRY DATE IS SUBJECT TO ACCELERATION IN ACCORDANCE WITH THE TERMS ATTACHING TO THE
WARRANTS) AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certificate FW#<B>2018-04-F&laquo;Number&raquo;</B> dated April&nbsp;30,
2018 (the &#8220;Issue Date&#8221;), representing <B>&laquo;Warrants&raquo;</B> Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FINDER&#8217;S WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROMIS
NEUROSCIENCES INC.<BR>
</B></FONT>(Incorporated under the laws of Canada)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&laquo;Registration&raquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMis Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on April&nbsp;30, 2018, at a price of CAD$0.48 per Common
Share until 5:00 pm (EST) on April&nbsp;30, 2023 (the &#8220;Expiry Date&#8221;). The Expiry Date may be accelerated by the Issuer at
any time following the four-month anniversary of the issue date of the Warrants and prior to the Expiry Date if the volume-weighted average
trading price of the Common Shares on the TSX is greater than CAD$1.00 for any twenty (20) consecutive trading days, at which time the
Issuer may accelerate the Expiry Date by issuing a press release announcing the reduced term of the Warrants, whereupon the Warrants will
expire on the thirtieth (30<SUP>th</SUP>) calendar day after the date of such press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite&nbsp;200, 1920 Yonge Street, Toronto, Ontario,
M4S 3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form&nbsp;attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer as
it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise of the
Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder pursuant to said
exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such person
shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares are to be issued to a person
other than the Holder, the Holder&#8217;s signature on the Subscription Form&nbsp;must be guaranteed by a Canadian chartered bank, a Canadian
trust company or a member firm of the TSX. The Issuer will cause the certificates representing such Common Shares to be mailed to the
Holder at the Holder&#8217;s address stated above or such other address(es) as may be specified in the Subscription Form, within five
business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer shall use all reasonable commercial efforts to preserve and maintain its corporate existence and to ensure that the Common Shares
outstanding or issuable from time to time upon the exercise of the Warrants are listed and posted for trading on the TSX </FONT>(or such
other exchange on which the Common Shares may be listed), provided that this clause shall not be construed as limiting or restricting
the Issuer from completing a consolidation, amalgamation, arrangement, takeover bid or merger that would result in the Common Shares ceasing
to be listed and posted for trading on the TSX (or such other exchange on which the Common Shares may be listed), so long as the holders
of Common Shares receive securities of an entity which is listed on a stock exchange in Canada, or cash, or the holders of the Common
Shares have approved the transaction in accordance with the requirements of applicable corporate and securities laws and the policies
of the TSX (or such other exchange on which the Common Shares may be listed). In addition, the Issuer shall make all requisite filings
under applicable securities legislation necessary to remain a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are non-transferable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legending Of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE AUGUST 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval of the TSX </FONT>(or such other exchange on which the Common Shares may be listed), if at any time after the date hereof
and prior to the expiry of the Warrants, and provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a &#8220;Capital
Reorganization&#8221;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be entitled to receive, at
no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was theretofore entitled to acquire upon
such exercise, the aggregate number of shares, other securities or other property which such Holder should have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be, the Holder had been the
registered holder of the number of Common Shares to which such Holder was theretofore entitled to acquire upon exercise of the Warrants.
If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the application of the provisions
set forth herein with respect to the rights and interests of the Holder relative to a Capital Reorganization, to the end that the provisions
set forth herein shall correspond as nearly as may be reasonably possible to the effect of the Capital Reorganization in relation to any
shares, other securities or other property thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
adjustment shall be made in respect of any event described herein if the Holder is entitled to participate in such event on the same terms,
without amendment, as if the Holder had exercised the Warrants prior to or on the effective date or record date of such event, subject
to the written consent of the TSX </FONT>(or such other exchange on which the Common Shares may be listed). The adjustments provided for
herein are cumulative and such adjustments shall be made successively whenever an event referred to herein shall occur, subject to the
limitations provided for herein. No adjustment shall be made in the number or kind of Shares or other securities which may be acquired
on the exercise of a Warrant unless it would result in a change of at least one-tenth of a Share or other security. Any adjustment which
may by reason of this paragraph not be required to be made shall be carried forward and then taken into consideration in any subsequent
adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for herein
or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other securities
in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To the extent that
the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be exercised in respect
of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a whole number of Common Shares
or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common Share or other security, to be paid
in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not be required to make any
payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants
with and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue
this Warrant and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant
represents a valid, legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ProMis Neurosciences Inc.<BR>
Suite&nbsp;200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
</FONT>416 847 6899</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Rest of Page&nbsp;Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized officer on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">PROMIS NEUROSCIENCES INC.</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMis Neurosciences Inc.<BR>
Suite&nbsp;200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Facsimile: 416 847 6899</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>of the Warrants evidenced thereby in accordance with the terms thereof, and accordingly hereby irrevocably subscribes for the Shares
(as described therein) to be received thereon and irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The
Undersigned hereby irrevocably directs that the Shares to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.&nbsp;of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U> AND IT MUST
PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States Securities Act of 1933, as amended (the &#8220;U.S. Securities Act&#8221;), or any applicable
State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule&nbsp;902(k)&nbsp;of Regulation
S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities laws, unless an
exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>day
of
 &nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;,
20<U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="width: 5%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 51%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Witness<BR>
<B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature of registered holder or Signatory thereof</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If applicable, print Name and Office of Signatory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Print Name of registered holder as on certificate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Street Address</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form&nbsp;and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form&nbsp;indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant
to be converted: (i)&nbsp;the signature of the registered holder on this Subscription Form&nbsp;must be medallion guaranteed by an authorized
officer of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii)&nbsp;the registered
holder must pay to the Issuer all applicable taxes and other duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form&nbsp;is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or
any other person acting in a fiduciary or representative capacity, this Subscription Form&nbsp;must be accompanied by evidence of authority
to sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>32
<FILENAME>filename32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.14</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE
AUGUST 31, 2018.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M.&nbsp;(EST) ON APRIL 30, 2023 (WHICH EXPIRY DATE IS SUBJECT TO ACCELERATION IN ACCORDANCE WITH THE TERMS ATTACHING TO THE
WARRANTS) AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certificate #<B>2018-04-&laquo;Number&raquo;</B> dated April&nbsp;30,
2018 (the &#8220;Issue Date&#8221;), representing <B>&laquo;Warrants&raquo;</B> Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROMIS
NEUROSCIENCES INC.<BR>
</B></FONT>(Incorporated under the laws of Canada)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&laquo;Registration&raquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMis Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on April&nbsp;30, 2018, at a price of CAD$0.48 per Common
Share until 5:00 pm (EST) on April&nbsp;30, 2023 (the &#8220;Expiry Date&#8221;). The Expiry Date may be accelerated by the Issuer at
any time following the four-month anniversary of the issue date of the Warrants and prior to the Expiry Date if the volume-weighted average
trading price of the Common Shares on the TSX is greater than CAD$1.00 for any twenty (20) consecutive trading days, at which time the
Issuer may accelerate the Expiry Date by issuing a press release announcing the reduced term of the Warrants, whereupon the Warrants will
expire on the thirtieth (30<SUP>th</SUP>) calendar day after the date of such press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite&nbsp;200, 1920 Yonge Street, Toronto, Ontario,
M4S 3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form&nbsp;attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer as
it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise of the
Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder pursuant to said
exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such person
shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares are to be issued to a person
other than the Holder, the Holder&#8217;s signature on the Subscription Form&nbsp;must be guaranteed by a Canadian chartered bank, a Canadian
trust company or a member firm of the TSX. The Issuer will cause the certificates representing such Common Shares to be mailed to the
Holder at the Holder&#8217;s address stated above or such other address(es) as may be specified in the Subscription Form, within five
business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Issuer shall use all reasonable commercial efforts to preserve and maintain its corporate existence and to ensure that the Common Shares
outstanding or issuable from time to time upon the exercise of the Warrants are listed and posted for trading on the TSX </FONT>(or such
other exchange on which the Common Shares may be listed), provided that this clause shall not be construed as limiting or restricting
the Issuer from completing a consolidation, amalgamation, arrangement, takeover bid or merger that would result in the Common Shares ceasing
to be listed and posted for trading on the TSX (or such other exchange on which the Common Shares may be listed), so long as the holders
of Common Shares receive securities of an entity which is listed on a stock exchange in Canada, or cash, or the holders of the Common
Shares have approved the transaction in accordance with the requirements of applicable corporate and securities laws and the policies
of the TSX (or such other exchange on which the Common Shares may be listed). In addition, the Issuer shall make all requisite filings
under applicable securities legislation necessary to remain a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are transferable and the term &#8220;Warrantholder&#8221;
shall mean and include any successor, transferee or assignee of the current or any future Warrantholder. The term &#8220;Warrantholder&#8221;
shall mean and include any successor of the Warrantholder. The Warrants may be transferred by the Warrantholder completing and delivering
to the Issuer the transfer form attached hereto as Schedule&nbsp;&#8220;B&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legending Of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE AUGUST 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to approval of the TSX </FONT>(or such other exchange on which the Common Shares may be listed), if at any time after the date hereof
and prior to the expiry of the Warrants, and provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a &#8220;Capital
Reorganization&#8221;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be entitled to receive, at
no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was theretofore entitled to acquire upon
such exercise, the aggregate number of shares, other securities or other property which such Holder should have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be, the Holder had been the
registered holder of the number of Common Shares to which such Holder was theretofore entitled to acquire upon exercise of the Warrants.
If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the application of the provisions
set forth herein with respect to the rights and interests of the Holder relative to a Capital Reorganization, to the end that the provisions
set forth herein shall correspond as nearly as may be reasonably possible to the effect of the Capital Reorganization in relation to any
shares, other securities or other property thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
adjustment shall be made in respect of any event described herein if the Holder is entitled to participate in such event on the same terms,
without amendment, as if the Holder had exercised the Warrants prior to or on the effective date or record date of such event, subject
to the written consent of the TSX </FONT>(or such other exchange on which the Common Shares may be listed). The adjustments provided for
herein are cumulative and such adjustments shall be made successively whenever an event referred to herein shall occur, subject to the
limitations provided for herein. No adjustment shall be made in the number or kind of Shares or other securities which may be acquired
on the exercise of a Warrant unless it would result in a change of at least one-tenth of a Share or other security. Any adjustment which
may by reason of this paragraph not be required to be made shall be carried forward and then taken into consideration in any subsequent
adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for herein
or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other securities
in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To the extent that
the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be exercised in respect
of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a whole number of Common Shares
or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common Share or other security, to be paid
in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not be required to make any
payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants
with and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue
this Warrant and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant
represents a valid, legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ProMis Neurosciences Inc.<BR>
Suite&nbsp;200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
</FONT>416 847 6899</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Rest of Page&nbsp;Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized officer on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">PROMIS NEUROSCIENCES INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMis Neurosciences Inc.<BR>
Suite&nbsp;200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Facsimile: 416 847 6899</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise <FONT STYLE="text-transform: none"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT>
of the Warrants evidenced thereby in accordance with the terms thereof, and accordingly hereby irrevocably subscribes for the Shares
(as described therein) to be received thereon and irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The
Undersigned hereby irrevocably directs that the Shares to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt; width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="padding-top: 3pt; width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No.&nbsp;of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, (I)&nbsp;THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U>,
(II)&nbsp;THE UNDERSIGNED MUST PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES AND (III)&nbsp;THE TRANSFER FORM&nbsp;SET FORTH
IN SCHEDULE &#8220;B&#8221; TO THE WARRANT CERTIFICATE MUST BE COMPLETED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States Securities Act of 1933, as amended (the &#8220;U.S. Securities Act&#8221;), or any applicable
State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule&nbsp;902(k)&nbsp;of Regulation
S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities laws, unless an
exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">DATED the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>&nbsp;day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">}</P></TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Witness<BR>
<B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature of registered holder or Signatory thereof</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If applicable, print Name and Office of Signatory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Print Name of registered holder as on certificate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Street Address</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- 2 -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form&nbsp;and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form&nbsp;indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant
to be converted: (i)&nbsp;the signature of the registered holder on this Subscription Form&nbsp;must be medallion guaranteed by an authorized
officer of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii)&nbsp;the registered
holder must pay to the Issuer all applicable taxes and other duties and (iii)&nbsp;the Transfer Form&nbsp;set forth in Schedule &#8220;B&#8221;
to the Warrant Certificate must be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form&nbsp;is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or
any other person acting in a fiduciary or representative capacity, this Subscription Form&nbsp;must be accompanied by evidence of authority
to sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;B&#8221;<BR>
FORM&nbsp;OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers
unto<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>(include
name and address of the transferee) Warrants exercisable for common shares of ProMis Neurosciences Inc. (the
 &#8220;Corporation&#8221;) registered in the name of the undersigned on the register of the Corporation maintained therefor, and
hereby irrevocably
appoints&nbsp;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
the attorney of the undersigned to transfer the said securities on the books maintained by the Corporation with full power of
substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
20___.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Transferor guaranteed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 47%">Medallion Signature Guarantee Stamp of Transferor</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;Signature of Transferor </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Address of Transferor</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned transferee hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(check one)</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">said transferee was not offered the Warrants in the United
    States and is not in the United States or a &#8220;U.S. Person&#8221; (as defined in Regulation S under the United States Securities
    Act of 1933, as amended (the &#8220;U.S. Securities Act&#8221;)), and is not acquiring the Warrants for the account or benefit of
    a person in the United States or a U.S. Person; or</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">enclosed herewith is an opinion of counsel (which the transferee understands must be satisfactory to the Corporation) to the effect that no violation of the U.S. Securities Act or applicable securities laws will result from transfer, exercise or deemed exercise of the Warrants.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">It is understood that the Corporation may require additional evidence necessary to
    verify the foregoing.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The signature to this transfer must correspond with the name written upon the face of this Warrant Certificate
in every particular without any changes whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Transfer Form&nbsp;indicates
that common shares are to be issued to a person or persons other than the registered holder of the Warrant Certificate, the signature
on this Transfer Form&nbsp;must be guaranteed by a Canadian</FONT> chartered bank, or eligible guarantor institution with membership in
an approved signature guarantee medallion program. The guarantor must affix a stamp bearing the actual words &#8220;Signature Guaranteed&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>33
<FILENAME>filename33.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.15</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS
NEUROSCIENCES INC.<BR>
</B></FONT><B><U>OPTION COMMITMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E</FONT>ffective
this 2<SUP>th</SUP> day of January&nbsp;2019 (the &#8220;<B>Effective Date</B>&#8221;) ProMIS Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;)
has granted to [NAME], an Option to acquire 1,000,000 Common Shares (&#8220;<B>Optioned Shares</B>&#8221;) up to 5:00 p.m.&nbsp;(EST)
on the 2<SUP>th</SUP> day of January&nbsp;2029 (the &#8220;<B>Expiry Date</B>&#8221;) at a Subscription Price of Cdn&nbsp;$0.25 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Optioned Shares may be acquired as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Options will not be exercisable
unless and until they have vested and then only to the extent that they have vested. The Options will vest as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">250,000 </FONT>Optioned Shares will vest immediately</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">750,000 Options Shares will vest equally over thirty-six (36) months.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The grant of the Option evidenced hereby is made subject to Acknowledgements
and Agreements of the Optionee set out herein, the terms and conditions of any applicable consulting or employment agreement, the Corporation&#8217;s
Stock Option Plan, the terms and conditions of which are hereby incorporated herein. To exercise your Option, deliver a written notice,
which shall be substantially in the form attached hereto as Exhibit&nbsp;1 hereto, specifying the number of Optioned Shares you wish to
acquire, together with cash or a certified cheque or bank draft payable to the Corporation for the aggregate Subscription Price, to the
Corporation. A certificate for the Optioned Shares so acquired will be issued by the transfer agent as soon as practicable thereafter.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signed by the Executive Chairman</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- 2 -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acknowledgements and Agreements of the Optionee</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Optionee acknowledges receipt of a copy of the Plan and represents
to the Corporation that the Optionee is familiar with the terms and conditions of the Plan, and hereby accepts this Option subject to
all of the terms and conditions of the Plan. The Optionee agrees to execute, deliver, file and otherwise assist the Corporation in filing
any report, undertaking or document with respect to the awarding of the Option and exercise of the Option, as may be required by the TSX
or securities regulatory authorities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, notwithstanding anything else contained in this Option Commitment
and the Plan, the Optionee acknowledges and agrees as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp; the exercise
of this Option will be subject to the policies, procedures and&nbsp;conditions&nbsp;adopted by the Corporation from time to time to comply
with its obligations imposed under applicable tax law, including, without limitation,&nbsp;the Corporation's withholding, remittance and
other funding liabilities&nbsp;under applicable tax law (collectively, the &#8220;<B>Tax Obligations</B>&#8221;); and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">(b)&nbsp;&nbsp; as a condition of
exercise of this Option, the Optionee must deliver, in addition to the Subscription Price in respect of which this Option is being exercised,
a certified cheque, wire transfer or bank draft payable to the Corporation for the amount determined by the Corporation to be the appropriate
amount on account of such Tax Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Optionee:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
    signed:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- 3 -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT&nbsp;1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS
NEUROSCIENCES INC.<BR>
</B></FONT><B>STOCK OPTION PLAN</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NOTICE OF EXERCISE OF OPTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%">TO:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><B>PROMIS NEUROSCIENCES INC.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">________________________________</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">________________________________</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(or such other address as the Corporation may advise)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby irrevocably gives notice, pursuant to the Stock Option Plan (the &quot;Plan&quot;) of </FONT><B>PROMIS NEUROSCIENCES
INC.</B> (the &quot;Corporation&quot;), of the exercise of the Option to acquire and hereby subscribes for (<B>cross out inapplicable
item):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">all of the Optioned Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                 </U>&nbsp;of the Optioned Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">which are the subject of the Option Commitment attached hereto <B>(attach
your original Option Commitment)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned tenders herewith cash or a certified cheque or bank draft (<B>circle one</B>) payable to &quot;</FONT> <B>PROMIS NEUROSCIENCES
INC.</B>&quot; in an amount equal to the aggregate Subscription Price of the aforesaid Optioned Shares and directs the Corporation to
issue the certificate evidencing said Optioned Shares in the name of the undersigned to be mailed to the undersigned at the following
address (<B>provide complete address</B>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">___________________________________&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">___________________________________&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">___________________________________&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned acknowledges the Option is not validly exercised unless
this Notice is completed in strict compliance with this form and delivered to the required address with the required payment prior to
5:00 p.m.&nbsp;local time in Toronto, Ontario on the Expiry Date of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DATED the __________ day of __________________ , 20 ____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U></U></FONT><B>Signature
of Optionee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>34
<FILENAME>filename34.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
identified information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns.
Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
this form for all non-U.S. Persons (Feb.25.2020)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>NON-U.S.
PERSONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 5pt; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HAVE
                                            YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    following items in this Subscription Agreement must be completed. (Please initial each box.) </B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    information and answers in the boxes on pages&nbsp;1, 2 and 3.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sign
    the execution page&nbsp;on page&nbsp;1 of this Subscription Agreement. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    Schedule &#8220;1&#8221; Accredited Investor Representation Letter and sign</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delivery
of Subscription forms may be made by</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>email
to:</U></B> [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>facsimile
to:</U></B> fax #: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delivery
of certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS
Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite&nbsp;200, Toronto, ON M4S 3E2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Alternatively,
delivery of funds may also be made via electronic wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>To
wire Canadian $ funds:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
Bank: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
Address: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transit
# [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
# [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
#:[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT
Code: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency:
Canadian</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary:
PROMIS NEUROSCIENCES INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
address: 1920 Yonge Street, Suite&nbsp;200, Toronto, ON M4S 3E2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>If
you wish to wire funds in currency other than CDN$, please contact the Corporation by email: </U></B>[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">__________________________________________________________________________&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIPTION
FOR UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProMIS
                                            Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            undersigned (the &ldquo;<B>Subscriber</B>&rdquo;, including, if applicable, each Disclosed
                                            Principal (as hereinafter defined) for whom the undersigned is acting hereunder) hereby irrevocably
                                            subscribes for and agrees to purchase the number of units of the Corporation (the &ldquo;<B>Units</B>&rdquo;)
                                            set forth below for the aggregate subscription amount set forth below (the &ldquo;<B>Aggregate
                                            Subscription Amount</B>&rdquo;), representing a subscription price of <B>CDN$0.20</B> (or
                                            <B>US$0.15)</B> per Unit, on the terms and conditions set forth in &ldquo;Terms and Conditions
                                            of Subscription for Units of ProMIS Neurosciences Inc..&rdquo; attached hereto (together
                                            with the face pages and the attached Schedules, the &ldquo;<B>Subscription Agreement</B>&rdquo;).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Unit consists of one common share of the Corporation (a &#8220;<B>Common Share</B>&#8221;) and one transferable share purchase warrant
(a &#8220;<B>Warrant</B>&#8221;). Each whole Warrant entitles the holder to purchase one Common Share (a &#8220;<B>Warrant Share</B>&#8221;)
at any time for a five year period at a price of <B>CDN$0.35</B> per Warrant Share. The Units, the Common Shares, the Warrants and the
Warrant Shares are hereinafter referred to together as the &#8220;<B>Securities</B>&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Units: _____________________________________</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CDN$0.20
    per Unit, or if subscribing in US$, @ US$0.15 per Unit</B></FONT></P></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aggregate
    Subscription Amount: CDN$ _____________</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Or,
    if subscribing in US$: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;US$ _____________</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 4pt 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    and Signature of Subscriber</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
    Subscriber </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Individual
    Subscriber (e.g., Corporation)</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name of Non-Individual Subscriber) </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
    of Individual Subscriber) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
    of Authorized Signatory) </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name and Official Capacity or Title of Signatory) <BR>
    The signatory represents that he has authority to bind the Subscriber. </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ONLY
                                            IF</U> the Subscriber is signing as agent or trustee for a principal (a &#8220;Disclosed
                                            Principal&#8221;) and is not purchasing as trustee or agent for accounts fully managed by
                                            it, so as to be deemed to be purchasing as principal pursuant to National Instrument 45-106,
                                            complete the following and, if applicable, ensure that all Schedules are completed on behalf
                                            of such Disclosed Principal:</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>_____________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</FONT></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address
    of Subscriber - Residential for Individual / Business for Non-Individual Subscriber</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    of Subscriber </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Telephone
    Number) </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City,
    Province, Postal Code </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Facsimile
    Number) </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Email
    address) </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
                                            INSTRUCTIONS</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 5.4pt; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DELIVERY
    INSTRUCTIONS</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 2%">&nbsp;</TD>
  <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 1pt; width: 45%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Register
                                            the Common Shares and Warrants as set forth below (only complete if different from above):</i></font></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
  <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-top: 1pt; width: 2%">&nbsp;</TD>
  <TD STYLE="border-top: Black 1pt solid; padding-top: 1pt; width: 45%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Deliver
                                            the Common Shares and Warrants as set forth below:</i></font></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; width: 2%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Name)</font></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Name)</font></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Account
    reference, if applicable)</font></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Account
    reference, if applicable)</font></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address)</font></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Contact
    Name)</font></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid"></TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address)</font></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INFORMATION
REGARDING THE SUBSCRIBER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
check the appropriate box (and complete the required information, if applicable) in each section:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
                                            Holdings</B>. Prior to giving effect to the issuance of the securities being subscribed for
                                            under this Subscription Agreement, the Subscriber and all persons acting jointly and in concert
                                            with the Subscriber currently own, directly or indirectly, or exercise control or direction
                                            over (provide additional detail as applicable):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________
    common shares of the Corporation and the following other kinds of rights and convertible securities (including but not limited to
    convertible debt, warrants and options) entitling the Subscriber to acquire additional common shares of the Corporation:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    shares of the Corporation or rights or securities convertible into shares of the Corporation.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insider
                                            Status</B>. The Subscriber either:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    an &#8220;Insider&#8221; of the Corporation as defined in the Policies of the Exchange (as hereinafter defined) by virtue of being:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            director or executive officer of the Corporation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            director or executive officer of a company that is an Insider or subsidiary of the Corporation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
                                            carrying more than 10% of the voting rights attached to all the Corporation&#8217;s outstanding
                                            voting shares; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Corporation itself if it holds any of its own securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    not an Insider of the Corporation.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
                                            Group Status</B>. The Subscriber either:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    a Member of the &#8220;Pro Group&#8221;, which is defined in the Rules&nbsp;of the Exchange as either individually or as a group:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            member (i.e. a member of the Exchange under the Exchange requirements);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employees
                                            of the member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners,
                                            officers and directors of the member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">affiliates
                                            of the member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other persons as the Exchange may determine; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">associates
                                            of any parties referred to in paragraphs 1 through 5 above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    not a member of the Pro Group.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant
                                            Status</B>. The Subscriber either:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    a &#8220;Registrant&#8221; as defined in the <I>Securities Act</I> (British Columbia) by virtue of being a person registered or required
    to be registered under the <I>Securities Act</I> (British Columbia.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
    not a Registrant.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation hereby accepts the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS
NEUROSCIENCES INC</B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Terms of the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in
part. The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or
deduction, if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this Subscription
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding
section 2(a)&nbsp;above, this Offering will not in any way restrict the Corporation from issuing additional securities of the Corporation
at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including an amendment
to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s acceptance
of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be part of a
transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior to the
Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which are outstanding
on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Representations and Warranties of the Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power and authority
to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules&nbsp;and policies of the
Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British Columbia
and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation enforceable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the issue of
the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or any law,
regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is a party
or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition, and,
as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all requisite corporate
action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued as fully paid and
non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding against
the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations or proceedings
for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acknowledgements, Warranties and Covenants of the Subscriber</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber
is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon acceptance
by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at such time,
including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be able to
resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy until
expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any certificates
(or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8220;<B>Unless permitted under securities
legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT>that date
that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange in connection
with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s acceptance
of the Offering, including, without limitation, the conditions noted in paragraphs 4(h)&nbsp;and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior to the
Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which are outstanding
on a non-diluted basis prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">the Exchange may require as a condition
of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10% Insider Rule, the
votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new &#8220;Insider&#8221;
or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering, that the Corporation
obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person and its associates
and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities legislation,
and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering memorandum,
or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and review by,
prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U></FONT>) relating to the Corporation and not upon
any oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge of
any &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly
disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence or place
of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it was not
created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution and
will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and not for the
benefit of any other person and not with a view to the resale or distribution of all or any of the Units and it <U>fully complies with
one or more of the sub-paragraphs set forth below</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is
an &#8220;accredited investor&#8221; within the meaning of applicable securities laws, including National Instrument 45-106 entitled
 &#8220;Prospectus and Registration Exemptions&#8221; (&#8220;<B>NI 45-106</B>&#8221;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has
concurrently executed and delivered a Representation Letter in the form attached as Schedule I to this Subscription Agreement, including
Appendix &#8220;A&#8221; and Appendix &#8220;B&#8221; thereto; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is neither an individual nor a company established solely to acquire the Units and the cost of the Units purchased by it has
an aggregate acquisition of not less than $150,000; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________
(<B>to be initialled by Subscriber, if applicable)</B> - if it is not purchasing under subparagraph 5(f)(i), or (ii), it is purchasing
pursuant to an exemption from prospectus and registration requirements (particulars of which are enclosed herewith or will be provided
on or before the Closing Date) available to it under applicable securities legislation and shall deliver to the Corporation such further
particulars of the exemption(s)&nbsp;and the Subscriber&#8217;s qualifications thereunder as the Corporation may request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable prospectus
exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase on behalf
of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other person, and
not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
and each beneficial purchaser has provided to the Corporation all of the information required by pages&nbsp;1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity
of each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of the principals complies with one or more of subparagraphs 5(f)(i)&nbsp;through (f)(ii), as applicable, and the same is so indicated
for each such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the </FONT>Subscriber is a resident of a country other than Canada or the United States (a &#8220;<B>Jurisdiction Outside CAN-US</B>&#8221;)
then in addition to the other representations and warranties contained herein, the Subscriber represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
</FONT>Subscriber is knowledgeable of, or has been independently advised as to, the applicable securities laws of the Jurisdiction Outside
CAN-US which would apply to this Subscription Agreement, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
</FONT>Subscriber is purchasing the Subscriber&#8217;s Shares pursuant to exemptions from any prospectus, registration or similar requirements
under the applicable securities laws of that Jurisdiction Outside CAN-US or, if such is not applicable, the Subscriber is permitted to
purchase the Subscriber&#8217;s Shares under the applicable securities laws of the Jurisdiction Outside CAN-US without the need to rely
on an exemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
applicable securities laws of the Jurisdiction Outside CAN-US in which the </FONT>Subscriber resides do not require the Corporation to
file a prospectus, registration statement or similar document or to register the Securities or to make any filings or seek any approvals
of any kind whatsoever from any regulatory authority of any kind whatsoever in the Jurisdiction Outside CAN-US;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery of this Subscription Agreement, the acceptance of it by the Corporation and the issuance of the Securities to the Subscriber
complies with all applicable laws of the </FONT>Subscriber&#8217;s jurisdiction of residence or domicile and all other applicable laws
and will not cause the Subscriber to become subject to or comply with any disclosure, prospectus or other offering document or reporting
requirements under any such applicable laws; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Subscriber will, if requested by the Corporation, or its counsel deliver to the Corporation a certificate or opinion of local counsel
from the Jurisdiction Outside CAN-US in which the Subscriber resides which will confirm the matters referred to in subsections (ii),
(iii)&nbsp;and (iv)&nbsp;above to the satisfaction of the Corporation and its counsel, acting reasonably</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber to find out
what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements to provide
the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being advised
by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial and territorial
securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units pursuant to this
exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or damages, will not
be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound by this
Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have been
given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all action
pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding and enforceable
obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and deliver this
Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal and this
Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and binding
agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as
to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment and it, or
where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and delivery
of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation of
an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit such
sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock exchange
or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such reports,
undertakings and other documents with respect to the issue of the Units as may be required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any of the terms
or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s constating
documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent proceeds of
crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that the Corporation
may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription Agreement
and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering) Act
</I>(Canada) and to the best of the Subscriber&#8217;s knowledge (i)&nbsp;none of the subscription funds to be provided by the Subscriber
(A)&nbsp;have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States
of America, or any other jurisdiction, or (B)&nbsp;are being tendered on behalf of a person or entity who has not been identified to
the Subscriber, and (ii)&nbsp;it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases
to be true, and to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the Subscriber
may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain independent
legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently advised as
to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties and covenants
under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
information provided by the Subscriber on pages&nbsp;1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information
Regarding The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation and stock
exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies with
all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of its
officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund its ongoing
development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such future financings
may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are not available, the
Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure of its business
venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as a result
of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a)&nbsp;this duly completed and executed Subscription
Agreement, including all applicable Schedules hereto and Appendices thereto; and (b)&nbsp;the Aggregate Subscription Amount subscribed
for under this Subscription Agreement in accordance with the Instructions on the Cover Page&nbsp;or payment of the same amount in such
other manner as is acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber acknowledges
and agrees that it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription Price as a result
of the exchange of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s counsel,
in Vancouver, British Columbia at 10:00 a.m.&nbsp;(Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such </FONT>date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance
of this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation
will deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certificates (or
DRS) representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by the Corporation
of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective to create
a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing, any funds
advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to the Corporation,
which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing does not occur within
90 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Privacy Legislation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed Principal
for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation, including,
without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable similar
replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing the
Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for so
long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact that
the Corporation may be required by applicable securities legislation, stock exchange rules&nbsp;and/or Investment Industry Regulatory
Organization of Canada rules&nbsp;to provide regulatory authorities with any personal information provided by the Subscriber respecting
itself (and any Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has
the authority to provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the
Subscriber is acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose
the Subscriber&#8217;s personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber or
any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
use and disclosure to the Corporation&#8217;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada Revenue
Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect to reports of trade
and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena compelling such
disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to professional advisers of the Corporation in connection with the performance of their professional services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s prior written
consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Subscriber further acknowledges and agrees that the TSX collects personal information in forms submitted by the Corporation, which will
include personal information regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided
for in Appendix 6A to the TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U></FONT> and is incorporated
herein by reference. The Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the
British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information
in forms submitted to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information,
and the Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O.&nbsp;Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&nbsp;899-6500 or
(800)&nbsp;373-6393, Facsimile: (604)&nbsp;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission,
Suite&nbsp;600, 250 &#8211; 5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and,
in the case of the Ontario Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities
Commission, Suite&nbsp;1903, Box 5520, Queen Street West, Toronto, Ontario M5H&nbsp;3S8, Telephone: (416)&nbsp;593-3682, Facsimile: (416)&nbsp;593&#45;8252.
The Subscriber consents to the collection of personal information by the applicable securities regulatory authorities, including, without
limitation, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both as of
the execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The
representations, warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the
Corporation in determining the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against
all losses, claims, costs, expenses and damages or liabilities which it may suffer or incur which are caused or arise from an
inaccuracy or breach thereof and reliance thereon. The Subscriber undertakes to immediately notify the Corporation by written notice
to ProMIS Neurosciences Inc. sent to its office at 1920 Yonge Street, Suite&nbsp;200, Toronto, ON&nbsp;M4S 3E2 or by email to [***]
of any change in any statement or other information relating to the Subscriber set forth herein which takes place prior to the
Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel retained
by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms and conditions
set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the Corporation
and their respective heirs, executors, administrators, successors and permitted assigns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in accordance
with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably attorn to
the exclusive jurisdiction of the courts of the Province of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time
is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without the consent
in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial owner
and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there are no representations,
covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither this Subscription
Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by
the party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and other documents
contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment qu&#8217;elles
ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&#8217;y rattachent soient r&eacute;dig&eacute;s
dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I<BR>
REPRESENTATION LETTER<BR>
(FOR CANADIAN ACCREDITED INVESTORS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of units of the
Corporation (&#8220;<B>Units</B>&#8221;) by the undersigned subscriber or, if applicable, the principal on whose behalf the undersigned
is purchasing as agent (the &#8220;<B>Subscriber</B>&#8221; for the purposes of this Schedule I), the Subscriber hereby represents, warrants,
covenants and certifies to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Subscriber is purchasing the Units as principal for its own account or is deemed to be acting as principal
pursuant to applicable securities laws, including National Instrument 45-106 entitled &#8220;Prospectus and Registration Exemptions&#8221;
(&#8220;<B>NI 45-106</B>&#8221;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Subscriber is an &#8220;<B>accredited investor</B>&#8221; within the meaning of applicable securities
laws, including NI 45-106, by virtue of satisfying one or more of the categories set out in Appendix &#8220;A&#8221; to this Representation
Letter;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">If the Subscriber is an individual, he or she has completed the attached <B>Form&nbsp;45-106F9 -- <I>Form&nbsp;for
Individual Accredited Investors</I></B> set out in Appendix &#8220;B&#8221; to this Representation Letter unless the individual qualifies
under a category set out in Appendix &#8220;A&#8221; other than (j), (k)&nbsp;or (l)&nbsp;of the definition of &#8220;<B>accredited investor</B>&#8221;;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Upon execution of this Schedule I by the Subscriber, this Schedule I shall be incorporated into and form
a part of the Subscription Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________________, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Print name of Subscriber</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Signature</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Print name of Signatory (if different from Subscriber)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Title</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMPORTANT: PLEASE INITIAL APPENDIX &#8220;A&#8221;
OVER PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &#8220;A&#8221;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE: THE SUBSCRIBER MUST INITIAL BESIDE THE APPLICABLE PORTION
OF THE DEFINITION BELOW AND COMPLETE EACH QUESTION WHICH FOLLOWS THE APPLICABLE PORTION OF THE DEFINITION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accredited
Investor &#8211; </B></FONT>(as defined in National Instrument 45-106, and in Ontario, as defined in Section&nbsp;73.3 of the <I>Securities
Act</I> (Ontario) as supplemented by the definition in National Instrument 45-106) includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; width: 12%; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2.5pt; width: 7%; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; width: 81%; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a Canadian financial institution, or a Schedule
III bank,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a.1)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a financial institution described in paragraph
1, 2 or 3 of subsection 73.1 (1)&nbsp;of the <I>Securities Act</I> (Ontario),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, the Business Development Bank of Canada
incorporated under the <I>Business Development Bank of Canada Act</I> (Canada),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b.1)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, the Business Development Bank of Canada,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a subsidiary of any person referred to in
paragraphs (a)&nbsp;or (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required
by law to be owned by directors of that subsidiary,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c.1)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a subsidiary of any person or Corporation referred
to in clause (a.1) or (b.1), if the person or Corporation owns all of the voting securities of the subsidiary, except the voting securities
required by law to be owned by directors of that subsidiary,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a person registered under the securities
legislation of a jurisdiction of Canada as an adviser or dealer,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d.1)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a person or Corporation registered under the securities
legislation of a province or territory of Canada as an adviser or dealer, except as otherwise prescribed by the regulations,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual registered under the securities legislation of
a jurisdiction of Canada as a representative of a person referred to in paragraph (d),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e.1)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual formerly registered under the securities legislation
of a jurisdiction of Canada, other than an individual formerly registered solely as a representative of a limited market dealer under
one or both of the <I>Securities Act</I> (Ontario) or the <I>Securities Act</I> (Newfoundland and Labrador),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, the Government of Canada or a jurisdiction
of Canada, or any crown corporation, agency or wholly owned entity of the Government of Canada or a jurisdiction of Canada,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f.1)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, the Government of Canada, the government of a province
or territory of Canada, or any Crown corporation, agency or wholly owned entity of the Government of Canada or of the government of a
province or territory of Canada,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a municipality, public board or commission in Canada and a
metropolitan community, school board, the Comit&eacute; de gestion de la taxe scolaire de l&#8217;&icirc;le de Montr&eacute;al or an
intermunicipal management board in Qu&eacute;bec,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any national, federal, state, provincial, territorial or municipal
government of or in any foreign jurisdiction, or any agency of that government,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a pension fund that is regulated by the
Office of the Superintendent of Financial Institutions (Canada), a pension commission or similar regulatory authority of a jurisdiction
of Canada,</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i.1)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a pension fund that is regulated by either the
Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a province
or territory of Canada,</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 2.5pt; text-align: center; width: 12%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; width: 7%; padding-bottom: 2.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; width: 81%; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">an
    individual who, either alone or with a spouse, beneficially owns financial assets having an aggregate realizable value that before taxes,
    but net of any related liabilities, exceeds $1,000,000,</P>
                                                                                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">[If this is your
    applicable category, you must also complete <U>Form&nbsp;45-106F9 attached as Appendix B</U>]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j.1)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who beneficially owns financial assets having
an aggregate realizable value that, before taxes but net of any related liabilities, exceeds $5,000,000, </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">an
    individual whose net income before taxes exceeded $200,000 in each of the 2 most recent calendar years or whose net income before taxes
    combined with that of a spouse exceeded $300 000 in each of the 2 most recent calendar years and who, in either case, reasonably expects
    to exceed that net income level in the current calendar year,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">[If this is your
    applicable category, you must also complete <U>Form&nbsp;45-106F9 attached as Appendix B</U>]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">an
    individual who, either alone or with a spouse, has net assets of at least $5,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">[If this is your
    applicable category, you must also complete <U>Form&nbsp;45-106F9 attached as Appendix B</U>]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person, other than an individual or investment fund, that
has net assets of at least $5,000,000 as shown on its most recently prepared financial statements,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">an
    investment fund that distributes or has distributed its securities only to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -37.7pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
    person that is or was an accredited investor at the time of the distribution,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -37.7pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
    person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment], or 2.19 [Additional
    investment in investment funds], or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -37.7pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
    person described in paragraph (i)&nbsp;or (ii)&nbsp;that acquires or acquired securities under section 2.18 [Investment fund reinvestment],</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an investment fund that distributes or has distributed securities
under a prospectus in a jurisdiction of Canada for which the regulator or, in Qu&eacute;bec, the securities regulatory authority, has
issued a receipt,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust Corporation or trust corporation registered or authorized
to carry on business under the <I>Trust and Loan Companies Act</I> (Canada) or under comparable legislation in a jurisdiction of Canada
or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust Corporation or trust corporation, as the
case may be,</FONT></TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; width: 12%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; text-align: justify; width: 7%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; width: 81%; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person acting on behalf of a fully managed account managed
by that person, if that person is registered or authorized to carry on business as an adviser or the equivalent under the securities
legislation of a jurisdiction of Canada or a foreign jurisdiction,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a registered charity under the Income Tax Act (Canada) that,
in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of
the jurisdiction of the registered charity to give advice on the securities being traded,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an entity organized in a foreign jurisdiction that is analogous
to any of the entities referred to in paragraphs (a)&nbsp;to (d)&nbsp;paragraph (i)&nbsp;[and in Ontario, paragraphs (a.1) to (d.1) or
paragraph (i.1)] in form and function,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person in respect of which all of the owners of interests,
direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited
investors </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an investment fund that is advised by a person registered as
an adviser or a person that is exempt from registration as an adviser,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person that is recognized or designated by the securities
regulatory authority or, except in Ontario and Qu&eacute;bec, the regulator as an accredited investor, </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v.1)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-right: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a person or Corporation that is recognized or designated
by the Commission as an accredited investor,</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.5pt; border: Black 1pt solid; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT></TD>
    <TD STYLE="padding-top: 2.5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust established by an accredited investor for the benefit
of the accredited investor&#8217;s family members of which a majority of the trustees are accredited investors and all of the beneficiaries
are the accredited investor&#8217;s spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child
or grandchild of that accredited investor, of that accredited investor&#8217;s spouse or of that accredited investor&#8217;s former spouse.
</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: __________________, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 50%; border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif">Print name of Subscriber</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif">Signature</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif">Print name of Signatory (if different from Subscriber)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif">Title</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the purposes hereof:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.1in; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>control
    person</B>&#8221;</FONT> has the meaning ascribed to that term in securities legislation except in Manitoba, Ontario, Quebec, Nova Scotia,
    Newfoundland and Labrador, Prince Edward Island, the Northwest Territories and Nunavut where &#8220;control person&#8221; means any person
    that holds or is one of a combination of persons that hold:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a sufficient number of any of the securities of an issuer so as to affect materially the control of the issuer; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">more than 20% of the outstanding voting securities of an issuer except
    where there is evidence showing that the holding of those securities does not affect materially the control of that issuer;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>eligibility adviser</B>&#8221;</FONT> means:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person that is registered as an investment dealer or in an equivalent category of registration under the securities legislation of the jurisdiction of a Subscriber and authorized to give advice with respect to the type of security being distributed; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Saskatchewan or Manitoba, also means a lawyer who is a practicing member in good standing with a law society of a jurisdiction of Canada or a public accountant who is a member in good standing of an institute or association of chartered accountants, certified general accountants or certified management accountants in a jurisdiction of Canada provided that the lawyer or public accountant must not:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&#9;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have a professional, business or personal relationship with the issuer, or any of its directors, executive officers, founders or control persons; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&#9;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">have acted for or been retained personally or otherwise as an employee,
    executive officer, director, associate or partner of a person that has acted for or been retained by the issuer or any of its directors,
    executive officers, founders or control persons within the previous 12 months;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>financial
    assets</B>&#8221;</FONT> means (i)&nbsp;cash, (ii)&nbsp;securities or (iii)&nbsp;a contract of insurance, a deposit or an evidence of
    a deposit that is not a security for the purposes of securities legislation. These financial assets are generally liquid or relatively
    easy to liquidate. The value of a purchaser&#8217;s personal residence would not be included in a calculation of financial assets;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;<B>financial statements</B>&#8221; for the purposes of paragraph
    (m)&nbsp;of the &#8220;accredited investor&#8221; definition must be prepared in accordance with generally accepted accounting principles;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>founder</B>&#8221;</FONT> means, in respect of an issuer, a person who:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acting alone, in conjunction or in concert with one or more persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the issuer; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">at the time of the trade is actively involved in the business of the
    issuer;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>fully
    managed account</B>&#8221;</FONT> means an account of a client for which a person makes the investment decisions if that person has full
    discretion to trade in securities for the account without requiring the client&#8217;s express consent to a transaction;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<B>investment
    fund</B>&#8221;</FONT> has the meaning ascribed thereto in National Instrument 81-106 - <I>Investment Fund Continuous Disclosure</I>;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<B>net assets</B>&rdquo; means all of the purchaser&rsquo;s
    total assets minus all of the purchaser&rsquo;s total liabilities. Accordingly, for the purposes of the net asset test, the calculation
    of total assets would include the value of a purchaser&rsquo;s personal residence and the calculation of total liabilities would include
    the amount of any liability (such as a mortgage) in respect of the purchaser&rsquo;s personal residence. To calculate a purchaser&rsquo;s
    net assets under the &ldquo;accredited investor&rdquo; definition, subtract the purchaser&rsquo;s total liabilities from the purchaser&rsquo;s
    total assets (including real estate). The value attributed to assets should reasonably reflect their estimated fair value. Income tax
    should be considered a liability if the obligation to pay it is outstanding at the time of the distribution of the security;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>related liabilities</B>&rdquo; means:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD STYLE="width: 90%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liabilities incurred or assumed for the purpose of financing the acquisition or ownership of financial assets; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">liabilities that are secured by financial assets;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>spouse</B>&rdquo; means an individual who:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is married to another individual and is not living separate and apart within the meaning of the <I>Divorce Act</I> (Canada), from the other individual; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is living with another individual in a marriage-like relationship, including a marriage-like relationship between individuals of the same gender; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#9;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">in Alberta, is an individual referred to in paragraph (i)&nbsp;or (ii)&nbsp;immediately
    above or is an adult interdependent partner within the meaning of the <I>Adult Interdependent Relationships Act </I>(Alberta); and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &#8220;B&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;45-106F9 - <I>Form&nbsp;for Individual
Accredited Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARNING!</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>This investment is risky. Don&#8217;t invest
    unless you can afford to lose all the money you pay for this investment.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border: Black 1pt solid; padding: 3pt 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;1 TO BE COMPLETED BY ISSUER OR SELLING SECURITY HOLDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;About your investment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Type of securities:&nbsp;&nbsp;&nbsp;Common Shares and Warrants</FONT></P></TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:&nbsp;&nbsp;ProMIS Neurosciences Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Risk acknowledgement</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This investment is risky. Initial that you understand that:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>initials</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk of loss </B></FONT>&#8211; You could lose your entire investment of $________. </TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity risk</B></FONT> &#8211; You may not be able to sell your investment quickly &#8211; or at all.</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lack of information </B></FONT>&#8211; You may receive little or no information about your investment.</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lack
    of advice &#8211; </B></FONT>You may not receive advice from the salesperson about whether this investment is suitable for you unless
    the salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investments.
    To check whether the salesperson is registered, go to <U>www.aretheyregistered.ca</U>.</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Accredited investor status</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You must meet at least <B>one </B>of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>initials</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5pt 3pt 0.275in; text-indent: -0.2in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Your net income before taxes was more than $200,000 in each for the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.)</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5pt 3pt 0.275in; text-indent: -0.2in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Your net income before taxes combined with your spouse&#8217;s was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5pt 3pt 0.275in; text-indent: -0.2in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Either
alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the case and securities.</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 5pt 3pt 0.275in; text-indent: -0.2in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Either
alone or with your spouse, you may have net assets worth more than $5 million. (Your net assets are your total assets (including real
estate) minus your total debt.)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 5pt 3pt 0.275in; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Your name and signature</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First and last name (please print):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;5 TO BE COMPLETED BY SALESPERSON</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Salesperson information</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement</I>.]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First and last name of salesperson (please print):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding: 3pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of firm (if registered):</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 3pt 5pt; width: 46%">&nbsp;</TD>
    <TD STYLE="padding: 3pt 5pt; width: 10%">&nbsp;</TD>
    <TD STYLE="padding: 3pt 5pt; width: 32%">&nbsp;</TD>
    <TD STYLE="padding: 3pt 5pt; width: 12%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 5pt; border: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;For more information about this investment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS
    Neurosciences Inc.<BR>
    </FONT>Kristi Lanier, Finance Director<BR>
    Tel: [***]<BR>
    E-mail: [***]<BR>
    Website: www.promisneurosciences.com<BR>
    <B>For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at
    <U>www. securities-administrators.ca</U></B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>35
<FILENAME>filename35.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.17</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
identified information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns.
Redacted information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>NON-U.S.
PERSONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HAVE
                                            YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    following items in this Subscription Agreement must be completed. (Please initial each box.) </B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
    information and answers in the boxes on pages&nbsp;1, 2 and 3.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sign
    the execution page&nbsp;on page&nbsp;1 of this Subscription Agreement. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete
    Schedule &ldquo;1&rdquo; Accredited Investor Representation Letter and sign</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delivery
of Subscription forms may be made by</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>email
to:</U></B> [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>facsimile
to:</U></B> fax #: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Delivery
of certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS
Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite&nbsp;200, Toronto, ON M4S 3E2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Alternatively,
delivery of funds may also be made via electronic wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>To
wire Canadian $ funds:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
Bank: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
Address: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
# [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
#:[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT
Code: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency:
[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary:
PROMIS NEUROSCIENCES INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
address: 1920 Yonge Street, Suite&nbsp;200, Toronto, ON M4S 3E2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>If
you wish to wire funds in currency other than CDN$, please contact the Corporation by email: </U></B>[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>______________________________________________________________________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIPTION
FOR UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProMIS
                                            Neurosciences Inc. (the &ldquo;Corporation&rdquo;)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned (the &ldquo;<B>Subscriber</B>&rdquo;, including, if applicable, each Disclosed Principal (as hereinafter defined) for whom
the undersigned is acting hereunder) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation
(the &ldquo;<B>Units</B>&rdquo;) set forth below for the aggregate subscription amount set forth below (the &ldquo;<B>Aggregate Subscription
Amount</B>&rdquo;), representing a subscription price of <B>CDN $0.25</B> on the terms and conditions set forth in &ldquo;Terms and Conditions
of Subscription for Units of ProMIS Neurosciences Inc..&rdquo; attached hereto (together with the face pages&nbsp;and the attached Schedules,
the &ldquo;<B>Subscription Agreement</B>&rdquo;). Each Unit consists of one common share of the Corporation (a &ldquo;<B>Common Share</B>&rdquo;)
and one share purchase warrant (a &ldquo;<B>Warrant</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
whole Warrant entitles the holder to purchase one Common Share (a &ldquo;<B>Warrant Share</B>&rdquo;) at any time for a five year period,
at a price of <B>CDN $0.35</B> per Warrant Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Units, the Common Shares, the Warrants and the Warrant Shares are hereinafter referred to together as the &ldquo;<B>Securities</B>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Units:</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aggregate
    Subscription Amount: CDN $_____</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    and Signature of Subscriber</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
    Subscriber </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Individual
    Subscriber (e.g., Corporation)</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name of Non-Individual Subscriber) </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
    of Individual Subscriber) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
    of Authorized Signatory) </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print
    Name and Official Capacity or Title of Signatory) <BR>
    The signatory represents that he has authority to bind the Subscriber. </FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ONLY
                                            IF</U> the Subscriber is signing as agent or trustee for a principal (a &ldquo;Disclosed
                                            Principal&rdquo;) and is not purchasing as trustee or agent for accounts fully managed by
                                            it, so as to be deemed to be purchasing as principal pursuant to National Instrument 45-106,
                                            complete the following and, if applicable, ensure that all Schedules are completed on behalf
                                            of such Disclosed Principal:</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>_____________________________________________________________________________________________</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>_________&nbsp;</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
    of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</FONT></P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address
    of Subscriber - Residential for Individual / Business for Non-Individual Subscriber</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 51%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    of Subscriber </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Telephone
    Number) </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City,
    Province, Postal Code </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 3pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Facsimile
    Number) </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Email
    address) </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
                                            INSTRUCTIONS</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 5.4pt; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 5.4pt; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DELIVERY
    INSTRUCTIONS</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Register
                                            the Common Shares and Warrants as set forth below (only complete if different from above):</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Account
    reference, if applicable)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_____________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Deliver
                                            the Common Shares and Warrants as set forth below:</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Account
    reference, if applicable)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Contact
    Name)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INFORMATION
REGARDING THE SUBSCRIBER</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
check the appropriate box (and complete the required information, if applicable) in each section:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
                                            Holdings</B>. Prior to giving effect to the issuance of the securities being subscribed for
                                            under this Subscription Agreement, the Subscriber and all persons acting jointly and in concert
                                            with the Subscriber currently own, directly or indirectly, or exercise control or direction
                                            over (provide additional detail as applicable):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________
                                            common shares of the Corporation and the following other kinds of rights and convertible
                                            securities (including but not limited to convertible debt, warrants and options) entitling
                                            the Subscriber to acquire additional common shares of the Corporation:</FONT></TD>
</TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
                                                                                                                                          <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            shares of the Corporation or rights or securities convertible into shares of the Corporation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insider
                                            Status</B>. The Subscriber either:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
                                            an &ldquo;Insider&rdquo; of the Corporation as defined in the Policies of the Exchange (as
                                            hereinafter defined) by virtue of being:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            director or executive officer of the Corporation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            director or executive officer of a company that is an Insider or subsidiary of the Corporation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
                                            carrying more than 10% of the voting rights attached to all the Corporation&rsquo;s outstanding
                                            voting shares; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Corporation itself if it holds any of its own securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
                                            not an Insider of the Corporation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
                                            Group Status</B>. The Subscriber either:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
                                            a Member of the &ldquo;Pro Group&rdquo;, which is defined in the Rules&nbsp;of the Exchange
                                            as either individually or as a group:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            member (i.e. a member of the Exchange under the Exchange requirements);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employees
                                            of the member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partners,
                                            officers and directors of the member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">affiliates
                                            of the member;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            other persons as the Exchange may determine; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">associates
                                            of any parties referred to in paragraphs 1 through 5 above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
                                            not a member of the Pro Group.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant
                                            Status</B>. The Subscriber either:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
                                            a &ldquo;Registrant&rdquo; as defined in the <I>Securities Act</I> (British Columbia) by
                                            virtue of being a person registered or required to be registered under the <I>Securities
                                            Act</I> (British Columbia.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;Is
                                            not a Registrant.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation hereby accepts the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">PROMIS NEUROSCIENCES
    INC.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page
                                            <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Terms of the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in
part. The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or
deduction, if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation is offering (the &ldquo;<B>Offering</B>&rdquo;) the Units on a private placement basis under the terms of this Subscription
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notwithstanding
section 2(a)&nbsp;above, this Offering will not in any way restrict the Corporation from issuing additional securities of the Corporation
at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including an amendment
to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&rsquo;s acceptance
of the Offering (provided that no material changes shall be made to the terms hereunder without the prior written consent of the Subscriber),
including, without limitation, in the event that the issuance of the Units hereunder may result in, or be part of a transaction that
may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior to the
Closing (the &ldquo;<B>25% Dilution Rule</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which are outstanding
on a non-diluted basis prior to the Closing (the &ldquo;<B>10% Insider Rule</B>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Representations, Warranties and Covenants of the Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power and authority
to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is listed on the TSX (the &ldquo;<B>Exchange</B>&rdquo;) and as a result is subject to the rules&nbsp;and policies of the
Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is a &ldquo;reporting issuer&rdquo; in good standing under the securities laws of the provinces of Ontario, British Columbia
and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation enforceable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the issue of
the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or any law,
regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is a party
or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition, and,
as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&rsquo;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sale, issuance and delivery of the Units at the closing (the &ldquo;<B>Closing</B>&rdquo;) will have been approved by all requisite corporate
action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued as fully paid and
non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding against
the Corporation or its directors, officers or promoters and to the best of the Corporation&rsquo;s knowledge no investigations or proceedings
for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;T</FONT>he
legend endorsed on the DRS representing the Common Shares and Warrant Shares shall expire four months (&ldquo;<B>Expiry Date</B>&rdquo;)
after the Closing Date. After the Expiry Date, the Corporation shall undertake best commercial efforts to deliver or cause to be delivered,
no later than two (2)&nbsp;trading days on the Exchange (&ldquo;<B>Trading Day</B>&rdquo;) following the delivery by the Subscriber to
the Corporation or, with notice to the Corporation, to the transfer agent of the Corporation (&ldquo;<B>Transfer Agent</B>&rdquo;) of
a DRS representing the Common Shares or Warrant Shares, as the case may be, that is free from all such restrictive and other legends
(such date, the &ldquo;<B>Legend Removal Date</B>&rdquo;). In addition to the Subscriber&rsquo;s other available remedies, in the event
that the Subscriber delivers a DRS representing the Common Shares or Warrant Shares, as the case may be, to the Corporation or, with
notice to the Corporation, to the Transfer Agent, the Corporation shall pay to the Subscriber, in cash, (i)&nbsp;as partial liquidated
damages and not as a penalty, for each $1,000 of Common Shares or Warrant Shares (based on the volume weighted average price of the Common
Shares on the Exchange on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend,
$10 per Trading Day (increasing to $20 per Trading Day five (5)&nbsp;Trading Days after such damages have begun to accrue) for each Trading
Day after the Legend Removal Date until such DRS is delivered without a legend and (ii)&nbsp;if the Corporation fails to (a)&nbsp;issue
and deliver (or cause to be delivered) to the Subscriber by the Legend Removal Date a DRS representing representing the Common Shares
or Warrant Shares, as the case may be, so delivered to the Corporation by the Subscriber that is free from all restrictive and other
legends and (b)&nbsp;if after the Legend Removal Date the Subscriber purchases (in an open market transaction or otherwise) Common Shares
to deliver in satisfaction of a sale by the Subscriber of all or any portion of the number of Common Shares or Warrant Shares, or a sale
of a number of Common Shares equal to all or any portion of the number of Common Shares or Warrant Shares, as the case may be, that the
Subscriber anticipated receiving from the Corporation without any restrictive legend, then, an amount equal to the excess of the Subscriber&rsquo;s
total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the Common Shares so purchased (including
brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;) over the product of (A)&nbsp;such
number of Common Shares or Warrant Shares that the Corporation was required to deliver to the Subscriber by the Legend Removal Date multiplied
by (B)&nbsp;the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery
by the Subscriber to the Corporation of the applicable Common Shares or Warrant Shares (as the case may be) and ending on the date of
such delivery and payment under this clause (i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Corporation shall, by 9:00 a.m.&nbsp;Eastern Time on the date after this Subscription Agreement is accepted by the Corporation and confirmed
with the Subscriber in writing (&ldquo;<B>Effective Date</B>&rdquo;), issue a press release disclosing the material terms of the transactions
contemplated hereby. From and after the issuance of such press release, the Corporation represents to the Subscriber that it shall have
publicly disclosed all material, non-public information delivered to the Subscriber by the Corporation or any of its Subsidiaries, or
any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction
Documents. Notwithstanding the foregoing, the Corporation shall not publicly disclose the name of the Subscriber, or include the name
of the Subscriber in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of
the Subscriber, except to the extent such disclosure is required by law or Trading Market regulations, in which case the Corporation
shall provide the Subscriber with prior notice of such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
with respect to the material terms and conditions of the transactions contemplated by this Subscription Agreement, which shall be disclosed
pursuant to clause (j)&nbsp;above, the Corporation covenants and agrees that neither it, nor any other Person acting on its behalf will
provide the Subscriber or its agents or counsel with any information that constitutes, or the Corporation reasonably believes constitutes,
material non-public information, unless prior thereto the Subscriber shall have consented to the receipt of such information and agreed
with the Corporation to keep such information confidential. The Corporation understands and confirms that the Subscriber shall be relying
on the foregoing covenant in effecting transactions in securities of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>As
of the date hereof, the Corporation has reserved and the Corporation shall continue to reserve and keep available at all times, free
of pre-emptive rights, a sufficient number of Common Shares for the purpose of enabling the Corporation to issue Warrant Shares pursuant
to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>No
consideration (including any modification of any Subscription Agreement) shall be offered or paid to any Person to amend or consent to
a waiver or modification of any provision of the Subscription Agreement unless the same consideration is also offered to all of the parties
to the Subscription Agreements. For clarification purposes, this provision constitutes a separate right granted to the Subscriber by
the Corporation and negotiated separately by the Subscriber, and is intended for the Corporation to treat the Subscribers as a class
and shall not in any way be construed as the Subscribers acting in concert or as a group with respect to the purchase, disposition or
voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acknowledgements, Warranties and Covenants of the Subscriber</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber
is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon acceptance
by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at such time,
including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be able to
resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy until
expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any certificates
or Direct Registration Statements (DRS) representing the Securities may bear the following legend indicating that the resale of such
Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;<B>Unless permitted under securities
legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT>that date
that is 4 months and a day after the Closing Date].&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange in connection
with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&rsquo;s acceptance
of the Offering, including, without limitation, the conditions noted in paragraphs 4(h)&nbsp;and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior to the
Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which are outstanding
on a non-diluted basis prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">the Exchange may require as a condition
of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10% Insider Rule, the
votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new &ldquo;Insider&rdquo;
or a new &ldquo;Control Person&rdquo;, the Exchange may require as a condition of its acceptance of the Offering, that the Corporation
obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person and its associates
and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities legislation,
and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering memorandum,
or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and review by,
prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has relied solely upon information publicly available on SEDAR (at <FONT STYLE="color: Black"><U>www.sedar.com</U></FONT></FONT>) relating
to the Corporation and not upon any oral or written representation as to fact or otherwise made by or on behalf of the Corporation and
it does not have knowledge of any &ldquo;material fact&rdquo; (as defined under applicable securities legislation) about the Corporation
that has not been publicly disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is resident in the province set out in the &ldquo;Subscriber&rsquo;s Address&rdquo;, which is the ordinary residence or place
of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it was not
created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution and
will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and not for the
benefit of any other person and not with a view to the resale or distribution of all or any of the Units and it <U>fully complies with
one or more of the sub-paragraphs set forth below</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is
an &ldquo;accredited investor&rdquo; within the meaning of applicable securities laws, including National Instrument 45-106 entitled
 &ldquo;Prospectus and Registration Exemptions&rdquo; (&ldquo;<B>NI 45-106</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has
concurrently executed and delivered a Representation Letter in the form attached as Schedule I to this Subscription Agreement, including
Appendix &ldquo;A&rdquo; and Appendix &ldquo;B&rdquo; thereto; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is neither an individual nor a company established solely to acquire the Units and the cost of the Units purchased by it has
an aggregate acquisition of not less than $150,000; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________
(<B>to be initialled by Subscriber, if applicable)</B> - if it is not purchasing under subparagraph 5(f)(i), or (ii), it is purchasing
pursuant to an exemption from prospectus and registration requirements (particulars of which are enclosed herewith or will be provided
on or before the Closing Date) available to it under applicable securities legislation and shall deliver to the Corporation such further
particulars of the exemption(s)&nbsp;and the Subscriber&rsquo;s qualifications thereunder as the Corporation may request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable prospectus
exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase on behalf
of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other person, and
not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
and each beneficial purchaser has provided to the Corporation all of the information required by pages&nbsp;1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity
of each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of the principals complies with one or more of subparagraphs 5(f)(i)&nbsp;through (f)(ii), as applicable, and the same is so indicated
for each such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the </FONT>Subscriber is a resident of a country other than Canada or the United States (a &ldquo;<B>Jurisdiction Outside CAN-US</B>&rdquo;)
then in addition to the other representations and warranties contained herein, the Subscriber represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
</FONT>Subscriber is knowledgeable of, or has been independently advised as to, the applicable securities laws of the Jurisdiction Outside
CAN-US which would apply to this Subscription Agreement, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
</FONT>Subscriber is purchasing the Subscriber&rsquo;s Shares pursuant to exemptions from any prospectus, registration or similar requirements
under the applicable securities laws of that Jurisdiction Outside CAN-US or, if such is not applicable, the Subscriber is permitted to
purchase the Subscriber&rsquo;s Shares under the applicable securities laws of the Jurisdiction Outside CAN-US without the need to rely
on an exemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
applicable securities laws of the Jurisdiction Outside CAN-US in which the </FONT>Subscriber resides do not require the Corporation to
file a prospectus, registration statement or similar document or to register the Securities or to make any filings or seek any approvals
of any kind whatsoever from any regulatory authority of any kind whatsoever in the Jurisdiction Outside CAN-US; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery of this Subscription Agreement, the acceptance of it by the Corporation and the issuance of the Securities to the Subscriber
complies with all applicable laws of the </FONT>Subscriber&rsquo;s jurisdiction of residence or domicile and all other applicable laws
and will not cause the Subscriber to become subject to or comply with any disclosure, prospectus or other offering document or reporting
requirements under any such applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
are restrictions on the Subscriber&rsquo;s ability to resell the Securities and it is the responsibility of the Subscriber to find out
what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements to provide
the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being advised
by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial and territorial
securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units pursuant to this
exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or damages, will not
be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound by this
Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have been
given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all action
pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding and enforceable
obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and deliver this
Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal and this
Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and binding
agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as
to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment and it, or
where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
understands that the Units are being offered for sale only on a &ldquo;private placement&rdquo; basis and that the sale and delivery
of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation of
an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit such
sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any of the terms
or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&rsquo;s constating
documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent proceeds of
crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that the Corporation
may in the future be required by law to disclose the Subscriber&rsquo;s name and other information relating to this Subscription Agreement
and the Subscriber&rsquo;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering) Act
</I>(Canada) and to the best of the Subscriber&rsquo;s knowledge (i)&nbsp;none of the subscription funds to be provided by the Subscriber
(A)&nbsp;have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States
of America, or any other jurisdiction, or (B)&nbsp;are being tendered on behalf of a person or entity who has not been identified to
the Subscriber, and (ii)&nbsp;it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases
to be true, and to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation&rsquo;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the Subscriber
may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain independent
legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently advised as
to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties and covenants
under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
information provided by the Subscriber on pages&nbsp;1, 2 and 3 of this Subscription Agreement and under the heading &ldquo;Information
Regarding The Subscriber&rdquo; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;it
will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation and stock
exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies with
all applicable laws of the Subscriber&rsquo;s jurisdiction of residence and domicile and will not cause the Corporation or any of its
officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund its ongoing
development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such future financings
may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are not available, the
Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure of its business
venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Subscriber is capable of assessing the proposed investment as a result of the Subscriber&rsquo;s financial experience or as a result
of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a)&nbsp;this duly completed and executed Subscription
Agreement, including all applicable Schedules hereto and Appendices thereto; and (b)&nbsp;the Aggregate Subscription Amount subscribed
for under this Subscription Agreement in accordance with the Instructions on the Cover Page&nbsp;or payment of the same amount in such
other manner as is acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber acknowledges
and agrees that it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription Price as a result
of the exchange of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&rsquo;s counsel,
in Vancouver, British Columbia at 10:00 a.m.&nbsp;(Vancouver time) or such other time as the Corporation may determine (the &ldquo;<B>Closing
Time</B>&rdquo;) on such date (the &ldquo;<B>Closing Date</B>&rdquo;) the Corporation may determine within 2 days of its acceptance of
this Subscription Agreement. The Corporation shall complete the Offering in one Closing. At the Closing Time, the Corporation will deliver,
or cause to be delivered, according to the instructions set out under Delivery Instructions herein the DRS representing the Common Shares
and a certificate representing the Warrants as registered in the name of the Subscriber or its nominee as set out under Registration
Instructions provided that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate
Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by the Corporation
of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective to create
a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing, any funds
advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to the Corporation,
which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing does not occur within
5 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Privacy Legislation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&rsquo;s (and any Disclosed Principal
for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation, including,
without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable similar
replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing the
Subscriber&rsquo;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for so
long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact that
the Corporation may be required by applicable securities legislation, stock exchange rules&nbsp;and/or Investment Industry Regulatory
Organization of Canada rules&nbsp;to provide regulatory authorities with any personal information provided by the Subscriber respecting
itself (and any Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has
the authority to provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the
Subscriber is acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose
the Subscriber&rsquo;s personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber or
any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
use and disclosure to the Corporation&rsquo;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada Revenue
Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect to reports of trade
and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena compelling such
disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to professional advisers of the Corporation in connection with the performance of their professional services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&rsquo;s prior written
consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure
to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Subscriber further acknowledges and agrees that the TSX collects personal information in forms submitted by the Corporation, which will
include personal information regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided
for in Appendix 6A to the TSX Company Manual, a copy of which may be viewed at the TSX website, <FONT STYLE="color: Black"><U>www.tsx.com
</U></FONT></FONT>and is incorporated herein by reference. The Subscriber further acknowledges that the securities regulatory authorities,
including, without limitation, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities
Commission, collect personal information in forms submitted to it by the Corporation, including information about the Subscriber, the
Subscriber&rsquo;s address and contact information, and the Subscriber&rsquo;s subscription. The Subscriber acknowledges that any such
securities commission is entitled to collect the information under authority granted to each respective regulatory authority under applicable
securities legislation for the purpose of administration and enforcement of the applicable securities legislation. The Subscriber acknowledges
that it may obtain information regarding the collection of this information by contacting, in the case of the British Columbia Securities
Commission, British Columbia Securities Commission, P.O.&nbsp;Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British
Columbia, V7Y 1L2, Telephone: (604)&nbsp;899-6500 or (800)&nbsp;373-6393, Facsimile: (604)&nbsp;899-6581, in the case of the Alberta
Securities Commission, Alberta Securities Commission, Suite&nbsp;600, 250 &ndash; 5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone:
(403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario Securities Commission, the Administrative Assistant to the
Director of Corporate Finance, Ontario Securities Commission, Suite&nbsp;1903, Box 5520, Queen Street West, Toronto, Ontario M5H&nbsp;3S8,
Telephone: (416)&nbsp;593-3682, Facsimile: (416)&nbsp;593&#45;8252. The Subscriber consents to the collection of personal information
by the applicable securities regulatory authorities, including, without limitation, the British Columbia Securities Commission, the Alberta
Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both as of the
execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units.. The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS
Neurosciences Inc. sent to its office at 1920 Yonge Street, Suite&nbsp;200, Toronto, ON&nbsp;M4S 3E2 or by email to [***] of any change
in any statement or other information relating to the Subscriber set forth herein which takes place prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel retained
by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms and conditions
set out herein, issue to the Subscriber a DRS evidencing the Subscriber&rsquo;s ownership of the Common Shares and a certificate representing
the Subscriber&rsquo;s ownership of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the Corporation
and their respective heirs, executors, administrators, successors and permitted assigns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in accordance
with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably attorn to
the exclusive jurisdiction of the courts of the Province of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time
is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without the consent
in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial owner
and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there are no representations,
covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither this Subscription
Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by
the party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this Subscription Agreement (including attachments), references to &ldquo;$&rdquo; or &ldquo;Cdn. $&rdquo; are to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and other documents
contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment qu&rsquo;elles
ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&rsquo;y rattachent soient r&eacute;dig&eacute;s
dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I<BR>
REPRESENTATION LETTER<BR>
(FOR CANADIAN ACCREDITED INVESTORS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &ldquo;Corporation&rdquo;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of units of the
Corporation (&ldquo;<B>Units</B>&rdquo;) by the undersigned subscriber or, if applicable, the principal on whose behalf the undersigned
is purchasing as agent (the &ldquo;<B>Subscriber</B>&rdquo; for the purposes of this Schedule I), the Subscriber hereby represents, warrants,
covenants and certifies to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Subscriber is purchasing the Units as principal
                                            for its own account or is deemed to be acting as principal pursuant to applicable securities
                                            laws, including National Instrument 45-106 entitled &ldquo;Prospectus and Registration Exemptions&rdquo;
                                            (&ldquo;<B>NI 45-106</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Subscriber is an &ldquo;<B>accredited investor</B>&rdquo;
                                            within the meaning of applicable securities laws, including NI 45-106, by virtue of satisfying
                                            one or more of the categories set out in Appendix &ldquo;A&rdquo; to this Representation
                                            Letter;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">If the Subscriber is an individual, he or she
                                            has completed the attached <B>Form&nbsp;45-106F9 -- <I>Form&nbsp;for Individual Accredited
                                            Investors</I></B> set out in Appendix &ldquo;B&rdquo; to this Representation Letter unless
                                            the individual qualifies under a category set out in Appendix &ldquo;A&rdquo; other than
                                            (j), (k)&nbsp;or (l)&nbsp;of the definition of &ldquo;<B>accredited investor</B>&rdquo;;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Upon execution of this Schedule I by the Subscriber,
                                            this Schedule I shall be incorporated into and form a part of the Subscription Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________________, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Print name of Subscriber</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Print name of Signatory (if different from Subscriber)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMPORTANT: PLEASE INITIAL APPENDIX &ldquo;A&rdquo;
OVER PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &ldquo;A&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE: THE SUBSCRIBER MUST INITIAL BESIDE THE APPLICABLE PORTION
OF THE DEFINITION BELOW AND COMPLETE EACH QUESTION WHICH FOLLOWS THE APPLICABLE PORTION OF THE DEFINITION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accredited
Investor &ndash; </B></FONT>(as defined in National Instrument 45-106, and in Ontario, as defined in Section&nbsp;73.3 of the <I>Securities
Act</I> (Ontario) as supplemented by the definition in National Instrument 45-106) includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 5.4pt; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a Canadian financial institution, or a Schedule
III bank,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a.1)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a financial institution described in paragraph
1, 2 or 3 of subsection 73.1 (1)&nbsp;of the <I>Securities Act</I> (Ontario),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, the Business Development Bank of Canada
incorporated under the <I>Business Development Bank of Canada Act</I> (Canada),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b.1)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, the Business Development Bank of Canada,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a subsidiary of any person referred to in
paragraphs (a)&nbsp;or (b), if the person owns all of the voting securities of the subsidiary, except the voting securities required
by law to be owned by directors of that subsidiary,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c.1)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a subsidiary of any person or Corporation referred
to in clause (a.1) or (b.1), if the person or Corporation owns all of the voting securities of the subsidiary, except the voting securities
required by law to be owned by directors of that subsidiary,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a person registered under the securities
legislation of a jurisdiction of Canada as an adviser or dealer,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d.1)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a person or Corporation registered under the securities
legislation of a province or territory of Canada as an adviser or dealer, except as otherwise prescribed by the regulations,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual registered under the securities legislation of
a jurisdiction of Canada as a representative of a person referred to in paragraph (d),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e.1)&#9;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual formerly registered under the securities legislation
of a jurisdiction of Canada, other than an individual formerly registered solely as a representative of a limited market dealer under
one or both of the <I>Securities Act</I> (Ontario) or the <I>Securities Act</I> (Newfoundland and Labrador),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#9;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, the Government of Canada or a jurisdiction
of Canada, or any crown corporation, agency or wholly owned entity of the Government of Canada or a jurisdiction of Canada,</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding: 5.4pt; text-align: center; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f.1)&#9;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, the Government of Canada, the government of a province
or territory of Canada, or any Crown corporation, agency or wholly owned entity of the Government of Canada or of the government of a
province or territory of Canada,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a municipality, public board or commission in Canada and a
metropolitan community, school board, the Comit&eacute; de gestion de la taxe scolaire de l&rsquo;&icirc;le de Montr&eacute;al or an
intermunicipal management board in Qu&eacute;bec,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any national, federal, state, provincial, territorial or municipal
government of or in any foreign jurisdiction, or any agency of that government,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">except in Ontario, a pension fund that is regulated by the
Office of the Superintendent of Financial Institutions (Canada), a pension commission or similar regulatory authority of a jurisdiction
of Canada,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i.1)&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Ontario, a pension fund that is regulated by either the
Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a province
or territory of Canada,</FONT></TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="border: Black 1pt solid; padding: 5.4pt; width: 0.75in; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-top: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; width: 0.5in">(j)&nbsp;&nbsp;</TD>
<TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify">an individual who, either alone or with a spouse, beneficially owns financial assets having an aggregate realizable value that before taxes, but net of any related liabilities, exceeds $1,000,000, <BR>
<BR>
[If this is your applicable category, you must also complete <U>Form&nbsp;45-106F9 attached as Appendix B</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j.1)&#9;</FONT></TD>
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an individual who beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related liabilities, exceeds $5,000,000, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify">an individual whose net income before taxes exceeded $200,000 in each of the 2 most recent calendar years or whose net income before taxes combined with that of a spouse exceeded $300 000 in each of the 2 most recent calendar years and who, in either case, reasonably expects to exceed that net income level in the current calendar year, <BR>
<BR>
[If this is your applicable category, you must also complete <U>Form&nbsp;45-106F9 attached as Appendix B</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify">an individual who, either alone or with a spouse, has net assets of at least $5,000,000, <BR>
<BR>
[If this is your applicable category, you must also complete <U>Form&nbsp;45-106F9 attached as Appendix B</U>]</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)&#9;</FONT></TD>
<TD STYLE="border-right: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements,</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-top: Black 1pt solid; padding: 5.4pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding: 5.4pt">an investment fund that distributes or has distributed its securities only to:</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; width: 0.75in">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; width: 0.5in">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; width: 0.5in">(i)&nbsp;&nbsp;</TD>
<TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 5.4pt">a person that is or was an accredited investor at the time of the distribution,</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center; width: 0.75in">&nbsp;</TD>
<TD STYLE="border-top: Black 1pt solid; padding: 5.4pt; width: 0.5in">&nbsp;</TD>
<TD STYLE="border-top: Black 1pt solid; padding: 5.4pt; width: 0.5in">(ii)&nbsp;&nbsp;&nbsp;</TD>
<TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding: 5.4pt">a person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment], or 2.19 [Additional investment in investment funds], or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt">(iii)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; border-right: Black 1pt solid">a person described in paragraph (i)&nbsp;or (ii)&nbsp;that acquires or acquired securities under section 2.18 [Investment fund reinvestment],</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(o)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator or, in Qu&eacute;bec, the securities regulatory authority, has issued a receipt,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(p)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a trust Corporation or trust corporation registered or authorized to carry on business under the <I>Trust and Loan Companies Act</I> (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust Corporation or trust corporation, as the case may be,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(q)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a person acting on behalf of a fully managed account managed by that person, if that person is registered or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(r)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities being traded,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(s)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a)&nbsp;to (d)&nbsp;paragraph (i)&nbsp;[and in Ontario, paragraphs (a.1) to (d.1) or paragraph (i.1)] in form and function,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(t)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by law to be owned by directors, are persons that are accredited investors </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; text-align: center; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(u)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 5.4pt; text-align: justify; border-right: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(v)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a person that is recognized or designated by the securities regulatory authority or, except in Ontario and Qu&eacute;bec, the regulator as an accredited investor, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">_______</FONT></TD>
<TD STYLE="padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(v.1)&#9;</FONT></TD>
<TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding: 5.4pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">in Ontario, a person or Corporation that is recognized or designated by the Commission as an accredited investor,</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border: Black 1pt solid; width: 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 5.4pt; border-bottom: Black 1pt solid; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&#9;</FONT></TD>
    <TD STYLE="padding: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust established by an accredited investor for the benefit
of the accredited investor&rsquo;s family members of which a majority of the trustees are accredited investors and all of the beneficiaries
are the accredited investor&rsquo;s spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child
or grandchild of that accredited investor, of that accredited investor&rsquo;s spouse or of that accredited investor&rsquo;s former spouse.
</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dated: __________________, 201__.</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Print name of Subscriber</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Print name of Signatory (if different from
    Subscriber)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the purposes hereof:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>control person</B>&rdquo; has the meaning ascribed to that term in securities legislation except in Manitoba, Ontario, Quebec, Nova Scotia, Newfoundland and Labrador, Prince Edward Island, the Northwest Territories and Nunavut where &ldquo;control person&rdquo; means any person that holds or is one of a combination of persons that hold: &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a sufficient number of any of the securities of an issuer so as to affect materially the control of the issuer; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">more than 20% of the outstanding voting securities of an issuer except where there is evidence showing that the holding of those securities does not affect materially the control of that issuer; &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>eligibility adviser</B>&rdquo; means:</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person that is registered as an investment dealer or in an equivalent category of registration under the securities legislation of the jurisdiction of a Subscriber and authorized to give advice with respect to the type of security being distributed; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in Saskatchewan or Manitoba, also means a lawyer who is a practicing member in good standing with a law society of a jurisdiction of Canada or a public accountant who is a member in good standing of an institute or association of chartered accountants, certified general accountants or certified management accountants in a jurisdiction of Canada provided that the lawyer or public accountant must not:</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have a professional, business or personal relationship with the issuer, or any of its directors, executive officers, founders or control persons; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have acted for or been retained personally or otherwise as an employee, executive officer, director, associate or partner of a person that has acted for or been retained by the issuer or any of its directors, executive officers, founders or control persons within the previous 12 months; &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>financial assets</B>&rdquo; means (i)&nbsp;cash, (ii)&nbsp;securities or (iii)&nbsp;a contract of insurance, a deposit or an evidence of a deposit that is not a security for the purposes of securities legislation. These financial assets are generally liquid or relatively easy to liquidate. The value of a purchaser&rsquo;s personal residence would not be included in a calculation of financial assets; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>financial statements</B>&rdquo; for the purposes of paragraph (m)&nbsp;of the &ldquo;accredited investor&rdquo; definition must be prepared in accordance with generally accepted accounting principles; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>founder</B>&rdquo; means, in respect of an issuer, a person who:</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acting alone, in conjunction or in concert with one or more persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the issuer; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#9;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time of the trade is actively involved in the business of the issuer; &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>fully managed account</B>&rdquo; means an account of a client for which a person makes the investment decisions if that person has full discretion to trade in securities for the account without requiring the client&rsquo;s express consent to a transaction; &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>investment fund</B>&rdquo; has the meaning ascribed thereto in National Instrument 81-106 - <I>Investment Fund Continuous Disclosure</I>; &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify">&ldquo;<B>net assets</B>&rdquo; means all of the purchaser&rsquo;s total assets minus all of the purchaser&rsquo;s total liabilities. Accordingly, for the purposes of the net asset test, the calculation of total assets would include the value of a purchaser&rsquo;s personal residence and the calculation of total liabilities would include the amount of any liability (such as a mortgage) in respect of the purchaser&rsquo;s personal residence. To calculate a purchaser&rsquo;s net assets under the &ldquo;accredited investor&rdquo; definition, subtract the purchaser&rsquo;s total liabilities from the purchaser&rsquo;s total assets (including real estate). The value attributed to assets should reasonably reflect their estimated fair value. Income tax should be considered a liability if the obligation to pay it is outstanding at the time of the distribution of the security; &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B>related liabilities</B>&rdquo;</FONT> means:</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
<TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&#9;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">liabilities incurred or assumed for the purpose of financing the acquisition or ownership of financial assets; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&#9;</FONT></TD>
<TD STYLE="text-align: justify">liabilities that are secured by financial assets; &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B>spouse</B>&rdquo; </FONT>means an individual who:</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)&#9;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">is married to another individual and is not living separate and apart within the meaning of the <I>Divorce Act</I> (Canada), from the other individual; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&#9;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">is living with another individual in a marriage-like relationship, including a marriage-like relationship between individuals of the same gender; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(iii)&#9;</FONT></TD>
<TD STYLE="text-align: justify">in Alberta, is an individual referred to in paragraph (i)&nbsp;or (ii)&nbsp;immediately above or is an adult interdependent partner within the meaning of the <I>Adult Interdependent Relationships Act </I>(Alberta); and &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &ldquo;B&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;45-106F9 - <I>Form&nbsp;for Individual
Accredited Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARNING!<BR>
<BR>
This
investment is risky. Don&rsquo;t invest unless you can afford to lose all the money you pay for this investment.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;1 TO BE COMPLETED BY ISSUER OR SELLING SECURITY HOLDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&nbsp;&nbsp;&nbsp;About your investment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type of securities:&nbsp;&nbsp;&nbsp;Common Shares and Warrants</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:&nbsp;&nbsp;ProMIS Neurosciences Inc.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;Risk acknowledgement</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This investment is risky. Initial that you understand that:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your<BR>
 initials</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk of loss </B>&ndash; You could lose your entire investment of $________.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity risk</B> &ndash; You may not be able to sell your investment quickly &ndash; or at all.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 8pt 5.4pt 2pt; border-right: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lack of information </B>&ndash; You may receive little or no information about your investment.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lack
    of advice &ndash; </B>You may not receive advice from the salesperson about whether this investment is suitable for you unless the
    salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investments.
    To check whether the salesperson is registered, go to <U>www.aretheyregistered.ca</U>.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;Accredited investor status</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You must meet at least <B>one </B>of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your<BR>
 initials</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 22pt; text-indent: -14.65pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Your net income before taxes was more than $200,000 in each for the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 22pt; text-indent: -14.65pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Your net income before taxes combined with your spouse&rsquo;s was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 0.75in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 22pt; text-indent: -14.65pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the case and securities.</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 22pt; text-indent: -14.65pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;Either alone or with your spouse, you may have net assets worth more than $5 million. (Your net assets are your total assets (including real estate) minus your total debt.)</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;Your name and signature</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First and last name (please print):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; width: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;5 TO BE COMPLETED BY SALESPERSON</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;Salesperson information</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement</I>.]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First and last name of salesperson (please print):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of firm (if registered):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 8pt; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION&nbsp;6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding: 8pt 5.4pt 2pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&nbsp;&nbsp;&nbsp;For
    more information about this investment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 8pt 5.4pt 2pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS
    Neurosciences Inc.<BR>
    </FONT>Kristi Lanier, Finance Director<BR>
    Tel: [***]<BR>
    E-mail: [***]<BR>
    Website: www.promisneurosciences.com<BR>
    <B>For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at
    <U>www.securities-administrators.ca</U></B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>36
<FILENAME>filename36.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.18</B></P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated
by: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">U.S. Persons only (Nov. 27, 2018)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>U.S. PERSONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following items in this Subscription Agreement must be completed.
    (Please initial each box.)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Provide
    information and answers in the boxes on pages 1, 2 and 3.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Sign the execution page on
    page 1 of this Subscription Agreement.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Complete Schedule &#8220;1&#8221;,
    Accredited Investor Certificate and sign</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="width: 2%">&#8239;</TD>
    <TD STYLE="width: 13%">&#8239;</TD>
    <TD STYLE="width: 85%">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Delivery of Subscription forms may be made
by</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>email to</U></B>: &#9;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -45pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -45pt"><B><U>courier/mail
to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in"><B><U>Delivery of
certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Alternatively, delivery of funds may also be made via electronic
wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>To wire US $ funds:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Account # [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank #:[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currency: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Beneficiary: PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary address: 1920 Yonge Street, Suite 200, Toronto, ON M4S
3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intermediary/Correspondent Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABA #: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>If you wish to wire funds in currency other than US$, please
contact the Corporation by email: </U></B>[***]<B>__________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FOR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The undersigned (the &#8220;<B>Subscriber</B>&#8221;, including, if applicable, each Disclosed Principal (as hereinafter defined) for
whom the undersigned is acting hereunder) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation
(the &#8220;<B>Units</B>&#8221;) set forth below for the aggregate subscription amount set forth below (the &#8220;<B>Aggregate Subscription
Amount</B>&#8221;), representing a subscription price of <B>US$0.173 per Unit</B> (or <B>CDN$0.23 per Unit</B>) on the terms and conditions
set forth in &#8220;Terms and Conditions of Subscription for Units of ProMIS Neurosciences Inc..&#8221; attached hereto (together with
the face pages and the attached Schedules, the &#8220;<B>Subscription Agreement</B>&#8221;). Each Unit consists of one common share of
the Corporation (a &#8220;<B>Common Share</B>&#8221;) and one transferable share purchase warrant (a &#8220;<B>Warrant</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each whole Warrant entitles the holder to purchase
one Common Share (a &#8220;<B>Warrant Share</B>&#8221;) at any time for a five year period, subject to acceleration (as noted below),
at a price of <B>CDN$0.48</B> per Warrant Share. At any time after the expiry of the four-month hold period applicable to the Warrants,
the Corporation may accelerate the expiry of the Warrants if if either one of the conditions (a &#8220;<B>Trigger Condition</B>&#8221;)
below is met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the twenty-day volume-weighted average
                                            trading price (&#8220;<B>20 day VWAP&#8221;</B>) of the Common Shares on the TSX, and/or
                                            such other exchange on which the Common Shares may be listed, is greater than CDN$1.00, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Corporation enters into a partnering
                                            deal within eighteen months of the Closing of this Subscription that results in minimum proceeds
                                            to the Corporation of US$5M and the 20 day VWAP is greater than CDN$0.48 at any time following
                                            the announcement of such a partnering deal,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">provided that, in either case, (i)
the Corporation disseminates a press release announcing the occurrence of the applicable Trigger Condition, and (ii) the accelerated
expiry date is not less than 30 calendar days after such news release is disseminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For greater certainty, the 20 day VWAP of the
Common Shares shall be calculated by dividing the total value by the total volume of Common Shares traded (on all exchanges, including
the TSX and such other exchange on which the Common Shares may be listed) for the twenty trading days immediately preceding the applicable
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Units, the Common Shares, the Warrants and
the Warrant Shares are hereinafter referred to together as the &#8220;<B>Securities</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Number of Units: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#9;</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Aggregate Subscription Amount: US$<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P></TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and Signature of Subscriber</B></FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">Individual
    Subscriber </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Individual
    Subscriber (e.g., Corporation)</FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name of Non-Individual Subscriber) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature
    of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature
    of Authorized Signatory) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-left: 5.4pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name and Official Capacity or Title of Signatory) <BR>
    The signatory represents that he has authority to bind the Subscriber. </FONT></TD>
    </TR>
  <TR>
    <TD STYLE="padding-left: 5.4pt; width: 44%">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; width: 2%">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; width: 4%">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; width: 50%">&#8239;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B><U>ONLY IF</U> the Subscriber is signing as agent or trustee
    for a principal (a &#8220;Disclosed Principal&#8221;) and is not purchasing as trustee or agent for accounts fully managed by it,
    so as to be deemed to be purchasing as principal pursuant to National Instrument 45-106, complete the following and, if applicable,
    ensure that all Schedules are completed on behalf of such Disclosed Principal:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)<BR></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)&#8239;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 6pt 5pt; border: Black 1pt solid; text-align: center"><B>Address of Subscriber
    - Residential for Individual / Business for Non-Individual Subscriber</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 6pt 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 5pt; border-left: Black 1pt solid; text-align: justify">Address of Subscriber</TD>
    <TD STYLE="padding: 6pt 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; text-align: justify">(Telephone Number)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 5pt; border-left: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 6pt 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 5pt; border-left: Black 1pt solid; text-align: justify; width: 44%">City, Province, Postal Code</TD>
    <TD STYLE="padding: 6pt 5pt; text-align: justify; width: 4%">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; text-align: justify; width: 52%">(Facsimile Number)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 5pt; border-left: Black 1pt solid; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 6pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">(Email
    address)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 47%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>REGISTRATION INSTRUCTIONS&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="padding-top: 0.05pt; padding-bottom: 0.05pt; width: 3%">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%; padding-top: 0.05pt; padding-bottom: 0.05pt"><B>DELIVERY INSTRUCTIONS</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Register the Common Shares and Warrants as set forth below
    (only complete if different from above):</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>&nbsp;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 0.05pt 0.05in">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Deliver the Common Shares and Warrants as set forth below:</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Contact Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 80%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INFORMATION REGARDING THE SUBSCRIBER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please check the appropriate box (and complete
the required information, if applicable) in each section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Security Holdings</B>. Prior to giving effect
                                            to the issuance of the securities being subscribed for under this Subscription Agreement,
                                            the Subscriber and all persons acting jointly and in concert with the Subscriber currently
                                            own, directly or indirectly, or exercise control or direction over (provide additional detail
                                            as applicable):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">_________________
                                            common shares of the Corporation and the following other kinds of rights and convertible
                                            securities (including but not limited to convertible debt, warrants and options) entitling
                                            the Subscriber to acquire additional common shares of the Corporation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&#8239;</TD>
    <TD STYLE="width: 0.5in; text-align: left">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&#8239;</TD>
    <TD STYLE="width: 0.5in; text-align: left">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">No
                                            shares of the Corporation or rights or securities convertible into shares of the Corporation.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Insider Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            an &#8220;Insider&#8221; of the Corporation as defined in the Policies of the Exchange (as
                                            hereinafter defined) by virtue of being:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a director or executive officer of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a director or executive officer of a company
                                            that is an Insider or subsidiary of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a person that beneficially owns or controls,
                                            directly or indirectly, voting shares of the Corporation carrying more than 10% of the voting
                                            rights attached to all the Corporation&#8217;s outstanding voting shares; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Corporation itself if it holds any of
                                            its own securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            not an Insider of the Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Pro Group Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            a Member of the &#8220;Pro Group&#8221;, which is defined in the Rules of the Exchange as
                                            either individually or as a group:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the member (i.e. a member of the Exchange
                                            under the Exchange requirements);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">employees of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">partners, officers and directors of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">affiliates of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">such other persons as the Exchange may determine;
                                            and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">associates of any parties referred to in
                                            paragraphs 1 through 5 above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            not a member of the Pro Group.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Registrant Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            a &#8220;Registrant&#8221; as defined in the <I>Securities Act</I> (British Columbia) by
                                            virtue of being a person registered or required to be registered under the <I>Securities
                                            Act</I> (British Columbia.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            not a Registrant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation hereby accepts the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>&#8239;,&#8239;
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold">PROMIS NEUROSCIENCES INC.</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&#8239;</TD>
    <TD STYLE="width: 47%">&#8239;</TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in
part. The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or
deduction, if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this
Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>notwithstanding section 2(a) above, this Offering will not in any way restrict the Corporation from issuing additional securities
of the Corporation at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including
an amendment to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be
part of a transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis
prior to the Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which
are outstanding on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representations and Warranties of the Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power
and authority to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules and policies
of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British
Columbia and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation
enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the
issue of the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or
any law, regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is
a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> The Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition,
and, as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all
requisite corporate action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued
as fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding
against the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations
or proceedings for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledgements, Warranties and Covenants of the Subscriber</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber
is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon
acceptance by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole
number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at
such time, including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be
able to resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy
until expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any
certificates (or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8220;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT></B></FONT><B>that
date that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange in connection
with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, the conditions noted in paragraphs 4(h) and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or
both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis
prior to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the issuance of listed Shares <FONT STYLE="font-size: 10pt">during any six month period to insiders </FONT>representing more
than 10% of the number of Shares which are outstanding on a non-diluted basis prior to the Closing<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the Exchange may require
as a condition of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10%
Insider Rule, the votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new
 &#8220;Insider&#8221; or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering,
that the Corporation obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person
and its associates and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all
of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities
legislation, and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering
memorandum, or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and
review by, prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U>) relating to the Corporation and not
upon any oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge
of any &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly
disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence
or place of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it
was not created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution
and will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and
not for the benefit of any other person and not with a view to the resale or distribution of all or any of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable
prospectus exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase
on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other
person, and not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it and each beneficial purchaser has provided to the Corporation all of the information required by pages 1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity
of each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each of the principals complies with subparagraph (h)(ii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the Subscriber is a U.S. Investor and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware that none of the Securities have been nor will be registered under the United States <I>Securities Act of 1933</I>,
as amended (&#8220;<B>U.S. Securities Act</B>&#8221;) and that these securities may not be offered or sold in the United States without
registration under the U.S. Securities Act or compliance with requirements of an exemption from registration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>has completed Schedule I - U.S. Accredited Investor Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber has no intention to distribute either directly or indirectly any of the Securities in the United States or to any
U.S. Persons (as defined in Schedule I - U.S. Accredited Investor Certificate ) and is not subscribing as part of a scheme to avoid the
registration requirements of the U.S. Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>there is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>there are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber
to find out what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements
to provide the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being
advised by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial
and territorial securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units
pursuant to this exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or
damages, will not be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound
by this Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have
been given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all
action pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>this Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding
and enforceable obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and
deliver this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal
and this Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and
binding agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>that any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment
and it, or where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and
delivery of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation
of an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit
such sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock
exchange or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such
reports, undertakings and other documents with respect to the issue of the Units as may be required, including, without limitation a
U.S. accredited investor, a representation letter in the form attached as Schedule I;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any
of the terms or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s
constating documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent
proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that
the Corporation may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription
Agreement and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering)
Act</I> (Canada) and to the best of the Subscriber&#8217;s knowledge (i) none of the subscription funds to be provided by the Subscriber
(A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States of
America, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the Subscriber,
and (ii) it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and
to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the
Subscriber may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain
independent legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently
advised as to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties
and covenants under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the information provided by the Subscriber on pages 1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information
Regarding The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the
Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation
and stock exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies
with all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of
its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-weight: bold; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund
its ongoing development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such
future financings may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are
not available, the Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure
of its business venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as
a result of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a) this duly completed and executed Subscription Agreement,
including all applicable Schedules hereto and Appendices thereto; and (b) the Aggregate Subscription Amount subscribed for under this
Subscription Agreement in accordance with the Instructions on the Cover Page or payment of the same amount in such other manner as is
acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber acknowledges and agrees that
it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription Price as a result of the exchange
of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s counsel,
in Vancouver, British Columbia at 10:00 a.m. (Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance
of this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation
will deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certifcates (or
DRS) representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by the Corporation
of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective to create
a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing, any funds
advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to the Corporation,
which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing does not occur within
90 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Privacy Legislation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed Principal
for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation, including,
without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable similar
replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing the
Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for so
long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact that
the Corporation may be required by applicable securities legislation, stock exchange rules and/or Investment Industry Regulatory Organization
of Canada rules to provide regulatory authorities with any personal information provided by the Subscriber respecting itself (and any
Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has the authority to
provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the Subscriber is
acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose the Subscriber&#8217;s
personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-weight: bold">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> for internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber
or any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure to the Corporation&#8217;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada
Revenue Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect
to reports of trade and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure
to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena compelling such
disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to professional advisers of the Corporation in connection with the performance of their professional services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s
prior written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Subscriber further acknowledges
and agrees that the TSX collects personal information in forms submitted by the Corporation, which will include personal information
regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided for in Appendix 6A to the
TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U> and is incorporated herein by reference. The
Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the British Columbia Securities
Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information in forms submitted
to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information, and the
Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&#8239;899-6500 or (800)&#8239;373-6393,
Facsimile: (604)&#8239;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission, Suite 600, 250 &#8211;
5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario
Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities Commission, Suite 1903,
Box 5520, Queen Street West, Toronto, Ontario M5H&#8239;3S8, Telephone: (416)&#8239;593-3682, Facsimile: (416)&#8239;593&#45;8252. The Subscriber
consents to the collection of personal information by the applicable securities regulatory authorities, including, without limitation,
the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both as of the
execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against all losses, claims, costs, expenses
and damages or liabilities which it may suffer or incur which are caused or arise from an inaccuracy or breach thereof and reliance thereon.
The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS Neurosciences Inc. sent to its office at
1920 Yonge Street, Suite 200, Toronto, ON&#8239;M4S 3E2 or by email to <FONT STYLE="font-size: 10pt">[***] </FONT>of any change in any
statement or other information relating to the Subscriber set forth herein which takes place prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-weight: bold">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel retained
by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms and conditions
set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the Corporation
and their respective heirs, executors, administrators, successors and permitted assigns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in accordance
with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably attorn to
the exclusive jurisdiction of the courts of the Province of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Time
is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without the consent
in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial owner
and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there are no representations,
covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither this Subscription
Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by
the party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and other documents
contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment qu&#8217;elles
ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&#8217;y rattachent soient r&eacute;dig&eacute;s
dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-weight: bold">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">U.S. ACCREDITED INVESTOR CERTIFICATE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of Units of ProMIS
Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;) by the undersigned Subscriber, or if applicable, the principal on whose behalf
the undersigned is purchasing as agent, the Subscriber and the Corporation agree that Unit Subscription Agreement is amended (I) to attach
this Certificate thereto and (II) to the extent of any inconsistencies with the Unit Subscription Agreement, have the provisions of this
Certificate prevail to the extent of any inconsistencies with the Unit Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of this Certificate, a &#8220;<B>U.S.
Investor</B>&#8221; is: (a) any person who is, or who is purchasing Units for the account of or benefit of, a U.S. Person or a person
in the United States; (b) any person who was offered Units in the United States; or (c) any person who executed or delivered the Subscription
Agreement to which this Certificate is attached in the United States. A &#8220;<B>U.S. Person</B>&#8221; has the meaning assigned in
Rule 902(k) of Regulation S (&#8220;<B>Regulation S</B>&#8221;) under the United States <I>Securities Act of 1933</I>, as amended (the
 &#8220;<B>U.S. Securities Act</B>&#8221;), which definition includes: (a) any natural person resident in the United States; (b) any partnership
or corporation organized or incorporated under the laws of the United States; (c) any trust of which any trustee is a U.S. Person; (d)
any partnership or corporation organized outside the United States by a U.S. Person principally for the purpose of investing in securities
not registered under the U.S. Securities Act, unless it is organized or incorporated, and owned, by accredited investors (within the
meaning assigned in Rule 501(a) of Regulation D (&#8220;<B>Regulation D</B>&#8221;) under the U.S. Securities Act) who are not natural
persons, estates or trusts; (e) any estate of which any executor or administrator is a U.S. person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms not specifically defined in
this Certificate will have the meaning ascribed to them in the Subscription Agreement to which this Certificate is attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber covenants, represents and warrants
to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">it understands (A) that the Units, the
                                            underlying Common Shares and Warrants, and the Warrant Shares (together with the Common Shares
                                            and Warrants, the &#8220;<B>Securities</B>&#8221;), have not been and will not be registered
                                            under the U.S. Securities Act or the securities laws of any state of the United States; and
                                            (B) the offer and sale contemplated hereby is being made in reliance on an exemption from
                                            such registration requirements in reliance on Rule 506(b) of Regulation D under the U.S.
                                            Securities Act and/or Section 4(a)(2) of the U.S. Securities Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">it has such knowledge and experience in
                                            financial and business matters as to be capable of evaluating the merits and risks of an
                                            investment in the Units and it is able to bear the economic risk of loss of its entire investment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Corporation has provided to it the
                                            opportunity to ask questions and receive answers concerning the terms and conditions of the
                                            Private Placement, and it has had access to such information concerning the Corporation (including
                                            access to the Corporation&#8217;s public filings available on the Internet at www.sedar.com)
                                            as it has considered necessary or appropriate in connection with its investment decision
                                            to acquire the Units, and that any answers to questions and any request for information have
                                            been complied with to the Subscriber&#8217;s satisfaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">it is acquiring the Units for its own
                                            account, or for the account of one or more persons for whom it is exercising sole investment
                                            discretion, (a &#8220;<B>Beneficial Purchaser</B>&#8221;), for investment purposes only and
                                            not with a view to resale or distribution and, in particular, neither it nor any Beneficial
                                            Purchaser for whose account it is purchasing the Units has any intention to distribute either
                                            directly or indirectly the Securities in the United States or to, or for the account or benefit
                                            of, a U.S. Person or person in the United States; provided, however, that this paragraph
                                            shall not restrict the Subscriber from selling or otherwise disposing of such Securities
                                            pursuant to registration thereof pursuant to the U.S. Securities Act and any applicable state
                                            securities laws, or under an exemption from such registration requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the address of the Subscriber set out
                                            on the front page of the Subscription Agreement is the true and correct principal address
                                            of the Subscriber and can be relied on by the Corporation for the purposes of state blue-sky
                                            laws and the Subscriber has not been formed for the specific purpose of purchasing the Units;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">it has not purchased the Units as a result
                                            of any form of general solicitation or general advertising (as those terms are used in Regulation
                                            D), including advertisements, articles, press releases, notices or other communications published
                                            in any newspaper, magazine or similar media or on the Internet, or broadcast over radio or
                                            television, or the Internet or other form of telecommunications, including electronic display,
                                            or any seminar or meeting whose attendees have been invited by general solicitation or general
                                            advertising;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 36.7pt">(g)</TD><TD STYLE="text-align: justify">it acknowledges that the Securities
                                            are &#8220;restricted securities&#8221;, as such term is defined in Rule 144(a)(3) under
                                            the U.S. Securities Act, and may not be offered, sold, pledged, or otherwise transferred,
                                            directly or indirectly, without prior registration under the U.S. Securities Act and applicable
                                            state securities laws, and it agrees that if it decides to offer, sell, pledge or otherwise
                                            transfer, directly or indirectly, any of the Securities absent such registration, it will
                                            not offer, sell, pledge or otherwise transfer, directly or indirectly, such Securities, directly
                                            or indirectly, except (i) to the Corporation, (ii) outside the United States in an &#8220;offshore
                                            transaction&#8221; meeting the requirements of Rule 904 of Regulation S under the U.S. Securities
                                            Act, if available, and in compliance with applicable local laws and regulations, (iii) in
                                            compliance with the exemption from the registration requirements under the U.S. Securities
                                            Act provided by Rule 144 thereunder, if available, and in accordance with any applicable
                                            state securities or &#8220;blue sky&#8221; laws, or (iv) in a transaction that does not require
                                            registration under the U.S. Securities Act or any applicable state laws and regulations governing
                                            the offer and sale of securities, and, in the case of each of (iii) and (iv) it has prior
                                            to such sale furnished to the Corporation an opinion of counsel in form and substance reasonably
                                            satisfactory to the Corporation stating that such transaction is exempt from registration
                                            under applicable securities laws and that the legend referred to in paragraph (h) below may
                                            be removed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.1pt"></TD><TD STYLE="width: 33.9pt">(h)</TD><TD STYLE="text-align: justify">it acknowledges that the certifcates
                                            (or DRS) representing the Common Shares and Warrant Shares, as well as all certifcates (or
                                            DRS) issued in exchange therefor or in substitution thereof, until such time as is no longer
                                            required under the applicable requirements of the U.S. Securities Act or applicable state
                                            securities laws, will bear, on the face of such certifcate (or DRS), the following legend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="text-transform: uppercase">&#8220;</FONT>THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED&#8239;STATES SECURITIES&#8239;ACT OF 1933, AS AMENDED (THE &#8220;U.S.
SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES
FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY
(A) TO THE COMPANY; (B) OUTSIDE THE UNITED&#8239;STATES IN ACCORDANCE WITH RULE&#8239;904 OF REGULATION&#8239;S UNDER THE U.S.&#8239;SECURITIES
ACT AND IN ACCORDANCE WITH ALL LOCAL LAWS AND REGULATIONS; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES
ACT PROVIDED BY RULE&#8239;144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE
(C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY TO SUCH EFFECT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">THE PRESENCE OF THIS LEGEND MAY IMPAIR
THE ABILITY OF THE HOLDER HEREOF TO EFFECT &#8220;GOOD DELIVERY&#8221; OF THE SECURITIES REPRESENTED HEREBY ON A CANADIAN STOCK EXCHANGE.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">provided, that if the Common Share
or the Warrant Shares are being sold outside the United States in compliance with the requirements of Rule 904 of Regulation S and such
Securities were issued at a time when the Corporation qualifies as a &#8220;foreign issuer&#8221; (as defined in Regulation S), the legend
set forth above may be removed by providing a declaration to the registrar and transfer agent of the Corporation, as set forth in Appendix
 &#8220;A&#8221; attached hereto (or in such other form as the Corporation may prescribe from time to time); and provided, further, that,
if the Common Shares or Warrant Shares are being sold otherwise than in accordance with Rule 904 of Regulation S and other than to the
Corporation, the legend may be removed by delivery to the registrar and transfer agent and the Corporation of an opinion of counsel of
recognized standing in form and substance satisfactory to the Corporation that such legends are no longer required under applicable requirements
of the U.S. Securities Act or state securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(i)</TD><TD STYLE="text-align: justify">it understands and acknowledges that
                                            the Corporation is not obligated to remain a &#8220;foreign issuer&#8221; within the meaning
                                            of Regulation S;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(j)</TD><TD STYLE="text-align: justify">it acknowledges that the certificates
                                            representing Warrants, as well as all certificates issued in exchange therefor or in substitution
                                            thereof, until such time as is no longer required under the applicable requirements of the
                                            U.S. Securities Act or applicable state securities laws, will bear, on the face of such certifcate
                                            (or DRS), the following legend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8220;THE WARRANTS REPRESENTED HEREBY
AND THE SECURITIES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE &#8220;U.S. SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH
SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY
OR INDIRECTLY, ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES
ACT AND IN ACCORDANCE WITH ALL LOCAL LAWS AND REGULATIONS; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES
ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE
(C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY TO SUCH EFFECT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">THE WARRANTS REPRESENTED HEREBY MAY
NOT BE EXERCISED BY OR ON BEHALF OF A U.S. PERSON OR A PERSON IN THE UNITED STATES UNLESS THE SECURITIES ISSUABLE UPON EXERCISE OF THE
WARRANTS HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR EXEMPTIONS
FROM SUCH REGISTRATION REQUIREMENTS ARE AVAILABLE. &#8220;UNITED STATES&#8221; AND &#8220;U.S. PERSON&#8221; ARE AS DEFINED BY REGULATION
S UNDER THE U.S. SECURITIES ACT.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(k)</TD><TD STYLE="text-align: justify">it understands and acknowledges that
                                            (A) if the Corporation is deemed to have been at any time previously an issuer with no or
                                            nominal operations and no or nominal assets other than cash and cash equivalents, Rule 144
                                            under the U.S. Securities Act may not be available for resales of the Securities, and (B)
                                            the Corporation is not obligated to make Rule 144 under the U.S. Securities Act available
                                            for resales of such Securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(l)</TD><TD STYLE="text-align: justify">it understands and agrees that there
                                            may be material tax consequences to the Subscriber of an acquisition, disposition or exercise
                                            of any of the Securities. The Corporation gives no opinion and makes no representation with
                                            respect to the tax consequences to the Subscriber under United States, state, local or foreign
                                            tax law of the undersigned&#8217;s acquisition or disposition of such Securities. In particular,
                                            no determination has been made whether the Corporation will be a &#8220;passive foreign investment
                                            company&#8221; within the meaning of Section&#8239;1297 of the United States Internal Revenue
                                            Code of 1986, as amended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">it understands and agrees that the financial
                                            statements of the Corporation have been prepared in accordance with International Financial
                                            Reporting Standards as issued by the International Accounting Standards Board, and therefore
                                            may be materially different from financial statements prepared in accordance with U.S. generally
                                            accepted accounting principles and may not be comparable to financial statements of United
                                            States companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">it consents to the Corporation making
                                            a notation on its records or giving instruction to the registrar and transfer agent of the
                                            Corporation in order to implement the restrictions on transfer set forth and described herein;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">it understands and acknowledges that the
                                            Corporation is incorporated outside the United States, consequently, it may be difficult
                                            to provide service of process on the Corporation and it may be difficult to enforce any judgment
                                            against the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">it understands that the Corporation does
                                            not have any obligation to register the Securities under the U.S. Securities Act or any applicable
                                            state securities laws or to take action so as to permit resales of the Securities. Accordingly,
                                            the Subscriber understands that absent registration, the Subscriber may be required to hold
                                            the Securities indefinitely. As a consequence, the Subscriber understands that it must bear
                                            the economic risks of the investment in the Securities for an indefinite period of time;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">it, and if applicable, each Beneficial
                                            Purchaser for whose account it is purchasing the Units, is an &#8220;accredited investor&#8221;
                                            as defined in Rule 501(a) of Regulation&#8239;D by virtue of satisfying one or more of the
                                            categories indicated below (<B>please hand-write your initial on the appropriate lines and
                                            write &#8220;SUB&#8221; for the criteria the Subscriber meets and &#8220;BEN&#8221; for the
                                            criteria any persons for whose account or benefit the Subscriber is purchasing the Shares
                                            meets</B>):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-top: 12pt; padding-right: 6pt; text-align: left"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="width: 15%; padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 1.</TD>
    <TD STYLE="width: 75%; padding-top: 12pt; padding-right: 6pt; text-align: justify">A bank, as defined in Section 3(a)(2) of the U.S.
    Securities Act, whether acting in its individual or fiduciary capacity; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 2.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A savings and loan association or other institution as defined
    in Section 3(a)(5)(A) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 3.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A broker or dealer registered pursuant to Section 15 of the
    <I>U.S. Securities Exchange Act of 1934</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 4.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">An insurance company as defined in Section 2(a)(13) of the
    U.S. Securities Act; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 5.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">An investment company registered under the <I>Investment Company
    Act of 1940</I>; or</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-top: 12pt; padding-right: 6pt; text-align: left"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="width: 15%; padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 6.</TD>
    <TD STYLE="width: 75%; padding-top: 12pt; padding-right: 6pt; text-align: justify">A business development company as defined in Section
    2(a)(48) of the <I>Investment Company Act of 1940</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 7.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A small business investment company licensed by the U.S. Small
    Business Administration under Section 301(c) or (d) of the <I>Small Business Investment Act of 1958</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 8.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A plan established and maintained by a state, its political
    subdivision or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, with assets
    in excess of U.S. $5,000,000; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 9.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">An employee benefit plan within the meaning of the <I>Employee
    Retirement Income Security Act of 1974</I> in which the investment decision is made by a plan fiduciary, as defined in Section 3(21)
    of such act, which is either a bank, savings and loan association, insurance company or registered investment advisor, or an employee
    benefit plan with total assets in excess of U.S. $5,000,000 or, if a self-directed plan, the investment decisions are made solely
    by persons who are accredited investors; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 10.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A private business development company as defined in Section
    202(a)(22) of the <I>Investment Advisers Act of 1940</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 11.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">An organization described in Section 501(c)(3) of the <I>Internal
    Revenue Code</I>, a corporation, a Massachusetts or similar business trust, or a partnership, not formed for the specific purpose
    of acquiring the Shares, with total assets in excess of U.S. $5,000,000; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 12.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A director, executive officer or general partner of the Corporation;
    or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 13.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A natural person whose individual net worth, or joint net
    worth with that person&#8217;s spouse, exceeds U.S. $1,000,000 (<B>note: </B>for the purposes of calculating net worth, (i) the person&#8217;s
    primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person&#8217;s primary residence, up
    to the estimated fair market value of the primary residence at the time of the sale of the securities, shall not be included as a
    liability (except that if the amount of such indebtedness outstanding at the time of the sale of the securities exceeds the amount
    outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess
    shall be included as a liability); and (iii) indebtedness that is secured by the person&#8217;s primary residence in excess of the
    estimated fair market value of the primary residence shall be included as a liability); or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 14.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A natural person who had an individual income in excess of
    U.S. $200,000 in each year of the two most recent years or joint income with that person&#8217;s spouse in excess of U.S. $300,000
    in each of those years and has a reasonable expectation of reaching the same income level in the current year; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">Category 15.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify">A trust, with total assets in excess of U.S. $5,000,000, not
    formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described
    in Rule 506(b)(2)(ii) under Regulation&#8239;D; or</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify; width: 10%"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify; width: 15%">Category 16.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; text-align: justify; width: 75%">An entity in which each of the equity owners meets
    the requirements of one of the above categories &#8211; if this alternative is selected, identify each equity owner and provide statements
    from each demonstrating how they qualified as an accredited investor.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated _______________, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 1.5%"><B>X</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 48.5%">&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">Signature of individual (if Subscriber <B>is </B>an individual)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 1.5%"><B>X</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 48.5%">&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">Authorized signatory (if Subscriber is <B>not</B> an individual)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name of Subscriber (<B>please print</B>)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name of authorized signatory (<B>please print</B>)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Official capacity of authorized signatory (<B>please print</B>)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Appendix
 &#8220;A&#8221; to CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Form
of Declaration for Removal of Legend &#8211;<BR>
Rule 904 Under the U.S. Securities Act of 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD>To:</TD><TD STYLE="text-align: justify">ProMIS Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;)</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">To:</TD><TD STYLE="text-align: justify">Computershare Trust Company of Canada, as registrar and transfer agent
                                 for the common shares of the Corporation.</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                                                           </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (A) acknowledges that the sale
of _________________ common shares of the Corporation to which this declaration relates, represented by certifcate (or DRS) number _______________,
is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the &#8220;<B>U.S.
Securities Act</B>&#8221;), and (B) certifies that (1) the undersigned (a) is not an &#8220;affiliate&#8221; of the Corporation, as that
term is defined in Rule 405 under the U.S. Securities Act, or is an affiliate solely by virtue of being an officer or director of the
Corporation, (b) is not a &#8220;distributor&#8221; as defined in Regulation&#8239;S, and (c) is not an affiliate of a distributor; (2)
the offer of such securities was not made to a person in the United States and either (a) at the time the buy order was originated, the
buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the buyer was outside
the United States, or (b) the transaction was executed on or through the facilities of the Toronto Stock Exchange, the TSX Venture Exchange
or any other &#8220;designated offshore securities market&#8221;, and neither the seller nor any person acting on its behalf knows that
the transaction has been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate of the seller nor any
person acting on their behalf has engaged or will engage in any directed selling efforts in the United States in connection with the
offer and sale of such securities; (4) the sale is bona fide and not for the purpose of &#8220;washing off&#8221; the resale restrictions
imposed because the securities are &#8220;restricted securities&#8221; (as that term is defined in Rule 144(a)(3) under the U. S. Securities
Act); (5) the seller does not intend to replace such securities with fungible unrestricted securities; and (6) the contemplated sale
is not a transaction, or part of a series of transactions, which, although in technical compliance with Regulation S, is part of a plan
or scheme to evade the registration provisions of the U. S. Securities Act. Terms used herein have the meanings given to them by Regulation&#8239;S
under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated __________________, 20______.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 1.5%"><B>X</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 48.5%">&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">Signature of individual (if Seller <B>is </B>an individual)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 1.5%"><B>X</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 48.5%">&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">Authorized signatory (if Seller is <B>not</B> an individual)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name of Seller (<B>please print</B>)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Name of authorized signatory (<B>please print</B>)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Official capacity of authorized signatory (<B>please print</B>)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Affirmation by Seller&#8217;s Broker-Dealer<BR>
(Required for sales pursuant to Section (B)(2)(b) in Appendix &#8220;A&#8221; to Certificate above)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have read the representation letter of ____________
(the &#8220;<B>Seller</B>&#8221;) dated _______________, pursuant to which the Seller has requested that we sell, for the Seller's account,
____________________ common shares of the Corporation represented by certifcate (or DRS) number _________________ (the &#8220;<B>Shares</B>&#8221;).
We have executed sales of the Shares pursuant to Rule 904 of Regulation S under the United States Securities Act of 1933, as amended
(the &#8220;<B>U.S. Securities Act</B>&#8221;), on behalf of the Seller. In that connection, we hereby represent to you as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">no offer to sell the Shares was made to a
                                            person in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the sale of the Shares was executed in, on
                                            or through the facilities of the Toronto Stock Exchange, the TSX Venture Exchange or another
                                            &#8220;designated offshore securities market&#8221; (as defined in Regulation S under the
                                            U.S. Securities Act), and, to the best of our knowledge, the sale was not pre-arranged with
                                            a buyer in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">no &#8220;directed selling efforts&#8221;
                                            were made in the United States by the undersigned, any affiliate of the undersigned, or any
                                            person acting on behalf of the undersigned; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">we have done no more than execute the order
                                            or orders to sell the Shares as agent for the Seller and will receive no more than the usual
                                            and customary broker&#8217;s commission that would be received by a person executing such
                                            transaction as agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of these representations: &#8220;<B>affiliate</B>&#8221;
means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control
with, the undersigned; &#8220;<B>directed selling efforts</B>&#8221; means any activity undertaken for the purpose of, or that could
reasonably be expected to have the effect of, conditioning the market in the United States for the Shares (including, but not be limited
to, the solicitation of offers to purchase the Shares from persons in the United States); and &#8220;<B>United States</B>&#8221; means
the United States of America, its territories or possessions, any State of the United States, and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal counsel to the Corporation shall be entitled
to rely upon the representations, warranties and covenants contained in this letter to the same extent as if this letter had been addressed
to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated ___________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><I>Name of Firm</I></TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&#8239;</TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD>
  <TD>&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>37
<FILENAME>filename37.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.19</B></P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="margin: 0; text-align: justify"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6)
of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="margin: 0; text-align: right">U.S. Persons only (Oct 21, 2019)</P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>U.S. PERSONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following items in this Subscription Agreement must be completed.
    (Please initial each box.)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-left: Black 1pt solid; vertical-align: top; font-size: 10pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; font-size: 10pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: bottom; font-size: 10pt; padding-left: 5pt">Provide
    information and answers in the boxes on pages 1, 2 and 3.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; font-size: 10pt; padding-left: 5pt">Sign the execution page on page
    1 of this Subscription Agreement.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; font-size: 10pt; padding-left: 5pt">Complete Schedule &#8220;1&#8221;,
    Accredited Investor Certificate and sign</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; padding-right: 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; padding-left: 5pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 1pt">
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 2%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 13%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 85%; padding-left: 5pt">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Delivery of Subscription forms may be made
by</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>email to</U></B>: &#9;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -45pt"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -45pt"><B><U>courier/mail
to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in"><B><U>Delivery of
certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Alternatively, delivery of funds may also be made via electronic
wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>To wire US $ funds:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Account # [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank #:[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currency: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Beneficiary: PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary address: 1920 Yonge Street, Suite 200, Toronto, ON M4S
3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intermediary/Correspondent Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABA #: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>If you wish to wire funds in currency other than US$, please
contact the Corporation by email: </U></B>[***]<B>__________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FOR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (the &#8220;<B>Subscriber</B>&#8221;,
including, if applicable, each Disclosed Principal (as hereinafter defined) for whom the undersigned is acting hereunder) hereby irrevocably
subscribes for and agrees to purchase the number of units of the Corporation (the &#8220;<B>Units</B>&#8221;) set forth below for the
aggregate subscription amount set forth below (the &#8220;<B>Aggregate Subscription Amount</B>&#8221;), representing a subscription price
of <B>US$0.15 per Unit</B> (or <B>CDN$0.20 per Unit</B>) on the terms and conditions set forth in &#8220;Terms and Conditions of Subscription
for Units of ProMIS Neurosciences Inc..&#8221; attached hereto (together with the face pages and the attached Schedules, the &#8220;<B>Subscription
Agreement</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Unit consists of one common share of the
Corporation (a &#8220;<B>Common Share</B>&#8221;) and one transferable share purchase warrant (a &#8220;<B>Warrant</B>&#8221;). Each
whole Warrant entitles the holder to purchase one Common Share (a &#8220;<B>Warrant Share</B>&#8221;) at any time for a five year period
at a price of <B>CDN$0.35</B> per Warrant Share. The Units, the Common Shares, the Warrants and the Warrant Shares are hereinafter referred
to together as the &#8220;<B>Securities</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><B>Number of Units: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><B>US$0.15 per Unit, or if subscribing in CDN$, @ CDN$0.20
    per Unit</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&#8239;</P></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Aggregate Subscription Amount: US$ <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>or, if subscribing in CDN$: CDN<FONT STYLE="font-size: 10pt">$
    <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></B></P></TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and Signature of Subscriber</B></FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-left: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Individual
    Subscriber </FONT></TD>
    <TD STYLE="padding: 4pt 5pt; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Individual
    Subscriber (e.g., Corporation)</FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-left: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding: 4pt 5pt; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name of Non-Individual Subscriber) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-left: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature
    of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding: 4pt 5pt; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature
    of Authorized Signatory) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding: 4pt 5pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-bottom: Black 1pt solid; vertical-align: top; text-align: justify">&#8239;</TD>
    <TD STYLE="padding: 4pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name and Official Capacity or Title of Signatory) <BR>
    The signatory represents that he has authority to bind the Subscriber. </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-right: 5pt; padding-left: 5pt"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B><U>ONLY IF</U> the Subscriber is signing as agent or trustee
    for a principal (a &#8220;Disclosed Principal&#8221;) and is not purchasing as trustee or agent for accounts fully managed by it,
    so as to be deemed to be purchasing as principal pursuant to National Instrument 45-106, complete the following and, if applicable,
    ensure that all Schedules are completed on behalf of such Disclosed Principal:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_______________________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)<BR>
    &#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_______________________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    </TR>
  <TR STYLE="font-size: 1pt">
    <TD STYLE="padding-right: 5pt; font-size: 1pt; width: 44%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; font-size: 1pt; width: 2%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; font-size: 1pt; width: 4%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; font-size: 1pt; width: 50%; padding-left: 5pt">&#8239;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><B>Address of Subscriber
    - Residential for Individual / Business for Non-Individual Subscriber</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 45%; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 4%; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 51%; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">Address of Subscriber</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">(Telephone Number)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">City, Province, Postal Code</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">(Facsimile Number)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 4pt; padding-bottom: 4pt; text-align: justify">(Email
    address)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; width: 47%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>REGISTRATION INSTRUCTIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P></TD>
    <TD STYLE="padding: 0.05pt 0.05in; width: 3%">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 50%; border-bottom: Black 1pt solid; padding: 0.05pt 0.05in"><B>DELIVERY INSTRUCTIONS</B></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; text-align: left; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Register
                                            the Common Shares and Warrants as set forth below (only complete if different from above):</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 0.05pt 0.05in">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Deliver
                                            the Common Shares and Warrants as set forth below:</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Contact Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#9;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INFORMATION REGARDING THE SUBSCRIBER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please check the appropriate box (and complete
the required information, if applicable) in each section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Security Holdings</B>. Prior to giving effect to the issuance of the
                                securities being subscribed for under this Subscription Agreement, the Subscriber and all persons acting
                                jointly and in concert with the Subscriber currently own, directly or indirectly, or exercise control
                                or direction over (provide additional detail as applicable):</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">___________
                                            common shares of the Corporation and the following other kinds of rights and convertible
                                            securities (including but not limited to convertible debt, warrants and options) entitling
                                            the Subscriber to acquire additional common shares of the Corporation:</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt">&#8239;</TD><TD STYLE="padding-top: 5pt; text-align: left">&#8239;</TD><TD STYLE="padding-top: 5pt; text-align: justify">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt">&#8239;</TD><TD STYLE="padding-top: 5pt; text-align: left">&#8239;</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5pt; text-align: justify">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding-top: 5pt">&#8239;</TD><TD STYLE="padding-top: 5pt; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="padding-top: 5pt; text-align: justify">No
                                            shares of the Corporation or rights or securities convertible into shares of the Corporation.</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Insider Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in">&#8239;</TD><TD STYLE="text-align: left; width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            an &#8220;Insider&#8221; of the Corporation as defined in the Policies of the Exchange (as
                                            hereinafter defined) by virtue of being:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">a director or executive
                                            officer of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 3pt; width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">(b)</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">a
                                            director or executive officer of a company that is an Insider or subsidiary of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 3pt; width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">(c)</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">a
                                            person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
                                            carrying more than 10% of the voting rights attached to all the Corporation&#8217;s outstanding
                                            voting shares; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Corporation itself if it holds any of
                                            its own securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            not an Insider of the Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Pro Group Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            a Member of the &#8220;Pro Group&#8221;, which is defined in the Rules of the Exchange as
                                            either individually or as a group:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">1.</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">the
                                            member (i.e. a member of the Exchange under the Exchange requirements);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 3pt; width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">2.</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">employees
                                            of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 3pt; width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">3.</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">partners,
                                            officers and directors of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 3pt; width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">4.</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">affiliates
                                            of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 3pt; width: 1in"></TD><TD STYLE="padding-bottom: 3pt; width: 0.5in">5.</TD><TD STYLE="padding-bottom: 3pt; text-align: justify">such
                                            other persons as the Exchange may determine; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">associates of any parties referred to in
                                            paragraphs 1 through 5 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            not a member of the Pro Group.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Registrant Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            a &#8220;Registrant&#8221; as defined in the <I>Securities Act</I> (British Columbia) by
                                            virtue of being a person registered or required to be registered under the <I>Securities
                                            Act</I> (British Columbia.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is
                                            not a Registrant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation hereby accepts the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>PROMIS NEUROSCIENCES
INC</B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 3%">By:</TD>
                                                       <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&#8239;</TD>
                                                       <TD STYLE="text-align: justify; width: 50%">&#8239;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is
contracting) that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in
whole or in part. The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without
interest or deduction, if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is
contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this
Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>notwithstanding section 2(a) above, this Offering will not in any way restrict the Corporation from issuing additional securities
of the Corporation at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including
an amendment to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be
part of a transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis
prior to the Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which
are outstanding on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representations and Warranties of the Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power
and authority to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules and policies
of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British
Columbia and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation
enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the
issue of the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or
any law, regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is
a party or by which it is bound.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT> The Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition,
and, as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all
requisite corporate action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued
as fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding
against the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations
or proceedings for such purposes are pending or threatened.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledgements, Warranties and Covenants of the Subscriber</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf
the Subscriber is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon
acceptance by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>no fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole
number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at
such time, including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be
able to resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy
until expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any
certificates (or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8220;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT></B></FONT><B>that
date that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange
in connection with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, the conditions noted in paragraphs 4(h) and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or
both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis
prior to the Closing; or</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the issuance of listed Shares <FONT STYLE="font-size: 10pt">during any six month period to insiders </FONT>representing more
than 10% of the number of Shares which are outstanding on a non-diluted basis prior to the Closing<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the Exchange may require
as a condition of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10%
Insider Rule, the votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new
 &#8220;Insider&#8221; or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering,
that the Corporation obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person
and its associates and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all
of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
represents, warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities
legislation, and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering
memorandum, or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and
review by, prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U>) relating to the Corporation and not
upon any oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge
of any &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly
disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence
or place of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it
was not created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution
and will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if the Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and
not for the benefit of any other person and not with a view to the resale or distribution of all or any of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable
prospectus exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase
on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other
person, and not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it and each beneficial purchaser has provided to the Corporation all of the information required by pages 1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity
of each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each of the principals complies with subparagraph (h)(ii);</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the Subscriber is a U.S. Investor and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware that none of the Securities have been nor will be registered under the United States <I>Securities Act of 1933</I>,
as amended (&#8220;<B>U.S. Securities Act</B>&#8221;) and that these securities may not be offered or sold in the United States without
registration under the U.S. Securities Act or compliance with requirements of an exemption from registration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>has completed Schedule I - U.S. Accredited Investor Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber has no intention to distribute either directly or indirectly any of the Securities in the United States or to any
U.S. Persons (as defined in Schedule I - U.S. Accredited Investor Certificate ) and is not subscribing as part of a scheme to avoid the
registration requirements of the U.S. Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>no securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber
to find out what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements
to provide the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being
advised by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial
and territorial securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units
pursuant to this exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or
damages, will not be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound
by this Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have
been given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all
action pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>this Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding
and enforceable obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and
deliver this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal
and this Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and
binding agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>that any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will refund the purchase price of the Shares;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment
and it, or where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and
delivery of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation
of an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit
such sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock
exchange or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such
reports, undertakings and other documents with respect to the issue of the Units as may be required, including, without limitation a
U.S. accredited investor, a representation letter in the form attached as Schedule I;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any
of the terms or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s
constating documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent
proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that
the Corporation may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription
Agreement and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering)
Act</I> (Canada) and to the best of the Subscriber&#8217;s knowledge (i) none of the subscription funds to be provided by the Subscriber
(A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States of
America, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the Subscriber,
and (ii) it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and
to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the
Subscriber may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain
independent legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently
advised as to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties
and covenants under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the information provided by the Subscriber on pages 1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information
Regarding The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the
Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation
and stock exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies
with all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of
its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund
its ongoing development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such
future financings may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are
not available, the Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure
of its business venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as
a result of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a) this duly completed and executed Subscription
Agreement, including all applicable Schedules hereto and Appendices thereto; and (b) the Aggregate Subscription Amount subscribed for
under this Subscription Agreement in accordance with the Instructions on the Cover Page or payment of the same amount in such other manner
as is acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber acknowledges and agrees
that it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription Price as a result of the exchange
of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s
counsel, in Vancouver, British Columbia at 10:00 a.m. (Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance
of this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation
will deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certifcates (or
DRS) representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance
by the Corporation of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective
to create a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing,
any funds advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to
the Corporation, which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing
does not occur within 90 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Privacy Legislation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed
Principal for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation,
including, without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable
similar replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing
the Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for
so long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact
that the Corporation may be required by applicable securities legislation, stock exchange rules and/or Investment Industry Regulatory
Organization of Canada rules to provide regulatory authorities with any personal information provided by the Subscriber respecting itself
(and any Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has the authority
to provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the Subscriber
is acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose the Subscriber&#8217;s
personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> for internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber
or any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure to the Corporation&#8217;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada
Revenue Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect
to reports of trade and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena
compelling such disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to professional advisers of the Corporation in connection with the performance of their professional services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s
prior written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Subscriber further acknowledges
and agrees that the TSX collects personal information in forms submitted by the Corporation, which will include personal information
regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided for in Appendix 6A to the
TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U> and is incorporated herein by reference. The
Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the British Columbia Securities
Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information in forms submitted
to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information, and the
Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&#8239;899-6500 or (800)&#8239;373-6393,
Facsimile: (604)&#8239;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission, Suite 600, 250 &#8211;
5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario
Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities Commission, Suite 1903,
Box 5520, Queen Street West, Toronto, Ontario M5H&#8239;3S8, Telephone: (416)&#8239;593-3682, Facsimile: (416)&#8239;593&#45;8252. The
Subscriber consents to the collection of personal information by the applicable securities regulatory authorities, including, without
limitation, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both
as of the execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against all losses, claims, costs, expenses
and damages or liabilities which it may suffer or incur which are caused or arise from an inaccuracy or breach thereof and reliance thereon.
The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS Neurosciences Inc. sent to its office at
1920 Yonge Street, Suite 200, Toronto, ON&#8239;M4S 3E2 or by email to [***] of any change in any statement or other information relating
to the Subscriber set forth herein which takes place prior to the Closing Time.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> The Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any
counsel retained by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms
and conditions set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the
Corporation and their respective heirs, executors, administrators, successors and permitted assigns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed
in accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably
attorn to the exclusive jurisdiction of the courts of the Province of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Time is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without
the consent in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the
beneficial owner and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there
are no representations, covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither
this Subscription Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in
writing signed by the party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian
dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and
other documents contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment
qu&#8217;elles ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&#8217;y rattachent
soient r&eacute;dig&eacute;s dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">U.S. ACCREDITED INVESTOR CERTIFICATE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of Units of ProMIS
Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;) by the undersigned Subscriber, or if applicable, the principal on whose behalf
the undersigned is purchasing as agent, the Subscriber and the Corporation agree that Unit Subscription Agreement is amended (I) to attach
this Certificate thereto and (II) to the extent of any inconsistencies with the Unit Subscription Agreement, have the provisions of this
Certificate prevail to the extent of any inconsistencies with the Unit Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes of this Certificate, a &#8220;<B>U.S.
Investor</B>&#8221; is: (a) any person who is, or who is purchasing Units for the account of or benefit of, a U.S. Person or a person
in the United States; (b) any person who was offered Units in the United States; or (c) any person who executed or delivered the Subscription
Agreement to which this Certificate is attached in the United States. A &#8220;<B>U.S. Person</B>&#8221; has the meaning assigned in
Rule 902(k) of Regulation S (&#8220;<B>Regulation S</B>&#8221;) under the United States <I>Securities Act of 1933</I>, as amended (the
 &#8220;<B>U.S. Securities Act</B>&#8221;), which definition includes: (a) any natural person resident in the United States; (b) any partnership
or corporation organized or incorporated under the laws of the United States; (c) any trust of which any trustee is a U.S. Person; (d)
any partnership or corporation organized outside the United States by a U.S. Person principally for the purpose of investing in securities
not registered under the U.S. Securities Act, unless it is organized or incorporated, and owned, by accredited investors (within the
meaning assigned in Rule 501(a) of Regulation D (&#8220;<B>Regulation D</B>&#8221;) under the U.S. Securities Act) who are not natural
persons, estates or trusts; (e) any estate of which any executor or administrator is a U.S. person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms not specifically defined in
this Certificate will have the meaning ascribed to them in the Subscription Agreement to which this Certificate is attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber covenants, represents and warrants
to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">it understands (A) that the Units, the
                                            underlying Common Shares and Warrants, and the Warrant Shares (together with the Common Shares
                                            and Warrants, the &#8220;<B>Securities</B>&#8221;), have not been and will not be registered
                                            under the U.S. Securities Act or the securities laws of any state of the United States; and
                                            (B) the offer and sale contemplated hereby is being made in reliance on an exemption from
                                            such registration requirements in reliance on Rule 506(b) of Regulation D under the U.S.
                                            Securities Act and/or Section 4(a)(2) of the U.S. Securities Act;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">it has such knowledge and experience in
                                            financial and business matters as to be capable of evaluating the merits and risks of an
                                            investment in the Units and it is able to bear the economic risk of loss of its entire investment;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Corporation has provided to it the
                                            opportunity to ask questions and receive answers concerning the terms and conditions of the
                                            Private Placement, and it has had access to such information concerning the Corporation (including
                                            access to the Corporation&#8217;s public filings available on the Internet at www.sedar.com)
                                            as it has considered necessary or appropriate in connection with its investment decision
                                            to acquire the Units, and that any answers to questions and any request for information have
                                            been complied with to the Subscriber&#8217;s satisfaction;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">it is acquiring the Units for its own
                                            account, or for the account of one or more persons for whom it is exercising sole investment
                                            discretion, (a &#8220;<B>Beneficial Purchaser</B>&#8221;), for investment purposes only and
                                            not with a view to resale or distribution and, in particular, neither it nor any Beneficial
                                            Purchaser for whose account it is purchasing the Units has any intention to distribute either
                                            directly or indirectly the Securities in the United States or to, or for the account or benefit
                                            of, a U.S. Person or person in the United States; provided, however, that this paragraph
                                            shall not restrict the Subscriber from selling or otherwise disposing of such Securities
                                            pursuant to registration thereof pursuant to the U.S. Securities Act and any applicable state
                                            securities laws, or under an exemption from such registration requirements;</TD></TR></TABLE>




<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the address of the Subscriber set out
                                            on the front page of the Subscription Agreement is the true and correct principal address
                                            of the Subscriber and can be relied on by the Corporation for the purposes of state blue-sky
                                            laws and the Subscriber has not been formed for the specific purpose of purchasing the Units;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">it has not purchased the Units as a result
                                            of any form of general solicitation or general advertising (as those terms are used in Regulation
                                            D), including advertisements, articles, press releases, notices or other communications published
                                            in any newspaper, magazine or similar media or on the Internet, or broadcast over radio or
                                            television, or the Internet or other form of telecommunications, including electronic display,
                                            or any seminar or meeting whose attendees have been invited by general solicitation or general
                                            advertising;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 36.7pt">(g)</TD><TD STYLE="text-align: justify">it acknowledges that the Securities
                                            are &#8220;restricted securities&#8221;, as such term is defined in Rule 144(a)(3) under
                                            the U.S. Securities Act, and may not be offered, sold, pledged, or otherwise transferred,
                                            directly or indirectly, without prior registration under the U.S. Securities Act and applicable
                                            state securities laws, and it agrees that if it decides to offer, sell, pledge or otherwise
                                            transfer, directly or indirectly, any of the Securities absent such registration, it will
                                            not offer, sell, pledge or otherwise transfer, directly or indirectly, such Securities, directly
                                            or indirectly, except (i) to the Corporation, (ii) outside the United States in an &#8220;offshore
                                            transaction&#8221; meeting the requirements of Rule 904 of Regulation S under the U.S. Securities
                                            Act, if available, and in compliance with applicable local laws and regulations, (iii) in
                                            compliance with the exemption from the registration requirements under the U.S. Securities
                                            Act provided by Rule 144 thereunder, if available, and in accordance with any applicable
                                            state securities or &#8220;blue sky&#8221; laws, or (iv) in a transaction that does not require
                                            registration under the U.S. Securities Act or any applicable state laws and regulations governing
                                            the offer and sale of securities, and, in the case of each of (iii) and (iv) it has prior
                                            to such sale furnished to the Corporation an opinion of counsel in form and substance reasonably
                                            satisfactory to the Corporation stating that such transaction is exempt from registration
                                            under applicable securities laws and that the legend referred to in paragraph (h) below may
                                            be removed.</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.1pt"></TD><TD STYLE="width: 33.9pt">(h)</TD><TD STYLE="text-align: justify">it acknowledges that the certifcates
                                            (or DRS) representing the Common Shares and Warrant Shares, as well as all certifcates (or
                                            DRS) issued in exchange therefor or in substitution thereof, until such time as is no longer
                                            required under the applicable requirements of the U.S. Securities Act or applicable state
                                            securities laws, will bear, on the face of such certifcate (or DRS), the following legend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="text-transform: uppercase">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="text-transform: uppercase">&#8220;</FONT>THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED&#8239;STATES SECURITIES&#8239;ACT OF 1933, AS AMENDED (THE &#8220;U.S.
SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES
FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY
(A) TO THE COMPANY; (B) OUTSIDE THE UNITED&#8239;STATES IN ACCORDANCE WITH RULE&#8239;904 OF REGULATION&#8239;S UNDER THE U.S.&#8239;SECURITIES
ACT AND IN ACCORDANCE WITH ALL LOCAL LAWS AND REGULATIONS; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES
ACT PROVIDED BY RULE&#8239;144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE
(C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY TO SUCH EFFECT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">THE PRESENCE OF THIS LEGEND MAY IMPAIR
THE ABILITY OF THE HOLDER HEREOF TO EFFECT &#8220;GOOD DELIVERY&#8221; OF THE SECURITIES REPRESENTED HEREBY ON A CANADIAN STOCK EXCHANGE.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">provided, that if the Common Share
or the Warrant Shares are being sold outside the United States in compliance with the requirements of Rule 904 of Regulation S and such
Securities were issued at a time when the Corporation qualifies as a &#8220;foreign issuer&#8221; (as defined in Regulation S), the legend
set forth above may be removed by providing a declaration to the registrar and transfer agent of the Corporation, as set forth in Appendix
 &#8220;A&#8221; attached hereto (or in such other form as the Corporation may prescribe from time to time); and provided, further, that,
if the Common Shares or Warrant Shares are being sold otherwise than in accordance with Rule 904 of Regulation S and other than to the
Corporation, the legend may be removed by delivery to the registrar and transfer agent and the Corporation of an opinion of counsel of
recognized standing in form and substance satisfactory to the Corporation that such legends are no longer required under applicable requirements
of the U.S. Securities Act or state securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(i)</TD><TD STYLE="text-align: justify">it understands and acknowledges that
                                            the Corporation is not obligated to remain a &#8220;foreign issuer&#8221; within the meaning
                                            of Regulation S;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(j)</TD><TD STYLE="text-align: justify">it acknowledges that the certificates
                                            representing Warrants, as well as all certificates issued in exchange therefor or in substitution
                                            thereof, until such time as is no longer required under the applicable requirements of the
                                            U.S. Securities Act or applicable state securities laws, will bear, on the face of such certifcate
                                            (or DRS), the following legend:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8220;THE WARRANTS REPRESENTED HEREBY
AND THE SECURITIES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED
(THE &#8220;U.S. SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH
SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY
OR INDIRECTLY, ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES
ACT AND IN ACCORDANCE WITH ALL LOCAL LAWS AND REGULATIONS; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES
ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE
(C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY TO SUCH EFFECT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">THE WARRANTS REPRESENTED HEREBY MAY
NOT BE EXERCISED BY OR ON BEHALF OF A U.S. PERSON OR A PERSON IN THE UNITED STATES UNLESS THE SECURITIES ISSUABLE UPON EXERCISE OF THE
WARRANTS HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR EXEMPTIONS
FROM SUCH REGISTRATION REQUIREMENTS ARE AVAILABLE. &#8220;UNITED STATES&#8221; AND &#8220;U.S. PERSON&#8221; ARE AS DEFINED BY REGULATION
S UNDER THE U.S. SECURITIES ACT.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt">(k)</TD><TD STYLE="text-align: justify">it understands and acknowledges that
                                            (A) if the Corporation is deemed to have been at any time previously an issuer with no or
                                            nominal operations and no or nominal assets other than cash and cash equivalents, Rule 144
                                            under the U.S. Securities Act may not be available for resales of the Securities, and (B)
                                            the Corporation is not obligated to make Rule 144 under the U.S. Securities Act available
                                            for resales of such Securities;</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 38.1pt"></TD><TD STYLE="padding-bottom: 10pt; width: 33.9pt">(l)</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">it
                                            understands and agrees that there may be material tax consequences to the Subscriber of an
                                            acquisition, disposition or exercise of any of the Securities. The Corporation gives no opinion
                                            and makes no representation with respect to the tax consequences to the Subscriber under
                                            United States, state, local or foreign tax law of the undersigned&#8217;s acquisition or
                                            disposition of such Securities. In particular, no determination has been made whether the
                                            Corporation will be a &#8220;passive foreign investment company&#8221; within the meaning
                                            of Section&#8239;1297 of the United States Internal Revenue Code of 1986, as amended;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0.5in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.5in">(m)</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">it
                                            understands and agrees that the financial statements of the Corporation have been prepared
                                            in accordance with International Financial Reporting Standards as issued by the International
                                            Accounting Standards Board, and therefore may be materially different from financial statements
                                            prepared in accordance with U.S. generally accepted accounting principles and may not be
                                            comparable to financial statements of United States companies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0.5in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.5in">(n)</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">it
                                            consents to the Corporation making a notation on its records or giving instruction to the
                                            registrar and transfer agent of the Corporation in order to implement the restrictions on
                                            transfer set forth and described herein;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0.5in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.5in">(o)</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">it
                                            understands and acknowledges that the Corporation is incorporated outside the United States,
                                            consequently, it may be difficult to provide service of process on the Corporation and it
                                            may be difficult to enforce any judgment against the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 0.5in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.5in">(p)</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">it
                                            understands that the Corporation does not have any obligation to register the Securities
                                            under the U.S. Securities Act or any applicable state securities laws or to take action so
                                            as to permit resales of the Securities. Accordingly, the Subscriber understands that absent
                                            registration, the Subscriber may be required to hold the Securities indefinitely. As a consequence,
                                            the Subscriber understands that it must bear the economic risks of the investment in the
                                            Securities for an indefinite period of time; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">it, and if applicable, each Beneficial
                                            Purchaser for whose account it is purchasing the Units, is an &#8220;accredited investor&#8221;
                                            as defined in Rule 501(a) of Regulation&#8239;D by virtue of satisfying one or more of the
                                            categories indicated below (<B>please hand-write your initial on the appropriate lines and
                                            write &#8220;SUB&#8221; for the criteria the Subscriber meets and &#8220;BEN&#8221; for the
                                            criteria any persons for whose account or benefit the Subscriber is purchasing the Shares
                                            meets</B>):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="width: 15%; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 1.</TD>
    <TD STYLE="width: 71%; padding-right: 6pt; padding-left: 6pt; text-align: justify">A bank, as defined in Section 3(a)(2) of the U.S.
    Securities Act, whether acting in its individual or fiduciary capacity; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 2.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A savings and loan association or other
    institution as defined in Section 3(a)(5)(A) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity;
    or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 3.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A broker or dealer registered pursuant
    to Section 15 of the <I>U.S. Securities Exchange Act of 1934</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 4.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">An insurance company as defined in Section
    2(a)(13) of the U.S. Securities Act; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 5.</TD>
    <TD STYLE="padding-top: 12pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">An investment company registered under
    the <I>Investment Company Act of 1940</I>; or</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; width: 14%; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; width: 15%; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 6.</TD>
    <TD STYLE="padding-bottom: 10pt; width: 71%; padding-right: 6pt; padding-left: 6pt; text-align: justify">A business development company
    as defined in Section 2(a)(48) of the <I>Investment Company Act of 1940</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 7.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A small business investment company
    licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the <I>Small Business Investment Act of 1958</I>;
    or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 8.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A plan established and maintained by
    a state, its political subdivision or any agency or instrumentality of a state or its political subdivisions, for the benefit of
    its employees, with assets in excess of U.S. $5,000,000; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 9.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">An employee benefit plan within the
    meaning of the <I>Employee Retirement Income Security Act of 1974</I> in which the investment decision is made by a plan fiduciary,
    as defined in Section 3(21) of such act, which is either a bank, savings and loan association, insurance company or registered investment
    advisor, or an employee benefit plan with total assets in excess of U.S. $5,000,000 or, if a self-directed plan, the investment decisions
    are made solely by persons who are accredited investors; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 10.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A private business development company
    as defined in Section 202(a)(22) of the <I>Investment Advisers Act of 1940</I>; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 11.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">An organization described in Section
    501(c)(3) of the <I>Internal Revenue Code</I>, a corporation, a Massachusetts or similar business trust, or a partnership, not formed
    for the specific purpose of acquiring the Shares, with total assets in excess of U.S. $5,000,000; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 12.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A director, executive officer or general
    partner of the Corporation; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 13.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A natural person whose individual net
    worth, or joint net worth with that person&#8217;s spouse, exceeds U.S. $1,000,000 (<B>note: </B>for the purposes of calculating
    net worth, (i) the person&#8217;s primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person&#8217;s
    primary residence, up to the estimated fair market value of the primary residence at the time of the sale of the securities, shall
    not be included as a liability (except that if the amount of such indebtedness outstanding at the time of the sale of the securities
    exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the
    amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person&#8217;s primary residence
    in excess of the estimated fair market value of the primary residence shall be included as a liability); or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 14.</TD>
    <TD STYLE="padding-bottom: 10pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">A natural person who had an individual
    income in excess of U.S. $200,000 in each year of the two most recent years or joint income with that person&#8217;s spouse in excess
    of U.S. $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 15.</TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; text-align: justify">A trust, with total assets in excess of U.S. $5,000,000, not
    formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described
    in Rule 506(b)(2)(ii) under Regulation&#8239;D; or</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; padding-right: 6pt; padding-left: 6pt; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></TD>
    <TD STYLE="width: 15%; padding-right: 6pt; padding-left: 6pt; text-align: justify">Category 16.</TD>
    <TD STYLE="width: 71%; padding-right: 6pt; padding-left: 6pt; text-align: justify">An entity in which each of the equity owners meets
    the requirements of one of the above categories &#8211; if this alternative is selected, identify each equity owner and provide statements
    from each demonstrating how they qualified as an accredited investor.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated _______________, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 50%">&#8239;</TD>
    <TD STYLE="white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT>&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 48%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of
    individual (if Subscriber <B>is </B>an individual)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT>&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    signatory (if Subscriber is <B>not</B> an individual)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subscriber
    (<B>please print</B>)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of authorized
    signatory (<B>please print</B>)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official capacity
    of authorized signatory (<B>please print</B>)</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">__________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Appendix
 &#8220;A&#8221; to CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Form
of Declaration for Removal of Legend &#8211;<BR>
Rule 904 Under the U.S. Securities Act of 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">To:</TD><TD STYLE="text-align: justify">ProMIS Neurosciences Inc.
                                            (the &#8220;<B>Corporation</B>&#8221;)</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">To:</TD><TD STYLE="text-align: justify">Computershare Trust Company of Canada, as
                                            registrar and transfer agent for the common shares of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (A) acknowledges that the sale
of _________________ common shares of the Corporation to which this declaration relates, represented by certifcate (or DRS) number _______________,
is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the &#8220;<B>U.S.
Securities Act</B>&#8221;), and (B) certifies that (1) the undersigned (a) is not an &#8220;affiliate&#8221; of the Corporation, as that
term is defined in Rule 405 under the U.S. Securities Act, or is an affiliate solely by virtue of being an officer or director of the
Corporation, (b) is not a &#8220;distributor&#8221; as defined in Regulation&#8239;S, and (c) is not an affiliate of a distributor; (2)
the offer of such securities was not made to a person in the United States and either (a) at the time the buy order was originated, the
buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the buyer was outside
the United States, or (b) the transaction was executed on or through the facilities of the Toronto Stock Exchange, the TSX Venture Exchange
or any other &#8220;designated offshore securities market&#8221;, and neither the seller nor any person acting on its behalf knows that
the transaction has been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate of the seller nor any
person acting on their behalf has engaged or will engage in any directed selling efforts in the United States in connection with the
offer and sale of such securities; (4) the sale is bona fide and not for the purpose of &#8220;washing off&#8221; the resale restrictions
imposed because the securities are &#8220;restricted securities&#8221; (as that term is defined in Rule 144(a)(3) under the U. S. Securities
Act); (5) the seller does not intend to replace such securities with fungible unrestricted securities; and (6) the contemplated sale
is not a transaction, or part of a series of transactions, which, although in technical compliance with Regulation S, is part of a plan
or scheme to evade the registration provisions of the U. S. Securities Act. Terms used herein have the meanings given to them by Regulation&#8239;S
under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated __________________, 20______.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 50%">&#8239;</TD>
    <TD STYLE="white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT>&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 48%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">Signature of individual (if Seller <B>is </B>an individual)</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT>&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">Authorized signatory (if Seller is <B>not</B> an individual)</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">Name of Seller (<B>please print</B>)</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">Name of authorized signatory (<B>please print</B>)</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">Official capacity of authorized signatory (<B>please print</B>)</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Affirmation by Seller&#8217;s Broker-Dealer<BR>
(Required for sales pursuant to Section (B)(2)(b) in Appendix &#8220;A&#8221; to Certificate above)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have read the representation letter of ____________
(the &#8220;<B>Seller</B>&#8221;) dated _______________, pursuant to which the Seller has requested that we sell, for the Seller's account,
____________________ common shares of the Corporation represented by certifcate (or DRS) number _________________ (the &#8220;<B>Shares</B>&#8221;).
We have executed sales of the Shares pursuant to Rule 904 of Regulation S under the United States Securities Act of 1933, as amended
(the &#8220;<B>U.S. Securities Act</B>&#8221;), on behalf of the Seller. In that connection, we hereby represent to you as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">no offer to sell the Shares was made to a
                                            person in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the sale of the Shares was executed in, on
                                            or through the facilities of the Toronto Stock Exchange, the TSX Venture Exchange or another
                                            &#8220;designated offshore securities market&#8221; (as defined in Regulation S under the
                                            U.S. Securities Act), and, to the best of our knowledge, the sale was not pre-arranged with
                                            a buyer in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">no &#8220;directed selling efforts&#8221;
                                            were made in the United States by the undersigned, any affiliate of the undersigned, or any
                                            person acting on behalf of the undersigned; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">we have done no more than execute the order
                                            or orders to sell the Shares as agent for the Seller and will receive no more than the usual
                                            and customary broker&#8217;s commission that would be received by a person executing such
                                            transaction as agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of these representations: &#8220;<B>affiliate</B>&#8221;
means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control
with, the undersigned; &#8220;<B>directed selling efforts</B>&#8221; means any activity undertaken for the purpose of, or that could
reasonably be expected to have the effect of, conditioning the market in the United States for the Shares (including, but not be limited
to, the solicitation of offers to purchase the Shares from persons in the United States); and &#8220;<B>United States</B>&#8221; means
the United States of America, its territories or possessions, any State of the United States, and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal counsel to the Corporation shall be entitled
to rely upon the representations, warranties and covenants contained in this letter to the same extent as if this letter had been addressed
to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated ___________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif">Name of Firm</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 45%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>38
<FILENAME>filename38.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.20</B></P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain identified information has been excluded from
the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because
it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is
indicated by: [***]</I></B></FONT></P>

<P STYLE="text-align: right">Use this form for U.S. Persons only (date: April 13, 2018)&#8239;</P>

<P STYLE="text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>U.S. PERSONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following items in this Subscription Agreement must be completed.
    (Please initial each box.)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Provide information and answers in the boxes on pages 1, 2 and 3.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Sign the execution page on page 1 of this Subscription Agreement. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">Complete Schedule &#8220;1&#8221;, Accredited Investor Certificate and sign</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 3pt; padding-bottom: 3pt; font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="width: 2%">&#8239;</TD>
    <TD STYLE="width: 13%">&#8239;</TD>
    <TD STYLE="width: 85%">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Delivery of Subscription forms may be made
by</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>email to</U></B>: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: left; text-indent: -45pt"><B><U>courier/mail to</U></B>:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: left; text-indent: -45pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>Delivery of certified cheque, money order or bank
draft may be made by courier/mail to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Alternatively, delivery of funds may also be made via electronic
wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>To wire US $ funds:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Account # [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank #:[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currency: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Beneficiary: PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary address: 1920 Yonge Street, Suite 200, Toronto, ON M4S
3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intermediary/Correspondent Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABA #: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>If you wish to wire funds in currency other than US$, please
contact the Corporation by email: </U></B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>______________________________________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FOR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The undersigned (the &#8220;<B>Subscriber</B>&#8221;, including, if applicable, each Disclosed Principal (as hereinafter defined) for
whom the undersigned is acting hereunder) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation
(the &#8220;<B>Units</B>&#8221;) set forth below for the aggregate subscription amount set forth below (the &#8220;<B>Aggregate Subscription
Amount</B>&#8221;), representing a subscription price of <B><U>US$0.30</U></B> per Unit, on the terms and conditions set forth in &#8220;Terms
and Conditions of Subscription for Units of ProMIS Neurosciences Inc.&#8221; attached hereto (together with the face pages and the attached
Schedules, the &#8220;<B>Subscription Agreement</B>&#8221;). Each Unit consists of one common share of the Corporation (a &#8220;<B>Common
Share</B>&#8221;) and one-half of a transferable share purchase warrant (a &#8220;<B>Warrant</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each whole Warrant entitles the holder to purchase
one Common Share (a &#8220;<B>Warrant Share</B>&#8221;) at any time for a five year period, subject to acceleration (as noted below),
at a price of <B>CDN$0.48</B> per Warrant Share. At any time after the expiry of the four month hold period applicable to the Warrants,
the Corporation may accelerate the expiry of the Warrants if the twenty-day volume-weighted average trading price of the Common Shares
on the TSX, and/or such other exchange on which the Common Shares may be listed, is greater than <B>CDN$1.00</B> (the &#8220;<B>Trigger
Event</B>&#8221;) provided that (a) the Corporation gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated
expiry date is a date which is not less than 30 calendar days after the date of such notice. For greater certainty, the twenty-day volume-weighted
average trading price of the Common Shares shall be calculated by dividing the total value by the total volume of Common Shares traded
(on all exchanges, including the TSX and such other exchange on which the Common Shares may be listed) for the twenty trading days immediately
preceding the date of the Trigger Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Units, the Common Shares, the Warrants and
the Warrant Shares are hereinafter referred to together as the &#8220;<B>Securities</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 10 5.4pt; vertical-align: middle; font-size: 10pt; width: 5%; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Units:</B></FONT></TD>
    <TD STYLE="padding: 10 5.4pt; border-bottom: Black 1pt solid; border-top: Black 1pt solid; font-size: 10pt"><B>____________________________________________</B></TD>
    <TD STYLE="border: Black 1pt solid; padding: 10 5.4pt; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aggregate
    Subscription Amount: US$ _________________<BR>
    <U>(multiply # of Units by US$0.30)</U></B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-bottom: 3pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name and Signature of Subscriber</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-left: black 1pt solid; padding-top: 6pt; text-align: justify; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual Subscriber </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; padding-top: 6pt; text-align: justify; width: 5%">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: black 1pt solid; padding-top: 6pt; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Individual Subscriber (e.g., Corporation)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-left: black 1pt solid; padding-top: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: black 1pt solid; padding-top: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name of Non-Individual Subscriber) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-left: black 1pt solid; padding-top: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding-left: 5.4pt; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: black 1pt solid; padding-top: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of Authorized Signatory) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.4pt; border-left: black 1pt solid; border-bottom: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.4pt; border-bottom: black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-bottom: 6pt; padding-left: 5.4pt; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name and Official Capacity or Title of Signatory) <BR>
The signatory represents that he has authority to bind the Subscriber. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B><U>ONLY IF</U> the Subscriber is signing as agent or trustee
    for a principal (a &ldquo;Disclosed Principal&rdquo;) and is not purchasing as trustee or agent for accounts fully managed by it, so as
    to be deemed to be purchasing as principal pursuant to National Instrument 45-106, complete the following and, if applicable, ensure that
    all Schedules are completed on behalf of such Disclosed Principal:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><B>Address of Subscriber - Residential for Individual / Business for Non-Individual Subscriber</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; border-left: Black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 4%; padding-top: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 51%; border-bottom: Black 1pt solid; padding-top: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">Address of Subscriber </TD>
    <TD STYLE="padding-left: 5.4pt; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Telephone Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">City, Province, Postal Code </TD>
    <TD STYLE="padding-left: 5.4pt; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Facsimile Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Email address) </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="padding-bottom: 6pt; border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>REGISTRATION INSTRUCTIONS</B> &#8239;</TD>
<TD STYLE="padding: 0.05pt 0.05in 6pt; font-size: 10pt">&#8239;</TD>
<TD COLSPAN="3" STYLE="padding: 0.05pt 0.05in 6pt; border-top: Black 1pt solid; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DELIVERY INSTRUCTIONS</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD COLSPAN="2" STYLE="text-align: justify; border-top: Black 1pt solid; padding-right: 5.4pt"><I>Register the Common Shares and Warrants as set forth below (only complete if different from above):</I></TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt"><I>Deliver the Common Shares and Warrants as set forth below:</I></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 45%">(Name)</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt; width: 2%">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 45%">(Name)</TD>
<TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 2%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">(Account reference, if applicable)</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">(Account reference, if applicable)</TD>
<TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">(Address)</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">(Contact Name)</TD>
<TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">(Address)</TD>
<TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
<TD STYLE="border-left: Black 1pt solid; padding-top: 0.05pt; padding-right: 0.05in; padding-left: 0.05in; font-size: 10pt">&#8239;</TD>
<TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INFORMATION REGARDING THE SUBSCRIBER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please check the appropriate box (and complete
the required information, if applicable) in each section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt">1.</TD><TD COLSPAN="2" STYLE="padding-bottom: 10pt; text-align: justify"><B>Security Holdings</B>. Prior to giving effect to the issuance of the securities being subscribed for
under this Subscription Agreement, the Subscriber and all persons acting jointly and in concert with the Subscriber currently own, directly
or indirectly, or exercise control or direction over (provide additional detail as applicable):</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&#8239;</TD><TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
                              <TD STYLE="text-align: justify">_________________ common
shares of the Corporation and the following other kinds of rights and convertible securities (including but not limited to convertible
debt, warrants and options) entitling the Subscriber to acquire additional common shares of the Corporation:</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
                              <TD STYLE="text-align: justify">No shares of the Corporation
or rights or securities convertible into shares of the Corporation.</TD></TR>
                                                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Insider Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is an &#8220;Insider&#8221;
of the Corporation as defined in the Policies of the Exchange (as hereinafter defined) by virtue of being:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">(a)</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">a director or executive officer of the Corporation;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">(b)</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">a director or executive officer of a company that is an Insider or subsidiary of the Corporation;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">(c)</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">a person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
carrying more than 10% of the voting rights attached to all the Corporation&#8217;s outstanding voting shares; or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 1in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.5in">(d)</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">the Corporation itself if it holds any of its own securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is not an Insider of
the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Pro Group Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Is a Member of the &#8220;Pro
Group&#8221;, which is defined in the Rules of the Exchange as either individually or as a group:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">1.</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">the member (i.e. a member of the Exchange under the Exchange requirements);</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">2.</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">employees of the member;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">3.</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">partners, officers and directors of the member;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">4.</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">affiliates of the member;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 6pt; width: 1in"></TD><TD STYLE="padding-bottom: 6pt; width: 0.5in">5.</TD><TD STYLE="padding-bottom: 6pt; text-align: justify">such other persons as the Exchange may determine; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-bottom: 10pt; width: 1in"></TD><TD STYLE="padding-bottom: 10pt; width: 0.5in">6.</TD><TD STYLE="padding-bottom: 10pt; text-align: justify">associates of any parties referred to in paragraphs 1 through 5 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is not a member of the
Pro Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Registrant Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is
a &#8220;Registrant&#8221; as defined in the <I>Securities Act</I> (British Columbia) by virtue of being a person registered or
required to be registered under the <I>Securities Act</I> (British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is
not a Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Corporation hereby accepts
the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">________________________, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PROMIS NEUROSCIENCES INC</B></FONT><B>.</B></TD>
<TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2">&#8239;</TD>
<TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 4%">By:</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 46%">&#8239;</TD>
<TD STYLE="width: 50%">&#8239;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in part.
The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or deduction,
if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this Subscription
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>notwithstanding
section 2(a) above, this Offering will not in any way restrict the Corporation from issuing additional securities of the Corporation
at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including an amendment
to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be
part of a transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which
are outstanding on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representations and Warranties of the Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power
and authority to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules and policies of
the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British
Columbia and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation enforceable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the
issue of the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or
any law, regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is
a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition,
and, as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all requisite corporate
action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued as fully paid and
non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding against
the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations or proceedings
for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledgements, Warranties and Covenants of the Subscriber</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber
is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon acceptance
by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole
number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at such
time, including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be
able to resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy
until expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any
certificates (or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8220;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT></B></FONT><B>that
date that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in addition to the compensation payable to the Placement Agent, as described in section 10, the Corporation may pay fees or issue
finder warrants or both to one or more finders in accordance with the policies of the Exchange in connection with the Offering and subject
to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, the conditions noted in paragraphs 4(h) and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or
both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the issuance of listed Shares <FONT STYLE="font-size: 10pt">during any six month period to insiders </FONT>representing more than
10% of the number of Shares which are outstanding on a non-diluted basis prior to the Closing<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the Exchange may require
as a condition of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10% Insider
Rule, the votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new
 &#8220;Insider&#8221; or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering,
that the Corporation obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person
and its associates and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all
of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it
has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities legislation,
and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering
memorandum, or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and
review by, prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it
has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U>) relating to the Corporation and not upon any
oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge of any
 &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence or place
of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it was not
created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution
and will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
the Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and not for
the benefit of any other person and not with a view to the resale or distribution of all or any of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable prospectus
exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase
on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other
person, and not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it and each beneficial purchaser has provided to the Corporation all of the information required by pages 1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity of
each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each of the principals complies with subparagraph (h)(ii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Subscriber is a U.S. Investor and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware that none of the Securities have been nor will be registered under the United States <I>Securities Act of 1933</I>,
as amended (&#8220;<B>U.S. Securities Act</B>&#8221;) and that these securities may not be offered or sold in the United States without
registration under the U.S. Securities Act or compliance with requirements of an exemption from registration; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>has completed Schedule I - U.S. Accredited Investor Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Subscriber has no intention to distribute either directly or indirectly any of the Securities in the United States or to any U.S. Persons
(as defined in Schedule I - U.S. Accredited Investor Certificate ) and is not subscribing as part of a scheme to avoid the registration
requirements of the U.S. Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>there are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber
to find out what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements to
provide the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being
advised by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial
and territorial securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units
pursuant to this exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or
damages, will not be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound
by this Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have
been given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all
action pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>this
Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding and enforceable
obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and deliver
this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal and
this Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and binding
agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment
and it, or where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and
delivery of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation
of an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit
such sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock
exchange or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such
reports, undertakings and other documents with respect to the issue of the Units as may be required, including, without limitation a
U.S. accredited investor, a representation letter in the form attached as Schedule I;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any
of the terms or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s
constating documents, or any agreement to which the Subscriber is a party or by which it is bound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent
proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that
the Corporation may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription
Agreement and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering)
Act</I> (Canada) and to the best of the Subscriber&#8217;s knowledge (i) none of the subscription funds to be provided by the Subscriber
(A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States of
America, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the Subscriber,
and (ii) it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and
to provide the Corporation with appropriate information in connection therewith;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the
Subscriber may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain
independent legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently
advised as to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties
and covenants under this Subscription Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the information provided by the Subscriber on pages 1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information
Regarding The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the
Units;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation
and stock exchange rules, if applicable, in the future;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies
with all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of
its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund
its ongoing development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such
future financings may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are
not available, the Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure
of its business venture; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as
a result of advice received from a registered person other than the Corporation or any affiliates thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>Closing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>&#8239;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a) this duly completed and executed Subscription Agreement,
including all applicable Schedules hereto and Appendices thereto; and (b) the Aggregate Subscription Amount subscribed for under this
Subscription Agreement in accordance with the Instructions on the Cover Page or payment of the same amount in such other manner as is
acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber acknowledges and agrees that
it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription Price as a result of the exchange
of such funds into Canadian dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s counsel,
in Vancouver, British Columbia at 10:00 a.m. (Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance
of this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation
will deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certifcates (or
DRS) representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by the Corporation
of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective to create
a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing, any funds
advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to the Corporation,
which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing does not occur within
90 days of its acceptance of this Subscription Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Privacy Legislation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed Principal
for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation, including,
without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable similar
replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing the
Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for so
long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact that
the Corporation may be required by applicable securities legislation, stock exchange rules and/or Investment Industry Regulatory Organization
of Canada rules to provide regulatory authorities with any personal information provided by the Subscriber respecting itself (and any
Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has the authority to
provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the Subscriber is
acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose the Subscriber&#8217;s
personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> for internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber
or any Disclosed Principal for whom the Subscriber is acting hereunder;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure to the Corporation&#8217;s transfer agent and registrar;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>for
use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada Revenue
Agency;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure
to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect to reports of trade
and similar regulatory filings;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure
to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena compelling such
disclosure and where there is no reasonable alternative to such disclosure;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure
to professional advisers of the Corporation in connection with the performance of their professional services;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure
to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s prior written
consent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure
to a court determining the rights of the parties under this Subscription Agreement; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure as otherwise required or permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">The
Subscriber further acknowledges and agrees that the TSX collects personal information in forms submitted by the Corporation, which will
include personal information regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided
for in Appendix 6A to the TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U> and is incorporated
herein by reference. The Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the
British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information
in forms submitted to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information,
and the Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&#8239;899-6500 or (800)&#8239;373-6393,
Facsimile: (604)&#8239;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission, Suite 600, 250 &#8211;
5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario
Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities Commission, Suite 1903,
Box 5520, Queen Street West, Toronto, Ontario M5H&#8239;3S8, Telephone: (416)&#8239;593-3682, Facsimile: (416)&#8239;593&#45;8252. The
Subscriber consents to the collection of personal information by the applicable securities regulatory authorities, including, without
limitation, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Placement Agent Compensation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subscriber
understands and acknowledges that the Corporation has engaged the services of the NOBLE Capital Markets (the &#8220;<B>Placement Agent</B>&#8221;)
pursuant to a certain placement agent agreement, whereby the Placement Agent has agreed to act as the Corporation&#8217;s placement agent
in connection with the sale of Securities to U.S. based purchasers. As compensation for the Placement Agent&#8217;s services, the Corporation
will pay the Placement Agent as follows: (i) a payment of a one-time non-refundable US $[***] retainer fee; (ii) at each closing of any
sale of Securities to U.S. based purchasers, a cash fee equal to [***]% of the aggregate gross proceeds (the &#8220;Placement Fee&#8221;)
received by the Corporation from a sale of securities, and (iii) warrants to purchase shares of common stock equal to the aggregate gross
proceeds received from a sale of Securities to the Corporation divided by the price at which the Corporation&#8217;s stock was sold to
the investors(s) at each Closing multiplied by [***]%. Such warrants shall have a term of 5 years, and will be exercisable at the Market
Price (as determined on the relevant date in accordance with TSX policies), and will be transferable to Placement Agent employees and
affiliates. Placement Agent shall be granted piggy-back registration rights with respect to the Securities underlying such warrants in
the event that the Corporation files a registration statement with SEC and becomes a public reporting company in the United States prior
to the expiration of the holding period under the U.S. Securities Act.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation will pay all of its reasonable costs relating to the Offering contemplated hereby, including, without limitation, audit expenses,
issuance costs and taxes, and legal fees for the Placement Agent (up to a maximum of $[***]) related to the preparation of the offering
documents, up to a maximum of $[***].</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both as of the
execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against all losses, claims, costs, expenses
and damages or liabilities which it may suffer or incur which are caused or arise from an inaccuracy or breach thereof and reliance thereon.
The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS Neurosciences Inc. sent to its office at
1920 Yonge Street, Suite 200, Toronto, ON&#8239;M4S 3E2 or by email to [***] of any change in any statement or other information relating
to the Subscriber set forth herein which takes place prior to the Closing Time.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel retained
by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms and conditions
set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the Corporation
and their respective heirs, executors, administrators, successors and permitted assigns</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">16.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in accordance
with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably attorn to
the exclusive jurisdiction of the courts of the Province of British Columbia.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">17.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Time
is of the essence of this Subscription Agreement.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">18.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without the consent
in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial owner
and as otherwise herein provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">19.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there are no representations,
covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither this Subscription
Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by
the party against whom any waiver, change, discharge or termination is sought.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">20.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">21.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">22.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and other documents
contemplated hereby be drawn up in the English language.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Les parties
aux pr&eacute;sentes reconnaissent et confirment qu&#8217;elles ont convenu que la pr&eacute;sente convention de souscription ainsi que
tous les avis et documents qui s&#8217;y rattachent soient r&eacute;dig&eacute;s dans la langue anglaise.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SCHEDULE I</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">U.S. ACCREDITED
INVESTOR CERTIFICATE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In connection with
the purchase of Units of ProMIS Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;) by the undersigned Subscriber, or if applicable,
the principal on whose behalf the undersigned is purchasing as agent, the Subscriber and the Corporation agree that Unit Subscription
Agreement is amended (I) to attach this Certificate thereto and (II) to the extent of any inconsistencies with the Unit Subscription
Agreement, have the provisions of this Certificate prevail to the extent of any inconsistencies with the Unit Subscription Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For the purposes
of this Certificate, a &#8220;<B>U.S. Investor</B>&#8221; is: (a) any person who is, or who is purchasing Units for the account of or
benefit of, a U.S. Person or a person in the United States; (b) any person who was offered Units in the United States; or (c) any person
who executed or delivered the Subscription Agreement to which this Certificate is attached in the United States. A &#8220;<B>U.S. Person</B>&#8221;
has the meaning assigned in Rule 902(k) of Regulation S (&#8220;<B>Regulation S</B>&#8221;) under the United States <I>Securities Act
of 1933</I>, as amended (the &#8220;<B>U.S. Securities Act</B>&#8221;), which definition includes: (a) any natural person resident in
the United States; (b) any partnership or corporation organized or incorporated under the laws of the United States; (c) any trust of
which any trustee is a U.S. Person; (d) any partnership or corporation organized outside the United States by a U.S. Person principally
for the purpose of investing in securities not registered under the U.S. Securities Act, unless it is organized or incorporated, and
owned, by accredited investors (within the meaning assigned in Rule 501(a) of Regulation D (&#8220;<B>Regulation D</B>&#8221;) under
the U.S. Securities Act) who are not natural persons, estates or trusts; (e) any estate of which any executor or administrator is a U.S.
person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Capitalized terms
not specifically defined in this Certificate will have the meaning ascribed to them in the Subscription Agreement to which this Certificate
is attached.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Subscriber
covenants, represents and warrants to the Corporation that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            (A) that the Units, the underlying Common Shares and Warrants, and the Warrant Shares (together
                                            with the Common Shares and Warrants, the &#8220;<B>Securities</B>&#8221;), have not been
                                            and will not be registered under the U.S. Securities Act or the securities laws of any state
                                            of the United States; and (B) the offer and sale contemplated hereby is being made in reliance
                                            on an exemption from such registration requirements in reliance on Rule 506(b) of Regulation
                                            D under the U.S. Securities Act and/or Section 4(a)(2) of the U.S. Securities Act;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it has such
                                            knowledge and experience in financial and business matters as to be capable of evaluating
                                            the merits and risks of an investment in the Units and it is able to bear the economic risk
                                            of loss of its entire investment;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Corporation
                                            has provided to it the opportunity to ask questions and receive answers concerning the terms
                                            and conditions of the Private Placement, and it has had access to such information concerning
                                            the Corporation (including access to the Corporation&#8217;s public filings available on
                                            the Internet at www.sedar.com) as it has considered necessary or appropriate in connection
                                            with its investment decision to acquire the Units, and that any answers to questions and
                                            any request for information have been complied with to the Subscriber&#8217;s satisfaction;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it is acquiring
                                            the Units for its own account, or for the account of one or more persons for whom it is exercising
                                            sole investment discretion, (a &#8220;<B>Beneficial Purchaser</B>&#8221;), for investment
                                            purposes only and not with a view to resale or distribution and, in particular, neither it
                                            nor any Beneficial Purchaser for whose account it is purchasing the Units has any intention
                                            to distribute either directly or indirectly the Securities in the United States or to, or
                                            for the account or benefit of, a U.S. Person or person in the United States; provided, however,
                                            that this paragraph shall not restrict the Subscriber from selling or otherwise disposing
                                            of such Securities pursuant to registration thereof pursuant to the U.S. Securities Act and
                                            any applicable state securities laws, or under an exemption from such registration requirements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#8239;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the address
                                            of the Subscriber set out on the front page of the Subscription Agreement is the true and
                                            correct principal address of the Subscriber and can be relied on by the Corporation for the
                                            purposes of state blue-sky laws and the Subscriber has not been formed for the specific purpose
                                            of purchasing the Units;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it has not
                                            purchased the Units as a result of any form of general solicitation or general advertising
                                            (as those terms are used in Regulation D), including advertisements, articles, press releases,
                                            notices or other communications published in any newspaper, magazine or similar media or
                                            on the Internet, or broadcast over radio or television, or the Internet or other form of
                                            telecommunications, including electronic display, or any seminar or meeting whose attendees
                                            have been invited by general solicitation or general advertising;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.3pt"></TD><TD STYLE="width: 36.7pt"><FONT STYLE="font-size: 10pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it acknowledges
                                            that the Securities are &#8220;restricted securities&#8221;, as such term is defined in Rule
                                            144(a)(3) under the U.S. Securities Act, and may not be offered, sold, pledged, or otherwise
                                            transferred, directly or indirectly, without prior registration under the U.S. Securities
                                            Act and applicable state securities laws, and it agrees that if it decides to offer, sell,
                                            pledge or otherwise transfer, directly or indirectly, any of the Securities absent such registration,
                                            it will not offer, sell, pledge or otherwise transfer, directly or indirectly, such Securities,
                                            directly or indirectly, except (i) to the Corporation, (ii) outside the United States in
                                            an &#8220;offshore transaction&#8221; meeting the requirements of Rule 904 of Regulation
                                            S under the U.S. Securities Act, if available, and in compliance with applicable local laws
                                            and regulations, (iii) in compliance with the exemption from the registration requirements
                                            under the U.S. Securities Act provided by Rule 144 thereunder, if available, and in accordance
                                            with any applicable state securities or &#8220;blue sky&#8221; laws, or (iv) in a transaction
                                            that does not require registration under the U.S. Securities Act or any applicable state
                                            laws and regulations governing the offer and sale of securities, and, in the case of each
                                            of (iii) and (iv) it has prior to such sale furnished to the Corporation an opinion of counsel
                                            in form and substance reasonably satisfactory to the Corporation stating that such transaction
                                            is exempt from registration under applicable securities laws and that the legend referred
                                            to in paragraph (h) below may be removed.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.1pt"></TD><TD STYLE="width: 33.9pt"><FONT STYLE="font-size: 10pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it acknowledges
                                            that the certifcates (or DRS) representing the Common Shares and Warrant Shares, as well
                                            as all certifcates (or DRS) issued in exchange therefor or in substitution thereof, until
                                            such time as is no longer required under the applicable requirements of the U.S. Securities
                                            Act or applicable state securities laws, will bear, on the face of such certifcate (or DRS),
                                            the following legend:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">&#8220;</FONT><FONT STYLE="font-size: 10pt">THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED&#8239;STATES SECURITIES&#8239;ACT OF 1933, AS AMENDED (THE &#8220;U.S.
SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES
FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY
(A) TO THE COMPANY; (B) OUTSIDE THE UNITED&#8239;STATES IN ACCORDANCE WITH RULE&#8239;904 OF REGULATION&#8239;S UNDER THE U.S.&#8239;SECURITIES
ACT AND IN ACCORDANCE WITH ALL LOCAL LAWS AND REGULATIONS; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES
ACT PROVIDED BY RULE&#8239;144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE
(C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE
COMPANY TO SUCH EFFECT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#8239;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">THE PRESENCE
OF THIS LEGEND MAY IMPAIR THE ABILITY OF THE HOLDER HEREOF TO EFFECT &#8220;GOOD DELIVERY&#8221; OF THE SECURITIES REPRESENTED HEREBY
ON A CANADIAN STOCK EXCHANGE.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">provided,
that if the Common Share or the Warrant Shares are being sold outside the United States in compliance with the requirements of Rule 904
of Regulation S and such Securities were issued at a time when the Corporation qualifies as a &#8220;foreign issuer&#8221; (as defined
in Regulation S), the legend set forth above may be removed by providing a declaration to the registrar and transfer agent of the Corporation,
as set forth in Appendix &#8220;A&#8221; attached hereto (or in such other form as the Corporation may prescribe from time to time);
and provided, further, that, if the Common Shares or Warrant Shares are being sold otherwise than in accordance with Rule 904 of Regulation
S and other than to the Corporation, the legend may be removed by delivery to the registrar and transfer agent and the Corporation of
an opinion of counsel of recognized standing in form and substance satisfactory to the Corporation that such legends are no longer required
under applicable requirements of the U.S. Securities Act or state securities laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            and acknowledges that the Corporation is not obligated to remain a &#8220;foreign issuer&#8221;
                                            within the meaning of Regulation S;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt"><FONT STYLE="font-size: 10pt">(j)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it acknowledges
                                            that the certificates representing Warrants, as well as all certificates issued in exchange
                                            therefor or in substitution thereof, until such time as is no longer required under the applicable
                                            requirements of the U.S. Securities Act or applicable state securities laws, will bear, on
                                            the face of such certifcate (or DRS), the following legend:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;THE
WARRANTS REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES
ACT OF 1933, AS AMENDED (THE &#8220;U.S. SECURITIES ACT&#8221;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER
HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION
S UNDER THE U.S. SECURITIES ACT AND IN ACCORDANCE WITH ALL LOCAL LAWS AND REGULATIONS; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION
UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS;
OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND,
IN THE CASE OF CLAUSE (C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE
SATISFACTORY TO THE COMPANY TO SUCH EFFECT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">THE WARRANTS
REPRESENTED HEREBY MAY NOT BE EXERCISED BY OR ON BEHALF OF A U.S. PERSON OR A PERSON IN THE UNITED STATES UNLESS THE SECURITIES ISSUABLE
UPON EXERCISE OF THE WARRANTS HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH
STATE OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS ARE AVAILABLE. &#8220;UNITED STATES&#8221; AND &#8220;U.S. PERSON&#8221; ARE
AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 35.45pt"><FONT STYLE="font-size: 10pt">(k)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            and acknowledges that (A) if the Corporation is deemed to have been at any time previously
                                            an issuer with no or nominal operations and no or nominal assets other than cash and cash
                                            equivalents, Rule 144 under the U.S. Securities Act may not be available for resales of the
                                            Securities, and (B) the Corporation is not obligated to make Rule 144 under the U.S. Securities
                                            Act available for resales of such Securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#8239;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.1pt"></TD><TD STYLE="width: 33.9pt"><FONT STYLE="font-size: 10pt">(l)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            and agrees that there may be material tax consequences to the Subscriber of an acquisition,
                                            disposition or exercise of any of the Securities. The Corporation gives no opinion and makes
                                            no representation with respect to the tax consequences to the Subscriber under United States,
                                            state, local or foreign tax law of the undersigned&#8217;s acquisition or disposition of
                                            such Securities. In particular, no determination has been made whether the Corporation will
                                            be a &#8220;passive foreign investment company&#8221; within the meaning of Section&#8239;1297
                                            of the United States Internal Revenue Code of 1986, as amended;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(m)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            and agrees that the financial statements of the Corporation have been prepared in accordance
                                            with International Financial Reporting Standards as issued by the International Accounting
                                            Standards Board, and therefore may be materially different from financial statements prepared
                                            in accordance with U.S. generally accepted accounting principles and may not be comparable
                                            to financial statements of United States companies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(n)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it consents
                                            to the Corporation making a notation on its records or giving instruction to the registrar
                                            and transfer agent of the Corporation in order to implement the restrictions on transfer
                                            set forth and described herein;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(o)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            and acknowledges that the Corporation is incorporated outside the United States, consequently,
                                            it may be difficult to provide service of process on the Corporation and it may be difficult
                                            to enforce any judgment against the Corporation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(p)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it understands
                                            that the Corporation does not have any obligation to register the Securities under the U.S.
                                            Securities Act or any applicable state securities laws or to take action so as to permit
                                            resales of the Securities. Accordingly, the Subscriber understands that absent registration,
                                            the Subscriber may be required to hold the Securities indefinitely. As a consequence, the
                                            Subscriber understands that it must bear the economic risks of the investment in the Securities
                                            for an indefinite period of time; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(q)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it, and
                                            if applicable, each Beneficial Purchaser for whose account it is purchasing the Units, is
                                            an &#8220;accredited investor&#8221; as defined in Rule 501(a) of Regulation&#8239;D by virtue
                                            of satisfying one or more of the categories indicated below (<B>please hand-write your initial
                                            on the appropriate lines and write &#8220;SUB&#8221; for the criteria the Subscriber meets
                                            and &#8220;BEN&#8221; for the criteria any persons for whose account or benefit the Subscriber
                                            is purchasing the Shares meets</B>):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="width: 12%; text-align: justify"><FONT STYLE="font-size: 10pt">Category 1.</FONT></TD>
    <TD STYLE="width: 75%; text-align: justify"><FONT STYLE="font-size: 10pt">A bank, as defined in Section 3(a)(2)
    of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 2.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A savings and loan association or other institution
    as defined in Section 3(a)(5)(A) of the U.S. Securities Act, whether acting in its individual or fiduciary capacity; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 3.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A broker or dealer registered pursuant to Section
    15 of the <I>U.S. Securities Exchange Act of 1934</I>; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 4.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">An insurance company as defined in Section 2(a)(13)
    of the U.S. Securities Act; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 5.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">An investment company registered under the <I>Investment
    Company Act of 1940</I>; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#8239;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="width: 12%; padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 6.</FONT></TD>
    <TD STYLE="width: 75%; padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A business development company as defined
    in Section 2(a)(48) of the <I>Investment Company Act of 1940</I>; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 7.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A small business investment company licensed by
    the U.S. Small Business Administration under Section 301(c) or (d) of the <I>Small Business Investment Act of 1958</I>; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 8.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A plan established and maintained by a state, its
    political subdivision or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees,
    with assets in excess of U.S. $5,000,000; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 9.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">An employee benefit plan within the meaning of the
    <I>Employee Retirement Income Security Act of 1974</I> in which the investment decision is made by a plan fiduciary, as defined in
    Section 3(21) of such act, which is either a bank, savings and loan association, insurance company or registered investment advisor,
    or an employee benefit plan with total assets in excess of U.S. $5,000,000 or, if a self-directed plan, the investment decisions
    are made solely by persons who are accredited investors; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 10.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A private business development company as defined
    in Section 202(a)(22) of the <I>Investment Advisers Act of 1940</I>; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 11.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">An organization described in Section 501(c)(3) of
    the <I>Internal Revenue Code</I>, a corporation, a Massachusetts or similar business trust, or a partnership, not formed for the
    specific purpose of acquiring the Shares, with total assets in excess of U.S. $5,000,000; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 12.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A director, executive officer or general partner
    of the Corporation; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 13.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A natural person whose individual net worth, or
    joint net worth with that person&#8217;s spouse, exceeds U.S. $1,000,000 (for the purposes of calculating net worth, (i) the person&#8217;s
    primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person&#8217;s primary residence, up
    to the estimated fair market value of the primary residence at the time of the sale of the securities, shall not be included as a
    liability (except that if the amount of such indebtedness outstanding at the time of the sale of the securities exceeds the amount
    outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess
    shall be included as a liability); and (iii) indebtedness that is secured by the person&#8217;s primary residence in excess of the
    estimated fair market value of the primary residence shall be included as a liability); or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 14.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A natural person who had an individual income in
    excess of U.S. $200,000 in each year of the two most recent years or joint income with that person&#8217;s spouse in excess of U.S.
    $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 15.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">A trust, with total assets in excess of U.S. $5,000,000,
    not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as
    described in Rule 506(b)(2)(ii) under Regulation&#8239;D; or</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">Category 16.</FONT></TD>
    <TD STYLE="padding-top: 12pt; text-align: justify"><FONT STYLE="font-size: 10pt">An entity in which each of the equity owners meets
    the requirements of one of the above categories &#8211; if this alternative is selected, identify each equity owner and provide statements
    from each demonstrating how they qualified as an accredited investor.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#8239;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dated _______________, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 48%"><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of individual (if Subscriber
    <B>is </B>an individual)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized signatory (if Subscriber is
    <B>not</B> an individual)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subscriber (<B>please print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of authorized signatory (<B>please
    print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official capacity of authorized signatory
    (<B>please print</B>)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">__________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B><U>Appendix
 &#8220;A&#8221; to CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Form
of Declaration for Removal of Legend &#8211;<BR>
Rule 904 Under the U.S. Securities Act of 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ProMIS
                                            Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Computershare
                                            Trust Company of Canada, as registrar and transfer agent for the common shares of the Corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned
(A) acknowledges that the sale of _________________ common shares of the Corporation to which this declaration relates, represented by
certifcate (or DRS) number _______________, is being made in reliance on Rule 904 of Regulation S under the United States Securities
Act of 1933, as amended (the &#8220;<B>U.S. Securities Act</B>&#8221;), and (B) certifies that (1) the undersigned (a) is not an &#8220;affiliate&#8221;
of the Corporation, as that term is defined in Rule 405 under the U.S. Securities Act, or is an affiliate solely by virtue of being an
officer or director of the Corporation, (b) is not a &#8220;distributor&#8221; as defined in Regulation&#8239;S, and (c) is not an affiliate
of a distributor; (2) the offer of such securities was not made to a person in the United States and either (a) at the time the buy order
was originated, the buyer was outside the United States, or the seller and any person acting on its behalf reasonably believed that the
buyer was outside the United States, or (b) the transaction was executed on or through the facilities of the Toronto Stock Exchange,
the TSX Venture Exchange or any other &#8220;designated offshore securities market&#8221;, and neither the seller nor any person acting
on its behalf knows that the transaction has been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate
of the seller nor any person acting on their behalf has engaged or will engage in any directed selling efforts in the United States in
connection with the offer and sale of such securities; (4) the sale is bona fide and not for the purpose of &#8220;washing off&#8221;
the resale restrictions imposed because the securities are &#8220;restricted securities&#8221; (as that term is defined in Rule 144(a)(3)
under the U. S. Securities Act); (5) the seller does not intend to replace such securities with fungible unrestricted securities; and
(6) the contemplated sale is not a transaction, or part of a series of transactions, which, although in technical compliance with Regulation
S, is part of a plan or scheme to evade the registration provisions of the U. S. Securities Act. Terms used herein have the meanings
given to them by Regulation&#8239;S under the U.S. Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Dated __________________,
20______.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%"><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of individual (if Seller <B>is
    </B>an individual)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized signatory (if Seller is <B>not
    </B>an individual)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Seller (<B>please print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of authorized signatory (<B>please
    print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official capacity of authorized signatory
    (<B>please print</B>)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Affirmation
by Seller&#8217;s Broker-Dealer<BR>
(Required for sales pursuant to Section (B)(2)(b) in Appendix &#8220;A&#8221; to Certificate above)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have read the
representation letter of ____________ (the &#8220;<B>Seller</B>&#8221;) dated _______________, pursuant to which the Seller has requested
that we sell, for the Seller's account, ____________________ common shares of the Corporation represented by certifcate (or DRS) number
_________________ (the &#8220;<B>Shares</B>&#8221;). We have executed sales of the Shares pursuant to Rule 904 of Regulation S under
the United States Securities Act of 1933, as amended (the &#8220;<B>U.S. Securities Act</B>&#8221;), on behalf of the Seller. In that
connection, we hereby represent to you as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no offer to
                                            sell the Shares was made to a person in the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the sale of
                                            the Shares was executed in, on or through the facilities of the Toronto Stock Exchange, the
                                            TSX Venture Exchange or another &#8220;designated offshore securities market&#8221; (as defined
                                            in Regulation S under the U.S. Securities Act), and, to the best of our knowledge, the sale
                                            was not pre-arranged with a buyer in the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no &#8220;directed
                                            selling efforts&#8221; were made in the United States by the undersigned, any affiliate of
                                            the undersigned, or any person acting on behalf of the undersigned; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we have done
                                            no more than execute the order or orders to sell the Shares as agent for the Seller and will
                                            receive no more than the usual and customary broker&#8217;s commission that would be received
                                            by a person executing such transaction as agent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For purposes of
these representations: &#8220;<B>affiliate</B>&#8221; means a person that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the undersigned; &#8220;<B>directed selling efforts</B>&#8221; means
any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the
United States for the Shares (including, but not be limited to, the solicitation of offers to purchase the Shares from persons in the
United States); and &#8220;<B>United States</B>&#8221; means the United States of America, its territories or possessions, any State
of the United States, and the District of Columbia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Legal counsel to
the Corporation shall be entitled to rely upon the representations, warranties and covenants contained in this letter to the same extent
as if this letter had been addressed to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Dated ___________________.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><I>Name of Firm</I></FONT></TD>
                                                                                 <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
  <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>39
<FILENAME>filename39.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.21</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0">Use this form for all non-U.S. Persons (date: April 13, 2018)</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NON-U.S. PERSONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The following items in this Subscription Agreement must be
completed. (Please initial each box.)</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;Provide information and answers in the boxes on pages 1, 2 and 3.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Sign the execution page on page 1 of this Subscription Agreement. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt">&#8239;<FONT STYLE="font-size: 10pt">Complete Schedule &#8220;1&#8221; Accredited Investor Representation Letter and sign</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Delivery of Subscription forms may be made
by</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>email to:</U></B> [***], with a copy
to [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>facsimile to:</U></B> fax #: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in"><B><U>Delivery of
certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Alternatively, delivery of funds may also be made via electronic
wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>To wire Canadian $ funds:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Account # [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank #:[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currency: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Beneficiary: PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary address: 1920 Yonge Street, Suite 200, Toronto, ON M4S
3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>If you wish to wire funds in currency other than CDN$, please
contact the Corporation by email: </U></B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FOR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (the &#8220;<B>Subscriber</B>&#8221;, including, if applicable, each Disclosed Principal (as hereinafter defined) for
whom the undersigned is acting hereunder) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation
(the &#8220;<B>Units</B>&#8221;) set forth below for the aggregate subscription amount set forth below (the &#8220;<B>Aggregate Subscription
Amount</B>&#8221;), representing a subscription price of <B>CDN$0.375</B> per Unit, on the terms and conditions set forth in &#8220;Terms
and Conditions of Subscription for Units of ProMIS Neurosciences Inc..&#8221; attached hereto (together with the face pages and the attached
Schedules, the &#8220;<B>Subscription Agreement</B>&#8221;). Each Unit consists of one common share of the Corporation (a &#8220;<B>Common
Share</B>&#8221;) and one-half of a transferable share purchase warrant (a &#8220;<B>Warrant</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each whole Warrant entitles the holder to purchase
one Common Share (a &#8220;<B>Warrant Share</B>&#8221;) at any time for a five year period, subject to acceleration (as noted below),
at a price of <B>CDN$0.48</B> per Warrant Share. At any time after the expiry of the four month hold period applicable to the Warrants,
the Corporation may accelerate the expiry of the Warrants if the twenty-day volume-weighted average trading price of the Common Shares
on the TSX, and/or such other exchange on which the Common Shares may be listed, is greater than <B>CDN$1.00</B> (the &#8220;<B>Trigger
Event</B>&#8221;) provided that (a) the Corporation gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated
expiry date is a date which is not less than 30 calendar days after the date of such notice. For greater certainty, the twenty-day volume-weighted
average trading price of the Common Shares shall be calculated by dividing the total value by the total volume of Common Shares traded
(on all exchanges, including the TSX and such other exchange on which the Common Shares may be listed) for the twenty trading days immediately
preceding the date of the Trigger Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Units, the Common Shares, the Warrants and
the Warrant Shares are hereinafter referred to together as the &#8220;<B>Securities</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B></B>&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Number of Units: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></B></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;</P></TD>
    <TD COLSPAN="4" STYLE="text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B></B>&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Aggregate Subscription Amount:
    CDN$<U> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;</P></TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name and Signature of Subscriber</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">Individual Subscriber </FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Individual Subscriber (e.g., Corporation)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print Name of Non-Individual Subscriber) </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature of Individual Subscriber) </FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature of Authorized Signatory) </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">(Print Name and Official Capacity or Title of Signatory)</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">The
signatory represents that he has authority to bind the Subscriber. </FONT></P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="text-align: justify; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B><U>ONLY IF</U> the Subscriber is signing as agent or trustee
    for a principal (a &#8220;Disclosed Principal&#8221;) and is not purchasing as trustee or agent for accounts fully managed by it, so as
    to be deemed to be purchasing as principal pursuant to National Instrument 45-106, complete the following and, if applicable, ensure that
    all Schedules are completed on behalf of such Disclosed Principal:</B></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)<BR>
    <BR>
    </P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; width: 44%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 49.7%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.3%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><B>Address of Subscriber - Residential for Individual / Business for Non-Individual Subscriber</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 51%; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">Address of Subscriber </TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Telephone Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">City, Province, Postal Code </TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Facsimile Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Email address) </TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 47%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>REGISTRATION INSTRUCTIONS</B></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;&nbsp;</P></TD>
    <TD STYLE="text-align: justify; width: 3%; padding: 0.05pt 0.05in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0.05pt 0.05in"><B>DELIVERY INSTRUCTIONS</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Register the Common Shares and Warrants as set forth below
    (only complete if different from above):</I></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B></B>&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P></TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; padding: 0.05pt 0.05in">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Deliver the Common Shares and Warrants as set forth below:</I></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Contact Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0.05in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INFORMATION REGARDING THE SUBSCRIBER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please check the appropriate box (and complete
the required information, if applicable) in each section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">1.</TD><TD COLSPAN="2" STYLE="text-align: justify"><B>Security Holdings</B>. Prior to giving effect to the issuance of the securities being subscribed for
under this Subscription Agreement, the Subscriber and all persons acting jointly and in concert with the Subscriber currently own, directly
or indirectly, or exercise control or direction over (provide additional detail as applicable):</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 5%">&nbsp;</TD><TD STYLE="text-align: justify; width: 5%">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
                                           <TD STYLE="text-align: justify; width: 90%">_________________ common shares of the Corporation and the following other kinds of rights and convertible securities (including but
not limited to convertible debt, warrants and options) entitling the Subscriber to acquire additional common shares of the Corporation:</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                           <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                           <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
                                           <TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
                                           <TD STYLE="text-align: justify">No shares of the Corporation
or rights or securities convertible into shares of the Corporation.</TD></TR>
                                                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Insider Status</B>. The Subscriber either:</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is an &#8220;Insider&#8221;
of the Corporation as defined in the Policies of the Exchange (as hereinafter defined) by virtue of being:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a director or executive officer of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a director or executive officer of a company that is an Insider or subsidiary of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
carrying more than 10% of the voting rights attached to all the Corporation&#8217;s outstanding voting shares; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Corporation itself if it holds any of its own securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is not an Insider of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Pro Group Status</B>. The Subscriber either:</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is a Member of the &#8220;Pro Group&#8221;, which is defined in the Rules of the Exchange as either individually or as a group:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify">the member (i.e. a member of the Exchange under the Exchange requirements);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify">employees of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify">partners, officers and directors of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">4.</TD><TD STYLE="text-align: justify">affiliates of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">5.</TD><TD STYLE="text-align: justify">such other persons as the Exchange may determine; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">6.</TD><TD STYLE="text-align: justify">associates of any parties referred to in paragraphs 1 through 5 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Is not a member of the Pro Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">4.</TD><TD COLSPAN="2" STYLE="text-align: justify"><B>Registrant Status</B>. The Subscriber either:</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                               <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD><TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
                                           <TD STYLE="text-align: justify">Is a &#8220;Registrant&#8221; as defined in the <I>Securities Act</I> (British Columbia) by virtue of being a person registered or required
to be registered under the <I>Securities Act</I> (British Columbia.</TD></TR>
                                                                                                                                               <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                               <TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
                                           <TD STYLE="text-align: justify">Is not a Registrant.</TD></TR>
                                                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Corporation hereby accepts
the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
  2018.</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>PROMIS NEUROSCIENCES INC.</B></TD>
  <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black thin solid; width: 46%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in
part. The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or
deduction, if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this Subscription
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>notwithstanding
section 2(a) above, this Offering will not in any way restrict the Corporation from issuing additional securities of the Corporation
at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including an amendment
to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s acceptance
of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be part of a
transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which are outstanding
on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representations and Warranties of the Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power
and authority to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules and policies of
the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British Columbia
and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>This
Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation enforceable
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the
issue of the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or
any law, regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is
a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition,
and, as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all requisite
corporate action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued as fully
paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>No
order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding against
the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations or proceedings
for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledgements, Warranties and Covenants of the Subscriber</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber
is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon
acceptance by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>no
fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at such time,
including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be
able to resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy
until expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any
certificates (or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8220;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT></B></FONT><B>that
date that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange
in connection with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s acceptance
of the Offering, including, without limitation, the conditions noted in paragraphs 4(h) and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or
both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the issuance of listed Shares <FONT STYLE="font-size: 10pt">during any six month period to insiders </FONT>representing more than
10% of the number of Shares which are outstanding on a non-diluted basis prior to the Closing<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the Exchange may require
as a condition of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10% Insider
Rule, the votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new
 &#8220;Insider&#8221; or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering,
that the Corporation obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person
and its associates and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all
of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it
has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities legislation,
and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering
memorandum, or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and
review by, prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it
has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U>) relating to the Corporation and not upon any
oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge of any
 &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence or place
of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it was not
created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution
and will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and not
for the benefit of any other person and not with a view to the resale or distribution of all or any of the Units and it <U>fully complies
with one or more of the sub-paragraphs set forth below</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Subscriber</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is an &#8220;accredited investor&#8221; within the meaning of applicable securities laws, including National Instrument 45-106
entitled &#8220;Prospectus and Registration Exemptions&#8221; (&#8220;<B>NI 45-106</B>&#8221;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>has concurrently executed and delivered a Representation Letter in the form attached as Schedule I to this Subscription Agreement,
including Appendix &#8220;A&#8221; and Appendix &#8220;B&#8221; thereto; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Subscriber is neither an individual nor a company established solely to acquire the Units and the cost of the Units purchased
by it has an aggregate acquisition of not less than $150,000; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>__________
(<B>to be initialled by Subscriber, if applicable)</B> - if it is not purchasing under subparagraph 5(f)(i), or (ii), it is purchasing
pursuant to an exemption from prospectus and registration requirements (particulars of which are enclosed herewith or will be provided
on or before the Closing Date) available to it under applicable securities legislation and shall deliver to the Corporation such further
particulars of the exemption(s) and the Subscriber&#8217;s qualifications thereunder as the Corporation may request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable
prospectus exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase
on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other
person, and not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it
and each beneficial purchaser has provided to the Corporation all of the information required by pages 1 to 3 of this Subscription Agreement
and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity of each beneficial
purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>each
of the principals complies with one or more of subparagraphs 5(f)(i) through (f)(ii), as applicable, and the same is so indicated for
each such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if the Subscriber is a resident of a country other than Canada or the United States (a &#8220;<B>Jurisdiction Outside CAN-US</B>&#8221;)
then in addition to the other representations and warranties contained herein, the Subscriber represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Subscriber is knowledgeable of, or has been independently advised as to, the applicable securities laws of the Jurisdiction
Outside CAN-US which would apply to this Subscription Agreement, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Subscriber is purchasing the Subscriber&#8217;s Shares pursuant to exemptions from any prospectus, registration or similar
requirements under the applicable securities laws of that Jurisdiction Outside CAN-US or, if such is not applicable, the Subscriber is
permitted to purchase the Subscriber&#8217;s Shares under the applicable securities laws of the Jurisdiction Outside CAN-US without the
need to rely on an exemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
applicable securities laws of the Jurisdiction Outside CAN-US in which the Subscriber resides do not require the Corporation to file
a prospectus, registration statement or similar document or to register the Securities or to make any filings or seek any approvals of
any kind whatsoever from any regulatory authority of any kind whatsoever in the Jurisdiction Outside CAN-US;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the delivery of this Subscription Agreement, the acceptance of it by the Corporation and the issuance of the Securities to the
Subscriber complies with all applicable laws of the Subscriber&#8217;s jurisdiction of residence or domicile and all other applicable
laws and will not cause the Subscriber to become subject to or comply with any disclosure, prospectus or other offering document or reporting
requirements under any such applicable laws; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Subscriber will, if requested by the Corporation, or its counsel deliver to the Corporation a certificate or opinion of local counsel
from the Jurisdiction Outside CAN-US in which the Subscriber resides which will confirm the matters referred to in subsections (ii),
(iii) and (iv) above to the satisfaction of the Corporation and its counsel, acting reasonably</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>no
securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there
is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there
are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber to find out
what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements to
provide the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being
advised by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial
and territorial securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units
pursuant to this exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or
damages, will not be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound by this
Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have been
given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all
action pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>this
Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding and enforceable
obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>in the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and deliver
this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal and
this Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and binding
agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>as
to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>that any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>that any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment and
it, or where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>it
understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and delivery
of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation of
an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit such
sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock
exchange or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such
reports, undertakings and other documents with respect to the issue of the Units as may be required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> the entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any
of the terms or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s
constating documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent
proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that
the Corporation may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription
Agreement and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering)
Act</I> (Canada) and to the best of the Subscriber&#8217;s knowledge (i) none of the subscription funds to be provided by the Subscriber
(A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States of
America, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the Subscriber,
and (ii) it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and
to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the
Subscriber may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain
independent legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently
advised as to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties
and covenants under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the information provided by the Subscriber on pages 1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information
Regarding The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>it does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>it will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation
and stock exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies
with all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of
its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund
its ongoing development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such
future financings may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are not
available, the Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure of
its business venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as
a result of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a) this duly completed and executed Subscription
Agreement, including all applicable Schedules hereto and Appendices thereto; and (b) the Aggregate Subscription Amount subscribed
for under this Subscription Agreement in accordance with the Instructions on the Cover Page or payment of the same amount in such
other manner as is acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber
acknowledges and agrees that it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription
Price as a result of the exchange of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s
counsel, in Vancouver, British Columbia at 10:00 a.m. (Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance of
this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation will
deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certificates (or DRS)
representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by
the Corporation of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective
to create a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing,
any funds advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to
the Corporation, which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing
does not occur within 90 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Privacy Legislation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed
Principal for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation,
including, without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable
similar replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing
the Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for
so long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact
that the Corporation may be required by applicable securities legislation, stock exchange rules and/or Investment Industry Regulatory
Organization of Canada rules to provide regulatory authorities with any personal information provided by the Subscriber respecting itself
(and any Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has the authority
to provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the Subscriber is
acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose the Subscriber&#8217;s
personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>for internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber
or any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>for use and disclosure to the Corporation&#8217;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>for use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada
Revenue Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>disclosure to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect
to reports of trade and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>disclosure to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena
compelling such disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>disclosure to professional advisers of the Corporation in connection with the performance of their professional services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s
prior written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>disclosure to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>for use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Subscriber further acknowledges
and agrees that the TSX collects personal information in forms submitted by the Corporation, which will include personal information
regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided for in Appendix 6A to the
TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U> and is incorporated herein by reference. The
Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the British Columbia Securities
Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information in forms submitted
to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information, and the
Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&nbsp;899-6500 or (800)&nbsp;373-6393,
Facsimile: (604)&nbsp;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission, Suite 600, 250 &#8211;
5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario
Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities Commission, Suite 1903,
Box 5520, Queen Street West, Toronto, Ontario M5H&nbsp;3S8, Telephone: (416)&nbsp;593-3682, Facsimile: (416)&nbsp;593&#45;8252. The Subscriber
consents to the collection of personal information by the applicable securities regulatory authorities, including, without limitation,
the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both
as of the execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against all losses, claims, costs, expenses
and damages or liabilities which it may suffer or incur which are caused or arise from an inaccuracy or breach thereof and reliance thereon.
The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS Neurosciences Inc. sent to its office at 1920
Yonge Street, Suite 200, Toronto, ON&nbsp;M4S 3E2 or by email to <FONT STYLE="font-size: 10pt">[***] </FONT>of any change in any statement
or other information relating to the Subscriber set forth herein which takes place prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel
retained by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms
and conditions set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the
Corporation and their respective heirs, executors, administrators, successors and permitted assigns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in
accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably
attorn to the exclusive jurisdiction of the courts of the Province of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Time is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without
the consent in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial
owner and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there
are no representations, covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither
this Subscription Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing
signed by the party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and
other documents contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment
qu&#8217;elles ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&#8217;y rattachent
soient r&eacute;dig&eacute;s dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I<BR>
REPRESENTATION LETTER<BR>
(FOR CANADIAN ACCREDITED INVESTORS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of units of the
Corporation (&#8220;<B>Units</B>&#8221;) by the undersigned subscriber or, if applicable, the principal on whose behalf the undersigned
is purchasing as agent (the &#8220;<B>Subscriber</B>&#8221; for the purposes of this Schedule I), the Subscriber hereby represents, warrants,
covenants and certifies to the Corporation that:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Subscriber is purchasing the Units as principal for its own account or is deemed to be acting as principal
pursuant to applicable securities laws, including National Instrument 45-106 entitled &#8220;Prospectus and Registration Exemptions&#8221;
(&#8220;<B>NI 45-106</B>&#8221;);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Subscriber is an &#8220;<B>accredited investor</B>&#8221; within the meaning of applicable securities
laws, including NI 45-106, by virtue of satisfying one or more of the categories set out in Appendix &#8220;A&#8221; to this Representation
Letter;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">If the Subscriber is an individual, he or she has completed the attached <B>Form 45-106F9 -- <I>Form for
Individual Accredited Investors</I></B> set out in Appendix &#8220;B&#8221; to this Representation Letter unless the individual qualifies
under a category set out in Appendix &#8220;A&#8221; other than (j), (k) or (l) of the definition of &#8220;<B>accredited investor</B>&#8221;;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Upon execution of this Schedule I by the Subscriber, this Schedule I shall be incorporated into and form
a part of the Subscription Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________________, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Print name of Subscriber</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">By:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Signature</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Print name of Signatory (if different from Subscriber)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Title</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMPORTANT: PLEASE INITIAL APPENDIX &#8220;A&#8221;
OVER PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &#8220;A&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE: THE SUBSCRIBER MUST INITIAL BESIDE THE APPLICABLE PORTION
OF THE DEFINITION BELOW AND COMPLETE EACH QUESTION WHICH FOLLOWS THE APPLICABLE PORTION OF THE DEFINITION.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accredited Investor &#8211; </B>(as defined in National Instrument
45-106, and in Ontario, as defined in Section 73.3 of the <I>Securities Act</I> (Ontario) as supplemented by the definition in National
Instrument 45-106) includes:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; width: 12%; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; width: 7%; text-align: left; padding-bottom: 5.4pt">(a)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">except in Ontario, a Canadian financial institution, or a Schedule III bank,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(a.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">in Ontario, a financial institution described in paragraph 1, 2 or 3 of subsection 73.1 (1) of the <I>Securities Act</I> (Ontario),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(b)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">except in Ontario, the Business Development Bank of Canada incorporated under the <I>Business Development Bank of Canada Act</I> (Canada),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(b.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">in Ontario, the Business Development Bank of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(c)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">except in Ontario, a subsidiary of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of
the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(c.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">in Ontario, a subsidiary of any person or Corporation referred to in clause (a.1) or (b.1), if the person or Corporation owns all of
the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(d)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">except in Ontario, a person registered under the securities legislation of a jurisdiction of Canada as an adviser or dealer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(d.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">in Ontario, a person or Corporation registered under the securities legislation of a province or territory of Canada as an adviser or
dealer, except as otherwise prescribed by the regulations,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(e)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">an individual registered under the securities legislation of a jurisdiction of Canada as a representative of a person referred to in
paragraph (d),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(e.1)</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">an individual formerly registered under the securities legislation of a jurisdiction of Canada, other than an individual formerly registered
solely as a representative of a limited market dealer under one or both of the <I>Securities Act</I> (Ontario) or the <I>Securities Act
</I>(Newfoundland and Labrador),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(f)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">except in Ontario, the Government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the
Government of Canada or a jurisdiction of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.1in; padding-top: 5.4pt; text-align: left; padding-bottom: 5.4pt">(f.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">in Ontario, the Government of Canada, the government of a province or territory of Canada, or any Crown corporation, agency or wholly
owned entity of the Government of Canada or of the government of a province or territory of Canada,</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.1in; text-align: left; padding-top: 5.4pt; padding-bottom: 5.4pt">(g)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt">a municipality, public board or commission in Canada and a metropolitan community, school board, the Comit&eacute; de gestion de la taxe
scolaire de l&#8217;&icirc;le de Montr&eacute;al or an intermunicipal management board in Qu&eacute;bec,</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 5.4pt">(h)</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 5.4pt">any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that
government,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; text-align: justify; padding-bottom: 5.4pt">(i)</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">except in Ontario, a pension fund that is regulated by the Office of the Superintendent of Financial Institutions (Canada), a pension
commission or similar regulatory authority of a jurisdiction of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; text-align: justify; padding-bottom: 5.4pt">(i.1)</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt"> in Ontario, a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension
commission or similar regulatory authority of a province or territory of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(j)&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">an
    individual who, either alone or with a spouse, beneficially owns financial assets having an aggregate realizable value that before taxes,
    but net of any related liabilities, exceeds $1,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">[If this
is your applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 5.4pt">(j.1)</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; border-bottom: Black 1pt solid; text-align: justify; padding-bottom: 5.4pt">an individual who beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related
liabilities, exceeds $5,000,000,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; border-bottom: Black 1pt solid; padding-bottom: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(k)</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; border-bottom: Black 1pt solid; padding-bottom: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">an
    individual whose net income before taxes exceeded $200,000 in each of the 2 most recent calendar years or whose net income before taxes
    combined with that of a spouse exceeded $300 000 in each of the 2 most recent calendar years and who, in either case, reasonably expects
    to exceed that net income level in the current calendar year,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">[If this is your
    applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; border-bottom: Black 1pt solid; padding-bottom: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(l)</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; border-bottom: Black 1pt solid; padding-bottom: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">an individual
    who, either alone or with a spouse, has net assets of at least $5,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">[If this is your
    applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-left: 0.1in; text-align: justify; padding-bottom: 5.4pt">(m)</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-top: 5.4pt; text-align: justify; padding-bottom: 5.4pt">a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared
financial statements,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-left: 0.1in; padding-bottom: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n)</P></TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">an
investment fund that distributes or has distributed its securities only to:</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt; width: 12%">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; padding-top: 5.4pt; padding-left: 0.1in; padding-bottom: 5.4pt; width: 7%">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; padding-top: 5.4pt; padding-bottom: 5.4pt; width: 5%">(i)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt">a person that is or was an accredited investor at the time of the distribution,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; padding-top: 5.4pt; padding-left: 0.1in; padding-bottom: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; padding-top: 5.4pt; padding-bottom: 5.4pt">(ii)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; text-align: justify; padding-top: 5.4pt; padding-bottom: 5.4pt">a person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment], or 2.19 [Additional
investment in investment funds], or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 5.4pt; text-align: center; padding-bottom: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; padding-top: 5.4pt; padding-left: 0.1in; padding-bottom: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5pt; padding-top: 5.4pt; padding-bottom: 5.4pt">(iii)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; text-align: justify; padding-top: 5.4pt; padding-bottom: 5.4pt">a person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 [Investment fund reinvestment],</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 5.4pt; text-align: center">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; padding-left: 0.1in; text-align: justify">(o)</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; text-align: justify">an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator
or, in Qu&eacute;bec, the securities regulatory authority, has issued a receipt,</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5.4pt; width: 12%; padding-left: 4.5pt; text-align: center">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 5.4pt; width: 7%; padding-left: 0.1in; text-align: justify">(p)</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; text-align: justify">a trust Corporation or trust corporation registered or authorized to carry on business under the <I>Trust and Loan Companies Act</I> (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account managed by the trust Corporation or trust corporation, as the case may be,</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; width: 12%; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify; width: 7%">(q)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: left">a person acting on behalf of a fully managed account managed by that person, if that person is registered or authorized to carry on business
as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(r)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser
or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities
being traded,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(s)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) paragraph
(i) [and in Ontario, paragraphs (a.1) to (d.1) or paragraph (i.1)] in form and function,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(t)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by
law to be owned by directors, are persons that are accredited investors</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(u)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(v)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">a person that is recognized or designated by the securities regulatory authority or, except in Ontario and Qu&eacute;bec, the regulator
as an accredited investor,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(v.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">in Ontario, a person or Corporation that is recognized or designated by the Commission as an accredited investor,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 5.4pt; border: Black 1pt solid; text-align: center; padding-bottom: 5.4pt">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; padding-left: 0.1in; text-align: justify">(w)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 5.4pt; padding-bottom: 5.4pt; text-align: justify">a trust established by an accredited investor for the benefit of the accredited investor&#8217;s family members of which a majority of
the trustees are accredited investors and all of the beneficiaries are the accredited investor&#8217;s spouse, a former spouse of the
accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited investor&#8217;s
spouse or of that accredited investor&#8217;s former spouse.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: __________________, 201__.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif">Print name of Subscriber</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 50%; text-align: left">Signature</TD><TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 50%">Print name of Signatory (if different from Subscriber)</TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif; width: 50%; text-align: left">Title</TD><TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the purposes hereof:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>control person</B>&#8221; has the meaning ascribed
to that term in securities legislation except in Manitoba, Ontario, Quebec, Nova Scotia, Newfoundland and Labrador, Prince Edward Island,
the Northwest Territories and Nunavut where &#8220;control person&#8221; means any person that holds or is one of a combination of persons
that hold:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">a sufficient number of any of the securities of an issuer so
as to affect materially the control of the issuer; or</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">more than 20% of the outstanding voting securities of an issuer
except where there is evidence showing that the holding of those securities does not affect materially the control of that issuer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>eligibility adviser</B>&#8221; means:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">a person that is registered as an investment dealer or in an
equivalent category of registration under the securities legislation of the jurisdiction of a Subscriber and authorized to give advice
with respect to the type of security being distributed; and</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">in Saskatchewan or Manitoba, also means a lawyer who is a practicing
member in good standing with a law society of a jurisdiction of Canada or a public accountant who is a member in good standing of an
institute or association of chartered accountants, certified general accountants or certified management accountants in a jurisdiction
of Canada provided that the lawyer or public accountant must not:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(A)</FONT></TD><TD STYLE="text-align: justify">have a professional, business or personal relationship with
the issuer, or any of its directors, executive officers, founders or control persons; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: justify">have acted for or been retained personally or otherwise as an
employee, executive officer, director, associate or partner of a person that has acted for or been retained by the issuer or any of its
directors, executive officers, founders or control persons within the previous 12 months;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>financial assets</B>&#8221; means (i) cash, (ii) securities
or (iii) a contract of insurance, a deposit or an evidence of a deposit that is not a security for the purposes of securities legislation.
These financial assets are generally liquid or relatively easy to liquidate. The value of a purchaser&#8217;s personal residence would
not be included in a calculation of financial assets;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>financial statements</B>&#8221; for the purposes of
paragraph (m) of the &#8220;accredited investor&#8221; definition must be prepared in accordance with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>founder</B>&#8221; means, in respect of an issuer,
a person who:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">acting alone, in conjunction or in concert with one or more
persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the issuer;
and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">at the time of the trade is actively involved in the business
of the issuer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>fully managed account</B>&#8221; means an account
of a client for which a person makes the investment decisions if that person has full discretion to trade in securities for the account
without requiring the client&#8217;s express consent to a transaction;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>investment fund</B>&#8221; has the meaning ascribed
thereto in National Instrument 81-106 - <I>Investment Fund Continuous Disclosure</I>;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify">&#8220;<B>net assets</B>&#8221; means all of the purchaser&#8217;s
total assets minus all of the purchaser&#8217;s total liabilities. Accordingly, for the purposes of the net asset test, the calculation
of total assets would include the value of a purchaser&#8217;s personal residence and the calculation of total liabilities would include
the amount of any liability (such as a mortgage) in respect of the purchaser&#8217;s personal residence. To calculate a purchaser&#8217;s
net assets under the &#8220;accredited investor&#8221; definition, subtract the purchaser&#8217;s total liabilities from the purchaser&#8217;s
total assets (including real estate). The value attributed to assets should reasonably reflect their estimated fair value. Income tax
should be considered a liability if the obligation to pay it is outstanding at the time of the distribution of the security;</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">&#8220;<B>related liabilities</B>&#8221; means:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">liabilities incurred or assumed for the purpose of financing
the acquisition or ownership of financial assets; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">liabilities that are secured by financial assets;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">&#8220;<B>spouse</B>&#8221; means an individual who:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify">is married to another individual and is not living separate
and apart within the meaning of the <I>Divorce Act</I> (Canada), from the other individual;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify">is living with another individual in a marriage-like relationship,
including a marriage-like relationship between individuals of the same gender; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify">in Alberta, is an individual referred to in paragraph (i) or
(ii) immediately above or is an adult interdependent partner within the meaning of the <I>Adult Interdependent Relationships Act </I>(Alberta);
and</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &#8220;B&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 45-106F9 - <I>Form for Individual Accredited
Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARNING!</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>This investment is risky. Don&#8217;t invest
    unless you can afford to lose all the money you pay for this investment.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; text-align: left; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>SECTION 1 TO BE COMPLETED BY ISSUER OR SELLING SECURITY HOLDER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>About your investment</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Type of securities:&nbsp;&nbsp;&nbsp;Common Shares and Warrants</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Issuer:&nbsp;&nbsp;ProMIS Neurosciences Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Risk acknowledgement</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">This investment is risky. Initial that you understand that:</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Your initials</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Risk of loss </B>&#8211; You could lose your entire investment of $________. </TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Liquidity risk</B> &#8211; You may not be able to sell your investment quickly &#8211; or at all.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Lack of information </B>&#8211; You may receive little or no information about your investment.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Lack
    of advice &#8211; </B>You may not receive advice from the salesperson about whether this investment is suitable for you unless the
    salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investments.
    To check whether the salesperson is registered, go to <U>www.aretheyregistered.ca</U>.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Accredited investor status</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">You must meet at least <B>one </B>of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Your initials</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: -0.2in; padding-right: 5.4pt; text-align: justify; padding-top: 12pt; padding-left: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Your net income before taxes was more than $200,000 in each for the 2 most recent calendar years, and you expect it to be more than $200,000 in the current calendar year. (You can find your net income before taxes on your personal income tax return.)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: -0.2in; padding-right: 5.4pt; text-align: justify; padding-top: 12pt; padding-left: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Your net income before taxes combined with your spouse&#8217;s was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border: Black 1pt solid; text-indent: -0.2in; padding-right: 5.4pt; text-align: justify; padding-top: 12pt; padding-left: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the case and securities.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: -0.2in; padding-right: 5.4pt; text-align: justify; padding-top: 12pt; padding-left: 0.3in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Either alone or with your spouse, you may have net assets worth more than $5 million. (Your net assets are your total assets (including real estate) minus your total debt.)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Your name and signature</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">First and last name (please print):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Signature:</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Date: </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>SECTION 5 TO BE COMPLETED BY SALESPERSON</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Salesperson information</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">[<I>Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement</I>.]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">First and last name of salesperson (please print):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Telephone:</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Email:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Name of firm (if registered):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>SECTION 6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For more information about this investment</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5.4pt"><P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">ProMIS Neurosciences Inc.<BR> Kristi Lanier, Finance Director<BR> Tel: <FONT STYLE="font-size: 10pt">[***]</FONT><BR> E-mail: <FONT STYLE="font-size: 10pt">[***]</FONT><BR> Website: www.promisneurosciences.com<BR> <B>For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at</B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B><U>www.
                                            securities-administrators.ca</U></B></P></TD></TR>
  <TR>
    <TD STYLE="width: 56%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>40
<FILENAME>filename40.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.22&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&#8239;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain identified information has been excluded
from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by:
[***]</I>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NON-U.S. PERSONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The following items in this Subscription Agreement must be completed.
    (Please initial each box.) </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&#8239;</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;Provide information and answers in the boxes on pages 1, 2 and 3.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;Sign the execution page on page 1 of this Subscription Agreement. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&#8239;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#8239;&#8239;Complete Schedule &#8220;1&#8221; Accredited Investor Representation Letter and sign</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="width: 2%">&#8239;</TD>
    <TD STYLE="width: 13%">&#8239;</TD>
    <TD STYLE="width: 85%">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Delivery of Subscription forms may be made
by</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>email to:</U></B> [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>facsimile to:</U></B> fax #: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><B><U>Delivery of
certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Alternatively, delivery of funds may also be made via electronic
wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>To wire Canadian $ funds:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Account # [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank #:[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currency: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Beneficiary: PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary address: 1920 Yonge Street, Suite 200, Toronto, ON M4S
3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>If you wish to wire funds in currency other than CDN$, please
contact the Corporation by email: </U></B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>_______________________________________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FOR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The undersigned (the &#8220;<B>Subscriber</B>&#8221;, including, if applicable, each Disclosed Principal (as hereinafter defined) for
whom the undersigned is acting hereunder) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation
(the &#8220;<B>Units</B>&#8221;) set forth below for the aggregate subscription amount set forth below (the &#8220;<B>Aggregate Subscription
Amount</B>&#8221;), representing a subscription price of <B>CDN$0.23</B> or <B>US$0.173</B> per Unit, on the terms and conditions set
forth in &#8220;Terms and Conditions of Subscription for Units of ProMIS Neurosciences Inc..&#8221; attached hereto (together with the
face pages and the attached Schedules, the &#8220;<B>Subscription Agreement</B>&#8221;). Each Unit consists of one common share of the
Corporation (a &#8220;<B>Common Share</B>&#8221;) and one transferable share purchase warrant (a &#8220;<B>Warrant</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each whole Warrant entitles the holder to purchase
one Common Share (a &#8220;<B>Warrant Share</B>&#8221;) at any time for a five year period, subject to acceleration (as noted below),
at a price of <B>CDN$0.48</B> per Warrant Share. At any time after the expiry of the four-month hold period applicable to the Warrants,
the Corporation may accelerate the expiry of the Warrants if if either one of the conditions (a &#8220;<B>Trigger Condition</B>&#8221;)
below is met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the twenty-day volume-weighted average trading price (&#8220;<B>20 day VWAP&#8221;</B>) of the Common
Shares on the TSX, and/or such other exchange on which the Common Shares may be listed, is greater than CDN$1.00, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Corporation enters into a partnering deal within eighteen months of the Closing of this Subscription
that results in minimum proceeds to the Corporation of US$5M and the 20 day VWAP is greater than CDN$0.48 at any time following the announcement
of such a partnering deal,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">provided that, in either case, (i) the
Corporation disseminates a press release announcing the occurrence of the applicable Trigger Condition, and (ii) the accelerated expiry
date is not less than 30 calendar days after such news release is disseminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For greater certainty, the 20 day VWAP of the
Common Shares shall be calculated by dividing the total value by the total volume of Common Shares traded (on all exchanges, including
the TSX and such other exchange on which the Common Shares may be listed) for the twenty trading days immediately preceding the applicable
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Units, the Common Shares, the Warrants and
the Warrant Shares are hereinafter referred to together as the &#8220;<B>Securities</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Number of Units: <U>___________________________________</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Aggregate Subscription Amount: CDN$<U> __________</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name and Signature of Subscriber</B></FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="padding-left: 0.125in; vertical-align: top; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">Individual Subscriber </FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Individual Subscriber (e.g., Corporation)</FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-left: 0.125in; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print Name of Non-Individual Subscriber) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-left: 0.125in; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature of Individual Subscriber) </FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature of Authorized Signatory) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print Name and Official Capacity or Title of Signatory) <BR>
The signatory represents that he has authority to bind the Subscriber. </FONT></TD>
    </TR>
  <TR>
    <TD STYLE="width: 44%">&#8239;</TD>
    <TD STYLE="width: 2%">&#8239;</TD>
    <TD STYLE="width: 4%">&#8239;</TD>
    <TD STYLE="width: 50%">&#8239;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B><U>ONLY IF</U> the Subscriber is signing as agent or trustee
    for a principal (a &#8220;Disclosed Principal&#8221;) and is not purchasing as trustee or agent for accounts fully managed by it, so as
    to be deemed to be purchasing as principal pursuant to National Instrument 45-106, complete the following and, if applicable, ensure that
    all Schedules are completed on behalf of such Disclosed Principal:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)<BR>
    <BR>
    </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&#8239;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><B>Address of Subscriber - Residential for Individual / Business for Non-Individual Subscriber</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 4%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 0.125in; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">Address of Subscriber </TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Telephone Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 0.125in; vertical-align: top; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">City, Province, Postal Code </TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Facsimile Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-left: 0.125in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Email address) </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>REGISTRATION INSTRUCTIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="width: 3%; padding: 0.05pt 0.05in">&#8239;</TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0.05pt 0.05in"><B>DELIVERY INSTRUCTIONS</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Register the Common Shares and Warrants as set forth below
    (only complete if different from above):</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 0.05pt 0.05in">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Deliver the Common Shares and Warrants as set forth below:</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Contact Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INFORMATION REGARDING THE SUBSCRIBER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please check the appropriate box (and complete
the required information, if applicable) in each section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Security Holdings</B>. Prior to giving effect to the issuance of the securities being subscribed for
under this Subscription Agreement, the Subscriber and all persons acting jointly and in concert with the Subscriber currently own, directly
or indirectly, or exercise control or direction over (provide additional detail as applicable):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%"> _________________ common shares of the Corporation and the following other kinds of rights and convertible securities (including but
not limited to convertible debt, warrants and options) entitling the Subscriber to acquire additional common shares of the Corporation:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 5%">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 89%">&#8239;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 5%">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 89%">&#8239;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%"> No shares of the Corporation or rights or securities convertible into shares of the Corporation.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Insider Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%">Is an &#8220;Insider&#8221; of the Corporation as defined in the Policies of the Exchange (as hereinafter defined) by virtue of being:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a director or executive officer of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a director or executive officer of a company that is an Insider or subsidiary of the Corporation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
carrying more than 10% of the voting rights attached to all the Corporation&#8217;s outstanding voting shares; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Corporation itself if it holds any of its own securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%"> Is not an Insider of the Corporation.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Pro Group Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%">Is a Member of the &#8220;Pro Group&#8221;, which is defined in the Rules of the Exchange as either individually or as a group:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the member (i.e. a member of the Exchange under the Exchange requirements);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">employees of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">partners, officers and directors of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">affiliates of the member;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">such other persons as the Exchange may determine; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">associates of any parties referred to in paragraphs 1 through 5 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%"> Is not a member of the Pro Group.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Registrant Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%">Is a &#8220;Registrant&#8221; as defined in the <I>Securities Act</I> (British Columbia) by virtue of being a person registered or required
to be registered under the <I>Securities Act</I> (British Columbia.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 6%">&#8239;</TD>
  <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
  <TD STYLE="text-align: justify; width: 89%">Is not a Registrant.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>ACCEPTANCE:</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Corporation hereby accepts the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>PROMIS NEUROSCIENCES INC</B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 4%">By: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&#8239;</TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in part.
The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or deduction,
if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this
Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>notwithstanding section 2(a) above, this Offering will not in any way restrict the Corporation from issuing additional securities
of the Corporation at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including
an amendment to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be
part of a transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which
are outstanding on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representations and Warranties of the Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power
and authority to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules and policies of
the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British
Columbia and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation
enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the
issue of the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or
any law, regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is
a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> The Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition,
and, as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all requisite
corporate action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued as fully
paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding
against the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations
or proceedings for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledgements, Warranties and Covenants of the Subscriber</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf
the Subscriber is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon
acceptance by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>no fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole
number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at such
time, including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be
able to resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy
until expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any
certificates (or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8220;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT></B></FONT><B>that
date that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange
in connection with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, the conditions noted in paragraphs 4(h) and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or
both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the issuance of listed Shares <FONT STYLE="font-size: 10pt">during any six month period to insiders </FONT>representing more than
10% of the number of Shares which are outstanding on a non-diluted basis prior to the Closing<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the Exchange may require
as a condition of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10% Insider
Rule, the votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new
 &#8220;Insider&#8221; or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering,
that the Corporation obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person
and its associates and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all
of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities
legislation, and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering
memorandum, or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and
review by, prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U>) relating to the Corporation and not
upon any oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge
of any &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly
disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence
or place of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it
was not created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution
and will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and not
for the benefit of any other person and not with a view to the resale or distribution of all or any of the Units and it <U>fully complies
with one or more of the sub-paragraphs set forth below</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>is an &#8220;accredited investor&#8221; within the meaning of applicable securities laws, including National Instrument 45-106
entitled &#8220;Prospectus and Registration Exemptions&#8221; (&#8220;<B>NI 45-106</B>&#8221;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>has concurrently executed and delivered a Representation Letter in the form attached as Schedule I to this Subscription Agreement,
including Appendix &#8220;A&#8221; and Appendix &#8220;B&#8221; thereto; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is neither an individual nor a company established solely to acquire the Units and the cost of the Units purchased
by it has an aggregate acquisition of not less than $150,000; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> __________ (<B>to be initialled by Subscriber, if applicable)</B> - if it is not purchasing under subparagraph 5(f)(i), or (ii),
it is purchasing pursuant to an exemption from prospectus and registration requirements (particulars of which are enclosed herewith or
will be provided on or before the Closing Date) available to it under applicable securities legislation and shall deliver to the Corporation
such further particulars of the exemption(s) and the Subscriber&#8217;s qualifications thereunder as the Corporation may request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable
prospectus exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase
on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other
person, and not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it and each beneficial purchaser has provided to the Corporation all of the information required by pages 1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity of
each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each of the principals complies with one or more of subparagraphs 5(f)(i) through (f)(ii), as applicable, and the same is so indicated
for each such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the Subscriber is a resident of a country other than Canada or the United States (a &#8220;<B>Jurisdiction Outside CAN-US</B>&#8221;)
then in addition to the other representations and warranties contained herein, the Subscriber represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is knowledgeable of, or has been independently advised as to, the applicable securities laws of the Jurisdiction
Outside CAN-US which would apply to this Subscription Agreement, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Subscriber&#8217;s Shares pursuant to exemptions from any prospectus, registration or similar
requirements under the applicable securities laws of that Jurisdiction Outside CAN-US or, if such is not applicable, the Subscriber is
permitted to purchase the Subscriber&#8217;s Shares under the applicable securities laws of the Jurisdiction Outside CAN-US without the
need to rely on an exemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the applicable securities laws of the Jurisdiction Outside CAN-US in which the Subscriber resides do not require the Corporation
to file a prospectus, registration statement or similar document or to register the Securities or to make any filings or seek any approvals
of any kind whatsoever from any regulatory authority of any kind whatsoever in the Jurisdiction Outside CAN-US;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the delivery of this Subscription Agreement, the acceptance of it by the Corporation and the issuance of the Securities to the
Subscriber complies with all applicable laws of the Subscriber&#8217;s jurisdiction of residence or domicile and all other applicable
laws and will not cause the Subscriber to become subject to or comply with any disclosure, prospectus or other offering document or reporting
requirements under any such applicable laws; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber will, if requested by the Corporation, or its counsel deliver to the Corporation a certificate or opinion of local
counsel from the Jurisdiction Outside CAN-US in which the Subscriber resides which will confirm the matters referred to in subsections
(ii), (iii) and (iv) above to the satisfaction of the Corporation and its counsel, acting reasonably</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>no securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#8239;</B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> there is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber
to find out what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements to
provide the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being
advised by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial
and territorial securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units
pursuant to this exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or
damages, will not be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound by this
Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have been
given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all
action pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>this Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding
and enforceable obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and deliver
this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal and
this Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and binding
agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>that
any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment and
it, or where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and
delivery of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation
of an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit such
sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock exchange
or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such reports,
undertakings and other documents with respect to the issue of the Units as may be required;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any
of the terms or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s
constating documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent
proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that
the Corporation may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription
Agreement and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering)
Act</I> (Canada) and to the best of the Subscriber&#8217;s knowledge (i) none of the subscription funds to be provided by the Subscriber
(A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States of
America, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the Subscriber,
and (ii) it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and
to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the Subscriber
may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain independent
legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently advised as
to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties and covenants
under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
information provided by the Subscriber on pages 1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information Regarding
The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>it will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation
and stock exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies
with all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of
its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund its ongoing
development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such future financings
may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are not available, the
Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure of its business
venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as
a result of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a) this duly completed and executed Subscription
Agreement, including all applicable Schedules hereto and Appendices thereto; and (b) the Aggregate Subscription Amount subscribed
for under this Subscription Agreement in accordance with the Instructions on the Cover Page or payment of the same amount in such
other manner as is acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber
acknowledges and agrees that it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription
Price as a result of the exchange of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s
counsel, in Vancouver, British Columbia at 10:00 a.m. (Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance of
this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation will
deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certificates (or DRS)
representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by
the Corporation of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective
to create a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing,
any funds advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to
the Corporation, which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing
does not occur within 90 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Privacy Legislation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed Principal
for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation, including,
without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable similar
replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing the
Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for so
long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact that
the Corporation may be required by applicable securities legislation, stock exchange rules and/or Investment Industry Regulatory Organization
of Canada rules to provide regulatory authorities with any personal information provided by the Subscriber respecting itself (and any
Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has the authority to
provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the Subscriber is
acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose the Subscriber&#8217;s
personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>for internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber
or any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure to the Corporation&#8217;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>for use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada
Revenue Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect
to reports of trade and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena
compelling such disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure to professional advisers of the Corporation in connection with the performance of their professional services;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s
prior written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>disclosure to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>for use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Subscriber further acknowledges
and agrees that the TSX collects personal information in forms submitted by the Corporation, which will include personal information
regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided for in Appendix 6A to the
TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U> and is incorporated herein by reference. The
Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the British Columbia Securities
Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information in forms submitted
to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information, and the
Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&#8239;899-6500 or (800)&#8239;373-6393,
Facsimile: (604)&#8239;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission, Suite 600, 250 &#8211;
5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario
Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities Commission, Suite 1903,
Box 5520, Queen Street West, Toronto, Ontario M5H&#8239;3S8, Telephone: (416)&#8239;593-3682, Facsimile: (416)&#8239;593&#45;8252. The Subscriber
consents to the collection of personal information by the applicable securities regulatory authorities, including, without limitation,
the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">General</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both as of the
execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against all losses, claims, costs, expenses
and damages or liabilities which it may suffer or incur which are caused or arise from an inaccuracy or breach thereof and reliance thereon.
The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS Neurosciences Inc. sent to its office at
1920 Yonge Street, Suite 200, Toronto, ON&#8239;M4S 3E2 or by email to <FONT STYLE="font-size: 10pt">[***] </FONT>of any change in any
statement or other information relating to the Subscriber set forth herein which takes place prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel retained
by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms and conditions
set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the Corporation
and their respective heirs, executors, administrators, successors and permitted assigns</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in accordance
with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably attorn to
the exclusive jurisdiction of the courts of the Province of British Columbia.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Time is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without
the consent in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial
owner and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there are no representations,
covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither this Subscription
Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by
the party against whom any waiver, change, discharge or termination is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and other documents
contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment qu&#8217;elles
ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&#8217;y rattachent soient r&eacute;dig&eacute;s
dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE I<BR>
REPRESENTATION LETTER<BR>
(FOR CANADIAN ACCREDITED INVESTORS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&#8239;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of units of
the Corporation (&#8220;<B>Units</B>&#8221;) by the undersigned subscriber or, if applicable, the principal on whose behalf the
undersigned is purchasing as agent (the &#8220;<B>Subscriber</B>&#8221; for the purposes of this Schedule I), the Subscriber hereby
represents, warrants, covenants and certifies to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Subscriber is purchasing the Units as principal for its own account or is deemed to be acting as principal
pursuant to applicable securities laws, including National Instrument 45-106 entitled &#8220;Prospectus and Registration Exemptions&#8221;
(&#8220;<B>NI 45-106</B>&#8221;);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Subscriber is an &#8220;<B>accredited investor</B>&#8221; within the meaning of applicable securities
laws, including NI 45-106, by virtue of satisfying one or more of the categories set out in Appendix &#8220;A&#8221; to this Representation
Letter;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify">If the Subscriber is an individual, he or she has completed the attached <B>Form 45-106F9 -- <I>Form for
Individual Accredited Investors</I></B> set out in Appendix &#8220;B&#8221; to this Representation Letter unless the individual qualifies
under a category set out in Appendix &#8220;A&#8221; other than (j), (k) or (l) of the definition of &#8220;<B>accredited investor</B>&#8221;;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in">4.</TD><TD STYLE="text-align: justify">Upon execution of this Schedule I by the Subscriber, this Schedule I shall be incorporated into and form
a part of the Subscription Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________________, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2" STYLE="border-top: Black 1pt solid">Print name of Subscriber</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 7%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 43%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Signature</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Print name of Signatory (if different from Subscriber)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Title</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IMPORTANT: PLEASE INITIAL APPENDIX &#8220;A&#8221;
OVER PAGE</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APPENDIX &#8220;A&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&#8239;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE: THE SUBSCRIBER MUST INITIAL BESIDE THE APPLICABLE PORTION
OF THE DEFINITION BELOW AND COMPLETE EACH QUESTION WHICH FOLLOWS THE APPLICABLE PORTION OF THE DEFINITION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accredited Investor &#8211; </B>(as defined in National Instrument
45-106, and in Ontario, as defined in Section 73.3 of the <I>Securities Act</I> (Ontario) as supplemented by the definition in National
Instrument 45-106) includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; width: 10%; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 6pt 0 6pt 2pt; width: 5%; text-indent: 0; text-align: justify">(a)&#9;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-right: Black 1pt solid; width: 85%; text-indent: 0; text-align: justify">except in Ontario, a Canadian financial institution, or a Schedule III bank,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(a.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify">in Ontario, a financial institution described in paragraph 1, 2 or 3 of subsection 73.1 (1) of the <I>Securities Act</I> (Ontario),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(b)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; text-indent: 0">except in Ontario, the Business Development Bank of Canada incorporated under the <I>Business Development Bank of Canada Act</I> (Canada),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(b.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify">in Ontario, the Business Development Bank of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(c)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; text-indent: 0">except in Ontario, a subsidiary of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of
the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(c.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify">in Ontario, a subsidiary of any person or Corporation referred to in clause (a.1) or (b.1), if the person or Corporation owns all of
the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(d)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; text-indent: 0">except in Ontario, a person registered under the securities legislation of a jurisdiction of Canada as an adviser or dealer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(d.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-indent: 0; text-align: justify">in Ontario, a person or Corporation registered under the securities legislation of a province or territory of Canada as an adviser or
dealer, except as otherwise prescribed by the regulations,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(e)&#9;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-right: Black 1pt solid; text-align: justify; text-indent: 0">an individual registered under the securities legislation of a jurisdiction of Canada as a representative of a person referred to in
paragraph (d),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(e.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; text-indent: 0">an individual formerly registered under the securities legislation of a jurisdiction of Canada, other than an individual formerly registered
solely as a representative of a limited market dealer under one or both of the <I>Securities Act</I> (Ontario) or the <I>Securities Act
</I>(Newfoundland and Labrador),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(f)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; text-indent: 0">except in Ontario, the Government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the
Government of Canada or a jurisdiction of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(f.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify">in Ontario, the Government of Canada, the government of a province or territory of Canada, or any Crown corporation, agency or wholly
owned entity of the Government of Canada or of the government of a province or territory of Canada,</TD></TR>
  </TABLE>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 0 6pt 4pt; width: 10%; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-align: justify; width: 5%; text-indent: 0">(g)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; width: 85%; text-indent: 0">a municipality, public board or commission in Canada and a metropolitan community, school board, the Comit&eacute; de gestion de la taxe
scolaire de l&#8217;&icirc;le de Montr&eacute;al or an intermunicipal management board in Qu&eacute;bec,</TD></TR>
</TABLE>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0; width: 10%">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify; width: 5%">(h)&#9;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-indent: 0; text-align: justify; width: 85%">any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that
government,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(i)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-align: justify; text-indent: 0">except in Ontario, a pension fund that is regulated by the Office of the Superintendent of Financial Institutions (Canada), a pension
commission or similar regulatory authority of a jurisdiction of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(i.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-indent: 0; text-align: justify"> in Ontario, a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension
commission or similar regulatory authority of a province or territory of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify; padding-right: 0; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify; padding-right: 5pt; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">an individual
                                                                                                                                                                                   who, either alone or with a spouse, beneficially owns financial assets having an aggregate realizable value that before taxes, but
                                                                                                                                                                                   net of any related liabilities, exceeds $1,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">[If this is your
    applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(j.1)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0">an individual who beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related liabilities,
exceeds $5,000,000,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0; text-align: justify; padding-right: 0; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; text-indent: 0; border-bottom: Black 1pt solid; text-align: justify; padding-right: 5pt; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">an
    individual whose net income before taxes exceeded $200,000 in each of the 2 most recent calendar years or whose net income before taxes
    combined with that of a spouse exceeded $300 000 in each of the 2 most recent calendar years and who, in either case, reasonably expects
    to exceed that net income level in the current calendar year,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">[If this is your
    applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0; text-align: justify; padding-right: 0; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(l)&#9;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; text-indent: 0; border-bottom: Black 1pt solid; text-align: justify; padding-right: 5pt; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">an individual
    who, either alone or with a spouse, has net assets of at least $5,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">[If this is your
    applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="padding: 6pt 0 6pt 2pt; text-indent: 0; text-align: justify">(m)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; text-indent: 0; text-align: justify">a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared
financial statements,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify; padding-right: 0; padding-left: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0; text-align: justify; padding-right: 5pt; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: auto; margin-bottom: 0pt; text-align: justify">an
    investment fund that distributes or has distributed its securities only to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: auto; margin-bottom: 0pt; text-align: justify">&#8239;</P>
    <P STYLE="text-indent: -0.25in; margin: 0pt auto 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
    person that is or was an accredited investor at the time of the distribution,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: auto; margin-bottom: 0pt; text-align: justify">&#8239;</P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt auto 0pt 0.25in; text-align: justify">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;a
    person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment], or &#8239;2.19 [Additional
    investment in investment funds], or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: auto; margin-bottom: 0pt; text-align: justify">&#8239;</P>
    <P STYLE="text-indent: -0.25in; margin: 0pt auto 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(iii)&#8239;&#8239;&#8239;&#8239;a
    person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 [Investment fund
    reinvestment],&#8239;&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: auto; margin-bottom: 0pt; text-align: justify">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 6pt 0 6pt 4pt; text-align: justify; text-indent: 0">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 6pt 0 6pt 2pt; text-align: justify; text-indent: 0">(o)&#9;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 6pt 5pt 6pt 0; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0">an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator
or, in Qu&eacute;bec, the securities regulatory authority, has issued a receipt,</TD></TR>
  </TABLE>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 10%; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 5%; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(p)</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; width: 85%; text-align: justify; text-indent: 0">a trust Corporation or trust corporation registered or authorized to carry on business under the <I>Trust and Loan Companies Act</I>
(Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account
managed by the trust Corporation or trust corporation, as the case may be,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(q)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; text-indent: 0">a person acting on behalf of a fully managed account managed by that person, if that person is registered or authorized to carry on business
as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(r)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; text-indent: 0">a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser
or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities
being traded,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(s)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; text-indent: 0">an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) paragraph
(i) [and in Ontario, paragraphs (a.1) to (d.1) or paragraph (i.1)] in form and function,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(t)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; text-indent: 0">a person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required by
law to be owned by directors, are persons that are accredited investors</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(u)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; text-indent: 0">an investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; text-indent: 0; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(v)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; text-indent: 0">a person that is recognized or designated by the securities regulatory authority or, except in Ontario and Qu&eacute;bec, the regulator
as an accredited investor,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: 0; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-indent: 0; text-align: justify">(v.1)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-right: Black 1pt solid; text-indent: 0; text-align: justify">in Ontario, a person or Corporation that is recognized or designated by the Commission as an accredited investor,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; text-indent: 0; padding-top: 6pt; padding-bottom: 6pt; padding-left: 4pt; text-align: justify">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 2pt; text-align: justify; text-indent: 0">(w)&#9;</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0">a trust established by an accredited investor for the benefit of the accredited investor&#8217;s family members of which a majority of
the trustees are accredited investors and all of the beneficiaries are the accredited investor&#8217;s spouse, a former spouse of the
accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited investor&#8217;s
spouse or of that accredited investor&#8217;s former spouse.</TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Dated: __________________, 201__.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif">Print name of Subscriber</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif">Signature</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif">Print name of Signatory (if different from Subscriber)</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif">Title</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><I>&#8239;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&#8239;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For the purposes hereof:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: justify">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;<B>control person</B>&#8221; has the meaning ascribed to that
    term in securities legislation except in Manitoba, Ontario, Quebec, Nova Scotia, Newfoundland and Labrador, Prince Edward Island, the
    Northwest Territories and Nunavut where &#8220;control person&#8221; means any person that holds or is one of a combination of persons
    that hold:</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;</FONT></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">a sufficient number of any of the securities of an issuer so as to affect materially the control of the issuer; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">more than 20% of the outstanding voting securities of an issuer except
    where there is evidence showing that the holding of those securities does not affect materially the control of that issuer;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0">&#8220;<B>eligibility adviser</B>&#8221; means:</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;</FONT></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">a person that is registered as an investment dealer or in an equivalent category of registration under the securities legislation of the jurisdiction of a Subscriber and authorized to give advice with respect to the type of security being distributed; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;</FONT></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0">in Saskatchewan or Manitoba, also means a lawyer who is a practicing member in good standing with a law society of a jurisdiction of Canada or a public accountant who is a member in good standing of an institute or association of chartered accountants, certified general accountants or certified management accountants in a jurisdiction of Canada provided that the lawyer or public accountant must not:</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.1in"><FONT STYLE="font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">have a professional, business or personal relationship with the issuer, or any of its directors, executive officers, founders or control persons; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.1in"><FONT STYLE="font-size: 10pt">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;</FONT></FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">have acted for or been retained personally or otherwise as an employee,
    executive officer, director, associate or partner of a person that has acted for or been retained by the issuer or any of its directors,
    executive officers, founders or control persons within the previous 12 months;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;<B>financial assets</B>&#8221; means (i) cash, (ii) securities
    or (iii) a contract of insurance, a deposit or an evidence of a deposit that is not a security for the purposes of securities legislation.
    These financial assets are generally liquid or relatively easy to liquidate. The value of a purchaser&#8217;s personal residence would
    not be included in a calculation of financial assets;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;<B>financial statements</B>&#8221; for the purposes of paragraph
    (m) of the &#8220;accredited investor&#8221; definition must be prepared in accordance with generally accepted accounting principles;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="margin-top: 0; margin-bottom: 0">&#8220;<B>founder</B>&#8221; means, in respect of an issuer, a person who:</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239; </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">acting alone, in conjunction or in concert with one or more persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the business of the issuer; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239; </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">at the time of the trade is actively involved in the business of the
    issuer;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;<B>fully managed account</B>&#8221; means an account of a client
    for which a person makes the investment decisions if that person has full discretion to trade in securities for the account without requiring
    the client&#8217;s express consent to a transaction;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8220;<B>investment fund</B>&#8221; has the meaning ascribed thereto
    in National Instrument 81-106 - <I>Investment Fund Continuous Disclosure</I>;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  </TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt; width: 0.6in">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>net assets</B>&rdquo; means all
of the purchaser&rsquo;s total assets minus all of the purchaser&rsquo;s total liabilities. Accordingly, for the purposes of the net
asset test, the calculation of total assets would include the value of a purchaser&rsquo;s personal residence and the calculation of
total liabilities would include the amount of any liability (such as a mortgage) in respect of the purchaser&rsquo;s personal residence.
To calculate a purchaser&rsquo;s net assets under the &ldquo;accredited investor&rdquo; definition, subtract the purchaser&rsquo;s total
liabilities from the purchaser&rsquo;s total assets (including real estate). The value attributed to assets should reasonably reflect
their estimated fair value. Income tax should be considered a liability if the obligation to pay it is outstanding at the time of the
distribution of the security;&#8239;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>related liabilities</B>&rdquo; means:</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 6%; padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; &#8239;</FONT></TD>
    <TD STYLE="width: 88%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liabilities incurred or assumed for the purpose of financing the acquisition or ownership of financial assets; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">liabilities that are secured by financial assets;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>spouse</B>&rdquo; means an individual who:</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; &#8239;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is married to another individual and is not living separate and apart within the meaning of the <I>Divorce Act</I> (Canada), from the other individual; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; &#8239;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is living with another individual in a marriage-like relationship, including a marriage-like relationship between individuals of the same gender; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239; &#8239;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">in Alberta, is an individual referred to
in paragraph (i) or (ii) immediately above or is an adult interdependent partner within the meaning of the <I>Adult Interdependent Relationships
Act </I>(Alberta); and&#8239;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>APPENDIX &#8220;B&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 45-106F9 - <I>Form for Individual Accredited
Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&#8239;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARNING!</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This investment is risky. Don&#8217;t invest
    unless you can afford to lose all the money you pay for this investment.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-indent: 0; text-align: justify; border: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>SECTION 1 TO BE COMPLETED BY ISSUER OR SELLING SECURITY HOLDER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt; text-indent: 0"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>About your investment</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Type of securities:&#8239;&#8239;&#8239;Common Shares and Warrants</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">Issuer:&#8239;&#8239;ProMIS Neurosciences Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-indent: 0; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>SECTIONS 2 TO 4 TO BE COMPLETED BY THE PURCHASER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt; text-indent: 0"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Risk acknowledgement</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">This investment is risky. Initial that you understand that:</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Your <BR>
initials</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Risk of loss </B>&#8211; You could lose your entire investment of $________. </TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Liquidity risk</B> &#8211; You may not be able to sell your investment quickly &#8211; or at all.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Lack of information </B>&#8211; You may receive little or no information about your investment.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><B>Lack
    of advice &#8211; </B>You may not receive advice from the salesperson about whether this investment is suitable for you unless the
    salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investments.
    To check whether the salesperson is registered, go to <U>www.aretheyregistered.ca</U>.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 5.4pt; text-indent: 0"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Accredited investor status</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">You must meet at least <B>one </B>of the following criteria to be able to make this investment. Initial the statement that applies to you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about whether you meet these criteria.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Your<BR>
 initials</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 0.375in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Your
net income before taxes was more than $200,000 in each for the 2 most recent calendar years, and you expect it to be more than $200,000
in the current calendar year. (You can find your net income before taxes on your personal income tax return.)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-left: 0.375in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Your net income before taxes combined with your spouse&#8217;s was more than $300,000 in each of the 2 most recent calendar years, and you expect your combined net income before taxes to be more than $300,000 in the current calendar year.</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; width: 46%">&#8239;</TD>
    <TD STYLE="text-align: justify; width: 42%">&#8239;</TD>
    <TD STYLE="text-align: justify; width: 12%">&#8239;</TD></TR>
  </TABLE>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5pt; border: Black 1pt solid; text-align: justify; padding-top: 12pt; padding-left: 0.375in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the case and securities.</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-top: 12pt; padding-left: 0.375in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Either alone or with your spouse, you may have net assets worth more than $5 million. (Your net assets are your total assets (including real estate) minus your total debt.)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-top: 12pt; padding-left: 5.4pt; text-indent: 0"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Your name and signature</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">First and last name (please print):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">Signature:</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">Date: </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt"><B>SECTION 5 TO BE COMPLETED BY SALESPERSON</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-top: 12pt; padding-left: 5.4pt; text-indent: 0"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Salesperson information</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">[<I>Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement</I>.]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">First and last name of salesperson (please print):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">Telephone:</TD>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">Email:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt">Name of firm (if registered):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5.4pt"><B>SECTION 6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-top: 12pt; padding-left: 5.4pt; text-indent: 0"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>For more information about this investment</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-right: 5pt; padding-left: 5.4pt">ProMIS Neurosciences Inc.<BR>
Kristi Lanier, Finance Director<BR>
Tel: <FONT STYLE="font-size: 10pt">[***]</FONT><BR>
E-mail: <FONT STYLE="font-size: 10pt">[***]</FONT><BR>
Website: www.promisneurosciences.com<BR>
<B>For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at <FONT>www.securities-administrators.ca</FONT></B></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5pt; text-align: justify; width: 56%">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; text-align: justify; width: 32%">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; text-align: justify; width: 12%">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>41
<FILENAME>filename41.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.23</B></P>



<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Use this form for all non-U.S. Persons (Oct 21,
2019)</P>

<P STYLE="margin: 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
PROMIS NEUROSCIENCES INC.<BR>
SUBSCRIPTION AGREEMENT<BR>
FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NON-U.S. PERSONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5pt; padding-left: 5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HAVE YOU COMPLETED THIS SUBSCRIPTION AGREEMENT PROPERLY?</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The following items in this Subscription Agreement must be
completed. (Please initial each box.) </B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&#8239;</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 5pt; vertical-align: top; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-left: 5pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; vertical-align: bottom; border-right: Black 1pt solid; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Provide information and answers in the boxes on pages 1, 2 and 3.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; font-size: 10pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Sign the execution page on page 1 of this Subscription Agreement. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>&#8239;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt; font-size: 10pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Complete Schedule &#8220;1&#8221; Accredited Investor Representation Letter and sign</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 5pt; width: 2%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; width: 13%; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; width: 85%; padding-left: 5pt">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Delivery of Subscription forms may be made
by&#8239;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>email to:</U></B> [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><U>facsimile to:</U></B> fax #: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: -1.5in"><B><U>Delivery of
certified cheque, money order or bank draft may be made by courier/mail to</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ProMIS Neurosciences Inc. Attention: CFO<BR>
1920 Yonge Street, Suite 200, Toronto, ON M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Alternatively, delivery of funds may also be made via electronic
wire transfer</U></B> in accordance with the wire transfer instructions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>To wire Canadian $ funds:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary Bank: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank Address: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Account # [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bank #:[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SWIFT Code: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currency: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Beneficiary: PROMIS NEUROSCIENCES INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficiary address: 1920 Yonge Street, Suite 200, Toronto, ON M4S
3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>If you wish to wire funds in currency other than CDN$, please
contact the Corporation by email: </U></B>[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#8239;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FOR UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (the &#8220;<B>Subscriber</B>&#8221;, including, if applicable, each Disclosed Principal (as hereinafter defined) for
whom the undersigned is acting hereunder) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation
(the &#8220;<B>Units</B>&#8221;) set forth below for the aggregate subscription amount set forth below (the &#8220;<B>Aggregate Subscription
Amount</B>&#8221;), representing a subscription price of <B>CDN$0.20</B> (or <B>US$0.15)</B> per Unit, on the terms and conditions set
forth in &#8220;Terms and Conditions of Subscription for Units of ProMIS Neurosciences Inc..&#8221; attached hereto (together with the
face pages and the attached Schedules, the &#8220;<B>Subscription Agreement</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Unit consists of one common share of the
Corporation (a &#8220;<B>Common Share</B>&#8221;) and one transferable share purchase warrant (a &#8220;<B>Warrant</B>&#8221;). Each whole
Warrant entitles the holder to purchase one Common Share (a &#8220;<B>Warrant Share</B>&#8221;) at any time for a five year period at
a price of <B>CDN$0.35</B> per Warrant Share. The Units, the Common Shares, the Warrants and the Warrant Shares are hereinafter referred
to together as the &#8220;<B>Securities</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 5pt; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><B>Number of Units: _________________________</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><B>CDN$0.20 per Unit, or if subscribing in US$,</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><B>@ US$0.15 per Unit</B></P></TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; padding-top: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Aggregate Subscription Amount: CDN$ <U>________________</U></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>Or, if subscribing in US$: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">US$
     <U>________________</U></FONT></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name
    and Signature of Subscriber</B></FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Individual
    Subscriber </FONT></TD>
    <TD STYLE="padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Non-Individual
    Subscriber (e.g., Corporation)</FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name of Non-Individual Subscriber) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature
    of Individual Subscriber) </FONT></TD>
    <TD STYLE="padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Signature
    of Authorized Signatory) </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    </TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-left: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5pt; vertical-align: top; padding-top: 5pt; padding-left: 5pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5pt; vertical-align: top; border-bottom: Black 1pt solid; padding-top: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Print
    Name and Official Capacity or Title of Signatory) <BR>
    The signatory represents that he has authority to bind the Subscriber. </FONT></TD>
    </TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: Black 1pt solid; padding-top: 5pt; vertical-align: top; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0.05in"><B><U>ONLY IF</U> the Subscriber is
    signing as agent or trustee for a principal (a &#8220;Disclosed Principal&#8221;) and is not purchasing as trustee or agent for accounts
    fully managed by it, so as to be deemed to be purchasing as principal pursuant to National Instrument 45-106, complete the following
    and, if applicable, ensure that all Schedules are completed on behalf of such Disclosed Principal:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><U>_____________________________________________________________________________________________</U><BR>
    (Name of Disclosed Principal and, if Disclosed Principal is not an individual, of the contact person of Disclosed Principal)<BR>
    <BR></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><U>_____________________________________________________________________________________________</U><BR>
    (Address and Telephone Number of Disclosed Principal or, if Disclosed Principal is not an individual, of the contact person of Disclosed
    Principal)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&#8239;</P></TD>
    </TR>
  <TR STYLE="font-size: 1pt">
    <TD STYLE="font-size: 1pt; padding-top: 5pt; width: 44%; padding-right: 5pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="font-size: 1pt; padding-top: 5pt; width: 2%; padding-right: 5pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="font-size: 1pt; padding-top: 5pt; width: 4%; padding-right: 5pt; padding-left: 5pt">&#8239;</TD>
    <TD STYLE="font-size: 1pt; padding-top: 5pt; width: 50%; padding-right: 5pt; padding-left: 5pt">&#8239;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: center"><B>Address of Subscriber - Residential for Individual / Business for Non-Individual Subscriber</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 4%; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">Address of Subscriber </TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Telephone Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">City, Province, Postal Code </TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Facsimile Number) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">(Email address) </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 47%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><B>REGISTRATION INSTRUCTIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="width: 3%; padding: 0.05pt 0.05in">&#8239;</TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0.05pt 0.05in"><B>DELIVERY INSTRUCTIONS</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Register the Common Shares and Warrants as set forth below
    (only complete if different from above):</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">______________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; padding: 0.05pt 0.05in">&#8239;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"><I>Deliver the Common Shares and Warrants as set forth below:</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Account reference, if applicable)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Contact Name)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">(Address)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">__________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INFORMATION REGARDING THE SUBSCRIBER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please check the appropriate box (and complete
the required information, if applicable) in each section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Security Holdings</B>. Prior to giving effect to the issuance of the securities being subscribed for
under this Subscription Agreement, the Subscriber and all persons acting jointly and in concert with the Subscriber currently own, directly
or indirectly, or exercise control or direction over (provide additional detail as applicable):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>
                                                                                                                                common shares of the Corporation and the following other kinds of rights and convertible securities (including but not limited to
                                                                                                                                convertible debt, warrants and options) entitling the Subscriber to acquire additional common shares of the Corporation:</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">No shares of the Corporation or rights or securities convertible into shares of the
                                                                              Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Insider Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is an &#8220;Insider&#8221; of the Corporation as defined in the Policies of the Exchange (as
                                                                              hereinafter defined) by virtue of being:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a director or executive officer of the Corporation;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a director or executive officer of a company that is an Insider or subsidiary of the Corporation;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                                                                        </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a person that beneficially owns or controls, directly or indirectly, voting shares of the Corporation
carrying more than 10% of the voting rights attached to all the Corporation&#8217;s outstanding voting shares; or</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Corporation itself if it holds any of its own securities.</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is not an Insider of the Corporation.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Pro Group Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is&#8239;a Member of the &#8220;Pro Group&#8221;, which is defined in
the Rules of the Exchange as either individually or as a group:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the member (i.e. a member of the Exchange under the Exchange requirements);</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">employees of the member;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">partners, officers and directors of the member;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">affiliates of the member;</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">such other persons as the Exchange may determine; and</TD></TR><TR STYLE="vertical-align: top">
<TD>&#8239;</TD><TD>&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">associates of any parties referred to in paragraphs 1 through 5 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is not a member of the Pro Group.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Registrant Status</B>. The Subscriber either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is a &#8220;Registrant&#8221; as defined in the <I>Securities Act </I>(British Columbia) by virtue
                                                                          of being a person registered or required to be registered under the <I>Securities Act</I> (British Columbia.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Is not a Registrant.</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ACCEPTANCE:</B> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The Corporation hereby
accepts the subscription as set forth above on the terms and conditions contained in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</U>, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>PROMIS NEUROSCIENCES
    INC</B></FONT><B>.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 47%">&#8239;</TD>
    <TD STYLE="width: 50%">&#8239;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AND CONDITIONS OF SUBSCRIPTION FOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITS OF PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Terms of the Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that this subscription is subject to acceptance or rejection by the Corporation, in its sole and absolute discretion, in whole or in part.
The parties agree that this Subscription and all money tendered herewith will be returned to the Subscriber, without interest or deduction,
if this Subscription is not accepted by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting)
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation is offering (the &#8220;<B>Offering</B>&#8221;) the Units on a private placement basis under the terms of this
Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>notwithstanding section 2(a) above, this Offering will not in any way restrict the Corporation from issuing additional securities
of the Corporation at prices, on terms and in amounts as may be determined by the Corporation, in its sole and absolute discretion, including
an amendment to the Offering to increase the size of the Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, in the event that the issuance of the Units hereunder may result in, or be
part of a transaction that may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing (the &#8220;<B>25% Dilution Rule</B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares during any six month period to insiders representing more than 10% of the number of Shares which
are outstanding on a non-diluted basis prior to the Closing (the &#8220;<B>10% Insider Rule</B>&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares that will materially affect control of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representations and Warranties of the Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation hereby represents and warrants to the Subscriber (and acknowledges that the Subscriber is relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is a duly amalgamated and validly subsisting corporation under the laws of Canada and has full corporate power
and authority to perform each of its obligations as herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is listed on the TSX (the &#8220;<B>Exchange</B>&#8221;) and as a result is subject to the rules and policies of
the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation is a &#8220;reporting issuer&#8221; in good standing under the securities laws of the provinces of Ontario, British
Columbia and Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Subscription Agreement, when accepted by the Corporation, will constitute a legal, valid and binding obligation of the Corporation
enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The execution and delivery of, and the performance of the terms of this Subscription Agreement by the Corporation, including the
issue of the Securities, does not and will not constitute a breach of or default under the constating documents of the Corporation or
any law, regulation, order or ruling applicable to the Corporation or any agreement, contract or indenture to which the Corporation is
a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> The Corporation is not a party to any actions, suits or proceedings which could materially affect its business or financial condition,
and, as at the date hereof, no such actions, suits or proceedings have been threatened or, to the best of the Corporation&#8217;s knowledge,
are pending, except as disclosed in information which has been filed by the Corporation with the various Canadian securities commissions
under applicable securities legislation and the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale, issuance and delivery of the Units at the closing (the &#8220;<B>Closing</B>&#8221;) will have been approved by all requisite
corporate action on or before the Closing Date and, upon issue and delivery at the Closing, the Units will be validly issued as fully
paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No order ceasing or suspending trading in the Securities nor prohibiting sale of the Securities has been issued to and is outstanding
against the Corporation or its directors, officers or promoters and to the best of the Corporation&#8217;s knowledge no investigations
or proceedings for such purposes are pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledgements, Warranties and Covenants of the Subscriber</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges, warrants and agrees (on its own behalf and, if applicable, on behalf of each person on whose behalf
the Subscriber is contracting) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Offering, of which this Subscription Agreement forms a part, is not subject to a minimum subscription level and as such, upon
acceptance by the Corporation, subscription funds are immediately available for use by the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>no fractional Warrants shall be issued and the Corporation shall round down any fractional number of Warrants to the nearest whole
number;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may complete additional financings in the future which may have a dilutive effect on existing shareholders at such
time, including a Subscriber hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is aware of the characteristics of the Units, the risks relating to an investment therein and of the fact that it may not be
able to resell the Securities except in accordance with limited exemptions under applicable securities legislation and regulatory policy
until expiry of the applicable restriction period and compliance with the other requirements of applicable law, and it agrees that any
certificates (or DRS) representing the Securities may bear the following legend indicating that the resale of such Securities is restricted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in">&#8220;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unless
permitted under securities legislation, the holder of this security must not trade the security before <FONT STYLE="text-transform: uppercase">[</FONT></B></FONT><B>that
date that is 4 months and a day after the Closing Date].&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-align: justify; text-indent: 0in"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Closing is subject to the terms of the conditional approval of the Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may pay fees or issue finder warrants or both to one or more finders in accordance with the policies of the Exchange
in connection with the Offering and subject to compliance with applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of the Units shall be subject to any conditions that may be imposed by the Exchange as part of the Exchange&#8217;s
acceptance of the Offering, including, without limitation, the conditions noted in paragraphs 4(h) and 4(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units hereunder may result in, or be part of a transaction that may result in, either or
both</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the issuance of listed Shares representing more than 25% of the number of Shares which are outstanding on a non-diluted basis prior
to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the issuance of listed Shares <FONT STYLE="font-size: 10pt">during any six month period to insiders </FONT>representing more than
10% of the number of Shares which are outstanding on a non-diluted basis prior to the Closing<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">the Exchange may require
as a condition of its acceptance of the Offering that the Corporation obtain shareholder approval (excluding, in the case of the 10% Insider
Rule, the votes attached to the Shares held by Insiders and their associates and affiliates); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the event that the issuance of the Units may result in, or be part of a transaction that may result in, the creation of a new
 &#8220;Insider&#8221; or a new &#8220;Control Person&#8221;, the Exchange may require as a condition of its acceptance of the Offering,
that the Corporation obtain shareholder approval (excluding the votes attached to the Units held by the new Insider or new Control Person
and its associates and affiliates) of the new Insider or new Control Person, as the case may be, prior to the issue of a portion or all
of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber (on its own behalf and, if applicable, on behalf of each person on whose behalf the Subscriber is contracting) represents,
warrants and covenants to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has been independently advised as to the restrictions with respect to trading in the Securities imposed by applicable securities
legislation, and no representation has been made to it by or on behalf of the Corporation with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has not received or been provided with, nor has it requested, nor does it have any need to receive, any prospectus or offering
memorandum, or any other document describing the business and affairs of the Corporation which has been prepared for delivery to, and
review by, prospective purchasers in order to assist it in making an investment decision in respect of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has relied solely upon information publicly available on SEDAR (at <U>www.sedar.com</U>) relating to the Corporation and not
upon any oral or written representation as to fact or otherwise made by or on behalf of the Corporation and it does not have knowledge
of any &#8220;material fact&#8221; (as defined under applicable securities legislation) about the Corporation that has not been publicly
disclosed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is resident in the province set out in the &#8220;Subscriber&#8217;s Address&#8221;, which is the ordinary residence
or place of business of the Subscriber and such beneficial purchaser, if applicable, and, if the Subscriber is a corporate entity, it
was not created nor is it used solely for the purpose of acquiring the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Units to be held for investment purposes only and not with a view to immediate resale or distribution
and will not recall or otherwise transfer or dispose of the Units except in accordance with the provisions of applicable securities legislation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Units as principal for its own account, it is purchasing such Units for investment only and not
for the benefit of any other person and not with a view to the resale or distribution of all or any of the Units and it <U>fully complies
with one or more of the sub-paragraphs set forth below</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>is an &#8220;accredited investor&#8221; within the meaning of applicable securities laws, including National Instrument 45-106
entitled &#8220;Prospectus and Registration Exemptions&#8221; (&#8220;<B>NI 45-106</B>&#8221;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>has concurrently executed and delivered a Representation Letter in the form attached as Schedule I to this Subscription Agreement,
including Appendix &#8220;A&#8221; and Appendix &#8220;B&#8221; thereto; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is neither an individual nor a company established solely to acquire the Units and the cost of the Units purchased
by it has an aggregate acquisition of not less than $150,000; or</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> __________ (<B>to be initialled by Subscriber, if applicable)</B> - if it is not purchasing under subparagraph 5(f)(i), or (ii),
it is purchasing pursuant to an exemption from prospectus and registration requirements (particulars of which are enclosed herewith or
will be provided on or before the Closing Date) available to it under applicable securities legislation and shall deliver to the Corporation
such further particulars of the exemption(s) and the Subscriber&#8217;s qualifications thereunder as the Corporation may request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if it is not purchasing as principal (and is not otherwise deemed to be purchasing as principal for the purposes of the applicable
prospectus exemption under applicable provincial and territorial securities laws in Canada),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it is duly authorized to enter into this Subscription Agreement and to execute all documentation in connection with the purchase
on behalf of each beneficial purchaser, each of whom is purchasing as principal for its own account, not for the benefit of any other
person, and not with a view to the resale or distribution of all or any of the Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it and each beneficial purchaser has provided to the Corporation all of the information required by pages 1 to 3 of this Subscription
Agreement and it acknowledges that the Corporation may be required by law to disclose to certain regulatory authorities the identity of
each beneficial purchaser of Units for whom it may be acting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>each of the principals complies with one or more of subparagraphs 5(f)(i) through (f)(ii), as applicable, and the same is so indicated
for each such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the Subscriber is a resident of a country other than Canada or the United States (a &#8220;<B>Jurisdiction Outside CAN-US</B>&#8221;)
then in addition to the other representations and warranties contained herein, the Subscriber represents and warrants that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is knowledgeable of, or has been independently advised as to, the applicable securities laws of the Jurisdiction
Outside CAN-US which would apply to this Subscription Agreement, if any;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is purchasing the Subscriber&#8217;s Shares pursuant to exemptions from any prospectus, registration or similar
requirements under the applicable securities laws of that Jurisdiction Outside CAN-US or, if such is not applicable, the Subscriber is
permitted to purchase the Subscriber&#8217;s Shares under the applicable securities laws of the Jurisdiction Outside CAN-US without the
need to rely on an exemption;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the applicable securities laws of the Jurisdiction Outside CAN-US in which the Subscriber resides do not require the Corporation
to file a prospectus, registration statement or similar document or to register the Securities or to make any filings or seek any approvals
of any kind whatsoever from any regulatory authority of any kind whatsoever in the Jurisdiction Outside CAN-US;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the delivery of this Subscription Agreement, the acceptance of it by the Corporation and the issuance of the Securities to the
Subscriber complies with all applicable laws of the Subscriber&#8217;s jurisdiction of residence or domicile and all other applicable
laws and will not cause the Subscriber to become subject to or comply with any disclosure, prospectus or other offering document or reporting
requirements under any such applicable laws; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber will, if requested by the Corporation, or its counsel deliver to the Corporation a certificate or opinion of local
counsel from the Jurisdiction Outside CAN-US in which the Subscriber resides which will confirm the matters referred to in subsections
(ii), (iii) and (iv) above to the satisfaction of the Corporation and its counsel, acting reasonably</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>no securities commission or similar regulatory authority has reviewed or passed on the merits of the Units;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> there is no government or other insurance covering the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are risks associated with the purchase of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>there are restrictions on the Subscriber&#8217;s ability to resell the Securities and it is the responsibility of the Subscriber
to find out what those restrictions are and to comply with them before selling any of the Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation or its agent has advised the Subscriber that the Corporation is relying on an exemption from the requirements to
provide the Subscriber with a prospectus and (except for Subscribers who qualify for a prospectus exemption herein by virtue of being
advised by a registered dealer) to sell the Units through a person or company registered to sell securities under applicable provincial
and territorial securities laws in Canada (including the <I>Securities Act </I>(Ontario) and, as a consequence of acquiring the Units
pursuant to this exemption, certain protections, rights and remedies provided by the Acts, including statutory rights of rescission or
damages, will not be available to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if a corporation, partnership, unincorporated association or other entity, it has the legal capacity to enter into and be bound
by this Subscription Agreement and further certifies that all necessary approvals of directors, shareholders, partners or otherwise have
been given and obtained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if an individual, it is of the full age of majority and is legally competent to execute this Subscription Agreement and take all
action pursuant hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>this Subscription Agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding
and enforceable obligation of the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>in the case of a subscription by it for Units acting as agent for a disclosed principal, it is duly authorized to execute and deliver
this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of such principal and
this Subscription Agreement has been duly authorized, executed and delivered by or on behalf of, and constitutes a legal, valid and binding
agreement of, such principal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it acknowledges that no representation has been made to it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as to the future value or price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will resell or repurchase the Shares; or;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>that any person will refund the purchase price of the Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment and
it, or where it is not purchasing as principal, each beneficial purchaser, is able to bear the economic risk of loss of its investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it understands that the Units are being offered for sale only on a &#8220;private placement&#8221; basis and that the sale and
delivery of the Units is conditional upon such sale being exempt from the requirements as to the filing of a prospectus or the preparation
of an offering memorandum in prescribed form or upon the issuance of such orders, consents or approvals as may be required to permit such
sale without the requirement of filing a prospectus or delivering an offering memorandum in prescribed form and that certain protections,
rights and remedies provided by applicable securities legislation, in connection with the filing of a prospectus may not be available
to the Subscriber;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if required by applicable securities legislation, regulations, rules, policies or orders or by any securities commission, stock
exchange or other regulatory authority, the Subscriber will execute, deliver, file and otherwise assist the Corporation in filing, such
reports, undertakings and other documents with respect to the issue of the Units as may be required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> the entering into of this Subscription Agreement and the transactions contemplated hereby will not result in a violation of any
of the terms or provisions of any law applicable to the Subscriber, or if the Subscriber is not a natural person, any of the Subscriber&#8217;s
constating documents, or any agreement to which the Subscriber is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the funds representing the Aggregate Subscription Amount which will be advanced by the Subscriber hereunder will not represent
proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) Act</I> (Canada) and the Subscriber acknowledges that
the Corporation may in the future be required by law to disclose the Subscriber&#8217;s name and other information relating to this Subscription
Agreement and the Subscriber&#8217;s subscription hereunder, on a confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering)
Act</I> (Canada) and to the best of the Subscriber&#8217;s knowledge (i) none of the subscription funds to be provided by the Subscriber
(A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the United States of
America, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the Subscriber,
and (ii) it shall promptly notify the Corporation if the Subscriber discovers that any of such representations ceases to be true, and
to provide the Corporation with appropriate information in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation&#8217;s counsel, McMillan LLP, is acting solely for the Corporation and in connection with the Offering and the
Subscriber may not rely upon McMillan LLP in any respect. The Subscriber acknowledges that it has been encouraged to and should obtain
independent legal, income tax and investment advice with respect to its subscription for Units and accordingly, has been independently
advised as to the meanings of all terms contained herein relevant to the Subscriber for the purposes of giving representations, warranties
and covenants under this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the information provided by the Subscriber on pages 1, 2 and 3 of this Subscription Agreement and under the heading &#8220;Information
Regarding The Subscriber&#8221; is true and correct in all material respects and will be true and correct as of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it does not act jointly or in concert with any other Subscriber under the Offering for the purposes of the acquisition of the Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>it will not resell the Securities or any of them, except in accordance with the provisions of applicable securities legislation
and stock exchange rules, if applicable, in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the delivery of this subscription, the acceptance hereof by the Corporation and the issuance of the Units to the Subscriber complies
with all applicable laws of the Subscriber&#8217;s jurisdiction of residence and domicile and will not cause the Corporation or any of
its officers or directors to become subject to or require any disclosure, prospectus or other reporting requirement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation may complete additional financings in the future in order to develop the business of the Corporation and to fund
its ongoing development; there is no assurance that such financings will be available and, if available, on reasonable terms; any such
future financings may have a dilutive effect on current securityholders, including the Subscriber; and if such future financings are not
available, the Corporation may be unable to fund its ongoing development and the lack of capital resources may result in the failure of
its business venture; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Subscriber is capable of assessing the proposed investment as a result of the Subscriber&#8217;s financial experience or as
a result of advice received from a registered person other than the Corporation or any affiliates thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Closing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>The
Subscriber agrees to deliver to the Corporation, not later than the Closing Time: (a) this duly completed and executed Subscription
Agreement, including all applicable Schedules hereto and Appendices thereto; and (b) the Aggregate Subscription Amount subscribed
for under this Subscription Agreement in accordance with the Instructions on the Cover Page or payment of the same amount in such
other manner as is acceptable to the Corporation. If payment is made in a currency other than Canadian dollars, the Subscriber
acknowledges and agrees that it shall be responsible to make up for any deficiency in the payment of the Aggregate Subscription
Price as a result of the exchange of such funds into Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sale of the Units pursuant to this Subscription Agreement will be completed at the offices of McMillan LLP, the Corporation&#8217;s
counsel, in Vancouver, British Columbia at 10:00 a.m. (Vancouver time) or such other time as the Corporation may determine (the &#8220;<B>Closing
Time</B>&#8221;) on such date (the &#8220;<B>Closing Date</B>&#8221;) the Corporation may determine within 45 days of its acceptance of
this Subscription Agreement. The Corporation may complete the Offering in one or more Closings. At the Closing Time, the Corporation will
deliver, or cause to be delivered, according to the instructions set out under Delivery Instructions herein the certificates (or DRS)
representing the Units as registered in the name of the Subscriber or its nominee as set out under Registration Instructions provided
that the Subscriber shall have delivered to the Corporation the completed Subscription Agreement and the Aggregate Subscription Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The obligations of the parties hereunder are subject to acceptance of the terms of the Offering by the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation shall be entitled to rely on delivery of a copy of executed subscriptions by electronic means, and acceptance by
the Corporation of such electronic subscriptions (including, without limitation by facsimile or email delivery) shall be legally effective
to create a valid and binding agreement between the Subscriber and the Corporation in accordance with the terms hereof. Prior to Closing,
any funds advanced to the Corporation on account of the Aggregate Subscription Amount shall constitute a non-interest bearing loan to
the Corporation, which loan shall be due and payable to the Subscriber on the request of the Subscriber in the event that the Closing
does not occur within 90 days of its acceptance of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Privacy Legislation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges and consents to the fact that the Corporation is collecting the Subscriber&#8217;s (and any Disclosed
Principal for whom the Subscriber is acting hereunder) personal information (as that term is defined under applicable privacy legislation,
including, without limitation, the <I>Personal Information Protection and Electronic Documents Act</I> (Canada) and any other applicable
similar replacement or supplemental provincial or federal legislation or laws in effect from time to time) for the purpose of completing
the Subscriber&#8217;s subscription. The Subscriber acknowledges and consents to the Corporation retaining the personal information for
so long as permitted or required by applicable law or business practices. The Subscriber further acknowledges and consents to the fact
that the Corporation may be required by applicable securities legislation, stock exchange rules and/or Investment Industry Regulatory
Organization of Canada rules to provide regulatory authorities with any personal information provided by the Subscriber respecting itself
(and any Disclosed Principal for whom the Subscriber is acting hereunder). The Subscriber represents and warrants that it has the authority
to provide the consents and acknowledgements set out in this paragraph on behalf of all Disclosed Principals for whom the Subscriber is
acting. In addition to the foregoing, the Subscriber agrees and acknowledges that the Corporation may use and disclose the Subscriber&#8217;s
personal information, or that of each Disclosed Principal for whom the Subscriber is acting hereunder, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for internal use with respect to managing the relationships between and contractual obligations of the Corporation and the Subscriber
or any Disclosed Principal for whom the Subscriber is acting hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure to the Corporation&#8217;s transfer agent and registrar;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure for income tax related purposes, including without limitation, where required by law, disclosure to Canada
Revenue Agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to securities regulatory authorities (including the TSX) and other regulatory bodies with jurisdiction with respect
to reports of trade and similar regulatory filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to a governmental or other authority (including the TSX) to which the disclosure is required by court order or subpoena
compelling such disclosure and where there is no reasonable alternative to such disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to professional advisers of the Corporation in connection with the performance of their professional services;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> disclosure to any person where such disclosure is necessary for legitimate business reasons and is made with the Subscriber&#8217;s
prior written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>disclosure to a court determining the rights of the parties under this Subscription Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>for use and disclosure as otherwise required or permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Subscriber further acknowledges
and agrees that the TSX collects personal information in forms submitted by the Corporation, which will include personal information
regarding the Subscriber. The Subscriber agrees that the TSX may use this information in the manner provided for in Appendix 6A to the
TSX Company Manual, a copy of which may be viewed at the TSX website, <U>www.tsx.com</U> and is incorporated herein by reference. The
Subscriber further acknowledges that the securities regulatory authorities, including, without limitation, the British Columbia Securities
Commission, the Alberta Securities Commission and the Ontario Securities Commission, collect personal information in forms submitted
to it by the Corporation, including information about the Subscriber, the Subscriber&#8217;s address and contact information, and the
Subscriber&#8217;s subscription. The Subscriber acknowledges that any such securities commission is entitled to collect the information
under authority granted to each respective regulatory authority under applicable securities legislation for the purpose of administration
and enforcement of the applicable securities legislation. The Subscriber acknowledges that it may obtain information regarding the collection
of this information by contacting, in the case of the British Columbia Securities Commission, British Columbia Securities Commission,
P.O. Box 10142, Pacific Centre, 701 West Georgia Street, Vancouver, British Columbia, V7Y 1L2, Telephone: (604)&#8239;899-6500 or (800)&#8239;373-6393,
Facsimile: (604)&#8239;899-6581, in the case of the Alberta Securities Commission, Alberta Securities Commission, Suite 600, 250 &#8211;
5<SUP>th</SUP> St. SW, Calgary, Alberta, T2P 0R4, Telephone: (403) 355-4151, Facsimile: (403) 297-6156, and, in the case of the Ontario
Securities Commission, the Administrative Assistant to the Director of Corporate Finance, Ontario Securities Commission, Suite 1903,
Box 5520, Queen Street West, Toronto, Ontario M5H&#8239;3S8, Telephone: (416)&#8239;593-3682, Facsimile: (416)&#8239;593&#45;8252. The
Subscriber consents to the collection of personal information by the applicable securities regulatory authorities, including, without
limitation, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber agrees that the representations, warranties and covenants of the Subscriber herein will be true and correct both
as of the execution of this Subscription Agreement and as of the Closing Time and will survive the issuance of the Units. The representations,
warranties and covenants of the Subscriber herein are made with the intent that they be relied upon by the Corporation in determining
the eligibility of a purchaser of Units and the Subscriber agrees to indemnify the Corporation against all losses, claims, costs, expenses
and damages or liabilities which it may suffer or incur which are caused or arise from an inaccuracy or breach thereof and reliance thereon.
The Subscriber undertakes to immediately notify the Corporation by written notice to ProMIS Neurosciences Inc. sent to its office at 1920
Yonge Street, Suite 200, Toronto, ON&#8239;M4S 3E2 or by email to <FONT STYLE="font-size: 10pt">[***] </FONT>of any change in any statement
or other information relating to the Subscriber set forth herein which takes place prior to the Closing Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges and agrees that all costs incurred by the Subscriber (including any fees and disbursements of any counsel
retained by the Subscriber) relating to the sale of the Units to the Subscriber shall be borne by the Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Subscriber acknowledges that upon a subscription being accepted by the Corporation, the Corporation will, subject to the terms
and conditions set out herein, issue to the Subscriber certificates (or DRS) evidencing the Subscriber&#8217;s ownership of the Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The terms and provisions of this Subscription Agreement shall be binding upon and enure to the benefit of the Subscriber and the
Corporation and their respective heirs, executors, administrators, successors and permitted assigns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The contract arising out of this Subscription Agreement and all documents relating thereto shall be governed by and construed in
accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable therein. The parties irrevocably
attorn to the exclusive jurisdiction of the courts of the Province of British Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> Time is of the essence of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither party to this Subscription Agreement may assign all or part of its interest in or to this Subscription Agreement without
the consent in writing of the other party hereto, except for the assignment by a Subscriber who is acting as nominee or agent to the beneficial
owner and as otherwise herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Subscription Agreement represents the entire agreement of the parties hereto relating to the subject matter hereof and there
are no representations, covenants or other agreements relating to the subject matter hereof except as stated or referred to herein. Neither
this Subscription Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing
signed by the party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The covenants, representations and warranties contained herein shall survive the closing of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In this Subscription Agreement (including attachments), references to &#8220;$&#8221; or &#8220;Cdn. $&#8221; are to Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The parties hereto acknowledge and confirm that they have requested that this Subscription Agreement as well as all notices and
other documents contemplated hereby be drawn up in the English language. <B>Les parties aux pr&eacute;sentes reconnaissent et confirment
qu&#8217;elles ont convenu que la pr&eacute;sente convention de souscription ainsi que tous les avis et documents qui s&#8217;y rattachent
soient r&eacute;dig&eacute;s dans la langue anglaise.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE I<BR>
REPRESENTATION LETTER<BR>
(FOR CANADIAN ACCREDITED INVESTORS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>TO:</B></TD><TD STYLE="text-align: justify"><B>ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase of units of the
Corporation (&#8220;<B>Units</B>&#8221;) by the undersigned subscriber or, if applicable, the principal on whose behalf the undersigned
is purchasing as agent (the &#8220;<B>Subscriber</B>&#8221; for the purposes of this Schedule I), the Subscriber hereby represents, warrants,
covenants and certifies to the Corporation that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The Subscriber is purchasing the Units as principal for its own account
                                or is deemed to be acting as principal pursuant to applicable securities laws, including National Instrument
                                45-106 entitled &#8220;Prospectus and Registration Exemptions&#8221; (&#8220;<B>NI 45-106</B>&#8221;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Subscriber is an &#8220;<B>accredited investor</B>&#8221; within
                                the meaning of applicable securities laws, including NI 45-106, by virtue of satisfying one or more of
                                the categories set out in Appendix &#8220;A&#8221; to this Representation Letter;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">If the Subscriber is an individual, he or she has completed the attached
                                <B>Form 45-106F9 -- <I>Form for Individual Accredited Investors</I></B> set out in Appendix &#8220;B&#8221;
                                to this Representation Letter unless the individual qualifies under a category set out in Appendix &#8220;A&#8221;
                                other than (j), (k) or (l) of the definition of &#8220;<B>accredited investor</B>&#8221;; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Upon execution of this Schedule I by the Subscriber,
                                            this Schedule I shall be incorporated into and form a part of the Subscription Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________________, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>Print name of Subscriber</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Signature</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Print name of Signatory (if different from Subscriber)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD>
  <TD>Title</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMPORTANT: PLEASE INITIAL APPENDIX &#8220;A&#8221;
OVER PAGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></B></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &#8220;A&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>NOTE: THE SUBSCRIBER MUST INITIAL BESIDE THE
APPLICABLE PORTION OF THE DEFINITION BELOW AND COMPLETE EACH QUESTION WHICH FOLLOWS THE APPLICABLE PORTION OF THE DEFINITION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>Accredited Investor &#8211; </B>(as defined
in National Instrument 45-106, and in Ontario, as defined in Section 73.3 of the <I>Securities Act</I> (Ontario) as supplemented by the
definition in National Instrument 45-106) includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 10%; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 6%; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(a)</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0.5in; border-top: Black 1pt solid; border-right: Black 1pt solid; width: 84%; text-indent: -0.5in; text-align: justify">except
    in Ontario, a Canadian financial institution, or a Schedule III bank,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(a.1)</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0.5in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: justify">in
    Ontario, a financial institution described in paragraph 1, 2 or 3 of subsection 73.1 (1) of the <I>Securities Act</I> (Ontario),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(b)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">except in Ontario, the Business
    Development Bank of Canada incorporated under the <I>Business Development Bank of Canada Act</I> (Canada),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(b.1)</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0.5in; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: -0.5in; text-align: justify">in
    Ontario, the Business Development Bank of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(c)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">except in Ontario, a subsidiary
    of any person referred to in paragraphs (a) or (b), if the person owns all of the voting securities of the subsidiary, except the
    voting securities required by law to be owned by directors of that subsidiary,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(c.1)</TD>
    <TD STYLE="padding-right: 5pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">in Ontario, a subsidiary of
    any person or Corporation referred to in clause (a.1) or (b.1), if the person or Corporation owns all of the voting securities of
    the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(d)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">except in Ontario, a person
    registered under the securities legislation of a jurisdiction of Canada as an adviser or dealer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(d.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">in Ontario, a person or Corporation
    registered under the securities legislation of a province or territory of Canada as an adviser or dealer, except as otherwise prescribed
    by the regulations,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(e)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">an
    individual registered under the securities legislation of a jurisdiction of Canada as a representative of a person referred to in
    paragraph (d),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(e.1)</TD>
    <TD STYLE="border-right: Black thin solid; padding-right: 5pt; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">an
    individual formerly registered under the securities legislation of a jurisdiction of Canada, other than an individual formerly registered
    solely as a representative of a limited market dealer under one or both of the <I>Securities Act</I> (Ontario) or the <I>Securities
    Act</I> (Newfoundland and Labrador),</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(f)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">except in Ontario, the Government
    of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the Government of Canada or a jurisdiction
    of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 8pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(f.1)</TD>
    <TD STYLE="padding-right: 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">in
    Ontario, the Government of Canada, the government of a province or territory of Canada, or any Crown corporation, agency or wholly
    owned entity of the Government of Canada or of the government of a province or territory of Canada,</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 10%; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 6%">(g)</TD>
    <TD STYLE="padding: 6pt 5pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 84%">a
    municipality, public board or commission in Canada and a metropolitan community, school board, the Comit&eacute; de gestion de la
    taxe scolaire de l&#8217;&icirc;le de Montr&eacute;al or an intermunicipal management board in Qu&eacute;bec,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">(h)</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">any
    national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that
    government,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="text-align: justify">(i)</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; text-align: justify">except in Ontario, a pension
    fund that is regulated by the Office of the Superintendent of Financial Institutions (Canada), a pension commission or similar regulatory
    authority of a jurisdiction of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="text-align: justify">(i.1)</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; text-align: justify">in Ontario, a pension fund
    that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar
    regulatory authority of a province or territory of Canada,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(j)</P></TD>
    <TD STYLE="padding-left: 5pt; text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">an
                                            individual who, either alone or with a spouse, beneficially owns financial assets having
                                            an aggregate realizable value that before taxes, but net of any related liabilities, exceeds
                                            $1,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">[If this
    is your applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">(j.1)</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">an
    individual who beneficially owns financial assets having an aggregate realizable value that, before taxes but net of any related
    liabilities, exceeds $5,000,000,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(k)</P></TD>
    <TD STYLE="padding-left: 5pt; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">an
                                            individual whose net income before taxes exceeded $200,000 in each of the 2 most recent calendar
                                            years or whose net income before taxes combined with that of a spouse exceeded $300 000 in
                                            each of the 2 most recent calendar years and who, in either case, reasonably expects to exceed
                                            that net income level in the current calendar year,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">[If
    this is your applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(l)</P></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: justify; border-bottom: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">an
                                            individual who, either alone or with a spouse, has net assets of at least $5,000,000,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">[If this is
    your applicable category, you must also complete <U>Form 45-106F9 attached as Appendix B</U>]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.65pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="text-align: justify">(m)</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; text-align: justify">a person, other than an individual
    or investment fund, that has net assets of at least $5,000,000 as shown on its most recently prepared financial statements,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n)</P></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5pt; padding-left: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">an
                                            investment fund that distributes or has distributed its securities only to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(i)&#8239;&#8239;&#8239;&#8239;a
    person that is or was an accredited investor at the time of the distribution,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(ii)&#8239;&#8239;&#8239;a
    person that acquires or acquired securities in the circumstances referred to in sections 2.10 [Minimum amount investment], or 2.19
    [Additional investment in investment funds], or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#8239;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(iii)&#8239;&#8239;a
    person described in paragraph (i) or (ii) that acquires or acquired securities under section 2.18 [Investment fund reinvestment],</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -37.7pt">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">(o)</TD>
    <TD STYLE="padding: 6pt 5pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">an
    investment fund that distributes or has distributed securities under a prospectus in a jurisdiction of Canada for which the regulator
    or, in Qu&eacute;bec, the securities regulatory authority, has issued a receipt,</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 10%; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 6%; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(p)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify; width: 84%">a
    trust Corporation or trust corporation registered or authorized to carry on business under the <I>Trust and Loan Companies Act </I>(Canada)
    or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on behalf of a fully managed account
    managed by the trust Corporation or trust corporation, as the case may be,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(q)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">a
    person acting on behalf of a fully managed account managed by that person, if that person is registered or authorized to carry on
    business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a foreign jurisdiction,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(r)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">a
    registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser
    or an adviser registered under the securities legislation of the jurisdiction of the registered charity to give advice on the securities
    being traded,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(s)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">an
    entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) to (d) paragraph
    (i) [and in Ontario, paragraphs (a.1) to (d.1) or paragraph (i.1)] in form and function,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(t)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">a
    person in respect of which all of the owners of interests, direct, indirect or beneficial, except the voting securities required
    by law to be owned by directors, are persons that are accredited investors</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(u)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">an
    investment fund that is advised by a person registered as an adviser or a person that is exempt from registration as an adviser,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(v)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">a
    person that is recognized or designated by the securities regulatory authority or, except in Ontario and Qu&eacute;bec, the regulator
    as an accredited investor,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-indent: -0.5in; text-align: justify">(v.1)</TD>
    <TD STYLE="padding: 6pt 5pt 6pt 0.5in; border-right: Black 1pt solid; text-indent: -0.5in; text-align: justify">in
    Ontario, a person or Corporation that is recognized or designated by the Commission as an accredited investor,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 8pt; text-align: left">_______</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.6in; text-align: justify; text-indent: -0.5in">(w)</TD>
    <TD STYLE="padding-right: 5pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 6pt; padding-bottom: 6pt; text-align: justify">a
    trust established by an accredited investor for the benefit of the accredited investor&#8217;s family members of which a majority
    of the trustees are accredited investors and all of the beneficiaries are the accredited investor&#8217;s spouse, a former spouse
    of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited investor, of that accredited
    investor&#8217;s spouse or of that accredited investor&#8217;s former spouse.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: __________________, 201__.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><I>Print name of Subscriber</I></TD>
  <TD>&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><I>Signature</I></TD>
  <TD>&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><I>Print name of Signatory (if different from Subscriber)</I></TD>
  <TD>&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&#8239;</TD>
  <TD STYLE="width: 50%">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><I>Title</I></TD>
  <TD>&#8239;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the purposes hereof:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.1in; text-align: justify">&#8239;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>control person</B>&#8221; has the
    meaning ascribed to that term in securities legislation except in Manitoba, Ontario, Quebec, Nova Scotia, Newfoundland and Labrador,
    Prince Edward Island, the Northwest Territories and Nunavut where &#8220;control person&#8221; means any person that holds or is
    one of a combination of persons that hold:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">a sufficient number of any of the securities
    of an issuer so as to affect materially the control of the issuer; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">more than 20% of the outstanding voting securities
    of an issuer except where there is evidence showing that the holding of those securities does not affect materially the control of
    that issuer;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3">&#8220;<B>eligibility adviser</B>&#8221; means:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">a person that is registered as an investment
    dealer or in an equivalent category of registration under the securities legislation of the jurisdiction of a Subscriber and authorized
    to give advice with respect to the type of security being distributed; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">in Saskatchewan or Manitoba, also means a
    lawyer who is a practicing member in good standing with a law society of a jurisdiction of Canada or a public accountant who is a
    member in good standing of an institute or association of chartered accountants, certified general accountants or certified management
    accountants in a jurisdiction of Canada provided that the lawyer or public accountant must not:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.1in"><FONT STYLE="font-size: 10pt">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="text-align: justify; padding-right: 5.4pt">have a professional, business or personal relationship with the issuer, or
    any of its directors, executive officers, founders or control persons; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.1in"><FONT STYLE="font-size: 10pt">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">have acted for or been retained personally
    or otherwise as an employee, executive officer, director, associate or partner of a person that has acted for or been retained by
    the issuer or any of its directors, executive officers, founders or control persons within the previous 12 months;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>financial assets</B>&#8221; means
    (i) cash, (ii) securities or (iii) a contract of insurance, a deposit or an evidence of a deposit that is not a security for the
    purposes of securities legislation. These financial assets are generally liquid or relatively easy to liquidate. The value of a purchaser&#8217;s
    personal residence would not be included in a calculation of financial assets;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<B>financial statements</B>&#8221;
    for the purposes of paragraph (m) of the &#8220;accredited investor&#8221; definition must be prepared in accordance with generally
    accepted accounting principles;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt">&#8220;<B>founder</B>&#8221; means, in respect of an issuer, a
    person who:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt">acting alone, in conjunction or in concert
    with one or more persons, directly or indirectly, takes the initiative in founding, organizing or substantially reorganizing the
    business of the issuer; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">at the time of the trade is actively involved
    in the business of the issuer;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#8220;<B>fully managed account</B>&#8221;
    means an account of a client for which a person makes the investment decisions if that person has full discretion to trade in securities
    for the account without requiring the client&#8217;s express consent to a transaction;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#8220;<B>investment fund</B>&#8221; has
    the meaning ascribed thereto in National Instrument 81-106 - <I>Investment Fund Continuous Disclosure</I>;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify; padding-right: 5.4pt">&#8239; &#8220;<B>net assets</B>&#8221; means all of the purchaser&#8217;s
    total assets minus all of the purchaser&#8217;s total liabilities. Accordingly, for the purposes of the net asset test, the calculation
    of total assets would include the value of a purchaser&#8217;s personal residence and the calculation of total liabilities would
    include the amount of any liability (such as a mortgage) in respect of the purchaser&#8217;s personal residence. To calculate a purchaser&#8217;s
    net assets under the &#8220;accredited investor&#8221; definition, subtract the purchaser&#8217;s total liabilities from the purchaser&#8217;s
    total assets (including real estate). The value attributed to assets should reasonably reflect their estimated fair value. Income
    tax should be considered a liability if the obligation to pay it is outstanding at the time of the distribution of the security;
    &#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt">&#8220;<B>related liabilities</B>&#8221; means:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="text-align: justify; width: 92%; padding-right: 5.4pt">liabilities incurred or assumed for the purpose of financing the
    acquisition or ownership of financial assets; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">liabilities that are secured by financial
    assets;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt">&#8220;<B>spouse</B>&#8221; means an individual who:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="text-align: justify; padding-right: 5.4pt">is married to another individual and is not living separate and apart within
    the meaning of the <I>Divorce Act</I> (Canada), from the other individual;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="text-align: justify; padding-right: 5.4pt">is living with another individual in a marriage-like relationship, including
    a marriage-like relationship between individuals of the same gender; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-size: 10pt">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    </FONT></FONT>&#8239;</TD>
    <TD STYLE="padding-right: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">in Alberta, is an individual referred to
    in paragraph (i) or (ii) immediately above or is an adult interdependent partner within the meaning of the <I>Adult Interdependent
    Relationships Act </I>(Alberta); and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX &#8220;B&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 45-106F9 - <I>Form for Individual Accredited
Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&#8239;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-top: 5.4pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARNING!</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>This investment is risky. Don&#8217;t invest
    unless you can afford to lose all the money you pay for this investment.</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#8239;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
    1 TO BE COMPLETED BY ISSUER OR SELLING SECURITY HOLDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; padding-right: 5pt; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    About your investment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    of securities:&#8239;&#8239;&#8239;Common Shares and Warrants</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:&#8239;&#8239;ProMIS
    Neurosciences Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTIONS
    2 TO 4 TO BE COMPLETED BY THE PURCHASER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    Risk acknowledgement</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    investment is risky. Initial that you understand that:</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
    initials</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    of loss </B>&ndash; You could lose your entire investment of $________. </FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
    risk</B> &ndash; You may not be able to sell your investment quickly &ndash; or at all.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lack
    of information </B>&ndash; You may receive little or no information about your investment.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lack
    of advice &ndash; </B>You may not receive advice from the salesperson about whether this investment is suitable for you unless the
    salesperson is registered. The salesperson is the person who meets with, or provides information to, you about making this investments.
    To check whether the salesperson is registered, go to <U>www.aretheyregistered.ca</U>.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
    Accredited investor status</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    must meet at least <B>one </B>of the following criteria to be able to make this investment. Initial the statement that applies to
    you. (You may initial more than one statement.) The person identified in section 6 is responsible for ensuring that you meet the
    definition of accredited investor. That person, or the salesperson identified in section 5, can help you if you have questions about
    whether you meet these criteria.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
    initials</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5pt; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-left: 0.125in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Your net income before taxes was more than $200,000 in each for the 2 most recent calendar years, and you expect it to be more than
    &#8239;&#8239;&#8239;&#8239;&#8239;$200,000 in the current calendar year. (You can find your net income before taxes on your personal income
    tax return.)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-right: 5pt; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-left: 0.125in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your net income before taxes combined with your spouse&rsquo;s
was more than $300,000 in each of the 2 most recent calendar years, and you &#8239;&#8239;&#8239;&#8239;expect your combined net income before
taxes to be more than $300,000 in the current calendar year.</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 9pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either alone or with your spouse, you own more than $1 million in cash and securities, after subtracting any debt related to the case and &#8239;&#8239;&#8239;&#8239;securities.</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 9pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either alone or with your spouse, you may have net assets worth more than $5 million. (Your net assets are your total assets (including &#8239;&#8239;&#8239;&#8239;real estate) minus your total debt.)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Your name and signature</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By signing this form, you confirm that you have read this form and you understand the risks of making this investment as identified in this form.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First and last name (please print):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-top: 12pt; padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION 5 TO BE COMPLETED BY SALESPERSON</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; Salesperson information</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Instruction: The salesperson is the person who meets with, or provides information to, the purchaser with respect to making this investment. That could include a representative of the issuer or selling security holder, a registrant or a person who is exempt from the registration requirement</I>.]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First and last name of salesperson (please print):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-top: 12pt; padding-right: 5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of firm (if registered):</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION 6 TO BE COMPLETED BY THE ISSUER OR SELLING SECURITY HOLDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; For more information about this investment</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 12pt; padding-right: 5pt; padding-left: 5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMIS Neurosciences Inc.<BR>
Kristi Lanier, Finance Director<BR>
Tel: [***]<BR>
E-mail: [***]<BR>
Website: www.promisneurosciences.com<BR>
<B>For more information about prospectus exemptions, contact your local securities regulator. You can find contact information at <U>www.securities-administrators.ca</U></B></FONT></TD></TR>
  <TR STYLE="font-size: 1pt">
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 46%">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 25%">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; padding-right: 5pt; width: 9%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&#8239;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>42
<FILENAME>filename42.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.24</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2021.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2025 AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certificate <B>FW#-2020-11-<FONT STYLE="font-family: Wingdings">&#117;</FONT></B> dated [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2020 (the &#8220;Issue Date&#8221;),
representing <B>[<FONT STYLE="font-family: Wingdings">&#108;</FONT>] </B>Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FINDER&#8217;S WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
</B>(Incorporated under the laws of Canada)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[FINDER]<BR>
[ADDRESS]<BR>
<BR>
</B></FONT>(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMis Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2020, at a price of CAD$0.20 per Common Share until
5:00 pm (EST) on [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2025 (the &#8220;Expiry Date&#8221;), subject to acceleration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time after the expiry of the four month
hold period applicable to the Warrants, the Issuer may accelerate the expiry of the Warrants if the twenty-day volume-weighted average
trading price of the Common Shares on the TSX, or such other exchange on which the Common Shares may be listed, is greater than $0.60
provided that (a) the Issuer gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated expiry date is
a date which is not less than 30 calendar days after the date of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer
as it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise
of the Warrants, the Issuer shall issue or cause to be issued the requisite number of Shares to be issued to the Holder pursuant to
said exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such
person shall be deemed the holder of such Shares with effect from the date of such exercise. If Shares are to be issued to a person
other than the Holder, the Holder&#8217;s signature on the Subscription Form must be guaranteed by a Canadian chartered bank, a
Canadian trust company or a member firm of the TSX. The Issuer will cause the certificates representing such Shares to be mailed to
the Holder at the Holder&#8217;s address stated above or such other address(es) as may be specified in the Subscription Form, within
five business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Shares to which the Holder is entitled on such exercise, shall
wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Shares
issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable commercial
efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable from time to time
upon the exercise of the Warrants are listed and posted for trading on the TSX (or such other exchange on which the Common Shares may
be listed), provided that this clause shall not be construed as limiting or restricting the Issuer from completing a consolidation, amalgamation,
arrangement, takeover bid or merger that would result in the Common Shares ceasing to be listed and posted for trading on the TSX (or
such other exchange on which the Common Shares may be listed), so long as the holders of Common Shares receive securities of an entity
which is listed on a stock exchange in Canada, or cash, or the holders of the Common Shares have approved the transaction in accordance
with the requirements of applicable corporate and securities laws and the policies of the TSX (or such other exchange on which the Common
Shares may be listed). In addition, the Issuer shall make all requisite filings under applicable securities legislation necessary to remain
a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are non-transferable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legending Of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Shares will be,
issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable securities
law. To the extent that the Issuer relies on such Exemption, the Shares may be subject to restrictions on resale and transferability contained
in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2021.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a
 &#8220;Capital Reorganization&#8221;) any Holders who shall thereafter acquire Shares pursuant to the Warrant shall be entitled to
receive, at no additional cost, and shall accept in lieu of the number of Shares to which such Holder was theretofore entitled to
acquire upon such exercise, the aggregate number of shares, other securities or other property which such Holder should have been
entitled to receive as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be,
the Holder had been the registered holder of the number of Shares to which such Holder was theretofore entitled to acquire upon
exercise of the Warrants. If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the
application of the provisions set forth herein with respect to the rights and interests of the Holder relative to a Capital
Reorganization, to the end that the provisions set forth herein shall correspond as nearly as may be reasonably possible to the
effect of the Capital Reorganization in relation to any shares, other securities or other property thereafter deliverable upon the
exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Shares or other securities which shall be issuable
on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole discretion,
may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory approvals,
if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question shall
be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of any
event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the Holder had
exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of the TSX (or such
other exchange on which the Common Shares may be listed). The adjustments provided for herein are cumulative and such adjustments shall
be made successively whenever an event referred to herein shall occur, subject to the limitations provided for herein. No adjustment shall
be made in the number or kind of Shares or other securities which may be acquired on the exercise of a Warrant unless it would result
in a change of at least one-tenth of a Share or other security. Any adjustment which may by reason of this paragraph not be required to
be made shall be carried forward and then taken into consideration in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for
herein or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Shares or other
securities in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To
the extent that the Holder would otherwise be entitled to acquire a fraction of a Share or other security, such right may be
exercised in respect of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a
whole number of Shares or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Share or other
security, to be paid in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not
be required to make any payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMis Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">PROMIS NEUROSCIENCES INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Authorized Signatory</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProMis Neurosciences Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite 200, 1920 Yonge Street</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toronto, Ontario</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M4S 3E2</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    [***]</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>of the Warrants evidenced thereby in accordance with the terms thereof, and accordingly hereby irrevocably subscribes for the Shares
(as described therein) to be received thereon and irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The
Undersigned hereby irrevocably directs that the Shares to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U> AND IT MUST
PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States <I>Securities Act</I> of 1933, as amended (the <I>&#8220;1933 Act&#8221;</I>), or any
applicable State securities laws and may not be offered or sold in the United States or to U.S. Persons without registration under the
<I>1933 Act</I> and any applicable State securities laws, unless an exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Witness</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.05in; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-top: Black 1pt solid; width: 45%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of registered holder or Signatory thereof</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Please
    Note Instruction 2]</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If applicable, print Name
    and Office of Signatory</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name
    of Witness</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name
    of registered holder as on certificate</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Witness</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Street Address</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupation of Witness</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City, Province
    and Postal Code</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.05in">}<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>43
<FILENAME>filename43.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Certain identified information has been excluded from the exhibit pursuant
to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***]</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.25</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MAY 23, 2019.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON JANUARY 22, 2024 (WHICH EXPIRY DATE IS SUBJECT TO ACCELERATION IN ACCORDANCE WITH THE TERMS ATTACHING TO THE
WARRANTS) AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certificate <B>FW#-2019-F</B>&nbsp;<FONT STYLE="font-family: Wingdings">&#117;</FONT>&nbsp;dated
<FONT STYLE="font-family: Wingdings">&#117;&nbsp;</FONT>(the &#8220;Issue Date&#8221;), representing <FONT STYLE="font-family: Wingdings">&#117;&nbsp;</FONT>Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FINDER&#8217;S WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>(Incorporated under the laws of Canada)<B><BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[FINDER]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[ADDRESS]<BR></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B></B></FONT>(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMis Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase
one common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on January 22, 2019, at a price of CAD$0.48 per Common
Share until 5:00 pm (EST) on January 22, 2024 (the &#8220;Expiry Date&#8221;). The Expiry Date may be accelerated by the Issuer at any
time following the four-month anniversary of the issue date of the Warrants and prior to the Expiry Date if the twenty-day volume-weighted
average trading price (&#8220;<B>20 day VWAP</B>&#8221;) of the Shares on the TSX, and/or such other exchange on which the Common Shares
may be listed, is greater than $1.00, or the Issuer enters into a partnering deal within 18 months of closing of the private placement
pursuant to which this Warrant was issued to the Holder with minimum proceeds of US$5 million and the 20 day VWAP is greater than $0.48
at any time following the announcement of such a partnering deal. The Company may accelerate the expiry date of the Warrants by issuing
a press release announcing the reduced warrant term whereupon the Warrants will expire on a day that is not less than 30 calendar day
after the date of such press releas<B>e.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer as
it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise of the
Warrants, the Issuer shall issue or cause to be issued the requisite number of Shares to be issued to the Holder pursuant to said exercise,
registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such person shall be
deemed the holder of such Shares with effect from the date of such exercise. If Shares are to be issued to a person other than the Holder,
the Holder&#8217;s signature on the Subscription Form must be guaranteed by a Canadian chartered bank, a Canadian trust company or a member
firm of the TSX. The Issuer will cause the certificates representing such Shares to be mailed to the Holder at the Holder&#8217;s address
stated above or such other address(es) as may be specified in the Subscription Form, within five business days of the exercise of the
Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Shares to which the Holder is entitled on such exercise, shall
wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Shares
issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable commercial
efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable from time to time
upon the exercise of the Warrants are listed and posted for trading on the TSX (or such other exchange on which the Common Shares may
be listed), provided that this clause shall not be construed as limiting or restricting the Issuer from completing a consolidation, amalgamation,
arrangement, takeover bid or merger that would result in the Common Shares ceasing to be listed and posted for trading on the TSX (or
such other exchange on which the Common Shares may be listed), so long as the holders of Common Shares receive securities of an entity
which is listed on a stock exchange in Canada, or cash, or the holders of the Common Shares have approved the transaction in accordance
with the requirements of applicable corporate and securities laws and the policies of the TSX (or such other exchange on which the Common
Shares may be listed). In addition, the Issuer shall make all requisite filings under applicable securities legislation necessary to remain
a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are non-transferable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legending Of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Shares will be,
issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable securities
law. To the extent that the Issuer relies on such Exemption, the Shares may be subject to restrictions on resale and transferability contained
in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MAY 23, 2019.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a
 &#8220;Capital Reorganization&#8221;) any Holders who shall thereafter acquire Shares pursuant to the Warrant shall be entitled to
receive, at no additional cost, and shall accept in lieu of the number of Shares to which such Holder was theretofore entitled to
acquire upon such exercise, the aggregate number of shares, other securities or other property which such Holder should have been
entitled to receive as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be,
the Holder had been the registered holder of the number of Shares to which such Holder was theretofore entitled to acquire upon
exercise of the Warrants. If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the
application of the provisions set forth herein with respect to the rights and interests of the Holder relative to a Capital
Reorganization, to the end that the provisions set forth herein shall correspond as nearly as may be reasonably possible to the
effect of the Capital Reorganization in relation to any shares, other securities or other property thereafter deliverable upon the
exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Shares or other securities which shall be issuable
on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole discretion,
may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory approvals,
if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question shall
be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of any
event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the Holder had
exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of the TSX (or such
other exchange on which the Common Shares may be listed). The adjustments provided for herein are cumulative and such adjustments shall
be made successively whenever an event referred to herein shall occur, subject to the limitations provided for herein. No adjustment shall
be made in the number or kind of Shares or other securities which may be acquired on the exercise of a Warrant unless it would result
in a change of at least one-tenth of a Share or other security. Any adjustment which may by reason of this paragraph not be required to
be made shall be carried forward and then taken into consideration in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for
herein or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Shares or other
securities in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To
the extent that the Holder would otherwise be entitled to acquire a fraction of a Share or other security, such right may be
exercised in respect of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a
whole number of Shares or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Share or other
security, to be paid in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not
be required to make any payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMis Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Finder&#8217;s Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 46%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 4%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 46%">Authorized Signatory</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMis Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; width: 15pc">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 467.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise ______________of the Warrants evidenced thereby in
accordance with the terms thereof, and accordingly hereby irrevocably subscribes for the Shares (as described therein) to be received
thereon and irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The Undersigned hereby irrevocably directs
that the Shares to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black medium double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black medium double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black medium double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U> AND IT MUST
PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States <I>Securities Act</I> of 1933, as amended (the <I>&#8220;1933 Act&#8221;</I>), or any
applicable State securities laws and may not be offered or sold in the United States or to U.S. Persons without registration under the
<I>1933 Act</I> and any applicable State securities laws, unless an exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the  ________day of _______________, 20_____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}<BR>
}</P></TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Signature of Witness<BR>
<B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Signature of registered holder or Signatory thereof</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If applicable, print Name and Office of Signatory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Print Name of registered holder as on certificate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Street Address</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- 2 -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>44
<FILENAME>filename44.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.26</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: justify"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6)
of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [</I>***<I>]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MAY 23, 2019.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON JANUARY 22, 2024 (WHICH EXPIRY DATE IS SUBJECT TO ACCELERATION IN ACCORDANCE WITH THE TERMS ATTACHING TO THE
WARRANTS) AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate #2019-01-&laquo;Number&raquo; dated January 22, 2019
(the &#8220;Issue Date&#8221;), representing &laquo;Warrants&raquo; Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
</B>(Incorporated under the laws of Canada)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[HOLDER NAME]<BR>
[ADDRESS]<BR>
<BR>
</B></FONT>(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMIS Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on January 22, 2019, at a price of CAD$0.48 per Common
Share until 5:00 pm (EST) on January 22, 2024 (the &#8220;Expiry Date&#8221;). The Expiry Date may be accelerated by the Issuer at any
time following the four-month anniversary of the issue date of the Warrants and prior to the Expiry Date if the twenty-day volume-weighted
average trading price (&#8220;<B>20 day VWAP</B>&#8221;) of the Shares on the TSX, and/or such other exchange on which the Common Shares
may be listed, is greater than $1.00, or the Issuer enters into a partnering deal within 18 months of closing of the private placement
pursuant to which this Warrant was issued to the Holder with minimum proceeds of US$5 million and the 20 day VWAP is greater than $0.48
at any time following the announcement of such a partnering deal. The Issuer may accelerate the expiry date of the Warrants by issuing
a press release announcing the reduced warrant term whereupon the Warrants will expire on a day that is not less than 30 calendar day
after the date of such press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer as
it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise of the
Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder pursuant to said
exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such person
shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares are to be issued to a person
other than the Holder, the Holder&#8217;s signature on the Subscription Form must be guaranteed by a Canadian chartered bank, a Canadian
trust company or a member firm of the TSX. The Issuer will cause the certificates representing such Common Shares to be mailed to the
Holder at the Holder&#8217;s address stated above or such other address(es) as may be specified in the Subscription Form, within five
business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable commercial
efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable from time to time
upon the exercise of the Warrants are listed and posted for trading on the TSX (or such other exchange on which the Common Shares may
be listed), provided that this clause shall not be construed as limiting or restricting the Issuer from completing a consolidation, amalgamation,
arrangement, takeover bid or merger that would result in the Common Shares ceasing to be listed and posted for trading on the TSX (or
such other exchange on which the Common Shares may be listed), so long as the holders of Common Shares receive securities of an entity
which is listed on a stock exchange in Canada, or cash, or the holders of the Common Shares have approved the transaction in accordance
with the requirements of applicable corporate and securities laws and the policies of the TSX (or such other exchange on which the Common
Shares may be listed). In addition, the Issuer shall make all requisite filings under applicable securities legislation necessary to remain
a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon
the exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other
governmental authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other
than the filing of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to
secure such filing, registration, approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are transferable and the term &#8220;Warrantholder&#8221;
shall mean and include any successor, transferee or assignee of the current or any future Warrantholder. The term &#8220;Warrantholder&#8221;
shall mean and include any successor of the Warrantholder. The Warrants may be transferred by the Warrantholder completing and delivering
to the Issuer the transfer form attached hereto as Schedule&nbsp;&#8220;B&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legending Of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MAY 23, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a &#8220;Capital
Reorganization&#8221;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be entitled to receive, at
no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was theretofore entitled to acquire upon
such exercise, the aggregate number of shares, other securities or other property which such Holder should have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be, the Holder had been the
registered holder of the number of Common Shares to which such Holder was theretofore entitled to acquire upon exercise of the Warrants.
If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the application of the provisions
set forth herein with respect to the rights and interests of the Holder relative to a Capital Reorganization, to the end that the provisions
set forth herein shall correspond as nearly as may be reasonably possible to the effect of the Capital Reorganization in relation to any
shares, other securities or other property thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of
any event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the
Holder had exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of
the TSX (or such other exchange on which the Common Shares may be listed)<FONT STYLE="font-size: 10pt">. The adjustments provided
for herein are cumulative and such adjustments shall be made successively whenever an event referred to herein shall occur, subject
to the limitations provided for herein. No adjustment shall be made in the number or kind of Shares or other securities which may be
acquired on the exercise of a Warrant unless it would result in a change of at least one-tenth of a Share or other security. Any
adjustment which may by reason of this paragraph not be required to be made shall be carried forward and then taken into
consideration in any subsequent adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for herein
or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other securities
in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To the extent that
the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be exercised in respect
of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a whole number of Common Shares
or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common Share or other security, to be paid
in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not be required to make any
payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PROMIS NEUROSCIENCES INC.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder of
the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise <U>________________________</U> of the Warrants evidenced thereby in accordance
with the terms thereof, and accordingly hereby irrevocably subscribes for the Shares (as described therein) to be received thereon and
irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The Undersigned hereby irrevocably directs that the Shares
to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, (I) THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U>, (II)
THE UNDERSIGNED MUST PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES AND (III) THE TRANSFER FORM SET FORTH IN SCHEDULE &#8220;B&#8221;
TO THE WARRANT CERTIFICATE MUST BE COMPLETED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States Securities Act of 1933, as amended (the &#8220;U.S. Securities Act&#8221;), or any applicable
State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule 902(k) of Regulation
S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities laws, unless an
exemption from registration is available; and</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;day
of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 4%"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Signature of Witness</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Signature of registered holder or Signatory thereof</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If applicable, print Name and Office of Signatory</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Print Name of registered holder as on certificate</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Street Address</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">}</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties and (iii) the Transfer Form set forth in Schedule &#8220;B&#8221; to the
Warrant Certificate must be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;B&#8221;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;(include
name and address of the transferee) Warrants exercisable for common shares of ProMIS Neurosciences Inc. (the
 &#8220;Corporation&#8221;) registered in the name of the undersigned on the register of the Corporation maintained therefor, and
hereby irrevocably
appoints&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;
the attorney of the undersigned to transfer the said securities on the books maintained by the Corporation with full power of
substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;day
of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Transferor guaranteed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Medallion Signature
    Guarantee</FONT></TD><TD STYLE="width: 2%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature of Transferor</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Stamp of Transferor</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 463.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Address of Transferor</FONT></TD></TR>
  </TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned transferee hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(check one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">said transferee was not offered the Warrants in the United States and is not
    in the United States or a &#8220;U.S. Person&#8221; (as defined in Regulation S under the <I>United States Securities Act of 1933</I>,
    as amended (the &#8220;U.S. Securities Act&#8221;)), and is not acquiring the Warrants for the account or benefit of a person in
    the United States or a U.S. Person; or</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">enclosed herewith is an opinion of counsel (which the transferee understands must be satisfactory to the Corporation) to the effect that no violation of the U.S. Securities Act or applicable securities laws will result from transfer, exercise or deemed exercise of the Warrants.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">It is understood
that the Corporation may require additional evidence necessary to verify the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The signature to this transfer must correspond with the name written upon the face of this Warrant Certificate
in every particular without any changes whatsoever.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">If the Transfer Form indicates that common shares are to be issued to a person or persons other than the
registered holder of the Warrant Certificate, the signature on this Transfer Form must be guaranteed by a Canadian chartered bank, or
eligible guarantor institution with membership in an approved signature guarantee medallion program. The guarantor must affix a stamp
bearing the actual words &#8220;Signature Guaranteed&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>45
<FILENAME>filename45.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.27</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted
information is indicated by: [***]</I></B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE
OCTOBER 27, 2019.</B></P>

<P STYLE="margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON JUNE 26, 2024 AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate #2019-06-&laquo;Number&raquo; dated [Issue Date], 2019
(the &#8220;Issue Date&#8221;), representing &laquo;Warrants&raquo; Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
</B>(Incorporated under the laws of Canada)<B><BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[HOLDER NAME]<BR>
[ADDRESS]<BR>
<BR>
</B></FONT>(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMIS Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on June 26, 2019, at a price of CAD$0.35 per Common Share
until 5:00 pm (EST) on June 26, 2024 (the &#8220;Expiry Date&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer
as it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise
of the Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder
pursuant to said exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form,
and each such person shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares
are to be issued to a person other than the Holder, the Holder&#8217;s signature on the Subscription Form must be guaranteed by a
Canadian chartered bank, a Canadian trust company or a member firm of the TSX. The Issuer will cause the certificates representing
such Common Shares to be mailed to the Holder at the Holder&#8217;s address stated above or such other address(es) as may be
specified in the Subscription Form, within five business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of DRS (or Certificates)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable commercial
efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable from time to time
upon the exercise of the Warrants are listed and posted for trading on the TSX (or such other exchange on which the Common Shares may
be listed), provided that this clause shall not be construed as limiting or restricting the Issuer from completing a consolidation, amalgamation,
arrangement, takeover bid or merger that would result in the Common Shares ceasing to be listed and posted for trading on the TSX (or
such other exchange on which the Common Shares may be listed), so long as the holders of Common Shares receive securities of an entity
which is listed on a stock exchange in Canada, or cash, or the holders of the Common Shares have approved the transaction in accordance
with the requirements of applicable corporate and securities laws and the policies of the TSX (or such other exchange on which the Common
Shares may be listed). In addition, the Issuer shall make all requisite filings under applicable securities legislation necessary to remain
a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are transferable and the term &#8220;Warrantholder&#8221;
shall mean and include any successor, transferee or assignee of the current or any future Warrantholder. The term &#8220;Warrantholder&#8221;
shall mean and include any successor of the Warrantholder. The Warrants may be transferred by the Warrantholder completing and delivering
to the Issuer the transfer form attached hereto as Schedule&nbsp;&#8220;B&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legend Endorsed
on DRS (or Certificates)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE OCTOBER 27, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a
 &#8220;Capital Reorganization&#8221;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be
entitled to receive, at no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was
theretofore entitled to acquire upon such exercise, the aggregate number of shares, other securities or other property which such
Holder should have been entitled to receive as a result of such Capital Reorganization if, on the effective date or record date
thereof as the case may be, the Holder had been the registered holder of the number of Common Shares to which such Holder was
theretofore entitled to acquire upon exercise of the Warrants. If determined appropriate by the Issuer acting reasonably,
appropriate adjustments shall be made in the application of the provisions set forth herein with respect to the rights and interests
of the Holder relative to a Capital Reorganization, to the end that the provisions set forth herein shall correspond as nearly as
may be reasonably possible to the effect of the Capital Reorganization in relation to any shares, other securities or other property
thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of any
event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the Holder had
exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of the TSX (or such
other exchange on which the Common Shares may be listed). The adjustments provided for herein are cumulative and such adjustments shall
be made successively whenever an event referred to herein shall occur, subject to the limitations provided for herein. No adjustment shall
be made in the number or kind of Shares or other securities which may be acquired on the exercise of a Warrant unless it would result
in a change of at least one-tenth of a Share or other security. Any adjustment which may by reason of this paragraph not be required to
be made shall be carried forward and then taken into consideration in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for
herein or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other
securities in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To
the extent that the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be
exercised in respect of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a
whole number of Common Shares or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common
Share or other security, to be paid in cash for the fair market value for the securities so eliminated, always provided that the
Issuer shall not be required to make any payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%">By:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 46%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%"><B>&nbsp;</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Authorized Signatory</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise  ____________________________________of the Warrants evidenced thereby in accordance
with the terms thereof, and accordingly hereby irrevocably subscribes for the Shares (as described therein) to be received thereon and
irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The Undersigned hereby irrevocably directs that the Shares
to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, (I) THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U>, (II)
THE UNDERSIGNED MUST PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES AND (III) THE TRANSFER FORM SET FORTH IN SCHEDULE &#8220;B&#8221;
TO THE WARRANT CERTIFICATE MUST BE COMPLETED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States Securities Act of 1933, as amended (the &#8220;U.S. Securities Act&#8221;), or any applicable
State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule 902(k) of Regulation
S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities laws, unless an
exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the ______day of <U>_________________</U>, 20<U>_______</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P></TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Signature of Witness<BR>
<B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Signature of registered holder or Signatory thereof</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If applicable, print Name and Office of Signatory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Print Name of registered holder as on certificate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Street Address</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. DRS (or Certificates) representing the Shares to be
acquired on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all
required documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties and (iii) the Transfer Form set forth in Schedule &#8220;B&#8221; to the
Warrant Certificate must be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;B&#8221;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto
_________________________________________________________________________________________________________________________ (include name
and address of the transferee) Warrants exercisable for common shares of ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)
registered in the name of the undersigned on the register of the Corporation maintained therefor, and hereby irrevocably appoints
__________________________________ the attorney of the undersigned to transfer the said securities on the books maintained by the
Corporation with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
20___.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Transferor guaranteed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-top: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Medallion
Signature Guarantee</B></FONT></TD><TD STYLE="text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature
                                            of Transferor</B></FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stamp of Transferor</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
                                            of Transferor</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned transferee hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(check one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">said transferee was
not offered the Warrants in the United States and is not in the United States or a &#8220;U.S. Person&#8221; (as defined in Regulation
S under the <I>United States Securities Act of 1933</I>, as amended (the &#8220;U.S. Securities Act&#8221;)), and is not acquiring the
Warrants for the account or benefit of a person in the United States or a U.S. Person; or</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">enclosed herewith
is an opinion of counsel (which the transferee understands must be satisfactory to the Corporation) to the effect that no violation of
the U.S. Securities Act or applicable securities laws will result from transfer, exercise or deemed exercise of the Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">It is understood
that the Corporation may require additional evidence necessary to verify the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The signature to this transfer must correspond with the name written upon the face of this Warrant Certificate
in every particular without any changes whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">If the Transfer Form indicates that common shares are to be issued to a person or persons other than the
registered holder of the Warrant Certificate, the signature on this Transfer Form must be guaranteed by a Canadian chartered bank, or
eligible guarantor institution with membership in an approved signature guarantee medallion program. The guarantor must affix a stamp
bearing the actual words &#8220;Signature Guaranteed&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>46
<FILENAME>filename46.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.28</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6)
of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B>THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;U.S. SECURITIES ACT&#8221;) OR THE SECURITIES LAWS OF ANY STATE OF THE
UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER
THE U.S. SECURITIES ACT; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER,
IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION
UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE (C) OR (D), THE SELLER FURNISHES TO
THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY TO SUCH EFFECT.</B></P>

<P STYLE="margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MAY 23, 2019.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON JANUARY 22, 2024 (WHICH EXPIRY DATE IS SUBJECT TO ACCELERATION IN ACCORDANCE WITH THE TERMS ATTACHING TO THE
WARRANTS) AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate #2019-01-&laquo;Number&raquo; dated January 22, 2019
(the &#8220;Issue Date&#8221;),<BR>
representing &laquo;Warrants&raquo; Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
</B>(Incorporated under the laws of Canada)<B><BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[HOLDER NAME]<BR>
[ADDRESS]<BR>
<BR>
</B></FONT>(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMis Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on January 22, 2019, at a price of CAD$0.48 per Common
Share until 5:00 pm (EST) on January 22, 2024 (the &#8220;Expiry Date&#8221;). The Expiry Date may be accelerated by the Issuer at any
time following the four-month anniversary of the issue date of the Warrants and prior to the Expiry Date if the twenty-day volume-weighted
average trading price (&#8220;<B>20 day VWAP</B>&#8221;) of the Shares on the TSX, and/or such other exchange on which the Common Shares
may be listed, is greater than $1.00, or the Issuer enters into a partnering deal within 18 months of closing of the private placement
pursuant to which this Warrant was issued to the Holder with minimum proceeds of US$5 million and the 20 day VWAP is greater than $0.48
at any time following the announcement of such a partnering deal. The Issuer may accelerate the expiry date of the Warrants by issuing
a press release announcing the reduced warrant term whereupon the Warrants will expire on a day that is not less than 30 calendar day
after the date of such press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THESE WARRANTS MAY NOT BE EXERCISED BY OR ON
BEHALF OF A U.S. PERSON OR A PERSON IN THE UNITED STATES UNLESS THE COMMON SHARES ISSUABLE UPON EXERCISE OF THESE WARRANTS HAVE BEEN REGISTERED
UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS
ARE AVAILABLE. &#8220;UNITED STATES&#8221; AND &#8220;U.S. PERSON&#8221; ARE AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer as
it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise of the
Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder pursuant to said
exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such person
shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares are to be issued to a person
other than the Holder, the Holder&#8217;s signature on the Subscription Form must be guaranteed by a Canadian chartered bank, a Canadian
trust company or a member firm of the TSX. The Issuer will cause the certificates representing such Common Shares to be mailed to the
Holder at the Holder&#8217;s address stated above or such other address(es) as may be specified in the Subscription Form, within five
business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable
commercial efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable
from time to time upon the exercise of the Warrants are listed and posted for trading on the TSX <FONT STYLE="font-size: 10pt">(or
such other exchange on which the Common Shares may be listed), provided that this clause shall not be construed as limiting or
restricting the Issuer from completing a consolidation, amalgamation, arrangement, takeover bid or merger that would result in the
Common Shares ceasing to be listed and posted for trading on the TSX (or such other exchange on which the Common Shares may be
listed), so long as the holders of Common Shares receive securities of an entity which is listed on a stock exchange in Canada, or
cash, or the holders of the Common Shares have approved the transaction in accordance with the requirements of applicable corporate
and securities laws and the policies of the TSX (or such other exchange on which the Common Shares may be listed). In addition, the
Issuer shall make all requisite filings under applicable securities legislation necessary to remain a reporting issuer not in
default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are transferable and the term &#8220;Warrantholder&#8221;
shall mean and include any successor, transferee or assignee of the current or any future Warrantholder. The term &#8220;Warrantholder&#8221;
shall mean and include any successor of the Warrantholder. The Warrants may be transferred by the Warrantholder completing and delivering
to the Issuer the transfer form attached hereto as Schedule&nbsp;&#8220;B&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legending Of Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MAY 23, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate bears, all certificates
issued in exchange therefore or in substitution thereof, all certificates representing Shares issued in the United States, or to a U.S.
Person (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act (&#8220;Regulation S&#8221;)), and all certificates issued
in exchange therefore or in substitution thereof, will bear the following legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED HEREBY [<I>for
Warrants add</I>: AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF] HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE &#8220;U.S. SECURITIES ACT&#8221;) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF,
BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED
ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT; (C)
IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN
COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES
ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE (C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF
COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY TO SUCH EFFECT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">[<I>For Common Shares add</I>: AND THE
PRESENCE OF THIS LEGEND MAY IMPAIR THE ABILITY OF THE HOLDER HEREOF TO EFFECT &#8220;GOOD DELIVERY&#8221; OF THE SECURITIES REPRESENTED
HEREBY ON A CANADIAN STOCK EXCHANGE.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided</I>, that if the Securities are being
sold outside the United States in compliance with the requirements of Rule 904 of Regulation S and the Securities were acquired when the
Issuer qualified as a &#8220;foreign issuer&#8221; (as defined in Rule 902(e) of Regulation S), the legend set forth above may be removed
by providing providing a declaration to the Issuer and the Issuer&#8217;s transfer agent for the Common Shares in the form set forth either
in Schedule &#8220;B&#8221; hereto (or as the Issuer may prescribe from time to time);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided further</I>, that, if any of the Securities
are being sold pursuant to Rule 144 of the U.S. Securities Act, if available, the legend may be removed by delivering to the Issuer and
the Issuer&#8217;s transfer agent for the Common Shares an opinion of counsel of recognized standing in form and substance satisfactory
to the Issuer, to the effect that the legend is no longer required under applicable requirements of the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a &#8220;Capital
Reorganization&#8221;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be entitled to receive, at
no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was theretofore entitled to acquire upon
such exercise, the aggregate number of shares, other securities or other property which such Holder should have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be, the Holder had been the
registered holder of the number of Common Shares to which such Holder was theretofore entitled to acquire upon exercise of the Warrants.
If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the application of the provisions
set forth herein with respect to the rights and interests of the Holder relative to a Capital Reorganization, to the end that the provisions
set forth herein shall correspond as nearly as may be reasonably possible to the effect of the Capital Reorganization in relation to any
shares, other securities or other property thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of any
event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the Holder had
exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of the TSX (or such
other exchange on which the Common Shares may be listed). The adjustments provided for herein are cumulative and such adjustments shall
be made successively whenever an event referred to herein shall occur, subject to the limitations provided for herein. No adjustment shall
be made in the number or kind of Shares or other securities which may be acquired on the exercise of a Warrant unless it would result
in a change of at least one-tenth of a Share or other security. Any adjustment which may by reason of this paragraph not be required to
be made shall be carried forward and then taken into consideration in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for
herein or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other
securities in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To
the extent that the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be
exercised in respect of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a
whole number of Common Shares or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common
Share or other security, to be paid in cash for the fair market value for the securities so eliminated, always provided that the
Issuer shall not be required to make any payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMis Neurosciences Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Suite 200, 1920 Yonge Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Toronto, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 3%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;</TD>
                                                    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Authorized Signatory</TD>
                                        <TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;A&#8221;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMis Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(the &#8220;Issuer&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U>
of the Warrants evidenced thereby in accordance with the terms thereof, and accordingly hereby irrevocably subscribes for the Common
Shares (as described therein) to be received thereon and irrevocably surrenders the Warrant Certificate to the Issuer for such
purpose. The Undersigned hereby irrevocably directs that the Common Shares to be received by the Undersigned be registered as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, (I) THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U>, (II)
THE UNDERSIGNED MUST PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES AND (III) THE TRANSFER FORM SET FORTH IN SCHEDULE &#8220;C&#8221;
TO THE WARRANT CERTIFICATE MUST BE COMPLETED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States <I>Securities Act</I> of 1933, as amended (the &#8220;U.S. Securities Act&#8221;), or
any applicable State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule 902(k)
of Regulation S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities
laws, unless an exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">either (<B><U>one of the following must be checked</U></B>):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">the Undersigned at the time of the exercise of the Warrant(s) (i) is not a U.S. Person, (ii) is not resident
in the United States, (iii) is not exercising the Warrant(s) on behalf of, or for the account or benefit of a U.S. Person or a person
in the United States and (iv) did not receive an offer to exercise the Warrant(s) or execute or deliver this Subscription Form in the
United States, and has, in all other respects, complied with the terms of Regulation S or any successor rule or regulation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">the Undersigned (i) is a U.S. Person or is resident in the United States, (ii) is an &#8220;accredited
investor&#8221; as such term is defined in Rule 501(a) of Regulation D (&#8220;Accredited Investor&#8221;) under the U.S. Securities Act,
or all of its equity owners are Accredited Investors, and (iii) <B>has completed and delivered herewith the U.S. Accredited
Investor Status Certificate in the form attached to this Subscription Form as Exhibit 1; or</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- A<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">The Undersigned is resident in the United States or is a U.S. Person and has delivered to the Issuer and
the Issuer&#8217;s transfer agent an opinion of counsel (which will not be sufficient unless it is in form and substance satisfactory
to the Issuer) to the effect that with respect to the securities to be delivered upon exercise of the Warrant(s), the issuance of such
securities has been registered under the U.S. Securities Act and applicable state securities laws or an exemption from the registration
requirements of the U.S. Securities Act and applicable state securities laws is available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The undersigned holder understands that unless
the first box above is checked, the certificate representing the Common Shares will bear a legend in the form required by the Warrant
Certificate restricting transfer without registration under the U.S. Securities Act and applicable state securities laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certificates representing Shares will not be
registered or delivered to an address in the United States unless the second or third box above is checked.</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The Undersigned represents and warrants that (a) the subscription proceeds representing the aggregate
exercise price which will be advanced by the Undersigned to the Issuer will not represent proceeds of crime for the purposes of the Proceeds
of Crime (Money Laundering) Act (Canada) (the &#8220;PCML Act&#8221;) or the United States Uniting and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism Act (the &#8220;PATRIOT Act&#8221;), and the Undersigned acknowledges that
the Issuer may in the future be required by law to disclose the Undersigned&#8217;s name and other information relating to the exercise
of the Warrants and the Undersigned&#8217;s subscription for the underlying Common Shares, on a confidential basis, pursuant to the PCML
Act and/or the PATRIOT Act, and to the best of the Undersigned&#8217;s knowledge (i) none of the subscription funds to be provided by
the Undersigned (A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the
United States, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the
Undersigned, and (ii) it shall promptly notify the Issuer if the Undersigned discovers that any of such representations ceases to be true,
and to provide the Issuer with appropriate information in connection therewith;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">If the Undersigned has indicated that the undersigned is an Accredited Investor by marking the second
box in Item 3 above, the Undersigned represents and warrants to the Issuer that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Undersigned has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of an investment in the Common Shares subscribed for herein, and the Undersigned is able to bear the economic
risk of loss of his or her entire investment;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the Undersigned is: (i) purchasing the Common Shares for his or her own account or for the account of
one or more Accredited Investors with respect to which the Undersigned is exercising sole investment discretion, and not on behalf of
any other person; (ii) is purchasing the Common Shares for investment purposes only and not with a view to resale, distribution or other
disposition in violation of United States federal or state securities laws; and (iii) in the case of the purchase by the Undersigned of
the Common Shares as agent or trustee for any other person or persons (each a &#8220;Beneficial Owner&#8221;), the Undersigned has due
and proper authority to act as agent or trustee for and on behalf of each such Beneficial Owner in connection with the transactions contemplated
hereby; <U>provided that</U>: (y) if the Undersigned, or any Beneficial Owner, is a company or a partnership, syndicate, trust or other
form of unincorporated organization, the Undersigned or each such Beneficial Owner was not incorporated or created solely, nor is it being
used primarily to permit purchases without a prospectus or registration statement under applicable law; and (z) each Beneficial Owner,
if any, is an Accredited Investor; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- A<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the Undersigned has not exercised the Warrant(s) as a result of any form of general solicitation or general
advertising, including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media
or broadcast over radio, television or other form of telecommunications, or any seminar or meeting whose attendees have been invited by
general solicitation or general advertising.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">If the Undersigned has indicated that the Undersigned is an Accredited Investor by marking the second
box in Item 3 above, the Undersigned also acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Issuer has provided to the Undersigned the opportunity to ask questions and receive answers concerning
the terms and conditions of the offering, and the Undersigned has had access to such information concerning the Issuer as he or she has
considered necessary or appropriate in connection with his or her investment decision to acquire the Common Shares subscribed for herein;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">if the Undersigned decides to offer, sell or otherwise transfer any of the Common Shares subscribed for
herein, the undersigned must not, and will not, offer, sell or otherwise transfer any of such Shares directly or indirectly, unless (i)
to the Issuer, (ii) outside the United States in accordance with Rule 904 of Regulation S under the U.S. Securities Act and in compliance
with applicable local laws or regulations, or (iii) pursuant to an exemption from registration under the U.S. Securities Act and applicable
state securities laws after providing a legal opinion reasonably satisfactory to the Issuer;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the Common Shares subscribed for herein are &quot;restricted securities&quot; under applicable federal
securities laws and that the U.S. Securities Act and the rules of the United States Securities and Exchange Commission provide in substance
that the undersigned may dispose of the Common Shares only pursuant to an effective registration statement under the U.S. Securities Act
or an exemption therefrom;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">the Issuer has no obligation to register any of the Common Shares subscribed for herein or to take action
so as to permit sales pursuant to the U.S. Securities Act (including Rule 144 thereunder);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">the certificates representing the Common Shares subscribed for herein (and any certificates issued in
exchange or substitution for such Shares) will bear a legend, in the form required by the certificate representing the Warrants, stating
that such securities have not been registered under the U.S. Securities Act or the securities laws of any state of the United States and
may not be offered for sale or sold unless registered under the U.S. Securities Act and the securities laws of all applicable states of
the United States or an exemption from such registration requirements is available;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">the financial statements of the Issuer have been prepared in accordance with International Financial Reporting
Standards, which differ in some respects from United States generally accepted accounting principles, and thus may not be comparable to
financial statements of United States companies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">it consents to the Issuer making a notation on its records or giving instructions to any transfer agent
of the Issuer in order to implement the restrictions on transfer set forth and described in this Subscription Form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the ____ day of <U>_____________</U>,
20<U>____</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; width: 43%">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt; width: 52%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Witness</FONT></TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of registered holder or Signatory thereof</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If applicable, print Name and Office of Signatory</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name of registered holder as on certificate</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Street Address</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">}</FONT></TD>
    <TD STYLE="padding-left: 6pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- A<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties and (iii) the Transfer Form set forth in Schedule &#8220;C&#8221; to the
Warrant Certificate must be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- A<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. Accredited Investor Status Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the exercise of certain outstanding
warrants of ProMis Neurosciences Inc. (the &#8220;Company&#8221;) by the holder, the holder hereby represents and warrants to the Company
that the holder, and each beneficial owner (each, a &#8220;Beneficial Owner&#8221;), if any, on whose behalf the holder is exercising
such warrants, satisfies one or more of the following categories of Accredited Investor, as such term is defined in &sect; 501(a) of Regulation
D under the United States <I>Securities Act of 1933, </I>as amended (the &#8220;U.S. Securities Act&#8221;). <B>Please hand-write your
initials on the appropriate lines and write &#8220;W/H&#8221; for the holder that is the signatory to the Subscription Form to which this
Exhibit 1 is attached, and &#8220;BEN&#8221; for each beneficial owner, if any, on each line that applies.</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">1. Initials _______</FONT></TD>
    <TD STYLE="width: 75%; padding-top: 9pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any bank as defined in Section 3(a)(2) of the U.S. Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the U.S. Securities Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to Section 15 of the U.S. Securities Exchange Act of 1934; any insurance company as defined in Section 2(a)(13) of the U.S. Securities Act; any investment company registered under the U.S. Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the U.S. Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of US$5,000,000; any employee benefit plan within the meaning of the U.S. Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of US$5,000,000, or, if a self-directed plan, with investment decisions made solely by persons that are &#8220;accredited investors&#8221; (as such term is defined in Rule 501 of Regulation D of the U.S. Securities Act);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">2. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Any private business development company as defined in Section 202(a)(22) of the U.S. Investment Advisers Act of 1940;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">3. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any organization described in Section 501(c)(3) of the U.S. Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of US$5,000,000; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">4. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any trust with total assets in excess of US$5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person (being defined as a person who has such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the prospective investment);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">5. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">A natural person whose individual net worth, or joint net worth with that person&#8217;s spouse, at the time of purchase, exceeds US$1,000,000 (for the purposes of calculating net worth, (i) the person&#8217;s primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person&#8217;s primary residence, up to the estimated fair market value of the primary residence at the time of this certification, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of this certification exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person&#8217;s primary residence in excess of the estimated fair market value of the primary residence shall be included as a liability); </FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- A<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">6. Initials _______</FONT></TD>
    <TD STYLE="width: 75%; padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">A natural person who had annual gross income during each of the last two full calendar years in excess of US$200,000 (or together with his or her spouse in excess of US$300,000) and reasonably expects to have annual gross income in excess of US$200,000 (or together with his or her spouse in excess of US$300,000) during the current calendar year, and no reason to believe that his or her annual gross income will not remain in excess of US$200,000 (or that together with his or her spouse will not remain in excess of US$300,000) for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">7. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any director or executive officer of the Corporation; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 9pt; padding-left: 30.6pt"><FONT STYLE="font-size: 10pt">8. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any entity in which all of the equity owners meet the requirements of at least one of the above categories&#8211; if this category is selected you must identify each equity owner and provide statements from each demonstrating how they qualify as an Accredited Investor.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated _______________ 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt">&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of individual (if Subscriber <B>is </B>an individual)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized signatory (if Subscriber is <B>not</B> an individual)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subscriber (<B>please print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of authorized signatory (<B>please print</B>)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official capacity of authorized signatory (<B>please print</B>)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- A<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;B&#8221;<BR>
FORM OF DECLARATION FOR REMOVAL OF LEGEND &#8211;<BR>
RULE 904 UNDER THE U.S. SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in">To:&#9;</TD>
                                                                                   <TD STYLE="text-align: justify">ProMIS Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;)</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">To:</TD><TD STYLE="text-align: justify">Computershare Trust Company of Canada, as registrar and transfer agent for the common shares of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (A) acknowledges that the sale
of _________________ common shares of the Corporation to which this declaration relates, represented by certificate number _______________,
is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the &#8220;<B>U.S. Securities
Act</B>&#8221;), and (B) certifies that (1) the undersigned (a) is not an &#8220;affiliate&#8221; of the Corporation, as that term is
defined in Rule 405 under the U.S. Securities Act, or is an affiliate solely by virtue of being an officer or director of the Corporation,
(b) is not a &#8220;distributor&#8221; as defined in Regulation&nbsp;S, and (c) is not an affiliate of a distributor; (2) the offer of
such securities was not made to a person in the United States and either (a) at the time the buy order was originated, the buyer was outside
the United States, or the seller and any person acting on its behalf reasonably believed that the buyer was outside the United States,
or (b) the transaction was executed on or through the facilities of the Toronto Stock Exchange, the TSX Venture Exchange or any other
 &#8220;designated offshore securities market&#8221;, and neither the seller nor any person acting on its behalf knows that the transaction
has been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate of the seller nor any person acting on
their behalf has engaged or will engage in any directed selling efforts in the United States in connection with the offer and sale of
such securities; (4) the sale is bona fide and not for the purpose of &#8220;washing off&#8221; the resale restrictions imposed because
the securities are &#8220;restricted securities&#8221; (as that term is defined in Rule 144(a)(3) under the U. S. Securities Act); (5)
the seller does not intend to replace such securities with fungible unrestricted securities; and (6) the contemplated sale is not a transaction,
or part of a series of transactions, which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the
registration provisions of the U. S. Securities Act. Terms used herein have the meanings given to them by Regulation&nbsp;S under the
U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated __________________, 20______.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt">&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Signature of individual (if Seller <B>is </B>an individual)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Authorized signatory (if Seller is <B>not</B> an individual)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name of Seller (<B>please print</B>)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name of authorized signatory (<B>please print</B>)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Official capacity of authorized signatory (<B>please print</B>)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- B<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Affirmation by Seller&#8217;s Broker-Dealer<BR>
(Required for sales pursuant to Section (B)(2)(b) above)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have read the representation letter of ____________
(the &#8220;<B>Seller</B>&#8221;) dated _______________, pursuant to which the Seller has requested that we sell, for the Seller's account,
____________________ common shares of the Corporation represented by certificate number _________________ (the &#8220;<B>Shares</B>&#8221;).
We have executed sales of the Shares pursuant to Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the
 &#8220;<B>U.S. Securities Act</B>&#8221;), on behalf of the Seller. In that connection, we hereby represent to you as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">no offer to sell the Shares was made to a person in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the sale of the Shares was executed in, on or through the facilities of the Toronto Stock Exchange, the
TSX Venture Exchange or another &#8220;designated offshore securities market&#8221; (as defined in Regulation S under the U.S. Securities
Act), and, to the best of our knowledge, the sale was not pre-arranged with a buyer in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">no &#8220;directed selling efforts&#8221; were made in the United States by the undersigned, any affiliate
of the undersigned, or any person acting on behalf of the undersigned; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">we have done no more than execute the order or orders to sell the Shares as agent for the Seller and will
receive no more than the usual and customary broker&#8217;s commission that would be received by a person executing such transaction as
agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of these representations: &#8220;<B>affiliate</B>&#8221;
means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control
with, the undersigned; &#8220;<B>directed selling efforts</B>&#8221; means any activity undertaken for the purpose of, or that could reasonably
be expected to have the effect of, conditioning the market in the United States for the Shares (including, but not be limited to, the
solicitation of offers to purchase the Shares from persons in the United States); and &#8220;<B>United States</B>&#8221; means the United
States of America, its territories or possessions, any State of the United States, and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal counsel to the Corporation shall be entitled
to rely upon the representations, warranties and covenants contained in this letter to the same extent as if this letter had been addressed
to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated ___________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Name of Firm</TD><TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 46%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="text-align: center; width: 34%">&nbsp;- B<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="text-align: right; width: 33%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &#8220;C&#8221;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the undersigned hereby sells,
assigns and transfers unto&nbsp;<U>&nbsp;&nbsp;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;(include name and address of the transferee) Warrants exercisable
for common shares of ProMis Neurosciences Inc. (the &#8220;Issuer&#8221;) registered in the name of the undersigned on the register of
the Issuer maintained therefor, and hereby irrevocably appoints <U>&nbsp;&nbsp;&nbsp;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&#9; </U>the attorney of the undersigned to transfer the said
securities on the books maintained by the Issuer with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
20___.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Transferor guaranteed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 49%; text-align: left"><FONT STYLE="font-size: 10pt">Medallion Signature
    Guarantee</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-size: 10pt">Signature of Transferor</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Stamp of Transferor</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Address of Transferor</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned transferee hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(check one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left">&nbsp;<FONT STYLE="font-family: Wingdings; font-size: 13pt">&#168;</FONT></TD><TD STYLE="text-align: justify">said transferee was not offered the Warrants in the United States
and is not in the United States or a &#8220;U.S. Person&#8221; (as defined in Regulation S under the <I>United States Securities Act
of 1933</I>, as amended (the &#8220;U.S. Securities Act&#8221;)), and is not acquiring the Warrants for the account or benefit of a person
in the United States or a U.S. Person; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 13pt">&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">enclosed herewith is an opinion of counsel (which the transferee
understands must be satisfactory to the Issuer) to the effect that no violation of the U.S. Securities Act or applicable securities laws
will result from transfer, exercise or deemed exercise of the Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">It is understood
that the Issuer may require additional evidence necessary to verify the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The signature to this transfer must correspond with the name written upon the face of this Warrant Certificate
in every particular without any changes whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">If the Transfer Form indicates that common shares are to be issued to a person or persons other than the
registered holder of the Warrant Certificate, the signature on this Transfer Form must be guaranteed by a Canadian chartered bank, or
eligible guarantor institution with membership in an approved signature guarantee medallion program. The guarantor must affix a stamp
bearing the actual words &#8220;Signature Guaranteed&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>47
<FILENAME>filename47.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.29</B></P>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES
ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;U.S. SECURITIES
ACT&#8221;) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF, BY PURCHASING SUCH SECURITIES, AGREES FOR THE
BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED
STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT; (C) IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION
UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS;
OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND,
IN THE CASE OF CLAUSE (C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE
SATISFACTORY TO THE COMPANY TO SUCH EFFECT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [<FONT STYLE="font-size: 14pt">&#9679;</FONT>], 2021.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON [<FONT STYLE="font-size: 14pt">&#9679;</FONT>], 2025 AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER
FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate #2020-11-[<FONT STYLE="font-size: 14pt">&#9679;</FONT>]-US
dated [<FONT STYLE="font-size: 14pt">&#9679;</FONT>], 2020 (the &#8220;Issue Date&#8221;), representing [<FONT STYLE="font-size: 14pt">&#9679;</FONT>]
Warrants.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Incorporated under the
laws of Canada)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">THIS CERTIFIES that, for
value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[HOLDER NAME]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[ADDRESS]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(hereinafter referred to as the &#8220;Holder&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &#8220;Warrants&#8221;) of ProMIS Neurosciences Inc. (the &#8220;Issuer&#8221;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in; text-align: justify">Each Warrant entitles the Holder to purchase
one common share (each a &#8220;Common Share&#8221;) of the Issuer, as constituted on [<FONT STYLE="font-size: 14pt">&#9679;</FONT>],
2020, at a price of CAD$0.20 per Common Share until 5:00 pm (EST) on [<FONT STYLE="font-size: 14pt">&#9679;</FONT>], 2025 (the
 &#8220;Expiry Date&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time after the expiry of the four month
hold period applicable to the Warrants, the Issuer may accelerate the expiry of the Warrants if the twenty-day volume-weighted average
trading price of the Common Shares on the TSX, or such other exchange on which the Common Shares may be listed, is greater than $0.60
provided that (a) the Issuer gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated expiry date is
a date which is not less than 30 calendar days after the date of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &#8220;Securities&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THESE WARRANTS MAY NOT BE EXERCISED BY OR ON
BEHALF OF A U.S. PERSON OR A PERSON IN THE UNITED STATES UNLESS THE COMMON SHARES ISSUABLE UPON EXERCISE OF THESE WARRANTS HAVE BEEN REGISTERED
UNDER THE U.S. SECURITIES ACT AND THE APPLICABLE SECURITIES LEGISLATION OF ANY SUCH STATE OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS
ARE AVAILABLE. &#8220;UNITED STATES&#8221; AND &#8220;U.S. PERSON&#8221; ARE AS DEFINED BY REGULATION S UNDER THE U.S. SECURITIES ACT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &#8220;A&#8221; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer as
it may designate by notice in writing delivered to the Holder at the Holder&#8217;s address stated above. Upon the due exercise of the
Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder pursuant to said
exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form, and each such person
shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares are to be issued to a person
other than the Holder, the Holder&#8217;s signature on the Subscription Form must be guaranteed by a Canadian chartered bank, a Canadian
trust company or a member firm of the TSX. The Issuer will cause the certificates representing such Common Shares to be mailed to the
Holder at the Holder&#8217;s address stated above or such other address(es) as may be specified in the Subscription Form, within five
business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of DRS or Certificates</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable
commercial efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable
from time to time upon the exercise of the Warrants are listed and posted for trading on the TSX (or such other exchange on which
the Common Shares may be listed), provided that this clause shall not be construed as limiting or restricting the Issuer from
completing a consolidation, amalgamation, arrangement, takeover bid or merger that would result in the Common Shares ceasing to be
listed and posted for trading on the TSX (or such other exchange on which the Common Shares may be listed), so long as the holders
of Common Shares receive securities of an entity which is listed on a stock exchange in Canada, or cash, or the holders of the
Common Shares have approved the transaction in accordance with the requirements of applicable corporate and securities laws and the
policies of the TSX <FONT STYLE="font-size: 10pt">(or such other exchange on which the Common Shares may be listed). In addition,
the Issuer shall make all requisite filings under applicable securities legislation necessary to remain a reporting issuer not in
default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are transferable and the term &#8220;Warrantholder&#8221;
shall mean and include any successor, transferee or assignee of the current or any future Warrantholder. The term &#8220;Warrantholder&#8221;
shall mean and include any successor of the Warrantholder. The Warrants may be transferred by the Warrantholder completing and delivering
to the Issuer the transfer form attached hereto as Schedule&nbsp;&#8220;B&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legend Endorsed
on DRS Certificates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &#8220;Exemption&#8221;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months and one day after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [<FONT STYLE="font-size: 14pt">&#9679;</FONT>], 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&#8220;TSX&#8221;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &#8220;GOOD DELIVERY&#8221;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate bears, all certificates
issued in exchange therefore or in substitution thereof, all certificates representing Shares issued in the United States, or to a U.S.
Person (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act (&#8220;Regulation S&#8221;)), and all certificates issued
in exchange therefore or in substitution thereof, will bear the following legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED HEREBY [<I>for
Warrants add</I>: AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF] HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF
1933, AS AMENDED (THE &#8220;U.S. SECURITIES ACT&#8221;) OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE HOLDER HEREOF,
BY PURCHASING SUCH SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED
ONLY (A) TO THE COMPANY; (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT; (C)
IN ACCORDANCE WITH THE EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF AVAILABLE, AND IN
COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS; OR (D) IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES
ACT AND ANY APPLICABLE STATE SECURITIES LAWS, AND, IN THE CASE OF CLAUSE (C) OR (D), THE SELLER FURNISHES TO THE COMPANY AN OPINION OF
COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY TO SUCH EFFECT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">[<I>For Common Shares add</I>: AND THE
PRESENCE OF THIS LEGEND MAY IMPAIR THE ABILITY OF THE HOLDER HEREOF TO EFFECT &#8220;GOOD DELIVERY&#8221; OF THE SECURITIES REPRESENTED
HEREBY ON A CANADIAN STOCK EXCHANGE.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided</I>, that if the Securities are being
sold outside the United States in compliance with the requirements of Rule 904 of Regulation S and the Securities were acquired when the
Issuer qualified as a &#8220;foreign issuer&#8221; (as defined in Rule 902(e) of Regulation S), the legend set forth above may be removed
by providing providing a declaration to the Issuer and the Issuer&#8217;s transfer agent for the Common Shares in the form set forth either
in Schedule &#8220;B&#8221; hereto (or as the Issuer may prescribe from time to time);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>provided further</I>, that, if any of the Securities
are being sold pursuant to Rule 144 of the U.S. Securities Act, if available, the legend may be removed by delivering to the Issuer and
the Issuer&#8217;s transfer agent for the Common Shares an opinion of counsel of recognized standing in form and substance satisfactory
to the Issuer, to the effect that the legend is no longer required under applicable requirements of the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a &#8220;Capital
Reorganization&#8221;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be entitled to receive, at
no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was theretofore entitled to acquire upon
such exercise, the aggregate number of shares, other securities or other property which such Holder should have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof as the case may be, the Holder had been the
registered holder of the number of Common Shares to which such Holder was theretofore entitled to acquire upon exercise of the Warrants.
If determined appropriate by the Issuer acting reasonably, appropriate adjustments shall be made in the application of the provisions
set forth herein with respect to the rights and interests of the Holder relative to a Capital Reorganization, to the end that the provisions
set forth herein shall correspond as nearly as may be reasonably possible to the effect of the Capital Reorganization in relation to any
shares, other securities or other property thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&#8217; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&#8217; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&#8217;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of any
event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the Holder had
exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of the TSX (or such
other exchange on which the Common Shares may be listed). The adjustments provided for herein are cumulative and such adjustments shall
be made successively whenever an event referred to herein shall occur, subject to the limitations provided for herein. No adjustment shall
be made in the number or kind of Shares or other securities which may be acquired on the exercise of a Warrant unless it would result
in a change of at least one-tenth of a Share or other security. Any adjustment which may by reason of this paragraph not be required to
be made shall be carried forward and then taken into consideration in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for herein
or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other securities
in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To the extent that
the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be exercised in respect
of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a whole number of Common Shares
or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common Share or other security, to be paid
in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not be required to make any
payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROMIS
    NEUROSCIENCES INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black thin solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE &#8220;A&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SUBSCRIPTION FORM</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.5in">TO:</TD><TD STYLE="text-align: justify">ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">(the &#8220;Issuer&#8221;)</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="border-bottom: Black thin solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise _________________________________ of the
Warrants evidenced thereby in accordance with the terms thereof, and accordingly hereby irrevocably subscribes for the Common Shares
(as described therein) to be received thereon and irrevocably surrenders the Warrant Certificate to the Issuer for such purpose. The
Undersigned hereby irrevocably directs that the Common Shares to be received by the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; width: 31%; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 50%; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; width: 19%; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black thin solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, (I) THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U>, (II)
THE UNDERSIGNED MUST PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES AND (III) THE TRANSFER FORM SET FORTH IN SCHEDULE &#8220;C&#8221;
TO THE WARRANT CERTIFICATE MUST BE COMPLETED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &#8220;Securities&#8221;)
have not been registered under the United States <I>Securities Act</I> of 1933, as amended (the &#8220;U.S. Securities Act&#8221;), or
any applicable State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule 902(k)
of Regulation S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities
laws, unless an exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">either (<B><U>one of the following must be checked</U></B>):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">the Undersigned at the time of the exercise of the Warrant(s) (i) is not a U.S. Person, (ii) is not resident
in the United States, (iii) is not exercising the Warrant(s) on behalf of, or for the account or benefit of a U.S. Person or a person
in the United States and (iv) did not receive an offer to exercise the Warrant(s) or execute or deliver this Subscription Form in the
United States, and has, in all other respects, complied with the terms of Regulation S or any successor rule or regulation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">the
                                            Undersigned (i) is a U.S. Person or is resident in the United States, (ii) is an &#8220;accredited
                                            investor&#8221; as such term is defined in Rule 501(a) of Regulation D (&#8220;Accredited
                                            Investor&#8221;) under the U.S. Securities Act, or all of its equity owners are Accredited
                                            Investors, and (iii) <B>has completed and delivered herewith the U.S. Accredited Investor
                                            Status Certificate in the form attached to this Subscription Form as Exhibit 1; </B>or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">The Undersigned is resident in the United States or is a U.S. Person and has delivered to the Issuer and
the Issuer&#8217;s transfer agent an opinion of counsel (which will not be sufficient unless it is in form and substance satisfactory
to the Issuer) to the effect that with respect to the securities to be delivered upon exercise of the Warrant(s), the issuance of such
securities has been registered under the U.S. Securities Act and applicable state securities laws or an exemption from the registration
requirements of the U.S. Securities Act and applicable state securities laws is available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The undersigned holder understands that unless
the first box above is checked, the certificate representing the Common Shares will bear a legend in the form required by the Warrant
Certificate restricting transfer without registration under the U.S. Securities Act and applicable state securities laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certificates representing Shares will not be
registered or delivered to an address in the United States unless the second or third box above is checked.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">4.</TD><TD STYLE="text-align: justify">The Undersigned represents and warrants that (a) the subscription proceeds representing the aggregate
exercise price which will be advanced by the Undersigned to the Issuer will not represent proceeds of crime for the purposes of the Proceeds
of Crime (Money Laundering) Act (Canada) (the &#8220;PCML Act&#8221;) or the United States Uniting and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism Act (the &#8220;PATRIOT Act&#8221;), and the Undersigned acknowledges that
the Issuer may in the future be required by law to disclose the Undersigned&#8217;s name and other information relating to the exercise
of the Warrants and the Undersigned&#8217;s subscription for the underlying Common Shares, on a confidential basis, pursuant to the PCML
Act and/or the PATRIOT Act, and to the best of the Undersigned&#8217;s knowledge (i) none of the subscription funds to be provided by
the Undersigned (A) have been or will be derived from or related to any activity that is deemed criminal under the law of Canada, the
United States, or any other jurisdiction, or (B) are being tendered on behalf of a person or entity who has not been identified to the
Undersigned, and (ii) it shall promptly notify the Issuer if the Undersigned discovers that any of such representations ceases to be true,
and to provide the Issuer with appropriate information in connection therewith;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">5.</TD><TD STYLE="text-align: justify">If the Undersigned has indicated that the undersigned is an Accredited Investor by marking the second
box in Item 3 above, the Undersigned represents and warrants to the Issuer that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Undersigned has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of an investment in the Common Shares subscribed for herein, and the Undersigned is able to bear the economic
risk of loss of his or her entire investment;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the Undersigned is: (i) purchasing the Common Shares for his or her own account or for the account of
one or more Accredited Investors with respect to which the Undersigned is exercising sole investment discretion, and not on behalf of
any other person; (ii) is purchasing the Common Shares for investment purposes only and not with a view to resale, distribution or other
disposition in violation of United States federal or state securities laws; and (iii) in the case of the purchase by the Undersigned of
the Common Shares as agent or trustee for any other person or persons (each a &#8220;Beneficial Owner&#8221;), the Undersigned has due
and proper authority to act as agent or trustee for and on behalf of each such Beneficial Owner in connection with the transactions contemplated
hereby; <U>provided that</U>: (y) if the Undersigned, or any Beneficial Owner, is a company or a partnership, syndicate, trust or other
form of unincorporated organization, the Undersigned or each such Beneficial Owner was not incorporated or created solely, nor is it being
used primarily to permit purchases without a prospectus or registration statement under applicable law; and (z) each Beneficial Owner,
if any, is an Accredited Investor; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the Undersigned has not exercised the Warrant(s) as a result of any form of general solicitation or general
advertising, including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media
or broadcast over radio, television or other form of telecommunications, or any seminar
or meeting whose attendees have been invited by general solicitation or general advertising.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">6.</TD><TD STYLE="text-align: justify">If the Undersigned has indicated that the Undersigned is an Accredited Investor by marking the second
box in Item 3 above, the Undersigned also acknowledges and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(a)</TD><TD STYLE="text-align: justify">the Issuer has provided to the Undersigned the opportunity to ask questions and receive answers concerning
the terms and conditions of the offering, and the Undersigned has had access to such information concerning the Issuer as he or she has
considered necessary or appropriate in connection with his or her investment decision to acquire the Common Shares subscribed for herein;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(b)</TD><TD STYLE="text-align: justify">if the Undersigned decides to offer, sell or otherwise transfer any of the Common Shares subscribed for
herein, the undersigned must not, and will not, offer, sell or otherwise transfer any of such Shares directly or indirectly, unless (i)
to the Issuer, (ii) outside the United States in accordance with Rule 904 of Regulation S under the U.S. Securities Act and in compliance
with applicable local laws or regulations, or (iii) pursuant to an exemption from registration under the U.S. Securities Act and applicable
state securities laws after providing a legal opinion reasonably satisfactory to the Issuer;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(c)</TD><TD STYLE="text-align: justify">the Common Shares subscribed for herein are &quot;restricted securities&quot; under applicable federal
securities laws and that the U.S. Securities Act and the rules of the United States Securities and Exchange Commission provide in substance
that the undersigned may dispose of the Common Shares only pursuant to an effective registration statement under the U.S. Securities Act
or an exemption therefrom;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(d)</TD><TD STYLE="text-align: justify">the Issuer has no obligation to register any of the Common Shares subscribed for herein or to take action
so as to permit sales pursuant to the U.S. Securities Act (including Rule 144 thereunder);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(e)</TD><TD STYLE="text-align: justify">the certificates representing the Common Shares subscribed for herein (and any certificates issued in
exchange or substitution for such Shares) will bear a legend, in the form required by the certificate representing the Warrants, stating
that such securities have not been registered under the U.S. Securities Act or the securities laws of any state of the United States and
may not be offered for sale or sold unless registered under the U.S. Securities Act and the securities laws of all applicable states of
the United States or an exemption from such registration requirements is available;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(f)</TD><TD STYLE="text-align: justify">the financial statements of the Issuer have been prepared in accordance with International Financial Reporting
Standards, which differ in some respects from United States generally accepted accounting principles, and thus may not be comparable to
financial statements of United States companies; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in">(g)</TD><TD STYLE="text-align: justify">it consents to the Issuer making a notation on its records or giving instructions to any transfer agent
of the Issuer in order to implement the restrictions on transfer set forth and described in this Subscription Form.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="text-align: justify; width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">}<BR>
}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="text-align: justify; width: 51%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Signature of Witness</FONT></P>
                                                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>[Please
Note Instruction 2]</B></FONT></P></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of registered holder or Signatory thereof</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If applicable, print Name and Office of Signatory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Print Name of registered holder as on certificate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Street Address</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-size: 10pt">A<FONT STYLE="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. Certificates representing the Shares to be acquired
on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all required
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties and (iii) the Transfer Form set forth in Schedule &#8220;C&#8221; to the
Warrant Certificate must be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>U.S. Accredited Investor Status Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the exercise of certain outstanding
warrants of ProMis Neurosciences Inc. (the &#8220;Company&#8221;) by the holder, the holder hereby represents and warrants to the Company
that the holder, and each beneficial owner (each, a &#8220;Beneficial Owner&#8221;), if any, on whose behalf the holder is exercising
such warrants, satisfies one or more of the following categories of Accredited Investor, as such term is defined in &sect; 501(a) of Regulation
D under the United States <I>Securities Act of 1933, </I>as amended (the &#8220;U.S. Securities Act&#8221;). <B>Please hand-write your
initials on the appropriate lines and write &#8220;W/H&#8221; for the holder that is the signatory to the Subscription Form to which this
Exhibit 1 is attached, and &#8220;BEN&#8221; for each beneficial owner, if any, on each line that applies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; width: 25%; padding-top: 9pt"><FONT STYLE="font-size: 10pt">1. Initials _______</FONT></TD>
    <TD STYLE="width: 75%; padding-top: 9pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any bank as defined in Section 3(a)(2) of the U.S. Securities Act, or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the U.S. Securities Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to Section 15 of the U.S. Securities Exchange Act of 1934; any insurance company as defined in Section 2(a)(13) of the U.S. Securities Act; any investment company registered under the U.S. Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the U.S. Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of US$5,000,000; any employee benefit plan within the meaning of the U.S. Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of US$5,000,000, or, if a self-directed plan, with investment decisions made solely by persons that are &#8220;accredited investors&#8221; (as such term is defined in Rule 501 of Regulation D of the U.S. Securities Act);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; padding-top: 9pt"><FONT STYLE="font-size: 10pt">2. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">Any private business development company as defined in Section 202(a)(22) of the U.S. Investment Advisers Act of 1940;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; padding-top: 9pt"><FONT STYLE="font-size: 10pt">3. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any organization described in Section 501(c)(3) of the U.S. Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of US$5,000,000; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; padding-top: 9pt"><FONT STYLE="font-size: 10pt">4. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any trust with total assets in excess of US$5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person (being defined as a person who has such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the prospective investment);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; padding-top: 9pt"><FONT STYLE="font-size: 10pt">5. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">A natural person whose individual net worth, or joint net worth with that person&#8217;s spouse, at the time of purchase, exceeds US$1,000,000 (for the purposes of calculating net worth, (i) the person&#8217;s primary residence shall not be included as an asset; (ii) indebtedness that is secured by the person&#8217;s primary residence, up to the estimated fair market value of the primary residence at the time of this certification, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of this certification exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be included as a liability); and (iii) indebtedness that is secured by the person&#8217;s primary residence in excess of the estimated fair market value of the primary residence shall be included as a liability); </FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; width: 25%; padding-top: 9pt"><FONT STYLE="font-size: 10pt">6. Initials _______</FONT></TD>
    <TD STYLE="width: 75%; padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">A natural person who had annual gross income during each of the last two full calendar years in excess of US$200,000 (or together with his or her spouse in excess of US$300,000) and reasonably expects to have annual gross income in excess of US$200,000 (or together with his or her spouse in excess of US$300,000) during the current calendar year, and no reason to believe that his or her annual gross income will not remain in excess of US$200,000 (or that together with his or her spouse will not remain in excess of US$300,000) for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; padding-top: 9pt"><FONT STYLE="font-size: 10pt">7. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any director or executive officer of the Corporation; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.3in; text-align: right; padding-top: 9pt"><FONT STYLE="font-size: 10pt">8. Initials _______</FONT></TD>
    <TD STYLE="padding-top: 9pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any entity in which all of the equity owners meet the requirements of at least one of the above categories&#8211; if this category is selected you must identify each equity owner and provide statements from each demonstrating how they qualify as an Accredited Investor.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated _______________ 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>X </B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
    Signature of individual (if Subscriber <B>is </B>an individual)<BR>
    <BR>
    <B>X </B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    </U>Authorized signatory (if Subscriber is <B>not</B> an individual)<BR>
    <BR>
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
    Name of Subscriber (<B>please print</B>)<BR>
    <BR>
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    </U>Name of authorized signatory (<B>please print</B>)<BR>
    <BR>
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    </U>Official capacity of authorized signatory (<B>please print</B>)</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE &#8220;B&#8221;<BR>
FORM OF DECLARATION FOR REMOVAL OF LEGEND &#8211;<BR>
RULE 904 UNDER THE U.S. SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ProMIS Neurosciences Inc. (the &#8220;<B>Corporation</B>&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">To:</TD><TD STYLE="text-align: justify">Computershare Trust Company of Canada, as registrar and transfer agent for the common shares of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (A) acknowledges that the sale
of _________________ common shares of the Corporation to which this declaration relates, represented by certificate number _______________,
is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the &#8220;<B>U.S. Securities
Act</B>&#8221;), and (B) certifies that (1) the undersigned (a) is not an &#8220;affiliate&#8221; of the Corporation, as that term is
defined in Rule 405 under the U.S. Securities Act, or is an affiliate solely by virtue of being an officer or director of the Corporation,
(b) is not a &#8220;distributor&#8221; as defined in Regulation&nbsp;S, and (c) is not an affiliate of a distributor; (2) the offer of
such securities was not made to a person in the United States and either (a) at the time the buy order was originated, the buyer was outside
the United States, or the seller and any person acting on its behalf reasonably believed that the buyer was outside the United States,
or (b) the transaction was executed on or through the facilities of the Toronto Stock Exchange, the TSX Venture Exchange or any other
 &#8220;designated offshore securities market&#8221;, and neither the seller nor any person acting on its behalf knows that the transaction
has been prearranged with a buyer in the United States; (3) neither the seller nor any affiliate of the seller nor any person acting on
their behalf has engaged or will engage in any directed selling efforts in the United States in connection with the offer and sale of
such securities; (4) the sale is bona fide and not for the purpose of &#8220;washing off&#8221; the resale restrictions imposed because
the securities are &#8220;restricted securities&#8221; (as that term is defined in Rule 144(a)(3) under the U. S. Securities Act); (5)
the seller does not intend to replace such securities with fungible unrestricted securities; and (6) the contemplated sale is not a transaction,
or part of a series of transactions, which, although in technical compliance with Regulation S, is part of a plan or scheme to evade the
registration provisions of the U. S. Securities Act. Terms used herein have the meanings given to them by Regulation&nbsp;S under the
U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated __________________, 20______.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt"><B>X<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B><BR>
    Signature of individual (if Seller <B>is </B>an individual)<BR>
    <B><BR>
    X<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B><U><BR>
    </U>Authorized signatory (if Seller is <B>not</B> an individual)<BR>
    <BR>
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
    Name of Seller (<B>please print</B>)<BR>
    <BR>
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    </U>Name of authorized signatory (<B>please print</B>)<BR>
    <BR>
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
    </U>Official capacity of authorized signatory (<B>please print</B>)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <FONT STYLE="font-size: 10pt">B<FONT STYLE="font-family: Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></FONT> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Affirmation by Seller&#8217;s Broker-Dealer<BR>
(Required for sales pursuant to Section (B)(2)(b) above)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have read the representation letter of ____________
(the &#8220;<B>Seller</B>&#8221;) dated _______________, pursuant to which the Seller has requested that we sell, for the Seller's account,
____________________ common shares of the Corporation represented by certificate number _________________ (the &#8220;<B>Shares</B>&#8221;).
We have executed sales of the Shares pursuant to Rule 904 of Regulation S under the United States Securities Act of 1933, as amended (the
 &#8220;<B>U.S. Securities Act</B>&#8221;), on behalf of the Seller. In that connection, we hereby represent to you as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">(1)</TD><TD STYLE="text-align: justify">no offer to sell the Shares was made to a person in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the sale of the Shares was executed in, on or through the facilities of the Toronto Stock Exchange or
the TSX Venture Exchange signated and, to the best of our knowledge, the sale was not pre-arranged with a buyer in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">(3)</TD><TD STYLE="text-align: justify">no &#8220;directed selling efforts&#8221; were made in the United States by the undersigned, any affiliate
of the undersigned, or any person acting on behalf of the undersigned; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">(4)</TD><TD STYLE="text-align: justify">we have done no more than execute the order or orders to sell the Shares as agent for the Seller and will
receive no more than the usual and customary broker&#8217;s commission that would be received by a person executing such transaction as
agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of these representations: &#8220;<B>affiliate</B>&#8221;
means a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control
with, the undersigned; &#8220;<B>directed selling efforts</B>&#8221; means any activity undertaken for the purpose of, or that could reasonably
be expected to have the effect of, conditioning the market in the United States for the Shares (including, but not be limited to, the
solicitation of offers to purchase the Shares from persons in the United States); and &#8220;<B>United States</B>&#8221; means the United
States of America, its territories or possessions, any State of the United States, and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal counsel to the Corporation shall be entitled
to rely upon the representations, warranties and covenants contained in this letter to the same extent as if this letter had been addressed
to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated ___________________.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black thin solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Firm</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black thin solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black thin solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE &#8220;C&#8221;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(include name and address of the transferee) Warrants exercisable for common shares of ProMIS Neurosciences Inc. (the
 &#8220;Issuer&#8221;) registered in the name of the undersigned on the register of the Issuer maintained therefor, and hereby
irrevocably appoints <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>the attorney of the undersigned to transfer the said securities on the books maintained by the
Issuer with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
20___.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Transferor guaranteed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black thin solid; width: 48%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black thin solid; width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><B>Medallion Signature Guarantee</B></TD>
  <TD>&nbsp;</TD>
  <TD><B>Signature of Transferor</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><B>Stamp of Transferor</B></TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD><B>Address of Transferor</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned transferee hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(check one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify; width: 95%">said transferee was not offered the Warrants in the United States and is not in the
                                                   United States or a &#8220;U.S. Person&#8221; (as defined in Regulation S under the <I>United States Securities Act of 1933</I>, as
                                                   amended (the &#8220;U.S. Securities Act&#8221;)), and is not acquiring the Warrants for the account or benefit of a person in the
                                                   United States or a U.S. Person; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify; width: 95%">enclosed herewith is an opinion of counsel (which the transferee understands must be
                                                   satisfactory to the Issuer) to the effect that no violation of the U.S. Securities Act or applicable securities laws will result
                                                   from transfer, exercise or deemed exercise of the Warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">It is understood
that the Issuer may require additional evidence necessary to verify the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify">The signature to this transfer must correspond with the name written upon the face of this Warrant Certificate
in every particular without any changes whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify">If the Transfer Form indicates that common shares are to be issued to a person or persons other than the
registered holder of the Warrant Certificate, the signature on this Transfer Form must be guaranteed by a Canadian chartered bank, or
eligible guarantor institution with membership in an approved signature guarantee medallion program. The guarantor must affix a stamp
bearing the actual words &#8220;Signature Guaranteed&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="text-align: justify; margin: 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>48
<FILENAME>filename48.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.30</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Unless permitted under securities legislation,
the holder of this security must not trade the security before March 5, 2021.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;The securities represented by this
certificate are listed on the Toronto Stock Exchange "TSX"; however, the said securities cannot be traded through the facilities of TSX
since they are not freely transferable, and consequently any certificate representing such securities is not "good delivery" in settlement
of transactions on TSX.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SPECIAL WARRANT CERTIFICATE<BR>
<FONT STYLE="font-variant: small-caps">PROMIS NEUROSCIENCES INC</FONT>.<BR>
(a corporation existing under the laws of Canada)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 60%">Certificate Number: SW <FONT STYLE="font-family: Wingdings">&#117;</FONT></TD>
  <TD STYLE="text-align: left; width: 40%">Number: <FONT STYLE="font-family: Wingdings">&#117;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Issue Date: November 4, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS IS TO
CERTIFY</B> that, for value received, <FONT STYLE="font-family: Wingdings">&#117;</FONT> (the &ldquo;<B>Holder</B>&rdquo;) is the
registered holder of the number of special warrants (the &ldquo;<B>Special Warrants</B>&rdquo;) of <FONT STYLE="font-variant: small-caps">Promis
Neurosciences Inc</FONT>. (the &ldquo;<B>Corporation</B>&rdquo;) stated above and for each Special Warrant held is entitled to
acquire in the manner and at the time, and subject to the terms and restrictions contained in the Special Warrant Terms (attached
hereto as Schedule A), all without payment of any consideration, one common share of the Corporation (a &ldquo;<B>Share</B>&rdquo;)
and one transferable share purchase warrant (a &ldquo;<B>Warrant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Special Warrants represented
by this Special Warrant Certificate will be deemed to be automatically exercised at 1:00 p.m. PT (the &ldquo;<B>Deemed Exercise Time</B>&rdquo;)
on the earlier of the date (the &ldquo;<B>Conversion Date</B>&rdquo;) that is (i) the third business day after a receipt for a final prospectus
(the &ldquo;<B>Prospectus</B>&rdquo;) qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special
Warrants and (ii) 4 months and one day after the issue date of the Special Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special Warrants will be deemed
to have been exercised, delivered and surrendered by the holder thereof immediately prior to the Deemed Exercise Time without any further
action on the part of the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Special Warrant Certificate
(which includes the &ldquo;Special Warrants Terms of <FONT STYLE="font-variant: small-caps">Promis Neurosciences Inc</FONT>.&rdquo; attached
hereto) shall be construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall be entitled
to rely on delivery of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including,
without limitation by facsimile or email delivery) shall be legally effective between the Holder and the Corporation in accordance with
the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>
the Corporation has caused this Special Warrant Certificate to be executed by its duly authorized officer as of the Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>PROMIS
NEUROSCIENCES INC</B></FONT><B>.<FONT STYLE="text-transform: uppercase">&nbsp;</FONT></B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 4%">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 46%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Authorized Signatory</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIAL WARRANTS TERMS<BR>
OF<BR>
<FONT STYLE="font-variant: small-caps">PROMIS NEUROSCIENCES INC.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Holder acknowledges and agrees that each Special Warrant will automatically convert into one Share and one Warrant on the Conversion
Date and no Special Warrants may be exercised by the holder thereof prior to the Conversion Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Each Warrant will entitle the holder to purchase one Share at any time for a period of sixty months, subject to acceleration (as
noted below), at a price of $0.20 per share. At any time after the expiry of the four month hold period applicable to the Warrants, the
Corporation may accelerate the expiry of the Warrants if the twenty-day volume-weighted average trading price of the Shares on the TSX
(the &ldquo;<B>Exchange</B>&rdquo;), or such other exchange on which the Shares may be listed, is greater than $0.60 (the &ldquo;<B>Trigger
Event</B>&rdquo;) provided that (a) the Corporation gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated
expiry date is a date which is not less than 30 calendar days after the date of such notice. For greater certainty, the twenty-day volume-weighted
average trading price of the Common Shares on the Exchange shall be calculated by dividing the total value by the total volume of Common
Shares traded on the Exchange for the twenty trading days immediately preceding the date of the Trigger Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the deemed exercise of any of the Special Warrants represented by this Special Warrant Certificate, the Holder shall no longer have any
rights this Special Warrant Certificate with respect to such Special Warrants, other than the right to receive certificates issuable
on the exercise of those Special Warrants, and those Special Warrants shall be void and of no further value or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Special Warrants, the Shares and Warrants issuable upon the exercise of the Special Warrants, and any shares issuable upon
the exercise of the Warrants, have not been and will not be registered under the United States Securities Act of 1933, as amended (the
 &ldquo;<B>U.S. Securities Act</B>&rdquo;), or under the securities laws of any state of the United States. The Special Warrants may not
be exercised in the United States or by, or for the account or benefit of, any U.S. person or any person in the United States unless the
Special Warrants, and the Shares and Warrants issuable upon exercise hereof, have been registered under the U.S. Securities Act and any
applicable state securities laws or unless an exemption from such registration is available. &ldquo;United States&rdquo; and &ldquo;U.S.
person&rdquo; are as defined in Rule 902 of Regulation S under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The holding of the Special Warrants evidenced by this Special Warrant Certificate does not constitute the Holder a shareholder
of the Corporation or entitle such holder to any right or interest in respect thereof except as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
any case where there is a capital reorganization (such as a share sub-division or consolidation or a transaction with an equivalent
effect) or similar event (such as a merger) affecting the capital structure of the Corporation, the Corporation shall give notice to
the Holder of the particulars of the event and, if determinable, the adjustment to the conversion terms of the Special Warrant to
account for the event, such adjustment being subject to the approval of the Exchange. As a condition precedent to the taking of any
action which would require an adjustment in any of the rights under the Special Warrant, the Corporation will provide the right to
the Holder to convert the Special Warrants into the Shares and Warrants prior to the occurrence of the event. The Corporation shall
use its best efforts to take any action which, in the opinion of the Corporation&rsquo;s counsel, may be necessary in order that the
Corporation, or any successor to the Corporation or successor to the undertaking or assets of the Corporation will be obligated to
and may validly and legally issue all the Shares and Warrants or other securities of the Corporation, as applicable, pursuant to
this Special Warrant Certificate to which the Holder would be entitled to receive thereafter and to exercise the Special Warrants in
accordance with the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Special Warrants are not transferable without the prior written consent of the Corporation, and provided that, where such consent
is obtained, such transfer is made in accordance with applicable securities laws and the Holder gives a 72 hour prior notice to the Corporation
of such transfer by delivering a form of transfer in the form attached hereto as Schedule &ldquo;B&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time
shall be of the essence hereof.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;B&rdquo;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">TO:</TD><TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps"><B>PROMIS NEUROSCIENCES INC</B></FONT><B>. </B>(the &ldquo;<B>Corporation</B>&rdquo;)<BR>
<BR>
</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">RE:</TD><TD STYLE="text-align: justify">Special Warrants of the Corporation held by the undersigned holder (the &ldquo;<B>Holder</B>&rdquo;) pursuant
to a certificate (the &ldquo;<B>Special Warrant Certificate</B>&rdquo;) dated ______________________________ and bearing the certificate
number ___________________</TD></TR></TABLE>

<P STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms used but not defined herein
shall have the meanings given to them in the Special Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the Holder hereby sells,
assigns and transfers unto <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Name)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U> (the &ldquo;Transferee&rdquo;) of &nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Address)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>Special Warrants of the Corporation registered in the name of the undersigned on the register of the Corporation maintained therefor,
and hereby irrevocably appoints the Corporation to be the attorney of the undersigned to transfer the said securities on the books maintained
by the Corporation with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Holder hereby represents, warrants and certifies
that the transfer of the Special Warrants was not made in the United States, or to or for the account or benefit of a U.S. Person or a
person in the United States, and the contemplated transfer is not a transaction, or part of a series of transactions which, although in
technical compliance with Regulation S, is part of a plan or a scheme to evade the registration provisions of the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Holder guaranteed by:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X
    </B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    (if Holder is an individual)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medallion
    Signature Guarantee</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stamp</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized
    signatory (if Holder is not an individual)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Holder (please print)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of authorized signatory (please print)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official
    capacity of authorized signatory (please print)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>49
<FILENAME>filename49.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Unless permitted under securities legislation,
the holder of this security must not trade the security before March 5, 2021.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;The securities represented by this
certificate are listed on the Toronto Stock Exchange "TSX"; however, the said securities cannot be traded through the facilities of TSX
since they are not freely transferable, and consequently any certificate representing such securities is not "good delivery" in settlement
of transactions on TSX.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>"THE
SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;U.S. SECURITIES ACT&rdquo;), OR UNDER ANY STATE SECURITIES LAWS, AND SUCH SECURITIES
MAY BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN
ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS,
(C) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT PROVIDED BY RULE 144, IF AVAILABLE, AND IN COMPLIANCE WITH
APPLICABLE U.S. STATE SECURITIES LAWS, (D) IN COMPLIANCE WITH ANOTHER EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT AND APPLICABLE
STATE SECURITIES LAWS, OR (E) UNDER AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT; PROVIDED THAT IN THE CASE OF TRANSFERS
PURSUANT TO (C) OR (D) ABOVE, A LEGAL OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM AND SUBSTANCE SATISFACTORY TO THE CORPORATION
MUST FIRST BE PROVIDED TO THE CORPORATION TO THE EFFECT THAT SUCH TRANSFER IS EXEMPT FROM REGISTRATION UNDER THE U.S. SECURITIES ACT
AND APPLICABLE STATE SECURITIES LAWS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SPECIAL WARRANT CERTIFICATE<BR>
<FONT STYLE="font-variant: small-caps">PROMIS NEUROSCIENCES INC</FONT>.<BR>
(a corporation existing under the laws of Canada)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 60%">Certificate Number: SW <FONT STYLE="font-family: Wingdings">&#117;</FONT></TD>
  <TD STYLE="text-align: left; width: 40%">Number: <FONT STYLE="font-family: Wingdings">&#117;</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Issue Date: November 4, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS IS TO
CERTIFY</B> that, for value received, <FONT STYLE="font-family: Wingdings">&#117; </FONT>(the &ldquo;<B>Holder</B>&rdquo;) is the
registered holder of the number of special warrants (the &ldquo;<B>Special Warrants</B>&rdquo;) of <FONT STYLE="font-variant: small-caps">Promis
Neurosciences Inc</FONT>. (the &ldquo;<B>Corporation</B>&rdquo;) stated above and for each Special Warrant held is entitled to
acquire in the manner and at the time, and subject to the terms and restrictions contained in the Special Warrant Terms (attached
hereto as Schedule A), all without payment of any consideration, one common share of the Corporation (a &ldquo;<B>Share</B>&rdquo;)
and one transferable share purchase warrant (a &ldquo;<B>Warrant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Special Warrants represented
by this Special Warrant Certificate will be deemed to be automatically exercised at 1:00 p.m. PT (the &ldquo;<B>Deemed Exercise Time</B>&rdquo;)
on the earlier of the date (the &ldquo;<B>Conversion Date</B>&rdquo;) that is (i) the third business day after a receipt for a final prospectus
(the &ldquo;<B>Prospectus</B>&rdquo;) qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special
Warrants and (ii) 4 months and one day after the issue date of the Special Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special Warrants will be deemed
to have been exercised, delivered and surrendered by the holder thereof immediately prior to the Deemed Exercise Time without any further
action on the part of the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Special Warrant Certificate
(which includes the &ldquo;Special Warrants Terms of <FONT STYLE="font-variant: small-caps">Promis Neurosciences Inc</FONT>.&rdquo; attached
hereto) shall be construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall be entitled
to rely on delivery of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including,
without limitation by facsimile or email delivery) shall be legally effective between the Holder and the Corporation in accordance with
the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>
the Corporation has caused this Special Warrant Certificate to be executed by its duly authorized officer as of the Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>PROMIS
 &nbsp;NEUROSCIENCES INC</B></FONT><B>.<FONT STYLE="text-transform: uppercase">&nbsp;</FONT></B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 4%">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 46%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Authorized Signatory</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPECIAL WARRANTS TERMS<BR>
OF<BR>
<FONT STYLE="font-variant: small-caps">PROMIS NEUROSCIENCES INC.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder acknowledges and agrees that each Special Warrant will automatically convert into one Share and one Warrant on the Conversion
Date and no Special Warrants may be exercised by the holder thereof prior to the Conversion Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Each Warrant will entitle the holder to purchase one Share at any time for a period of sixty months, subject to acceleration (as
noted below), at a price of $0.20 per share. At any time after the expiry of the four month hold period applicable to the Warrants, the
Corporation may accelerate the expiry of the Warrants if the twenty-day volume-weighted average trading price of the Shares on the TSX
(the &ldquo;<B>Exchange</B>&rdquo;), or such other exchange on which the Shares may be listed, is greater than $0.60 (the &ldquo;<B>Trigger
Event</B>&rdquo;) provided that (a) the Corporation gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated
expiry date is a date which is not less than 30 calendar days after the date of such notice. For greater certainty, the twenty-day volume-weighted
average trading price of the Common Shares on the Exchange shall be calculated by dividing the total value by the total volume of Common
Shares traded on the Exchange for the twenty trading days immediately preceding the date of the Trigger Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>After the deemed exercise of any of the Special Warrants represented by this Special Warrant Certificate, the Holder shall no longer
have any rights this Special Warrant Certificate with respect to such Special Warrants, other than the right to receive certificates issuable
on the exercise of those Special Warrants, and those Special Warrants shall be void and of no further value or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Special Warrants, the Shares and Warrants issuable upon the exercise of the Special Warrants, and any shares issuable upon
the exercise of the Warrants, have not been and will not be registered under the United States Securities Act of 1933, as amended (the
 &ldquo;<B>U.S. Securities Act</B>&rdquo;), or under the securities laws of any state of the United States. The Special Warrants may not
be exercised in the United States or by, or for the account or benefit of, any U.S. person or any person in the United States unless the
Special Warrants, and the Shares and Warrants issuable upon exercise hereof, have been registered under the U.S. Securities Act and any
applicable state securities laws or unless an exemption from such registration is available. &ldquo;<B>United States</B>&rdquo; and &ldquo;<B>U.S.
person</B>&rdquo; are as defined in Rule 902 of Regulation S under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The holding of the Special Warrants evidenced by this Special Warrant Certificate does not constitute the Holder a shareholder
of the Corporation or entitle such holder to any right or interest in respect thereof except as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
any case where there is a capital reorganization (such as a share sub-division or consolidation or a transaction with an equivalent
effect) or similar event (such as a merger) affecting the capital structure of the Corporation, the Corporation shall give notice to
the Holder of the particulars of the event and, if determinable, the adjustment to the conversion terms of the Special Warrant to
account for the event, such adjustment being subject to the approval of the Exchange. As a condition precedent to the taking of any
action which would require an adjustment in any of the rights under the Special Warrant, the Corporation will provide the right to
the Holder to convert the Special Warrants into the Shares and Warrants prior to the occurrence of the event. The Corporation shall
use its best efforts to take any action which, in the opinion of the Corporation&rsquo;s counsel, may be necessary in order that the
Corporation, or any successor to the Corporation or successor to the undertaking or assets of the Corporation will be obligated to
and may validly and legally issue all the Shares and Warrants or other securities of the Corporation, as applicable, pursuant to
this Special Warrant Certificate to which the Holder would be entitled to receive thereafter and to exercise the Special Warrants in
accordance with the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Special Warrants are not transferable without the prior written consent of the Corporation, and provided that, where such consent is
obtained, such transfer is made in accordance with applicable securities laws and the Holder gives a 72 hour prior notice to the Corporation
of such transfer by delivering a form of transfer in the form attached hereto as Schedule &ldquo;B&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Time shall be of the essence hereof.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;B&rdquo;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">TO:</TD><TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps"><B>PROMIS NEUROSCIENCES INC</B></FONT><B>. </B>(the &ldquo;<B>Corporation</B>&rdquo;)<BR>
<BR>
</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">RE:</TD><TD STYLE="text-align: justify">Special Warrants of the Corporation held by the undersigned holder (the &ldquo;<B>Holder</B>&rdquo;) pursuant
to a certificate (the &ldquo;<B>Special Warrant Certificate</B>&rdquo;) dated ______________________________ and bearing the certificate
number ___________________</TD></TR></TABLE>

<P STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms used but not defined herein
shall have the meanings given to them in the Special Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the Holder hereby sells,
assigns and transfers unto <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Name)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U> (the &ldquo;Transferee&rdquo;) of &nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Address)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>Special Warrants of the Corporation registered in the name of the undersigned on the register of the Corporation maintained therefor,
and hereby irrevocably appoints the Corporation to be the attorney of the undersigned to transfer the said securities on the books maintained
by the Corporation with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of a Special Warrant Certificate that
contains a U.S. restrictive legend, the undersigned hereby represents, warrants and certifies that (one (only) of the following must be
checked):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">(A) &nbsp;&nbsp;&nbsp;&nbsp;the transfer is being made only to the Corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">(B) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the transfer is being made outside the United States in accordance with Rule 904 of Regulation
S under the United States Securities Act of 1933, as amended (the &ldquo;<B>U.S. Securities Act</B>&rdquo;), and in compliance with any
applicable local securities laws and regulations, and the holder has provided herewith the Declaration for Removal of Legend substantially
in the form attached as Schedule C to the Special Warrant Certificate; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">(C) &nbsp;&nbsp;&nbsp;&nbsp;the transfer is being made within the United States or to, or for the account or benefit of, U.S.
persons, in accordance with a transaction that does not require registration under the U.S. Securities Act or any applicable state securities
laws and the undersigned has furnished to the Corporation an opinion of counsel of recognized standing in form and substance reasonably
satisfactory to the Corporation to such effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S. person</B>&rdquo; and &ldquo;<B>United
States</B>&rdquo; are as defined in Regulation S under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Warrants shall only be transferable in
accordance with all applicable laws. Without limiting the foregoing, if the Special Warrant Certificate bears a legend restricting the
transfer of the Special Warrants except pursuant to an exemption from registration under the U.S. Securities Act, this Form of Transfer
must be accompanied by a Form of Declaration for Removal of Legend in substantially in the form attached as Schedule C to the Special
Warrant Certificate (or such other form as the Corporation may prescribe from time to time), or a written opinion of counsel of recognized
standing in form and substance reasonably satisfactory to the Corporation to the effect that the transfer is exempt from registration
under the U.S. Securities Act and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of a Special Warrant Certificate
that does not contain a U.S. restrictive legend, if the proposed transfer is to, or for the account or benefit of, a U.S. person or
a person in the United States, the undersigned transferor hereby represents, warrants and certifies that the transfer of the Special
Warrants is being completed pursuant to an exemption from the registration requirements of the U.S. Securities Act and any
applicable state securities laws, in which case the undersigned transferor has furnished to the Corporation an opinion of counsel of
recognized standing in form and substance reasonably satisfactory to the Corporation to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">If transfer is to, or for the account or benefit of, a U.S. person or a person in the United States, check
this box.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of the transfer of the Special Warrants
represented by this Special Warrant Certificate to, or for the account or benefit of a U.S. person or a person in the United States, the
transferor acknowledges and agrees that the Special Warrant Certificate(s) representing such Special Warrants issued in the name of the
transferee will be endorsed with a U.S. restrictive legend in customary form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    of Holder guaranteed by:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X
    </B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature
    (if Holder is an individual)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medallion
    Signature Guarantee</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stamp</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorized
    signatory (if Holder is not an individual)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Holder (please print)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of authorized signatory (please print)</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Official
    capacity of authorized signatory (please print)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: center"><B>SCHEDULE &ldquo;C&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF DECLARATION FOR REMOVAL OF LEGEND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in">TO:</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>PROMIS NEUROSCIENCES INC</B></FONT><B>. </B>(the &ldquo;<B>Corporation</B>&rdquo;)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (A) acknowledges that the sale
of the special warrants (the &ldquo;<B>Securities</B>&rdquo;) of the Corporation represented by certificate number _______________, to
which this declaration relates, is being made in reliance on Rule 904 of Regulation S under the United States Securities Act of 1933,
as amended (the &ldquo;<B>U.S. Securities Act</B>&rdquo;), and (B) certifies that (1) the undersigned is not an &ldquo;affiliate&rdquo;
(as defined in Rule 405 under the U.S. Securities Act) of the Corporation (except solely by virtue of being an officer or director of
the Corporation) or a &ldquo;distributor&rdquo;, as defined in Regulation S, or an affiliate of a &ldquo;distributor&rdquo;; (2) the offer
of such Securities was not made to a person in the United States and at the time the buy order was originated, the buyer was outside the
United States, or the seller and any person acting on its behalf reasonably believe that the buyer was outside the United States; (3)
neither the seller nor any affiliate of the seller nor any person acting on their behalf has engaged in any directed selling efforts in
connection with the offer and sale of such Securities; (4) the sale is bona fide and not for the purpose of &ldquo;washing off&rdquo;
the resale restrictions imposed because the Securities are &ldquo;restricted securities&rdquo; (as such term is defined in Rule 144(a)(3)
under the U.S. Securities Act); (5) the seller does not intend to replace the Securities sold in reliance on Rule 904 of Regulation S
under the U.S. Securities Act with fungible unrestricted securities; and (6) the contemplated sale is not a transaction, or part of a
series of transactions which, although in technical compliance with Regulation S, is part of a plan or a scheme to evade the registration
provisions of the U.S. Securities Act. Unless otherwise specified, terms used herein have the meanings given to them by Regulation S under
the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X </B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Signature of individual (if Holder is an individual)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>X</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Authorized signatory (if Holder is not an individual)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of Holder (please print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of authorized signatory (please print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Official capacity of authorized signatory (please print)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>50
<FILENAME>filename50.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.32</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"><B>UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE
[<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2021.</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE COMMON SHARES UNDERLYING THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&ldquo;TSX&rdquo;); HOWEVER, THE COMMON SHARES CANNOT BE TRADED THROUGH THE FACILITIES OF THE
TSX SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH COMMON SHARES IS NOT &ldquo;GOOD DELIVERY&rdquo;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE WARRANTS EVIDENCED HEREBY ARE EXERCISABLE
UNTIL 5:00 P.M. (EST) ON [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2025 AFTER WHICH TIME THEY WILL EXPIRE AND BE OF NO FURTHER FORCE AND EFFECT OR VALUE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate #2020-11-[<FONT STYLE="font-family: Wingdings">&#108;</FONT>] dated [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2020 (the &ldquo;Issue Date&rdquo;),
representing [<FONT STYLE="font-family: Wingdings">&#108;</FONT>] Warrants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>WARRANT CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES INC.<BR>
</B>(Incorporated under the laws of Canada)<B><BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES that, for value received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt"><B>[HOLDER NAME]<BR>
[ADDRESS]<BR>
<BR>
</B></FONT>(hereinafter referred to as the &ldquo;Holder&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">is the registered holder of that number of warrants
(the &ldquo;Warrants&rdquo;) of ProMIS Neurosciences Inc. (the &ldquo;Issuer&rdquo;) set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Underlying Securities and Exercise Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Warrant entitles the Holder to purchase one
common share (each a &ldquo;Common Share&rdquo;) of the Issuer, as constituted on [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2020, at a price of CAD$0.20 per Common Share until
5:00 pm (EST) on [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2025 (the &ldquo;Expiry Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time after the expiry of the four month
hold period applicable to the Warrants, the Issuer may accelerate the expiry of the Warrants if the twenty-day volume-weighted average
trading price of the Common Shares on the TSX, or such other exchange on which the Common Shares may be listed, is greater than $0.60
provided that (a) the Issuer gives notice of the same in writing to the holder of the Warrants, and (b) the accelerated expiry date is
a date which is not less than 30 calendar days after the date of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants and Common Shares are collectively
referred to herein as the &ldquo;Securities&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Warrant Exercise Procedure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants may be exercised at any time prior
to the expiry of the Warrants by surrendering to the Issuer at its head office, at Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S
3E2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">this Warrant Certificate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscription Form attached as Schedule &ldquo;A&rdquo; hereto, duly completed and executed; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a cheque, bank draft or money order made payable to the Issuer in the aggregate amount of the exercise
price,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or such other office or agency of the Issuer
as it may designate by notice in writing delivered to the Holder at the Holder&rsquo;s address stated above. Upon the due exercise
of the Warrants, the Issuer shall issue or cause to be issued the requisite number of Common Shares to be issued to the Holder
pursuant to said exercise, registered in the name of the Holder or such other person as may be specified in the Subscription Form,
and each such person shall be deemed the holder of such Common Shares with effect from the date of such exercise. If Common Shares
are to be issued to a person other than the Holder, the Holder&rsquo;s signature on the Subscription Form must be guaranteed by a
Canadian chartered bank, a Canadian trust company or a member firm of the TSX. The Issuer will cause the certificates representing
such Common Shares to be mailed to the Holder at the Holder&rsquo;s address stated above or such other address(es) as may be
specified in the Subscription Form, within five business days of the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the due exercise of a Warrant, the Warrant
shall be deemed tendered for purposes thereof by the Holder without further notice or action by the Holder, and all rights under such
Warrant, other than the right to receive certificates representing the Common Shares to which the Holder is entitled on such exercise,
shall wholly cease and terminate and such Warrants shall be void and of no further effect or value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Partial Exercise, Exchange and Replacement
of DRS (or Certificates)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants represented by this Warrant Certificate
may be exercised in whole or in part from time to time. If the Warrants are exercised in part, the Issuer shall deliver, with the Common
Shares issued pursuant to such exercise, a new Warrant Certificate representing the balance of the Warrants remaining unexercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant Certificate may be exchanged, upon
its surrender to the Issuer and payment of such administration fee, not exceeding $10.00, as the Issuer may require, for new Warrant Certificates
of like tenor in denominations which in the aggregate represent the number of Warrants represented hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Warrant Certificate is lost, stolen, mutilated
or destroyed, the Issuer may on such reasonable terms as it may in its discretion impose, including but not limited to the payment of
any administration fee, not exceeding $10.00, and the provision of any indemnity by the Holder, issue and countersign a new Warrant Certificate
of like tenor, denomination and date as the Warrant Certificate so lost, stolen, mutilated or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Warrants shall rank <I>pari passu</I>, notwithstanding
the actual date of issue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covenants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer covenants and agrees that so long as
any Warrants evidenced hereby remain outstanding, it shall reserve and there shall remain unissued out of its authorized capital a sufficient
number of Common Shares to satisfy the right of purchase herein provided for and such Common Shares shall be issued as fully paid and
non-assessable Common Shares and the holders thereof shall not be liable to the Issuer or to its creditors in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall use all reasonable commercial
efforts to preserve and maintain its corporate existence and to ensure that the Common Shares outstanding or issuable from time to time
upon the exercise of the Warrants are listed and posted for trading on the TSX (or such other exchange on which the Common Shares may
be listed), provided that this clause shall not be construed as limiting or restricting the Issuer from completing a consolidation, amalgamation,
arrangement, takeover bid or merger that would result in the Common Shares ceasing to be listed and posted for trading on the TSX (or
such other exchange on which the Common Shares may be listed), so long as the holders of Common Shares receive securities of an entity
which is listed on a stock exchange in Canada, or cash, or the holders of the Common Shares have approved the transaction in accordance
with the requirements of applicable corporate and securities laws and the policies of the TSX (or such other exchange on which the Common
Shares may be listed). In addition, the Issuer shall make all requisite filings under applicable securities legislation necessary to remain
a reporting issuer not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the issuance of the Common Shares upon the
exercise of the Warrants requires any filing or registration with or approval of any securities regulatory authority or other governmental
authority or compliance with any other requirement under any law before such Common Shares may be validly issued (other than the filing
of a prospectus or similar disclosure document), the Issuer agrees to take such actions as may be necessary to secure such filing, registration,
approval or compliance, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transfer of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants are transferable and the term
 &ldquo;Warrantholder&rdquo; shall mean and include any successor, transferee or assignee of the current or any future Warrantholder.
The term &ldquo;Warrantholder&rdquo; shall mean and include any successor of the Warrantholder. The Warrants may be transferred by
the Warrantholder completing and delivering to the Issuer the transfer form attached hereto as Schedule&nbsp;&ldquo;B&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Holding of Warrants</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer may treat the Holder as the absolute
owner of the Warrants represented hereby for all purposes, and the Issuer shall not be affected by any notice or knowledge to the contrary
except where the Issuer is required to take notice by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Warrant Certificate or in the
holding of a Warrant evidenced hereby shall be construed as conferring upon the Holder any right or interest whatsoever as a shareholder
of the Issuer or entitle the Holder to any right or interest in respect of any Common Shares except as herein expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Resale Restrictions and Legend Endorsed
on DRS (or Certificates)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants have been, and the Common Shares
will be, issued pursuant to an exemption (an &ldquo;Exemption&rdquo;) from the registration and prospectus requirements of applicable
securities law. To the extent that the Issuer relies on such Exemption, the Common Shares may be subject to restrictions on resale and
transferability contained in applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the Securities are subject to a hold
period, or any other restrictions on resale and transferability, the Issuer may place a legend on the certificates representing the Securities
as may be required under applicable securities laws, or as it may otherwise deem necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate representing Common Shares issued
upon the exercise of this Warrant prior to the date which is four months after the Issue Date will bear the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">UNLESS PERMITTED UNDER SECURITIES LEGISLATION,
THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [<FONT STYLE="font-family: Wingdings">&#108;</FONT>], 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THE SECURITIES REPRESENTED BY THIS CERTIFICATE
ARE LISTED ON THE TORONTO STOCK EXCHANGE (&ldquo;TSX&rdquo;); HOWEVER, THE SECURITIES CANNOT BE TRADED THROUGH THE FACILITIES OF THE TSX
SINCE THEY ARE NOT FREELY TRANSFERABLE AND CONSEQUENTLY ANY CERTIFICATE REPRESENTING SUCH SECURITIES IS NOT &ldquo;GOOD DELIVERY&rdquo;
IN SETTLEMENT OF TRANSACTIONS ON THE TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that at any time subsequent to the date
which is four months and one day after the date hereof any certificate representing such Common Shares may be exchanged for a certificate
bearing no such legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Capital Adjustments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to approval of the TSX (or such other
exchange on which the Common Shares may be listed), if at any time after the date hereof and prior to the expiry of the Warrants, and
provided that any Warrants remain unexercised, there shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a reclassification of the Common Shares, a change in the Common Shares into other shares or securities,
a subdivision or consolidation of the Common Shares into a greater or lesser number of Common Shares, or any other capital reorganization,
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a consolidation, amalgamation or merger of the Issuer with or into any other corporation other than a
consolidation, amalgamation or merger which does not result in any reclassification of the outstanding Common Shares or a change of the
Common Shares into other shares or securities,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events being called a
 &ldquo;Capital Reorganization&rdquo;) any Holders who shall thereafter acquire Common Shares pursuant to the Warrant shall be
entitled to receive, at no additional cost, and shall accept in lieu of the number of Common Shares to which such Holder was
theretofore entitled to acquire upon such exercise, the aggregate number of shares, other securities or other property which such
Holder should have been entitled to receive as a result of such Capital Reorganization if, on the effective date or record date
thereof as the case may be, the Holder had been the registered holder of the number of Common Shares to which such Holder was
theretofore entitled to acquire upon exercise of the Warrants. If determined appropriate by the Issuer acting reasonably,
appropriate adjustments shall be made in the application of the provisions set forth herein with respect to the rights and interests
of the Holder relative to a Capital Reorganization, to the end that the provisions set forth herein shall correspond as nearly as
may be reasonably possible to the effect of the Capital Reorganization in relation to any shares, other securities or other property
thereafter deliverable upon the exercise of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Issuer shall pay any dividend payable in stock upon its Common Shares or make any distribution to
the holders of its Common Shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Issuer shall offer for subscription pro rata to the holders of its Common Shares any additional shares
or stock of any class or other rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there shall be any subdivision, consolidation, capital reorganization, or reclassification of the capital
stock of the Issuer, or merger, amalgamation or arrangement of the Issuer with, or sale of all or substantially all of its assets to,
another corporation; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">the Issuer shall give to the Holder at least twenty
days&rsquo; prior written notice of the date on which the books of the Issuer shall close or a record shall be established for such dividend,
distribution or subscription rights, or for determining rights to vote with respect to such subdivision, consolidation, capital reorganization,
reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up, and in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding-up,
at least twenty days&rsquo; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing
clause shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common
Shares shall be entitled thereto, and such notice in accordance with the foregoing shall also specify, in the case of any such subdivision,
consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution, liquidation or winding&#45;up,
the date on which the holders of Common Shares shall be entitled to exchange their Common Shares for securities or other property deliverable
upon such subdivision, consolidation, capital reorganization, reclassification, merger, amalgamation, arrangement, sale, dissolution,
liquidation or winding-up as the case may be. Each such written notice shall be given by first class mail, postage prepaid, addressed
to the Holder at its address as shown on the books of the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case the Issuer, after the date hereof, shall
take any action affecting any securities of the Issuer, other than as previously set out herein, which in the opinion of the directors
would materially affect the rights and interests of the Holder hereunder, the number of Common Shares or other securities which shall
be issuable on the exercise of the Warrants shall be adjusted in such manner, if any, and at such time as the directors, in their sole
discretion, may determine to be equitable in the circumstances, provided that no such adjustment will be made unless all necessary regulatory
approvals, if any, have been obtained. In the event of any question arising with respect to any adjustment provided for herein, such question
shall be conclusively determined by a firm of chartered accountants appointed by the Issuer at its sole discretion (who may be the Issuer&rsquo;s
auditors) and any such determination shall be binding upon the Issuer and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No adjustment shall be made in respect of any
event described herein if the Holder is entitled to participate in such event on the same terms, without amendment, as if the Holder had
exercised the Warrants prior to or on the effective date or record date of such event, subject to the written consent of the TSX (or such
other exchange on which the Common Shares may be listed). The adjustments provided for herein are cumulative and such adjustments shall
be made successively whenever an event referred to herein shall occur, subject to the limitations provided for herein. No adjustment shall
be made in the number or kind of Shares or other securities which may be acquired on the exercise of a Warrant unless it would result
in a change of at least one-tenth of a Share or other security. Any adjustment which may by reason of this paragraph not be required to
be made shall be carried forward and then taken into consideration in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any adjustments provided for herein
or otherwise, the Issuer shall not be required, upon the exercise of any Warrants, to issue fractional Common Shares or other securities
in satisfaction of its obligations hereunder and, except as provided for herein, any fractions shall be eliminated. To the extent that
the Holder would otherwise be entitled to acquire a fraction of a Common Share or other security, such right may be exercised in respect
of such fraction only in combination with other rights which in the aggregate entitle the Holder to acquire a whole number of Common Shares
or other securities. The Holder shall be entitled, upon the elimination of any fraction of a Common Share or other security, to be paid
in cash for the fair market value for the securities so eliminated, always provided that the Issuer shall not be required to make any
payment if for less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Representation and Warranty</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer hereby represents and warrants with
and to the Holder that the Issuer is duly authorized and has the corporate and lawful power and authority to create and issue this Warrant
and the Common Shares issuable upon the exercise hereof and perform its obligations hereunder and that this Warrant represents a valid,
legal and binding obligation of the Issuer enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Miscellaneous Provisions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delivery or surrender of documents shall be
valid and effective if delivered personally or if sent by registered letter postage prepaid, and any notice shall be valid and effective
if made in writing and transmitted as aforementioned or if transmitted by facsimile with confirmed receipt, in each case addressed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
to the Issuer,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">M4S 3E2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>if to the Holder, at its address appearing in the register of holders of Warrants maintained by the Issuer,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and such shall be deemed to have been effectively
made and received on the date of personal delivery, if delivered; on the fourth business day after the time of mailing or upon actual
receipt, whichever is sooner, if sent by registered letter (except the delivery of documents to exercise the Warrants, in which case actual
receipt is required); or on the first business day after the time of facsimile transmission, if sent by facsimile. In the case of a disruption
in postal services, any delivery or surrender of documents or notice sent by mail shall not be deemed to have been effectively made or
received until it is actually delivered. The Issuer and the Holder may from time to time change their address for service hereunder by
notice in writing delivered in one of the foregoing manners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as herein provided, any and all of the
rights conferred upon the Holder herein may be enforced by the Holder through appropriate legal proceedings. No recourse under or upon
any covenant, obligation or agreement herein contained shall be had against any shareholder, officer or director of the Issuer, either
directly or through the Issuer, it being expressly agreed and declared that the obligations under the Warrants are solely corporate obligations
of the Issuer and no personal liability whatsoever shall attach to or be incurred by the shareholders, officers or directors of the Issuer
in respect thereof. This Warrant Certificate shall be binding upon the Issuer and its successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Warrant shall be governed in accordance with
the laws of British Columbia and the laws of Canada applicable therein. The parties hereby attorn to the jurisdiction of the courts of
British Columbia in the event of any dispute hereunder. Time shall be of the essence hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Issuer shall be entitled to rely on delivery
of an executed Certificate by electronic means, and acceptance by the Holder of such electronic Certificate (including, without limitation
by facsimile or email delivery) shall be legally effective between the Holder and the Issuer in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Issuer has caused this
Warrant Certificate to be signed by its duly authorized signatory on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%">By:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 46%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%"><B>&nbsp;</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Authorized Signatory</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;A&rdquo;<BR>
SUBSCRIPTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">TO:</TD><TD>ProMIS Neurosciences Inc.<BR>
Suite 200, 1920 Yonge Street<BR>
Toronto, Ontario<BR>
M4S 3E2</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Facsimile: [***]</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned, being the registered holder
of the attached Warrant Certificate of the Issuer, does hereby irrevocably exercise
_________________________________________________ of the Warrants evidenced thereby in accordance with the terms thereof, and
accordingly hereby irrevocably subscribes for the Shares (as described therein) to be received thereon and irrevocably surrenders
the Warrant Certificate to the Issuer for such purpose. The Undersigned hereby irrevocably directs that the Shares to be received by
the Undersigned be registered as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name in Full</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 2.25pt double; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 2.25pt double; border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of<BR>
Common Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-top: 3pt; padding-right: 6pt; padding-left: 6pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IF COMMON SHARES ARE TO BE ISSUED TO A PERSON
OR PERSONS OTHER THAN THE UNDERSIGNED REGISTERED HOLDER, (I) THE SIGNATURE OF THE UNDERSIGNED MUST BE <U>MEDALLION GUARANTEED</U>, (II)
THE UNDERSIGNED MUST PAY TO THE ISSUER ALL APPLICABLE TAXES AND OTHER DUTIES AND (III) THE TRANSFER FORM SET FORTH IN SCHEDULE &ldquo;B&rdquo;
TO THE WARRANT CERTIFICATE MUST BE COMPLETED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Undersigned registered holder hereby represents,
warrants and certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">the Undersigned is a resident at the address set forth in this Subscription Form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">the Undersigned acknowledges that the Warrants and Common Shares (collectively, the &ldquo;Securities&rdquo;)
have not been registered under the United States Securities Act of 1933, as amended (the &ldquo;U.S. Securities Act&rdquo;), or any applicable
State securities laws and may not be offered or sold in the United States or to U.S. Persons (as defined in Rule 902(k) of Regulation
S under the U.S. Securities Act) without registration under the U.S. Securities Act and any applicable State securities laws, unless an
exemption from registration is available; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">the Undersigned has no intention to distribute, either directly or indirectly, any of the Securities in
the United States or to U.S. Persons.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED the ______day of <U>_________________</U>, 20<U>_____</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">}</P></TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Signature of Witness<BR>
<B>[Please Note Instruction 2]</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Signature of registered holder or Signatory thereof</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If applicable, print Name and Office of Signatory</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Print Name of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Print Name of registered holder as on certificate</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Address of Witness</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Street Address</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">Occupation of Witness</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-size: 10pt">City, Province and Postal Code</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>INSTRUCTIONS:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of a Warrant may exercise its right to convert the Warrant into Shares by completing and surrendering this Subscription
Form and the ORIGINAL Warrant Certificate representing the Warrants being converted to the Issuer, together with the aggregate amount
of the exercise price for the Shares, as provided for in the Warrant Certificate. DRS (or Certificates) representing the Shares to be
acquired on exercise will be sent by prepaid ordinary mail to the address(es) above within five business days after the receipt of all
required documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form indicates that Shares are to be issued to a person or persons other than the registered holder of the Warrant to
be converted: (i) the signature of the registered holder on this Subscription Form must be medallion guaranteed by an authorized officer
of a chartered bank, trust company or an investment dealer who is a member of a recognized stock exchange, and (ii) the registered holder
must pay to the Issuer all applicable taxes and other duties and (iii) the Transfer Form set forth in Schedule &ldquo;B&rdquo; to the
Warrant Certificate must be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Subscription Form is signed by a trustee, executor, administrator, custodian, guardian, attorney, officer of a corporation or any
other person acting in a fiduciary or representative capacity, this Subscription Form must be accompanied by evidence of authority to
sign satisfactory to the Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;B&rdquo;<BR>
FORM OF TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the undersigned hereby sells,
assigns and transfers unto<U>_____________________________________________________________________________________________________________________
__</U> (include name and address of the transferee) Warrants exercisable for common shares of ProMIS Neurosciences Inc. (the &ldquo;Corporation&rdquo;)
registered in the name of the undersigned on the register of the Corporation maintained therefor, and hereby irrevocably appoints _______________________________
the attorney of the undersigned to transfer the said securities on the books maintained by the Corporation with full power of substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this _______ day of ___________________,
20___.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature of Transferor guaranteed by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-top: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Medallion
Signature Guarantee</B></FONT></TD><TD STYLE="text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature
                                            of Transferor</B></FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stamp of Transferor</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
                                            of Transferor</FONT></TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned transferee hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(check one)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">said transferee was
not offered the Warrants in the United States and is not in the United States or a &ldquo;U.S. Person&rdquo; (as defined in Regulation
S under the <I>United States Securities Act of 1933</I>, as amended (the &ldquo;U.S. Securities Act&rdquo;)), and is not acquiring the
Warrants for the account or benefit of a person in the United States or a U.S. Person; or</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">enclosed herewith
is an opinion of counsel (which the transferee understands must be satisfactory to the Corporation) to the effect that no violation of
the U.S. Securities Act or applicable securities laws will result from transfer, exercise or deemed exercise of the Warrants.</P></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">It is understood
that the Corporation may require additional evidence necessary to verify the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The signature to this transfer must correspond with the name written upon the face of this Warrant Certificate
in every particular without any changes whatsoever.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">If the Transfer Form indicates that common shares are to be issued to a person or persons other than the
registered holder of the Warrant Certificate, the signature on this Transfer Form must be guaranteed by a Canadian chartered bank, or
eligible guarantor institution with membership in an approved signature guarantee medallion program. The guarantor must affix a stamp
bearing the actual words &ldquo;Signature Guaranteed&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>51
<FILENAME>filename51.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.33</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certain identified information has been
excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv)
because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information
is indicated by: [***]&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">TECHNOLOGY LICENSE
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">DR. NEIL ROY CASHMAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">AND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">AMORFIX LIFE SCIENCES
LTD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">-AWAITING SCHEDULE
C-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">PATENT APPLICATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">FEB. 1, 2006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">TECHNOLOGY
LICENSE AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>THIS
AGREEMENT</B> is made and effective as of the 1st day of February 2006.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>BETWEEN:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt"><B>DR. NEIL ROY CASHMAN</B>,
located at [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">(hereinafter &#8220;<B>CASHMAN</B>&#8221;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">- and -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt"><B>AMORFIX LIFE SCIENCES LTD.</B>,
with offices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">located at 3080 Yonge St.,
Suite 6020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Toronto, Ontario, M4N 3M1,
Canada</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">(hereinafter &#8220;<B>Licensee</B>&#8221;
or &#8220;<B>AMF</B>&#8221;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
CASHMAN, while employed by the University of Toronto (&#8220;University&#8221;), made an invention titled &#8220;A Disease-Specific Epitope
for Superoxide Dismutase-1&#8221; (&#8220;Invention&#8221;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
CASHMAN disclosed the Invention to the University on June 6, 2005 described in Schedule A;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
by an Assignment of Rights from the University on July 14, 2005, Schedule B, CASHMAN requested and received full ownership to the Invention
to exploit for commercialization purpose under the University&#8217;s Invention Policy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
Licensee is a public biotechnology corporation engaged in the research and development of human diagnostic and therapeutic drugs for
the treatment of misfolded protein diseases;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
Licensee wishes to file a patent application listed in Schedule C;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
Licensee, subject to approval of Toronto Stock Venture Exchange (&#8220;TSX&#8221;), wishes to commercialize, develop, manufacture, market,
distribute and sell products which may be derived in whole or in part from the practice of the Technology and therefore desires to obtain
a license for the Technology; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B>
CASHMAN, subject to approval by the University, is willing to grant a license under the terms and conditions set forth hereinafter; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>NOW THEREFORE
</B>in consideration of the premises and the mutual covenants, terms, conditions and agreements contained herein, and other good and
valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">INTERPRETATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Definitions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In this
Agreement, the following terms have the meanings set forth below unless there is something in the subject matter or context inconsistent
therewith:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Affiliate</B>&#8221;
shall mean any company or other legal entity controlling, controlled by or under common control with Licensee. The term &#8220;control&#8221;
means the ability to direct the management and policies of said entity, whether through ownership of equity, by contract or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Agreement</B>&#8221;
means this Technology License Agreement including all attached schedules, as the same may be supplemented, amended, restated or replaced
in writing from time to time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Calendar
Quarter</B>&#8221; shall mean the period of time ending on March 31, June 30, September 30 and December 31 of each year;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Confidential
Information</B>&#8221; means this Agreement and its terms and conditions, the Know-how, the Materials and any information, which is non-public,
confidential or proprietary in nature, including, without limitation, business information, trade secrets, and any information related
to the Technology, whether written, oral or in electronic form, provided that tangible materials are marked as confidential, and provided
that information given orally is identified as confidential at the time of disclosure, and confirmed as confidential in writing within
fifteen (15) days, but shall not include information that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">is
                                            or becomes generally available to the public other than as a result of any act by a Party
                                            to this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">is
                                            rightfully received from a Third Party without similar restriction or without breach of this
                                            Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">a
                                            Party is able to demonstrate, in writing, was known to it on a non-confidential basis; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">was
                                            independently developed by a Party without the use of any of the Confidential Information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Effective
Date</B>&#8221; shall mean the date first shown in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Field
of Use</B>&#8221; means the practice of the Technology as it relates to research, diagnostic and therapeutic applications of the Technology;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>First
Commercial Sale</B>&#8221; has occurred when a Licensed Product is sold to a Third Party purchaser anywhere in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Net
Sales</B>&#8221; shall mean, with respect to any Licensed Product, the invoiced sales price of such Licensed Product billed to independent
customers who are not Affiliates and paid, </FONT>less the following amounts, to the extent actually included in the invoiced sales price:
(a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such independent customers for spoiled, damaged,
out dated and returned Product; (b) actual freight and insurance costs incurred in transporting such Product in final form to such customers;
(c) trade discounts, cash discounts, quantity discounts, rebates and other price reduction programs; (d) sales, value added and other
direct taxes incurred; and (e) customs duties, surcharges and other governmental charges incurred in connection with the exportation
or importation of such Product in final form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Improvements</B>&#8221;
means any and all improvements, variations, updates, modifications or enhancements to the Technology that are within the scope of the
claims of the resultant Patents set out in the disclosure as set forth in Schedule A and which are solely owned or controlled by CASHMAN;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Including</B>&#8221;
means &#8220;Including without limitation&#8221; and the term &#8220;Including&#8221; shall not be construed to limit any general statement
which it follows to the specific or similar items or matters immediately following it;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Know-how</B>&#8221;
means any and all trade secrets, technical expertise, knowledge, confidential information and know-how, whether patentable or unpatentable
relating to the design and manufacture of the Licensed Product, whether in written, machine readable, drawing or oral form, including,
without limiting the generality of the foregoing, all technical information, raw material data, product specifications, processes and
designs, operating and production data, calculations, computer programs, instructions and techniques, quality control and other standards,
and drawings relating thereto whether developed by SWCHSC or the Licensee that exists as of or following the date of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Licensed
Product</B>&#8221; means any product derived from, or partially from, at least one claim of the Patents set forth in Schedule C or derived
from the Know-how or from the Improvements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Material</B>&#8221;
means the Original Material together with any Progeny or Unmodified Derivatives;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Milestones</B>&#8221;
refers to the events which Licensee has agreed to accomplish within defined periods of time. The Milestones are described in Schedule
D of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Original
Material</B>&#8221; means hybridomas and antibodies defined in the Field of Use and described in the Patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Parties</B>&#8221;
means CASHMAN and the Licensee collectively, and &#8220;Party&#8221; means any of them;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Patents</B>&#8221;
means the patents and/or patent applications listed in Schedule C appended hereto, and shall include any divisional, re-examination,
renewal, continuation or continuation-in-part applications based on the said patents and patent applications, any patents which may issue
on, from or as a result of any of the foregoing, and any reissue of said patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Prime
Rate</B>&#8221; means the rate of interest expressed as a rate that The Royal Bank of Canada establishes at its office in Toronto as
the reference rate of interest that it will </FONT>charge on that day for Canadian dollar demand loans to its customers in Canada and
which it at present refers to as its prime rate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Progeny</B>&#8221;
means an unmodified descendant from the Original Material, such as virus from virus, cell from cell, or organism from organism;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Technology</B>&#8221;
means the Patents, the Know-how and the Improvements that are owned and controlled by CASHMAN and related to DSE 2 and 3;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Territory</B>&#8221;
means each and every country of the world;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Third
Parties</B>&#8221; means a party who deals with a Party to the Agreement at arm&#8217;s length, as that term is defined in the Income
Tax Act (Canada) on the date hereof; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;<B>Unmodified
Derivatives</B>&#8221; means substances created by Licensee which constitute an unmodified functional sub-unit or an expression product
of the Original Material including, but not limited to, subclones or unmodified cell lines, purified or fractionated sub sets of the
Original Material, proteins expressed by DNA/RNA supplied by Licensor, monoclonal antibodies secreted by a hybridoma cell line, or sub
sets of the Original Material such as novel plasmids or vectors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Captions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Captions
or descriptive words at the commencement of the various sections are inserted for convenience only, and are in no way to be construed
as part of this Agreement or as a limitation upon the scope of the particular section to which they refer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Currency</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Unless
specified otherwise, all statements of or references to dollar amounts in this Agreement are to lawful money of the United States of
America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.4</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Schedules</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The following
schedules form part of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Schedule A&nbsp;&nbsp;&nbsp;&nbsp;University
of Toronto Invention Disclosure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Schedule B&nbsp;&nbsp;&nbsp;&nbsp;Assignment
of Rights from University to CASHMAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Schedule C&nbsp;&nbsp;&nbsp;&nbsp;Patent
Applications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">Schedule D&nbsp;&nbsp;&nbsp;&nbsp;Milestones</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
2<BR>
<BR>
TECHNOLOGY LICENSE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Grant
                                            of License for Technology</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Subject
to the terms and conditions hereinafter set forth, CASHMAN hereby grants to Licensee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">an
                                            exclusive license, within the Territory and within the Field of Use, to make, have made,
                                            use, sell or import any Licensed Product, the claimed subject matter of any Patents and Improvements,
                                            to disclose Confidential Information to sub-licensees, and to otherwise practice the Technology;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">an
                                            exclusive right to grant sub-licenses of all rights set out in Section 2.1(a) above.; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">an
                                            exclusive option to purchase the Technology within (5) years from the Effective Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Reserved
                                            Rights</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
and the University, reserve the royalty-free right to a non-assignable, non-transferable, perpetual, royalty free, non-exclusive license
to use the Technology for research, teaching and administrative purposes,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Publication
                                            Rights</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
and Licensee shall have the right to publish or disclose the results arising from any research in relation to the Technology. The Party
proposing the publication or disclosure (hereinafter &#8220;1st Party&#8221;) will provide a copy of any such proposed publication or
disclosure to the other Party (hereinafter &#8220;2nd Party&#8221;) for review at least thirty (30) days before submission for publication
or disclosure. Upon receipt of such notification from the is Party, the 2nd Party will have twenty (20) days to request the 1st Party
to either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Delay
                                            publication up to sixty (60) additional days to enable the 2nd Party to secure intellectual
                                            property protection of any intellectual property that would be disclosed or published; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Delete
                                            any Confidential Information provided by the 2nd Party from the manuscript or proposed disclosure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
3<BR>
<BR>
CONSIDERATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Consideration</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In consideration
of the granting of this license, Licensee agrees to carry out those activities set out in Schedule D: Milestones hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Royalty</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In consideration
of the granting of this license, Licensee, together with all Affiliates, shall pay a royalty payment (&#8220;Royalty Payment&#8221;)
of [***] ([***]%) of the Net Sales, in respect of all sales of Licensed Products sold by Licensee or its Affiliates, made during the
term of this Agreement. Subject to section 2.1c, when Licensee elects to purchase the Technology, the Royalty Payments to CASHMAN will
cease effective the signing date of the Assignment Fee agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assignment
                                            Fee</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In accordance
with section 2.1(c), Licensee shall have the option to purchase the Technology owned by CASHMAN upon payment of additional consideration
in the amount of $100,000, payable in cash and/or equity in Licensee at fair market value (valued as of the date of the exercise of the
option) in such proportion as may be agreed by Licensee and CASHMAN. Upon exercise of the option and payment of all such additional consideration,
CASHMAN will cooperate to have ownership of all Patents and other registered intellectual property protection covering the Technology
transferred to the Licensee or its designate in a timely fashion. Notwithstanding such assignment, the Technology shall remain subject
to the provisions of section 2.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.4</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Accounting
                                            and Records</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            Royalty payments under Section 3.2 are to be paid by Licensee to CASHMAN on a quarterly basis
                                            and shall be made within thirty (30) days after the end of the Calendar Quarter of each year
                                            during the term of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            Parties acknowledge that the royalties and fees payable hereunder for all sales of Licensed
                                            Products within Canada are subject to the Canadian Goods and Services Tax (&#8220;GST&#8221;).
                                            Licensee hereby agrees to remit such amounts to CASHMAN as required under Canadian GST legislation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Royalties
                                            shall be paid to CASHMAN free and clear of all taxes including income and turn-over taxes,
                                            except such taxes as the Licensee shall be required by law to withhold.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                            agrees to keep complete and accurate books of account in which the particulars of all sales
                                            of Licensed Product are recorded in sufficient detail to enable royalties payable hereunder
                                            to be determined.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN,
                                            or their authorized representatives, shall have the right from time to time, upon forty five
                                            (45) days prior written notice to Licensee, to audit Licensee&#8217;s said books and records
                                            of accounts and all of the documents and other materials in the possession or under the control
                                            of Licensee with respect to the subject matter of this Agreement. CASHMAN reserves the right
                                            to confirm any information learned in the course of such audit with individuals or corporations
                                            that have purchased a Licensed Product from Licensee to verify the accuracy of Licensee&#8217;s
                                            royalty payments and compliance with the terms hereunder. Licensee shall preserve and keep
                                            available to CASHMAN all such books and records, documents, contracts, and other data with
                                            respect thereto for a period of six (6) years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
                                            the event that any audit of the books and records of Licensee reveals an error in excess
                                            of ten percent (10%) to the detriment of CASHMAN, then Licensee shall bear all the costs
                                            of said examination and pay forthwith all outstanding amounts together with the appropriate
                                            interest thereon. Further, in the event of an error in excess of ten percent (10%) to the
                                            detriment of CASHMAN, CASHMAN may terminate this Agreement according to Section 6.2 herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Each
                                            royalty payment hereunder shall be accompanied by a statement of the Net Sales certified
                                            correct by the chief financial officer of Licensee. In addition, Licensee shall provide to
                                            CASHMAN within thirty (30) days following March 31st and September 30th in each year, a progress
                                            report in relation to the development of the Licensed Products, a written report of marketing
                                            activity undertaken in the preceding fiscal year, and a forecast of sales for the next fiscal
                                            year. Further, Licensee agrees to provide CASHMAN with an analysis of the general market
                                            situation, or such activities by competitors that may materially affect the market for Licensed
                                            Products, whether adverse or beneficial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">h)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Interest
                                            shall be payable on any amounts owed by one Party to another Party which are not paid when
                                            due, at the Prime Rate plus 3% per annum, compounded monthly. The payment of interest shall
                                            not be deemed an alternative to the payment of amounts owing on the due dates, which payment
                                            shall be deemed to be in default, and if such default is not remedied within thirty (30)
                                            days of written notice thereof, CASHMAN may terminate this Agreement as provided in Section
                                            6.2 herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
4<BR>
<BR>
INTELLECTUAL PROPERTY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Know-how</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
shall furnish the Know-how and Original Material to Licensee within a reasonable period of time following the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Patents
                                            and Patent Applications</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee,
                                            in the name of CASHMAN, shall file, prosecute and maintain the Patents. Licensee, in consultation
                                            with CASHMAN, shall determine in which countries to pursue patent applications. In the event
                                            that Licensee elects not to support a patent application or to continue prosecution in any
                                            country, CASHMAN may, at its sole discretion, file such patent or continue such prosecution
                                            in that country at its own expense. In such a case, Licensee would not have any rights to,
                                            or in, any patents arising from such applications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                            undertakes to keep CASHMAN reasonably advised of the progress of prosecution and of any actions
                                            Licensee proposes to take or has taken in connection with the prosecution or maintenance
                                            of the Patents. Licensee will diligently endeavor to provide CASHMAN with copies of correspondence
                                            and all actions issued by patent authorities. CASHMAN agrees to cooperate with Licensee on
                                            all matters related to discussions, drafting of responses and any document in general necessary
                                            in this connection.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Improvements</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Either
Party hereto shall inform the other Party promptly of any patent filings associated with the Improvements. Licensee agrees to pay all
expenses associated with the filing and prosecution of such patent applications that are owned and controlled by CASHMAN. Such applications
shall then be included in the definition of Patents. If Licensee elects not to pay all expenses associated with the filing and prosecution
of such patent applications for such Improvements, CASHMAN shall have the right to apply for patents at its own expense, and Licensee
shall have no rights to any patents resulting from such applications. It is understood that Licensee shall not be obligated to undertake
responsibility with respect to any such Improvements or developments unless it elects to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.4</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Infringement</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Each
Party shall notify the other Party promptly of any infringement, limitation or unauthorized use of any Patents by a Third Party of which
such Party becomes aware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
shall have the sole right, at its own expense to bring any action on account of any such infringements, limitations or unauthorized use
of the Patents. CASHMAN agrees, at the request of Licensee, to execute the writ and such other papers as may require the signature of
CASHMAN in the prosecution of such suit, and to render to Licensee all reasonable assistance in the prosecution of such suit. Licensee
agrees to reimburse CASHMAN for its reasonable expenses incurred in complying with any such request of Licensee. Finally, CASHMAN shall
have the right to be represented in the litigation by counsel of CASHMAN&#8217;s choice, but at CASHMAN&#8217;s own expense. Licensee
shall be entitled to keep all the proceeds obtained from such a suit or settlement resulting from such suit and CASHMAN shall receive
8% of the proceeds of any judgment or settlement less the legal fees and costs incurred by Licensor in connection with such suit. If
Licensee does not undertake such action, it shall notify CASHMAN of its election within sixty (60) days following the receipt of notice
of such infringement. CASHMAN may then prosecute the same, at its expense, provided that CASHMAN notifies Licensee of CASHMAN&#8217;s
intention to file suit at least fifteen (15) days prior to filing thereof. In such event, unless Licensee then notifies CASHMAN within
such fifteen (15) day period that Licensee agrees to bear one-half of the expense of prosecuting such suit, all recoveries had or obtained
in such suit shall be the sole property of CASHMAN whereby no settlement will be made without the prior written approval of Licensee.
If Licensee notifies CASHMAN that Licensee agrees to bear one-half of such expenses, and if Licensee pays CASHMAN from time to time as
expenses are incurred, then all recoveries had or obtained in such suit shall be divided equally between CASHMAN and Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
will defend, at its expense, any suit against Licensee to the extent it is based on a claim that use of the Technology as permitted hereunder
in the Territory infringes any patent applicable in the Territory. Further, CASHMAN will pay those damages or costs finally awarded by
a court or tribunal of final appeal against Licensee in such action which are attributable to such claim, provided that Licensee:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>notifies
                                            CASHMAN promptly in writing of any such action and all prior related claims</U>;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>gives
                                            CASHMAN sole control of the defense of same and all negotiations for its settlement or compromise</U>;
                                            <U>and</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>provides
                                            to CASHMAN, at CASHMAN&#8217;s expense, all available information, assistance and authority
                                            to make such defense</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.5</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Confidentiality</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Confidential
                                            Information is the property of the Party disclosing it, and the ownership of any and all
                                            right, title and interest therein, including all intellectual property rights, shall at all
                                            times remain exclusively vested in the disclosing party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">For
                                            a period of three (3) years from the date of disclosure of Confidential Information, each
                                            Party agrees to maintain in confidence all Confidential Information disclosed with the same
                                            degree of care as it normally takes to preserve its own confidential information of similar
                                            grade, but in any event, no less than a reasonable degree of care.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Each
                                            Party may only disclose Confidential Information to persons with a &#8220;need to know&#8221;
                                            who have written obligations of confidence, and the Confidential Information shall only be
                                            used to carry on or facilitate business as contemplated under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">d)&#9;A
                                            Party may disclose Confidential Information pursuant to the requirements of a government
                                            agency or pursuant to a court order, provided that the Party shall take all reasonable steps,
                                            including, but not limited to the seeking of an appropriate protective order, to preserve
                                            the confidentiality of the Confidential Information provided.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">If
                                            this Agreement is terminated for any reason, any Party in receipt of Confidential Information
                                            shall promptly deliver or destroy all Confidential Information of the disclosing Party without
                                            retaining copies thereof, except where such copies are required for audit, inspection or
                                            legal proceeding arising from this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
5<BR>
<BR>
REPRESENTATIONS, WARRANTIES AND INDEMNITY</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Representations
                                            and Warranties of Parties </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
represents and warrants to CASHMAN that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                            is a corporation duly organized, validly existing and in good standing, and it has the right
                                            and authority to enter this Agreement, and do all acts and things as required or contemplated
                                            to be done, observed and performed by them hereunder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
represents and warrants to Licensee that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
                                            is an individual in good standing, and it has the right to grant the license to the Licensee
                                            as provided herein and that such grant is not in conflict with any other agreement to which
                                            he is a party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
hereby disclaims any representation and warranty of: fitness for any particular purpose; merchantability; scope, patentability or validity
of the Patents set out in Schedule C; that the Technology is safe for any use or purpose whatsoever ; or non-infringement of any Third
Party rights. Further, any Material delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous
properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Both
CASHMAN and Licensee represent and warrant to each other that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            execution, delivery and performance of this Agreement does not contravene any law, rule or
                                            regulation of any Party or of the jurisdiction in which it is incorporated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Indemnity</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
shall indemnify and hold harmless the CASHMAN from and against any and all claims, threats, loss, liability, damage or expense, including
reasonable attorney&#8217;s fees, by reason or arising out of any acts or failure to act by or out of any use of Technology, Patents,
Materials or Licensed Products by sub-licensees or by Licensee or its servants, agents, officers, directors, stock-holders, employees,
or customers. The Party seeking indemnification shall give the Licensee prompt notification of any such claim, threat, loss, liability,
damage or expense. The indemnity provided herein shall survive any termination or assignment of this Agreement without time limit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Insurance</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee,
at its own expense and at all times, during the term of this Agreement, shall carry and maintain in full force and effect comprehensive
general liability insurance policy in the amount of one million dollars ($1,000,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
6<BR>
<BR>
TERM AND TERMINATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Term</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">This
Agreement shall come into effect upon the Effective Date, and unless earlier terminated, shall terminate on the expiration or invalidity
of the last issued Patent or twenty (20) years, whichever is longer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            occurrence of any one or more of the following events shall constitute a fundamental breach
                                            of this Agreement and shall, in addition to any other right or remedy either Party may have,
                                            permit a Party hereto to terminate this Agreement upon fourteen (14) days prior written notice
                                            to the other Party:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">if
                                            either Party breaches any covenant or obligation in this Agreement whatsoever and such breach
                                            is not fully remedied within thirty (30) days after the Party in breach receives written
                                            notice of such breach from the other Party;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">if
                                            a Party breaches any material covenant or obligation in this Agreement, including, but not
                                            limited to, the obligations of Licensee under Sections 3.1 and 3.2); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.5in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">iii.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">in
                                            the event of any adjudication of bankruptcy, appointment of a receiver by a Court of competent
                                            jurisdiction, assignment for the benefit of creditors, involving a Party either voluntary
                                            or involuntary, or appointment of a receiver by a Party for any reason whatsoever. Such termination
                                            shall not impair or prejudice any other right or remedy that CASHMAN may otherwise have under
                                            this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Termination
                                            as set forth in this Section shall not relieve any of the Parties of any obligations accrued
                                            under this Agreement prior to the date of termination. The following provisions shall survive
                                            termination of this license: Sections 3.3 (Accounting &amp; Records); 4.5 (Confidentiality);
                                            5.2 (Indemnity); 6.3 (Termination); 7 (Dispute Resolution); and 8 (General Provisions).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Effect
                                            of Termination</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Upon
termination of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                            shall cease use of Technology, Licensed Products, Materials and Patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                            shall pay promptly all amounts it owes to CASHMAN; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Licensee
                                            shall, at the direction of and in the sole discretion of CASHMAN, terminate any and all sub-licenses
                                            granted under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
7<BR>
<BR>
DISPUTE RESOLUTION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Dispute</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In the
event of any dispute, claim, question or difference arising out of or relating to this Agreement or the breach thereof, the Parties hereto
shall use their best efforts to settle such disputes, claims, questions or differences. To this effect, they shall consult and negotiate
with each other, in good faith and understanding of their mutual interests, to reach a just and equitable solution satisfactory to the
Parties. If they do not reach such solution within a period of thirty (30) days, then upon notice by a Party to the other Party the disputes,
claims, questions or differences shall be finally settled by arbitration in accordance with the provisions of the Arbitration Act, 1991
(Ontario) and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Arbitration
                                            Tribunal</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The arbitration
tribunal shall consist of one arbitrator appointed by mutual agreement of the parties or, in the event of failure to agreement within
thirty (30) days, any party may apply to a judge of the Ontario Court (General Division) to appoint an arbitrator. The arbitrator shall
be qualified by education and training to pass upon the particular matter to be decided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Time</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The arbitrator
shall be instructed that time is of the essence in proceeding with his determination of any dispute, claim, question or difference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.4</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Location
                                            of Arbitration</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The arbitration
shall be conducted in English and shall take place in Toronto, Ontario.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.5</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Award</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The arbitration
award shall be given in writing and shall be final, binding on the Parties, not subject to any appeal, and shall deal with the questions
of costs of arbitration and all matters related thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.6</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Judgment</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Judgment
upon the award rendered may be entered into any court having jurisdiction or application may be made to such court for a judicial recognition
of the award or an order of enforcement thereof, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">ARTICLE
8<BR>
<BR>
GENERAL</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.1</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Time</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Time
is of the essence of each provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.2</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assignment
                                            and Sub-licenses</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">This
                                            Agreement may only be assigned or transferred by the Licensee, upon prior written consent
                                            by CASHMAN, to any Affiliate on the condition that (i) such Affiliate becomes a Party to
                                            this Agreement, (ii) such Affiliate agrees to perform all obligations of the Licensee hereunder
                                            (iii) that such assignment shall not relieve the Licensee from observing and performing its
                                            obligations under this Agreement and (iv) that Licensee shall cause such Affiliate to observe
                                            and perform the covenants and obligations to be observed and performed by Licensee hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
                                            Licensee is responsible for any and all activities of any sub-licensee and the sub-licensee
                                            shall adhere to all confidentiality and indemnity requirements set forth in this Agreement.
                                            No sub-license granted by Licensee shall be less favorable with respect to any term or condition
                                            to CASHMAN than the license granted herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.3</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Notices</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Any notice,
demand or other communication required or permitted to be given or made hereunder shall be in writing and shall be sufficiently given
or made if delivered personally or sent by prepaid registered mail to its address or by telecopier to the number and to the attention
of the person set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
                                            the case of a notice to CASHMAN:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention: Dr. Neil Cashman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Telecopier No.: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
                                            the case of a notice to Licensee:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">AMORFIX LIFE SCIENCES LTD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">3080 Yonge St., Suite 6020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Toronto, Ontario</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">M4N 3M1, Canada</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention: Dr. George Adams,
CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Telecopier No.: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Each
notice sent in accordance with this Section shall be deemed to have been given and received:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">if
                                            delivered, on the day it was delivered if received within normal business hours;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">if
                                            mailed, on the third business day following the date on which it was mailed, unless an interruption
                                            of postal services occurs or is continuing on or within the three business days after the
                                            date of mailings in which case the notice shall be deemed to have been received on the third
                                            business day after postal service resumes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1in"></TD><TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">if
                                            sent by telecopier, on the day it was received, or on the first business day thereafter if
                                            the day on which it was sent was not a business day or outside normal business hours.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Either
Party may by notice to the other, given as aforesaid, designate a changed address or telecopier number.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.4</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Conflict</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">In the
event any term or any part of any term of this Agreement is determined to be void or unenforceable, such term or part of a term shall
be considered separate and severable from this Agreement and the remaining terms shall continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.5</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Governing
                                            Law</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">This
Agreement shall be interpreted and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable
therein. Unless specified otherwise, reference in this Agreement to a statute refers to that statute as it may be amended, or to any
restated or successor legislation of comparable effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.6</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Further
                                            Assurances</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The Parties
agree to execute, acknowledge and deliver all such further instruments, and to do all such other acts, as may be necessary or appropriate
to carry out the intent and purpose of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.7</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Waiver
                                            of Rights</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">The failure
of a Party at any time to request the other Party hereto to comply with any of the terms, conditions or covenants hereof shall not be
deemed a waiver of such terms, conditions or covenants. Waiver by a Party of a breach of any term or condition of this Agreement shall
not be considered a waiver of any subsequent breach of the same or of any other term or condition hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.8</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Public
                                            Disclosure</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">A Party
will not use the name of the other Party, nor any member of such Party&#8217;s staff in any advertising or publicity without the prior
written approval of an authorized representative of the body whose name is to be used. However, a Party may notify others of the fact
that this Agreement is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.9</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Consulting
                                            Option</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">CASHMAN
will provide technical knowledge and advice on an ad hoc basis towards fulfilling the objectives of this Agreement. Such assistance shall
be subject to the terms and conditions of a separate contract for services between CASHMAN and Licensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.10</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Force
                                            Majeure</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">No Party
shall be responsible or liable to the other for failure or delay in the performance of this Agreement due to war, fire, accident or other
casualty, labor disturbance, act of the public enemy, act of God, or any other contingency beyond that Party&#8217;s reasonable control.
In the event of applicability of this Article, the Party affected by such force majeure shall use its best efforts to eliminate, cure
and overcome any such causes and resume performance of its obligations as soon as possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.11</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Entire
                                            Agreement</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">This
Agreement sets forth the entire agreement and understanding of the Parties relating to the subject matter contained herein and merges
all prior discussions and agreements </FONT>between them, and neither Party shall be bound by any definition, condition, warranty or
representation other than expressly stated in this Agreement. Any amendment to this Agreement shall not be effective unless it is in
writing and signed by the duly authorized signing officers of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.12</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Facsimile
                                            Execution</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">To evidence
the fact that it has executed this Agreement, a Party may send a copy of its executed counterpart to the other Party by facsimile transmission.
That Party shall be deemed to have executed this Agreement on the date it sent such facsimile transmission. In such event, such Party
shall forthwith deliver to the other Party the counterpart of this Agreement executed by such Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"><FONT STYLE="font-size: 10pt"><B>8.13</B></FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Succession</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">This
Agreement shall be binding upon and ensure to the benefit of the Parties hereto and their respective heirs, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>IN WITNESS WHEREOF</B>,
the Parties have caused this Agreement to be executed in a legally binding manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>CASHMAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">/s/
    Neil Roy Cashman</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dr. Neil Roy Cashman</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>AMORFIX LIFE SCIENCES LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">/s/
    George Adams</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Dr. George Adams,</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Page 16 of 17</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE A</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">University of Toronto
Invention Disclosure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[Intentionally Omitted]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE B</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Assignment of Rights
from University to CASHMAN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">[Intentionally omitted]<BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE C<BR>
PATENT APPLICATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-weight: normal">[Intentionally
omitted]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">SCHEDULE D<BR>
MILESTONES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; font-size: 10pt; width: 12%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Milestones</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; width: 88%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Contribute
    $[***], cash and/or in-kind, over three (3) years from the Effective Date of the Agreement towards the development of the Technology.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">As
    part of up front considerations pay filling costs for the Patent(s) and any foregoing cost associated with the prosecution and maintenance
    of the Patent(s) during the Term of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><U>ASSIGNMENT</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In consideration
of one dollar and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Neil
Cashman</B>, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Marty
Lehto</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">whose full post
office addresses are</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">do hereby confirm
that we have sold and assigned, and do hereby sell and assign to <B>Amorfix Life Sciences Ltd</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">whose full post
office address is 3080 Yonge Street, Suite 6020, Toronto, Ontario, Canada M4N 3N1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">all our right,
title and interest in the United States of America, Canada and all other countries, in an invention and patent applications described
in the attached Schedule A and any patents which may issue therefrom, and in and to any divisions, continuations, continuations-in-part
and extensions of the patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We agree that we
will, without further consideration, but at the expense of the assignee, do all such things and execute all such documents as may be
necessary or desirable to obtain and maintain the patents and patent applications and for additions and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">modifications thereto
in any and all countries, and to vest title thereto in the assignee, its successors, assigns and legal representatives or nominees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Signed at ______________________
this _____ day of ________________ 2006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-size: 10pt">Signature of Witness&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 49%"><FONT STYLE="font-size: 10pt"><B>Neil Cashman</B></FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Signed at ______________________
this _____ day of ________________ 2006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-size: 10pt">Signature of Witness&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 49%"><FONT STYLE="font-size: 10pt"><B>Marty Lehto</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We confirm and
accept the assignment of the invention and all related patent applications and patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Signed at ______________________
this _____ day of <U>________________</U> 2006</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom"><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Amorfix Life Sciences Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-size: 10pt">Signature of Witness</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 4%">By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.75in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5.75in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Schedule &#8220;A&#8221;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-left: 2pt; font-size: 10pt; width: 34%; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Tile</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; width: 33%; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Application
    No.</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; width: 33%; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt"><B>Filing
    Date</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 2pt; font-size: 10pt; padding-top: 3pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>52
<FILENAME>filename52.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.34</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information
that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SERVICE AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNIVERSITY OF SASKATCHEWAN<BR>
<FONT STYLE="font-weight: normal">a statutory corporation pursuant to <I>The University of Saskatchewan Act, 1995</I>, of Saskatchewan<BR>
as represented by its Vaccine and Infectious Disease Organization-International Vaccine Centre,<BR>
a division of the University of Saskatchewan, having an office at 120 Veterinary Road,<BR>
Saskatoon, Saskatchewan, Canada S7N 5E3 (hereinafter &#8220;VIDO-InterVac&#8221;)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ProMIS Neurosciences, Inc.<BR>
<FONT STYLE="font-weight: normal">a body corporate under the laws of Canada, having an office for the conduct of its business<BR>
located at 1920 Yonge St., Suite 200, Toronto, Ontario, Canada M4S 3E2 (hereinafter the<BR>
 &#8220;Purchaser&#8221;)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS </B>the Purchaser wishes to engage
the services of VIDO-InterVac on the terms and conditions and understandings hereinafter set forth; and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS </B>VIDO-InterVac is willing to perform
the services, and to make its premises, facilities, and services available, and VIDO-InterVac wishes to perform the services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS </B>the Purchaser and VIDO-InterVac
may wish to pursue a collaboration including animal studies and funding to further develop the Material if the Services produces positive
results</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW THEREFORE</B>, in consideration of the
foregoing premises, and the mutual covenants herein contained, the Parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">1.</FONT></TD><TD><U>OBLIGATIONS OF THE PURCHASER</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Purchaser shall provide to VIDO-InterVac funds in the amount of [***] ($[***]) (the &#8220;Fee&#8221;) for conducting the work
as specified in Appendix A as Stage 1 (the &#8220;Services&#8221;). Seventy Five percent of the Fee ($[***]) shall be due upon execution
of this Agreement, and the remaining twenty five per cent of the Fee ($[***]) shall be due 30 days after the final report has been received
as per Section 2.4. No work will be performed on the Services until initial payment is received by VIDO-InterVac. Appropriate invoices
will be emailed to [***] by University of Saskatchewan Controller&#8217;s Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
payment is not received prior to the expiry of the thirty (30) day period following execution of the Agreement or receipt of final report,
then interest will accrue on the outstanding balance at the rate of one and one half percent (1.5%) per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Purchaser
shall provide test material (the &#8220;Material&#8221;) as further described in Appendix A to VIDO-InterVac at the sole risk and
expense of Purchaser. Purchaser shall be responsible for complying with all laws and regulations concerning the export of the
Material and assumes all liability for the transport and delivery of the Material. Purchaser will obtain any appropriate import
permit as may be required for the import of any biological samples resulting from the performance of the Services (the
 &#8220;Resulting Material&#8221;) as further described in Appendix A. VIDO-InterVac will provide reasonable assistance to Purchaser
to obtain the permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If applicable, Purchaser shall be liable for the replacement cost of any animal that dies or is euthanized solely as a result of
an adverse reaction to any vaccination administered in performance of the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Purchaser
shall complete a short user satisfaction survey (attached as Appendix B) within 30 days of the end of Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">2.</FONT></TD><TD><U>OBLIGATIONS OF VIDO-InterVac</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
shall receive and administer the Fee in accordance with the terms of this Agreement. VIDO-InterVac shall carry out the Services in accordance
with acceptable research standards, the research policies of VIDO-InterVac, and in accordance with the proposal approved by the Purchaser
(Appendix A). VIDO-InterVac shall not disclose, transfer or distribute any Material to any third party, or otherwise use any Material
in any research or other activity, outside of the Services hereunder without the written direction or consent of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
will apply to obtain any appropriate import permit as may be required for the import of any Material. Purchaser will provide all assistance
required to VIDO-InterVac to obtain the permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
shall use the Material only in performing the Services. Upon completion of the Services any unused Material shall be destroyed. Any Resulting
Material will be kept for 3 months after the expiry of this Agreement at which point Resulting Material will be destroyed unless otherwise
agreed to by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
shall provide the Purchaser a final report upon completion of the Services. This report will contain data, but no intellectual contribution
(such report and all such data and related information being the &#8220;Data&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
shall comply with all applicable laws, rules and regulations concerning the Services, the Material, the Resulting Material and the Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
will permit the use of VIDO-InterVac premises, facilities, and services for the research in accordance with the applicable policies and
priorities of the VIDO-InterVac.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Upon
request VIDO-InterVac will permit a representative of the Purchaser, including agents, to visit the premises of VIDO-InterVac from time
to time to oversee the Services (each a &#8220;<B>Visitor</B>&#8221;). Prior to any Visitor entering VIDO-InterVac, VIDO-InterVac requires
the following from Purchaser and/or Visitor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">a letter stating that Visitor is at VIDO-InterVac for Purchaser&#8217;s employment purposes</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">a copy of government issued photo identification (e.g., passport or drivers license).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purchaser may also request to VIDO-InterVac that
the Visitor be permitted to actively participate in the Services (<B>&#8220;Participating Visitor</B>&#8221;). If VIDO-InterVac agrees
to allow a Participating Visitor, the Purchaser and/or Participating Visitor agree to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Supply proof of liability insurance as per Section 7.1,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Complete University of Saskatchewan specific online Biosafety Training and Animal Training (as required)
and VIDO-InterVac specific containment level 3 (CL3) training (CL3 work only) and CL3 Lab Specific Training as required.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">A signed agreement to abide by the operational policies of VIDO-InterVac.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, security background checks will be
required for any Participating Visitor working in containment level 3, but may be required for any Participating Visitor at VIDO-InterVac&#8217;s
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">3.</FONT></TD><TD><U>CONFIDENTIALITY</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Parties agree to keep confidential and not disclose to others information designated in writing as confidential and supplied by them
for the purpose of developing the Services (&quot;Confidential Information&quot;). The obligation to keep such information confidential
shall not apply to information which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">is already known to the Party to which it is disclosed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">is or becomes part of the public domain without breach of this Agreement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">is obtained from third parties which have no obligation to keep confidential to the contracting parties;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is required to be disclosed by law, but only to the extent so required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties agree not to use Confidential Information
for any purpose other than the purposes set forth in this Agreement for a period of five (5) years from the Effective Date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">4.</FONT></TD><TD><U>TERM, AMENDMENT, RENEWAL AND TERMINATION</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
term of this agreement shall be from 1-September-2020 (&#8220;Effective Date&#8221;) to 28-February-2021 (&#8220;Term&#8221;). The performance
of the Services is contingent upon the Material arriving at VIDO-InterVac in a timely manner. If the Material does not arrive at VIDO-InterVac
in time such that the Term remains suitable the Parties may extend the Term. The Parties may only further amend, renew or extend the
Agreement by mutual consent and in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>This Agreement may be terminated by either Party by giving thirty (30) days written notice to the other. In the event of termination,
the Parties shall take all necessary steps to effect the orderly termination of the Services, including any final reporting required.
The Purchaser agrees that the Fee is non-refundable. If VIDO-InterVac fails to obtain any import permit required for the Material within
the Term VIDO-InterVac shall return any uncommitted funds, less administrative expenses, to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">5.</FONT></TD><TD><U>OWNERSHIP OF MATERIAL, RESULTING MATERIAL, DATA AND PUBLICATION.</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Unless
otherwise agreed to in writing, all Material, Resulting Material and Data resulting from the Services shall become property of Purchaser.
Notwithstanding the above, the Parties agree that VIDO-InterVac shall retain ownership to its background intellectual property and material
(including but not limited to cell lines and challenge strains) and all rights to any processes, software (including codes), technology,
means and know-how developed by it in the performance of the Services, including, without limitation, those which relate to laboratory
testing, animal models and data collection or management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac agrees that no right or license to the Material is granted or implied as a result of the Services hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
anything to the contrary in this Agreement VIDO-InterVac may disclose the identity of the Purchaser as a supporter of VIDO-InterVac.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Purchaser acknowledges that publication is important to VIDO-InterVac; however, VIDO-InterVac will not publish or disclose any
Data or results generated as a result of its performance of the Services to any third party without Purchaser&#8217;s prior written consent.
If Purchaser consents to publication of Data or results from Services, VIDO-InterVac will give Purchaser sixty (60) days in which to review
and comment thereon prior to publishing. If the publication is joint, the Purchaser and VIDO-InterVac will work together to draft the
publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">6.</FONT></TD><TD><U>WARRANTY</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
provides no warranties, whether statutory, express or implied, with respect to the results of the Services requested by the Purchaser.
If the Purchaser should decide to take action based on the results of the Services provided, the implementation and results of such action
shall be at the Purchaser's own risk. The Purchaser waives any claims that it may have against VIDO-InterVac regarding the use of such
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">7.</FONT></TD><TD><U>INSURANCE &amp; INDEMNIFICATION</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Purchaser, at its own expense and without limiting its liabilities herein, shall insure its operations under a contract of General Liability
Insurance, in an amount not less than $5,000,000 inclusive per occurrence, insuring against bodily injury, personal injury and property
damage including loss of use thereof. This insurance shall include blanket contractual liability. Proof of insurance must be provided
prior to Service being initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Purchaser shall indemnify and save harmless VIDO-InterVac, and its respective administrators, officers, students and employees, from
and against any and all liability, loss, and expense (including reasonable solicitor's fees and expenses of litigation) on claims relating
to injury or damages arising out of or resulting from, or that are alleged to arise out of or result from, the actions or omissions by
the Purchaser, its servants or agents, with respect to or connected with the Services provided pursuant to this Agreement; except to
the extent that any such liability, loss and /or expense is the result of VIDO-InterVac&#8217;s negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">8.</FONT></TD><TD><U>NOTICES</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice, approval, consent or other communication
under this Agreement shall be effectively given if in writing and delivered in person, by courier, by registered mail or if transmitted
by facsimile addressed to a Party at its address as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">Purchaser:</TD><TD>ProMIS Neurosciences, Inc.<BR>
1920 Yonge St., Suite 200<BR>
Toronto, Ontario M4S 3E2<BR>
Fax: [***]</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Dr. Elliot Goldstein (CEO)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in">VIDO-InterVac:</TD><TD>[***]<BR>
<BR>
Fax: [***]<BR>
Attention: Business Development</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                         <TR STYLE="vertical-align: top">
<TD>and copy to: </TD><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">University of Saskatchewan<BR>
[***]</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0">Fax: [***]</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Contracts Specialist</P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: [***]</P>
</TD></TR>
                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such notice is deemed to have been received:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">on the day of delivery, if hand delivered;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">when the Party acknowledges receipt, if sent by registered mail; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">the day of transmission with a receipt notification, if sent by facsimile.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Either Party may change the above-noted address
by way of a notice sent in accordance with this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">9.</FONT></TD><TD><U>GENERAL CONDITIONS</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
shall be deemed to be and shall be an independent contractor and as such VIDO-InterVac shall not be entitled to any benefits applicable
to employees of the Purchaser. Nothing herein shall be considered as placing VIDO-InterVac and the Purchaser in the position of partners
or joint venturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Neither
Party is authorized or empowered to act as agent for the other for any purpose and shall not on behalf of the other enter into any contract,
warranty or representation as to any matter, except as may be explicitly provided for herein or authorized in writing. Neither shall
be bound by the acts or conduct of the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac
may not assign this Agreement without the written consent of Purchaser. Subject to the limitation of assignment of this Section 9.3,
this Agreement shall be binding upon the Parties and their respective successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Purchaser
shall not use or permit others to use the name of the VIDO-InterVac, or refer to their participation in the research and the Services,
for any sales or promotional purposes without the written consent of VIDO-InterVac.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>This Agreement, including Appendix A, constitutes the entire understanding between the Parties. No modification or alteration
of this Agreement will be effective unless agreed to in writing by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">10.</FONT></TD><TD><U>DISPUTES RESOLUTION</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Disputes
which the Parties cannot resolve by negotiation will be submitted to arbitration in accordance with the provisions of <I>The Arbitration
Act, 1992</I>, Statutes of Saskatchewan, or its successor legislation in force from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Parties shall appoint a single arbitrator to adjudicate the issue. If the Parties cannot agree on a single arbitrator, the opposing disputing
party shall each appoint one arbitrator and the two arbitrators shall appoint a third, and the three arbitrators shall constitute the
panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
panel&#8217;s adjudication of unanimity or two-thirds majority shall be binding on the Parties. The Parties shall each bear its own proportionate
share of the arbitration costs unless otherwise awarded by the arbitrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">11.</FONT></TD><TD><U>FORCE MAJEURE</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&#8220;Force
Majeure&#8221; means anything outside the reasonable control of a Party, including but not limited to, acts of God, fire storm, earthquake,
explosion, accident, war, rebellion, insurrection, sabotage, epidemic, quarantine restrictions, labour dispute, labour shortage, transportation
embargo, failure or delay in transportation, or an act or omission (including laws, regulations, disapprovals or failure to approve)
of any government or government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
VIDO-InterVac is wholly or partially precluded from complying with its obligations under this Agreement by Force Majeure, then its obligations
to perform in accordance with this Agreement will be suspended for the duration of the Force Majeure. As soon as practicable after an
event of Force Majeure arises, VIDO-InterVac shall notify the other Party of the extent to which it is unable to perform its obligations
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>VIDO-InterVac shall be not responsible to another for any delay in the performance of, or failure to perform, its obligations under
this Agreement where such delay or failure is caused by circumstances beyond the reasonable control of VIDO-InterVac, including, without
limitation, causes including strikes, lockouts or any other labour disruptions, war, natural disaster, disease or epidemic, or acts of
God. In the event of any such delay or failure in performance, VIDO-InterVac shall be granted an extension of time for performance that
is equitable in light of the cause of the delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">11.</FONT></TD><TD><U>COUNTERPARTS</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This agreement may be executed in one or more
counterparts, each of which together shall constitute one and the same Agreement. For purposes of executing this Agreement, a facsimile
(including a PDF delivered via email) copy of this Agreement, including the signature pages, will be deemed an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="text-transform: none">12.</FONT></TD><TD><U>GOVERNING LAW</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall be governed by and interpreted
in accordance with the laws of the Province of Saskatchewan and the Parties hereby expressly attorn to the jurisdiction of the courts
of Saskatchewan for enforcement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF, </B>the
duly authorized officers of the Parties have executed this Agreement on the date last written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AGREED:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font-size: 10pt; border-collapse: collapse; width: 95%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 49%; font-size: 10pt; font-weight: bold">PURCHASER &nbsp; &nbsp; &nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; font-size: 10pt; font-weight: normal"> /s/ Elliot Goldstein</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Name: Elliott Goldstein</TD>
    <TD>&nbsp;</TD>
    <TD>Date &nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Title: President &amp; CEO</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Witness:</TD>
    <TD>&nbsp;</TD>
    <TD>Date </TD></TR>
  </TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font-size: 10pt; border-collapse: collapse; width: 95%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><B>UNIVERSITY OF SASKATCHEWAN</B></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 49%">/s/</TD>
    <TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">For Chair, Board of Governors</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Date </TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">For Secretary, Board of Governors</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Date </TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic">Acknowledged by:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: normal; font-style: normal">/s/ Volker Gerdts</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Volker Gerdts, Director </TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>APPENDIX A &#8211; THE SERVICES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>APPENDIX B &#8211; USER SATISFACTION SURVEY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;of 9</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>53
<FILENAME>filename53.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.35</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt; text-align: justify"><B><I>Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation
S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information
that the registrant treats as private or confidential. Redacted information is indicated by: [***]</I></B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS ASSIGNMENT</B> is made the <U>18</U><SUP>th
</SUP>day of February, 2005 between <B>NEIL R. CASHMAN</B> (&quot;<B>Cashman</B>&quot;) and <B>MARTY LEHTO</B> (&quot;<B>Lehto</B>&quot;)
(together the &quot;<B>Assignors</B>&quot;) and <B>THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO</B> (&quot;<B>University</B>&quot;)
and <B>AMORFIX LIFE SCIENCES LTD</B> (the &quot;<B>Assignee</B>&quot;), a corporation incorporated under the laws of Canada (collectively
the &quot;<B>Parties</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B> the Assignors have invented an
epitope protection technology, and have filed a PCT application entitled &quot;Epitope Protection Assay&quot; on August 20, 2004 to the
Canadian Receiving Office (the &quot;Patent Application&quot;) attached as Schedule A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Cashman disclosed the technology
to the University on October 30, 2002 by way of an invention disclosure form attached as Schedule B (the &quot;Invention Disclosure&quot;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B> Cashman assigned all rights, title
and interest in the epitope protection technology to the University on September 3, 2003 which agreement is attached as Schedule C. The
University assigned all rights, title and interest in the epitope protection technology back to Cashman on September 19, 2003 (the &quot;University
Assignment&quot;) which agreement is attached as Schedule D, subject to certain terms and conditions including but not limited to a [***]
percent ([***]%) revenue share (the &quot;Revenue Interest&quot;) and a non-exclusive licence to use the Invention solely for research,
administration and academic purposes (collectively, the &quot;Rights of the University&quot;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B> the Invention Disclosure was subsequently
amended on September 21, 2004 which agreement is attached as Schedule E, to include Lehto as an inventor and the University Assignment
was amended accordingly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, subject to the Rights of the University,
the Assignors have the right -to assign and transfer all rights, title and interest in the Invention to the Assignee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B> the Assignee will have [***] ([***])
common shares (&quot;Founder shares&quot;) issued and outstanding at an issue price of $0.00001 per Founder share following the issuance
of Founder shares pursuant to clause 3.1.1, of which Cashman and Lehto are the beneficial owners of [***] Founder shares and [***] Founder
shares, respectively;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B> the Assignee intends to complete
a reverse take-over with a corporation (&quot;pubco&quot;) listed on the TSX Venture Exchange, pursuant to which the Assignee would either
become a wholly-owned subsidiary of the pubco or amalgamate with the pubco;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>AND WHEREAS</B>, the Assignee, the full post
office address of whose registered office is Suite 1400, 1055 West Hastings Street, Vancouver, British Columbia, V6E 2E9, is desirous
of acquiring the entire right, title and interest in and to the technology and the associated patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW THEREFORE THE PARTIES HERETO AGREE AS FOLLOWS</B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>DEFINITIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">&quot;Invention&quot; means the epitope protection technology as described in the Invention Disclosure
as revised including any Patent Rights and Know-How.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">&quot;Improvements&quot; means any and all improvements, variations, updates, modifications or enhancements
to the Invention created by either one or both of the Assignors that are within the scope of the claims of the
Patent Rights which have been created under any Research Agreement with the University.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">&quot;Know-How&quot; means any and all trade secrets, proprietary know-how, confidential information,
materials, research data and protocols directly and exclusively related to the Patent Rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">&quot;Patent Rights&quot; means the Patent Application, including any patents issuing therefrom and any
further applications claiming priority from this application, as well as any continuations, divisionals thereof, or any substitute application
therefore or equivalent thereof, and any patent issuing thereon, including any re-issues, renewals, extensions, or re-examinations thereof,
and any confirmation patent or registration patent, or patent of additions based on any such patent of the above in all jurisdictions
of the world.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify">&quot;Research Agreement&quot; means any agreement between the University and Assignee, in the standard
form and which includes a right of first refusal to obtain the rights to commercially exploit intellectual property developed under the
agreement on terms (including compensation to the University) that generally reflect the industry norm.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>ASSIGNMENTS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">Subject to the terms and conditions set out below, the Assignors for themselves and for their successors
and assigns, hereby sell, assign and transfer to the Assignee all right, title, interest and obligations which they now have, or may hereafter
have, in the Invention, as assigned to them under the University Assignment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">The Assignors agree to execute any applications, transfers, assignments and/or such other documents the
Assignee may consider necessary or desirable from time to time for the purpose of obtaining, maintaining or vesting in and/or assigning
to Assignee absolute title to any patents, copyright, integrated circuit topography, industrial design or trade mark registrations for
the Invention; or for the purpose of applying for, prosecuting, obtaining or protecting any such patents, copyright, integrated circuit
topography, industrial design or trade mark registrations in any and all parts of the world and Assignors further agree to cooperate and
assist in every way possible in the prosecution and protection of any such applications and the rights granted in respect thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>CONSIDERATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">In consideration for this sale, assignment and transfer of the Invention, the Assignee shall:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.1.1</TD><TD STYLE="text-align: justify">pay $10.00 to each of the Assignors and issue to the University one million, two hundred and fifty thousand
(1,250,000) Founder shares at a deemed price of $0.00001 per share; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.1.2</TD><TD STYLE="text-align: justify">enter into a Research Agreement with the University to fund further research to be conducted by or under
the supervision of Cashman to develop the Invention further.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">The University acknowledges that the shares it receives under clause 3.1.1 above are in full and final
payment of its Revenue Interest related to the assignment of the Invention hereunder and no further compensation
or other amounts shall be due from the Company or the Inventors to the University with respect to this assignment or the Company's use
of the Invention.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify">All transfers of shares shall be permanent and non-refundable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>LICENSE TO USE</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">The Assignee acknowledges that the University has reserved a non-assignable, non-sublicensable, non-transferable,
perpetual, royalty free, non-exclusive license to use the Invention for research, teaching and administrative purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The Assignee acknowledges that the Assignors reserve a non-assignable, non-sublicensable, non-transferable,
perpetual, royalty free, non-exclusive license to use the Invention for research, teaching and administrative purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>TERM AND TERMINATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">The term of this Agreement shall be for the life of any patents directly related to the Invention, unless
otherwise terminated in accordance with the provisions herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">An Assignor or the University may terminate this Agreement upon 30 days written notice to Assignee if
Assignee is in breach of any of its obligations hereunder, and if Assignee has not resolved its breach to the satisfaction of the Assignor
or University within the 60 days termination period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">An Assignor or the University may terminate this Agreement upon sixty (60) days written notice to Assignee
until such time that the Assignee has been successful in achieving the following milestones:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.3.1</TD><TD STYLE="text-align: justify">a minimum of $1.2 million gross proceeds in financing to be raised by the Assignee or its successor or
affiliate, of which at least 75% will be committed by the Assignee or its successor or affiliate to the further development of the Invention
by June 30, 2005; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.3.2</TD><TD STYLE="text-align: justify">a minimum of $200,000 committed by the Assignee or its successor or affiliate under a Research Agreement
by April 30, 2005.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">This Agreement and the rights granted hereunder shall terminate immediately and revert to Assignor in
the event of any adjudication of bankruptcy, appointment of receiver by a Court of competent jurisdiction, assignment for the benefit
of creditors, involving Assignee either voluntary or involuntary, or appointment of a receiver by Assignee for any reason whatsoever.
Such termination shall not impair or prejudice any other right or remedy that Assignor may otherwise have under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.5</TD><TD STYLE="text-align: justify">In the event of termination under 5.2, 5.3 or 5.4 all rights, title, interest and obligations granted
herein shall revert to the Assignors and the Assignee will execute an assignment to the Assignors of all the patents granted for the Invention
including any Improvements created by the Assignee then in its possession or control, if any, and the Assignee shall refrain from further
use of such Invention.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD>DISPUTE RESOLUTION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">The Parties shall use their best efforts to settle in a fair and reasonable manner any disputes arising
in connection with this Agreement. Any matter that cannot be settled by the Parties between themselves shall be first submitted to a mediator
chosen jointly by the Parties. In the event that mediation does not bring a resolution satisfactory to each Party within 30 days, the
matter shall be submitted to arbitration before a single arbitrator pursuant to the Arbitration Act of Ontario.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD>LIABILITY</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">Assignee shall at all times during the term of this Agreement and thereafter, indemnify, defend and hold
Assignors, their successors and assigns, harmless against all claims, proceedings, demands and liabilities of any kind whatsoever, including
legal expenses and reasonable attorneys' fees, arising out of the death of or injury to any person or persons or out of any damage to
property, resulting from use of the Invention for any purpose, or arising from any right or obligation of Assignee hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">Except as otherwise expressly set forth in this agreement, Assignors, for themselves and their successors
and assigns, make no representations and extend no warranties of any kind, either express or implied, including but not limited to warranties
of merchantability, fitness for a particular purpose, validity of rights and interests claims, issued or pending, and the absence of latent
or other defects, whether or not discoverable. Nothing in this agreement shall be construed as a representation made or warranty given
by Assignors that the practice by Assignee of the rights granted hereunder shall not infringe the rights and interests of any third party.
In no event shall Assignors, their successors or assigns, be liable for incidental or consequential damages of any kind, including economic
damage or injury to property and lost profits, regardless of whether Assignors shall be advised, shall have other reason to know, or in
fact shall know of the possibility.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B> the Parties have caused
this Agreement to be signed by their duly authorized officers as of the day and date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">SIGNED in the presence of:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">/s/ Marty Lehto</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">/s/ Neil R. Cashman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">Name of Witness: Marty Lehto</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21"><B>NEIL R. CASHMAN</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">SIGNED in the presence of:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">/s/ Neil Cashman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">/s/ Marty Lehto</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">Name of Witness: Neil Cashman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21"><B>MARTY LEHTO</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21"><B>THE GOVERNING COUNCIL
    OF THE UNIVERSITY OF TORONTO</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21"><B>AMORFIX LIFE SCIENCES
    LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Peter B. Munsche</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ David Raffa</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">David
    Raffa</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">Peter
    B. Munsche</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">VP
    Consumer Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">Assistant
    Vice-President</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">Technology
    Transfer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D21">University
    of Tortono</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &quot;A&quot;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Patent Description</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &quot;B&quot;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Confidential
Invention Disclosure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &quot;C&quot;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Assignment of
Rights to the University of Toronto by Inventor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &quot;D&quot;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Assignment of
Rights from the University of Toronto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE &quot;E&quot;</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">Amendment to
University of Toronto Confidential Invention Disclosure and Related Assignment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Intentionally omitted]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35(1)
<SEQUENCE>54
<FILENAME>filename54.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit&nbsp;10.35.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;This <B>Amending Agreement</B> is made
the 1<SUP>st</SUP> day of April, 2005 between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEIL R. CASHMAN </B>(&quot;Cashman&quot;),
<B>MARTY LEHTO </B>(&quot;Lehto&quot;) (together the &quot;Assignors&quot;), <B>THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO </B>(&quot;University&quot;)
and <B>AMORFIX LIFE SCIENCES LTD </B>(the &quot;Assignee&quot;) (collectively the &quot;Parties&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties entered into an assignment agreement
dated the 18<SUP>th</SUP> day of February, 2005 under which the Assignors with the permission of the University assigned and transferred
all rights, title and interest in their epitope protection technology to the Assignee (the &quot;Assignment Agreement&quot;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As partial consideration for the assignment of
rights the Assignee was required to fund further research at the University to develop the invention further under the supervision of
Cashman; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Assignee did not enter into a research agreement
with the University for at least $200,000.00 in research funding by April 30, 2005 the University or the Assignors could revoke the assignment
upon 60 days written notice; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The imminent departure of Cashman from the University
has made those conditions impossible to achieve and thus the Parties now wish to amend the Assignment Agreement by reference herein; thus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Except as otherwise defined herein, any capitalized terms used in this Amending Agreement shall have the
meanings prescribed by the Assignment Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Article 3.1.2 of the Assignment Agreement is deleted and replaced by the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.1.2</TD><TD STYLE="text-align: justify">fund further research to be conducted by or under the supervision of Cashman to develop the Invention
further;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The milestones in Article 5.3 of the Assignment Agreement are deleted and replaced by the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.3.1</TD><TD STYLE="text-align: justify">a minimum of $1.2 million gross proceeds in financing to be raised by the Assignee or its successor or
affiliate</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.3.2</TD><TD STYLE="text-align: justify">a minimum of $200,000.00 spent by the Assignee or its successor or assignee on the further research and
development of the Invention.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The Assignee agrees to indemnify and hold harmless the University and the Assignors for any and all loss
or damages suffered by the Assignee with respect to further research and development of the Invention and the Assignee further releases
and relieves the University and the Assignors of all liabilities, duties and obligations, incurring as a result of the Assignee's inability
to undertake further research and development of the Invention at the University.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">All other terms of the Assignment Agreement remain unchanged and in full force and effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Parties have caused this
Agreement to be signed by their duly authorized officers as of the day and date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">SIGNED
    in the presence of:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Vigen Nazarian</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">/s/
    Neil R. Cashman</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Witness:
    Vigen Nazarian</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21"><B>NEIL
    R. CASHMAN</B></FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">SIGNED
    in the presence of:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">s/
    Vigen Nazarian</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">/s/
    Marty Lehto</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of Witness:
    Vigen Nazarian</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 0.75in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21"><B>MARTY
    LEHTO</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21"><B>AMORFIX LIFE SCIENCES
    LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Peter B.
    Munsche</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ George Adams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">George Adams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">Peter B. Munsche</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">Assistant Vice-President</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">Technology Transfer</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1E1D21">University of Toronto</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>55
<FILENAME>filename55.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.36</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns. Redacted
information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMIS NEUROSCIENCES<BR>
1920 YONGE ST.<BR>
TORONTO, ONTARIO, M4S 3E2, CANADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;21, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eugene Williams<BR>
[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Gene,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of ProMIS Neurosciences
Inc., a corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite&nbsp;200, Toronto, Ontario,
M4S 3E2 (the &ldquo;<B>Company</B>&rdquo;),&nbsp;I am pleased to offer you employment with the Company. The purpose of this letter is
to summarize the terms of your employment with the Company, should you accept our offer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be employed to serve
on a full-time basis as Chief Executive Officer (CEO) effective on January&nbsp;1, 2022. As CEO you will report to the ProMIS Neurosciences
Inc. Board of Directors (the &ldquo;<B>Board</B>&rdquo;). You will be responsible for duties as are consistent with such position as well
as other duties assigned by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your base salary will be at
the rate of $480,000 USD per year, paid twice a month on the 15<SUP>th</SUP> and last days of the month at rate of $20,000 per payroll
period. All pay will be subject to tax and other withholdings as required by law. Such base salary may be adjusted from time to time in
accordance with normal business practice and in the sole discretion of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ProMIS Neurosciences Inc.
employees who join between January&nbsp;1 and December&nbsp;31 of a given calendar year are eligible to be considered for a salary merit
increase during the next calendar year&rsquo;s Annual Compensation Review process. The Annual Compensation Review process, if and when
implemented, is anticipated to take place in the first quarter of the calendar year. Salary merit increases, if any, will be awarded at
the Company&rsquo;s discretion on the basis of your performance, and will be pro-rated based on the number of months that you actually
worked during the previous calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may participate in any
and all bonus and benefit programs that the Company establishes and makes available to its employees from time to time, provided you
are eligible under (and subject to all provisions of) the plan documents governing those programs. Subject to these programs, you will
be eligible to receive a bonus targeted at a percentage to be determined of your annualized base salary being determined by the Company
in its sole discretion, based on your performance and that of the Company against goals established by the Board. You must commence your
employment by January&nbsp;in order to be eligible for a bonus for the calendar year during which you were hired. If you join the Company
between January&nbsp;1st and September&nbsp;30th, you will be eligible for a pro-rated bonus for that calendar year. You must be employed
through the date bonuses are disbursed to employees generally in order to be eligible for the bonus. Regardless of your date of employment,
you will be eligible to participate in the benefit plans and programs made available by the Company from time to time for employees generally,
subject to plan terms and generally applicable Company policies. These currently or will include but are not limited to: health insurance
such as medical, dental and vision; company-paid basic life insurance, accidental death&nbsp;&amp; dismemberment, and short- and long-term
disability; paid time off such as vacation, sick leave and company-paid holidays; 401(k)&nbsp;retirement savings plan; and employee stock
purchase plan. You will be entitled to Directors and Officers insurance and such other insurance may be maintained by the Company. The
bonus and benefit programs made available by the Company, and the rules, terms, and conditions for participation in such benefit plans,
may be changed by the Company at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ProMIS Neurosciences Inc.
will award 3,000,000 stock options to you at the initiation of this contract. Options will be priced at a trailing 5-day VWAP. As per
the ProMIS Neurosciences Inc. Stock Option Plan, all granted Options shall have a 10-year exercise period from the date the Options have
been granted to the Employee, and will vest at 1/48<SUP>th</SUP> per month over the four (4)&nbsp;years following the award providing
you remain on the ProMIS Neurosciences Inc. Board of Directors. Upon termination of this Agreement all vested Options will be exercisable
at any time during the 12 months following such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Option Commitment (as
defined in the ProMIS Neurosciences Inc. Stock Option Plan) or stock option agreement between the parties shall include the terms set
out in herein. ProMIS Neurosciences Inc. hereby represents and warrants that all necessary corporate action has been taken by or on behalf
of ProMIS Neurosciences Inc. to grant the Options in accordance with this paragraph 3.0(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may be eligible to receive
such future stock option grants as the Board of Directors of the Company shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your employment is
terminated by the Company without Cause (as defined below) or you terminate your employment for Good Reason (as defined below) or
your employment is terminated as a result of a Change in Control (as defined below) and provided you execute and allow to become
effective (within 60 days following the termination or such shorter period as may be directed by the Company) a release of claims in
form included in <U>Exhibit&nbsp;A</U> (the &ldquo; Separation Agreement&rdquo;), (i)&nbsp;the Company will pay you as severance pay
an aggregate amount equivalent to 18 (eighteen) months of your then current base salary (pro-rated, if applicable), less all
applicable taxes and withholdings, which severance pay will be paid ratably in accordance with the Company&rsquo; s regular payroll
practices beginning in the Company&rsquo;s first regular payroll cycle after the Separation Agreement becomes effective; provided,
however, that if the 60th day referenced above occurs in the calendar year following the date of your termination , then the
severance pay shall begin no earlier than January&nbsp;l of such subsequent calendar year; and (ii)&nbsp;should you timely elect and
be eligible to continue receiving group medical coverage pursuant to the &ldquo;COBRA&rdquo; law, and so long as the Company can
provide such benefit without violating the nondiscrimination requirements of applicable law, the Company will for a period of 12
(twelve) months following your termination continue to pay the share of the premium for such coverage that is paid by the Company
for active and similarly-situated employees who receive the same type of coverage. The remaining balance of any premium costs shall
timely be paid by you on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA Attached as Appendix
A are the terms and conditions applicable to the payment of any severance hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">For purposes of this Agreement:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Cause&rdquo; means any of: (a)&nbsp;your
conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b)&nbsp;a
good faith finding by the Company&rsquo;s Board of Directors that you have (i)&nbsp;engaged in dishonesty, willful misconduct or gross
negligence that has a material adverse effect on the Company, (ii)&nbsp;committed an intentional act that materially injures the reputation,
business or business relationships of the Company, (iii)&nbsp;materially breached the terms of any restrictive covenants or confidentiality
agreement with the Company, (iv)&nbsp;fail or are unable to materially fulfill the role of CEO; provided that in the case of (b)&nbsp;that
you were given written notice of such violation or failure by the Board and a period of 30 days to cure (provided that the Board determines
that such violation or failure is curable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Change of Control&rdquo; shall
mean, regardless of form thereof, consummation of (a)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated
basis to an unrelated person or entity, (b)&nbsp;a merger, reorganization or consolidation in which the outstanding shares of capital
stock of the Company are converted into or exchanged for securities of the successor entity and the holders of the Company&rsquo;s outstanding
voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the successor entity immediately
upon completion of such transaction, (c)&nbsp;the sale of all or a majority of the outstanding capital stock of the Company to an unrelated
person or entity or (d)&nbsp;any other transaction in which the owners of the Company&rsquo;s outstanding voting power immediately prior
to such transaction do not own at least a majority of the outstanding voting power of the successor entity immediately upon completion
of the transaction; provided, however, that &ldquo;Change of Control&rdquo; shall not include any financing transaction of the Company
(whether public or private) that would otherwise be and/or trigger a &ldquo;Change of Control&rdquo; under (c)&nbsp;and/or (d)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Good Reason&rdquo; means the
occurrence, without your prior written consent, of any of the following events: (i)&nbsp;a material reduction in your authority, duties,
or responsibilities; (ii)&nbsp;the relocation of the principal place at which you provide services to the Company by at least 50 miles
and to a location such that your daily commuting distance is increased; (iii)&nbsp;a material reduction of your base salary (other than
in connection with, and in an amount substantially proportionate to, reductions made by the Company to the base salaries of other members
of management); or (iv)&nbsp;a material breach by the Company of its obligations under this offer letter. No resignation will be treated
as a resignation for Good Reason unless (x)&nbsp;you have given written notice to the Company of your intention to terminate your employment
for Good Reason, describing the grounds for such action, no later than 90 days after the first occurrence of such circumstances, (y)&nbsp;you
have provided the Company with at least 30 days in which to cure the circumstances, and (z)&nbsp;if the Company is not successful in curing
the circumstance s, you end your employment within 60 days following the cure period in (y). Good reason shall not apply to an agreed
upon transition to a new CEO where you remain a member of the ProMIS Neurosciences Inc. Board of Directors and act as a continuing consultant
to the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be required to execute
a Non-Solicitation, Confidentiality and Assignment Agreement in the form attached as <U>Exhibit&nbsp;B</U>, as a condition of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You represent that you are
not bound by any employment contract, restrictive covenant or other restriction preventing (or that purports to prevent) you from entering
into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this
letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You agree to provide to the
Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration
Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States. If that is the
case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter shall not be construed
as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter the Company&rsquo;s policy
of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause,
at any time, with or without notice. Although your job duties, title, compensation and benefits, as well as the Company&rsquo;s personnel
policies and procedures, may change from time to time, the &ldquo;at-will&rdquo; nature of your employment may only be changed by a written
agreement signed by you and the Chairpersons of the Nominating/Governance Committee and the Compensation Committee of the Company&rsquo;s
Board of Directors<B>, </B>which expressly states the intention to modify the at-will nature of your employment. Similarly, except as
expressly provided herein, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation
or grant you any benefit beyond the end of your employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In return for the compensation
payments set forth in this letter, you agree to devote your full business time, best efforts, skill, knowledge, attention, and energies
to the advancement of the Company&rsquo;s business and interests and to the performance of your duties and responsibilities as an employee
of the Company and not to engage in any other business activities without prior approval from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an employee of the Company,
you will be required to comply with all Company policies and procedures. Violations of the Company&rsquo;s policies may lead to immediate
termination of your employment. Further, the Company&rsquo;s premises, including all workspaces, furniture, documents, and other tangible
materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet
and email) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy
with regard to any Company premises, materials, resources, or information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
</FONT>offer letter is your formal offer of employment and supersedes all prior or contemporaneous agreements, discussions and understandings,
whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes
under this letter will be governed by the laws of the Commonwealth of Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon execution of this agreement,
this agreement shall replace and terminate all prior agreements respecting compensation as between the parties and as between Promis Neurosciences
Inc. and Virtua LLC. For greater certainty Promis Neurosciences Inc. shall, notwithstanding this agreement, pay to Virtua LLC all agreed
compensation outstanding as at the date of this agreement following which all obligations by the employer to Virtua LLC shall terminate
If you agree with the provisions of this letter, please sign this letter in the space provided below and return it to the chair of the
ProMIS Neurosciences Inc. Nominating/Governance committee, at your earliest convenience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very Truly Yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ProMIS NEUROSCIENCES Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Richard Gregory</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%"><FONT STYLE="font-size: 10pt">Richard Gregory</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chair of the Compensation Committee</FONT></TD></TR>
  </TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing correctly sets forth the terms of my employment by ProMIS
NEUROSCIENCES Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December&nbsp;21, 2021 &nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Eugene Williams</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%">Eugene Williams</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Viritua LLC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Per: /s/ Euggne Williams</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Eugene Williams</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>I have the authority to bind the Corporation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Payments Subject to Section&nbsp;409A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Subject to this Appendix A, any severance payments that may be due under the Agreement shall begin only
upon the date of your &ldquo;separation from service&rdquo; (determined as set forth below) which occurs on or after the termination of
your employment. The following rules&nbsp;shall apply with respect to distribution of the severance payments, if any, to be provided to
you under the Agreement, as applicable:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">It is intended that each installment of the severance payments under the Agreement provided under shall
be treated as a separate &ldquo;payment&rdquo; for purposes of Section&nbsp;409A. Neither the Company nor you shall have the right to
accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section&nbsp;409A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If, as of the date of your &ldquo;separation from service&rdquo; from the Company, you are not a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then each installment of the severance payments shall be made on the dates
and terms set forth in the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">If, as of the date of your &ldquo;separation from service&rdquo; from the Company, you are a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Each installment of the severance payments due under the Agreement that, in accordance with the dates
and terms set forth herein, will in all circumstances, regardless of when your separation from service occurs, be paid within the short-term
deferral period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation
Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent permissible under Section&nbsp;409A and shall be paid on the dates and terms set
forth in the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Each installment of the severance payments due under the Agreement that is not described in this Appendix
A, Section&nbsp;1(c)(i)&nbsp;and that would, absent this subsection, be paid within the six-month period following your &ldquo;separation
from service&rdquo; from the Company shall not be paid until the date that is six months and one day after such separation from service
(or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period
and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments,
if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence
shall not apply to any installment of payments if and to the maximum extent that that such installment is deemed to be paid under a separation
pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii)&nbsp;(relating
to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation
Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;must be paid no later than the last day of your second taxable year following the taxable year in
which the separation from service occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Appendix A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
determination of whether and when your separation from service from the Company has occurred shall be made and in a manner consistent
with, and based on the presumptions set forth in, Treasury Regulation Section&nbsp;1.409A-1(h). Solely for purposes of this Appendix A,
Section&nbsp;2, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered a single employer under Section&nbsp;414(b)&nbsp;and
414(c)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of the
Agreement (including this Appendix) are determined to constitute deferred compensation subject to Section&nbsp;409A but that do not satisfy
an exemption from, or the conditions of, that section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Appendix A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF SEPARATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Place on Company Letterhead]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B><U>VIA HAND DELIVERY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Name]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[Insert Address]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear [Insert Name]:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the termination
of your employment with <B>[Insert Company Name] </B>(the &ldquo;Company&rdquo;) on <B>[Insert Termination Date]</B>, you are eligible
to receive the severance benefits described in paragraph 2 below if you sign and return this letter agreement to me by <B>[Return Date]
[and it becomes binding between you and the Company]</B>. By signing and returning this letter agreement <B>[and not revoking your acceptance]</B>,
you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered
paragraphs below, including the release of claims set forth in paragraph 3. Therefore, you are advised to consult with an attorney before
signing this letter agreement and you have been given at least <B>[seven (7)&nbsp;/ twenty-one (21) / forty-five (45)]<SUP>11</SUP></B>
days to do so. <B>[If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7)&nbsp;day
period after you have signed it by notifying me in writing. If you do not so revoke, this letter agreement will become a binding agreement
between you and the Company upon the expiration of the seven (7)&nbsp;day period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you choose not to sign
and return this letter agreement by <B>[Return Date] [or if you timely revoke your acceptance in writing]</B>, you shall not receive any
severance benefits from the Company. You will, however, receive payment for your final wages, any unpaid bonus, and any unused vacation
time accrued through the Termination Date, as defined below, and reimbursement for any unpaid business expenses. You may also, if eligible,
elect to continue receiving group medical insurance pursuant to &ldquo;COBRA.&rdquo; Please consult the COBRA materials to be provided
by the Company under separate cover for details regarding these benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following numbered paragraphs
set forth the terms and conditions that will apply if you timely sign and return this letter agreement <B>[and do not revoke it in writing
within the seven (7)&nbsp;day period]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>Termination
Date and Resignation as a Director </B>&ndash; Your effective date of termination from the Company is <B>[Insert Termination Date] </B>(the
 &ldquo;Termination Date&rdquo;). You agree to resign, as of the Termination Date, from your position as a Director of the Company, and
to sign and return to the Company all letters and documents that the Company may reasonably require in order to secure your resignation.
As of the Termination Date, all salary payments from the Company will cease and any benefits you had as of the Termination Date under
Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> <I>Note: except for factual information, bracketed/bolded
provisions and alternatives will be dependent on age of executive at time of termination and whether termination is an individual termination
or part of a group termination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Description
of Severance Benefits </FONT></B><FONT STYLE="font-size: 10pt">&ndash; If you timely sign and return this letter agreement <B>[and do
not revoke your acceptance]</B>, and provided you abide by all of the obligations set forth herein, the Company will provide you with
the severance benefits set forth in <B>[Section&nbsp;____)] </B>of the <B>[Insert Date] [Offer Letter] </B>between you and the Company
(the &ldquo;Severance Benefits&rdquo;) as follows: [SET OUT THE SEVERANCE BENEFITS AND PAYMENT DATES].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Release
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; In consideration of the Severance Benefits, which you acknowledge you would not otherwise
be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates,
subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders,
partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual
and corporate capacities) (collectively, the &ldquo;Released Parties&rdquo;) from any and all claims, charges, complaints, demands, actions,
causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings,
omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&rsquo; fees and costs), of every kind and
nature that you ever had or now have against any or all of the Released Parties arising up to the date you sign this Agreement, including,
but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including,
but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &sect; 2000e et seq., the Americans With Disabilities
Act of 1990, 42 U.S.C. &sect; 12101 et seq., <B>[the Age Discrimination in Employment Act, 29 U.S.C. &sect; 621 et seq.,] </B>the Genetic
Information Nondiscrimination Act of 2008, 42 U.S.C. &sect; 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. &sect; 2601 et
seq., the Worker Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C. &sect; 2101 et seq., the Rehabilitation Act
of 1973, 29 U.S.C. &sect; 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &sect; 1681
et seq., and the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29 U.S.C. &sect; 1001 et seq., all as amended;
<B>[all claims arising out of the Massachusetts Fair Employment Practices Act., Mass. Gen. Laws ch. 151B, &sect; 1 et seq., the Massachusetts
Wage Act, Mass. Gen. Laws ch. 149, &sect; 148 et seq. (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil
Rights Act, Mass. Gen. Laws ch. 12, &sect;&sect; 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &sect; 102
and Mass. Gen. Laws ch. 214, &sect; 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &sect; 1 et seq., Mass. Gen.
Laws ch. 214, &sect; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &sect; 105D,
and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &sect; 52D, all as amended</B>]; <B>[Insert any other applicable
state&rsquo;s citations;] </B>all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional
distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, all claims arising out
of or relating to your <B>[Insert Date] </B>Employment Agreement); all claims to any non-vested ownership interest in the Company, contractual
or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of
your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal,
state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement releases
claims to vested benefits or to enforce this Agreement or prevents you from filing a charge with, cooperating with, or participating in
any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge
that you may not recover any monetary benefits in connection with any such claim, charge or proceeding).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Continuing
Obligations </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You acknowledge and reaffirm your obligation to keep confidential and not
to use or disclose any and all non-public information concerning the Company that you acquired during the course of your employment with
the Company, including, but not limited to, any non-public information concerning the Company&rsquo;s business affairs, business prospects,
and financial condition. You further acknowledge and reaffirm your obligations set forth in the <B>[Insert Name of Restrictive Covenant
Agreement(s)] </B>you executed for the benefit of the Company, which remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Non-Disparagement
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; You understand and agree that, to the extent permitted by law, you will not, in public
or private, make any false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any
media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the
Company, regarding the Company or any of the other Released Parties, or regarding the Company&rsquo;s business affairs, business prospects,
or financial condition. Notwithstanding the above, nothing in this Section&nbsp;will interfere with your ability to comply with legal
process or the requirements of applicable federal or state laws or regulations or to cooperate with any agency investigation. The Company
agrees to direct its officers, directors, employees and consultants not to, in public or private, make any false, disparaging, derogatory
or defamatory statements to any person or entity, including, but not limited to, any media outlet, industry group, financial institution
or current or former employee, board member, consultant, client or customer of the Company, regarding you, your involvement with the Company,
or your reputation, nor will the Company assist any others in engaging in such activities. Notwithstanding the above, nothing in this
Section&nbsp;shall interfere with the Company&rsquo;s ability to comply with legal process or the requirements of applicable federal or
state laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Continued
Assistance &ndash; </FONT></B><FONT STYLE="font-size: 10pt">You agree that after the Termination Date you will provide all reasonable
cooperation to the Company, including but not limited to, assisting the Company in transitioning your job duties and performing any other
tasks as reasonably requested by the Company. The Company shall: (a)&nbsp;compensate you for the reasonable value of your time for any
such cooperation and assistance; (b)&nbsp;pay out-of-pocket expenses consistent with Company policies; and (c)&nbsp;not interfere with
requirements you may have in new employment (including self-employment or consulting).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Cooperation
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; To the extent permitted by law, you agree to cooperate fully with the Company in the
defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the
future against or on behalf of the Company, whether before a state or federal court, any state or federal government agency, or a mediator
or arbitrator. Your full cooperation in connection with such claims or actions shall include, but not be limited to, reasonable requests
to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation
or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company. You agree that you
will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third
party with information concerning any actual or potential complaint or claim against the Company. In connection with such cooperation,
the Company will not interfere with requirements you may have in new employment (including self-employment or consulting), and, at the
Company&rsquo;s expense: (a)&nbsp;compensate you for the reasonable value of your time for any such cooperation and assistance; (b)&nbsp;reimburse
you for out-of-pocket expenses; and (c)&nbsp;provide legal counsel if necessary to advise you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Return
of Company Property </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You confirm that you have returned to the Company all keys, files,
records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices,
cellular phones, pagers,&nbsp;etc.), Company identification, and any other Company-owned property in your possession or control and have
left intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your employment.
You further confirm that you have cancelled all accounts for your benefit, if any, in the Company&rsquo;s name, including but not limited
to, credit cards, telephone charge cards, cellular phone and/or pager accounts, and computer accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Business
Expenses and Final Compensation </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You acknowledge that you have been reimbursed by the
Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are
owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment
by the Company, including payment for all wages (including overtime), bonuses, commissions, and accrued, unused vacation time, and that
no other compensation is owed to you except as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amendment
and Waiver </FONT></B><FONT STYLE="font-size: 10pt">&ndash; This letter agreement shall be binding upon the parties and may not be modified
in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties
hereto. This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs,
executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter agreement shall
operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in
that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Validity
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; Should any provision of this letter agreement be declared or be determined by any court
of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby
and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Confidentiality
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; To the extent permitted by law, you understand and agree that as a condition of the Severance
Benefits herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting
in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except
to your immediate family, your attorneys, financial advisors, and as required by law, and except as otherwise agreed to in writing by
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nature
of Agreement &ndash; </FONT></B><FONT STYLE="font-size: 10pt">You understand and agree that this letter agreement is a severance agreement
and does not constitute an admission of liability or wrongdoing on the part of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Acknowledgments
 &ndash; </FONT></B><FONT STYLE="font-size: 10pt">You acknowledge that you have been given at least <B>[seven (7)&nbsp;! twenty-one (21)
! forty-five (45)] </B>days to consider this letter agreement, and that the Company advised you to consult with an attorney of your own
choosing prior to signing this letter agreement. <B>[You understand that you may revoke this letter agreement for a period of seven (7)&nbsp;days
after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until
the expiration of this seven (7)&nbsp;day revocation period. You understand and agree that by entering into this letter agreement, you
are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers
Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[Eligibility
for Severance Program &ndash; Attached to this letter agreement as Attachment A is a description of (i)&nbsp;any class, unit or group
of individuals covered by the program of severance benefits which the Company has offered to you, and any applicable time limits regarding
such severance benefit program; and (ii)&nbsp;the job title and ages of all individuals eligible or selected for such severance benefit
program, and the ages of all individuals in the same job classification or organizational unit who are not eligible or who were not selected
for such severance benefit program.]</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Voluntary
Assent </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You affirm that no other promises or agreements of any kind have been made to
or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and
intent of this letter agreement. You state and represent that you have had an opportunity to fully discuss and review the terms of this
letter agreement with an attorney. You further state and represent that you have carefully read this letter agreement, understand the
contents herein, freely, and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Applicable
Law </FONT></B><FONT STYLE="font-size: 10pt">&ndash; This letter agreement shall be interpreted and construed by the laws of the <B>[Commonwealth
of Massachusetts]</B>, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and recognize the
jurisdiction of the courts of the <B>[Commonwealth of Massachusetts]</B>, or if appropriate, a federal court located in the <B>[Commonwealth
of Massachusetts] </B>(which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit,
action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Entire
Agreement </FONT></B><FONT STYLE="font-size: 10pt">&ndash; This letter agreement contains and constitutes the entire understanding and
agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and cancels
all previous oral and written negotiations, agreements, and commitments in connection therewith. Nothing in this paragraph, however, shall
modify, cancel or supersede your obligations set forth in paragraph 4 above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Tax
Acknowledgement </FONT></B><FONT STYLE="font-size: 10pt">&ndash; In connection with the Severance Benefits provided to you pursuant to
this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you
shall be responsible for all applicable taxes with respect to such Severance Benefits under applicable law. You acknowledge that you are
not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Benefits set forth
in paragraph 2 of this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
about the matters covered in this letter agreement, please call me at <B>[Insert Phone Number].</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">[NAME] [TITLE]</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby agree to the terms
and conditions set forth above. <B>[I have been given at least [twenty- one (21) / forty-five (45)] days to consider this letter agreement
and I have chosen to execute this on the date below. I intend that this letter agreement will become a binding agreement between me and
the Company if I do not revoke my acceptance in seven (7)&nbsp;days.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Insert Name]</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To be returned in a timely
manner as set forth on the first page&nbsp;of this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Employee Non-Solicitation, Confidentiality and
Assignment Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration and as a
condition of NAME (&ldquo;I&rdquo;, &ldquo;Me&rdquo;, or &ldquo;You&rdquo;) employment or continued employment by ProMIS Neurosciences.
(&ldquo;ProMIS&rdquo;), the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><B><U>Proprietary
Information</U></B><U>. I agree that all information, whether or not in writing, whether or not disclosed before or after I was first
employed by ProMIS, concerning the business, technology, business relationships or financial affairs of ProMIS or its subsidiaries, affiliates,
and associated entities (collectively, the &ldquo;Company&rdquo;) that the Company has not released to the general public (collectively,
 &ldquo;Proprietary Information&rdquo;), and all tangible embodiments thereof, are and will be the exclusive property of the Company.
By way of illustration, Proprietary Information may include information or material that has not been made generally available to the
public, such as: (a)&nbsp;<I>corporate information</I>, including plans, strategies, methods, policies, resolutions, notes, email correspondence,
negotiations or litigation; (b)&nbsp;<I>marketing information</I>, including strategies, methods, customer identities or other information
about customers, prospect identities or other information about prospects, or market analyses or projections; (c)&nbsp;<I>financial information</I>,
including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price
lists; and (d)&nbsp;<I>operational and technological information</I>, including plans, specifications, manuals, forms, templates, software,
designs, methods, procedures, formulas, discoveries, inventions, improvements, biological or chemical materials, concepts and ideas;
and (e)&nbsp;<I>personnel information</I>, including personnel lists, reporting or organizational structure, resumes, personnel data,
compensation structure, performance evaluations and termination arrangements or documents. Proprietary Information includes, without
limitation, (1)&nbsp;information received in confidence by the Company from its customers or suppliers or other third parties, and (2)&nbsp;all
biological or chemical materials and other tangible embodiments of the Proprietary Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Recognition
of Company&rsquo;s Rights</U></B><U>. I will not, at any time, without the Company&rsquo;s prior written permission, either during or
after my employment, disclose or transfer any Proprietary Information to anyone outside of the Company, or use or permit to be used any
Proprietary Information for any purpose other than the performance of my duties as an employee of the Company. I will cooperate with the
Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all
copies and other tangible embodiments of Proprietary Information in my possession or control upon the earlier of a request by the Company
or termination of my employment. The term &ldquo;Proprietary Information&rdquo; hereunder will not include information that I can establish
by competent written evidence (i)&nbsp;is or becomes generally known within the Company&rsquo;s industry through no fault of mine; (ii)&nbsp;was
known to me at the time it was disclosed; (iii)&nbsp;is lawfully and in good faith made available to me by a third-party who did not derive
it from the Company and who imposes no obligation of confidence on me; or (iv)&nbsp;is required to be disclosed by order of a governmental
authority or a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection
available for like material, and provided I first give reasonable advance written notice of such requirement to the Company, and permit
the Company to intervene in any relevant proceedings to protect its interests in the Proprietary Information, and provide full cooperation
and assistance to the Company in seeking to obtain such protection.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rights
of Others</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I understand that the Company is now and may hereafter be subject to non-disclosure
or confidentiality agreements with third persons which require the Company to protect or refrain from use of proprietary information.
I agree to be bound by the terms of such agreements in the event I have access to such proprietary information.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Commitment
to Company; Avoidance of Conflict of Interest</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. While an employee of the Company,&nbsp;I
will devote my full-time efforts to the Company&rsquo;s business and I will not engage in any other business activity that conflicts
or reasonably could potentially conflict with my duties to the Company. I will advise the president of the Company or their nominee at
such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict
of interest as an employee of the Company. I will take whatever action is requested of me by the Company to resolve any conflict or appearance
of conflict which it finds to exist.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Developments</U></FONT></B><FONT STYLE="font-size: 10pt"><U>.
I hereby assign and transfer and, to the extent any such assignment cannot be made at present, hereby agree to assign and transfer, to
ProMIS and its successors, designees and assigns, all my right, title and interest in and to all Developments (as defined below) that:
(a)&nbsp;are created, developed, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction (collectively,
 &ldquo;conceived&rdquo;) during the period of my employment and six (6)&nbsp;months thereafter and that relate to the business of the
Company or to products, methods or services being researched, developed, manufactured or sold by the Company; or (b)&nbsp;result from
tasks assigned to me by the Company; or (c)&nbsp;result from the use of premises, Proprietary Information or personal property (whether
tangible or intangible) owned, licensed or leased by the Company (collectively, &ldquo;Company-Related Developments&rdquo;), and all
patent rights, trademarks, copyrights and other intellectual property rights in all countries and territories worldwide claiming, covering
or otherwise arising from or pertaining to Company-Related Developments (collectively, &ldquo;Intellectual Property Rights&rdquo;). I
further agree that &ldquo;Company-Related Developments&rdquo; include, without limitation, all Developments that (i)&nbsp;were conceived
by me before my employment, (ii)&nbsp;relate to the business of the Company or to products, methods or services being researched, developed,
manufactured or sold by the Company, and (iii)&nbsp;were not subject to an obligation to assign to another entity when conceived. I will
make full and prompt disclosure to the Company of all Company-Related Developments, as well as all other Developments conceived by me
during the period of my employment and six (6)&nbsp; months thereafter. I acknowledge that all work performed by me as an employee of
the Company is on a &ldquo;work for hire&rdquo; basis. I hereby waive all claims to any moral rights or other special rights which I
may have or accrue in any Company-Related Developments. &ldquo;Developments&rdquo; mean inventions, discoveries, designs, developments,
methods, modifications, improvements, processes, biological or chemical materials, algorithms, databases, computer programs, formulae,
techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To preclude any possible uncertainty,&nbsp;I
have set forth on <U>Exhibit&nbsp;A</U> attached hereto a complete list of Developments conceived by me before my employment that are
not Company-Related Developments (&ldquo;Prior Inventions&rdquo;). I have also listed on <U>Exhibit&nbsp;A </U>all patent rights of which
I am an inventor, other than those contained within Intellectual Property Rights (&ldquo;Other Patent Rights&rdquo;). If no such disclosure
is attached,&nbsp;I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company,&nbsp;I
incorporate a Prior Invention into a Company product, process or research or development program or other work done for the Company,&nbsp;I
hereby grant to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, worldwide license (with the full right
to sublicense through multiple tiers) to make, have made, modify, use, offer for sale, import and sell such Prior Invention. Notwithstanding
the foregoing,&nbsp;I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without
the Company&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I understand that to the extent
this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement
to assign certain classes of inventions made by an employee, this Section&nbsp;will be interpreted not to apply to any invention which
a court rules&nbsp;and/or the Company agrees falls within such classes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Documents
and Other Materials</U></B><U>. I will keep and maintain adequate and current records of all Proprietary Information and Company-Related
Developments conceived by me, which records will be available to and remain the sole property of the Company at all times. All files,
letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification
sheets, program listings, blueprints, models, prototypes, materials or other written, photographic or other tangible material containing
or embodying Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property
of the Company to be used by me only in the performance of my duties for the Company. In the event of the termination of my employment
for any reason,&nbsp;I will deliver to the Company all of the foregoing, and all other materials of any nature pertaining to the Proprietary
Information of the Company and to my work, and will not take or keep in my possession any of the foregoing or any copies. Any property
situated on the Company&rsquo;s premises and owned by the Company, including laboratory space, computers, disks and other storage media,
filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Enforcement
of Intellectual Property Rights</U></B><U>. I will cooperate fully with the Company, both during and after my employment with the Company,
with respect to the procurement, maintenance and enforcement of Intellectual Property Rights, as well as all other patent rights, trademarks,
copyrights and other intellectual property rights in all countries and territories worldwide owned by or licensed to the Company. I will
sign, both during and after the term of this Agreement, all papers, including copyright applications, patent applications, declarations,
oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its
rights and interests in any Company-Related Development or Intellectual Property Rights. If the Company is unable, after reasonable effort,
to secure my signature on any such papers,&nbsp;I hereby irrevocably designate and appoint each officer of the Company as my agent and
attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable
in order to protect its rights and interests in </U>the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Solicitation</U></FONT></B><FONT STYLE="font-size: 10pt"><U>.
In order to protect the Company&rsquo;s Proprietary Information and good will, during my employment and for a period of twelve (12) months
following a for Cause (as defined below) termination of my employment (the &ldquo;Restricted Period&rdquo;),&nbsp;I will not, directly
or indirectly, in any manner, other than for the benefit of the Company, (a)&nbsp;call upon, solicit, divert or take away any of the
customers, business or prospective customers of the Company or any of its suppliers, and/or (b)&nbsp;solicit, entice or attempt to persuade
any other employee or consultant of the Company to leave the services of the Company for any reason. I acknowledge and agree that if
I violate any of the provisions of this Section, the running of the Restricted Period will be extended by the time during which I engage
in such violation(s).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Government
Contracts</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I acknowledge that the Company may have from time to time agreements with
other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding
inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to comply
with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under Section&nbsp;5,&nbsp;I
also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required
to be in the United States under any contract between the Company and the United States or any of its agencies.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Prior
Agreements</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I hereby represent that, except as I have fully disclosed previously in writing
to the Company,&nbsp;I am not bound by the terms of any agreement with any current or previous employer or other party that interferes
with my performance under this Agreement or obligates me to refrain from using or disclosing any trade secret or confidential or proprietary
information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of
such previous employer or any other party, or to assign any patent rights, trademarks, copyrights or other intellectual property rights.
I further represent that my performance of all the terms of this Agreement as an employee of the Company does not and will not breach
any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment
with the Company. I will not disclose to the Company or induce the Company to use any confidential or proprietary information or material
belonging to any previous employer or others.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies
Upon Breach</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I understand that the restrictions contained in this Agreement are necessary
for the protection of the business and goodwill of the Company and I consider them to be reasonable for such purpose. Any breach of this
Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in
addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Use
of Voice,&nbsp;Image and Likeness</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I give the Company permission to use my voice, image
or likeness, with or without using my name, for the purposes of advertising and promoting the Company, or for other purposes deemed appropriate
by the Company in its reasonable discretion, except to the extent expressly prohibited by law.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Publications
and Public Statements</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I will obtain the Company&rsquo;s written approval before publishing
or submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. To
ensure that the Company delivers a consistent message about its products, services and operations to the public, and further in recognition
that even positive statements may have a detrimental effect on the Company in certain contexts, any statement about the Company which
I create, publish or post during my period of employment and for six (6)&nbsp;months thereafter, on any media accessible by the public,
including but not limited to electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer
of the Company before it is released in the public domain.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Employment Obligation</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I understand that this Agreement does not create an obligation
on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment
agreement signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated
by the Company or me at any time and for any reason. Without limiting the foregoing in any manner, You may be immediately terminated,
without notice, for Cause or without Cause. &ldquo;Cause&rdquo; as used herein shall mean: (i)&nbsp;a breach of Your obligations under
this Agreement or any other agreement you have with the Company; (ii)&nbsp;the failure or refusal to follow the instructions of Your
supervisor or the Board of Directors of the Company, as the case may be; (iii)&nbsp;the commission by You of any act of dishonesty, moral
turpitude, fraud, or breach of trust; (iv)&nbsp;conviction of, or pleading guilty or no contest to, any felony or any lesser crime; (v)&nbsp;the
failure to adhere to policies and procedures adopted by the Company </U>from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival
and Assignment by the Company</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I understand that my obligations under this Agreement
will continue in accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits
(if any) or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following
the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators.
The Company will have the right to assign this Agreement to its affiliates, successors and assigns. I expressly consent to be bound by
the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred
without the necessity that this Agreement be resigned at the time of such transfer.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
to Future Employers and Others</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. During the period in which the terms of the Non-Solicitation
agreement described in Section&nbsp;8 and the Developments agreement in Section&nbsp;5 remain in force,&nbsp;I will provide a copy of
this Agreement to any prospective employer, partner or co-venturer prior to entering into an employment, partnership or other business
relationship with such person or entity.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exit
Interview</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. If and when I depart from the Company,&nbsp;I may be required to attend an
exit interview and sign an &ldquo;Employee Exit Acknowledgement&rdquo; to reaffirm my acceptance and acknowledgement of the obligations
set forth in this Agreement. During the Restricted Period following termination of my employment,&nbsp;I will notify the Company of any
change in my address and of each subsequent engagement, employment or business activity, including the name and address of my employer,
party to which I render services or other post-Company employment or engagement plans and the nature of my activities.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U></FONT></B><FONT STYLE="font-size: 10pt"><U>.
In case any provisions (or portions thereof) contained in this Agreement will, for any reason, be held invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement
will be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more
of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope,
activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable
law as it will then appear.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. This Agreement constitutes the entire and only agreement between the Company
and me respecting the subject matter hereof, and supersedes all prior agreements and understandings, oral or written, between us concerning
such subject matter. No modification, amendment, waiver or termination of this Agreement or of any provision hereof will be binding unless
made in writing and signed by an authorized officer of the Company. Failure of the Company to insist upon strict compliance with any
of the terms, covenants or conditions hereof will not be deemed a waiver of such terms, covenants or conditions. In the event of any
inconsistency between this Agreement and any other contract between the Company and me, the provisions of this Agreement will prevail.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.&#8239;&#8239;</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Interpretation</U></FONT></B><FONT STYLE="font-size: 10pt"><U>.
This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted,
enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the
Suffolk County Business Litigation Session for purposes of enforcing this Agreement, and waive any objection that I might have to personal
jurisdiction or venue in this court. As used in this Agreement, &ldquo;including&rdquo; means &ldquo;including but not limited to&rdquo;.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BY SIGNING BELOW,&nbsp;I CERTIFY
THAT I HAVE THE RIGHT TO CONSULT AN ATTORNEY PRIOR TO ENTERING INTO THIS AGREEMENT, HAVE READ THIS AGREEMENT CAREFULLY AND, AM SATISFIED
THAT I UNDERSTAND IT COMPLETELY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the undersigned has executed
this agreement as a sealed instrument as of the date set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eugene Williams</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Employee's full name)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type of print name:</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Williams</FONT></TD>
    <TD STYLE="width: 16%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="3" STYLE="text-align: left"><B>Accepted and agreed:</B></TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="3" STYLE="text-align: left">ProMIS NEUROSCIENCES</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">By:</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">/s/ Neil Warma</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 5%">&nbsp;</TD>
<TD STYLE="text-align: left; width: 5%">Title:</TD>
<TD STYLE="text-align: left; width: 40%">Chairman, Nominating and Governance Committee</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left">Date:</TD>
<TD STYLE="text-align: left">12/22/2021</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit B<BR> Signature Page</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>56
<FILENAME>filename56.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.37</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns. Redacted
information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>PROMIS NEUROSCIENCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1920 YONGE ST.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TORONTO, ONTARIO, M4S 3E2, CANADA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;21, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gavin Malenfant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Gavin;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of ProMIS Neurosciences.,
a corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite&nbsp;200, Toronto, Ontario,
M4S 3E2 (the &ldquo;<B>Company</B>&rdquo;),&nbsp;I am pleased to offer you employment with the Company. The purpose of this letter is
to summarize the terms of your employment with the Company, should you accept our offer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be employed to serve
on a full-time basis as Chief Operating Officer (COO) effective on January&nbsp;1, 2022. It is contemplated that you will commence full
time employment on January&nbsp;1, 2022 with the previously agreed upon consulting effort to be devoted prior to the full time start date.
As the COO you will report to the CEO. You will be responsible for duties as are consistent with such position as well as other duties
assigned by your manager and the Company. You will initially be based remotely from your home office in Massachusetts; however, it is
understood that the Company may change your work location based on the Company&rsquo;s future needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your base salary will be at
the rate of $380,000 USD per year, paid twice a month on the 15<SUP>th</SUP> and last days of the month at rate of $15,833.33 per payroll
period, subject to tax and other withholdings as required by law. Such base salary may be adjusted from time to time in accordance with
normal business practice and in the sole discretion of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ProMIS Neurosciences employees
who join between January&nbsp;1 and December&nbsp;31 of a given calendar year are eligible to be considered for a salary merit increase
during the next calendar year&rsquo;s Annual Compensation Review process. The Annual Compensation Review process, if and when implemented,
is anticipated to take place in the first quarter of the calendar year. Salary merit increases, if any, will be awarded at the Company&rsquo;s
discretion on the basis of your performance, and will be pro-rated based on the number of months that you actually worked during the previous
calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may participate in any
and all bonus and benefit programs that the Company establishes and makes available to its employees from time to time, provided you are
eligible under (and subject to all provisions of) the plan documents governing those programs. Subject to these programs, you will be
eligible to receive a bonus targeted at a percentage to be determined of your annualized base salary being determined by the Company in
its sole discretion, based on your performance and that of the Company against goals established by the Board. You must commence your
employment by September&nbsp;30th in order to be eligible for a bonus for the calendar year during which you were hired. If you join the
Company between January&nbsp;1st and September&nbsp;30th, you will be eligible for a pro-rated bonus for that calendar year. You must
be employed through the date bonuses are disbursed to employees generally in order to be eligible for the bonus. Regardless of your date
of employment, you will be eligible to participate in the benefit plans and programs made available by the Company from time to time for
employees generally, subject to plan terms and generally applicable Company policies. These currently or will include but are not limited
to: health insurance such as medical, dental and vision; company-paid basic life insurance, accidental death&nbsp;&amp; dismemberment,
and short- and long-term disability; paid time off such as vacation, sick leave and company-paid holidays; 401(k)&nbsp;retirement savings
plan; and employee stock purchase plan. You will be entitled to Directors and Officers insurance and such other insurance may be maintained
by the Company. The bonus and benefit programs made available by the Company, and the rules, terms, and conditions for participation in
such benefit plans, may be changed by the Company at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Option Commitment (as
defined in the ProMIS Neurosciences Inc. Stock Option Plan) or stock option agreement between the parties shall include the terms set
out in herein. ProMIS hereby represents and warrants that all necessary corporate action has been taken by or on behalf of ProMIS to grant
the Options in accordance with this paragraph 3.0(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may be eligible to receive
such future stock option grants as the Board of Directors of the Company shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your employment is terminated
by the Company without Cause (as defined below) or you terminate your employment for Good Reason (as defined below) and provided you execute
and allow to become effective (within 60 days following the termination or such shorter period as may be directed by the Company) a release
of claims in form attached as <U>Exhibit&nbsp;A</U> (the &ldquo; Separation Agreement&rdquo;), (i)&nbsp;the Company will pay you as severance
pay an aggregate amount equivalent to 12 (twelve) months of your then current base salary (pro-rated, if applicable), less all applicable
taxes and withholdings, which severance pay will be paid ratably in accordance with the Company&rsquo; s regular payroll practices beginning
in the Company&rsquo;s first regular payroll cycle after the Release Agreement becomes effective; provided, however, that if the 60th
day referenced above occurs in the calendar year following the date of your termination , then the severance pay shall begin no earlier
than January&nbsp;l of such subsequent calendar year; and (ii)&nbsp;should you timely elect and be eligible to continue receiving group
medical coverage pursuant to the &ldquo;COBRA&rdquo; law, and so long as the Company can provide such benefit without violating the nondiscrimination
requirements of applicable law, the Company will for a period of 12 (twelve) months following your termination continue to pay the share
of the premium for such coverage that is paid by the Company for active and similarly-situated employees who receive the same type of
coverage. The remaining balance of any premium costs shall timely be paid by you on a monthly basis for as long as, and to the extent
that, you remain eligible for COBRA Attached as</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Appendix A are the terms and
conditions applicable to the payment of any severance hereunder. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Cause&rdquo; means any of: (a)&nbsp;your
conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b)&nbsp;a
good faith finding by the Company&rsquo;s Board of Directors that you have (i)&nbsp;engaged in dishonesty, willful misconduct or gross
negligence that has a material adverse effect on the Company, (ii)&nbsp;committed an intentional act that materially injures the reputation,
business or business relationships of the Company, (iii)&nbsp;materially breached the terms of any restrictive covenants or confidentiality
agreement with the Company; provided that in the case of (b)&nbsp;that you were given written notice of such violation or failure by the
Board and a period of 30 days to cure (provided that the Board determines that such violation or failure is curable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Change
of Control&rdquo; shall mean, regardless of form thereof, consummation of (a)&nbsp;the sale of all or substantially all of the assets
of the Company on a consolidated basis to an unrelated person or entity, (b)&nbsp;a merger, reorganization or consolidation in which the
</FONT>outstanding shares of capital stock of the Company are converted into or exchanged for securities of the successor entity and the
holders of the Company&rsquo;s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding
voting power of the successor entity immediately upon completion of such transaction, (c)&nbsp;the sale of all or a majority of the outstanding
capital stock of the Company to an unrelated person or entity or (d)&nbsp;any other transaction in which the owners of the Company&rsquo;s
outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the successor
entity immediately upon completion of the transaction; provided, however, that &ldquo;Change of Control&rdquo; shall not include any financing
transaction of the Company (whether public or private) that would otherwise be and/or trigger a &ldquo;Change of Control&rdquo; under
(c)&nbsp;and/or (d)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Good Reason&rdquo; means the
occurrence, without your prior written consent, of any of the following events: (i)&nbsp;a material reduction in your authority, duties,
or responsibilities; (ii)&nbsp;the relocation of the principal place at which you provide services to the Company by at least 50 miles
and to a location such that your daily commuting distance is increased; (iii)&nbsp;a material reduction of your base salary (other than
in connection with, and in an amount substantially proportionate to, reductions made by the Company to the base salaries of other members
of management); or (iv)&nbsp;a material breach by the Company of its obligations under this offer letter. No resignation will be treated
as a resignation for Good Reason unless (x)&nbsp;you have given written notice to the Company of your intention to terminate your employment
for Good Reason, describing the grounds for such action, no later than 90 days after the first occurrence of such circumstances, (y)&nbsp;you
have provided the Company with at least 30 days in which to cure the circumstances, and (z)&nbsp;if the Company is not successful in curing
the circumstance s, you end your employment within 60 days following the cure period in (y).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You will be required to execute
a Non-Solicitation, Confidentiality and Assignment Agreement in the form attached as <U>Exhibit&nbsp;B</U>, as a condition of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You represent that you are
not bound by any employment contract, restrictive covenant or other restriction preventing (or that purports to prevent) you from entering
into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this
letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You agree to provide to the
Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration
Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States. If that is the
case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter shall not be construed
as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter the Company&rsquo;s policy
of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause,
at any time, with or without notice. Although your job duties, title, compensation and benefits, as well as the Company&rsquo;s personnel
policies and procedures, may change from time to time, the &ldquo;at-will&rdquo; nature of your employment may only be changed by a written
agreement signed by you and the Company&rsquo;s Chief Executive Officer<B>, </B>which expressly states the intention to modify the at-will
nature of your employment. Similarly, except as expressly provided herein, nothing in this letter shall be construed as an agreement,
either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In return for the compensation
payments set forth in this letter, you agree to devote your full business time, best efforts, skill, knowledge, attention, and energies
to the advancement of the Company&rsquo;s business and interests and to the performance of your duties and responsibilities as an employee
of the Company and not to engage in any other business activities without prior approval from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an employee of the Company,
you will be required to comply with all Company policies and procedures. Violations of the Company&rsquo;s policies may lead to immediate
termination of your employment. Further, the Company&rsquo;s premises, including all workspaces, furniture, documents, and other tangible
materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet
and email) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy
with regard to any Company premises, materials, resources, or information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This offer letter is your
formal offer of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings, whether written
or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes under this
letter will be governed by the laws of the Commonwealth of Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT><B><I>Certain identified
information has been excluded from the exhibit pursuant to Item 601(a)(6)&nbsp;of Regulation S-K due to personal privacy concerns. Redacted
information is indicated by: [***]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you agree with the provisions
of this letter, please sign this letter in the space provided below and return it to Elliot Goldstein, at your earliest convenience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">Very Truly Yours, </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>ProMIS NEUROSCIENCES</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Williams</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&nbsp;&amp; CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing correctly sets forth the terms of my employment by ProMIS
NEUROSCIENCES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gavin T. Malenfant</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021 &ndash; 12 &ndash; 21 </FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gavin T. Malenfant</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APPENDIX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Payments Subject to Section&nbsp;409A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Subject to this Appendix A, any severance payments that may be due under the Agreement shall begin only
upon the date of your &ldquo;separation from service&rdquo; (determined as set forth below) which occurs on or after the termination of
your employment. The following rules&nbsp;shall apply with respect to distribution of the severance payments, if any, to be provided to
you under the Agreement, as applicable:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">It is intended that each installment of the severance payments under the Agreement provided under shall
be treated as a separate &ldquo;payment&rdquo; for purposes of Section&nbsp;409A. Neither the Company nor you shall have the right to
accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section&nbsp;409A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If, as of the date of your &ldquo;separation from service&rdquo; from the Company, you are not a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then each installment of the severance payments shall be made on the dates
and terms set forth in the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">If, as of the date of your &ldquo;separation from service&rdquo; from the Company, you are a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Each installment of the severance payments due under the Agreement that, in accordance with the dates
and terms set forth herein, will in all circumstances, regardless of when your separation from service occurs, be paid within the short-term
deferral period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation
Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent permissible under Section&nbsp;409A and shall be paid on the dates and terms set
forth in the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Each installment of the severance payments due under the Agreement that is not described in this Appendix
A, Section&nbsp;1(c)(i)&nbsp;and that would, absent this subsection, be paid within the six-month period following your &ldquo;separation
from service&rdquo; from the Company shall not be paid until the date that is six months and one day after such separation from service
(or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period
and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments,
if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence
shall not apply to any installment of payments if and to the maximum extent that that such installment is deemed to be paid under a separation
pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii)&nbsp;(relating
to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation
Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;must be paid no later than the last day of your second taxable year following the taxable year in
which the separation from service occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Appendix A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The determination of whether and when your separation from service from the Company has occurred shall
be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section&nbsp;1.409A-1(h). Solely
for purposes of this Appendix A, Section&nbsp;2, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered
a single employer under Section&nbsp;414(b)&nbsp;and 414(c)&nbsp;of the Code.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The Company makes no representation or warranty and shall have no liability to you or to any other person
if any of the provisions of the Agreement (including this Appendix) are determined to constitute deferred compensation subject to Section&nbsp;409A
but that do not satisfy an exemption from, or the conditions of, that section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Appendix A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF SEPARATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Place on Company Letterhead]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B><U>VIA HAND DELIVERY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>[Insert Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>[Insert Name]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>[Insert Address]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Dear [Insert Name]:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the termination
of your employment with <B>[Insert Company Name] </B>(the &ldquo;Company&rdquo;) on <B>[Insert Termination Date]</B>, you are eligible
to receive the severance benefits described in paragraph 2 below if you sign and return this letter agreement to me by <B>[Return Date]
[and it becomes binding between you and the Company]</B>. By signing and returning this letter agreement <B>[and not revoking your acceptance]</B>,
you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered
paragraphs below, including the release of claims set forth in paragraph 3. Therefore, you are advised to consult with an attorney before
signing this letter agreement and you have been given at least <B>[seven (7)&nbsp;/ twenty-one (21) / forty-five (45)]<SUP>1</SUP></B>
days to do so. <B>[If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7)&nbsp;day
period after you have signed it by notifying me in writing. If you do not so revoke, this letter agreement will become a binding agreement
between you and the Company upon the expiration of the seven (7)&nbsp;day period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you choose not to sign and return this letter agreement by <B>[Return Date] [or if you timely revoke your acceptance in writing]</B>,
you shall not receive any severance benefits from the Company. You will, however, receive payment for your final wages, any unpaid bonus,
and any unused vacation time accrued through the Termination Date, as defined below, and reimbursement for </FONT>any unpaid business
expenses. You may also, if eligible, elect to continue receiving group medical insurance pursuant to &ldquo;COBRA.&rdquo; Please consult
the COBRA materials to be provided by the Company under separate cover for details regarding these benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this </FONT>letter agreement
<B>[and do not revoke it in writing within the seven (7)&nbsp;day period]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> <I>Note: except for factual information, bracketed/bolded
provisions and alternatives will be dependent on age of executive at time of termination and whether termination is an individual termination
or part of a group termination.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><B>Termination
Date and Resignation as a Director </B>&ndash; Your effective date of termination from the Company is <B>[Insert Termination Date] </B>(the
 &ldquo;Termination Date&rdquo;). You agree to resign, as of the Termination Date, from your position as a Director of the Company, and
to sign and return to the Company all letters and documents that the Company may reasonably require in order to secure your resignation.
As of the Termination Date, all salary payments from the Company will cease and any benefits you had as of the Termination Date under
Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Description
of Severance Benefits </FONT></B><FONT STYLE="font-size: 10pt">&ndash; If you timely sign and return this letter agreement <B>[and do
not revoke your </B>acceptance<B>]</B>, and provided you abide by all of the obligations set forth herein, the Company will provide you
with the severance benefits set forth in <B>[Section</B></FONT><B>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">)] </FONT></B><FONT STYLE="font-size: 10pt">of
the <B>[Insert Date] [Offer Letter] </B>between you and the Company (the &ldquo;Severance Benefits&rdquo;) as follows: [SET OUT THE SEVERANCE
BENEFITS AND PAYMENT DATES].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Release
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; In consideration of the Severance Benefits, which you acknowledge you would not otherwise
be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates,
subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders,
partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual
and corporate capacities) (collectively, the &ldquo;Released Parties&rdquo;) from any and all claims, charges, complaints, demands, actions,
causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings,
omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&rsquo; fees and costs), of every kind and
nature that you ever had or now have against any or all of the Released Parties arising up to the date you sign this Agreement, including,
but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including,
but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &sect; 2000e et seq., the Americans With Disabilities
Act of 1990, 42 U.S.C. &sect; 12101 et seq., <B>[the Age Discrimination in Employment Act, 29 U.S.C. &sect; 621 et seq.,] </B>the Genetic
Information Nondiscrimination Act of 2008, 42 U.S.C. &sect; 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. &sect; 2601 et
seq., the Worker Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C. &sect; 2101 et seq., the Rehabilitation Act
of 1973, 29 U.S.C. &sect; 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &sect; 1681
et seq., and the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29 U.S.C. &sect; 1001 et seq., all as amended;
<B>[all claims arising out of the Massachusetts Fair Employment Practices Act., Mass. Gen. Laws ch. 151B, &sect; 1 et seq., the Massachusetts
Wage Act, Mass. Gen. Laws ch. 149, &sect; 148 et seq. (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil
Rights Act, Mass. Gen. Laws ch. 12, &sect;&sect; 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &sect; 102
and Mass. Gen. Laws ch. 214, &sect; 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &sect; 1 et seq., Mass. Gen.
Laws ch. 214, &sect; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &sect; 105D,
and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &sect; 52D, all as amended</B>]; <B>[Insert any other applicable
state&rsquo;s citations;] </B>all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional
distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, all claims arising out
of or relating to your <B>[Insert Date] </B>Employment Agreement); all claims to any non-vested ownership interest in the Company, contractual
or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of
your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal,
state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement releases
claims to vested benefits or to enforce this Agreement or prevents you from filing a charge with, cooperating with, or participating in
any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge
that you may not recover any monetary benefits in connection with any such claim, charge or proceeding).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Continuing
Obligations </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You acknowledge and reaffirm your obligation to keep confidential and not
to use or disclose any and all non-public information concerning the Company that you acquired during the course of your employment with
the Company, including, but not limited to, any non-public information concerning the Company&rsquo;s business affairs, business prospects,
and financial condition. You further acknowledge and reaffirm your obligations set forth in the <B>[Insert Name of Restrictive Covenant
Agreement(s)] </B>you executed for the benefit of the Company, which remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Non-Disparagement
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; You understand and agree that, to the extent permitted by law, you will not, in public
or private, make any false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any
media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the
Company, regarding the Company or any of the other Released Parties, or regarding the Company&rsquo;s business affairs, business prospects,
or financial condition. Notwithstanding the above, nothing in this Section&nbsp;will interfere with your ability to comply with legal
process or the requirements of applicable federal or state laws or regulations or to cooperate with any agency investigation. The Company
agrees to direct its officers, directors, employees and consultants not to, in public or private, make any false, disparaging, derogatory
or defamatory statements to any person or entity, including, but not limited to, any media outlet, industry group, financial institution
or current or former employee, board member, consultant, client or customer of the Company, regarding you, your involvement with the Company,
or your reputation, nor will the Company assist any others in engaging in such activities. Notwithstanding the above, nothing in this
Section&nbsp;shall interfere with the Company&rsquo;s ability to comply with legal process or the requirements of applicable federal or
state laws or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Continued
Assistance &ndash; </FONT></B><FONT STYLE="font-size: 10pt">You agree that after the Termination Date you will provide all reasonable
cooperation to the Company, including but not limited to, assisting the Company in transitioning your job duties and performing any other
tasks as reasonably requested by the Company. The Company shall: (a)&nbsp;compensate you for the reasonable value of your time for any
such cooperation and assistance; (b)&nbsp;pay out-of-pocket expenses consistent with Company policies; and (c)&nbsp;not interfere with
requirements you may have in new employment (including self-employment or consulting).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Cooperation
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; To the extent permitted by law, you agree to cooperate fully with the Company in the
defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the
future against or on behalf of the Company, whether before a state or federal court, any state or federal government agency, or a mediator
or arbitrator. Your full cooperation in connection with such claims or actions shall include, but not be limited to, reasonable requests
to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation
or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company. You agree that you
will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third
party with information concerning any actual or potential complaint or claim against the Company. In connection with such cooperation,
the Company will not interfere with requirements you may have in new employment (including self-employment or consulting), and, at the
Company&rsquo;s expense: (a)&nbsp;compensate you for the reasonable value of your time for any such cooperation and assistance; (b)&nbsp;reimburse
you for out-of-pocket expenses; and (c)&nbsp;provide legal counsel if necessary to advise you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Return
of Company Property </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You confirm that you have returned to the Company all keys, files,
records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices,
cellular phones, pagers,&nbsp;etc.), Company identification, and any other Company-owned property in your possession or control and have
left intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your employment.
You further confirm that you have cancelled all accounts for your benefit, if any, in the Company&rsquo;s name, including but not limited
to, credit cards, telephone charge cards, cellular phone and/or pager accounts, and computer accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Business
Expenses and Final Compensation </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You acknowledge that you have been reimbursed by the
Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are
owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment
by the Company, including payment for all wages (including overtime), bonuses, commissions, and accrued, unused vacation time, and that
no other compensation is owed to you except as provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amendment
and Waiver </FONT></B><FONT STYLE="font-size: 10pt">&ndash; This letter agreement shall be binding upon the parties and may not be modified
in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties
hereto. This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs,
executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter agreement shall
operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in
that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Validity
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; Should any provision of this letter agreement be declared or be determined by any court
of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby
and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Confidentiality
</FONT></B><FONT STYLE="font-size: 10pt">&ndash; To the extent permitted by law, you understand and agree that as a condition of the Severance
Benefits herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting
in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except
to your immediate family, your attorneys, financial advisors, and as required by law, and except as otherwise agreed to in writing by
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Nature
of Agreement &ndash; </FONT></B><FONT STYLE="font-size: 10pt">You understand and agree that this letter agreement is a severance agreement
and does not constitute an admission of liability or wrongdoing on the part of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Acknowledgments
 &ndash; </FONT></B><FONT STYLE="font-size: 10pt">You acknowledge that you have been given at least <B>[seven (7)&nbsp;! twenty-one (21)
! forty-five (45)] </B>days to consider this letter agreement, and that the Company advised you to consult with an attorney of your own
choosing prior to signing this letter agreement. <B>[You understand that you may revoke this letter agreement for a period of seven (7)&nbsp;days
after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until
the expiration of this seven (7)&nbsp;day revocation period. You understand and agree that by entering into this letter agreement, you
are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers
Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">[Eligibility
for Severance Program &ndash; Attached to this letter agreement as Attachment A is a description of (i)&nbsp;any class, unit or group
of individuals covered by the program of severance benefits which the Company has offered to you, and any applicable time limits regarding
such severance benefit program; and (ii)&nbsp;the job title and ages of all individuals eligible or selected for such severance benefit
program, and the ages of all individuals in the same job classification or organizational unit who are not eligible or who were not selected
for such severance benefit program.]</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Voluntary
Assent </FONT></B><FONT STYLE="font-size: 10pt">&ndash; You affirm that no other promises or agreements of any kind have been made to
or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and
intent of this letter agreement. You state and represent that you have had an opportunity to fully discuss and review the terms of this
letter agreement with an attorney. You further state and represent that you have carefully read this letter agreement, understand the
contents herein, freely, and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Applicable
Law </FONT></B><FONT STYLE="font-size: 10pt">&ndash; This letter agreement shall be interpreted and construed by the laws of the <B>[Commonwealth
of Massachusetts]</B>, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and recognize the
jurisdiction of the courts of the <B>[Commonwealth of Massachusetts]</B>, or if appropriate, a federal court located in the <B>[Commonwealth
of Massachusetts] </B>(which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit,
action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Entire
Agreement </FONT></B><FONT STYLE="font-size: 10pt">&ndash; This letter agreement contains and constitutes the entire understanding and
agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and cancels
all previous oral and written negotiations, agreements, and commitments in connection therewith. Nothing in this paragraph, however, shall
modify, cancel or supersede your obligations set forth in paragraph 4 above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Tax
Acknowledgement </FONT></B><FONT STYLE="font-size: 10pt">&ndash; In connection with the Severance Benefits provided to you pursuant to
this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you
shall be responsible for all applicable taxes with respect to such Severance Benefits under applicable law. You acknowledge that you are
not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Benefits set forth
in paragraph 2 of this letter agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any <B>questions</B>
about the matters covered in this letter agreement, please call me at <B>[Insert Phone Number]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[NAME] [TITLE]</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
hereby agree to the terms and </FONT>conditions set forth above. <B>[I have been given at least [twenty- one (21) / forty-five (45)] days
to consider this letter agreement and I have chosen to execute this on the date below. I intend that this letter agreement will become
a binding agreement between me and the Company if I do not revoke my acceptance in seven (7)&nbsp;days.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.6in; width: 93%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 51%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Insert Name]</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To be returned in a timely
manner as set forth on the first page&nbsp;of this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NON-SOLICITATION, CONFIDENTIALITY and ASSIGNMENT
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Employee Non-Solicitation, Confidentiality and
Assignment Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration and as a
condition of NAME (&ldquo;I&rdquo;, &ldquo;Me&rdquo;, or &ldquo;You&rdquo;) employment or continued employment by ProMIS Neurosciences.
(&ldquo;ProMIS&rdquo;), the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Proprietary
Information</U></B><U>. I agree that all information, whether or not in writing, whether or not disclosed before or after I was first
employed by ProMIS, concerning the business, technology, business relationships or financial affairs of ProMIS or its subsidiaries, affiliates,
and associated entities (collectively, the &ldquo;Company&rdquo;) that the Company has not released to the general public (collectively,
 &ldquo;Proprietary Information&rdquo;), and all tangible embodiments thereof, are and will be the exclusive property of the Company. By
way of illustration, Proprietary Information may include information or material that has not been made generally available to the public,
such as: (a)&nbsp;<I>corporate information</I>, including plans, strategies, methods, policies, resolutions, notes, email correspondence,
negotiations or litigation; (b)&nbsp;<I>marketing information</I>, including strategies, methods, customer identities or other information
about customers, prospect identities or other information about prospects, or market analyses or projections; (c)&nbsp;<I>financial information</I>,
including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price
lists; and (d)&nbsp;<I>operational and technological information</I>, including plans, specifications, manuals, forms, templates, software,
designs, methods, procedures, formulas, discoveries, inventions, improvements, biological or chemical materials, concepts and ideas; and
(e)&nbsp;<I>personnel information</I>, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation
structure, performance evaluations and termination arrangements or documents. Proprietary Information includes, without limitation, (1)&nbsp;information
received in confidence by the Company from its customers or suppliers or other third parties, and (2)&nbsp;all biological or chemical
materials and other tangible embodiments of the Proprietary Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Recognition
of Company&rsquo;s Rights</U></B><U>. I will not, at any time, without the Company&rsquo;s prior written permission, either during or
after my employment, disclose or transfer any Proprietary Information to anyone outside of the Company, or use or permit to be used any
Proprietary Information for any purpose other than the performance of my duties as an employee of the Company. I will cooperate with the
Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all
copies and other tangible embodiments of Proprietary Information in my possession or control upon the earlier of a request by the Company
or termination of my employment. The term &ldquo;Proprietary Information&rdquo; hereunder will not include information that I can establish
by competent written evidence (i)&nbsp;is or becomes generally known within the Company&rsquo;s industry through no fault of mine; (ii)&nbsp;was
known to me at the time it was disclosed; (iii)&nbsp;is lawfully and in good faith made available to me by a third-party who did not derive
it from the Company and who imposes no obligation of confidence on me; or (iv)&nbsp;is required to be disclosed by order of a governmental
authority or a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection
available for like material, and provided I first give reasonable advance written notice of such requirement to the Company, and permit
the Company to intervene in any relevant proceedings to protect its interests in the Proprietary Information, and provide full cooperation
and assistance to the Company in seeking to obtain such protection.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Exhibit B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>3.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Rights
of Others</FONT></U></B><U><FONT STYLE="font-size: 10pt">. I understand that the Company is now and may hereafter be subject to non-disclosure
or confidentiality agreements with third persons which require the Company to protect or refrain from use of proprietary information.
I agree to be bound by the terms of such agreements in the event I have access to such proprietary information.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>4.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Commitment
to Company; Avoidance of Conflict of Interest</FONT></U></B><U><FONT STYLE="font-size: 10pt">. While an employee of the Company,&nbsp;I
will devote my full-time efforts to the Company&rsquo;s business and I will not engage in any other business activity that conflicts or
reasonably could potentially conflict with my duties to the Company. I will advise the president of the Company or their nominee at such
time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict
of interest as an employee of the Company. I will take whatever action is requested of me by the Company to resolve any conflict or appearance
of conflict which it finds to exist.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>5.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Developments</FONT></U></B><U><FONT STYLE="font-size: 10pt">.
I hereby assign and transfer and, to the extent any such assignment cannot be made at present, hereby agree to assign and transfer, to
ProMIS and its successors, designees and assigns, all my right, title and interest in and to all Developments (as defined below) that:
(a)&nbsp;are created, developed, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction (collectively,
 &ldquo;conceived&rdquo;) during the period of my employment and six (6)&nbsp;months thereafter and that relate to the business of the
Company or to products, methods or services being researched, developed, manufactured or sold by the Company; or (b)&nbsp;result from
tasks assigned to me by the Company; or (c)&nbsp;result from the use of premises, Proprietary Information or personal property (whether
tangible or intangible) owned, licensed or leased by the Company (collectively, &ldquo;Company-Related Developments&rdquo;), and all patent
rights, trademarks, copyrights and other intellectual property rights in all countries and territories worldwide claiming, covering or
otherwise arising from or pertaining to Company-Related Developments (collectively, &ldquo;Intellectual Property Rights&rdquo;). I further
agree that &ldquo;Company-Related Developments&rdquo; include, without limitation, all Developments that (i)&nbsp;were conceived by me
before my employment, (ii)&nbsp;relate to the business of the Company or to products, methods or services being researched, developed,
manufactured or sold by the Company, and (iii)&nbsp;were not subject to an obligation to assign to another entity when conceived. I will
make full and prompt disclosure to the Company of all Company-Related Developments, as well as all other Developments conceived by me
during the period of my employment and six (6)&nbsp; months thereafter. I acknowledge that all work performed by me as an employee of
the Company is on a &ldquo;work for hire&rdquo; basis. I hereby waive all claims to any moral rights or other special rights which I may
have or accrue in any Company-Related Developments. &ldquo;Developments&rdquo; mean inventions, discoveries, designs, developments, methods,
modifications, improvements, processes, biological or chemical materials, algorithms, databases, computer programs, formulae, techniques,
trade secrets, graphics or images, audio or visual works, and other works of authorship.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Exhibit B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To preclude any possible uncertainty,&nbsp;I
have set forth on <U>Exhibit&nbsp;A</U> attached hereto a complete list of Developments conceived by me before my employment that are
not Company-Related Developments (&ldquo;Prior Inventions&rdquo;). I have also listed on <U>Exhibit&nbsp;A </U>all patent rights of which
I am an inventor, other than those contained within Intellectual Property Rights (&ldquo;Other Patent Rights&rdquo;). If no such disclosure
is attached,&nbsp;I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company,&nbsp;I
incorporate a Prior Invention into a Company product, process or research or development program or other work done for the Company,&nbsp;I
hereby grant to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, worldwide license (with the full right
to sublicense through multiple tiers) to make, have made, modify, use, offer for sale, import and sell such Prior Invention. Notwithstanding
the foregoing,&nbsp;I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without
the Company&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">I
understand that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a </FONT>requirement
in an employee agreement to assign certain classes of inventions made by an employee, this Section&nbsp;will be interpreted not to apply
to any invention which a court rules&nbsp;and/or the Company agrees falls within such classes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>Documents
and Other <U>Materials</U></B><U>. I will keep and maintain adequate and current records of all Proprietary Information and Company-Related
Developments conceived by me, which records will be available to and remain the sole property of the Company at all times. All files,
letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification
sheets, program listings, blueprints, models, prototypes, materials or other written, photographic or other tangible material containing
or embodying Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property
of the Company to be used by me only in the performance of my duties for the Company. In the event of the termination of my employment
for any reason,&nbsp;I will deliver to the Company all of the foregoing, and all other materials of any nature pertaining to the Proprietary
Information of the Company and to my work, and will not take or keep in my possession any of the foregoing or any copies. Any property
situated on the Company&rsquo;s premises and owned by the Company, including laboratory space, computers, disks and other storage media,
filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Enforcement
of Intellectual Property Rights</U></B><U>. I will cooperate fully with the Company, both during and after my employment with the Company,
with respect to the procurement, maintenance and enforcement of Intellectual Property Rights, as well as all other patent rights, trademarks,
copyrights and other intellectual property rights in all countries and territories worldwide owned by or licensed to the Company. I will
sign, both during and after the term of this Agreement, all papers, including copyright applications, patent applications, declarations,
oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its
rights and interests in any Company-Related Development or Intellectual Property Rights. If the Company is unable, after reasonable effort,
to secure my signature on any such papers,&nbsp;I hereby irrevocably designate and appoint each officer of the Company as my agent and
attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable
in order to protect its rights and interests in </U>the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Exhibit B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>8.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Non-Solicitation</FONT></U></B><U><FONT STYLE="font-size: 10pt">.
In order to protect the Company&rsquo;s Proprietary Information and good will, during my employment and for a period of twelve (12) months
following a for Cause (as defined below) termination of my employment (the &ldquo;Restricted Period&rdquo;),&nbsp;I will not, directly
or indirectly, in any manner, other than for the benefit of the Company, (a)&nbsp;call upon, solicit, divert or take away any of the customers,
business or prospective customers of the Company or any of its suppliers, and/or (b)&nbsp;solicit, entice or attempt to persuade any other
employee or consultant of the Company to leave the services of the Company for any reason. I acknowledge and agree that if I violate any
of the provisions of this Section, the running of the Restricted Period will be extended by the time during which I engage in such violation(s).</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>9.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Government
Contracts</FONT></U></B><U><FONT STYLE="font-size: 10pt">. I acknowledge that the Company may have from time to time agreements with
other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding
inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to comply
with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under Section&nbsp;5,&nbsp;I
also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required
to be in the United States under any contract between the Company and the United States or any of its agencies.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Prior
Agreements</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I hereby represent that, except as I have fully disclosed previously in writing
to the Company,&nbsp;I am not bound by the terms of any agreement with any current or previous employer or other party that interferes
with my performance under this Agreement or obligates me to refrain from using or disclosing any trade secret or confidential or proprietary
information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of
such previous employer or any other party, or to assign any patent rights, trademarks, copyrights or other intellectual property rights.
I further represent that my performance of all the terms of this Agreement as an employee of the Company does not and will not breach
any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment
with the Company. I will not disclose to the Company or induce the Company to use any confidential or proprietary information or material
belonging to any previous employer or others.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies
Upon Breach</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I understand that the restrictions contained in this Agreement are necessary
for the protection of the business and goodwill of the Company and I consider them to be reasonable for such purpose. Any breach of this
Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in
addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Exhibit B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>12.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Use
of Voice,&nbsp;Image and Likeness</FONT></U></B><U><FONT STYLE="font-size: 10pt">. I give the Company permission to use my voice, image
or likeness, with or without using my name, for the purposes of advertising and promoting the Company, or for other purposes deemed appropriate
by the Company in its reasonable discretion, except to the extent expressly prohibited by law.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>13.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Publications
and Public Statements</FONT></U></B><U><FONT STYLE="font-size: 10pt">. I will obtain the Company&rsquo;s written approval before publishing
or submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. To
ensure that the Company delivers a consistent message about its products, services and operations to the public, and further in recognition
that even positive statements may have a detrimental effect on the Company in certain contexts, any statement about the Company which
I create, publish or post during my period of employment and for six (6)&nbsp;months thereafter, on any media accessible by the public,
including but not limited to electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer
of the Company before it is released in the public domain.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>14.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Employment Obligation</FONT></U></B><U><FONT STYLE="font-size: 10pt">. I understand that this Agreement does not create an obligation
on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment
agreement signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated
by the Company or me at any time and for any reason. Without limiting the foregoing in any manner, You may be immediately terminated,
without notice, for Cause or without Cause. &ldquo;Cause&rdquo; as used herein shall mean: (i)&nbsp;a breach of Your obligations under
this Agreement or any other agreement you have with the Company; (ii)&nbsp;the failure or refusal to follow the instructions of Your supervisor
or the Board of Directors of the Company, as the case may be; (iii)&nbsp;the commission by You of any act of dishonesty, moral turpitude,
fraud, or breach of trust; (iv)&nbsp;conviction of, or pleading guilty or no contest to, any felony or any lesser crime; (v)&nbsp;the
failure to adhere to policies and procedures adopted by the Company from time to time.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival
and Assignment by the Company</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. I understand that my obligations under this Agreement will
continue in accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits
(if any) or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following
the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators.
The Company will have the right to assign this Agreement to its affiliates, successors and assigns. I expressly consent to be bound by
the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred
without the necessity that this Agreement be resigned at the time of such transfer.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
to Future Employers and Others</U></FONT></B><FONT STYLE="font-size: 10pt"><U>. During the period in which the terms of the Non-Solicitation
agreement described in Section&nbsp;8 and the Developments agreement in Section&nbsp;5 remain in force,&nbsp;I will provide a copy of
this Agreement to any prospective employer, partner or co-venturer prior to entering into an employment, partnership or other business
relationship with such person or entity.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Exhibit B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>17.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Exit
Interview</FONT></U></B><U><FONT STYLE="font-size: 10pt">. If and when I depart from the Company,&nbsp;I may be required to attend an
exit interview and sign an &ldquo;Employee Exit Acknowledgement&rdquo; to reaffirm my acceptance and acknowledgement of the obligations
set forth in this Agreement. During the Restricted Period following termination of my employment,&nbsp;I will notify the Company of any
change in my address and of each subsequent engagement, employment or business activity, including the name and address of my employer,
party to which I render services or other post-Company employment or engagement plans and the nature of my activities.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>18.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Severability</FONT></U></B><U><FONT STYLE="font-size: 10pt">.
In case any provisions (or portions thereof) contained in this Agreement will, for any reason, be held invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement
will be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more
of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope,
activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable
law as it will then appear.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>19.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Entire
Agreement</FONT></U></B><U><FONT STYLE="font-size: 10pt">. This Agreement constitutes the entire and only agreement between the Company
and me respecting the subject matter hereof, and supersedes all prior agreements and understandings, oral or written, between us concerning
such subject matter. No modification, amendment, waiver or termination of this Agreement or of any provision hereof will be binding unless
made in writing and signed by an authorized officer of the Company. Failure of the Company to insist upon strict compliance with any of
the terms, covenants or conditions hereof will not be deemed a waiver of such terms, covenants or conditions. In the event of any inconsistency
between this Agreement and any other contract between the Company and me, the provisions of this Agreement will prevail.</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>20.</U></B></FONT><B><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Interpretation</FONT></U></B><U><FONT STYLE="font-size: 10pt">.
This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted,
enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the Suffolk
County Business Litigation Session for purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction
or venue in this court. As used in this Agreement, &ldquo;including&rdquo; means &ldquo;including but not limited to&rdquo;</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> Exhibit B - <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>BY SIGNING BELOW,&nbsp;I
CERTIFY THAT I HAVE THE RIGHT TO CONSULT AN ATTORNEY PRIOR TO ENTERING INTO THIS AGREEMENT, HAVE READ THIS AGREEMENT CAREFULLY AND, AM
SATISFIED THAT I UNDERSTAND IT COMPLETELY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
has executed this agreement as a sealed instrument as of the date set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed:</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gavin T. Malenfant</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Employee's full name)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type of print name:</FONT></TD>
    <TD STYLE="padding-left: 0.125in; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gavin T. Malenfant</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Accepted and agreed:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ProMIS NEUROSCIENCES</P>



<P STYLE="font-size: 10pt; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eugene Williams</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and CEO</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;21, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit&nbsp;B<BR>
Signature Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>57
<FILENAME>filename57.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.38</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt">Final<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROMIS
NEUROSCIENCES INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCK
OPTION PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PURPOSE
AND INTERPRETATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
purpose of the Plan is to provide the Corporation with a equity-related mechanism to attract, retain and motivate Directors, Officers,
Employees and Consultants and create incentives for such individuals to contribute toward the long term goals of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Affiliate</B></FONT>
means a company that is a parent or subsidiary of the Corporation, or that is controlled by the same entity as the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Associate</B></FONT>
has the meaning assigned by the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Blackout
Period</B></FONT> means the period during which the relevant Optionee is prohibited from exercising an Option due to trading restrictions
imposed by the Corporation in accordance with its securities trading policies governing trades by Directors, Officers and Employees in
the Corporation&#8217;s securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Board</B></FONT>
means the board of directors of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Change
of Control</B></FONT> means an occurrence when a Person, other than the current &quot;control person&quot; of the Corporation (as that
term is defined in the Securities Act), becomes a &quot;control person&quot; of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Close
Person</B></FONT> means the spouse or other family member of an Optionee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Shares</B></FONT> means common shares without par value in the capital of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Consultant
</B></FONT>means an individual, other than an Employee, Officer or Director that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">provides
on an ongoing bona fide basis, consulting, technical, managerial or like services to the Corporation or an Affiliate of the
Corporation, other than services provided in relation to a &quot;distribution&quot; (as that term is described in the Securities
Act);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">provides
the services under a written contract between the Corporation or an Affiliate and the Person or the Consultant Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">in
the reasonable opinion of the Corporation, spends or will spend a significant amount of time and attention on the business and affairs
of the Corporation or an Affiliate of the Corporation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">has
a relationship with the Corporation or an Affiliate that enables the Person or Consultant Company to be knowledgeable about the business
and affairs of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Consultant
Company</B></FONT> means for an individual consultant, a company or partnership of which the Person is an employee, shareholder or partner;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporation</B></FONT>
means ProMIS Neurosciences Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Directors</B></FONT>
means the directors of the Corporation as may be elected from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Disability</B></FONT>
means a medically determinable physical or mental impairment expected to result in death or to last for a continuous period of not less
than 6 months, and which causes an individual to be unable to engage in any substantial gainful activity, or any other condition of impairment
that the Board, acting reasonably, determines constitutes a disability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Employee
</B></FONT>means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Person who is considered an employee under the <I>Income Tax Act</I> (Canada) (i.e. for whom income tax, employment insurance and CPP
deductions must be made at source);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Person who works full-time for the Corporation or any Affiliate providing services normally provided by an employee and who is subject
to the same control and direction by the Corporation over the details and methods of work as an employee of the Corporation, but for whom
income tax deductions are not made at source; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Person who works for the Corporation or any Affiliate on a continuing and regular basis for a minimum amount of time per week providing
services normally provided by an employee and who is subject to the same control and direction by the Corporation over the details and
methods of work as an employee of the Corporation, but for whom income tax deductions need not be made at source;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Expiry
Date</B></FONT> means the day on which an Option lapses as specified in the Option Commitment therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Former
Option Plan</B></FONT> means the Corporation&#8217;s stock option plan made effective September&nbsp;21, 2005;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Independent
</B></FONT>means independent as defined under Section&nbsp;1.4 of National Instrument 52-110 <I>Audit Committees</I>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Insider</B></FONT>
means an insider as defined in the TSX Policies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investor
Relations Activities</B></FONT> means generally any activities or communications that can reasonably be seen to be intended to or be primarily
intended to promote the merits or awareness of or the purchase or sale of securities of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Market
Price</B></FONT> means the 5-day volume weighted average trading price as calculated in accordance with the TSX Policies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Officer</B></FONT>
means a duly appointed senior officer of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Option</B></FONT>
means the right to purchase Common Shares granted hereunder to a Service Provider;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Option
Commitment</B></FONT> means the notice of grant of an Option delivered by the Corporation hereunder to a Service Provider and substantially
in the form of Schedule A hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Option
Effective Date</B></FONT> for an Option means the date of grant thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Optioned
Shares</B></FONT> means Common Shares subject to an Option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Optionee</B></FONT>
means an individual to whom an Option is granted by the Corporation under the&nbsp;Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Issue</B></FONT> means the number of Common Shares outstanding on a non-diluted basis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Person</B></FONT>
means a company or an individual;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plan</B></FONT>
means this Share Option Plan, as may be amended from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plan
Shares</B></FONT> means the total number of Common Shares which may be reserved for issuance as Optioned Shares under the Plan as provided
in &sect;2.4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Regulatory
Approval</B></FONT> means the approval of the TSX and any other securities regulatory agency that may have jurisdiction in the circumstances;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reserved
for Issuance</B></FONT> refers to Common Shares that may be issued in the future upon the exercise of stock options which have been&nbsp;granted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Securities
Act</B></FONT> means the Securities Act, R.S.O. 1990, c. S.5, as amended from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Service
Provider</B></FONT> means a Person who is a bona fide Director, Officer, Employee or Consultant, and also includes a company, of which
100% of the share capital is beneficially owned by one or more Service Providers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share
Compensation Arrangement</B></FONT> means the Plan described herein and any other stock option, stock option plan, employee stock purchase
plan or any other compensation or incentive mechanism involving the issuance or potential issuance of shares to one or more Service Providers,
including a share purchase from treasury which is financially assisted by the Corporation by way of a loan, guaranty or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Subscription
Price</B></FONT> means the amount payable per Common Share on the exercise of an Option, as determined in accordance with &sect;3.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Triggering
Event</B></FONT> means the occurrence of one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
Change of Control of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
proposed merger, amalgamation, arrangement or reorganization of the Corporation with one or more corporations that is approved by the
Board; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
take-over bid as that term is defined in the Securities Act but excluding an exempt take over bid as determined under the Securities Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TSX
</B></FONT>means the Toronto Stock Exchange and any successor thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TSX
Policies</B></FONT> means the rules&nbsp;and policies of the TSX as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SHARE
OPTION PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Establishment of Share Option Plan and Termination
of Former Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Share Option Plan is hereby established to recognize contributions made by Service Providers and to create an incentive for their
continuing relationship with the Corporation and its Affiliates. The Plan replaces and supersedes the Former Option Plan. Those
share options granted under the Former Option Plan by the Corporation prior to the adoption of this Plan are included hereunder.
Notwithstanding the foregoing, options granted under the Former Option Plan are not affected by this Plan to the extent that the
terms of the Plan would materially decrease the rights or benefits accruing to such optionee or materially increase the obligations
of such optionee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Eligibility</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Options
may be granted hereunder to all Service Providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Options Granted Under the Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to specific variations approved by the Board, all terms and conditions set out herein will be incorporated into and form part of an Option
granted hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Maximum Plan Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
maximum aggregate number of Plan Shares that may be Reserved for Issuance under the Plan at any point in time is 20% of the Outstanding
Issue at the time Plan Shares are Reserved for Issuance as a result of the grant of an Option, less any Common Shares reserved for issuance
under share options granted under Share Compensation Arrangements other than this Plan, unless the Plan is amended pursuant to TSX Policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
no event may the number of Common Shares Reserved for Issuance to any one person pursuant to an Option exceed 5% of the Outstanding Issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shares Not Acquired</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Any
Common Shares not acquired under an Option granted under the Plan which has expired or been cancelled or terminated may be made the subject
of a further Option pursuant to the provisions of the Plan. For greater certainty options which are exercised thereupon increase the number
available to the Plan by the relevant percentage of outstanding shares as provided hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Powers of the Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board will be responsible for the general administration of the Plan and the proper execution of its provisions, the interpretation of
the Plan and the determination of all questions arising hereunder. Without limiting the generality of the foregoing, the Board has the
power to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">allot Common Shares for issuance in connection with Options granted under the&nbsp;Plan,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 91.5%">grant Options hereunder,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 91.5%">subject to &sect;4.5, 4.6, and 4.7 and subject to Regulatory Approval or any shareholder approval required
under law, amend, suspend, terminate or discontinue the Plan, or revoke or alter any action taken in connection therewith, except that
no amendment or suspension of the Plan will, without
the written consent of the affected Optionees, alter or impair any Option granted under the Plan,&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 91.5%">delegate all or such portion of its powers hereunder as it may determine to one or more committees of
the Board, either indefinitely or for such period of time as it may specify, and thereafter each such committee may exercise the powers
and discharge the duties of the Board in respect of the Plan so delegated to the same extent as the Board is hereby authorized so to do.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adjustments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
number of Common Shares subject to an Option will be subject to adjustment in the events and in the manner following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">in the event that the Board determines that any dividend or other distribution (whether in the form of
cash, Common Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger,
consolidation, combination, issuance of warrants or other rights to purchase Common Shares or other securities of the Corporation to all
holders of common shares <I>pro rata</I> whether as a dividend or otherwise or other similar corporate transaction or event affects the
Common Shares such that an adjustment is determined by the Board to be appropriate in order to prevent dilution or enlargement of the
benefits or potential benefits intended to be made available under the Plan, then the Board will, in such manner as it may deem equitable,
adjust any or all of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 11.5%"></TD><TD STYLE="width: 4.5%">(i)</TD><TD STYLE="text-align: justify; width: 84%">the number and type of Common Shares (or other securities or other property) that thereafter may be made
the subject of Options,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 11.5%"></TD><TD STYLE="width: 4.5%">(ii)</TD><TD STYLE="text-align: justify; width: 84%">the number and type of Common Shares (or other securities or other property) subject to outstanding Options,
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the purchase or exercise price with respect to any Option;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">provided, however, that the number of
Common Shares covered by any Option or to which such Option relates will always be a whole number,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 91.5%">an adjustment will take effect at the time of the event giving rise to the adjustment, and the adjustments
provided for in this Section&nbsp;are cumulative,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 91.5%">the Corporation will not be required to issue fractional shares in satisfaction of its obligations hereunder.
Any fractional interest in a Common Share that would, except for the provisions of this &sect;2.8(c), be deliverable upon the exercise
of an Option will be cancelled and not be deliverable by the Corporation, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 91.5%">if any questions arise at any time with respect to the Option price or number of Common Shares deliverable
upon exercise of an Option in any of the events set out in this &sect;2.8(d), such questions will be conclusively determined by the Corporation&#8217;s
Auditors, or, if they decline to so act, any other firm of Chartered Accountants, in Toronto, Ontario that the Corporation may designate
and who will have access to all appropriate records and such determination will be binding upon the Corporation and all Optionees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SHARE
OPTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Subscription Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Subscription Price of an Option will be set by the Board at the time such Option is allocated under the Plan, and cannot be less than
the Market Price, calculated on the day before the grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Term of Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
as described in this &sect;3.2, the term of an Option will be such period after the Option Effective Date of the Option, not exceeding
10 years, as the Board determines at the time of granting of the Option. If the Expiry Date for an Option occurs during a Blackout Period
applicable to the relevant Optionee, or within five business days after the expiry of a Blackout Period applicable to the relevant Optionee,
then the Expiry Date for that Option will be the date that is the tenth business day after the expiry date of the Blackout Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vesting of Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Vesting
of Options is at the discretion of the Board, and will generally be subject to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Service Provider remaining employed by or continuing to provide services to the Corporation or any of its Affiliates as well as, at the
discretion of the Board, achieving certain milestones which may be defined by the Board from time to time or receiving a satisfactory
performance review by the Corporation or any Affiliate during the vesting period; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">remaining
as a Director of the Corporation or any of its Affiliates during the vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event of a Triggering Event, in its discretion the Board may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">provide
in the case of a particular Optionee that the Options held by that Optionee may be exercised by the Optionee in full or in part at any
time before the applicable vesting period for those Options; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">cause
all or a portion of any of the Options granted under the Plan to be exchanged for incentive stock options of another corporation upon
the occurrence of a Triggering Event in such ratio and at such exercise price as the Board deems appropriate, acting reasonably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Right to Exercise</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Option may be exercised after the Optionee, if a Director has ceased to be a Director or if an Employee or other Service Provider has
left the employ or service of the Corporation, except as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">in the case of death of an Optionee, all unvested rights of the Optionee under the Option will be deemed
to have become fully vested immediately before the time of such Optionee's death, and the personal representatives of the Optionee will
be entitled to exercise the Option at any time by the earlier of (i)&nbsp;the Expiry Date of the Option, and (ii)&nbsp;the first anniversary
of the date on which the Optionee died;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify; width: 91.5%">in the case of an Optionee becoming unable to work due to Disability whether or not such Optionee is entitled
to or in receipt of disability benefits, all unvested rights of the Optionee under the Option will be deemed to have become fully vested
immediately before the time of such Optionee's termination and the Options will be exercisable by such Optionee or by the personal representative
designated by the Optionee on or before the date which is the earlier of one year following the termination of employment, engagement
or appointment as a director or officer and the applicable Expiry Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 91.5%">in the case of an Optionee that is not an Independent Director of the Corporation resigning his office,
or terminating his employment or service, or being dismissed without cause, the option rights that have accrued to such Optionee up to
the time of termination will be exercisable within the six months after the date of termination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 91.5%">in the case of an Optionee that is an Independent Director of the Corporation resigning his office, or
terminating his employment or service, or being dismissed without cause, the option rights that have accrued to such Optionee up to the
time of termination will be exercisable within one year after the date of termination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(e)</TD><TD STYLE="text-align: justify; width: 91.5%">in the case of an Optionee being dismissed from office, employment or service for cause, the Option and
all option rights that had accrued to the Optionee to the date of termination will immediately terminate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">but provided that in no event may the term of
the Option exceed 10 years. Notwithstanding the provisions of &sect;3.5(c), in its discretion and subject to the receipt of any required
Regulatory Approval, the Board may extend the time period for exercise of an Option in the circumstances set out in &sect;3.5(c)&nbsp;and
may also permit the option to be exercised in respect of any Options that vest during any agreed upon severance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Limited Right to Assign</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Unless
approved by the TSX and the Board, an Option may be exercisable only by the Optionee to whom it is granted and will not be assignable
except as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">to
a Close Person or a Person controlled by the Optionee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">to
the Optionee&#8217;s or a Close Person&#8217;s Registered Retirement Savings Plan or Registered Retirement Income Fund or to a trustee,
custodian or administrator acting on behalf of, or for the benefit of, the Optionee or a Close Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">for
estate planning or estate settlement purposes; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">as
contemplated by &sect;3.5(a)&nbsp;and &sect;3.5(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Option Commitment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Upon
grant of an Option hereunder, the Chief Financial Officer of the Corporation will deliver to the Service Provider an Option Commitment
detailing the terms of his Option and upon such delivery the Service Provider will be an Optionee in the Plan and have the right to purchase
the Optioned Shares at the Subscription Price set out therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manner of Exercise</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">An
Optionee who wishes to exercise his Option may do so by delivering</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">a written notice to the Corporation specifying the number of Optioned Shares being acquired pursuant to
the Option, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 91.5%">cash or bank draft or a certified cheque payable to the Corporation for the aggregate Subscription Price
for the Optioned Shares being acquired.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Delivery of Certificate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Not
later than five days after receipt of the notice of exercise and payment in full for the Optioned Shares being acquired, the Corporation
will direct its transfer agent to issue a certificate to the Optionee for the appropriate number of Optioned Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>GENERAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transferability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
benefits, rights and options accruing to any Optionee under the Plan will not be transferable by an Optionee other than in the manner
provided for in the Plan. During the lifetime of an Optionee, all benefits, rights and options may only be exercised by the Optionee or
by his guardian or legal representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Nothing
contained in the Plan will confer upon any Optionee any right with respect to employment or provision of services with the Corporation
or an Affiliate, or interfere in any way with the right of the Corporation or an Affiliate to terminate the Optionee&#8217;s employment
or service at any time. Participation in the Plan by an Optionee will be voluntary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Representation or Warranty</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Corporation makes no representation or warranty as to the future market value of Common Shares issued in accordance with the provisions
of the Plan or to the effect of the <I>Income Tax Act</I> (Canada) or any other taxing statute governing the Options or the Common shares
issuable thereunder or the tax consequences to a Service Provider. Compliance with applicable securities laws as to the disclosure and
resale obligations of each Optionee is the responsibility of such Optionee and not the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Interpretation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Plan will be governed and construed in accordance with the laws of the Province of Ontario.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendment of the Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to any specific limitations contained in the Plan, the Board reserves the right, in its absolute discretion, to at any time amend, modify
or terminate the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
 &sect;4.5, the Board may not, without approval of the holders of a majority of the issued and outstanding equity securities of the Corporation
present and voting in person or by proxy at a meeting of holders of such securities, amend the Plan or an Option to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">increase the number of Common Shares reserved for issuance under the Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 91.5%">make any amendment that would reduce the Subscription Price of an outstanding Option granted to an Insider
(including a cancellation and reissue of an Option to an Insider at a reduced Subscription Price);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 91.5%">amend or delete &sect;3.2 to extend the term of any Option beyond the Expiry Date of the Option or, except
as already contemplated under &sect;3.2, allow for the Expiry Date of an Option to be greater than 10 years;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 91.5%">permit assignments, or exercises other than by the Optionee, of Options beyond that contemplated by &sect;3.5,
except for an amendment that would permit the assignment of an Option for estate planning or estate settlement purposes; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(e)</TD><TD STYLE="text-align: justify; width: 91.5%">amend the Plan to provide for other types of compensation through equity issuance, unless the change to
the Plan or an Option results from the application of &sect;2.8.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Without
limiting the generality of &sect;4.5, the Board may make the following amendments to the Plan without obtaining shareholder approval:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">amendments to the terms and conditions of the Plan necessary to ensure that the Plan complies with the
applicable regulatory requirements, including without limitation the TSX Policies or the rules&nbsp;of any national securities exchange
or system on which the Common Shares are then listed or reported, or by any regulatory body having jurisdiction with respect thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 91.5%">making adjustments to outstanding Options in the event of certain corporate transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 91.5%">the addition of a cashless exercise feature, payable in cash or securities, whether or not such feature
provides for a full deduction of the number of underlying securities from the Plan reserve;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 91.5%">a change to the termination provisions of an Option or the Plan which does not entail an extension beyond
the original Expiry Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(e)</TD><TD STYLE="text-align: justify; width: 91.5%">amendments to the provisions of the Plan respecting administration of the Plan and eligibility for participation
under the Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(f)</TD><TD STYLE="text-align: justify; width: 91.5%">amendments to the provisions of the Plan respecting the terms and conditions on which options may be granted
pursuant to the Plan, including the provisions relating to the Subscription Price, the option period, and the vesting schedule; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(g)</TD><TD STYLE="text-align: justify; width: 91.5%">amendments to the Plan that are of a &#8220;housekeeping nature&#8221;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Shareholder Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
an Optionee nor the Optionee&#8217;s legal representative will be, or have any of the rights and privileges of, a shareholder of the Corporation
with respect to any Common Shares issuable to such Optionee upon the exercise or payment of any Option, in whole or in part, unless and
until such Common Shares have been issued in the name of such Optionee or such Optionee's legal representative without restrictions thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Rights to Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Service Provider, Optionee or other Person will have any claim to be granted any Option under the Plan, and there is no obligation for
uniformity of treatment of Service Providers, Optionees or holders or beneficiaries of Options under the Plan. The terms and conditions
of Options need not be the same with respect to any Optionee or with respect to different Optionees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with Rules&nbsp;and Laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Corporation will not be required to issue any Common Shares under the Plan unless such issuance is in compliance with all applicable laws,
regulations, rules, orders of governmental or regulatory authorities and the requirements of any stock exchange upon which Common Shares
of the Corporation are listed. The Corporation will not in any event be obligated to take any action to comply with any such laws, regulations,
rules, orders or requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adoption of Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Plan was approved by the Board on August&nbsp;9, 2007 and is effective as of such date, subject to acceptance of the TSX and approval
by the shareholders of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
plan was amended by the Board, and approved by the shareholders of the Corporation, effective October&nbsp;13, 2010, March&nbsp;27, 2013,
September&nbsp;29, 2014 and June&nbsp;29, 2015, subject to acceptance of the TSX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Final</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>PROMIS
NEUROSCIENCES INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT><B><FONT STYLE="text-transform: uppercase"><U>STOCK OPTION PLAN</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OPTION COMMITMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notice is hereby given that, effective this _______
day of ______________________________, 20___ (the &#8220;Effective Date&#8221;) ProMIS Neurosciences Inc. (the &#8220;Corporation&#8221;)
has granted to ________________________, an Option to acquire __________ Common Shares (&#8220;Optioned Shares&#8221;) up to 5:00 p.m.&nbsp;(EST)
on the _______day of ___________________, 20__ (the &#8220;Expiry Date&#8221;) at a Subscription Price of Cdn.&nbsp;$_____ per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optioned Shares may be acquired as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%">___</TD>
<TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 91.5%">IN ACCORDANCE WITH THE VESTING PROVISIONS SET OUT IN THE PLAN; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">___</FONT></TD>
                          <TD STYLE="width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 91.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">AS </FONT>FOLLOWS:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(a)</TD><TD STYLE="text-align: justify; width: 91.5%">&#9679; Optioned Shares (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT>%)
                                                           will vest and be exercisable on or after the Grant Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(b)</TD><TD STYLE="text-align: justify; width: 91.5%">&#9679; additional Optioned Shares (&#9679;%) will vest and be exercisable on or after
                                                           &#9679; [date];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(c)</TD><TD STYLE="text-align: justify; width: 91.5%">&#9679; additional Optioned Shares (&#9679;%) will vest and be exercisable on or after
                                                           &#9679; [date];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.5%"></TD><TD STYLE="width: 3%">(d)</TD><TD STYLE="text-align: justify; width: 91.5%">&#9679; additional Optioned Shares (&#9679;%) will vest and be exercisable on or after
                                                           &#9679; [date];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grant of the Option evidenced hereby is made
subject to the terms and conditions of the Corporation&#8217;s Stock Option Plan, the terms and conditions of which are hereby incorporated
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To exercise your Option, deliver a written notice,
which shall be substantially in the form attached hereto as Exhibit&nbsp;1 hereto, specifying the number of Optioned Shares you wish to
acquire, together with cash or a certified cheque or bank draft payable to the Corporation for the aggregate Subscription Price, to the
Corporation. A certificate for the Optioned Shares so acquired will be issued by the transfer agent as soon as practicable thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROMIS NEUROSCIENCES INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 40%">Chief Financial Officer</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 60%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Optionee acknowledges receipt of a copy of the Plan and represents
to the Corporation that the Optionee is familiar with the terms and conditions of the Plan, and hereby accepts this Option subject to
all of the terms and conditions of the Plan. The Optionee agrees to execute, deliver, file and otherwise assist the Corporation in filing
any report, undertaking or document with respect to the awarding of the Option and exercise of the Option, as may be required by the TSX
or securities regulatory authorities. The Optionee further acknowledges that if the Plan has not been approved by the shareholders of
the Corporation on the Grant Date, this Option is not exercisable until such approval has been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Signature of Optionee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date signed:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 39%">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">Print Name</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left">Address</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROMIS
NEUROSCIENCES INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCK OPTION PLAN</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NOTICE OF EXERCISE OF OPTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:</FONT></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-size: 10pt"><B>ProMIS Neurosciences Inc.</B></FONT></TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">1<FONT STYLE="font-size: 10pt">920 Yonge Street, Suite&nbsp;200</FONT></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Toronto ON, M4S 3E2</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">(or such other address as the Corporation may advise)</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned hereby irrevocably gives notice, pursuant to the Stock
Option Plan (the &quot;Plan&quot;) of ProMIS Neurosciences Inc. (the &quot;Corporation&quot;), of the exercise of the Option to acquire
and hereby subscribes for (<B>cross out inapplicable item):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">all of the Optioned Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;of
                                 the Optioned Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">which are the subject of the Option Commitment attached hereto <B>(attach
your original Option Commitment)</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned tenders herewith cash or a certified cheque or bank
draft (<B>circle one</B>) payable to &quot;ProMIS Neurosciences Inc.&quot; in an amount equal to the aggregate Subscription Price of the
aforesaid Optioned Shares and directs the Corporation to issue the certificate evidencing said Optioned Shares in the name of the undersigned
to be mailed to the undersigned at the following address (<B>provide complete address</B>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 30%"></TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; width: 35%"></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt"></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt"></TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt"></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned acknowledges the Option is not validly exercised unless
this Notice is completed in strict compliance with this form and delivered to the required address with the required payment prior to
5:00 p.m.&nbsp;local time in Toronto, Ontario on the Expiry Date of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATED
the</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">day of</FONT>&nbsp;<U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">,
20</FONT><U>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 5%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 23%"><FONT STYLE="font-size: 10pt"><B>Signature of Optionee</B></FONT></TD>
    <TD STYLE="width: 72%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>58
<FILENAME>filename58.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.39</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMORFIX LIFE SCIENCES LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFERRED SHARE UNIT PLAN FOR<BR>
CANADIAN SENIOR OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PART&nbsp;1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
purpose of this Plan is to provide an alternative form of compensation to satisfy annual and special bonuses payable to Senior Officers.
The form of compensation will enable Senior Officers to participate in any increase in the value of the Company as evidenced by the increase
in value of the Shares and will promote a greater alignment of interests amongst Senior Officers and the Company&#8217;s shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
this Plan,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Applicable
Withholding Tax </B></FONT>has the meaning set forth in &sect;3.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Awarded
Amount </B></FONT>has the meaning set forth in &sect;2.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Board
</B></FONT>means the Board of Directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Committee
</B></FONT>means the Nominating/Compensation Committee of the Board, or any other persons designated by the Board to perform the duties
contemplated herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company
</B></FONT>means Amorfix Life Sciences Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Deferred
Share Unit </B></FONT>means a right granted by the Company to an Eligible Person to receive, on a deferred payment basis, a Share or the
Fair Market Value thereof, or a combination thereof on the terms contained in this Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Eligible
Person </B></FONT>means any person who is a Senior Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Fair
Market Value </B></FONT>means five-day volume weighted average trading price as calculated in accordance with the TSX Policies as at,
and including, the relevant determination date or such other applicable date referenced herein provided that such date is a business day
and if it is not then calculated as at and including the last business day which proceeded such applicable date referenced herein, except
that if the Shares are not listed on the TSX, the Fair Market Value will be the value established by the Board based on the five-day average
closing price per Share on any other public exchange on which the Shares are listed calculated as at, and including, the relevant determination
date or such other applicable date referenced herein provided that such date is a business day and if it is not then calculated as at
and including the last business day which proceeded such applicable date referenced herein, or if the Shares are not listed on any public
exchange, by the Board based on its determination of the fair value of a Share;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Insider
</B></FONT>means an insider as defined in the TSX Policies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Option
</B></FONT>means the right to purchase Shares granted pursuant to the Company&#8217;s stock option plan approved by the Board on August&nbsp;9,
2007, as may be amended from time to time in accordance with its terms, or any successor plan accepted for filing by the TSX;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Issue </B></FONT>means the number of Shares outstanding on a non-diluted basis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plan
</B></FONT>means this Deferred Share Unit Plan, as amended from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Reserved
for Issuance </B></FONT>refers to Shares that may be issued in the future upon the exercise of Deferred Share Units which have been or
are granted pursuant to this Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Senior
Officer </B></FONT>means any senior officer of the Company, or its subsidiary, appointed and approved by the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Service
Provider </B></FONT>means a person who is a bona fide director, officer, employee or consultant of the Company or its affiliates, and
also includes a company, of which 100% of the share capital is beneficially owned by one or more such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share
</B></FONT>means a Common share in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share
Compensation Arrangement </B></FONT>means the Plan described herein and any other stock option, stock option plan, employee stock purchase
plan or any other compensation or incentive mechanism involving the issuance or potential issuance of shares to one or more Eligible Persons,
including a share purchase from treasury which is financially assisted by the Company by way of a loan, guaranty or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Terminated
Service </B></FONT>means that the Eligible Person has ceased to be a Senior Officer, other than as a result of death;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total
Compensation </B></FONT>for a particular Senior Officer means the aggregate of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
discretionary annual bonus determined by the Board for which Senior Officers may be eligible and may be awarded if their individual performance
and contribution results in, amongst other things, the positive financial performance of the Company or any of its subsidiaries, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
bonus, that is not an annual bonus, that may be awarded to a Senior Officer at the discretion of the Board; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TSX
</B></FONT>means The Toronto Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effective Date</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to the approval of the shareholders of the Company and acceptance by the TSX, this Plan will be effective as of June&nbsp;11, 2008, and
amended August&nbsp;7, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Administration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board will, in its sole and absolute discretion, but taking into account relevant corporate, securities and tax laws,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">interpret
and administer this Plan,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">establish,
amend and rescind any rules&nbsp;and regulations relating to this Plan, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">make
any other determinations that the Board deems necessary or desirable for the administration of this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may correct any defect or any omission
or reconcile any inconsistency in this Plan in the manner and to the extent the Board deems, in its sole and absolute discretion, necessary
or desirable. Any decision of the Board in the interpretation and administration of this Plan will be final, conclusive and binding on
all parties concerned. All expenses of administration of this Plan will be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delegation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board may, to the extent permitted by law, delegate any of its responsibilities under this Plan and powers related thereto (including,
without limiting the generality of the foregoing, those referred to under &sect;1.4) to the Committee or to one or more officers of the
Company and all actions taken and decisions made by the Committee or by such officers in this regard will be final, conclusive and binding
on all parties concerned, including, but not limited to, the Company, the Eligible Person, and their legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PART&nbsp;2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AWARDS UNDER THIS PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Determination of Deferred Share Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board will, in its sole and absolute discretion, decide at the time of declaring or awarding any Total Compensation to any Eligible Person
the amount (the &#8220;<B>Awarded Amount</B>&#8221;) of the Total Compensation that will be satisfied in the form of Deferred Share Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issue of Deferred Share Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
number of Deferred Share Units (including fractional Deferred Share Units, computed to three digits) to be credited to an Eligible Person
for services will be determined by dividing the Awarded Amount by the Fair Market Value as at the last trading day before the date the
Awarded Amount is declared by the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Maximum Shares Reserved</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to adjustment as provided for herein, the maximum aggregate number of Shares that may be Reserved for Issuance pursuant to this Plan is
1,000,000 Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
no event may the number of Shares that are Reserved for Issuance to any one person pursuant to Deferred Share Units and Options exceed
5% of the Outstanding Issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shares Not Acquired</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Any
Shares not acquired under a Deferred Share Unit granted under the Plan which has expired or been cancelled or terminated may be made the
subject of a further Deferred Share Unit pursuant to the provisions of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
any date on which a cash dividend is paid on Shares, an Eligible Person&#8217;s account will be credited with the number of Deferred Share
Units (including fractional Deferred Share Units, computed to three digits) calculated by</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">multiplying
the amount of the dividend per Share by the aggregate number of Deferred Share Units that were credited to the Eligible Person&#8217;s
account as of the record date for payment of the dividend, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">dividing
the amount obtained in &sect;(a)&nbsp;by the Fair Market Value on the date on which the dividend is paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eligible Person&#8217;s Account</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">A
written confirmation of the balance in each Eligible Person&#8217;s account will be sent by the Company to the Eligible Person upon request
of the Eligible Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adjustments and Reorganizations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event of any dividend paid in shares, share subdivision, combination or exchange of shares, merger, consolidation, spin-off or other
distribution of Company assets to shareholders, or any other change in the capital of the Company affecting Shares, the Board, in its
sole and absolute discretion, will make, with respect to the number of Deferred Share Units outstanding under this Plan, any proportionate
adjustments as it considers appropriate to reflect that change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PART&nbsp;3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMINATION OF SERVICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Termination of Service</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">An
Eligible Person who has Terminated Service may elect to receive one Share in respect of each whole Deferred Share Unit credited to the
Eligible Person&#8217;s account (determined in accordance with &sect;3.2) net of Applicable Withholding Tax, by filing with the Secretary
of the Company a notice of redemption in the form prescribed from time to time by the Company on or before December&nbsp;15 of the first
calendar year commencing after the date on which the Eligible Person has Terminated Service. If the Eligible Person fails to file such
notice on or before that December&nbsp;15, the Eligible Person will be deemed to have filed with the Secretary of the Company a notice
of redemption on that December&nbsp;15 and will be deemed to have elected to redeem all of his or her Deferred Share Units. The date
on which a notice is filed or deemed to be filed with the Secretary of the Company is the &#8220;Filing Date&#8221;. The Company may
defer the Filing Date to any other date if such deferral is, in the sole opinion of the Company, desirable to ensure compliance with
 &sect;4.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuance of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
issuance of the Shares will be made by the Company as soon as reasonably possible following the Filing Date. In no event will the issuance
be made later than December&nbsp;31 of the first calendar year commencing after the Eligible Person has Terminated Service. Fractional
Shares may not be issued, and where an Eligible Person would be entitled to receive a fractional Share in respect of any fractional Deferred
Share Unit, the Company will pay to such Eligible Person, in lieu of such fractional Share, cash equal to its Fair Market Value, calculated
as at the Filing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Death</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
the event of the death of an Eligible Person, the Company will, within two months of the Eligible Person&#8217;s death, pay cash equal
to the Fair Market Value of the Shares which would be deliverable to the Eligible Person if the Eligible Person had Terminated Service
in respect of the Deferred Share Units credited to the deceased Eligible Person&#8217;s account (net of any Applicable Withholding Tax)
to or for the benefit of the legal representative of the Eligible Person. The Fair Market Value will be calculated on the date of death
of the Eligible Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Applicable Withholding Tax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company is authorized to deduct such taxes and other amounts as it may be required by law to withhold (&#8220;<B>Applicable Withholding
Tax</B>&#8221;), in such manner as it determines, including, without limiting the generality of the foregoing, by delivering fewer Shares
than an Eligible Person otherwise would have received. The Company may require Eligible Persons, as a condition of receiving Shares otherwise
to be delivered to them under this Plan, to deliver undertakings to, or indemnities in favour of, the Company respecting the payment by
such Eligible Persons of applicable income or other taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>PART&nbsp;4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Transferability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Deferred
Share Units and all other rights, benefits or interests in this Plan are non-transferable and may not be pledged or assigned or encumbered
in any way and are not subject to attachment or garnishment, except that if the Eligible Person dies, the legal representatives of the
Eligible Person will be entitled to receive the amount of any payment otherwise payable to the Eligible Person hereunder in accordance
with the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Right to Service</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Neither
participation in this Plan nor any action under this Plan will be construed to give any Eligible Person a right to be retained in the
service of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Applicable Trading Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board and each Eligible Person will ensure that all actions taken and decisions made by the Board or the Eligible Person, as the case
may be, pursuant to this Plan comply with any applicable securities laws and policies of the Company relating to insider trading or &#8220;blackout&#8221;
periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Successors and Assigns</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Plan will enure to the benefit of and be binding upon the respective legal representatives of the Eligible Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Plan Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board reserves the right, in its absolute discretion, to at any time amend, modify or terminate the Plan without obtaining shareholder
approval as it deems necessary or appropriate, but no amendment will, without the consent of the Eligible Person or unless required by
law, adversely affect the rights of an Eligible Person with respect to Deferred Share Units to which the Eligible Person is then entitled
under this Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
 &sect;4.5, the Board may not, without approval of the holders of a majority of the issued and outstanding equity securities of the Company
present and voting in person or by proxy at a meeting of holders of such securities, amend the Plan or a Deferred Share Unit to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">increase
the number of Shares reserved for issuance under the Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">permit
assignments, or exercises other than by the Eligible Person, of Deferred Share Units beyond that contemplated by &sect;4.1, except for
an amendment that would permit the assignment of a Deferred Share Unit for estate planning or estate settlement purposes; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">amend
the Plan to provide for other types of compensation through equity issuance, unless the change to the Plan or a Deferred Share Unit results
from the application of &sect;2.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Without
limiting the generality of &sect;4.5, the Board may make the following amendments to the Plan without obtaining shareholder approval:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">amendments
to the terms and conditions of the Plan necessary to ensure that the Plan complies with the applicable regulatory requirements, including
without limitation the TSX Policies or the rules&nbsp;of any national securities exchange or system on which the Shares are then listed
or reported, or by any regulatory body having jurisdiction with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">making
adjustments to outstanding Deferred Share Units in the event of certain corporate transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
change to the termination provisions of a security or the Plan which does not entail an extension beyond the original termination date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">amendments
to the provisions of the Plan respecting administration of the Plan and eligibility for participation under the Plan, including, without
limitation, to expand the class of Eligible Persons to include any or all Service Providers; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">amendments
to the Plan that are of a &#8220;housekeeping nature&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Plan Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Board may terminate this Plan at any time, but no termination will, without the consent of the Eligible Person or unless required by law,
adversely affect the rights of an Eligible Person with respect to Deferred Share Units to which the Eligible Person is then entitled under
this Plan. In no event will a termination of this Plan accelerate the time at which the Eligible Person would otherwise be entitled to
receive any Shares or cash in respect of Deferred Share Units hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Plan and all matters to which reference is made in this Plan will be governed by and construed in accordance with the laws of British
Columbia and the laws of Canada applicable therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reorganization of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
existence of this Plan or Deferred Share Units will not affect in any way the right or power of the Company or its shareholders to make
or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business,
or to create or issue any bonds, debentures, shares or other securities of the Company or to amend or modify the rights and conditions
attaching thereto or to effect the dissolution or liquidation of the Company, or any amalgamation, combination, merger or consolidation
involving the Company or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding,
whether of a similar nature or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Shareholder Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Deferred
Share Units are not considered to be Shares or securities of the Company, and an Eligible Person whose account is credited with Deferred
Share Units will not, as such, be entitled to exercise voting rights or any other rights attaching to the ownership of Shares of other
securities of the Company, or be considered the owner of Shares by virtue of such crediting of Deferred Share Units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Other Benefit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
amount will be paid to, or in respect of, an Eligible Person under this Plan to compensate for a downward fluctuation in the price of
a Share, nor will any other form of benefit be conferred upon, or in respect of, an Eligible Person for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unfunded Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
greater certainty, this Plan will be an unfunded plan, including for tax purposes. Any Eligible Person holding Deferred Share Units or
related accruals under this Plan will have the status of a general unsecured creditor of the Company with respect to any relevant rights
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>tm2135630d1_drs3-12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drs3-12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #C PP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 0XP<G P<D] /4_2FDC/4<-D\CC &<\]A@GT!
M%*QPK'(&%)R1D# /)&1D#N,C([CK7Y\_\%*OVS_$'[!G[+FL_M!>$OA//\</
M$MC\0OA/X'T3X5V&KS:-JWBJ?X@>.]'\.7]GX?N8-,U5K[Q-%HUQJ4_AO13;
MVEMK&N16%A<7\,=PTHRJSA2C[:I*,*=&\YSG*,(1CRM3E*<Y1C&,(WE*4I)1
MBG)M)-IJ^EO.WW:_@_Q1]P^*?$_A_P 'Z#KGBGQ7K.F>'?#/AG2]1U_Q#K^M
M7T&FZ3HFBZ3;27NI:KJ=_<210V5C86D3W5S<RR+'%"N]F&0#\=_L.?M[?"#]
MO[P]\9/&_P $-,\<P>"?A%\:-5^"_P#PD'C;PS+X8A\=7NF^#/!/C=/&?A#3
M[W;JTG@_5-+\;:>NDW.K6NGWUP8Y;B2T$4\)'YZ_\%%/VJ?!7QAE_9]^!?A+
MQ5H/BK]F'XI_ ?QE^WM^U)XRT5[?5+'Q7^Q=\)K#PYJ?@GP-IM]'=+9Q:7^T
M;X_UG0M&N=7B:2XN? WAWQ?I5J#<S+=#ZY_X))?#/Q%X%_8R\&>.O'>G_P!E
M_%']J+Q-X[_:Y^*-A]F%D-'\5_M">(9_'&G>%8[6-S%;VG@?P9=^%O!>G00*
MR0Z;X=M(RYPLMU\9E_&.%S+CCB#@C!8:=:7"F0Y-FN=9A"M'V.#QG$6+S&>2
M93*FG=XK%91E699S.3DG##4:%)0C4K0K+>="4</3Q#5HSG.G'HVZ2CSNSU=I
M22>UFFMT?ID9XT92S(H+*@)94&^1ECC7D@;I'8+&@.7=@J!BP%6!C);<,$8Z
MCJ#@_E@#V.<U^.?_  7FT_5IO^"5W[3OB'PSXTU;X=>,_AM=?!'XN>!_B%X?
MN)X-<\#>+OAC\?\ X6>,-$\5:8MN5>ZN]*N=*,T.GDA=08+:"2%IA-'ZK^S)
M_P %#/ /B_\ 8LT#]H_]K'QC\+_V>/&/@/5O%WP7_:@TK7O$UGH/A;X>_M,?
M![Q/J?P]^+O@[0UU35;_ %"?2]0\6Z'>>)?A_I9OM6U[5O ?B/PQ=&;4VO5N
MF^N6(PWM:>$=6$:]6E.M'#J<?:NC2E"%2I&FI>TG"E4E&%:K"#IQJ3CSSBZD
M>?%J3:Y8R?,TE:,FVVMM$VW9)V6MM=M3]-\J.<@ D]2.2.N/I@Y].:=UZ5_/
MS\<O^"UWCFYU_P"'OP__ &&/V'?BM^TYXY^+VKW6C?"?4OBYK%[^RYX8^(5M
M:);RZIXW^'/@OQ%X4\8?&_QI\,/ T%[9ZE\1/C%XE^&?PJ^ >E65SI5M#\7Y
M?$.N:)HMW^[/@BX\7W?A'PQ<^.M.T'1_&D^@Z1-XPTKPQJE]KGAO3O$\EA;O
MKUCX?UK4]-T?4=6T6UU)KJ'3-1O=*T^ZN[5(99[2%RRF<#F&!S/#0Q>7XO#8
MW"U.9TL3A,3A\7AZJC4JTI.GB,+7Q-"HE5H5J;=.O42J4:T&U.E4A!-.+<6F
MFMTTTU=)ZII-:23U2T:Z-7ZVBC_/Y45V""BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBDR,@=S_]?_"@!:*"<4=: \@HHHH **** "BBB@ HHHH
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MSC36ZL'2_3:_GN?LSYB9QG)R!P"<$] V!\I]FP1WIY.!GG\ 2?R&37SMX_\
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M)M0LY]'OI?%&J):)<">8CUKPSX*^,OQF^$?Q_P#$'@OXG_"CQTGP*_X*X?\
M!0GXD>-/V3?VD?C-XH^&7@W]I'X2^#=16"[\*V'CO3+C4;SPW??#JWNEU'P=
M!JVBZC\+M"UVYM)O%TVEZ397+.7M^0-273UU6W?<_K?UWQ)H'ABQ.J>)-;T?
MP_IGVFULCJ.NZI8Z18?;;^XBM+&S-WJ$]O;_ &J]N9DMK2#S/,N)V2&)7DD1
M3KB12=HP2 . 01ST&1P!D@9Z9('%?SZ_M+_M$>%_BU_P14^ _P"T%X2^$]MH
M7AKQ=K'[)%WX?^&/[0FB:7\9)/"\:_&_P3X6CAOIO'%GJ-OXON-(DMI+_P $
M?$&XM5O]7LUT+QAIR6MQ=6T4?#^)_P!NO]L/PY\8_%WC6/XQ:!>?"WX>_P#!
M8GX6_L#M\%V^&'@6'1/$OP9^+_\ 8>E7NHZYXX%@OCJU\>>#M4\66>I^$]6T
M+6=)TLQZ-'8^+M"\5+J%Q<1.VC?1;BMI?Y?J?TA>8!G((&< GOR!D<<C!SGI
MVIOGIG #'G:>,8/'Y\Y4@=&5D.&!%?RF_%CXW_M,?LL^)O\ @MG\9?AK^TIX
MEE\=_#/XZ_LT6_@#P!\2O"_PN\0>!8['XF)\+](M]9N="B\':;XJAT/2-'UB
M]\+6@\-ZYH>GZC:RSZUJW]I>+B/$,7UK_P %+/VO?CU^QE\-M,^'_@?]H#XP
M^._C[\/OV=_B3^T9XL\2:'\'_P!CS2=#US2/#/BK2M(MM>^,6N_&CQ+\+/!]
MI\+UU;6?^$-TSX;_ +-G@OQ+^T+=1Q6/B*[U#4DLKMO$:W5^FOX;@?O5:>(M
M"O\ 4]8T2PUG2;[6O#O]G_V_HUGJ5E=:KH8U:"2ZTDZQI\$TEWIG]IVT4EQI
M_P!MA@^V0(\UOYL:,PT_.&0-I^8@ D@#.,X_I^![ X_D5\=?M2?%GX._'W_@
MJS^U;\+OC-X5^'/Q$\.^!O\ @D_\2)?@K=^%O!/B&W_:!U;Q[\+K'1)_AS?2
M>*DN?&$&CW\6OZEI'AV+X:3>'?%MMXCUBQN9/$.H6L,&D7/V'^V?^WA^U3X#
M\2_\% O%O@?XK:1\"[?]@KX,? 7XF?#;X$:[\/\ P)XF'[3?B/X@V"^*M8T+
MQYJGB"PUWQZ=&\6:A&?@YX2L?A!JW@76=,\2W:ZA=^(+Z]"6J%];=0/Z$M;\
M2^'_  U:)?\ B+6](T"PEO;338+[6]4L=)LY]1U"9;?3["&ZU">W@DO;ZX98
M+2U20SW$S+%#&[D"C2?$GA_7_P"T_P"PM<T?6_[$U6ZT'6O[(U2QU+^R->L1
M$U]HFI_8IY_L&KV230M=Z==>3>6RS0F:%!*A/\D'[??[2/QE_:%L_BO9_$SX
MG:3\,?#7P0_X*5?L(?!KPY^R;>>'OAU<W5VMY=_#/QWJ/CN_\5RVD7Q/OO$M
M]K^NZHNC&SU2W\(Q^'M":WD\-W&HR7MS8Z^A?MI?M$>#OVI?V@OV7O@#X(U+
MP3:?$3_@H5_P4 U[Q#XN_9B^'G[%?ACXK>*KOX1^ ?V=#H>E>=^UQ\0/A1\#
M?&OBW5+_ ,?WWC'XJ>(-;U#7OB]K/A;PSI]EHIL;*SU/4M* /ZWQ(,X((Z9S
MZDXP!U/.!GH2>,TWSEQD#(QG.0!@ DGGL,8SZG'7./YV/$?[;_[=7PI^(?[)
M'B#]JA1\*/A9X@\'_ ;P-\;/#_P(E_94^,/B'PM^TM\7OC9#X T*V_:+\!7/
MQ$UGXC:=\(_B-X*N+?4_#7B;]D_Q3XKF\)^()-4O-1?Q'HNG3:?;YO\ P4(_
M;V_:9^"/QS_;ST3X>?M)^!?A9H?[)'[*WP;_ &COA=\+M;\ ?#?7-4^,7C3Q
M!K=_IVK_  [UC5/%4;^([OPEXON;2Q\,+;>"TTWQM;:_XETM] \46CK%I-^+
M6]NF_P#7S _HY\Y>H!(YYZ=,Y!STQM;Z[>.JY<9%&/<\>XY.1[$!C^&.I K\
M)?B1^U_^UM;?M6_M(:;X<UZYT7X=?LV?\$\OAC^UVO[/-C\/_!FH>*O&OQ7\
M26OQ'DU#X>^(_%.I:7K/B.Q\&O<:#:+K]EX<O-.\5+?:/'!X<\1Z?%/J"WG!
M? ?]M#]JFV\=?#CPSK_Q^\.?M):5\=O^"7_Q)_;8\1ZO:>!/AIX;'[,WQ/\
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MU'Q,NFVFHH ?K#13-QR1@<9/WO3_ (#QG]*4,2<8';OGJ,^G\OK1_G;KVO\
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M%[PCXK\7MX9L9;:&]\1Q^'M"\77NKMHME-=VL-WJ*V;6UK-=6RSO&9 *I?\
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MC_Q--XW^ B^%K?Q/K-U=QP:GXQU8IK>JSSQ)=:G-)*I;\D;K_@HM\3_A,O[
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MNJZ6^_\ X /RV/T_\0_\$Q?AAXLU_4/%/B[XX?M ^*_%.J:/9Z!J_BKQ1)\
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MO%GA?QYXU^//[1GC3QUX'GL[KP3XX\87/P'\4>,_!=S87_\ :EE<>$/%>O\
MP"O_ !#X9GL]3"ZE:2Z%J-A-:WZK?6S17:K,?SW^/_['7['.N_\ !<C]DC1]
M?_92_9@U>T^)_P"R7^UQ\6OB'INL_ CX3:E%\0?BCH/Q%^#3:/\ $WQ?;7_A
M2<^*?B!H9U#43I7C764O?$FE1ZIJ\=IJELFJ:A'>?GE^T5X=_9<M=+_X+2>.
M[6R^%VC_ /!0SP?^UXT7[$WC;P+!X5T[]LW2/BV? GPVB^&>A?!K7/#@@^,A
MT/4_$N[3M>\-:)<2^$M4\,3^*K7Q%H]WHDNNV\K7O*ZTVWTW _H.UC_@F/\
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MIX7\;^*/ E@T=_I.C>/=&NX;#XIZ#!>Z-J>C^+M"TG7M.^S?V6?VCHOV??\
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MY-\9OA#\-?CY\,O'?P:^,?@O1/B'\+OB/X>O?"_C7P7XAM#=Z1KVB:@J;XW
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M+EU\7OVD=6_:!\,?M'?M ?$K6?"GA?XJ^*/"WPWU?X)Z=\*_#O@"QU"?X;_
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M=^'FK7B>.=0?Q9J">(/%_BO3='T^QT>PT[3+G4;OV3]I[Q;\)?!?P:\1:_\
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M_P 0OV9/B=\3?VZY/A5^WE_P2Z\<>"O^"@7[/GPU^!.L^+OB9^W3\#]!UO\
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M;6-!\2W'PK\77MG\3="^%.L:OJ]Q9P23V7P_EFN?"4VJZ';7&DQWL^_\IO\
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MO@KID&L?\%D?@AJ>AWGAWX4^,]*\7Z5IGPWU?P=\./AW=_"/4_!OB'3QXD\
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M[.5O;+VW+SWDQZMOO-MKR49)-:)*3E+WFE?V<8T4_9VC%U%%%6,*8R*QRW8
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MUHIIJ3Y6T_M0C+F4N:*M>=.2Y7+EO)\R3NKR5[M<MGZJ_P"&S_#0_GV\'?\
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M1CTP2 /P'%25_9:U2?=)_@N]G]^O?6YX84444P"BBB@ HHHH **** "BBB@
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MX"_]2K2:_P!ZK R3Z]?PH \$_P"%/_$/_HZKX\_^$Y^S!_\ 0XT?\*?^(?\
MT=5\>?\ PG/V8/\ Z'&O>Z* /!/^%/\ Q#_Z.J^//_A.?LP?_0XT?\*?^(?_
M $=5\>?_  G/V8/_ *'&O>Z* /!/^%/_ !#_ .CJOCS_ .$Y^S!_]#C1_P *
M?^(?_1U7QY_\)S]F#_Z'&O>Z* /!/^%/_$/_ *.J^//_ (3G[,'_ -#C1_PI
M_P"(?_1U7QY_\)S]F#_Z'&O>Z* /!/\ A3_Q#_Z.J^//_A.?LP?_ $.-'_"G
M_B'_ -'5?'G_ ,)S]F#_ .AQKWNB@#P3_A3_ ,0_^CJOCS_X3G[,'_T.-'_"
MG_B'_P!'5?'G_P )S]F#_P"AQKWNB@#P3_A3_P 0_P#HZKX\_P#A.?LP?_0X
MT?\ "G_B'_T=5\>?_"<_9@_^AQKWNB@#P3_A3_Q#_P"CJOCS_P"$Y^S!_P#0
MXT?\*?\ B'_T=5\>?_"<_9@_^AQKWNB@#P3_ (4_\0_^CJOCS_X3G[,'_P!#
MC1_PI_XA_P#1U7QY_P#"<_9@_P#H<:][HH \ E^$'Q&"-L_:K^/*L05##PW^
MR\2I8$!@'_9R52RL05#94M@,"I./=[<N%5'E:9DCC5I'$8=V"J/-<1QPH'E;
M>7$<21!E(1(MI2IR 1@\C_)I BKDJ ,\G' YZ\=!G&3@<G)ZDT .HHHH ***
M* $/0_0U^8W_  4)^'W[8WCWQ-^S7'^R/\1/$OPPDTF__:*F^)GB?3]'OO%O
MAD:5J/[//CC2_ ^E>)?!-M\4/A=%K5_J7Q"FT2'P/JUWJFI?\(AXP_LW7X+2
M'[.9H_TZHP/04 ?BA^Q;>?\ !0C1?C=\.8_CM\'_ (Q+\(=3^ /A[X+>(/&G
MC+XS^&?$*:1\0/AW\.?#'B:P^(VL_#$ZUJWB&#5O&GCN'XP^'?$OQ(DUC5M7
M\03^(/A;I-^CZ3HMO>6/*Z'X#_X*5&3]F;3K;XC?M!^$O#FD?#_P=X<^+>AI
M<?![Q,=8UOQMXM^+^G^/_$GB[QE\0_#GCGX@MXF\!^&C\/=7\,7NB>*X-,TZ
MX-B]YIGB*V-WIT7[L8'H/R_SZ"C ]!Z=.WI0!_*%_P $V/!O_!;KPM^S+\2_
M@Y\;]1^.O@B#P=X.^$/PT^$.O^,+/X!:K\7_  E<Z/\ %G1?"^LW_P /;U?
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M0W6I:QK.KZE<V>CZ#H&CV=_KGB'7+_3M#T/3M0U?4;&RN #LZ_F\_P""H_\
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MXI^$+PIJ?A[Q)ID[B6PN'@DT3Q3H;Z=XM\*ZEJOAO6]+U._^M8F0DG<N2JX
M(R%()'0XZ8(ZX7&><U_+5^T9X)_:Q^&GC_PO\9OC)\"-7^"'[0_PTMA:?#W_
M (**_L56_B/XQ_!+7?#UH&V_#/\ ;0^!=G:V/QGU+X :Z%OY-;TO5_#7Q3TO
MX71W2^+/!7BKP5JXO;J?[]_9Q_X*X>"?&'A/1-4_:,^&OB'X5C4;*:^LOCY\
M&[;5/VG_ -B3XCV]C<K97_B3X??M$_!6Q\8V/A?3"_VJXO\ 3?C#I'@&Z\-R
MP/I&K:C<7\ ,GR7A_P"*V89C@,-EWBMPN_"/C^@\/@\?DN=9KEF,X<SS%5*?
M+]?X"XPABL)E'$.48^M0KXG#8&I5RWBG 4G]7S+AY<BQU7HQ.#4)N>#J+&8>
M=Y1G27[RG'?]]2UE%QT3<>:+WC*SY5^SGF1YV^8F3T&Y<G!P>,YX/'UXJG=,
MA(.]0 !N?)RNT2 <@@ @MN(SN8!@!D+CX0M/^"I7_!,N^C6XM/\ @HE^PT8]
MJLT;_M9? BTN8 204O+.\\>PW=I,C!DEANX(;B*1721 ZE:\B^+'_!4OX'7O
MAJ[L_P!B:?3OV^?C#J=P-!\(^&_V>=:MO&?P=TW7)HIMVK?%[]HK0EU+X/\
MP\\'>'&DANO$<=QXKO/&D\;QV.@^%M4NYBMO^JY]GN4<.Y1C,ZXBS'+\BR3
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M&59XNA0:KPE4AR585I2]V,Z;YKTXV?-HKZ.^G]D7_$3]_P $AO\ HL?Q+_\
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MZ<TOFIUYQSSC/0D$^N 01D=Z_%W1?AK^V#\(+.U7X)_MS?$[Q18::I$'@O\
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M@X.3G&<]LT\,&&0<C_)_D:_-0_M2_ME>.=,CO?AU^QQ\/_A0;P1);Z?^U_\
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M=:CKNDM\-_BI\2=#U6R\.:I\._B+''JDO@_P?J$+7T]SH/C:'S6TK5KFQO\
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M,N5CWMLR06<_-0!-1110 4444 (>AQUP??\ 3(S^8^M?GA\>?V]HO@=^UO\
M!O\ 9IU#X=:)?>&OB%X<T#7O%WQ)UCXHP>%==T*7QSK7Q#\-^"=-^&WPV;P;
MK'_"UWL]8^&VK7/Q4NKWQO\ #F/X=>&-9\,:[8Q^-+G5+G1=._1#K7!^*/A=
M\-/&NL>'O$?C/X>>!_%_B'PA]N'A+7O%/A+0?$.M>%QJC6;ZD/#NJ:KIUY?Z
M*-0?3]/>^&F3VWVMK&S:X\S[+#L /Y^O"?[>M[^W'^TU_P $E?$<7@6T^&UI
MHW[<W[44&K^%;3X<_M$>-%A;3?\ @G3^W3H_@W^U?VD/'GP<^ GPK\ >.HM*
MB\0ZMXS_ &>=,\/?%36/&6C^)_ 'Q"\#_%%/"'@3Q!_PEG]'[=/S_P#06K\H
M?VIO _AGP)^U[_P1[TKP#\/;[PCX6E_;=_:8U74I? <7@OPK\)K7Q-KG_!-G
M]N6_N?\ A,?!VG:MI.NZS\2O%L_]KZOX3\3Z7X-UO3-,T[1?B?!XN\3^'=5\
M4>%;#QA^KS=/S_\ 06IK=">WSC_Z5$A/W3_O)_,U_EK?\'+'_*9#]J#_ +%[
M]GW_ -9Y^&%?ZE)^Z?\ >3^9K_+6_P"#EC_E,A^U!_V+W[/O_K//PPK_ %7_
M &,O_*7N9_\ 9C^._P#U<\!GPWB%_P D_'_L983_ --XH_""BBBO^J _$0I&
MZ'Z'^5+2-T/T/\JY,=_ EZ3_ /3-4J'Q1_Q1_P#2D?Z6'_!JO_RBKM_^SD?C
M)_Z3^"Z_I:64XRQ7L"0" 3WQDY^F?QK^:;_@U6&?^"5EL/7]I+XR#_R!X+K]
ML_VJOC9XA^!7P>U'XA>&[#2]2U6VUCP[8)::P9S9I#K-[';W3E+6XMI9)H$)
M6!$G4,Y.0V,'_A_^G=Q)E7!WTF/I;\5Y[6J8?)>'?%;Q)SC-:]&C4Q%:E@,O
MQ>58C$SI8>DG5K5%"45&%/WFW9:NZ_<<7Q+E'!?AU4XOX@K5<-D7#/"U?.\W
MQ-&E/$5,/EV6X6>*Q=6&&I)UJ\XTE[D*:<F[I)MH^I3*X;&8P/DZAMQRP!'!
MQDC[O7GD@@5+O'M^9_\ B:_"4_\ !3WXRDDGP1\.F'[LJIC\0%0W)#(#K()(
MY+$D 'H*/^'G_P 9_P#H1_AQ_P!^_$'_ ,N:_P S7]._Z-T7[W%6>1=VM>#\
M^G&2A)P4HM17Q6O*^KEK9;'\U/Z?'T9DVI<7YRI)RCIP;Q#RM1DX)I^SLV^6
M3DUW@[*ZO^ZTJK,AC8X![J>0>Q&Y&&1U&0>:\;^'O[//P/\ A/H6E^&_AI\+
M/ /@71=$FU.YT:Q\+>#_  WHD&DW.L:A>ZMJ5QIL>GZ1;I8SW>J:C?:A-+:K
M$\EW=3S2%WD8G\C?^'G_ ,9_^A'^''_?OQ!_\N:/^'G_ ,9_^A'^''_?OQ!_
M\N:S?T[?HT2G3J2XGS6=2E?V52? ^=3J4N9Q<O95)T9SI\SC%R5.<%)Q@Y*3
MC%QZ*?[07Z.-'#XC"4./N**&#QCIO&8/#\.<7X?!XQT8UH498W!X?$X?"8R5
M*GB<33I2Q>&Q4J5+$XFE3=.EB<13K_N):Z;:V,?DQ/,ZF(1@2NKDJA)SD1H<
MCS"2HPC#(V\+AUO9Q0M(%=B,[MI.64L.@XVE.ZDJ6.<$D$U^47[.?[>GQ-^,
M/QO\!_#3Q#X5\%Z=H_BA?%GVR\T@:M'?P#0_!^M>(;>2V^V:G<PR2&\TNVAE
MC,#G[%/>2Y0Q!J_62$G++GG!8'L!\Q5?4X'?'YU_0/AAXM<&>,_#^*XJX&S#
M&9KD^#S?$Y/7Q&-R_$Y76_M+"4,#B:L50QL?;2INAF%"4:OVZJGRR]VS_<O"
M;Q6X \8>&L3Q/X<8S$8[(,MS;&Y!6J5,LQ.2QI9E@,'EV+KX;ZAB84Y3HO"9
MMA>2:IN#FVHM<K1+#:QQ[RI?YSR&QVQS@J,'M@?+Z#O4@MT#E]SY)SC*A<^O
M"@GUY)YI\1)# ]5;!/\ >.U22/;)P/7&:DK]'U=G+65MW[S^]ZMVM=WW7I;]
M.C",(QC""IQ5I*$?=2O[VJ@TG\3;3NN9MVNKD0A49&YCN))X3O[A >#R.<^I
M(XH\E>>3R ,X3/'T7GGG!R,]L9%2T4_F_O?^8[1NGRQNMO=BK6;>B223O*6J
M2?O25[2DG"L*J/O,3P2QVY) (R<*!T/.  >O7FGB,#N3TZX[?A_DFGT4=+/5
M>>OYW_X'2UE8LE>R2O>]M%K+G>BLM9:NR5WY:!2,<#\1_GW_  I:1C@?R^HY
M'4C^=*3:3:W2TZ=O-?FOT;(VD*@'*GGD=#M'4@%N3CU(/< _=,)F9G"CGC@I
MR#QDX)(R1@_>"G((57/3YR_:K^)/QM^%GP<\2^*_V=/V>=<_:?\ C KV.F>#
M?A3HWCOX;?#:RN-1U)Y8D\0^*_%WQ/\ &/@O1K#PGH31K<:O;Z->:IXJU%I+
M73]&TAVN9]1T[\6[WPK_ ,%2/B[)#JO[0S?\%"-#%PUQ>W'PJ_8UA_8 _9Q\
M :))<I$\NBVGCC5/VTO'OQF\1V=J4:*#5=?\<V4]\"\JV.GM,\(^,XRXSH<&
MY?'&U<@XOXEKU(N5'*^#>&L;Q!FM7EE#GC["CB<NP5&2A.3A+%9EA(S<+)2=
MI'10P[Q$FO;8>A!7YJE>3C&-DVKN,*DM6DKJF[7Z:V_HR627^ZQZ$M@L.Y(
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M2@TG6G\-SZ'XA\1Q"^U+^S+%[2[NM2NK$V=U<?Z.7&U26R%P3C'R_*.1VX)
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M#>C7K7$-O%XY^/7B+X4_#BRE8SZOXTTS3[>ZNX/[MQV;9=E>!Q69YAC\)E^
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M==\*:U=F.-?M<6F>"O!>G^>K26EC:V[BS3] ?V3OA1XI^"7[-7P+^$GCJ_\
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MGA;5'^,T5EXJ2XN/%5]XF\6VFM:+X/T7PXG@2[U _P!K1?#W_!/W_@@KX_\
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MU/P:_P"S>OVG/_5C?LE5]"U\]>)_^3J?@U_V;U^TY_ZL;]DJ@#_(;_X."_\
ME,S_ ,% /^RTP_\ J#^$:_'"OV/_ .#@O_E,S_P4 _[+3#_Z@_A&OQPH ].^
M"?\ R6;X1_\ 93O 7_J5:37^]+/_ *F7_<;^5?X+7P3_ .2S?"/_ +*=X"_]
M2K2:_P!Z6?\ U,O^XW\J /\ &A_X.#O^4R/[='_91?"'_JI/AY7XU5^RO_!P
M=_RF1_;H_P"RB^$/_52?#ROQJH _>K_@V+_Y3C?L/_\ 73]H_P#]9'^/=?[
M=Q\MK(P//E+_ ..\C^?-?X_G_!L7_P IQOV'_P#KI^T?_P"LC_'NO]@.Y_X\
MY/\ KD/Y"@#_ !T?^"A7_!33_@HKX)_;\_;B\%^#_P!NC]K7POX0\'_M?_M,
M^%O"?A?0?V@?BCIF@>&?#&@?&CQOI>@^'-!TJT\3QV6E:%H>F6MKINC:390P
MV&EZ?;6]E8P06T$4:_'W_#UO_@IS_P!)!OVS/_$D?BW_ /-97/\ _!3'_E)#
M_P %!/\ L]S]J_\ ]7MX^KXAH _JX_X-RO\ @H3^W?\ &[_@LI^QO\*?C%^V
M5^T]\4?ACXLG^/?_  E/P\\??'+XD^*_!7B3^P_V7?C=XBT0:_X8UKQ'>:-K
M*Z-XATK2O$&EQZC9W,=AKFE:9JULL=_86MQ%_J/^(_\ D#7?M+9\]_FO+9B/
MIECCVQ]:_P A_P#X->O^4Z?["_\ UW_:0_\ 61?C[7^O!XC_ .0-=_\ 76R_
M]*K2@#_ SO\ _C^O?^ONY_\ 1SU4JW?_ /']>_\ 7W<_^CGJI0!_<7_P9%?\
MG#_MS_\ 9*/@U_ZEOC>O[F_^"B__ "8)^VM_V:;^TG_ZIWQK7\,G_!D5_P G
M#_MS_P#9*/@U_P"I;XWK^YO_ (*+_P#)@G[:W_9IO[2?_JG?&M '^&S1110!
M_<#_ ,&0O_)S_P"W)_V0;X:?^K#OJ_OL_:F_:=^&/['_ ,"OB#^T5\9M4N]$
M^&7PQTAM=\7ZO8:/JVOW6G:4EU;6<EU#HVB6UYJ^HND]Y;QBWL+2>5UD-QA8
M(Y6C_@3_ .#(7_DY_P#;D_[(-\-/_5AWU?U@_P#!Q JK_P $=_VX,  ?\*EN
M20.AQX@T)!GUP%!&><@'.!B@#Y(_XBT/^"//_1;O&_\ X83XS?E_R*PI#_P=
MH_\ !'K!Q\;?&Y."0#\!/C, 2!D*6_X18[0QP"^UB@)8(Y&QO\G6E7@Y],GU
M' )P0>"#W'<4 ?[;'_!/+_@J=^R/_P %.]#^)&O_ +*'C;6/&NG_  FU3PYH
M_C>75_ GC?P.=,O_ !7::Q?:%!;IXQT323J9NK70]1EE?36NH[01(MV\+3VJ
MW'Z/U_"1_P &/O\ R23_ (* #T^)OP&QZ_\ (I_$WO\ @*_NWH **** "BBB
M@ IK?=/('!Y/3\:=37.%)XX'<9'X\C^8H _*_P#;;M]*;]O'_@C%<R^&_#5U
MK</[67[4EOI_B^[\*:O>>,=!TJ?_ ()N_M?/K'AK0O'$.A3Z#X=\->++NUT'
M5/%?A34O$NDZMXRU+P;X*U?0M"\0V/@/Q!?^&/U0;I^?_H+5^8O[:K72_MJ_
M\$<D37?'-M8O^V-^T4UQX7L/#VCW7PUUBZC_ .":/[;RV>O^+?%L_A*]\0:+
MXX\-PR7NG_#OP[IOCOPWI'BC0?%7Q1U+7?"/C6\\'^'-8\ ?ITW3\_\ T$TU
MNA/;YQ_]*B0G[I_WD_F:_P M;_@Y8_Y3(?M0?]B]^S[_ .L\_#"O]2D_=/\
MO+_,U_EK?\'+'_*9#]J#_L7OV??_ %GGX85_JO\ L9?^4O<S_P"S'\=_^KG@
M,^&\0O\ DGX_]C+"?^F\4?A!1117_5 ?B(4C=#]#_*EI&Z'Z&N3'?P)>D_\
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M#/J?]A[G]KCX.*22#'\2L@G/7X6^,%."<D9!(.",@\]L?TC11H2HQP 2 ,@
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MMZA\6OVK[WQ'K.E_M6?\%,?BEK6OF_\ C!XW\,?$BP.D:MH'PV^+.OQ7UO\
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M8VFFZ;IUI;6&G:?801V]C96%G;1V=G9VD$4<4<5M:6L,5O;1I'&D<$:1HB(
MBZM?48:A2P]&&'ITZ4*=&G2HPC3A&$/9T:5.E",8QTC3IPI4J=.*TA3ITH+2
MG%F<I<TI3;;E*3;D]6TWS:O=^\W)_P!YR>[(I C))DCA&W$]%!4G)R0,8Y.2
M!ZFOQ)_;"BTZR_X*M_L,W^EW 'B;7/V5OVOM#\6VL3[6F\#:7KGPKUC0I[P%
M0\L%KXNGE6S+MM2XN)F7+2%C^U%[<0V\<S3/##$L$TMQ--,88HXHXV>>229V
M6.**.,,SRN0D:!G8A5)'X&?LWZIX@_:K_:(^,W_!0?Q9;2V/@WQ-9:E^SG^Q
MOH$T4 $?[,'P]\9:C/J7QGG+O/.-2_:/^(-K>>+-"DM396<GPNT7P)*MJ6U&
M6XG_ (U_:!^(_"_AQ]%+Q9EQ%5H/$\9<.XG@?AK*JD(SJYSQ%Q+/#X3#4\-2
M:?M'EN&I8O.<55Y9K#4LOP[E%5,9AI+VL@PU;$YIA?9MI4*D:TI)M<J@TW9_
MWE[MD[N^S5S[_:,$;<;2#NQC(.3D#YBP.><#'? &!Q\C?MAOHGB+PO\ !GX$
M>)M,U#4/#G[5_P"TW\&?V<?$UU:7L>GV>G>#-<NM:^)GC>+7+J0EY--\8>"/
MA5XB^%]K9PE9KO7?'FB6J'9(\<GUP9.<YP3PPQT S]T=1GK[9'ID^/\ QZ^#
M.@?M ?"WQ#\+?$.O^-/",&K7OA;Q!H?C;X;ZW!X;^(O@#QQX"\5Z'X]^'GQ"
M\ Z]<V.J6NE^+_ GCKPWX>\6:%<7>G7VFS7VD)9ZQI^J:/=ZAI5[_P KGT>>
M*N$. _'#PLXQX_RW$YOP;PKQQD&=\1X;#*I4K5<)@,9.J\10HTU!XJI@\3]1
MS;#X3VM.>/CD]3#QE[>M2C/]4QRG5P>-P^&ER8C$4YPA*4DH-N#CRJ^B;YI)
MNVU2S=KGZG:?!;PHL=LD4-O%&D-M;V\:0PV]M&H%O!#%$%1((H0L4<:JL:Q(
MB*J!0HT@J\G:?4XR,G/4D<@CU)Y  Z!<?BOIG[6'_!0;]G1H-,^-GP%\,_MP
M_#'3;*WM(_C3^RK/I?PR_:(FCM+**!=4^(_[+WQ#UV#P/K^N:B\4MYKVK_ W
MXLV^GWFJ22W7AOX3>&=-GMO#]C]!?"__ (*O?L7_ !#\3VG@#Q#\0/$W[/\
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M^]^8KE;='^RMBYSM&<YSCOQS_P".C\@*^>_$X'_#4_P;7''_  SU^TV,=O\
MDHW[)5 '^0-_P7L.NM_P5_\ V\6\3KHR>(#\9(/[37P])?R:*)SX)\*8_L]]
M5CAU%X?+"9:YB5O,WX^0H3^0U?L?_P '!?\ RF9_X* ?]EIA_P#4'\(U^.%
M'I?P8\W_ (7!\*?L_E?:?^%E>!/L_GEQ;^?_ ,)3I?E_:#$&F$.['F&)6D"Y
MV@L0*_W+9Y_VG,2 6GP$* $?/J7Q%Z$\[C'I)W84-G;]PXR<9K_#5^"?_)9O
MA'_V4[P%_P"I5I-?[TEPH,,N0#^[<<C/##!&#V(X/J..E '^,;_P7S_M\_\
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M-\+9;G;:F9E_UBM<D_::_LV99;3X!A&DL]P.I?$4@DW4"H<)I8=AO"Y5/F9
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M_9W430E#,;@76V7.SR5.&Q_?? TC "7;O$:%]F[87(P_EE@"T>1N0GY@K@.
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MS!+"5JM6C!8BEB)5*2BY1="C4A;W_=2Y9-R=[J,7+X5*2_Q2LO\ \^M[_P"
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MV9U:\30-*\":'XI\-IX]_:/\(#0I-*>Q_:2T7QO\1O GCVYNWU3PKJFA(/\
MA']-_5S]J'_@GOX8^(MWXA^,_P"S'J^A?LL?M@S7T/B.Q^-/A+PVH\*_%'7;
M$RM_PC/[47PYT:?2M'^-G@OQ/!(^C:OJVM1M\0_#MO-!J?@[Q1IEW8K#-\6^
M /$?PI_;+'BOX!?MI_LL_##3?VF_V?IK%/BM^SY\9_!GA/XN:#I%AKTMS;>&
MOC-\"/$WC/P[?V_CCX&?$D65RWA/QSHL-GJ.DZO;ZAX+\9V&B^*='GMKCYS_
M (@)E_[-3/N(_%['>%&'^D?X09L\HIT.,JU/ X#Q4\%J^$QV*]C4JX*OAJ^0
MU<JSNOF%'#5N),"LLDL7A<NIXZ&34JDL-C-WC_\ 6BC3P%+%RRW&04N?#5.6
M>&Q]VI*TH*.(O32MR2G-[RC%ZN/Z(_L2_LM?#[]A[X5WOP9\"_M!?%OXL?#F
MU\0RZMX"TOX\?$[0_B'??"OP_)IUK91_#[P+XF73=,UP^"K:Z@FU73M/\27_
M (AN=-N+ZZM;6]M[%K:UM?M:TUS2=0)CL-0L+^:,%FCLKZUNY%!)^9X[:>5D
M49.XXVCU%?S5?M#_ +,_[$?PPU3X9_"[X0_\$WO@E\=/VBOCM?>(;'X2?!_P
MQX!\)>#O#RZ/X+AT>Z\?_%/XH^+9--DT'X<_!WX:Q^)?#-MXF\33Z??WEYKW
MB?PIX0\+:1J>N^)-.MA5G_X)1?M4Z!H5SKOP^^"?_!.+X;>*;VP2%],_9LUK
M]J#]ESQ]H_FQRN8-&^.?PXUBT34M5TZ^,,MM?^)O NK^'KR>$-J'AZZTRXN-
M/D_T"\#?I6<5?2 X8P7'/"7T>./,LX'S#&5<)EO$7$?&/AKD3SAT*JI8S%9+
ME>88VEC,WPF&G"4)XFA+"X?&5,/7H8'%XS$0<*?S>8Y33RVO+#ULTPM:JHN3
MI8>CC7.G+EOR5).$HQD[K1RE+5-JQ_3C#(LBGC'/5AAP<XYSR, '\/3FOB;_
M (*+_#B'XI_L._M5^$R=E_'\%_&GB[P[<(H>6S\5_#O27^('A6\B!Y22#Q#X
M6TPQ$;6#))T4DUX]_P $P?%'[;;_  R^(/PG_;L^'/C#PW\2O@Q\0&\.^"/B
MAXF\1^!_&<7QP^%.MZ='J_A;7_\ A,? UMHNE>)/%7A6==2\+>*-8E\(>#KK
M4UM=&U6\T2+4-3OBWTM^VWXBM_"?[''[5WB6Z>-(-&_9Q^-=RN^14!N!\./$
M5O:1"64JH-Q>3)$IW;F=U10SD*W]@SITL104<:E"AB(5:&)BKTXTL+B:4*-=
M2YG!TG!.>LW"4%&3O%7DO$BY1ES0O=I/5--M7:=G9WZ6:OW5W8_%_P"/7B[]
MFWQ+X+_92^+_ ,2-7^*/A[]K;QI\,[?6/V:M8_97\*>/_''[9%]?:AX&T_Q/
M\0+7X>>"?A-H/B?Q/XT^'6C3W2:GX_TOQ_X;U#X&Z=*UA)XZN-.35;5[KU_]
MCG_@I]^TQ'\2?#'[.'[=W[$O[8GP^UGQ-XAT3P;\*?VO;#]ECQC:?!GXI7>M
MW T_PY'\;?"_@"Y^)FG_ +-OQ)U:XGT^+4?[.\4^./A TO\ ;'B'5?%'PSTJ
MUD\.Z9Y=^R;J>E?LW?MQ?LOZY\5!9:5X9_:K_P"";?P1_9;^$WQ"UM"FG^&/
MV@_@5XJ\2?%+6?@>NM2PBS\+:C^T!X'^)\/BKPS8:A>:='X\\0_!._T.QDU#
M7]/T#3Y/Z+[<9!W *&;8ZAB!G^)67 &0"P<$<<Y(Q7\)_L^> ,MX1\$LLSO)
M/$[BOCS*N,<5G^8/(,PS/!8_A#@G$4.+^*,'5R#AG*E0GF&2ULM5*EALVHU\
MP4<=B*D<QIY9A,/"A4Q/O\28IU<P5&6'AA94(03LE[2HYTJ4N:;3N[WO'W6T
MF[R=G;\^O^"FO[%MI^W/^R#\5_@YH_\ 9&D?%P^$_&&K_ 3Q_J438\$_%6\\
M'ZYX<TV[6[43&ST'Q9I6LZKX'\4/(+R"'PQK]]?"TNKNSL-GT?\ LG:/\4?#
MW[,W[._A_P"-NDVFA?&/P_\ !#X6:%\5M(T_7+/Q/I^G_$/1O!&D:;XMM++Q
M!IR166KV\6M6UWY&JP1_9[^!HY(_X37T-M3 08 &/E!'H<9'?H3SZ9[4*H7.
M%QSP<YSU_+_/I7]\JG!2<E%*3MS222E+EORJ4DE*25W92E)*[Y5&[O\ /W?=
M_>Q^!Z44458!1110 4444 %%%% !1110 4444 %%%% !11119=D 4444 %%%
M(>0>_!]L_CVH 7(]:^>O$Y_XRH^#1Z_\8]?M.=.?^:C?LE5H_$/X@^-?"OQ
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M%;:QO9FFTR6=9;6!8Q#-$K'>&KXF_P"(*G]OG_HY3]F3IG[WC_IZ_P#(N=*
M/Y(/@G_R6;X1_P#93O 7_J5:37^]+/\ ZF7_ '&_E7^;%X%_X,S_ -O/P=XX
M\&^+9?VBOV9]0A\*^*_#OB.:PAN/'D$MY%HFKV.J2VD4S^&V2*:YB@\N*1U*
M*TB,^%.:_P! J\^*'QZA\1:3X9;]GG39YM9TCQ#JZ:I!\6O-\/Z=;^'KOPY9
MSV>LZPOPY-KIVKZJWB:WFT'2W\VXU:UTKQ!<0[8-'N'(!_D:?\'!W_*9']NG
M_LHOA#_U4GP]K\:J_MF_X+$?\$2E^,G_  4._: ^.?Q9_P""D'_!-;]D#7OC
M5?\ A7QYI7P1_:&_:A\)^$OB5H?AV/P=H7@^SU*_LO$)\+7-_IVKW_A/5+C3
MM5M=*2QN$66W2:6XM+DK^9'_  X*^%?_ $F__P"",W_B97PT_P#FCH \Z_X-
MB_\ E.-^Q!_UT_:/_P#61_CW7^P'<_\ 'G)_UR'\A7^:=_P2G_X)T? O_@G/
M^WQ\!/VR?%G_  5[_P""0OQ5\/\ P:;XI-?> ?#'[<_PA\.:WKQ^('P8^(?P
MMLS9:UK&N7>GV1TZ^\;6FKW)GMG:>RTVXM8FCGEMY!_95;_\%H_V,;V]U?2S
M^U+_ ,$Z+<:9]ABDOKO_ (*6?LW0:;J?V^V6Z9M&NED=KU+!6^SWSO#:^1>J
M;>,3(#* #_)W_P""F/\ RDA_X*"?]GN?M7_^KV\?5\0U_57^U7_P1P^#/[1/
M[4/[2?[0.C?\%GO^".OA/1OCK\?OC'\8](\*ZI^VQ\*]4U+PUI?Q.^(GB3QM
MI^@ZEJ5GKUK:7VHZ-::W!IU]>6=O#:W5Q;R36\8A=5'@?_#@KX5_])O_ /@C
M-_XF5\-/_FCH X?_ (->O^4Z?[#'_7?]I#_UD7X^U_KP>(_^0-=_]=;+_P!*
MK6O\VC_@E#_P3K^!W_!-_P#;^^ /[:'B;_@KW_P2!^*VA?!EOBDU_P" O#G[
M<_PE\-ZUKO\ PL#X*_$?X66GV'6-5UB]T^U_LS4/&]IJ]VMS PGL+"ZMXB)Y
M8L_V/G_@L[^Q=JE]JNAS?M2_\$[((M/&DW$FHS_\%+/V;(M,U);QI;E8](N_
M-<7<M@]F8=6@>*U^SF>W5&GCN!(I9]GKMH]?337Y ?XU=_\ \?U[_P!?=S_Z
M.>JE?T92_P#! _X63222M_P6]_X(RJ9'=R!^V5\- ,NQ<@@>)" 0690 2-J@
MYYIG_#@KX5_])O\ _@C-_P")E?#3_P":.@#]7/\ @R*_Y.'_ &Y_^R4?!K_U
M+?&U?W-_\%%_^3!?VUO^S3?VDO\ U3WC6OX]_P#@@[\'_P!G#_@CM\1/VA/'
M/CC_ (*B_P#!)KXZQ_&CP?X#\,Z38^#?V_?@IX0E\/S^$=:\0ZK=W6HR:_J&
MHI>17T>L6\-LMIY<D+P3/(?FB(_=_P#:"_X*G?L=?M%? ']I#X$67[7W_!./
MP;J'Q%^%_P 3?@S9>)]>_P""C_[.LNDVU_\ $/X6W&EV/BO3H;6[6?7_  _I
M5QXNACNVM[BSN)-4T?6M+"Q369=P#_("HK^BX?\ ! OX6$ M_P %OO\ @C,#
MCD#]LOX:D ^@/_"1#(]#@?04O_#@KX5_])O_ /@C-_XF5\-/_FCH _5+_@R&
M_P"3G_VY/^R#?#3_ -6)?5_6'_P<1?\ *'?]N#_LDMU_ZD>AU_.A_P $'?@W
M^SM_P1S^*OQ^^(WC7_@J1_P27^.EO\9OA]X4\%:?IG@[]OOX*^$+C09_#OB6
M\UVXOKZ?7M3OXKNWNXIXH(8K8)(CK(91MVY_6W_@H+^WA^R!_P %#?V&_P!H
MG]EW0?VUO^";GPHUCXO:%XK^'>D>*_&__!1'X /:Z)?^'_&LFF'Q)=^'[66+
M4=4\-:\?#LFL>';NTN('UC0-4T;6H1%%=+ H!_D^THZ_@W\C7]%W_#@KX5_]
M)O\ _@C-_P")E?#3_P":.@_\$"_A6.?^'WW_  1G..R_ME?#/<?9=WB55)]
MS*"<991R #^A+_@Q]_Y))_P4!_[*;\!O_43^)U?W;Y'K_G_)%?RE?\&Y_P#P
M3>^-G_!-GX)_&[Q%X5^(_P"S-^V7\/\ ]I[Q/X%\5^!OBA\!/C5'=^ /[/\
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M_B5^TY^SUXV\??$&+X<>!M5TOP'!\5M<TKP_\2_B'%I=WXN^*EYXQ\?:S?\
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MTUR4TU[-*-DB%Z<'2C*<^6CA\/&524JC='#)<B]I-N<V^9OFFW.3UFW+G;_
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MHH **** /#?VC?@GI?[1GP8^(WP0USQM\3/AYHGQ,\/-X7UGQ=\'?&,WP_\
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MN3BFU'F4')V0='Y+;OY+S/&? WQF_:2_;D^-W[4/C;]CGP5KOPZ\7_M%>._
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MX\J"2>*&R\-:#%/_ &MXM\1>'?#]M?:O:?D%^T-=_$/XV"\_:E_X*0ZQX9^
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M36K8BL^:K6J3J3DW>\I2?Y)126R222LD,"E1VP,]0.-W!P1V'I]!C@5^8O\
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MY:Z9IMS:^&++48Y;B3[O )VEA\P)Z8XZC)Y[C'3N>@&<?V&>&.HHHH ****
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MC./V O\ Q9;^T5_]*=H_X6)_P5-_Z,X_8"_\66_M%?\ TIV@L_0&@Y[=??\
MS^G?U%?G]_PL3_@J;_T9Q^P%_P"++?VBO_I3M'_"Q/\ @J;W_8X_8"."#_RD
MM_:*Z@Y'_.)WU% $/_!,OG]FKQ:1@#_AN#_@J+E02<?\;-/VN<CY\MA3@8 4
M*1@?* H_0>OD#]AKX-?$[X%?L_Q>"_C%;^!+#XBZ[\;?VLOC-XCTCX9^+=?\
M?>"?#S?M'?M7_&O]H72/"VB>-_%/@'X5Z]XJ7PKH/Q1TSP[J.O7WPW\''5=6
MTR^N[?1K2T>W5_K^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!G^0].IY]/YI/^"Z\<-Q^T!^POX8OX+IHOC%9?$+X'>'IX4**_B7Q?\ '/\
M93\07FG"0X'VB\\"^#_&4JQ1#SY;2VNRH9$D:OZ7J^5OVE?V/?@_^U;J7P%U
M?XK6FLR:G^S;\=_"/[1/PMU#0-1@TV[T_P"('@^SU/3;6'4FN]/U.'4/#>JZ
M9JUY8:WI*PVTEW"\<D-Y:W,,4R\>,P5#'X>>&Q%*%2C4J4JDH5$G>5"M2KTV
MKIK^)0A)=4[/H&O-S)V:5M/ZZGU+'&B ;$5<?( H  5/E4#'  4  #I^=24U
M00,'!.23CIDDG^M.KL6B26B2LEV7;Y;?( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 9*2(Y".H1R. >0I(X.0?H>*A( )QD;A<%N3S@
M@#OP .@& "20,DDE% $V!O''\)/_ 'S@#\@S#\?88?110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>tm2135630d1_drs3-13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drs3-13.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? :4# 2(  A$! Q$!_\0
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M\!^%_@K\6O"?PJA\>>+?"GPF\0:AX>\0?$:74?#>J>)/B'X.L?$6GV/AS_A
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MU3X,>)]1\4V?P;^,7Q)_9V^)$]_X-\;>$%T+XN?"2_L],\<>$;;_ (3/0/#
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M7X8?$'XZ?ME?'7PQ\>K+Q-^TO\8OBS^WGK_A[Q;?>/+'3O"_[8&@7/A_P7\
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M\6OVG/'.D7FA^+-&^ ?A6QM[>QU;6+VTLM$\+?\ "V/C=KVH76K:1###\/\
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M$MYH+Z^MM5;X?SSK?71#RU^O/_!3+QCX'^(?Q\_X(IZ=\)/%'AKQA^T+8_\
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M  B\732Z(EWX7\50>%/!.E^$=1B;2=5A:WO]#U".RGC;3+^V>*>TN!%,A6(
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M)W"ORC7_ ((Z_MX.RNG@CP/#@*=@^)FD(JX !"C?*#G))^8@MDC&0!^CLO\
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M$C_MZ_L[01VVFPB35_B<QF@M+>&["V_P(^+%U!%'<QIOAM_[1CM)[@,,F))
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MY>_\%7OVB/BG^RU^Q#\1OBU\)O%&B_#?Q38>._@EX+U'XM^)?#4WC7PW\%/
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M4?;8C)ITO:_5JM3V?M(PG*'/;FC&35[,_P =?VJWA?XE^&F8>"=+Q&\/>-N
MJN;8/CV65T^,^%L[X9GF4<#C.&Z>-> CG."P;Q:PE2K2AB?8*?L)U*<:O(YQ
M3EJ0?ZIO^NB_^@O4=2#_ %3?]=%_]!>OX?AM/_N%_P"GHG^2%/XH_P#7RC_Z
M=1]^?\$M/^3^OV>?^PM\4O\ UG_XL5_;'IW_ !YQ?67_ -'25_$Y_P $M/\
MD_K]GG_L+?%+_P!9_P#BQ7]L>G?\><7UE_\ 1TE?Z??0P_Y-?FO_ &76<_\
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M.XT.6X+8OE#>.?L[_L#_ +7%U^U/\+/VL_V\OVQ_#'[1OB_X"^%?B-H/P'\
M_"SX/0?"+X>^&=3^*&F_\(IXO\>:\LFJZS?Z[XCE\,.^BV!#PQZ='J-V@!:-
MV?Z8_P""D7[4/B[]D/\ 9%\=?&CP#8>%+KQ[9^+OA%\//#>K?$2:ZL/AKX/U
M3XS?%GP;\+=/^(/Q'OM/FCN(?A[\/CXTF\5>(9C+;QM;:$S7]Q9V[/<K^<_[
M&'[??[4=Y^T%^S-^S?\ M ?%G]G?]HK6OBKXO_;;^&7C_P 6_!G3-,\*ZYI.
MM_LYZK?>)OA[\5-(\(:)JVM1VOPD\0>%[:3P.EQJ3K=:AXE\0Z-J$%]=*9".
M?+X59UJ\(0BJF IWPZM&%2HGAL^Q=94KQO-K!UU5FW)/V-1OF_=U?JRQTHK"
MQFVE!R2C-Z0?O0BM4M4Y3II;I2J4KZU:*K?T54445T#"BBB@#!\5?\BQXC_[
M .L?^F^XK\1?^#:7_E"+^P7_ -BC\8/_ %HSXOU^W7BK_D6/$?\ V =8_P#3
M?<5^(O\ P;2_\H1?V"_^Q1^,'_K1GQ?H _=BBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K^4_P#X._/^4;_P!_[/L^'?_K.7[4U?U85_*?\ \'?G_*-_
MX _]GV?#O_UG+]J:OZD^A%_RE_\ 1K_[/#P?_P"GLW/&XA_Y$6;?]@-?\H'^
M=$WWE_W#_P"BXZL0_<7_ 'Q_Z$*KM]Y?]P_^BXZL0_<7_?'_ *$*_P"SE_P(
M?XI?^I6'/YUI_%3]:_\ Z8Q)<L_O)_U\G_T-*_0;X'_\DZTO_K_UK_TYW%?G
MS9_>3_KY/_H:5^@WP/\ ^2=:7_U_ZU_Z<[BO\"_](3_Y0NX1_P"S[<"_^LQQ
MT?[9?L*/^4P^)/\ LQ''?_K6\ 'K=%%%?\7ZZ^C_ $/^MS,/]VE_V_\ ^H^*
M)K3_ (_;3_KM'_Z.BK]+KW_61?\ 7NG_ *-FK\T;3_C]M/\ KM'_ .CHJ_2Z
M]_UD7_7NG_HV:OROQ0^/(O\ KWCO_2,*?\3O^EH_\E7]"?\ [%OTA/\ UHN
M2G4@_P!4W_71?_07J.I!_JF_ZZ+_ .@O7Y=#:?\ W"_]/1/^/FG\4?\ KY1_
M].H^_/\ @EI_R?U^SS_V%OBE_P"L_P#Q8K^V/3O^/.+ZR_\ HZ2OXG/^"6G_
M "?U^SS_ -A;XI?^L_\ Q8K^V/3O^/.+ZR_^CI*_T^^AA_R:_-?^RZSG_P!9
MSA8_V0_9[_\ )EN(O^SF9Q_ZRO"A=HHHK^OC^[0HHHH **** "BBB@ HHHH
M**** "BBB@!K_<;_ '6_D:_!#_@AU_R4?_@MI_VFM_:Q_P#41^$U?O>_W&_W
M6_D:_!#_ ((=?\E'_P""VG_::W]K'_U$?A-0!^^-%%% 'Y@_\%5?C0GP0_8A
M^*.OQ?#;X4?%VZ^(7B3X2? RP\&_'=KA/@-?WG[1/Q/\$?!JUUCXQWCQR6*?
M#?PZ?'!\1>);J>YLK5-#TMH?MEM<I$9/P;_X)3^,_AC\+O\ @H,MU\ ?V:/V
M//A/^S+^UC\9OVL_V;_@+/\ "+P)<V'Q]F\*_LD:!'K'B#XX2>/[G5KN3Q%\
M$?B%X_TCQ+X5TF+2;#3=.L=3?0+8M=-$LJ_OC_P4\^(^A_"W]B_XHZKXB_9;
MTW]LS3O%^I> _A5:_LYZ_J/AS3O"/Q/U_P"+_P 2/#?P_P#!5GXN\4>+=-U;
M0_#_ (1L_%WB70M?UC6Y[06O@G2K"?6C=6<.FVDR_)7[#_P>_:L\!_'GX3S_
M !(_X)-_L0?LB_#KP!\*?&GPJ\-?%;X&?M#:;X_\9_#;P=>ZK<^*X? /A'P;
M'\*/!B6NA>-_&\46IZY<Z=?2W$B:B+F^>6Y-R@63S4,9BIN*<82JX:JY2C#E
MK/ABBHTT_:25U-TI1E'VE.3A&G&LY4\/2S&,R][*Z$$G+VDTZ<HO^(UB8X7:
MZ:_?1J4I7Y>6<Y<R4*M>OEO[S4C$*I8]%!)P"3@#)X )/'8 D]A2TR4XCD.2
M,(YR%=B/E/(6,K(Q'948.3PI#$&F]-7LM7Z+5_D61_:$/19#QD8C8DC:')*@
M%DPIR%E5&8\(&/%!N$&2%D<!@CE%W;)"8PJ/SD$F10S &.,!VF>-49A^:/[=
MG[;OQ3_8RTS3/B!IG[,MA\3/@QI=KX,?XG?$K7?C_P"#OAAJ U_Q=\3/#'PZ
M\/\ P>^!OP[D\(?$'QK\<?CMK!UV37]&\(:_#\+/ ^KV]JGAS1?BV_C:[F\/
MV'REXR_X+;>"?AW<?'WQ%X^^ GB'3O@W\-_!W[=&L_"#QA8>.$O_ (B_%WQ-
M_P $]/&7@7X9_'[P+XX^%.J_#SP]IWP'EU_QSX[32?A1?ZAX_P#%MWXHTSPY
MK4WC72OAOXEN?#7A/Q%48RDH.*<E5G"G3M9\]2K.G3IPBKW<IU*M.$597E.*
MNKW5*$VVE%MQ3DUIHHIR;>MK)1;;OHE?:U_V_P#$TR2^%_$A3<0-#UE261D(
M9;"Z#!E<*ZXVY!90&5D9"RNI/XE?\&TO_*$7]@O_ +%'XP?^M&?%^O:/ 7_!
M4?X S^"_BWH?[9WQ&_9O_8;^-?PT^+GQ$_9Y\4_#CXI_M5_#4>#==\>^#_AQ
M\+OB;>7WP=^)OQ0T7X'ZW\3=$B\!_'?X81^)]3E\"^'#X6\2ZM=Z"MG>:3#H
MWBGQ%XG_ ,&U,BQ_\$1_V"E(=\^$?BV"T<<CA&F_:-^+ZQAU"^8HR'#2^68$
M".[S"/8[W6HU</5E1KP=.K!I2A)Q;5XQFM83G%IPG&2<9RBXRBU)IF<)1FKP
M?,GLTFMM]U':S6W0_=RBBBLB@HHIKN$4LW08]!U( Y) ZD=2*3:2;>B2;;U=
MDM]DW]R;\F&^BU8ZBJCWB1AB8Y-R_P !,*,1@G(:66.+&!QF09["JT.K6\TR
MVX1TG8,1$TUD[$*-Q/[F[E' YZ_7!!K14YR@ZBBW!+F<E_+:][?$U;M%_?H9
M.OAU;FQ&'@Y5%2C&IB,/3J2JMV5.-*K6IU93;T48TFV]KFI147FG_GF__?4/
M_P =J*6Z,00_9YY-SJF(_(8KD$EVS,N(U )9N<#G%9Q?,U%7;;LERR6NO648
MI;=9)>>U]DN9I)P;>R]I3Z)OK42V3>ZV+5%51>1L4"+(X<D;U"%%*C)#'>,$
M>P/'/3FG1W*2.B*'R\32@D+@*CK&02&/S$L"  05!.0< VX36\6M[Z;6WOKI
M:W6S\B8RC+DY91E[2G*K#EE&2E2A)1G.+C*2<8R:3=]WHGN6****D84444 %
M?RG_ /!WY_RC?^ /_9]GP[_]9R_:FK^K"OY3_P#@[\_Y1O\ P!_[/L^'?_K.
M7[4U?U)]"+_E+_Z-?_9X>#__ $]FYXW$/_(BS;_L!K_E _SHF^\O^X?_ $7'
M5B'[B_[X_P#0A5=OO+_N'_T7'5B'[B_[X_\ 0A7_ &<O^!#_ !2_]2L.?SK3
M^*GZU_\ TQB2Y9_>3_KY/_H:5^@WP/\ ^2=:7_U_ZU_Z<[BOSYL_O)_U\G_T
M-*_0;X'_ /).M+_Z_P#6O_3G<5_@7_I"?_*%W"/_ &?;@7_UF..C_;+]A1_R
MF'Q)_P!F(X[_ /6MX /6Z***_P"+]=?1_H?];F8?[M+_ +?_ /4?%$UI_P ?
MMI_UVC_]'15^EU[_ *R+_KW3_P!&S5^:-I_Q^VG_ %VC_P#1T5?I=>_ZR+_K
MW3_T;-7Y7XH?'D7_ %[QW_I&%/\ B=_TM'_DJ_H3_P#8M^D)_P"M%P"4ZD'^
MJ;_KHO\ Z"]1U(/]4W_71?\ T%Z_+H;3_P"X7_IZ)_Q\T_BC_P!?*/\ Z=1]
M^?\ !+3_ )/Z_9Y_["WQ2_\ 6?\ XL5_;'IW_'G%]9?_ $=)7\3G_!+3_D_K
M]GG_ +"WQ2_]9_\ BQ7]L>G?\><7UE_]'25_I]]##_DU^:_]EUG/_K.<+'^R
M'[/?_DRW$7_9S,X_]97A0NT445_7Q_=H4444 %%%% !1110 4444 %%%% !1
M110 U_N-_NM_(U^"'_!#K_DH_P#P6T_[36_M8_\ J(_":OWNE94CD9B%54=F
M9BJJJJI)+,Q"J  22Q"@<D@<U_,Q_P $??VJ?V7OA'^T?_P5[^#?Q6_:4_9_
M^&7QA^)W_!;+]I>#X;_"7X@_&;X<>#/BAX_E\2Z?\*/"OAM/!?P^\1^)=-\7
M>*/^$C\4QS^&?#S:)H]ZFN>(;:[T32FN]3M+FUB /Z:J*** /RL_X*YVOP)N
M_P!@3XVZ5^TE)\<+GX7^(;KP!X=OO#?[-NO/X;^./Q,\5:_\2/!>D_#KX7>
M-5*30RZO\4/'DOASPF^E3/I^G:C8ZM'H^K7MEI/GSK^1_P#P3#\%^,?@=^VA
M\+?!'[5GP8_X*D?LI?$SQCX2^)]S^S3X9_:2_P""E\?[<7[-GQAT3P_X8FG\
M5Z!K&E^%)+70_!_QA\.^$KN;Q=HW@#4--NI(;31M1U.PU2=]*<5^PO\ P5;3
M]G\_L-?&FY_:?\7^/OA]\-M)N/ ^LZ'XX^$]M=:E\8/"_P 6]*\?^%=0^"NN
M?"+2[2&:[UCXEP?%X^!X_!&@PHS:GJZP0!4LI7N5_%[_ ()A?$CXA?%K]NWX
M<W7_  46^+7[>FM?M*^$? _Q#;]BOP!^UY^QY\,OV1_!6M:')X7&C?%#XI>$
MK3X7>(O&6E>./B3>^$=2OH9[;7K[26\,:)<:Q_9^E,FI(]N\GC-U<SC",I*=
M&I3BJ7,ZKRO_ %9H..#MS7ECXN4G7J2DTJ%VZME+ESQUX9?@N:\?95(*ISI<
ML4\]EB?=Y;Z/#M57=-IMN*ORP/ZWZ:ZED=0Q0LK*'7;N4D$!AO5TRO4;D=<C
MYE89!K"[4D#RY &V!. 2^X'?A02W[K \S('7(S@U:/0^_'Y\5,FHJTG9.Z_1
M[7[FFJ]5T\UT^]'YR_M0?\$ZO#W[3OQR^ OQ\O\ ]I+]HOX1>)/V;X=4NOAA
MX0^%]I^S/X@^%6F^+]<CDL-1^)MU\.OV@_V:_COHLOQ0M] D;PSX>\=6QL]<
M\(:!)>:?X.N/#KZKK-WJ?FNJ?\$<_P!D_P 3^*/C5KGC:X^)_C?PK\:_"7[2
M?A1?A%XB\6^'D^&WP:G_ &RM1\(^)_VK?%?P3D\.^!?#?Q T+Q=\;O&_@?0O
M&.KZGXG\=^)['P3K,FIQ?"?2?A]X;U&]\+W/ZP%&(P" <]>O'I^?\S2E#A0"
M,CKU SZC]<?A5*ZC&G&3482A*+?PJ5.4)P:2>C4H1::2=U=.\8L'.?+S:\\U
MRR2=FE).,KOR4I/>[ZWZ_F1:?\$M/V.;3X=^,;;X[_"+P#^VIX]UGQI\3_C1
MXD^,W[8_PB^ /QC^)/B#XD^._#_A#PWK'B18K/X.>#_A[X-QX&^%?PK\#Q:1
M\,_ 7@C1;GP]\/?#']KV6JZ_97/B'4/ES_@VJ1F_X(C_ + Y4*JIX4^+C;0Q
M^<_\-%_&)9"Q*,Z%25D&R7;,6DB=(XPN[]O?%"L/#/B,D\?V#K&>3_T#KFOQ
M&_X-J&V_\$0_V"VQG'A'XP'@C/\ R<9\7^F>.>GX]1S3E.<IRJU)NI-K5^\W
MI&W9N3LNS;LDET)48TD^5Z*[]%JWILEN]%][/W:HJL;E00"I!/097TSV/X?7
MBF_;(RZH%D8L2 0IP,#.23@=/0GDBLX2]HKQC.UF[NG4AHI.+^.$/M1?R][6
M+4GIR2>T7\+GT^%;NU[V7IY;Z%NH;AQ'"[E'D VC9&AD=MSJHPHZX)R2<!0"
MS$*"0OFC^Z_Y#_&J>H3[;.X98R[A!Y:.K;7D+J(U.Q@P!<J"01M'.0!FM(QE
M*48Q:4I-*+;C9-M)-^]LFTWY)]B%[S48MQE)J,9<M^5MI)VGRQ=FU\4E'^9I
M7:KO(8W,;2JA?(A::95B9]K,4\I)1,) J.<E F$8Y)QG/^U11W2;IB9</N"7
M48M,8QRDTKLQ/\+84!L'%?B/_P %TOVHOC]^R_\ LZ_"'QU^SI\3-3^%OB3Q
M!\?=.\)Z_KFDZ+X9U>YU3PS<_#7XC>(9-&=?$FD:]IT&W5M/TN;>MF;K_09C
M!)$9#(/Y>G_X+%?\%,MY8?M;>+8RI9=R^!/@U)*>Q*W,OPW:Y4=F"3*&&58%
M?E/Y3Q?XN\-\&YK'*<^RW-,1BO84\;2GEU+#RY*%6=2G2KOVU>EHZE&IRP<7
M=I/FY6F_[\^CK^SD\<OI/>&U'Q9X!XJ\,<IR'&9WG7"\,OXNS+BG"8V>)R#&
M8; 9KB(4,DR',<.U1Q.*I4XREBZ4IS]HHI0BJD_]$C[?%_?A_P# BT_^*H%S
M'<?N@T3;@056>$D]N/*8L.O4@KZ]J_SM?^'QG_!33_H[SQM_X1'P>_\ G=TH
M_P""Q7_!360,@_:[\:DE2 #X(^#V#GY<$CX=D <YRR2+D#*-V^6J?2-X$G"4
M5E_%4W)64:F'R^G"3O'24XXU2A'JY)IJRUU9^[_\45OI11]Z?'/@1*"^.*SC
MQ NX[22]OP_['5-_Q;P[IZ)_Z)EL8+=UMDV1;OF\IG#R,'^7.02HSEE!&02K
MC)P";UJL88A&#;58 ]& 9E)!'H2 1Z5^$O\ P0F_:B_:$_:D_9[^+GC+]H?X
MFZC\6-<\,_'C4_"OA[6=9TKPOI&I:1X>A^&GP[\11Z84\(^'O#.FW%O'J>M:
MI+'))I\UXWVD1R2E$0O^Z4,@CD5EVF%HG+  B5I2\9#$,!\BID=>I'7.1^RY
M'G>%S_)LOSC+HSP^#S",*E..(E3J5*J?M5[.]&MB+5OW;O&<E)6=WRV;_P R
M/%;PPSWP7\2^-?"WBAY5B>(/#[B"?"^.J\-RQ57+(U_JF"QU7V=7%T,).MA_
M98_"U.>-*[52*=-5(SA'5HJK]J3^ZWZ?XTAO$! V,2V[ &W)VJ6( SU('';/
M>O92;T2E]SZ:GPCNDVU)))R;Y):**<FWILDF_D6Z*I->JI.8I,!-Q(*X!SC8
M?FX;GZ>]64E$A( / Y/H<D8^O>IBU**FK\LFTFTXW:O=6DHRZ/[.MKJZU)4E
M+9_:E'JGS0C"4E9I/W8U(-V5K25F]4I*_E/_ .#OS_E&_P# '_L^SX=_^LY?
MM35_5A7\I_\ P=^?\HW_ ( _]GV?#O\ ]9R_:FK^I?H1?\I?_1K_ .SP\'_^
MGLW/(XA_Y$6;?]@-?\H'^=$WWE_W#_Z+CJQ#]Q?]\?\ H0JNWWE_W#_Z+CJQ
M#]Q?]\?^A"O^SE_P(?XI?^I6'/YUI_%3]:__ *8Q)<L_O)_U\G_T-*_0;X'_
M /).M+_Z_P#6O_3G<5^?-G]Y/^OD_P#H:5^@WP/_ .2=:7_U_P"M?^G.XK_
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M?/>^";Z]FEB!MA97MG&K?:$G _6+_A_#\)1,&/[/?Q3S"CPEV\4^"-[EF1E
M;[4$9 (R3@ [B,?+FOY2/@L ?A388X U/42V>7.-7U? !Z!>=V/4D#BO3&9
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M\IA\2?\ 9B.._P#UK> #UNBBBO\ B_77T?Z'_6YF'^[2_P"W_P#U'Q1-:?\
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MLA^SW_Y,MQ%_V<S./_65X4+M%%%?U\?W:%%%% !1110 4444 %%%% !1110
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M;]MSQ1\0?V_-.^#/P;^(WA#X\>+OA1_P6/L/B3^T.-)M_!T/[4'AO]ICXG?
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MQ_\ E$K^W?\ ]D/U'_T_^'J_R4Q]Z3\?_1AK_6L_X+C_ /*)7]N__LA^H_\
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MQVU*QM]4^%L_Q*/PIU[P5,G@33KC4?A;)8:=X/B\6VTK0^-K:]FU2:'39S*
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MC_R5?T)_^Q;](3_UHN 2G4@_U3?]=%_]!>HZD'^J;_KHO_H+U^70VG_W"_\
M3T3_ (^:?Q1_Z^4?_3J/OS_@EI_R?U^SS_V%OBE_ZS_\6*_MCT[_ (\XOK+_
M .CI*_B<_P""6G_)_7[//_86^*7_ *S_ /%BO[8]._X\XOK+_P"CI*_T^^AA
M_P FOS7_ ++K.?\ UG.%C_9#]GO_ ,F6XB_[.9G'_K*\*%VBBBOZ^/[M"BBB
M@ HHHH **** "BBB@ HHHH **** &R#*..F489YXR#Z$'\B#Z$=:_ K_ ((?
M0B3XD_\ !;1B<$_\%K?VK W&=RP^%/A/(BX/R A\$-M+@9P0S;A^^K_<;_=;
M^1K\$/\ @AU_R4?_ (+:?]IK?VL?_41^$U '[XT444 ?EC_P5UC^#*_L"_&C
M5?CM^T9JW[)W@?P9JOPM^(>B_M!:+H<_BS4OAW\3OAU\3?!?CCX0ZQ9^!K:Q
MU&[\<1Q_%#0/!TE[X.TVR>?Q3;SOH<#0S7$DL?XY_P#!./\ :2U;]L']O+X'
M^(/VC/V_/'W[3WQ ^#?A?XF/\!/A3X0_X)V?%_\ 8[^&UMK7B/P/K6C^./BE
M\3?&GC/1[JS\17L_A3[9H?A_PZ=2TS1K+6E-U::<+AG67]1_^"MGB[P'XM_9
M7^-'P5M/VFOV//@'\;_"&G? 7X^Z/XE_:L\7KIG@CX3V&G_M!>#KCX??&C7;
M"*Y^VPVR>/?"FKZ+\+;O4M*U#PUXM^*>EZ-X0U32]1TR/5=.G^8OV OV[OVE
MOCI^TUX-^&_Q7_X*(_\ !#_]H?PEJF@^*;JX^&O[$OBKXC:Q^T/XCU#3/#ES
M>6>H:-9^)?B=XET2'3=/OE_M'Q3"-%G/]C174=E'82[9[;3*7*-:HHJ7,X5+
M*FVI3BLCI8&7*XPGS6Q&'Q47%*[C@\7)N"HRG//,Y1K8&$D_=C4I-JNE#E?^
MLV5<O*GRW]I3PTM?:<O+B\%+FMBX0I_T84445F:!1110!@^*O^18\1_]@'6/
M_3?<5^(?_!M1_P H0OV#?^Q/^,7_ *T7\7Z_;SQ5_P BQXC_ .P#K'_ION*_
M$/\ X-J/^4(7[!O_ &)_QB_]:+^+])[/T?Y,3V?H_P F>[?\%Q_^42O[=_\
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M_P"DR/\ 6?%?P)^M+_U(PY]Q_!3_ ))19?\ 83U+_P!.VK5Z2_6X_P"OB/\
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MTK]!O@?_ ,DZTO\ Z_\ 6O\ TYW%?GS9_>3_ *^3_P"AI7Z#? __ ))UI?\
MU_ZU_P"G.XK_  +_ -(3_P"4+N$?^S[<"_\ K,<='^V7["C_ )3#XD_[,1QW
M_P"M;P >MT445_Q?KKZ/]#_K<S#_ ':7_;__ *CXHFM/^/VT_P"NT?\ Z.BK
M]+KW_61?]>Z?^C9J_-&T_P"/VT_Z[1_^CHJ_2Z]_UD7_ %[I_P"C9J_*_%#X
M\B_Z]X[_ -(PI_Q._P"EH_\ )5_0G_[%OTA/_6BX!*=2#_5-_P!=%_\ 07J.
MI!_JF_ZZ+_Z"]?ET-I_]PO\ T]$_X^:?Q1_Z^4?_ $ZC[\_X):?\G]?L\_\
M86^*7_K/_P 6*_MCT[_CSB^LO_HZ2OXG/^"6G_)_7[//_86^*7_K/_Q8K^V/
M3O\ CSB^LO\ Z.DK_3[Z&'_)K\U_[+K.?_6<X6/]D/V>_P#R9;B+_LYF<?\
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M\*LL"&40G4]45MP._?\ VQJ^T#'  48;@DG!!XP?2V*'[1AP,W$95L9!7;<
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MREQ::629%*]])*63Y/57*_M/DDF]K7MYEVOY3_\ @[\_Y1O_  !_[/L^'?\
MZSE^U-7]6%?RH_\ !WR5_P"'<7P # D']NKX>$G.-N/V=/VI%R?498# [D'.
M!S_6_P!"%.7TP/HUI?\ 1X.$7LWI&IG,GI%2>T7TLMVXQ3E''B%I9'FMVE?!
M5E=NRO+D2N^FK/\ .@;[R_[A_P#1<=6(?N+_ +X_]"%5U#.%;&!MQUR<%$XZ
M=0."<>IP.E3Q9"@'D^8H'.,?Q9/KT (!'L.1G_LRA7A5PU&48UTIN,HJ>%Q,
M':K5PU:',I4;PM"24^=1Y)J4)-2IU.3^=J=E.,6U>+K7=]-:.)2L]GJU_6A=
ML_O)_P!?)_\ 0TK]!O@?_P DZTO_ *_]:_\ 3G<5^?EI@2QYC;RQ< -\XW$[
MD+,/EP%'/'4=R>E?H+\$MI^'FF^4K;/[1UO86;)9/[3N-K9"CJ.V/RZ5_@?_
M *0C+G^A?P>E"M'F\>N"::Y\/B()2I\,<><W,Y44E'3W9M\LG*"BW*<(O_;#
M]A6XT_IA\3MM34/ ?CEMTDZM^;B_P_BE%4U*4I7;;2CI&,Y-VBSUFBC#_P!W
M^?\ \31M/<E3_+&2#R!DGD8[X_&O^,1P<4V]=+:*?6W>"5OF?]:V-KQGAYQA
M"NY<M627U:NG+EPN+ERQYJ<4Y2M:,;IRDXQ6K1-:?\?MI_UVC_\ 1T5?I=>_
MZR+_ *]T_P#1LU?FC:8-Y:GTGB&<Y S+&3D8YSCCG@>N:_2R\_UB9GC)$84;
M%. N]R%;.,LI)#$  \?4_E?B=!RGD?+[S4,;I&-24M:>%Z*D]NMVMTUS+5?\
M4O\ I:6G%GT)HOFN\G\?\1']W6E&5.MQ+P)!*-2%*=+VD'!NI2=15(P:GRRB
MVU5J0?ZIO^NB_P#H+U%@?\]A_P!\C_&IV5!#$%F4M)O:0'/RLC,B 8Z!E(SU
M))X(-?F%*E-R<&G#F5U*<*L8)45*O/FDZ3M[E*7+H[RM'2_,O^/:,E&4&U-^
M_!NU.IHH2<Y-WIJR44]>_P!Y]]?\$M/^3^OV>?\ L+?%+_UG_P"+%?VQZ=_Q
MYQ?67_T=)7\47_!*](W_ &^?V;B6R\VO?%!)4!^[ /@-\4EED7CC9$[L2<C@
M''!!_M?L?+^RP^4V^,ABK9!SN=B>GH21[8P23S7^G7T,%?PQSN*U5#CO-5.:
M4E!^UX?X;A#DE*,>=<U&I?1623MJC_93]GS"</!CB6,H37)XG9U!R<)J#E#A
MOABC+EE*,5+WZ<DK+:SLKV5NBBHFD(ST 4X.?T[^X[=>.]?UW*7*KM-^EF]F
M]KIMNSLHJ4FUHF?W8E?Y:DM%>::]\5O /AG49='\0^/_  )X>U>.*.5M,U_Q
M7H.CZE$EPI>VGET_4-2MKE;6= 7BGVA95!* @$U37XV_"3:N_P"*_P ,@VT;
MA_PGGA(<XYX_M@X^F:UA0QM6G"K3RO.ZE&K"-2C6AD.>2HUZ4K\M6C664.E5
MIRL^6=.<E))M72N2W':,Z<VMXPJ0<DMN9IRC97O&_=-6ZGJ]%>5?\+L^$7_1
M6/AE_P"%[X2_^7%5)/C;\+RT;0_%7X8")9F6=Y/''A0@0AG 96_MR,*?E&.&
MW [L <5:PN.<X0>5YU%U).,92R'/N3F4)U.64HY+44'*,)\KFHQDXM<RLQJU
MFYRITH+>=6K1IP3M)Q3E*JE>;CR06\IRA%?%=>P45S5EK:W5I:7J7=C=6=Y8
M17UM>V3I<6EY;W*B:UN[.>*:6*XM)[=XYX989'CFC=9(I61E-:BWF54[MVY5
M;<JIAL@$$9DS@YR,\X/-<\)*:;C&IRW]V<J%>$:D=5SP=2C!RBW&2UC"::=Z
M<59O)5J=H*4HPJSHTZ[P]2I1AB*5.JGR^VI2K>X[IP:4II33CS/<T:*HB[&1
MR>HZA,?C^\K(M]:EFE$3>7&X=D=7C(=61-\BR;9'BB:-"&(\V0[3D@=#:C4D
MTHTJLUKS3C!\E-6T=24G#E4K-)J,]4T[=6ZD;-KEDTI-0C5PTJD^2+J3]G3^
MLJ=3V=*,ZU3DC)4Z5.=2;BDN;I:*R'N;WSLQ[&AV$[3"!A@VWF<W"\$YQB#G
ML<<U=^TG_GFW_CG_ ,<IN-K>_3=U>ZJ0MUNG[RU5M5TT*C*,W)4VY.-E.\9T
MU&32?(W6C1C*233E[*56,;QO/5%JBJC7+;6Q&V<''"GG'' DR>>P//2LB#4[
MR0*61DRPYFLY849%($C*ZRS8(Y"[E"E@02*AJIIR4JE9?:E1=&:AVYKXB$M=
M6N6,]$[VT3ODJV<E2G*,?BE&5%J-]KKVZFVTFTHPF[)^2?0/]QO]UOY&OP0_
MX(=?\E'_ ."VG_::W]K'_P!1'X35^]+R_NR<@9R.AZ8QZ]<\=Q^ K\%O^"'7
M_)1_^"VG_::W]K'_ -1'X34E*+E**:YH6YXW]Z#DKQ4DMFUJM62M5>S2>UU:
M_P GJOFD?OC1115#(?L\9<R'>7.1N+L<*Q!*A<[-I V_=SMXS3/LL7R\N,,&
M."%#$2&4;@H /S$@\ E202<YJS10 4C'"L1U )'X"EI",@@]""/SH>S]'^0$
M32;4#G@!26/IM^]P.N,' S@^G2OB[_@H7^TMXB_9"_8C_:L_:;\):%9>)?%?
MP/\ @CX^^('A;0=32Y?3;O7]#T>\30Y-9CM62>70X-9-I?ZPD,D$K:/!>K'/
M ^V9/M0QJ5VD97D$'G(;J#ZYKF?%W@KPIX^\,^(O!?C70=-\5>$?%V@ZIX7\
M4^&M=M(=2T3Q%X<UNQN--U?1-8TZZ22VO]-U*PN[FTO;6>-XIX9G1U(8UA4A
M4<*"IVYH5J,JMWHZ<:M*5117VFZ<:B4792NHMQ4G)52<8U*DJBYH.,N2*T;?
M+))-_97,X^\KM)72=K/\#(?^"Q&G?LRZ%\</@[^VW;?%3XQ?$GX9?M)_&G]F
MK0_BE^R_^S)XT\6Z'X_L/ ?P5_9G^+7_  E'BWP=X*O?$]E\-=;'_#35EX1A
MT4:UJ%IJ,O@?6[LW=M=K+:K^<?\ P1A_X+#?LX?L2_\ !,G]E;]E_P".WP<_
M;<TWXK_"GP]\0M/\7V?AS]CGXT>)=$M[CQ!\8?B#XTL5L-<L]#BM-00Z'XET
MEYGA4K;W,DD#DM&V?ZU?@=^S[\&OV:_A]8_"OX$^ -$^&?@#3M0U35K?P[X=
M^V+!+JVMWC7VK:K?WE[=7FIZKJFH7+!KG4-3O;R\DBC@MC-]FMX(H_6VA4+G
MS)QC<<^=)SG?@'GHN\XP 3M3<3L4CLKSIRK3G1@_9ZN$'R4VVDK1:7/"'-);
MIS4.;5RY7?"DIPBW4:NKNZDY*RNT[M)NR2O=+5/H?R0?\%//^"V/[*W[4W[
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MO_X;?'^T\(>"8/"NL_ ?]JY[U+^6ZWP?LT_%F:-/-N9[J3RI$\/?O59[MQD
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M!X?[1T3P_8:9>^3)_8P#Q?:K:4QL.J[2"17H,?\ P<8?L)1YQ\*_V^#G@_\
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MR?$WPOXMB\7^)?!_QB^-'Q1\?VVOWZ> /!^M>&X8+77]:\5>'+&&WNTN)8=
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MUCPCX;DTC5[.32]8\-RS1VZW3)<QW-JRB0NY0;U,C_C^WP4^-JG;_P ,U_M
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M?JSADV74J64492G3J2BXYC3^L8A^SG%4XP<54E:G'^.37O@%X._91_X)@?\
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MSP6LTWP\LX+7X;W]Q8:7<:AX2NI]*TV2U^@?VG/V1/V>/VQ_@AXJ_9Q_:/\
MA\/B+\&O&UUX:O?$WA >*O&WA%M2O/!_B'1O%/AN['B/P+XD\,^*[.XTO7?#
M^D7L<MAKEJ\Z68LKHSV$]S:S=>$J1PN*PV*Y%5G3GPS2K)VBY8? 9+3RSB/$
MPDX33Q><U\1C\1&G*FJ:=# 2G4I.594^G'4*&.I8S S4U@L95XFJRDY7G3AC
M\5DF(X<P\</&4(>RR6>4U:O-]94E4Q=14X54HV_EHNOV>_B3^T;_ ,%O/^"S
MO@;X>_MU_%S]BB70_@K^R3XSU74_@AJ?@/0OB)XQ&@?"G1SHVKWGBOQ-HVI:
MSI_PL\"3-(OC?3O"U]H%QJ#:_HECK&KK;QBVN_VY_P""(W[4WQ?_ &PO^"?G
MPN^+_P =M?TOQK\2K;Q'\3?AMK'Q'T.PM-.T3XIVOPQ\=:MX1TOXDZ5;Z<S:
M8;;Q3IUA;73W.GA+:]N4N+I%)D9S<^.W_!#;_@EE^TWX^^(OQ5^/7[*MA\3O
MB9\5M-^&^D>-/'_B+XL?'9O&%S8?"CPUI?A#P?#H/B*R^*%GJO@N0^'=&T[3
MO%ESX+NO#]U\1!%+=?$*?Q1>WEY<W'Z.?";X/_##X$?#_P *?"GX.>!_#WPX
M^&_@;1X= \(>"O"MBFF>'_#VCVY+QV.FZ?$?*@B,A>:5@#+<7$DUQ.\L\TDC
MX8"/U;*<KR^O/VM3*,CP6186<*:C3^KX#,L\Q%&K)R?M'5G@<QP="K*7,W/#
MRC&U.,)3US&K5QV94\P48T?:S<\;24VX+V60Y3EN'A07*E-?7<'BJ]5R5%*$
MZ=2,95*M2%/TBBBBF(**** "OY[O^#AQ/B'+\%_V+(_A)HG@#Q)\4?\ AOW]
MGE_A]H'Q7&KCX8ZSXL&LW8TC2_'LFA12ZK%X8OK@BWU-[("X$#L8@[@(W]"-
M>!_'G]F#X(?M-6_PWM?C;X-N/&,'PD^)WA;XQ_#^.#Q;XU\*#0_B+X*N6O/#
M.OS'P9XC\.MK<6FW+M*=$\0'5?#]XV!?Z5=*J@8U</3Q-7 QKRG'#4<TRW%X
MKV=O:SPN$Q7MZ].FG:,JE2*C&,9N,).ZE)+=\THPK\BBYSPN*I4^;X/:UL/4
MI4W.VJ@IRBYN-Y**;BFTD?AG\%?V+/VXKC]L_P (?\%%O^"A#?L#_ FR_94^
M!GQ;T#PAX3_8?T7XGWT'C*T\46+ZGXC\6?%[7O'EAI&O7&C>!]/TJ6:R\.^'
MK:_;4Y))B'L)E1IOQV^&'[;O[>=O^UK_ ,$^?VBO"W[1/[>_Q3^!_P"V3^U=
MJ7PH\3^*OCQI_P "OA)^QI\5? >I/=G3=/\ V:_V4] \7_$/XJ>%--T;2+66
M[G^(WB#5K-9KC33&WV+4;V]L(?[N-3\/:)K.FZCHVK:99ZCI.L6=WIVK:;>0
MK<66IZ??V\MI>V-_;R[H[NTN[6::WN+:=7AFAEDCD1D8@_E%X$_X(-_\$EOA
MAXIL_&_P]_8Y\*^$/&&E_&#PK\==#\3:'\0?C+::WX:^(G@R_P!4U/09?"FH
MK\1S<^%/!J7NLZA)JOPN\.2:9\+_ !$CVL'B'P=JEOINF16?;@\1)YK@,3F4
M(U<!@\-A\/[##\KFU#-,9B,1>G4485'4P53#4XRJ5/XD:D&HQA2JO'%4E6R?
M&X:A.5#-,5'$\F+7-[.C5J9<J%"K&:?M>:CC*<)JT6E2E.2C*<5!_A[\3V_;
MP^/GC?\ X+V>+/!O_!1_]J/X)^#OV(OB/XS\8_ #X:_#7Q'X:LM$@\5_#7X!
MS?$BU\,>)_%7B;0=:\5:;\)=5N[:RTO4/AYX+U/1=-OM3O;W5M8@OHO+"?:/
M[='CG4?VC/\ @VB\6_M-?%71_#&L?&KXJ?\ !-?X5?$KQ5XQB\+:-IVH-XL\
M7>!/!WB37[[1VAM-^A6%YK>K:OJ%AIFE/::=IL-^UOI]O;P;4K]J])_8/_96
MT*#]K.WTGX9W5E'^W)<^(;S]J Q?$+XGM+\2+KQ5X.?P#KT]M<2>,WG\ R7O
MA.1M+1OAK)X/-DPCO[#[+J4,5XE[7?V(?V8?$G[(\/["FL_#22[_ &5[?X5Z
M%\$X?A<OC;XAVA3X8^&M.L-)T7PS_P )O9^++?XBLMII^F65NVKOXM;7;L1,
M][J=S+-.\GD5:.-GD%/ QG2CF=/+^$Z*K1E.-#ZYEL\=4SZHZD8^T<,3.K@_
MJE25.52NJ"=6.&]E!RZ8RA_:>*Q+@HX2MG6<8JC3A;VE+*,;@\FIX+ 6]V+]
MAC<#C\7.#FXPECI*,ZEY*/XH_MU?%J[^#7["W[ 'PB^"_P 3?C1\"_BA^U:G
MP-^'-OH/[%GPA^'>N_M4?&+2-.^$NG:[K_A7X3^-/&GC7X=^#O@]K21VZ7%_
M\5?$$WB-M'TN2]L-,T*;4=4AN+?\L_AO^VM^WUH'_!+W_@M3X8^)'QH_:4\-
M?%3]B'XF>"/"WPE\9_%GXD^"/$7[4_PRT'Q!Y6MZEIGQ"^+GPGA?PYXC\3PV
M[1->1:7<7T>@I>WGA@ZE<R6=PY_J_P#VF/\ @FG^Q#^V)\&OA[\ ?VD?@1I7
MQ-^%WPH;0V^'.CWOB[XB:!KOA ^'=(AT#3AH_CWPEXOT#X@0*^BP1:;JJ/XH
MD77[5-FNC4B2QQOAG_P2O_X)^_!WP3\<OAG\-?V9O!GA7X9_M)>'O#7A?XV?
M#:SU;QG=?#WQUI/A+1Y=!T4W7@C4O$U[X8TC55TN9X=4\0>'M+TCQ!X@G$=_
MX@U/4]0BBND]534GQ'[2ZEF.,QE?*:R7/4PE.?$?#6;4(58MQ5.5;+LMSW*\
M4Z<JOLZ>;R]FYJ4I4^7"4E3PV30Q#E*K@Z. IX]0:E3JU*<<XIXV="34&[PQ
MF G1]I&/M'AZL*GLVJ<Y?GIXY_:5^(UO_P %"?\ @CQ\'=*^+GC.'1?BW^S3
M\4/'GQ;\!67B68:/\1(H? 7AE=$\7^,=+MIVDUFYMM:DU66VU#5+:R@ANGGF
M@O9+C?;C]_-+=I+16:,Q'S9AL+%^%E9059E1V1@ 4+HCE2-R*>*_,_\ 9S_X
M(P_\$S?V2O'_ ($^*?[//[+NC?#?XB?#:7Q9+X3\867Q$^,6N:Y OC6UMK'7
M;76[OQ3\0]<;Q=IPM+.W@T/2_%PUS3?"B*__  BUKHQFF,GZ>Q11PKLC7:N6
M;&2<LQ+,222<DDDU5:I3J4Z"A%PG'$YY6K*RY52Q^<5L;EF&A)6<X99ETZ>7
MP;A#W*:24DN9XT,-.A4H)575I4\HR##5'+FC*>8X+)I8+-JZ@Y37L\1C(T:E
M"IS\]6E%SJTZ51<LI****P.P**** "LZX<+( 2P+,\9VLRC:T<AR,$;7& =W
M!&!@\UHU ]O#(P9U)(.X?,XP=I7HK#.58C!R.^,@&HJ1<HR4;<SA54;[<TJ%
M>$+Z/15)TW+JHJ35VDG%13<&J;2FY4FFW9)1KT)SU2>KIPJ):6<G%.R;:_@Q
M^+7QM_X*&P_LJ?\ !8_]OGPM_P %%_VDO#,O_!/?_@JM\9?"?P&^ >FZYX6U
M'X5:GX7\/_&;X3:/<^"_B@=1\/:GXP\0_#;3?"_CVSTWPQ\*4\5V'@K28]/O
MXY_#X?5[PP?K#\'M=_:Z_9X_X*V_!GX-_$[]LWXP?M%_#_\ ;9_8A^+GQ^\>
M^!/B+#X7LO!7P@^*/@$^&H+*+]G[P]X4TK3K/X>^"H#K3:;8:.QU/4+NQ6*Z
M\4:UXD\0QMJ[?KGJW_!+?]AC7/@A^TW^SEJWP5N[WX-?MB_&'Q#\?/VBO!TO
MQ6^,X_X3WXL>*_$/AKQ3X@\46OB!/B&OBCP0FI:YX0\.W<OA_P"'^M>%?#*1
M:>;"#1HM/O+ZTN?;-4_9!_9XUKX\_"K]IK4_ ,UU\;O@G\./$GPD^&7C0^,O
M'D2>&_A]XO>QD\1>'W\,P>*(_"&N+J3Z;8L^I^(M U;6(# OV74(-S[LJ<,0
MJ5.C.=)1EEN'P%>I&GS58N?AUQ)P[C:M*4DFYQXLS#(L\PTVX5)T\I5>4Z-:
M,<-4C%QJU77J4%"-18O-L7A8R]R"E+C3AK.\BA5<(RLL/DF"SW"XJT9*.*Q&
M%H0AB*%:M7H_R=ZO^V_^TWIO_!O:WQ]O_P!I'XGP?M"7'[<=]\*K;XJP_$B4
M_$:"W;]LV;P\? TGB>.Z@U6YL++X=6\VF+IEO<274GA:(6C6EOI4*SP>W?M$
M_&CQC^SW_P %A/\ @J%\=? WA^3Q7X[^%O\ P1G\ ^-O">CI;P,FH:]I'B.]
MEL[@VUS]NCEM-/O+HZQ<V^ZY66'3I+5VGA>3=^LOB/\ X(#_ /!(?Q7XU^)W
MQ$U?]C#PD/&7Q?\ $EAXO\:ZUI'Q"^-'AQSXET_Q!;^*EU?PC9>'OB3I>F_#
M>ZOO$%K%J6N?\*YL_"L7B.4RQ:_'J5M<3PR?2WQ/_82^"FO^/_CE^T+X&T:U
M\!?M4_&+]G^Y_9YNOC3JDGB#XBZ'I'@:"VN%\,Z???!CQ;XBO/A'KFGZ1J$Z
MW=S:R^#DGUF-I;/5[N[M99(VFO4K0R_$ODC#,*N%Q,57I>]&%9>'V0<.87#.
M;49K!8GB'+,?C\9)0<X8;,ZN)5*OB[TCT:;PT*\(TJ<IX;ZSA*GLJG+%NE'Q
M&P_%F+C*SE&_]BK$9?AU9I5W3HWIX6\E_,?_ ,)G^V;\&?A__P $??C5JG_!
M5'XZ_&\_M^?M3?"'Q#\6OAWK_B+P58^'-6T?Q-HJZ]K^B_!>[\+:7HNMZ3\)
M+-;B#3/&'@C5[[Q)X6"+ID^F)HEXUP-2^N/^"=\"7'[2O_!=OXE>,?@SHG[2
M7_!03X>?M4>/(_!OP3\8^(O!.D?$7Q'^SAI'@S0;[]FSP-X%\2?$*.^TGP;\
M-_$\J7EKX7\27VEZ=X96\$4EX\A@=D^=OV-_^#=O]JCX5_'7X(:[\9;C_@FU
MX2^$OP)^/FG_ +0FI_%7]F7P!^T$O[4/[1'BSPQ;:E:>%]#\=:9\1M6L/@[\
M#/!4SZA'K=YX(_9^L-#\!Z/J-JMEIG@^\MKBXNS_ $+_ +8?_!)+_@G3^WUK
M^D>,?VK?V7/!GQ(\<:-!86=G\0=*UWQW\+_B+)I6F6^H6^FZ!JGQ"^$?BOP'
MXSUSPSIZ:K?267AG6]<U#P_:W4J7L.FI>06\\7?5DE6KXK#N$Z&/JYU05"2C
M3E@LJS-\.5(86#Y:L:U.D\JQ^%J8=SC'$X7'SDZU%N5(\JE3Y*L\/6G.K.A1
MR6LJKBJ3>-R_'\1XF22I2IVH5%FF$O*T9SEADIQ_=4V_S#_X)5>,?AM^T+IO
M_!4;]DSPK^Q+KO\ P2Q^)WA'Q_#9?M!:?\)_VA?!GQ \:GXF_M*>#_&NM7'C
M'P;\0OA]H.G>%O _BWPSIFAJNA'PM<:S#X9,VEMIZ:5-I)A@Y[_@BO\  CX:
M?LU_\%)_^"Y_P)^$6D7>C_#OP!\0_P!A:#0K75-<UKQ/K$L^L_L]^*/$^N:I
MKWB;Q'>ZGX@\1^(=;\2ZOJNNZ_K^MZC?ZMK&M:A?:C?W4]S<2R-^ZG[+_P"Q
M/^R?^Q7X&N/AQ^RK\!OA]\#?"6H365UKEIX%TEK'5/%=]IUA+IEAJ?C;Q/<S
MW?BCQSJ]I8SS00:OXOUG6]302R2"[\UV<['PP_9-^ /P;^,W[0W[07PW\"R^
M'?BY^U5J7P^U?X\^*F\6^-]9C\<ZC\+/#-UX/\"W2>'-?\2:IX5\*OHGAR]N
M-.=?!FB>'H]6#1W.M)J-Y;V]Q%E!NE4JNG%*#X5PW#M.\I.\L$L \)RJ;J3H
M8+#JA6PN&PSJUOJV%I8>,74YG[)^QJ+#U*2G[U7B+#9]-R=U&?/4>,C&7+S.
M4HJ@Z=V^>?M93E3O[WN=P,%C@?QD?@I';L1C//?'-;%0/;0R?>4GKCYF&,]>
M003GU.?;%3T^:3NI6^*ZMVY()W\^:+[Z6UW2W@FE*]N:4U)V[*C2I[][P?E:
-WHBBBBD4%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>tm2135630d1_drs3-16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drs3-16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %3 FL# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_*^+M?\
M^"VOA2P^(WC'PYHWP4_:/\:-X&\07OAG4M1\-^#X=1L#>6DICE5)4NOHP#!6
MVNI*C-?:-?GO_P $R/\ D8?VH?\ LOWBO_T*VKMPL:?LYU*D;VMUMNSHHQBX
MRE)7L=E_P^MT_P#Z-G_:\_\ #=K_ /)-'_#ZW3_^C9_VO/\ PW:__)->Y44>
MWP__ #Z_\F8^:E_+^)X;_P /K=/_ .C9_P!KS_PW:_\ R31_P^MT_P#Z-G_:
M\_\ #=K_ /)->Y44>WP__/K_ ,F8<U+^7\3PW_A];I__ $;/^UY_X;M?_DFC
M_A];I_\ T;/^UY_X;M?_ ))KW*BCV^'_ .?7_DS#FI?R_B>&_P##ZW3_ /HV
M?]KS_P -VO\ \DT?\/K=/_Z-G_:\_P##=K_\DU[E11[?#_\ /K_R9AS4OY?Q
M/#?^'UNG_P#1L_[7G_ANU_\ DFC_ (?6Z?\ ]&S_ +7G_ANU_P#DFO<J*/;X
M?_GU_P"3,.:E_+^)X;_P^MT__HV?]KS_ ,-VO_R31_P^MT__ *-G_:\_\-VO
M_P DU[E11[?#_P#/K_R9AS4OY?Q/#?\ A];I_P#T;/\ M>?^&[7_ .2:/^'U
MNG_]&S_M>?\ ANU_^2:]RK)\9^.=(^'FB/J.MZC:Z;9ID"2=]OF,%+;$'5W(
M5L*H+'' -:4I4JDU3IT6V]DFVV95\3AJ%-UJUHQ6K;=DEYMZ(\C_ .'UNG_]
M&S_M>?\ ANU_^2:/^'UNG_\ 1L_[7G_ANU_^2:Y/Q;_P4*NKL7$?AKPOM!V_
M9[O4[CZ;M\$?']X#$WH3W6L_0OV_?%.E^=_;7A?2K_=M,(LYY+(Q]<[@WG;L
M\8QMQ@]<\?;0\/\ -I4O:?54GV=17?XV7S:?D?E57QRX+IXCV/MFUUDH5'%;
M_P!V[VW2:U6NYWG_  ^MT_\ Z-G_ &O/_#=K_P#)-'_#ZW3_ /HV?]KS_P -
MVO\ \DUWWP@^/OAOXV:=YFD7?E7B;S+IUT42\A52!O*!CE#N7YE)7YL9W @=
MI7QV+IQPM5T,10<9+=-M'Z;EV:8#'X>.+P4E4IRV<977]>6ZZGAO_#ZW3_\
MHV?]KS_PW:__ "31_P /K=/_ .C9_P!KS_PW:_\ R37N5%<WM\/_ ,^O_)F=
MO-2_E_$\-_X?6Z?_ -&S_M>?^&[7_P"2:/\ A];I_P#T;/\ M>?^&[7_ .2:
M]RHH]OA_^?7_ ),PYJ7\OXGAO_#ZW3_^C9_VO/\ PW:__)-'_#ZW3_\ HV?]
MKS_PW:__ "37N5%'M\/_ ,^O_)F'-2_E_$\-_P"'UNG_ /1L_P"UY_X;M?\
MY)H_X?6Z?_T;/^UY_P"&[7_Y)KW*BCV^'_Y]?^3,.:E_+^)X;_P^MT__ *-G
M_:\_\-VO_P DT?\ #ZW3_P#HV?\ :\_\-VO_ ,DU[E11[?#_ //K_P F8<U+
M^7\3PW_A];I__1L_[7G_ (;M?_DFC_A];I__ $;/^UY_X;M?_DFO<J*/;X?_
M )]?^3,.:E_+^)X;_P /K=/_ .C9_P!KS_PW:_\ R31_P^MT_P#Z-G_:\_\
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M&S_M>?\ ANU_^2:]RHH]OA_^?7_DS#FI?R_B>&_\/K=/_P"C9_VO/_#=K_\
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MB>&_\/K=/_Z-G_:\_P##=K_\DT?\/K=/_P"C9_VO/_#=K_\ )->Y44>WP_\
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M)EU5S>0Z+!^[TRSF93]GBXRV%XWR$;FZ]EW,$%>I_P#!8G_DQ#5/^QO\&_\
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M"@&=VY0H)RH&)%P2=P7R_$C TL3E,<?)?O*;2OWC+=??9K>VMMV?2>!>;XC
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M"6KSVT2A=Y8S)F/:%Y)W<8.<8(%'1+_7_'6GO<Z%H>L:Q:)(86FL;*6YC1\
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M^"]#U?3-'^&_@+2=-\0PK;ZK:6?A^T@@U.(9PDZ+&%E4;C@.".3ZUWU?)_\
MP_#_ &7?^BG_ /EN:M_\BUUTH8FM=TE*6U[7?I?]#6"JS^"[/<+?]D_X66?@
M>X\,1?#3P!%X:N[I;Z?24\/6BV,UPH"K,T(CV-(   Q&<#K6KHGP(\#^&M/L
M+33O!GA33[72K[^U+*&VTBWBCL[O9Y?VB-50!)=GR[UPV.,XKYZ_X?A_LN_]
M%/\ _+<U;_Y%H_X?A_LN_P#13_\ RW-6_P#D6M_J>8/>G/[I%^PKM6<7]SZG
MT9'\'/",4,,:^%?#BQVVJMKL*C3(0(M18L3>*-O%P2S$RCY_F//)KYZ\)_\
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M:M_\BU=2CF4X\DH3MO\ "_/R\W]["=+$3^*+^Y]=_P CT_XC?L'?"[Q[X/\
M%.F67A+0_!U[XPM);+4M;\-Z7::?JTL4KJ\JF<1$L)"HWJX97!(8'-<G\'O^
M"6?PE^%6H:_<7VB:?XT7Q"MJ)K37-!T=;" VWFB-X[2TL[>W$F)I 9#&7(.-
MV"0><_X?A_LN_P#13_\ RW-6_P#D6C_A^'^R[_T4_P#\MS5O_D6E&AF48N,8
M3MZ/_(KDQ+7+9_<_+_)?<>]W?[-OP[O_  UI6BS^ ?!<VCZ%=->Z;82:';-;
M:=<,Q=IH8RFV.0LS,64 DDG.33?$W[,WPW\:Z+_9NL_#[P1JVG?;I=4^RWNA
M6L\/VN7)EN-CH5\U\G<^-S9Y)KP;_A^'^R[_ -%/_P#+<U;_ .1:Y/XX?\%\
MO@+X#^%VJ:KX+U__ (3WQ+:^5]CT+[#J.E_;MTJ(_P#I$MH4CV1L\G(^;9M'
M)%1' 9A*22ISNWV>[\_U)C0Q%TE%_C_75_>S[ L_AGX;T^\T:X@\/Z)!<>'+
M5K'298[")7TNW955H8"%S%&51 53 (11C@5:\(^#M(\ >';;2-!TK3M$TFR!
M6WLK"V2VMX 26(2- %7))/ ZDUY=^Q;^W-X(_;P^'5SXC\$Q^(8(-/G^RWMO
MJNF26SVDV6Q'YHW6\C[ LA6&5RBRQ;]A<"O8ZXJT:L).G5NFMT_Z\W]_F82C
M*+Y9:!7AG[)?_)??VG_^RF67_J&^&:]SKXG^*'B+PEX(_:9^*H\.?&/]I[PS
MK&I:Y9W?BK2O WPM/B;2;+4O[%TV*,+<GPY?XD:PBL':,7#8\S.U2Q%8DGN6
MJ_!'QII>D_%23P[J^FV&J^,_$5MJVGN+AXC]F2TL8)K>27RG,#RK;3()8TD,
M8D5U&X8'F'PS_9$^)GPO^*.H>+K&'PG<7&J-?6[:?J?C'5-4:S@NK;38C)]N
MN+5I[AXWT\$(ZJ"LNT.FP9X[_A;7_5?_ -N;_P 1_P#_ ,#:/^%M?]5__;F_
M\1__ /P-J>56MY<ORLE;YI?+5JS;#F>_G?Y[_G_P;GTC\'_V8M-\+_L]^'?"
M/B2VMM0OK+1M+L-2FM+F9(YIK*-!&\3 JZA77(("D]ZZKP)\%?#OPY>1]-M;
MV222**W\S4-2N=1DCBBSY<:-<22%$7).U2!DDXR<U\B?\+:_ZK_^W-_XC_\
M_@;1_P +:_ZK_P#MS?\ B/\ _P#@;6LIN4G/J]62DDE'HC[&N_ACHUWX5BT;
MR;NWL8)OM$7V6^GMIHI-Y<LLT;K(N2S9PW(8@\'%4-#^!'A;PWK6FW]CILEO
M-I,4<-JBWD_D1[(WB5S"7\MI!&[KYC*7(/+=*^2/^%M?]5__ &YO_$?_ /\
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ML;9;.VNX[*)9[>!00L2.%W*@#, H. &/'-0M(\O]=?ZUOT>Y4E=MKL_OZ/\
MJWXGE&O?M#^*+#X?>%=?6#0K2WGT(:WKKFUGO8K?Y4/E[8I/M$$1_>?Z1Y$Z
MKL.Y!WYS_@H&1/X^_9M*G(;XFSD$<Y_XI+Q&:]RUSX1^%/$]OIT.I>&/#VH1
M:0NRP2YTV&5;)?E.(@RD(,HGW<?<7T%>(?\ !0.-I/B#^S>$5G(^)ERQ"C.
M/"/B0D_0 $_A7R?'B<N%\QC:[="M^,)?\-_P3T\ETS+#RO\ ;A_Z4O\ @M_Y
M(U/BIXITOX;?!3Q%XAUG0;[Q+I.A6+ZA>:;96D=W<7$,0\QMD4C*KLJJ6VYR
M=G&3@'YD^*_Q[^!7AGX0>#?'-GIOC*'P[XU\377AK0KZQUK2;.WUEHEF(O!<
M:I>QP+:O]EE\IC(CR[EQ&V]"?L'1C%JFF2VTOS1SQM&X_P!EACZ=*Y7P%^R3
MX8\!>#?@WHME?:V;3X((B:$9)HM]R$TV;3A]IQ& W[F=S^[$?SA3TRI_BWAS
MQ#SOAG QJY%BJU)WNXTZDHPG[DU:<5[K?-R)-IV3;2NDU];QSP3E6?22S+"4
MZS2:3G!.4=4URR^)*]W))J]DMF[^/?LG^-/A3\:_B=K7A:Q\#^+[?5?#,=W-
M'?>)7LYK?688=1NM.DF2*VNI0JK<6TR+]HAA9@@90VUB/H/Q;9@HW'7C_/\
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M<'&M%6?+MY+YW[^5]CY$_8M_:K^+WQ!^*'P=N_&OB?P[K&A?%[PIJ-\-(L-
M%C_8\U@T8$PG,KO*\PD^<$*BX^1!UK[@KG=#^$/A/PQ)HS:;X7\.Z>WAR"6U
MTEK;388CI<4N/,C@VJ/*1]HW*F V!G.*Z*IQN(IUI\U./*M>W\TFMNT6E\C"
M33=UY?E8****XR0KRC]O#_DQWXR_]B+K?_IOGKU>O*/V\/\ DQWXR_\ 8BZW
M_P"F^>M\-_&AZK\RZ?QH^NZ***P, K\]_P#@F1_R,/[4/_9?O%?_ *%;5^A%
M?GO_ ,$R/^1A_:A_[+]XK_\ 0K:NVA_N]7_MW\SHI?PY_(^I****XC,****
M"BBB@ HHHH **** "BBB@ HHHH **** /#/^"G__ "C2_:'_ .R9>)/_ $U7
M->YUY3^W?\-=:^,W[#WQE\'^&K+^TO$7BOP-K>C:5:>='#]JN[BPGAACWR,J
M+ND=1N=@HSDD#FL+_AX=X!_Z 'QS_P##*^,O_E70!Z5J_@FZO_C/H/B))+<6
M6EZ/J.GRHS'S6DN)K)T*C&-H%L^<D')7 .3CYU\+?L:>/O"7Q&\4>*K>T^'Z
MW^I:C::C#9V]TEC;ZA+;W_VC?-)!IB2H71WYF-Y(K#'FN')'H'_#P[P#_P!
M#XY_^&5\9?\ RKH_X>'> ?\ H ?'/_PROC+_ .5=$?=E&<=XWM\W?\PE:4'3
M>SW-[X;?LSZ?:_"G2-+\4VEO+K5LQN;F?3-0N8@LYR,Q2J8Y H4)V7E%;&X
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MNMDDKZV/*S3-\7F#7UBHK+9+1?=W\V?1=%?.G_"J_P!O;_GM^R'_ -]^(O\
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M^(O_ (FC_A5?[>W_ #V_9#_[[\1?_$T?4O\ IY'[P]E_>7WGT717SI_PJO\
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MI?\ R17T;10!\Y?\.EOV??\ H0/_ "N:E_\ )%'_  Z6_9]_Z$#_ ,KFI?\
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M"!_Y7-2_^2*/^'2W[/O_ $('_E<U+_Y(KZ&_M*W_ .>\/_?8H_M*W_Y[P_\
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M/_?8H_M*W_Y[P_\ ?8H#0^>?^'2W[/O_ $('_E<U+_Y(H_X=+?L^_P#0@?\
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M_ATM^S[_ -"!_P"5S4O_ )(H_P"'2W[/O_0@?^5S4O\ Y(KZ&_M*W_Y[P_\
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M,#FM%5:3IS?++:Z2L_D?+<8XROA<M=7#RY976J(?^(B?XS?]"=\)/_!3??\
MR97ZY_LV>-9?C'^SIX!\7:G9:=!J7BKPYIVL7<=K"5@CFN+6.5UC#%F"!G(
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M7_Y^9OR3_P")H^RO_P _,WY)_P#$U/10!!]E?_GYF_)/_B:/LK_\_,WY)_\
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M=<?*I;^51_;T_NS?]^7_ ,*GHI%D'V]/[LW_ 'Y?_"C[>G]V;_OR_P#A4]%
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MOT^OVIK\1^E%_P EU4_Z]4_R9]3P'_R*E_BD0?;T_NS?]^7_ ,*/MZ?W9O\
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MZ?\ XFD63T5!YEQ_SRA_[^G_ .)H\RX_YY0_]_3_ /$T 3T5!YEQ_P \H?\
MOZ?_ (FCS+C_ )Y0_P#?T_\ Q- $]%0>9<?\\H?^_I_^)H\RX_YY0_\ ?T__
M !- $]%0>9<?\\H?^_I_^)H\RX_YY0_]_3_\30!/14'F7'_/*'_OZ?\ XFCS
M+C_GE#_W]/\ \30!/7XK?\''/_)[WA;_ +$:T_\ 2_4*_:+S+C_GE#_W]/\
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MQ> H5(8N'*VU;5/IY-D]%1Q-*6^=(U&.JN3_ $%25_-Y]L>,?"S_ )3(2_\
M9&6_]/B5]EU\:?"S_E,A+_V1EO\ T^)7V700]PHHHH$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?$_PI_P"4F?[4
MG_<I_P#IJ:O=*\+^%/\ RDS_ &I/^Y3_ /34U>Z4%K8^:?C%\=_ _B'6[V*\
MO/V?]<FDAN-'OK?7/B.MN/LRSAT1X?LDJ[RR!F! ,;K@,V-U>K?LP6^DV_P7
MTS^Q#HC6$TUS.'TCQ'-XBM99'N)'D<7TRK),S.6+%AD,67G&:YK]I?4O'R:]
M;Q^&M5UO0]&L;%=0NIM'T6/4;R](NX4GB7S89D!2W9Y$C6,R2-]W(1E/4_LU
MZMK>M?"2SF\0W>M:AJ*W-W%]MU;3!IEU>Q+<2+%*UL(XC#NC"$*R!@,9SU)2
M_A_UW?YN[^]A4^+Y_P#MO^5E?T1WE%%% PHHHH **** "BBB@ HKA=7_ &FO
MA_H_PT\<^,/^$NT._P##OPS^WKXJN],N1J/]A26$1FO()TM][K/#&,M#M\P9
M VY(!P_V=_VQ_!_[1'V72XI_^$4\?MIB:SJ'P_UZ_L8_%N@6C^68I+[3X+B9
M[;?'-;OM<AE%Q$KA')0 'JU%%% !1110 45\I?&3_@L9\)?@5^UKJGPFU^S\
M<Q?\(M_9L?BSQE'H;-X2\$S:BNZPBU.^+#[-Y^Z$+*4,(,Z[I%V3>5]6T %%
M%% !117F_P"U5^UW\-_V(_A)-XY^*?BJQ\(^&(KJ*R%U<1RSR7%Q*2$AAAB5
MY9I" S%8T8A(Y'("(S  ](HKS?\ 95_:[^&_[;GPDA\<_"SQ58^+O#$MU+9&
MZMXY8)+>XB(#PS0RJDL,@!5@LB*2DD;@%'5CZ10 4444 %%>;_M=_M%0?LG_
M +-_BOQ]+I-]XANM$M532]%LHII+G7M2GE2VL-/B$,4L@DN;N:"!6$;;3,&(
MP#7C7P5_X*!7?PW\:^%O '[3>N?"GX;_ !A^+&IS77@KP7H6HW-]-::8\<7V
M:UU"Z=?)^W>?]HMQ(IC@NI(@MOO8,H /JVBBB@ HHHH **^)_CW_ ,%Q/AO^
MS5_P40_X4CXNTV^TWPQ96NG6>M_$!VE32?#.NZ@DMQ9:;?;X5CBCFM(O.%RL
MS*-S!E5(IY8OMB@ HHHH ***^?O^"EG[9.I?L5_LWQZOX6T:Q\3_ !)\9Z[8
M>#/ >A7LKPVVL:[?R^7;Q2RC"I&BK+,WF21*X@,?FQLZL #Z!HKY$_X)+?\
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MQ+8?#;48GU+1_B;X&(>#4]/LIHX!8^?8374,D$,:RRRP:NLA:YDGN(;KW/\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^)_A3_RDS_:D_P"Y3_\
M34U>Z5X7\*?^4F?[4G_<I_\ IJ:O=*"UL>*_M(?#%O'/Q$T2ZUKP'J/Q*\)V
M=C,J:1;75H([6^9@HN)H+JXAAE_=,ZHV6:,[B -VX=A^SAX9U?P?\)K*PUF&
M^M)HKBZ:UM+V^^W75C:-<2-;02S[W\QXX3&A(=P-N-S8W'YW^,?A_P ,?$SX
MKZ]I]U\++;PK807TD=_XC_X57=:]K6MR!D+2VSK836J1O\X\Z1IW8?\ +)#A
MJ^BOV<O!GA?X??!K1M'\&Z=J>E>';)9%M;?4;.ZM+E29&+L\=RJS LY9OF4
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M\2/A;^T!X/UV?7['XG:?K+PZ#JWP[EN;*Y@NM5MI^-7NXI@MD;.S@MK.6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#QCX6?\ID)?^R,M_Z?$K[+KX4\/?%+0OA__P %LO#.DZO??9-0
M\<?"Z71-$B\F23[;>)?7%^T654A,6MC=2;G*K^ZVYW,JM]UT$/<****!!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWWKG_P 31_PJO]LC_GM^S-_WWKG_ ,30%SVBBO%_^%5_MD?\]OV9O^^]<_\
MB:/^%5_MD?\ /;]F;_OO7/\ XF@+GM%%>+_\*K_;(_Y[?LS?]]ZY_P#$T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>tm2135630d1_drs3-17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drs3-17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z ?8# 2(  A$! Q$!_\0
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MFBDE>3>H4*!EF)X  X/:OGS_ (:.\7_] W0_^_$O_P =H_X:.\7_ /0-T/\
M[\2__':!'T%)X0T=Y;:1$O('MH$MHS;:A<0_NT^ZK;'&X#)^]FIK+PSI=AJ
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M#P%J,5G+92ZL\%HUK]C:%+BXN4E3*Y?;*Y6(E0RA%!"[OO,.!WJJ%4*H  &
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M/-0QQ-=1I(UJF6(6$E<H 6)'<<>@H N6]_K&HZS<FS-C'IMG<BVDCFB8RS$
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M:[_V[_\ HB.OKN."&*25XXD1Y6WR,J@%VP!D^IP /H!7R+\;!_Q=[7?^W?\
M]$1T >?T444 %%%% #AS01@TVER*1=PHHXI0* $IX^M*L9W<T$\\4BU%K<:P
MZBF5-E<\CK37C/WEY'?VIIA*%]41T444S$**** "N@\=_P#)0O$O_85NO_1K
M5S]=!X[_ .2A>)?^PK=?^C6H Y^BBB@ HHHH **** "BBGPPR3RK'&NYV. /
M4T; W894\<+L,JI/L!6I::'-#</]N1H1$,LKCGV%:@N(5N3+"HAR!\JGC\JY
MYXA+2.IS3Q"6D-3'_LZ::P9(X&:>(@LJ@E@.>M9%>@Z?JMI!((O+5&.?F/(P
M3DAO45B>)?"TNF$WUEOGT]\$OP3$Q[-CMZ'W]:QI8K]YR5-+[>9C1Q7[SV=3
M2^WG_70YFB@@@X(P:*[CO"BBB@#H/ G_ "4+PU_V%;7_ -&K7/5T/@3_ )*%
MX:_["MK_ .C5KG\4 )1110 4Y&V,#3:*J,G%J2W0%_*3  G&:6%0C$D@ <53
M5\<-TJ198\$,"1]:^@P^9TW456:7,O7>W73\C-PTLBZKJ<8Y'8TKH&&*K&XC
M*[<$"I[*.2ZF6"V5Y9&^ZH')^E>]'-L+)<E2<7%K5WM;RL^G],Q=.2U(VPL1
M*BHXX))" B,Y)P !FMNRTUHW>:\0*L3C]TXY9O0^U78Y((9W9!M5V),8/R\]
MAZ5\CF=:6+GS8:-X15K[)N_3\"U6]GHM3G[BRDDL%FBB+"+(D*\XX')K+KTC
M3[JQE0V#H%#H(G([KC'Y]\_TKE?$?ABZT*YW*&FL9&Q#<8X/^R?1A_\ JKQ5
M.I2J^QKQ<9;J_5$4<1>3A+1]#!HHHKH.H**** "BBB@#[_HHHH **** "BBB
M@ HHHH *^0/C9_R5[7?^W?\ ]$1U]?U\@?&W_DKVN_\ ;O\ ^B(Z ."&#2[%
MIG0T\^U)FD;!M QSFC9G@ DGI1F@DGO2'H-(QP>HI*<<8[YIM49R04 \T44!
M<L;MT ]0:CIT; QLN.3TIAJ3HD[I,6I$;'7\O6HJ7I03&5G<=+$ -PX'<>E0
MU85MZE3U/0U7Q@D&B(JJ6ZZA1115&05T'CO_ )*%XE_["MU_Z-:N?KH/'?\
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MVMCWIB.R-N4X/M244K"LA6.YBQQR<\4E%%,9TOP^M9KCX@>'FC0D1ZG;.Q]
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M/C;_ ,E>UW_MW_\ 1$=?7]8]]X3\-ZG>27E_X?TJ[NI,;YI[..1VP !EB,G
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MM<NA1]E'EN?$%%?;_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
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2 .)HK54\-973^3(5!I63/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>tm2135630d1_drsimg0001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg0001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> <(# 2(  A$! Q$!_\0
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M"\#HBH 3N(''7C\:+6=@W/4O^&E;#_H6[G_P*7_XFC_AI2Q_Z%NX_P# I?\
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M316M_P (OX@_Z 6I_P#@))_A1_PB_B#_ * 6I_\ @))_A0!DT5K?\(OX@_Z
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M8T^Z67<($<$!PO(8<_A64GB.7PDGBSPY*@NYKB5X8[D-Q&P)5V'^\O%6M/\
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MT..?QKG?^$S^*'V,V_V._P!Q39Y_]FGSL?[^W.:YU8/& T.XT?\ LC4C9SW
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M.WP*QE6Y310N;?\ PLOXE_\ 0H:7_P"!2_\ QRC_ (67\2Q_S*&E_P#@4O\
M\<K+6 '_ /508/:N&>8\KM8U5'S-/_A9GQ*_Z%'2O_ M?_CE!^)OQ) R?"6D
M@>]VO_QRL9H>::8,]J%F/]T/8>9IM\6_'RDAO#FA@CL;]/\ X[2?\+=\>_\
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M]O\ K^O?_2J6M85%,B4;&_1116A)\W?'Z+/Q&L)/32D'_D66O,.U>J?'T?\
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MW.:&PLVYUVAAG Z9J1S$L.5/[P8P,?G2.C"-96.Y5/0GUK!^Z6F$(+3GRW*
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M&_()(]ZU$8R0LJK\_:IG'ET1JXK=EV-(=T@>1F&/E*]S2+%'Y<BNC>:3D5!
MLZQ^<N"4QD]@:M.UQ$J79==TA/3M6<HVZD,BFA$T:KL^9<[L^E."!0&V_*%
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M%1/!C.:T;0 KS5@VH<YQQ7S^-H^U]Y'UF&Q2MJ9*6N%W-TH56,V[!('%:KP
M]N!VIAC5!G;QZ5RT4HOEDOE_FSL5>Y4*RC3GB8A8GD].U9\VR+4 =^Y "J_E
MUK3GBDDMG#,0@/Z53N;:(3QB(;B4Q]*];"*'*[_Y(5/1W]2L?,@TN0F+B9]X
M/KBIRDAN[.&9AY2'G!]1FHY1<2:=%"QVKN&WV6KBV5J][$DLI=A&PR>/8&NJ
M,H1=Y/[D5*7*KOS_ ,BFBV[7%Q).Y9]@4,/X3_\ JJ+[0T6FL@M&V2MO5F[]
MJL/<H;2Z$<!PSDID<-@8J417;0PV,I6,;@!(O/!Y_K71&S>J_'\5_D2G9J_?
M\D4'%UA+>2*-<G:K'D#/-1R6EPUPB7$H53E5D]0*T+FRD:=;:\N<X4E,''/8
MFJCV4&YX)YV8K@*P8X![TI0BH\VG=V7XFU.HM+,HM;O(SM)=*K 95NYJ'[,Y
MC=S<@2@?* >IJW)!:;?*&XL3\LG/W:9LMSM1XF5E.YGP<E:Y)1:=_P!%L=<9
MZ;E7R)D@#K/\_38.IJ=8C&R'S58,<,F.E6#%9R3(5#1A1\Y.>:00VZ7!=,K"
MXP<GO6<GRQ_X'X JEV.DMS')''YJR(_\([5)]D,EP+5W1FQ\K \"IK2SB=Y
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MTVD.$DBE.2#@>M=5X2_Y DO_ &$+[_TJEKF)2'E) XKI_"?_ "!9?^PA??\
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M'X?U%:FGZI:ZF@\MML@'S1-U'^(K2=R!P*YR_P!(-U<^;;)]GG!R&4X!/O\
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M4NK[6.VM1IUZ,L5@7I'647O'T>S7XCQ-;][ZP_\  R+_ .*I?/MO^?\ L/\
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M_"">$/\ H5-#_P#!=#_\31_P@GA#_H5-#_\ !=#_ /$T#=-'ES)#MXO+ _\
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?:6T>=D,$8C1<DDX4<#))/XU<8*+;$W<L44450C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>tm2135630d1_drsimg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #F 7(# 2(  A$! Q$!_\0
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M6MM=L\%WX;\,W.@6L=OL0+&T$]_>NT@<2$R"500RC8"I9NPH **** "BBB@
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M'1W_ "@H^.?_ ' /_4@TROO^O@#_ (.CO^4%'QS_ .X!_P"I!IE '\@5%%%
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M@1\<= _:/^%6D>,O#$EY/H>N0+<6LMQ:O 9%(!RNX8=>>)(RT;8RKL.:Z^@
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MEH7P.^%GB7QKXIOO[+\,^#]*NM;U>\\F2?[)9VT+S3R^7&K2/MC1FVHK,<8
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M_7VI0 5XM_P;G_\ (C_M=?\ 9SGC+_T7I]>TUXM_P;G_ /(C_M=?]G.>,O\
MT7I] 'Z*U_+GXA_Y/0_:M_[+KXN_]+C7]1E?RY^(?^3T/VK?^RZ^+O\ TN-
M&A1110!]N_\ !JS_ ,G9_MF_]R1_Z1ZG7[/U^,'_  :L_P#)V?[9O_<D?^D>
MIU^S] 'XA?$O_E.Q^VO]/ O_ *CZUZ#7GWQ+_P"4['[:_P!/ O\ ZCZUZ#6T
M=@"LW_@F%_RL.ZM_V;K-_P"I+;5I5F_\$PO^5AW5O^S=9O\ U);:E/8#]CJ_
M!+_@X5_Y3D^&/^R%6O\ Z?[^OWMK\$O^#A7_ )3D^&/^R%6O_I_OZR ^<***
M* .__P""9W_*=7]E#Z^+O_4?N:_H]K^<+_@F=_RG5_90^OB[_P!1^YK^CV@
MHHHH **** ([NW%W:R1$LHE0H64X(R,<>]?D%+_P1?\ VFQ^S5_PRBEW\"F^
M /\ PF0\0'QPS7H\7_8O[1^VG_1_*,']H9RGF[MI7C(K]6/C1\2;GX1?#?4/
M$5MX7\2>,6TP)))I6@0QSZC/&74.T,4CH)"BDN45M[!2$5F*J?@#]IO_ (*:
M?%OXP?&'1E_9A;4_%/AVQM8HKW3[#P NK7,>MFX=9=,U\75_9W.A(L2Q'<]N
M6_>2MD^6(V /TDM+<6EK'$"S") @9CDG QS[U)3+=G:W0R +(5!< Y /?%/H
M **** /@#_@Z._Y04?'/_N ?^I!IE??]? '_  ='?\H*/CG_ -P#_P!2#3*^
M_P"@#\S_ /@Y]T"Q\5_L_?LRZ7JEE::EIFI?M$^%K6[M+J%9H+J%[;4E>.1&
M!5T9205((()!KYY^*/\ P3!^$?Q ^P_V3X4\)^!_LGF>;_8G@CPW+]MW;<>9
M]MTZYQLVG'E[/OMNW?+M^D?^#E[_ )(Y^RQ_V<CX2_\ 1&HU4H ^0=-_X(P?
M#72KR_GCU:[9]2G%S,)O!7@V9$811Q8C5]$*Q)MC4[(PJEB[D;W=F\Q_X*L?
ML1?#3X!?\$M/'EYI/@_PG-XFTG^S_*\1_P#",:38:J?,U>U!^>RM;>-/W<AC
M_=HN4X;<2Q/Z&5\F?\%R_P#E%I\4/^X3_P"G>RH _>.O@#_@Z._Y04?'/_N
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M[^L@/G"BBB@#O_\ @F=_RG5_90^OB[_U'[FOZ/:_G"_X)G?\IU?V4/KXN_\
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M O\ ZCZUZ#6T=@"LW_@F%_RL.ZM_V;K-_P"I+;5I5F_\$PO^5AW5O^S=9O\
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M^&<TOAN]>RU:TN99X+F*5Y)+>1+:0Q.(OG#QDA021]*_\/\ 3_JRO]O_ /\
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M;W?B73[ZWU_[=//-:1Y$=M''\CNSAEDX* ?-0!_+C_PZ=_:F_P"C:?C_ /\
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M_M#[5<:1\*[F6SD^T:C=72;&EDC<X29 <H/F#8R,$^R>/_\ @M[9?"C^Q?\
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MAIIRW?9XS@VX-N]N:_?FDJ:N^]Y0<Y]^:R/9/^";G[:/C']JK7_$%KXY\1>
M-)\4Z-"6UCX:0^&-0T3Q5X&F9D>)+MKN\D^W0-#(NV[AMH(96PT98,57ZUKX
M0^"?Q0^&GPM^-O\ PL3Q#XC_ &P?BCXMM="?PWIM]XI^ WB&,Z38231SS11#
M3O#5H',DD,)9YO-;]TNTKEMWM_\ P\L^'7_0N?'_ /\ #$^-_P#Y4TW;DBEO
M;7[WWUVMNVUM>5KNM>>3Z7T^Y?K?HK[V5['T!17S_P#\/+/AU_T+GQ__ /#$
M^-__ )4T?\/+/AU_T+GQ_P#_  Q/C?\ ^5-2,^@**^?_ /AY9\.O^A<^/_\
MX8GQO_\ *FC_ (>6?#K_ *%SX_\ _AB?&_\ \J: %_X*P?\ *+/]I7_LE7BC
M_P!-%U7OPZ5\0_\ !0C]MKPQ\<?V!OCAX*\+^#OC_JGB;QAX U[1-(L_^%'^
M,X/M=Y<Z=<0P1>9)I:QIND=1N=E49R2!DU]O#I0 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>tm2135630d1_drsimg11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $5 O0# 2(  A$! Q$!_\0
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M%6!P0?QJ.@#T#_A=OQ#_ .AA_P#)*W_^-T?\+M^(?_0P_P#DE;__ !NO/Z*
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M7O!_B'PPD+ZUI-Q9I-_JWD *L?3(R,^W6B^EP\CI?^%V_$/_ *&'_P DK?\
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MI]\K/"3^XN=A59P "2OTSBBXS;_X7;\0_P#H8?\ R2M__C='_"[?B'_T,/\
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M)Z9(KYWHJ;:6]?RM^'ZLJ^M_ZWO^.GW'IEEX@'A_X-:A%9:O$-9U75MLODW
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M^OG?^NX4444Q!12[6VEL':#@G'&:2@ K?\"_\E!\-?\ 85M?_1JU@5O^!?\
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MOM).YO[O8#K]*SO$?Q2M-9T+7=,M="N+<ZQ+'/+//J33E&5@V I4 +V &/Y
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M[\E_Y,[_ (#=]EY_^D_YF(?AY8Z9XVUC0=3EUF]-CL:&+1K#SYIT89#'G"
MKG/KQ6O8_#W1M!^,6CZ+J4UQ=:?>1)<V\<]N S%LXCE7/'0Y_#BL^W^+CS7W
MB675M)>XAUQHV9;6\:WDA$8PBAPIR,8!X'?UQ6?JOQ+?4/&VA>)+?25MCI,,
M4*VQN#()%0G^(C(R#CG)[\TH:.-_G]S_ %L*6O-;Y?A_P3<3X<:-K7B;Q+<:
M=-JLNC:2Y$L%E9![AIFD8>5$F<%0!]X]NW>JEW\)7'CS1=#M;NXBLM6M_M:R
M7D'ES6Z $NLB9^^,8[#)IL/Q1TVVU/61!X9>/2-:56O+5=0?S/.#%C(DF/EY
M;[N.PZ<UF6WCZVT?QMIWB#0](EMX[.,QO;W5\]PTX.X,2[#Y<AN@& 1GFE'3
ME3_K1_K;Y?,<OM-?UM^E_G\CKM0L?#UC\$_$<?AS4[J^MO[4A#FYA",C @<$
M<,#U!]^:\9KT#6_B%I-WX2U#PYHOA5-*M;RX2Y:3[:TK;P<G.5Y&, #(QCOF
MO/Z2O=M^7Y#=K67G^85O^!?^2@^&O^PK:_\ HU:P*W_ O_)0?#7_ &%;7_T:
MM4(^X**** "O@"OO^O@"@ K5T3PSK?B-IET;3;B], !D$*YVYSC/Y&LJMWP?
MJ%[8^*=,2TO+BW6:\@6412L@<;QPV#R.3UJHJ[2%)V5QNL^#_$7AZU2YU?1[
MNR@=_+629, M@G'Y UB5[CX@M]1UKXS^)+9K>SU"QT^+[0(]7NY$L[3$:?O&
M53R.2,#^]GM5B7PCX<O_ !CX!N/[/TMH=8CN!>1:=Y@M93&IPR!L$#\!T[]:
MF-Y)/O\ \'_)CE9-KM_P/\SP:BO7]"MO#?B3QGK @\-Z;86NBZ;-]GCNIV%L
M\J285[A\CKGG)J^N@^$_$_Q&\,Z#!::.H%LUSJO]DR,8I)@I8Q*^X@KP.G(R
M1GT%K:W7\M=?P_():7\O^!_F>(U+<6MQ:.J7,$L+.@=1(A4E3T(SV/K7J'C
M^$DT"*\CC\.?VW::@H6TT@3B*:V'590X'S9'+"I?CEJ5M/JFCVD>EVT,W]FV
M\_VE"V_80P$?)QM'7UI7T^?Z7';6S_K6QY+17K^B6V@:+\/O">LW'A6UU6]U
M"_EM)7G+$;?,(^Z."V!A<].>#6L_A/PKX=\1?$*2XT6/4;/1XK:YM;:21E"%
MQN*;@<XR0.<\"F]&[]+_ (6?ZH2UV_J[:_0\*J6WM;B\E\JV@EGDP6V1(6.
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M^N_^1X_<^'M5M- L]<GM"FFWKM';S[U(=E)!& <CH>H[5F5ZI8^%M-U?P1X
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M;Q9SL8'!&>>AXJ"I3NKE-6=CH/#O_($\6?\ 8*3_ -++:N?KH/#O_($\6?\
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MN7:&,K,N ,,FW;C"CM4LWQ'\67&I:;J$NJ[KK32YLW^SQ 1;QA@%"X(QQ@C
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M +91_P *$_ZF7_R1_P#ME%];ATL<#:_$'Q-9:]>ZS;ZCLN[X!;D>2ABE4
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M^%"?]3+_ .2/_P!LH \:HKV7_A0G_4R_^2/_ -LH_P"%"?\ 4R_^2/\ ]LH
M\:HKV7_A0G_4R_\ DC_]LH_X4)_U,O\ Y(__ &R@#QJBO9?^%"?]3+_Y(_\
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M"N-%^V,=/N;@74T3(I+RXQN+$;OUKU'_ (4)_P!3+_Y(_P#VRC_A0G_4R_\
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M>U:__"V_''V.*U_MU_*CC\KF"(LRX*X8E<MP3USZ]>:[#_A0G_4R_P#DC_\
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M]RF,8QMPW7^+-8UW=SW][/>7+[YYY&ED? &YF.2<#@<FO7_^%"?]3+_Y(_\
MVRC_ (4)_P!3+_Y(_P#VR@#QJBO9?^%"?]3+_P"2/_VRC_A0G_4R_P#DC_\
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M7_2-R_O.NZW5>>S&C_A0G_4R_P#DC_\ ;* /&J*]E_X4)_U,O_DC_P#;*/\
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MX22'_GRN_P#R'_\ %4>WI?SK[U_F'U>M_(_N?^1M45B_\))#_P ^5W_Y#_\
MBJ/^$DA_Y\KO_P A_P#Q5'MZ7\Z^]?YA]7K?R/[G_D;5%8O_  DD/_/E=_\
MD/\ ^*H_X22'_GRN_P#R'_\ %4>WI?SK[U_F'U>M_(_N?^1M45B_\))#_P ^
M5W_Y#_\ BJ/^$DA_Y\KO_P A_P#Q5'MZ7\Z^]?YA]7K?R/[G_D;5%8O_  DD
M/_/E=_\ D/\ ^*H_X22'_GRN_P#R'_\ %4>WI?SK[U_F'U>M_(_N?^0NB?\
M(6\1_P#813_TEMZV:Y;3M56TOM6GDM+@K>72S1A=F0HABCY^;KF,_ABK_P#P
MDD/_ #Y7?_D/_P"*H]O2_G7WK_,/J];^1_<_\C:HK%_X22'_ )\KO_R'_P#%
M4?\ "20_\^5W_P"0_P#XJCV]+^=?>O\ ,/J];^1_<_\ (VJ*Q?\ A)(?^?*[
M_P#(?_Q5'_"20_\ /E=_^0__ (JCV]+^=?>O\P^KUOY']S_R-JBL7_A)(?\
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M_P"$=N?^?^+_ ,!S_P#%UX/]EXCR^_\ X!]#_:V'\_N_X)E45J_\([<_\_\
M%_X#G_XNC_A';G_G_B_\!S_\71_9>(\OO_X ?VMA_/[O^"95%:O_  CMS_S_
M ,7_ (#G_P"+H_X1VY_Y_P"+_P !S_\ %T?V7B/+[_\ @!_:V'\_N_X)E45J
M_P#".W/_ #_Q?^ Y_P#BZ/\ A';G_G_B_P# <_\ Q=']EXCR^_\ X ?VMA_/
M[O\ @F516K_PCMS_ ,_\7_@.?_BZ/^$=N?\ G_B_\!S_ /%T?V7B/+[_ /@!
M_:V'\_N_X)E45J_\([<_\_\ %_X#G_XNC_A';G_G_B_\!S_\71_9>(\OO_X
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M^?W?\$RJ*U?^$=N?^?\ B_\  <__ !='_".W/_/_ !?^ Y_^+H_LO$>7W_\
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M_:V'\_N_X)E45J_\([<_\_\ %_X#G_XNC_A';G_G_B_\!S_\71_9>(\OO_X
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MJ,6HO=W=Q>).\[32E,R,T8C^8*H& H&, ?C1=>+]+LM06UN!>(AD\HW1LY!
MLFX*$,FW&23U''!R16]0NX/LSG;GPA:W#7B+J&H06=[)YES9Q2((I2?O<E2Z
MAN^UAG)K1M]$M;:]O;F(NK7<4<3H"-JJ@(&T8XX/O6C12MI8.MRII>G0Z1I5
MKIUNSM#;1+$C2$%B ,<X YJCXN_Y$O7?^P=<?^BVK9K&\7?\B7KO_8.N/_1;
M4V[ZL-CTVBBB@#G_ !W_ ,D\\2_]@JZ_]%-61+((HGD*LP12V%&2<>@[FM?Q
MW_R3SQ+_ -@JZ_\ 135ET,#SAM \1W7A*ZO4FMH;RXG.JK;/9/YZR@AD3?YF
M <*J_<]JW[>.6^\::?JCV,T<9T@_-+$1Y3LZG821PV,\=>M=111_7X6!Z_UY
MW//[/2)X?!=E NG2),NMK.T8@(8*+O.\C&<;,<_W?:E\36DT7B?^SK>-C;^)
M42*<J?N&(_O&_&(X^H%=_59["UDU&+4'BS=0QM%&Y8_*K$%N,XYVCG&>*.W]
M=$OT0/K_ %UO^K.*US2+VXG\3I;6,LD3I8E(PF!.D9)=%)X/RC&/?'>IM4:7
MQ!JT%U8:??1Q6>GW0EDN+62 L9$ 6)5< L<C/ (&!SS7<44FKJW];-?J-.SO
M_73_ ".(2&YTY/!]]<65W);VEDT,Z10/(\,C1H Q106_A93@<9J]X/CE^U:_
M=/I\]E%=7_G1)-%Y993&GS8]SDGOG.<'-=315-W;?K^+N2EHEZ?@<9+<#2O&
M&O7=SI%_/%<6T*12P633"0JK9C^4$\Y'7Y>.2*QM-TC4]#FTJ2]FU2TC&EK!
MOTZT6Y,3B1F,;+Y<A PRC(&#MY/2O3**E*W]>O\ F/\ K\O\CA9+%--L/#<]
MI%J=Q9VNHRS2F6T8SJ'67YC&B @;FZ;1@$<57\67.K:C#KED%U:.%K8+96]G
MI^];H,F6,CLC;>3C;E",=R17H5%#5U;^NG^0T[._]?UJ0609;"V#@AQ$H8-U
MS@=:GHHJF[NY*5E8****0PK&\7_\B5KW_8.N/_1;5LUC>+_^1*U[_L'7'_HM
MJ -FBBB@ HHHH **** "BBB@ HHHH *QO%__ ")6O?\ 8.N/_1;5LUC>+_\
MD2M>_P"P=<?^BVH V:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M&T3_ )"WB/\ ["*?^DMO6S6-HG_(6\1_]A%/_26WK9H **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,;6_P#D+>'/^PB__I+<5LUC:W_R%O#G_81?_P!)
M;BMF@ HHHH **** "BBB@ JM%8P0WD]VJDS38W,3G   P/0<#Z_@*LT4 %%%
M% &-K?\ R%?#G_81?_TEN*V:QM;_ .0KX<_["+_^DMQ6S0 4444 %<K+)';?
M$Z)KE@@N=+\JU+\!G60EU7WQM./0>U=55:^TZQU. 07]G;W<(;<(YXED4'UP
M1UY-'6X=+'/"=;GXCRO9A9OL>F&*Z*,.':0,B$^N QQVS7.AM2M=>T&XO]#O
MQJ%S?S33MYD!#DPN B?O3\J+CKC@$]3BNSB\*:+:7T-[86,=A/%WLAY(D7^Z
MZK@./J#CM6I);P32Q2RPQO)"2T3LH)0D8)!['!(XH6EOZ[@];_UTL5]4U2VT
M>P>[NBVT$*J(NYY'/"HH'5B> *Y2XTB_B\&^)]0NHUCU35())I(8SGRE$>U8
M\_Q$*.3W).*Z^^TZQU. 07]G;W<(;<(YXED4'UP1UY-1V&C:7I1<Z=IMG9F3
M <V\"Q[L=,[0,TFKIC3LT<UJ<]M='P:EFZ.SW231!3G]TL+;C],$#\14[$^*
M_$%I+ H_L?29S)YY'_'S< %<)_LIDY;N>!T-;MGHNE:=/)-8Z99VLL@P[P0*
MC,.O) YJO'X6\/13+-'H.EI*C!E=;.,,".00<=:J^M_F3;2WR,K6B?%&H#0;
M50UE;3))J5R1\JE2&6%?5SP3_='N175UDS>%_#US.\\^A:9+-(Q9Y'M(V9B>
MI)(Y-:H 50J@ #@ =J2V&]Q:*** "L;Q=_R)>N_]@ZX_]%M6S6-XN_Y$O7?^
MP=<?^BVH ]-HHHH Y_QW_P D\\2_]@JZ_P#135SGD^*_^@5HO_@UE_\ D>NC
M\=_\D\\2_P#8*NO_ $4U6* .4\GQ7_T"M%_\&LO_ ,CT>3XK_P"@5HO_ (-9
M?_D>K47C?0998T6YN566<VR3/8SI"TNXKM$I0)G<".O6KI\1Z4/$0T W>-4,
M7FB QMRO/.[&WL>,YXH#8R/)\5_] K1?_!K+_P#(]'D^*_\ H%:+_P"#67_Y
M'K7U+Q%I6D7]C8WUV(KF_?R[:/8S%SD#L#@9(&3@<T'Q%I0\1#0#=@:F8O.$
M!1AE?9L;2?;.: ,CR?%?_0*T7_P:R_\ R/1Y/BO_ *!6B_\ @UE_^1ZZ"UU.
MSO)[R&";=)9R>5<#:1L;:&QDCGA@>/6J^B^(-+\16TMQI5U]HBBE,3MY;)AL
M \;@,C# Y'!S0!C^3XK_ .@5HO\ X-9?_D>CR?%?_0*T7_P:R_\ R/6I:>)]
M'OI]2AMKSS'TSF[ C?$?WNAQAON,/ESR*@TSQ?IFJ:LVF(E];7>UGB2]LY(/
M/08RZ;U&0"V,<'@\8YH!Z%+R?%?_ $"M%_\ !K+_ /(]'D^*_P#H%:+_ .#6
M7_Y'KJZS-#U<ZU:3W:V_E0+<RPP-OW>:B,5W]!@$@X'/&#WH Q_)\5_] K1?
M_!K+_P#(]'D^*_\ H%:+_P"#67_Y'K9U#Q!I>E:C8V%[="*ZOF*VZ;&.\@@<
MD A>6 YQR:>=7MUU]-&*2_:&M3=!L#9M#!<9SG.3Z4 8?D^*_P#H%:+_ .#6
M7_Y'H\GQ7_T"M%_\&LO_ ,CUU=4-,U>WU5[Y($E4V5TUK)O &64 DC!/'S#T
MH P_)\5_] K1?_!K+_\ (]'D^*_^@5HO_@UE_P#D>NKHH Y3R?%?_0*T7_P:
MR_\ R/61XLA\3#P=KAGTW24A&GS^8T>I2,P7RVR0#  3CMD?45Z%6%XU_P"1
M#\1?]@RY_P#134 4?)\5_P#0*T7_ ,&LO_R/1Y/BO_H%:+_X-9?_ )'KJZ*
M.4\GQ7_T"M%_\&LO_P CT>3XK_Z!6B_^#67_ .1ZZNB@#E/)\5_] K1?_!K+
M_P#(]'D^*_\ H%:+_P"#67_Y'KJZ* .4\GQ7_P! K1?_  :R_P#R/1Y/BO\
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M7G_/_??^!<G_ ,51_:F'\_N_X(?V3B.Z^_\ X!Z;17F7VJ\_Y_[[_P "Y/\
MXJC[5>?\_P#??^!<G_Q5']J8?S^[_@A_9.([K[_^ >FT5YE]JO/^?^^_\"Y/
M_BJ/M5Y_S_WW_@7)_P#%4?VIA_/[O^"']DXCNOO_ . >FT5YE]JO/^?^^_\
M N3_ .*H^U7G_/\ WW_@7)_\51_:F'\_N_X(?V3B.Z^__@'8:#_R&?%'_833
M_P!([:MVO+XWFB>5X[N[1YFWR,MS("[8"Y//)PJC/H .U/\ M5Y_S_WW_@7)
M_P#%4?VIA_/[O^"']DXCNOO_ . >FT5YE]JO/^?^^_\  N3_ .*H^U7G_/\
MWW_@7)_\51_:F'\_N_X(?V3B.Z^__@'IM%>9?:KS_G_OO_ N3_XJC[5>?\_]
M]_X%R?\ Q5']J8?S^[_@A_9.([K[_P#@'IM%>9?:KS_G_OO_  +D_P#BJ/M5
MY_S_ -]_X%R?_%4?VIA_/[O^"']DXCNOO_X!Z;17F7VJ\_Y_[[_P+D_^*H^U
M7G_/_??^!<G_ ,51_:F'\_N_X(?V3B.Z^_\ X!Z;17F7VJ\_Y_[[_P "Y/\
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MFB?E6R3Z#T%4]!U'7]%TKPI->W>GSZ;J"V]F+6*W9'AW(Q1@Y8[R< ,-H''
M')/4Z?X7MK"#58S>WMR^J$M<S3NI<DH$R,* .!TQ@=ACBJVG>"[73YM.9M2U
M.[M]-!^QVUS*C1Q,5V[LA0S$ D#<Q SP!Q@6]_3];B>WW_I8YSPM=K!:>$X#
M:6LIGN[\":6/=)#@R',9_A)Z'U%6-1\2>)1:>(=4M9M,BL]$N9$^SO;N[W*H
MH)#/O 3AAC /(].*Z*R\)6%C_9?E37)_LV6:6'<R_,9=V[=QR/F.,8_&G2^%
M;&72]:T]I;@1:O))).0R[E+J%.WCC@=\TE=)?U_+_DQ]?Z_O?YHY3Q!XWU*U
MU'4XK'4])M)K)(FMM/N83)-?M(@("XD4]3@!03D<\&O0K;SA:Q?:61Y]@\QH
MT**6QS@$D@>V3]:\\U#P_K$.I:U+;66NF>:6-[&?3-2CAA&R-%7S$>0 DE<-
MF-A@#%>@6"74>G6R7TB27:Q*)W08#/@;B/;.:I6L+6_]>18K#\:?\B)XA_[!
MES_Z*:MRL/QI_P B)XA_[!ES_P"BFI#.THHHH Y_QW_R3SQ+_P!@JZ_]%-5B
MJ_CO_DGGB7_L%77_ **:IG.U&.TM@$X'4TGH@,BW\6>'KJ:\B@UNP=[(;KC$
MZXC'&23G&!D GH#P>:TI[ZTMG1)[J")I%9D$D@4L%&6(SU ')]*X;P_;22SO
MX?@CU.?PS/8R*\6IV#P/:$G C61E7S 0S#'S$;1\U4/#<%_JMGJK7T,CW&B:
M?+HT)^\99 #O=<==RB(>O6B3LF_*_P!U_P!;?>-*[MYV_KY7.ZLO$VA:CJ+:
M?8ZQ8W-VJ[S##.KMCGT/.,<^G&>HJV-3L#:)="^MOLSN(UF\U=C,6VA0<X)W
M<8]>*XR#2KB"Q^'RQV$L;6CKYX6$CR0;9PV[CY<L0#GO6.!?IX3L?#PT;5&O
M;?5TDF86CB)(Q=A]XD(VL""/NDGJ2  35M>]R^=OQ2_+4E/2_E^C?YH]!U+Q
M+H>CW,=MJ6L6-G/)RL<]PJ,1SS@G@<'D\9XJM:ZZS^(=<L[IK>*RTZ&"43$[
M<!U8L68G&!M]JQTN&T+Q5XBDO=+U"Z74/)DMGM;-YUE41A#&2H*J0P/WRH^;
M.>M9OB/1M3OKCQ>+2UN,31V#1[$'[Y8R6=4W#:QP",<C. >M1?1/^OZ136MC
MK;3Q-I6LV%[+HFJZ?=2VRODF;Y$89 +XY"9!^;H1R,U*FMVEEH]G=:SJ>F6[
MS0JS2K<!87; ),;,1E>>/8BN6BM(K^6^O4O/$=[>KI<\"B_TW[,@5L':,01[
MFR!@ GOZT^WTRY9OA]YUC*19PL9]\)_<-]GP-V1\IW<<]Z?EZ?K_ )$W_7]/
M\S;OO%EDGAK^V]*DAU* LJHL$A+2$D#:@4$F3GA#CG@E>M0^"/$\_BK1!>W-
MHMK*H0/'\P;)4$DHP^53G*X9LJ0<YR OAFSFM]9\4F6WDBAGU$21;T*K(##&
M"R^HR#R.X-=##!%;01P01)%#&H5(XU"JJCH !T%/];#?;L24444@"BBB@ HH
MHH *PO&O_(A^(O\ L&7/_HIJW:PO&O\ R(?B+_L&7/\ Z*:@#=HHHH *KZA$
M\^FW448W.\+JHSC)((%6**35TT-.SN>9W/@_7#H_AZWM(Q"\VFQ:5K(\Q?W<
M("DL.>2,2+QG[]=)::;J&EZ]XAOK6P62*2VMELHC,J"5HT8;,\[>H&2*ZBBJ
M;NV_7\?Z_$E(\\N=,UAM?N->T7PS)I=RMC,DB23P*U_,_P!S<$=E^4Y8NQ!.
M<477@?5-,\.Z5_9NK7U[>Z3-%<06DGV=(W8'$@#"-6^96?JW?G->AT4EIM_6
MMQO7?^N@#ITQ1110 5A>-?\ D0_$7_8,N?\ T4U;M87C7_D0_$7_ &#+G_T4
MU &[7,^-G5--LV=@JB[&23@?ZMZZ:BIG%2BXOJK%0DX24ET:?W'E'VNV_P"?
MB+_OL4?:[;_GXB_[[%>KT5YG]DTOYG^!ZO\ ;%7^5?B>4?:[;_GXB_[[%'VN
MV_Y^(O\ OL5ZO11_9-+^9_@']L5?Y5^)Y1]KMO\ GXB_[[%'VNV_Y^(O^^Q7
MJ]%']DTOYG^ ?VQ5_E7XGE'VNV_Y^(O^^Q1]KMO^?B+_ +[%>KT4?V32_F?X
M!_;%7^5?B>4?:[;_ )^(O^^Q1]KMO^?B+_OL5ZO11_9-+^9_@']L5?Y5^)Y1
M]KMO^?B+_OL4?:[;_GXB_P"^Q7J]%']DTOYG^ ?VQ5_E7XGE'VNV_P"?B+_O
ML4?:[;_GXB_[[%>KT4?V32_F?X!_;%7^5?B>4?:[;_GXB_[[%'VNV_Y^(O\
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M1.O/GG_PQA:]_P AGPO_ -A-_P#TDN:W:PM>_P"0SX7_ .PF_P#Z27-;M;&
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M68O$FDAQ&JD@!&8$@/SG'I7(316NL:EXAEUK4KJV.EV\)M2E])"($:#)EP&
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M_DGGB7_L%77_ **:K%5_'?\ R3SQ+_V"KK_T4U<YYWBO_H*Z+_X*I?\ Y(H
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MO_H*Z+_X*I?_ )(H\[Q7_P!!71?_  52_P#R10!U=%<IYWBO_H*Z+_X*I?\
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MNQG/OFG6^@:-::@^H6VDV$-ZY):YCMD61B>N6 R<]ZQ?.\5_]!71?_!5+_\
M)%'G>*_^@KHO_@JE_P#DB@#I+RRM=0M7M;VVAN;>3&^*:,.C8.1D'@\BJ=AX
M<T/2K@W&G:-IUG,5*F2WM4C;![94 XXK'\[Q7_T%=%_\%4O_ ,D4>=XK_P"@
MKHO_ (*I?_DB@#;L=!T?2YY)]/TJQM)I!AY+>W2-G&<X) !/-5H_"'AF&=)X
MO#ND),C!UD6RC#*P.00=O!K-\[Q7_P!!71?_  52_P#R11YWBO\ Z"NB_P#@
MJE_^2* -@^'-#.H_VB=&TXWV_P S[2;5/-W?WMV,Y]ZTZY3SO%?_ $%=%_\
M!5+_ /)%'G>*_P#H*Z+_ ."J7_Y(H ZNL/QI_P B)XA_[!ES_P"BFJAYWBO_
M *"NB_\ @JE_^2*R/%4WB8^#];$^I:0\)L)_,6/39%8KY;9 )G(!QWP?H: /
M6J*** .?\=_\D\\2_P#8*NO_ $4U9=:GCO\ Y)YXE_[!5U_Z*:LN@ HHHH *
M*** "BD)"J68@ #))[4V&:*X@2>"1)8I%#)(C!E8'H01U% #Z*C2>&666*.6
M-Y(B%D56!*$C(!';@@_C4E !115:SO[:_P#/^RR^8()F@D.T@!UZCD<X]J +
M-%%% !1110 444A(52S$  9)/:@!:QO%_P#R)6O?]@ZX_P#1;5K0S17$"3P2
M)+%(H9)$8,K ]"".HK)\7_\ (E:]_P!@ZX_]%M0!LT444 %%%% !1110 44A
M(52S$  9)/:FPS17$"3P2)+%(H9)$8,K ]"".HH ?1110 5C>+_^1*U[_L'7
M'_HMJV:QO%__ ")6O?\ 8.N/_1;4 ;-%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!C:)_P A;Q'_ -A%/_26WK9K&T3_ )"WB/\ ["*?^DMO6S0
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M /7W?_\ M2H-0TC3Y]"\;:E-9PR7T%U.8;AUR\15%9=AZKR<\8I)Z+^OY?\
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M'DJPX(VE1&$9><_,IYP>U3:3HT.DBY99[BYN+J3S9[BX8%Y&Q@=
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M]B*SJPQ*C>HI6\[V_%FE*>&<K4W&_E:_X(TM+U3['MM[AO\ 1NB.?^67L?\
M9_E].G25S>EZ7]LVW%PO^C=40_\ +7W/^S_/Z=>DKZ'!^U]DO;;_ (V\_/\
MIZGSF-]C[9^QV_"_EY?TM#&UO_D+>'/^PB__ *2W%;-8VM_\A;PY_P!A%_\
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M(_\  V/_ .*H V:*QO\ A+_#/_0Q:1_X&Q__ !5'_"7^&?\ H8M(_P# V/\
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MC_A+_#/_ $,6D?\ @;'_ /%4 ;-%8W_"7^&?^ABTC_P-C_\ BJ/^$O\ #/\
MT,6D?^!L?_Q5 &S16-_PE_AG_H8M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\
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M,6D?^!L?_P 51_PE_AG_ *&+2/\ P-C_ /BJ -FBL;_A+_#/_0Q:1_X&Q_\
MQ5'_  E_AG_H8M(_\#8__BJ -FBL;_A+_#/_ $,6D?\ @;'_ /%4?\)?X9_Z
M&+2/_ V/_P"*H V:*QO^$O\ #/\ T,6D?^!L?_Q5'_"7^&?^ABTC_P #8_\
MXJ@ T3_D+>(_^PBG_I+;ULUQ^D>*?#T6IZ^\FO:6BRWZO&6O(P'7[- N1SR,
M@CZ@^E:__"7^&?\ H8M(_P# V/\ ^*H V:*QO^$O\,_]#%I'_@;'_P#%4?\
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MAJ3B[IFS16-_PE_AG_H8M(_\#8__ (JC_A+_  S_ -#%I'_@;'_\53$&M_\
M(6\.?]A%_P#TEN*V:X_5_%/AZ74] >/7M+=8K]GD*WD9"+]FG7)YX&2!]2/6
MM?\ X2_PS_T,6D?^!L?_ ,50!LT5C?\ "7^&?^ABTC_P-C_^*H_X2_PS_P!#
M%I'_ (&Q_P#Q5 &S16-_PE_AG_H8M(_\#8__ (JC_A+_  S_ -#%I'_@;'_\
M50!LT5C?\)?X9_Z&+2/_  -C_P#BJ/\ A+_#/_0Q:1_X&Q__ !5 &S16-_PE
M_AG_ *&+2/\ P-C_ /BJ/^$O\,_]#%I'_@;'_P#%4 ;-%8W_  E_AG_H8M(_
M\#8__BJ/^$O\,_\ 0Q:1_P"!L?\ \50 :W_R%?#G_81?_P!);BMFN/U?Q3X>
MEU/07CU[2W6*_9Y"MY&0B_9IQD\\#) ^I%:__"7^&?\ H8M(_P# V/\ ^*H
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MX56!QD;AGY<CH3C/&.M9WA.TMO[3U/4HKW7+NXN%B2:75+'[+G;NV[5\F+)
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M0D*0+\P'S$<CCI[XIFJ^)-%T*+?J^K65D=F_;-.JL1ZJIY/0]!6;\0;6XO?
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M\/Z9K-C?S7LX>,R)&'%NBY*><P. =NT9YR:ZZ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JFIZ99ZQITUA?P^=:S !TW
M%<X((Y!!Z@444 6P,# HHHH *J1:99PZI<:FD.+RXC2*24L3E$R5 !.!]X]/
M6BB@ O\ 3+/4UMQ>0^:+>=+B+YBNV1?NG@C.,]#Q5NBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#.U;0[#6U@%['*6MW\R&6&>2&2-B""5>-E89!(//-&D
MZ%I^B"X^PQ2![AP\TLT\DTDA P-SR,S' X )XHHH T:*** "BBB@ HHHH **
M** "BBB@ HHHH **** *FFZ99Z3:FVL8?*B,CRD;BQ+NQ9B222<DFK=%% !1
M110 4444 %%%% %34],M-8TZ:POX?.M9@ Z;BN<$$<@@]0*M@8&!110 4444
M %%%% !4!L[=KU;TQ*;E8S$LAZJI.2!Z9(&?7 ]*** )Z*** "BBB@ HHHH
M**** .=/@;P^SDM;7)A,WGFU-]/]G+[MV?)W^7][G&W&:Z*BB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>tm2135630d1_drsimg12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ O$# 2(  A$! Q$!_\0
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MO^I1_P#*E_\ :J\ HH ]_P#^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &JO **
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MN]N+*VT34I[NV.)X(K1V>(_[2@97\:9!H&LW-Q/!;Z3?RS6[JDT<=L[-&Q.
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M'_RI?_:J/^&FO^I1_P#*E_\ :J\ HH ]_P#^&FO^I1_\J7_VJC_AIK_J4?\
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MH ]__P"&FO\ J4?_ "I?_:J/^&FO^I1_\J7_ -JKP"B@#W__ (::_P"I1_\
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MCP7;>)[[7F@@N)2I6WT]YXX%$@0^8ZGY",YVD<],YI?U^-@_K\_\CS^BO?\
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MO^)_ WAY/#7BB6+PAJ'A^71746M_<74CI??/MX#\<CGY<]1SV,^L>#_ PO\
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MZF/-$9@V!0=A( 8GGKP.>^*@\%>$O#>FP>#M:U>YU=M5U:_#626<:-!&8Y0
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M%%'6X@HHHH **** "N@\9?\ (<MO^P5IO_I%#7/UT'C+_D.6W_8*TW_TBAH
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M*H\;?] 7_P FH?\ XNC_ (51XV_Z O\ Y-0__%U],44 ?,__  JCQM_T!?\
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M_P! 7_R:A_\ BZ^F** /F?\ X51XV_Z O_DU#_\ %T?\*H\;?] 7_P FH?\
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M'72_^P=>?^C+:MF@"EJMU+9:=)/"$,@9%&\$CE@.Q'K6+_;>I>MI_P!^6_\
MBZU/$'_(&D_ZZ1?^C%KG:\S,<55H.*INU[]%W/5RW"TJ\9.HKVMU?8O?VWJ7
MK:?]^6_^+H_MO4O6T_[\M_\ %U1HKSO[2Q/\WX(]/^S,+_+^++W]MZEZVG_?
MEO\ XNC^V]2];3_ORW_Q=4:*/[2Q/\WX(/[,PO\ +^++W]MZEZVG_?EO_BZ/
M[;U+UM/^_+?_ !=4:*/[2Q/\WX(/[,PO\OXLO?VWJ7K:?]^6_P#BZ/[;U+UM
M/^_+?_%U1HH_M+$_S?@@_LS"_P OXLO?VWJ7K:?]^6_^+H_MO4O6T_[\M_\
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M(_\  V/_ .*H_P"$O\,_]#%I'_@;'_\ %4 ;-%8W_"7^&?\ H8M(_P# V/\
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M2/\ P-C_ /BJ/^$O\,_]#%I'_@;'_P#%4 :[QI)MWHK;6W+N&<'U'O3JQO\
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M-_Z!UI_WY7_"C^R--_Z!UI_WY7_"J7_"7^&?^ABTC_P-C_\ BJ/^$O\ #/\
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MA:69)+HQ2K]G1P56VEPF2HRH*C&0.@X%:FA11P^(/$442+'&DL"HB# 4"!,
M#L*WI((9I(GDBC=XFWQLR@E&P1D>AP2/H35*;0-&N-1749])L);Y2"MR]LC2
M@CH0Q&>.U'_!_$'_ )?@<+I=C8:7X>\,:AIUO!:ZO=74,;- H1[I&;]Z'P/G
M 3<W.<$ \5Z2DB29V.K;25.TYP1U%4+'P_HNF73W5AI%A:7#@JTMO;)&[ G)
M!(&3R!4^GZ?!IL#Q0 _O)7FD9OO.[L68G\3^6!1TM_73_('O?^NO^9:HHHH
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MS_Y\+[\H_P#XNN2HH_M:K_*OQ_S#^QZ/\S_#_(ZW_A,[/_GPOORC_P#BZ/\
MA,[/_GPOORC_ /BZY*BC^UJO\J_'_,/['H_S/\/\CK?^$SL_^?"^_*/_ .+H
M_P"$SL_^?"^_*/\ ^+KDJ*/[6J_RK\?\P_L>C_,_P_R.M_X3.S_Y\+[\H_\
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M%%% '+:S_P CYHG_ &#+_P#]&VE:-9VL_P#(^:)_V#+_ /\ 1MI6C0 4444
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M=;@$.P D6/R@<9Q]SC'3\:K0^$M'MKFVN+>*Z@DMHHX(_*OIT7RT)*JRA\,
M2?O YR<UBKXNCU:327M;F!?+U3[/=FTN1/"X^SR/\KC&Y>G4 Y'3BM/3O%)O
M+JQ$]@]O;:DC26$ID#&0!=V'7'R$K\P +< YVGBC;4'L6I/#&DRZFVH/!,9V
MF6<@74HC\Q0 '\O=LW84<XS3V\.:6SW3-!(1=3)/*AN)-AD1@P8+NVJ<J"<
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M .!,O_Q5'_")Z-_S[2_^!,O_ ,56U11RQ[+[E_D'/+N_O?\ F8O_  B>C?\
M/M+_ .!,O_Q5'_")Z-_S[2_^!,O_ ,56U11RQ[+[E_D'/+N_O?\ F8O_  B>
MC?\ /M+_ .!,O_Q5'_")Z-_S[2_^!,O_ ,56U11RQ[+[E_D'/+N_O?\ F8O_
M  B>C?\ /M+_ .!,O_Q5'_")Z-_S[2_^!,O_ ,56U11RQ[+[E_D'/+N_O?\
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M\RUX 5T.<XYS^'I5\[Q7_P!!71?_  52_P#R10!U=%<IYWBO_H*Z+_X*I?\
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MH[."X,92W4C'RE4#'"C;EBQQGUJEYWBO_H*Z+_X*I?\ Y(H\[Q7_ -!71?\
MP52__)%#U @TKP((M M]/U74KNY,=D]J(PZ&.#>NUVC.P,3C(&\G . !6U=>
M&[.\^W>9)./MM@+"3:PXC&_D<?>^<^HZ<5F>=XK_ .@KHO\ X*I?_DBCSO%?
M_05T7_P52_\ R13;N.[O<T8_#WV?46NK/5;^T21T>:VC$+1S,JA<G=&6&54
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M"V[# [<#@8SWH6^O];?\$'Y&IJ.I0Z;%&TB22RROY<,,2Y>5\$[1G Z G)(
M R2!6<?%NEH@:9IH?EDW"1,%9(\;HO=^> ,[AR"12W?AFU$D5UI$5GIU[%/Y
M_F+:@K(Q5E.]5*EN';N#G\C2F\'-=P;;G4F\TSO>&2WB,>+DX"2 ;CP@& I)
MSW)H OS:_%:7<PNF>-$MH9?(\@F0-([*JY#$$D@#:!U[G/$%GXCFN)M2!TZ\
M9K>9(H[98<2[C&&8,2=G!S\V[:>,$Y&5U#PY+?W,ET;Y8[DPVZJP@RJR0R-(
M&(W<J2V-N>G>JESX2O;L3R7.I6D\L]RL\L<UB6MW"Q[ AB\S)'1AEC@C/I@
MOR>*K(0V;V]O>W3WD<DD,4,!+'RR P.<;2"?XL#C&<XREKXE6^UFWL[6PN);
M6>U%RMX&0*%)QRI(8>G3.>W>FZ5X972SIFVY5EL8IX@JP[ PE=6X&?EQMQC^
M5&F^'9M+N;"2&^C9+>U-M,KP',B[MP*D-\ISZAOPHZAT-:^NS9P!UM;BY=FV
MI% H+,>O4D*HX/+$#MG) JA_PDED]O:2VT5S<O=*SQPQ1?.%4@.2#C&TG!'4
MG@ GBEU_1I-:MH(DFMU6.7S'BNK?SX9AM(VNFY<X)##GJ!5"U\+76F0:?_9N
MH6\4]I'+#F6T+QLDCA\!%==I! QSCV] &/E\32^9K,8T^XMX]/M_.%W(%=3\
MFX9CWA_PXZ<E35U=?M/LS.2YD6Y2T*A.3(VW! STPP;KTJM<^'KFX.JJ=0C\
MK4K3R)<V^75PA3>"& Q@YVX_&G_\(VG]OPZE]I/EQQC-OLX:95*"7.>NQBN/
MIZ4NG]>?_ #^OR(-*\337]]96@L)IDN+-;HWB!(T /\ TS+E@.W4G/MS6A;:
M]9W0L_+$F^ZEDB5"HW(R;M^[GC!7'U(]:IZ9X=FTJ;37AOHV2ULQ:3*\!S*H
M.05(;Y#GU#53&BZE;^(-3O[10HEDC%J9-I6/?L,[@9S@A%XX.0>QS5=?Z[@^
MMCJZQO"__()G_P"PC??^E4M;-8WA?_D$S_\ 81OO_2J6D!LT5@/KMRGBM+#R
M8O[-;_1S/SO%SM\P+Z;=GZD5=L]0FN-2U6V9$*VCHL>W@MNC#<\^II7TN!I4
M5S_A;6;G6K=[B>ZLF8<26<43)+:/DYCDW,<D8(SM7ID#!XZ"G:P!1110 444
M4 %%%% !1110 4444 %%%% &-<_\CKI?_8.O/_1EM6S6-<_\CKI?_8.O/_1E
MM6S0!%<W,5G;M/.Q6-< D*3U.!P.>IJC_P )!IO_ #UE_P# >3_XFCQ!_P @
M:3_KI%_Z,6N=KAQF,>&<4HWO?J>A@L$L2I-RM:W0Z+_A(--_YZR_^ \G_P 3
M1_PD&F_\]9?_  'D_P#B:YVBN+^UY?R+[V=W]C1_G?W(Z+_A(--_YZR_^ \G
M_P 31_PD&F_\]9?_  'D_P#B:YVBC^UY?R+[V']C1_G?W(Z+_A(--_YZR_\
M@/)_\31_PD&F_P#/67_P'D_^)KG:*/[7E_(OO8?V-'^=_<CHO^$@TW_GK+_X
M#R?_ !-'_"0:;_SUE_\  >3_ .)KG:*/[7E_(OO8?V-'^=_<CHO^$@TW_GK+
M_P" \G_Q-'_"0:;_ ,]9?_ >3_XFN=HH_M>7\B^]A_8T?YW]R.B_X2#3?^>L
MO_@/)_\ $UF:]JMI>Z=%%;M*[K>6LI'D./E2XC=CR.RJ3^%4**/[7E_(OO8?
MV-'^=_<CHO\ A(--_P">LO\ X#R?_$T?\)!IO_/67_P'D_\ B:YVBC^UY?R+
M[V']C1_G?W(Z+_A(--_YZR_^ \G_ ,31_P )!IO_ #UE_P# >3_XFN=HH_M>
M7\B^]A_8T?YW]R.B_P"$@TW_ )ZR_P#@/)_\31_PD&F_\]9?_ >3_P")KG:*
M/[7E_(OO8?V-'^=_<CHO^$@TW_GK+_X#R?\ Q-'_  D&F_\ /67_ ,!Y/_B:
MYVBC^UY?R+[V']C1_G?W(Z+_ (2#3?\ GK+_ . \G_Q-'_"0:;_SUE_\!Y/_
M (FN=HH_M>7\B^]A_8T?YW]R.B_X2#3?^>LO_@/)_P#$T?\ "0:;_P ]9?\
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MG2HI[" 6QC(MIU;SKE",M(C;@ !R/NMRIR1GCHZ.EPZV"BBB@ HHHH ****
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M )!,_P#V$;[_ -*I: *#>"X# S_;KK^T#<_:Q/Y\OE"7?N!\G?LQT&/2KO\
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MP_\ (ON_X(?7,1_._O\ ^ <__P ([<_\_P#%_P" Y_\ BZ/^$=N?^?\ B_\
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MP_\ (ON_X(?7,1_._O\ ^ <__P ([<_\_P#%_P" Y_\ BZ/^$=N?^?\ B_\
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M\?K=UG_D?-$_[!E__P"C;2C6-771X;=OL=S=R7$X@BAM]FYF()ZNRJ!A3WH
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M0G(_,4 <M]OU?_H4]7_[_6G_ ,?H^WZO_P!"GJ__ '^M/_C]=,E_9R2O$EW
MTB*69%D!*@$J21V ((^H-1#6-,.E_P!IC4;0Z?C/VKSU\K&<9WYQUXZT <]]
MOU?_ *%/5_\ O]:?_'Z/M^K_ /0IZO\ ]_K3_P"/UT4>K:;-IAU*+4+1[ *6
M-TLRF( =3OSC P<\]J=/J=A:P">XO;:&$QF4222JJE./FR3C'S#GW'K0!S?V
M_5_^A3U?_O\ 6G_Q^C[?J_\ T*>K_P#?ZT_^/UT\UY:VSP)/<PQ-._EPAW"F
M1L9VKGJ< \"H;O5+2S,\;31O<PP&X-L)460QC^+#, !D8R2![T!N<]]OU?\
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MZB@#D?M^K_\ 0IZO_P!_K3_X_1]OU?\ Z%/5_P#O]:?_ !^NNHH Y'[?J_\
MT*>K_P#?ZT_^/T?;]7_Z%/5_^_UI_P#'ZZZB@#D?M^K_ /0IZO\ ]_K3_P"/
MT?;]7_Z%/5_^_P!:?_'ZZZB@#D?M^K_]"GJ__?ZT_P#C]'V_5_\ H4]7_P"_
MUI_\?KKJ* .1^WZO_P!"GJ__ '^M/_C]'V_5_P#H4]7_ ._UI_\ 'ZZZB@#D
M?M^K_P#0IZO_ -_K3_X_1]OU?_H4]7_[_6G_ ,?KKJ* .1^WZO\ ]"GJ_P#W
M^M/_ (_1]OU?_H4]7_[_ %I_\?KKJ* /.KF]U0^,--8^&=4#BPNP(C+:[F'F
M6^2/WV,# !R0?F& ><:_V_5_^A3U?_O]:?\ Q^M&[_Y'S2/^P9??^C;6MV@#
MD?M^K_\ 0IZO_P!_K3_X_1]OU?\ Z%/5_P#O]:?_ !^NNHH Y'[?J_\ T*>K
M_P#?ZT_^/T?;]7_Z%/5_^_UI_P#'ZZZB@#D?M^K_ /0IZO\ ]_K3_P"/T?;]
M7_Z%/5_^_P!:?_'ZZZB@#D?M^K_]"GJ__?ZT_P#C]'V_5_\ H4]7_P"_UI_\
M?KKJ* .1^WZO_P!"GJ__ '^M/_C]'V_5_P#H4]7_ ._UI_\ 'ZZZB@#D?M^K
M_P#0IZO_ -_K3_X_1]OU?_H4]7_[_6G_ ,?KKJ* .1^WZO\ ]"GJ_P#W^M/_
M (_61XDO=4;2X0_AG5(A]OLCN>6U()%S%@<3$Y)P!VR1D@9->BUA>+?^0-;_
M /83T_\ ]*X: ,[[?J__ $*>K_\ ?ZT_^/T?;]7_ .A3U?\ [_6G_P ?KKJ*
M .1^WZO_ -"GJ_\ W^M/_C]'V_5_^A3U?_O]:?\ Q^NNHH Y'[?J_P#T*>K_
M /?ZT_\ C]'V_5_^A3U?_O\ 6G_Q^NNHH Y'[?J__0IZO_W^M/\ X_1]OU?_
M *%/5_\ O]:?_'ZZZB@#D?M^K_\ 0IZO_P!_K3_X_1]OU?\ Z%/5_P#O]:?_
M !^NNHH Y'[?J_\ T*>K_P#?ZT_^/T?;]7_Z%/5_^_UI_P#'ZZZB@#D?M^K_
M /0IZO\ ]_K3_P"/T?;]7_Z%/5_^_P!:?_'ZZZB@#D?M^K_]"GJ__?ZT_P#C
M]9'AN]U1=,G">&=4E'V^])9);4 $W,F1S,.0<@]LC@D8->BUA>$O^0/<_P#8
M3U#_ -*YJ ,[[?J__0IZO_W^M/\ X_1]OU?_ *%/5_\ O]:?_'ZZZB@#D?M^
MK_\ 0IZO_P!_K3_X_1]OU?\ Z%/5_P#O]:?_ !^NNHH Y'[?J_\ T*>K_P#?
MZT_^/T?;]7_Z%/5_^_UI_P#'ZZZB@#D?M^K_ /0IZO\ ]_K3_P"/T?;]7_Z%
M/5_^_P!:?_'ZZZB@#D?M^K_]"GJ__?ZT_P#C]'V_5_\ H4]7_P"_UI_\?KKJ
M* .1^WZO_P!"GJ__ '^M/_C]'V_5_P#H4]7_ ._UI_\ 'ZZZB@#D?M^K_P#0
MIZO_ -_K3_X_1]OU?_H4]7_[_6G_ ,?KKJ* .1^WZO\ ]"GJ_P#W^M/_ (_4
M4%S?S>+O#"W6AWUB@OY2);B2!E)^R7''[N1CG\,<=:[.LG4_^1A\*_\ 83D_
M]([F@#KJ*** .6UG_D?-$_[!E_\ ^C;2J?B:"\D72[BSLI;QK6^6:2&%T5RH
M1P<;V4=6'>KFL_\ (^:)_P!@R_\ _1MI5R:X2!XE=9297V+LB9P#@GYB =HX
MZG _.@#C[O1]6U2'5M0DL6MI[Q[2.&T>5"ZQPR[BSD,4#'<QP"> .<\!^IZ9
M>W/B1;C3=+O;"Z>9%N=12XC^SW$ !R'C$FYFVD@$ID''S8%=A)(D4;22.J(@
M+,S'  '4DT(Z2QK)&RNC ,K*<@@]"#2L@.;\,'5M,T[3M#N]&G LXA;M?+/$
M875%PK ;O,RV%X*C!)YXR5T1M1/B?5I[G1+VTM[KRS'-+) 1\B[2"$D8\]N/
MKBNEHIMW=V'2QSMYX>O[GQ5:ZK'KEY%;Q12(8%6'Y=QC.U<Q$[3L.23GI@CF
MNBJ.>>&VA::>5(HEQEY&"@9..IJ2CI8 HHHH **** ,+PE_R!KC_ +">H?\
MI9-7,:UX3U:;1M0FL;8'49+FZ3RC*J^?;3.3C/0$':XSZ$<9KI_"7_(&N/\
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M'.,#Y3D"KFF>&"-0T6:>PN'M[>.]=QJ(MVDBDE=".(OD&</C;T!P<9KM0,#
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M\_,O_@-+_P#$TFTMV-)O9&U16+_PEFC?\_,O_@-+_P#$T?\ "6:-_P _,O\
MX#2__$TN:/=?>O\ ,?)+L_N?^1M45B_\)9HW_/S+_P" TO\ \31_PEFC?\_,
MO_@-+_\ $T<T>Z^]?YAR2[/[G_D;5%8O_"6:-_S\R_\ @-+_ /$UFZ]XAT^^
MTB2WM)YC.TD17$,B$8D4D[B!C !/6ASBM6U]Z_S!4YMV2?W/_(ZRBL#0-?\
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MJOK<'K<****0!1110 4444 85W_R/FD?]@R^_P#1MK6[6%=_\CYI'_8,OO\
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M*3:=P:(Y6+:W P%S[UZ514M7CRC3M*YQ6B12Z7XGTNTCOKV>&\TEYYEN;AI
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M_P#83T__ -*X: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\)?\
M('N?^PGJ'_I7-6[6%X2_Y ]S_P!A/4/_ $KFH W:*** "BBB@ HHHH ****
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M&?\ H7=(_P# */\ ^)K(\.>%O#T^F3/-H.ER,+^\0%[.,D*MS*JCD=   /0
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MT_[_ "_XTTF]D)M+<I?\(AX9_P"A=TC_ , H_P#XFC_A$/#/_0NZ1_X!1_\
MQ-7?[7TW_H(VG_?Y?\:/[7TW_H(VG_?Y?\:?++L+FCW*7_"(>&?^A=TC_P
MH_\ XFC_ (1#PS_T+ND?^ 4?_P 35W^U]-_Z"-I_W^7_ !H_M?3?^@C:?]_E
M_P :.678.:/<I?\ "(>&?^A=TC_P"C_^)H_X1#PS_P!"[I'_ (!1_P#Q-7?[
M7TW_ *"-I_W^7_&C^U]-_P"@C:?]_E_QHY9=@YH]RE_PB'AG_H7=(_\  */_
M .)H_P"$0\,_]"[I'_@%'_\ $U=_M?3?^@C:?]_E_P :/[7TW_H(VG_?Y?\
M&CEEV#FCW*7_  B'AG_H7=(_\ H__B:/^$0\,_\ 0NZ1_P" 4?\ \35W^U]-
M_P"@C:?]_E_QH_M?3?\ H(VG_?Y?\:.678.:/<I?\(AX9_Z%W2/_  "C_P#B
M:R/$?A;P]!I<+PZ#I<;&_LT)2SC!*M<QJPX'0@D'U!-=)_:^F_\ 01M/^_R_
MXUD>(]1L9]+A2&\MY&%_9N0DJDA5N8V8\'H "3Z &CEEV#FCW+7_  B'AG_H
M7=(_\ H__B:/^$0\,_\ 0NZ1_P" 4?\ \35W^U]-_P"@C:?]_E_QH_M?3?\
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M0%[.,D*MS(%'(Z   >@%=A6-X7_Y!4__ &$;[_TJEH /^$0\,_\ 0NZ1_P"
M4?\ \31_PB'AG_H7=(_\ H__ (FMFB@#&_X1#PS_ -"[I'_@%'_\31_PB'AG
M_H7=(_\  */_ .)K9HH QO\ A$/#/_0NZ1_X!1__ !-'_"(>&?\ H7=(_P#
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MQ-2]+3_O\W_Q%>9F.%JUW%TU>U^J[GJY;BJ5",E4=KVZ/L4:*O?V)J7I:?\
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M.F*U*G_X0>;_ *&S7/\ OBS_ /D>C_A!YO\ H;-<_P"^+/\ ^1Z (*QO"_\
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M$'F_Z&S7/^^+/_Y'H @HJ?\ X0>;_H;-<_[XL_\ Y'H_X0>;_H;-<_[XL_\
MY'H @HJ?_A!YO^ALUS_OBS_^1Z/^$'F_Z&S7/^^+/_Y'H @HJ?\ X0>;_H;-
M<_[XL_\ Y'H_X0>;_H;-<_[XL_\ Y'H @K#\0:W8>'+_ $'5]3F\JSMKZ1I'
MQD\VEP  .Y)( ^M='_P@\W_0V:Y_WQ9__(]9NN?"BR\1V L]5\0ZU=0JQD1'
M^S*%?:5#?)"I.-QXSB@#GO\ AH[P?_T#=<_[\0__ !VBN?\ ^&9?^IN_\IO_
' -MHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>tm2135630d1_drsimg13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg13.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #8 I@# 2(  A$! Q$!_\0
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M[(OB?_A:WCNQ\>G2_&O_  3W_:/U[1OAX;/X7_#/X7Q>$?A3I1_X*C6;>!_
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M_P"&]/V1?$__  M;QW8^/3I?C7_@GO\ M'Z]HWP\-G\+_AG\+XO"/PITH_\
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M/_%:W[1__P!-CK] Z* /S\_X5M_P5+_Z/)_8$_\ %:W[1_\ ]-CH_P"%;?\
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M?1VU/6****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4R6+WA8,R>MTI^RYY^S[^]Z]/P"G[7DC[3M[G?EZ_CL%%%%26%%%% !1110
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MQ?'&"^K<)^'6:2G3H8?AVMQ?QI@92R^O1>(\V\%?MG>*9O!6GGX1_P#!.?\
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MGB?XG_"WQE>?M1_L[^#[&]UO6O@Y\9?%44?QF\"Z!%&Z6$/PM^-5Y%/<^/\
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M @^_M5FJ"2=?>X0?FV"/P_QYJ_7Z?&#A3IP_E4E]TG?\S]AI6G%UE_R^;?\
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M\.Q'4_%D&C1^%OA?X?C.UM?^)WC"]D\#_#C0D<GYKC7?&>J:=:1EL(KR(20
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M3ZR?R-3O]QO]UOY&H.\GUD_D:PK?"O\ K[A?_4B)-3>'IB/_ %'/Y(OV^O\
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MA>*7_8?P'_[\Y_+-_P '<_\ REE^#?\ VCI^&W_K2?[2]?S%U_3I_P '<_\
MREE^#?\ VCI^&W_K2?[2]?S%U_K-^Q__ .4-LM_[.?XE_P#JTR8_K7Q!_P"2
MAJ?]@V'_ /2 K_40_P"#83_E"#^Q3_U\?M.?^M>_'JO\N^O]1#_@V$_Y0@_L
M4_\ 7Q^TY_ZU[\>J_D;]N;\/T8/^QIXI?^J/(#Z#PQ_YFWI2_P#3<C]]1U3_
M *ZM_-*MU4'5/^NK?S2K=?X T_BE_AC_ .G,2?IT/X=/_"_S84445J4%%%%
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M 4445904444 %%%% !37^XW^ZW\C3J:_W&_W6_D: /S_ /\ @FI_R;O\1/\
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M>" PQDX/!_#/(XJ6I]WECRWMRKO_ %L='NZ<N_VO7S^04444""BBB@ HHHH
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M/QYXL3]O222\DUF+]HK5](\2:K<Z3H)D7PD6\,?'O6+;]D#[*?%4%KX>FO\
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M3E]9KNKA\+3@OXL,36J;X$_/'_@H5X<T7]J*Q^'O["-G;ZA+J?QV\5:5XO\
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M44 %-?[C?[K?R-.IK_=;_=;IMST/3=\O_?7R^O&: /S_ /\ @FI_R;O\1/\
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MLY_!7_Z\+_T]3)G\%7UPWYY@?RB?\%=/^4X__!4#Z_L<_P#K(/PSKX@K[?\
M^"NG_*<?_@J!]?V.?_60?AG7Q!7\&^.7_)S<_P#^P?)__5; _P POI'_ /)Y
M>+?^O/#G_K-Y8*O4?4?SK^Z#_@V(_P"4(O[%_P#U^_M,?^M<?':OX7UZCZC^
M=?W0?\&Q'_*$7]B__K]_:8_]:X^.U?I/T<O]RXY_P9)_Z>JG[3]#OX?$?_NS
M/_4OB(_?./\ @_X!_P"TZN53C_@_X!_[3JY7]7/XI_\ 7R?YH_M2G_#A_AA_
MZ9H#7^XW^ZW\C4'>3ZR?R-3O]QO]UOY&H.\GUD_D:PK?"O\ K[A?_4B)-3>'
MIB/_ %'/Y(OV^O\ E8L\/_\ :&'P_P#^MP>-Z^AJ^>?V^O\ E8L\/_\ :&'P
M_P#^MP>-Z^AJ_O#Z/G_)M\+_ -CSB#_U-I'^;7TJO^3N8C_LE^%O_43,!&Z'
MZ'^5>Q_\&PG_ "@\_8G_ .O[]J'_ -;!_:!KQQNA^A_E7L?_  ;"?\H//V)_
M^O[]J'_UL']H&OS_ .DWMPK_ ->LT_\ 3V"/U'Z'?\#C_P#[".%__2\Q/Q!_
MX+Z_\IP?AU_VBE\!_P#K7_QIKX#K[\_X+Z_\IP?AU_VBE\!_^M?_ !IKX#K_
M $E_9^_\HZX#_LM^./\ U99>?R5].3_D^N(_[([A7_TSFP5_5K_P;&?\H0/V
M)_\ KY_:9_\ 6P_C[7\I5?U:_P#!L9_RA _8G_Z^?VF?_6P_C[7\^?M,_B\*
M/^P+C7_WDG[3^SV_A>*7_8?P'_[\Y_+-_P '<_\ REE^#?\ VCI^&W_K2?[2
M]?S%U_3I_P '<_\ REE^#?\ VCI^&W_K2?[2]?S%U_K-^Q__ .4-LM_[.?XE
M_P#JTR8_K7Q!_P"2AJ?]@V'_ /2 K_40_P"#83_E"#^Q3_U\?M.?^M>_'JO\
MN^O]1#_@V$_Y0@_L4_\ 7Q^TY_ZU[\>J_D;]N;\/T8/^QIXI?^J/(#Z#PQ_Y
MFWI2_P#3<C]]1U3_ *ZM_-*MU4'5/^NK?S2K=?X T_BE_AC_ .G,2?IT/X=/
M_"_S84445J4%%%% !1110 C=#]#_ "I@QO&/3IZ<?X8HF8+%*QW86-V.Q"[X
M"DG8BJY=N/E0(Y8X 5B<'\QOV_OVSOBM^RMJ?[*FC?#3]GKXK?&S5/CQ\=3X
M$\16GPPL_A1K%U:>&?"GPU\5_%#Q?HFFV_Q5^-'P>L+/Q-XE\.^%M7D\*WNH
M31:'!:>%O%TWB.]T75Y/!&D^-N;$RY?8+^?$4X_*]_S+C"\92_E37WJY^FZ]
MC_M+_7_&IJ^"_P#@G9^TA\1?VMOV1?@A^T%\3/A[KGPV\4?%3PY%XV&AZY%X
M;M5FT'7-2U&]\,:UHD/A_P 5>.;5?#^O>%+C3;K1%O;W2O%#6:7#^)M#\,W\
ML=DWWI774HNC5J*33;Y+M;>[&W779]3&%15.:WV)6^]7_0****DL_-O_ (*E
M6_A>Z_8F^*FG>+/$?Q3\)IJE_P#"S3_#E_\  FW\+S_%NY^)=]\7O L'PRT'
MX>1>.9+;P38>(/$/Q.D\+:38ZSXSOK/POIES?QZCXCO(M(M+EQYO_P $M_'?
MQ[U[PY\9/ O[4/CG]H[6_C_\./&WA.#QEX"_:0TG]E"'Q)\.]'\3^$8]3\-R
M^'O$O['>G:9\)?%_A7QI86U]K,4PU+6O$NE:O:W,6LH)4W3^V_\ !1N;P[%^
MQS\=+?Q=/X/@\.:OX;@T;68OB)\ ?B'^U5X/O--U3Q+X8L+^TUC]GKX4WVD?
M$KX@R7-K)<PV.D^"-6TYK&X=/&-Y?VT&G2SP?"W_  0LNH[7X9?M">&= \)>
M"=-\":)\5_#<OAKX@> _V0_C_P#LCV'Q1U;7?A]H^I^+]6\2>%OVD_&'C#XL
M>+/%7A:^AM?!,OB_Q!>PV"^'M%\*:5I0FAC"A9?;VV>O33%8+\<)+K=NUG;9
M:6NWN9YC?V&2Z/\ W?%VOL_]II7<?=6G>\I^\M%!>Z_WHHHHI+>7JOR+6R]%
M^05^?GPZ_P"4I_[8O_9@7_!-G_UHG_@JK7Z!U^?GPZ_Y2G_MB_\ 9@7_  39
M_P#6B?\ @JK5#/T#HHHH **** "BBB@ HHHH *1@2K ':2" PZ@D8!_ \TM%
M '->)?#OAKQEH&J>&?&&@Z'XD\,Z[8WFGZYX<\26%GJFC:OIMU%);7]CJVF:
MA#<6.HZ;>6LDUO?V=Y;RVMS:RRP7*2PR/&W-?#KX4_#3X0>'K?P9\(OA_P"!
MOAEX-L;M[F#P;X \(^'O!7AJSN;F17N+V'1?#VD6=J+VX;+RW2)&)F4,\GRE
MJ]*HH **** "BBB@"*89AF&,YBD&!U.4(QS@?G7SC^TU\;;3]G7X'>//BB;
M:[K.BZ>ND>"O"L;8NO&OQ!\0WUOX7^''@FS^8%KSQ7XTU71?#UN5.1)?*^3M
M85]'3L5AF8*SE8I&"KMW,0A(5=[QIN/0;G1<GYG49(_"CXE?&GXI?M"?\%1_
MA7^SG/\ #?P_J'[/W[,GC*+QIKWBFS\7:U>:%J_QGU3X67/BSX>_V[=0?#N[
MT^V\9^!-"U#Q!XET+X:S75G!>WL6F^-9_B5I[Z=%X.O_ !<^S+^S\'0B]L=C
M:.!O:]O;VBY-+6T4VWTLE=I,^:XGSJGE.#P])M+&9GC*. RAV<O^%*LU&[2=
M[0PLJLV[6]VS:3;/TM_9%^!MQ\ /@IX1\#:YJD7B#Q[>S:OX]^*WBGRT$WBO
MXN?$GQ)J'COXD>(Y9(T F&I^+M>UL6[RLTD6G0Z7;Y A5(_J^LZ.!5D9LCEX
M0!SP(V4KCL,X Q[_ %K1KU*%&&&A'#4Y.4:,8;JUN>/,TO*Z>NK?5W/=PN&H
MX.A2PV&C&-"G"+2CK^_J+GQ;?G+$2E)_WI2(I\&&8':08I,AR0A&PYWE06"X
M^\5!(&2 37\?G_!8K]FS]L+]H?\ ;JTOPA^SWX6\9>+],U'X!>%O$TGA70_%
M>FZ!H2#0_%GB'1=?U#7K*X\7>'=+>Y6[.@?9'O!'J5^C16UDSC1%$/\ 8'/_
M *B;[O\ JI/O?=^X?O?[/K[9K\T_V/[\?%OXF_M,_M07IM;^/Q_\2(?@O\,9
MHF:.<_!_]G;6M7\%M-,0#A-1^-6J?%W681G]]IU[HV2HB 'RG&_#U#BO*\%P
M]7DX0S'-L,Y.+:DJ>#ISQ=1[-<JC32ES<J;DHJ2<K/\ IKZ,WBOQ!X"\3\6^
M,>195P_GE?(N"LRX.P&4\64O:Y%B^)O$6O1RC(:L$G&;S3+<-DW$F9T:=-J4
ML+AI-RIQ7M#VOX\_ W7OC[^S%XD^!$'C*;X=W?Q'\&:#X$\4^)8]*&O:I;>'
M+V.QTKQ?IFGPVVJV<.G:GXA\+_VYH-IX@EO-3M]&N;Y-4%AK#6JV-Q\R7O\
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M14;C%RBKRT2^;2 9*J^3,0I?$;_*%#EL(?E"' <GH%)PQX) -?@7^WC\0O\
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M7\:^./$5_;^&? '@;1PWWM5\6^+]5T?P]IXP?]*OXW(*JP/'_L>_!'7?@?\
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M4/\ ZV#^T#7Y_P#2;VX5_P"O6:?^GL$?J/T._P"!Q_\ ]A'"_P#Z7F)^(/\
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MU)P2DG&ZZK_@G=^Q[J7[%'P:O?A+K?CFY^)>LW_CG6?&NI>-GU#Q>]GXAO\
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M^.F^(/Q"O_B;XHT#XG)XKUHKK7@O_A$_AG\'6\":!%+X?UH?$>6Y;Q%!^I=
M"-T/T/\ *H)<^0V-^=KX\O;YF=K8\O=\N_\ N;OEW8SQFIVZ'Z'^51,,Q@'H
M<@X)!YSW&"/J#D=JF7POT_R$]CXM_:DM];U"3P3I#_MFZ1^R1X.U=-7E\5W>
MD:=\.=/^)WCUK:XT+99^ /'WQ5U#Q/X3\":8D3F+79=-^'/BCQ)+%K<=UI.N
M>&]1C2_-C]DGX,?LH_"71O&\G[,6J^'O&,OCGQF/&'Q;\>6/Q7U3XS^,_'OC
M^=%MIO$7C_QKKWBWQ9JE[J<4*F2"RGOX]-TI'FC\/Z1HUO'% /*O^"DGAKP5
M!\&K;XH^)[#Q/KFJ>#]>\.>$O"6B:)\13\*/"M[XA^,?C_P3X$T?4?B%XQ&A
M^*4T/P9I.HZC87?B?73X:\3'3-$34K\^'=7,:V,ODG_!)?XI>#OB7\+_ !%>
M^$=%U;3+C4/#_P"SM\2M>G?XN+\9-*2_^-/P2\(_$*7PE_;O_"(^ O\ A%_$
MW@Q=0>T\6^$QI]\6MKOPIXH.KZF?%HTF)X.GS4J\OY915M[WIWU[?KU%B[7P
MMO\ GU+HE9JK':VKWW>JV5D?L !@ >@Q12 YS[$C\J6E&*C>W5W_  L4MEZ+
M\B&X_P"/>?\ ZXR_^@-7\_\ _P &OO\ R@Q_8?\ ^N/[2?\ ZUS\?Z_H N/^
M/>?_ *XR_P#H#5_/_P#\&OO_ "@Q_8?_ .N/[2?_ *US\?ZF?P5_^O"_]/4R
M)_!5]<-^>8'\HG_!73_E./\ \%0/K^QS_P"L@_#.OB"OM_\ X*Z?\IQ_^"H'
MU_8Y_P#60?AG7Q!7\&^.7_)S<_\ ^P?)_P#U6P/\POI'_P#)Y>+?^O/#G_K-
MY8*O4?4?SK^Z#_@V(_Y0B_L7_P#7[^TQ_P"M<?':OX7UZCZC^=?W.?\ !L=G
M_AQ_^QKM4.WVG]IO:A+J&/\ PUM\=\*6B2210QX)CC=P#E$9L*?TGZ.?^X\<
M_P"#)/\ T]5/VGZ'?P>(_P#W9G_J7Q$?OFQQ$2" 1'D$D*!A4.2Q!"CU)! Z
MD$5^6W_!13_@F?X'_P""B,/P;C\9>/\ QG\/[[X3>,H-8L;_ ,(:1X:BOM6\
M-W7CWP1K?B'1-0\37G@RZ\8J;W2_",EEI7AN/6V^%=QJ5_9>,/BGX"^*4W@C
MP>UC[W\3/^"@G[!GP9\;ZM\-/C)^VY^R7\(/B9X>;2VU[X??$W]HKX/^ /B)
MHD>OZ!H_B/09-6\(^)_%NE>(-+CUK0-1TK7M*BO]);^U=-U#2+B-9(;J.,_@
MG^VU%_P;D_\ "F/!+?"%?^");^+/^&O?^"?CZS_PJY/V%[K7E^&+?M\?LZ#X
MWQZM%X-C2^'PYL?@E/X[B^*,NI)_PCM_\,Y_%,/C%4T.2_)_JZ=.\YR=[PJ3
M6W^&7Z_A]W]KTI\M)1_GC3?G;ZOAOEU_R[G]/7P\\*V_@3PAX.\"Z9+/+IOA
M#PAX:\,V=R^C^'=!BNH?#.GP:$)8]'\):;HWA70IGAT]9+G0_#>@:+X4B$WF
M>$K*SLH9[>#T?O)]9/Y&OQS^"/[57_!!G]F4>(I/V:_VDO\ @D;^SQ_PF":!
M)XR7X&?&7]C/X51^*IO#IUR'PZ_BT> ?%?AMO$%[H=OX@\06NC-JT5S;Z1-X
MAUAX_-BNYU7]./A5\5/AC\</ ^@_%#X.?$;P%\6/AKXB?5H?#OCKX7^+=#\?
M^"-7FT/7M0T'78](\6>%M2U[PYKLFC>(M(OO#NH36-V3INI:9KD3SP30S6\&
M-6I[2*=G[E;"1>F]\0G^FWF<[I>S<?[_ -9?W89_F?R[?M]?\K%GA_\ [0P^
M'_\ UN#QO7T-7SS^WU_RL6>'_P#M##X?_P#6X/&]?0U?W?\ 1\_Y-OA?^QYQ
M!_ZFTC_-WZ57_)W,1_V2_"W_ *B9@(W0_0_RKV/_ (-A/^4'G[$__7]^U#_Z
MV#^T#7CC=#]#_*O8_P#@V$_Y0>?L3_\ 7]^U#_ZV#^T#7Y_])O;A7_KUFG_I
M[!'ZC]#O^!Q__P!A'"__ *7F)^(/_!?7_E.#\.O^T4O@/_UK_P"--? =??G_
M  7U_P"4X/PZ_P"T4O@/_P!:_P#C37P'7^DO[/W_ )1UP'_9;\<?^K++S^2O
MIR?\GUQ'_9'<*_\ IG-@K^K7_@V,_P"4('[$_P#U\_M,_P#K8?Q]K^4JOZM?
M^#8S_E"!^Q/_ -?/[3/_ *V'\?:_GS]IG\7A1_V!<:_^\D_:?V>W\+Q2_P"P
M_@/_ -^<_EF_X.Y_^4LOP;_[1T_#;_UI/]I>OYBZ_IT_X.Y_^4LOP;_[1T_#
M;_UI/]I>OYBZ_P!9OV/_ /RAMEO_ &<_Q+_]6F3']:^(/_)0U/\ L&P__I 5
M_J(?\&PG_*$']BG_ *^/VG/_ %KWX]5_EWU_J&_\&Q )_P""'W[%@ R3+^T^
M ,J,G_AKSX]8&75D&3W967^\I&17\C?MS-5]%]=\T\4E_P"8/(#Z#PQ_YFWI
M2_\ 3<C]^!U3_KJW\TJW7R%\:/VV?V-OV;?%-AX&_:(_:V_9J^!/C/4=!A\6
MZ7X0^,_QU^$WPG\4ZEX8O-0U73++Q/IVB>//%_AO6;G3=2U'1]:TB#5X+<:4
MVHZ/K$+2HUO-&OX6_M'_ +9OP1^&W@3PWX@^#_\ P<DP>._%NH_'O]E+X=:]
MH?\ PMO_ ((L>)(M/^%WQ5_:A^$GPK^/'C--&\*?L5P:FB_#/X+>*_'/CNU\
M1:U&OAGP)'X9/B[Q,^H^"M)\0:+J'^ 4%9OSC%K_ ,&XM=?0_3X?PJ3[QE^$
MFC^HU_NM_NG^1JK*"JO(L;2,OF.L:E SL%)"#S)(H]S$!1OEC3+#=(@RP_'_
M .!_[?7[ /PC_P"$KN/'W_!<[]G[]I8^)%T!])B^-7[3_P#P3;\-OX(CL_[9
MENE\)Q_ +P#\!+B2W\3+K%G=7P\=WOC>=+/P]H8T0Z/=R>))O%/Z6?"_XK?#
M#XX> ]!^*'P;^(W@+XL?#7Q"=4@\/>._A?XMT/Q]X(U>?1/$&H:!KT>D>+/"
MVIZ]X=UV71O$6DWWAS4)+*[)T[4]+UR%IH)8I;:"*]&-104M8UZV&P[7^&L\
M2_PI/[]RZ;;J*FOM1;OZ-+]3\FO^"@G_  7*_9P_X)V?M%>&/V9/B!\!OVNO
MC3\3?%/P,T/]H'3C^S1\+_!/Q)\/Z=\/-8\=>./AO:S:I#KWQ9\"Z[#=P:[X
M.U"2866@SZ2\&K>'XCKZM.5B_)W]K/\ X.,O@#\>OACX4\#^#_V"O^"I6G:Q
MX<_:;_8K^--^?%/[,G@FRMSX3_9Q_;%^!O[2'C33K&/1/C1K[S^)]5\!_"S6
M[7PC8ZI8Z3IMUJDEM_:7B?2K$RZG#X?_ ,%OR/\ A^UX$/I_P29\)Q=3T_X;
M'^*W?U^?MT]:^5-H]6_[[?\ ^*K^ZOH__1)X9\:/#;!\=8WBC/<BKXO/.(L#
M]7RO*LGS*E6CEN8T\-[>I/,G&=&I=3I\E)N$X_O)M344OF,TXAQ& Q/U>E@_
MK,8QNY*WNMO2+=TW=)27;;4_;=_^#J3]E0HX'_!/S_@K9$2K?O)?V5/A@D<?
M!^>1V_:(*HB?>=F!"J"2,"OVP_85_;.^&G_!0?\ 9=^&?[77P<\/>/?"WPR^
M+,OCM_#6C?%'2O#VA>.+-_ /Q%\5_"W68=?TKPSXO\8:3;S?\)%X/UEK%;76
M+Y6L)-)DDDCF5XA_$N5 !Y;H?XF/\S7]'O\ P;##9_P0V_8A3V_:=_3]L#X_
M']<Y[5^??26^CMD_@+/@BOE6?9MGU//L3F\*];-<OR[+IX:="A0H4Z5&GESE
M"K&I&HZLJE62G&:5.*Y-3HRG-:V:NI*MAOJLJ-;!1C'3WXO$<[?R=E\S^=?_
M (.9?^4R/PN]_P#@FA\/B/H?VG/C_7XFU^V?_!S-_P ID/A9[_\ !,SX>?\
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M/^NB_P#H9JQ44OX4/^W_ /TMC?\ $J?]P_\ TEA7Y^?#K_E*?^V+_P!F!?\
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MC[7\^?M,_B\*/^P+C7_WDG[3^SV_A>*7_8?P'_[\Y_+-_P '<_\ REE^#?\
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M\_X-@O\ E!I^Q#_O_M0?^MB?'ZOYPVZ'Z'^5?T>?\&P7_*#3]B'_ '_VH/\
MUL3X_5^%_M&?X?A7Z<8?^H^4GI<,[8G_ +"<O_\ 3\C^=C_@YE_Y3'_"G_M&
M7X!_]:?_ &@J_$NOVT_X.9?^4Q_PI_[1E^ ?_6G_ -H*OQ+K_0W]EY_RBSA?
M^SD>(7_JPR8_T?\ H^_\FXH_]E%Q)_ZF80*_O<_X-B_^4)/[%_\ V$/VH/\
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MO'N<]:&Z'Z'^51,Q$,AP6VH_ +ACA<@ QJ\@/4 QJSCC8K, *Z)>[&4_Y?\
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MTVNM^C\O,_>5F4 @^AS^6?\ /!Q41:,8YSSD>_,G';'\7/Z"OYDO"'_!9O\
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M67B*3PA;^,XO"EU;>*M2\/3S+KVFZ+&FM6\3&*.XE]T_X;Y_8>_Z/._9(_\
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MRA"<J<Y1C+\)O^#N@!?^"L7P80'&W_@G7\-#D<XV_M*_M+DGUZ_UK^8_>?\
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M>5YEFD*,^9<\85IT)2A!SC&4$YKT^&L-7A'$NM%QE[? \MU;3VSOT7FMGO\
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M[LIKV*#6XVFCQQWCS_@I)^W;\0O@#K'BC7?"/_!1/3+CQ%\,=0UBS\;?"_\
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MEO\ KMBL-4BYT\=#A7/\+E^/P624N7ZQE\L5E>!=2DJ=:BL70:Q4OK*OT"_
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M%G5@G@\NSC"4,?.I@\1@U*&"I8=9'F5Z4.:GC:44Z+^5H>"?T;<O\./$3/\
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M!IFJR1F0Q1)/^3'["VN?$KX%? /0O#NO_L-V/@GXA:S97LGB5_BY_P $Q/\
M@JE\<OC(K3ZNTL,/BGXK_!K]A7PMX<F^S0*9M"T[1[O5ET=5L_+\3F1!<+\:
M_P#!+KXB_M!_!S]J+]I'Q=;_ +"?Q#^#<O@'6;CP3X6US7_V./\ @IC\6K7P
M;8ZSH/A;6_\ A5OC#P1\)_AW\7/$?AOQC?\ P^U[X?\ QBTVS\:>&?#^H)IG
MC$3WOB*;2O$WABQB].'@YXOX]U:L,^\',FRW@JA[7Q0E+Q X;S"IRMQ^OQPE
M\/3P59O,J=2$:>18WB'#5(2>)>(45"I+R<%COH-972\:\%7P/CCQ1[6EBX>
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MZU+XAZS9Z/K7A-?'WP].D^%YO#/ACTW_ (*D_M:_\%+7^"7@_P &_L4>-?\
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M,:U6I1DTO98:IC$WLW2DXJ*_O2:=DM7LM[/TT_ ;_@A):?'35_V>_%?[&O\
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M$HO^"6RH7_X=J_L"MA"Y _8V_9T?)4$\(OPY,CMQ@ #<3P.<&MB+X0>/(?\
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MK>\*EU=NS55I:=+K7SU8U_O.*_Q4;?\ @D_-3QM_P3,_X)3^!?!GBKQM>_\
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M)X5LA//XQ70=>N-.T74/L%_^"3__  2T5&8?\$T_V!,JK,/^,-/V<Y.0"?\
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MM'?33K;KXB?^"AW_  71QS_P;O #&<_\/;OV/C@ #_J4CQP.W<>G"#_@H?\
M\%T/^E=X?C_P5N_8_P#]K _Y%+IG=CM\IQ[]KX8_;B_:\^.7PP^!&J?!6V^
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M_ +QQJOAOQMXM\.Z'XHN_B-\4OBW;_'/PCXAB\*0^&)?'OAWP[^S]J&E:O\
MV1KNH?#3^P?$<B^#_P!,*TE3Y%%_SIR^YV?X_P"9G!ZS]5^3"BBBH+"BBB@
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M?M$_ V3X\>'OAMX>C\4'PI'X!^/?P3^-;7)T-M<.J+\%?B'H'Q!/A>.R&N:
M+(^)7T/^REUMQX@CTQ;M[U]%U5(DM)"BFMTN[_X!%=<V'G!_"VF_DDOU,/\
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AT#X _#^U\3:K<ZY+X#OKA?"ND^$_T3HHJC(**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>tm2135630d1_drsimg14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E ?L# 2(  A$! Q$!_\0
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M2N3USN?)S[T[);L=D3?\)=X9_P"ABTG_ ,#8_P#XJC_A+O#/_0Q:3_X&Q_\
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M!*J2,_E7 /\ $75!X>TJY6UL_P"T+BX*72%6V)'E1E1NSDB2/J>]=S)HL/\
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6TEM=01SP2J5DBE0,K@]00>"*IQ:!HT%JMK#I-A';K&T0B2V0($8@LN ,8)
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M,^$AJDU]#=W$,JVLL.]6=+0=0"/]5\W]*ZG5Y-FF3KLE(D1D+1X&S*GYB<C
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M8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
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MDOW=@*Q2-D@@X)'&3ZUW%%"T!ZE/5=.CU;3I;*622(/M(DBQO1E(967((R"
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M:WE]Y[O^M66]Y?\ @+_S/+Z]]^$G_)-=-_Z[7?\ Z4RUR7_"C[[_ *&FW_\
M!6W_ ,?KT?P?X>;PKX7M=&:[%VT#2L9A%Y88O(TGW<G&-V.IZ5UX/#SI2;D?
M.\19QA<?2IPH-W3;=U;I8W****[SY,**** "BBB@ HHHH **** .6C_Y*K/_
M -@2/_T>]=37+1_\E5G_ .P)'_Z/>NIJI=/0;"BBBI$%>$V_^H6O=J\)M_\
M4+7M9-\<_1&578[+X<_\AC5/^O>'_P!"DKT2O._AS_R&-4_Z]X?_ $*2O1*X
MLQ_WF?\ 70N'PH\"TO\ Y!-E_P!<$_\ 017;_#I/,U+74W,NZWMAN4X(YGY%
M<1I?_()LO^N"?^@BNY^&W_(6UK_KA:_^A35[>8_[H_D9P^-_,ZS^P7_Z#.J_
M]_E_^)JG<^%99[ZVG&KWVV+.6=P7'3[I &/UKI**^<5::V?Y?Y%.E![K\_\
M,Y7QVNWPW$NXMBYB&3U/6N KT#Q]_P B]'_U]1_S->?U\UFO\9>A]/E'\!^I
MZ=X/_P"12T[_ *Y?U-<G\0_^0[8_]>S_ /H0KK/!_P#R*6G?]<OZFN3^(?\
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M %%%% !115>^O[/3+.2\O[N"TM8\;YIY!&BY( RQX&20/QH Q_'?_)//$O\
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M_P 51_PG?@__ *&O0_\ P8P__%5T%%(9S_\ PG?@_P#Z&O0__!C#_P#%4?\
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MJOF#OR>.*JSV)NCL_P#A._!__0UZ'_X,8?\ XJC_ (3OP?\ ]#7H?_@QA_\
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M>3RV\ER%,<-L^USD*07/&%X'7YN,EV_K\/T!*^QT7_"=^#_^AKT/_P &,/\
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M# ."<#CTJW139)$AB>61PD:*69F.  .I- ',3M]I^*%I&HR+/2I)'/93)(H
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M *%?5O\ O[:?_'Z/[:U#_H5]6_[^VG_Q^CE86-FBL4ZWJ&#CPOJQ/;,MK_\
M'JJ3ZWXC8JEGX2F#-QYEU?0(B^YV,Q/X"CE86.D9@JEF(  R2>U<3>W<GCN\
M;2M.++X?B?\ TZ]4D"Y(/^IC/<9'S,.W'UL_\(SJVO8/BG4T:VSDZ;IX,<)]
MG<_,X]N!74V]O#:6\=O;1)##&H5(XU"JH'8 =*>D?4-A\<:0Q)%&BI&@"JJC
M  '0"G445 @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *B%K;K=M=B"(7+((VF"#>5!)
M"ENN 23CWJ6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>tm2135630d1_drsimg15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "A L<# 2(  A$! Q$!_\0
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M5S_B'_D.>$_^PK)_Z175 '04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4;C1=*O(Y([G3+*=))1,ZRP*P:0
M  .01RV .>O J]10!1.BZ49KJ8Z99F6[3R[AS NZ9,8VN<?,,=C6/XQM+:Q^
M&?B&UM+>*WMX](NECBB0(B#RFX ' KIJY_QW_P D\\2_]@JZ_P#134 =!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^OZ_I>1.E[F%X&A6V\-R0(9"D>IZ@BF21G8@7DPY9B2Q]R23WKI*Y_P;_R
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ME'H*=XA_Y#GA/_L*R?\ I%=4W:QFD^IT%%%%(HBN;F&SMI+FXD6.&-=S.QX
MK)L[6;5IX]2U*%HXT.ZTLW_Y9^CN.[^@_A^N33(!_P )#J(NWYTNTD(MT[7$
MJGF0^JJ1A?4@M_=-;U=#_<KE7Q/?R\O7O]W<6X4445SC"BBB@ HHHH ****
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M&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\
MQ5'_  G?@_\ Z&O0_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%4?\
M"=^#_P#H:]#_ /!C#_\ %4 =!17/_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_
M .AKT/\ \&,/_P 50!T%%<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0
M_P#P8P__ !5 '045S_\ PG?@_P#Z&O0__!C#_P#%5T% !1110 4444 %%%%
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M--A<[E7;PQWX)[A5]*K_ /"K_!_V'[+_ &'8_P#'W]J\W[)#YG^N\WR\[/\
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MF(J\?[SY.5^;<%Z[E4]J[NN.\1>#9=7O-3FM6M;<7FG?9]VTAC,) X9L#D<
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M; 7>T]P96&,D_* HR>N:Z^AVLA=6%%%%(84444 %%%% !1110 4444 %%%%
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M[;$K;4****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>tm2135630d1_drsimg16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #; AX# 2(  A$! Q$!_\0
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M1MXQNO#,OB1-#\VXCB\P6$7S3N=^U005!8,P(4@_D5'^VG^QUXH\50ZQ>_\
M!4;]M&;Q3</DFPDU2PTAYV) VZ<NB?9UCR?]7T]QV /WGHKS+]E+X=_$#X7_
M  T?2_B%\2E^*]^MTTNGZ])H$.C7;V;*OEQ7,<#&*253NS*B1!@1E 02?3:
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M\(/$'AF/S/MMAHGPTU'1[^XS&PC\NZEUVZCCQ(48[H'W*K*-I8.H![!1110
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M_I=PJS7'S _O95#OU8 DUT=?/X_;)^(I'_)IWQ__ /!OX(_^:&OH"@ HHHH
M**** "BBB@ HHHH *SO%OC#2? /AVZU?7=4T[1=)LE#W-[?W*6UO;J2%!>1R
M%49(')ZD5HUS7QD^&-M\:OA3XA\(WM_J.FV'B6PETR[N+ Q"X6"52DBH94=
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MZW'X2N-)M/%,EC,NDSZI$\ME#=%"(GF1"':,/@L%() (!%:]I&(;6-0[2A4
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M&92 ?6\4JS1JZ,&1@&5E.00>XIU-B4QQJ"Q<@ %FQEO<XXIU !1110 4444
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M;R"XU75;O5+A 5NU'EK/>2J@QD(J!F9@6/8?\1*_[;'_ $*G[+7_ (+->_\
MDV@#^@NBOA[_ (((_P#!2'XB_P#!3G]E3QOXQ^)VE>"](\1^$_']_P"$5B\+
MVUS!920VUG8S!R+B:9RYDN9!G<!M"?*""3]PT ?B;_P=L_\ )QG['?\ W.O_
M *2Z57YRU^C7_!VS_P G&?L=_P#<Z_\ I+I5?G+0 4444 >S_P#!(;_E.O\
MLN?]S7_ZC]W7],M?S-?\$AO^4Z_[+G_<U_\ J/W=?TRT %%> ?\ !6#_ )19
M_M*_]DJ\4?\ IHNJ_E*^&'[*O@+Q%\-?#VH7F@^==WVF6UQ/)]MN%WR/$K,<
M"0 9)/ &* /ZM/\ AVG\.O\ H8_C_P#^'V\;_P#RVKR#_@GM^Q+X8^./[ WP
M/\:^*?&/Q_U3Q-XP\ :#K>KWG_"\/&<'VN\N=.@FGE\N/5%C3=([':BJHS@
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MCSJ5A\0_$/A_2-#;QE:>'4L_#D&J:DEK<QW=V'26*)8;>%(QR4D4@[4-:_\
MP:X_\H*/@9_W'_\ U(-3H ^_Z_D"_P"#H[_E.O\ '/\ [@'_ *C^F5_7[7\@
M7_!T=_RG7^.?_< _]1_3* /@"BBB@ K]_O\ @QC_ .;HO^Y4_P#<U7X U^_W
M_!C'_P W1?\ <J?^YJ@#]_J*** "BBB@ HHHH **** /Y0?C'_R?5^U1_P!E
MN\6_^G!ZHU>^,?\ R?5^U1_V6[Q;_P"G!ZHT %%%% 'ZY_\ !HG_ ,F*_&O_
M ++=KO\ Z;]*K]6:_*;_ (-$_P#DQ7XU_P#9;M=_]-^E5^K- 'XF_P#!VS_R
M<9^QW_W.O_I+I5?G+7Z-?\';/_)QG['?_<Z_^DNE5^<M !1110![/_P2&_Y3
MK_LN?]S7_P"H_=U_3+7\S7_!(;_E.O\ LN?]S7_ZC]W7],M '@'_  5@_P"4
M6?[2O_9*O%'_ *:+JOYC/@M_R1SPG_V!K/\ ]$)7].?_  5@_P"46?[2O_9*
MO%'_ *:+JOYC/@M_R1SPG_V!K/\ ]$)0!TU%%% !7[F?\&N/_*"CX&_]Q_\
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M"]O[8?PL\:?$+7=/\-_LU37?Q*U^+Q'J:7&GZVT<%Q'I6GZ6JPA;M2L?D:;
MQ#%CO>0[MI55[#_B)7_;8_Z%3]EK_P %FO?_ ";0!_0717YN?\$!_P#@K9\8
M/^"F/C;XXZ#\6]%^&VDW?PN&@_87\(6=[!'<?V@E\\GFFYN)BVT6T6W:$P2^
M=V1C](Z /AK_ (+K_P#).OV=O^R[>&O_ $7>ULUC?\%U_P#DG7[.W_9=O#7_
M *+O:V: "BBB@#Y__;G_ .1__9E_[+MX5_\ 1LU?J97Y9_MS_P#(_P#[,O\
MV7;PK_Z-FK]3* "BBB@#EOC1\2;GX1?#?4/$5MX7\2>,6TP)))I6@0QSZC/&
M74.T,4CH)"BDN45M[!2$5F*J?@#]IO\ X*:?%OXP?&'1E_9A;4_%/AVQM8HK
MW3[#P NK7,>MFX=9=,U\75_9W.A(L2Q'<]N6_>2MD^6(V^OO^"A<?B&Y_9%\
M56_A7QCI/@37KLVMO;:KJ&O#08SONH5>W2_\N4VLLZ%H8YEC=DDE0JN<5X+^
MRO\ \$N]0USX2_VC\7;[7-,^)]EJ4DGAGQ9HWCFXUCQ;X?TTI#LM9M>:VMI-
M10RK-(8KF&2';*J%7"\ 'W#;L[6Z&0!9"H+@'(![XI]8WA'Q[H7C9M1AT77=
M*UN71+HZ?J(L[R*X:RN517,,P0GRY-KHQ1@#AU.,$5LT 9?C;P/HOQ+\)ZAH
M'B/1]+U_0M6A:VOM.U*TCNK2\B;K'+%("CJ>X8$5Q]M^R'\)[/X+R?#>'X7_
M  [B^'DKF1_"R>&[-=%=BV\L;,1^23N^;.SKSUKT2B@#/\*^%-+\">&['1M$
MTVPT;2-,A6VL[&QMTM[:TB486..- %10.   !7PA_P &N/\ R@H^!G_<?_\
M4@U.OO\ KX _X-<?^4%'P,_[C_\ ZD&IT ??]?R!?\'1W_*=?XY_]P#_ -1_
M3*_K]K^0+_@Z._Y3K_'/_N ?^H_IE 'P!1110 5^_P!_P8Q_\W1?]RI_[FJ_
M &OW^_X,8_\ FZ+_ +E3_P!S5 '[_4444 %%%% !1110 4444 ?R@_&/_D^K
M]JC_ ++=XM_].#U1J]\8_P#D^K]JC_LMWBW_ -.#U1H **** /US_P"#1/\
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M_9V_[+MX:_\ 1=[6S6-_P77_ .2=?L[?]EV\-?\ HN]K9H **** /G_]N?\
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M0==L: *N6)8X')8GJ:Z2@ HHHH _E!^,?_)]7[5'_9;O%O\ Z<'JC5[XQ_\
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M^B[VMFL;_@NO_P DZ_9V_P"R[>&O_1=[6S0 4444 ?/_ .W/_P C_P#LR_\
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M/4?BGK5IXI\&^ -'\$P>?_9&K:5XRN]2U6^Q,H@^T6,FEV\5OOAW.^R[FV.
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MU8N@,9=5$D9;]6: "BBB@"&_E,%C,XB,Q2-F$8_Y:8'3\:_%W]EG_@F;J_\
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M/I2TB?<'TI: /YF_^"OG_*=?]J'Z>%/_ %'[2O%Z]H_X*^?\IU_VH?IX4_\
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M /\ AH?_ +KH ^@/^"L'_*+/]I7_ +)5XH_]-%U7\QGP6_Y(YX3_ .P-9_\
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M/_3OX,KZ H ^7_ '[,'Q]^%']M?\(MX^_9@\-?\ "2ZK/KNK_P!E? K4;/\
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MR5[]Y1:1^@7_  KG]J;_ *+)\ /_  S>K_\ S3T?\*Y_:F_Z+)\ /_#-ZO\
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M #3U] 44 ?/_ /PKG]J;_HLGP _\,WJ__P T]'_"N?VIO^BR? #_ ,,WJ_\
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4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>tm2135630d1_drsimg19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg19.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %[ @,# 2(  A$! Q$!_\0
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M_P#"G/[-_;'_ .%H?V7_ ,)-_P (5_P[:_X*._\ "0?\(G_;/_"*?\)AY?\
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M!5?^$Z_:0DT/Q3\+A<^%OAGX9?XH>+7UCP_#X.\)SQ1?/YM\([KXD_M%3?\
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MS1#XI<_&FS^%]I\:KCP:N@^*5E7X7OXG_P"$+'BH^*'T%O#$A;Q$K:&=$7Q
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MX@\+(/AR_A;X;_$7XFI\-?"?A+5W\3^"O@Z?!WBIHO"_]1_[).J^/M=_9E^
M6J_%KQ]\,_BM\1;_ .$G@F]\8_$_X.^)#XM^&/Q#\1/X:TY=5\>_#[Q9_8?A
M=M<\.>*)V?7;76H_#F@0.NL*MO"D2J& /IJBBB@ HHHH **** "BBB@ HHHH
M **\[U?Q9J&G:E-:Q1V/D0@?-<,R$\#^Z1C'^''KE_\ "9ZQ_P \K'_OS+_\
M577' 8F24DE:236VS2:_!H#U+;_M+^=&W_:7\Z\L_P"$RU?_ )Y67_?J?_XN
MC_A,M7_YY67_ 'ZG_P#BZ?\ 9^*[+\#3D?<]3V_[2_G1M_VE_.O+/^$RU?\
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M^I__ (NC_A,M7_YY67_?J?\ ^+H_L_%=E^ <C[FE\0/"B^._ _BWP./$FO\
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MDS:5J=@Y0!T$MM/+&60@D.4#'[M?GZG_  4Q_9U'@CQSX[O=>\4:)9?#?0?
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M3_\ Q=']GXKLOP#D?<]3V_[2_G1M_P!I?SKRS_A,M7_YY67_ 'ZG_P#BZ/\
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M<XRE'V?+1J.4XOE3_P!%HL0P&TD'J>P_SQ^OI2D*,M@9[D 9-?P:?L)?MO\
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M_P#22S]O[_Q,C]HW_P">!7WW]L2[+[Y?Y'Z-[=_RG^S917^,G_P]=_X*D_\
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ME?\ !4".1(;G_@I+^WDLC_(TS?MB_M%NQ0D!MP/CII$&!S&) K ;3N!J<_\
M!4W_ (*<O//"/^"D?[?KQ12,5:/]KK]I "5"5*H47QX-D1R0I=BB*H"@ C'Q
M&/X,X3Q6+6,E&[<E4:2E*,G%0I7=VW).*Y'&4_>A*2DN2\5^YY%]([Q6X=IN
MA#_5N[XAJ9_"KGZE[>AQ!6J<.UVZ,Z6?4%0R*ED/#CX=HRAAY3H<-\1\2Y!1
MJ^TXCG6E_JE^'_V9K_3/^"B7Q._:1/A.&#P1KWP/\-6^A>)?[;TM2_Q=U2];
M1O%EX_A?^VQXATO68_AGX8\):*FO_P#"-MM#&/<=LBG[U#!P&5@5YZ<@]NOL
M17^/1HG_  4R_P""G>I:K8;?^"C?[?,UI)>R0W5N?VP_VC"6VE@V[/C[><@%
M6^7YEX8;37O)_P""CO\ P47AM+IY_P#@H#^VP'A((FMOVK_CS96:@G&Y53QP
M.@SE@JX[< UZL<\RO@CFP='+7S9O7J\0M1<-*G$,[5.;5/645;I\2,<KX%X\
M\9L+EF<9AFM%QX+X8X8X7X;G5J5TUPWPMPU)4XQ:52-N2H^=M1;J<NKY.<_U
MH**_R$M5_P""D/\ P4X@$UY#_P %&?V[EM3R8+?]L3X^AK8$X&?^*]Z#IPIS
MQS7 7/\ P5%_X*;028?_ (*1_M]@ _\ 1X_[1^,]O^9\_KZ'.:]W#<7X;%_"
MF_E_DW_PQ^?9_P"'/$'#F)OC%!;[2D[KH[N/7_@=S_8LHK_'3;_@J%_P4\DR
M(O\ @H]^WJ,6Y)Q^V/\ M(9)Z9^7QX>_&/N^]8UQ_P %1O\ @J1G_1O^"DO[
M?TOKM_;,_:.8_E_PGB8_/O7;_K!AWMR_-M?H?+X_(,UPRO;[F_\ )'^R+17^
M2%;_ /!2#_@I1;67F3_\%"/VXS-]G_T=I/VM_CW>?:3NY+#_ (3QL;<]2P.?
M>N4O/^"FG_!28W)#_P#!0W]NF#S<C]W^UU\>K%5.<CYE\=8 ]ABO$H>(&"Q#
MM_9KOJE;E:WZ/FV_S/U7'^ 7$>7898K%YG15TFESUD];='2LO+6^VC3/]>BB
MO\?23_@IA_P4YR;>/_@HY^WI,PZ-_P -B?M'DGZY\> X[]" >V:^N/V</^"B
MO_!1'5OV;_\ @I?XCU[]OK]MG6O$/@']DOX7>(? .LZU^U/\>M4O/ _B35OV
M^OV,_!FJ^)/"FHMX[9M!UNZ\&>*O%?AE_$.@["?">NZ_X7EW1>)R']3#\48;
M%.R6KMOMKLN^MU_31^>YQPCFV28;ZUC%&VNJ;;NNFL5K\]+'^JG17^,G_P /
M7?\ @J3_ -)+/V_O_$R/VC?_ )X%'_#UW_@J3_TDL_;^_P#$R/VC?_G@5ZW]
ML2[+[Y?Y'Q?MW_*?[-E%?XR?_#UW_@J3_P!)+/V_O_$R/VC?_G@4?\/7?^"I
M/_22S]O[_P 3(_:-_P#G@4?VQ+LOOE_D'MW_ "G^S917^,G_ ,/7?^"I/_22
MS]O[_P 3(_:-_P#G@4?\/7?^"I/_ $DL_;^_\3(_:-_^>!1_;$NR^^7^0>W?
M\I_K]_M*>#/$GC_]G7XZ> O!UF=6\5>-O@S\0O"/A?31<Z78G6/$6K^%=7T3
M1]*_M?6A_P (_H@_M[KV49+=R/SI'[*?Q_\ A'?_  1^(/PAT'QWXS\;>!_V
M+_BQX&N=+\6_'#3?$VG^$OCSK?ASX8Z;X.\->&$\;>.CH&BZ3+KVBZNUU)X>
M">%&?1F$@4_\(MC_ #)(_P#@JO\ \%2Y#)C_ (*5?M]$Q<D-^V-^T4W.,Y&?
MB$<,,\%>1G@]:<G_  59_P""H\TL4:_\%)/V^=^5#$_M@_M%$L3C:?\ DH);
M*C(5@#A21N R3\)G?#V69[B%F.(36915**E%NZC3I\3PI::)V7$TTF^9OD]W
ME;;C\AQ!PADW$69PS?&Q:S/*VI1FF[2Y.*N&>*G9;.U7AB$=5)*,Y-6:][_4
M8_9S_94^/?[,OQP^$5ZNL^$OB)\+-3_9Y7X)_%+4/"'A9?AHOA2\^');Q=\.
M/%&MZ5KOQ3\5^(?BCK?B36M:\8Z"?$/A;PO$PDU= _A:.$NS<GK'[ 7QMN?^
M"J>A?MEZ=^U%\>+#X06G[-^O^"[_ $"RUGX 1ZA:^)5^//@CXB?\,ZMI(_9M
M&OG]G+Q)X<T;4M:\6^(SXH;XM_\ "1Q)''\6_"ZQ[Z_DI_X*R?MJ_MI?#/1?
M@+H'PL_;(_:E^']]+X<OKOQ-?^ ?VA_C%X2UK7;PZ87TS4=<U+1?&_AT:V=V
MG,09-RY:1MI=\'\"[W_@I_\ \%3]/F>RF_X*._M]_:EX"#]L#]HR2.5VEP/+
MW>/P/EW!6)48 ))PN:^-\%^..'>+N"\HSSAO+:F19+B%Q,Z?#7$$HNI%/%2H
MMRY5)1<IT9*G&<9\U.JTG#VD7#\R^C3QKPKQ]X94N(^%,MXGR3*,[E*,>%^*
M.(O:U:4>&8+A>ZY%;EJ2X8CQ#)*=U.2;<HI)?ZAWQA_8^USXZ?M<>+?$GC2Z
M\8:)\ ?$?[,VD?"[Q)=>"?%OA;1%\:ZE!\1]6U'4/AKJ:,?$'CS1-*U[1=35
MH_$GAIO#7E-_Q3:>+3-Y2K\O?&;]BS]IJQ^(/QW^*?[/GAW3_#_BQ_BSI&C?
M!MH_$/A:PM[CX#>-/V9O"'P/\>:M&!K8316^'NM:9I^M^&/#WB")?%$B_#8%
M/"7B)&0M_F]P?\%4O^"H3Q>8_P#P4A_;TD0W'E,DO[8/[1$J,6'1E?Q\0R@A
M6*LN-RHW5%(].^'W_!3C_@ICJ%U-)=?\%&?V\9HR2DWG_M:_'NZM@<D-)+GQ
MYY<\TH.'D<;W  )XX^CS[ACA_$87,IXNE*I#VD\^<8KG2J25"52G%-7C*2I0
MUBH:RNN:=FO]"O#;Q<\3*6<\/</<.SX9CECX>H</0X<XCI7X;GD.&>4\OUB*
M]E&M3X@HY/+AGB:.)JUH5^%Y?54L-14XU/\ 1UUW]A?QSI'[/?[?_P )?!GP
M^C67Q;XW\#>(/V453Q7X7M+R_N/A9\)/AII?@#Q#I>I-KFWP?K/A_P :^%'B
M/_"3+X9C)*R,&C.X_J+\)? 5E\+?A7\-OAKH.BV^C:5X&\">#O"UMH]LP46K
MZ1I3Z/L53G"\G!)X Q\U?Y.]_P#\%,/^"C+K%:_\/#OV\(66$1W(7]L'X^@H
M\@,9"X\>Y0%%1 IVG"E,$*JCSG5_^"EG_!4"P7RY_P#@H[^WJ&AD8V\L7[8O
M[1Y)AXVAO^*]&U@F 2IQCH2M3PY#),KQ$J^&RR<.:E'(H<[BE*$*O$LDJ;4]
M7)<12ULK0;U=TEZ/BCB_$K/<D64Y_F7"^=93'B6/$SG!<2_\E-'A7AKA7EFY
MN[;X;X:YGJX_ZT/B6I[LY3B?[#=%?XV?_#U#_@J!OS_P\J_;\QZ_\-D?M'9Z
M?]CYG_..G-+)_P %3_\ @J-C]W_P4E_;]!_[/*_:-/KZ^/5]O\:^\_M^7;[[
M+\T?SQ_9.,Z6=NTF_P#VP_V2Z*_QT/#G_!3[_@J+J&M1VC_\%'?V]S%!!>7-
MS;W/[:'Q^. -[$$GQ\%Z[2%*-DY(*8.?2;C_ (*8?\%+K1(A#_P4._;L$P.+
MAO\ AKKX^ D@\X/_  G?! Y(Y]..M<F*XOP>$Q,<+++4W))I1:TNY*SO9W=K
MV5]&O,^IX9X"S;BS+,TS;!\G+?E?-*:;;Z148R3^;6ODC_7E 7D@#YNIP/FX
MP,^O''/;B@\ X&<#@#O@=!_(5_E>?LO?\%)?VT/%DOB?X:_$?_@H-^VGX?\
M$7C*]TKP[H'Q&US]JO\ :0UJQ\#+J>L:*SWSZ7JWQ8_L&)E92&U\XDA\,'Q
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MR?,'Q8Y9MP\[J5GROXHN3_"%KWNNCU?3#\2:%;C39-1M#%:3V#HK88EKO>0
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MQE\E_$$V\NN06-E/?2W,%L+361<C3C86^H!G$@T@J#&-$0E"-^W* X_ASN>
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M6O -GI]]XHT:UU.WU"^TZZN8[2[M=+U#3+'4+M'("V.FOJX,8=BT<8+-\Q?
MP0I/"9W,,]R!CVJTX: QR1^F.>X[=S^8]?P-2I)T6E9<[DM7ULN_33OII\L7
M@D\/F"P[WT;>KULKN_:R6CTM96/M_3KWQM'X:O/$L6F^*GMI]6DT;3/*MWL[
MZ+1C(HU>^&FJ&42LK:3HA=R8OE,9?>0M?HY^Q1JUW\-?A?X@\>Z7\8/AE8>)
MOC#\1G^#GB[X?^+M'TSQ+XPT+P)_9]KK8^(6BZ>NO>&=LJ:L'T.,(8_#K/'L
M\P8&W\0_"GB35?"FNVU_<F]O-/2]M8-<TL73#^T;:(I(UADX#;HE(C+8 X;
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MVN]?=2TNY2:LE?OJW9)-O3RCS?G$4OY8/'O[_G[X[B(>0",R9FSTP?Q[=?\
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M'>OIC61HGB#P5X<U0W$=AKFJZ:ECJTDUP+.VMY].$=@K#'#9VJX4D?.1G !
M^9SR+C7RW%.W/.2IM\KFXMVE>R=V[<ZNE:\:=K)*)^[>"\OK7#7'F5PERO)8
M0XIA&57_ %<EQ)35^&9T>=I2:A4J\.RA"5E3C4XDYG?FE(TZZU\S):6=S,\&
MKSEI-/TN ->VL.<",*00S.-.!5 P ;((YS5R#Q*VIVFO_P!I:K>?Z59'2Y8Y
MXOL5VMJNQ7_M*RS]S(4L"TNS ;?WKC_A"NJ"[UTZO;ZF-'2#R[?5U+B#1K]=
M3+QR-?+F-$<#4D"JY'F'*\*2O?PZ58R0ZQ96MSIL]S<Z'-K^N+=Q%;K2%TT2
MEM/&6R9@8P6'R[@X.%P0?FLPP^&PV*>%:<I1C1FJE):Q<>67O6C=/1:WTG:+
MNZKO^V\)YAF6<\,Y7Q#AFG'.I<54Y\,\3R?+S1C/X4E#VL)R4YJ2CR*+GTX9
MLOF24^3+*B&&0LA&/]L," PX..H./I7Z5_\ !/WP3??$GX)_\%./!L-P]M>:
MS^QA\.)=/96VO<76E?M\_L9Z[9@$C(W0:'*IQR"^<FOS0NY?WCMR,G([\%CG
M'.,9]?05^R'_  2+TU;RW_X*#P2#R8$_9!^'TLI@R-V_]MG]E2-=P'3EP./<
MCO7VF<9CB<CX>XBS;#<KJ95PWQ'7@Y1YDJE'AUU+V^TG.-/FCKS136B=S^>/
M"WAO)N,/%OPVX,XD3?#&=>*'"O"W$D(M1G+AGBKBJE3<:<VGR3E"I*,9ZN$G
M&6T6C\0[F"YCN;JWD-S'*)BDB3QE6.%!^?Y1MDP<A>"1@X(YJH(5=G52<^:J
MJ>H.S:9#GM@Y[<\C-?>O[;7PCU'P)\3[W4H=/M]/T_Q,UM<7-M%"V[3M?A@*
MZD,=&6YC1=6(4H(X[]% *M@?'ND^']2UV=;31-*GN[V"T#SP@;KZY#,?NZ<N
MX@YR"%8DX(/(I\/<29?Q)D.69_@JBE2S6G&I[LE[CE&%U)<L6IJ;Y'&TK/EL
MVIJWQ?C;X99GX&^)_''AKQ2WS<&<0U*3XAE3=.EGW#TYREPYQ%24IR2H\1T)
MT:E*2FU'GFG)JGSR]!\3^#_A[JWBRRM/A[XGU*S\-RZ+8:CJVK^/=.N+'^Q+
M]E!U+39!I$_B634Q;'F-HO\ 7;PK(BAMW0^$/"WPYT*>PO=?CO/B+<08NFT&
MW_XDNA@;BVS4LL=;U*,-C"6\<3;05:1U)6M7P3\$=0N3_;_CZ^L/!WAFVMQJ
M-Q/K=UIIU"5%U(#[#IGA>:0Z_K!+#[J((PN2650,^ZZ;XR^%WA'2+S3/A=I6
MI:IXHGEL#<^/]:D;16M-,U7&D?V7IFDIK*(8VSAOF\2NRAMH3DCY7.,_Q#C3
MRO*<=Q#G,HTH0G.DTHI>]&4\3Q+9R]HTVI*ERU.6$5R\TW,_EK.>)J6';RG(
M)<3Y[R)1;AR>SBE;F?$?%"4%'NU2@JDM+IN39[UK7P_\,6'A2Y\9W6C:O9:]
MI>B'2]4M]'M-4UW_ (1RQTIAHVDZ4!PNBC<<G7_^*8 \4M@@]:X+Q]\0OBA^
MS?I/@SP;HVDZ;X3\0>,_"R_$#6?%#6X?7K7PWJYUG2-,\,K'YR)H\H":H/$X
MD \3.[ M+$$S6E%KK>$/#OC#0_&/C/Q-8C5=+T\:X1JA47FH@_VR3J^D_P!N
M9UO0C@$9'/UXJI?Z?\"_B@-5\??&K]H_4-%UW3QI^E:)HUAH2>++_6/#XU(-
MHZQ@ZV'CT5-%#@%9"?#?R*$!.P_DF7*G[?GXAI5\_P EE4G&4H</<2<1RJ.<
M*:X=IT:4(5HN-*?MI.I*52'LWAY3C9/F^<X?H\-_5N&_]=<O?&O"4N*)1DUP
MOQ9Q1.2FVN%[RTYN%I)N3C+W9-/FYM%*7X%:;\0OVE[CQO\ #_Q9K7CG6DLO
M#OB/Q]I.GZ?,+UKW7='T]O[6=TU9\Q:01J3>(/%S$F01Z.#N)*/7R;K7P/>S
M^($GA:S\1:7=6MUJNO6MK-9,5OLZ2=64 L6VH@_LDL6(+;1SST^GKKQEIFGV
M4B>&@_A[4M,L1IUCK^CW=Q&VKET9)Y+[4!+#K#/.?MY<RJP9;^.'Y4)->8_\
M(O>>-;F>]UN7[3=7EYO;582;2YM[Y';?J3*H5?[5(4EW9VR-4;!7<=OT&3YK
MF&6YEFF*TR/)90IT_P#5]4J<_9R@YWK12<$W)>Q<HQ;J:2@TY23/](L?]!;%
MY=FL<7X+\=/*8<9\,<RX5_U:A"/#?$\N5N]6G[T=5R2YE*TTJD.)G3=G[/\
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M^"3P^%(_:Y_9%FU?SH_B[%_P41_8)C\&37/VXV4OA2;XZZ4GCU6^QI_8BO\
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M1I[=-GKIU:;[6^15BU[RKCSO]3U[$?K_ )YKTKP?XW6VE6(3$'D0?OP!G.
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M[=.?UZUSG[GS._3_ #[9_3;6K:Q32R>3_H_Y_3K_ /JZ]:RQ/Z_Y'K9?B/\
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MW6@>-/%&AV>I:9JFF6.ID6MU;W'R7M@"PTG4P1SRA7)[9((P0:\,>W:&4&3
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MQ5Q-7M4DYKAQ59>UCPQPSS.37"M.+?\ JQ'GORRE)\M1LHVMU-:R^=#-B?\
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M_=YH+AF=YM1M+F]W>TI-0DO._BK&\)TS3XV*+I4=];P1F$!@7U&=GR&!W%F
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MNE-I&E::M_N).AVND"Q@_L1#L6* %!"58-X7MX<]X^_KWY]NW\L9Q7JOPO\
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M? O]JWQ/\ _!GCOPGX5\,^#[G5?&=SIFHV'C76-%%YXY\!ZUHUSYVF:_\/\
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MED.]2'Z$$$-C%>E^ +BQ\.7T.LWL2:C;M;7L-_;3VE]=:A!/\YTQF*0AO,(
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MVEZIH;:3K+C6F+!UUK8T>54GRS5]&>2$WT>IP7$\3M T4RM:WZ@C=IC!>I4
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MM[-+&(V/ [Y.?_K54II-N[T\O+7_ #^8TFW=Z>7EK_G\S[H_X)C,P_X*2_\
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MFV4DX)[\\$ 9Y/6DO6N+P,]SB8)<9/)&<8SCW)Y^OKQ6WHDL.IN]M*/]%D)
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M5^]+)^)_]9;M)MWDI_"ERW<H)M6:=N6UFT?(NJW\MS<B:7J6YR.@QG []?\
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M2NZM_P!FY_ G_P!-6LU_-@O4?4?SKX7,/^1AF/\ U]G^5,\ZK\;'O&T9PX_
M'K],C\ZCHHKS3(**** "BBB@ HHHH ZS0/,N=<TI$FAM9Y=5LV2XF;%O;D,&
M1G9MW *J3ZD'D$[J_4KXU?!%E\"I9Z[JUK-XK\.ZBMJ0;?4]8O$T+2?$+^$)
M]635#I!UM/!GA_6HS'#&=!B$[ZN4QX@'AU5U_P#)^TG^SW\,[JR ,,"(@'/;
MIP?PYYYZU]P>"M)N?%GA[P?=^,_&UAIOPSUCQ%_PAEKJ'B-=5US4/!4>G7VC
MW&L:KI6E1R*/[$C35-(/B+6(H&>033%?"[,D<<GP?&6&Q=3&\-YIA,R_LO\
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MF'^M$=%./$_#%23X6OM=M5&DXWLVHV6NGQ+^U3\+$T3PUX8\1QQ-$+-VT^^
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MYQD<6N224N=W23Y9-W<':5XQ;?>]B/P-X]L[!K?2$2.1EM2E]>3REF)8DJH
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MSV'ZCOFKUGI\]GK8TV0&-X+@VQ4]N>A_$'/)X(JUXL!CO9+7M"N[MT/7\?\
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M=^#/#UKI-M':V&N^-M7UF%;_ ,7MX\U+3)#JNG+XG1ED_L:/3Y3H*Z&N@^'
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M"DY4W[-\J4G3A=N[7-HY0Y6I.+OR\Q^7T'CS6]52::YO)X;?RB?*MV8 WVT
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M]!^OOCTK@_-/O_WT?\*_5,N_Y%65?+\V>+#X8_X5^2/P<_X*)_\ !?O]G?\
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MZF_XB^OV+?\ HU?]I_\ \&GPJ_\ E]7^?/E_0?Y_&C+^@_S^-/\ U@S+^?\
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M/]!C_B+]_8M_Z-3_ &G_ /P;_"K_ .7M0_\ $7W^Q?\ ]&L_M/\ _@V^%/\
M\OZ_S[<OZ#_/XT9?T'^?QH_U@S+^?\&+ZS6_G/\ 02_XB^_V+_\ HUG]I_\
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M\'6_[)=U:1WI_93_ &G$@D8J7EU7X6,A(X.&;75SSQT[=:NR_P#!U=^QY%%
MP_9R_:+N)1U@_M+X6[1^/]NXY[<\'IWK^#8LT9B1OW@A@\C_ %V0#DG*G' &
M[@?=Z')JI<ZA<!(8B#Z0 <'D\X]!TY..Q/H?/7'W%4G:.9M[V36MM7VZ+=^3
MZ'UB\..!<-A$L9E:<DDI/9-VC>R6BNV[)-I.R/[Q/^(L#]C\)YA_9B_:0!!Z
M?V[\*@!_Y7L].<=/Y5?T_P#X.J_V0=0#1+^S/^TE#,F/LYN=2^%A%UGIN(UW
M@G&!GGTK^#*VM6N%.!R2">?USQ@9]?PKJ]-T^YL@DDBF.&/B><CA<G\,D]
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MN5/V/[/"@F2,Q>9$,@PY(8#ZGG'3CV.:B&FW5ZT4<49%R&X,'+'('  Z_@>
M1WKQW3/B7?:OJ$UJVGV]FANVQ:FW NEY.-/5@/,.!@%1U8$Y ''H[_$6UM89
MY;>&72M1L 9KV'>_^D$NJG ."A1CRI&,$_45B<DS;"2Y5!2F^71>\];))M-K
M>2T;>K6IQ\/^*?AQQ'A)8QYFX91>2UCR<RBN:3AS73M!-IMQ;2DXQ=DEZEJF
MFAO!]]I*S1K;10R>=OGY%V,@%FY4\?*?<$YZU\+:]IUM8S2P6TQ>6%GW\\#/
M.%)Y Y'T[8.:[_Q1\3M2:UEL;"=C:/<.+FX!.+GG!XZ#.#R/QYYJ[X?\(Z9X
M[T2:YL=3L]/UVWF^6QOH&*W7.&W:HN0&!!&)  PY4]:^CX?P.+X>PT\3FM6U
M*I6O+7W4[M+VVCM%.4K6;=GLVFC\A\8>*>'_ !JS3*>'^"<M4\ZR+AAPC[R3
MG%?%3X7YN52E&*YK/633<;\UCPFXTMI0=F2<\8Z<'@@D_P Q^%:GA;3%NM2C
MMRQG;[1@".9;;<> ,,RX3IP2O'0<XKHM1\":G:P'^TEOK:[F=##%<V\B">U.
M<L-Q4\$8'!'/7K6UX5^'M\+JWEO;RUL4\X&.,S_Z7*H;)<!0Q&>F^0K@].A!
M^QQ&;X59?43S%=;)-R7K&U[VZ]-WLC^9\HX"SZ7$^5_\8O4LY0YHMI)7=ES\
MS48:6:3]Z5THJ\T>JW][#IE[<F[T:T1[646$#1!KM(3GYI(R  Z#^^=W))[8
M-J6]L;E%E%W(+:3(564NI R.WS*>QX_.MJ\DTW4=.U-9?'FGAY]6VSV$&D*U
MM:QJSL5TW4S(S!E!V!""&0*2T@R3Q^EZ5):N+=-9@U5&B%Q.#";6U@=CA0.[
MXX!? 5B1CG./SEQH/"\TY<E2G9I+VW,MFU%UJ7NV33?,U=RNE9Q<O[/J/-</
MF2PN&]GG64YW=N4'PM>,N:HDI/A?B92:<(I-M)Q46FU&"98E1IYA<QQF;'^D
MX,'RXR3RO(P#Z<=#7/NUU&TQ$I21N9R3C(''.,9[=,5T=[%';RA9+G8TQ%M;
MD0%LDX ) ("XSCUYZ@FL[2HCJ1<26]S'+:S_ +^&;@#!Z-D*RMD;3E2>N?2M
MJ#Y<-]:O>"\NEV^MGZZ)7UMHD>?F-!8G-8Y3>V;RYO=6TM$W*\4[.UY+WKN-
M[7>W4>$(PVH1R7DWV6T;Y9[B>8G'') .3G'0 'GG/!KZ;^ MC#I/P _X*EZY
M+)-]FG_9,^%.G7$%E< ?9_\ C8=^Q:PWDY#J0GR9^5MQSU-?*\:(7A+RR@11
M?ZN4\X4?<4@Y"]\<<#\:^O?A386L7['G_!3.5)/,GN_V7O@O&",C*M_P4 _8
MQ4D?@Q'7/';BNW(YN6>Q4K?\*T94KV6BBY2>JO=M\S>W2RTN>5XFX1U?#+,X
MP47+@N7^LT92E=N34*:5ER^[>=G'=:R=FU;\]O"_[0WC/P%%-9>!6MM!BFE'
MVFY-LMW>3 ;L DEAL!)P 4!)ZDYKT;0_VI-=\27%II/Q"AM-0@:Y2!-:L;.T
ML]7C$CA6:^/EJVIH@)R)V!;D+,6.ROC9PP8;,E>."IC!XSTQG\QCJ:[_ ,(^
M&=1O[W%K9RW%\2H@MX 7(/KP"S,<<  =N2<U]5FO"_"<H2Q6+RJ@YMJ:Q$DE
MBN;FUDL0YJI=K1IOEY=&F[-?SIP%X^>/\<RROA_A[C[BG^QXS7+PG&3J<*\F
MMTN%HP]@[W:2A!5'?W9IMM_<VH6'_"06\DWAJ>2W"0*;G46$B#[6Q+, QP<D
MX /))R2:YVV":+=[-2BM;_5@KM<ZSYSW@NLY(.U@Z!MIP9-I;(.?6M73;V_G
MD2PU:'[->V,3+>M8W&Z"_P#[0(8$E#M.X2*C%2=PY."I-*;2!;O=:PM= P<+
M/DL6/1CWP>V?RK\8<_JOM,$V^17;::NTTDOWR2YHV5[/2]GRI[?Z7UL/@\^6
M6<1X5<N;Q:3<KQ2M?F<>%'S*G4A-R@Y<SJ)J7[QQDF^%\5>'K/Q)-',8&T^,
MG!FL@S*".X#$[<>Q_I7SWJ\FH>"]1N-.C_TN59#%-<01?+=6C , H.3R,DD#
MJ/F/%?4-KPEU)(1,!,5)(ZDY&<8YSQP/7->/?$#5?#\%N88;2\EUB*43F\\H
M"SM[+'.(^6ZGEB  2,'FON.'L=B'BY96Z;S.G)NW+=J_=WLVOA<M&[.Z3:T_
ME_QPX6RN.5_Z[X3,XY!G+DN:5D^=W:LHQ2BIRC'25O=CS*3LVSI_"'B&+Q+H
M\7F11"]MLF0'YMQ![C..VW@#)X]JWK])C:M$A806UQF.X Z$'*D@]O3/U)KY
MR\#ZUJL6N110:K<Z9I4USFYE@+XX RS*A4L!_=!Z\D8%=]XI\9O->R:79V]X
MEQ"0L]Y=R8&3C@*N#SCD[B?UK;,>'\3_ &I_LKBZ<OWW+?3#I;)IVU2O??3=
MM[>'PQXOY7BN!'BN(E+^UHJ/#',W33XG:5URQ2<E=)N4I.,7[S3W/0391I (
MG1?+W<3RYR/R';_ZW2H)(%D6-X/*! _? #J<\$@@X'?L.N37EUW\1);,3@Q+
MJ GMF^S%X#A0>FH#()!497YL@DX8C%:?AWQK-J#2W5]91W<6W,\$!-GRV,7O
M[M>#N8DD KDD$ &L7DN:0P_UF6MG]ZZZ.WIK:S6NS1Z%#Q2X#S',UE.$YKM/
M51^&UFKRBI67E[S<7)^9Z/I6F7$]WYL23I9V@^T3@\K:[V X]B<8]\],'!\7
M=+76M*L7N+B&/[&HM+;R)P"+0 G@!F.%.5!R"03QTKD]0^(MLD*RV,\T=C>P
MY>U$(M<_V<,#=AG1SD$A@2=Y.<MQ7D^J>/+S5+NW6?,UM%"/W . 1@@CCG.3
MGO\ 2M,NR/-\3F>#QO\ !="Z:E\5]5R]=;W4D^B>G?GXP\4?#C+N#LUX4_Y'
MCSVRNG=.R34M'=02LU\,G=W5FDN%EM8CG]/KW(]O;I^E9TENXZR$>O.<>@[_
M )8/X=_<M3^'(:VAU+P]>I?R31DOIUK;Z@+ZR( !#91E9<9^=9"#P "!QYW<
M^&+H3^5&&ENMS":"8'.0?<DGOW!'ZU^@X',<+7M:;?EJI)ZW5G?7TO>S['\B
M9]P'GN7V^LY4[64HSA).$XR^&4)1=IWU=D[I:]3H_A]:RRSW5Y'I\5Y+9V=W
M<%KB8M;L,;&P">6PP94_B;:.V:[ZVO[>Q>*W?3X[=Y8SF<HQ52#P#V [$Y!]
M^><CPIX9?15OKB[UC3HM]K=P/;K,+C[._"@HH9\/D *=S*.376:]9:1=RV4<
M'C"TF'DVD<4LNE:A8#;R/MK[D?>,]7'+ $JIQ@_+9A6H8G,)))SIVL[*M:]K
M\NW*U%-Z6Z\RY8NY^\<%93FF2<'Y=:,<GSAQ<E"4N%G*7-5Y7*TYN<92C[J;
M;M)<K:?-;/EF+%HS(3)Y'D0XYQDD  GH.H'U[<U0GBDBAEVP_+.1^_\ ;.<9
MYQD_A^8J_;VH*.WGF1<^1;R"(6YN #G/V$ L<\<EL[B 23TS[Z7[+'/Y1%Q+
M$6 AB@8A54?\?^_IM&0.0#@@G K@BKU^6/5K3OK9.[MIMOIU['U.82_V/ZYB
MURIQOHTW'3:R<KRWUBG=)<K:U*3R3F6+RI/-$Q(('8XP!Z=>I[]1GOZ#91VY
MT.]-TZF:6W7^S[6278QW'/V\*#SM52J D9RP.1S7+VMDQABO?*F^;[*UN9CP
M=HYQQAE)4!<8&/PK0TZ&"61P]R9IY23-)S@'))ZX)/U/X>N.)<;;6=/6]M7K
MU>BLDK7;U[=5VY#A\30Q.R?]MQEO*RM*#2=WJW).^M[)W;NDCSEOACJ,Q,MM
M=Z?+ Y)CD-]8@LO3) E&.01C Z45[*;#P<A*SSRK,IQ(&!R&]^>N,45N^)\U
MOHZMNG_" _TJI?<DNR2/(_X@/D$_?_M+AA<WO6_UM2MS:VM9VWVN[;7>Y_LG
M_%:7'CWQ"/0:</RTK11S_(?XBO-O.'M^1KT+XM_\E \0?[FG_P#IJT6O/*_J
MK+?^11E/^%?DC^+\/_NJ]'^A_FV_\'4?_*5/5?\ LW?X%?\ IGU>OYO$ZGZ?
MU%?TA_\ !U'_ ,I4]5_[-W^!7_IGU>OYO$ZGZ?U%?G&;_P#(RS#_ *^S_*)Y
M%?XG_A_S+/W?+9#\W7/'7/0_RY[5'5V<EF'F"")#T-O!@9Q[A3T_V_SYQ2KS
M3GB]'U>OSUOJ[6OJ5Z***"PHHHH OS6DR7)M,K+,)S;CR)DN0QSM(38?FYZ'
MY<D$8!!-4]Y]!^O^-,HH 5>H^H_G6C'(81*-BGS8<?O8@<=#N3.0.1\K#@G&
M>E9R]1]1_.MJRMH[DB'S8A+,2%W;N._7@#/Z?G6=39&5;2*]?Z_+^NF.Q8C&
MTC\_\*D48 !K5FL/]%^UQ2^=@_O_ /9)/YGG!/)_K62QP./I5I)+0J%55;R3
MO9V=]&FNZ>WEW7W$-%%%,L**** "BBB@#[H_X)GM_P ;'OV #T+?MM?LJ?K\
M>/ G'ZU\QZ[''+XK\2111'SAXH\0@^N?[38)P>H&" .F?7K7TO\ \$T>/^"D
M'_!/T=O^&V?V5/\ U?/@05Y9INEVNH?$#Q"ESYL$"^*=>/[B$7A4'59?NJS
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MK1RY-M$MOE6;N<D$'+'N,9S]*_8>$J$<LRODPE1U6FVY:KWGNU]IW>M[)/\
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M,HMO632<7;HW%)M62R]8N/.$P$GE+(#C 6\"@X;K\HYXXY/Y@CR6-YHM0N;
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MX1<7OV>>:;-VP#(&W<!5*MC!QACD@]SO?$'7H[%(M' M[E-XNEE4EB,@YPS
M<8SG('4 >_C+,,9E^:U,HCEV^KN[75KW?YN[;=]$[,_1<1P=PQQ9X=97XA8O
MBEIQ?2,?M)+V?*N5QN]II-VB[VU1QFDF*]TJZC21XM0MIV:&40*+2X"C);G
M#JV,C:<@\CO7T/\ LVWDEU^RO_P4^MY)3(?^&5_@\KGR,G#?\%#_ -BU2<X
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MCBOZ*?B)I$OQ0L+'PQKFD#1? 4]M]KM=:T[4M*%\?$.?^@OK1&/^0L,C.?\
MB3'NN3^>_P"V/^SOJD_@_3_'7A[4](\66NEG3]'U;4(H8[>^T=-,C>/^S/)T
MO69(VT55<E'V;U89C*288?G' /CIF>>9QE.#XJQV'RFKG/[EQAA[TX1G+FH\
MU>,I476KRC4HNE4]Y<E-1524^:/E9WPIP%EN0/*L'E3><1C+EC+BMN_%#BE.
MFHI<SC:/,E_QB]YVN[:'P9\&_!E[\1]2DT;2%OKJ]TVPWPK<P%&X8D*&0D*"
M23TX[\5Z=\5OV>#HU\0FG:EX7DL-*^UZBNM0'[=<MD_.5SR=LFFJ!GK(S=>O
MO'[,GPB\;:%H>D?$KPWI_AC5=9N9"UIIMSJFFB^U>PX5M-"-XA\.NN2,D;V)
M)P#TQZA\8/%^OP:OIZ_&K1[#Q@FLV_VM+876VPLWU@C^UM6)T5E&KZX, ERP
MV8T)F.U:]O-^/,TI\?U,)D&8X>>5T^:$X>VC+B!5J%_:N%.\:4Z32;BWR1;5
MH-R48GN<.Y:LRRC*^%,<N%<Z<HQE)+F_UI5HJVK;Y>5+E;CJXK72Y^='@#0;
M.QEN9[0F"Y6Y^1;CC[*,GG(R&.<CD$@>]>IV\A7S88_*N#*0,1*<W&#D'& <
MCKR <G&.:^B?C=\,8O"&G>%]7T/3!!X?%O?&Y:V&6NO[5+9U35C]U=;.1D8P
M=JX.!S\OZ5J5S<0B[BBC-K:3K$&/2WNG&Y6Y.[G:2,Y!P.A%>A2SZ/%>'6?8
M-OEDI7C*RG"4)3@XU.B=TWU7+)+649'[SX3YCP_A.&<JP64\L>;G:27Q/24I
M)6M9*5Y-W=VG;E;2NQ37$>1>#,GD9'^D G)Z#//..@R?4<UQ7B%Y)K>2.*0Y
MC;,_!P_;Y?QP.IZ#MR>@U'Q!86T5U(1$NWD=1GZ<= /Z?2O'M=^*%A;!4MK=
M;@@G[3#-!FUG(R5Z'?\ *#@_=Y.1CD5[>39;C,3B74PU&22:UY6HVOL]/M)W
M23ZKM9GB3QEPQDF5/"9MQ/%/EG9)RE.5KI:1U=VDY6U:T7O6-;1;IM40M/=3
M$Q0&"VMQ:DDYYQU(QDDD]<G!(P*]$U[4[*PT'2K*P@,%_8?VD-3UK[4/L&KD
M$C&E8 Z#5N1@'H0!FO";#XF01Q?9X;>2" G_ %,!('U/!]<G(SU/:M#^WCJD
M/[M9I5:YLC<61)"OL#9Q@DY)!7&!C/0C&?IL3E&)>*YZ]-QI<VB;4K65DF[1
M;LNZM>VNB/P++^,N'\1E26$S59WG/+VDMDMEROHOA6MELE=GC/BK4Y=8UJ[O
M)I3(TQ9@YXR<\8'7C R.GKUR/0/ GB*ZNEM="\[@N191R$A%NVX7!YVEC\I(
MR,]L]77O@W3YI]0 6:*'YYM/F_B SN3<!C(*]#U! [G(YW3-.8W,T*>2##<_
M:(9K<8LQTR,$<#H0#SQM/%?75J^78S+?J_2E&.J=N5:)76S]ZUT];7=GK;\
MP& XQX5XPAFRTGG-2IS6<OWBYGS0DI6=EHXNUK\MI+KWU[JI5KL2VEY:""Y-
ML0XR%QGAB5!#8Z<D<@Y.:6.^T^X6/#1>9Y&)H@.2 3DD9!)(VDE>XR.F:S#I
M<ENQG4K< '$TLF2#G&02>23CTY_6N);PSJ<]W"(W/[V=1YA)QRP!],8!SCCJ
M<YKS,-AL%B&_WBI]FN:[>W35:KKW6Q]]F'$/%66\K>4O.G*RE&Z?+=W3O%.+
M>JBW91T=Y-GJ$^IVD4,NYO/E+#;%$2 H!SN) QP1TYYX[FFW>@:SXDL;Z2&#
MR(;&U%Q<+-<&S:XRP544,,NQ)^5 .O3DXKSV\N)-)U2*W>87FZ39-+82C+9_
MYYWX ;!/5E!7(P2<FOU'^)WPYT3PUHV@:Y:Z?I&A7%L/#_A_Q2EOJ;7XM?&'
M_"!Z+K&K:9K**\;:3K:RC5F*#P[$&==AD&":^?SS-:7#57*H0A*I+-ZDXTFK
MR7/14)M6L^5-.W-)17.U'5Z1[>&N(,CXVXO? /$&9O)7G49Q44H^_**^%5);
MRM*-TI)=W9M'YAV4-_9R"1XC:Q' G\[/^EG/"J#C 'M@9YR>:[?7%A%A#-9S
M31Q2+:M<0SP _9V R!G)##()4C!85)XMU^+5-2D*10QO$,G^$#!Y&#D]O7MS
MCI6=]N:\LI;8 _9;@C_MWP?O#.>0!@^H!->[*6)Q+R[%N#IW>BN]$W?EU3>_
MO)MKY(=#+\KR5<3\/8/-/[;5FHRMROG3=WHTU'2S5K6DY/\ F7+>=/)\YC#E
MN2Q4Y/Y^G3\**LW.KZ[:7$MO::=$UM$Y6%G@ 8IU!.1G.2:*]'V%;_IRO)U5
M=>3\UU/C/K&&C[M3-N)U4C[LTN%;I36DK-J[7,G9O5[O4_V-_P!NG]H7X4_L
MF^%?B]^T)\=?$EQX2^%'PZM_!]YXHUV'0-1\3ZA:-KDG@WPAI6FZ7I.B%=<U
M;_A(]=UG2/#\KL5C3^V69V502OY6?!3_ (*+?'S]IG]J+X?_  :^%W[&7B7X
M,?"76?A-X>_:.\4_$[]K+QCIW@/XI>(?V=]8\3ZM\-AJWPZ^!GPP3Q(FB:YX
MF\=Z6R>$1\1_%;',4A/A!8S%))^J_P"V]+XWB\._%T> /@;X:_:9\5SZ3X;L
M[;X%>._&OA/X;^$_B1IVKC11J^EZYXP\9Z'XJ\-Z-HWAO0AK'B.0^(_#+*7T
M8X=OO5_)S^QIXP^%_B#_ (*<^"O#W[,__!->^_9J\<Z!KL=O^U!\4/\ @G__
M ,% %^)?[*OAWP7+I&L2Q^ OVC/"7@OX1']F#6=!?6='$@^'_A?Q3X5\4GQ/
MHX&X^,?#P5_W7+\2_;\+X5-?!YKH[M-:IVO:W5)['X3B+_V9Y::=;W[Z^6EO
MGJ?D5_P<^6@F_P""G?BB6WGG^VP?L_\ P('V>#[HT[^RM:P3W(!(SC\>M?AC
M\-3JCWLU_J+1ZE:6^C7]M;[M1P %4[=.!W%LC<2%P, Y&<@#]Y/^#ERST_4?
M^"J.LV<MU!8:B?V>/@3<6.J7-PVVU1-)\7NH9EZ&0-I2@C!0H6YW8K^<W7+B
M6UU>]ELA#I\MB-LXM\V8&UUTQ@HY(.3EAQG>V>I)_)N)\.L3G.:94E=WDF^6
M]EHE:6FC>ETVT[IJS3/A\]PZS#%9GE+T<DU=Q?NI\MFFFG9\J5XMR3NFMFOT
M#M;;3+[Q$L?ABY;0+_4='M!J,VF$Z-=VEIIR#5-:L%TM65=I,>HYT('$FR,#
M. #YGK=_X8\&:#KK:EXE_M*XMA]I\/Z#+;Z??Z?=WIU+1Q,QU72-=8IMAWNP
M"ME5.#R37S6WQP\<^3I4%E=QZ<=(@*6LUK\K]?O<Y&[MC'KD]"/+KO4KS4[J
M2XU&XFNYY29)&EE+Y;.26WD[F)Z<YZ;0,5\%E/ N8K$K^T\Q_=^[>FY*<Y<L
MW)+VC@G!.-H*S5HWTO*3/@LG\-<RCB;YKFG-E:<?W?\ $G-QFY/]XTI4U;E@
MG&7-R\RT<Y->DQ_%/4Y=>BUF2VL(+A9,[H+=4NL8Z_;B"Y<]F#].-O)S]J?#
MKQ&=4TJ#SI[$7@.H^(+!FU?4+8W=XVW^U674-*P&)QD$L%']C:X ZEEW?F@S
M-]UUY/(/T/?C@\5[/X ^(<WAN:#2;^?_ (D4VIV.I7L]KIL5[>_)Q^[_ +5"
M@@HV.3M8\AG4XKU.*^%Z.99=;"1Y:D%=15]4KZ;OF?2R:;3DKJY[7&W!6&S3
M++97%1J4TDDKJ\5=\NLG=KHE:ZE))Q/J_P "^$O$?A_3_&*W%K9VESX@U W<
MD[6Q M;-7U8&_4X+*BZLPP>Q  /:OB?Q1?WWBSQ+?ZA=B9I;F\OW4*.0P8_>
M)''+#(.1C&>.*]ZU_P",FFW]E/I&DRW\UY?7:K>/;G4+/3]35FX#Z:.!C)^4
ML"#D #BOT/\ V7OV17T;0[#XH^(M'L+O6M:T\Z\F@ZFNJ"]MK$ZFH>5< 'YF
M'#%B6B76M_"+7PF8\487P\P>9<6<6I+-,YJ1A2A'EC*I5E&$6DY2;7NQ3E-K
ME3<592E:/YMG'&^$\)<MS7B_CJ"6:9U.G1X=I0E&E4FTDYP][VDHJT+SJ.*A
M"4O>7-)1/Q$E@:%GMY)"RC##8=H/J<,.ON<^^.:J&4YC)_A.#Z=,>W<>WY5^
MEO[8WP*\/Z;JJ>*?!=J=/@N;@1:Q:PS8L[.5-,.JZF58\^6O[P[?NL%/RGC/
MYG2H8\J1DEN/S[<>WZ]:_4.$^*,LXMR3 9O@>91JIN4)64X/K&6B6^L7RQNG
M>RN?L?!/&N5\=Y!EV?Y4Y*%2+O":M4IRB[<LU9>3B[*\6FDEO92)[F3T08_$
M^OYC@=R*UY-/2SOH[6ZG* FRW7JPG-HO!.$)&X*I )/4+G&0<2:*8LS>9M\X
MCR )LX!/![<8QM(/(Q78WVJ:-?M:E#?33-:_9KG^V'1K&R'_ %"@C;TQC(#A
M>3P,&O3K8BNL1;E;BEK:U^9VL];VL[^3Z]#VJ^-Q"Q+M%N*5V[;-[:N^G8Y.
M72#((C ,QG[$&\CYOF<;2<==Q.X@^N">]<W)&T$DL?!P2 .PY/\ D=/7Z]E?
MW\=G:0165YP<"[AM[IL762.?EX 'N#Z\FN0O+AKJ=I5B$(/&.>WU'OZ?ETK7
M#>WUY_AL[/JM=+KK?9V[OR-L#]9U<KVULVM=>Z\_+OY6*%%%%=AVEL0$;CG.
M'5&]PQ /Y9]O3FOOG]A7P38^-_'7BK0M10S?9/##ZO:YT[2]0L1+IU];RJ-3
MAUL'2O) ; 9T<MPJ;I-ZU\*6UG=W=PEO;(9YI[M($A53F9V;:H&""3G&,$=C
MUYK[/^$OQ;\7?LFP6?B3PM8>"_%U]\7? U[!=V_C#PG#XGL-)L1XFUG219:9
M'KB3:2-6@O\ 0$UN+68$(ML11H=XE67Y'C["YEF7#>9Y1D3Y,YSBG*GD#G+V
M=JL:D9.3FTTG&G&2L]Y-=FU\#XFX3,\UX.S?(.'Y1AQ3G=)4^'92J>RC"HG"
MKSRFTXJT(3E%224VXI;-QW/V\_A'JGPI^+LGVJ/2X)=<T73M1N_[(GU:1C>L
M7-[=ZM%K9.KZ;K#R8:YBEC ^5=B8^]\#;R6&X=7#<GL,#G/KQ^>?8?6GQ>^.
M7CSX[^$M.N_',KZM?>!BND1ZI)IXDNX[+5&+10ZSJYY:-6RGAU)&8K^\C3!
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MX?CK"XOB?%\094H93=/AI2BN>;3E!23A>ZE&SYI)-WMHM20332)#\T_[T9N
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M<"[\L,&7E3DMG+<<+[9K=M]4OO%%O%=7<OE216RVZ^3  ;@#/#8PI/S8))Z
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MKWB'4_$5W-+/<2B-97,43LQ8L2<;5)PN.![\=,<TK.W%[)'IL*P^?)<!%GF
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M<W!=:@\4?G$&7)N=QGQ>D<>I8]?F'&[^532W4QF&V7$.?M'[\'_1\G.#V)'
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M_#J_^'>N:EJKZ%I6ZYU*[G\.>)+0WU\R_P!F:/HNX$CYE+:JP!Z$@X.00/Y
M^D)X8\=8;Q-H>+/#?"RXD53_ %5J2C34H\LG"<*V'=/EKQFY472<,1&@K1E!
M\[DGR?XQ>,OASQ/P%XVY7XG<$<,+CC^P^*4UPM=/F7"UN&(SXH?NWBU+F5GR
MM/3W=7\Z_M??"CX5Z;X+\%_$:UT[5;36'^$FOZYK4FIR&[O;C5-+;R]'T[5]
M-X\N/^W#J_\ PB[D_P#"*[0,[@#X4K\''\7O=V=_-/%&+MDMFAMA+>D.;@X5
M&S)G*'@X! ZX/"C]"_VD?VO-7\=S^*/$O@S7'\*^'O$>FZ9X$O?A[:V!AL?$
M'APM'K.K'5=.8%8]#.O:5'LT(YVNZ$_**_-33O"8UR^C:UO8["*XNA$UO(KF
M0;,,7VC("@D#[O7E1DBOZM\%L@S/(.$(PXQG-5E)2BI2J5982A&5:I]1DYQ5
MY4N:$>>FG"RE;D<9I?UYP^^.<DX-X%X2PK4<XOQ(Y<-1<(\L>)ZT9<-IM^Z_
M]7:-Z<.>4?9R_>6=S5T+QGXKDE_LJP!OY;A@/LTR_,>"1@,0!QZ^YY-=U8ZA
M=ZLLEIK=E(;LP?:+>[N&<G:IW!=/' /F#.,$@@'H1BKMG;>$=/FDT_1H#?:A
M#$;AFL+<W3D8!+DQ[B5 89*C@\<DUT2Z-XJ\6.\VFV[3R6D)@L;N6]S>2;2?
M+7["Y9RH!.,E5 )R<G-?>9AC\&Y3MEW]CP3LJM9J@[N27-RN3;;O\/O.UWNC
M]MX7X:XIP^&6#?$\^.,V349<+\,)<40M=J4'JG&HE:2G\/-RQA+F=SGR7C:<
M)&9AY&/.((QG +8./7&,Y'J>:@DMY'BXC\V/_7YZ>BD'K]#UQ7?:RVCZ:42+
MS;J\4AKC[MU8W7W3]A4#:Q4X +C/(PH!"XXJ344DG,J10KY\[?N%S_HY/13G
MH.<#/.!]*\G#UY5XJ2@TGU[OOTZ]=.U[GZ'F^ PF78F6#Q>9QD]4U%*23;]+
M/97W;>K;2;559I)+FY>Y$T,;[FM_]'(%SNX)W$]5SC(R #C.3@:FDV]]J44V
M@:'9PZUJ^K7(TV#3;9/MEX7U0LJC3T.6!)RH=&W+D]LXY;6];@.G_)#%;73-
MB&2WA-SDJ>5W*2<$=&P<<Y&217]$'_!![]DOX6?%*T^(O[07C[1AXNUKPCXG
MT[POX/N+D:A%IVDZDNEMJ^KEAE4U<@:IH^5+*.I/&#7R/BIX@95X2>'.><?Y
M_E^(]CD4:4:>'P\7*IB,5.K&AA*,M5"$9UI\LIM\Z@I1IQG.2Y?YB\>/'[(O
M W@_,^*L2O[;C91NO=DO]9Y6<4FI.Z2MRJ-N5VYKRYH\3\"_^"#_ ,7-1UCP
MSXS\;?%;X<>$?A\-*AU73?#6F6>I?$/7+O4]0TO25U;3M6T18?#>@-H_B/45
M>/Q.K>*'V>&B_ADF91Y#?<VC?\$*_@9X:\9:9\0?#/C.?^T/#5]I^O>'?#/B
MK3Y5\%/XAT>59=+&KZMIFNKX@;1!(H8Z-&-[*6C,S1LZ-^\-H--E^V0P-!BW
M_P!&\B Y^R=!D=.>?0   ]JR?'D21^$/$$<,UC8/<Z'J&EV]S=69O+(:@VF,
MVEY!!.[O[DGI@;O\9,]^FS](CBW/(QAQM_J]"4UAXQX<X;H4J*HU*L'&>(IJ
MG5J59<DHNMB&Z2<?;2I^RC)I_P#.UQ#])+QYXEXC6:?ZSK(W%-+ACA.$(MWO
M*2;Y7*3;7N.4KPTBI)73_AI_:@^$/BGQ[^V1\3/ G@K4=(^+7Q*\3^)+&_M]
M3^''B7_A.M \7ZAK6IG=J0UC&[1=N\9'B,JWS M@'-?-?[1?[*WQY_98O/#\
M/QN\$S^$4\4MJ"^%M134]*US3O$)TDQG5&TW5='U>2-U1M1!8C()/)S7]=W[
M$'[!W@W]FOQ7XP\=V6D&/Q%XR&GZ8-8ATTWPO/#R#1=7!)UK72V/$>N8\0?=
M(4:.HQR!7GO_  5O_8QM?VC?V9-3U3P1?74OQ%_9_M]<\;^%]/GNOMA\0:#H
MVFA_%FF(P8E671$#*W  T;&#7]S\(?33X>P/BCP+X88.#Q'AU.EPSPMQ'QAB
M836*C7GAXX:A-0I5)4>'L/#B6&%PTH575C"E6JU/W;HQY?\ 2/(OIV94^,>!
M/#[!Y5%<(/\ XQ7_ %J^R^*DI:2V>O-*]K7M;JS^)9M;L Q ,^/PHKF&TXAB
M-UL/K<CTSZT5_I9]0PO=?>C^PO\ 6'/_ "_ _P!M;XPS&/XH>(R>,RZ)GI_T
M+>DC_P#5W]>>*_ SX&_\$G/V=/ GQ)\&:_HWQ^U+XK?$[]E;XQ_ B[\,ZEJN
MD_"V\\?? SX._ GPOXVUOX0_LN-JG@K1/#6N^!=$\3#XNK\0?BWKVNQP^)/V
M@DC\.#QA AW^+6_=WX]6ZZEX[\;Z<E[J>EB_T^TL?[2T>[^PZEHYU3PWI$;:
MKHY/76E9"J$]4"DY)X_&S]D/_@GIXZ_9O_:9_:'^./B?]K;]J;XI>'/'OCGP
M;JG@_P *>/?C+X9\76'Q,T_2/@+X/^&^L:Q^TIH[_"CPVNL^//#.MZ7JT7PB
M'A7Q-%'_ ,(CH/P\)0RF663]SRN@G@<GE_9O/[D7S_S7C\7_ &]N?+V_V9:;
M?AH?QT_\'1;_ /&TC4>O/[._P,7_ ,I&JG\N?Z5_.4W4_4_SK^C#_@Z(_P"4
MI&I?]D ^"W_IKUBOYTG8L<'L<?S^GK_]>OSK//\ D;9C_P!?%^C/*Q'\>>GV
MFK_<U^9'3W;>>!^G_P"OTIE%>,8A1110 4444 7'N9Y46&2:9H83PI.<'..>
M1@^F2?SR:IT44 %.Y<]AQ^F?Y\^U-HH **** -TN8R1!YC;977=G*."P:$YZ
M%@Q  !SC).!S7U3^QSK\&A?M/? S5-7TJ;68M.^)OAV\O]/A@^UO?%[N&-8E
MC!.[,;;,'DX)]37RG [%\H)&96:01<;4(!S(W3(4?=7.,]NA'[-_\$Z/V<M'
M\)ZUHG[87[0/B7P;\-?A+\-]7MI]*B\6ZB9M?\6Z](T4TDZ>&85EUCR;6-1)
M&CP1OK/F26WA\SS1.(_A_%+B/ \-\#<0ULS=;$0SG(<;P[A\'3YGCN)<5B*%
M2A2X=X?4*;E5K5U-05.DIR:C*7N4X^]^8>-7%F1<+>&7'&*S:\ZF;<-<0\-\
M.\.8?GEQ!Q/Q#Q'@\5A\-PWP[2I1G5GB*TZK47&G^[CS3E90FS^O,I!=0E)0
ML\$\ RLUN,')^89 ;!/; 'UR :R/$6M6WAO1;S5KFYTZS@LX<0)J-T+1;F]Y
M*6"E@2K,OSNZYVCD-UK\B?BK_P %K/V4?".AWC?#Z[\3_$'Q#* -*;3/#ZVN
MB(#DK+J UB;P_.CJ 0-,MTC9>!YZAE%?FS)^WC\?OVWI=0TB<VOA+0?"KWGB
M?^R/"^F7\>GV>B:=&$GU/4]44Z_KAU16.EPAV+1;0K,5!6O\4>"_HD^+N<P6
M<\495/@GA/#U55KU>)H^RQ*C*?(O9\/1J2K>\_=E*:I\O,G%U):'_/-X>?08
M\<L_P_\ K%QOP[4X"X1RFIS5*G%?N8J493DFJ/#?M'7DI-)5'-T(MR3E[1;?
MOQ'I7B8+#>7US>^&O%VIW3/=ZA96XU*2[O-5+$E"NC: JEB26QXEDR2=JKS7
M8WOC>V\':WX=\-ZC>ZIXIBG(MYY-.MK"T-I?OIX O]2(5_[7"*<'^Q9,^&D4
M['9P0R_"8V3>'-)U4"XFMYH6L](\J#4KW[%:!_[6TS2R257_ )!#$\9&T@]!
MFMGQM\.]'UR:]UV)WL?$MD?[7TS5P["\MM04Y_LP+]T\C(8@D8STXK\YQ.8Y
M9_;DLKSFC^XC.LE)4U&TVI0BG+WJJC"T?<<YQC).*;=T_P IS#-,KCQ#+)^(
MJ7+E$95TN6*C*-25Z4%?6K"-+9TW5FHS32^TG^2_[1<6L6O_  4C_P""5EG
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MV-LQ)@AC+,#D8Y+-EO=FQC..E58[^_OB/.!DCAF\^""]A:Y5L\'(((*D?>&
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M5XQE4BG-1FI\,:.,THVBO;8=0F\/^*KKQ&B_VM:ZO-=P1+<W.H$6<IR"Z8)
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M-#<,=AEC\@DB&;;<X/TPJ>HQMX.>N.>Z\.SR:5:?:X8&E7S]OD;6+*-N?MH
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M  NGYKO<[N&<0L-Q/E6*3DFIQ;<;MM\T6UKTEHGV5]--?K)M!U!F)&GN0?\
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M[L[C"Z\S>03/DX_BR./7 'X]:\997[?,'B<7)M-<L8)OE2LI7WTO):J*3O\
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M\]_^";?[!#39_P!8?V/_ -GO=T'.?^%>=??K1_PZ=_X)9?\ 2-/]@#_Q#?\
M9U_^=S6&':H;7?X_+I_6RL*A1]BFKMWMOY7_ ,_\K(_Q"R3'YL9[\?D>OY>W
MX^L5?[?/_#IW_@EE_P!(T_V /_$-_P!G7_YW-+_PZ?\ ^"6?_2-3]@'_ ,0W
M_9U_^=S6YN?XBD<A@:.6(XE4D^P[#\_:I9[^ZN$$4LI,8.0O;\<?G_3M7^W-
M_P .G_\ @EG_ -(U/V ?_$-_V=?_ )W-'_#I_P#X)9_](U/V ?\ Q#?]G7_Y
MW-!'(KW>KUU:OUNK:VTZ'^(+5J.4!#YF2,\>I_3![Y]OI7^W?_PZ=_X)9?\
M2-/]@#_Q#?\ 9U_^=S1_PZ=_X)9?](T_V /_ !#?]G7_ .=S06?X@U%?[?/_
M  Z=_P""67_2-/\ 8 _\0W_9U_\ G<T?\.G?^"67_2-/]@#_ ,0W_9U_^=S0
M!_B#45_M\_\ #IW_ ()9?](T_P!@#_Q#?]G7_P"=S1_PZ=_X)9?](T_V /\
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M^P1^QC:8('^C?LP_!2 XP#R8O!*$\G/-"?\ !-W_ ()Y7@S=_L*?L?7)R?\
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MCJX0]4D_9J^#;+QC^'_A#<?I6=/_ ,$PO^";"IE?^"??[$X/J/V6?@?ZJ/\
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I/7_L0:*YO]5,/WH?^$\'^/4^E?TF,8VW]6XIU;?_ "4RZN__ #X/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>tm2135630d1_drsimg2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg2.jpg
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M\BNOO%(=X^HH97]/+_6>4JCW%.'\_3VPL[.SN+BXNKJ*YT^M5@LK"=,'KTN
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M\5+O89"+>@^H]X2H]X2H]S0:8N]!9>'_H4FHS9RBWA/$E 0,\F**%U.\F)*
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MAMR8XL64! SR8HH74[R8DH!!7DSQ4N]AD(MZ#ZCWA*CWA*CW-%+OZ<+2YRC
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M:&B])W1^3R+,F!R-PWCO'?3?YVA,IJ:F$O>II!COO</8?X'A>EZO\)))9><
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M#RA>O;VGOL>G3Y_BU^O=WU/OK"JU]W D_7QXH[/!5Q;??O+D[44,;GS(*_'
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C(C(IU'M$1$1D,OSE+_\?TWX_+S7;55X     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>73
<FILENAME>tm2135630d1_drsimg22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg22.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $^ =D# 2(  A$! Q$!_\0
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M4_#QG#R>)(1(L1;#?[SI_7H!P8_:_P#^"[$F=G[5_P#P5FY[#XX?MFG&._\
MR,/YXX[&E?\ :\_X+NQ'][^U;_P5GAZD[OC=^V;'GTY/B$=!U&[.<Y'>O6_B
M-_P2<^)WP6_9(\*_MD>-_BEX-L/A+XX^$?AGQKH6I6MIC[;\5?%GQ2\9_#'1
M_@OX0U<!1KGB"30?ASXN^(\WB7PV#X6\+_"_16D+>*2_A<>*O+OVKO\ @GOH
M/[-7P;^#OQ]\&?M6_!#]HSP!\8?%/Q#^'IU+X;VOC[03X;^(GPWTKP9K/B_P
ML-(\;:!X9/C30?\ BL-''_"P_#6?"A8#L0!YU?,/8/'1M%N#T]W=M^46WVT3
MTZ6T.)U\1K[J:]7_ )=RB/VP_P#@NS']_P#:M_X*R_\  OCC^V:O\_$/^?YL
M_P"&RO\ @NC_ -':?\%7O_#Z?ME__-%7YWW\47V>?[5#_P O7X=O_KG\/I7+
MC1[6Y@F\IH1-!R>2,C/3G'T_.KH9@I:\J^ZZ_%"6/CUC^*_R/TW_ .&R_P#@
MNE_T=K_P5A_\/K^V?_\ -%2?\-D_\%T_^CM?^"LW_A]?VR__ )?U^8 TJ"*0
M_N?/_P _R^GZ5!+I?^2?T/\ ,?C]:W]NOY?Z^\?U_#=S]1O^&Q_^"Z7_ $=I
M_P %9/\ P^W[9/\ \T%'_#8G_!=;_H[;_@K%_P"'R_;,_P#FAK\PH[&6),R"
M#_2+7/)'3/TX/2IKJUQ;P?ZC_KV'8]O;\.O/YKZQY/\ KYB^O13MR_=+_AC]
M./\ ALO_ (+I?]':_P#!6'_P^O[9_P#\T5'_  V7_P %TO\ H[7_ (*P_P#A
M]?VS_P#YHJ_)VZL9H7/F'KW_ ,_7T_#BLZN@[C]<?^&R?^"Z/_1VW_!6'_P^
MG[9O_P T%+_PV5_P70_Z.T_X*P?^'T_;._\ FBK\J-/<*9N@!'0_Y_4T^*US
M^^Y]>_<_T_*L76L[-;>O^9@ZUG9INWF_\S]4_P#AL7_@NK_T=K_P5C_\/C^V
M;_\ -!6OHW[5G_!>SQ-JEIH?AS]I;_@KGKFNZC<&STW0]$^,?[9NH:CJ%WD
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M_P""LW_A]?VR_P#Y?TO_  V7_P %TO\ H[7_ (*P_P#A]?VS_P#YHJ]RL_\
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M_@K><_WOC;^V;D>G_,PD]_4=J^G-#_X(M?'#X;_M1?M>_ T^/OA-K6N_L;?
M[3/CM/XFLFU<:?\ &!M7\ Z%\3/"'PM^'FD:]H/ASQ#I/Q7\4>!M6UUV\.>)
M/#*$2^$/$!5A%&GB0>H>(OV*+70OV:/ 7QN^*O[6?P4^!'B?XW> /&'Q"^ _
MP:U/0?BAKOCKQ[X?\)#7]&*ZL/!7@CQ-H?PPT/XBZYHVJ^'_ (3-XD\1^%HO
M%IFC5))/&B7"0_4Y3D^"S+"M?VE&.:MZ0Y>9:[:*,OF[)+KW/K\GX?PF8X7Z
MWBLS4;NRM'=VOND_.[?*N[[_  6_[7?_  7;0$/^U-_P5F'H%^-7[9H .3T
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M7\^N<]SU..*ZO3?$&DS ;(FLKX* MRQ)QJ'HOH.IX&/;)KSG5-4\P3Q>2/\
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MEZ?\!?KYZ/<R1J<^CR-%)#;8G'/V;K@_Y_"N<UBV\V ;!Y(SFUYZC//YCO\
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M=:_3LPH87#97_J]Y?+7UZ?+]4?JN84,+AL@ROA[R3]/GI^-M/G;PZ^TN;?\
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MQ_I5M<_F>_\ B.]$MU!;2>=]LN)S^'M[\_X=<8%>O_:&*WQ9ZV'SC%?\Q?\
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M./3WYJQ::+-=V\P^UF"#(NL7'M_4_P"%=&)(;&TFNX8+>$G&VXMCW.,=>/\
M#Z8-3VNNZ3:R8B'[FX_X^?\ 1@#^ _/IZG'I7V&'R_"]U>W_  +_ ('V.'P&
M%_YBVOO^7W=#S_4+:*V@_P">)-J3D\Y)SZCKZ_\ ZJX(2RR3]YH?M./8C.3^
MF?;\J]O\26L-];_:[:'$'V7[)]H/'YYYZ9]^?R\F^QE)_*["XSSUR"!]>G/^
M/4_.9SEZPV*7U31?=?9+R_X&Q\WG.7XKZTNWE_5FO(ZCPO;&6\YSY\%U_P ?
M/(^R8Z=,9YSQZ_G7KR:+J/B+5=3UB323?Q0Y9U!^PJ,\+WQD>G)'!-<_X2TN
MSL;@_P!L36\'VBUS:W%S_IX]>WOQ_7M76ZSKDVJ:ZT.CP>1#JS 6NG!M2(Y'
M8#ELXZJ6& ?Q^QR#+\+ALK7UOOLK>BO?_A]+H^XR#+\+ALK3QCZK:VKV5_)/
M]#$EBL#X@GOUTVXM(+%L#31J09K5M)('_$VRNX$D  #OG Y.=3Q':L;:"6.T
M@,NK6V+33M/R1=9/3OMZ9QCL3C-<I<:1?+K4S7WV@%#G4C@9!&#^//8UZ-XR
MBO+'P[ VD?N8;!LV]SDC4+0DY/(Z9SGC%>KAT_[+S3%XM+:]^M_RV_'R/4PZ
M_P"$OB?1=7YWNK^6JZZ:[Z'RSK=K-%<W&2O_ !\-CR#D9[8/KGID]<^M<9.F
MPYZ'GWZG\LD?AZ5[%J&E7<F@PZC-Y_\ I%T1:FXNC_IG3. 2.G/?WKRK4_X?
M\^E?DF;X;6_I;^OG_P .?B^<8;ZOKW2MY>:_ H^60,<8^I]<^GK7[+?M)>$M
M'OOB5\,[V_BMY[B?]B[_ ()X8M[BU_ZL$_9CY![]>O&<^M?C5']]?K7[._M*
MW1C^)'PN\[2+#7L_L2_\$\;6UTZYZG_C 7]F0YY[GK_/VZ.$,/\ 6<UMOI==
MNG^9W\$?\C5K?_*VWXGFW_%$^'-'@FM=!T>>?I_:5S_GC/U]ZI:SKUG=200V
M%Y;Z5]HXNK;3;7_B7V?\_P ^A]^:O:#X<&LZ??7EWH]MI4'V7_CVN=4_X\].
M/7G/ZUQWBC0?^$7-C>?Z/]A_XEUY]IN?]/\ M@_Z@_;_ #ZX _=\P_M3+<+]
M;PG_ ")_Z_K0_=\1_:F6X7ZWA/\ D3D%UXCAM=<L;S[9J%]KFG_\_/\ RYX_
M^O\ A^7'SUXW\4?VSX@U74C#Y'VBZQ_HW7C_ /5_]>KWC+7III/)EAN+&?/_
M %X?\2X?SZ'M7E<7G>;/Y69^WI_+KUY[]^^:_'>*.(,5F6%_LD_'>*.(,5B?
M^$DO2_NCD?Y_G_7D51\WRN!_7KR?\]N:@\V;'[WO^)_S^7Z5!Y1_Y[']/\:^
M(/@,1T]'^3.JT6ZFBO,_Z1!!_P _(_'K^?Z8'-;GV#[7>0>5^_FGNO\ 1;;I
M]L/_ -;_  XKG+#][_K1_GK^GK^5>FVL1M;>"\B_<?9[7K_^K\<?2OHLGP_U
MD^CR?#_63#^P:EY<_E0^1;_:OLG^/ICV]/UK*NK#[+'/]E^S^?\ 9<W7_+^>
MO?O]<?\ ZN_L->T>+_EM;^3<?\A0"U!-H>/K_GG&:I:_HVF_9['^R_\ 2(/^
M)@+JYMK8V'VSMS^G?@8XQ7JXC+\+]5/<_L?"_5?K>I\__;YI+CR)?]?_ )_+
MG_/'/9:#:PW5Y_I7[^#O_G\^_7OGFN<O]+^S7'D_\M[BZ_T6Y/K^'T'X'BO7
M/"_ASR]1L9M4&(+BVS=7&I71XS@_\P0Y..G)SZYKP\GR_%8G-#YS)\OQ6)S0
MZF;3[OQ1K_G7]G;SPV^F:?G^S;7 QQC']B=><Y'M^%7KJPT'4/%%C-I<.L:'
M8Z?:_9,ZE:Z5_:']H]^/7I_C6KJOB.&UD@A\.?N(/LNG:3:_9KO_ (_,GKZ_
MYX !S7#Z]:Z]+K'G2Q7$$]Q_Q]6V!V]\<]O?D5]_B/JN&/O\P_LO#?U_7]=3
ML?%$6CW6C_VEY-SI5C;_ /'K_P O_P!LXZ]O0>WX5\R^*+#RKB>;_EA<?R_#
MCWKZPUFU_L+P1!#;6FG:IY%WIWV4FU/]H#43GCC)/7_)YKP>ZTN\UC2Y]>NO
MW_VG5/LGM>:C_D_@,=N#P\48?ZS_ &7A/Z_KT.'BC+_Z_K^NI\_O]W[F>?\
M6\\_TY^IJ&NDU2+R?];QS_Q[YZ$?D??CZ5SIP3P"JD\ Y.!Z^YK\S/R^:ZW_
M  _716\WJ?TQ_P#!N-_RF:_X)#_]D:_:W_\ 4%_;_K_6+K_)T_X-QO\ E,U_
MP2'_ .R-?M;_ /J"_M_U_K%USF9_GT?\'3DWV7]N?]J&?_K!I^SS^G_!9'X9
M?Y/;'O7\/<6H32Q^3GS_ /2OICO]/_K5_;__ ,'4/_)[W[47_:#7]GC_ -?(
M?#&OX<HI88O/A_<>3_S\\GG.?S)X_P#U5Y>/_P CR\?_ )'12^3Y?[K]_/\
M9?\ CV^RC\/;U_P%<M+)_K_,_<$\#V]L>_X_G5[S?*\B>*;]_P#Y]/P_STP[
MK][<?NC_ )[# X__ %UP8?#_ .>IQE&3M^/]*DI_E?\ /7\>G?\ 3';KS]1B
MIXHO-\C\,_YS]?ZUUG0'FK_SQ_0_XU/%%!Y7KC_EY_R>P'?_ !J>62:Z\_M_
MCGZ9_'T_*I["UF\SR8OM'O\ A^(/UZX]J "QB\V/_4_ONUQR!^ _&J5]=RY\
MD@X[8]?K^O?UKZ'\?_"ZS\%>"=#U;S;G^U-9S]JMI[C[%8G3L$C@8)S@<YX'
M//-?-7 )$A/G9'XG QGU[^WX5P9?C\)F.'^MX5WCS.-]=;.UUY;/TV/.P%?#
M9DN;"][:]TD[6\K]_D1U9_UO^M/OV]?\\?RJ'ROW?_Z\^O\ /]>.E3?ZWTQC
MWZ _S_*N\]$OQ10^7YWDW G/KG\_?_)/>K'E0R_OKK_7\_Z-WY//^>N:K_\
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MSP0"<D'FOL,GX?Q698J]U;KZ)._Y/\3[?(.'\5F.*^JX3U;>UDFVWTV7;O\
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MZ-F'B!BL3E?]DX0X[6;J:_N/.EF_SGCM5&+SHI)_;\.GO^74_G1%+YLF8O\
M]?3V[GKZ_P [WE>=GS.>/8_K^)_*ORL_)/\ :_+\0M?]*X]/P^OI_7/\KMK8
M?:I(/+Q/!_T\^G3_ #QVYYJQI<L/E_ZFWG_TO_CY_E]>U:HL+R_N/._Y=^?]
M&Z_CT_3TKU</A_K)W8?#A%:V<5S!"/M G^U<VUM]/I_A]?3H]4OY]+T_R?)_
M<?\ 'I=6USQ]C_Q^G7]*^A?@U\#/^$\_MS6/MGV&#P_I6HZM=7-M;?;]0L\=
M_P#/ZU\O>,I9KK6+_,W_ "]?\?'3[9[\]_\ /K7J_P"[87_9#U<1_LV%..EN
MOWO[K_P&]NV/7_/%7K#69HO^6UQ!_I6?7\>?\^E8E311?O/)_P"?COQ@_P">
MN/S]O#P^(Q6&/#P^(Q6&._EM8;^/SO)\_G_)_'U'IUKJK66\FMX+/GR/^)=_
MI/VKUY]NA_E[5RN@W7E6\$US#^XM_P#CZ_Z?/\__ *_8U369O+GGBA\B#_EU
MMOY?YQ^!S7U6'Q&%PV%^MGU7UC"X;"_6STW5=4TW[18S2S6^?^77_1>G^1C/
M7GMSBH+768=4^T0W,/D0$:<,_:O3/]!Q_.O"/[4F^SS^5@<?;..O&?\ .!UY
MHL+^:U\^'G_2/^?GMZ=1S[\5P_ZT8KS_ *^8_P#6?%>9]-:K=7D4GDZ+>^?;
MW%K_ ,@W_F']\^F*X[QEK.I2V\'G:;I^E6-O_P @NVT2V_X_/4\>WTQ5'01_
M:D<$WG>1G%I_I/'V/_#FL/5/L<N?-FMX/]*XMOM7MCI_D?RKZ/$9QBL3A?Z[
MGMXC.,5B<*>+Z['#Y8F)@^VL1FV'6T&<GKP3QQG//Z\Q]M/V7[)Y8Q][?GMG
MTQUS[X[]:Z;Q%BU064<WGC(R1Z?S/?\ '\37&?+GONQ^&W_'-?G6(_WE^I^9
M8G_>)/UU_P _EW3/Z8O^#<?_ )3-_P#!(?\ [(I^UO\ ^H-_P4"K_6/K_)T_
MX-QO^4S7_!(?_LC7[6__ *@O[?\ 7^L77.8'^>[_ ,'3O_)\?[4?_:"_]G;_
M -?)?#:OX<(1#^_\V'CCO_7K]/?L:_N:_P"#I0&3]N3]J()U_P"'%O[/1'T/
M_!9+X:$?I_/UK^%[]]SY7^?7KVZ=.<XKS,?_ !_^W4>5F'^\Q7]U_D:TO!GA
MBF_+T]^W\NG;-84O[W_VU'_UO\_6M;GR\^3_ -?7V;WS_DU>EL/]1>1>F#]I
M]O7Z=3_7OD</^[>IS?E?N^_Z?7_Z_P!..M$O[KG/Z_\ UO3]:U_LOE']U]GX
MXNA^O\\_3K]:YBFFE_U/?_./H>G(_$5A?OJKW_S++28G6$B(=>+DYXR<<>W?
M/Z5^B_[,/P;\*ZEHL/B[Q%]GU6XOB5MK:X&EBPM"#U*GGKQC QG'6OSF1V?R
M/W((M_\ IV!_7O\ 4^W85[%X<^/GCWPQIECH]I=F&QT^Z^U6WV;_ $'W[#OV
M&!7RO&.4YOGV1RRK*<U>33G)MR5W*6]]E?7>ZL[:;:'S7%.7YIF.5O!Y5F?+
MKMM;?37;6UOD>_\ [:7BC1]0\3Z5X6TP^?!H&F:=]JN>1G4?[*R?PSVZ?7&1
M\'RYEDF_Y89Z?AVZ?YQ^%;WB36M2\1ZQ>:C?S_Z;?[KJY^T\#DYY]S]/PK%<
M+#$OF=QG'3I^/^1^->IPSDZX<R+*\H5VDDVV]Y-WD^OVV_)I7W9W</Y=_8F5
M99E7:WXNW?I;>Y3B_P"/?\5_K259YMH_WIY[#_/?_/-3V%I-+Y\T1]_7KS^7
M].]>Z>N&?-_UO_/UZ?K_ )X^E9-W_K?SJ_=2@R_E_HWX>P';_P"L>]01?O9,
MR_N(/^?G!Z>Q_I_]>@Z"K5J*7S<\8Q1Y7[S''_@*/IZ_C]>.M3VMK^\\G_2#
M!ZVW?U^O^<\4%XG]?\B?4(O*C@)^OU/KQZ?K^8KG+^^_T@^5%TZ?_6ZYZ]^F
M:MZOJ!1Q:1QA1 3[]#U)[]^?UQ6#*YEA\P\'=M/U'7&<_P"0*ZL/A_ZV7_#:
M>FGWO 89Q7,UHU=?YZ%&60R.6/\ G^5?J%_P1=_Y2F_L/?\ 9;M,_P#35K5?
ME['Y>?WF?PSZ'TYZU^H7_!%W_E*;^P]_V6[3/_35K5=QZA\$VUL8SR<]OP]3
M[^E:EMB/F(>?Y&?])^TX_P#K8&:R[J$VIS(?.^T?EG/KS_B#5ZUM9O(\Z+GZ
MVW3KW_#_  XK[BAU^?Z'W^'Z^B_)&%J8,=Q@<XP?M R<_08[X_R:I0V,P/&.
M?Z>GH?KVQ7?6FEPW4<\UU#<?Z/\ ].OKP/P_SGURS8110'RO]?S_ *1SQ[?_
M %SZ=J/[/_YB_P /T_I'/B,OQ3_VM[?U_7](PK6+RNO?]<_Y^G-=':VOVK]]
M%%;P0?:OQ_KTQ^7Z02Q>3&89/W__ $\VWU_ ''?K_(5?BEFL<_N?)/V7[)C[
M2.>_;CD]>N..>E&'P_\ 7X?U\_-G1A\.?0'PB\%Z=XEUU3=7EP-,MKO3K4BW
M!S=G5F*G<.Q!!XQQR..E?67QB\0^'?!?PTF\,6=J(H;_ &FVMXAO!U", #5/
M[5)^=0JA1&."OR\*"1^?.D>-;WPS<&;3R)P!FV8YX!^GK^E2>*/'FO>,K>";
M6;RXG^S_ .B>HL_Z_P"?K7[?P_Q_D'#G!N:Y3E.5IYUGB:_UKMM?I_3VLV?N
MO#_B1D'#G!N:Y1A,K7]M9XFF[:I2Z)]+KS6R;/)+^7/^M]_ZGZ_IG'4<51\J
M:*/SC,>>/<_3_P"O^7%:UU;&648_?>?W[_\ Z_I]*KQ13?OX8H<_T[>H^GUY
MZ5^!8C#_ -?U_6OW?SKB,/\ [448I?-^O^1W_P _A7?V$LT6EY/[^#GM[_7_
M #CBN.M;6:6\_==N_P"?^>,_TK>O@+$P6<8;S[#*W G ^]QQCCCG''J._-;Y
M>_JOY_TO2[^\[LOTM\OT,C5/W=S/Y4/&>N#QZY'].XXS7+2NP[8_S_,]L\?7
MFNI^U?;[C^? Y/\ GOTX[U#+811>>/.@/7&.<?YXZ8Z=JPQ%\3^?]:HX,1A_
MK/:W]>GS,. $R#'H?U[_ *5ZI8W,,E@1'#<3G[-C'H1ZC]/KGI7(:3HEYJ-Q
MD0MY(/-S]GP/J<<^W^/%;FNR'P]:P6D1_P!(N;=;H]VM"QQQP<G@]OK6V7MX
M;#/%[12^;?Y;'=E[>&PSQ;M;\;_EWU.:U*^*0S22?\?!( _$_P"'YYZUQMU+
M]JESGI[C]?P_^M5NZU6XNX/)D.??\..G3]/Q[YWF'S <'GH>/K_/G].G-?.X
M_$/$XF_1_P!?KL?+XG'/$[K371^3U_3[ON9&,A1^?TSS7Z7_ +9$7_%W?ASG
M]P3^Q=_P3N_Y=?\ JP/]F/\ 3/?\<U^:@D)P>,'V-?I+^VS;3M\6OAT8SDG]
MB3_@F^;:WSU)_8#_ &8R3ZG/7MFC#_I^A.&MTMMKWV/FN+R8O]5-Y_\ I7.>
MOIZ]/TKE?$<4T5SQ^_S_ -//K^?;U]ZW-+^VRV_G10YQC_CVM?Y_3_.!@C5M
M=+AO_/ANIO\ EZQ_QZXYXS^7MGW]^[ZOBL2=_P!7Q6)PIYS%:S?O_P!S_G./
M?_/YU/%:_P!>G\^?R.?P/:NQ&C7EK@Q#_KUZ?Z9WX]P*)8IK6W\F4^1]H]O;
M\OJ,_K7/]0_JYA]7Q7UHHZ7:PR_\>L/GP?7_ (\SW_SW_&OJC]GCX+3?&3Q[
MI7A2*:W@L;?.K:I<\_VA9Z=_:O?CMWZ>]?+VC70L(K?]S<3>O^?\\=<BO</A
M5\:=8^#?B"#7O#D-OY]OI?\ I7VG&+S/K^OO^'7UL/\ 5<,>YA_]F/Z%/C)X
M-^$O[+7[*?Q-TW1M-M[&^\0:#J.DZ#<ZE:Z4/$&L>(O^)U_8_P#Q-]$Z<]?I
MQGFOY9M>\DW'[W]_.;H_:[G\^/\ /;MZ_8GQD_:Y^(?QS\+Z'H/BV;SX/#__
M !Z@W7]H?;/[8_S_ $XQ7R#JD4PD@O)<&"X_X]?]%Y^@Q_/&/6M^(,1_:6%#
MB#$?6<*<[Y7[R#IQ]?Q^OOZ4DO\ K/\ GO/T^GZ\<=3^-7Y;7'^JX'^>Q]>O
M^14$44WVC]U_Y+<?GV_+^E?+'RQV.@RS6NGSS2_:/L,X%W_GK_GK65K,4,4?
M[KTX_P!%Z'I[8''0&KUU"=+T^"SEXO[@?U_#ZX_EWP[J_P#M5QY/N/KU_P Y
MSW^@KV\1_NOU3[CV\P_W7ZH<K*1%'^.?I_GUY^E3Q2P^?^7^>WY=L_GN2Z-_
MTVMX+?I_I./_ -7_ .KBH+72[VZN/)M?^/C_ /7^'X=>WT\/ZOBOZ1X?U?%?
MTCT;098?[/GY\^>W_P"G7VP,YSU_SGMP&J:S##%^\_<?9_\ CU_T7_/'OTX[
M5U5_GP1H_G77[^?4.;7_ *=/7_'^G.*\?FUR;4LV4L/^OXMAR,'G/;G.#STS
MWZ5[F(Q'U;"_UT/<Q&)^K87ZI_7]?TC(O]4^U2>:/ZC/M_G/Y=,&K,O^O/F]
M/;IC\>/7IW]Z)8O*D_=YX]^_IS_GIUYKYP^</Z9/^#<;_E,U_P $A_\ LC7[
M6_\ Z@O[?]?ZQ=?Y.'_!N/\ \IF_^"0__9%/VM__ %!O^"@5?ZQ] '^?3_P=
M+ R_MT?M1","8G_@A;^SR0,]!_P^2^&I!S[@@_B:_AFD,TAF/D^1!.1:?\>N
M#D'/!^O<=NV:_N9_X.G+K[+^W'^U#,#_ *C_ ((:?L\$<^O_  61^&1_/FOX
M;K'Q TEQ#/%+]AFS@L,[>_?T]SCO7#CD[1:3TU[VZK;T/,Q]W9I/2W^9[O\
MLXZ1X$U'XH:':_$F^-MHHNADC L;HY/_ "%CU' Y*X..,X)!^U?VN+CX(W/@
MR$^&6T.S\3V]NMKHFG:+;:99?\Q7!)_L4X)"D@;O7 -?FA%"D<UE]JFN98KV
M[S='_C](L >QZY'L <<^E4-6U!IKN>*.8W%OG_1?M7'^@?@!S@8Y[9/KC\_S
M#AF6<\297G_]K5H1R=/]W&4HTY_9NX\Z3U333IR>GNOHOA\PX?>=Y_E>;?VF
M[TV[Q?1II._;727EI?MGW6);C_GM/<=_<_S_ *?2H)1TFE]A_P#JR/S_ %'6
MM6ZB_=P310_\NH]OK^?3I5&**&7]S+_Z5#]<G';OV]:^LKM)IN]DM;;VZGU;
M_JY!_P!<_P ?Z_=_"I_^F,N/\?K^/_Z_6B8O*]8.UUUS_+_//K5[_6Y\V'O[
M_P#UO7CM5 +%YV#-+_\ P7X]OTY]J27]['!Y7_Z^WY=?;GOTJ>67'_MUW/\
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M?/)%CAE.3T.#C)[GZ@UKZU<S0:>D)GNH$^TWIN/FR<$#8 >>V,+T[8/2J?\
M9\VJ6@FMA;^?C-UVSG.,<$8QTZYZ5^M\;\8?ZW87*\IPF5QR-9''IN]?RTT7
M>]]K/]-X_P",/];L+E64X3A>.1K)(_96KUZ/3W;+1=[WV1QUM;&.Y@AXF&/M
M7&.@QU'^>>U)]JBAN)XI<SY_T7OCKUR?<>N.OM5B*UDB_<XQ +G_ )>/]!YR
M,9R>/P/'3'I0EL?*N,12\Y]>1[=A^GXCFOR;_=MC\N_VG96_ UC:>9+YMM-;
MY%K]K((]\'/T/MQCUKJM"T$Q>1]E/GFXM?M?_'W]@_7&1TKB(FGLI?WT-QDV
MY^S08]>_88!YP*],T:4?8+$1Q6\\Q_M$6WTSR0.,^OU Y'6O4R?#X7$XK_(]
M3)\/A<3BM5KY:^MOQMUVNC"N]!GBN)_W/GS6X_TKK_H?O_GV%48O#!D(B[@\
M$=O3T'K_ "-=C-JDW_'F!Y\]O_Q]7-MSZ_0?T]O180#832Q9G^SG%U]HN=Q)
MZ'CC)].><BO6_L_"_63UO[/PF)Q7]?,Y"[LM*M(/]&G:S/V8_P"DW5L2;S/4
M <XSC P.H_/ EB@B\B:+_3A]E_X]OZ_Y_2NRNK W49AM?W\]Q_R#/U_M?.?Q
M(]1VK@-2O;W2#/)(/(N/LOV0?Z+CU[G@'COGUQVKYO,+87LDMEV/E,X_V6_1
M)7[)>?8H75A>2_Z9%#^XM_7\?\^^<9.*YU_-S\V?P_S^>./QJ&#4KRVEQ'*1
MP.GO@>F??KU]174VMQ:74A\VW@A\\\D#@8[>PZ_ES[_+8?ZKB=,+=?AU/G,.
M_K+WMZV[V_,@L/M=S)!#W[$?_J_*L;Q!=&ZNS@XQBWQUZ9&<_P#U_P!:]0A/
MF^196$)G_P ?\_GS[UY9KYBCU"]%M_J!=<?3.>WU/YXYS1F">'PJMW7_  /Z
M\S?,5]6POU3I_7];G)459EE\WZ_CSSGOQTSWJM7SA\>2_P 1STV_IQG^M?J-
M^VE=&U^(GPYA_LW3[[[1^Q;_ ,$WC_I7_9@?[,?8?S[\_2ORX/WG_P!T_P A
M7Z=?M;^,-"TWXP^ ++4X+DF#]B[_ ()W 7-M@9)_X)W?LQ@  ]>3[]<\5W8'
M3%)^OYG;@/\ >4[].KV_KJ?*VEW7G2?8_)_<7%U]DNKFVM?^/,?G_4_@,5_3
M[^R_^QO^R7:_L[:5KVJ7FG^(]5\0?VC=ZIXM\2:5]@U#1_\ B5?\3C2O^H)]
M!WSDU_-UH-U-XCN+'S;S3X-*M_\ EYTVU']H?X?SZD5T=_K,.E^"Y[/2]>U"
MQGU#5-1%WIMM=:K8:?\ V=Z]_P"O>ON,G^JX;"GW.3_5<-A?K?\ 7]7#XOZ7
MX;M?%'BK1_!&I?VKX5T_7]1L]!N?^8A>=OY_AW]CY):VLW[BS\GS_M'_ !Z<
MG_/_ -?].XTNPFUG2I]2M?L\_P#V]<V?M_\ JKG(HKR+4)X;7_EX_P"/7_IS
MQ]?\/PKRO^8KZV>5B/\ >OK91NI;.*\G\W,$'_+IQC_)]O;UH^P?O(,_ZBX!
M_G]?7M_0U1U31IHKCSXOM%Q ?^/7[3=8_P \?Y-06LLL7_+G_H_%W_QZ\\\=
M_;K_ /7XX?K/K_7R,/\ >3L;"PO(O(\W_2(-1N_LGV:VXXX_SQG]*O:IHQ^V
MS_Z']GG_ .@;_C[$YZ<\9K<TR_ABT^#S;.X^T?:OM8ZY'..?Z>_?H:U1K,/E
MW'V^S_XFO_'W=>O<\CC_ #WK['^S\+]5/JL/E^%_LL\RB\.31>?Q]GGN/U_^
MOW_PX-7O[&L]&D@\J\M_MO\ Q]YN>-/_ $]O7FNQM?)-G<7DO_,/NA=W/VG@
MV?XX_P ^OKSFM6D,MO/-@WT^L?\ (+MNOMV_P]<'%>5B,OPO_,(8?V?A<-_N
MAP&JQ?N[&\EO#?3_ )"[_P#U?C^595_82R1^=:V>H>_^BCZ=O7MS6KJF=!N(
M)KJSMX)]/Q:?Z3^7'Z?_ *Z\LA\3ZO;2B\CGQZ9[_P">G?'K7SF88C"_6O0^
M5S'3%7\F=%-+YMM/#_RW^U?\?/\ C^>>GU[UJZ?JEYG[':_O_P#IYMOY_P#U
M\?SX-+NM-OXOMEU#;P"XNOH,?X_ESC\>JM8OLOD6=A96Y_Y^OLUJ?[1_M'IW
MZ<?YZT8?#_H_Z_KMH88?#_6>VQYUXZN?+,%EY_G_ &<'K_D8_7K7FA^^OT_Q
MKO?&UM$NL3PQ2@]NAXZ].<9_'FN"/WU^G^-<&/\ ][_KR//S#_>GZ/\ (BJ3
MRSY?F=LX_7'K4=6N8O-$D7)X';'/X\'COWZ5Q'&?TQ_\&XW_ "F:_P""0_\
MV1K]K?\ ]07]O^O]8NO\G3_@W&_Y3-?\$A_^R-?M;_\ J"_M_P!?ZQ= '^>U
M_P '5O\ R>S^U7_V@L_9U_\ 7T'PNK^"_>?0?K_C7]Z/_!U5_P GN?M5_P#:
M"O\ 9U_]?0?#"OX*Z .ATW4I[>;$?H#S]?Z=L5U%M=8/[W/_ &[]?Q(_3_\
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M9?\ 5>N>GT_S]/RKLO"6LZE8^>;'/-KR>.G&<<^GT%>KP_G'U;%+ZWY[+O\
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M/_,X;GR_-\\_EWQ]/T]*/*AB\_D\# ]O_K=OPJ#RO*_UI/7N?\_X?TG\K]Y
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MP>@(^E56R_%8?#+%RTC^.O5_T_\ (Q^'^KX9=/NO;I?^F?'UA86<MQ ,_O\
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M+K/Q$T96'Q[;Q=\(VR_P7\#?$?6/B#\2/$<C^&/B;\5AXG\3:+\/6E\)>%%
M3PMN:_\ M<?#?0[/_@@!^U/=6M_?^!/V,QX<^&_Q?\)>#;;2+[Q?:^*?V;_V
ME]'^+FNKHND/X@\+"[U[Q/\ "[XB^$/$'A,Z_P")/"X_X2C5I<^*P(9''/\
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M_P"*YTG6?#PZ'&C C .3^.'_  C%KYD/)YQNY//H3SS^O^'#]?PJT>GY_EZ
M_K-O]J5G]Z\_Z_X!]/)^W[\=7.!X)_8PSZ#_ ()O?\$[Q^A_9D7_ /53_P#A
MO[XX[,?\(7^QK_XK=_X)X8_]9GSC'?I7RM<^&(1)_P ?8A]CSZ?X?B>O2LO[
M#Y5OG_E@?^?@?R  ]O\ ZU;MKM\O^#U ^N?^&_?CI_T)7[&'_BN#_@G?_P#0
MRT?\-^_'3_H2OV,/_%<'_!.__P"AEKXXNM,EB_?1?OX<\'G_ /5_^KM6/6P'
MW#_P\"^.O_0D_L8?^*WO^">/_P!#)4O_  \(^/?_ $*7[&__ (K?_P""=_\
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M>G7U^[OY'[*_\1#O_!8/_H[W_P P'^RU_P#..J4_\'#O_!8.3_6?M?@\8Y^
MW[+(_E\##^M?B=3TZGZ?U%;T.OI_D<1^V/\ Q$._\%@_^CO?_,!_LM?_ #CJ
M9_Q$-_\ !8+_ *.\?_PQG[-?_P Z&OQ6HKV+/O\ F*S[_F?M:?\ @X6_X+#
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M^_LK_B.?@4V/P_6O:/V@OVI_^"JO[1_[5\7A'X!_M*?M9:MXT\1?L=_LH?M
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M>%OCKX2^&GQ.^$?Q:^%W[/OB_P#8^^ _Q$3X&_#']H*R^"_[,7A'XH:%X@^
M7A5/A5XO_:1^!_A_QEXZF^$[?$3X;_%SQ$?$WAAXVU\#PEXH\5H)0,7X&?\
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M6KTUU#+<3^5^X@-U_P ?-S].N?QSUS7EXF[Q3[*WY6_$#5MO)B!\K]Q_HO\
MR[>_X8]N>E3RRWD47DR\3_\ 3MC'?_/7%<K++YMQ!-%CK_GWZG\.<5JQ2_Z/
M^Z%QT^R?Z-W_ /U>HKG^K?U_4CH)Y;68_P"JFR!_];Z=OQKG/[/FEN/]=;_\
M?7/VD^WX=?\ ]76NCM;K]Y^Z^T03\?9?M/3/OUS_ %Y%%U=]/-_?_:/^?GZ^
M_!_#_P#7OA_K7]?\$YRCY4TT<_VJ;K_QZXM>G;WX_*N7OK8"W_=9.+DBYQV/
M.#SZ?SKT26+RM+_<_:/(Q_Q\_:C_ $X_R?>N.NI81;SV<LUQ_P!.OOC_ !'7
M_.'AF[_]O+966E^B^_UUW XRBK7D';YN>,YQ[]?R_#KW[U5KU "OU&_X(N_\
MI3?V'O\ LMVF?^FK6J_+FOU&_P""+O\ RE-_8>_[+=IG_IJUJ@#\N:*** "B
MBB@ Z5(A/3MC^O\ ]>D\L]R/Y_X5,%)Z"N^AA\0WHK+SU =DLYZ<MG\L_P!*
MOVEM+=3>2GW=V3W!/_Z_;TXJF%_># [9QV__ %5UWA.+-_GG.XCZY&3@?@/Y
M#FOOO#[(,-Q;QEPQP]BFTL\XG4';^5MZ/ULCAQ-;ZKAYXC6T%_7SMU._T81^
M%'N G[^Y-L=Q.>"<Y/\ /M^=:]OKUTX N6)A/J.1],<#M]<<=:H6ME'-=G[4
M3Z$Y)/.,#K^ _ CIQU4JVL3>3Y/G_P#3SU/IT]3^O&.U?[*\ 9!G^2Y9]5X?
MS7_4?A#(_P#DEN%;O5N]WQ6W=MMM[ZO=MMGYMC\1A<3B+8J'-)J[E;2*6ZC\
M];[ZV2T.;N;\2'S8H?(&>@]>A[BKVD7TLDGDO%Y.<G[1Z?Y^O/7 Y%;<@,<<
M$/8'/]>_.?\ Z_3N7NC?:;0318[#%N/Y_P#ZNG45^C8?@_C+#9I_K#E'%']N
M?V%OPKIN<"Q.%M9QM=Z2=[I7Z;7^?X$>JW\MJ808\9X'?=C.>W_U^WM5V^UG
M[?9":0>5/]G'V@>O/!]>?;TYXKFHO[2CC-I-#Y\'8'G/<\\]?7^F2-P137T(
M\T018],COP?7T].>_K[F7\0<49WBN*?JE_['SQ?\DI;1:=]]_P#@&&(H87#*
M"LERROS7N]6GMKM:^B^\\0\4Z8T8%T?^6YX'OUZ]OP^O2N'88QG]/HO]?:O5
MO&SQ"(QQ] 3Z<XYP>_''./\ Z_DY)8Y^@_G_ /7K_%3Z2'#^5\.>*&:83*;-
M=;;7Z_UZ;GZED->>(RV+E=:75][+1?(K4Y6VT]E&,CC'ZU%7\W5:5M5Z-,]L
M*^UOV]/^2X>!_P#LR_\ X)P?^N[?V8:^*:^UOV]/^2X>!_\ LR__ ()P?^N[
M?V8:YP/BFBBK5M%'+)M.?H?\\_GFM_;^7]?>!9@MII6B\L9)/7T.>N.>OM^/
M-?6?PE^'UG+I^JZEJG[@Z?I?VOU^V?Y]L#%>(>&/#T37-B9HKF_A-T/M5M;=
M< 8[>PQ_^K-?8=AHT$MO?:;X<.H>?;Z7IW_'M=?\P[G^V-*&?\#[5]CPOEZ^
MM?6\7V/N>%\G5_K>*T71=E?^OZT.5ETN;_0=2U36-'@@\076;7[-_P N>G:/
M_,?A^N:U99;*_P!/_P!2?]'TO4?M5M]E_P"0QS_Q)Q_:Y'Y#WKG-4\.7D4D^
MI7_V>WAT?5/]%MK:Z^WY![9SC_(J"PUG[+_RQN/(^U?;+6VN?^0A9_AV_,>X
MKZ/ZQA?(]\R;^6S-Y ;#%C_U\Y_/_#U^N*^F_AS8:#?_ -E:QK.O6_V[4+7[
M)=::;7(_M'UZ=^_/_P!;YEEBAU#6/.\DP?:+K[7=?:3_ ,>?Z?\ UCG\:[_1
MIIK;]S_H]_!<77^BVW3[&/S]O3^5?V)]$?A?*\-BLTXW_LO^W,XR/_DE3X/B
M#B#%9;BOJAZ-XH\6PW^L>5+_ ,2K^S_]$M;:V_Y<_P#B:\:KCZ?Y[UYE?W_V
M_P#X]9OW%O\ Z)_:7_/YW_P'>M75;^S^T6\/]CG5;[_EZMK:U_X^_<_TS^9K
M*NHH;6,P^3Y'VC_CUMAG_0_\.OX^F*_T?S#A_C+,L+_9/$/BA_;G_-5'X[G&
M<87,L5];PF5_,PXKJ\^TC]SY_P!G_P!$'VGG_'/?FKVJ>=%9^==3>1<?]//&
MH=?I_P#7Z5N#PWY5A-KM_P#:/W!'V6V-T!?WAXY.DD@#WR<#UQ7.2W-[]G_=
M?:((/LOV/[-=76?\_C7#E^'XR\+LA_VO_A<R?//^:J_#^O\ @GSG^RXDT?#\
M]Y/;7#@^08#FV)N<9)ZXY('.>G6N@ETN'Q'I\\-_#;SSC/V7_H('I_7Z>@]:
MR=!EFEE\G_1Q!G_CVMO4<_\ $X_Q]_I79>'+:REUR?S?W!M_^7FYNL?A_GTX
M[UAXGY?BN-?"Y91QM_PN9/D7"GY'V7 $L-0S_+,-A=7)MM^;=WOW;/GKQ'X2
MFTN3_2I[?R/M7^B_]/G7KV'IV(Z>U>.ZI+]ECG\KW]#[<?Y'I7V)\:K"&6X@
MFB^S^?/:_P#+M=9%G]>W]1],&OD+5+":;SX3#Z\_H:_P.XXR_"9;FGU3";'[
M1QAE^%RW%?5,(>=W-P9N@ZM]J]\GC'Y<_P JS:T;ZPGM"/-^G7_)K.KX^OO$
M^./ZU/\ @VN_Y.__ .".7_9Z7_!9/_UV5^R_7^I)7^6W_P &UW_)W_\ P1R_
M[/2_X+)_^NROV7Z_U)*YP/\ /;_X.JO^3W/VJ_\ M!7^SK_Z^@^&%?P5U_>I
M_P '57_)[G[5?_:"O]G7_P!?0?#"OX*Z "GIU/T_J*94D4AC<,/\_P Z .OB
M_P!7!/$//G^R_P!<_P"/IG/KUQ+FZF^TP7D9/G_3/(/'\_\ ]=%M)/?2" S>
M1#^>,?UQ[=31Y)D(A\XS?Z5]E&<_@1WQG_Z]8;/7INO7N OG<CRX29A_I1\_
M_32<8]5_$EA]<5-;>;+'^]Z6_P#HG]<'/7\LGC\4M8NT7[_'XY_QZCM_3%*+
M'F3F4^1[XYZ\C\O:C>_]=;?T@+OF_9;C'^CS]?I@9[^G/U_$UN6O[W_4_O\
M_1?SS^>?Q]>W%<M%P9^DW^C=?3^9R/\ /-3V5U+_ *F3F 9P3G%KR<GD<=,8
M)[#W%/V'F_N?^0'4^;^\_>_OX._V;K9Y]>O'\N>^*GM;#[5Y_P!EFMX(/LN/
MLUS^/?GU_2J/V^T\O]W_ ,_>/])Z]ZU;J6:Z_P!5]G@^T?\ 'U[>YQCGZ>W)
MKSM5NK>OE^NW],"CY7[N#[5^X@M^/Y=QV[@=.>U3RR_\3">'_1Y_M'_3J>V?
M?]!1=2BZC]8+?(M;;)Y_09/^?>LJ*+_EM_S\6O;D6?7\?P_6A;-_U?\ /N_P
MW VY;H6MOY/^D#_GZ_Z?/\_Y!SSB7=UY4<'EG]QU^S?\^?\ GZ47,D1(EB%P
M3;\7-P!D\G^O3G\#65-]^:[EE$^/^7:YZG)Z'DCCV Z_2NK#K\U]]U^@!%%-
M=?ZK]Q_B?Z_CQ5*ZM8K6XFA\[SO(X],]/Y>@XY&>*);GS?\ 5 P#_KY/^?3W
M_"J+.7P#_GK]/6NT!E?J-_P1=_Y2F_L/?]ENTS_TU:U7Y<U^HW_!%W_E*;^P
M]_V6[3/_ $U:U0!^7-%%% !3TZGZ?U%,HKHH;R L4445[!SCRV"_J<#^A[=O
MISBMW0;O[+>PRF7D$'/4X]SQ[?GTK"8?-]3C]!_C3F?: P(Q^.?T^O\ GMZ'
M#_$&)X;S[*\VPOQ9+)-:O?Y:[_GLRI8=5Z$E=*[:];6/>X91^YF3]]#^?<Y!
MZG/;WZ\]]RV N8.(O)GM_3T_+OSZ>AKQ?1O%!TS,4T7GP]\Y)Y_/'''O^5=Q
M#JEKJ@\Z&[$&>1;FXR<_7';TY_*O]7_"_P"D1P;Q9E:;S3_A8?\ S2KT5NZ;
M2NO2_P!Y\!F&08G#^E[<UG>UWTO;7U^9V.EQC[1-YDWG0CG(SZ>_Y]@,>]=4
MFHVEE!Y4?7G)X]>_Y?7K7F=M>QVO^K[8R.>W/.0,9^OYUD7_ (B87$$H_P"6
M'IT/4]_0_C^=?T)P_P#2 X6X X7^N:?VQW_/7]#YZ633S'$M/F4=':UD[)I-
MI.U[7U_,]*GOA+^]\L8/;D<]LYYY)QC&< <'I7-:AJ\D,/FB/CG!(^O?G\/K
M7*7?B.8)@'RL8 ([].OTXS_,5Q^I:[/,90).IQ]>>?3M].?PK\(\6/I497EN
M5YH\IS7_ (6+=E\NS^1ZV7\-8CZPDXJR=[WE>W5=%Y]]-KE#6;_[=<2F4GD9
MXQP<_3KR/Q]>E89(VK@\C'Z4')SSGN>O0X.>2?T]/>F5_DGG^<8K.\TS/-L6
M]<Z=_1[K]/4_2J,;-)N]FG\V["DDG)J%^H^G]33**^8Q&(==IM&P5]K?MZ?\
MEP\#_P#9E_\ P3@_]=V_LPU\4U]K?MZ?\EP\#_\ 9E__  3@_P#7=O[,-<P'
MQ36_ID41D'F_\_.!Z8'N.?Y8_.J/[J*W[_:)Q[D $_CQGZ]?456A\[_EE[__
M %_\_P#UJZ /M/X/W6I6MQ/_ &7,;&^^R_Z)<_\ $J_LX\]OY^O7BO1M=_T6
M3[':_N)[?2]1N_M/VK_F(_\ 0*XSW)XS] .WR)X*\?WNBV%SI<F&@O\ /V6Z
MGY%GJ _B! Z8Y![@@G%?15_XMAFM_#DW^D3XM?\ 2K;3;7KJ7<]O\^E?HO#^
M897_ &7]4Q?]?J?JG#^<97_9?U/%_P##?UYD$7G11P&66W_TC2_[6_X^^!U/
MICU'3_Z_.7_GW]O/YLWV&"W_ -$^T][SJ/0_H?YUJW^J0W5Q/J5@;C_GU%M<
MVO\ QYXZY[]OQK#\477E:?!#%#Y$ TO_ $JV^R_\>>I<_P"??GK6^(^J_P!?
MU_P/D&(Q'ZK_ (;^N^I>(AM;CR9?^/&V_P"7G[*?],Y[^_Z>X%;DOV.ZM_MD
M7[\_\NOV;/T^OKWS^M>=:I=?8+?0[.UYGT^U_P!*N;;_ (\.W^<<C\.3=M=4
MFA\B\\[SX/K_ ,>?KG_#BOW?Z._C1A?#?-,TRG-O^1/GG_FJGP_$&3_VEA?]
MD/:?#D4WF^=_Q[P6]K]KNKK/_'EUP/YY_F*O2ZI9Z7_JM-N(+[4"?M5S<_U_
M+OWK@-'UZ*6X\Z6:YMX/M6+O_2L6']G=?Y?_ %O6I[^_\K4/]%^SSV_/;[?^
M?L/0YXK_ $TR?QGX7S'*\KQ>59IPKG;3L^*GQ4TT_1V::>Z:O<_'?[/Q6&PO
M^UFKYL_F07DLWGS_ /7U_@._M_\ JRC=>;;WWE1>OX^OY>G>J/V__7_:[SR,
M?\>G_3G_ )X^N*U8HH;JW_=36\'_ "#B>G]!SV[5]CF'TF,A_P"23_M3_A'/
M*R_@_%8G_:\6;GA>PFU2X%Y%^X^S_P"B75MG[!ZGU]?\XQ7IN@ZIIEA;SZEK
MTWG_ -GG3KNUN;:Z^P?]PKZ?]C+UK@-+_LV63SKJ$SP6_P#R[7/^@?; /IC^
M?'Z5SFO:]>75O_8,4UQY$]UJ.K77VFUXYYT?@_A_GBOX?^D1](#"\297_J]P
M]FA_1GA_P?A>$O\ A6Q8:]JLWB/4)_W(GOM8NO\ 2K?IWQQT]/Y].:\Y\1Z#
M]@L_]*^T0P?\>G_U_;U]!Z\<4M8\3GPG>VXNOM&JDVO^B<?8._H/S/Z<UY9=
M^-=4N+G[5J ^W$]!<^_Z?7KTYQW_ ,Z,XSC#8G$WQ=_[76E];+Y_UL'$&<8;
M$XF]O^%=:7Z7]=B7Q':VDMO^]_[=;G/^/M_G!X\M="I]OY?E7476J"ZDQ=3F
M?^?IQ]#6)?1_NQ+'"=N<FX!Z^W^>1Q[U\HZZ:L[?>O\ ,^./ZO/^#:[_ )._
M_P"".7_9Z7_!9/\ ]=E?LOU_J25_EN?\&V4GF?M?_P#!'0'J/VT?^"RA^F?^
M"97[+W^?Y^I_U(ZX0/\ /;_X.J3G]MO]JO!X_P"'%?[.I_/_ (+/_##^F*_@
MKP3T!-?WT?\ !T?IAU3]NO\ :AL^\_\ P0L_9[QCJ,?\%D_AG@Y_S]:_B@T_
MP!H=S/#*#!-;P8^U@9 _$#CZ^HKAQN8X7+E%SYOAUY;>=EKI_P /U ^?%/)^
M;/'3&/\ /TK5CTG5)3;PC3[D37'-J/L[?Z5STR<=O3@CKZU]+16'@_2XQ#I>
MF_O_ +5C%ST]^/Y?7\R^\1WD5S!_Q[V,^=0^RW(./L?]?7WKS'Q$Y/\ V;+9
M2\YO7ULK[=E=]M3?V#[KY+_@'S=;6VI6UYY7E7-O+TN%+?8BHSG&>,#\.IS@
M5U]AHT44GG7=IFWG_P"7FV_,CZ?_ *R>*]-O]9AU#0_)EA\_[/=?:_M-U:_\
M3"\U'O\ V/J_^?6O.;^_^U1W$T7V?R/^7O[-D?CU_P ^XK=XG$XJUERZ6=FW
M?K?7\K6TZ[@E;]#<BL/[+-B+JS_X^/\ CTN?M8_L_P#L[\/;_.3FLJ7PYH]U
M<0#[9C[1_P _/Z8]QC_]=97FS>7!-=?]NOV;G3S]?_U?AUJ]YLW^NBA\_I]J
M'^?3]<=^Z_VE/?YZ_G_PPSG_ !%X:OM$GE'V2<VP;[.+@C(W# _'.,>G8USD
M3-OE&8!YQ-L.?NEL#(]!P.?6O;;K4+R_L_.FFU"<6]K_ *+^/Y_SQ[]J\8N8
MX9;@BVB,/^DD"WSTQTQU&.,8],\=J[\OQ&)Q*LTU)=5L]]T]O*V_743773^O
M^';*]S%#%F'!\_//MTP"?H/\*3SYO^?W^56+JU\J43 >1"2!QZC_ /61WK+=
M-O\ G^7M^O\ 3L,"Z+J78/+F/G9SQZ>QZ?GW^N:GMI?-E_>XA@N!]DR!G'Y_
M7G/3^>7'&TK[4!]?<?Y-=5;6,%M83_;X)Y9^G' M..ISGKWYZ]JR:2]?2S5_
MP[?T[@2Q746_R8H?(M[?_1?LV?\ C\U#)'7M[=/3O1Y7[SSOL?D0=1C\?;_/
MUJ&+2YK;_3+J7, _TKN2<'COU)XQ^ ]]NPM9OL<'V_[1_P 3#_CUN1_RY@?D
M<'U_PKGQ'7UM^.H' W($=P?+XZ$8_P#K55K8U*VFAN!$8?(VD6N/4@C _P ]
M>U8]=H!7ZC?\$7?^4IO[#W_9;M,_]-6M5^7-?J-_P1=_Y2F_L/?]ENTS_P!-
M6M4 ?ER3GDT58J_:V,EPY\M#*3GE02?;..H/Y=/>O5P&4XK,<5]5PJYFWY_D
MA-V5[-^BO^1G$-V;/U'_ -B*DBC;).>3Z8Y_/C\?TKK8_"EY(W[S;'CGYYU_
M+')/YCIG)XK;T[0XH&!8";H..!D#(X[Y['G' ]S^R<,> /'N>8I1Q>6RR6*U
M3G9-/TN[??MN>7B,WPN'6]WVM?YMV2_!&#8>'+O4FPA,</4-<$+CGN<8_3@^
M_78D\#7JG,4]E-SU#<XY_P!GGIZX_"NA%S.?*-J)X<=<$<9/7MQV]N#VJM]O
MG%Q@Y';IQT_Q_3WK^G\O\&/"7),JRW!<0Y9Q5G>;R=WQ1%N,;[I*%VK)/1-2
MLK69XCS',F_=BHI;1=W9);-N*NVM7HK^1R5WX3U*V?,R;]O>#//8]3GCZ]>W
M<8<MD;27]['Y6/7./4=?8<G_ .OGV^V^V*3+&)S"/^/HCG\>,9SV'4#-9>M6
M=MJ%G),\164L Q7)('<CU[^U8<>_11X8IY%F>=<(9K+(I0LX\+<4V;NM4UQ3
M:UWVY==K:AA\_P 2\0HXM)II:J]][;:*_73NMCQ&K$5UY7IGZCZ^O'X8_P '
M2PF-S'[\^O\ ];G_ #VJD<;P",Y7^IK^$<0\5EM[=&?4Q2;MZ_@;46J31?\
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MN@N/^/KGBS_'Z<>^<=JX,OOB?][TL[W5[IW36M]+/5;:]=K,R;J_FB,$,O\
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M.&SG#<Z:BUH^VJOLMK6?IL5=TAXRWXC_ .M0 _KCZG/^-:$-C-=2F*WC,H/
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M1?:]_P (]_:G)\(Z1HH_XGFNX(.T;>G)'6OO?_@H_P#\$G?A]^QU\-X/B/\
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MG Q=_:!_;$_:=^.VN:KX;^+GQ1\3Z[I.@_VC:W6B6]T=/T"\ U7&=7TC0_\
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M0_/T_ 5>^T^:)S:C&>EL1_QYCU!QZ^YYR*/-_P! @$T,$&/^7G[5S>8'H.G
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M2_[<\5>.->\8>*O%7]@_VMJGB3Q9J>J^+?$&L#1SG_B<:OK?';1^,>N:\/\
ML@TO5)[R7_7V^E_:]+^TVO%GJ/Y\^^,]*]4^&EJ?[+@'A?4O%&DS_:OM>J7-
MM='_ )!W]E=>Q_IUKN+KPEH6J#[9XHU*W@GN/]+M;;1+72K#4+/_ *A/_8"]
M0.?KTK]I\+_!?Q&\2,5]4X(X7_X1_P#S5=3AS#$87#87*L7BSXTUF/7I=0S=
M?O\ ^T.?]&S?^O?T[<>I[]"*ZAM7^QQ3>?!_Q]_Z3=<6?OHW7]>M?37BCX?>
M&XO/ATOQ5J/G_P#$N^U:;<_\A#]3^59=UX7T&_DTJSBL[?\ X]?[)^T_9?\
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MK40RR'S3G' M\\''^?\ /2H)I89,^6.<^F#V' ]__K>M>7_S%?+]3@/ZR?\
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M&T\^#!^R_9CTP.>?;@9]<^N*^@I8O-\/_8XIM/\ /%UJ-I_QZ_\ 'GV'U_\
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MU]?\05/_  5-_P"B^?L ?^'3_:*_^A5IX_X,K/\ @J=W^/G_  3_ #_W5/\
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M2^,OV;;CQ*^BW#> HI[6#Q"INKN&=+V*/PU O_",Q\*G&CJI*7I_PR_4U/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>74
<FILENAME>tm2135630d1_drsimg23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg23.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %^ J0# 2(  A$! Q$!_\0
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M4_9TTY?A+X6T7P0/#FO^+=7_ .$OUSQ%/XE3XQ>)M$T3Q5<K\,(2R5\RS?\
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M4]QHQ^$&J:G\6T^%WAAO!NA>&XM5CF^*<W_")^(7M="TFXN$BDF9?#;?2?\
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M%U?PSXN\-0Q1>)_!\;KXK\50)X36*0^I_P##VWX"_!WX8_%CXG_M7?$OX?\
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M?@\1:%<.=+2'<?#TZ"#5(YXPSAD'XAZ5^PK\<M?\=?LM?&[XF:Q82?%/2_\
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MS]IO7/A?^UA^S%_P4+?2]+\!?&#2/!6D_#._75]'_9/\1:)H_COPTVB>+_\
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M)?%=IXS_ .%N^/\ X>:I^QIH$/P9U7]G/7VD^'$'PPT+Q_XA7]HCPKXGMOB
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M&TEVO"'_  4-^.=]XT^+/PUU+X+_  J\2_$V^_;V^*/[%W[,V@V'Q0\5^ O
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M &6?"'[+6D_$L^*?"?QOC^%OA7XDS_'0?%C4]$T#PUX=F^._Q/2=?$(7Q?\
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MNG7?PZT?7=7L?'4?@WX-?$+X5>"=?\'>&M)^*PT#PSXD^)>CP>)8_B(8]?\
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MPK/'!(5E6W6-3%7LW[)_[5A_:0OOV@-(N?#G@S2%^!7Q-TGX?R>+_A]\3_\
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MPQ^&_"_[-_PJT!M ^!/[4Q_:M\':F/AW\%/@'\,OA+HNNGQV9= \3CPIX/\
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MK2X\8>(O%/B/Q& ?4=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*[_X*+0?M?6/@'XA3_![P]\7M,_8=LI]6'A>T\'V?[,^M:6='^(OBW2/"_\
MPL ?$&7X@>)/V[5^&[OXE'PY/AG_ (4#\,EF:4&193SG[ 'BNT\2Q?\ !/;Q
M#X2UBX^*'B6[^&'[07A3XP>'H[7PSX=D_9ZTWQG_ &)\1_%_Q.UAM%T+PUXA
M,GQ-^+GPX\(>'4T'X@MXCG^*_P#PG4?Q;\$)%X3\*^)KB;]_:\M^%GPP\&_!
MKP#X3^%7PYT63PYX \"Z+I_A[PGHS:KJVMO8Z7IRN%C&LZWJVNZ]J_E[]N_7
M+B:<D+OG8XR ?CCK'[5W[1MW<_%;6OA#\8]5^(OB?0[?_@H_H/B_X.ZI\-/
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MXP7XB^*]9\:>+],\6:Q_9*3:[HMQK^NZJ/[#\0>?;A=L$BEU8R>^44 >)Q?
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M%^/OC%_C!X-^$F/$Z^*O"_[.?LQ?%SQ5^T=HMU\5/''P_P!;^&ECI^H:;%X
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MVD2%)?H$[< 8)!Z>WJ.F.W3Z].,_$_[7_C+]E3PAH7A"']IJ'1]<;4]2O/\
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M;UMUMZ['VO1117T9Z@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!&V H'O_C_C7@FC6NI^.?B')XIU6RMH?!OP[U75-)^'D4EEJ@U;5O&N
M-3\*^,/'#AM598M%T>WU75?AYX72[\/PS #QSXJCN+CPEXE\*72W_&FN?VS+
M9?#WPY<"ZU?Q/J.IVGB*;2/%,FB7OAWPII/]G2>,-2BU/2KBWU_2]5$6K:)X
M;C?PQ-#XG\,^(O&N@^) UK#"_B*#TO0= TCPKH.B^'="M8-,T3P]INGZ%HFG
M0#9:6>EZ38)I6EZ:HSGRX(0B1@ O^["DDJ,]-E@Z#;ZQ:2ZJ.J;W^U=I7M=7
M>ET<.E>O;M^/])7.EHHHKF.XC0<Y[8X_S^!KEM=US1O"NCZIXC\1ZM8:'H6B
M:?>ZOK>M:QJ$>FZ-I-CIT+ZAJ>HZKJFK/Y.EZ3!'$7FD=Q##;(921#&6CZES
MC:!VY_+I7XD_\%1O&Z?%WQE\#_V!](U/6]%N/B_JO_"U?C-J6D?VJ#I'P=\&
MMKD>C:4W_$H?0'G^(OC+0]13PO/)XB/_  C/BOP9X<?Q5X:N;3Q/%M]#)<KE
MG6:4\'%.]6:5]^2"BY3FU_=A';9MJ^AY.;YC_8^6SQC^PDOF[V7S;]=-#UC]
MH?\ X*M?LP?#[X*?$+Q9\(OBMX"^*'Q.T?1A_P (3X*MKV]#ZQXAU34H=)T5
M]55AHKCP_P"'YM07Q#XN,=S!<0>%-&UZ9'$L8DK\J_BO8_MB?L\_!V__ &F;
M7]KKXMZY\4[KPRUO\6_#7C76UO?A^S?$K6%TK2M,^'&CJ!X>\%?\*X\0>+=7
M;PJ3GS",>#_^$7!/A0^Q?M#_ +#W@/X@^#_#EG\&_!'PG^&7CCPOXR\.^(=+
MUO\ X0/2O[/O-.T< ZQI7C#2/[!_XK;I@>'?$O/_ !)?I7V7KWAS0?&6A3Z#
MXR\-^'_$>AZA_9W]J>&];TK2M>\/WA'_ !.?^01K?_(;_P")Y7[1E&0</Y-A
M9JBEB.=Z^VA2FE&R]U1]FXV;5W=7;U;:22_'\?F.?9SBDL0N11T2@W%;WZ-;
M?=Z'YL?&_P#99@\$_L7> 8/A-X4\067QH^$&J?#SX@^&-1^'&EZJ?'][\5-9
MU71=&\8ZHVK:)_PE'B$@Y/B(CPUXH(\)_P#"&>'P?^*-\,#&K\6_V<O#7[/_
M .R5I?B/P)!IWAWXW? #2_#WC;0OBSX=']@Z^?&1U711XQU0ZKH@(UW_ (2;
M0O[8\.D>)AXI&#X?SG%?IG7G?Q:\):EX\^$_Q-\!:--I\&J^,/ASXS\):7<Z
MEQI]GJ&L>%=:T72/[8_\&_OW]17M8?'8EW^N13NK.Z3O%W]UW3YHW<KQ=XOF
ME[NKOY7]GX7N^^SW[^NF^_F?:O[,?C.V\;Z=I/Q0T?3]'TK0/VF/A_X,^/UI
MHVGZI_:=[X=\=R^%?!_A/XC^&=2U%-'\/B72;2WA^'?E/+8/XHG\80_$(>*5
ML89/#OAR'[. 7/?CI[X7/7MD#\_U_$#_ ()V_%75AX<T+]G3Q##::!\4?V*/
M%WAKP#XZET/5#J?A[XH?#+XL1:[HFEG03KB1>(K4Z#XQU7P=KOBUFT40>=X+
M\//'XFCD\57?AGP]^X V8R"<@!B/4;,GGGG''U_.OP7BS+WEN:U:,HI.,I<O
MME[[@I/V=12YI\T9Y'*A*+YKVT:4DS]LX9QRQ>6PDF^^FUVDFME]J^ENO8D^
M7;WP3^.?Z?X?6@-@?*OXD_S[?AGO0PQM7/')/TZD_P \5^5WQ_\ VO?'/B7Q
M_P")/@!^R5?^'H_%?@VTU&Q^*_QR\6:%J?B?P%\.M2QJVCCP+X)EMI!H7C'X
MW>'=:']LW4'B=Y/!?AJ7P[K?AGQ,GB'Q;'XF\,>'ODLWS?"9-A7B\7*T4[:=
M?\ST<?C\+EV&>*Q4N6G&W1/?HEU?DO\ @GZ)^-_B1X%^&V@S^)_B%XT\)> ]
M @FM+:?Q#XR\2Z1X5T$7<Q816,FLZU-;6T;2%7*(S>8XWE!\LNWY,C_X*-_L
M6NQCTWX_^#M>E8K>FST6#7]>U)-.W27.LZK]ATK2VE&A^%]$6;7O%>LB-K7P
MCX:T_4O$WBJ2TL8+J['P-8_LR>!=9O['Q=\;[B]_:/\ BE;Z#INDZIX]^+ZK
MXJ']GZ*H0:7H_A'60/#O@G0EUO5=6U\>'3T76 O_ !57C%1XJKZ(M;6&PMX+
M.UAM[&QM[7[):VUM:?\ 'GGM[#KSC_Z_P%?C_,J_^Y94]^LG?YVM;LCYU\05
MW_ND;KM*[?X;>B;/H_0_^"A'[%&MWHTVU_:<^#T5Q' 6>76?&6E^'[%D'.5U
M36Y-'T9F X")-O;(50.A^OM.U6PU.SM=1T^\MKRRO+=)[2\MKA;BSN;1T62.
M[21<1N&4J049A\W+D D?D?XM\$>#_'FGP:/XW\'^%_&.E6]U_:UKIOBW0=+U
M[3[/4?\ H*_V1K?/_,7_ )<=:\5L_@OXV^#:0ZM^QW\1KGX*:A;Z[IWBS4?A
MIJYU7Q5\!OB%J@TEM&73?%7A9?GT"3Q'NTCP[XL\1^&2/%6-'92#XP;POXJ\
M+&'X_P QH:9OE3A=;P;37FTV[KJTK>0\-Q!7;_VR/*N\=?FT[W^3OV/WMW(.
MJX_X$:?\K+Z ?AC_ #FOB_\ 9=_:QT+]HY?%NA7_ (*\1_"OXL> -5;3/''P
MI\9W>D7>MZ?8R#RM*\6:)JNEO+%XN\&:^BQQ6VO0^6DTNGR;8! ^AW.N_9J\
M(P[#;_.OTK X[#9EAX8G#3YX2:6]]]M='_D?3T*^&Q&'6)PTE*#5TU_2^YV:
MZV)J***ZCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (3
MM_VB?P']/Y5C:IJNG:/876I:K=VVG:=8V]W<WUY>W"6UE;6D:&26\OG=HHT5
M$C+,79%4%V)0_=X'XI?%'PC\*/"&H^,_%NJP6.G64%^EG;)=Z;_:WB#4A82Z
MII_AKPIIT\L+:[XQUT6#1^&O#EJ[7>MROY:122.L:?BU\7_CC\3/C9KFN3^*
M-<OO#G@6XMTTS0OA5X6\3:O:: +%=.>35/\ A8FJZ0WAT_$M?$4CLWBKPUXB
M9?",?A9M \(Q^#T'_"5>*OBE]SP-X>YYQWBYK J$,J@H*KB*J:I0YM>6Z]ZI
M4E%3<(13C#25644U&?T.0</8S.Y*-..BOS-MV>NR2ZN_IW\_T1\9_M\? 3PY
MH1U?P?/XL^,=Y*L=QH6E?"W1?MMOXHL5O8!_:>B^//&<_A'X2S:*VC3GQ#!K
M%Q\1+6+Q+X<M[N\\(2>(YA9PW'BG_#S'2IU>_7]E[]H>UM8$C-W87^L_LYMX
MDO)#E6BT/2M"^.WB#P]J,-M'OC\22>(?$_AEB+C16\)1>*6:X;0?@@HO4D_4
MD?X4F8QUQ^.<?KQ7])X/P X'PN'2QE7B7.&T]75C3<KQM\$*;VE[T?>=GOS)
M:_H^'\/,BH+WIU)/JU:-^E[15O/?LG>VOZH> _\ @H!\%_%]M]H\5>&/BM\(
MM8%[(D'ASQSX1BUN^NK);9HAJ0UGX/:_\4? 4(F,ER$\/:SXHA\7>;IC/-X6
MC$V@2W/VAX;\3Z#XNT#1O$OA;6-)U_P]XCTW3M>T'Q#HVHV&M:'KNAZI8VVI
M:9K&CZMI_FVVJ:-K>ER+)::Q%-+#<PF*:V:>*2-V_G?PZ\YSZ]_Y]OIC],UT
MOPR\>^,_@CJZ:M\+KT:9;OXE'B#Q'X!FU+4[+P)XK?579_%3ZMI&CC_A'M&U
MSQ#)JQ?_ (3_ ,.^%SXH?Q7_ &#XL\:#Q8C/X4\5?)\4_1[I0PDL5PGFE2I-
M*4E0Q+IWJ67N0I5H*,.:4ERIUDX\TTIR@DF>5F/A]05Y91)SM?276RV3LG=]
M+]U>R/Z)U*8Q@@>I/XY''(/O4WRJOJ#^.?\ /^>:^<?V?OCMX>^/7@6'QAH=
MGJ7AR]M=:\1:)XF\(ZO)8MKGA[7]!U;5M%E2_BC+E=#\0_V:OB7P9K4G]C?\
M)9X1UCP_XJABCA\0(A^B PV$G. 1C/;KR,9R.U?S!C<%7P->6%Q,?9YG3<J<
MXSBXN,HR<9)I[17S35FI233/S'$8?$8;$2PV(C9QT:>Z?5/S_"UFFT]9-IVX
M[YR1^E>;?$?5-<T?PGJ]UX5329/%LL5KI?A!/$/]H_\ ".GQ'K6J6VC:&VMC
M1%?7ET8:SJ.E_P#"1O" ZVV]D9&#-7IFX;=W;_(]Z\+EN-,\7_%>2QET];R+
MX1Z=8ZH-353=Z=:^/?&>G:WI:6$<D;F6V\1^&? KZD]WI#A9%\,?%S1+D1^3
MX@A<;82*=9U]TDFT]FE]EZJZ;LFKZJZ/,QMOJ_U?O9>=_P#/=GH'A'P]%X5\
M/:/H4%W>:H=-MC%=:SJL@?5M8O6P^I:OJDK$%M6US59)=7GD5422::0A(0$2
MNPSN^\%(]R ?Q_\ U>]?A=:IX@^(/QB_:J;Q'\4?CK%;>$OVD-?\)^%M-\._
MM#_'WP#X?TCPWI'P]^&.LC2=)T;P5X[\,>'E_P")WK6M H> &88Y.>N_X5]%
M_P!%/_:4_P#$L_VI_P#Y[%?80X(QV+IQQD<QH*,XQFD_:W2G&,[-)6O[]G;3
M332UOEGQ?A,-+ZJ\MJ)Q;6G*D[-KK=GW#^VE\#_%G[1G[.7C/X1>"K[P]IGB
M/Q1/X/FL=3\3W6HVFAV(T/Q5HVM7;7$FDZ+X@FYBTMT6-+:0^;)EI$1=S<MX
MD_9S\:ZO^WG\-?VH[75?"D/@'P1^SSXT^$.J:/-=ZO\ \)==:_XF\50Z]INH
MZ?IPT1]%.CQK&;>:27Q%%<[\E;8JF3\CGX?1'K\3_P!I0_7]K/\ :F/_ +UB
MD_X5[#_T4[]I/_Q++]J;_P">Q7HX7AG/,)A7@L)FV'5/ESZ"BJ=1M0XDC&&(
MC>3U52%.$:.B=+E3ES7:.2OQ5@\1B/K3RN;VU;C=V;<;O?2[VWT['[1[S_>7
M_OI/\:-Y_O+_ -])_C7XN?\ "O(?^BG?M)_^)9?M3?\ SV*/^%>0_P#13OVD
M_P#Q++]J;_Y[%>;_ *CXG_H9X7_P&M_D=/\ KI'_ *%E3[X_Y'[2 !D(!SR3
M@?EV_F.]>%ZO-K_ACXI:+XACMXI_!?C70X? /B!WBOSJF@>)='U;6-6^'NK+
MYNJG11X;U]=<\5>'/$<BVO\ PDK^)M3^'<2H=/.NR:!\3_\ !+WQ5XL\3^!O
MVH++Q=XS\;^-9/!7[9?QG\#^%[SQ[XN\5>.?$&C^#-%TGX>G1O# UWQKK'B7
MQ ^D0M-,\<4MT% GFE$:.3(WZ(_$#0+WQ=X*\3^']*U7^P-8U71+ZST'Q%%:
MI?2>'/$+(W]B>)8[&5HXYIO#FN?V=KD2O( 9=/42/& 6;YO%8=Y3F]3*<6TY
MTY2ISDKI*4>6[BGK:/-&2ONHM?:1[N&Q,<XRV&9X2]I+FBM[I=_7O?\ )G?+
MMQ\OXTZO,_ASJ^N:UX4TB[\5)I">+88;K3/%\?A[^T1X='B/1=4N-'UQM#_M
MM5UXZ,=9T_4_^$<>8%VM=C,S'#5Z1N.PG/.<9_STXKSZM/V-;V&E]5IJM.SZ
MQ>Z?5-,]2A7]OAUB$M'?U^?9]T?'?[4W[3L/[/.A>$-+T3PQ/XZ^+GQ8UF\\
M*_"CX?V^IV=BVL:EINCRZUK/B;Q5-)-&^B>!?"P,(\7:_H5GK\UI_:VA@0,E
M[&]M\!_#OX87^@ZE_P +&^)GBC5_BE\==7T >'O&?Q1\2:IJN;W3EU/6/& \
M+>$=)/\ Q3_@OP-_;>JJ/^$?\.>&/"_A8A1D]*OZ5K'B[XL_&SXN_&_Q-XKB
MUWP>GB7Q!\(O@5X7BLRMIX!^'_P\\4ZSX1\::KI@8_\ "/ZW+\;_ ![X2/B.
M7Q$QW?\ ",:+X!+>,"Q\+^%?"WJM?AW$&<8K.LT<4W_8R=M]VM&]--T^^EK'
MQ68YA_:&*Y$_=3:MT;6C=KM/5.VKTM;N%%%%>,>8%>9?%+X/>!_B[8Z9;>*[
M*^BUGPS<G5/ WC3P[J8T/Q]\.?$+#;I/BCPCXMT;/B#1M<.N:3H_B$@C!&C>
M'P>M>FT4 >A?LH?M,>*;[6-/_9S_ &D)]'L_C=9Z*M]X#^(&GW$6G^'OVE?#
M.A0XU;Q)HVE$#^POBCX9T;^S)OBQ\/26\J>=_&'@U9/!+/%X7_1=2 "R]#P/
MQY^G0<^]?AW\<=#NAX4C^)7@_P .6.M_%GX)7#?$KX3W4VB/K6I_\)!X17^U
MV\*I)H#+XECT3XE#2?\ A'?%F@>%V5_%)UH,K!AD?L;X$\4Z9X[\$>$/'>C&
M*;3/&?A;0?$VF213?:DET[6M,AUC3<7RA5D'EZ@A60+L.\F,8)Q^H<(9M7S/
M"RPN,24\G<8RDOM>ZTF_-*_RZ7N?9Y%F&)Q47A\7_$CU[I[^5]+-_-[L[ZBB
MBON#W0HHHH **** "BBB@ HHHH **** "BBB@ HHK-O[ZSTJTGU#4+FWL;*Q
MMS/=75S<"TL[>-!RTC,=JKUX?/\ "HRS 4 6HSZ%,>HQ^//7/X_H*BFP3]V,
MCK\Q'O\ 0].@XXP:^9?$7QZ%S9W=K\-M'F\47T;/ ^N:@S:-X6LYFT^1P4D<
M#6M:CCD9)%7089+>7)0^(K<#97$P^,OB]J&R?4/%?AW3/,!%U;>'_#TMZMON
M&,:;J6L2[9"0/^6T+ '+* 3S^49[XR<"Y)66'_M.6<S:VX=2Q+ANK.4:D(/7
M^24E^1]?@>!\^Q5%U\1"GE/=5YN,]D_X:ISFE9W3G&GS;+74[7X=_LW^"OAS
M\7/B#\9M+UGQ%J'C7XHAX];MKK55;P]9Z9#J+WT<.C:-;1QQ_: ?[,$FL:[-
MK<RO!,MBV@1:W<P2?3TNT#D@]AVZ]?;I]?>OBJX\6?%6V28Z7XYL+@" -:C7
MO"EC)>W$@& VHZGH\OAR*(9R,1>&5V^A.:ZS1/COXATV""W^(OA8( I%QK_@
M:/4O$&F.<'<TNCE!X@T@9VD)%_PD&3D&4 @KKA?'7@KBO$)8G-G1DH0I\W$4
M50O"G&-.G!-JJE&G3C&,(RTC%)*RT.=>'&:91AFLNI0J1U;A3J*I-.W,WR2C
M3<[NZ]R[YKIH^K=JOQT/H?Z=QCGCGZ]:=LXQGZ?AT^G?]/I7-^'?%&E>*=*M
M-;T&^M]2TN_MQ<V=U;,&21&Z%>F,_=*L,@@C)R,]*7XX[],^HZ@X_#'UK]-I
M5H5X1K4)7@]KO1VU_7\T?-5:-:BW0Q":DKIIIQDFNC32::M^NM[N$@%FQWC7
M\\K_ (5_/Q\1;>Z\=?\ !6+XXZ])87]WHGP3^!G@'P ^IZEJ2C3]+\3>,M/T
MCQEI.GZ1I UF$/H<NA:OXP?=Y:Y\5'7N2,&OWZ>>"V@:XNIHH(8;4W%Q/.P"
MVX +%VS@ #:3C(.1CG(!_G+\'_M ?!KQ7^W;^V]XNTKXJ>![[PUX_P#&W[-W
MP\^'6N7&O:-8Z;X^\7Z-\,]?T74O"_@Q=8 /C)&U?PCJCQ1>'#++XGCT8>*O
M"D]QX45[B3[[P^5L;FF*Y;\O#5>SM>W.Z2WM=>ZWU5U=:K0_/./?>P>58>_Q
M<2T4^E^52=^SU?WZK<^XJ*\+\9?M(?!KX?\ Q(\.?"OQCXPN-#\8>)SIW]EB
MY\,>*?\ A$+/4?&.J'1_!^E>+_B)_8/_  K[P5KGQ)UW1]9\.^$O#WQ)\3^%
MO%7Q7\5X\(>#3XIR,^BVOQ"\!W7CB^^&-KXW\'S_ !&T?0?^$LU3P!;>*-)_
MX6!H_AWC1?\ A*M8\(_\C#_8/_4Q8]#CBOT7ZPL2?$6_'5'7T5SWBCQ;X5\#
M^']5\8>-_$GA_P '>%?#]J;O7O$GBW5-*T'P_H^G=M5UC5];QX>T0FN.NOCG
M\$[#_A%?M7Q@^%]A_P )QI?AW5O ?VGXC>%<>,-.\8?\B?JO@_\ XGV-;T+Q
M-_S*/_"-8_X2SC'-4!X[X"T*QTG_ (**>+?"=MK'B#X=WO[5G[&GB_PMX<\4
MV]OXGO--UOXX>$-5T;5=,\4:2Q5O#Q\<_#7P%X3;Q)&F/"Z^%YA''))#XL\5
M//XD_;[X5:UXD\4_#SPMK'C'2K?1O&=SH_V/QKI5J8VL=)\8:6O]B^*=,TE(
M=8\1Q'1X-?TO4X+,_P!OW3&"&%Y)I)I9"GX[6\#ZO_P48_8:L])AN-5F\(Z'
M^TMXJ\8VNF6SW[^$/#^L?"Y?!VB^*?%8CQ+HVC^)->!\/Q^(-?\ WI\6J/"$
M8#[<?K9X*U*ZTSXA?$SX>:N\<T-O?:?\1/!16"547PGXN5_[8TQ[F4L-6UO0
M?B;I'BS6;KRHUA\.>&_&7@*WWJ\X2OSSCV"Q5>,(N+E+AW"RFKWE&%%5>'G]
MJ]OW=.3B[)1M.,911]IP2EAZ5I72;G'LFZB7$B>VZ]I)7OUMZ_-_[:/QD\6>
M%+;P3\"OA)J-WIWQ6^-.H7MO)XTM(I+I_A)\,]&$=QXQ^(,JVN@^((5UJY#1
M> ?AG:^(CX;T_4/%^M).?$T'_".W$<WSG\-?ASX5^$'@?0_A[X(L[BQ\*^'[
M74?[+MKFZU6__P"0SJO]LZQC5];_ .H[J^L=?Q]*YFWNM5^('[5_[57Q,UO4
MOM!\(^)?#7[.?@;1OL:*WA[P=\.?">A^,M99]6B2&/6W\2^.?B+J_B#_ (J*
M*)/"04+'XKC15C7UVOY,XAS#^T<TS/$+X8>[%=K>[?3JVM7Z!F>)>*Q?+TBV
MDOGK\V[W\DE>R04445YIQA1110!X=\7? &K7-[X7^-'PLTS3C^T'\$EU+7_A
M-J.IW.J-I^L Y&L^ -8!UWPR-<T+XDZ%_;'A[!\3D>$CK72OUH^!?Q8\.?';
MX3^!OBUX;MY+;2_&F@VVHG3KI4.IZ!J:2-I?B;PKK#.B@ZUX6\0:?JOASQ"B
MD+'>Z1/&@8HK'X(KM/V'+O5M%\8_M._"^^FN9]%TCXB^&_BUX%MKR_DOXK+P
MW\6?#&W5AH<$;'1-#TN;XK> _B5K*Z#;(ID\3R^(/%=T;E?$EMKMQ];PAF"P
MV9O"/;.KS7DXIZ[_ ,MT_(]GA[$/#XEX)WMJUZ_\-^2/TLHHHK];/MPHHHH
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MX_PZR-$^)7C7Q1)X8U=O$^A3>&_#"^&(])UR(#S4D%3FG%^5Y1FV69/B(O\
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M!;[-XCN'K?M/>,O$/P__ &<?V@/'?A/43IOBOP1\%_B?XM\,:H(=/O1INO\
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MK&D_#C3_ !-\^CZ\MR/#,OBN+Q%'H364\GB3^RO^$9&Q[Q98OY:?CA_P3_\
MC_XS\8>*_ 7[/GPM^%=MX6^"WP%\(>"/AO\ %OQ[\0O'O[/GB"^_:^'BCP5\
M?8OVD-(&C? OXX?\+J3X;Z_X1^$ \*Z!XD\4^&?"WA!3\7_A&OBN0CQ4OA;^
MBS_@KZ5C_8ZOKV^BFG\.V7Q>^#%WXP3[+]ML#X<C^(6C"9M9C& -'%R^EBX(
MX4F)3EB<YPY /J!7^BG"V6K$\,N:^*IQ/2<M_L0LEU2MSRZ*[?H?RMQ!F.*P
MO$T$DG%05KJZUUNM4[_-]>C:/P%^)OB3XG_%3Q#\6Y_!GPS^)4O[0OC#0/V
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M>+)1JW@'1E&LZIJ\B1R:WK3XW+XA>-'\6*1N56R!].U#%%#%'!#%%Y$%N/\
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M^2<5W?75N[_,_GE_9-_X).?M+?LH?L__ !*^"V@_$+X/:I8?M)?L>?$GX/\
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M7/\ &BR_:'O_ (R6T#MHFJ?$FSU*;P+%=OIFIIJ,GAH?#:36/A#HZB$S*O\
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MKU/ZBX>>4X?@?AB.:)2P$>&*;I137M;23UIMV<8MIJ4I7I<RE>$FFG[GX?\
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M5@Y6<)UH*2ERM.$>>K*/++27-&DURV;=[)-I(\C/<1]5R3,\4MXP>W=M)?\
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MH\21BKWDK<JM&R/T'@BNVLPPBWIU$U=O[2:?7\O4NT445\ ?;A1110 4444
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M:;H^G/JVIRD9&=EO$S[ 1OP5R&P0 ?'/Q[_;C^"O[.'Q%\,_#;XAQ>+)M?\
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M0 5FWEG9:E:3:??6EO>6-[;F"XMIX/MEG=6C @QNI!C965N ^>H(#?*U:5%
M'R'=?L<?L_E]NB^&O$?@.S57":#\)_BK\8?@[X35W.#>?\(E\+O&WA3PT=6#
M?,=;.AF[9>&FZ$+<_LE?"2\DMYM9O/BIK)LX-/M+*UD^.?QHTVPGTW2R7M-*
MUG2="\;:)HWBP*#Y=]?^+X/$?B7Q3&A;QAXA\0EBR?6?R_WO_'X__B:/E_O?
M^/Q__$U\]_JQPYM_J[P];M_8-%+7=64%%)ZW2C;66GO,];_67B#FYGQ!G[GH
M^=YXW4;CR\K=22G4;BX0:DZCDN6#4DX0<>&\$>"/"/P\\/V'A7P/X9T/P5X:
MTW[>-*\-^&-'T[0=$TO^T[Z34]0_LS2=)ABT>V$FK7\D\J0P(GVB6Y<>86D:
M3N\?+GT/YC@?Y_&ERI.3N/Y?EZT[<N,8X'8].OX_7I7N4Z,</AU0H*W+\+:L
MD_*R_+_@'E5*M>O6=>NVWKO)R;;W;=VWYMN_GNQ]%%%:B"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"OMV\9&W&2<YX]<_AS^0ZU
M_,Y_P4[^/4?Q+^-TGP[TG5])O?!/P.M]1TJXU/3]0:Z_M3Q_K#:3+XNCUG4M
MW_"-,WA>;3].\.IHOE)<>&?$>B^.$NY;NXA;P]X;_5S]N?\ :O\ $W[+>B>#
M4T?P8^OP_$71/BAID/BNS\1:3I]]X'\9Z7I>BGX?:FWA;68ROB+P_+K&L,_B
MYA@^%_#NF3W13Q!<_9O#/B'\,_V*?V>;K]H7X[>%_#EW<M'X'\)[_'WQ-OM0
MN=4O[[7] T?4=(?_ (1EW:.2+5M:^(^N:II!\6O,IC/AC^W?%(\6R>-I8XG_
M ';PAR'#Y/1S7Q/XABY9%PW&\+)-U:\^:'N/FLG32]E:22]I63;4$YK\-\5L
M]KYMB,M\/LIDEF^?.[;T4*<4GK?IO)N^T>^A^W?_  3>^ 6I?!/X#1ZWXL\/
M2>'/B1\7-5C\9>*-,U+2O[.\5>']!VG2_!7A+5I);<:Z4T+16_MV?P]K\TA\
M*>+_ !AXVB78TDRG]%PA\R7_ &E)SVY((QCV_P C-/R@5.  >@''XX_Q^F:D
M!&2,<@#'T_\ K5^+9OFF*SO-,QS;&R4JN;59UIM;*4[MI)Z\JBU&-];15]6S
M];RC*<+DV5Y;E.$_AY1",(]VDGOYZ_CJ.HHHKB/7(R  1P#@_P#?()/^?\X_
M-;_@IIX;MF^"'P_^,.JZP-*\/_LR_M _"SXZ>)X$TT7XO_"4;>(/AEXQ8-YT
M91O"_AKXIZG\0GA2S\3_ /"3OX-'@X>&;K_A)6:/])V;]XH['C\,9_J:\W^)
M/@#PK\5_ 7C+X:^.](3Q!X,\=^&=>\*^*]!FNM3TX:WH&MZ;)HVK:4^IZ1/;
M:UIBW,<X5M4T6:&: ?OH&CN/)FKMRO&O+\QR[%K5PJTZNB3;46G**O9>_"4H
MWNOBW6ZX,?AEF&6YCA']N#CU72Z_*_R^1^<M%?-'P8U'6_A1X[\7_L8_$AM6
MN/'/P/\ "WAS5OAYXT\1-I9U'XT?L]?VGK.C^$?BAI6CZ)KJL/$'A?\ LH?#
MOQ>KJK?\)6?^$P*C_A*!X3\*_2]?NM6I"M3A5IR4Z=2G&<)Q::E&2C)-6OT>
MJ>J:::3C)+\7::;35FFTUV:_K^KH\\^+7PTT'XT_"?XF_!_Q;/K%CX5^+'PY
M\9_#+Q1<Z)=_8/$%GX=\8>%=;\&ZQ_8_&/[>_L+5_P#/%?(O[&W_  3F^$O[
M&7B'Q3XWT'XK_M&?'KXB>)O!OA[X9+\1?VGOBQ_PMGQ?X:^%7A#51K.D?"OP
M@QT+PSH.C>!?[=U;_A(_^$>?PTQ )"D# K[]HKD^K87ZU];[?Y=KG0L3BUA'
M@T[*5KKO;;6U[7UW7G>RL445F:KK.FZ!I>JZ]KVI:?H>AZ/I>HZMKVMZE=?8
M-/T?3M&_Y#&JZQJ__,$T+Z?AQ72<Q\Y_M2_"E_VC-!^%_P"S#]I;3=._:.^-
MG@WP/XEUE;I++4-&\'>$=+UGX]_$=])U.31]?31_&Z>!?A)K&@^%5_X1WQ+X
M7/BC5]"7Q>2[#Q4?Z % *^WEJ/RP #Z9P?PYK\?OV%O"NI?'#XL^(OVQ]?T+
MQ5X>\#>'O"VK?"#]EK3_ !1X>;13XN\%>*CX+\8>,_CZNDZNLF=)^(TNE:'X
M<^$.M>&T\+S2?"W2->;Q=#<CQ!X<MO"_[ !O]8/[HY]R"/Y<BOS/CO'^WQ^#
MRV%2,J.14_J\>5QE%U')^WDI1E)247[.D]=)4YJR:=OTCA'+EA<%]<::></V
MCOVL^56?DV_FBQ1117Q9]@%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 5RH 4]^@S],=O7Z=LU
M^*O_  5E^/\ _9.@^&_V;O#^NWMGKGBF#3_'GQ*TZTMF$D_PYDU'5M(\)Z/+
MJ94-'_PE/C?1]0E*>'I)O,/@P>&?&GD^$/%@M_$G[ ^)O$^D^$/#VN^+?$%_
M;:9H'AO1M2UW6]2N&"66FZ+H^GR:IJFI2%5)\JWA1I9&^8B-"Z@E2&_D(UWQ
M#XU_:D^.]WK7]@2V/Q ^.?CF)-/\+Z8K>*KW2YM9VQZ-I2:FTDSZVWP[\%Z4
MJ^*==,GASPRWA?P<OBL-X9\(^&0?"_ZQX,<+X/,N(I<19M",,CX*BL7B*D_A
M<E94HN3:BG!0]K*37NJG'6+>OY)XO9_B\NR)Y#E-GG.>_NZ<5NHZ<UNKYG:*
MVOJK.VGZB_\ !)?X&RS:IXV_:!UZPT5M.@LA\./  DO9;S7K2[,JZIXSU1E$
M+Q:7"(F\*^'_  T'D7Q/$P\;QW/E0W8NO$G[NL254GWS^'_ZOYUY!\'?A9X6
M^"7PT\&_"KP+%-#X:\%:+8Z#ITU[;Z>-2U.5% U;Q-KQT?2M"CU3Q#XJUHZG
MXH\4>(/L\+^(_$VM:WXDG3=<J!Z\7#90#@=,^W\_3GU[U\5QIQ-B^+N)\UXA
MK[UZDI*F_LTXV4(:67-&$>:3LFY2=[\J;^VX1X?P_"F0Y;E%-_PX[]Y/5[]+
MO2_3:VI/1117SA]*51M141R,YZ<9[?D>#3R=S%"N5[8X]^O<'OZ]>G3Q7Q9\
M(Y/$_P 3_A_\2T\9^+-*_P"$%M-?M5\+:7J)MO#_ (A.M(D9?6H%7,S0;%**
M#E@J*=NW)]J7H(]_S 8/IG@'G_(S^OG8>MB*U;&QQ&!Y8Q:47S1?M(V_S^>E
M]C6M1P]&A@?88U2O%.2Y7'EE=I0NVU.\;2YHJVMGJCA_&GCKP?\ #7PMJGC;
MXA^+_#7@/P?HYT_^T_%GC/7=-\,>'M$_M74XM'TM=6UG5FCT32/.UC4].T2*
M:XE7?/-$KNSM%%7B?QO_ &N_V?/V9M4\*Z-\8_&^H^$&\3V>K:PD]KX'^(/B
MS1?"7A/1]5T70M4\?_$K6?!GA;Q'H?P9^%>AZQK.CZ+<_$OXGW?A'X:6\^J6
MT<GBO>]P5^8/^"@7P*^+_P"U[XH^#'[+NAZ!HMK^S?XLL?BI\0/VE/B!XPT6
M7Q?X0ND\(^%8_!GPY^#"^$]#\=_#C7]4UKQ3XT^("?$F+7(_$T<7AN7X+1M\
MLMU\OYK^(OAG\3M7O-<_9^^/>C?'_P"+7QE\&_\ !,;PW\+]+UWX0/J>FW_Q
MB^*GP@^,_P"TW\,?ASXK^(FD+KTG@#6O!'[26D:7I/CX^&/VF1XB_97$VKR1
M_&8*@0OZ)D?TU0S0S112Q2"6*49AE'S!@0<$''?!P<<]#[V*_)O]HKX9>/?B
M5X)_8ST+]J+P_P#&_5_"MKX,O;[]I?0?V,O'GQ\^&5E9?M#:1X'\&:OX5G9O
MV?OB%X9^,>M?">'QII?Q!T#PGX;'B3Q)X9B\3ZQ\/?%'C%W'AJ+Q'!\3_&SX
M ?M/7_QC'Q/^#$7[:6E_M.1_M+_$6Q\::[XA^./QKC_9S/["T7P=\;IX2\.>
M$?!W_";^(OV>5UHRZI\.="\(:+X8\)_\+ZD^/W]O^./%S+;CQ1XO< _='XS?
M&KX9_L\> YOB1\6M;N] \,0ZYX:\.VTNC>%_%7CKQ)XA\3^,?$V@^$?!WA3P
MI\._ 6B>)/'OC;QGXG\0:KI.A>&_#GA/POXD\13RNJ10NPE+>S1.)8XY!_$N
M?S&#^M?RT^._^"?7QRU;Q;\#_"S#]M'Q]X$/C#_@E'\<OB'K?C3]L3]J+Q%J
M5M\<-,\?_''0/VP/%\6JS_%=O$'@G6=!\ 1?".Y\2:)X67PMX5\([/#MSX$\
M*>$Y(%E3V/6/V??VFYM0^,WC?3YOVQ;+]M#QGXF_;GTOXA>-= ^,GQZTWX)W
M?[/$W@/]H71OV0-,^$7A1O';?LRZ/XC\-:UXL_9O/@]?A]X6_P"%K>%/%NB_
M$'Q;XO=6;QB?$X!_1Q17\WW[6W[ _P 9]/UOXO>$?V;/%?[<^C?#OX+_ +!&
MJ^*_V64\*?MC?M)7+7?[;>I?&GXH^+CXHUG5=>^*WB?Q%\5/'":/K,8&A_$?
M_A)O",_A37$\,Q^%73P]X37PU]!^,?V:M8\"_#'QU\!+;PK\>O%?P5F_:H\2
MZKX6UGQ1\3OVOOCEXMTOP=XL_9<\'^+M9U8?\(;\>/#'QF\:1^(?VD=7^)#^
M%)_$?Q*;PE\+OBB]MXUMW\->+O#/A/Q3X8 /V)\7>,/!_@#PYJWB_P =>*]
M\$>%](MQ>:UXL\7:[I6@>'M)5=MB9M4UG69(]#TI3(T<3NTT<9D)#KR1)VM?
MS^:W^SW\:XEL_BM)'^UY'^U#XD_8+_8U\+:9J6@?&S]H\>$[CXP^$M6\>1_'
M+2_%_A+1OBG'\'O^$W\.:!K.DZZI^(_A9$D\4ZQXA\6^#I;GQIXB\62R_/\
M\:?@)^VK?:I\8_'7@!?V[H?VT=8^-W[;=OJ?BW1OV@?C+H?[.%U^R.OP7_:&
MC_99TGX;^$M#\>O^SZ#&?%_P@7X3>'O#/A8?'WPG^T$WB#Q?XS?PP1XK\5H
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MC+\2?$GPR\5? ,ZKH+_LT>+?%8^)WQ>\->% #]+J*** "BBB@ HHHH ****
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M-+^ _P 4O@[H_A;1=4U7R[B:2V7XA:?(NMZ[+YS0Z.YE+W3QLH!XO8?MC_\
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M+S3;'4/%_B!<Z?X0\":,^JE4C\0>+/$DFD^&_#"&3RY_$>L0H5 <(WR-X?\
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M+_AEX3\9>&_%?C?QAX:\,^(_#LTWTEG>/D(^O/\ ^O\ EW% #Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BOY[?^"M/_!0OXF_L@?MV_P#!'OX(^!_C
MOH?PO\"_M/?M'>(O#O[17AK5-"\ :DOB/X6_VO\ #+1=&;6=8\:^'M?UOP3H
MMQKGB?6-%3Q%X;\1>%764SNDK1^'"(_Z$J "BOYE/^#GG]K[QK^RG^R+^SE/
M\*OC%\6_A/\ $OQK^UW\.[W[5\%_&?B?P=XP\1?"OX;^%?&WBSXOQ:G_ ,(3
MK7AGQ#KG@6/1DT9_%\!EE\/)YFAFZ6)=L@_H;L==M_B+\,[?Q-\*/&'AVYM?
M'G@J'Q!\-_B!96B^*?"TJ>+-*.K>$?%@TV/5;:VU_2'BU/2-=$<&OVQ\1Q.=
MD\"RHX /P6^#G[:AUK_@XT_:E_9AO/C_ .,;WX>V_P"QA\/-!\!?"G5?'NKW
M7PDB_:"\+:SX+\:?$K2_"'@Z75QX#7XLV_P^\8Z-K_BA-!MAXJ_X1N+7$G55
MBF,?]'-?S.:1_P &]4WA7]G3]F_PIX?_ &P=2M?VQ/@'^W9K_P"WUJ/[8FI_
M!AM1F^)OQ5\9ZHLGC#2?&'PU/Q9CG&BZ]H.B>#- GV?$H[O^$0!^0>(KB)?Z
M8Z "BBB@ HHHH ^!OVD/VR-;_9Y_:"_9(^",/P \?_$G1/VH/%'Q#T?6/B=X
M>\7_  I\/Z/\(-.^&_@*X\;:MK&N:/XX\;>'=<\81V^B:7JGB+Q)!X=C^TP>
M$M$UMO"B^,/&S>'/!OB3PGP/_P %6_!=_P"'G^)?Q(_9Y^//P5^ ?B#PSI_Q
M7^$OQ^^(.J? =O /Q'_9UD\6?#/PAJ_Q_P!6TK1?BY+X_P#A5X)\*Q_%KPA\
M0?%FB?%#PEX8\7>&_A=JY\72>&!+H'BWPUX7^X?BE^SQ\/\ XM^,_@OX_P#%
M"Z]%XO\ V?O%OB3Q7X!OM%U*2PML^-?"VN_#KQCX;UO1M5CN-$US0O%/@G7]
M0\/3"X@6>W222Y\,7/AZ0EG\1\/_ /!/[X&Z%I?A+PC<WGCWQ)\/OAMX5\,_
M#[X7_#OQCKFE:YX1\ ?"WPI\0/!?Q'B^%FE%]"77]>\$7FO_  \^&T7B1?B/
MX@\8^*O$WACP)H'A&X\6/X3E\46GB4 \4OO^"F?@[2+?5O'B^$_B9J_AC6O@
M9^SI\1?@[\'G^&FE^%/B[\2_$?[4GQ\\;?!CX/V&D>*O&7QQB\-0O\4==TKP
MC/X<\,_$#PC\*%^%OAG7'\5^-O&,D+>+/"/PL]Z^.G[6&M_!?]CS4/V@_B#X
M"'P0^)FIZ=X9\*>%?A5\9O%W@&_7P_\ &CXE>)-&^'/PZ\*^-_%7PQ\=^)O
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M/XC^,XG\7R+\0/B%KD:)HW@_5IKG7?#:>&7N/%$?AZ)89/"7_"41O\T?"/\
MX*:^+Y/#GP>^$/CW]GWXL>(/VK_B?^SK\'_BM\)=$EU_X+Z5H'[02>./!"MK
MGBO5?%N@^-'\+_!EK7QGX3\;>(_$WAZ>VGE\.?"PZ!XI\(^&O$WBZXNOA;X:
M )OVH?\ @F/\7_VK;WX>^,OB7^TUX,O/& ^'5_\ ";X_>'M/\ ?M=_#W]G_X
MS>#W\?ZKXOT/2O\ A2'[/_\ P4>^"-S&/#\6N:WX8GTGXT_$K]ICPSXDBUJY
M:?PS AEBF]>^$7_!.=_A1^T%X,^-\'Q>;6H?!_QL_;M^,<?A/_A7@T\7C?MJ
MZQX,U=O"YUI/'$D<7_"M7\(JG_"02>&I'\7C5Y,6WA4(PD^:/CM_P5.\>:O^
MS7^U=?? /X"_%/2?C[^SA\,?VC1\:Y[K7?@WJ&G?LU_$/X=>&?'.F:1J>D/K
MGB%]"^-D3^-](T7Q!X8CT'PX]K+\+(]9\6^+8+;Q@D?PC\5_;OP6_;Y^&/QG
M^,<?P \->$/BI_PM'1=2^/6@_$NPUG0/#&GZ=\+9_@/K/PQTO6-8\9:D/'$W
M_$F^)B_%_P"'GB#X1OX53Q4?%7A?6VN9(M ;PUXDBLP#\X/B[_P1N\6:1-^U
M7XO^&'Q4E^*VF>/O#W[;/Q'^#WP1^(>I_M/7_B;P?\;_ -JGX6_%'1M6C^'6
MMZY^W-X>_8^\'1W/CKXI>+(TUZ?]CF+Q+%X/\2WGA;Q%XW%W(_B]_J;X)_L%
M?&:!_P!F_P"(OQY^-?AO7?B)\$-9^!-UI?A_PI\'%\)K:_#KX&?!G]H#X;^%
MOA=XLU4?%KQ?HFN^.TU[]H_QIXA\6_&+PY!X5\)>*Y= T"/P?\(?!\&)1ZW\
M4_\ @H!X4^%OB;]H^Z\3_#GQ/IGP;_9)M?#VE?&CXSZQXT^%?A+P];?$'QMI
MWPNUWX?^$O"NE>,/'7AJ)]#N-#^+,,WB[XC_ !'\1?##PEX/NM%9'DO+2>;Q
M'X=\"\ ?\%@/A)\1K_X.V/A_PSHNMO\ %']HG4OV=+[XP^#/BOX9\<?L@Z/\
M0M(\*?"_QI#X2\)_M;>$=!N/A[XT\=?$?0?B3I.@?![P#X@B\'#XG?%GP;X_
M^$*^)O#7B[P[X9@\6 &[J/\ P3K^,Y^',?PR\,?M-^ ="T2Z\'?';]GW6M:O
MOV:-=UW7[O\ 99^.WBK1O%4GA?1GD_:/B\-Z;^T=X7*ZRG_#0DOA?Q%\+_%8
MU6.7Q=^S9,_AVV1O%O"W_!*+QIXWTC5_@9\5?B9-X7_8[\%?M >(OB#\/OA/
MIG@W3;SXP^(WT7X4_P#"G?AQXI7]H+1?'C^'M!\"_P!@ZLWB.3X=R_ Q/%D?
MBO1HT'C'PYX0(\(CZH\4?\%%]%\ >+[2P\1_L^?%>#X?^+/&OC[X1_!CQGI^
MM_"R\UOXN_';X9_%'Q;\-/%W@/1_!_\ PG8C\':+XAUO1_,\$_$+XC>)?"=I
MXE==<A\71>$'C\,R^+.<T3_@I)JFH>-/$_P U3]E'XH6/[8?A&__ +-UOX+:
M1\0_@WJ/@&VU34/A:?B]X+U3_A=FL>._#F@2>"_$OAK_ $:XF'AH^+?#/BBW
MUJ&7P7-:'POXC\4 'RO8_P#!&3X@Q?"KQCX'UO\ : ^"?COXF^)O%GP:U*P_
M: ^*7P?_ &^/BS\7O!EA\!]-\9'X<ZQ\./B!\3_^"L7BGXD_"SXK>&-:\:ZI
MXB\'_$+X(_$WX6^$O"JZQX^\,2?"KQ)!XL5_#'[-^.?@YH?Q,\#>'_!'C/Q9
M\7IH/#UUX<U@:_X ^,GQ.^!OC/6M6\)GS%OM:\7_   \0?#'Q!J^E^(97(\3
M^&?-7P=XD)3S?"1MUCCB_//P9_P5^_9_\81?$3Q/>^&?&/P^^'?@']D'P;^V
M =4^*UUX:\">-O'WPO\ &7A+1/&L/B7X1>'-6UT^ OB?X#\*KK<WP\^+'Q&\
M.?$I?#'PK^+.DVWA3QBR>%?$WA?Q=<_3G[&W[7_A+]L/X=^./&GA"_\ AEXD
MD^'WCZ]\$:[J/P$^-_AC]HGX2:MJ<?A_1?&FF#PA\;=!MO#.AZ_,/#GB_08_
M%^BS^'O#4OA'Q9!KOA=5\2>$8_#7C/Q> >D:?^S9X7D^,UI\>/&'C/XJ?$GQ
M[HMMJ5E\.]-\;>.M57X9_"S2]335H6_X0KX/^$%\,_"!O&J:5KFN>'/^%S^)
M_"'B?X]2^$]<UKP<WQ6E\%7 \-CX;^*7_!*GPG\3;SP#X@F^) T/XC?#O]N7
M7?VK]+\;V/@-KNYO?AKXR_:&\'_M(^+_ -G+5=-G\<0PG0O$7C+X:_#BXE\=
MQR2R0>*?!/A_Q8/"#I)X@\-W?%_L[?\ !3#XP_&#X8?!.VL?V:+_ ,=?M,_&
M'5?VAO$MU\//#_C/P#\.?!VA_ GX!?M)1_!WQ;X_/BG6?'GQ)!US0-(\6>$=
M \/> I)3<>,OBBOB")I_"G@MHO%EI]7?'K]N?P/\(?V4/AU^U0D_PDT/P]\5
MK/X>:KX+B_:6_: \ ?LH>#GTWXA>'7\<1Z3J_P 2?&G_  DOAV/QR/ T.IIX
M9\,^'H?$[^*O%L0MC<>'O!Z>)?&WAD ^1_B1_P $J?B-\7O#?A?X??$']ISP
M[<?#_P"#UG%X;_9GTWPI^SKJ6@^(_!?@T_&GX+_$W5!\>?&&M?'CQ1#\;/&<
M'A_X(^$_A[X6\1^%?#WP)A1]8\3>+O%OA+QA=7,-OX9^K]%_8;\/V_QH^./Q
MOU/XH?%"X\3?$KXS6WQC\!>&O"WQ-^/GPQ^'_A#4Q\!?@G\'HM(^)WP[^&?Q
MQ\,?#C]IG1I)/A#%XG:'XC^%&T"&#7M:\*I;Q7,GB3Q1XG\A\3?M9^-?%'Q%
M^#NM?#'Q-J&E_"KXOC_@G5XQT+1M3T'PK?ZJO@_]I7Q;^TP?%VFZG(I\0I#_
M ,))X=\(>$5D">("?##Z.TGA"?S6GDNO3OBQ^T3XT^%_[27Q!L-8T+XRZS\)
MOAG\%O@+XDTSPW\/[;X!W.F>.OB-\<_BE\8_AGHVC:D/&^N^'OB%#K/B/7=
M\&>'/!GD>)O"7A5/% UZ?QBY\+ W4@!^?-W_ ,$2_B5JGAOP%J4/[9^L^'/B
M5\.?$WQ3L_ FC^"[3]N#X:?LX^!/@5\6_"?POT+5_@'X+^&WPN_X*5>%/VA/
M!O@;P]KGP@T7Q1X-\-:#^V'%\"?"D>M^(/"/ACX-0^%SX6A\+^J>,?\ @C?8
MZWX"M-&\"_&]_A)XM\#_ !$^#/Q,^#U]\/+/X^?#7P/X&O\ X1_LB>"_V/-3
M\,ZFOP9_:T^&'[0NJ>!/$G@;0];UKPM%H'[3OA'QAX6EUC2(?&GC#XH16_BQ
M/&OO/AK_ (*17>H_&7P3^R[K_P"RW\6O#G[4/B'Q-#X?\9^ X?&/P<UCP-X"
MLM$\!_!WXE^./%[_ !;'CQ(O&7AW0/ _Q<@D\*K;^#[7Q1XO\6Z'/X5G\)^&
MH77Q0M3XC?\ !2Z7P!KOCG3=._97^-7B?1_#'@O]H#X@Z+XGM?%GP>LAXO\
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M[%Y/@[PF_AYAX@Z;X%_MZ^!OCY^T/K/P+\*>&-?\-?9?@5\//CUX;UKXDJ?
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MSJ2EM.\0^%-=TS7=#O  #^YU71I)H'(R-XC=PFY0W)"U^$D'_!,CXY6<VO\
MP;\4^$?A/^T?^S/X%E^,FO? 4_$G]J?QW\%_%TFH_%W]G_5_@]KWA?XC^$_A
M=^QAXJ\11Q>(_P#A,/B/X9/Q&T+]ISQ$WAGPGK6@>,K7X0R^,/#<'A>7]*/@
M%\#/BNW[,;?!;]J+QEX@O?$-\NM>'R_PN^/GQ7NO&/A+P NJ.O@KPGI7[6'A
M_0/V;OC/XW\7>'O#]AIL=U\9'\.?#;XE>(9&9O%<WBB_AG\9^)P#[ \1Z_IW
MAKP]KGB741(-,\/:+J6O:@T4)9A8:-I\FJ3[0>K"&-FC ZL"IQAC7PUHO_!1
MW]FSQ/#X&O/#DGQ!UK1/B9\1O@7\*/"_BR+P!K<7@J[^*/[0_AO6/%GA#P$/
M&$@_X1[6/$/A?P_I(E^*D7AJX\00_#.;6-"\+>*Y8/%TLWAZ/M?#7[&_@'X6
M^&/B;IOPP\6?M#ZOK?Q'\ >(/!31_'C]LG]K[]H[0;0:EI6III<VDZ1^T%\<
M?BIHO@Z6.Z98YM>\+Z!#XB:T8Q3O+$LD<GY;6O\ P3?_ &U?A#\'?V8?@?\
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MSE\'-7T?Q%X&\%>(I_&FDZ[XB\1'XA^/_BO\8_BU\3/$.O\ BSPR?!NJZO\
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MFT?3_P!G9O&1^$$0D_X2!FU1?#!\:>+0TVO/<+XGCUF4>+6\0&.)8]CQ_P#
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M?Q&\/?#>Q\3:]&KNVF:*^N:S FJ.(Y$><*DB^'H1-X@NE\B(NH!SOPX_8X^
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M]CGQMK/C+2?%>I^#/&?C#2=&T?XZ_!365U37;CXA"V'B+1X/$7A0Z]X8>W2
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MN?\ @GI\%)O@3\6?V>M/U;QOIGA?XJ?'WQ+^T?\ VZ;'X6:_JWP^^)^L^/\
M1OB;H@\':/XT^%_B?X>S:!X4US2-)A\,^&_B/\-_B/H1\,P2>%_%L7B>VE1)
M #K?"7[:_P -_&'CW2_AMI'ASQG9_$&71/&/B/QEX/US4?A78>(OAQX=^'?C
M_6OAIXTUG5]%D^*:MXQT?PQXTTHVWB;7?@RWQ3A@75O#(FD \3^&M_&^&O\
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MS?M!P>&_#8^#NM^%_"WQ$;X92^'/%_Q377/"D7_"-^%H/#7B_P 7 %7X&?\
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M_:#TKXI:S\)_ .H?&BS\+6_PKUCX6^&/@%\:OV<OBK\0?B5X?^,/Q6T7X->
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MD1>)CHDT"^(U@M$E29$Q!Y-I_P"R9^ROI'CGX9_$C3_V:?@+IWQ!^"'ABR\
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MSI/@G0;I?%__  5%\>ZYJ_QJUWXR?':,:;^Q5\:M#T1-)T8:U\5_"WB'0_\
MA8B^+?+B\.+XI'A/X3H2/!W@Z3PAX8'A4?J9X-_9M_9V^'GAEO!?P_\ @!\%
M?!/@^Z\&CX:7/A'PE\)O /A7PY+\._[2U[7G^'SZ)H7AV'19? XUOQ;XKUQ?
M#4D/_".-XDU_79U@$WB&]D?H4^"7P=BG>9?@_P##-)Y_^%A17,W_  @_A=GN
ME^,&K'5_BTLN-(EWCXF:M_Q/?&ZL9%\7W2F?Q4))/W@ /A'X<?MS^+OBS^T'
MXZ^&_@6#P=XDT'X4>(=)MOBKX#\-^$?%>N^/O ?@[7/V<O\ A<W@_P <ZK\1
M(/$<?@0ZQ\1/'6IZ+\/O"_PW?PLOB=K:0^*=\D'FQ1?+T?\ P4Y^.OA[XB_"
M[X5^,[3X,:H?C_\ !O\ 9I^-OA;XH?#;X3?&/Q7X<^"EI^TAJ_C;2O"/PP^)
M/PZT'QOXJ\0?$_Q%XFN?"/\ 8/PE\2^&_$GPN;XJW$?B%U\&^%!X:D67[2\/
M?\$U_@#X:_;$7]M6Q369_B18IJ5SX7T&\\(_ 1]-\%:QK7@9_AEJFI:)\68O
MA);?M2MX?3P+)JGA^U^#WB#X^>)/@)X9BUE&\*_":UD\+>$)/#/N\/[&/[(-
MM\/_ (D?"BU_94_9O@^%GQ@\4-XW^+'PTM?@=\,X_ 'Q1\9?VAIFKQ^*OB+X
M0BT!= \<>(1JNDZ;</K7BBUNKEKC2;9F<"VMWB /SN^)G[>G[7'@KX:_$KQ;
M??"KX9?#SQ%\$?V9/VE_VHO&.F_$7PKX_>_^(W@_X"?%?7?"'@YO"GA-/'7A
MCQ)\+Q\;?A;H[?$9V\5-XL\5?"6?7- \*MX0^*4I9ZZ#P_\ \%#/'FI_!#]H
M']I+6=<^"GA_PC\/?B_\6/@GX2^#'_".>*-?^)7AK4OA%^T OP;U7XK?$KQ7
MH_CR2ZUO03HFJ>%?C'XF^&_AKX&^%_$GA/P=KND1S>,'7Q!9^)T_1'P]^S+^
MSIX4\$K\,_"W[/\ \$O"WPZF\"^(?A:/A[X>^%'@?0_!_P#PJ[Q?J%QJGC#X
M=?\ ")Z9H:>'E\">*-4U/4Y_%GA**R7POXCFU.6YO(I99F+5S^RM^S$WBWXF
M^-I/V;?@-)XV^-7A _#_ .+_ (Q;X/\ @)O%?Q2^'LFF1Z')X$^(>N2Z"VL^
M,_!3:'I&D:+)X8\333>'&L[>&-+=U1(8P#\W?$O[=W[4&F_&WX/?LZZQIGP5
M^%-]\;O'G[0>B?#SX]_&CX=_$[P#H/C?P5\"_@Q\%OC$_BOPA^SKXT\>^%/'
MT6N#6?&OQ'^'<WA[Q#\45E,?POUWXOP[O"?E>%&^5/V'/VR_V@?B3\7/VA?V
MG-6U3X8Z)\)/B#XR_P"";]MXM^'VIVWCSQ>;)_VC_@#\+M#&M?!_QDWCGPSH
MO@CP2-9\8:7X]+>(_AGXG'C&&YG28>&=Z^+%_3[Q#_P2O_8+\0ZI\+H&_9D^
M!FD?"KX6P?%1[3]GCP_\$_@QIO[.OB[4?BZG@E-:\3?$/X1CX?\ _".>(-?T
M/_A6OA&7PMKY\J:RDTMV/G QJ/KO3?@W\(]&GU>;2OA1\.=(EUK4_!&K:M/I
M?@;PM82:QJ?PT&E:7\-]3U0)HT2ZGJWPZ71='?P;<2%I?"RZ/H<?A9H!#&
M?AY\4_V[M?\ CKX3^(W@?PU\1/#?CGPS877_  31^._PY^*/@/X/?&;]GO4;
MOP/\>?VU]&\'P:,_A3XG>./$GB'QQH>O>'_")\0)\1/#9\->%O%/A;7IO"#>
M%KAW:=_K#7/C5\6%U'3(O"OBC1="^&K> /\ @IWK_C'P'XANO'WBSQ;XRO\
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M'C+1M#3Q#_P@VA+HNCM:^&I;L^&(QI6A%(XTMHU3WB@ HHHH **** "BBB@
MHHHH **** *;ID*3@80H<XXW9'XCD$]OK7XU_LJ?$J_^*GBW]F7XE^"M3U;2
M? 7[0_PO^.?[5=UX6U2Z\'_9$\&_$OQ;X)^,'PXL-8T:82>//^$Y\*K\7?["
M;Q#\./$\GPKV#Q'_ ,)C'XL;Q/\ "E?"_P"JOQ%T2^\3>"?&'AG2KV/3M4\0
M^%/$N@V&IS+=!+.]U72WTR&_E^P%)0L#2I+NBVRIL'EX!*U_&O;:/X+\??\
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MD^'FO?M+>)_ OC#QPK:0/#O@WQ'\1O%C!?!VJP-XN\)^*/%B0^)_$GE_P/\
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MKX,2_LZ?$S1/ ?QR@UCXTCP]H_CS6O$O@;_A)?B7\,/BSXC\0^#/'*^+Y_\
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MM#_:1D_:ZUKQ!\2I1J_B+QOHOQ0_9C\.?#%_"OB'X?3?"/Q-X?M/"DWBK]H
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M7BS3/A3K/QU^'/AYO&L7B+3_ .QO"1_XISX6[5>7Q?X.\6S[CXLZ#XC?'?\
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M8^)O#:E5R-K/A/@S_@J+^P)\:OV]_'_[,2>(_C)X%\'?LD_#7XZ^'OC5\2?
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M_<_VMIEQX\)\(^+O"5D[!W\,:JGA#P.YU=?#LC,L>N2>'?#?BF*)8T\7/XG
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M !1110 4444 %%%% !1110 4444 %%%% $4B#80.Y[_C@?2OYV?VP/V;=0\
M?&34M;/P_P##$USXGG^,_BO]FC]KE_ASJGBKQ%^SI\4OBQ_:_B_6?#/B_P 5
M:'X=\0KX,\/^(O'6M^+-_B3Q#XB^%?@_Q1X6D^'OP> ^*7C+Q1XH!_HKX ]
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M]BC]H']F[XN_$CX/:-XJU_XT?LO_ +3?A^WU7PG\*_C7HGQ'U7QQ\$[7QYK
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MX(:AK_[3G[.6BWFLMXF_9C^,GBV0>$/BT?">G:1X'\52:-X_\0:ZNK:_X/\
M ?B/PU\3YO%?BN/79O,'PD^)WPMG;^MWXF?M/_\ !/CXBZ4?$OB7XS?!@ZQ?
M7'A^U\<^/-&^. _9V^*6D>$/",PUYDD\8?"_QSX<^(']K[%T36H_#Z^(_"OA
MGQ/%K7@5BTLDGA+POXEVLM5>^^KTTTY7ZVZ=->VO\N^+W$.6<6^(?$O%N5Y0
M\ARC/O\ C*90]U\DFVN*FY1M%I<5<SYU:_-&32E)QBGCT+XUU?X@^"-:^,WQ
M2\2_LP?#W5OA9X>^)$'B8>!+\^$?&WC/5/&OPY;P!\1/B-I.O^&OB'HFL_#4
MZY^SC^T.B_$?PWXL\3Q>$B?%/QD;Q0/B5X5\4>$_KC]IK5?A]\0K6?\ 9,\2
M:SX/U_7?VB-,LO!8^#^NW6CGQ'XS^%,FL-I?[1FHGPGJL40;P[X4^%$TFNIX
MC=)/#+^*%\.>%I7EG\5>&?#'BWS!O$/A#X__  $\6?!C]F?X87GCSX8^,/#&
MH_#R?QKX\TOQ98?#&9/%7A;6=(/Q UWQ7XSU_P *>//C3HC_ /$E\1R>*?AI
MXF^)7B7Q7))'"WC#PKXL<>)_#7V3\,/A78> ]9^(?B>ZU#4?$_CCXE>(=,U_
MQEXKU,,AO3HWA?1?!GA+2=&TL[D\'>'_  [H6C;X_#GAH0>&1XHUOQWXP>,>
M*O&'B:623\V/$-._8(_9MTK6/[2M-&^*5OI*Z_J7B&/X:']I7]I0_ 2TO=4U
M!=5;1M-_9UD^+<G[/VE^"!.Y8?#^+X9)X0*["?"Y!8R_9UI9V>GVL-I9V\%G
M8VMN(+:VM[<6EI:6B@$(J !%V@=%V#OL7YF-JB@"Q1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ;-J]_JVC>%(XR-$T7XBZ'H^D_%KPES*?#?B9-9FN9//D\+/XD^O_P#@I/\
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MX?#T,GAM9IO$L7\5G_!(G]HS6_BL?A__ ,$LO%OP3^&'Q.TRP^,WQ"_: O/
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MLOC9<:5\)]8OM-\$?L8C3?BCH@^+'A*3XD^*UU/2#\6?V9O@YXRA^&.MR/\
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M]KJS_;OU3QU\ K']FZ^\8Z1X%U2T2R^)VI?#FU_9IM8](\3:EXP\%'6M6^,
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MX)_%7X%66K?'KQEX=N_A_P#$OX:Z9X4UVR^%.B_!S6Y?"?B76M*T;Q%\3_\
MA'XO$GCG2]+\0.%^)_BL0^)=:'@U/%$L<26Y /"=&\*?\%1=<^'O[/%K_;WQ
M8\,^-I]&^(GA;XR?%;XH:#^P4?C]X7T[6_VN?V>UT3Q-J>C?#+0_%7[/NC:T
M?V;M(^,'B"/PW\,O^%I^$FDT7P^OC(>+/'0\+D_JO\&[+QY:?#3P=9_%+6;S
M7/B#9>&=+T;Q3K6IV?AFVU+7=3T53I\GB;5SX*C@\-+K7B68?\)#/#X8MO#W
MAQ9=39/#OA?PY$C6-K[%10 5X7\8O@YX?^,_A.V\*^)KK5K*WM-7;6-.OM)N
MV1[+4!IFLZ&A&FN)O#OB#3#H>M:E;?\ "->+/#_BGPA<?++XL\*^)HT,9]TJ
M#R1[?F: /%?@K\'_  U\!OAWH_PR\'7FKWV@:9XA\?\ B5;C6M3?4=3?4OB-
M\0/$/Q,UKSM2VJQ1=<\7:H(%"EDT( $,8U#>TTODCV_,T>2/;\S0 E%+Y(]O
MS-'DCV_,T 8E_IUAJEA=Z=?V<%Y87ULUMJ-E<VJWEG=63JZ/8LC (0P<G#*P
M)8DH1P/Y+_\ @LQ_P27\"?L^?#JY_;V_8!^#WB'1/C)\&/B#X)^)/BGX/_#2
MQED^&&I^&O"^I-JNK^.=+^'>E*NL>#]7^'1TK2M<D3X;/H7AD^$QKIF\*EY&
M\3^&?ZZ3$HXP/H,__JK.OK&QU&TGT^^M;:[L+^W^SW-K=6_VNTNK1@04=2"A
MW*QX;/." <*PM2:O:Z=TTU\46FFI1DK2C)-)II_*Z37T?"?&?$O N:1S;A?-
M)Y/))QG&+_=U834HSI5J4E.E5I3C*494ZD)*47RN\7*,_P#.R^.'[87PU^#G
M[;/_  3Z_P""UOPDMO!NK^ OVF/ 6IZI\8OV;/!NN^%]/\?>!/VD=,\,:]\&
M_CAX4U;PIKFN?#/76\$?$/6E*>%OC'XC;_A%%\5Z'KGQ?\96WB2%_!WA/Q=_
M7QX_\#?"[X^^ ]$^,'PY\4^+/A_\6O&'@_PUXK^#.H_LY>(-,\*-XD75;+P;
MXR\*ZMK>E:QX-\3_  Z\;MXKMM(^#:>)_$?Q)\+?$[PI\(?#7_" W'A#Q5X;
M1A\2_$OPYHW_  ;$_P#!.;1OBQ\3?B!_PC.K:KX=\?\ CZR\:>'_  ;J>^\L
M?A'81ZII.LZUX ^'-LVL+X E\"^(Q'KGAXIX_P#AGXM\6^%_"^L1_P#"$^,/
M"GBSPYX9\6P_L%H_["G[&?AWPZ/#5G^RC^S_ #:)+(AUJSU'X2^!?$#^(+Y4
MDB_M7Q9J>N:'<:YXSUYWU/5FF\1>)IM>\0ZZ==\0RW,\K>(+CSU)MRDY.[E)
MR;[MMMO9;MM[+5[)W.+.LTKYK6I5L1F$LWITJ5.G3A*_N4X1484TW*6D(Q45
M[TG:*M)I(\STCQ#\"_#OASQ7\+=.U7QM^UWXEO\ 0O#]W\0[?2M-TWXD_$#5
M;O2/#$!^'6DZVO@K1O"_PZ^##>)1HK-\))F7X5_">/Q5HWC_ ,6#Q1X:\8'Q
M;XJE]7^%7[.T>F:AX ^)?Q8?2/%7Q6\#_#30_AUX-;[)+>^'OA9I\3R+JX\(
MC7-9\12GQQXG T;1/&'Q#CD@/C"+P5H$D'AGPS;Y\--[MX ^%?PV^%&A6_@_
MX6?#SP7\,_"L-Q>WMMX<^'_A31_".@6M]JCL^IR)H^@:3!H<;RN06<1 ,RB-
MLJ@)](\D>WYFI/)$HI?)'M^9J>@ HHHH **** "BBB@ HHHH **** "BBB@
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M2Z+X0\*>"O">D:!JDOAW6]#?7O#UOX;^'?@K1;CPMK37OA[5[/PEH3:E9O)
M0N='^RG^SW!J<^LW/PTTW4;_ %8:H4FUG5O$OB"*STZ^T7XE:3<:1IEEK&M7
M%IX?T)O#WQ<^)FC_ /",Z$EEX?%OXUUO%D#*C  Y[P=^W-^RS\0_@1X<_::^
M'?Q<TWXB?!+QEXQTWX?>%?''P]T'Q7X]7Q%XRUKQT?AKI/AG1]"\&:%XA\2:
MKK$OCE8_#R+!X?E;S)$<L4$DK>7^(/\ @IY^PEX5\ >'OB=XW_:$T#P;\/\
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M_#?Q*N==^)GQ4U^3XG>''TO5-%TK2?B?_:OCBX_X6C%X>\/ZUJ.D^%#\1?\
MA)?^$,@F4>&19% ];'B']E3X :GJ^I>(M1^'D%MJVMW%K;ZCJ?A_Q%XJ\.7U
MWJ$WQ9U+XP:+K$LGAS6="*Z]X<^+/B'5OB)X7\3;Y/$'@WQ)K.KW/A:]T\7'
MS 'C_P #_P!N+]F?]H#XI^$M"_9VU&/XDVGQ3^&GC3XBO\8O"WAK6+3P?JMA
M\-9?@V=/T9?&>M^&]"TCQUKK:+\=M)>VB\,>(O$C^$4CU>U\6V]FP<++KG_!
M0']GGPG*+[7-:UKPWX%33;77E\8^)?AY\:-*3Q#H2_#+XW_&*35_!FDR?"J;
MQ!XS1? _P.U_7H=<0P>%/$MK)]D\'^*O$_C&&W\'^(/;O O[./P7\"^-]0^)
M_A#P8EAX_N[/4=#O?&%_KWBC7M;N7UI/!>F>*;]Y/$NNZ\@UKQ='\-/AZOB[
MQ1D^(_&2^#?#3>,;[7VT.S%<M>_LB_LVZS:'0=<^%NGZ]I\FGDV5MXEUOQ3X
MHCTS0+CPKXS^&R^']'.N:[=-X?T&Q\!_$?QMX5\/>%]#%EX?\'Z3XMUZ#PS:
MV"3HE 'E\W_!3']AU?C?J?[-/_#0>E:C^T5X=M[2\U7X$:)X7^(.N_%NWCU;
M3=!UVSTR?X=:+X.D\5-X@@T'Q/H>LW/AV/0_^$CT1&O3<VRKH'B1;7JH?VV_
MA8/BOX=^&=[IGCC1H-?7XQ6UQXQ\6^#O%7A?2;7Q!\(?BI\%?@^^DQ1:SH:-
MK>C>(_$7QPT=T\4>'A-X:\*C1M;?QG/X:<ND?IFH_LV?![7]1\1>(9?#NL:3
M=>/-<TOQ?J[>&/'?COPC:WOBZRM]+GA\=#0_"/B+P_HNB?$-;70M/T__ (3[
M0[:W\:-;6Z*WB'#,HYCXC?LA? SXE>'?'NAZOX<U*UD^)/AOXE> M<\1:?X@
MU0^)]+T'XM7'@BP^)">$]5UN;7_^$9E\1ZA\/?!NO3'2(;1!XHT>/QD%3Q03
MJ! (M4_:B^ B7'PT\80-XA\0Z?\ $'X97OQ#^&WQ&T#X5^.O%.F:AX1\5^)O
MAKX3TG2=(U?1O#D^O)JWQ+UWQ7X*_P"$5\.P1^9XJ\K1YE0D>&#-SGQ;_;%T
M#P%X8\(>,_#7A/6_&_A?7K7XB:YXAENM#^*/A?4_"'ASX2:QH^B>/YM8T9?A
M1XFUSP_K6@ZSJMQ#<+\2(?A9X3\.3:/<#Q=XU\*)%YDOM>O? 'X4ZQI/A'2;
MGPM'8Z1X&\,-X/\ !=CX<U7Q!X-C\*^&H+KPAKFF:;H"^"]9\.1Z5'X;UCX>
M^$M:\*26L8NO">K>'M(NO"5UX=EM(Y4S[WX!?"GQ!H&@>%;K1-;ET?0)O&(M
M[6/QSX]TNYU:/7_$,-YX^TSQ=K6F^*$UKQWH/CO7XSK/C'1?'EWXIL?&EW))
M-XHAOF;90!R/QP_;)_9K_9T\._$;Q?\ '#XI:?\ "GP9\*+GP]8>/_'/B[0O
M%MCX$\.:EXQBT=O"NEKXO_X1W_A'-8U[7%\5:)*OA[0==N/$FW5$#P*$+1_/
ML'_!4W]EZ1=.\7#Q8K? K5_AUXT^*^G_ ![LH-8USP?=>#/"DW[,/]FZN-+T
M7P]-X@.A^(8/VH_"I76G@,'AB70M93Q?]AC4LOUWXL_9_P#A9X^O=:N_$'AR
MZO9?$6I>&?%FI-'XJ\8:3#;>+?"ITYO!_C?1++1]=M8?#OC_ $#^PM'-KX\\
M,/H'C*$:'H\,>O\ D6RI'B7/[,?P9UHQW4WAG5/[:E\-ZWH,_C*W\<>.]*^(
M-[X<\<-X%?Q1IFI_$'3/$<7CS4D\3K\)OA['XI%UXH;_ (2#^P87OW<[ED .
MK\1_ WX+>/\ Q]\._BYXX^#_ ,,/&/Q5^%(OV^%?Q1\6_#SPEXA^(OPY;6PD
M>M2> /%FM>'I_$?@N3Q!"BQ>)!X=N-!-PA,<Y<1B1?:*X?PEX7TKP-X?L/#F
M@6HL-"TBUGLM+TU+O4+N#2M/MKAPNFZ=_:-S>-!I-E!B+0M(S]CT&SCCTBPV
MZ<L:0]Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>75
<FILENAME>tm2135630d1_drsimg24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg24.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '9 E,# 2(  A$! Q$!_\0
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M:-XD/PL^*2:9?^+?"N@Z_P"%?$VMZ-$RDMHWAWQ7X7F>1]S3LR9 !];>$?\
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M"GPF_8BN;Z)/VG/VM/C!\9/'>G_'/PU=^,=5^._Q3\,?"6'XW_'#POXST,>
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MCCP?\%O"GQ?UGQS\-I/ VA_$;7IPGC-_#7BWPQXD\4>%M"?PC;^)+9?$[^>
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M+PAXB\A9+AY!YD-NJ.]?744@E2*2(CRW4GGKCH,?0BOY%O\ @J1X4U#XX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\(_$7]HG]IGXL?#3X7>(M(D7^R]7\&_"CXH_%GQ-\/=%UBW 6:%QX6D_L&9
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MA3Q]X,\2Z#(6>#Q#X7\2>'_$,2B1(Y0LC))]-44 ?BQ^TM_P2^^'7A7]A_\
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MB]@M-4DN(M.OG4YV+(VE:N(\EC(VFN4/R,:VJ "BBB@ HHHH **** "BBB@
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M47Q4T#4/"WB71]6;4HO#OPCU+2-<6Y^&/@>=QI</B+PMX5$?AB>/2="WJ?\
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M5\%-#\0ZG!#8ZCKVF?"7P)H/@?3=5U6)"((-5UR/1HKB>.',&^1A&?ER_O\
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M"3PZI'IDD3^$?B-X@\/6W@+QGM&JZ86@\-^(KN9#,64>1YLR]?\ \,U?#_\
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MN5\&6S&YU>>!?"7B7Q9(?['M;641CQ#/KWA7JM?U+]HB+QE\+$\+^#?@S<>
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M9CEF:8=XG+<?#-(*I5I\T&FO:Y)-PJ*Z;7,JB:?]ZZ:332TZ***ZST0HHHH
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MXC^+&C_#9T/BOQ"J?\+6'ASQ<8Y?& RW]C%%% !1110 4444 %%%% !1110
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M%JBBBNT]8**** "BBB@#,-S"4BWC#2@E%"!\ D@$\\9((&<^O2G9W(XD?>@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/X@30^(+GQ3<_P#"5^-/$5R/$2I<1P6_CFI?L+>+;7XF?&CXD_"3]NO]K_\
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M^PKR\')X\3ULQ6+S>4(4X)Q5",8M5?=]VJI)N4(\S4N5N-K)<BU/I.BBBO\
M/,^O"BBB@#^;_P#X*7?\%$_V_/V,?VE_#WP\^'GPN^"WC'X:?%NTT*7]G^:Z
M\&?$3Q)XV\3:X(=#T/Q9X)U%=)\::"=2\8Q>-M09X=(\-: Z'PSXN\$1^:_B
M:6X1_//V^['X9?\ !4C]F/P)8? [XB_"WXP_MS? +POIOQ$UOP)\']8UM= \
M1Z;JT7@_PC\;],\'GQ3XDT%(O#\>O:GX:\3>%M=\0C7/$$?_  C.A^&#&9?$
M]T[_ -'7B+PQX<\23Z!>ZWHVDZOJ'A[6I]=\.7FIZ59WU_H.MS:)J_AN74=#
MGN$>?1]4;P_XHUG1VU.R0/)H&K:O9&86NKW ?XH_8Q_83^'_ .QIK?[1WB#P
MBNE_VG^T)\8]>\:VVEZ1ITNDZ#X,^'T6HW\W@/X9:1I*O!H*Z;H4FK^*];%Q
MHOAWPVUNWBX^&&/B2'PUHOB6[_HWA/Q<X'X7R?A/B/(^%I<$>+OAA[&IPMQ/
MPRJDH^)N(K8MPXBGQC#$5J[H4:/"?/2FLO5-<25*M15Z:BH*'[IPSXF<*Y'E
M'#6=Y1PO'A[Q#X%5&I0QG#E1RI\759XMQJPXKIU)2E3BN&)>S<:#@Z\ZDE[B
M2.I_8#_9'L/V,OV8_ ?P6M1I<GB6VL8]>^)6MZ<MK(GBGXEZT8M0\7:M_:L>
MA^'+C5M(@U)/^$<\*:IK/A^WUV#X=Z/X0T*Y ?0XVB^YP%61G/2)%0>Y P,>
MF3_D9IR%$?!8O(1P>PSU_'W_ "J4[&#KC@<L<#/'I^)YS^!]?Y_SC-\?G><9
MCG>:595LUSFK5Q%:M/6=2K6J3JU9RU=KSF[):1A&$8I1A%'XWFN:9AG.9YCG
M>9S=3,\VJSK5JDG=SG4E*3;?5MR>B225HJT8JUFBBBN(\\**** "BBB@ HHH
MH SFB:54D((DCZ@@Y('/3MZ>G3OBOSU_:^_8!^&W[8FN^%=9^(7C?XF:&/!6
MG:A!H&@>#KSP3I^G07VMRV,FI:HUUK'@C7]>;4]0.G:7 4_X2(:"MOHT0-H#
M-KK7GZ*9#ID-TZM_]<9.,]1QU[5$%8\%HY!_M#./8DX[>V.!Z5X>>Y#D?%.6
M5,CS_*Z><935454HU_>I2Y7>*DE*/,DTG9O=+LF>!Q)PSD7&&2U<AXHRREG6
M45K>UP]6+E3J*+4H\\%*/,E)*5F[7BG:Z5N(\#^%/^$,\(^&O"G]M^(?$W_"
M-^&M"\/G7_%^IMKWBSQ =&TZUTD:QXHU=[=FU?7M;\IKGQ'K30H;J[EN;DQQ
MF0NGA7[:_P &?&?[0?[(_P"TA\"/ -YX>M?&WQ@^#GQ ^'OAFZ\7ZEJ6D>%K
M'7?%NB2:-IDVMZMHNA^*-9TO1DDF>>Y>U\+Z_($W*L,H5(Y?K8 ,!Z9SP,9/
M^>.#37*],=/P&/3O[=J];#T52PZP_2UM-?3NWW;W\^_L4J7U?#O#X?1>MVOO
M;_/?=GQE\%O$G[<UWXCT;1/CG^SO^RC\/?A_;Z6;;4/%7PF_;.^-'QE\86M_
MIE@G]F)IGPY\:?L'?!30&@N)55;F9OB<LMM"=PB\0.I8_-WAW]B'XLZ/_P *
MF6[U_P"'9'P__P""H'QT_;.U7[)J_B17N_A7\3?^&@%T?2M'/_"$J8_'0_X6
M_I!\6>'R5\*.8_$7E>,'+0B7]8J*V-S\P_BK^R3\8-=_8I^'OP/\"ZM\-Y_C
M-\+?B)\'?C!X:'C#7?%.G_#/Q)XG^#WQ]T#XS0^%M7\6:3X,\1^)/#^A>)8M
M&N/#KZ\O@OQ;)X:75D=O"GB5;=%N/*[+]C#]ISQGX"^,$WQ);X&>%OB)\7/^
M"BO[,_[9UWX:\$^-_B#XL\(>$/AW\(I/V7D\7>!$\9:[\*?"^N^-/'$?_"BO
M&@\,ZY+\,/"WA[Q/_;/AQF3PB/\ D6OV0HH _(/X5_L<_M+> /VUH_BYIMW\
M,_A-\%U\>_&?QIX[MO@Y^T1^U'J'AS]HS3OB1H^L?V%HOBS]@[QOHTW[,?[/
MOCW0O'&JZ5\2/&W[0WPT^)GBOQ9\5/%7@G7)I?"7AP_';Q2G@_YUU3]G;]H[
M]C3Q%\/?BI\.M*\$_%GXIW%K^W[X+UOP7=>&OVNM<^'MI\/OVD?VIYOVE?"'
MCK2/%?P1_9M^.KZ-X]\*[='\/>,/AQXH\)^%T^*[:YKK>"?B_P"%Y/"CGQ+_
M $#44 ?S@>#?^"<GQ[U_]D__ ()IZY8Z/.?C-\ /V2[OX'_$7X/ZQ^U;^U7_
M ,$^R)/B5IOPOUO5]1?XL?L@IXG\?QCX:Z[\.X/#[?!WQ)X;;PKXH@U^6XF\
M5>%/%'A/PP9/UE\"_LOS_#WX7_L9_"GPW!X/M-%_9CUOPG=ZI:Z<?'2Z"MCX
M/^"7Q$^&<4/@D>/O$7Q,\?DRZWXMTF6W_P"%@?$GQ3KW_"+Q7/VSQ=XCNUD-
MW]M44 ?(7[&GP2\7?L^?"#5O 7C:]T'4-:O/C;^TK\2[67PS>7]SI_\ PC_Q
MA_:!^)7Q.\*:>TFKZ+H+G7(_#_B[2X_%0\F-#XICO)%EFMYX)3\#R?LI_M[:
M[\$_C[^QG)H?[*_@;X%_'SXK_M73ZY^T;HO[0'Q7\<_&GP]\&?VD_C=\3/B5
MK&EZ/^SCKG[)OA?X?MX_7P)X^?X>I(?VFO\ A%?"7B24>,86\7QZ _A3Q/\
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MYXUJ+7_$DDLS^4]K&K&=?J&B@ HHHH **** /S^\6?\ !-;_ ()U^-_%&O\
MCGQO^P!^Q/XV\8>-]<U+Q5XT\6^+OV4O@/X@\7^+/$FNZK)J^O\ B;Q5KNK>
M 9=<UK7]=UC4)-9\2:QJTTTUQ<SR2W9>:26YDIS?\$H_^"7R([)_P34_8"+Y
M^0/^QS^SH!CO@GX?  ] !T./I7SE^UI_P60^ G[&WQT\0? _XJ?"7]H:]\1:
M'I^B:U;^(M!\)>"V\(^)=#U?18=6M]7\*7^N_$SPY<ZMI@U(ZGX;N=571K>
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M:!;/HWPN^#7[17P\^'7APM%I<,MW)X:\)Z,/$>MO=^*K_P"T>(]?O;Z;D_\
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M/$'F2>-!X4\,2+XC?]2Z_+'_ (*D?$KP]X8^%W[//P_U+3O'=[XD^*'[??\
MP363PY>^&_A5\4?%G@/33X._X*9_L;ZSJR?$/XK>$/!7B#X<_!UYX=L'A?\
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M"UMX<18=%NOA7]BS]E#XB?MB?&7PK:>(=%\8W?PBTZZLH_B%\07LK[4="L-
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MM;CPN]YH5Q\R?\$^-5\=_P#!3K1_"W[7?[8WP8^%L=U\ ?B*8/V1=6\(:?\
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MS'XP^#WPP\9ZG\3_ (]_#'XO>!O@-\#=;@_X2CQ=K_AGPY\1?B?XP)\0^"O
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MWX8^(EYHVL#2OB+X7TB+X5Z+\0O&N@:[\/(]6\ :_P")Y?B'X8\)^'/$-O\
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M^//VIOCWH?QP^(?B/XJ?#C]DNV^)>F_$KP%X/^&GP/T+_A=GQ$T;2M9T_P
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M2NKG75.C&P@N=.;0C!I\D:ZDNO+JNN#6;H6HA\/RP&/P]KC7=QH$\GAZ/Q$
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MOM?"P!VM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _'7_ (*TZE\"(-*_8RM?B!\59?!_QNOOV_OV _\ A0GP
MG_X:(\8?#N3XPQP?\%&_V-3\5V/[/6D?$#PWX8_:87X?^#DM]?7_ (2[X=_$
MU?A MV/&?A23PK>73>(I?V*K\_\ _@I7_P FZ_#K_M(!_P $G?\ UZ9^QK7Z
M 4 ?FIX\_P""9'[+_CSX^6WQ[UWPSJAU"XU%->\2^ K*;2H?ASXQ\1N[-)XD
M\5Z#)I8DU;4;N00ZAXD@CUR'1/$ATYSXE\.>(3K_ (C.N?H@Q79)#$BS,@3]
MTV=F$ 50I!RVP<=LC/4<U:=PRG#83:)%9"0&4$ Y![@\=,9XYJJ7D#S-B-;7
MRMT;JJAR<X4;AABP;&>?7L*Y<#@,#@7C7A,#"E)R4YQC&*]O*T79.UY2DMTF
MI:-Z._-[G$G&7%G%N%X=P?$_$G$6>4>'\''AOAB&*Q%2O#AO!1<YQP^'C4E*
M-&C&>T;26D(\TH0I1I;=%%%=1X9_E6_\0YW_  69<L3^QM.S;&4*O[0'[+F0
MS#"G!^.9?;D@%E4@'D-Z_P"I[#$1"(S@;EW,000KL2KJIY&(R/E[$8P<8-6E
MP' V*&(X(0CC/0-QZ 8'\P34@"Y(P%( .0.Q).,>N3S7].?2A^F)XH?2TJ\#
M5?$O(N#<G_U$AQ+1X=7!^7Y]@5-<3SX>J8E8F6?\3\3>VE;ARC&E).FJ</:)
MNHZG-'Q\CR#!</PJ1P?M'[7EE)U)J;?+=)JT(VLV^[;WM:S\Q\=^!M(^(_@[
MQ!X*U^_\6V6C>)]*DTF_U/P'X_\ 'GPI\8P63%9 ='^(?PR\0>%/B!X1U(&(
M*-<\,>)?#]\B,T<=RBEE;^>3X:?L2_M.WO[4^IW_ ,5?AM^V79_LZZO)?>#=
M GT?_@I;^T'X;\;^$/!1\0W>H^!-?^(GQ#\*?MI3_%GXPIX=EO\ 5KN^\->)
M?B5XOM/#TGCSQ6WPYT^[A6V\*G^EB1<R)*FWD8#*GF' [*1(T8&.HR,=Q59[
MV&X,ULIBE90 T4,T;RJ%)S\F0&.>2JGCD_=%?QUQ#PH\^K<.XF.:Y_E#R/B+
M_6.V0UH4U7G[.I1>'QCE3E&>'G&K)SCRV<ISE&,'RV\#BCA&/%&8\+YC+B7B
M;(WP=Q(N)*=/ANM1I4L8_85*3H<0PJ9%5=>@Z=6I>G&4'JIJ:G"$H?BQ9?"/
M]AJ[_:DU+]DA/B=_P4&'Q4TG05UJYO;G_@J?_P %+M/\/W6J26.E:V? VG:E
MJW[:D>OZQXT_X1'5H?&RKH&@2Z"OAR/6(U\2?:=!\2VEM^O?A/P]9^"_#WAS
MPGI%QKMSHGA30-)\.Z7=^*?%'B[X@>++JPTG3K;1]'G\5>./&^L^)?&WC'7G
MCME?Q)XI\5^(O$/B?Q'>A_$?B?Q!=7=[<33_ )\Q_P#!.KX(WO[6NH_M&6'Q
ME^+MK\8=*\8Z'\7]1\*:5XT\"V=O96FLZSK/]DZ9JVDZ9X(BU^+P1XAAT?Q)
MX!#3:V+CQ)X6T77?##>);F+_ (2(3?IY)QEL1B4HT9+XV!U.0C Y4*1@CU.<
MG )K'A*OQAB)\2_ZTY?2IP7$]:/#:C*,N;AFI[.6&E.+2Y*D4JCFES)WCRIJ
MZ,N",;QMB(<1_P"NN X9A*/$_$<>%Y<+U9U%+A5>[A7B;I<O$GQ*O9R3;C*\
M6N4UZ***^O/O HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOGW]I7X^^$O
MV7O@GX]^/7CO1?'7B+P[\/\ 3K"YO/#7PX\(:EXZ\?>);[6-8TG0]%\->$O"
MFBH]QKFN:_KFKZ5HMI%$55IY5!>--TL?QW_P3=_X*+VW[??[-'Q0_:3\0?!G
MQ%^SM9_##XW_ !E^%FM^ O%GB'_A*?&EDGP<EB76-4\6V^DZ!H$6A^(3#<26
M]YX#MU\1'PS+I:JOBSQ(9$DC /U&HK\"?V8O^"U6O?'+QQ^PLWCG]D\?"SX'
M?\%)M4^,^E?LJ?%#3/CJGQ&\9"[^#VE:OK17XQ_"F+X2^&-%^&1\6Z5I,S^%
M?^$5^)GQ/*$AO%Z>&"'!^P/VLOB]^TC\./VMO^">GACP1XO\&>'/@-\8_CSX
MR^''Q8\,_P#",OKOCWQZP_9^^-OQ$T33D\3ZV9M$\#Z%H&M^#-$N6M_#L,GB
M7Q1<%-OBOPSX=M[GPQXK )_^"F/A3PQJ_P %?@MXKU;PUHFJ>)/"/[?7_!+M
M/"7B34M(TJ_UOPT-;_X*;_L<:-K3Z%JLJ23Z.WB'1V$-RNAK;&:$XD.]56OT
MOK\__P#@I7_R;K\.O^T@'_!)W_UZ9^QK7Z 4 4@!M1Q& VWC=P%4$=O?GKT]
M^M1R)%LF+QGYE D [C/!'!QR!Q@C\Q7S5^U1\?[3]FKX#>/?C/J&BS>*4\&6
MGA^)-"M]2CTA]4U/7_$.E^'=-A_M*</%IZC4=3B#2%64#..3QX7_ ,$^OVP/
M%?[8OPKU_P 9^)_ D/A76/"/B"V\*7FLZ/JMG>>#O%.IC2=-UC5)-'TPZI+X
MGT(Z8NJ6(FT/Q!!.L5KJ6CK:^*/$5Q_PD::%YO\ :^7X?-(Y+[2V92@IJFHR
M7-"Z:DZG1)--)M/KZ_9X+PXXNS'P_P S\3\-E+?!F3<3TN$ZO$CJ4>2'$M>C
M*K3P_LN?VK<J<;N2IN*4DG=W4?T:HHHKTCXP**** ,=79&5<(H;:GR\_(52)
M"V>\,GR$\'!4@$"OQV_9R_X*/Z?\8OV]?BA\"UFTBY^&M[87?AWX):MIEO;W
M5UJVN?#R'6=3\:ZP=8T0Z_#K.C?$&!=7U;PKKDGB#1O#\?A?P!HD$&B1^)/$
M=U]I_86:2.*)D:2.%UA$KRL"V59H@SC /5R5 XPVQLCDCYOT+]DS]EWPWK.E
M^)=!_9^^"6AZ[H5]!K/A[4]+^&'@BSU'1-4TP/?:=JFD7UOH4,NDZG:-LGAN
M()(IHCEXI4)4U\1Q7@^*\RS3AK$<,9W3R3*\HXAC7XEI2C>?$^'C3E1_U>IR
M2O34Y5%4=63:C.%-6Y82C+\\XQR;C?,,QX'Q?!_$M#(LKR7BB.(XJHU:$ZSX
MFX:=&K3?#<9Q:C14Y5/:<]D_:T\AU<%-2_.E/V//VSK?_@H:W[6EEXW^%O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/[,OQ/;]G8>(#\5[6PT/4M 'A:/?K(TW2O$>BZAXG32HR)VU'5&\&IJ:1:%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_ ?PK\5#P+XP"^ Q\.]=^)/B[QO;^$FM[CX=J\7]*(G$K_NI&SY*R%3U =
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?P_X4_X5C\.OBC]D\0>9)XT'A3PQ(OB-_P!2Z_/_ /X*5_\ )NOPZ_[2 ?\
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MRRC_ (;(_:*_Z1._M_\ _AQO^"67_P!,LK[_ ** /@#_ (;(_:*_Z1._M_\
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MK_I$[^W_ /\ AQO^"67_ -,LK[_HH ^ /^&R/VBO^D3O[?\ _P"'&_X)9?\
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MX6CF\51?:M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A.-.&I:)'K&C>(='ABUW0Y&F\L>//AW-XK\'NZ1/%XH=W2-OTIK\?OV+/\
M@GI\;/@U\?[S]KC]L7]ISPY^U!^T3I_[.OA?]E'P/XB\"?!?1_@+X2\.?!KP
MOXLD\7ZC>Z[HND^)/$#^,?'?BWQ(T/B#Q)KV[PQX3\.2!K+PAX.MXV,@_8&@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^?OB_P#M,?LY? &Z
M\'6'Q[^/?P<^#-[\1-3?P_\ #VW^+'Q3\!?#>[\>:_"L*3Z/X-B\8:_H$FO:
MTK:GI:R1:"DDRS:QI$8 6>,-^*__  7DM/VE-#^&?ACXM^%/V@_CC\&?V=/!
M?_"/:1K,W[+%KXJ'Q1TSXZ_$#Q_HF@^#?CU\7U\%:'XE\0^-OV;/@9H$@\1O
M\&?"$4?B#XL>,Y=&\*^+A'X2F?Q7X6 /3?\ @JG\(_\ @I+\4?#WQ?\ !?PM
M^%O[._[7?[%?Q:^$\O@?QA^S*FJZQ\#/VN/!NO,RK#\3_A-\7/$NL>(?A%XT
M\0^&=7)\7>&]"\0+\,I(+CP_X>M?"4W_  EB7/B^;W?_ ((S?M%_%/\ :-_X
M)\_!S4?CUI?C#0?VC/@_<>(/V<OV@M"^(VES:+X_L_BI\#M6_P"$0GU3QEH[
MB-XO$?B7P\GA3QSXE=76,7&O.L8DC(-?47[$7C']IOQ[^RQ\%/&/[8/@GP)\
M/OC[K_@;PUJOCKPU\/M0\676FQWVH:7I&HB_UC1O&GAGPSX@\$^,7\UAXM^'
M4H\4P^$/$9G\/P^,O$P@:X'HWP0^ GPR_9]T7QGX;^&&EZC:V7C[XG?$#XR^
M+;[7O$OBKQAXA\0_$3XBZR-7\6:MKGBGQGJWB'6]88N(-"LA+=;?#WAK2=&\
M-6L*PV42D ]]HHHH **** "BBB@ HHHH **** "BBB@ KS?XE_$#PO\ "?X?
M>._BAXVU.30_!7P\\(^)?&OC'75TG4M2_LCPWX3TE]:UO53I>CQOK6J"UTBP
MEE$6BPS._DE$AD;:HJ_%GXP?"[X$^ ]>^*'QC^(?@[X5_#GPI;?:O$GCCQYX
MDTGPOX4TI6(11J>L:S)'#"SY 0%]\G10[C:/A3]I3X5_M#_M4Z7\%?CE^P3^
MWKX-^&WA:Q\/:]?7/A;6/ACX!_:8_95_:=\$^,QI3M!XRDT7Q'X:\0M&ITIU
MMO$WPW^(ZK':SZQ!';K_ &_<2L ?9_@O7_A)^T;\/_A7\:/"+>&_B)X.\2:'
MI'Q1^$OC1=-TS4'M;+Q=X9+:+XH\)R:Q%-)HVI3Z%JX7S!'&VS4G24L'DC7\
M6/\ @D#_ ,$D_C7^Q1>:GX\_:I_:$\4?$_Q%X.U_XR^"/V8/@]X3\4ZO8? [
MX&?!SXA_%7Q=XQU/5D\(Z.OAOPYXS^*WQ/FU<^(O%7B+Q1X?UR;PMX>CT#PC
M9R+#X9B>&M_P0Y\0?$_X%^(OVP_^"77Q)LO!>O6O[#_Q T3Q/\/_ !_\%_%7
MBGQ?\(/#GP^_:1;7?B1HG[.1UCQCH>@:[H7CKX,%=5>'09D=QX0\0:!"\:2^
M'9/$GBK^AZ@ HHHH **** "BBB@ HHHH **** "BBB@ KS?XE_$#PO\ "?X?
M>._BAXVU.30_!7P\\(^)?&OC'75TG4M2_LCPWX3TE]:UO53I>CQOK6J"UTBP
MEE$6BPS._DE$AD;:HSOBO\7OA;\"/ NL_$[XS_$?P5\*?AUH+Z?:Z]X[^(GB
M?2?!WA+0_P"V-4AT?2DU/6M9FAT*V,^M:EIFBQO/,@\ZX7?)]V-OC#]K[]GS
M]K3XX:[\.OBC^Q[^W';_  2M] T#5-/\0_!GXA?!3X>_'G]E[X]Z!XG:.4#Q
MCIIE\)?$/2W\0JNDVY\3^&/B==PP^%DN!X3\*I<>(_%4OB@ ]8^+'PR^!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>76
<FILENAME>tm2135630d1_drsimg3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &  LH# 2(  A$! Q$!_\0
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M</\ \<H OT5F-XBE2[2$Z;?;Y$9U&^'HI4'_ ):?[0J3^V)_^@9>_P#?</\
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M#_\ '* +]%4/[8G_ .@9>_\ ?</_ ,<H_MB?_H&7O_?</_QR@"_15#^V)_\
MH&7O_?</_P <H_M>?_H&7O\ WW#_ /'* +]%0:;?#4["&X5619XUD"MC*@C.
M#C(S^-3T %%%% !1110 4444 %%%% !1110 4444 %%%(QP/QH 6BOAGQI^V
M+\8O ?CW5_!_BEX_"?B;Q1XOCTKPFD_A^WDL_P"P)_$\6FIJL%Q%>S>;,EE<
MV>8KJ. BXO8F\IXPR5] _LB_'G4_B9\$K6]\5$7.O6?B3Q#X5GNK#3I5AOY-
M(UF^TS[447>(//6R\W86P#(54G H ]EHJA_PD4/_ #ROO_ .7_XFC_A(8/\
MGE??^ <O_P 30!?HK.D\3VT3*&2^!=MJ_P"AS<G!/]WV-._X2&#_ )Y7W_@'
M+_\ $T 7Z*H?\)#!_P \K[_P#E_^)H_X2&#_ )Y7W_@'+_\ $T 7Z*H?\)#!
M_P \K[_P#E_^)H_X2&#_ )Y7W_@'+_\ $T 7Z*H?\)#!_P \K[_P#E_^)H_X
M2&#_ )Y7W_@'+_\ $T 7Z*H?\)#!_P \K[_P#E_^)H_X2&#_ )Y7W_@'+_\
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M_"0P?\\K[_P#E_\ B: +]%4/^$A@_P">5]_X!R__ !-'_"0P?\\K[_P#E_\
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MXKW!9WM98([BX,31?N)<JH(-><_LY_\ !>[XO>/_ (1ZUKWBOPM\/+2:[O\
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M^9_^'9_P-5F,5IXZL_,7:ZV?Q$\36RR#G[PCOE#=3U]:A7_@F!\"TDW"/XD
M]?\ DI_BOK]/[0KZ>HI?4,+_ ,^X_<B?[,P?_/F/_@*_R/F%_P#@F%\#'?=Y
M?Q'SZ_\ "S_%?_RPJQ_P[:^#/V980WCT1( J*?'6N,5 Z?,UT6/U))/<FOI:
MBC^S\+_S[C]R#^R\%_SYC_X"O\C%^'FE6^B^ ]%L[4%;:UL((H@6+$(L:A<D
M\G@#D\UM51\,?\BWI_\ U[1_^@BKU=:TT1W))*R"BBB@ HHHH **** "BBB@
M HHHH **** "D+8I:0C- 'Q#>?\ !8?3/B'\7O%'@[X=Q^$=7D@N]"TGP]J$
M^M).U_<7^M2:5=7<MG$?-6TM60NH+(]QA<&*.:&9O?OV=?VAC\:?A3HVKZ^N
ME:+KD/B+6O#E[;Q7/[B>\TG4+W3+J2WWX<Q/+9R2(&&Y4=0W()K0^+'['_@G
MXT^(-3U;6[&]_M/4[+3;(W=I?S6LUJ-/OGU"REA:-AY<L5VYD#C[V K;E^6M
M[X;_  ET3X&>!]#\,^'8)[?2[*[EE'GW,EU<7,TS33SSS32,TDLTLTDDLDCL
M6=Y&8DDF@#IO^$DT[_G_ ++_ +_K_C1_PDFG?\_]E_W_ %_QJYBC% &-JOB+
M3VN;'_3K/BXR?WR_W']ZN_\ "2:=_P _]E_W_7_&C5>+FP_Z^?\ V1ZN8H I
M_P#"2:=_S_V7_?\ 7_&C_A)-._Y_[+_O^O\ C5S%!% %1/$-A(X5;ZT9B< "
M922?SKY\\9?MM:K\4O$VH^%_@1I&B^,K[3+EK'5/&.LWK6O@[09UR)(A.@,F
MI74; AK:S!1&1HY[FU? .3XV\2:G^WOXNUOP]H^M7_A;X">%+F:P\4>(K*Y^
MR77CJ\@DDBO-*M+C(>VT^W>-H[JZC(DEDWPQ21B*9V]#\*7MWXL\,:=X?^&6
MGV'@OP)I=K'8V>J0Z>L$*6R*$2+3+3 01J@ 65U$0 78DJ\CEQ.,A1M'>3VB
MMW_P/-V2ZLXL7CJ="T-93>T5N_T2[MM)=6>/>,?V9O!6N31_\+Y^('B/X^>(
MKS$P\)*QM?#AY)V1^'[1_(DMP>CZF]VR\;ISQ7J7@#PMJ6G>%+70/#5MX-^#
M/@ZU79;:5HD%H][ GHBQ@6EM]%2;Z@]/3_A_\,](^'%C+#IENRR7#^;=74TC
M3W5[)W>:9R7D;W8\# &  *Z'%<WU6O7UQ,[+^6.GWRTD_ERKR9R?4\3B-<74
MY5_+!M??/23_ .W>1=TS@_ _PR\&^!=4;4H)+>]UF1-DFJ:C?&]OG7T\Z5F9
M5_V5POH*ZW^W]-S_ ,?]E_W_ %_QJ_MHQ7;0P]*C#DI145Y*QZ.&PM'#P]G0
MBHKLE8I?\)%IW_/_ &?_ '_7_&@^(=./_+_9?]_U_P :NXHQ6QN4?^$AT[_G
M_L_^_P"O^-*/$>G#_E_L_P#O^O\ C5W%&* */_"0Z=G_ )"%G_W_ %_QJG#K
M^G_\)!<G[=9[?LT6#YZ_WY?>MK%4H#_Q4ES_ ->T/_H4M "#Q!IH_P"7^R_[
M_K_C2GQ%IQ_Y?[+_ +_K_C5W%&* */\ PD&FY_X_[/\ [_K_ (T#Q#IP_P"7
M^S_[_K_C5[%&* *7_"1Z=C_D(6?_ '_7_&C_ (2+3O\ H(6?_?\ 7_&KN*,4
M 4AXBTX#_D(6?_?]?\:3_A(=._Z"%I_W_7_&KV*,4 4O^$BT[_H(6?\ W_7_
M !H'B/3A_P Q"S_[_K_C5W%&* ,K5+O0]<MO)O9=*O(=P;RYVCD7(Z'!XS3?
M"5O9PVUW'8K;QVB7+"-;=5$8^5<X XZY_'-:^*I:-_Q\7_\ U\G_ - 2@"]1
M110 4444 %%%% !1110 49HK&^(&M:GX=\':A>Z-IL&L:I;PE[:SGO!913OV
M#S%6$:=V;:Q !PK' (!LUEJ)AXR<LT1@-F-BA"'5MYW$MG!!&W P,8;).1CY
M'B_X*Z6MS\,3XHMO!<6J:?H6E:WXF\3W>G>(8[C3[;0])U 64^H:;<>2/[16
M4B66!2D DCMILLC>4LOUVI_XJ4=_]%.?^^Z -&BDS1F@"E<?\C+:?]>T_P#Z
M%#5ZJ%P?^*EM/^O:?_T*&KV: %I&.%H)P*^6OV_?BG??$/Q7H?P \*373ZWX
M\M6O?%)LY/*GL?#_ .\C:(3#)MI+Z1)(%EQO2W@U&6(^=;Q@Y5JT*4'4F[)?
MU\V]DEJWH8XBO3H4W5JNR7]675MO1):MZ+4Y[Q?\1&_;<^)<7D0?V]\*-*NF
M'A[04^2'XC7UNX#ZI>.RD+H5K, L/!%Y,C2JLL2VWVCZ3\"?"_\ L369M=U>
M==8\47D7DSWY0HD$><^1;QDMY,.>< EG(!=F.,1?!?X+V'PB\.+;VT-G]KF2
M);B6VMEMX52-!'%!!$O$-M"@"11#A$'4L69NW1=HKDHT9U9*MB%KTCTC_G+N
M]ELNK?%0P]2M)8C%;[QCTCY^<^[V6T>KD1 A:=29HS7H'IBT4F:,T +129HS
M0 M%)FC- "U1\0_\@L_]=(__ $8M7<U2\0G_ (E9_P"ND?\ Z,6@"]129S1F
M@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T4 4O#'_ "+6G_\ 7M'_ .@B
MKU4?#!_XIO3_ /KVC_\ 015Z@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MI&Z4 +FLS7C-]OTORQ%L^U_O=Q.=OE28VX[[L=>V:^=O%?\ P4A@\&?$SQ=X
M.O/ ^IR>)- O-+L+*TLM9L;O[1<:G?K96,-XT<A%A)+YB7027<QM-TBAW1HA
MZO\  WXVVO[0WPTTCQ+:Z=>Z0XU:^TF^T^[*--I]]875U87ENS1LR/Y=S;3(
M'0E7"A@<$4 >BT444 4M6_X^;#_KY_\ 9'J[5+5N;FP_Z^?_ &1ZNT %?./[
M<WQ>O-3U+2OA#X;U^X\,:OXMLI-5\3^([6[%M-X.\,PR)'=W<<@Y2\N6<6EJ
M1AEDEEN%W?8W4^^>+O%VF> O"VI:YK5_;:7H^C6DM]?WMRXC@M+>)#))*['A
M45%))/  -?)/_!/7P'JO[2#Z[\=_&=C>6A^)NI1:UI&F7BE9K73K?<FD02J3
ME5MH&,OD_<%[>7TPW;HF7DQ6(<+4Z:O.6W;3=OR7YM+J<.-Q4J?+2HJ]2=[+
MIIO)_P!U:7\VENT>P?#/X.V/B7PEH6FKH@\,_#3PU:P67AOPFD'V>-[:!56&
M2ZBZA%5$\JV. H :0%R$C]CAC"'   QP/2G1H4I]/#86-*\KWD]V]W_P%T6R
M*PF#C03DW><OBD]W_DET6R"BBBNH[ HI"<5Y?\;OVV_@]^S5XDM='^(/Q0\!
M>"M7O;;[9!8:UKEO9W4L&XIYHB=P^S<"N[&"01G(- 'J-%?/9_X*S?LQ!<_\
M+^^$G'_4T6G_ ,74G_#V+]EG_HY;X ?^'#TC_P"2* /H"BOG_P#X>Q?LL_\
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MIX/_ !X6?_?E?\*^7/\ AA;XMQ 11_M!:_*F[FXGM[_S57G *)J"HS'CYAM
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M3CO^8].3VLOY'^'^8_;3_D?_ )+_ )GU!_PCNG_\^-G_ -^%_P */^$=T_\
MY\;/_OPO^%?.=E^S1^T?8:.(!^T[87=TA;_2KOX8V!+ \KN6*XC7@YZ8R !C
M.6*V/[.7[2JV\HNOVE_#TDI&(7@^%MM&J'(^\&O6W<9Z$<D>F#7._P"5_A_F
M5[27\K_#_,^B?"JB/PQIRJ  +6(  8 ^05?K&^'UO=6?@71H;ZYCOKV.P@2X
MN8X/(6XD$:AG$>YM@8Y.W<<9QDXS6S6AJ%%%% !1110 4444 %%%% !1110
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MUN+'%A9#-Q@_N%Y^1_:KG_"-:=_T#[+_ +\+_A2ZM_Q\V'_7S_[(]6WDV=J
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M4?V%%_STO/\ P*E_^*H N;>*"H-4_P"PHO\ GI>?^!4O_P 51_847_/2\_\
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M1X%^I?"WPRT+P-X:T_1M#T^/1=&TFW2TL=/T]WM;2QA10J1111D)&BJ %50
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M "233O$GB;3_  ?X=OM6U6^M-,TO3+:2[O+R[E6&WM(8U+/)([$*J*H)+$@
M DU\L_$OXLW?CS4_#&MZMX?DUG6/$,\D_P +/AI=2?9I-7EA\MAK^K[E)MK>
MW\R.8[T?[&DD1\N;4)K:V3HJ5&O=CO\ UJ==2JT^2&LG_5W_ %J1_'_XP/\
M$;3]$E\0^&];U/3?$LY'@WX71Q+#K'CN2,J?MFJ+)Q:Z;'NCD>*8*D:F,W.Z
M65+-?6?@?^S=?Z5XL7Q]\1]1M?%?Q,FAD@AG@1TTKPK:R-DV.EPN28T("":Y
M;]_=M&ID*QI!;P:'[/\ ^SRWPROM3\3^)=43Q=\2?%$:)KGB)K80!HD9VBL+
M.'+?9K" R.(H S$EGEE>:>6::3T\MMHITU'5[]QTZ2AJ]6]W_73R # H)Q2;
MZ\W^-?[5W@7X">'+G5/$6OZ=9VUI.+661[J&*.*=N%@:61UC65CPL3.)'/"*
MQXI5L13I*]1V_7T[_(WC"4G:)Z26 JK/KEI:ZA;VLMS!'=7>[R(7D59)MHRV
MU2<M@<G'2OFBU^,WQM_:7"_\*]\,MX#T&<@KXD\7Z?)9IY9R-T&G2A;^Z8$'
M*7$6F 95DFF'70\+?\$R_!NL7*:C\5+_ %;XT:V1N?\ X29E_L>)RH!,6F1A
M;9F!W;)KE;BZ4.5^T,*YXUZ]1KV<.5=Y:?<EK_X%RV[,OD@OB>OE_7Y7/I#?
M['\J!("*\23_ ()J_L^)&RCX)?"Q5<88#PS: ,/?Y.:BC_X)C?LZ1V[0CX%?
M"987(9HQX6L@K$="1Y>,UUOGOH1IU/:GUJTCF\MKJW$FW=L,J[L>N,]*2WUZ
MRNV BO+64D;@$F5LC.,\'UKQ,?\ !+[]G 0^7_PH;X0^7NW;?^$3L=I/KCR^
MM++_ ,$P?V<KDGS/@1\(Y-QW'?X4LFR>F>8^M<W^U=X_<_\ ,O\ =>9[F)E9
M<@Y'J*J:[F732%#$^9'P!_MK7B__  [ _9QV*O\ PH?X1;4^ZI\)V6%SUP/+
MJK-_P36^!WARU\VP^'FE6+!HT'V:YN80JEU&T;)1@>@' XKHC[3[5B/=/?P<
MT9KP\_\ !.+X-)%LB\&_9U+;CY&KWT.3TYV3#-03?\$U?@Y/*CGPSJ0,9X"^
M)M54'Z@7.#^-#<^B_'_@ N7J>[YHS7S^O_!,/X-K=^=_PCNNYSNV'Q=K!CS_
M +OVK'X=/:HYO^"8'P?>1FCT7Q!;[FRP7Q3J<@/J!OG;:#[8QU&#S6+J5TK\
MB?S_ . 5RP[_ (?\$^A:,U\]+_P3 ^$88YTGQ 5[+_PDNH?*>_(EW'/N2!VQ
MDTV7_@F#\)U7_1]/\06LG3>-?NY\?\!F=T_2I]O76KI_BA\D.DOP/H;./_U4
M9KYU;_@F5\.]I79J95AM^:Y;('L01S[]/:I/^'='AI R+XA\=NA/#S>,==:8
M#ZK?JGT^3ZYI?6JO_/F7WP_^3#V<?YE^/^1]#9HS7SU_P[:\&M][Q3\6B#U"
M^/-47\OWV0/QS[T+_P $U? V>?$?Q=*=E_X6)K Q_P "%QN/XDT_K-7_ )]/
M[X__ "0<D?YE^/\ D?0N:,U\^C_@FI\/B1YFM?%R9?[O_"S-?C_5+M3^M2?\
M.U?AJ7YO?BS@]1_PM;Q1C_TX5:K57_R[:^:$XP7VCW#PP?\ BF]/_P"O:/\
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M2;"1< W\P-[.I)@6%?(NSC/%SG-T<*KM;M_#'U[O^ZOFU=7]%4TES5-OQ?\
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M?1?WI?\ :H ZBBL+_A9_AH?\S#H?_@?%_P#%4?\ "T?#/_0Q:%_X'Q?_ !5
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MRC'X/^&)\8O-6MTEUFXCY&^WTV"8K;%D8,LE]=38(*S::I^4>B_!O]A_P?\
M!C7[#7H8F\2^,M.MWM8/%'B)!?ZO;Q.,2QV[_+%90R=6@LHH(">?+%>Q@8KQ
MGXM_\%$?@C\$-?;1O$'Q.\(Q^(Q)Y2Z!87HU/6YG[K'I]KYET[<=%B)KHP^"
MIPE>G&\GUU;^]W=O+8B=5M6;T/6Q:7H_Y>X/_ ?_ .RI#;WH_P"7N'_P'_\
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M> ?#W@HP>']9O]7N1?W[7UE>1+ (HTN8WCA W^9M,69(Y%DD5SL!#\A\+?\
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M;_X)$?LV^%&B:T^ /P(,L#[XYKGP'97,RMNW B27<V0>ASQ@8Z5ZYX"_9_\
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M/%/A?3?&_AN_T;6=/LM6TC5K:2ROK&]@6>VO8)%*212QN"KHZLRLK @@D$4
M?G-XR_;;^+DG[)?P_P#&(\=7&C>(M-_9[D^*\ZV^EV"Q^.=:B%C_ *++'+"^
MRV9I1&T=J8I,ZC'MD5EC-?H=)J;6_BN0-9WWE16P43+%OCD);.%(R<C'.0.H
MZURVC_LD_"SP]H7A[2]/^&OP_L=,\(ZB=8T*SM_#MG%!HM\6+&ZM46,+!,68
MDR1A7R2<UZ$J[0/:@"E_;T?_ #[WW_@,_P#A1_;T?_/O??\ @,_^%7J1C@4
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M10!1_MZ/_GWOO_ 9_P#"C^WH_P#GWOO_  &?_"KU% %'^WH_^?>^_P# 9_\
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MBW&P"%[D+YK1XBC^4MC]VG'RC'4@8I:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(R: ,"
MEHH **** "BBB@ HHHH **** .?^+/Q B^$_PL\2^*9[2ZOX/#6E76JR6UL
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MFE_X2/3_ /G^L_\ O\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\
MO\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^- %VBJ7_  DF
MG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X
M233_ /G^L_\ O\O^- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^
M- %VBJ7_  DFG_\ /]9_]_E_QH_X233_ /G^L_\ O\O^- %VBJ7_  DFG_\
M/]9_]_E_QI&\3:;&I8ZA9  9),Z@#]: +U%4O^$CT_\ Y_K/_O\ +_C1_P )
M)I__ #_6?_?Y?\: +M%4O^$DT_\ Y_K/_O\ +_C1_P ))I__ #_6?_?Y?\:
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M_D;.G/>GQ_L<_M%VTC,OQQ^&TKOC=(W@WQ2K'VP/%F/R J%5QK_Y=1_\#?\
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MBHZ]I/AG1;GQY"UOX<EGM6ME>*P+I;W]Z;.(74EM"(DDF^=&56/L_B/]CO\
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MZ*36ZU/T,_X?D_LX?]!_XC_^&G\6_P#RLH_X?D_LX?\ 0?\ B/\ ^&G\6_\
MRLK\\Z*K_B'.&_Y_2^Y$_P#$0,1_SZ7WL_0S_A^3^SA_T'_B/_X:?Q;_ /*R
MC_A^3^SA_P!!_P"(_P#X:?Q;_P#*ROSSHH_XASAO^?TON0?\1 Q'_/I?>S]
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M4U2Y\.3:Q'IM_)I%M,+>:^6W<VT4A&0C28VAB.@)S1XC\*:IX/O([?5M-O\
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MK:YT2PN%(9(](T!'EA1XVY2:07-X,_/<LJC;U/PF\"P? 3P]=>!?!EQ'XO\
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M((4?WUH TJ*.E% !1110 4444 %%%% !1110 5^,O[6?_*1[]I7_ +&_2?\
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M)SM(/S&O-J[/Q9\<]8\9_"W2/"5Y%8G3]%NYKRWF5'^T,9,Y1F+$%5SA1M!
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M?[0__"^/#_CJPO?#6K^$/$O@>_&CZUI&H3V]P]O+)8VU]$R2P2/'(C07<7S
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MQ@XQP1T()!X-!_X)E_LY#_F@?P<_\(W3_P#XU1>O_*OO?_R(<V)_EC_X$_\
MY$TO^'A/P$'_ #7'X/\ _A9:=_\ 'JHZ_P#\%#_@ =+N(C\=/@V))(F"JWC7
M35W<>\U-B_X)H_L[1LA'P%^#H,;;E_XHW3_E/K_JO85T7AK]DSX6_"/0+]?"
MWPU\ ^'%ECD=QIGAZTM [%3DG9&,YR:N#JW]Y+[_ /@(T@ZS?OI)>3;_ $1E
MK_P4-^ 3IN7XY?!XKZCQGIN/_1U*O_!0KX!L./CC\'S]/&6G?_'J-7_X)\?
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MBZGVDOO_ . 7%U;>\E][_P CL%_:P^%S=/B5X /_ ',-G_\ '*4_M7?"\?\
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MJNKAWRR4JF^B?-)*+\[0::\XV/I:..P,:,:.(5XRC#;=<O,Y>C<_PE?4[/\
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MB/@6Q]!X]TK_ ./TA_X*A_LS@X_X:)^!>1U'_">Z5Q_Y'IW0'M'_  C>G?\
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M_P O*/\ AU[\7?\ HM/PX_\ #8WO_P O*]G\<?M>>)[^?X36OP\\#Z1KM_\
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M(+3P!XMMGC?X1>*TN7:74/#3*R0'3A+)&!"V^1$*1EHP[*98PWL7_#=7@_\
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M)&!V6PF+&]N9&P0(UG F/'DX.P>A' *E>59J%_G)_+\KV5MC!U^;2&OY??\
MY7/0_&7[4/A#P?X@N=$COKO7_$5J0LVCZ%92ZI>P,WW5E2!6$&>QF*+@$D@
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MAM-?DC\*/%.N?&CX&_L[_"'PCJ5[IGB?XB6_B#XAC5+:7;<>';?7=0U2236
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MJ\8__+2CZM4\OZ^0>VB?5M%?*7_#"O@__H:?CO\ ^'J\8_\ RTH_X85\'_\
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M_P"AI^.__AZO&/\ \M*KZM4\OZ^0O;1/JVBOE+_AA7P?_P!#3\=__#U>,?\
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MO\CYU@^'?[7\#Y/Q:_9UF&,8?X5ZO^?&OBK4WA/]KBWBA$?C[]G.Y?'[UV\
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M\%ZE\<;WXIZ?\76LX97NO$,O@NQT*.YA^UQ3K,?[%\L67VA1&G^D"5HS'B0
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M_P!-EO7E/[%&C^*OV:?CQI7P\^)T6M:GXQ\5^'KW4K+Q%'\4-<\5Z?JRVEQ
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MXT6ROA:Z;=120WCR-,L:K+.7VHI261X@(U*QJV6/2>/_ /E(Y\*/^R<>,_\
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M,_\ IJMJ^@*^3/<"BBB@ K+\9W:V7A>]=A(5\HK\D32')X'"@G&3R<8 R20
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MDX '%=3_ ,,B?M(?]%L^"/\ X9_5/_FEKZTHH^M55HI![&'8^2_^&1/VD/\
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M]%L^"/\ X9_5/_FEKZTHH^MUOY@]A3['R7_PR)^TA_T6SX(_^&?U3_YI:/\
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MRQO@!DA$HB#  $1@@ 8% =3TS[%>_P#/\/\ OP/\:/L5[_S_  _[\#_&KU%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",TM%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>77
<FILENAME>tm2135630d1_drsimg4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg4.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #0 I0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !111D>M !129'J/SHR/4?G0 M%)D>H_/TZTM !1110
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MLFO:=IT'B>=-Q64?MQ_P3I^&G[0G[-WA+]L#QG:_L_?$3_A7'Q-_:8UGQO\
MLP?LIVVM^$? GBWP+\)]6U'5);Z_MM%^(OBGP]X5^&-AKQU2TUE_AU/K.B:U
MI<.A3QQ:%!J,MO;S>I:-.-2M[:-5>SS?DJ)27UF659MP9E=*$%"#499MA^,*
M_$*C/DCR9573E*HO<Y*W^S3PU.\>:5?*L.TTTW&IA.+\&YMRE=J#X9C"\4XW
MK4&W3C4HQK?K#X<_9R_9X\$_#S7?A1X5^ WP5\'_  E\21WG_"4?#+P_\*_
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M5]K>IQI%\/[_ ,6"ZT'1_%R:K=6BV^J7EE<Q?FE\6?A'\0?&O[#_ , ?A_\
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M\*Z+K_G>,=3^-G[0WA+6-2CO[VW>Y@-YH/@[PY93(CE%72XI8@LS.[_SJ_\
M$4Q_P66_Z.(\-_\ AM?#/_R/0!_KK45_D4_\13'_  66_P"CB/#?_AM?#/\
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M ,CT?\13'_!9;_HXCPW_ .&U\,__ "/0!_KK45_D4_\ $4Q_P66_Z.(\-_\
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M&%QP<Y'7 _R,_P#B*8_X++?]'$>&_P#PVOAG_P"1Z/\ B*8_X++?]'$>&_\
MPVOAG_Y'H _UUJ*_R*?^(IC_ (++?]'$>&__  VOAG_Y'H_XBF/^"RW_ $<1
MX;_\-KX9_P#D>@#_ %UB0.2<#U-("#T(/T.:_P DOPA_P="_\%CM9\6^%]*O
M/VA_#IL]2\1:+IUVJ_#?PRFZVOM3M+6<;A "/W<K %2".36]\5O^#GG_ (+"
M>%OB9X]\.Z/^T+X?33-#\5ZUI%@C_#?PTVVUTZ^FM8@-T&<E8]Q)R3D<D8H
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M,CU'YBO\C.U_X.D_^"RDLT2O^T/X;8>?$70?#;PRI>) [RKN^S'&Y5"\<DD
M<9KTWXW?\'.'_!7GP?\ %;QKX;\+_M'>&GT#2M3MX-->/X=>%+R)H7TRQG?R
M[A()4=?.EE^[(0#D=<T ?ZP&0>AS17^13_Q%+_\ !98?\W$^&V]S\-/# _#
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M8]:N&_=BU<RZG<!TC1/,(1:]CB#"-0R[2,_*2"0-QQDJ2"2,$G.2<D\DBO\
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MK%<$XQV/< TH:/Y>G;O8!E%%%:@%%%% !1110 4445%39>OZ %?OG_P;3_\
M*6;X"?\ 7WH7_JSOAI7X&5^^?_!M/_REF^ G_7WH7_JSOAI60'^P+1110!_F
M"_\ !Z?_ ,I3OV?O^T?_ ,*O_6B?VJJ_D!K^O[_@]/\ ^4IW[/W_ &C_ /A5
M_P"M$_M55_(#6L.OJ_S ****L HHHZT/9^C_ "8!2@9(^H!]LGU[4!2<8!Y[
MX)[XJW%%NP,<^@[_ ,R<YX'6M,+A)XF48ZQYFDFTUS7:7NW2YKMV]WF^_03?
M]71%Y0'(8$CD#<.<=NE#=#]#_*K3P[021@@$X((Z GI_2J^#Z'\O3K7?C,ME
M@Y<DHR4FG=.,XR5KZN+C%V7FEUN^RC*_9?\ ;R?ZE:BK'7IS_D_X'\C2-T/T
M/]:\UX=I<UW;=.RY6UK92O;I;1M^5]"KKNB"BBBE_7]; %%%% !1110 4Y/O
MK_O+_,4VG)]]?]Y?YBD]GZ/\@/HJ]_Y-+\-_]G#>./\ U6WPXKYSKZ,O?^32
M_#?_ &<-XX_]5M\.*^<ZP **** "BBG)]X?C_(T -&<\=>U2@,>".#W&,_YS
M[4^.-F;A&.3\ORM@]R!Q_+GTZUL0V;85F0H,KRRX/) )PPS[]N!S[9SJ**>J
MTBWNKZ=$KW;^3UZ';A,%/%7E%-QC))M1DXWO:SDDXI^3DGV1G16DTBG8K$ 9
MR,D#G."0IY.<#UX ZYIDD<D7RL>XX)],X)'7G)_$$<=:[VPGM+1)XQ$C,ZX4
ML>AYYP>N#S@9_&N;O8M[M(0I#/GY<' .<KP>F.,G/8#BN.&)YIV\[ZK6_P T
MK_>>]C.'X8?"0K1FI3FO>46FX;7YDG>/J_G8P0C,<$$<Y([CKU/ Z=.G?OS4
MRIMY!Z=NG7UY.?\ 'O6BEN\CX12< Y/!7UZC')R!USG('2IYX=ENW[H!]RC<
MHW'OD''0$#W_  Q6ZKISC%M*[77:]_/RW9Y]/+_9TY5/Y%=-];6V[[]%_P #
MGI.WX_TJ.IG^Z1W# D=P &R<=>.]0X/H:Z%LOZ['CU/C?G9_?T"BBBF0%%%%
M !1110!UO@'_ )'GP;_V-?AS_P!/-E76?'?_ )+-\4/^QY\2?^G*:N3\ _\
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MY)Z'LIKH[^:=_P 5<AHHHK@&%%%% !3D^^O^\O\ ,4VG)]]?]Y?YBD]GZ/\
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MI8RTDFW"!T+8+)GK?CIXB\5^&;JRO-;\FWO_ !=I<FJ6\.]XI8M.OFA6.4P
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M07S2"=-RLJNZIO*L%(9@#AN!C!!X/?KDUMI(K[GVC:/F*@ Y522W&>01U/0
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M*_I<#Z)O21^R;X9(ZC]H?QP?_,:_#D>A]:^=VD9@022#].Q![*/3UKZ(O?\
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M^4. C D\$#K@$8'U^F/5RCZ&W#7%O#.49]P]BI8/&0I0HXRMC5]7P=2O))+
MXC$U73H4YXF36'=*K5A4?MG%4VW9O$\05L-4]G*G4]YM)<KONES1NM;7OHF_
MS/ [C2Y(<N%)3MP3D#)X/?T';OD5261HSF+D(2"5YZ=<XR2>Q],?C7J%[*MK
M=?9)(HQ"S;',@'"ME2RG!QGL?Q.17'>(-)&EW"&(YCN5,H;^$@D<*>G3 [9'
M2OXL\5?""/!%3B+-^%ZULKX9S&CEW%:?N9AEF=8BJJ6#I4Z#:KPRW$8KV=.G
MB)TZ>'JTI7IU)IIGNY=CI8F,?::2FE*%VK2B^K_O)=KM/=6U.5GG:4D,",X[
M8S@C(.?H>/KGVK+][)[LF#[;AT_#%3R(<DX)&23P>[$Y] /YGFHP"6'^\N/I
MD$_CU_I[_P GYI]9J8FKB<5)U*E1--KWK-JUW:]DKZMVTUN>Y%V226G6_P#7
M];GT)>_\FE^&_P#LX;QQ_P"JV^'%?.=?1EZ#_P ,F>&A@C/[0_C@?^8U^'!X
MY^A^G-?/"QEF P<'/;V/OGM_/TKQKKNOO-4F]$F_37\KD5%6A "2 "2,9 #'
M&>G>E$!W,$5F= 2P .5 &23D\ #D\<=Z+_?VZOHE;?5Z+N]BN26EXR2E)13<
M96<F[63<;-WOHG?1Z%4*QZ*Q^@)IRJP()4@>I! ]/YUH16\S$(L3ECR%QR>
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MH)$E9"]Q##(@7=D""*5G;J2%)XZ5X?XI^%[:7I<5U:W\%_"S&&WE@@(-Q()
MKHL@^\8QEVR.WOFGV?CSQ8=&&@7&IZE]CENC/L:=RF2ZNZE0_4%!P1Z=!Q72
MV6ORK;Z98A'E$5Q+,$GPZJ0CNV$Y8>9C;V.6YZ&OG,%/B3 O$XC,LQIXW#O'
M3JX:E1Y5[*FDKR<%4YHQY$XW<.5-.SE*5S]MXA?@#Q?ALGP7A]P/F?!D\'P3
ME639M_:W$>(S:6+XI>-G2FU5EE%.G4Q#JN[I>WISY7'F5."4SYEECFMYV@F#
M!XG*-O!!7&0<YYR,8(.,&FN?F88ZD=?;]?QKI?& 9O$&H3M"8#/<2,L6TKLR
MW(Q^&,8]?2N8.3DG/O\ Y[5]]3DJN&HXCK5CJM^S?SN?QWF6$>7X['Y:TU]3
MQM2*4DTW&G.4>:S2=K)-NUMF][CHR W/H1^8Z=Z?O9@S-G(P,]^HR,'IP._'
MXBEMG$<JLREQ@_*.^1C/T'>B5U8RX^7=("%YSCD9_,'-18RIS48-\RND_=NK
MMI:=;[C0_P K9)S\O]WU.>WI^M36IC:55G8K&67<0!P-V"<>@!YJI1D@@CU_
MQ_\ U?C3Y9/173Z/:WG?H*-=IQ<DVDU>[Z7UOJ=E<:99,T0L;DSB50I &0&.
M?ES@'.1Z9IM_H=QI48-RNT2;6 )^8*X/( /"^N0.3T]<NQOC$R;7 *$.,_[)
MSTQ^/3/'O5Z_NKC5IXTD=F+-&%Y."0"%1?8@Y Z>]<4XUU4O*=J:E>=]=$F]
M[Z6TN[KJ]KGV5)Y97P*E2PZJXYJ,,.KWBJTG"-VE=:WDDFDVVDKMJ\<-E+<P
ME(49RS87:I)48QNR!V)'4'@X&*9+I5[92+YJ3%=V S X#8Z8(QC@L.@& .>0
M?2RL?@VT@CCDBEO;N*.2X=T#?9XY%+^205(5R0L@89R$]#BJ-EXML+K4%36X
M1<V&X"["KL;9P,1,%R),$L.GR@CO7+4KUXMJG3=6"UDXJ_N[:25[M73]W1^9
M[U;A_AW#T*:S+,ZV SF4J48X.3=/#0KRY9QI8IU)05)2BI->U5-:0T=TSD+R
M99;58BH\YF49 P3VP/Z>O)/->D_#S5M#\)R76H:RJS/+$;9+<!'9MPW[B#P%
M.P#<"#G''6O+-?-F=0E:R=ET\RO);9)S&A+&.-R,?,HX)]OO>N(+B3+#S%>,
MG*ER>_.!WSC./RXZ'JK8>.,PD85'\4>67>R::T:MS*RT^=KGF8/BZOPOQ*\=
M@L'1Q>-R^G_L4JR4L+.HZ52AS2>L94Y4J]5J2E:_)JMCL/$.O6]W?37-O"OE
M2S2,J+C,88LR@ 8XQW[]>]<O)*URZ#G9NY7/"'H>>F,>PYXSR*JL$^\9%)_N
MKDC@\<\ 8P.W.>O%(&;Y<94 \'& <<8]>#[=OI6^%P].A",8?922N]7:_>VV
MNUD?,YEFV.S7&XK'8WV=&KC9N<Z.&Y72;E+F:DH722;TOM9*^QTW@R%H_'G@
MO"ML_P"$M\.X8C@_\3BR&01QC/%=1\>5'_"ZOBD'X'_"<^).3Z_VE+QP?0Y_
M*N8\%,3XY\&9?</^$K\. ?7^VK$_AP#^1[YKJ/CZI;XT?%(@9 \=^),D=/\
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MOK][M?E$C2;8R&Q&FT"-1QCD*6PO0DY.236;</$(P%DWNZ^8Z[7&QF) 3+*
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M$W_!EU_P56G_ -9^T#^P*?7_ (NO^T9GWQG]E4XXXS].PP:__$%A_P %3O\
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M (*F_P#1??V!/_#K_M%?_0IUF!_']17]@/\ Q!6?\%3?^B^_L"?^'7_:*_\
MH4Z/^(*S_@J;_P!%]_8$_P##K_M%?_0IT ?Q_45_8#_Q!6?\%3?^B^_L"?\
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M8$_\.O\ M%?_ $*='_$%9_P5-_Z+[^P)_P"'7_:*_P#H4Z /Y"4D3:HW#(4
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M_P#H4ZT-$K:VL[?Y_P"9_($D4D@8HI8("SG( 11C+.20$!) 4L0&8[5RW%.
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M<CS-K'<0P"JID/7KL'/;.,_T_'_@RO\ ^"II_P":^?L!X[C_ (6M^T3S^/\
MPRE_G\L/_P"(++_@J=Q_Q?O]@/ &%'_"U_VB, <]C^R@?7J,$]\U_7&3_37\
M1,JPV0Y76RK*<UR?)\LP^5QPF/J9M35&E1E2DJ^#GE.9Y97IXCEI*BW.O*DZ
M-2I%T^9J:^:>1X1>V45&]1RG*:6LI-WMK%[MW>B5EO>Q_,I-XM\/0 BV\06Y
MV1;")(I1YO SN9XE.XXR,[0 ><D9'C.OZW'>:O)-#(@B7>D<R'(;(^^-O.">
MF ?3IR/ZT?\ B"R_X*G]!\??V! "<D'XK_M$'UX_Y-0 '7L!QQ3#_P &5_\
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9FY7.6!VC(8^9+E@>"?-DR<GS'^\2H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>78
<FILENAME>tm2135630d1_drsimg5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $W NX# 2(  A$! Q$!_\0
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M2T'3+W3+.ZT=["3P]/#>Q2Z;^H5 !1110 4444 %%%% !1110 4444 %%%%
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MXG_V+_P@;>*/[4LIRWA :[_PD:6(34&TX6<B3'W@2$L5"/P,Y(P.F1UY^;!
M/3(()!P#_&!^U1^T!\:/'GQ6M/"^J_\ !0OQ'^R)%\2_^#?/]F3XH:I\:M:\
M8^*])^'_ (7^+7CS]HO1M+U7XD:_I_@N>V?PA?\ CXWK^#-7^)_A?3[#Q%X;
MTG6Y'TO4["&W3;\D>,?VI_AUXN_85^'>KZ1\3?"7P ^&_P"S+^TK^TM:?$?]
MFKQO_P %*/VV+C]FC_@I7_PK/X=>'CKUW^R+^W@OC*?X[7NG>$-8>V\3?"_X
M90Z_>^#=7^)EPFG6FF>,)K]Y-3 /[@M:_:.^'.@_M#^"?V8-0B\:?\+2\?\
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M\<-77X&:M^Q=X]\;?&GXB?M-?ME_M/?LN_#/QU^W7K.J:5XNU?2?B/\ M0_
MZSUKQ]J/B+X;:?J&M0?"?X=>*=>LO"EQIUDUPJ0W-M96MU_3]_P2?U+Q_JW_
M  3U_9BO?B;^T=X;_:Y\6GP-=6ES^T=X4O?%FJZ1\5M.TSQ)KFF:+XA&N^.-
M(T'Q5XEOH])L[/3-3\3ZSI%E=^([^PN-9<7!O?MEP ?H?1110 4444 %%%%
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M21R*'CD1U_9R*NCHRNCJ2K*0RD@@UT/_  734#_@D%_P418##-^R[\102.I
MLX!C/IC@^HP#G K]._!3-)X-\)22.[N_AG06=W=F=V;2K5F=V)+,S$DLS$LQ
M))))H _*0_\ !=+_ ()[X.-8_:KSU_Y1[_MZG@<DX_X9P';/?CK7UU^R1^WG
M^S1^V\/B:O[/?B_Q9KFH_!O7/#7A[XE^&_'?P@^+OP7\7>$]1\9^&H/&'A(Z
MEX2^,?@CP-XC^P^(_#5Q'K&CZC#ILME>V3)/',8IK=YOLBOQ?_8* _X>M_\
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MD^KW?P%^+]S;"[BM$TGX6:I\--6FT[2KS4(="U'4;JVTIZ$?MV"#T(/T(/\
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MX_X*'A">/V:_&!("@\F2P..1R&QP>I!W#!P3VWP__P""B_[.VC>!/ ^EW?\
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M6I45-Q5Y*+JU*:DTFFU%NR:;W1][[E]1^8K\8/V"B/\ AZW_ ,%X.1_R5_\
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MIVB#Q9I_B(WFI1:WXTTCQ;IYN]3U&[DT)[O4KBX7]G:* /RP_8%_X);^#O\
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MXRWGC+7_ !S/X2UBZD^%#Z5-\+VU;Q'>HND6.D67BZ.P6TC?QLLJ/(?V$HH
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M4?\ 0OXV_P#"2I_\P!_Q&KA/_H0^#?\ X;JW_P!%QPJS?\%D5 7^R?V%N!C
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MA8XBIAXR]M7I1PT)5H^M_P#!<GG_ ()#?\%$B1\G_#+WQ%![Y LHPW!]0#W
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MM_:7]/@;_P!_?B#_ (5[M10!X3M_:7]/@;_W]^(/^%&W]I?T^!O_ ']^(/\
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MM0NRJJHSL<,7!^4*8Y0OY26GPU_X+8>-]/U+3?&7[67_  3;^ ANXA:VFM?
M7]D+X\_&?Q+IBRNOF7MD_P =_P!H'1?#9U."$2):C4_#6IZ3<!Y3/IPPIC9_
MP['^*'Q&32+G]JK_ (*E?\%$?CE=VT<D.O>%/A7X\^&W[%OP>\36LMR9?L&H
M^ _V:OA]X9\5&%Q%# "WQ->^M]DDEO>P><%C^*Q7#/#5"<GF'''#T**NYT\I
MP>;\18BH[?#AJM#+,MP4G=<KE/,HP5_XMUR+UZ6)Q,DN3 U92E]NM.-&"\U"
M<G.*Z).[O=[6M]T_'+]J7]FS]F'19O$?[1?Q\^$/P5TF$Q*S?$GQ]X>\+Z@\
MET(S;Q6FC7MZ-9O6N#(A@2UTZ:63S8%2%S/&Q_/R]_X*/?M ?M./+X8_X)B_
ML=>,_BE!>K-;G]K_ /;"T[Q7^S-^QSX1W0DP:WI.BZIIB?M"?'YK.\\F"Z\+
M?#_P9X2AO;.Z@UC3O'4EDLJK],_ K_@F1^P-^SCJMMXE^%/[*GPMLO'-IYXC
M^)WCVRU7XR_%]TN5MTN(IOBO\8]4\=?$%[=C;1.EC_PD(L;:4.]I;PM*^[[O
M_>2J$&XJL:PK%$ !%&IPD%M&JE44858T5=H 1 @0!#S4<QX&RB=.IE>49IQ5
MCX13I8CB?ER_):,ESP<Z.299B*U;$.%J5J.89_\ 5U.#JRIMKV+N5''54_:U
M(89.]_JS3ERVNTYRNMKW:2OK9GXA>._^".6A?%KX7_&'QM^U-^T?\2_VC?VX
M?%/@^XOOAQ^UE=6@^&5G^RWXI\)7]CXX\"G]DWX2^$=2DT3X.>'-(\7^&?#=
M]XD:'4M;\8_$*ST^[T_Q9XDN='OY-&A^Z/\ @B)(^H?\$F_V"?MES)<WUM^S
M[X:LM4N0DT7VC6=,O;^QUF93<PPR20S:G!<213"&-98\2Q8CD KP?]MO]JOQ
M?XRU/Q3_ ,$_?V$KZP\?_MV_%309O"WB;6=(C_MGP'^Q)\-O%T#Z9XD^/_[0
M&N6_FZ1X;UO0M!GOI?A3\.+NZ;Q=XZ\:G25@\.W6@PZK(_7^-8M,_87TS_@G
M[_P3]\"?M'VO['?[/%C^S[\6=+O?VF]<L?A?<>)M9\5?L[P? G0/A_\ !KPW
MXD^/ECXU^$?A?Q;\6;;XF?$;XLZ_+XL\&^,]=U7PO\(O%/A_P%;:;=W6J^+?
M"O\ 9W@-'C#%9#F6;<4.K3P&:X["5<BR_$8=8:&&P^"PV*H5*F P,*%"CE^6
MS<\/'"0IT*<<3[%U_9MWQ6)^3SMX3VU.GA[.4*?)6G%N\ZC:?,Y)ZR5DFX\O
M;NC]F)854\22EB#L3>>2  % RJDMVW,HSCD9KE]'\7^#_$C6">'?%_AW7Y-5
M\-:5XSTM-%\0Z5J[:EX0UK:='\4Z>NGWD[W?AG6%)_LO7[=)=+O?]9;W,PRM
M?C+X'_;.^,^M?'_PG;G]H7PQKOBW6_VYOBA^RIXG_8-D\%?#U/%'@O\ 9W\"
M^(/'6A^$/VD;B_TF&'XR'QCXQ\$^$O"'[2>H_$B[UEOV>]2^%_Q7\,^"?"_P
MSTG6[:P^('B+\QO@G^T'XR_9E^!G[$WQ+^'5GILOB6Z_X(H?\$>OA[KOB"]O
M/"%DOPW^'WQ/^)7A;P3XO^)%Q?\ CO4=*\#Z))X?TK5+NV\-^)_B)>M\,_!W
MB_5-"\7_ !$TW7_!&A^(_#VI_N_L:6J]G"TGS2T>K[OWM]?+T/#:3WO][/Z_
MQ;(1G?+_ -]D?@1CJ.A]_3I4'E#(&91E\+N<@E,D;@.03W"[@S*"=H8[1^"?
MPY_;$^/GC7Q;\+_A3\>/VK_ 7[)_@35/#/Q8^(G@O]H;3/$7[*/C;Q7^TC9^
M%/BA;^$/!WPPN?B-<:1XT_9/TCQUX.\+31^)?CYX<^%_A)O$_BFV\1>%=3\
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M0![K163/KFE6[%)KZWBD ^[)(JGH#Z].14'_  D>C?\ 02M/^^S0!NT5A?\
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M3H.C'+Z+3UA.&"KU$E'WH--KR<1FV.Q-U.JX1=_=IW@K/H^5IM6=K-]#Y?\
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M;Y+S5H4\MJ12KX53OA<53E5Q,Z]5KEA.I.I45*IB9RJ7K03E)4E*I!01]/\
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ML?'Q/CCPP(O ]^;DV:V7C!FU3/AF[-Y#):K!K?V*83P_9UC::/RU_.C]BO\
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M=:E'$TOQM^)]RFR^TWPU>:=<*8IXSOM;R=0Y:-BLB2*G[DG]I+X/#KXAUO\
M\-]\1O\ YDZ /=**\*_X:3^#O_0PZW_X;[XC?_,G1_PTG\'?^AAUO_PWWQ&_
M^9.@#W6BO"O^&D_@[_T,.M_^&^^(W_S)T?\ #2?P=_Z&'6__  WWQ&_^9.@#
MW6BO"O\ AI/X._\ 0PZW_P"&^^(W_P R='_#2?P=_P"AAUO_ ,-]\1O_ )DZ
M /=:*\*_X:3^#O\ T,.M_P#AOOB-_P#,G1_PTG\'?^AAUO\ \-]\1O\ YDZ
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M?_,G1_PTG\'?^AAUO_PWWQ&_^9.@#W6BO"O^&D_@[_T,.M_^&^^(W_S)T?\
M#2?P=_Z&'6__  WWQ&_^9.@#W6BO%]-_:#^%&KZEIVD:?KNL2W^JZA9:98Q2
M^!O'UI%)>:A<Q6=K'+=W?AB"TM8WGFC62YNYX+6W0F:YFAA1Y%]C652Q7D8]
M>O&,\#.,9QS^&: ):CFP(W)&0!R.#QD9^]QC&<DX '.1C(DIK*KJ589!QD?0
MY'X@@$'J#R.: /P>_P""LNL?#?X5_%#X?_&+XQZW^SQXJ\)^)_V/OVPOV>?
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M< N,Y8KG8=PP&RNXX!W!@" 0*.YYY.2QSP,@AF((. I+!F*?(6VXJ>B@"O\
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MZ'-)WL[6OTNKJ_2ZZH/0XOQSX)\'?$KP9XG^'OQ$\,:'XV\#>-M#U7POXO\
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M51M'JW_?;_\ Q5.HH ;M'JW_ 'V__P 51M'JW_?;_P#Q5.HH ;M'JW_?;_\
MQ5&T>K?]]O\ _%4ZB@!NT>K?]]O_ /%4;1ZM_P!]O_\ %4ZB@!NT>K?]]O\
M_%4;1ZM_WV__ ,53JBFFC@0R2ND<:\LSG  ]CT_.@!^T>K?]]O\ _%4;1ZM_
MWV__ ,57/-XM\.QL4?5K0.O##S!P1U[\?X4W_A,/#?\ T%K3_OX* .CVCU;_
M +[?_P"*HVCU;_OM_P#XJN<_X3#PW_T%K3_OX*?'XIT*=MMOJ5M*V0,*X)!.
M>^<#Z&@#H-H]6_[[?_XJC:/5O^^W_P#BJ:CB0*RL"I.,\?-QD$?A@X^H[5)0
M W:/5O\ OM__ (JC:/5O^^W_ /BJ=10 W:/5O^^W_P#BJ-H]6_[[?_XJG44
M,* @C+<C'WF/Z$D'W!!!'!!!(,<4 C.=Q8XQW'4Y))R68ELG+LVW)"[03F>B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9QE!R!M8-@
MC.3@@ #UR<\<\?A4U5[@_(O&XE\#Z['/)R, @$9R.N.,TG:SO=)Z-I7>NGZZ
MOHKOH)[;M7LKJ3B[MI+WEJM6M5?KH]G\J_M6?#3Q=\3O"?POTKPAIL.K7GA[
MX_\ P?\ '.N6\VH6=A]F\*>$O$;7^O7J&[N(/M;V=N1*MC:F:]NW/EVT$KXQ
M^7UO_P $^OCQ8_!_X8^&?AUX:\*_"?XFW?P>_:D\#_%;QC9^*+#2GU'4OB!>
M7.I_#O2/%GB3P?%K'BC5- U2\D%N-2\*6WB*_P# .FWDTNAV$&HZ?8Z</V5^
M*7Q4\"?!OPY#XP^(GB&V\.:!/K6D>'(+NYBN9_M'B#Q#=QV.A:7;P6L,US<W
M>J7A2SMH85)EN'4 'J/*O!O[7?P"^(NNZ+X3\%^.['6O%'B:X\0Z/H>E7MEK
MFCI-XP\*MJ'_  D'@?5;V_T@1Z-XNTB73KYM3\-7F-=T_3K?[:FD26WE/+XF
M/AE$YNCC,13A.O2C2IT8UW2K1M"M%_58I^T6(J1J25*S]JU3ER37,S[KAW->
M,\ORW#U<FRJMB<KRO%8W&K&3RZMC,$Z\OJ>)Q:S"FZG]GXA8&6&HXF<,50K4
M81Y*DKWE"'R:GPP^(VC^+O@M\6_A=^QU;?"^T\&>&/C-\*/%?P@TGQ+\"= U
M1[CXM:9\-X=-^)NC7_A+Q6W@O6O!NA:I\.H].UJ36-9T+XCS>&]3AUK3/ ^I
M:KI[^$I_G/0/V+OC'X6T'PU8^./V8O GQH;_ (9#TCX!6^G'QOX#^S?#KXIW
M7Q%^)>NGQ=:Q^*Q8:?<^!M(T[7M(U'7_ !EH27'Q&TB)=%L_ ?@'Q7J&H^+[
M#PS^@W@W]N_X!:SX7^&&J^*_'7A70/$'Q"\"_"[QK<Z?H&H:YXI\(Z-8?%FW
MLD\)ZM%XVNO#'AEY/!6K:M>1Z9H7BWQ!H/A07PEMKO5-*T5YY;.T]V^*?QR^
M&OP8CT>\^)&NS>'[#6GE-OJ9T?6M0TNRM;6>QMKK4==U'3+&[L](T^UDU*R6
M:[U&6TC43/*"8(;EHN>6'R_D=>6/Y8TY49U(RJ4(THU:LZ-.BZE'ZM+V,Z].
M$:,HQ3:J*M.,J=2]6'H4\ZXOP6)IX"CD=18O&U,9##N-/,J^/Q]/"RQ=.JL-
MF,<REC<5'"SIXF52K1Q$JU51C%^VP\8TY?EAHG[(_P"T.OQB^#<GCSP7X>\7
M2?"SXB?#A-2^,&GW/PUT[1?&GP4L?@_;> O&=CKMQ/:CXQ>/O'6I:U]O@\7Z
M%\0[2Q\+CPD^DR>#M<UN>,^&+'S.W_80^+\'P>_9^\">(OA-XEB\.>!?@AXY
M_9_^(W@OX5Z_\ [?Q#)\0=2O/#-C;?M%>"]0\::S8^&&T7Q3I&@SS67B^[U7
MPS\=_"D*>'+R/P!#J2:AI=E^NGPD_:3^'WQE^(/QH^''A6U\2P:S\#O&UOX*
M\2WFHZ%<6FBZK<W'A/P3XNCU+PWJL;SPWFEO%XWM--A6Y^PZA>W>G:CJ%G8W
M.B?8]2N?,/"W[3'CCQ-\0OB/\(=-^#EB?B-X5\+VWC/2+&W^*GAC5_#$%A<>
M)_\ A&IO"_Q \3>&;3Q#_P *Z^(4(2XUJ/PU<Z=KMIJMA;3/I&LWDEIJJZ9R
M0RG()*%ZE2O&MB(PHU9UZM=5J^ G4H.C"M"5";K4GAZE&E1<*DJE/"2A%U>1
MU*GN5^,/$2DZV7U\LRO*JV283ZQB,-B</@LIE2PG$$98Q9A4PN*KU\/-3CG]
M+%8;$NG7EE.&Q[G2EA,%4JX"C;_:I\%^*/%7P>M?A7H/PP^)/Q7@U_2VTB:_
M\#?%7PQ\*]9TG5;'2A::/<>+/$_B'Q'H&HVWA?4[JXE'B#4_"EEXWUS3XD:Y
MM_ OB'$5G-\DWO[*O[22>&/$_P %M4T3P-XCMOCV_P"RUJ/Q#^,'A&_TOP?X
M.^&]S\(+7P':_&2'2? 4L.G>(+&77+'P;J$WP*TKPAH.I:)9ZEK6G:3XSN/A
M]HFCW.JW'K9_;_E\.:'XLU+QK\%-:@O/!?BKXJZ1J=OX%\<>&?$^F3>%O@3I
MND7'Q?\ &VFZWXHC^'UMJEKX%UC4KWPC=Z#86LNOZMXI\/:YIND:==/IS2-[
M)H'Q]^*_Q/\ '?BC3O@[\(?!7B#X7^ _'"> _%GQ#\?_ !;UOP!J>H:M:1:9
M=>(Y?AUX.T'X0_$A?$UKX>L]2%J9/%FM^ 1J>O0R:3:O%8K<ZU;]#>38_DJ1
MEB9N=)X2*IX2O"NJ-*<L/6I?5Y498AQ="$88B=2'+",8RC4BZD92\&F^,LAP
M^-P\L#@:>%I5JV,QE>MF.!K8:KCJV-HYA0G2QE+$QPM6O#,*^$Q.&PV!<J==
MTU.='ZEAYP/L^V.8L\XWOC=C.-QQT[8X'3(P1QBK%5[;'E8&<!WP6.6(W'D^
MGTZ#H"0!5BOI]5NK/MV[+9;*W1=K)IGYPGS>]IKK[KO&_6SZJ]]0HHHH **^
M&OV_X_B1+\'O"<?@BW^.EWX2D^+/A5/CE:?LQW?B/3OV@[CX0R:/XH29?A5J
M7@[4M'\7Z?K$7Q&;X<W/B"X\-ZC;:B? D'BR"1VTZ:^1OEW]I34/VN-7_8E\
M ^"/"EY\9/"WQ?TS2?@M=?&_Q;H7PF^+GQ*\<:AX:UW2/$XU+2/"EO\  ?X\
M?LR_$76?&R>(=!\.6/Q2U#X:_&[PIK_@S3]6FUIGO(-0>TO #]@V_P!9'_P/
M_P!!%?/_ ,"?^27>+O\ LMG[5'_K2WQ=KJOAU_PGUQ\'/ :>)+*P\)?$^;X;
M>&QK5A?W6O>.]*\-^.)/#5F+Z"_O-3UK3O$OBZRTG73(M_+J/B2RUK7H(91=
M:[%?73:HOS1\%]"_:-;X=^)GTWXK? ^UL$^+G[2$=S;ZA^SUX_U2YEU.W_:
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M\ ?_ !&?XB__ $65 'T%17S[_P (]^U/_P!%C^ /_B,_Q%_^BRH_X1[]J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ@ HHI"<#.,].F/7D\D# ')YZ ]>E "T4Q'#@D C!P<XR".Q )QQ@\]B#3Z
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M+&S_ &J?C/!:65C;0V=G:P1>-M56*WMK6V2*"W@B4!(X88TC10%50 !7YYT
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MMS\)/@_;(\C_  J^&V$0R'/@;PR,A%9WP1I9)(523\N$ +,3D*0#I/\ A/O
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M_P!#KX2_\*/1_P#Y,H_X3[P)_P!#KX2_\*/1_P#Y,K$_X4W\(?\ HE7PW_\
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M>]N5BMD96D6NT\*?\@.T^LO_ *,-?#7_  58_P"4<7[=X[']B[]JW([$?\*
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M5_B2Y6F[*-F^[LDS^NXYR2%;'T]^F >W_P"K/&89;BWB!,LJPC^](ZIT//\
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M0!CPW^UE^TUH**HZ;4TWXIHHRVT@!2NY 2AX-;]C^PUX+\-WMOJOP_\ C_\
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M@VSG&HZA=7LD#VMO<W26.DQ2L9+W5K"VBGG3Z#^'GB#6/$W@7P?XE\3^&)O
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MM;:,M-<3PPQR-7Z)6G^KD_Z^KS_TKFKY7_;H_P"31/VDO^R"_&;_ -5KXFH
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MTHX.-&7/F$E]9H\W_P .7O\ @GO_ -$W^+O_ (EQ^UU_\_*C_AR[_P $]_\
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M:AK5_KMWJGB./P]<C3]*\*Z/X?T?[0/_  4V_9B#;A9?M!G!Y _9;_:"QD
MJV/AUGIGH1@\8/ KW?\ 9L_93^'O[*7AWQAX#^$MUK6G?#'Q!XWU3Q[X?\!Z
MKJ%YK6G?#W4/$%I91>(M"\'ZAJ%W<:C;^#[_ %'3U\066A7\E[)I&LZGK\MK
MJ#6>IQ65C])&SC 8G#'!(R@.3V+Y)+N!P&R#W Z"C+\)F%'!86&,KX:IBH4(
M4\1)892YIPJ5G*2GSQ<^=.,TW%2O4NU&2G$]KB[-N!\PXESO&\/<-X_"9#BL
MQJ8C*,(LTI8!X/+YPPRP^#>#A@<4L/+"QC4HS@L?C8SG2G66)K+&25/\^?\
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M%%% !7JOP)_Y+?\ !O\ [*K\//\ U+M'KRJO5?@3S\;_ (-@=?\ A:OP\_\
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M[\/=)^&WBV6_-P+DZE<>+_A9%X+\2WFJ/.JR/J5_JEU?N5 >Y==^[!L_V#_
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M3]-TK3+6*UTW3K&T@6.*SL[&T@@M+>&*-(H((%B0"-%V?A;_ ,%/?VV+_P"
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M>H6VIV0G@/AL": W-K&)XMR-)$717C9@Z_L?^U)_P4=T[PU^R1X,^-?[&O\
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M_#VCW5YHWA;3(\AI]:\6:TFG>&]$MD_>7>K:I9VD(\V=<?EWXO\ ^"@/Q_\
M#7_!-OX]?&SXE_\ "L_AA^UE^R[\5-#^$/Q\A\":;JFO?"OP_P");'XU?#;1
M/$&J^$-)\8W>O:Y>>%_$7PL\:VFKZ)-JUU?WPDU%[BVE\V&W"0IW]M:$I>P=
M-34'&4OWB<H\L%+GDU!*I.*5X0E3D[\ZB#:7(FTG4FJ<%=:SES\L=]'+V55)
MNR;IR5]#\N?^(,3_ ()N_P#18/VF/_"@\+__ #,5W'PQ_P"#07_@G]\)?B5\
M/?BIX2^,?[1D7BWX8^.O"/Q#\,/J&L>$;[35\0^"?$&G>)=&_M&RE\-Q+>Z>
MVHZ9;+>V@EB:XM3+$D\+.LJ?IS^TI_P5$\.V'P\NKO\ 9O\ &FB^!O&_A3]H
MKX&_"'XS:G^U-^S;^T%IMG\$OAS\:K?Q)J7A_P",VO\ P:UC6_V>/B'XE\!>
M(-/\-ZG'X-\<V/B[2/!.NWVFZW;Q:U/<Z!JEI9?>7[)_Q1U#XO\ P8\.>/;_
M .._P,_:.?6-3\10)\4_V=/ FO\ PX^&6JQ:;KM_I8TFR\(>)OC'\>M;TG7?
M#4EG+HOB9;_XB74MQK5I=/\ V3X? _LU*4D[Z6MR6O>TE4C>+CIK&_N7MI+1
MV(YX\L))IJ:ERV:^*%VX2U]R7*N>*E;FC9K<Z>V\"_&O3IM)E@^-UE>V=EK&
MA76I:;>_"WPW;VFI:!:ZQ83^(M+6?2]4M;RRO=3T"+4K#3-1MV9=.U.YL]0G
MMKZWM9;&Y]RC>1B02N1GY<@XQ@<E3QUZ$ GK@=*G(!!!Y!&#35C13E5 .,9'
MIG./IGGZY/<U18^F/G:<'!XYX]1GJ".GM3Z*35TT]FK;)[^333]&FNZ#7IH^
MC(&VHN-I.Y<D8R<XP"<#D@ #L>!SR:8NW!.WY@."R,,COA<ELD9[GG R,5:H
MI<J:2=W;TMZ-<K372UEL'IN]W=N_RO\ UN561#%M8,RLNUHRN5=2"&#(5PRL
M,J5.0RD9STKPGQG^R]^S9\1[?4H/'_[/7P3\:Q:O()-47Q3\+?!&M-J$J%&2
M>\FU#0II[F9609DDE+,N5W8.*^@**E4]4^9IJRM!**:5[*VOY?F#U5O/K9JW
M:S6GK\C\PM;_ ."-'_!*3Q!=7]YJ7_!/+]DS[=J;/+>7^G?!KPGHU]+.[AFF
M2\T;3K&XMY6.YFE@EBE/(W%6.?.-2_X(0?\ !)6]E>2/]CCP7HADP?)\)>-/
MBKX-MUW!5_=VWACQWH]O&!Y8.%3Y2,X'!K]@V^ZW;@],@]/4<C\.:_*K]K#4
M-2M?^"B7_!,VQ@OKZWL;W_AI\ZA96]]/#::BT/@7PA);&_M(R+>\:VD:2:W:
M=':!I)FB9&D;/H9;E+S;%RPT94XRC@\RQCG5IPK/ER[+L7F#BE.E-IU/JKIW
M4ER<[E:5N5^/G68T<HPE/%U,/"M[3&Y=@K.,-\?CJ&#4KNC4?[I5O:**7O<O
M*VD[KE-/_P""$7_!)K3)89#^QSX0UC9(71/%/CKXM>++<NXP!+;^)?'^JPSA
M]PPLD4J%@C;256O0-%_X(T_\$G]%DT^YL_\ @GS^R9+=:6_FVEYJWP?\*:Y>
MQW"2&43/>:[::I<3N&8-&;J6=HE5$$FR-%7V_P#X*'WMWI_[ O[;=Y8W-S97
MEM^R5^T;+:7EG/<6=W:2Q_"#Q?Y-U;7=G-!=V\\#A)(;FUFAN8759;>:.9$=
M?HSX<[IO 7@H2@N6\'>&M[$DLSMHEBCDL6))=3U)RW4EF9C7D0]DZSI>SA&2
MPWMN:G&E%N]65+DM&A3;5U?1[:/N?3/*[9+3SQ*E&E4SJ>2JDH0C4]I3RNGF
MU2L^6,5R?5JKIQ5O>K)1DW%OE\]\%?LK?LQ_#F"PM_A]^SG\#O!4&FSFYT]?
M"_PH\!Z&UE<D*IGM9+'0(IH;@*%7SHY$?8% (5:]^V;(T5 %55")&HV(J( H
M554!0N  %  48 Z9J6' # = W&.F"!C%2UT<FEN::2M:S<6M.Z;[]$CSTG9?
M9TZ7NOO;C]T5_G6";01@[F)Y'7).6QE2 ,D<8Y.>1W:R$C.U3R<\=>A V@8;
MD9V]2?XLD&K=%)4VFFIR44FN1647?K+3FD[N[:E&[;NM1V76*>M]5?IVV7?3
M\CRO6OA9X,\4?\)1!XMTR\\9:3XI\0>"O%-_X9\8:MJOB3PIIFO_  ZOO#^K
M^#=0\+^&]6GO=(\+2Z/XA\,:%XM \/VVGI<>+;*/Q+<0S:S(]X/.M>_9+_9I
M\1?&6Q_:&\0? GX:ZU\;K"ZTB^L_B=J'A2PNO%L5]X?LAIFA:C+?-;[+G5]$
ML(XK+2-7GA?4-.L;6PM[6X1;"U$7TS44V[8 N-Q8!<@'GKT/'&,GD' .&!P:
MIQ3:>S2?+Y2EI*2[-I):6MT:"45)23VDK/S2UA?ORR5]=]4[7N>-77P2^$5W
MK6L>([KX8^#+K7_$/Q+\*_&77]:E\/Z=)?ZO\6? WA#PYX#\'?$34+IH?-N/
M&/ACP3X2\,>%]$UJ4M=V&B:%I6G0RK%91+'B>+?@)\/+W]G+QM^S?X6^&7PY
M/PS\0?"GQM\+-/\ A+K6GW.E?"F\\.>)_#6K:)_PA^N:9X=1-1L_!VIQ:BUE
MK2:+&M]!I-S>OI:17?V=1^(?[7__  47_:,TOPI^USI_P5^)GA&/P!J_[+__
M  4PU_\ 9_\ C!:_!AO#/B?X>_$K]@O3]4TCX@-X9U+4/CUXJNOB\OAWQ;I7
MB?X?S^,M7^%OPNT7PO\ $'1=!\3V^F?$'PWJ%GI.M?L7XX^'?COQC^S1'X*^
M(.K7_P 5OB7/I=C>7,WPF^(7Q1_8LE^(6NV=[)K>GZ38^)_AU\4]<\?^!+-M
M* 3Q!I]M\1O$%IKZZ?J":Q'=:+J-YI*"CJFW=I2C%V^&$IJ:C'5V2481LK74
M(Z*R2-7:[NHW<5;X7)R<VNSFVKVZ12UM<^2/@'_P3<MH;SXS^+/VF0=>U7XM
M>(/V7-2M_!&B_M!_M!?'0^'8OV/?B-I_QD^$6KZS\?\ XT3:!\6/'.MO\5].
ML_$5_I<VB^'/#%GH.GVG@Z\T[Q/;W&NZOK'UAJ_[$G[.^M_%J;XQ7OA?Q*-?
MO?'WA_XL:QX0M/B5\1K'X.^)/B[X1AT:'PO\6?$_P/L/%%I\*/$'Q*T(^'/#
MMYI_C'5?"5SK46K^'/#>N3W4VL^']$O[#\@5A7XO?L(?L]: _P 4_P!HCQ!^
MUK\7OCC\7/V.?@WJ>D_M:?M4^&C\._&5G\7_ (M2_%34=7\7?#OXP>#I/VB-
M!_8T^#OPX^)GB'0_C'\3;KQ#XH^,6F?!S1+#6/$*>*?B =-E]3_:0\*?M^?L
M]>#/VAOB;X$^(_Q$O?#7PJ^''QMO-%\47/Q#/Q.T[6/@=8?"L:#\&O#OASX1
M:WINHZ[8_M _"?Q5':_%'QG\=-:OM1U?QVGAWQYIOBZZ\:6/C?P?IWPZK7Y=
MOS*;;W/T3UC]@+]E+7IO&-QJWPN>XF\??M)^%/VM?$TH\5>+[::^^-_@J'21
MH&KPSVVLP3Z?X8BN]*N-:O?A[8R6_@+5=>\1^-M;U+PY<:IXV\4S:OM:;^Q7
M^SYIGCG6_B)8>&/%%MK6M?M#:9^U1/IB?$3Q^?"-C\=]*\#:[\.;CQWX?\$R
M^)6\+>'+CQ+X=\2:L?&^E:'I>GZ%XT\0RKXJ\1Z9J&OPIJ*UOV6/@#^RM\-M
M#\/?%']G6#2O$B_%3P'H^I_\+M3Q]KWQ)\4_'+PSJ:Z;K^G^//%_Q$USQ#KN
MH_$^_P!6>[LM3@\::U>ZI?11:F+'3;VUTV_%G)]B4"/)/A-\&?A_\%-'\3^'
MOAQI-[HVE^,?B9\3?B]X@AOM<UO7I+OQ[\7?&FK^/_'NK0SZWJ&H3:?;:KXI
MUS4[^VT6PEMM%T>*X&GZ-I]AI\,-LGJP&X9!/'R_-SP,<CCG. ?<^F*EHJ)0
M4[IM[IJVCC;LUKKU A/'S <$G*M@ $< X SD@=2>E(,X.<E?XE)!&#VP4R5/
M/&2<''/:>D) ZD#ZG'\Z7(TWRRY;]4KRO?>\I27RM:^M@/FOXF?L@?LI?&9;
MEOBQ^S/\!OB1)<N\UQ/XU^$O@7Q'=3RR(8I))[G4]$ENI9)(V9 SW#-C!)RH
M-?'.O?\ !$;_ ()1:U"(K;]A?X'^"9DN/M2ZG\)=)U?X-:T'8;6QK7PJU?P?
MJODNIVM:&]:W",PVL,HWZMT$@#)( ]3P*<H<V_+*[3?/%33MM=34XNSO:\7:
MXTVOM2_\"EUWV::OY-'XPZG_ ,$$/^"8.IRQRCX,?%_398TVI)H?[9'[96@^
M60=ZOLTKX\VT1E4G:LC(7"_)GRC(##)_P0,_X)JWPCCU3P+^TCJMO;11V]K:
MZK^WE^W)=6]I;Q E+:WB_P"&A45+9&D=TB#L@DEF"[5XK]I.O2BLI83#2:E/
M"X.4X_#-X/".4=6_=D\(Y+5]&OQ"[VO)+MSU;>?_ "]ZGX]V'_!"7_@E[8)!
M#)^SUXGUJWA6-'M/%/[1W[3WBVPO8T)<IJFG^)/C#JUEJL;$E98]3M[E)U 6
M564D5[=X/_X)*?\ !,+P#J(UKPE^P#^R;H^K+Y*C5D^!_@2[U+$3(49K[4-%
MO+IY0R(Q=Y2TCKOD=BS&OT6HJU2BK\JA"]T^2E1A=/H^2C3NNNKT>JLQ7:V;
M7_;TGI\YRM\K'%^#OAWX#^'U@=,\!>"?!_@;3FP3I_@_PQHOAJR("HOS6NBV
M5C"3B*-?NGB-!]U5"]?@$ [C@##9Y.3SP2,]\9YP.F.34M%/D>GO/2UKZVMM
M;F<M5T?1; 0JA#JV%"[6P #Q]W &>WX#IT'2IJ**J*M?K=WO;7IOJ[O3?3II
MIJ!1115 %,D&4<$9!1@0,9.01CG(_/CUI]% >C:?1K=/HUYIZKS2/%/C%\(M
M$^,WA[PYX;U_4=:TFR\-?$_X3?%6VN-$:P$UUJOP@^(GAKXEZ)HU[_:>GZE&
MVA:SJWANTTK7TMH8-2?1[N_32K[3-1:VU&U\"^+O[&/AOXI>-?$_Q$MOB%\0
M/!'B[7=5_9YU[3KWP]:>#;VS\.:S^S3XP\0^-_!%_I&G>)_"&OVER-9UCQ1=
M)XNM=>AU>"ZL;.T31TT:[^T7C_=%%<]7"T:JES03YU:;]Y.2Y9QNI1E&4)I3
M=IP:DFE9IZGJ8#.\URSV:P6.K484Z>(HJDXTJU!TL6Z4L53E0K0E2G#$U*-.
MI7A4A-56G%M1;/BW7_V1?#/Q-?0+_P"-GC'Q=\7]6TWX/_%_X+ZK>^(]*\%>
M'AKWAOXO^+?AUXMO-5FL_ ?A;PM9Z-XC\'7GPP\.V?@W6/#MOI,^GPFZU2^7
M4M=-CJ6GX/AS]D;Q9H'Q/\#_ !+O/VFOC!XHU'P7X0\)^!+"Q\7^$O@9JUHO
MA[0;"UM_$26.H1_"6WUS1M5^*-[:_P!L?$?7=$U/3=2U&]>WL=#N_#_AO1_#
MWA_2/O"BL)99@Y<MZ3DZ;3I2G6KRG!QK/$PE*:J0E5J0Q#=6%2HI2A*T8.--
M>S.FEQ+G=*E.A#&P="I"O2G1G@,MJ451Q-.M2Q%+#49X65+ PJPK2C)8)8>T
M8PBKQ@K_ !9I'[)=CI7C'XD_%&Q^)_CNQ^+/C:"_TOP_\1;3PU\'[&_^&GA_
M4-?7Q'=:'X3\+0?"X^ M6;49(H-)UGQ5\0?"OC;QYK&CVUE;:CXMFN].TN]L
MJ/@K]BSP9X4\0_#WQS?>-/'_ (L\<^#/CIXL_:$U/Q-K1\(V7_"9^-O%GP6^
M)/P+GT[6= \->$] \-:-X:L/!GQ+U"XTW3_".C^'[@:WH.A:AJNH:KOUJ'5O
MN&BM(X'"PFYPHQ5_:OE?O0O6G&K6FX<L82JU*D*;G6G&564:<:;GR))8SS_.
MJD)4ZF8UI1GAH8-VA2C)8.E1K4*.$IRBFZ6%I0Q.)E#"TG##JM7JXAP]M.<I
M^%>*O@SH7B_XK?"?XNZCJ>N6NN_!VR\?6.@:39?8!HFKQ?$32]%TO5SKHN=-
MFU.2;3XM$M9=&.EZEIBQS2W9OUU"%HX8N2\9_L]S:Y\7+#XU>"?B?X_^%7C"
M?PWH'@CQ[%X4M? FIZ'\3/!GA;Q#JGBCPYH?B72O'G@CQLEE-H=]XB\66NE^
M(/"T_AS7K33_ !5KMHE^6EL)[#ZBHJOJM![TXO\ >T\0K.<.7$TX1IJM'V<Z
M;C)QA%247&,TFIJ:;.:CF6.H2HRA74E1PM;!1IUJ5.OAY86M)U)4:F&K*I0J
MQ]K:NO:PFXXB,:]-TZL(2C^:Y_X)S?#=/AE\8/@S9>-_%^G_  N^*?P]^(/P
MXTKPW8^#_@I::I\-/#7Q%2_M[VV\%>/(_A0?B+?1>&;+4'L?!UGX]\6>,[73
M]-M;'3=7M]>L["TBAZ'XC?L(>%/B+:?$;0[OXE_$;1?"GQ?^*>L?%/Q_H^C:
M/\+9KZYUC6=-\*:.;7PWXJ\1_#OQ#XH\#?V38^%430O$?@O5]#\86$VN:W<1
M>(/MG]AWV@_H/167]G81PC3=&+C!W@KS7)92CRT^6:5*'+.K'DA%0M5DFFK'
MH4^*.(*525:GF=2-:=:.(G4^KX2;GB8SPU3ZS*-6E5@\0ZN$P]=XAQ=9XFE'
M$S=6LKRK6:>7;QH%90H "L79@  !N:1Y'9N/F9G8DY)8GDV:**[ON^6WRU?Y
ML\%N[;[MO75ZMMW;U;UNV]6VV]6PHHHH **** "HV+!@20$!&, Y)((^;T Z
MYZ<\CC-244 ?S=Z!_P $]/$?BKXP?LV^(/B9\&OB9J^C?$#XS?\ !16+]K6X
MUOQYXTDT[Q9\)]5U7Q?XE_9E\*_$NVM_'$4.J_#2+Q-I_@KQ#\,O!:6]QX?T
M#7['2-3M-'TN^BFN4\[?P)\?_P!GK]A?]O+Q%\6O#'Q.\,:]XI^!?[%'PY\*
M7^L>(9#XR\;:QH&G3?#34?"%OK0UV/6]<U%TU31O"&JV3Z[9:UXAM]5?2;'6
MEO[Z.]7^H<]#CT/O^G>N<\1^&-"\8:%JOAGQ;H6C^*/#>OV%QI>O>'?$.EZ?
MK>AZUI-["8;W2]6TC4[:YT_4=.O(OW%W8W5O+;W$./,7(.X _F)_9?\ A<O@
M3Q!%\</A#\"O&FI>(?V<OVVO&GB_]I[]E'X?_#_QCX?\3? :S^.G['WP_P#"
M7P]L/@AX=^--W!??%C_A5GAOQ#I?Q3$JZ;X&U35Q\6_&M]X8^&6B0S6/AVX]
MB^.\O[5WQ&_X)V?MU> O%W@?]M7]I7Q+\1O$FM?#+]DNX^+O[/GP<\,?M$OX
M3U/X3_#2\U_4/&WAKX%_#+X%>#?"_A";XF+\0-,T3Q%JGA/1]0O-(MK"SU*Z
MU-5M;BX_?7X8?"CX8_!3P=H_PX^#GPW\"?";X=^'8YTT#P'\-/"6@^!O!NB+
M=3RW5T-)\,^&+#3-%T_[3<S23S"ULXA)*\DLFZ1RQ]#H X[P!XN3Q[X0T+QE
M%X>\7^$X?$-G]OB\-^/O#MUX3\8Z0IEEA^RZ_P"';TF[TJ\_<^:+:Y_?"&2)
MV.'&.QHHH ^1/VVO@O\ $C]HK]FCXM_ ;X8>*-'\$:[\7M%M? &L>+M8N=8L
MQHWP]\3:U9:;\47T:?1--U.^3Q-?_#Z?Q!I/APLL%L-8OK6>YN].MHFN*_+[
M]I__ ((QWNO:?=V?[)GQ7\6^%;KQQ^S3XY_90^)<G[3WQY_:6_:$TR+X8ZA>
M>%_%'POF\$Z9X_\ &GCUM';X<^-_#DNH2>&-#U#P9IFM:3K>HV::KIMUY-Q!
M^_E%82H1DJJ;_C<OM'9<\H1]E>C[1)5%AYNDISHJ=O:2J3C.'M)Q;3V4DJB4
M*D%"HN>E^\<N:7LW9<W++E6NBC&VVOY1^%/@5^W#8_&3XI_M;>/-"_98\2_'
M>?X#?#O]FKX6?"7PK\6_C)X.^#NN>&] ^(6J>-/'GQ6\<?$W4_@/XY\;>"-=
M\87>N2W_ (8^$VC_  R^)UGX$@T:V\,ZA\9/&[:Q<^,M+]G_ ."<GP;^/_[.
MW[,G@3X$?M :'\'].UOX56$WAKP[K?P=^)OC?XCZ3XPT2>_NM:DUW7(_&WP5
M^#-WX1U==1U2[TZ/0+&'QI:2V5G%JI\317%_-I5I]ZT5T-N33;VBHKK9<SE*
MW^)O7MK;1I1S4$FFG9Z)NRO*$*:I4H.VZI07+%[OW6]8MR*@D!+'D@"/=QDY
M()XX]<^A/%3T5,E=6O9]'O9K7;J6<MXF7Q&-!UY_"<>D3>*%T34CX6@\0W%[
M:: _B+[!<'1DUV[TVUU#4[?2)-4-DNIS:?975W#8"YEM[2ZN$AA?\./#7_!'
M76?AI\$_V4M:\ ?&CX@:]^V=^SG\2? OQ>UOQO\ $C]H3]HS7OV??&?CGQ[K
M-_:?ML+H_P &M6\0^*?!'@;2OCGX"^)7QRT?P]<^%_AOI^KZ1J?B307NKBSM
M)-?-U^^%%**<:BJQE:HG2=[)I^QG*<8R3TE3DYR52F]*D'R2;CH3.,:D>2:Y
MH<M6$H-OEG"M3]E4A.S3E%PO&W,MWK=MGX=? 7]A/]LCPI??L0>&?B_XJ_9J
MOOA]_P $](/BUXQ^%NM_#:_^+4'BCXZ_$[QQ\(_''P9^'>E?$7PIXH\+_P!G
M_"'P5\./"/Q/\>7'BW6O#/COXL:K\5/$#^'-3TSPI\*=)TC4/#&M>R_L)_ ;
M]L[X0_$#XF^.OVIO G[,OBCXD?'C5)O$_P :OVC?AU^T;\7/&OC'4I] 2ZMO
MA=\)OAM\&O&?[)GPZTCX;_L__#32=0OM+\%^!?\ A=OB2^T.[U3Q1XVUS5/'
M?Q \<^,?$FK_ *P44HTU%6CHE&M&*=W%.NZ3JR<;I2E4="CSO3F5.*=E=-.G
M%QFK*+J.BYR@N5VH0E"G"+O)PIQC.;C!-I2<9\SE"+*\(.XMV*XSC&2""..V
M 2 /;TQ5BBBJBN56NWVOLEI:,5TC&UHK5I:7=KNDK=NK=E:[;NV_-]7U/B;]
MO7]G#QE^UQ\!+W]G?PYXEL?"'A3XE^/_ (5Z=\;M:?6/$V@^([GX Z+X[T/Q
M1\7/"O@#5O"L+7]AXV\?>%]%F\ Z;J,]YI-II.G^)M6UB/5+?4-.LHI_SI_:
M"_X)(_$23X@^(_%_[(/Q@N/#\'Q;^'WPTT;XRI^US\7?VF/VDKJ]^(7[.'QU
M\#_%[]F[Q=H=YXR\>>(_%]QHN@:'=?&WX?\ BKPM:_$3P58?V?XQT/4]%)U6
M+6;JX_>^BL94(S4E)Z3G&I)Q2C4FZ=6A5ITIU(OFGAH/#TU[!V33JKVB56:;
M>L7!ZQE3KTW'2R6(C.-::]VZJ3C/E<TW*R5K-)K\BM _9C_;'C\9?M0_M*^+
M_#7['7BKXU_M!6W[.?PU'[-_B+Q1\5_%/[/,?P&_9[T[QX\FAZG\:;_X4:9X
MJM_B-\0?&GQ4\9^.O^$BN_V:_%WA?P+I-EX9^':^%/&]]!J7Q,N?>?V)?V;/
MB%\#]6^//C[XB6_PS\"ZK\?O'GA[Q?#\ _@3JOBOQ%\$_@Q;>$_!MCX(CM?"
M'B?Q=X6^'-WXDUGQJFDIXK\9ZOI?PE^%&BIJ5S9:/:^$K^[TN_\ &GBO[\HK
M;7F<V_>E'E:6D$FH)\M-.T;N+FVW*7M)U)J474FI2XIJ*:5HNE*ZTG*5""I4
M7*::;C&C&--P:Y9QA3O;V<%$JO.#\I!Z!@1@G.=O8?3Z#-6**&KJU]'OHG==
M5JFM5=7M=7TU*^_Y.SW3W7I]UUU9^=/[2W[%.L?M2?M0? KXB>._'_C/PO\
M SX _#CXH3^&O#WP<^,OQD^"'Q6U7X_?$F\\/^&D\5:CXP^$NM>"M5M_!?A;
MX4V/BG0[&PM?&+S:SJ_CS54U31_[/TZWEN_BCX8?\$YOVM/V2?C)I/B[]F+Q
M)\!?B)\&/A3XR_:4N/@Q\)OVA?B7\?+;QQ=?#;]JB3X;_$7QSX'\1_'&W\)_
M%O6O#FL>%/C[H_Q)\9:-XTUSPE\;[GQ5X3\4V^B:WIVE>(9Y?%.E_O;16:I1
MC&K3BHJE6Y_:4Y04XN56LJ]2HN=R<:CFI*,HN/)"I4BE:;1,XJIR.=VZ;IRC
MRMTTYTHSC&<XP:4Y/FBYN3M-TX-JZ37XAZ%_P1[\(-^S!I_@SQS\2/B7J/[4
MT/P3_:"\#7_Q:^%?QW_:2^ /PWO?%'[1_P 2?''QS\<Z3+\//AA\3-+T_4OA
M=;_%GQQ(;?2_%&E>(];UOPGX?T:U\0MJ<\3VZ_HU^QY\!KW]F/\ 9>^ /P$U
M+7M5\3ZQ\*OA)X"\#^(-<U+Q=XP\<IJ?B+0/"^FZ;KMQH_B#Q[>WWB<^&/[6
MM;L>%=*NC8VNA: ;'2;+2--M+6ULK/ZBHK5.:C.'M).%2K3JRBU%^_2I2I0:
MER\RLI7U;^%+S%R1O3=E>ESJG96C&,W>RBM+)N;7;G=M;MPHOW3@Y(.?0%<C
M)^IY&/UZU-1122LM7=Z7?>RM?[K%VM_6[[GPQ^W/^RQXF_;!T'X'_"=_%S>%
M/@KI'Q^\!_%C]H2WT/Q7XX\$_$3QCX.^$::IXY\ ^#_A[XK\!S:7K7AK4Y?C
M?I7PP\4ZOXAL_$OAS5=,T7PE=C0M075;JW>'X3^*/_!*;XC:?;_MB>$?V;OB
M^-/\"_M8>"?V=/$4]Q^TQ\2OV@/VAO%WAW]I/X#_ !<T?7+KQKJ6M>-?%NN^
M+-=\!^+?A-H/ASPW?Z';_$+1]4M]<\(Z3;Z7/I&E7TVHZ?\ NG124;*25H\S
MJ.<HQ49S]KR752:UJ*"IQ5)2O[))*#26JDN:U]>5TY0T^&5*=2I!KTG4FWTD
MIS3^-M?DCX.^!O\ P4"\)_&7XX?M?SZ/^QYK7QV^+>A_LY_!%/@>GQ0^..C?
M"6U^ GP"A^.WB"[\0P_'5/@KJGB_2/BUX\^*/QZUKQ5%HUS^SYXM\)>"O!'A
MC3OAW'KOBG6];O?B=8_1/[%'[-GC?]GKP[\;=>^)FK^#KOXH_M-_M%^./VG?
MB3X;^&T6KR?"WX>>*?'FA>"O"J^ OAWJ&O:?HNO>(]*T7P_X#T.\\1?$#6_#
M_A/4?B3\0]3\:?$2X\$>"1XIC\(Z']RT4HP48QBOAIT5AZ2=W[.BIRJ^SC=_
M"ZLYU7IS.<Y>\D^50Z<6T[>\JSQ%[OWJKI^RO+5<T/9>[[-^[=*5[H****LT
M"BBB@ HHHH **** &O\ =;/3:??L>PY_*ORA_:U;=_P4=_X)B-@@#_AJ-><$
MY'@+PD&^568@(P&\D!4) 9@>*_5R9%DAEC<%D>-T=064LK*58 J58$@D JRL
M.H(.#7\C'[<=E^W[\(_^"B/[/WP@^'?Q-O/&-QXDUGQ9J'[&'C[QSX>TOQ'J
MW@G1/B[%9>&/BAX9\4ZY<Z:D^O'X0)IBWT4NH+JE[!X.N_#6L?;KC6M9OK*S
M_0?#;(WGN?8W#PS/+,MG0X<XDKN>:UZF$H3H?V)F%"O4AB84<0G+!QQ$,77P
MZHNO5PE*O+#2E5A[(_-?%#.7DN1Y=6>6YIF-.KQ'P]!QRG#1QF(IU8YO@JE&
M-3#2G2DZ6)<)X:-:%1^RQ$Z+J4_9.52']!O_  48F1O^"??[<(!)_P",0?VC
MNQSM;X/^,8U90,[@S@#*AFYR5XKZ7^'4@3P%X(+@>7_PAGAO]XN"I8Z/9@!<
M'<QP"5VC!P-I.5#?AS_P55^''[2GP'_8\N]<^&/QM\;>// T_P +-=^!'[6&
ME?$!=.\47/C[PQ\3M.U+PWK7QAM7ETY3X2\61ZEXCO-.O+SP_+I>EZ7I.IZ1
M;V&D16NAKL^N?^"7:?M*^/\ X&:-^T)^TS\0=1UK6OBQI.DWOPR^'MKIUEX;
M\*^ ?A190>3X5O8]%T^TLQ/KOB_3UBUN\U6]FU">?1I-$\N='GG"?CRQ]./$
M=?*:%*>(]A@)-XM1=*C7PZQK5/$4E)SE'VRYE3I5G'$1J*I3KTX3IKG_ *A?
M!U6/@E@.-ZN=\.QP^,XYK8>GDO\ :%:IQ)#,UPUA<+B,MJY=' JA".%M+,*N
M.AF%;"0P%7"XE.I*O3PQ^IT!4AMN?O=^XVKM[D_=QD'OGZU-5>VSL8YR"P(P
MNT ;%Z=R"?FR<\DCKFK%>^MO/K:]K];7Z7O;RL?DZV6^EUJTWHVKMJ^KM>VZ
MO9V::11113&%13+(R[8]N2>=W3 !XP 2<GCL,9SD<&6B@#P33_V7OV<=(\;^
M+_B9I/[/GP-TSXE?$*:_NO'_ ,1-/^$O@"R\<^.KK5=&;PYJD_C#Q;;>'X]?
M\33:GX>DET/4Y=<U&_DO](EFTJY>73Y#;5GZ]^R-^RSXG^#>B?LZ>)?V9_V>
M_$?[/?AEK.7PW\"-=^#'PWU;X-:!-IEW=7NERZ+\+]1\-7/@?29-/N[V\N[-
M]/T&W-I=7U[<6OE2W,KM]%T4 >:Z-\(/A=X;F^']QX=^&?P\T*X^$_A75? O
MPMFT;P5X9TJ3X:^"==B\.V^M^#OA]+8:7;R^"_"NLV_A'PK#JGA[PX^G:3?Q
M>&M CO+2==%TL6GH!AD+?> 4,& !8X(# $;B=N!M&%"KGYAAAFK5% 'S_P#"
M[]E7]F?X(>,_&/Q&^#/[.?P%^$7Q!^([S2?$?QW\+_@_\/?A_P",O'\MQJ4F
MLW$OC3Q/X3\.Z3KGBA[G6)Y]4G.N7]_YNIR2:@Y:YD>0_0%%% "%@O7OG],9
M_F/\YK.U/6--T6RO=2U:\MM.TW3K2YO]1U&^N+>TL;"QLXGGN[R]NKB6*&UM
M;6WBEGGGG=(XX8Y'+8C?;<ESE#Z;AC&<D@8]QCJ<=0"/2LV\A@NDE@N8EEMI
M8I8)X9HO-BFBGS'+#-"X>.2WEB+PS+(CHRN%!Y*MFY\CG*2<J<(W<(N$9MQ3
ME-*4KQBY1^%U5RIJ^S9$W.S5-1<VK1YHSE",I*:@YJ#C-Q4U'F4'S-.VC<3Q
M3]GK]J?X#?M5>&O%7C'X ?$"T^)/A7P9XXU'X<Z_K^F:-XDTO3(O%VEZ-H7B
M&\T_3;CQ%H^CCQ#8C1?$VA:A:>(/#PU3P[J4&H)_9VK7<D5RD/)_M0?ME?"+
M]D/P[IWB_P"+^F_%$^$;R#4KS4/%G@7X4^./B#X9\)V6ES65K/?>.=?\*Z1J
M&D^"[.XN]0M;2PN?$=YI\5_=.\%JTKQ2A/CS]G;P+^TE^S!X7_;V\4>'/V<I
M/B#XI^)?[>7BWXE_"+X;6_Q'\!>"+?QA\)?$_@_X+^$K?QC9>(+F]U71=!L]
M)AT#Q%<IH&LPZ;K=Q!H M(M.MGNK-I?9/^"FOPC^)?Q[_8!_:4^$OPE\(W'B
MSXG>/?A]I>G^%O"%OJFBZ?/J>K)XH\-:K+I\6K:W?Z9H<<MK:65Y()[N_L[>
M7R.) \L;2?7X7+LFAQ5E^$Q56-;AO%9M@L%5KO-L%#%4<+B?[(6*Q%>O@G/V
M$<#',ZM=XJ>'IX2LL*X)J%/%NG\5'.<^Q7"N-Q4,/]3XFP^6XW&1PZRK&SPL
MJ]"><0PE"C1QT8.M/&2P&&@J'MY8BE]8YIW=7#>T@OO^"G?[.>FOX-L;WPC^
MU'%XE\=:3XO\2:#X$C_90^/U[\0SX/\  >IZ/I/BKQQ?>!-/\!W7BFR\&Z7>
MZ]I<;>(9=,%C=+=!K*2X"/MZF]_X*1?LA6]K^S-J>G?$Y_$>A?M;^)9?"7P6
M\0>'?#WB#4='U37X=3\/Z'+IWB:9["WN/!-Q#K/BC1M,NH/%5KIES87D\Z:A
M#:)9W3P_//[2?A#]HSP=^W'^S[^TO\*_V<O%O[0.@^!_V4OC/\(=6TOPGXY^
M%'@F>Q\=^-O%_P /M=\.V^NZE\2/&OAI+7P_<)X6NTU76-%M?$4U@)(;F#2K
M]HS"?SAUS_@F5^UA+X"\-^%]0\$^'-4\;Q?!_P#;)^/$=UX+\4Z'9^"/ ?[5
MWQ4^.'PR^.'PB^%7AW5-?U31M4N+'3M8\ VNDS^(1I$7AJVL#J4)UC[-'!J%
M[]5E7#_ ^.IY7B,RS*GE%#'4_:2]GQ!A,35I*M+BJA76+PF(I?7L#'):V X9
MJJ=:E0GFU',L52ITYUHTYP^-S;B?C_+IYEA\!E=7.,3@:L:;<^'L3A:3C"GP
M_B</+!5Z-6IA<PJ9K3Q/$%"4*-;$4LMJY?1J5)4H/]Y^^?PD_:]^!WQO^+_Q
MU^!OP[\1:CJWQ _9RO= TWXGVEQH6IZ=I5C>>)+CQ#9V$6C:U>0Q:?XA$5WX
M6UBVOYM*FGAL9X8XIW5YT!]1\!?&;X4_%*T\17_PY^('A3QM8^$O%NL^ _$=
M]X<UJQU.RTGQCX>$!USP[<W=O,UL=3TK[3"M[!#+*8)"\3D20S)'^3'[ G[)
MWQM^ G[0OCGQ-\3O JZ?H7Q6_91^&C?$;Q-;ZWH&I:1JO[0%W\4/B;XU^)?A
MQ;2RUR[U<2V$?Q&G$-XVGW&C7%O!+;:9K;Q)!%<?$>B_\$U?C)9>'_$/P=N/
MV9K_ ,.^'I?^"D&A?$OQ#X^\(?$;P;8:;\0OV6=0B^(-I8?V5/IOC2S\;Z/I
MO@'1M<U#2-3T&]TO3O$%Q:>/I;73[:XD&LPZ=RUN%^$*^:9A@L%Q.J-#"8#A
MVKA\7*> Q.&Q%;%4,RAG]2$JN*PD\1'#8K*U/ 8?"5'4JTLVRUU84J-24J';
M2XRXXI9;E>+Q'"/UK$8W&Y]2Q>%4,9A*V#A0KY?+(J+]E#&TZ3Q&&S.^+Q>-
MC1I+^RLRE%*K&G3G_3]'JVGS3"WBN[:6X:)9UMXKB"6=H&8*DZQ1R,[0ON4K
M( 4(8<@\4V#6-/NLFVN8KA0HDWP2PS(8R'*R[HY& A;RWV2MMC8J0&)! _GR
MT[]DO]JK1/\ @I;\.?B_H7P*'@;X-_#GXQVWA.Q\>_#[Q3\.(?"VN_LN:-\
M)/AUX/A\9R:AX\'QA\2Z_9ZMHOARQUCPC=>#;7PEX=GLK?5-).N3J-;E\)_9
M._X)Y?M-_!/P3\"YKGX/?%'PKXCUO_@G?^T[\'?VE4\"_&'P3I7C:]^)^IZO
M=0_!7PKH.N:SX[NO#.F>-+30H[#_ (5YXHM4/A'P7?-'<ZQJ6FQ2ZPPXUP=D
M\<%'$5.,<JC6JY=3QE/#P>#KSI5O;XMU,)B94\?2C#$/ T,/6A2A&4_KF)6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?C^&_C;1M#N-/^)?CGQAK'@+XBKHWA#3[73)K"Z\!Z]HWB&]TG6I=+L+R_\
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MZE*([/3HVFN;J2)8YF/Y%Z9^S]\>Y_\ @C'^TC\!F^&/B>S^*5^OQ[\/>"/
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M#WCS5;J&P^'FBPV5O8^";JQD\.:9I>C06'VF;RWPK\ ?V[?A5\)U/@*]^/\
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M,Q&88?*JF)P^+RO"9EEF(Q.,P.4X>M6I8AYG#^F=7VLQSG<1P1E5;!&PD+N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>79
<FILENAME>tm2135630d1_drsimg6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #) E@# 2(  A$! Q$!_\0
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M!\.W&N65SXWD\.ZGXF6#Q%=P21KH6D?V9H]\[:E<"6(3*B-&%W.OT_7Y/_\
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M5OQV_94AT#QKX@\*)K?Q%USX SZ+;>+/&O@;2M-U:YO;_P *7/\ ;-M-%#-
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MXG@U76+'3K?2],@L[6\B@AT^SB1+>/U*F 4444 %%%% !114;R;3C /RYR6
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M1110 4444 %%%% 'Y:_\%#_^"P_[$W_!+K6/A7HG[7/BWQQX9OOC+IWB[5?
MZ>$/AWK_ (WBN[/P3=:%9:^;^;14==.E@N?$FEK!'-EKA9)'3Y8V-?G'_P 1
M;_\ P1@_Z*K\:/\ PP7CO_Y'K\+_ /@^,_Y*9_P3H_[$7]I7_P!2#X+U_![0
M!_K)?\1;_P#P1@_Z*K\:/_#!>.__ )'H_P"(M_\ X(P?]%5^-'_A@O'?_P C
MU_DVT4 ?ZR7_ !%O_P#!&#_HJOQH_P##!>.__D>C_B+?_P"",/\ T5;XS_\
MA@O'?I[P#_$]!DD5_DW 9SVP,_J/\^OUZ4E '^LE_P 1;_\ P1@_Z*M\:/\
MPP7CS_XQ1_Q%O_\ !&#_ **K\:/_  P7CO\ ^1Z_R<@$*J20"<YXS@]/N].F
M#WZDC!IIVC&&#9Y(VXQSTYZ\ >W) H*<6K.ZU2>C5]>EM[G^L?\ \1;_ /P1
M@_Z*K\:/_#!>._\ Y'IA_P"#MS_@B^26_P"%K_&G)X_Y('X[X''3_1^.,_\
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M'EBY2E)I.*;/ZCXK^C7X;\.\#9/GF$\0)9[G:AGSS^A@IQAA*=? QP<LKPN
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MGZK-?^%]7%QHLV;VQBB@ENA&EW;!_P#&GA_UL7./WB<^GS#GBOZK/^#LL?\
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MC5-UJ56>&]E*7^J\G_!V[_P1@08'Q6^-.  !GX!>/,X48'/D$G/7DY_E3_\
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MP7K^#VO[PO\ @^,_Y*9_P3H_[$7]I7_U(/@O7\'M !1110 4444 +^7Z=_\
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M3G!++]X&N:)S[#M_+^GYUV'B:6<W6Z?)#8>W:1/+9D(PK-N)RBKC: 0"I7
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MHRY9I*<>:,9<LHWC%W2****9(^/_ %D?^^O_ *$*_JN_X.S0?^&J/^"?&/\
MI%M^SZ/S^)/QM''N,YXSCKC K^5&/_61_P"^O_H0K^JW_@[,_P"3JO\ @GP.
MH'_!+;]GPXY_Z*3\;L_RH _E7"$$$J"&' !)!V\[>%()(!4#MD@D' J>TRDO
MFK&7900BD#8S,& 7'5SZA2&S\N",TEN-\R1 _?95( SD<Y^APV 01Z'H:](N
M[/1]+AL+2.2XDED:&XFG$2#][(N+A<[BT:6\X,<9948D%F8@BN3$8F-%PA*$
MJDJBD^6-TG&*;E=QU6B2LG=WT:W//Q>,5!PI.G.I.LI\L8IV<81E*;=O)6WN
MTW:UKG'7\%Y']GNKJRCC,^)HF6-8H9%MP$9 BHBL4.U67EBQ!;<,L+VI^-M:
MU*SM[&8V5M!;(L4*:?8P6#1PKUBS;; XD8!I7D1I9'&7E.3G2\>WL<LVE6EH
M EO96&TN7#2W$\D[O<7$S!C&6,C+$GE97RH8LY<.Q\\.6)XR>Y]?<\X&?;CT
MK/#1AC,/AZ^(HP<ES3HQDG+V:YYI<JD]/=2NGS6O:[,\'3HXW#83$XC#4I3C
MSU*,:D93]C[\XKDC4DXQ?+%)IQG;;J=+;>+->MHY(H=7U*%'8.1'=R(';=G,
M@610<98JP7>&.0PJ5_$5YK6VS\0:C>WD+S PW,[O</8-N<^9"KR#"LSLTR\[
M@S8P<L>4![=CUZ]._0^E*I(.0.1W]#R,CIR,@@<\@=1Q6[PF&YG.-&E3J-J2
MJTZ5.%2,DK)QG&DI)]]7S7:DVFT^EX'"<WM(8>A2K7<HUJ5"A3JPFU;FC4C0
MC-/O>4KJ\7[C<7TE]9:KH4CO!>,;21I(8M0L9R;6ZC'0!HSDLRE?W<GSID ]
M 3AS3S32>9<323/A06D8NVT * &8] %Z8''J1D=%H,WVF.XTJZ>0VLX,NU$\
MZ194 *^4O168(1O(*K@;NG%+7=!U#0+U[+4(QE51XY5(:.5)$$BE'&0" PWJ
M2&# @\<U-.K"-:5*K[&.(UE"2483JTDE[UOBNF_>BI-)ZQ2B[+.E7IQQ,L/7
M=%8OE<J4E&,9UZ$5%N4;^]S0;:JTU)Q6DXIJ7+'$+*22<DELC@+P1SQN8*2?
M3/KP<8>K)W.>.21R/E;('S'YLG"D\\@\?>$'ZU+$K.ZQJ 6D81K[ECC''7KZ
M9'%=?-UE9I)WYKVTZO5:I+?LK69WMVO)VTU=]%9-R;=K=+\W=?>?7?[)?@CX
M"^(O&&K^)_VE=7\267PF\'Z4]Y?:-X-N;>U\6^+M<G?RM)\/Z)+<PW$%M$3O
MN-0O)8B(+9,_,TA5IOBA\5/AP/$UW-\#OA[#\*_"=O/*FD6+7\GB#Q+/;@B.
M*]UKQ%?@7,U])""TZV4=G91R'%K:P O7@>JQW^AV.GZ+<N;?9OOIE96B+37)
M!9&!*ER%7:A/!&.*XR6]8O(3EL[@"Q).TJ5/IUZCCH"0#U'QBR&&99WB,_Q.
M:9GCL/.A#!X#)YX[$QR+"8>A*I&6,CEE/V6&KYACJDY5JV*Q57$SIPIT*5*E
M2C3O/\__ -68YOQ'BN*,9G>=8_#U<-1P&7</O-,5#AG X;#.K&684\HP_L,%
MB\US.=6=;$X_&5L95HTJ>&PV'HX:-*3J=_J_B6XU@I=WEY=712Y7,4MP[2(-
MJ,LZ1D@!E?S,,&8[A@!02Q]!^$_Q+MO!^J)=3112B.6.Y#7[#]Y<V["2$22*
MLI5)&6,R*T9CD"_.@8AC\YFXD+APV,?=(. I&!D<GG(W<$@?+ZFF&21OF8G/
M ))YQR>>1SGH3DX/&<5ZN*R'!8W 5,MK4XK"U:;I.$5&FG3DI)Q?+&%[\TDY
M>Y)N3YI-V9[6,X7R[,,MK93B:48X*O2E2E3IKDM"=U*,?9QII.TIIR2A*]23
M;<K3C^A7Q#^.FK_%#3=3U76I8[O7[I;>VL7!EEM+?3(+?['%96\<[*L;PPNC
M2/;(T3)"$*I''&J_$VO66HVI>74X)%:1ML4A2()*B'Y" C,PR=J]MR@MZ@=M
M\)--UWQ7K-GX-TG3+[7KO4I8S::?8QR7%W!%&C/>7,2Q*\UO;1JS2W<I"0B.
M(MN.PUW?QI^&?B7PM96FH7^DWUMH[SO86U_<^<UI>369\J9[&<Q+!/&K@J?+
MD?&0226%?*Y/ALGX0S*CPW@OJ>%CB8*IA\*I*$EAU&U%8:E[=3I4Y2IN$*<J
M4H5.2M.,IN\U\3D.$R+@?.</PE@/J&#CBH^VPN"C4A3J4\*H^SH4L+1=>56E
M2G*E4A3HN#A4E#$5*<ZDN>:^7VF8 JNW ']U3@\!L$@D@@KZCKCCBH0A<\ \
MGJ>,]3@<$9VC.2>0">QI\HP2.<@ '(P!R!ZDDC&#QQ@CKFDCY(&. -Q)&3Z9
M XR!GISW)R.!^CP4=VM&KVO:_E>]HNU[7TVT=T?K<5>UE>^MM==&]-&]>CL]
M[V.HN?!/BBPT6S\17N@ZK:Z%J"&2QU>>PN4TV[VNJE(;\P-;,Y)X0RH6 )5'
M4&N8ECV.0<=!QSC/TV1GL> @QD$Y&2/H#X8_M(?$WX8Z1K7A32-6@UOP5XAE
MT277?!7BRQMO$'A;5E\/:A'J-C#/IFI1W"VL7FIY,RZ<]J]S [6TK212E'\T
M^(/B'1/%7BC4-=\/^$+'P)97BQRGPWI5U>WFFV=UY9:\>Q-[YD]K:S3$RQ66
M\PV,;BVA*PHH'G86MFCQ>(HX[ X:.%BW+"8_ XN56-2D^6U/&8+$TZ>)PF)A
M*4HJ5&IBL'74'44Z$Y>Q7E8/$9S+&XK#9AEN%C@HMU,!FN QLJL*U&T6L/C\
MOQ=&EB\#C4W4C!X>MC<%B(4I5W+"RDJ*X,T4YA@_@#]<@<C_ "?>FUZ)ZP5(
MFW@=R><@ 8RIX)/7KP0!P,9+$5'3@#@^AXS@X)] 1W/0>Q.<52W:LG=/XG:S
MWO=M:JSMKKJK,#^H+XQ+*?\ @W,_X)EM;R0QW*?M<_M:/:M<N1"'%ST<;2Q7
M;N!52".>&ZK_ #]_$3Q8O]G)HT<EK<WL\:C4EB)=;9D8.3'*0P)D(*[6^<#A
MD7&#^W/[5%Q-;_\ !MW_ ,$LWAEDB/\ PV1^UN"T;,G_ "UD +;>N,GWZXZF
MOYTV=2Q+/NW%F+,S;NX^;.[:3PHX)&2#P"!_:G"?TS.*>!/HOYM]'?@O*,5E
M%?B;$<4X7B?BF>?2K8#$Y%Q)GD,YKX?+.&?[/A2P&>U,+S\.8G.J^98A5\AJ
M?5J6!H8A4\9#YO$</T<3G5/-J\XU%0A1E0H>R7.JM*G*E>=;F?-35_:QI<J_
M>VESNUA0%>8!<?*68@X(+!2Q!!P!'D,H;J P^4@*#MBTU&]@5H]/#0C]TC+$
MH DE;Y$,BQAFW$$1!F!()"],5T=KI^CZ?HLUY<O+)>7T<L31[49;5(VBE01C
M*,)9@")6;=A0%55W&NRTR2W_ +%L+:UR9)9XK@RW.0^U%Q#$J#*A =S?,F_<
M!M.#@_R+P)D5;CWCKA/@_"QJTUG_ !#EV35\:Z<I+"X2K5IK&XNE#VM.%6="
MA3FJ'M)1A5KRHIR2<FC'9S[&*GAZ-2<88CV#JU8U(4W:#E5FN5MN,)1<+R5I
MM7BTC-MY;O3-(.@0W%K;VX(EE,5A%'--,R+FXENCLN7EC)8()&*@",B-6SG6
ML-2@T:R,6G7ET]ZZAY[P7#EU#G+E70MM9FPA"Y,B':3&@93B:S9M$Z1ZC=6T
M"SRG9;1L6G,9PHF#Y("DY&UF+9!Z 5<TA]+TX-;6DYO)&)*1^7NWX Z,QS_$
M0>,+R<[A@?ZJ<%>$7AWPAQ=Q#P]1X"\.^':>)PE;(\QSCCF&79UQ;A*^*P_M
M:.#P?">;8O.*L\WS6BHTZV.C2HYFJ==QAA<+[6C*?SF*A#$8=5)PEB'B*BQ%
M2G1HQ='%36CJUZTHS4N5:)-*FU!1<96:4][XS@ELI;+7OM%Y9,CH]L^27>=2
MOGJH92)X>&@D+,JNBG:1UX+7?#ESHA@U31=0?4-'FA2[MKRW)CNK0,<_9]1@
MCYMKJ!BJNZL\#DJR2%6PG9W]GI=[<Q331N^TLA\O ="&R=R ' '0G@$$G(ZU
M*VGRVT\WV**=M.%IF25PZP@E2V-C!E,;#.%('/S9!YK\\\;_ */^=<29/GV8
MY/E?AW5_U56 PW#N+X.R>CDN<X[+*&%S#&8F?%6"RO!0P-3+W@,'4P<,PJTX
M_P!B8O!4YXG%UZ>.KX:EOE^*P^7^SCA:<L/&KSU,7A*\8?4ZMW&/[I:.&(5V
MX249*I&2ISA*$82CYII5M<:_=K%>7EP\, ,LKN[NRP[^1'O) FE9G7<PW-D;
MF"DY]"MM<M/#Y*Z'I,$;JX0W=TKR7D@! #C<-JLJ@D^60"V $X!K+32Y?#5Q
M'J$JN^AZK&\*W)PKV\@G81M*AW%(S)'E>@=0=I&TD=GI]^;S48[2XL+>:-54
M6]Y%"K)*"H\N1G&59GZG!/.<_,*V^A/D_#>/X6RW&\#\9X#@CQ4S3BR>15>)
M8<)T>)\_R>MC%".383!UWALPJ\(9;7P'M\3#-L-ET89IFDI8/&YQE5?#8:-7
MISC&0KI5(TGB<LA14X8>G5>'IRE!R]K[:E"5.G4K4Y6BZ4VHTHI.G3J)N0]K
MJYU6#^TKJ\N[64V[)]EVGR)6 VKE&<8!*@G"@[F)QC 'LO[-_P ,? WQ(^.?
M@?P[\5OB#<?#;X3+I^H>*?BAXBM%@GU?3O"_AZ-KF\M]"M[F": ZWXBE:WT7
M0[<B4IJ%P;F6 V\1*>2ZF);76;6,K"UE"IFNY&(1(QY89@%8E0HYW$L!NW!<
M 8&LL?B#3]!U"^:%XXO%L<%U$)(%C==+MI)[73&AF)W3PR"5[F.%>1(;B0C=
M$I7]]^EWB<?#AJ?AK@.+^,LI\;N,^/:/ V5<791BLSH<8T,9P[EL^*>/_$_*
M83S/,:,\11RFF\@R[#X'"T^':><XN6)S"C361U?;<60T8U95<7.A!Y5AL!4Q
M%>G%QA3C'$N>'P>"]JZ=Z4Y56Y*K-NMRJ/LTW4CR_9G[1/Q<_9$A\03Z7^QK
M\(=;^&?@GP],T=GX]^(OB3_A._BYXOO%*LFI:IJ5W90:!X5MS.I^S:5X4TG3
MW$*1-?7UU*RM'\CZ]\1M8\9V&HR:EK^I:I<I)"[QW%])]IO6$J_;);=B%W;?
M^/F:-IED8@11%E0%O"1KL5O<O9);K<098.2\@EE(.UF9=Y&Y<#Y-H*[3U!(&
MQ%%9>7%?O=-:;US ULI.]P/E9T&<1QC(D'!''.*_@7AGP/X!\0<KRG+9XZKQ
M?GW"6!Q5'B7C'C/C'B#/>,_K^'K1P_U_,N->,<5.&:8*E5JI3Y,#D^#QV/:H
MX;#8?GP3/JLNSW-^'VUA:]2GAL3#V>$HJC3]C"G)\ZBZ%-1E"K)\T*E2=>M4
M<(IR:3LO=OAK\0['PAKBRWMGY]M*R6T\FH)YBQQO+&[SE\R7D=U$6RJPMY,F
MR(2QONE,GWUKO[5+_%>U>Q\4#2X="\.Z+/HWA#1M/DD@T72;=D26*4K<3V>F
MNR1HQA611?@ROO7,LV[\@7UF]N)I+=XC<P0L<WK1%Q+D >8J+_ -G\6>0!G)
MQ7K?@LZI8?/9R17*:JB6;Z7)"TYN+FY98X#:VV)';49& BMS!&UPQDVHC?P_
MEGB%]!+AGC_*>+^-_#/%YGCLS\-L@QF>8["Y[2EA%#+\M=.AGF(RC-,0Z%)U
M7[#$T:=;"T\;@L1AU*C2QJP\I8M_18;C>G4Q^ 7$F!P#C4G*A0Q="%)3HU:[
MO2K8BE"$E4A3J2E.I3FN=TY3A*7*U;G_ (@:7XEU"YO_ !%JMJCV-[=SWD+0
M)$J(ES(S".6)"TZ2C(#"1Y K HKC 6O +F4QSR[(DA&_!50P8A=QQDX^4\9&
M!E@#@%37Z3?%SX+>/O#O@JZE7PSXBMDTS3+?6/$*7=E>SV^A#59#+:V&OR&W
M;^S-88-MFM;YH9(;N.6T,:W,3J?S;ND!FD5V >,D$(K.,@MG+YP<M]W!)P5(
M4XK^8>!LXPN=9=.MA:F%JT*%7ZM3CA')QC2I14(-QC4K0O\ NI>^I.,^5SA[
MCBWTYCCLJQE24<NQ5+%2IRE#$.A4CB8^U@W&3C4I-R49<O-:<;Q3Y&VX7>8<
MMEN.Y.<'GH<$\GK_ ).*ZG2?!/BS6M%U;Q%I/AS6]3T+0WC35]7L-+O+S3],
M,P9H_M]S;P2Q6BNH)WSE$4#YG4$9Y7./?OSV/^?SP,^E>V_!#]H7XM?L\^++
M+QK\)O&&H>&M9LH]0AEMBD&J:!JEGJEE+I^I66M>&]3BN]"UBROK.9H9[?4K
M"X3Y(W0K)'&R_98R6.AA:L\LI8.OCH0Y\/0S#$8C"8.O./O>PK8O"T<37PJJ
MQ3IQQ,<-B(T9RC5J8>M3C4IR\N?M.5>R]GS<T+^T4W%P4H^T2Y)1DINGS>S;
M?*JBCSIP;/&'A8$#@=>3D#KMY;8%QGC.2HR,L.34!_R?7W&:^@OC3\8]#^,S
MZ+XAF^%_@SP+\0HFN8_&7B'P%"WA_P .>,[=;#2['2;R?P/ /["T/7;=[&]N
M]3U#0UM_[=NM2FN;RT62&-A\_$\GZD]B.3^.?S(JL)5Q%?#4JN*P4LOQ$N>-
M?"2Q-#&*E5A-QDJ6*PT84<30DN65#$1I4)5J34JF'P]7GI*^E[-)W<5)P<N7
MFFHN:IN4(SE&,92@I2<.=1<G*+8E%%%;@?V%?\&6?_*2CX[?]FA^*_\ U:/P
MLHH_X,L_^4E'QV_[-#\5_P#JT?A910!]<?\ !\9_R4S_ ()T?]B+^TK_ .I!
M\%Z_@]K^\+_@^,_Y*9_P3H_[$7]I7_U(/@O7\'N?\_YZ?A0 44'C]/U&:* "
MBBB@ &,\C/MTI1SV'TY[_3GCZ_SY55+$X&<>XX]^^1[#K2MC(VD<#)()&3[9
MQ@ =,_,><\G !V:LVFD]GWMO;2SMU&X(!X.._I[9_IFIX(GD951&D)' 09((
M9CSTP.,DD@8'K4.6P1DD=2#R.AY/.,XZ5-'/)#N\N5D8CJC,H/)ZD$$XR3D@
MG!*G!I.]M-^^V]^J_KIU+INFIQ=3GY%=OE4'+;1)3]QW>CYME=J[23^G/A%\
M)-5U*T;Q+J.FW:Z:\D=O#=+"SPE77]XD9&T3.7D02+&X=$4]Z\S^*7@^Z\*^
M*)X9U@^SW8-U;^5N*-&3\ZKNW?,&^\KDE&.#@5]-_LY_M)VO@?PO?>'/%\ZW
M^F:?)+/INFW-FD\;),JH5AE%O-*\ZN<1K<,R1(KF.2-C\WI'BW7?@C^TEI-]
M8V4</@SQ/;1SW6C:U<6:6\/VV-0MOIVISLB1"VU (8GDC:+RV8$%B'8?CDN(
M^*<FXQQU3.\DQE3AR-2.'_M7+H^WPN&PU1TWA\1*C)_6&Z;?^U>PIU>3WI14
MW%J7^E>$\%/ #Q-^C=PC@/#'Q2X=POC56P<\[7 /&>(AD>>YMGV!CCJ6<Y-A
M,SPT*F2)9A3BJ>0ULZQN6.<XX.E7]BL5"M1_,F0_=(!4E>><\Y8<<<<8[\C!
M]*8I^8$\G([]^,'W^AKK_%O@W7O!^J2:7K5B8)D7='(DJ7,$\ 9ECGCGA+QN
MLFTLF2,H =@R*Y^TTZYO)H8+6":YGE;"PP*97)XQA8U8\Y&#C'WCT!(_7J6(
MH5J,,11K4ZN'J052%:%2$J4J<ES*:J-QCRVZRLM&FE9H_P Y,?DN;Y9FE?)L
MQRS'8+-\+B98/$99B<'B*..I8NG-4I8>6$]E*NZJG:/+3A5<N:,H.:G"4ZR*
MS$!5WMD(OJ7)^4*!U8D#'!;..IS7L3:E;^"_!-WX<O;&%M=UN>VOR9,_:].A
MCB#VY7:X15G27)5U9L*%&,9.;>:)I7@:RM[J]U*UU'QH98W30D07MEHD+(KF
M?4;A";>YO=F5BL5E(C9_W^UD"GS:_OKO4+B2[OKB6ZN9V+RS3.6=R.!D\X Y
M"J#PN.@//!4IT\U]A_$6 H5XUN9QG2EBJ^'ES4_9WY7+"0J/F]HU:NTE!.E=
MR^QPN)Q'AY#,(R5%\6YGE57+E1C4P>.P^0Y5F^&=/,8X[D=>$.(,1AW3P\,$
MI^VR:G*I/&RIYA.&&PS+FZFNY#+-(SO@)\W)QDDG'0@<@]>><\U3IV<D\X],
M#WSZCT')_H*;7J1C&*Y8Q48K:*V2Z)'Y[4JU*U2=6M4G5J5).4ZDY.4I-VNW
M*3;;T6[?1=$*"001C/O@C]>*4,W&#WR._.,=\]N*;13_ $U7J1_P_P!VP?6B
MBB@ HHHH ?'_ *R/_?7_ -"%?U5_\'9W_)U/_!/K_M%K^SY_ZLGXW5_*I'_K
M(_\ ?7_T(5_59_P=G _\-4_\$^N/^<6W[/H'(ZCXD_&[TSQCZ?H10!_+%I?-
M];NV2$=6?G!8!AD YXR.,YXZUZM<:3&5N'WPS;9)8&4H BM&Y6*.)&4O&SH/
MD?\ @(W,>]>;:= 8@KNC!I&5HQC(;#8"9Y8EB0H"#.<Y!VUU$<VJ2P7MW'&C
M0V4+SN1/%%"'RL86,1L);F0_)\L3EN&8G8&QXV.C.K6@Z<XP4%R\TG:+;DO=
MNM=6[-+=>[W1X&9*K5KTI4:L*7LWR*4G:,G*2CRW6NKE9J.KVUNC&U'0]:FF
ME86TLP2(RD@%_P#1P6"N&50)$ C8>9T+)(2>#CF98)(P?,4C[O.<\DX(XXXY
M 'ZU<.JZB9?,^W70?88]PGD&V/+GRQDG;&=S'8I*D.V>6:EDU%IX&BECAW]1
M+%#;P,[C S,(X?WJXR>@8MN+,=QKTJ4<1!1C/V$HQ44HTXSI\JL^=KF;5DTY
M65M]NWJ4(8FE&,)NA.,5"-J49T^5?::YI--)W:2LW?9;F8,J>F>.F#W' /YC
M(S^M*"<Y(&#[@=3GW/?D=<'GM7?Z1X)O?$=E"^A![O5'N7MYK0&.*$[D#)Y;
MN(XU8N2-K2#:@W$!06'HLO[,_P 5=/N/#MMK7AK4-&D\3P1SZ<=2A:V6:*=C
MM:#S8U^TX@ G+VQF1DDA9&8R(K<.(SW)L'-4L9F>"PE9^T2H8C$T*->:I1<Z
MDJ=&K4A4JQA"+G)TXSY(+GGRQ]X\[%<2\/X"I[''YQE^!Q#]M;#XO%T,/B)Q
MH0E4J2I4*E6-6K"%.,JDY4J<^2'ORY8ZKC?AQX?U6^U#^U-.:%1IP,UP9)A"
M@C8&(*SLKAB^]E$97E6;IMW#ZA\.>!-/\:6=UI]W:K-9V5EJ%Y<(YC4W,\JG
M['Y-V(S,($E,<_VD%<JGDJOS-CS'QOI5W\'-*MO!&G;SK>HD:AKU^\;+<Q,&
M,%O#;953&NU&E! $QR3*D14(/)['XE^(]%6ZMK6\N5%U$\-W$]S*8<%PX8)&
M%#3C"EI6).XD >GR.,H9IQ+3EF.38RCAX3E;*L4[QE4PL9)3K5(QDO=G.-5X
M:3EK3<)I-5(GPN/PV<<7TI9MD&.PV&IN4/[%Q<HSC.KA(32EB:D%)/EJ5(UY
M823M^[<9OW:L#%\:>#-4\%^(;CP_?QV\US&L,BFQF^UQ-#<(9XMDJ9#.$91(
MH)*,I1QG(KZ\_8__ &-?BA^T'XACU?1O!FL:MX:T><K>SV]NT:)=O$/LAEN+
M@+;1*KN)MDK*7"C&U<$?&FH^+-<U.Y2[NK^1ITV^3(F%*!0R9##,O"Y10S9"
MG(VDY'ZP_P#!*K]NZT_9K^)'BOP_\3];UV?X<^-]&L0T1NFN;;2=>T>>5H=3
M$-T\Q19[*XDM9EMMCR"*$*ID"Y\SQ7Q_B'E'AAQ#C^",'E^<<88'*(U*>"G'
M%1EF$U.C3QU/+88=J4,6\+*=7"JI.TJE.I3NI3C)^+XWYGXKY#X-\59IX<8#
M*<^X]RW(X5J&7U*>/A4S6HJE"CF4,JHX22C3QGU.I5Q&#A4K+FJTJE.,U*I"
M3\-_;@_9LUCX*ZUHVH?9Y_[$O4_LYH[J"X@O;+4%C!>VOHIBS;C)'*T<L6Z!
ML;HF:-58_GBZLKN&0CYB-N1P#\N<YQD< 9XY[]*_L;\1?M9?L)?MU0ZQ\!/'
M>D:F+76=,EN=(\37^A-!=66KP"Y=]2TC5((EDMKK1D*W5L;^)K2\+2I-$FTR
M-_-A^UM^Q]XQ_9C\9W%LEQ!XY^&FJRSS^ OB;H,L-]HWB32?];%*YM/,-IJ%
MLDB6VH6\T4(2Z23:JL&1?S/Z/WB_FN?X"CP/XE\/9KP1XA8#"PQ6'P>>4J>'
MPW$65UY3G2KY1F"G]7JX_#6JQQF6UJD,PY80Q$*-9*MR?D/T6_'G.^)\NPWA
MOXP<+YYX<^*>68)8_"9?Q'AX8? \69-B*KG2QF19E&7U.MF6#O5CF628BO1S
M3V-.&,HT:]-8E4?C5%RQ'55/3(/IGGJ5VD@XSUR!C@V8H5D8"7$.0[=0>#E@
MBJ<L.02O/?/.:GM-/N+R58;6WDN[F8B.*&WC:69IF?";(T0N#G VA#N .,C@
M_H/X$_9C^&7PH^'L?QO_ &P/$>I^%[/4K?4+CX5_ ;06AF^)_P 4M5L@$MK_
M %^WVRR>!OAZEXK1ZCJFL6]A>W\9%KI8D=C(/Z%X@XCRWAVG1>+>(Q&+QU98
M3+,JRZA]=SG-<9-*<*&!RZE)U*L80YJN)Q-2.'R_!8>,\5C\=AL/2;J?U-Q/
MQ9E/"U##/'RQ.(Q^98F.!R?),HP[S#/\[QLTYQPN5951J.M6C",95\7CZRPV
M5Y=A(5,7F6:8/"T>:N_]E7Q3+^R5I&K?'_QKX1BU2#QKX6UKPE\+]'\0?:+&
M+5I]5M+B'4/$D%NACGN[;3XUM5MKA5%LXO&#,RM7Q/XS^)>O>+[VXN+RYE,#
MW4US;V[RNZ6RS2&3RXPQ("#.SN. #SDC<^,GQM\8_&S7K;6?%]^C6FAZ7:^'
M_"'AVQ6:WT'P;X8L686/ASP[8O(XL[&V5G>9I)+FYO+F22ZNKNXFE=QXTQ0[
MMHP,C )R2/P&,COTSG/6O)R'AB-',<=Q5GF%PCXJSJE@Z6,^K5:F)PF78'+U
MBJ65Y9@ZE=-U)83#XJH\;C(4<,\9C:^,G""PD<&GXO#'!<,-FN9<;<18+ 2X
MTXCHX*GF$L)6KXO!95E^5K&4<FR?!3Q'+&=3 87&55C\QIX;"O,<QQ./K1C]
M3A@5(=RY!;!..HZDXY)QCGC/^--#$# /H>@Z@Y'/7\?H.@%)_GTHK[/^M/*U
MOR7W'Z%_7Y+]%]P_>W(SUSZ'!)SD9S@YYR/F[ C)I"['J?\ /K]3W/4]Z;13
M;;W??\7=_>]7W#_._P ^_KY[^84444@"C/\ G_/^>OK12@9Q]>G?W/I]* /Z
M,_VL/^5;?_@EJ>N/VQOVM< DX_UC]1GGO^9QC)K^=!<NP48SG"YZXZGVY[9'
M?@@"OZ+OVKSG_@VW_P""6H'.?VQ_VM@/3(E<8)/3FOYX+"V8N)BK&-202NS(
MX.?E?\E/0'+ Y %3*2A!R>^R\VU^+LMG?2_;2*DU"$I-I=%?K)Z17S9Z7864
M,\%H^]8Y!:13+&PW(P4NLTLQ;[[A5P<$N%E;'3%)8:7>/?21VR.PE5ELO*8+
M"UQNW30J25 $R@LD;,?EPH&2*Q[-K^XDBLK1"\KPJDFV:&!4MU(*O<7$I(12
MP8NA6)650&WL8V7F+S5M0-W(?/FB\N;Y(8II_+5E C#@>827=5W%LDYP$(!&
M._@3/<=P?Q=E7$E"C@\=+*\5#&?4L;[50JTI^UI-QK4/]HPU;WG4P>*A"<L/
M6I1KJG6LZ<_F:>"Q->>(C#$4USTY24:B51P4I2Y7:#C4LVVUS;IR:>J9W^MZ
M#JVH:NB7-JUG?6\9CNX)G#,C1\;5YZDX( QUYP!@KI.DOI[7-W>WGD1QA8E8
MQMF.5R74J-J\!8B#P1@MW-<KIGC'4K*</.ZWJ%CODF'^E@$AB8;LJTH). 5<
MNC< J/O'U'2;2?QG8ZA#'=!;A[5+O3[>&&(13RQ3>3(E[P!#&JRF3S@RH&!\
MP_.HK_1+PXX]\(>+,9GWB14P/$,O%'+<;B^)L9EV:9A#^S,UK2R7#X"GF&*K
M91B\BA'#8?%X9U,7BX485JV(K8%4\+@<9-,X,?\ 7\NH4Z&*="GERIQI2KTH
MMJ$95%S*,9J=2*BI7:J2:C34I>^HLI6-U:PZ@LB2K-*Z,&9A\DP?D#YL$_+D
M?+C RHXK7NHM3UJ]BTZQ2.269UM88XW\F&%\#_6,_P!R.),N9&)P0-Q/?JY?
MV?OB];>$[/Q9-X7O+;1(;Y(&UB6%HK$(T32EUOP7MF*1X MEE%R['8D)?Y#K
M:UX1U?X/>%FUS5(C/XBUFWCBTL3AI(;:.]C%Q-?>:"L=RRJY2-T62V/S.LTI
M*JL^,'TO<!PWX2\2>'?#V*P6#XEXOJQCD6&RG%X6K0Q&*SC+L"\VHX[#/'XZ
MMC\)EU/$8]YMF&.Q5+#U\1'#U(8'$YE.==?(U,XR.OB:,<JSC*<US&K7KY=@
ML)2QN&Q2^N4&G45=X>K4]A]7ISC6K4IQA5C3LG'EE%&KX9\.3:YJ"Z)-##)=
MW\EI:3R)Y5W!'!&VRX<NRY\YMRJD(CY9PP?*$'R_XD>'=<^$_B SZ;%;_P#"
M.ZA=W#Z3:-<"^-IY?WHY578\2R$[HPRJO_+-00 3YU:?$#Q!HU_%J<.HWL5_
M&P>-HKF2)2"S,V1C<$!;Y(E$2L"=P=22,/6/&_B+6@8[V_=T#F4+D%PRMN.R
M5LR J  J[\ C$>TXQ_FKX<9[XE>%_&F!XRX'XOQ?#.,P="*CB\FQ.*P&+C55
M6G*,Z=2%2M0E&FZ5"2IU\%C*$W!N6'=51K4_:RSAG/Z.:JM5Q.7XG(\1AITL
MPR^K1J\M:M.7,J^'ESRC3E25U3Y5'FAS1YH\SM]G?LH?LN?'+]M+XIZ/X0\&
M^"==U[3H+NQO?$46CZ=<,SZ6&,DCLWELD=NT<(CEN)1Y$+,7E'S -^E'[>O_
M  3]\7?L_?"W1?%EAHTUO-X=00>*])OX);36M/N+9I(;Z[T^,236.IZ5%#=Z
M9'/<Z:8DM;A) 8V65C7QI_P2<_X*"^*OV'OVO_A]\1M6\6^)1\-=5BOO"/Q'
MT>WN_M=O>>'M9M6BBN#8ZBEU8^;I=['9W$-P+9+J#$YCE D8G^ROQ3_P6[_X
M)@_M-:C;_ #XG_#FY\8^'/'TFH:#J^OZEX.FU#PZU]-;V>GZ+ MY:PP:M!<:
MHTE\CZE9J8--AL;.(/>/?+#:?RC](+Z7OTUO#CZ:'A?XSU^".*/'+@/AW#4>
M)^(L[X<Q,\?Q"\NJRS?*^,,!CZ>>U\NREYE0RG$XK-,HPV#IT(XJM#"N5*;K
M8IP^_H/+L)A<QRK$5:.6X&O@,0XT_J6(]E7@XT'2IQQ5%5^2OAJU#V]2E6PT
M?:P:6&QM-JM3?^=M-HGFW4LT100N20Q4QF&27A6.XACC<5&?FP#R<<:5]!=Z
M;IB648+R1J_[X(=KEB"R*/[NU06(X( !X K]B_\ @I)_P2UG_9G\8^(OB!^S
MUXN7XS_LQ>(;^[_X1OQCH]U8W^N^ =3CF=KOP#\1=-TYA<V>L:/+YEE'?K;)
M'?VT27#K!/YRU^1.G6;S"'3M8FGBN%D$<+(KF7DL#;N"LC,<C8,J"4(YSDG_
M &K\ N)O#+QMX$?'G@YB)4\M\4\IS>EE_%O]M9?E"X>S"KF%"KF?!G'O#^;T
MJ>;^'G$D<=7PF)A@L[P]*M2JT:V%P.:8K)L9A\95^<Q=:K3A2E6DJE*A[.IR
M<CFJD4FHXC"SI-K$T%!>SFHR;U]IRIPN4O#E_)';-A)C(SF1ML8,(ABXGQ*0
M<,NY%"D':K*<?,&/WI^RYX='AO7--_:,^(&GS6'P@^&6H6^J7%U?2R:;I7BO
MQ'HUQ!K%CX3BG!1]2?4$LI8[FUL0\Q .XPC)/3? []D;P'?^"[GX\?M6?$.?
M]FS]F'PYJ2Z6-<ATXZG\6/C'XK>P^WP>!?@O\/+@G5/$%U<P)G5O&5W91>"_
M#5J6N=3U%I8Q;-\6_M ?M):S\7X-"\!^'X+SP5\"/AY=WX^%?PJCO[B[LO#\
M%VT<<^O:[/O,>N>-M9A1&UW6RL:.ZBUT^&RLHH[=OS?Z0WCCG6!X7XC^BGX<
M^(]'BRCA,,^"O%SCWAJE?A'*<!/"8Z'$?"/#F>4YXJ/$G'.)J9I4RO'U<NQR
MR_A&C4Q>)S/%RS-Y=P_@O%P/+G^9-X7+G]13K1S+&5JE2G0A3E#V3PV"K4+^
MWS&HVJEJ;C2P-!2J5,2\8J.&?:?M@?M<ZO\ M&_&SXJ?$'2])L_!WASQOXSU
MW7[/PGHT]Q+HVG0:C?S7"PV27+M((<NTB>=E@9&("EBM?%DDTDCL[L79B26<
M!F.22>3GN23CJ22:1VR<YR#SCGC*C(Z+TZ9&>.Y')8<=OZ_IU_7%?Q]D'#V3
M\+93@<CR/!4\%E^6X/"8#"THN4Y^PP6&H86@ZU:<IUL15]C0IJI7Q%:M6JS4
MIU:LYR=OT#"8+"8&E&CA*%.A3A&,(QIPC'W8I)7:2<F]Y2DY2G)RG)N4I,2E
M#$=#_G&/Y<9I*,_YY_+KTKV=M4]3J';F.#D\<?J3SZ\D]:;UZT?Y_P _Y^M%
M-ZMM[OKU^?4 HHHI ?V%?\&6?_*2CX[?]FA^*_\ U:/PLHH_X,L_^4E'QV_[
M-#\5_P#JT?A910!]<?\ !\9_R4S_ ()T?]B+^TK_ .I!\%Z_@]K^\'_@^,_Y
M*9_P3H_[$3]I3_U(/@Q_]:OX/P">,=>G^?SH 0=1VI<=>1QZ\=/3U]OUQ244
M %%!QVSTYSZ_X44 3(Q16920<$9]_7\CBH]O([Y7/XD$X_,<>OZ4F2/Y?_K_
M #HR>O7MS@_S^M V[J*Z13^]N[_0>@ /).!C/ SZ=">RD_CC&>M6;PV;3L;&
M.:.V"QX6XE26;=M'F%V2.%2-Q;&(QM&,MG-4\GU]/TZ?SHR?7U_7_/2E;WE*
M[VM:^GK;J^U]KL:E:$H<L/>E&7/R_O%RJ2Y5.^D7S7E&VK4==-9T8HV0S+D'
M.W)!  SGKP<D]ASDXQBMS3=:OM+CE6"=E@E>-Y8 S 2B-A)'E@/F'7;G@LP!
M&#SS@8CH3_G/'TY/'?)I=Q'IT&1M&#CGD$8Z]?4U-2E3K1<*D(RBVG).$6FT
M]]5?1;+[+UC8ZL%C\7E]:.(P>(JX>M34U"I2J3A./M(J,E>,DG"27+*#]RHG
M:=['TXGQ:\,ZAX;CT?6=*.IZK$D*0ZC<?NVBAA49CCD(Q)*5+)B4'@$KD-L7
M@=4\?W-K#=V_A=;72+2X,:3I:V<:W,<<2E8G6];?-&[EG>0*ZJ2P !VC'DD9
M&1NSM)^<*N-R[AGIQQSC(XZ ] /9;?P9IFIZ7IKM#+HZ7WG-:ZQ<,S07)BC.
M^$JY5?(21XP[HS2(I8E#V^8>59/DTXU'#$.E7KU*DH5*M2OAX3?ORY,/-N$(
M+EYHTZ--V]YJ#O)2_=*7B!XF^)6&K86CC<LIYCD^5X/!TL?A,+A\ISBO@H26
M#P]*OG-&A[:4Y2JJC/&YCF-"%2<J%.IBHR5%P\BFGEEW/(Q9V8EF8EF+OABQ
M8KNWD_,3G<V"3G/-=^BGJ,8Z],8!!&./8#& 1GG@?26G?LU>,O$-S/:^#[G0
M_%B0VEO<FZL-3@M59I2!-:1QWAAEFN;<DETB\Q=@W '@G.^(O[//B[X<VVD/
MJ:1:G)J</VAY])9KFQLU=UC2&2XV@2RAS@F/<"VY<!E85T0XKX<J8JA@J><8
M*6,Q'-[+"*JH5URTW4DIT9QI.BU"+?+4]G*6T(2E[AXV+^CYXUX7(<UXLQ?A
MOQ13X:RB5)8_B-Y>L1E#J5\9'!0^J9CA,7F%+,G/%UU&K5R]8NG3Y_;8O$4*
M,EB)_/-%=5/X8N;>9;0H\MUN<2P1*_FP!4$F9591M78&8G@\8Z\USKQA&=77
M!4X(&[([$9R1QUY'0'O7N4Z]*JKTY*:LFFNJ;M==6K[.UFM4VM3\HQN5X_+I
M<F-PU7#S4Y4W"I%Q<:D(J<Z<FURJI&+7-3<N>$KPJ0I5(RIJO12D#&1GM^>#
MG'Z4E;'GA1110 4444 /B_UD?^^G_H0K^LS_ (.KH-.D_:Q_X)^-J,WD1I_P
M2O\ @"\3L/W7G)\3?C& K_*VX-'++\N8E4A6>4(2*_DSB_UD?^^G_H0K^JW_
M (.SG;_AJ;_@GRFX[!_P2V_9]8+GY06^)/QL#''^T(TS_N+Z5%2'M(2@I./,
MK<T79I/JO/I\S.K#VE.=/FE#GBX\T':2OU1_+WJFJQ(\UOI[1M$Z>6&CCV,D
M65<H&8$$[B02F<\Y["N?AO+B':J2OY:MED+,8F ZED_VAZC/'UQ4R1^'?OZ]
M>M)4TZ-.G3]FH\VBYI2M*4G:W-K=)O5Z=6[6(HX:E1IJFH\VSE*?O.4DK<SO
M=)O5Z6LV[=2RZ1R/NC(BWL 8W90%+#.0Y*KL/JQ!7.UNFXQ%2N5.,]1@@\#)
M!##Y2#R<@XP#W-,R?_U\XYSQGIS^=.\Q@% )^7.,XPN<YVCMG)^G;G!&B5O-
M=GT[:K5_/?KY[)-=>FE_+SW^^YZ)H'C7^R-'&F10O:WQU 7 U:WF=94MC:M;
MO;>428R'9P[2D%\J(P0 17ZN_L4_'*Y^(7B"XTKQQ;P_$*7X8?#[5?$G@G0/
M%.JZI*;[Q#8-#+/I]A:V45WJ&HZEK6GV]MIUI%:&WAL3#%J+[8[1J_%PDGJ<
M_P"3_B?SKJ_"/C+Q-X%UFU\2^#]<U'PYK]E'<Q6NJ:3=SV%[ MU;26MP(;FV
MDCE7S[::>"5=VV2*:2-E*,5/PW&_ ^ XNR/,,N<:5''8BE-8/&5%5_V:O4E0
M522J8>5+&488C#TZ^$K2PV)I5(T<54E!N<8(_-O$7PXRSCOAS-LJ<:&&S/%T
M*G]GYA559_4\34GAE5:JX6=#'T:6*PM+$X&O/!XNA6A0QM:I3;J0IQ?OW[2O
MBX:WX\OM4G:R_MB_>:74+&SU"YU*+1I3<RM_9\ES=QPW0N[9&6.>.>.)TD1B
MR(<J/F&*Y:"5I=L<C/%+$PD19!B5-A8!P0'PQ*MC<APW7HES>7-[/)<3R-+-
M*[R/(QR[N[%W=F/+,S$L68DDGDYJLQ8GYNH&.@Z?A_/K7T^3Y71R?+<)EU)J
M4<-AZ5!2C'DBHTXQC&%.+<I0IP24(7G*<H0C*K*56=23^QR')J&193@<JHM2
MA@\+1PZE&+A'EI0C&-.G&4ZDXTJ22I4N:I.I*G3A.M.=:=:4G%\QI'Y: HSM
MY@7$C!P@VNV<,B;"4& 06;D@X"Q.\;;D9E8$$,O# X)R#GCV]>_&<1?Y_*ER
M?6O3_)W35D[IJS6J>ZNCV?)V:>C35TT]]'H_F>L>"/&E_HM[]KM]9N=,O(HY
M(X[F*=H7:.1/)=4974_O$W+(N<8.2N1S]P_!G]L7P1X=\)Z]X)^+FF:KX[\/
M2V>IQ^'=):V6XLM(UF^,D9O9IYI5N((7REP6T\Y653(UO,[%A^9 =AGD $Y/
MRCZ>G'!/3%2F0L<, 5*XP>H4'D#!R",' ';@  U\AQ!P-P]Q/3G1S;#U'"53
M#U:5;"S6$QF$K8:K[:C6PN.H06)P]2G)64Z<XR4)U8)N%6K&7P?%7AOPMQGA
MZF&SS#5W&I5PV(IXC 5_[/Q^$Q&$JQK8>O@\RPU-8S"U(5.9<U"I2E&E.O3C
M/DQ%:,OUBTG]L#PY\+_"=YK'P:\$> O"GC6<RP6_B:]\/:=KFJVL$\Z,9DU'
M4%G:-X8(4AL2L"N\LC2AR5?/YM?$#X@>,/B7XGUCQEXYU[5/$WB'6)GGO=5U
M>ZFN+R4&0E(\MGR+> 86&")$BB7*H"=Q/0^'_#6D:IX<6^DL;H(0+6_U%9I3
M'I;F4L;YX2C)-&J!0EON DE>,#'4>Y_#_P#9 U3XKGPO!\./B#\/?$&M^)[F
M>V_X1+6/$=IX6U71X_++6L^K7FJB'3$:XE7RD2.X:0RLL8!+<>!E& X'X"K9
MEF->J\'B<1B*N'QF>9LL5BJU*E0I.M+#XG-*BS.M@L%2I4E+DJRP>'G"*<E5
M<J<5\MD&6^&_AE7S;-L37AE^,Q6)KX;'\2Y\L9C\1A\/AZ;K5,)BL\JQS>ME
MV6T:="-7V=;^S\).,(3E#$S]G$^*')+,>!ECD#@9YZ#T_P :;7Z>?$K_ ()6
M?M.?"7X4ZG\2O%_A;3YKJPUFUT>Y\(^'=7BUWQ!I(N8I+V/5-86P\RSL]*FL
M87FAN6F*&)XG#!94(_.G5/#=]I)5+ZWELY73S(H+B-TEE7.T-'N #Q':VR12
M58#Y2>M?2\-\;<(\84<5B>%N(LHS_#8/&5,!B*^58VABZ5/%TJ=*K4I-TY*=
MHPK0:J>R5&:;=&K6A"4X_8\)>(O G'E#&XK@OBS(>)\+E^85\KQ6)R7,</CJ
M-/'8:G1JUJ%Z4E4:C2Q%*HJSP\,/4@Y3HXBM"$YQYFBII8C$Y1E(9=H(P>&.
M"0P/(QG'UJ&OJ4TU=;'V:::36S"BBB@84444 %%%*#T[@'./R_PII7^YO[@/
MZ0/VG([:7_@W'_X)4QWC%;=_VS?VM1(RE5(7S9 3N*R 8QR=C9Z<%A7X)+9Q
MM<V\6C-!*H<LS^43&CMA&N))-VS(0ES']Y<D,H/3]YOVI50_\&X'_!*X/]W_
M (;+_:T)Y/3S7)Z8Z=>A(&0.O/X<PWL*V86R$MDAQ&S",-%+)PP4MR3U49]3
MST-?TE]'3P7X3\5,SS?,N,N(*^!RCAF>$J5>'LNG&&9\11G'ZQB,-AZU:*PN
M$P\:4:='%8FO6I34,7.&&:Q#IM_.YY6JT*E"5-3FYPG%1E)JA"7,DIS2]Z<F
MM(I*RM)WU9P'B#1+G0'CGAOVF$\DR%T?:S%%4DD*0Q1R6*AEVCC)S@'EYY$N
M2)&81S'(E)!$<FP'#\ D,< $8;)(Q@X4^@>-=0M[RTLH@ACFA=]^TC#,5192
MW0KS$I50,?,?:O-^O/8X'?@#IP3]1P<#C;CI7@_2-X5X)X/\7.(<F\/EAX\+
M4L/D^)P%'#XC%XF&%GBLLHUL;@I5,<Y8MO#8QUJ4J=6=5PG1G[.<J<HR?;E%
M2M7P5&MB8I8B]2,I1C&+E%5)*":BE=<B7+OLGH[CC"V[:"'8[2#&0ZY;!VY!
MP6P22O4$8[G'I7@?6-6\.6^M7R:3=7UM=Z1+96\Z[D-E<O=6\T=]&% :=(5@
M?*+NCW,-XQP<WP)H5GKNK>1>R/\ 8[>-KB150D2&,_NHWP<8)!9CC&!M. >/
M8K_5)+=&:UL_)M;-ETZ!E0)%/(3YFQD"A57:I&T *0#D9&:_?_HY?1 7B5X=
MYCXM\;<>9GP%PI7Q^:9!PI+AG ?VOG^;9ID=.G5SS,\;0A4I4LLX=R55,#%R
MKR]KGF-J++\%7P\I4JDO%XAS:CSRR=8.&,E4ITJN(A5JRHTXTYSC4HPC4A[[
MK3E13<8I*$%)U.:#G%_0/[,7Q\UK6_&7@/X4>-?$=SJG@3Q3XRTVS\1:/K>N
MW&GZ#+;3W)6)KN:-94TZQM+J3^T+J:WLVN94CD168E8VZ;_@H!XTDU;QS>0:
MCHFC^#F\/746C:'X8T:ZU/R+K2M-M(K&#6ETC588KG2-,UHI_;VEV4X9K>RU
M6&(/*JAS\5WWAI[VY.K:?<#3M4CS?QB,-%%Y\$BLA@,!5[:=&"M'(F<-A< U
MYOXP\6^)_&7B'5?$/C#5M2UOQ)J=XT^KZKJUS/=ZC>72HL)>[N;AY)Y)%6)$
M)9B2J*,G%?QMX[?11XQ\(O%G <7<3S^O9)FU'/,/D/%$*=:5+B.M1QF&G6Q:
MH/%U8Y1F,\LQ6 H9SE>:8>6:X*'U>EA:^(PT7BSX#+_#G(,;Q_@>.,J^J8"&
M#RK%X?&Y71PSI58YGC,:ZL\71CAZE#+G#%X1/ XO%U<!7QLJ6&P\</B*5I*.
M!+<S3S>>YC+!]^#M*X5@0 AP#&,8VC@@'(P>;4MU;2VUPSP-]NNKAG:11$EI
M%&S%V6W@6)6CDW95=LH01_NQ&-H:LLEL'GOD=B>>HQCGGTY!)I"[$8))'/!Z
M#/7'IT'Y#TKY)Q5HI/2/+9*\;)+2&M[J.V]M+=#]OIM4TU&%-IP=-*4(R4$[
M:T]4HS5DE.S:O)VN[C\X((.T\'*GID \;<'@8Y'&<C. *]%\%>+K_2-6LKJ/
M5[G3;BSEBN8+V*8QO#+ _FQ/&Q'$R2;#&_.W!&&SFO-BQ)))R3U)Z\#'7Z<?
M2@DG_/'IT^E98K#4<90J8>M!2A4BX-2A"::E"4)7C.,E*,HR<90DG&492B])
M-/GQ&'IXFFZ=1:/9JW,MGHVM-M-U=)VTU_83]E#_ (*$^'/@]XBUR#XS1Z]\
M1?A]K]W;W_B3PG:6L6HCQ#?PM=-%=W']HW<<,<CRW<RW=S;36NH"*3,-QN C
M;U:R_;K^#_A1_$GC?X2?";X?:3XHL]6EUKP/JVN^&]-\9W&B2?8S]BMK*#6T
M9+"T$L\LU[:7-G=S6KVPL[>4KL"?A.)&!Z@]N0#^6?T].@KZ+^#7@O1/%FCZ
MY<W?AK4?$-_I7GO>16-U<VPBT@VZ>9>RFWAE"?86W3.S#YP 7R <_D&<>%O!
M>3XC.>)</B.)<J_MNGEV!XAP.3Y_F659-G&$PU>C"A2S/)L!F.695BG5M"A6
MQ&*C5K2I>RH+$*'LX!B.'X\44*61U.6U5P<6J-1<]6@E4<JOU/DK2=:E2]C5
ME%TZ?L[.I!0]IS5/VA/VBOBY^TEXXG\<_%WQOJOC36H+4:7IC79^SZ;HVF O
M<#3]"TJW2.PT>P,TC2_9;*&%9) COYBHNSY]/]!_(>O/^>..OZ(>#OV$+CXK
M^&KO5/A7\8?AYJ/B^37;'1]&^%GBS5O^$9\5:_;O/#;:KJEMJ5\B>';33M(D
MNK:3.HZG;7%S:QWEXL:0P M]\:7_ ,&Y/[?.F>#?B9XZ^(FA^ -!L/A]X<G\
M3V&A>'_'VD>-_$'CG1HX[A[?6O"-MX2DU6.^T6[DM9+:QOWD07DZF.&/ W5V
M9YXQ^"WAOEF7X'B#C3A?@7#T:U+*\KR+.?;<.8RM6JXS!X94LLRG%Y;AOK-)
MXW-\.L3C,-4J8.%;%5<1C,?&/UG&GK1X7S'**=++X954PF&PU!^PY84:&!C0
MI1C.4H8CVE/!Q3513E^]3O.\DVYS7\^U%>T>*O@OXS\$WVJV'C/0-0\(7>@W
MTND:M9:U!-'-::K"JNVF7$L:-"NH!742V@=I+=MT<Z))&RUYIJ&BW.GK;O<V
M\D*W""2+>"/-B8OY<T?7='(J@A_E4XZ9R*_3,)F6 Q\83P6+P^*IU+<E7#UJ
M5>E.\(U+TZU&I5HU%[.<*C=.M42A4ISDXQJ4Y353+<;2H_6)T)*BZ<:JJ6O&
M5.<_9PFGMRU)WC3DW%57":I.HX22PJ*4\<=Q]?\ ]7'0_ACN2=A]3_3_ !KN
M.$2BBB@ HHHH _L*_P"#+/\ Y24?';_LT/Q7_P"K1^%E%'_!EG_RDH^.W_9H
M?BO_ -6C\+** /KC_@^,_P"2F?\ !.C_ +$7]I7_ -2#X+U_""'PK#N<<XZ#
MT7KCDYSW&1P>:_N^_P"#XS_DIG_!.C_L1?VE?_4@^"]?P>T!L.XP,D]>>O&>
MN./SZY--/4XZ=J*.._\ /']#0 #/;MS10"1G'<8_"B@!>..<^HYX_P ^U.PN
MS=D;NFWC/7((]1@$'/J.U,I0,G]?P')_2@:]+]-?/K\ON[B4$8ZU.\>W&T#!
MZG#>GJ1@YY^[GL>F*@Z4)WU!IIM/IIU_5)]4%+@\>_\ G_/_ -8TE2[6X&1@
M G(Z@8<\]/[K8YZ\GDT E_7XO\"]I>G7NJWMII^GV\EU>WEREO;V\2EY99I"
M%544$[B<GMQR3P*]E\:RW&CRV'AV1F=]#LH8;RPN)2\=K>I"OVFT:)BP,L08
M,6'EB(^:B[LC9VO[+_A;3KSQ-XB\8>((8Y='\"^%/$&OE/,*2-J$,#P6!0%E
M#M%=NDB*2H;//'%?/.L:A+J-UJ%]+*S/<WL]U)O8AW\]Y",#=DE5*+(%R" "
M<<U\S/$QS//L1@(P7L<EPV#G6J-2M/&YG&M.%.,DTOW&#HQJ3M[\*F(I^\D?
MN.&R>KP3X29-Q94Q"_M'Q0SOB#!8#!TJRC7PW#7A]B<OIXK%XBERKW,WXFS*
MIA,-[5UZ%;#9'C']6=2,9R[+1_'&H:4BQ:;J=SI[+(LT<UG<2PO;N,XCC57$
M3I(2!(""6C#)G#,&]N/[1/BBZTRQL;AK=7LKBTNS%)!9WME=S6, M;9MMQ%Y
MMDS(2UY)'(6FD4R%269A\@!\'*D@@Y&#].F 0<9Y'IFMVQGE6,E>';<JX&YB
M,#(.3R&!)! ['!X.%F'#N58JI#$8C!8:K6IRYX59TH.K&;T<E4C&-2[3?O2G
M.2:4HN$DY,X,\:O$+AW#8G*<FXISC+<OQ=&GA\1@\+C,2L%4PV'DZE.DL'*M
M/"TU&:3:H8?"QKJ2HXR&-H0HTJ'TSJWB70?B?)$NH_V?X8U<">*76H)0K:M-
M+/$V;J-I ]M!YDC+YJ[S+YCD(<,1XUJW@W5-"CU&WN9+98BW[MKB./S;K.[Y
MK68!BR#RSAM_S D*,%@W.VC-&\K(R[B22)$ 0I&JL-C,V0[EG! SSL*J3\M>
MF+!<>*M*^P7 "_9+.*6+S91&88XY$5[B$%P]U)\^XVT7FS")'N @B20KP4\-
M+)'3CA:THY8Y)3HU7*M]4BO>_<U*DIU7&4Y-<E6K.,8NU)0BDC[3&Y]3\488
M[&9]E:K<<1IXBIA<VP$GET<]G6A+#5*.;87!8>&7PK1H4^>&+PV!P^(Q6(O+
M,)XF4ZV(CX'+$R$@\#>>IR5&3C/..0<^OKUXAP<XQ_G\:ZSQ!HJZ5=&V2?[4
M 0QGB&8BIR"Q8D,K C!5U5NF1DC=S<JQD@0A]P.')8;<X/3N.AZGMT&0*^PI
M5H580G%MQDK\W2W=W=TI=+ZOL?S9F>5XG+,7B<'B:<:-?"U94:E)U8U7[2+:
M<83I*5.IRJW/R3DH[\[ND5J*#U.?\_G16QY@4444 /C_ -9'_OK_ .A"OZJ_
M^#L[_DZG_@GU_P!HM?V?/_5D_&ZOY5(_]9'_ +Z_^A"OZJ_^#L[_ ).I_P""
M?7_:+7]GS_U9/QNH _E1^E%%% !1110 N!D9/'?CH?2E4XSGZ<Y/;OSTZ9X/
MM02IZ YPOI]X#YCZX/)^IYI3&P('7(!X]"< GCC/''4$@$ G%'X]-?,!<KM!
M!^8 ;NV1D@8Z\@$ \ =^HR6$<\9QCC(YP.,GKZ5,BJ=N[/\ %U! ) R!DG&W
M )/&1W'-69/)6#(!#LHVJ#P#SOR<Y*\8P>0<J.%%2Y)-*S;=_3^OP)<K.*LW
M=VNNGF_Z^=S/HHHJB@'4=^>GK5D03%U58VW-D+@$LVX@9 ZL?F(&.<C&3@57
M4991ZD#\S7TO^RW\(_\ A=/[0WP9^%\CQ+!X[^(WA?P[.TMP+=&M[S4K-KJ$
MS')A-U;QSV\4BAFWSJ5!9<5QYEF&&RG+,RS?&2E'"95E^.S+%<D)3E]6R_ X
MW,,0XQBFW+V&!JQC%1;E.<$NIY^<9GA,CR;.,]Q\I1P&293FF<XZ4(2J3C@\
MIRS,<VQ3A""<IS6%RS$*,(IN4YTTNI/\3O /C3X._#[P-X;\7Z?JWA+6/&UO
M)XPGTB_G$5S<Z#*L4>EZA+IZ,LUNER%=H#,5>ZB"M" B9/AVB:[<Z9=Q74%T
MT$L!$@DCN)8)5:%S(DT<D<Y9;I& :)@V0QYR<LWUG^W]XZT3Q[^T_P#%S4_"
M5E/:^#]$U]?!?A:.XN?M)M]$\'0Q^'[6.&0O(S6[/93NCN59]X=P'=L?$(//
M\@>A.>O3IW/J1GZ>%PE/%YEPME689MAJ>'S#/\NP^<YCA%2E%8>MF]*./6#G
M"LZDY2PV#Q. P\W7=;WN=\NUOF>!IXS-^"LDS7.L)3PN9<493A.(<UP/L'36
M%KY_0IYI'+ZT*KJ5*D\%@,;E>%J?6)UUS^T]VUE']0/ O_!2W]HK0]/MM'U'
MXI^*M6M/^$6'@Z1-<73/%VCW&CLUI:K#X@\,^*]/U#P[JTO]CV,.C->F"&_^
MSGSUNY$!A'DOQI_:'TGX\W6GV_B/PEX,\,7]I9Z=8#Q#X8L+?3(196$;J);;
M3+:6'3H+B\=S+>V%JEO;VKD>3O569OB.W>0.-K#Y<@J?X@,D Y^\<XV#!ZD,
M1QE[O+-)@XCD0,Y<*1YA'S*"K%0H&,#"@=R#DUY6%\-^#,MS)9KE&18#*,PC
M[24<5EU*.!E&=53C*<Z6$6$H5E[.;I*GB,/B*<8RDZ4:'/.F>+@?"+@#)\X_
MMW).',LR+-8>VJ+&Y/AZ>5U'5KTYTIU*U/+U@Z&*C[.;I^QQ>'Q-%4I<D(X>
M#<)=SJ7A.:PO%:SO(;RVFMQ/!>*R20F%H1(5<AC)'.A5D:)PIRA95".,\)=6
MS12N N1\I! 5@=P[\Y7H><<]3C@GNO#6LRR+-H\EK;7 FD8L;B<VB$RAT""8
M,JPB/*LAW#>5V%2#5'5/#<NE68N!.TKW2L#"%'F02I,T;QW,9(=&VH70MR4*
MOCYT!^IPU>M2K+#8N:<Y2C##OW.:O%1<I5)6<53=HMVDXPTE:[:3^UPV)KX?
M$/"8ZM%U')4\+*R_VFG9R=6486=&2A&3<9VC>_*]' X?:><X&,YR1].@YZ\=
M.._0TVM-[15B"-N^T,V0H *A3QM8Y;:2<'DGG.,YXSW0HVUN".H[CU!'J.>.
MW?!KTXRC*_*[[V\TG:Z[K?5::/Y^Q&<9WY7?MV:_FB_M1Z*2T;3MYLHI2 #P
M<C%)5%A1113_ .#_ ,$#^C/]J\[?^#;G_@ED<'_D\C]K8[NZXD<<>F2"?7(!
MK\!++QC>6RI'<V\5RD$/D1IL5 @!XD95&6E7(PS\L1CG%?OW^UA_RK;?\$M>
MO_)XW[6X_.:4_P L5_/IX9T-]<U-+4%4B$FZ0L^S('/E!V(4$]R6S@'H:_6/
M!G-?%"AQKE7#WA1F./PO$G%F/P634,%A)X=X?,JM6M.-"&84,73JX6KA<-*M
M7Q%26(@X4H0J2M*;H07%CXX/ZO.KC81E2H1=1RDG>"6KY7'6[:5DMW;I<&M]
M5\2WK"QLKBX8%BD42%A&@'S&5@45<=VPQ R#P *FU;PAK.D0E[J!3Y42RSI!
M-%/+;HV=K2QQ@-&K-P"<E>2>N*]MM(SI%KJ$%JD>F75J%6UA $D-XJJXD42;
M6,DA;!W!V!+CE<9.1<3Q&SN]5OFAWQV<D=S%,765GG7RXX$4C]Y(6.8E4,,9
M)&.O^B6>_0BX*P7!^89KQ[Q[Q1F'BSFV SOB7.<YFLLR3@KAK!9)7SBAF\)8
M'%1EG>,Q^ KY9%XC 9U_8\?['E3S++:$\'B<%4J?*4^(\1/$QIX;#4HX&%2G
M1A#]Y/$U955"4)77[M0DIZ2AS2YTXRM)21Q7@37+/3IS#(D:7<TH,<CNJK,A
M7RQ [;OE*D?*" &XXQ@UZV+Z>YOFM;JSCAT\1;XW90(3>/\ ("[@X5Q%O=6)
MW!5."!G'RZ>)#@E0K9 7MC&"K XXXQ@XR,]Z]%T+QP(+5=.UJ*:YM8T_T>:#
M:)TD#$YER1YQ"M( P.\#"#"C!^8^B%],K \$<.9=X.\>YS2X7X5RO'0QV19K
M2PE!<.9Q&E4Q=3%<.\<1_LW,,7A,MS9UX5:N>Y?AW7K5\'E-/,L)4J4*6)I:
MY]P_+$UJF8X:FZU>I&?M(7?M8.2@E4PRYH*4X6M&E4DH1C*KR-*3B_8K$7-K
M-:VUV(KA?.E-K=1H&,<(+ @.-I<8/\1R,9! %>0>/;"T-^NJVY5$U,S;SM5"
MMU:DH[[!A0ER C\CA\G& ,]U:>*O#%Q%;0QZI]C<;I)Y+M945T .(<'!+;<8
M,9SG@Y !KS[QMXAL=4-K86*2-9V+S@W+1>6LT[L%9H@P!V*@R ^TGHRX 8_O
MOTU/$#P:XN^C?B<JR_C_ ()XAQ&$S3*<UX"H95Q'E?%7$LN(*=')\/B,NI5\
M%3H9W3P64Y)B\QP^;X_/\'@Z%;#K*\LPE3'/+H.'E<.8;'X?.(U)X7$03A..
M*YZ52A1=)2FX74OW5YU.64(49MQES2E;FL>=.6(.[DYZ]<D<8STZ<DCVZ$D&
M,]3V]O2M:*. 6TKRY5E>0]/F(15\H #[K-(^.HY#[B F!E,""<\^_K7^'\I)
MRDDI)1?*N:/+=*]NBOIRW;^TY=4S](_K\>FFJWU6@E%%*.3TS[4@'*I) (/M
MD<?YZ_C7Z!^"/AA\0OA!^RI/\<O$>E:YX3\/_&C6_P"POAMJ-Q-<Z=;^/-'T
M6YO[7Q#<:;!'-$=2TS3]2TZXMY+XQ2VT=Y;SVP#L6%?"FB:5<ZYJVG:-:F%+
MG5M0L=+MI;B58;>*>_N5M89)IG*I'$)95:61B%C0,[,,&OWJ_P""Y5IX#^#/
M[1?PN_8G^&MD]OX;_8C_ &9/@S\$=4$6IIK&G7?Q4UGPQ8?$GXH:S9:C'-++
M<W=SJ_BZ"#5ENA$]MKUIJUJEK:V\,<0K(\-1X@\2.#>!JL(>RQV5<9\<YI7Q
M&"KXO!T<JX#P&#>6X;$TH8?$0=3/>-,ZX?R;"4JM#$0JUG*$HPY?;4^[ XG$
M9=..:48PG##58X>K'GJ0J7Q="NHRA[*<')4H4Y59J4E%VBK2LXO\=/#7B'4M
M'N&UD7,UA)N=6$5Q+:+--+&VWS1;.MP(9 Q5T7R<J2H=0./U!^ G_!5O]JOX
M):)X8\/Z'\9OBG/X8\#ZUIVM>'-'T?QG-9'3[+2Y-0EM_#5S!>6.IZ)JW@B&
M^U&ZGET77-,U*QN!,B?N38V\Z_D->R,+:'9*P>3>@#?*-P&6)##&[GC)R26X
M  SL:-*RV22>8\8,DD44S8\MY7(_=-O^01LS<$X7 R0<Y']#<2_1X\,/$'#8
M;@[C3AS+,]CE'"E3.<RQN?X; <0T9XO'IT\=6PTL?0QE'"0JY;G$L)"%2KEV
M"HX>M"->GBIU,*L.0XOS*I7A4E+FI1QLYX.'L:+5*M.E]7=65&JL1AW4E2YH
M3E]7J*;E)NFG.1^N/Q&_X*3:Y\8_!>H> OBOX"^%WQ 76-:\3>)K_P 50>!O
M!WPPUBX\5>,MVHZSX@\0V7P^L]#\+C5([Z>XU./5[/3+=]0U+4KRTB@MU62$
M?GUXW^$-I-!IWC#P#XGB\5Z2]Q/!=6D,5JLWAV]@>VD:TU+3TN)GM[.*VOED
MM[R!+^U,1&[R96:T3R2\OF:9H9(OW:2^9;W,-LXA@A\R4%2498I7<N8R3NVX
M 0 9KL/!/BC4=$O[@QB*,7U@;*6X CA2.&=UFCN76,R1S3R+']G+31,P5(X=
MPGA#K_+F:>"&2>%N6U<7X?UJF7XEX_'SSSAYT*KR>MB(-4<9.#Q.+Q,,OKQI
MK#6664J.'J.C"E.+@\/AJ'Z?PSF6#QV CPMFF!CB,KH3J5\KKX?E^O8'$SBL
M5"$%!OVM&I5@Z?L,;+$4:%/GJ82EAZKG4EY!XTT.\L-4G6YEM)[AII(FFLEA
MAM97@PC".".*':><H_EJ&13C@9'"E2HP0006!!XP> 1]1W'OST(KZ?\ &_PU
MM<ZGXK^WV5LMS-!J":-9ZI'JLIM;R'SH;O3[OSK@7T9;Y9%BG+V\N^UD!ECD
M5/GC[%$B3R70G8$2"V9!M)<,26D+Y4@#[P!R!C< 2 :R?,L/C,'&4*LJLJ+A
M1JR5*5).NXQ;ITX3:NH+G^'F7+"_-I**^"XCRS$Y=F=:&(HTL*ZLG4I8>%:-
M6:I-)QK34=8PJ)J5Y)24I>]%1<'+%_S_ )S14\T$D6"X #@,N"""K<J1@]"O
M/L"H."<""O933U7]?UU/GPHHHH _L*_X,L_^4E'QV_[-#\5_^K1^%E%'_!EG
M_P I*/CM_P!FA^*__5H_"RB@#ZX_X/C/^2F?\$Z/^Q%_:5_]/_P8K^#[/!'K
MC]*_O!_X/C/^2F?\$Z/^Q%_:5_\ 4@^"]?P>T *!DX'X^W.*3H?\_P!?\*7/
M3V_QS@TXC .<#A6 )R>5##!'8@]"21P#SDT ,P>O^>Y_H:*>#G/3@ C'J,D'
M]3G/? ZTS/\ G H *EB94D1B P!#$'D$#JN/7OU]NF<Q4Y201T..<')!QSR!
M]/\ ZXZTFKIKNFNVZ[CBW&49+=235U?9I[==MNNW4U-3\AI8I+< 1O!'E4!&
MV0+M<,6SN+,NXX^4AN*RB,8]P#6[8&VNY!:73+%#)@+,4+M;_,-SJFX.Z*"?
MW9<[OO#Y\5C2QE'*GGT(SA@#@$=R"!SSG.:SI.W[MWYH);_:3O9WZOH[,[\=
M3Y^7&P=-TL3.:<:=E[*K35-3@X+6,-5*FW:,E)I.ZL1#J/\ /\ZMQC)V[LY&
M"-H/!#Y]#R#QZ G)XJLO+#Z],9S^'_UO\:OVL3W%S# J[C*ZQXSMW*VX,-V.
M."<$8P,^M:MI+F;:BKN36]K-_.UDVE_P3CIPE4G"G"+G*<X0A%7]Z4I1BHZ)
M_$VH[/1_"]I?0MO?#X??"34-.1PWB/XD78BN_G=9-"\-:=.LL0=%VJ9M9N'=
MY%5I%^S0JN#N3/@<JI-DA%4.@V<G "DX]SD$'!QT&.,@^W_%N_GU:P\"W4HC
M:&S\+0:1 R6L<*L=-NKJ+R))(@JS7$$)1#/+ND9&6-G.U:\.965%F5P6D=E6
M)<EH\*&=1G &[.WCJ <G@5\WD:<\/5QTTJ>,S#%8G$8MI[2C.6%HT4VM84L+
MAZ$(1^RN9.\W*;_9_%2:PN<Y?PMAI2Q'#W!W#^3Y1D:E&,7/#8G"X?/LSS+E
MDM<3FF>9YFF*Q%6/-/$551G2Y<)2P]&C12)O,((Y"XQG SP ,G.,'';D''<F
MNCB1X86CV??&XX.% &,8(!^ZXP.H.!TX-9\:L2DNPA2P/ "L,'(& !@Y7.1U
MXR<'%7FO29%8@8BV@J4 #!>SKC!);_6'G<2<EC7J5I3FTDD[+5;[>:;M_P &
MQ\#EE&AA8U*E2<H\[C&C)I_#)2YI.\4_=C9MK5I.T5(GCECE7:6,89BI8XRS
M+AM@STQD#< !EO3BOH_X.216^F^(Y([)=9U"WM)6T/2[^"-[!KXI,OFW%Y*H
M$$=N)?.\MG"7 C*%&(C ^;7FBO6,D,:6^[.Y%4B/).#M(8,JG:1P3C&"#@8]
MY^&U[)I^EZI;Q7-U:W.IP/;:9(%:2)YYH9H6:ZR!$ZQ$;HP^'CW>9%E@"/F.
M)Z<IY75IQOS3K8?]W)SY7&-:G.?,Z?+5Y.12]HJ<HS=+VBBU=W_>_ G&T<'X
M@X#&U:E.5'#Y?FT5C**I.4I8C*\=A\,Z%'&QJX/ZW#%5:,L!+'4*N&AF:P4Z
M].I&G&4/HKX1_!31O&&E2WGBVZLF6_6YQHEK$UGJHN$C<)<K>W#&&.V!3>L>
MT%T&.%;=7R'X\^'^CZ%8ZG>:3J27CV^NW.ER:<>+J.W7S7@O4*@QO&6ADAFP
MW[J3;D$L"/2M1LO'WP[L=(U#4M;F=)7O+ZRTW^U//COM-)6(W<EI#)NB4Y9%
M>18WVY"XYSY]KFJ76L3:CXAEM/W4Z1M+:I)++:.\PW-<JT\DKEBVX$R2NY=S
M@$;A7SV0TLWP^;8O,EGM/'95BY4/J^&PM-1PE*5"=6$\+&-17<JM.5.-3$0=
MU.DHR;Y9,_9?%?'^'.:\ </\%OPJQ?"''W#N!S+^V<\SNM5QG$6-HYQ@\)C*
M.=8B>$_=4?[/QM"LZ>3UJ?U?ZMF<ZF!BE7C)^!.,,PYX)ZC'>FUIZHL2W<S0
MJHB<[D"Y*INP2HS@\'/7&">@XQFXZ^Q XZ<Y_P *_5H2YHQE:UTFT]T[:KY.
MZ^1_GQB*3H5ZU%M/V=24$UM))OE:\G'E:];;IB44451B/C_UD?\ OK_Z$*_J
MK_X.SO\ DZG_ ()]?]HM?V?/_5D_&ZOY5(_]9'_OK_Z$*_JK_P"#L[_DZG_@
MGU_VBU_9\_\ 5D_&Z@#^5&GE,#.?\^O6D!' ('H3WQ]>O'&,<X&,X.*?D88Y
MR,@XP>.>G)_S^E $5%. W<8QU.>>F<8ZX/Z=#2$8)'I0 @..13P[<@DD'J>3
MC/!/Y?Y]64H)'3Z?AZ?XT 6(R\QV DN>$!R06.0>><'!&.Q)P>M/NHT5@8R"
MI!!'&01_$, #:P"G. <EAZ5 DC*V\$ALCD'GKGG.=PX&,D_= /6MJU>VN%V2
MH%B8,DJJR[HB?]7<1L^Z1@K$F2,/AEPI8 C&4FX24[)Q6Z]>_P"GGVN8U).F
MU)+W-I6\]M/EIIN]_>,$CG'7T]^W%)5FX@$,S1JV^/)\N785$D9)V. 2<;L<
M =.WI4!Z >F>>Q^F<5JM4I+9Z_\ #_UY;FJ:DDT[II->C\NGIWN(.HS@\CJ<
M#KW/8>]?:?P LD^%GA/QA^TUJO\ 9BW7@ZR?PY\)-'O;J1[W7_B7XBAOM%LO
M$=E:1\O8?#B".\\17;W?EP2ZDNFV8C=9I&7XL'4?4=>GXU]'7WB?7V_9YM/
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M#MC'T/6OY[-,U5],$B[ XN-C;@6RI0DC:01SR0?0Y //'])_QT2SD_X-R/\
M@F&E[$CQM^U]^UFL?F(KA7-P0'!8-M 7.3E5(X;CI^ _B3P_H4\B65NEM:2B
M(-#>10&,EV)_=3HH"'YC@MMWA<,KC!6O[1\(/HT\?Y]X6TO'GP^X[X8P&;X#
M-,VR7"\,8VI+"YQ5QL<=6R2EA:&+KR>7P_MC#0Q=3"UL5&EAHS5##3Q>&Q.)
MHU(_/8_.,)2QW]EXO"UI4YPIU765G3Y;*;;BGS6IMQ3M=[OE:3,B#QU9)%9-
M=B>Z,4A,MM'@ !,;<,02&SW/ &[[W!'&>(/$\^M2X,,=M:I([I!'G>Y)X,[
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MD85K#7#:'KVJZU:SWE\EK?W"7J:KI\6J:5<7MG(;<7-]/>^<DUJA22.VCF6
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M'/.#UZ?-D=:A(P?7I^HS72RIIGG7BB9GM0%,7*QR)(Q(^52"T@Y(8YY4 G/
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M#6[F.4B"32/#<<US8Z9=)\RQ[[ZYFDMWS'--(TJ@M''7RO$GA7P3XN9GX?\
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M>AX( P,\<>I'8_A7TYK.IL-.AMIE@N[14EA(@@+@%5B^9UD&Z/:"$+<9"HP
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M YP.#R#17ZK&TDI)III-.ZLTU=-7WW/P)QE%N,HM2BW&2;46FM&FGV9^LO\
MP=Y?L'_MC_MF_$']A:__ &5OV<?BE\=['P#X.^/=EXRO/AUX=EUVW\-W?B'6
M_A5-HMMJLD4BBUFU*'1]3EM5< 2I97!4GRG"_P <?_#C/_@KW_TCS_::_P#"
M NO_ (_7^TK;?=;Z0_\ HB*K- C_ !8?^'&?_!7O_I'G^TU_X0%U_P#'Z/\
MAQG_ ,%>_P#I'G^TU_X0%U_\?K_:>HH _P 6'_AQG_P5[_Z1Y_M-?^$!=?\
MQ^C_ (<9_P#!7O\ Z1Y_M-?^$!=?_'Z_VGJ* /\ %A_X<9_\%>_^D>?[37_A
M 77_ ,?J6+_@AM_P5W1@7_X)X_M-L/F! \ 76<%2!C,^,@G(/8@&O]IFBAJZ
M:[Z#3<6I*UXM-75U==T]&NZ>C/\ %DD_X(:_\%>68E/^">?[3@0G@-X N20.
M>"1-SC-,_P"'&?\ P5[_ .D>?[37_A 77_Q^O]IZBA:*W_#@W=MZ:N^BLM>R
MZ>A_BQC_ ((:?\%>\$?\.]/VF^>G_% 76/?/[_\ #\^M)_PXS_X*]G_G'I^T
MSZ\^ +GG)ZX,_7_]?O7^T[10%]O+_.Y_BQ_\.-/^"O8 _P"->G[37!W?\B!<
MX_2;CWY[?D\_\$./^"OA7:?^">G[3>,<K_P@%UM)&0I/^D#HI8#N.V<\?[3-
M%*RWMJM@4FDTFTI;I-J_K9J_]:'^+'_PXS_X*]X)_P"'>G[37./^9 N>>>X\
M_(Z>GIT! +?^'&?_  5Z_P"D>G[37_AO[K_X_7^T]13$?XL/_#C3_@KW_P!(
M]/VFN?\ J0+KM_VV]_QY]*<?^"&O_!7LDX_X)Z?M-#)S_P D_NOI_P ]^./3
M^5?[3E%'2W_#_P##!_7W;'^+*O\ P0V_X*]#K_P3R_::([_\4!<YZ'&!YV.,
M DX/3!ZBE_X<;_\ !7K/_*//]II@0 =WP_N0<]2<B?()./F## R.17^TS11L
M^FGEZ;][65K[/6P?\#\+V_-^;TUT1_C?>&_^"3G_  6Q\,Z5)H5M^P1^TY<:
M295N(+*\^'<MP+:Z1-@D@G^TI-$"%&$WLN%78JX!-X_\$D_^"PEX&GU+_@G3
M^TZ=1)B07-KX$N#&\$:;?+E@GNB""V678ZI\Q4*HP*_V+Y?NC_>7^=./WE_X
M%_*O(JY!D]6I.O++\-&M6ES5*M*FJ-2<EJW*5-*,N=V=2]/]Y:/.Y637Z)@?
M%_Q*P6"PF4T^,<\Q&6Y71C0R_ 9CC*F98/!T'&:IT\-1QCJU*$:"G46'4,7R
MX95*D</"C3G.E+_&?O\ _@C3_P %@[C[0(/^">G[4$$=R6,L9\ S%&4D87:M
MUA %7K\Q!SG(88Y&;_@A_P#\%>Y RC_@GG^TX$_@4^ +HD$G/)^T>^"!T!YZ
M5_M(45W4<'AZ"4:5-02MMJ]$DFW:[:2WWU9\MF?$>=9Q4=3,<?5Q,OWME)M0
M@JU256K&G!2Y*<)U)N;A!*/,D[:)'^+*O_!#;_@KR)$<_P#!//\ :;VJZ9Q\
M/[K<<$$G'GC\\A1W(K^C_P#X.1/^"<O_  4(_:6_:._8E\2?LY?LF_&WXK>'
M_ O_  3F^"GPW\9:QX,\+/JUAX>\>Z5X]^*VH:]X-U66"YS:Z_I5EJ.AW=]:
M.NT0:C9M#+-NE$7^BW5>/_7R_P#7./\ ]'75;RC&<7&45*+5G%JZ:\T>%.$9
MQ<)Q4HR5G&23379IZ,_Q;YO^"'7_  5_GE>:3_@GO^TVTC\L[> ;D$DX!R3/
MC&>G?')Z<20?\$.O^"O,1^;_ ()Y?M-$<]/ %SE>I8C-QSV R>>>?7_:4HH<
M8M.%DHI)66FEM-MK=!.$7'DLE&R225DDE9)6M:W0_P 6NZ_X(=_\%>[AE(_X
M)Z?M.;50 !O -R<G)^;B<X)&T8R<8JJ?^"&G_!7L_P#.//\ ::[?\R!==AC_
M )[U_M/44XI12BM$NGW_ .;'&*BE&*LDK+^NK?5G^+#_ ,.,_P#@KW_TCS_:
M:_\ " NO_C]'_#C/_@KW_P!(\_VFO_" NO\ X_7^T]13*/\ %A_X<9_\%>_^
MD>?[37_A 77_ ,?H_P"'&?\ P5[_ .D>?[37_A 77_Q^O]IZB@#_ !8?^'&?
M_!7O_I'G^TU_X0%U_P#'Z/\ AQG_ ,%>_P#I'G^TU_X0%U_\?K_:>HH _P 6
M'_AQG_P5[_Z1Y_M-?^$!=?\ Q^M"W_X(>_\ !7E%V2_\$\_VG"JC"!/A_/\
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MA&$7*5E=J,8IMJ\FKR<I-R9Z1C'1*T(J,=$DM%I=I*[ZN[LKG^+#_P .,_\
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5RLMD>3)RDW)R=VVV]&VWJV[]3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>80
<FILENAME>tm2135630d1_drsimg8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_drsimg8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! 7P# 2(  A$! Q$!_\0
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MU7P^-1ET/4@FHZ;;WESH]S<V,%_%;7?V&2WEN+6VFD>%/Y+OC]X1^$?[8O\
MP5%^,$7COP9K7COX??&?_@W(M?'HT#XAO=:7X^U6W/BWPM\4_!:^+;CPG)HN
MIVGC#3_$FE^'M8UBVT26PB7Q!I\@AMQ; VQ_-[_@GCXI_96_X)9_ +_@EE_P
M5Y^%TFA:AX/\3?#_ .//[*?_  5%MOAEXQO/B1XDTSQSX[L?$GCSX"W/C/PE
M#XK\0/X"\87?B3X?^$[*71HM&\.P)HLUI?W>G(=3BO& /]',D $D@  DDG
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M6HIK'A76?&^N:EX2N=2\6:KX;U>"VU/0=0UZYOKW1K^&.^TRXM;N-)5^I**
M/,O#'P9^$O@KQE\0?B)X.^%GPW\)>/\ XMSZ3<_%;QSX9\#^%] \8_$VXT"U
MN-/T&;XA^)M)TJSUKQK+H>GW=W9:/)XDO=4?3;:YGM[1X8I75_);S]AW]B_4
M_AG??!/5/V0OV7-0^#&I^-)?B1J/PBO?V?OA-=_#&^^(EPLHN/'MYX"N/"4G
MA:Z\:3_:;A9O%-QI4NN2K--OOCYK@_4]% 'RC\(/V$?V(?V>?&"_$/\ 9_\
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M;::&5@#^QV(L=VY@V&."  .IX !. !C&>2,-_%4M-7H?]Y__ $-J=0 4444
M%%%% !1110 4444 %%%% #7^ZW./E/.<8X/.>,?7(Q7\]_\ P<&?L=?MF?M
M_ SX#?M)_P#!/[QEK'A_]JK]@;XIZS\?O /A?PZK)XH\?Z?=^'X]$\4Z!X4>
M1OL6KZVFC6\@G\!ZS:7VC?$SPW=^(/ M[9:D=>MM)U/^A*HW&U&VX0X R !@
M ]>AX R>A &: /\ ':_87\5?\%./V\/VGOVOOV9/V38!X(^)/_!2+Q!+/^V+
MXAT+1=5\+Z;X#^'%IXO\2:_\2X?$>OYNM0^&_P +M1UCQ??:7XTT>)VU[Q9:
M&P^%]J^J)XCO= \0_P"C%\?/^"8OQ<\._!W]G[XB_LO_ +;OQL^ ?[3G[#?[
M)>D_!/X8W^F?\(]J'[-OQ-TCP-X8TJ[UW2/C+\$M2T6_CUK1?B3K'@_0$UG4
M%UZ[U'PQ;Z9HNI:+9W&J^'].EK]3/AG^S7\ ?@W\0?C%\4_A1\'_  'X ^)/
M[0'B#3O%?QK\9>%?#]GI?B#XC:]I%G+9Z?J7B;48(PUW<0K+=S-%&8DEU'4]
M4UF>)]6U;4-0N>)\<?L6_LZ?$CXP3?'/QAX0\3:GX]U#1-%\-^)[6V^+GQET
M/X9_$+0?#,EW/X>TWXJ_ _P]\0-(^"?Q=AT22[G?2!\3/A]XLDL/W36\D?V:
MW\L X#PE^T18VW[$6B?M[?$SX?6?@?XAZO\ L@^%?B[X[T.*TDN-;TV?_A7[
M>/8OAQI4UX7U&2S/BO6;RST#1WD5KS4-3B:9'U"Y>1_9_P!E?X9:]\(?@#\,
M/!'BZ4WGCV+0/^$E^)FHF<WIOOBAXXU&Y\:?$F[CO#F2YM9O&NO:]'822-(Z
MZ;%9H[F.(5Z5\0/AYX-^*GAV+PI\0-!@\3>'(/%/@;QFND75S?VUJ_B3X:>.
M/#OQ(\%7UR+"ZM);NVT;QIX3\/:M)I=T\VCZL+$:?K5EJ6C75]8W'(?'3]G_
M .$/[2O@NP^'7QM\&P^.O!VF>.?A_P#$FST2YU7Q#HB6WCCX7>,=)\=^!==%
M]X9U?1=3D;1/%6B:7J/V*2]DTG4%M6L=9LM0TJXNK"X /Y\+Z]_:>N?CI_P6
M"_X*%?"KQO\ "*7X]?L;>*=;^"?@3X;?&;X>:EXKMD_9A^!?PJ\+_&Z_^$?A
M;Q7%XU\.W'P6MOCMJFJ:QXQU;QCH.FZQ:^(?$)\(ZIXEL+VP\+62Q_0G[6'[
M*7BC]LWX;:A^V5X?^)W@W]G7P'^UQ_P31TSX"_M7:3\8?#VL>)]2^%/P!\92
M1?&77/&7PZN+"ZLK2#XE>$/#_BKQWX<NM.U^&R\.ZG<RZ'K]_LO_  [!9S_I
MG\7?V#_V3OCQ\0I?BA\4OA';>)/%>K:=X>T7QS'9^+OB!X7\'?&;P]X4O#?>
M$_#7[0WPV\&^*] ^&W[2/A?PG=32R^%_"_QZ\)_$;P_X<:ZNAI&G6,-U<B;Z
M%\;?#OP;\2-.T/1?&N@QZ]H^@>,/"7CG3-)N;O4K;2AXI\ ZW9>*/!FI:AI]
MA>6MEK4/AGQ-I>D>)-*TO68+_2+;Q#H^BZ\EDVJ:)IES:@'XD_$[]HKXO_ +
MXJ?!:/P5\)-'\3?&KX@_LU?M!>.?@SX+^.WBO5_"^D? []C;]E7P]\.=5\7:
M!K.H:58ZGJW_  T)^T'XDUSX5W?B>;4[?[#X>&FZ=IWB>_:W\ C3[W]A?V:_
MCCH7[2_P ^"/[0GA?3=1T3P[\;OA9X)^*.D:'JYC;5-&LO&?AW3M>BTF_EB0
M07-QIQOVLYKNWQ;73PBXMBT$L9;F_P!HO]DS]G_]K'1_#6A_'CP _C&U\(ZA
MK-YX>O=,\7>.OA_XBT^V\4^'[[PIXS\/#Q;\-?$WA#Q3=>!_B%X6U"\\-?$G
MX>ZAK%UX$^)'AR8Z%XY\/:_IT<5HOO'A[0=$\+:-HGA?PSHVE^'?#?AS2=.T
M/P_X?T/3K32M$T/0]&L8M-TC2-'TVQBAL--TG3+"""QL+"RBBM[.UAM[:WBC
MMXPH -ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:7N_^!/U=K.3O9-I*+;:M;71<LM=KV=KZ*]G97N]W9?,_ET_X=X?\',&<?\
M#]?X29QG'_#(_P ),XSC./\ A4_3/'UXZT[_ (=V_P#!S&>G_!=7X3'_ +M%
M^$O_ ,Z>OZC< C&0,X&>X4$= !GJ,#W!]*ECS@Y_O-^AQ_2M8RYGII91;NFF
M^9;Q5WI>VNJWBFY)V6MWY*-]?M.]TM-EIOKW/Y;?^'=O_!S'_P!)U/A-_P"(
MB_"7_P"=/1_P[M_X.8_^DZGPF_\ $1?A+_\ .GK^I6BJ _EJ_P"'=O\ P<Q_
M])U/A-_XB+\)?_G3T?\ #NW_ (.8_P#I.I\)O_$1?A+_ /.GK^I6B@#^6K_A
MW;_P<Q_])U/A-_XB+\)?_G3UX9^T_P#LR_\ !R;^RU^S;^T!^TQK_P#P6U^&
M7BS1/V>_@M\3OC9J_A73_P!DWX06=_XFTWX7>#-9\;7WA^QO+CX2/;VE[K-M
MHDNG6ES<*;>&XN8WG*0B1U_L(KQS]H;X)>$/VEO@-\9_V=OB#/KMKX#^.WPL
M\??"#QI=>&+VTT[Q':^%?B-X7U/PEKUQH.H7^GZM966LPZ9JUR^F7=WI>HVU
MM>"*>>QNXXV@< ^>O^"9O[4?B[]M;]@G]EK]JGQ]X>\/^%?&OQL^%.C^+_%6
MA>%&OCX;L]>:YOM+U-]$CU.6YU&UTV^N=.?4+6PO;S4+C38KI=/?4M2-M]NN
M/NBOG;]DS]F7X=?L:?LY?"3]E[X2W'B:[^&_P6\*Q>#O"%UXRU.TUKQ1/I,-
MY=WZRZUJEAIFBV5[>-<7T^Z6VTJPA\O8B6ZA<GZ)H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH C*'!QP3C!.#MY' !X^7!*]AD@8R<_C
M9\$/V:OVS?V5=8_X*O\ Q>^%W@3X,?$GXG?M/_M=:/\ '+]F_P %^,_B?K?A
M7PIKOA)_!'PO\":Q'\1O$VF^#M9U'P?J>GV6@^)]4TW3['2]>AN;JTTJQ:[L
MX+R2ZMOV7HH _F;^,W_!*W]MGQE^UQ\3/"/AS6O@1>?L&?M _P#!0G]G#_@H
MI\1?'/B'7?$]I\=? ^O_  0B\%WOBGX+>'?!%AHLOA_Q!9>.M<^'6@'2O&5]
MXDM4T/3M2O3=Z;+/:A9_R[\7?LC_ +(G[+'_  =>?L+ZG^S?\3+GQO\ $[X_
M>/\ ]MKXZ?M6>%M1^)W@KQQJGPR^+OQ+^$GQL^(<'ANY\*^&-,TS6?AI87^D
M>-3J_AS0/&"7&JW_ (;N=)OX;V_C$NH7?]TDN H/RY!X# ')P<@<@_=SG'.W
M=P>0?XH_V@K?]CN'_@[E_8)?]GIM.;]H&>+X[/\ MJ_9;CXC37H^)J_LB>,H
M_AO_ &E%XMD;P=;,?A.OA]K>/X91PZ,^;B36T.OM=,0#^UY>A_WG_P#0VIU-
M7H?]Y_\ T-J=0 4444 073,MK<LAVNL$S(Q 8*PC8J=IX;! .#P>AXK_ "C;
M7_@X;_X+)36UM(_[;'B-WD@A<EO@]^S?NW.@)RW_  IL9YZX 4YZ=:_U<;O_
M (]+K_KWF_\ 1;5_AVZ=_P >=E_U[P?^BUK_ &@_8^>$GA=XK9QX\T/$SP[X
M)X_I9+EGAU5R>'&7"V2<2K*ZN-S3BF&,GEZSG!8V.$EBH8>A'$.A&/ME1I<^
MM.#7YUQ_CL;@8Y8\'C,5A75>+C4^KXBK14U"-*47)4Y1YFG)I-WT=K'[4?\
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M0]606&K6GGRV$=O<F>QFNK6X_D-K]NO^#<7_ )31_L5_]=OVC/\ UD;X^U^
M?2M^BW]&_A;Z,7TA.).'? CPAR3/\B\&O$3-,FSC*_#GA# 9GE698/AK%5L'
MF&7X["912Q6#QN$K)5L-BL-5I5\/5C&K2J0G%27JY%G><5\ZRFA6S3,*M*KF
M.$A4IU,9B)PG"5:*E&495'&47U333ZIG^J:@(&3CKP1UR#T[8QT!';CWJ9.G
MX_X5$/NC_>?^8J5.A^O]!7_(A2U=WJTHM.RNN9.-KI)M)+2]WNVVVV_WMO7U
MDV_N?^2'T445L 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 1R'"C&<[AC SSU]".W /!. "&*D?Q3?M"_%_]
MF/X@?\'<?[ ?P_\ @K\/M,\*?&/X+V_QY\-?M2^*[+X<^&/"5[\2/'GB+]DK
MQMXH\$ZWJOC'1B=<^)D^C?#V]T?P_%J_BO\ TW0XK'^Q;#-C&A/]K,N=H SD
MD8QP<X)Z@@],]/HWR;J_CA_:N^/7B'XI?\'7G_!,+X7ZK\$/BC\,]'_9\\.?
MM&>$O#'Q&\;:/?:;X)^.^G^+?V9?B%XRN_%OPGO;G2[*UUKP_P"&-0OY_!NM
MWNGWNJ01:_I5S://!-"\"@']D"]#_O/_ .AM3J:O0_[S_P#H;4Z@ HHHH KW
M?_'I=?\ 7O-_Z+:O\.W3O^/.R_Z]X/\ T6M?[B5W_P >EU_U[S?^BVK_  [=
M._X\[+_KW@_]%K7^\?[#S_D>_2,_[%'AA_ZM^+S\O\2?@RC_ !XW_P!-T2U1
M117_ $)P^%>B_*)^3O\ R_)!1115 %%%% !1110 5^W7_!N+_P IH_V*_P#K
MM^T9_P"LC?'VOQ%K]NO^#<7_ )31_L5_]=OVC/\ UD;X^U_-7TS/^42/I,_]
MF+\3?_66Q9[/#O\ R/\ )O\ L9X+_P!/Q/\ 5.'W1_O/_,5*G0_7^@J(?='^
M\_\ ,5*G0_7^@K_B6I=?\$/SD?T<]_F_RD/HHHK884444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1R_= P#EA@
M'N1R!^8^H^\OS 5_'%^U?-^U'+_P=?\ _!,./XW6WPOA^"T'AW]HU/V49O!+
M:BWC2[\ -^S+\0G\=2_%5;RYFM4U]/B*=9@T,:9%:VQ\/1VAEC>X\V5_['9,
M[>#CD=>F!S@^W'S#N,CC.:_CA_:N\#_M$>&?^#K_ /X)A^)/BY\9='^(GPF\
M=^'/VC-5_9K^'NG>%-*T*_\ @IX'TS]F7XAZ3XO\,ZUK=AHVG7GBZZ\2>/(-
M8\46NHZOJ&MW=C97L.FPW5M:006<0!_9 O0_[S_^AM3J:O0_[S_^AM3J "BB
MB@"O=_\ 'I=?]>\W_HMJ_P .W3O^/.R_Z]X/_1:U_N)7?_'I=?\ 7O-_Z+:O
M\.W3O^/.R_Z]X/\ T6M?[Q_L//\ D>_2,_[%'AA_ZM^+S\O\2?@RC_'C?_3=
M$M4445_T)P^%>B_*)^3O_+\D%%%%4 4444 %%%% !7[=?\&XO_*:/]BO_KM^
MT9_ZR-\?:_$6OVZ_X-Q?^4T?[%?_ %V_:,_]9&^/M?S5],S_ )1(^DS_ -F+
M\3?_ %EL6>SP[_R/\F_[&>"_]/Q/]4X?='^\_P#,5*G0_7^@J(?='^\_\Q4J
M=#]?Z"O^):EU_P $/SD?T<]_F_RD/HHHK884444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 44U75OND'W'3//&>F1M.1
MU!&" :3S$S@L ?0G!/?C.,_4>A]#@ 2497@X^9>??/R_^/8('<X'>OXX/VK/
M@/XQ^%W_  =??\$QOB?X@^/'Q/\ BCX=_:!T+]H[Q=X*^&7C34=5O?!7[/VG
M>%/V8?'G@W4_!_PLMK[7M4LM-T;Q5JNG3^-M>MM)TOP];OKFK23SVEY<2/>R
M_P!CTA!7K@ \MG &"1RV0,@^I^5@#U%?Q2?M!_!;]FSX<_\ !W-^P3\1O@W\
M2+?QC\7_ (XQ?'?Q/^T]X1B^(7A#Q7-\+_'7AC]D/QCX4\%^'KGPCH%I!XA^
M'$FL_#ZRT;Q,NE>,[B\U#6TU,:SICQ:5+!$H!_:\O0_[S_\ H;4ZFKT/^\__
M *&U.H **** *]W_ ,>EU_U[S?\ HMJ_P[=._P"/.R_Z]X/_ $6M?[B5W_QZ
M77_7O-_Z+:O\.W3O^/.R_P"O>#_T6M?[Q_L//^1[](S_ +%'AA_ZM^+S\O\
M$GX,H_QXW_TW1+5%%%?]"</A7HORB?D[_P OR044450!1110 4444 %?MU_P
M;B_\IH_V*_\ KM^T9_ZR-\?:_$6OVZ_X-Q?^4T?[%?\ UV_:,_\ 61OC[7\U
M?3,_Y1(^DS_V8OQ-_P#66Q9[/#O_ "/\F_[&>"_]/Q/]4X?='^\_\Q4J=#]?
MZ"HA]T?[S_S%2IT/U_H*_P"):EU_P0_.1_1SW^;_ "D/HHHK884444 %%%%
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MC_,O_)O_ )6*Z_F7WO\ ^0-*BLW^TD_YY-_WT/\ "C^TD_YY-_WT/\*.:/\
M,O\ R;_Y6%U_,OO?_P @:5%9O]I)_P \F_[Z'^%']I)_SR;_ +Z'^%'-'^9?
M^3?_ "L+K^9?>_\ Y TJ*S?[23_GDW_?0_PH_M)/^>;#W+# ^O%/FC_,O_)O
M_E8[K^9?C_\ (&E16<=2AW;4'F,>FUE*GZ,N[.>V ?R.:LQW D*KL92W4'JH
MVELL, A<@J"0 3@=>*+IMQO[RW34DUUNU*,=/.^^F]D'5+JW)6:DG[JO*ZE"
M+25MWHWHFWH6****8!1110 4444 %%%% !1110 4444 %%%% !1110 R3[N
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MGX%_^92OFS:W_/0_]\K_ (4;6_YZ'_OE?\*_GG_B._C1_P!';\3/_$WXH_\
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MX%?#+Q;XMU1];\2:WX?2^U;5'MK.T>[NA+<0M)-!I]O:6<<NS;N$%O#$V<A
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M\07=E97D6G07EI:0PV47]C[@E>#CD>G?C!!X()(!!Z^QY'\5?[1'@ZP\/?\
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M ?U'7?\ QZ77?_1YO_1;5_AWV"D65FW!7[- =P.0/W:YR>V.A/0'@D' /^D
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M\'_J+Q#=_P"RT?+_ &NGMIY'Y>45^H?_  XL_P""V?\ TCK^(_\ X</X-?\
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M^3J8*NG7H-8G+,7!*J^9JFIV4:D&_N[<?[A_7_"C<?[A_7_"OA+;_P %XO\
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M&C%4X1:G.3C>\$VW=?UNT5_+3_P]+_X.&?\ I !;_P#B6?@7_P"*H_X>E_\
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MS<>.]!_8I^)?QM30O$%M+J/A_1_C/\,/AKKNJ>(O"WB?2-)U+3=0;2]+\?\
MAV]L=0TR#4=*U&72S$B7&GS7"21<]6M&EA\=B&W*E@%AY8A27-5C#$^WC3J4
MDVX5XNK2J49*/L_9XF,,-4<9U*<Y:4J52M7P.'2C[7,:SI4-E!3A.A&4*M>2
M<*,7'$4ZM-S:E*'UFI"%6-&LZ?Z[;P,%@0#CVX8@ ]./F90?3(H#H6QGMG&>
M>3@#IZ\'C\*_"G]@/_@J-\6OVDOV'_VB_%?QO\*>!/A[^V]^R]\*]2\;^/\
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M(14YJM6C5G5YE1I.E347%0Y98SZU3DI4X0O.%*I*G[+WO:R<:EW549/\V/\
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MUSP;^S]^S1H=]%XL:S>\,L^EV/Q)^/?B[Q[K.K:5#-]EGN_"FD7\D0N"6/\
M0!7SE^R?^S?X*_9!_9L^"O[,?PYN+V\\(?!/X=^'_ >DZGJD4$6K:[+I-JBZ
MCXBU?[*%MVU?Q!J<E]K>HE-Y:_U"=VEFD)E;Z-H **** "BBB@ HHHH *8>A
M^C_SHHI/9B>Z]?T8WLOT?^1IS=&^B_S-%%)[?]O+_P!*0E\7R?YCFZ'Z'^5(
M?O+_ ,"_E111U^?^8NB_P/\ )!W_ .!?^R4@Z/\ 5OY444EU]'_Z4BGT]?\
M,5>W^ZO]:/X_^ _UHHI]?E_[>)?U]R$/1/JO\J7^/_@/]:**%U^?_I3#_/\
M^1'4445104UN_P#NM_2BBD]F)[KU_1C1]Y/]T?R-(/N-]?\ "BBA_P"7YH.B
M_KN.[O\ 0?R-#]!]?Z&BBCHOE^@/=?/\@7HOU/\ )J3_ ..444Q/I_B_S''H
M_P"/_H(I&Z-]1_):**G[7R_R$MOG'\HCEZ#Z#^5+115%A1110 4444 %%%%
B!1110 4444 %%%% !3'ZCZ-_*BB@!QZ?BO\ ,4M%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>81
<FILENAME>tm2135630d1_ex10-3d1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex10-3d1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !3 E@# 2(  A$! Q$!_\0
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M_!3GP1\3/VE_V-OC5^Q!\-OAYX>^*OCCP/X'_9W^*/A[7]8^*%QH7A,6L/\
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M).SO=7LS?ZS%V2?1-;72:36[[?\ #L_;9"K* 2,D9!SWP/?V[_UX<64# (Y
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MV/"/^"CD[Q_\$_?VWY-B2BV_94^/=Q!%&ICBN4D^&7B^*QTYHW )5[<VZNH
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MY,5P>AS@E2,YP2. <?TI0645O$UO]B6*W:!5,*QJ\$:JB6ALX8HXEC2VDA4
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M8R-/U&P=I(XYL*R2,,L2:]7()C8D$DYX.>?D!/'7KGC\AQ7+B,0_J6#PUO\
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MSX*>,/ FC?\ "T_'F@ZY$0(_%GBV^\,Q^%M4T,,KZ)%=13JBS,D@^\_V,/\
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MZDU:4850>H4#]*;$"%.00<C@_P"ZH_F#4E?+GT@4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2'H?H:**'L_1_D!4R2IS@Y90>!R
M"5!SQZ&O"_BO\$/@Y^T-;Z[\-OCI\+O /Q:\#7VE)]H\.>/O"NB^)K',Q1)&
M@;5+.XN+1F1F4-:3P,@=PA7>V2BNBFVJ?,FU)4W)--W35FFGO=/6YY\4N=+H
M]UT>O5'GOP?_ &,_V4/V1;%+?]FC]GCX1_!==<U_3QJLW@;P1HFEWMZLTP61
M)-0-K-?K&1C$<=RB(0K(JLJD?6L44;>5,RAI71"SM\S=S@;L[1DD[5PN3THH
MK*O.<Z<)3G*4G)WE*4I2?OI:MMO8Z()*I))))15DDDEI%Z)>;;^9<"J#D*H/
MJ  :6BBH.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>82
<FILENAME>tm2135630d1_ex10-3d1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex10-3d1img02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !9 HH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BHGF2-2
M[[@JXR=C'@_Q  $E1D9(!QWKA_B%\1?#?PQ\.ZAXK\6274.DZ;"TTW]G6-WJ
ME_((K>[N72WL;2%Y97\NUDV;3ALD-Y?&[\%OV@/^"HOQ&\>)-IGP5LC\-_"%
M[+]F?Q+J,CIXRNVFAD41P2HL=EI,BJ_F1K%<7;JR@%V8 4 ?L1^T/^UC\&_V
M<M)2Y\>ZZ)M?G DTGP3I<:77B?62Q"(UM9/@V]O&\D,DEY*42)&C;E7!K\*_
MC3_P4^^/_P 2/%ME#\+[D_"+0(KI+G1M$L_[/UCQ#K'V60N7UJ60A)TN8XI/
M.M+$2K#""TH5US7RQ^R[_P %"=(_:*_;1\$?\$_?C3X/3X[VOQ*OO%5K?_$?
MQ]I::3XX\#76B>"M6UPWOA3Q1((M9U2S":#!9B"'99,LQF(DE$0K\Q?V([7X
MO^%_^"G'ACXY?&0>([?X$_ SXO\ Q&TR#2=?+H;SPI;P^(_"VC#2-"O"EKK#
M6]M=6]U<7FH7,*RR0L\0\QD< ']4?[-?_!6'PYXE_LOPS^T-H<OA#7IY!#9>
M.=&@BNM$NH$G6&>ZUS3W"SZ$0Q\VYFM5GA2 -<N4PZ)^R6A>)_#WB;2;/7_#
MFLZ=K^AZG#'=:?K&CW46HZ7?6\C>6DUG?VC2VMS&64J6AE<!LKU!K^0S_@J7
MX$^%_P"T!^U]^P!\$?V7_B58_"[P?^U[J_BK1OB/X@^&C,+^U:WO85LVGTFW
MEA?2)+Y1J%I?KF"-I=TR"2'9)+Z_IM[^T[_P3+U+X>_L^Z5\4YYO"OPZ\+QV
M_A#P]+JLWBCP=J_A]]6>6234]/NH[>]@U6]GEF\VXDM[66U:1VA:1!N(!_5<
M)4+*N<,P9E5@02%QD@'L,C_]52=:_*;]G_\ X*D_"?QY?:1X8^+]G_PJ7Q7K
M>HVNE:1J-Y>6UWX0\0:K>LMO:6EOJD<HEM+Z[GVI;6<L!\QF969=GS?JI%(9
M 25 Q@'!SA\L'0YQRI SP,Y&.* ):*\8^-/QX\ ? #PY:>+OB3+KECX>OO$.
MA^%K?4-'\/ZIXA']O>)+R+3=#T^6VTFWN;J%]1OYHK6*=H#:1R2+]HN(0Q*U
M?&?[0/@CP'=ZE9:_IWC<SZ1X*N?B#J7]F>"/$>J16OABR9/MTYGM+&2.?4+*
M%GN+C2K1KB_"12)'#)-LC< ]Q_K17SS9?M/?"+6/AGX,^+OAG7+_ ,8^ /B#
MJNF:+X6USP?H&M>(A=ZEJ\SP6UO>VFG6,EWI#0W4<MGJ!U2&T%A>QR6TY$JX
MKB=9_;C_ &?/#\/QQN]8UKQ98V/[-UU;VWQJU!_A_P",IK3P,+JRM=3AN;U[
M;1IWOK4Z9=QZC+/I4=\MK9J\]T(%";P#Z\HKQ"__ &@/ &GR?#J)D\57\OQ4
MT'4/$W@V#1O!GBC6);S1=(MM*O-1U"[%CI4T6FQ6]MK6E31Q7<J7ER+L?9[9
M_+8GD?A[^UU\&?BIX>T_Q;X%OO%VM^&-5T?Q/K6G:T_PY^(.D6EY;^$WN5U>
MTMSKOAG3#+J<:Z=JSQV*;I9AIDPB\QI;<2 'T[17S'\-/VP/@#\7O^$=_P"$
M&\:2W8\9>%]?\9^#3X@\.>)?!*>+O#'A;4)-+\1ZMX=E\:Z3H$6I6^BW<%RN
MI!'22T@M;B^E1=/B>Z6_#^U/\))_#7B#QHMWXH'A#PYX7E\<2^)D\$^*[W1M
M9\(0.T%UX@\+W>F:3?IXALK2;Y;E+#=<) 'O%A>T"S2 'T;17R/XA_;?_9W\
M*>!++XGZ_P")_$6G?#J^\#:'\1XO&+_#?XCRZ'!X.\17B6&BZI>W,/A1VL3J
M5RZBRM)XQ<R1O#*\<:3Q%K=]^VE\ =*U'0-+UG7O%VA77BCQEH?@#0GUOX6_
M$[3;*_\ %GB:UBO/#NF#4I_"2V%NNLP3*;&\N9XK.1P\33I(I4 'U;17F.A?
M%SP=XF\5>._!6BS:S<^(/AM-:VWBV&?PMXIL+"SNK^T6^LH-/U>\T>'2]?:>
MU)F/_"/W6IM$F/-5&(0^'G]NW]F&+X;W7Q?O?B%<Z9\-+#Q^_P ,-1\8:GX,
M\<6>E:;XTCU,Z.^F:BTOAT3V%N-1#6K:K=P0Z5"ZDSWD2$-0!]?4?Y_.O&O$
M_P >?AUX0UWPIX;U?4-5EU;QOHFJ>(_"PT7PQXE\1:?J^BZ-:1:AJ-_!J>A:
M3J%E%#!8S1W2_:9H'FB97A6160MQG@_]KKX%>.M%\,^)?#_BJ_C\,^,IK>V\
M,^*/$?A#QGX0\.:O=7=Z=.M;*TU?Q-H&F6KWEW>JUK9PLZ"[N!Y4#NQ&0#Z8
MHKP#P]^TU\(O%>N?%WPSX?UK6M0U[X$WAL?BEID?@SQDMSX=N1I]MJBPPH^@
MJ=:DGT^[@O;:/1?M[SVS-.@\M'80Q?M/?"B[^P#3[WQ'J+7VD:1K]S':^#?%
M?F^']!\0/<1Z)K7B>)])6?0=.U/[--):O>Q+<R0123I:E%H ^A:*^19?VX?V
M>X-=L?"K:[XQD\4:KX6U[QMI7AZ#X5_$^35=5\*>&=4GT36O$.G6DGA&*2?2
M+?4[2[MH;IEB%W]FEFMT>)X7EO6_[:G[.MSX@UGPR?&NHZ?J7AW5O#.@>(KC
M6O WQ!T+0_#VM>-;32[[PEIVN>(]7\+6>B:3<>(+76+"33EO;V'SC*R@[HI0
MH!]645\W:5^UA\$];O?C-IVE^(M5N=1_9ZN-)MOC%I;^#O&EOJ_@Z?7K>[N=
M%@.FS>'EN=;N-2M;1KRVBT)=0,EE+%.A=BT2^Y^&_$5CXHT?2]=TQ;Q;#6=-
MM-6L1J%A?:5?+9WL:RVPO-+U.WL]1L+DH<RVMU;1RPL"L@#$ @&]1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !113)&*([!=Q568#(4$@< L2 ,GN> ,D^X ^FJZN6"Y^4X/!'
M/XU\X^)OVGOA?X7\;V?@/4M9A;7[[6/"OA^TM[?4]$6WFUSQ<MVVFV$<MWJ5
MK-.T,%E<S7SVEO<?9E4*T9=AM]'\5_%SX;^!=5T'1?&/C7POX:U;Q7J%EI?A
MG2]8UBTLM2UZ_P!0G%O:6^FV4KBXN7FE+1IMC +@8)5@0 >DT5Y?K'QD^&>@
M:W<>'-:\:^&]*URT\PW>GW^IQ6DEL+>QGU6:.:24"*.X72[>;4$M6D\^:U7?
M&A#*6M>!OBQ\/OB2-2'@7Q9H?B=]&DMX=4BTF\\Z;3VO+>*ZL&N8&2.:*"\M
MIHY[><Q^5+$ZO&S T >C45QFI^/_  EHVL67AW5M?TK3]=O[.?4;?2[F]CAO
M)--MCY=SJ"Q,0T5I#+\AN+K[-$<,5<[&QRUC\=OA'J7A_6_%MA\1/!U[X6\.
M:U'X=UOQ!9Z]9W.E:=KLOV<+I$UY SP2Z@\MY;116]K)<-*\N!AL*0#URBO'
MK[X]_"#3M%?Q#=_$'PK;Z1'+JT!OKG4XX(([C0EC?6X;CS%$UH^CPSPSZH9X
M5%E;S+/-B-@3Z98ZM;:E9VVH6<D-Q97<%M=6UU!,MQ;W5I>0)=6ES9SP>9%=
M036\L<JRQN4*$LI9<%@#5HKS#X=_%OP9\5;'7]2\$:C%K%KX7\<^,_AQKKJ2
MDNF>+? VNS^']9L+J J9HX;BZMS?:7=*K1ZAHESI^KQ?Z+?1E?0&O@,$1-L)
M!5V9-KI\Q+IL,C*!''(P\U8U#*!*T2$RJ 7^M%48[X28PF"2@($D;!-VX9:1
M6,;X==A$3N0P;=@+DQM>L"%,)$DC%44.XPJA%E>0-&K1A)-ZY1)1Y:^?G#[:
M -*BL[[<06!11M#9<.QCW+G=N<QJ(XP-H\U\*9"4P"N61[YPLCQ1)*%5B!YQ
M7 &=HD+1CRV8_*XPS(2A42*P:@#2Z45P7C_X@:9\.O!'BSQ]K=GJ%[HO@W0=
M1\2:Q;:)"M]J[Z5IENUU=O8V326ZW%PEO'-*(9+B D1'Y@2*\F^%7[5'P[^+
M>MZ'X;TG2?&WA?7_ !3\/-,^*WA72O&V@1:/<^)? &K2V]O;^(=&:RU'5K:>
M&&XNK=+RTFN+>_MED\U[;RP&(!]+452%VQ"XA<ELA-K1G?@;\J-^\ )RPE6-
MP2H"MDD>6_&;XQ>%_@AX U;XE>,H-9?PYHE[I-I?#0K.'4]2$^KW]OI5L%M1
M=0JT2WEW;)</YI:.)VD$;K&: /7Z*C1R^<C;P" ?OC(!PXZ*2""!DG&<X((J
M2@ HHHH Y'7H(9=5\,)+%',DNKW:2),GFH\<OAOQ$S1O')N1E#0HRJR84Y&,
M$@_!_P"T9_P3B^#OQI2[UGP?:VWPP\;OL*:AI%I&?#-[(R.'6^\.1NUFEP'V
M!;BRCMGB"\)*6+U]ZZM_R&O#._H-6N2NX=QH/B $KGT1FR1T4DG@FOP;_;E_
MX+@:#_P3V_;N@_9W^-'PRO/$/P5U[X9>"?&EMX]\%RN_C#PIKVO7^MP:FNJ:
M-?2&RUS09+;1I'B73UM[^&5Q&DY,B@@'\T'P4_:%^*7C'_@IO\,/AC\"O!FE
M6/Q&^%7Q1^)_@>R\:P:3IU]XRU5?#.B^*-"US4M)O]5@"VUG)HJZG=^1<&2)
MO(CVAF" _P!2'_!67X<> _"7_!.KXM_M3Z!X:T.U^.GPU^%GASQ%H7C>RMK2
MVCN?$%_<^']+U2YUK3;5&T/4GD%Y>-/'/982[82LYP ?Q'_8*_X(]^*_VC=:
M^)G_  4 \$?&S2]$UK4OC7\4]6^%?@W1KB[@:71/$&L:FN[Q5K<4IOM)OKCP
M[KD=P-(BEBN;.:62/4FD,BFN%^!?[7/BC]JK]I73?^"2^MZOX@NOV??C'XH\
M6?"GXS/JH>ZU&*?P7#J>N(O@V^FF9].5-=\,1)/=0X^T61,4Q DQ0!\5?\$6
MM0T#XN?MR?"/Q7\:_$^J7WC2\^*^A:9\-]>BUG4K+5-*UR]M[JXNK?0%B'V*
MV61MC*R0)%',6*1[0B#]4O\ @M+;:Q_P3SUWPAXDG\2:U\7;GX[MXDM_#LOB
M.[N)-5T6Z\.O!<.^N:E+))+?)"+RV^S):FTMPRMF&7)"XW[7%GX<_P"")/Q8
M^!OB"Z\">%?'ZC7K_P 5_!/2-#TZ&P35)/# 87DOB"\,0NM,O(H;J",W$4JL
MWS3!QYI"_0'[4?P6\:_\'%'@']CGXE_!F+_A1/A#P-/XRO/B[=?$5'U2;PZ-
M=72X+5?"-M;"#_A+5U*.PN387:.MK:3!#<H621F /Y7O@G\;_BI\;_VP/V=+
MOXB^*KF\L3\:OAF(=#LD&G^'K,_\)38.L,-C;1PQ2.H1&,MP\\Q()$@W,#_K
M!0IM>8J,!I,D?PELL68#&=Q!4,<X.!QQD_Y@OQB_9;\$?L9_\%?/ G[-?@;7
M_$'BGPK\.?CO\#X;+7O$;6S:S?W&JS:#J=\][]@2'3X(6N+MA9PVL2R)$&6X
M=R U?Z?R#YI,9 W CIUP"V/8\9[\T ?)W[9GPX\6_$[X*WF@>![ :IXBTOQY
M\,/&D6FI(L5QJNG^"_'>@>(=:TZUD>2)1?3:38WGV2)I$6:4B($[F 37?%^M
M>+?#WBWQCI?PZ^(MK:0^ -0\.:1H&L>$K_3_ !3K7B/69PEU:67AF^A%P;"S
MW1+<:W>Z;#I4\*RRQ74EJQGKIOVH?C)JGP&^&,WQ#TGPW9^*YX_%O@;PO+I-
MUJ$FFAD\:^*=*\)Q7:W,88A=/GU5;J1.KHDBJ PS7._M/?'C6_V?OAQX,\<6
MWA#3O%]]XD^)7PK^&U[8/JQTVWL+CXE^+]%\*6^KI<3!YI[+2+K6%O9HXV$D
MD4.!AFRH!\WVO[/GQ(^&/Q@^&WBSX"Z>4_9W^*GC3PKXC^.7P/UQ(] C^&7C
M*&VNKRZ^+G@6RA\F32_[>FDL[3QMX(TVX'A]M2,.OPZ;'.UX*[']GWP#KL_Q
MU_;[M?B)\.]?L_ 'QM^(7A>[\.77B2S_ .*:\>>"K?X2:'X \4QVPCN9DBA:
M\M=0LY[.[BMVO[-1>(7693%[Q\:/COHGP;\1_"'1=>LC<6GQ1\;V?@O5-7AO
M((;;P<FOV-[#I&O:T]S(@ATJ]UR+^Q[:;:BM.\<8E5OE'/\ C;]H34O"G[4G
MPV_9SC\''4K/Q]\*/''Q/E\6QZE''<Z-#X&OUL[G0(='6)S?R:A%=6L=C*6
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MW$UHDLD4GFK7S/\ %3X8?&;7OC=^U#XWTOX5^/\ Q7\-V^-/[.'C;5/A=?\
MA :9IOQW\"?#[PE9Z1KUQX/URYTV/5$\7> M>TJSU;0M,M]8TZV\26\%M;-
M[$30?MT(HPNT(NTDDKC*DL2S94\<LQ)XZDF@Q1D %%(   (R  "!M!X4@$@$
M8(!QG% 'Y??%CPAXFU_]N']E?XB^!O /Q&@^'?C3P=\0M)_:EO?^$7U'2O#V
MN:7H_A^/5?V?M.^(UKJ4, AU;PMXW:_N+&\MD%W9Q7,NG7\DED\5O%^G\8PY
M)!)* [S][D+D-C"Y. 0%55&#@ [LO$48P=B\# X[9!'Y%01Z$<=33L $G')Q
MD^N.E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;J#4I_#HA4)8W.@2Z9?WUR6FU-Y5\?\ #'[/?[9'A1]"TRQC\<)X/E^"_P
MK7XH:6_QJT[4]1UKXC>%_B5K5]\4=/T_5-1\5WE_I]]K'@2>R%_J]G+:Z7?V
MRC2[/;/EU_03PK\=?$7Q5T;QCXJ^%'@2/Q!X4\/>*=<\*:5>:SKD>AS>-;[P
MKJ9T[Q)=^'XS%)%%IUCJ8O;6"\O,Q:A/8W"Q+^[W/[4?B!X)BEO;6^\4^$[&
M^TC3#J>N6=UK^E12:/;PJOVZ>^,ETIBM["5Q%=RS^7%;'RS,8PZ*0#\N[KX$
M_M0^(OBAI5]K7_"=7'P0/[1GC#Q?8>#8_BPF@:OX:^$%]\*[G1]!T_6A9>+;
M35KVQO?B%%%?P:0=3GFTLR23S,;=R\6-H7[/_P"TCH?@1X/$6N>-O!]Z?V;+
MNVUOQ'K_ ,;;O7EB_: \-_$VYUWP?;WLG_"9ZC',M]X,M],T"\U72K,VEYI]
MY):-,;L%Z_5JV^)7PVN=-NM:M/''@^?3-/NDL[[4+;7])GM[:\EA9H+&>5;E
M@MQ<P1-+!"S>;<01-)$CHA8>-_M$?%+X>>$/AA/XMU/3?#'CZWTV]\%:]H^@
M?V]91MJ"ZGX@TW2=+UZU6*5S+;:>^HFZM_D:"6.)S&79#@ RQX&\?ZA^S%\0
M-/U'2Y-5^+/Q*^'WB6ZU3P^NO23VMOXK\4>'Y+.'P[IVJ:W?3V<6FVKRI;QW
M32PV\BAIO*1GP?ASP9^SI^UC\/\ 1[V/P_')J&K^)?V5? OPW\&Z[XB\3^#Y
M?$W[/?COPO;Z;;^+?!5C?07EO9WGAKQ[9Q7%_I&KZ=;75SINJ6T*ZK?0Q^6A
M_6S2O%OAK6+U]#LM;T&_UFWM$NM1T6SU.TN;NVM\*V1%#(9=D$CI$^]!Y;!%
M?:<9\IUGX[^$=#^-R? K4M+\067B2?X<ZM\3--U>YLEA\+:MX=T:X$6KQ6>J
M2R"-]2TVYD22[M4 'DXD<^5N( /CO6O!G[22ZKXY/A+PAXWNOAMXG\/^!/#>
MA^&-1^(,=OK'A[QMIGAG5[#Q;\09VEUV/6=1T2?4GT73&M+;5+?[=?6(UQ(S
M:^9%7BVM_!#]K+QA\!O$/A'XF>%_%WCCQ=K'PW^ .F^$+%_%^G"'0]<\%^([
MZ\^)(UT2ZI;Z2-8OU>TU ZE.9Y;^QMX;.&8R*?,_0W1?VHOAQK[?#>Q@M-<C
M\4_%J"_O/!GA"6QB&O3^'=-U"YTN?Q7?VJR+_9WAV699!;W=U(!>E1%;B4R8
M/&ZA^V5X6T;Q\/AM=?";XTW'B"7P]+XS@2/P;/-%/X.3Q'!X4E\2!89C(+!M
M7N(H526(2?9U$@79&2 #[8@Y!X"E2H4<A@OEH '4\@@Y&TY QD$]:GKYT^*W
M[1OP\^#GB3P!X7\:+XEAO_B;XCT#PMH,VE>'=1O-.CU/Q-?G2=.AUO5(@MEH
M[M=S09!G%UM&Y8BNTKYK\:OVT/!WP,C\3W?B?P!\4;_1?"WBG0O!BZWH_AZ2
M>U\2>./$IL3I'A3P?;R3I?>*M2N%U N(=,AEC1;2=9-J02%0#[5YS[?_ *O_
M *]%?-%O^TIX2?XQ>%?@[?>'?'NDZYXRD\667AO7M3\.7-MX6U+6O ^G1ZMX
MJT&'4FD:.2?3K%@ZW8B%O-(1'#.[,I;Z4\R,<;T&.,%@",=B"<@CT/(H Y77
MF$FL>%(T.YUU;42R@=CX8\0H.>!G<P&,Y^8=LX_#C_@I)_P2#TW]K']H*Q_:
MUT@6GC3QQHWP]T_P(OPR\4W*V_AEK+1GN;RWU#2GB1C<ZO\ :+IFCBN\0ER3
MV '[F:]X:&N^0S7]W93V=RUWI]]9R&.ZLIGL[RS8QC'ENFR[8[9,AC][[JU@
M)K.L>'GMX_$5LVH:<Q42>)-(A=?*G0YV:IID8:6*':#NF@#I@*NPAJ /Y$_V
M!O\ @K;X0_9?\8:S^RCX?_9X\0>-/!B>.O$[_$?Q9X*6'2Y_!GB>&(Z'KMQ=
MKJC+9^(H;;4-,BM9OLQL)?+EBD02*5W_ #?\&OV3?#_[+.A?M&_\%:_#OQ3T
MCXC_ +2WPE^*/BSXD_![]F^TCFM;(V'Q%^(,VA+9>-Y27U.^NM0\*ZU<W5LO
MAZS<6$R*;C)PX_8S_@DC^Q!I^N?LZ_M1>'?VD_@]>:%J'C']K[XS>,_"5[XC
MTQ--\5R^&->O9%T+Q'8W2G[6EC?PSRW%G;74GE^6Q:2/S0KCR+]O7]AFY_8]
M^%/CW]H&R\2'Q?\ !GP-9V.J^(X9(A9^)] TJ/4[*TM6"0_N]5C^V74,<95]
MT;A688YH _/K_@H'XGU7_@LKXO\ V!;?5/#FH?LSBWNO&?A'XV2^(KFVUNP^
M']QXIN].>QUBTN87AFOM)FBM96C6Y6RGM5N6ANE5(A*WK7Q=^*_Q4_X(E^'?
MA)X-USXCZQJ'A>STBZLOA#+H]Q:^(-%^(&BV<\5Y>6DL,86T6)KB[BS<7.Z6
MVAN56+S=@:OYW_C]_P %"O'7Q#@OM!^'-F_@GPY))<J==RMQXBO[21F9)9)H
MR$T^9]Q0*F]@%#9#-@?K#\=/V4_VB/V]_P!AS_@D!\.?@/X.\4_$/Q98?#[X
MFGQIXFU%9QH7AB'4]>C%MJ_B?Q!J#SPP:=.D4GD,CO+/L=(44J10!^7^L?M3
M:Y^V=_P54^&O[2?B;POIG@[4?B#^T%\(;I]#TR]FN[33;?2KW1M)BW3W(61I
M[B.T226,91&R(RP!K_4ZC/!&<[2![9"@$9P,D$'/IQS7\QW_  3@_P"#<;X,
M_LQ:]X1^+W[2OBV'XW_&+PY<V&NZ!X>T>&;2_ACX.UZQ)G2ZLXF"7VOWMK.5
M9+J\CA2&6,E%99%-?TWQ(Z ER&8D MD@LJYP2,8W<GH &&"2#0!\M_M=?"'Q
MQ\<_A2?A]X$U/PQH^IR^-?A_XDN;[Q.NH2V0L?!7BK3/%9MECL&687%W<Z5!
M;QR9VHCN2K$!AX_^T!\ ?VAOCSX8MO#NH^)_AAI-KI'QC^#7Q'T"PM[?7YK>
MTTOX4^)='\4W5G>7+S++=:IXCO\ 21"CQK#::;;O'+LGEC(/Z$X'H/RHP/0?
MD* /SO\ VA_V3/$7[17A+]H33/%T'@6W\6>.-#\*Z)\'O%5O+K)G\$'PO=IK
MFG7^HJTP,=W:^*5_M4'3U07$*F.5LL4=T_[/GQXUO]I'X#_'[7/%/@"&Z^&G
M[/OBWX1>,;.PCU7SM9\7>,19WLWC+0979EBTK3-0LK1Y-(OD>>]=;PQ7%LJQ
M%OT-**1C'&<\8]^OKUIOE)Z?H/\ "@#\M_%'[!=Q\3_$GC#X@>)KGPY\,/'&
MO>$/ ,<E_P#"VUC.D>)/C!\,_&,OC?P/\;M>\/S)86K^)?#6H1+86=I-+<R7
M]EJEY:W]^T-M;*OOWC#X*?$3XT>+?@QK?Q;M?!UIH'P.\7VGQATG0/"MYJ%V
MGBGXS:-H^J:%X;U.:ZU*)/[*\):#%KNK:E9V30SZE/>26QO+AI(C*?LP*JC
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M@*T[[7%:WA;X#_$CX??$/PG\6_#%_P"';K5]4^$G@CX4_&7P1<W$]IH_B ^
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M$K6T=M%)$L,;L9?,7YL>.>-O@S\?_%O[4&K?&OQ/X.\(>/?"'PTT7^R_V9?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BG19(98W57C
M>-TD1E5U=&4JZ,C JRLI(92"&&00<XJ6J>H7EK865W?7MS%9VEG;375S<SNL
M<-O!;H999Y796"QQ(I=B05V@Y4T ?E;J/[#/Q*B^+W_"9>$OB#HEG\.E^)NJ
MW]IX"U*QN?LD/PB^)FGK<?$OPU',B2.VK-K-I OA]&*Q6%M->1"5&9"4^(W[
M"GQ*N_BE<>,/A1X_T'PAX)MOB%HWC/1/ 5]ICR6B:9XJT&V\(?%S0KID#Q0V
M>IZ5#]OT.V1MEMJCW%P <E*^YG_:*^"?VV:Q?XE^'/MMGI5GXANM,$MV=2M?
M#]W=+8V>M76GI9+>6VG7MV1;V]S/&MI.6#0LV0*[?Q#\0_!'A*Z\'6OB3Q-I
M6CW/CO6K?P]X.M[N4B7Q+K=[:2W]OIFFIL8O-<6D4MRGF! D<3_,HH _.WXM
M_L)^.=<^)EQXP^#?Q!TGX=^';?Q%\./'6C>&)+&YGC7QCX8@N_#/C);D;FMX
M](\1^"905M-AMWU<+>.@P8ZK?&O]F#X]>-K&S_X0O0? -F;C]GCXV? &]T*Z
M\6ZM;6>FS>,3<CP7X[6^@L-EU=LDTU]J]M%^_L;YP+>8(H _5:(1NB."K\$!
MP." 2N,9P<#Y2>^/3%#00@%O+7(&X8!!!4  C'0C Y SGWH _*"P_93^/EAK
M?C?4IK;PJ#XJ^(_[*OBJSO+7Q%/?O8V?P4\-6^C>)[ORKRV7S+ZYO(UNM'@$
M:M(L9\UBQ#UUOPJ_9K^.OPT?X'7LFK:5K?B'X,:7\63XO\4W/B*X^W?M ZIX
MR%S8^%;/Q;=R13W2V.F+>IJ\]UJAN7TW4[&(Z>HCEDB/Z*W>K:99W5C976HV
M%K?:K*\>DVUU=6UM=ZC/;QY:*PM)98KB\>WC(,@3("D;^Q,.F:_H.LS7D&DZ
MWH^JR:5-':ZG!I.IV5]+I=X!-((]12SN9WL2!',3;W>U=T9VEB&H _.3Q+^S
M=\>K[XQCQ-H]KH,GA+6_VH_@7^T3J-VWC&^LI-$TGP1X#O\ PQXX\%1Z:(2+
MP7&J2VEUIKQ@:7J%JLT]U9?:?*9?#5_8'^/:?!+X<?"_PAXB\._"3QO\/O@G
M\=? >M?$#PSK=]%<^/O$WQ%U31[CPG#=?V7%;7LNCI]AU+6->U;4I)=3T34+
MN6#187M3)*W[.:??Z9J-@E[I=]9ZCI[!PE[8SPW%O(D8,#>5);$Q%HRCP.JG
M*LN"-P&.?D\7>##!K4X\5>&A!X>:8>(KDZ_IJQ^'WB62V UV7[:C:-.I1K20
MW>QMZO!(JL&50#Y;@^&'Q-E^#.L^ ?"GA/PS\*/%?Q#\(:[X5\:>,M%\3RB]
M\.:\GPOG\.>&OB+HJ:?9D7^H#Q796'VM2UKJ%M;3_P!MSR76HVLGG>(W'[-_
MQC7]GSPK\/=/\#^#--^(\/@[2O 7CSQM%XF-SJ/BMM'\$:WX<A\<;Y(ECU6\
MEU*^M=1FGUMKK5(D=W4RS0Q*GZ)3>-_!%OI>FZ_<^+_"D.B:U)##HVKS>(M*
MCTC5[RXF%N(]+OQ>?8K]Y)2$VVQDW2<' W$='//:VL$U[<7-O:VUI%)<7-S=
MRQ16MO;HHN)[F:5Y(K>.TBC4RO<,^R/!8_(,$ \3_94\!^./A9^SO\'/AK\1
MY[>\\;^!_ 6B^&_$]_::C+JUK?:OI4 M[B]M]1G2*:Y@N@%F1I8HY%9GC*;8
MU9OH3/ISSC]<'KZ?_JS7G=W\2_AYI>CVWB&^\?\ @O3_  ]J,[6VFZW?>+?#
M]KHVH3Q,JRP6.JW%^MG=3QR,4FC1_M",0C !4)UH_%_A>:[T[2XO%'A][_5[
M;[7I6GIKVERZAJEJWSK=:9 EY]HO;=U#F.>V!C*J2.%- '745S6F^(M#U;4+
MW2]+\0:/JM]I$HBU6PT[5;&]O=+E#!##J5K;7+W5K+ORK"Z09;*[0_3I1T'?
MW]: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX03C*R@GOY=HCD+ E?+?=A7<[0I) 2/]XYQG"I\['A?FQ52WN4\L!0[*&P)
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M\0:YJ'BFQ@U:R.G^)/$UQ;3W^G:P?[?O=5U>V-IJ*Q2Q17R2W6_Y,K&_PO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCPIXX\ ^&?%-[X5B\<Z_^UGJOQ6U'4OB FI>$_C-9?$ZYM[[X4Z-)HK7\O\
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MGBGX0ZOIOAG4/#_Q#\<^'_%/B?4U>]\'>&M/NDTKP+X2:-;NW6<I:VUEH_\
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>83
<FILENAME>tm2135630d1_ex10-3d4img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex10-3d4img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: IH# 2(  A$! Q$!_\0
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MBL4Z-/'*=N] >0-OK[U+LM[ G?8N^'/$_B__ (6!'X<\21Z<H>S:Y'V3)Z$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1:***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>84
<FILENAME>tm2135630d1_ex3-1d1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex3-1d1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A +,# 2(  A$! Q$!_\0
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MUKPY/!O$D4EXX91]TBSFP?SQ7/-=:UI]E;!M8U&9;W1H;FZFD =H"TT2R2(
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:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>85
<FILENAME>tm2135630d1_ex3-1d1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex3-1d1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A &<# 2(  A$! Q$!_\0
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8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>86
<FILENAME>tm2135630d1_ex3-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex3-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H $P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#VW7]7CT'1
M;C4I8WD2';E4 ).Y@O<CU]:XO_A;>G_\^-Y_W[3_ .+K=^(W_(AZE]8O_1J5
MX37/5J2C*R/HLHR[#XF@YU5K>V_DCW;POXUMO%%W<6\%O/$T,8<F15 .3CLQ
MKJ,UY)\(_P#D,ZE_U[K_ .A5ZI-=V]NA>:>.- P0LS  ,3@#ZDD5I3DW&[/-
MS+#PH8ETJ2TT\^A)),D6SS'5=[!5W'&3Z#WI^:\9\;>*M5.N'3MRQG3+TS12
M)P6Z%-PZ< X]\UZ%X7U^75-&M[[4Y;>"6^F=;:%3C(7C SRQ^5C1&HG)H*^7
M5:-"-9]?^'7X:^1NWET+.QN+I@2L,;2$#J0 3_2N!_X6WI__ #XWG_?M/_BZ
M[366#>']2*D$?99>0?\ 9-?./:HK3E%JQW9/@*&*A-U5LUU\CV33/B=9:EJE
MK8I9W2O<2B,,R* "?7YS7>5\[^%/^1OT?_K[3^=?1%.C-R3N89QA*6%J1C25
MDU^IRWQ&_P"1#U+ZQ?\ HU*\)KW;XC?\B'J7UB_]&I7A%95_B/9X?_W:7^)_
MDCT/X1_\AG4O^O=?_0JSOB7IDMMXIFNS:-';72*?,#;DD8#!SQ@' ''X]ZT?
MA'_R&=2_Z]U_]"KTW6;#^T]%O+$)$QGB9%$H.W=C@G'/!P>/2JC#FIV./%8S
MZKF;G:Z:2?\ 7D?.D\\MS())Y&DD"*FYCD[5 4#\  *=)<W5XMM \LDODKY4
M$8_A!.<*!W)_&N[N?ADFG16 NM5>26YNDMV,<0 7<#R,DYZ5T_A3P&?#6MS7
MCW4-W&T12(M%MDC.1R.2.1D5FJ4F[,]*KFV$A3YH.[5[:6OTTT+FFV,NF_#7
M[)/!Y$T>GR;X\Y(8JQ.??)Z=J\*'2OH_6_\ D :E_P!>LO\ Z :^<.U575K(
MYLAFZBJS>[=_ON;'A3_D;]'_ .OM/YU]$5\[^$_^1OT?_K[3^=?1%7A]F<7$
M7\:'I^IE>(]'_M_0;G3//\CSMG[S9NQM<-TR/2N$_P"%0'_H-_\ DK_]G116
MLJ<9.[/+P^/Q&'CR4I66^R.A\(^"#X5O;FX^W_:?.C";?)V8P<YZFNMQ1151
MBHJR,*]>I7G[2H[LJWFGP7S6QG1F-O,L\>&(PX!P??J:M8HHIF;;:2?0@OK;
M[987-KNV>=$T>[&=NX$9_6O-_P#A3YQ_R&__ "5_^SHHJ)0C+<Z</C:^&35*
M5K^A<TKX7'2]7L[_ /M?S/LTJR;/L^-V.V=W%>BT44XP4=B<1BJN)DI57=H_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>87
<FILENAME>tm2135630d1_ex3-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex3-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O )<# 2(  A$! Q$!_\0
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MMVN74=MS;DP?;'%4O$6O^)/!.BMJ-W:VNNVT9'FR0DVK1 G )4^9N'OD8]*
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GX.2><\\YH&>@455L;1[.%DDNIKJ1VWM+-C). . H  XZ 44"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>88
<FILENAME>tm2135630d1_ex3-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex3-1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J $T# 2(  A$! Q$!_\0
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HFLZ;KMA?37%BT5O.LCA'8D@'M\M>K4440@H[$8K&5<5)2J[KRL?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>89
<FILENAME>tm2135630d1_ex3-1img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2135630d1_ex3-1img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y )<# 2(  A$! Q$!_\0
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A5U5% $-I:PV5LEO I6-,X!8L>3DDD\DDDG)HJ:B@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
